<SEC-DOCUMENT>0001062993-24-012882.txt : 20240621
<SEC-HEADER>0001062993-24-012882.hdr.sgml : 20240621
<ACCEPTANCE-DATETIME>20240621160237
ACCESSION NUMBER:		0001062993-24-012882
CONFORMED SUBMISSION TYPE:	PRER14A
PUBLIC DOCUMENT COUNT:		130
FILED AS OF DATE:		20240621
DATE AS OF CHANGE:		20240621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Flora Growth Corp.
		CENTRAL INDEX KEY:			0001790169
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRER14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40397
		FILM NUMBER:		241060096

	BUSINESS ADDRESS:	
		STREET 1:		3230 W. COMMERCIAL BOULEVARD
		STREET 2:		SUITE 180
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33309
		BUSINESS PHONE:		416-861-2267

	MAIL ADDRESS:	
		STREET 1:		3230 W. COMMERCIAL BOULEVARD
		STREET 2:		SUITE 180
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33309
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRER14A
<SEQUENCE>1
<FILENAME>formprer14a.htm
<DESCRIPTION>FORM PRER 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:flgc="http://www.floragrowth.com/20240331" xmlns:ecd="http://xbrl.sec.gov/ecd/2023">

<head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
    <title>Flora Growth Corp.: Form PRER 14A - Filed by newsfilecorp.com</title>
</head>

<body>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; line-height: initial;">
        <div style="display: none;">
            <ix:header>
                <ix:hidden>
                    <ix:nonNumeric name="dei:DocumentType" id="Fxbrl_20240527144459834" contextRef="C_20240101to20240331">PRER14A</ix:nonNumeric>
                    <ix:nonNumeric name="dei:EntityCentralIndexKey" id="F20231025072913927_0" contextRef="C_20240101to20240331">0001790169</ix:nonNumeric>
                    <ix:nonNumeric name="dei:AmendmentFlag" id="F20231025072913927_1" contextRef="C_20240101to20240331">true</ix:nonNumeric>
                </ix:hidden>
                <ix:references>
                    <link:schemaRef xlink:type="simple" xlink:href="flgc-20240331.xsd"/>
                </ix:references>
                <ix:resources>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoImpairmentTestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselAssetGroupMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-06-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeAnnualImpairmentTestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeAnnualImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeAnnualImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:FGHMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfFghMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-06-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfFghMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-06-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfFghMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfJustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfJustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-06-30</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfJustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselAssetGroupMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-06-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:FGHMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-06-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-06-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:FGHMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoImpairmentTestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240304to20240308">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-03-04</xbrli:startDate>
                            <xbrli:endDate>2024-03-08</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:RestrictedStockAwardsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:RestrictedStockAwardsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtRangeAxis_srtMaximumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtRangeAxis_srtMaximumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-07-01</xbrli:startDate>
                            <xbrli:endDate>2023-07-05</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtOwnershipAxis_flgcCosechemosAndKasaWholefoodsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:OwnershipAxis">flgc:CosechemosAndKasaWholefoodsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_srtStatementGeographicalAxis_countryUS">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_srtStatementGeographicalAxis_countryUS">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_srtStatementGeographicalAxis_countryDE">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_srtStatementGeographicalAxis_countryDE">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_srtStatementGeographicalAxis_countryGB">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_srtStatementGeographicalAxis_countryGB">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">flgc:EuroCreditFacilityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">flgc:EuroCreditFacilityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_srtRangeAxis_srtMinimumMember_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">flgc:EuroCreditFacilityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_srtRangeAxis_srtMaximumMember_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">flgc:EuroCreditFacilityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220222_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-22</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-01</xbrli:startDate>
                            <xbrli:endDate>2022-02-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-28</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-01</xbrli:startDate>
                            <xbrli:endDate>2022-02-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapBusinessAcquisitionAxis_flgcJustBrandsLLCMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsFourMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsFourMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsFiveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsFiveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsSixMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsSixMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsSevenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsSevenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsEightMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsEightMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsNineMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsNineMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231101to20231115_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-11-01</xbrli:startDate>
                            <xbrli:endDate>2023-11-15</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220705">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-07-05</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230606">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-06-06</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220901to20220928_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-09-01</xbrli:startDate>
                            <xbrli:endDate>2022-09-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcHampsteadPrivateCapitalLimitedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:HampsteadPrivateCapitalLimitedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcDrManaloMorganMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:DrManaloMorganMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcDrManaloMorganMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:DrManaloMorganMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-17</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-17</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFourMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFiveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySixMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySevenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryEightMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryNineMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryElevenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwelveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryThirteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFiveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFourteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySixMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFifteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySevenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySixteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryEightMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySeventeenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryEighteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryNineMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryNineteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryElevenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwelveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryThirteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFourteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFifteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySixteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySeventeenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryEighteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryNineteenMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFourMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:TerminationBenefitsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:TerminationBenefitsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:TerminationBenefitsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230131_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:GerardoAndresGarciaMendezMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-02-01</xbrli:startDate>
                            <xbrli:endDate>2023-02-03</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20210101to20220314">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2021-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-03-14</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-02-03</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-05-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231101">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-11-01</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:RamonRicardoCastellanosSaenzAndMiriamOrtizMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-05-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:GerardoAndresGarciaMendezMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraGrowthCorpMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:FirstClosingMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-01</xbrli:startDate>
                            <xbrli:endDate>2024-04-16</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraGrowthCorpMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:SecondClosingMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-01</xbrli:startDate>
                            <xbrli:endDate>2024-04-16</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240401to20240422_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraGrowthCorpMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:FirstClosingMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-01</xbrli:startDate>
                            <xbrli:endDate>2024-04-22</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancialAssetNotPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables1To29DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables30To59DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables60To89DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">flgc:FinancingReceivables180PlusDaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancialAssetNotPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables1To29DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables30To59DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables60To89DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">flgc:FinancingReceivables180PlusDaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221201to20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-12-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-23</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-23</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcSupplierRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:SupplierRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-23</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcCustomersRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:CustomersRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-23</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapLicenseMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-23</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-24</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-01</xbrli:startDate>
                            <xbrli:endDate>2022-02-24</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220226to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-26</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TradenamesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-24</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcCustomersRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:CustomersRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-24</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcKnowHowMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:KnowHowMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-24</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-07-01</xbrli:startDate>
                            <xbrli:endDate>2022-07-20</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-07-20</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraBeautyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-01-18</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraBeautyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-01-18</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220131_usgaapBusinessAcquisitionAxis_flgcFloraMedSasMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraMedSasMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-01-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFloraMedSasMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraMedSasMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:OriginalHempAssetAcquisitionMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-02-28</xbrli:startDate>
                            <xbrli:endDate>2023-03-01</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:OriginalHempAssetAcquisitionMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-01</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221223_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-23</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240401to20240416_usgaapBusinessAcquisitionAxis_flgcTruhcHoldingGmbhMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-01</xbrli:startDate>
                            <xbrli:endDate>2024-04-16</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:FirstClosingMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-18</xbrli:startDate>
                            <xbrli:endDate>2024-04-22</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:SecondClosingMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-18</xbrli:startDate>
                            <xbrli:endDate>2024-04-22</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240402to20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:AegisCapitalCorpMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-02</xbrli:startDate>
                            <xbrli:endDate>2024-04-04</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:AegisCapitalCorpMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-04-04</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240407to20240408_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:AegisCapitalCorpMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-07</xbrli:startDate>
                            <xbrli:endDate>2024-04-08</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240402to20240404_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-02</xbrli:startDate>
                            <xbrli:endDate>2024-04-04</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240404_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-04-04</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240424to20240426_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-24</xbrli:startDate>
                            <xbrli:endDate>2024-04-26</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240224_usgaapBusinessAcquisitionAxis_flgcJustCBDMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-02-24</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240301to20240308_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-03-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-08</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapInvestmentTypeAxis_flgcFirstTrancheMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:FirstTrancheMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapInvestmentTypeAxis_flgcSecondTrancheMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:SecondTrancheMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapCollateralAxis_flgcHeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">flgc:HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapCollateralAxis_flgcHeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">flgc:HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapCollateralAxis_flgcFinancialIntermediariesMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">flgc:FinancialIntermediariesMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapCollateralAxis_flgcFinancialIntermediariesMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">flgc:FinancialIntermediariesMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtCurrencyAxis_currencyCAD">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtCurrencyAxis_currencyCOP">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:COP</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtCurrencyAxis_currencyGBP">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtCurrencyAxis_currencyEUR">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtCurrencyAxis_currencyCHF">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtCurrencyAxis_currencyCAD">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtCurrencyAxis_currencyGBP">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtCurrencyAxis_currencyEUR">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_flgcGermanSubsidiariesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">flgc:GermanSubsidiariesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:PharmaceuticalsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:PharmaceuticalsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:ConsolidatedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:PharmaceuticalsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:ConsolidatedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:ConsolidatedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:PharmaceuticalsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:ConsolidatedMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryUS">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryUS">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryDE">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryDE">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryGB">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryGB">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryCA">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryCA">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtStatementGeographicalAxis_countryUS">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryUS">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtStatementGeographicalAxis_countryDE">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryDE">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryCO">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtStatementGeographicalAxis_countryCO">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryGB">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtStatementGeographicalAxis_countryGB">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryCA">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_srtStatementGeographicalAxis_countryCA">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221201to20221223_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFGHOwnersMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FGHOwnersMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-12-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-23</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:DecemberTwoThousandTwentyTwoUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-08</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:DecemberTwoThousandTwentyTwoUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-12-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-08</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:NovemberTwoThousandTwentyOneUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-08</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:PlacementAgentMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:DecemberTwoThousandTwentyTwoUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-12-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-08</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220201to20220225_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustCBDOwnersMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustCBDOwnersMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-01</xbrli:startDate>
                            <xbrli:endDate>2022-02-25</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FloraBeautyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-01-18</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FloraBeautyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-01-18</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FloraMedSasMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FloraMedSasMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-01-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20220131">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220401to20220405">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-04-01</xbrli:startDate>
                            <xbrli:endDate>2022-04-05</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:SeptemberTwoThousandTwentyThreeUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-09-21</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:SeptemberTwoThousandTwentyThreeUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-09-01</xbrli:startDate>
                            <xbrli:endDate>2023-09-21</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:NovemberTwoThousandTwentyOneUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-09-21</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:DecemberTwoThousandTwentyTwoUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-09-21</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:PlacementAgentMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:SeptemberTwoThousandTwentyThreeUnitOfferingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-09-01</xbrli:startDate>
                            <xbrli:endDate>2023-09-21</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230131">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-01-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230401to20230426">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-04-01</xbrli:startDate>
                            <xbrli:endDate>2023-04-26</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230501to20230514">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-05-01</xbrli:startDate>
                            <xbrli:endDate>2023-05-14</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFourMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFourMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFiveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsSixMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFiveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsSixMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtCounterpartyNameAxis_flgcWarehousingAndOfficeSpaceMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">flgc:WarehousingAndOfficeSpaceMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtCounterpartyNameAxis_flgcRetailSpaceInMiamiMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">flgc:RetailSpaceInMiamiMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtCounterpartyNameAxis_flgcPompanoBeachMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">flgc:PompanoBeachMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_srtCounterpartyNameAxis_flgcFortLauderdaleMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">flgc:FortLauderdaleMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:CanadaIncomeTaxAuthorityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:CanadaIncomeTaxAuthorityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:USFederalIncomeTaxAuthorityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:USFederalIncomeTaxAuthorityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:USStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:USStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:ForeignIncomeTaxAuthorityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:ForeignIncomeTaxAuthorityMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedStatesRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:UnitedStatesRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:ColombiaRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcGermanyRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:GermanyRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcDenmarkRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:DenmarkRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedKingdomRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:UnitedKingdomRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:ColombiaRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcForeignRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:ForeignRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_usgaapCanadaRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:ColombiaRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedStatesRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:UnitedStatesRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcDenmarkRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:DenmarkRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcGermanyRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:GermanyRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedKingdomRevenueAgencyMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:UnitedKingdomRevenueAgencyMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapStatementOperatingActivitiesSegmentAxis_usgaapSegmentDiscontinuedOperationsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancialAssetNotPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables1To29DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables30To59DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables60To89DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">flgc:FinancingReceivables180PlusDaysPastDueMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-28</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-28</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-01</xbrli:startDate>
                            <xbrli:endDate>2022-02-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-01</xbrli:startDate>
                            <xbrli:endDate>2022-02-28</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-17</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220218to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-18</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220218to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-02-18</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-02-17</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsOneMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsTwoMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsThreeMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFourMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFourMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFiveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsSixMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFiveMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsSixMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TradenamesMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapTrademarksMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapReportingUnitAxis_flgcVesselMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20211231_usgaapReportingUnitAxis_usgaapFranchiseMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">us-gaap:FranchiseMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2021-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapReportingUnitAxis_flgcVesselMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_usgaapReportingUnitAxis_usgaapFranchiseMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">us-gaap:FranchiseMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapReportingUnitAxis_flgcVesselMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_usgaapReportingUnitAxis_usgaapFranchiseMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">us-gaap:FranchiseMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapReportingUnitAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapReportingUnitAxis_usgaapFranchiseMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">us-gaap:FranchiseMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_usgaapReportingUnitAxis_flgcVesselMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:ACAMullerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:GerardoAndresGarciaMendezMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:GerardoAndresGarciaMendezMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231101_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-11-01</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:ACAMullerMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2024-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240401to20240430_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-04-01</xbrli:startDate>
                            <xbrli:endDate>2024-04-30</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240331to20240331_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-03-31</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240501to20240507_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-05-01</xbrli:startDate>
                            <xbrli:endDate>2024-05-07</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">flgc:ColombianRelatedSubsidiariesAndColombianAssetsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">flgc:ColombianRelatedSubsidiariesAndColombianAssetsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">flgc:ColombianRelatedSubsidiariesAndColombianAssetsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">flgc:ColombianRelatedSubsidiariesAndColombianAssetsMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2022-01-01</xbrli:startDate>
                            <xbrli:endDate>2022-12-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2023-03-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
                                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:instant>2022-12-31</xbrli:instant>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:RestrictedStockAwardsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:RestrictedStockAwardsMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2023-01-01</xbrli:startDate>
                            <xbrli:endDate>2023-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                            <xbrli:segment>
                                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                            </xbrli:segment>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2024-01-01</xbrli:startDate>
                            <xbrli:endDate>2024-03-31</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                    <xbrli:unit id="CAD">
                        <xbrli:measure>iso4217:CAD</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="CAD_Per_Share">
                        <xbrli:divide>
                            <xbrli:unitNumerator>
                                <xbrli:measure>iso4217:CAD</xbrli:measure>
                            </xbrli:unitNumerator>
                            <xbrli:unitDenominator>
                                <xbrli:measure>xbrli:shares</xbrli:measure>
                            </xbrli:unitDenominator>
                        </xbrli:divide>
                    </xbrli:unit>
                    <xbrli:unit id="EUR">
                        <xbrli:measure>iso4217:EUR</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="Euro_Per_share">
                        <xbrli:divide>
                            <xbrli:unitNumerator>
                                <xbrli:measure>iso4217:EUR</xbrli:measure>
                            </xbrli:unitNumerator>
                            <xbrli:unitDenominator>
                                <xbrli:measure>xbrli:shares</xbrli:measure>
                            </xbrli:unitDenominator>
                        </xbrli:divide>
                    </xbrli:unit>
                    <xbrli:unit id="Pure">
                        <xbrli:measure>xbrli:pure</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="Segment">
                        <xbrli:measure>flgc:Segment</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="Shares">
                        <xbrli:measure>xbrli:shares</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="Trial">
                        <xbrli:measure>flgc:Trial</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="USD">
                        <xbrli:measure>iso4217:USD</xbrli:measure>
                    </xbrli:unit>
                    <xbrli:unit id="USD_Per_Share">
                        <xbrli:divide>
                            <xbrli:unitNumerator>
                                <xbrli:measure>iso4217:USD</xbrli:measure>
                            </xbrli:unitNumerator>
                            <xbrli:unitDenominator>
                                <xbrli:measure>xbrli:shares</xbrli:measure>
                            </xbrli:unitDenominator>
                        </xbrli:divide>
                    </xbrli:unit>
                    <xbrli:unit id="Violation">
                        <xbrli:measure>flgc:Violation</xbrli:measure>
                    </xbrli:unit>
                </ix:resources>
            </ix:header>
        </div>
        <div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <hr style="height: 3px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_1_integixAnchor"></span>
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><b><span style="font-size: x-large;">UNITED STATES </span></b><br/><b><span style="font-size: x-large;">SECURITIES AND EXCHANGE COMMISSION</span></b></p>
                <p style="margin-top: 0pt; text-align: center;">Washington, D.C. 20549</p>
                <p style="text-align: center;"><b><span style="font-size: x-large;">SCHEDULE <span style="-sec-ix-hidden: Fxbrl_20240527144459834;">14A</span> INFORMATION</span></b></p>
                <p style="margin-bottom: 0pt; text-align: center;"><b>Proxy Statement Pursuant to Section 14(a)</b></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>of the Securities Exchange Act of 1934</b></p>
                <p style="margin-top: 0pt; text-align: center;"><b>(<ix:nonNumeric id="Fxbrl_20240621223801423" name="dei:AmendmentDescription" contextRef="C_20240101to20240331">Amendment No. 1</ix:nonNumeric>)</b></p>
                <p style="background-color: #ffffff; text-align: justify;">Filed by the Registrant <b>&#9745;</b></p>
                <p style="background-color: #ffffff; text-align: justify;">Filed by a Party other than the Registrant <b>&#9744;</b></p>
                <p>&#160;</p>
                <p style="text-align: justify;">Check the appropriate box:</p>
                <p style="margin-bottom: 0pt; text-align: justify;">&#9745; Preliminary Proxy Statement</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&#9744; Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&#9744; Definitive Proxy Statement</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&#9744; Definitive Additional Materials</p>
                <p style="margin-top: 0pt; text-align: justify;">&#9744; Soliciting Material under &#167;240.14a-12</p>
                <p style="margin-bottom: 0pt; text-align: center;"><b><span style="font-size: x-large;"><span style="text-decoration: underline;">
                                <ix:nonNumeric id="Fxbrl_20240527144439699" name="dei:EntityRegistrantName" contextRef="C_20240101to20240331">Flora Growth Corp.</ix:nonNumeric>
                            </span></span></b></p>
                <p style="margin-top: 0pt; text-align: center;">(Name of Registrant as Specified In Its Charter)</p>
                <p style="text-align: center;">______________________________________________________________________<br/>(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</p>
                <p style="background-color: #ffffff; text-align: justify;">Payment of Filing Fee (Check all boxes that apply):</p>
                <p style="text-align: justify;">&#9745;<span style="display: inline-block; width: 10pt;">&#160;</span>No fee required</p>
                <p style="text-align: justify;">&#9744;<span style="display: inline-block; width: 10pt;">&#160;</span>Fee paid previously with preliminary materials</p>
                <p style="text-align: justify;">&#9744;<span style="display: inline-block; width: 10pt;">&#160;</span>Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</p>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_2_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><span style="color: #ff0000;"><b>Preliminary Proxy Statement - Subject to Completion, dated June 21, 2024</b></span></p>
                <p style="margin-bottom: 0pt; text-align: center;"><b>Flora Growth Corp.</b></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>3230 W. Commercial Boulevard, Suite 180</b></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Fort Lauderdale, Florida 33309</b></p>
                <p style="margin-top: 0pt; text-align: center;"><b>+1 786 889 5375</b></p>
                <p style="text-align: justify;">To the Shareholders of Flora Growth Corp.</p>
                <p style="text-align: justify;">You are cordially invited to attend the 2024 Annual and Special Meeting of Shareholders (the "Annual Meeting") of Flora Growth Corp., a corporation organized under the laws of the Province of Ontario (the "Company") to be held on August 14, 2024, at 11:00 a.m. Eastern Time. The Annual Meeting will be held at the offices of the Company's legal counsel, Miller Thomson LLP, 40 King Street West, Suite 5800, Toronto, ON M5H 3S1, Canada.</p>
                <p style="text-align: justify;">The matters expected to be acted upon at the Annual Meeting are described in detail in the accompanying Notice of Annual and Special Meeting of Shareholders and proxy statement.</p>
                <p style="text-align: justify;">We urge you to fill out and submit the enclosed proxy card today or follow the specific instructions on how to vote your shares by proxy, or through the Internet.</p>
                <p style="text-align: justify;">You may cast your vote by proxy over the Internet, or by completing and mailing a proxy card to ensure that your shares will be represented at the Annual Meeting. Your vote by proxy will ensure your representation at the Annual Meeting regardless of whether or not you attend. Returning the proxy does not deprive you of your right to attend and vote your shares at the Annual Meeting.</p>
                <p style="text-align: justify;">Thank you for your continued investment in Flora Growth Corp.</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">Clifford Starke</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%;">Chief Executive Officer</td>
                    </tr>
                    <tr>
                        <td style="width: 50%;">&#160;</td>
                        <td style="width: 50%;">&#160;</td>
                    </tr>
                </table>
                &#160;
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_3_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>NOTICE OF THE 2024 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS</b></p>
                <p style="text-align: justify;">To Our Shareholders:</p>
                <p style="text-align: justify;">NOTICE IS HEREBY GIVEN that the 2024 Annual and Special Meeting of Shareholders (including any adjournments or postponements thereof, the "Annual Meeting") of Flora Growth Corp., a corporation organized under the laws of the Province of Ontario (the "Company" or "Flora") is to be held on August 14, 2024, at 11:00 a.m. Eastern Time. The Annual Meeting will be held at the offices of the Company's legal counsel, Miller Thomson LLP, 40 King Street West, Suite 5800, Toronto, ON M5H 3S1, Canada.</p>
                <p style="text-align: justify;">We are holding the Annual Meeting for the following purposes, which are more fully described in the attached proxy statement (the "Proxy Statement") accompanying this Notice:</p>
                <p style="margin-left: 72pt; text-indent: -18pt; text-align: justify;">(1)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider, and if deemed advisable, elect as directors the four nominees named in the Proxy Statement for a term of office expiring at the 2025 Annual Meeting of Shareholders or until their respective successors are duly elected and qualified.</p>
                <p style="margin-left: 72pt; text-indent: -18pt; text-align: justify;">(2)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider, and if deemed advisable, re-appoint Davidson &amp; Company LLP, an independent registered public accounting firm, as auditors of the Company for the fiscal year ending December 31, 2024 and authorize the directors to fix their remuneration.</p>
                <p style="margin-left: 72pt; text-indent: -18pt; text-align: justify;">(3)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider and, if deemed advisable, approve, an amendment to the Company's 2022 Incentive Compensation Plan (the "2022 Plan") to increase the number of shares issuable thereunder from 950,000 to 2,500,000 shares (the "2022 Plan Amendment Proposal").</p>
                <p style="margin-left: 72pt; text-indent: -18pt; text-align: justify;">(4)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider and if deemed advisable, approve the grant of Stock Appreciation Rights to the Company's Chief Executive Officer and Chief Financial Officer, as described in more detail in the Proxy Statement.</p>
                <p style="margin-left: 72pt; text-indent: -18pt; text-align: justify;">(5)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider and, if deemed advisable, approve the issuance of 635,363 shares in accordance with Nasdaq Listing Rule 5635(a) to acquire the minority interest of TruHC Pharma GmbH ("Share Issuance Proposal").</p>
                <p style="margin-left: 72pt; text-indent: -18pt; text-align: justify;">(6)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider any other business that is properly presented at the meeting and any adjournment or postponement thereof.</p>
                <p style="text-align: justify;">Only holders of our common shares ("Common Shares" at the close of business on June 25, 2024 are entitled to notice of and to attend and vote at the Annual Meeting and any adjournments thereof. Each of the voting matters set forth in Items 1-5 above are deemed to be a "Proposal" and collectively, the "Proposals." <span style="background-color: #ffffff;">The vote required to approve the resolutions to be presented is set forth in each proposal brought for shareholders' approval in the accompanying Proxy Statement.</span></p>
                <p style="text-align: justify;"><b>The Notice of Internet Availability of Proxy Materials is being mailed to shareholders on or about&#160; ____, 2024 and will be available at </b><span style="color: #0000ff;"><span style="text-decoration: underline;">https://www.cstproxy.com/floragrowth/2024</span></span>.</p>
                <p style="text-align: justify;">Your vote is very important. Shareholders may vote their shares (1) at the Annual Meeting, (2) through the Internet in advance at <span style="color: #0000ff;"><span style="text-decoration: underline;">https://www.cstproxy.com/floragrowth/2024</span></span>, or (3) by completing and mailing a proxy card if you receive your proxy materials by mail. Specific instructions for voting through the Internet (including voting deadlines) are included in the Proxy Statement and in the proxy card. For specific instructions on how to vote your shares, please refer to the instructions in this Notice, in the section titled "INFORMATION ABOUT OUR ANNUAL AND SPECIAL MEETING" of the Proxy Statement or on the proxy card. <b>Whether or not you expect to attend the Annual Meeting, please vote at your earliest convenience by following the instructions in the Proxy Statement or the proxy card you received in the mail.</b></p>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_4_integixAnchor"></span>
                <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 50%;">&#160;</td>
                        <td style="width: 50%;">By order of the Board of Directors,</td>
                    </tr>
                    <tr>
                        <td style="width: 50%;">&#160;</td>
                        <td style="width: 50%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 50%;">&#160;</td>
                        <td style="width: 50%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 50%;">&#160;</td>
                        <td style="width: 50%;">Clifford Starke</td>
                    </tr>
                    <tr>
                        <td style="width: 50%;">&#160;</td>
                        <td style="width: 50%;">Chief Executive Officer</td>
                    </tr>
                </table>
                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;">Fort Lauderdale, Florida</p>
                <p style="margin-top: 0pt; text-align: justify;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2024</p>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_5_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;">TABLE OF CONTENTS</p>
                <table style="font-size: 10pt; width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">Page</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_6_integixAnchor">Summary Term Sheet</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_6_integixAnchor">1</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_6_integixAnchor">Information About our Annual and Special Meeting</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_6_integixAnchor">1</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_18_integixAnchor">Directors &amp; Executive Officers</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_18_integixAnchor">13</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_22_integixAnchor">Corporate Governance</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_22_integixAnchor">17</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_32_integixAnchor">Share Ownership</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_32_integixAnchor">27</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_34_integixAnchor">Section 16(a) Beneficial Ownership Reporting Compliance</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_34_integixAnchor">29</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_35_integixAnchor">Securities Authorized for Issuance under Equity Compensation Plans</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_35_integixAnchor">30</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_36_integixAnchor">Executive Compensation</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_36_integixAnchor">31</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_52_integixAnchor">Financial Statements</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_52_integixAnchor">47</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_52_integixAnchor">Proposal No. 1 - Election of Directors *</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_52_integixAnchor">47</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_53_integixAnchor">Proposal No. 2 - Re-appointment of Independent Registered Public Accounting *</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_53_integixAnchor">48</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_55_integixAnchor">Proposal No. 3 - Approval of the 2022 Plan Amendment Proposal *</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_55_integixAnchor">50</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_72_integixAnchor">Proposal No. 4 - Approval of the Stock Appreciation Rights Proposal *</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_72_integixAnchor">67</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_77_integixAnchor">Proposal No. 5 - Approval of the Share Issuance Proposal *</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_77_integixAnchor">72</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_126_integixAnchor">Audit Committee Report</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_126_integixAnchor">121</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_128_integixAnchor">Where to Get Additional Information</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_128_integixAnchor">123</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_128_integixAnchor">Cost of Proxy Statement</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_128_integixAnchor">123</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_128_integixAnchor">Shareholder Communications</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_128_integixAnchor">123</a></td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%;">&#160;</td>
                        <td style="width: 5%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="text-align: left; width: 89.9072%; background-color: #eeeeee;"><a href="#page_129_integixAnchor">Other Business *</a></td>
                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_129_integixAnchor">124</a></td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;">* To be voted on at the meeting</p>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span id="page_6_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: center; margin-top: 0px;"><b>SUMMARY TERM SHEET</b></p>
                <p style="margin-top: 0px;"><span style="font-size: 11pt; line-height: normal; font-family: Aptos, sans-serif;"><i><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;">This&#160;summary term sheet summarizes certain information contained in this proxy statement (this &#8220;Proxy Statement&#8221;) but may not contain all of the information that is important to you. You should read carefully this entire Proxy Statement, including the attached Annexes, for a more complete understanding of the matters to be considered at the 2024 Annual and Special Meeting of Shareholders (including any adjournments of or postponements thereof, the &#8220;Annual Meeting&#8221;).</span></span></i></span></p>
                <ul>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">On April 1, 2024, Flora Growth Corp., a corporation organized under the laws of the Province of Ontario (the &#8220;Company&#8221; or &#8220;Flora&#8221;) entered into a binding letter of intent to acquire all of the issued and outstanding shares of TruHC Pharma GmbH ("TruHC") from TruHC Holding GmbH ("TruHC Holding") in an all-stock deal (the &#8220;Acquisition&#8221;) in exchange for 2,770,562 common shares, no par value, of the Company (the &#8220;Common Shares&#8221;).</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">On April 16, 2024, the Company entered into a stock purchase agreement (the "Stock Purchase Agreement") with TruHC Holding. The Stock Purchase Agreement provides for the acquisition of 100% of the issued and outstanding shares of TruHC, of which 100% was owned by TruHC Holding. On April 22, 2024, the Company completed the first closing (the "First Closing") in exchange for a total of 2,135,199 Common Shares, representing approximately 77% of TruHC. The second closing (the "Second Closing") for the balance of 635,363 Common Shares will take place after the shareholders of Flora approve the Share Issuance Resolution (as defined below) at this Annual Meeting to allow for the issuance of the Common Shares in the Second Closing in accordance with Nasdaq Listing Rule 5635(a).</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">The Company determined that it is in the best of interest of shareholders of the Company to acquire TruHC to capitalize on the progressive legislative changes in the German cannabis framework. While the Company has had a presence in Germany, it has not historically had access to a European Union Good Manufacturing Practice ("EU-GMP") facility in Germany. As such, the Company believes TruHC acquisition meets the following criteria: (i) it is of a size that would be transformative to the Company's business while being able to be integrated in a relatively seamless manner; (ii) it is complementary to the Company's business with a solid foundation of core cannabis licenses; (iii) it has a debt-free balance sheet such that a transaction would be accretive to the Company; and (iv) it has an established and experienced management team in place to enable the Company to assume a strong position in the German cannabis market.</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">The Company considered the following factors in reaching its conclusion to approve the Acquisition:</span></li>
                </ul>
                <ul style="list-style-type: circle; margin-left: 30pt;">
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">TruHC, and its cannabis licenses, is expected to expand the Company's ability to benefit from Germany's changing medical cannabis regime and phased legalization of recreational cannabis;</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">TruHC's licenses, together with their anticipated impact, is expected to result in a stronger market position in Germany from both a medical and recreational cannabis perspective, particularly given the phased legalization of recreational cannabis in Germany;</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">TruHC's experienced and high-reputable management team, will be important factor in achieving a foothold in Germany's cannabis industry;</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">There are synergies to be had by combining the Company's existing distribution network and infrastructure in Germany with TruHC's facility and management team;</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">The addition of TruHC is expected to reduce our reliance on upon the success of Phatebo GmbH - the Company's current medical cannabis license holder and wholly owned subsidiary;</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">The combined expertise and industry relationships of the Company and TruHC is expected to broaden the distribution and future growth of our combined business, which would lead to an expanded and more diverse network, as well as greater market opportunities to launch more businesses in Germany; and</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">The Company's executive management has analyzed potential acquisition transactions and acquisition targets, as well as reaching out and having discussions with potential targets to identify the opportunity that could create the most value for the Company&#8217;s shareholders.</span></li>
                </ul>
                <ul>
                    <li style="margin-top: 0px;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">At this Annual Meeting, the Company is requesting that its shareholders vote on the following proposals:</span></li>
                </ul>
                <ol style="margin-left: 30pt;">
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">To elect as directors Kevin Taylor, Clifford Starke, Edward Woo and Brendan Cahill for a term of office expiring at the 2025 Annual Meeting of Shareholders or until their respective successors are duly elected and qualified;</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">To re-appoint Davidson &amp; Company LLP, an independent registered public accounting firm, as auditors of the Company for the fiscal year ending December 31, 2024 and authorize the directors to fix their remuneration;</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">To approve an amendment to the Company's 2022 Incentive Compensation Plan (the &#8220;2022 Plan&#8221;) to increase the number of Common Shares issuable thereunder from 950,000 to 2,500,000 Common Shares;</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">To approve the grant of stock appreciation rights of the Company ("Stock Appreciation Rights") to the Company's Chief Executive Officer and Chief Financial Officer, as described in more detail in this Proxy Statement; and</span><br/>&#160;</li>
                    <li style="margin-top: 0px; text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">To approve the issuance of 635,363 Common Shares in accordance with Nasdaq Listing Rule 5635(a) to acquire the minority interest of TruHC Pharma GmbH.</span></li>
                </ol>
                <p style="margin-top: 0px; text-align: justify;"><span style="font-size: 11pt; line-height: normal; font-family: Aptos, sans-serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;">Please see the sections entitled &#8220;<i>Proposal No. 1 &#8211; Election of Directors</i>,&#8221; &#8220;<i>Proposal No. 2 - Re-appointment of Independent Registered Public Accounting</i>,&#8221; &#8220;<i>Proposal No. 3 - </i></span></span><i><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;">Approval of the 2022 Plan Amendment Proposal</span></span></i><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;">,&#8221; &#8220;<i>Proposal No. 4 - </i></span></span><i><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;">Approval of the Stock Appreciation Rights Proposal</span></span></i><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;">,&#8221; and &#8220;<i>Proposal No. 5 - </i></span></span><i><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;">Approval of the Share Issuance Proposal.</span></span></i><span style="font-size: 10pt;"><span style="font-family: Times New Roman, serif;">&#8221;</span></span></span></p>
                <p style="text-align: center; margin-top: 0px;"><b>PROXY STATEMENT </b></p>
                <p style="text-align: justify; background-color: #ffffff;">Y<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">ou are receiving this Proxy Statement because you owned Common Shares, of Flora Growth Corp., a corporation organized under the laws of the Province of Ontario, as of June 25, 2024 (the "Record Date"), which entitles you to vote those shares at the Annual Meeting. Our Board of Directors (the "Board") is soliciting proxies from shareholders who wish to vote their shares at the Annual Meeting. By using a proxy, you can vote even if you do not attend the Annual Meeting. This Proxy Statement describes and provides information about the matters on which you are being asked to vote so that you can make an informed decision. Flora Growth Corp. is referred to in this document as "Flora", "we", "us", "our" and the "Company"</span>.</p>
                <p style="text-align: justify;">Electronic copies of the Notice of Annual and Special Meeting (the "Notice"), this Proxy Statement, including the form of proxy and our Annual Report for the fiscal year ended December 31, 2023 (the "2023 Annual Report") may be found and downloaded from <span style="color: #0000ff;"><span style="text-decoration: underline;">https://www.cstproxy.com/floragrowth/2024</span></span>. Otherwise, the materials are accessible on <span style="color: #0000ff;"><span style="text-decoration: underline;">www.sec.gov</span></span><span style="color: #0000ff;"><span style="text-decoration: underline;">/edgar</span></span>. Shareholders should review the information contained in this Proxy Statement together with our 2023 Annual Report, which accompanies this Proxy Statement.&#160;</p>
                <p style="text-align: justify;">Our Internet website and the information contained therein or linked thereto are not incorporated by reference or otherwise made a part of this Proxy Statement.</p>
                <p style="text-align: center;"><b>INFORMATION ABOUT OUR ANNUAL AND SPECIAL MEETING</b></p>
                <p style="text-align: justify;"><i><b>When and where is the Annual Meeting?&#160; </b></i></p>
                <p style="text-align: justify;">The Annual Meeting will be held on August 14, 2024, at 11:00 a.m. Eastern Time. The Annual Meeting will be held at the offices of the Company's legal counsel, Miller Thomson LLP, 40 King Street West, Suite 5800, Toronto, ON M5H 3S1, Canada.</p>
                <p style="text-align: justify;"><i><b>Who may attend the Annual Meeting? </b></i></p>
                <p style="text-align: justify;">Shareholders of record as of Record Date, or their duly appointed proxies, and our invited guests are permitted to attend the Annual Meeting.</p>
                <p style="text-align: justify;"><b>AS DETAILED FURTHER BELOW, REGISTERED SHAREHOLDERS HAVE THE RIGHT TO APPOINT A PERSON TO REPRESENT HIM, &#8206;HER OR IT AT THE ANNUAL MEETING OTHER THAN THE PERSON(S) DESIGNATED IN THE PROXY &#8206;CARD</b> either by striking out the names of the persons designated in the proxy card and by &#8206;inserting the name of the person or company to be appointed in the space provided in the proxy card or by &#8206;completing another proper form of proxy and, in either case, delivering the completed proxy card to Continental by &#8206;mail using the enclosed return envelope to Continental Proxy Services, 1 State Street, 30<sup>th</sup> Floor, New York, NY 10004-1561. Alternatively, you may vote by Internet at <span style="color: #0000ff;"><span style="text-decoration: underline;">www.cstproxyvote.com</span></span>.</p>
                <div>
                    <p style="text-align: center;">1</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_7_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>What is the difference between holding shares as a shareholder of record and as a beneficial owner?&#8206;</b></i></p>
                <p style="text-align: justify;">Most of our shareholders hold their shares through an intermediary such as a bank, broker or other nominee rather than having the &#8206;shares registered directly in their own name. Summarized below are some distinctions between shares held of &#8206;record and those owned beneficially.&#8206;</p>
                <p style="text-align: justify;"><i>Shareholder of Record ("Registered Shareholder")</i></p>
                <p style="text-align: justify;">If your shares are registered directly in your name with our transfer agent, Continental Stock Transfer &amp; Trust Company ("Continental"), you are the shareholder of the Company of record of the shares. As the shareholder of record, you have the right to grant a proxy to vote your &#8206;shares to representatives from the Company or to another person, or to vote your shares at the &#8206;Annual Meeting. Shareholders of record will receive paper copies of the Notice containing instructions on how to access and review proxy materials as well as directions on how to vote by proxy.</p>
                <p style="text-align: justify;"><i>Beneficial Owner ("Non-registered Shareholder")</i></p>
                <p style="text-align: justify;">If your shares are held through a bank, broker or other nominee (an "Intermediary"), it is likely that they are registered in the name of &#8206;the nominee and you are the beneficial owner of shares held in street name.&#8206;</p>
                <p style="text-align: justify;">As the beneficial owner of shares held for your account, you have the right to direct the registered holder to vote &#8206;your shares as you instruct, and you also are invited to attend the Annual Meeting. Your Intermediary has provided a voting instruction card, or otherwise provided voting instructions, for you to use in directing how your shares are to be voted.&#8206;</p>
                <p style="text-align: justify;"><i><b>How can I attend and participate in the Annual Meeting?</b></i></p>
                <p style="text-align: justify;">To gain admittance, you must bring a form of personal identification to the Annual Meeting, where your name will be verified against our shareholder list. If a broker or other nominee holds your Common Shares and you plan to attend the Annual Meeting, you should bring a recent brokerage statement showing your ownership of the Common Shares as of the Record Date, a letter from the broker confirming such ownership, and a form of personal identification.</p>
                <p style="text-align: justify;">We will hold our question and answer session with management immediately following the conclusion of the business to be conducted at the Annual Meeting.</p>
                <p style="text-align: justify;">The Chairman of the Annual Meeting has broad authority to conduct the Annual Meeting in an orderly manner, including establishing rules of conduct.</p>
                <p style="text-align: justify;"><i><b>What is the purpose of the Annual Meeting?</b></i></p>
                <p style="text-align: justify;">The Annual Meeting will be held for the following purposes:</p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">1.<span style="width: 28pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider, and if deemed advisable, elect as directors the four nominees named in the Proxy Statement for a term of office expiring at the 2025 Annual Meeting of Shareholders or until their respective successors are duly elected and qualified.</p>
                <div>
                    <p style="text-align: center;">2</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span></span>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify; margin-top: 10pt;">2.<span style="width: 28pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider, and if deemed advisable, re-appoint Davidson &amp; Company LLP, an independent registered public accounting firm, as auditors of the Company for the fiscal year ending December 31, 2024 and authorize the directors to fix their remuneration.</p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">3.<span style="width: 28pt; text-indent: 0pt; display: inline-block;">&#160;</span>T<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">o consider and, if deemed advisable, approve, an amendment to the 2022 Plan to increase the number of Common Shares issuable thereunder from 950,000 to 2,500,000 Common Shares (the "2022 Plan Amendment Proposal").</span></p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">4.<span style="width: 28pt; text-indent: 0pt; display: inline-block;">&#160;</span>T<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">o consider and if deemed advisable, approve the grant of Stock Appreciation Rights to the Company's Chief Executive Officer and Chief Financial Officer, as described in more detail in this Proxy Statement (the "Stock Appreciation Rights Proposal")</span>.</p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">5.<span style="width: 28pt; text-indent: 0pt; display: inline-block;">&#160;</span>To consider and, if deemed advisable, approve the issuance of 635,363 Common Shares in accordance with Nasdaq Listing Rule 5635(a) to acquire the minority interest of TruHC Pharma GmbH ("Share Issuance Proposal").</p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">6.<span style="width: 28pt; text-indent: 0pt; display: inline-block;">&#160;</span>To vote on such other business, if any, as may properly come before the meeting and any adjournment or postponement thereof.</p>
                <p style="text-align: justify;"><i><b>Can I vote at the Annual Meeting?</b></i></p>
                <p style="text-align: justify;">You may vote your shares electronically at the Annual Meeting by using the control number on your Notice, proxy card, or voting instruction form and following the instruction at <span style="color: #0000ff;"><span style="text-decoration: underline;">www.cstproxyvote.com</span></span>. If you have already voted previously by Internet, there is no need to vote again at the Annual Meeting unless you wish to revoke and change your vote.</p>
                <p style="text-align: justify;"><b>A shareholder of the Company has the right to appoint a person or company (who need not be a shareholder) other than the persons whose names appear in such form of proxy, to attend and act for and on behalf of such shareholder at the Annual Meeting and any adjournment(s) or postponement(s) thereof.</b> Such right may be exercised either by striking out the names of the persons specified in the form of proxy and inserting the name of the person or company to be appointed in the blank space provided in the form of proxy, or by completing another proper form of proxy and, in either case, delivering the completed and executed proxy to Continental Proxy Services, no later than 9:00 a.m. (Eastern Time) on August 9, 2024 or, if the Annual Meeting is adjourned, at least 48 hours (excluding Saturdays, Sundays and statutory holidays in the Province of Ontario) before the beginning of any adjournment(s) to the Annual Meeting.</p>
                <p style="text-align: justify;">The proxyholder does not need to be a shareholder of the Company, but the proxyholder does need to understand that the Registered Shareholder's vote will not be counted unless the proxyholder attends the Annual Meeting and votes the Registered Shareholder's shares.</p>
                <p style="text-align: justify;">If you are a Non-registered Shareholder and wish to appoint someone else as your proxyholder, including yourself, to participate in the Annual Meeting, including asking questions and voting, please follow the instructions in the voting instruction form or contact your intermediary for instructions.</p>
                <div>
                    <p style="text-align: center;">3</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span></span>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Can I vote by telephone or Internet?</b></i></p>
                <p style="text-align: justify;">For beneficial shareholders with shares registered in the name of a brokerage firm or bank, a number of brokerage firms and banks are participating in a program that offers Internet voting options. Shareholders should refer to the voting instruction form provided by their brokerage firm or bank for instructions on the voting methods they offer. Registered shareholders with shares registered directly in their names with Continental will also be able to vote by Internet. If your shares are held in an account at a brokerage firm or bank participating in this program or registered directly in your name with Continental you may vote those shares by accessing the Internet website address specified on your proxy card instead of completing and signing the proxy itself. Submitting an Internet proxy will not affect your right to vote electronically at the Annual Meeting should you decide to attend the Annual Meeting. The Internet voting procedures are designed to authenticate shareholders' identities, to allow shareholders to give their voting instructions, and to confirm that shareholders' instructions have been recorded properly.&#160;</p>
                <p style="text-align: justify;">The accompanying proxy card provides instructions on how to vote via the Internet. There will not be an option to vote by telephone.</p>
                <p style="text-align: justify;"><i><b>Who may vote?</b></i></p>
                <p style="text-align: justify;">The Board set June 25, 2024 as the Record Date for the Annual Meeting. Holders of Common Shares at the close of business on the Record Date are entitled to vote their shares at the Annual Meeting, and any further postponements or adjournments of the Annual Meeting.</p>
                <p style="text-align: justify;">T<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">here were 13,366,535 Common Shares issued and outstanding as of June 21, 2024. See "<i>What are the voting rights of Flora shareholders</i>?"</span></p>
                <p style="text-align: justify;">Of the Common Shares issued and outstanding and entitled to vote, 2,135,199 Common Shares were issued in the Acquisition (as described in "<i>Proposal No. 5 - Approval of the Share Issuance Proposal</i>" below) and are not entitled to vote on Proposal No. 5 for purposes of the listing rules of the Nasdaq Stock Market. The Company anticipates that these 2,135,199 Common Shares will be voted in favor of Proposal No. 5 for purposes of adopting the proposal under Ontario law. However, to comply with Nasdaq listing rules, the Company will instruct the inspector of election for the Annual Meeting to conduct a separate tabulation that subtracts 2,135,199 shares from the total number of shares voted in favor of Proposal No. 5 to determine whether that proposal has been adopted in accordance with applicable Nasdaq listing rules.</p>
                <p style="text-align: justify;"><i><b>How can I access the proxy materials over the Internet?</b></i></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">We have elected to provide a <i>Notice of Internet Availability of Proxy Materials</i> pursuant to 17 CFR &#167; 240.14a-16 ("Rule 14a-16") under the United States Exchange Act of 1934, as amended (the "Exchange Act"). In doing so, we are deemed to be in compliance with Canadian National Instrument 51-102, Section 9.1.5 - <i>Compliance with SEC Notice-and-Access Rules </i>("NI 51-102"), because the Company (a) is subject to, and complies with, Rule 14a-16 under the Exchange Act; and (b) residents of Canada do not own, directly or indirectly, outstanding voting securities carrying more than 50% of the votes for the election of directors, and none of the following apply: (i) the majority of the executive officers or directors of the Company are residents of Canada; (ii) more than 50% of the consolidated assets of the Company are located in Canada; or (iii) the business of the Company is administered principally in Canada.</span></p>
                <div>
                    <p style="text-align: center;">4</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;">The notice-and-access provisions of Rule 14a-16 are a set of rules developed by the United States Securities and Exchange Commission (the "SEC") that reduce the volume of materials that must be physically mailed to shareholders by allowing the Company to post this Proxy Statement and any additional materials online. Beneficial owners will be sent the <i>Notice of Internet Availability of Proxy Materials</i> at least 40 calendar days prior to the Annual Meeting date, including instructions on how to access all materials identified in the<i> Notice of Internet Availability of Proxy Materials</i>, which will be publicly accessible and free of charge on the Company's website as specified in the <i>Notice of Internet Availability of Proxy Materials</i></span>.<span style="background-color: #ffffff;"> Shareholders may choose to additionally receive a paper or e-mail copy of (i) the proxy materials, including the <i>Notice of Internet Availability of Proxy Materials</i>, Proxy Statement, and Form of Electronic Proxy Card; and (ii) the Company's Annual Report, at no charge, with the <i>Notice of Internet Availability of Proxy Materials</i> specifying that shareholders should make their requests by no later than August 4, 2024 in order to facilitate timely delivery. Except where specific requests are made in accordance with the provided instructions, all such documents will be available online only and shareholders will not receive a paper or e-mail copy of the proxy materials, other than the <i>Notice of Internet Availability of Proxy Materials</i>.</span></p>
                <p style="text-align: justify;">The <i>Notice of Internet Availability of Proxy Materials</i> is being sent to both registered and Non-registered Shareholders of the securities using notice and access pursuant to applicable laws. Electronic copies of this Proxy Statement and the Notice may be found and downloaded from <span style="color: #0000ff;"><span style="text-decoration: underline;">https://www.cstproxy.com/floragrowth/2024</span></span>. If you are a NOBO, and the Company or its agent has sent the <i>Notice of Internet Availability of Proxy </i>directly to you, your name, address and information about your holdings of securities have been obtained in accordance with applicable securities regulatory requirements from the Intermediary holding on your behalf.</p>
                <p style="text-align: justify;">The Company (and not the Intermediary holding on your behalf) has assumed responsibility for (i) delivering the <i>Notice of Internet Availability of Proxy </i>to you, and (ii) executing your proper voting instructions. Please return your voting instructions as specified in the request for voting instructions.</p>
                <p style="text-align: justify;"><i><b>What are the voting rights of Flora shareholders?</b></i></p>
                <p style="text-align: justify;">Holders of our Common Shares are entitled to one (1) vote per Common Share on each matter that is submitted to shareholders for approval.</p>
                <p style="text-align: justify;"><i><b>How do I revoke my proxy and change my vote? </b></i></p>
                <p style="text-align: justify;">You may change your vote or revoke your proxy at any time before the vote at the Annual Meeting. You may change your vote prior to the Annual Meeting by executing a valid proxy card bearing a later date and delivering it to us prior to the Annual Meeting at Flora Growth Corp. Attention: Chief Financial Officer, 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309. Only your latest dated proxy we receive at or prior to the Annual Meeting will be counted. You may also revoke your proxy and change your vote at any time before the final vote at the Annual Meeting by voting again via the Internet. Attendance at the Annual Meeting will not by itself revoke a previously granted proxy. If you hold shares in street name and wish to change your vote, you must follow the directions provided by your brokerage or other financial intermediary.</p>
                <div>
                    <p style="text-align: center;">5</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_11_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>What are the voting recommendations of the Board?</b></i></p>
                <p style="text-align: justify;">The Board recommends that you vote:</p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">"<b>FOR</b>" the election of each of the director nominees named in this Proxy Statement;</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">"<b>FOR</b>" re-appointment of Davidson &amp; Company LLP as the Company's independent registered public accounting firm for the 2023 fiscal year;</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">"<b>FOR</b>" approval of the 2022 Plan Amendment Proposal;</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">"<b>FOR</b>" approval of the Stock Appreciation Rights Proposal;</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">"<b>FOR</b>" approval of the Share Issuance Proposal.</li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>What happens if I submit or return my proxy card without voting?</b></i></p>
                <p style="text-align: justify;">When you properly submit your proxy, the shares it represents will be voted at the Annual Meeting in accordance with your directions.&#160; Unless otherwise specified in the proxy, shares of our Common Shares represented by proxies will be voted:</p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">FOR the election of each of the director nominees named in this Proxy Statement;</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">FOR re-appointment of Davidson &amp; Company LLP as the Company's independent registered public accounting firm for the 2023 fiscal year;</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">FOR approval of the 2022 Plan Amendment Proposal;</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">FOR approval of the Stock Appreciation Rights Proposal;</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">FOR approval of the Share Issuance Proposal; and</li>
                    <li style="margin-left: 64.52pt; text-align: justify; padding-left: 7.48pt;">In accordance with the recommendation of our Board "FOR" or "AGAINST" all other business as may properly be brought before the Annual Meeting and at any adjournments or postponements of the Annual Meeting.</li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>What constitutes a quorum?</b></i></p>
                <p style="text-align: justify;">The bylaws of the Company (the "Bylaws") provide that at each meeting of shareholders, holders of not less than 35% of Common Shares entitled to vote at a meeting of shareholders, present in person or represented by proxy, shall constitute a quorum.</p>
                <p style="text-align: justify;"><i><b>How many votes are needed for the proposals to pass?</b></i></p>
                <p style="text-align: justify;"><i>Election of Directors</i></p>
                <p style="text-align: justify;">Under our Bylaws, if a quorum is present, the director nominees will be elected if a simple majority of the votes cast at the Annual Meeting are cast "FOR" each director nominee.</p>
                <div>
                    <p style="text-align: center;">6</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_12_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">Shareholders entitled to vote may vote in favor of all of the nominees or any individual nominee or withhold their votes as to all the nominees or any individual nominee.</p>
                <p style="text-align: justify;"><i>Re-Appointment of Davidson &amp; Company LLP as our Independent Registered Public Accounting Firm</i></p>
                <p style="text-align: justify;">If a quorum is present, approval of the re-appointment of our independent registered public accounting firm requires that a simple majority of the votes cast at the Annual Meeting are cast "FOR" re-appointment.</p>
                <p style="text-align: justify;"><i>Approval of the 2022 Plan Amendment Proposal</i></p>
                <p style="text-align: justify;">If a quorum is present, approval of the amendment to the 2022 Plan to increase the number of Common Shares issuable thereunder from 950,000 to 2,500,000 requires that a simple majority of the votes cast at the Annual Meeting with respect to the 2022 Plan Amendment Proposal are cast "FOR" approval.</p>
                <p style="text-align: justify;"><i>Approval of the Stock Appreciation Rights Proposal</i></p>
                <p style="text-align: justify;">If a quorum is present, approval of the Stock Appreciation Rights Proposal to grant the Chief Executive Officer and Chief Financial Officer Stock Appreciation Rights requires that a simple majority of the votes cast at the Annual Meeting with respect to the Stock Appreciation Rights Proposal are cast "FOR" approval.</p>
                <p style="text-align: justify;"><i>Approval of the Share Issuance Proposal</i></p>
                <p style="text-align: justify;">If a quorum is present, approval of the Share Issuance Proposal requires that a simple majority of the votes cast at the Annual Meeting are cast "FOR" approval (subject to the separate tabulation of votes described in "Who may vote" set forth above).</p>
                <p style="text-align: justify;"><i><b>What is the effect of abstentions?</b></i></p>
                <p style="text-align: justify;">Proxies received but marked "ABSTAIN" will be included in the calculation of the number of Common Shares considered to be present at the Annual Meeting for purposes of determining a quorum, but abstentions will not have an effect on the outcome of any proposal.</p>
                <p style="text-align: justify;"><i><b>What are "broker non-votes" and what effect do they have on the proposals?</b></i></p>
                <p style="text-align: justify;">Broker non-votes occur when an Intermediary holds shares in "street name" for a beneficial owner and that nominee does not vote the shares because it (i) has not received voting instructions from the beneficial owner and (ii) lacks discretionary voting power to vote those shares with respect to a particular proposal. Broker non-votes are counted for purposes of determining the existence of a quorum at the Annual Meeting, but they will have no effect on the outcome of any proposal on which we receive a broker non-vote.</p>
                <p style="text-align: justify; background-color: #ffffff;">A broker is entitled to vote shares held for a beneficial owner on "routine" matters without instructions from the beneficial owner of those shares, which include the proposal to re-appointment Davidson &amp; Company LLP as our independent public accounting firm for the 2024 fiscal year (Proposal No. 2). On the other hand, absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on "non-routine" matters, which includes Proposal 1 and Proposals 3, 4 and 5 described in this Proxy Statement.</p>
                <div>
                    <p style="text-align: center;">7</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_13_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">If you hold your shares in street name, it is critical that you provide your Intermediary with instructions on how to cast your vote if you want it to count in the election of directors (Proposal No. 1), the 2022 Plan Amendment Proposal (Proposal No. 3), the Stock Appreciation Rights Proposal (Proposal No. 4) and the Share Issuance Proposal (Proposal No. 5) described in this Proxy Statement. If you hold your shares in street name, and you do not instruct your Intermediary how to vote, then it will not be voted for the election of directors, the 2022 Plan Amendment Proposal and the Stock Appreciation Rights Proposal.</p>
                <p style="text-align: justify; background-color: #ffffff;">If any other routine matters are properly brought before the Annual Meeting in addition to Proposal 2, then brokers holding shares in street name may vote those shares in their discretion for any such routine matters.</p>
                <p style="text-align: justify;"><i><b>What is "householding" and how does it work? </b></i></p>
                <p style="text-align: justify;">The SEC rules permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more shareholders sharing the same address by delivering only one <span style="background-color: #ffffff;"><i>Notice of Internet Availability of Proxy Materials</i></span> addressed to those shareholders, if consented to by the shareholders. This delivery method, called "householding," reduces our delivery costs and provides extra convenience for shareholders. Shareholders who participate in householding and who request to receive printed proxy materials will continue to receive separate proxy cards.</p>
                <p style="text-align: justify;">Once a shareholder has received notification from its broker that it will be "householding" communications to such shareholder's address, "householding" will continue until such shareholder is notified otherwise or until such shareholder notifies its broker or us that it no longer wishes to participate in "householding." A shareholder may revoke such shareholder's consent by notifying its broker or delivering written notice of such revocation to the Company at Flora Growth Corp., Attention: Chief Financial Officer, 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309. Upon written or oral request of a shareholder at a shared address to which a single copy of this <span style="background-color: #ffffff;"><i>Notice of Internet Availability of Proxy Materials</i></span> was delivered, we will deliver promptly separate copies of these documents or do so in the future if requested.&#160;</p>
                <p style="text-align: justify;"><i><b>How to Submit Shareholder Proposals for Next Year's Annual Meeting</b></i></p>
                <p style="text-align: justify;">Pursuant to Rule 14a-8 under the Exchange Act, our shareholders may present proper proposals for inclusion in our proxy statement and form of proxy and for consideration at the next annual meeting by submitting their proposals to us in a timely manner. Any shareholder of the Company who wishes to present a proposal for inclusion in the proxy statement and form of proxy for action at the 2025 annual meeting of shareholders (the "2025 Annual Meeting") must comply with our Bylaws and the rules and regulations of the SEC, each as then in effect. Such proposals must be mailed to us at our offices at Flora Growth Corp., Attention: Chief Financial Officer, 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309. Under the rules of the SEC and the <i>Business Corporations Act</i> (Ontario) (the "OBCA"), any shareholder proposal intended to be presented at the 2025 Annual Meeting must be received no later than December 25, 2024, which is 120 days prior to the one-year anniversary of the expected mailing date of this Proxy Statement in order to be considered for inclusion in our proxy statement and form of proxy relating to such meeting. Pursuant to the OBCA and the rules of the SEC, a shareholder must follow certain procedures to nominate persons for election as directors or to introduce an item of business at an annual meeting of shareholders. In order to be timely, we must receive notice of your intention to introduce a nomination or propose an item of business at our 2025 Annual Meeting before the close of business on December 25, 2024. If we change the date of our 2025 Annual Meeting by more than thirty days before, or more than thirty days after, the one-year anniversary of the Annual Meeting, then the written notice of a shareholder proposal that is not intended to be included in our proxy statement must be delivered, or mailed and received, not later than the ninetieth day prior to our 2025 Annual Meeting or, if later, the tenth day following the day on which public announcement of the date of such meeting is first made. You are advised to review our Bylaws, the OBCA and the applicable securities laws, which contain additional requirements with respect to director nominees.&#160;</p>
                <div>
                    <p style="text-align: center;">8</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_14_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">If a shareholder notifies us of an intent to present a proposal at the 2025 Annual Meeting at any time after December 25, 2024 (and for any reason the proposal is voted on at that meeting), it may be considered untimely and our proxy holders will have the right to exercise discretionary voting authority with respect to the proposal, if presented at the meeting, without including information regarding the proposal in our proxy materials. Under the rules of the SEC, in the event we change the date of our 2025 Annual Meeting by more than thirty days after the one-year anniversary of the Annual Meeting, the deadline for a shareholder to submit a proposal for the 2025 Annual Meeting is a reasonable time before we begin to print and send our proxy materials.</p>
                <p style="text-align: justify;"><i><b>Who tabulates the votes?</b></i></p>
                <p style="text-align: justify;">Prior to the Annual Meeting, we will select an inspector of election for the meeting. Such inspector will determine the number of Common Shares represented at the meeting, the existence of a quorum and the validity and effect of proxies, and shall receive, count and tabulate ballots and votes and determine the results thereof.</p>
                <p style="text-align: justify;"><i><b>Who pays the cost of this proxy solicitation?</b></i></p>
                <p style="text-align: justify;">The Company is making this solicitation. We pay the cost of soliciting your proxy, and we reimburse brokerage firms and others for forwarding proxy materials to you. Our directors, officers and employees may participate in the solicitation of proxies without additional consideration. We may engage the services of a professional proxy solicitation firm to aid in the solicitation of proxies from certain brokers, bank nominees, and other institutional owners. Our costs for such services, if retained, will not be significant.</p>
                <p style="text-align: justify;"><i><b>Will a list of shareholders entitled to vote at the Annual Meeting be available?</b></i></p>
                <p style="text-align: justify;">In accordance with the Company's Bylaws, a list of shareholders entitled to vote at the Annual Meeting will be available at our executive office in Fort Lauderdale, Florida and will be accessible prior to the Annual Meeting between the hours of 9:00 a.m. and 5:00 p.m. The list of shareholders will also be available in person at the Annual Meeting.</p>
                <div>
                    <p style="text-align: center;">9</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_15_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Where can I find voting results of the Annual Meeting?</b></i></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">We will announce the results for the proposals voted upon at the Annual Meeting and publish final detailed voting results in a Form 8-K filed within four business days of the Annual Meeting.</span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i><b>What are the implications of the Company being an emerging growth company and a smaller reporting company?</b></i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act") and a "smaller reporting company," as defined in Rule 12b-2 under the Exchange Act. As an emerging growth company and a smaller reporting company, we provide in this Proxy Statement the scaled disclosure permitted under the JOBS Act and otherwise as applicable to smaller reporting companies. In addition, as an emerging growth company, we are not required to conduct votes seeking shareholder approval on an advisory basis of (1) the compensation of our "named executive officers" or the frequency with which such votes must be conducted or (2) compensation arrangements and understandings in connection with merger transactions, known as "golden parachute" arrangements.</span></p>
                <div>
                    <p style="text-align: center;">10</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_16_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>
                <p style="margin-bottom: 0pt; text-align: justify;">This Proxy Statement contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Exchange Act that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Flora to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. Words such as "expects," "anticipates," "intends," "will," "may," "could," "should," "goals," "potential," "plans," "believes," "estimates," "predicts," "projects," variations of these words, and similar expressions are intended to identify these forward-looking statements. Without limiting the generality of the forgoing, forward-looking statements contained in this document include our expectations regarding our future growth, operational and financial performance, business prospects and opportunities and the completion and impact on our business of the Acqusition of TruHC. These forward-looking statements reflect our current views with respect to future events, are based on assumptions, estimates and facts as of the date of this Proxy Statement and are subject to known and unknown risks and uncertainties and other factors, many of which are outside of its control and the control of its directors, officers and affiliates. As a result of a number of known and unknown risks and uncertainties, our results or performance may be materially different from those expressed or implied by these forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:</p>
                <ul style="padding-left: 0pt; margin-top: 0pt; list-style-type: disc;">
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">costs relating to the Acquisition of TruHC and to recognize the anticipated benefits of the Acquisition, which may be affected by, among other things, competition, retain key licenses, employees and manage growth;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">receipt of shareholders approvals required by the Second Closing of the Acquisition receiving effectiveness of the registration statement;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">our limited operating history and net losses;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">changes in cannabis laws, regulations and guidelines, including stop sale orders;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">decrease in demand for cannabis and derivative products due to certain research findings, proceedings, or negative media attention;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">our ability to continue as a going concern absent access to sources of liquidity;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">damage to our reputation as a result of negative publicity;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">exposure to product liability claims, actions and litigation;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">risks associated with product recalls;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">product viability;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">continuing research and development efforts to respond to technological and regulatory changes;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">shelf life of inventory;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">our ability to successfully integrate business that we acquire;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">maintenance of effective quality control systems;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">risks associated with expansion into new jurisdictions;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">regulatory compliance risks;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">opposition to the cannabinoid industry; and</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">potential delisting resulting in reduced liquidity of our Common Shares.</li>
                </ul>
                <div>
                    <p style="text-align: center; margin-top: 10pt;">11</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_17_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">As a result of many factors, such as those listed above and set forth under the section entitled "Risk Factors" elsewhere in this Proxy Statement and Annex <span style="background-color: transparent;">D</span> or otherwise described in our filings with the SEC, including our most recent Annual Report on Form 10-K and in our subsequent Quarterly Reports on Form 10-Q, you should not place undue reliance on these forward-looking statements. You should read this Proxy Statement and the documents that we reference and have filed as exhibits thoroughly and with the understanding that forward-looking statements represent our management's beliefs and assumptions only as of the date of this Proxy Statement and our actual results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly; even if new information becomes available in the future.</p>
                <div>
                    <p style="text-align: center;">12</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_18_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>DIRECTORS &amp; EXECUTIVE OFFICERS</b></p>
                <p style="text-align: justify;"><b>Directors, Director Nominees &amp; Executive Officers</b></p>
                <p style="text-align: justify;">The Articles provide our Board consists of a minimum of one and a maximum of ten directors. The number of directors to be elected at the Annual Meeting has been fixed at four (4) and there are presently four (4) directors of the Company, each of whose term of office expires at the Meeting. All director nominees are to be elected at the Annual Meeting, each to hold office until the 2025 annual meeting of shareholders or until his or her successor is duly elected and qualified. Each shareholder of record on June 25, 2024 is entitled to cast one vote for each of our Common Shares either in favor of or against the election of each nominee, or to abstain from voting on any or all nominees. Although management does not anticipate that any nominee will be unable or unwilling to serve as a director, in the event of such an occurrence, proxies may be voted in the discretion of the persons named in the proxy for a substitute designated by the Board, unless the Board decides to reduce the number of directors constituting the Board. The election of each director requires the affirmative vote of the simple majority of votes cast at the Annual Meeting. Shareholders will vote for the election of each individual director separately.</p>
                <p style="text-align: justify;">The names of our current directors, director nominees, and executive officers and their respective ages, positions, biographies and, in the case of director nominees, their qualifications to serve as directors, are set forth below.</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 18%; padding-right: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Name and Place of<br/>Residence</b></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Position</b></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Age</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 18%;"><b>Executive Officers:</b></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center;">&#160;</td>
                        <td style="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 8%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-bottom: 0pt; background-color: #e6efff; width: 18%;">Clifford Starke<br/><i>Panama</i></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: center;">Chief Executive Officer and Director</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 8%;">40</td>
                    </tr>
                    <tr>
                        <td style="margin-bottom: 0pt; background-color: #e6efff; width: 18%;">Dany Vaiman<br/><i>Ontario, Canada</i></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: center;">Chief Financial Officer</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 8%;">38</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 18%;"><b>Non-Employee Directors:</b></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center;">&#160;</td>
                        <td style="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 8%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-bottom: 0pt; background-color: #e6efff; width: 18%;">Edward Woo<br/><i>British Columbia, Canada</i></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: center;">Director<sup><b>(1)</b></sup></td>
                        <td style="margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                        <td style="margin-bottom: 0pt; background-color: #e6efff; width: 8%;">45<br/>&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-bottom: 0pt; width: 18%;">Kevin Taylor<br/><i>Florida, USA</i></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center;">&#160;</td>
                        <td style="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center;">Director<sup><b>(1)</b></sup></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 8%;">55</td>
                    </tr>
                    <tr>
                        <td style="margin-bottom: 0pt; background-color: #e6efff; width: 18%;">Brendan Cahill<br/><i>Ontario, Canada</i></td>
                        <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 70%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: center;">Director<sup><b>(1)</b></sup></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 8%;">45</td>
                    </tr>
                </table>
                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;">____________</p>
                <p style="margin-top: 0pt; text-align: justify;">(1) Each nominee for director has been reviewed and recommended for nomination by our Nominating and Corporate Governance Committee and has consented to serve as a director if elected.</p>
                <div>
                    <p style="text-align: center;">13</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_19_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><b>Non-Director Executive Officers </b></p>
                <p style="text-align: justify;"><i><b>Dany Vaiman</b>,</i> <i><b>Chief Financial Officer:</b></i> Mr. Vaiman has served as the Company's Chief Financial Officer since June 2023 and as the Company's Senior VP Finance from December 2022 to June 2023. From February 2022 through the closing of the Company's arrangement with Franchise Global Health Inc. ("Franchise") on December 23, 2022 (the "Arrangement"), he served as the Chief Financial Officer of Franchise. Prior to that, Mr. Vaiman served as Corporate Controller (from July 2018 to July 2021) and as Assistant Controller (from June 2016 to June 2018) of Torex Gold Resources Inc.- a leading intermediate gold producer listed on the TSX. For seven years, Mr. Vaiman was with Ernst &amp; Young's Toronto Audit Group, specializing in publicly listed TSX and SEC clients. Mr. Vaiman is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) in Ontario, a Certified Public Accountant (CPA) in Illinois, and holds a Bachelor of Business Administration (Honours) from the Schulich School of Business.</p>
                <p style="text-align: justify;"><b>Director Nominees</b></p>
                <p style="text-align: justify;"><i><b>Clifford Starke, Chief Executive Officer and Director</b></i>: Mr. Starke was appointed as the Company's Chief Executive Officer in June 2023. Previously, he served as President from December 2022 to June 2023. Prior to his appointment, from February 2022 through the closing of the Company's acquisition of the business, Mr. Starke served as the Executive Chairman and Chief Executive Officer of Franchise Global Health Inc. Since May 2018, Mr. Starke has served as the Chairman of Hampstead Private Capital Ltd., a Bermuda based merchant bank investing in small to mid-cap, high growth companies in various sectors and primarily focused in the medical cannabis industry. Mr. Starke has over 18 years of investing and public markets experience and, over the last seven years, has acted as a financier, investor and operator of cannabis companies. Mr. Starke holds a Bachelor of Arts degree in History from Queen's University.<span style="background-color: #ffffff;"> Mr. Starke's qualifications to serve on our Board include his M&amp;A, public market investment and capital raising experience and knowledge of the cannabis industry. </span></p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Kevin Taylor, Chairman of the Board:</b></i> Mr. Taylor joined our Board in June 2023.&#160; Mr. Taylor <span style="color: #242424;">is a distinguished executive with over 30 years of experience in various senior leadership positions.&#160; Since June 2014, he has served as the President and CEO of Terei International Limited, a company providing merchant banking services in the small to midcap markets. Since April 2022, Mr. Taylor has served as Chairman and CEO of House of Lithium, a Canadian private equity firm, and from April 2022 until March 2023, he served as CEO and Chairman of SOL Global Investments Corp., a Canadian private equity firm.&#160; Since March 2022, Mr. Taylor has served as the Chairman of NetraMark Holdings Inc., a Canadian publicly traded AI health technology company trading under the symbol "AIAI."&#160; Previously, Mr. Taylor served as Vice President and General Manager for Nortel Networks Carrier business in the Caribbean and Latin America, where he played a critical role in the expansion of the company's telecommunications infrastructure and service offerings throughout the region.&#160; Mr. Taylor completed the Harvard Business School TGMP program, a program designed for experienced executives seeking to enhance their leadership skills. Additionally, he holds a Bachelor of Engineering - Science from the University of Western Ontario.&#160; Mr. Taylor's qualifications to serve on our board include his extensive investment and private equity experience and prior board memberships.</span></p>
                <div>
                    <p style="text-align: center;">14</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span id="page_20_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: justify; margin-top: 0px;"><i><b>Edward Woo,</b> </i><i><b>Director</b></i>: Mr. Woo joined our Board in December 2022. From August 2021 through the closing of the Arrangement, he served as the President and Chief Operating Officer of Franchise. Mr. Woo is a seasoned business executive with extensive experience in the consumer-packaged goods industry. Over the past 20 years, Mr. Woo focused his efforts on the tobacco industry in the areas of sales, trade marketing, business strategy, political mobilization and government affairs. As a former executive at Rothmans Benson &amp; Hedges Inc. and Philip Morris International, Mr. Woo held several leadership roles which included serving as Head of Regulatory &amp; External Affairs at the Global Headquarters in Lausanne, Switzerland (2016 through 2021) and as Regional Communications Director Latin America and Canada (from 2013 through 2016). Mr. Woo has extensive global experience and strong ties to the European markets and worked closely with over 30 markets in Europe, Middle East, Asia and Latin America on the rollout of Philip Morris' revolutionary IQOS product, with a particular focus on execution, supply chain, regulation and stakeholder engagement. Mr. Woo holds a BA in Economics from the University of Western Ontario. Mr. Woo's qualifications to serve on our Board include his extensive experience in the consumer-packaged goods industry, his regulatory knowledge and experience and his ties to the European markets.&#160;</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Brendan Cahill, Director: </b></i>Mr. Cahill joined our Board in May 2024. Brendan Cahill is a corporate executive and director with extensive capital markets experience.&#160; He was President &amp; CEO of Excellon Resources Inc. from 2012 to 2022, a silver, lead zinc producer in Mexico.&#160; Prior to Excellon, Brendan was VP Corporate Development &amp; Corporate Secretary of Pelangio Mines and Pelangio Exploration from 2008 to 2012, and an associate at Davies Ward Phillips &amp; Vineberg LLP, Canada's preeminent mergers &amp; acquisitions firm from 2005 to 2007. Brendan remains a board member of Excellon and is a board member of Group Eleven Resources, an Irish zinc explorer. He is also a cabinet member of the University Health Network's Transplant Cabinet and Psychedelic Cabinet and a member of the Law Society of Upper Canada.</p>
                <p style="text-align: justify;"><b>Family Relationships</b></p>
                <p style="text-align: justify;">There are no family relationships between any of our officers, directors or director nominees.</p>
                <p style="text-align: justify;"><b>Involvement in Certain Legal Proceedings</b></p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">Corporate Cease Trade Orders </span></p>
                <p style="text-align: justify;">To the knowledge of the Company, no proposed director of the Company is, as at the date of the Proxy Statement, or has been, within 10 years before the date of this Proxy Statement, a director, chief executive officer or chief financial officer of any company (including the Company) that,</p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">(a)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>was subject to an order that was issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer; or</p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>was subject to an order that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer.</p>
                <div>
                    <p style="text-align: center;">15</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_21_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="text-decoration: underline;">Bankruptcy and Insolvency </span></p>
                <p style="text-align: justify;">To the knowledge of the Company, except as noted below, no proposed director of the Company:</p>
                <p style="margin-left: 36pt; text-indent: -31.5pt; text-align: justify;">(a)<span style="width: 21pt; text-indent: 0pt; display: inline-block;">&#160;</span>is, as at the date of this Proxy Statement, or has been within 10 years before the date of this Proxy Statement, a director or executive officer of any company (including the Company) that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or</p>
                <p style="margin-left: 36pt; text-indent: -31.5pt; text-align: justify;">(b)<span style="width: 20.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>has, within the 10 years before the date of this Proxy Statement, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director.</p>
                <p style="text-align: justify;">Mr. Brendan Cahill, a director of the Company, was the sole director of Excellon Resources Inc.'s indirect, wholly-owned Mexican subsidiary San Pedro Resources S.A. de C.V. that, on November 30, 2022, filed a petition for bankruptcy with the Mexican Bankruptcy Court which, on December 15, 2022, accepted such petition for adjudication and, on March 28, 2023, declared San Pedro bankrupt.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">Penalties and Sanctions </span></p>
                <p style="text-align: justify;">To the knowledge of the Company, no proposed director of the Company has been subject to:</p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">(a)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or</p>
                <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable securityholder in deciding whether to vote for a proposed director.</p>
                <div>
                    <p style="text-align: center;">16</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_22_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>CORPORATE GOVERNANCE</b></p>
                <p style="text-align: justify;"><b>Overall Role of the Board</b></p>
                <p style="text-align: justify;">Our Common Shares are <span style="background-color: #ffffff;">listed on the Nasdaq Capital Market under the symbol "FLGC." </span>Pursuant to our Bylaws and applicable Canadian law, our business and affairs are managed under the direction of our Board. Directors are kept informed of the Company's business through discussions with management, by reviewing materials provided to them and by participating in meetings of the Board and its committees.</p>
                <p style="text-align: justify;"><b>Board Leadership Structure</b></p>
                <p style="text-align: justify;">The Company is led by Mr. Starke, who has served as Chief Executive Officer since June 2023. Mr. Taylor has served as the Company's Chairman since June 2023.</p>
                <p style="text-align: justify;">Although the Board does not have a formal policy on whether the roles of Chief Executive Officer and Chairman of the Board should be separated, we believe that our current Board leadership structure is suitable for us. The Chief Executive Officer is the individual selected by the Board to manage our Company on a day to day basis, and his direct involvement in our business operations makes him best positioned to lead productive Board strategic planning sessions and determine the time allocated to each agenda item in discussions of our Company's short- and long-term objectives. The Company has not developed a written position description for the Chairman of the Board, the Chief Executive Officer or the chair of any board committee. The Company has not adopted a specific maximum term limit for its Directors as it feels the shareholders of the Company should have the power to elect directors who they feel are appropriate regardless of how long such directors have served on the Board.</p>
                <p style="text-align: justify;"><i><b>Risk Oversight. </b> </i>One of the key functions of our Board is informed oversight of our risk management process. Our Board administers this oversight function directly through our Board as a whole, as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, and our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures. The Audit Committee also has the responsibility to review with management the process by which risk assessment and management is undertaken, monitor compliance with legal and regulatory requirements, and review the adequacy and effectiveness of our internal controls over financial reporting. Our Nominating and Corporate Governance Committee is responsible for periodically evaluating our company's corporate governance policies and systems.</p>
                <p style="text-align: justify;"><i><b>Diversity and Inclusion</b></i>. Although we do not have a formal diversity policy, the Nominating and Corporate Governance Committee, in accordance with its policies and procedures for director candidates, seeks to identify candidates who will enhance the Board's overall diversity. Currently, Mr. Woo qualifies as a diverse board member, representing 25% of the total number of directors of the Company.</p>
                <div>
                    <p style="text-align: center;">17</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_23_integixAnchor"></span>
                <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="width: 100%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;" colspan="5"><b>Board Diversity Matrix</b> (as of June 21, 2024)</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify; white-space: nowrap;">Total Number of Directors</td>
                        <td style="width: 54%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center; white-space: nowrap;" colspan="4">4</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify; white-space: nowrap;">&#160;</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Female</b></td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Male</b></td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Non-<br/>Binary</b></td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center; white-space: nowrap;"><b>Did not<br/>Disclose<br/>Gender</b></td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><b>Part I: Gender Identity</b></td>
                        <td style="width: 54%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;" colspan="4">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">Directors</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">4</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><b>Part II: Demographic Background</b></td>
                        <td style="width: 54%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;" colspan="4">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">African American or Black</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">Alaskan Native or Native American</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">Asian</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">1</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">Hispanic or Latin</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">Native Hawaiian or Pacific Islander</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">White</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">3</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">Two or More Races of Ethnicities</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 11%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 13%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">Nil</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">LGBTQ+</td>
                        <td style="width: 54%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;" colspan="4">Nil</td>
                    </tr>
                    <tr>
                        <td style="width: 43%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Did Not Disclose Demographic Background</td>
                        <td style="width: 54%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;" colspan="4">Nil</td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Policies Regarding the Representation of Women. </b></i>The Nominating and Corporate Governance Committee currently does not consider the level of representation of women on the Board or in executive officer positions in identifying and nominating candidates for election or re-election to the Board or as executive officers of the Company. However, informally, in identifying and selecting director or executive officer nominees, the Company values diversity, including, without limitation, diversity of experience, perspective, education, race, gender and national origin, as one among the many factors taken into consideration during the search process. The Company also considers, among other things, the qualifications, personal qualities, business background and relevant experience of individual candidates as well as the overall composition of the Board or executive officers with a view to identifying and selecting the most ideal and complementary candidates. The Nominating and Corporate Governance Committee and the Board intend to consider on an ongoing basis whether the Company should adopt specific policies and practices regarding the representation of women on the Board and in executive officer positions, including the setting of targets for such representation.</p>
                <p style="text-align: justify;">Currently the Company does not have women directors of executive officers.&#160;</p>
                <div>
                    <p style="text-align: center;">18</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_24_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Director Independence</b></i>. Our Board undertook a review of the independence of each director. Based on information provided by each director concerning his or her background, employment, and affiliations, our Board has determined that the Board meets independence standards under the applicable rules and regulations of the SEC, the listing standards of Nasdaq and National Instrument 52-110 - <i>Audit Committees </i>("NI 52-110"). The Board has affirmatively determined that the following Directors and Director Nominees are "independent" as defined in the listing standards of Nasdaq and under National Instrument 58-101 - <i>Disclosure of Corporate Governance Practices </i>("NI 58-101"): Kevin Taylor, Edward Woo, and Brendan Cahill. The Board has also determined that Clifford Starke is not "independent" as defined in the listing standards of Nasdaq and under NI 52-110. In making these determinations, our Board considered the current and prior relationships that each director has with our Company and all other facts and circumstances our Board deemed relevant in determining their independence, including the beneficial ownership of our Common Shares by each director, and the transactions involving them described in the section titled "Certain Relationships and Related Party Transactions." <span style="background-color: #ffffff;">While our Board has appointed Mr. Taylor as lead Director and Chairman of the Board, the breadth and depth of experience of the independent Directors as a whole provides the Board with important leadership qualities. All Directors, including independent Directors, are invited to openly provide their thoughts and opinions. The Board does not take any specific steps to provide leadership for its independent Directors.</span></p>
                <p style="text-align: justify;"><i><b>Code of Ethics. </b></i>Our Board has adopted a Code of Conduct and Ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer and other executive and senior financial officers. The full text of our Code of Conduct and Ethics is available on our website. We intend to disclose future amendments to certain provisions of our Code of Conduct and Ethics, or waivers of certain provisions as they relate to our directors and executive officers, at the same location on our website or in our public filings. The information on our website is not intended to form a part of or be incorporated by reference into this Proxy Statement. <span style="background-color: #ffffff;">The Board monitors&#160; compliance&#160; with&#160; the&#160; </span>Code of Conduct and Ethics <span style="background-color: #ffffff;">by requiring all action prohibited by the </span>Code of Conduct and Ethics <span style="background-color: #ffffff;">to be reported to&#160; the&#160; Audit&#160; Committee,&#160; if&#160; involving&#160; a&#160; director&#160; or&#160; officer, and to the Chief Compliance Officer, if involving anyone else.</span></p>
                <p style="text-align: justify;"><i><b>Orientation and Continuing Education. </b></i>The Nominating and Corporate Governance Committee is responsible for the onboarding of new directors and the continuing education of existing directors. Pursuant to its charter, the Nominating and Corporate Governance Committee develops and annually reviews orientation and education programs for new directors and provides ongoing education for all directors. Upon joining the Board, each director is provided with an orientation package regarding the role of the Board, its committees and its directors, and the nature and operation of the Company's current and past business. They are also provided with a copy of the Code of Conduct and Ethics, the Audit Committee Charter and the Nominating and Corporate Governance Charter The Board encourages directors to participate in continuing education opportunities in order to ensure that the directors maintain or enhance their skills and abilities as directors, and maintain a current and thorough understanding of the Company's business.</p>
                <div>
                    <p style="text-align: center;">19</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_25_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Board Meetings</b>. </i>The Board meets regularly during the year and holds special meetings and acts by unanimous written consent whenever circumstances require. Independent directors meet at regularly scheduled executive sessions without management present. All of our directors are encouraged to attend our Annual Meeting.</p>
                <p style="text-align: justify;">The following table sets forth the number of Board and committee meetings held and attendance by Directors for the fiscal year 2023. As provided below, each director attended at least 75 percent of the aggregate of the total number of Board meetings and the total number of meetings held by all committees of the Board on which he or she served during 2023.</p>
                <p style="margin-left: 5.4pt; text-align: center;"><b>Attendance of Directors</b><br/><i>(in person or by telephone)</i></p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 20%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><i>Director</i></td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><i>Board<br/>Meetings<br/>Attended</i></td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><i>Audit Committee<br/>Meetings Attended</i></td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><i>Compensation Committee<br/>Meetings Attended</i></td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><i>Nominating and Corporate<br/>Governance Committee<br/>Meetings Attended</i></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Kevin Taylor(1)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">3 of 3</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">2 of 2</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Clifford Starke</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">9 of 9</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Edward Woo</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">9 of 9</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">1 of 1</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">3 of 3</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Thomas Solomon(2)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">3 of 3</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">2 of 2</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Luis Merchan(3)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">1 of 1</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">John Timothy Leslie(4)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">6 of 6</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">1 of 1</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">3 of 3</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Dr. Beverley Richardson(5)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">6 of 6</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">2 of 2</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Juan Carlos Gomez Roa(6)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">8 of 8</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">2 of 2</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Dr. Annabelle Manalo-Morgan(7)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">6 of 6</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Marc Mastronardi(8)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">6 of 6</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">2 of 2</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">3 of 3</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Brandon Konigsberg (9)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">6 of 6</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">1 of 1</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">2 of 2</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 20%; background-color: #e6efff;">Hussein Rakine(10)</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">3 of 3</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                        <td style="width: 1%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">&#160;</td>
                        <td style="width: 19%; padding-right: 5.75pt; padding-left: 5.75pt; background-color: #e6efff; text-align: center;">N/A</td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">20</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_26_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 10pt;">(1)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Mr. Taylor was appointed as a Director, effective June 6, 2023.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(2)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Mr. Solomon was appointed as a Director, effective June 6, 2023.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(3)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Mr. Merchan resigned as a Director, effective April 12, 2023.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(4)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Mr. Leslie resigned as a Director, effective June 25, 2023.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(5)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Ms. Richardson resigned as a Director, effective August 9, 2023.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(6)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Mr. Roa resigned as a Director, effective October 12, 2023.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(7)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Ms. Manalo-Morgan did not stand for re-election at the Company's 2023 Annual General Meeting.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(8)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Mr. Mastronardi did not stand for re-election at the Company's 2023 Annual General Meeting.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(9)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Mr. Konigsberg did not stand for re-election at the Company's 2023 Annual General Meeting.</p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 0pt;">(10)<span style="width: 1.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Mr. Rakine resigned as a Director, effective September 26, 2023.</p>
                <p style="text-align: justify;"><i><b>Board Committees.</b> </i></p>
                <p style="text-align: justify;">Our Board has three standing committees: an Audit Committee; a Compensation Committee; and a Nominating and Corporate Governance Committee. Each of the committees reports to the Board as it deems appropriate and as the Board may request. The composition, duties and responsibilities of these committees are set forth below. In the future, our Board may establish other committees, as it deems appropriate, to assist it with its responsibilities.</p>
                <p style="text-align: justify;">The table below provides current committee membership information:</p>
                <table style="width: 59.96%; margin-right: auto; margin-left: auto; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-bottom: 0pt; white-space: nowrap; vertical-align: middle;"><b>&#160;</b><b>Name</b></td>
                        <td style="width: 19.92%; vertical-align: middle; text-align: center; white-space: nowrap;"><b>Audit<br/>Committee</b></td>
                        <td style="width: 19.94%; vertical-align: middle; text-align: center; white-space: nowrap;"><b>Compensation<br/>Committee</b></td>
                        <td style="width: 25.78%; vertical-align: middle; text-align: center; white-space: nowrap;"><b>Nominating and<br/>Corporate<br/>Governance<br/>Committee</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">Kevin Taylor</td>
                        <td style="width: 19.92%; vertical-align: middle; text-align: center;">Chair</td>
                        <td style="width: 19.94%; vertical-align: middle; text-align: center;">X</td>
                        <td style="width: 25.78%; vertical-align: top; text-align: center;">Chair</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">Edward Woo</td>
                        <td style="width: 19.92%; vertical-align: middle; text-align: center;">X</td>
                        <td style="width: 19.94%; vertical-align: middle; text-align: center;">Chair</td>
                        <td style="width: 25.78%; vertical-align: top; text-align: center;">X</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">Brendan Cahill</td>
                        <td style="width: 19.92%; vertical-align: middle; text-align: center;">X</td>
                        <td style="width: 19.94%; vertical-align: middle; text-align: center;">X</td>
                        <td style="width: 25.78%; vertical-align: top; text-align: center;">X</td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Committee Meetings</b></i>. During 2023, our Audit Committee held three meetings; our Compensation Committee held two meetings; and our Nominating and Corporate Governance Committee held three meeting.</p>
                <p style="text-align: justify;"><i><b>Audit Committee</b></i>.&#160; We have a standing audit committee established in accordance with Section 3(a)(58)(A) of the Exchange Act. Our Audit Committee is responsible for, among other things:</p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">appointing, compensating, retaining, evaluating, terminating and overseeing our independent registered public accounting firm;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">discussing with our independent registered public accounting firm their independence from management;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">reviewing, with our independent registered public accounting firm, the scope and results of their audit;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">approving all audit and permissible non-audit services to be performed by our independent registered public accounting firm;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">overseeing the financial reporting process and discussing with management and our independent registered public accounting firm any financial statements that we file with the SEC;</li>
                </ul>
                <div>
                    <p style="text-align: center; margin-top: 10pt;">21</p>
                </div>
                <hr style="break-after: page; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_27_integixAnchor"></span>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">overseeing our financial and accounting controls and compliance with legal and regulatory requirements;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">reviewing our policies on risk assessment and risk management;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">reviewing related person transactions; and</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal controls or auditing matters.</li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;">The Audit Committee is composed of Messrs. Kevin Taylor, Edward Woo and Mr. Cahill with Mr. Taylor serving as chair. Assuming all the directors included in Proposal 1 are elected, the Audit Committee is expected to be composed of Messrs. Kevin Taylor, Edward Woo and Mr. Cahill with Mr. Taylor serving as chair. Mr. Taylor, Mr. Woo and Mr. Cahill each qualify as an "audit committee financial expert" as such term has been defined in Item 407(d)(5) of Regulation S-K. All Audit Committee members, as well new expected members, are "financially literate" as defined in NI 52-110. Our Board has affirmatively determined that Messrs. Taylor, Woo and Mr. Cahill each meet the definition of "independent director" for purposes of serving on the Audit Committee under the Nasdaq rules, the independence standards under Rule 10A-3 of the Exchange Act and under NI 52-110. Both our independent registered public accounting firm and management personnel periodically meet privately with our Audit Committee.</p>
                <p style="text-align: justify;">Our Board has adopted a written charter for the Audit Committee.</p>
                <p style="text-align: justify;">The Report of the Audit Committee, which is set forth in this Proxy Statement, further describes the Audit Committee's responsibilities and its recommendation with respect to our audited consolidated financial statements for the year ended December 31, 2023.</p>
                <p style="text-align: justify;"><i><b>Compensation Committee</b></i>. Our Compensation Committee is responsible for, among other things:</p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">reviewing and approving the corporate goals and objectives, evaluating the performance and reviewing and approving the compensation of our executive officers;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">reviewing and approving or making recommendations to our Board regarding our incentive compensation and equity-based plans, policies and programs;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">reviewing and approving all employment agreement and severance arrangements for our executive officers;</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">making recommendations to our Board regarding the compensation of our directors; and</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">retaining and overseeing any compensation consultants.</li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;">The Compensation Committee is composed of Kevin Taylor, Edward Woo and Mr. Cahill, with Mr. Woo serving as chair. Assuming all the directors included in Proposal 1 are elected, the Compensation Committee is expected to be composed Kevin Taylor, Edward Woo and Mr. Cahill, with Mr. Woo serving as chair.&#160; Our Board has affirmatively determined that Messrs. Taylor, Woo and Mr. Cahill each meet the definition of "independent director" for purposes of serving on the Compensation Committee under the Nasdaq rules, the independence standards under Rule 10A-3 of the Exchange Act and under NI 58-101. Each member of our Compensation Committee is a non-employee director (within the meaning of Rule 16b-3 under the Exchange Act).&#160;</p>
                <p style="text-align: justify;">The Compensation Committee may establish and delegate authority to one or more subcommittees consisting of one or more of its members, when the Compensation Committee deems it appropriate to do so in order to carry out its responsibilities. In carrying out its responsibilities, the Compensation Committee shall be entitled to rely upon the advice and information that it receives in its discussions and communications with management and such experts, advisors and professionals with whom the Compensation Committee may consult.</p>
                <div>
                    <p style="text-align: center;">22</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_28_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">The Board is of the view that the members of the Compensation Committee collectively have the knowledge, skills, experience and background to make decisions on the suitability of the Company's compensation policies and practices. A description of such skills and experience for the committee members is set out in this Proxy Statement under the heading "<i>Directors, Director Nominees &amp; Executive Officers.</i>"</p>
                <p style="text-align: justify;">Our Board has adopted a written charter for the Compensation Committee. The Compensation did not receive any recommendations from any compensation consultants during the 2023 fiscal year.</p>
                <p style="text-align: justify;"><i><b>Nominating and Corporate Governance Committee.</b> </i>Our Nominating and Corporate Governance Committee is responsible for, among other things:</p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 28.52pt; padding-left: 7.48pt; text-align: justify;">identifying individuals qualified to become members of our Board, consistent with criteria approved by our Board;</li>
                    <li style="margin-left: 28.52pt; padding-left: 7.48pt; text-align: justify;">overseeing succession planning for our executive officers;</li>
                    <li style="margin-left: 28.52pt; padding-left: 7.48pt; text-align: justify;">periodically reviewing our Board' leadership structure and recommending any proposed changes to our Board;</li>
                    <li style="margin-left: 28.52pt; padding-left: 7.48pt; text-align: justify;">overseeing an annual evaluation of the effectiveness of our Board and its committees, including distributing annual written self and Board-assessments; and</li>
                    <li style="margin-left: 28.52pt; padding-left: 7.48pt; text-align: justify;">developing and recommending to our Board a set of corporate governance guidelines.</li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;">The Nominating and Corporate Governance Committee is composed of Mr. Taylor, Mr. Woo and Mr. Cahill, with Mr. Kevin serving as chair. Assuming all the directors included in Proposal 1 are elected, the Nominating and Corporate Governance Committee is expected to be composed Mr. Taylor, Mr. Woo and Mr. Cahill, with Mr. Taylor serving as chair.&#160; Our Board has affirmatively determined that Messrs. Woo, Taylor and Mr. Cahill each meet the definition of "independent director" for purposes of serving on the Nominating and Corporate Governance Committee under the Nasdaq rules, the independence standards under Rule 10A-3 of the Exchange Act and under NI 58-101.</p>
                <p style="text-align: justify;">Our Board has adopted a written charter for the Nominating and Corporate Governance Committee.</p>
                <div>
                    <p style="text-align: center;">23</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_29_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Director Nominations. </b></i>The Nominating and Corporate Governance Committee may solicit recommendations for the Board from any or all of the following sources: non-management directors, the Chief Executive Officer, other executive officers, third-party search firms, or any other source it deems appropriate, including shareholders. The Committee will evaluate all such proposed director candidates in the same manner, with no regard to the source of the initial recommendation of such proposed director candidate. In identifying and evaluating proposed director candidates, the Nominating and Corporate Governance Committee considers, in addition to the minimum qualifications and other criteria for Board membership, all facts and circumstances that it deems appropriate or advisable, including, among other things:</p>
                <p style="margin-left: 90pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">1.<span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span>The skills of the proposed director candidate.</p>
                <p style="margin-top: 0pt; margin-left: 90pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">2.<span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span>His or her depth and breadth of business experience.</p>
                <p style="margin-top: 0pt; margin-left: 90pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">3.<span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span>Whether the nominee would help achieve a mix that represents a diversity of background and experience, inclusive of gender, race, ethnicity, age, gender identity, gender expression, persons with disabilities and sexual orientation or other background characteristics.</p>
                <p style="margin-top: 0pt; margin-left: 90pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">4.<span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span>His or her independence.</p>
                <p style="margin-top: 0pt; margin-left: 90pt; text-indent: -18pt; text-align: justify;">5.<span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span>The needs of the Board.</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">The Nominating and Corporate Governance Committee will consider candidates recommended by the Company's shareholders who are eligible to serve as directors in accordance with the Company's Bylaws and the OBCA.</span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">Although we have not adopted a formal policy regarding the consideration of Board candidates recommended by our shareholders, the Board believes that the procedures set forth in our Bylaws are currently sufficient and that the establishment of a formal policy is not necessary. </span>Without limiting the requirements contained in our Bylaws, the recommendation must set forth (i) as to each person whom the shareholder proposes to nominate for election as a director (A) the name, age, business address and residence address of the person, (B) the principal occupation or employment of the person, (C) the class and number of Common Shares that are owned beneficially or of record by the person,&#160; (D) a description of all arrangements or understandings between the shareholder and each nominee and any other person or persons (naming such person or persons) and (E) any other information relating to the person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder; and (ii) as to the shareholder giving the notice (A) the name and record address of such shareholder as they appear on the Company's books, (B) the class and number of Common Shares that are owned beneficially and of record by such shareholder and the beneficial owner, if any, on whose behalf the nomination is made and (C) any material interest of the shareholder in such nomination. Such notice must be accompanied by a written consent of each proposed nominee to being named as a nominee and to serve as a director if elected.<b>&#160; </b></p>
                <p style="text-align: justify;">While we do not have a formal diversity policy with respect to Board composition, the Board believes it is important for the Board to have diversity of knowledge base, professional experience and skills, and the Corporate Governance and Nominating Committee takes these qualities into account when considering director nominees for recommendation to the Board.&#160; We believe diversity of perspectives and experience enhances our effectiveness. Given our commitment to diversity and related considerations in our appointment, hiring, and promotion practices, we have not adopted a formal diversity policy or specific diversity targets for determining Board membership or executive appointments. However, the Board remains committed to monitoring best practices and corporate governance developments in this area.</p>
                <p style="text-align: justify;"><i><b>Director Election - Majority Vote</b></i>. The election of each director requires the affirmative vote of the simple majority of votes cast at the Annual Meeting. Shareholders will vote for the election of each individual director separately. "Abstain" votes and broker-non votes will have no effect on the election of the director nominees.</p>
                <div>
                    <p style="text-align: center;">24</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_30_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Communications with the Company and the Board</b>.</i><b> </b>All interested parties, including shareholders, may communicate with the Company or our Board by letter addressed to Flora Growth Corp. Attention: Chief Financial Officer, 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309.</p>
                <p style="text-align: justify;"><b>Certain Relationships and Related Party Transactions</b></p>
                <p style="text-align: justify;">Except as set forth below, since January 1, 2022, there has not been nor are there currently proposed any transactions or series of similar transactions to which we were or are to be a party in which the amount involved exceeds the lesser of $120,000 or one percent (1%) of the average of our total assets at year-end for the last two completed fiscal years and in which any director, executive officer, holder of more than 5% of the Common Shares or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest.</p>
                <p style="text-align: justify;"><i><b>Transactions with Related Parties</b></i></p>
                <p style="text-align: justify;">In connection with the Arrangement, on October 21, 2022, the Company entered into a voting support agreement (the "Voting Support Agreement") with Clifford Starke pursuant to which the Company agreed to increase the size of the Board and appoint two nominees specified in writing by Mr. Starke who are qualified pursuant to the OBCA and who consented in writing to act as directors of the Company (the "Starke Nominees"), subject to the terms and conditions of the Voting Support Agreement. Upon appointment, the Company agreed that the Starke Nominees would comprise not less than 2/9<sup>ths </sup>of the total size of the Board, and the Company agreed to nominate the Starke Nominees for election as directors of the Flora Board at the Annual Meeting (and that such Starke Nominees were to comprise not less than 2/7<sup> ths </sup>of the total number of directors nominated by management of the Company for election to the Board at the Annual Meeting) and the Company is to use commercially reasonable efforts (subject to fiduciary obligations) to ensure that the Starke Nominees are elected as directors.&#160; On December 23, 2022, Mr. Starke was appointed as President and a director of the Company, along with Edward Woo as the second Starke Nominee. Both Mr. Starke and Mr. Woo are standing for re-election at the Annual Meeting.</p>
                <p style="text-align: justify;">On March 14, 2019, the Company entered into an agreement with 2227929 Ontario Corp., an entity controlled by Mr. Bharti, pursuant to which the Company utilized office space and shared services in exchange for consideration of CAD$15,000 per month. The term of this agreement expired by its terms on March 14, 2022.</p>
                <p style="text-align: justify;"><i><b>Indemnification Agreements and Directors' and Officers' Liability Insurance </b></i></p>
                <p style="text-align: justify;">We have entered into indemnification agreements with each of our executive officers and directors. We also maintain an insurance policy that covers liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.</p>
                <div>
                    <p style="text-align: center;">25</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span id="page_31_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: justify; margin-top: 0px;"><span style="color: #231f20;"><b>Related Party Transaction Policy</b></span></p>
                <p style="text-align: justify;">Our Audit Committee is responsible for the review, approval, or ratification of any potential conflict of interest transaction involving any of our directors or executive officers, director nominees, any person known by us to be the beneficial owner of more than 5% of our outstanding capital stock, or any family member of or related party to such persons, including any transaction required to be reported under Item 404(a) of Regulation S-K promulgated by the SEC.</p>
                <p style="text-align: justify;"><span style="color: #231f20;">In reviewing any such proposed transaction, our Audit Committee is tasked with considering all relevant facts and circumstances, including the commercial reasonableness of the terms, the benefit or perceived benefit, or lack thereof, to us, opportunity costs of alternate transactions, the materiality and character of the related person's direct or indirect interest and the actual or apparent conflict of interest of the related person. </span></p>
                <p style="text-align: justify;">Under our policy, employees are required to report any material transaction or relationship that could result in a conflict of interest to our compliance officer.</p>
                <p style="text-align: justify;"><b>Interest of Certain Persons in Matters to be Acted Upon</b></p>
                <p style="text-align: justify;">Other than as set forth in this Proxy Statement, the management of the Company is not aware of any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, of any person who has been a director or executive officer at any time since the beginning of the fiscal year ended December 31, 2023, or any proposed nominee for election as a director, or any associate or affiliate of any of the foregoing persons, in any matter to be acted upon at the Meeting other than the election of directors or the re-appointment of auditors. All of the directors and officers are entitled to receive Stock Options pursuant to the Company's Stock Option Plan and Awards pursuant to the 2022 Plan. See "<i>Executive Compensation</i>" for further details. Assuming the Stock Appreciation Rights Proposal in Proposal 4 is passed, the Company's Chief Executive Officer and Chief Financial Officer would be entitled to receive Stock Appreciation Rights. See "<i>Proposal No. 4 - Approval of Stock Appreciation Rights Proposal</i>" for further details.</p>
                <div>
                    <p style="text-align: center;">26</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_32_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>SHARE OWNERSHIP</b></p>
                <p style="text-align: justify;">The following table sets forth information known to us regarding beneficial ownership of Common Shares as of June 21, 2024 by:</p>
                <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>each person known by us to be the beneficial owner of more than 5% of outstanding Common Shares;</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>each of our executive officers, directors and director nominees;</p>
                <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;">&#8226;<span style="display: inline-block; width: 16.7pt;">&#160;</span>all of our executive officers, directors and director nominees as a group.</p>
                <p style="text-align: justify;">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days of June 21, 2024. In computing the number of Common Shares beneficially owned by a person or entity and the percentage ownership of that person or entity in the table below, all Common Shares subject to options, warrants and restricted stock units held by such person or entity were deemed outstanding if such securities are currently exercisable, or exercisable or would vest based on service-based vesting conditions within 60 days of June 21, 2024. These Common Shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person or entity.</p>
                <p style="text-align: justify;">The beneficial ownership of our common stock is based on 13,366,535 Common Shares outstanding as of June 21, 2024.</p>
                <p style="text-align: justify;">Unless otherwise indicated, we believe that each person named in the table below has sole voting and investment power with respect to all Common Shares beneficially owned by him.</p>
                <p style="text-align: justify;">Unless otherwise noted, the business address of each of these shareholders is c/o Flora Growth Corp. 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309.</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 47.9769%; white-space: nowrap;"><b>Beneficial Owner</b></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Number of Common Shares<br/>Beneficially Owned</b><sup><b>(1)</b></sup></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Percentage of<br/>Common Shares</b><br/><b>Beneficially Owned</b><sup><b>(1)</b></sup></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 47.9769%;"><i><b>Executive Officers</b></i></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 15%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 15%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 47.9769%;">Clifford Starke<sup>(2)</sup><sup>(</sup><sup>8</sup><sup>)</sup></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">1,340,056</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">10.03%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 47.9769%;">Dany Vaiman<sup>(3)</sup><sup>(</sup><sup>8</sup><sup>)</sup></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">170,850</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">1.28%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 47.9769%;"><i><b>Non-Employee Directors and Director Nominees</b></i></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">&#160;</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 47.9769%; background-color: #e6efff;">Edward Woo<sup>(4)</sup><sup>(</sup><sup>8</sup><sup>)</sup></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">86,719</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">0.65%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 47.9769%;">Kevin Taylor<sup>(5)</sup></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">138,736</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">1.04%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 47.9769%;">Brendan Cahill</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; width: 47.9769%;"><i><b>5% or greater shareholders</b></i><br/>Global X Management Company LLC<sup>(</sup><sup>6</sup><sup>)</sup></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;"><br/>988,368</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right;"><br/>7.39%</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; width: 47.9769%; background-color: #e6efff;">Ronald D. Schmeichel<sup>(</sup><sup>7</sup><sup>)</sup></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">1,254,277</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">9.38%</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; width: 47.9769%; background-color: #e6efff;"><i><b>All directors and executive officers as a group of 5 persons</b></i></td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">1,736,361</td>
                        <td style="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: right; background-color: #e6efff;">12.99%</td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">27</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_33_integixAnchor"></span>
                <p style="margin-left: 16pt; margin-bottom: 0pt; text-indent: -16pt; text-align: justify; margin-top: 10pt;">*<span style="width: 11pt; text-indent: 0pt; display: inline-block;">&#160;</span>Less than 1%</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(1)<span style="width: 7.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>P<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">ercentages are based on 13,366,535 Common Shares issued and outstanding as of June 21, 2024. Information as to the number of Common Shares beneficially owned, or over which control or direction is exercised, directly or indirectly, not being within the direct knowledge of the Company, has been furnished by the respective directors individually or obtained from the System for Electronic Disclosure by Insiders and may include Common Shares owned or controlled by spouses and/or children of such individuals and/or companies controlled by such individuals or their spouses and/or children.</span></p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(2)<span style="width: 7.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Includes (i) 473,995 shares held directly by Mr. Starke, (ii) 33,579 shares held by BTF Investments, Inc., a company owned and controlled by Mr. Starke, (iii) 300,347 shares held by Hampstead Private Capital Limited, a company owned and controlled by Mr. Starke, (iv) 5,820 shares held by YT Research, Inc., a company owned and controlled by Mr. Starke. Mr. Starke filed a 13D A-2 with the SEC on November 15, 2023.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(3)<span style="width: 7.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Includes 170,850 shares held directly by Mr. Vaiman.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(4)<span style="width: 7.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Includes (i) 84,698 shares held directly by Mr. Woo, (ii) 2,021 shares held by 1317433 B.C. Limited, a company in which Mr. Woo is the sole director and equity owner.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(5)<span style="width: 7.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Includes (i) 124,186 shares held directly by Mr. Taylor, (ii) 14,550 shares held by Taylor Capital LLC, a company in which Mr. Taylor is the sole director and equity owner.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(6)<span style="width: 7.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Global X Management Company LLC ("GXMC") is a registered investment advisor that furnishes investment advice to the Global X Cannabis ETF (the "Fund"), a separate series of Global X Funds, an investment company registered under Section 8 of the Investment Company Act of 1940. As a result of its role as investment advisor to the Fund, GXMC may be deemed to be the beneficial owner of the shares. However, GXMC does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Fund and disclaims any ownership associated with such rights. GXMC filed a 13G with the SEC on February 14, 2024. The address of GXMC is 605 3<sup>rd</sup> Avenue, 43<sup>rd</sup> Floor, New York, NY 10158.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(7)<span style="width: 6.51pt; text-indent: 0pt; display: inline-block;">&#160;</span>Ronald D. Schmeichel has voting and investment power with respect to 940,145 common shares registered in the name of RDS Private Capital II, LP as well as 314,132 common shares that Ronald D. Schmeichel owns directly. The principal address of RDS Private Capital II, LP and Mr. Schmeichel is 135 Yorkville Avenue, Suite 900, Toronto, ON M5R 0C7.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;">(8)<span style="width: 6.51pt; text-indent: 0pt; display: inline-block;">&#160;</span>Messrs. Starke, Vaiman and Woo have reported as a group pursuant to Amendment No. 1 on Form 13D filed by Mr. Starke with the SEC on April 21, 2023. The number of shares disclosed in the above table only reflect the shares held or controlled directly by each director of officer and each such personal specifically disclaims beneficial ownership of the securities and he does not directly own or control.</p>
                <div>
                    <p style="text-align: center;">28</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_34_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</b></p>
                <p style="text-align: justify;">Section 16(a) of the Exchange Act and the rules thereunder require our directors, executive officers and persons who beneficially own more than 10% of a registered class of our equity securities, to file reports with the SEC relating to their share ownership and changes in such ownership.</p>
                <p style="text-align: justify;">To the Company's knowledge, all transactions required to be reported pursuant to Section 16(a) for the year ended December 31, 2023 were timely reported by the Company's directors, officers and persons who own more than 10% of a registered class of the Company's equity securities.</p>
                <div>
                    <p style="text-align: center;">29</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_35_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS </b></p>
                <p style="text-align: justify;">The following table provides information as of December 31, 2023 with respect to our Common Shares that may be issued under the Company Stock Option Plan and 2022 Incentive Compensation Plan.</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-bottom: 0pt; width: 14%; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>&#160;</b><br/><b>&#160;</b><br/><b>&#160;</b><br/><b>Plan Category</b></td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 14%; text-align: center; white-space: nowrap;"><b>Number of<br/>Securities To Be<br/>Issued Upon<br/>Exercise Of<br/>Outstanding<br/>Options, Warrants<br/>and Rights</b></td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 14%; text-align: center; white-space: nowrap;"><b>Weighted Average<br/>Exercise Price Of<br/>Outstanding<br/>Options, Warrants<br/>And Rights</b></td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 14%; text-align: center; white-space: nowrap;"><b>Number Of Securities<br/>Remaining Available For<br/>Future Issuance Under<br/>Equity Compensation Plans<br/>(Excluding Securities<br/>Reflected in the first<br/>column)</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 14%; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">Equity Compensation Plans Approved by Shareholders<sup>(</sup><sup>1</sup><sup>)</sup></td>
                        <td style="padding-right: 0.75pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; border-top: 0.75pt solid #000000; width: 14%; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; border-top: 0.75pt solid #000000; width: 14%; text-align: center;">&#160;</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; border-top: 0.75pt solid #000000; width: 14%; text-align: center;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 14%; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><i>Stock Option Plan</i></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 14%; background-color: #e6efff; text-align: center;">41,785</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; border-top: 0.75pt solid #000000; width: 14%; text-align: center;">$28.23</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; border-top: 0.75pt solid #000000; width: 14%; text-align: center;">0</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 14%; background-color: #e6efff;"><i>2022 Incentive Compensation Plan</i></td>
                        <td style="padding-right: 0.75pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; border-top: 0.75pt solid #000000; width: 14%; text-align: center;">398,098(2)</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; border-top: 0.75pt solid #000000; width: 14%; text-align: center;">$9.13(3)</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; border-top: 0.75pt solid #000000; width: 14%; text-align: center;">124,186</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 14%;">Equity Compensation Plans Not Approved by Shareholders</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; width: 14%; text-align: center;">N/A</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; width: 14%; text-align: center;">N/A</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; width: 14%; text-align: center;">N/A</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 14%; background-color: #e6efff;">Total</td>
                        <td style="padding-right: 0.75pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; width: 14%; text-align: center;">439,883</td>
                        <td style="padding-right: 2.65pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; width: 14%; text-align: center;">N/A</td>
                        <td style="padding-right: 0.75pt; padding-left: 2.65pt; vertical-align: top; background-color: #e6efff; width: 14%; text-align: center;">124,186</td>
                    </tr>
                </table>
                <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;">(1)<span style="display: inline-block; width: 7pt;">&#160;</span>Includes the Company's Stock Option Plan and its 2022 Incentive Compensation Plan, which authorizes the granting of awards in any of the following forms: options, stock appreciation rights, restricted stock, restricted stock units, other equity-based awards and cash incentive awards.</p>
                <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify;">(2)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>Represents 7,500 Common Shares underlying options and 390,598 issued restricted Common Shares as of December 31, 2023.</p>
                <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify;">(3)<span style="display: inline-block; width: 7pt;">&#160;</span>The weighted exercise price represents the weighted exercise price of the 7,500 options outstanding under the 2022 Plan as of December 31, 2023.</p>
                <div>
                    <p style="text-align: center;">30</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_36_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>EXECUTIVE COMPENSATION</b></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i><b>Overview</b></i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">This section discusses the material components of our executive compensation program for our named executive officers ("Named Executive Officers") during our fiscal years ended December 31, 2023 and December 31, 2022. As a "smaller reporting company," we are required to provide executive compensation information for the following individuals: </span><span style="background-color: #ffffff;">(i) all individuals who served as the Company's principal executive officer ("PEO"), during the last completed fiscal year, regardless of compensation; (ii) the two most highly compensated executive officers (other than the PEO) who were serving as executive officers of the Company at the end of the last completed fiscal year and whose total compensation was greater than $100,000; and (iii) up to two additional persons who served as executive officers (other than as the PEO) during the last completed fiscal year but were not serving in that capacity at the end of the fiscal year if their total compensation is higher than any of the other two Named Executive Officers in the preceding group.</span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">In 2023, our Named Executive Officers and their positions were as follows:</span></p>
                <p style="text-indent: 36pt; text-align: justify;"><span style="background-color: #ffffff;">&#8226;&#160; &#160; Clifford Starke, our Chief Executive Officer;</span></p>
                <p style="text-indent: 36pt; text-align: justify;"><span style="background-color: #ffffff;">&#8226;&#160; &#160; Dany Vaiman, our Chief Financial Officer; </span></p>
                <p style="text-indent: 36pt; text-align: justify;"><span style="background-color: #ffffff;">&#8226;&#160; &#160; Luis Merchan, our former Chief Executive Officer;</span></p>
                <p style="text-indent: 36pt; text-align: justify;"><span style="background-color: #ffffff;">&#8226;&#160; &#160; Hussein Rakine, our former Chief Executive Officer;</span></p>
                <p style="text-indent: 36pt; text-align: justify;"><span style="background-color: #ffffff;">&#8226;&#160; &#160; Matthew Cohen, our former General Counsel;</span></p>
                <div>
                    <p style="text-align: center;">31</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_37_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;"><i><b>Summary Compensation Table</b></i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">The following table sets out the compensation for the Named Executive Officers for the years ended December 31, 2023 and 2022:</span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;"><b>Name and<br/>Principal<br/>Position</b></td>
                        <td style="width: 5.56%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Fiscal</b><br/><b>Year</b></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;"><b>Salary<br/>(US$)</b><sup><b>(1)</b></sup></td>
                        <td style="width: 7.2%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Bonus</b><br/><b>(US$)</b><sup><b>(2)</b></sup></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;"><b>Common<br/>Shares<br/>Awards<br/>(US$)</b><sup><b>(3)</b></sup></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;"><b>Option<br/>Awards<br/>(US$)</b><sup><b>(4)</b></sup></td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Nonequity<br/>Incentive Plan</b><br/><b>Compensation<br/>(US$)</b></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;"><b>Nonqualified</b><br/><b>Deferred</b><br/><b>Compensation</b><br/><b>Earnings<br/>(US$)</b><br/><b>($)</b></td>
                        <td style="width: 12.98%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>All Other</b><br/><b>Compensation</b><br/><b>(US$)</b><sup><b>(5)</b></sup></td>
                        <td style="width: 12.98%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Total</b><br/><b>Compensation</b><br/><b>(US$)</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;" rowspan="3">Clifford Starke, <i>Chief Executive Officer</i></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;"><br/>2023</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt; background-color: #e6efff;">371,233</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt; background-color: #e6efff;">-</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">249,167</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt; background-color: #e6efff;">8,116</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt; background-color: #e6efff;">628,516</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;">2022</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">7,014</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">-</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">24,300</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">31,314</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt; border-bottom: 0.75pt solid #000000;" rowspan="3">Dany Vaiman, <i>Chief Financial Officer</i></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;">2023</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt;">243,301</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt;">-</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right;">113,258</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right;">-</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt;">23,452</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt;">380,011</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt;">&#160;</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom;">&#160;</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom;">&#160;</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom;">&#160;</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;">2022</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt;">4,603</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt;">-</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt;">162,990</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt;">167,593</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt; border-bottom: 0.75pt solid #000000; background-color: #e6efff;" rowspan="3">Luis Merchan<i>, former Chief Executive Officer</i></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;">2023</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">433,615</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">-</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">495,000</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">48,120</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">976,735</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;">2022</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">378,310</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">-</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">540,000</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">101,145</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">48,120</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">1,067,575</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt;" rowspan="3">Hussein Rakine<i>, former Chief Executive Officer</i></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;">2023</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt;">84,615</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt;">-</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right;">296,400</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right;">-</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: right;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; text-align: right; padding-left: 4pt;">381,015</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt;">&#160;</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom;">&#160;</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom;">&#160;</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom;">&#160;</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;">2022</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt;">216,264</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt;">-</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">300,000</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">56,191</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt;">572,455</td>
                    </tr>
                    <tr>
                        <td style="width: 9.4%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff;" rowspan="3">Matthew Cohen,<br/><i>former General Counsel</i></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;">2023</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">145,824</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">60,000</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">31,250</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">237,074</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; padding-left: 4pt; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt; background-color: #e6efff;">2022</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">245,833</td>
                        <td style="width: 7.2%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">60,000</td>
                        <td style="width: 9.52%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">270,000</td>
                        <td style="width: 8.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">109,388</td>
                        <td style="width: 13.88%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">-</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">31,250</td>
                        <td style="width: 12.98%; padding-right: 4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; padding-left: 4pt; background-color: #e6efff;">716,471</td>
                    </tr>
                </table>
                <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;">(1)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Salary amounts represent actual amount of base salary earned by each Named Executive Officer in the applicable year.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(2)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Bonus amounts for 2022 and 2023 represent the actual amount of cash bonuses earned during 2022 and 2023, respectively, under the Company's annual bonus program. All such bonuses have been paid. Refer to "<i>Annual Bonus/Non-Equity Incentive Plan Compensation</i>" below.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;">(3)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Value based on trading price of the Common Shares on the date of the respective grants. These grants include grants of restricted Common Shares. See "<i>Narrative to the Summary Compensation Table-Equity-Based Compensation-Equity Awards to Named Executive Officers during 2022 and 2023.</i>" <span style="background-color: #ffffff;"><span style="text-decoration: underline;"><i> </i></span>for </span>information regarding these grants. Mr. Rakine forfeited the share awards granted to him in 2023 upon his resignation.</p>
                <div>
                    <p style="text-align: center;">32</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_38_integixAnchor"></span>
                <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;">(4)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Represents the aggregate grant date fair value of options granted to each Named Executive Officer, calculated in accordance with the Black Scholes method.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;">(5)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>For Messrs. Merchan and Cohen, respectively, in the form of a monthly stipend pursuant to the terms of their respective employment agreements, which included reimbursement payments in connection with health insurance premiums paid during fiscal years 2022 and 2023. Mr. Vaiman's amount includes vacation accrued but not taken for a total of $21,618 as well as health and dental benefits totaling $1,834. Mr. Vaiman's 2022 other compensation includes a change of control payment earned in 2022 due to the Company's acquisition of Franchise Global Health Inc. - of which Mr. Vaiman was the Chief Executive Officer at the time of the closing of the acquisition.</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i><b>Narrative to the Summary Compensation Table</b></i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Base Salaries</i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">We use base salaries to recognize the experience, skills, knowledge, and responsibilities required of all our employees, including our Named Executive Officers. Base salaries are reviewed annually, typically in connection with our annual performance review process, and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Annual Bonus/Non-Equity Incentive Plan Compensation</i></span></p>
                <p style="text-align: justify;">For 2023, our Named Executive Officers were eligible to earn a cash bonus under the Company's annual bonus program based upon achievement of both corporate and individual goals determined by the Board based on a target percentage of annual base salary.&#160; For 2022, the bonus targets as a percentage of base salaries were 100% for Mr. Merchan, and 50% for Mr. Cohen. For 2023, Mathew Cohen received a cash bonus of $60,000</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Equity-Based Compensation</i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">Certain of the Company's Named Executive Officers received grants of restricted Common Shares and options under the Company's option plan and 2022 Plan during 2022 and 2023. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><span style="text-decoration: underline;"><i>Company Stock Option Plan</i></span></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">The Company has a stock option plan whereby it may grant options for the purchase of Common Shares to any director, consultant, employee or officer of the Company or its subsidiaries. The aggregate number of shares that may be issuable pursuant to options granted under the Company's stock option plan will not exceed 10% of the issued and outstanding Common Shares of the Company. The options are non-transferable and non-assignable and may be granted for a term not exceeding five-years. The exercise price of the options is determined by the Board at the time of grant, but in the event that the Common Shares are traded on any stock exchange, may not be less than the closing price of such shares on such exchange on the trading date immediately precedent the date of grant, subject to all applicable regulatory requirements. The Company no longer makes any new grants under the stock option plan.</span></p>
                <div>
                    <p style="text-align: center;">33</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_39_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;"><span style="text-decoration: underline;"><i>2022 Plan</i></span></span></p>
                <p style="text-align: justify;">The 2022 Plan was adopted by the Company following shareholder approval at the Company's 2022 annual meeting (the "Shareholder Approval Date") and amended at the Company's 2023 annual meeting.</p>
                <p style="text-align: justify;">The purpose of the 2022 Plan is to assist the Company and its subsidiaries and other designated affiliates, which we refer to herein as "Related Entities", in attracting, motivating, retaining and rewarding high-quality executives and other employees, officers, directors consultants and other persons who provide services to the Company or its Related Entities, by enabling such persons to acquire or increase a proprietary interest in the Company in order to strengthen the mutuality of interests between such persons and the Company's shareholders, and providing such persons with performance incentives to expend their maximum efforts in the creation of shareholder value.</p>
                <p style="text-indent: 36pt; text-align: justify;"><i>Shares Available for Awards</i></p>
                <p style="text-align: justify;">Under the 2022 Plan, the total number of Common Shares reserved and available for delivery under the 2022 Plan ("Awards") at any time during the term of the Plan shall be equal to 950,000 Common Shares. Awards issued in substitution for awards previously granted by a company acquired by the Company or a Related Entity, or with which the Company or any Related Entity combines, do not reduce the limit on grants of Awards under the 2022 Plan. The maximum aggregate number of Common Shares that may be delivered under the 2022 Plan as a result of the exercise of stock options shall be 850,000 Common Shares.</p>
                <p style="text-align: justify;">If Proposal No. 3 included in this Proxy Statement is approved, the total number of Common Shares reserved and available for delivery under the 2022 Plan will be increased to 2 million Common Shares.</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">Subject to adjustment as provided in the </span>2022 Plan<span style="background-color: #ffffff;">, in any fiscal year of the </span>Company<span style="background-color: #ffffff;"> during any part of which the </span>2022 Plan<span style="background-color: #ffffff;"> is in effect, no participant who is a member of the Board but is not also an employee or consultant to the </span>Company<span style="background-color: #ffffff;"> or Related Entity may be granted any Awards that have a "fair value" as of the date of grant, as determined in accordance with FASB ASC Topic 718 (or any other applicable accounting guidance) that exceeds $250,000 in the aggregate.</span></p>
                <p style="text-align: justify;">The committee designated and empowered by the Board to administer the 2022 Plan ("Committee") is authorized to adjust the limitations described in the preceding paragraph and is authorized to adjust outstanding Awards (including adjustments to exercise prices of stock options and other affected terms of Awards) in the event that a dividend or other distribution (whether in cash, Common Share or other property), recapitalization, forward or reverse split, reorganization, merger, consolidation, spin-off, combination, repurchase, share exchange or other similar corporate transaction or event affects the Common Shares so that an adjustment is appropriate. The Committee is also authorized to adjust performance conditions and other terms of Awards in response to these kinds of events or in response to changes in applicable laws, regulations or accounting principles.</p>
                <div>
                    <p style="text-align: center;">34</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_40_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><i>Eligibility</i></p>
                <p style="text-align: justify;">The persons eligible to receive Awards under the 2022 Plan are the officers, directors, employees, consultants and other persons who provide services to the Company or any Related Entity. The foregoing notwithstanding, only employees of the Company, or any parent corporation or subsidiary company of the Company (as those terms are defined in Sections 424(e) and (f) of the Internal Revenue Code of 1986, as amended&#160; (the "Code"), respectively), are eligible for purposes of receiving any incentive stock options ("ISOs"). An employee on leave of absence may be considered as still in the employ of the Company or a Related Entity for purposes of eligibility for participation in the 2022 Plan.</p>
                <p style="text-indent: 36pt; text-align: justify;"><i>Administration</i></p>
                <p style="text-align: justify;">The 2022 Plan is to be administered by the Committee; provided, however, that except as otherwise expressly provided in the 2022 Plan, the Board may exercise any power or authority granted to the Committee under the 2022 Plan. Subject to the terms of the 2022 Plan, the Committee is authorized to select eligible persons to receive Awards, determine the type, number and other terms and conditions of, and all other matters relating to, Awards, prescribe Award agreements (which need not be identical for each person who has been granted an Award under the 2022 Plan which remains outstanding (a "Participant")), and the rules and regulations for the administration of the 2022 Plan, construe and interpret the 2022 Plan and Award agreements, correct defects, supply omissions or reconcile inconsistencies therein, and make all other decisions and determinations as the Committee may deem necessary or advisable for the administration of the 2022 Plan.</p>
                <p style="text-indent: 36pt; text-align: justify;"><i>Stock Options and Stock Appreciation Rights</i></p>
                <p style="text-align: justify;">The Committee is authorized to grant stock options, including both ISOs, which can result in potentially favorable tax treatment to the participant, and non-qualified stock options, and stock appreciation rights entitling the participant to receive the amount by which the fair market value of a Common Share on the date of exercise exceeds the grant price of the stock appreciation right. The exercise price per share subject to an option and the grant price of a stock appreciation right are determined by the Committee but may not be less than 100% of the fair market value of a Common Share on the date the award is granted. An option granted to a person who owns or is deemed to own stock representing 10% or more of the voting power of all classes of stock of the Company or any parent company (sometimes referred to as a "10% owner") will not qualify as an ISO unless the exercise price for the option is not less than 110% of the fair market value of a Common Share on the date such ISO is granted.</p>
                <p style="text-align: justify;">For purposes of the 2022 Plan, the term "fair market value" means the fair market value of Common Shares, Awards or other property as determined by the Committee or under procedures established by the Committee. Unless otherwise determined by the Committee, the fair market value of a Common Share as of any given date shall be the closing price of a Common Share on the business day that immediately precedes the date as of which the value is being determined as quoted on the Nasdaq Stock Market or such other national or regional securities exchange or market system constituting the primary market on which a Common Share is traded, as reported in The Wall Street Journal or such other source as the Company deems reliable or, if there is no sale on that date, then on the last previous day on which a sale was reported. The maximum term of each option or stock appreciation right, the times at which each option or stock appreciation right will be exercisable, and provisions requiring forfeiture of unexercised options or stock appreciation rights at or following termination of employment, generally are fixed by the Committee, except that no option or stock appreciation right may have a term exceeding ten years, and no ISO granted to a 10% shareholder (as described above) may have a term exceeding five years (to the extent required by the Code at the time of grant). Methods of exercise and settlement and other terms of options and stock appreciation rights are determined by the Committee. The Committee thus may permit the exercise price of options awarded under the 2022 Plan to be paid in cash, shares, other Awards or other property (including loans to participants).</p>
                <div>
                    <p style="text-align: center;">35</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_41_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><i>Restricted Stock and Restricted Stock Units</i></p>
                <p style="text-align: justify;">The Committee is authorized to grant restricted stock and restricted stock units. Restricted stock is a grant of Common Shares which may not be sold or disposed of, and which is subject to such risks of forfeiture and other restrictions as the Committee may impose. A participant granted restricted stock generally has all of the rights of a shareholder of the Company, unless otherwise determined by the Committee. An Award of restricted stock units confers upon a participant the right to receive Common Shares at the end of a specified deferral period, subject to such risks of forfeiture and other restrictions as the Committee may impose. Prior to settlement, an Award of restricted stock units carries no voting or dividend rights, or other rights associated with share ownership, although dividend equivalents may be granted, as discussed below.</p>
                <p style="text-indent: 36pt; text-align: justify;"><i>Dividend Equivalents</i></p>
                <p style="text-align: justify;">The Committee is authorized to grant dividend equivalents conferring on participants the right to receive, currently or on a deferred basis, cash, Common Shares, other Awards or other property equal in value to dividends paid on a specific number of Common Shares or other periodic payments. Dividend equivalents may be granted alone or in connection with another Award, may be paid currently or on a deferred basis and, if deferred, may be deemed to have been reinvested in additional Common Shares, Awards or otherwise as specified by the Committee.</p>
                <p style="text-indent: 36pt; text-align: justify;"><i>Bonus Stock and Awards in Lieu of Cash Obligations</i></p>
                <p style="text-align: justify;">The Committee is authorized to grant Common Shares as a bonus free of restrictions, or to grant Common Shares or other Awards in lieu of Company obligations to pay cash under the 2022 Plan or other plans or compensatory arrangements, subject to such terms as the Committee may specify.</p>
                <p style="text-indent: 36pt; text-align: justify;"><i>Other Stock-Based Awards</i></p>
                <p style="text-align: justify;">The Committee or the Board is authorized to grant Awards that are denominated or payable in, valued by reference to, or otherwise based on or related to Common Shares. The Committee determines the terms and conditions of such Awards.</p>
                <div>
                    <p style="text-align: center;">36</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_42_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><i>Performance Awards</i></p>
                <p style="text-align: justify;">The Committee is authorized to grant performance awards to participants on terms and conditions established by the Committee. The performance criteria to be achieved during any performance period and the length of the performance period is determined by the Committee upon the grant of the performance award. Performance awards may be valued by reference to a designated number of Common Shares or by reference to a designated amount of property including cash. Performance awards may be settled by delivery of cash, Common Shares or other property, or any combination thereof, as determined by the Committee.</p>
                <p style="text-indent: 36pt; text-align: justify;"><i>Other Terms of Awards</i></p>
                <p style="text-align: justify;">Awards may be settled in the form of cash, Common Shares, other Awards or other property, in the discretion of the Committee. The Committee may require or permit participants to defer the settlement of all or part of an Award in accordance with such terms and conditions as the Committee may establish, including payment or crediting of interest or dividend equivalents on deferred amounts, and the crediting of earnings, gains and losses based on deemed investment of deferred amounts in specified investment vehicles. The Committee is authorized to place cash, Common Shares or other property in trusts or make other arrangements to provide for payment of the Company's obligations under the 2022 Plan. The Committee may condition any payment relating to an Award on the withholding of taxes and may provide that a portion of any Common Shares or other property to be distributed will be withheld (or previously acquired Common Shares or other property be surrendered by the participant) to satisfy withholding and other tax obligations. Awards granted under the 2022 Plan generally may not be pledged or otherwise encumbered and are not transferable except by will or by the laws of descent and distribution, or to a designated beneficiary upon the participant's death, except that the Committee may, in its discretion, permit transfers subject to any terms and conditions the Committee may impose thereon.</p>
                <p style="text-align: justify;">Awards under the 2022 Plan are generally granted without a requirement that the participant pay consideration in the form of cash or property for the grant (as distinguished from the exercise), except to the extent required by law. The Committee may, however, grant Awards in exchange for other Awards under the 2022 Plan, awards under other Company plans, or other rights to payment from the Company, and may grant Awards in addition to and in tandem with such other Awards, rights or other awards.</p>
                <p style="text-indent: 36pt; text-align: justify;"><i>Acceleration of Vesting; Change in Control</i></p>
                <p style="text-align: justify;">The Committee may, in its discretion, accelerate the exercisability, the lapsing of restrictions or the expiration of deferral or vesting periods of any Award, and such accelerated exercisability, lapse, expiration and if so provided in the Award agreement or otherwise determined by the Committee, vesting shall occur automatically in the case of a "change in control" of the Company, as defined in the 2022 Plan (including the cash settlement of stock appreciation rights which may be exercisable in the event of a change in control). In addition, the Committee may provide in an Award agreement that the performance goals relating to any performance award will be deemed to have been met upon the occurrence of any "change in control."</p>
                <div>
                    <p style="text-align: center;">37</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_43_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><i>Amendment and Termination</i></p>
                <p style="text-align: justify;">The Board may amend, alter, suspend, discontinue or terminate the 2022 Plan or the Committee's authority to grant Awards without further shareholder approval, except that shareholder approval must be obtained for any amendment or alteration if such approval is required by law or regulation or under the rules of any stock exchange or quotation system on which Common Shares are then listed or quoted. Thus, shareholder approval may not necessarily be required for every amendment to the 2022 Plan which might increase the cost of the 2022 Plan or alter the eligibility of persons to receive Awards. Shareholder approval will not be deemed to be required under laws or regulations, such as those relating to ISOs, that condition favorable treatment of participants on such approval, although the Board may, in its discretion, seek shareholder approval in any circumstance in which it deems such approval advisable. Unless earlier terminated by the Board, the 2022 Plan will terminate at the earliest of (a) such time as no Common Shares remain available for issuance under the 2022 Plan, (b) termination of the 2022 Plan by the Board, or (c) the tenth anniversary of the Shareholder Approval Date. Awards outstanding upon expiration of the 2022 Plan shall remain in effect until they have been exercised or terminated or have expired.</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><span style="text-decoration: underline;"><i>Equity Awards to Named Executive Officers during 2022 and 2023</i></span></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Clifford Starke</i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">On December 23, 2022, Mr. Starke received 5,000 Restricted Common Shares, which vested in full on December 23, 2023. On November 10, 2023, Mr. Starke received 327,851 Restricted Common Shares, which vested in full on the same date. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Dany Vaiman</i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">During 2022, Mr. Vaiman did not receive any equity awards. On November 10, 2023, Mr. Vaiman received 149,024 Restricted Common Shares, which vested in full on January 1, 2024.</span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Hussein Rakine</i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">During 2022, Mr. Rakine received the following equity awards:</span></p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On October 5, 2022, 10,204 options to purchase Common Shares at an exercise price of $13.4. These options were subject to a vesting schedule that was based on the performance of the Company's Common Share price relative to a designated Cannabis ETF.</span></li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On September 12, 2022, 4,000 restricted Common Shares which were set to vest on July 5, 2023.</span></li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On October 5, 2022, 7,462 restricted Common Shares which were set to vest on July 5, 2024. </span></li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On December 5, 2022, 10,638 restricted Common Shares which were set to vest on July 5, 2025.</span></li>
                </ul>
                <div>
                    <p style="text-align: center; margin-top: 10pt;">38</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_44_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;">On April 16, 2023, Mr. Rakine received 60,000 restricted Common Shares which were set to vest on June 7, 2023. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">As a result of his resignation in June 2023, Mr. Rakine forfeited all of these unvested restricted Common Shares as well as the unvested October 5, 2022 options. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Luis Merchan</i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">During 2023 and as part of the Merchan Separation Agreement (as defined below), Mr. Merchan received 80,000 Common Shares of the Company. Further, Mr. Merchan acted in a consulting capacity for which he received 30,000 Common Shares. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">During 2022, Mr. Merchan was granted the following restricted Common Share grants: </span></p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On August 23, 2022, Mr. Merchan was granted 5,102 restricted Common Shares which were set to vest on July 5, 2023. </span></li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On October 5, 2022, Mr. Merchan was granted 16,417 restricted Common Shares which were set to vest on July 5, 2024. </span></li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On December 5, 2022, Mr. Merchan was granted 23,404 restricted Common Shares which were set to vest on July 5, 2025.</span></li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;">On October 5, 2022, Mr. Merchan also was granted 18,367 options to purchase Common Shares at an exercise price of $13.40. These options were subject to a vesting schedule that was based on the performance of the Company's Common Share price relative to a designated Cannabis ETF. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">As a result of his resignation in April 2023, Mr. Merchan forfeited all of these unvested restricted Common Shares as well the unvested October 5, 2022 options.</span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Matthew Cohen</i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">During 2022, Mr. Cohen was granted the following restricted Common Share grants:</span></p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On August 23, 2022, Mr. Cohen was granted 5,102 restricted Common Shares which were scheduled to vest on July 5, 2023.</span></li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On October 5, 2022, Mr. Cohen was granted 6,343 restricted Common Shares which were scheduled to vest July 5, 2024.</span></li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;"><span style="background-color: #ffffff;">On December 5, 2022, Mr. Cohen was granted 9,000 restricted Common Shares which were scheduled to vest on July 5, 2025. </span></li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;">On May 14, 2023, the Company fully accelerated the vesting of Mr. Cohen's aforementioned Restricted Shares to May 18, 2023. In connection with such vesting, Mr. Cohen agreed to forfeit 90,146 Restricted Shares to the Company in satisfaction of all applicable withholding taxes.</span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">On October 5, 2022, Mr. Cohen was also granted 9,183 options to purchase Common Shares at an exercise price of $13.4. These options vest based on a vesting schedule that was based on the performance of the Company's Common Share price relative to a designated Cannabis ETF. </span></p>
                <div>
                    <p style="text-align: center;">39</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span id="page_45_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: justify; margin-top: 0px;"><span style="background-color: #ffffff;">On January 26, 2022, Mr. Cohen was granted 2,500 options to purchase Common Shares at an exercise price of $29.60. These options vested on February 26, 2022. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Employee Benefits</i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">For 2022 and 2023 certain Named Executive Officers were eligible to participate in such employee benefit plans and programs to the same extent as the Company's other full-time employees, subject to the terms and eligibility requirements of those plans.</span></p>
                <p style="text-align: justify;"><i><b>Hedging and Pledging Company Securities </b></i></p>
                <p style="text-align: justify;">Our Insider Trading Policy prohibits our <span style="background-color: #ffffff;">directors, officers, employees, family members of such persons and entities controlled by such persons from engaging in hedging, short sales, or trading in publicly traded put or call options with respect to our securities</span>. Additionally, policy prohibits the same persons from purchasing our securities on margin, borrowing against any account in which our securities are held, or pledging our securities as collateral for a loan.</p>
                <p style="text-align: justify;"><i><b>Clawback Policy</b></i></p>
                <p style="text-align: justify;">Effective as of October 2, 2023, we adopted a clawback policy that provides for the recoupment of excess incentive compensation paid to executive officers, including the Named Executive Officers, in accordance with Nasdaq listing standards and Exchange Act Rule 10D-1. The policy applies to compensation that is granted, earned, or vested based in whole or in part upon the attainment of a financial reporting measure and provides for the reimbursement or forfeiture by the executive officer of the excess portion of the compensation received by the executive officers during the three preceding fiscal years.</p>
                <p style="text-align: justify;"><i><b>Compensation-Related Risk Assessment</b></i></p>
                <p style="text-align: justify;">Our Compensation Committee assesses and monitors whether any of our compensation policies and programs is reasonably likely to have a material adverse effect on our Company. The Compensation Committee and management do not believe that the Company presently maintains compensation policies or practices that are reasonably likely to have a material adverse effect on the Company's risk management or create incentives that could lead to excessive or inappropriate risk taking by employees. In reaching this conclusion, the Compensation Committee considered all components of our compensation program and assessed any associated risks. The Compensation Committee also considered the various strategies and measures employed by the Company that mitigate such risk, including: (i) the overall balance achieved through our use of a mix of cash and equity, annual and long-term incentives and time-and performance-based compensation; (ii) our use of multi-year vesting periods for equity grants; and (ii) the oversight exercised by the Compensation Committee over the performance metrics and results under the Stock Option Plan and the 2022 Plan.</p>
                <div>
                    <p style="text-align: center;">40</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_46_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;"><i><b>Outstanding Equity Awards at 2023 Fiscal Year-End</b></i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">The following table summarizes the number of outstanding restricted Common Shares and options in the Company held by our Named Executive Officers as of December 31, 2023.</span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; text-align: center; white-space: nowrap;" colspan="6"><b>Option Awards</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #ffffff; text-align: center; white-space: nowrap;" colspan="4"><b>Share Awards</b></td>
                    </tr>
                    <tr>
                        <td style="width: 12.44%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Name</b></td>
                        <td style="width: 8.58%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Number of</b><br/><b>Securities</b><br/><b>Underlying</b><br/><b>Unexercised</b><br/><b>Options (#)</b><br/><b>Exercisable</b></td>
                        <td style="width: 9.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Number of</b><br/><b>Securities</b><br/><b>Underlying</b><br/><b>Unexercised</b><br/><b>Options (#)</b><br/><b>Exercisable</b></td>
                        <td style="width: 10.86%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Equity</b><br/><b>Incentive</b><br/><b>Plan Awards:<br/>Number of</b><br/><b>Securities</b><br/><b>Underlying</b><br/><b>Unexercised</b><br/><b>Unearned</b><br/><b>Options</b><br/><b>(#)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Option</b><br/><b>Exercise</b><br/><b>Price ($)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Option</b><br/><b>Expiration</b><br/><b>Date</b></td>
                        <td style="width: 8.72%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Number of</b><br/><b>Shares or</b><br/><b>Units of</b><br/><b>Shares That</b><br/><b>Have Not</b><br/><b>Vested (#)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Market Value</b><br/><b>of Shares or</b><br/><b>Units of<br/>Shares</b><br/><b>That<br/>Have Not</b><br/><b>Vested ($)<br/>(1)(2)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Equity</b><br/><b>Incentive</b><br/><b>Plan Awards:<br/>Number of</b><br/><b>Unearned</b><br/><b>Shares, Units<br/>or Other<br/>Rights That<br/>Have Not<br/>Vested</b><br/><b>(#) (2)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Equity</b><br/><b>Incentive</b><br/><b>Plan Awards:<br/>Market or<br/>Payout Value of</b><br/><b>Unearned</b><br/><b>Shares, Units<br/>or Other<br/>Rights That<br/>Have Not<br/>Vested</b><br/><b>($) (1)(2)</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Clifford Starke</td>
                        <td style="width: 8.58%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 9.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 10.86%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 4.96%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 6.18%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">- <sup>(3)</sup></td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">- <sup>(3)</sup></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; padding-left: 4pt; padding-right: 4pt;">Dany Vaiman</td>
                        <td style="width: 8.58%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 9.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 10.86%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 4.96%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 6.18%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; padding-right: 4pt;">149,024</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">$201,182</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">- <sup>(3)</sup></td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; padding-right: 4pt;">- <sup>(3)</sup></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Luis Merchan</td>
                        <td style="width: 8.58%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 9.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 10.86%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 4.96%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 6.18%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; padding-left: 4pt; padding-right: 4pt;">Hussein Rakine</td>
                        <td style="width: 8.58%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 9.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="width: 10.86%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 4.96%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 6.18%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; padding-right: 4pt;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right;">-</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; padding-right: 4pt;">-</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Mathew Cohen</td>
                        <td style="width: 8.58%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 9.32%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 10.86%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 4.96%; vertical-align: top; border-bottom: 0.75pt solid #000000; padding-left: 4pt; border-top: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="width: 6.18%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                    </tr>
                </table>
                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;">(1) The market value of unvested stock awards is based on the closing market price of our Common Shares on December 29, 2023 of $1.35.&#160; </span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="background-color: #ffffff;">(2) See "<i>Narrative to the Summary Compensation Table-Equity-Based Compensation-Equity Awards to Named Executive Officers during 2022 and 2023</i>." for details regarding the vesting schedules of certain NEO options and restricted Common Share awards.&#160; </span></p>
                <p style="margin-top: 0pt; text-align: justify;"><span style="background-color: #ffffff;">(3)&#160; Messrs. Starke and Vaiman were granted Stock Appreciation Rights in connection with entering into a consulting agreement and executive employment agreement, respectively, on December 15, 2023. Such Stock Appreciation Rights grants are subject to forfeiture unless the Company's shareholders approve the grants at the Annual Meeting and therefore are not presented in this table. See "<i>Employment and Consulting Agreements, Arrangements or Plans.</i>" In addition, if the Company's shareholders approve the Stock Appreciation Rights Proposal, Messrs. Starke and Vaiman will be granted additional Stock Appreciation Rights on the date of the Annual Meeting. Such Stock Appreciation Rights have not been granted and therefore are not presented in this table. </span>See "<i>Proposal No. 4 - Approval of Stock Appreciation Rights Proposal</i>" for further details.</p>
                <p style="text-align: justify;"><i><b>Director Compensation</b></i></p>
                <p style="text-align: justify;">As a Named Executive Officer of the Company, information regarding the compensation for Mr. Starke for his services as an executive officer in 2023 is set forth in the section titled "<i>Summary Compensation Table</i>" above. Mr. Starke did not receive additional compensation for his service as a director.</p>
                <div>
                    <p style="text-align: center;">41</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_47_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">The following table provides summary information concerning compensation paid or accrued by us to or on behalf of our directors for services rendered to us during the last fiscal year.</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;"><b>Name</b></td>
                        <td style="width: 9%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><b>Fees</b><br/><b>Earned</b><br/><b>or Paid</b><br/><b>in Cash</b><br/><b>($)</b></td>
                        <td style="width: 10%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><b>Shares</b><br/><b>Awards</b><br/><b>($)(6)</b></td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><b>Option</b><br/><b>Awards</b><br/><b>($)(7)</b></td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><b>Non-<br/>equity<br/>incentive<br/>plan</b><br/><b>compensation</b><br/><b>($)</b></td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><b>Nonqualified<br/>deferred</b><br/><b>compensation<br/>earnings</b><br/><b>($)</b></td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><b>All other<br/>compensation</b><br/><b>($)</b></td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><b>Total</b><br/><b>($)</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Luis Merchan<sup>(1)</sup></td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt;">Kevin Taylor</td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">94,381</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">94,381</td>
                    </tr>
                    <tr>
                        <td style="margin-bottom: 0pt; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Thomas Solmon</td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">27,182</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">27,182</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt;">Clifford Starke<sup>(2)</sup></td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">John Timothy Leslie</td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">13,000</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">43,125</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">56,125</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt;">Dr. Beverley Richardson</td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">13,750</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">51,750</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">65,500</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Juan Carlos Gomez Roa</td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">14,000</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">51,750</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">65,750</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt;">Dr. Annabelle Manalo-Morgan<sup>(3)</sup></td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Marc Mastonardi</td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">15,750</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">51,750</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">67,500</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt;">Edward Woo<sup>(4)</sup></td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">12,000</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">56,629</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">31,070</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">99,695</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Hussein Rakine<sup>(5)</sup>&#160;</td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center; background-color: #e6efff;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; background-color: #e6efff; padding-left: 4pt;">-</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 4pt; padding-right: 4pt;">Brandon Konisberg&#160;</td>
                        <td style="width: 10%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">17,000</td>
                        <td style="width: 11%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">34,500</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 7%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; text-align: center;">-</td>
                        <td style="width: 8%; padding-right: 4pt; vertical-align: middle; text-align: center; padding-left: 4pt;">51,500</td>
                    </tr>
                </table>
                <p style="margin-left: 36pt; text-align: justify; margin-bottom: 0pt; margin-top: 10pt;">(1)<span style="width: 24.34pt; display: inline-block;">&#160;</span>Mr. Merchan was a Named Executive Officer of the Company for 2023. Mr. Merchan did not receive compensation for his service as director in 2023. As a Named Executive Officer of the Company, information regarding compensation for Mr. Merchan for his services as an executive officer in 2023 is set forth in the section titled "Summary Compensation Table" above.</p>
                <p style="margin-left: 36pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(2)<span style="width: 24.34pt; display: inline-block;">&#160;</span>Mr. Starke is a Named Executive Officer of the Company for 2023. Mr. Starke did not receive compensation for his service as director in 2023. As a Named Executive Officer of the Company, information regarding compensation for Mr. Starke for his services as an executive officer in 2023 is set forth in the section title "Summary Compensation Table" above.</p>
                <p style="margin-left: 36pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(3)<span style="width: 24.34pt; display: inline-block;">&#160;</span>During the fourth fiscal quarter of 2021, the Company entered into an agreement with Dr. Manalo-Morgan, a then member of our Board, to serve in the additional capacity as Medical Advisor to the Company.&#160; In connection with this agreement, Dr. Manalo-Morgan is responsible for developing and identifying medical applications of cannabinoids for the Company for the treatment of various ailments and (ii) supporting the Company's public relations efforts and assisting the Company with its media engagements. For these services, the Company paid her $15,000 per month for so long as the agreement remains in place. This agreement was terminated in 2023. As a result, Dr. Manalo-Morgan does not receive any compensation in consideration for her service as a director.</p>
                <p style="margin-left: 36pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(4)<span style="width: 24.34pt; display: inline-block;">&#160;</span>Excluded from fees paid in cash is compensation received by Mr. Woo as a change of control payment in relation to his service as President and Chief Operating Officer of Franchise Global Health Inc. - an entity acquired by the Company in December 2022.</p>
                <p style="margin-left: 36pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(5)<span style="width: 24.34pt; display: inline-block;">&#160;</span>Mr. Rakine was a Named Executive Officer of the Company for 2023. Mr. Rakine did not receive compensation for his service as director in 2023. As a Named Executive Officer of the Company, information regarding compensation for Mr. Rakine for his services as an executive officer in 2023 is set forth in the section titled "Summary Compensation Table" above.</p>
                <p style="margin-left: 36pt; text-align: justify; margin-bottom: 0pt; margin-top: 0pt;">(6)<span style="width: 24.34pt; display: inline-block;">&#160;</span>Represents the aggregate grant date fair value of restricted stock granted to each Director, calculated in accordance with the closing share price of the Company on the grant date. Messrs. Leslie, Roa, Mastronardi, Konisberg and Ms. Richardson forfeited their share awards upon their resignation from the Company.</p>
                <p style="margin-left: 36pt; text-align: justify; margin-top: 0pt;">(7)<span style="width: 24.34pt; display: inline-block;">&#160;</span>Represents the aggregate grant date fair value of options granted to each Director, calculated in accordance with the Black Scholes method.</p>
                <div>
                    <p style="text-align: center;">42</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_48_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="background-color: #ffffff;">The table below sets forth the aggregate number of share options of each non-employee director outstanding as of December 31, 2023. The below does not include any grants of restricted Common Shares granted in 2024 in consideration for services rendered in fiscal year 2023. </span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i><b>Outstanding Equity Awards at 2023 Fiscal Year-End</b></i></span></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">The following table summarizes the number of outstanding restricted Common Shares and options in the Company held by our Directors as of December 31, 2023.</span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="6"><b>Option Awards</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="2"><b>Share Awards</b></td>
                        <td style="width: 6.46%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>&#160;</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>&#160;</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; padding-left: 4pt; padding-right: 4pt;"><b>Name</b></td>
                        <td style="width: 8.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Number of</b><br/><b>Securities</b><br/><b>Underlying</b><br/><b>Unexercised</b><br/><b>Options (#)</b><br/><b>Exercisable</b></td>
                        <td style="width: 9.08%; padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Number of</b><br/><b>Securities</b><br/><b>Underlying</b><br/><b>Unexercised</b><br/><b>Options (#)</b><br/><b>Unexercisable</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Equity</b><br/><b>incentive</b><br/><b>plan awards:<br/>Number of</b><br/><b>securities</b><br/><b>underlying</b><br/><b>unexercised</b><br/><b>unearned</b><br/><b>options</b><br/><b>(#)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Option</b><br/><b>Exercise</b><br/><b>Price ($)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Option</b><br/><b>Expiration</b><br/><b>Date</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Number of</b><br/><b>Shares or</b><br/><b>Units of</b><br/><b>Shares That</b><br/><b>Have Not</b><br/><b>Vested (#)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Market Value</b><br/><b>of Shares or</b><br/><b>Units of Shares</b><br/><b>That Have Not</b><br/><b>Vested ($) (1)(2)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Equity</b><br/><b>incentive</b><br/><b>plan awards:<br/>Number of</b><br/><b>unearned</b><br/><b>shares, units or<br/>other rights that<br/>have not vested</b><br/><b>(#)</b></td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Equity</b><br/><b>incentive</b><br/><b>plan awards:<br/>Market or<br/>payout value of</b><br/><b>unearned</b><br/><b>shares, units or<br/>other rights that<br/>have not vested</b><br/><b>($)</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Edward Woo</td>
                        <td style="width: 8.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 9.08%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">5,000</td>
                        <td style="width: 9.08%; padding-right: 4pt; vertical-align: top; background-color: #e6efff; text-align: right; padding-left: 4pt;">-</td>
                        <td style="width: 5.52%; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right; padding-right: 4pt;">$7.00</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">3/17/2033</td>
                        <td style="padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right; padding-right: 4pt;">74,512</td>
                        <td style="padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right; padding-right: 4pt;">$100,591</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; padding-left: 4pt; padding-right: 4pt;">Kevin Taylor</td>
                        <td style="width: 8.96%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 9.08%; padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                        <td style="width: 9.08%; padding-right: 4pt; vertical-align: top; background-color: #e6efff; text-align: right; padding-left: 4pt;">-</td>
                        <td style="width: 5.52%; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right; padding-right: 4pt;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right; padding-right: 4pt;">124,186</td>
                        <td style="padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right; padding-right: 4pt;">$167,651</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                        <td style="padding-right: 4pt; padding-left: 4pt; vertical-align: top; background-color: #e6efff; text-align: right;">-</td>
                    </tr>
                </table>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt; margin-top: 10pt;">(1)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span><span style="background-color: #ffffff;">The market value of unvested stock awards is based on the closing market price of our Common Shares on December 29, 2023 of $1.35.&#160; </span></p>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 0pt;">(2)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span><span style="background-color: #ffffff;">See "<i>Narrative to the Summary Compensation Table-Equity-Based Compensation - Outstanding Equity Awards at 2023 Fiscal Year-End"<b> </b></i>for details regarding the vesting schedules of certain Directors options and restricted Common Share awards.&#160; </span></p>
                <p style="text-align: justify;"><i>Director Compensation Narrative</i></p>
                <p style="text-align: justify;">From the period from January 1, 2023 to March 31, 2023, each independent Board member received $10,000 per quarter for their services as board members. In addition, the chairperson of the Company's Audit Committee received $5,000 per quarter and the chairpersons of the Compensation and Nominating and Corporate Governance committees each received $3,750 per quarter. In addition, non-Chair committee members received $2,000 per quarter for each committee served upon. Subsequent to March 31, 2023, director compensation has been exclusively share-based.</p>
                <p style="text-align: justify;"><i><b>Employment and Consulting Agreements, Arrangements or Plans</b></i></p>
                <p style="text-align: justify;">The following describes the respective employment or consulting agreements entered into by the Company and its Named Executive Officers that are in effect as of the date hereof.</p>
                <div>
                    <p style="text-align: center;">43</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_49_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Clifford Starke</i></p>
                <p style="text-align: justify;"><i>Consulting Agreement and SAR Agreement</i></p>
                <p style="text-align: justify;">Effective December 15, 2023, Mr. Starke and the Company entered into a consulting agreement (the "Starke Agreement"), pursuant to which Mr. Starke will continue to serve as the Chief Executive Officer of the Company. The term of the Starke Agreement is for an indefinite period, unless sooner terminated in accordance with the agreement.</p>
                <p style="text-align: justify;">The Starke Agreement provides for a base salary of $420,000 (as may be increased by the Company's Board), applied retroactively to the date of appoint as Chief Executive Officer of the Company and the opportunity to participate in any equity compensation plan offered to other senior executives of the Company.</p>
                <p style="text-align: justify;">The Starke Agreement provides that upon execution thereof, Mr. Starke shall be granted 1,028,665 Stock Appreciation Rights, with an exercise price of US$1.21 per Stock Appreciation Right, representing the Company's closing share price on the grant date, which vest in 12 equal tranches. The first tranche will vest upon the Company's share price increasing by 50% from US$1.21 with each tranche thereafter requiring an additional 50% increase in share price to vest in accordance with the following schedule:</p>
                <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><b>Tranche</b></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><b>Percentage Increase in Flora</b><br/><b>Growth Corp. Share Price From</b><br/><b>Grant Date For Tranche to Vest</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">1</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">50%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">2</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">100%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">3</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">150%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">4</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">200%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">5</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">250%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">6</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">300%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">7</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">350%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">8</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">400%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">9</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">450%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">10</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">500%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">11</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">550%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">12</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">600%</td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;">The Stock Appreciation Rights expire 10 years from the grant date with a post-termination exercise period of one year. In addition to the foregoing, such Stock Appreciation Rights granted to Mr. Starke remain unexercisable, and subject to forfeiture, unless the Company's shareholders approve such Stock Appreciation Rights grant at this Annual Meeting.</p>
                <p style="text-align: justify;">In addition, upon termination of the Starke Agreement without "Cause" or resignation by Mr. Starke for "Good Reason," as those terms are defined in the Starke Agreement, Mr. Starke will, conditioned upon his execution of a separation and release agreement, be eligible to receive the following payments: an aggregate amount equal to 1.5x his base salary at the rate in effect on his last day of service, 50% of which shall be paid in a lump sum on the 3rd business day following the effective date of the separation and release agreement, and the remaining 50% of which shall be paid in 12 equal monthly installments commencing on the effective date of the termination of the Starke Agreement.</p>
                <div>
                    <p style="text-align: center;">44</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_50_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">In the event Mr. Starke is terminated without "Cause" or Mr. Starke resigns for "Good Reason" three months prior to or following a "Change in Control," as those terms are defined in the Starke Agreement, Mr. Starke will be eligible to receive the payments set forth above.</p>
                <p style="text-align: justify;">The foregoing description of the Starke Agreement is only a summary and is qualified in its entirety by reference to the full text of the Starke Agreement, which is filed as Exhibit 10.1 to the Current Report on Form 8-K filed by the Company on December 21, 2023.</p>
                <p style="text-align: justify;">During 2022, Mr. Starke was granted 5,000 restricted Common Shares which vested on December 23, 2023.</p>
                <p style="text-align: justify;">During 2023, Mr. Starke was granted 327,851 restricted Common Shares which vested on November 10, 2023.</p>
                <p style="text-align: justify;"><i>Dany Vaiman</i></p>
                <p style="text-align: justify;"><i>Executive Employment Agreement and SAR Agreement</i></p>
                <p style="text-align: justify;">Dany Vaiman and the Company, entered into an executive employment agreement on December 15, 2023 (the "Vaiman Agreement"), pursuant to which Mr. Vaiman will continue to serve as the Chief Financial Officer of the Company. The term of the Vaiman Agreement is for an indefinite period, unless sooner terminated in accordance with the agreement.</p>
                <p style="text-align: justify;">The Vaiman Agreement provides for a base salary of $275,000 (as may be increased by the Board) applied retroactively to the date of Mr. Vaiman's appointment as Chief Financial Officer of the Company, the opportunity to participate in any equity compensation plan of the Company, and other health, benefit and incentive plans offered to other senior executives of the Company. Mr. Vaiman is also entitled to paid time off and holiday pay in accordance with the Company's policies.</p>
                <p style="text-align: justify;">The Vaiman Agreement provides that upon execution thereof, Mr. Vaiman shall be granted 342,888&#160; Stock Appreciation Rights, with an exercise price of US$1.21, representing the Company's closing share price on the grant date,&#160; which vest in 8 equal tranches. The first tranche will vest upon the Company's share price increasing by 50% from US$1.21 with each tranche thereafter requiring an additional 50% increase in share price to vest in accordance with the following schedule:</p>
                <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><b>Tranche</b></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><b>Percentage Increase in Flora</b><br/><b>Growth Corp. Share Price From</b><br/><b>Grant Date For Tranche to Vest</b></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">1</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">50%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">2</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">100%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">3</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">150%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">4</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">200%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">5</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">250%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">6</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">300%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">7</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">350%</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">8</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">400%</td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">45</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_51_integixAnchor"></span>
                <p style="margin-top: 5pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                <p style="text-align: justify; margin-top: 10pt;">The Stock Appreciation Rights expire 10 years from the grant date with a post-termination exercise period of one year. In addition to the foregoing, such Stock Appreciation Rights granted to Mr. Vaiman remain unexercisable, and subject to forfeiture, unless the Company's shareholders approve such grant of Stock Appreciation Rights at this Annual Meeting.</p>
                <p style="text-align: justify;">In addition, upon termination of the Vaiman Agreement without "Cause" or resignation by Mr. Vaiman for "Good Reason," as those terms are defined in the Vaiman Agreement, Mr. Vaiman will, conditioned upon his execution of a separation and release agreement, be eligible to receive the following payments: an aggregate amount equal to 1.5x his base salary at the rate in effect on his last day of service, 50% of which shall be paid in a lump sum on the 3rd business day following the effective date of the separation and release agreement, and the remaining 50% of which shall be paid in 12 equal monthly installments commencing on the effective date of the termination of the Vaiman Agreement.</p>
                <p style="text-align: justify;">In the event Mr. Vaiman is terminated without "Cause" or Mr. Vaiman resigns for "Good Reason" three months prior to or following a "Change in Control," as those terms are defined in the Vaiman Agreement, Mr. Vaiman will be eligible to receive the payments set forth above, payable as set forth above.</p>
                <p style="text-align: justify;">The foregoing description of the Vaiman Agreement is only a summary and is qualified in its entirety by reference to the full text of the Vaiman Agreement, which is filed as Exhibit 10.2 to the Current Report on Form 8-K filed by the Company on December 21, 2023.</p>
                <p style="text-align: justify;">During 2023, Mr. Vaiman was granted 149,024 restricted Common Shares which vested on January 1, 2024.</p>
                <div>
                    <p style="text-align: center;">46</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_52_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>BUSINESS OF THE MEETING</b></p>
                <p style="text-align: justify;"><b>Financial Statements</b></p>
                <p style="text-align: justify;">The audited consolidated financial statements for the fiscal year ended December 31, 2023, together with the auditor's report thereon, will be presented to the Company's shareholders for review at the Annual Meeting. No vote by the shareholders is required with respect to this matter.</p>
                <p style="text-align: center;"><b>PROPOSAL NO. 1 - ELECTION OF DIRECTORS</b></p>
                <p style="text-align: justify;">The Nominating and Corporate Governance Committee recommended for nomination, and the Board nominated the following persons for election as members of our Board at the Annual Meeting of shareholders, who will hold office until the next annual meeting of the Company or until his or her successor is elected or appointed.</p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">Kevin Taylor</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">Clifford Starke</li>
                    <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">Edward Woo</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">Brendan Cahill</li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;">The section titled "Directors, Director Nominees &amp; Executive Officers" included in this Proxy Statement contains more information about the leadership skills and other experience that caused the Nominating and Corporate Governance Committee and the Board to determine that these nominees should serve as directors of the Company.</p>
                <p style="text-align: justify;">We believe that each of these director nominees possess the experience, skills, and qualities to fully perform his or her duties as a director and contribute to our success. Our director nominees have been nominated because they possess the highest standards of personal integrity, interpersonal and communication skills, are highly accomplished in their fields, understand the interests and issues that are important to our shareholders, and are able to dedicate sufficient time to fulfilling their obligations as directors. Our director nominees as a group complement each other with their respective experiences, skills, and qualities. While our director nominees make up a diverse group in terms of age, gender and professional experience, together they comprise a cohesive body in terms of Board process and collaboration.</p>
                <p style="text-align: justify;"><b>Vote Required</b>. The process for voting for election of each director will be by individual voting and not by slate. The Shareholders can vote for or withhold from voting on the election of each director on an individual basis. The election of each director requires the affirmative vote of the simple majority of votes cast at the Annual Meeting are cast "FOR" each director nominee.</p>
                <p style="text-align: justify;"><b>THE BOARD RECOMMENDS THAT SHAREHOLDERS VOTE "FOR" EACH OF THE NOMINEES DISCUSSED ABOVE AND PROXIES RECEIVED WILL BE SO VOTED UNLESS A SHAREHOLDER HAS SPECIFIED CONTRARY INSTRUCTIONS IN THE PROXY.</b></p>
                <div>
                    <p style="text-align: center;">47</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_53_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>PROPOSAL NO. 2 - RE-APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
                <p style="text-align: justify;">Our Audit Committee and Board has recommended that shareholders re-appoint Davidson &amp; Company LLP ("Davidson") as our independent registered public accounting firm for the 2024 fiscal year. Davidson &amp; Company LLP has served as the Company's independent registered public accounting firm since its appointment on October 30, 2020. In recommending Davidson as the Company's independent registered public accounting firm for 2024, the Audit Committee and Board considered several factors, including:</p>
                <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(1)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>The professional qualifications of Davidson, the lead audit partner, and other key engagement personnel.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(2)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>Davidson's independence and its processes for maintaining its independence.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(3)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>The appropriateness of Davidson's fees for audit and non-audit services.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;">(4)<span style="width: 7pt; text-indent: 0pt; display: inline-block;">&#160;</span>The results of management's and the Audit Committee's annual evaluations of the qualifications, performance and independence of Davidson.</p>
                <p style="text-align: justify;">The Board is soliciting proxies from Shareholders in favor of the re-appointment of Davidson &amp; Company LLP as the Company's auditors, to hold office for the fiscal year ending December 31, 2024, and to authorize the Board to determine their remuneration for the 2024 fiscal year.</p>
                <p style="text-align: justify;">A representative from Davidson is expected to attend the Annual Meeting of shareholders. A representative from Davidson will have the opportunity to make a statement if they desire to do so. A representative from Davidson is expected to be available to respond to appropriate questions.</p>
                <p style="text-align: justify;"><b>Vote Required</b>. The affirmative vote of a simple majority of the votes cast at the Annual Meeting are cast "FOR" re-appointment is required to re-appoint Davidson &amp; Company as the Company's auditors for the fiscal year ending December 31, 2024 and to authorize the Board to fix their remuneration.</p>
                <p style="text-align: justify;"><b>THE BOARD RECOMMENDS A VOTE "FOR" THE RE-APPOINTMENT OF DAVIDSON &amp; COMPANY LLP AS THE COMPANY'S AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024 AND AUTHORIZING THE BOARD TO FIX THEIR REMUNERATION, AND PROXIES EXECUTED AND RETURNED WILL BE SO VOTED UNLESS A SHAREHOLDER HAS SPECIFIED CONTRARY INSTRUCTIONS IN THE PROXY.</b></p>
                <p style="text-align: justify;"><b>Fees and Services of Independent Registered Public Accounting Firm</b></p>
                <p style="text-align: justify;">The table below summarizes the fees and expenses billed to us by Davidson for the years ended December 31, 2023 and 2022.</p>
                <div>
                    <p style="text-align: center;">48</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_54_integixAnchor"></span>
                <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Year</b></td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Audit Fees</b></td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Audit-Related Fees</b></td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Tax Fees</b></td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>All Other Fees</b></td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><b>Total</b></td>
                        <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">2023</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">530,000</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">192,318</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">--</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">--</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">722,318</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.75pt; padding-left: 5.75pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">2022</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">603,271</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">149,500</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">--</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">--</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;">752,771</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;"><i><b>Audit Fees.</b>&#160; </i>Audit fees consist of services rendered by an independent registered public accounting firm for the audit of our consolidated financial statements (including tax services performed to fulfill the auditor's responsibility under generally accepted auditing standards) and our internal control over financial reporting, reviews of the interim financial statements.</p>
                <p style="text-align: justify;"><i><b>Audit-Related Fees.</b> </i>Audit-related fees relate to assurance and associated services that traditionally are performed by the independence auditor including SEC filings, comfort letter, consents and comment letters in connection with regulatory filings.</p>
                <p style="text-align: justify;"><i><b>Tax Fees.&#160; </b></i>Tax fees consist of services rendered by an external auditor for tax compliance, tax consulting and tax planning.</p>
                <p style="text-align: justify;"><i><b>All Other Fees.</b>&#160; </i>All other fees are for any other permissible work that is not an Audit, Audit-Related or Tax Fee.</p>
                <p style="text-align: justify;"><b>Policy for Approval of Audit and Permitted Non-Audit Services</b></p>
                <p style="text-align: justify;">Our Audit Committee reviews and pre-approves the scope and the cost of audit services related to us and permissible non-audit services performed by the independent auditors, other than those for de minimis services which are approved by the Audit Committee prior to the completion of the audit.&#160; All of the services related to our Company provided by Davidson listed above have been pre-approved by the Audit Committee.</p>
                <div>
                    <p style="text-align: center;">49</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span id="page_55_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: center; margin-top: 0px;"><b>PROPOSAL NO. 3 - APPROVAL OF AMENDMENT TO THE 2022 PLAN </b></p>
                <p style="text-align: justify;"><b>Background</b></p>
                <p style="text-align: justify;">On July 5, 2022, in connection with the Company's 2022 annual and special meeting of shareholders, our shareholders approved our 2022 Plan, with the purpose of advancing the interests of our shareholders by enhancing our ability to attract, retain and motivate individuals to perform at the highest level. In connection with the Company's 2023 annual and special meeting of shareholders, our shareholders approved to increase the maximum number of Common Shares available for issuance under equity incentive awards granted pursuant to the 2022 Plan currently to 950,000 Common Shares. In addition, the maximum aggregate number of Common Shares that may be delivered under the 2022 Plan as a result of the exercise of stock options currently cannot exceed 850,000 Common Shares.</p>
                <p style="text-align: justify;">As of June 21, 2024, 124,187 Common Shares remain available for issuance under the 2022 Plan and 40,474 Common Shares were subject to outstanding awards under the 2022 Plan, including 7,500 Common Shares subject to outstanding options to purchase Common Shares.</p>
                <p style="text-align: justify;">On May 27, 2024, the Board approved, and recommended that it be submitted to the Company's shareholders for their approval, to amend the 2022 Plan to increase the number of Common Shares issuable under the 2022 Plan from 950,000 to 2,500,000 Common Shares. The Board believes that the 2022 Plan Amendment is necessary to continue to enable the Company to attract and retain qualified directors, officers, employees and consultants for the Company and its subsidiaries.</p>
                <p style="text-align: justify;"><b>Reasons for the Proposed 2022 Plan Amendment</b></p>
                <p style="text-align: justify;">As described above, we are seeking shareholder approval of an amendment to (i) increase the number of Common Shares issuable under the 2022 Plan from 950,000 to 2,500,000 Common Shares. In determining the amount of the increases contemplated by the 2022 Plan Amendment, the Compensation Committee and the Board considered, among other factors, the historical number of equity awards granted by the Company and potential future grants in the future. In addition, the Compensation Committee and the Board considered that due to general market volatility, the Company's share price has decreased as compared to its price at the time the 2022 Plan was adopted, and as a result, the original 950,000 Common Shares were utilized at rate quicker than management originally expected. If approved, the 2,500,000 Common Shares issuable under the 2022 Plan would represent 18.70% of the outstanding Common Shares as of June 21, 2024.</p>
                <p style="text-align: justify;">Since approval of the 2022 Plan, the Company has been able to incentivize its workforce and attract qualified employees, directors, officers and consultants. Because of the amount of Common Shares that remain available for issuance under the Company's 2022 Plan, the Company's ability to use long-term equity-based compensation as a significant component of its overall compensation would be quite limited going forward if the shareholders do not approve the 2022 Plan Amendment.</p>
                <p style="text-align: justify;">The purpose of this increase is to continue to be able to attract, retain and motivate executive officers and other employees, non-employee directors and certain advisors and consultants. Upon shareholder approval of the 2022 Plan Amendment, additional Common Shares will be reserved for issuance under the 2022 Plan, which will enable us to continue to grant equity awards to our officers, employees, consultants, advisors and nonemployee directors at levels determined by the Compensation Committee and the Board to be necessary to attract, retain and motivate the individuals who will be critical to our success in achieving our business objectives and thereby creating greater value for all our shareholders. Furthermore, we believe that equity compensation aligns the interests of our management and other employees with the interests of our other shareholders. Equity awards are a key component of our incentive compensation program. We believe that option grants and restricted stock grants have been critical in attracting and retaining talented employees and officers, aligning their interests with those of shareholders, and focusing key employees on our long-term growth. Approval of the 2022 Plan Amendment will permit us to continue to use share-based compensation to align shareholder and employee interests and to motivate employees and others providing services to us.</p>
                <div>
                    <p style="text-align: center;">50</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_56_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>We Manage Our Equity Award Use Carefully </i></p>
                <p style="text-align: justify;">Our Compensation Committee carefully monitors our total dilution and equity expense to ensure that we<b> </b>maximize shareholder value by granting only the appropriate number of equity awards necessary to attract, retain and motivate employees and other service providers.</p>
                <p style="text-align: justify;">Based on historical usage and our internal growth plans, we expect that the proposed increase of Common Shares to be reserved for issuance under the 2022 Plan to 2 million Common Shares would be sufficient for grants of awards until approximately 2026, assuming we continue to grant awards in a manner consistent with our historical usage and current practices and noting that future circumstances may require us to change our current equity grant practices. If the adoption of the 2022 Plan Amendment is approved, the share reserve under the 2022 Plan could last for a longer or shorter period of time, depending on our future equity grant practices, which we cannot predict with any degree of certainty at this time.</p>
                <p style="text-align: justify;">In light of the factors described above, and the fact that the ability to continue to grant equity compensation is vital to our ability to continue to attract and retain employees in the competitive labor markets in which we compete, the Board has determined that the proposed adoption of the 2022 Plan Amendment is reasonable and appropriate at this time.</p>
                <p style="text-align: justify;">The amount, if any, of awards to be awarded to employees, non-employee directors and consultants is determined by the Compensation Committee and is not presently determinable. Therefore, a New Plan Benefits Table is not provided. Information regarding awards to the NEOs in 2023 pursuant to the 2022 Plan and are provided in the section titled "<i>Narrative to the Summary Compensation Table-Equity-Based Compensation-Equity Awards to Named Executive Officers during 2022 and 2023"</i>.</p>
                <p style="text-align: justify;"><b>Summary of the 2022 Plan</b></p>
                <p style="text-align: justify;">A summary of the material provisions of the 2022 Plan, is included in this Proxy Statement under the section "<i>Executive Compensation-</i><span style="background-color: #ffffff;"><i><b> </b>Narrative to the Summary Compensation Table </i></span><i>- 2022 Plan</i>." The summary therein does not purport to be a complete description of all the provisions of the 2022 Plan and is qualified in its entirety by reference to the complete text of the 2022 Plan, which is set forth as Exhibit 4.5 to the Company's Registration Statement on Form S-8 (File No. 333-275576) filed with the SEC on November 15, 2023.</p>
                <div>
                    <p style="text-align: center;">51</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_57_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><b>Certain U.S. Federal Income Tax Consequences</b></p>
                <p style="text-align: justify;">The following is a summary of certain anticipated material U.S. federal income tax consequences generally applicable to awards to U.S. Participants (as defined below) made under the 2022 Plan.</p>
                <p style="text-align: justify;">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax consequences that may apply to a U.S. Participant with respect to awards under the 2022 Plan.&#160; In addition certain Participants in the Plan who are not U.S. Participants may be subject to U.S. federal income tax, depending on specific facts and circumstances, and this summary does not address U.S. federal income tax consequences with respect to those individuals.&#160; Further, this summary does not take into account the individual facts and circumstances of any particular U.S. Participant that may affect the U.S. federal income tax consequences of awards under the 2022 Plan.&#160; This summary does not address the U.S. federal net investment income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Participants.&#160; Except as specifically set forth below, this summary does not discuss applicable income tax reporting requirements.&#160; Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Participant.&#160; Each U.S. Participant should consult his or her own financial advisor, legal counsel, or accountant regarding the U.S. federal, U.S. state and local, and non-U.S. tax consequences of participation in the Plan.</p>
                <p style="text-align: justify;">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the "IRS") has been requested, or will be obtained, regarding the U.S. federal income tax consequences to a U.S. Participant arising from and relating to awards under the 2022 Plan.&#160; This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary.</p>
                <p style="text-align: justify;"><b>Each U.S. Participant should seek U.S. federal tax advice, based on such U.S. Participant's particular circumstances, from their own tax advisor.</b></p>
                <p style="text-align: justify;"><i>Scope of This Disclosure</i></p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">Authorities</span></p>
                <p style="text-align: justify;">This summary is based on the Code, Treasury Regulations, published IRS rulings, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the "Canada-U.S. Tax Convention"), and U.S. court decisions that are applicable as of the date of this document.&#160; Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive basis.&#160; This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">U.S. Participants</span></p>
                <p style="text-align: justify;">For purposes of this summary of U.S. federal income tax consequences, a "U.S. Participant" is an officer, director, employee, consultant or other person who provide services to the Company or any Related Entity who receives awards under the 2022 Plan and who is either a citizen of the U.S. or a resident alien of the U.S. for purposes of the Code and the Canada-U.S. Tax Convention.</p>
                <div>
                    <p style="text-align: center;">52</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_58_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="text-decoration: underline;">Non-U.S. Participants</span></p>
                <p style="text-align: justify;">For purposes of this summary, a "non-U.S. Participant" is an officer, director, employee, consultant or other person who provide services to the Company or any Related Entity who receives awards under the 2022 Plan but who is not a U.S. Participant.&#160; This summary does not address the U.S. federal income tax consequences of participation in the Plan by a non-U.S. Participant.&#160; Accordingly, a non-U.S. Participant should consult his or her own financial advisor, legal counsel, or accountant regarding the U.S. federal, U.S. state and local, and non-U.S. tax consequences (including the potential application of any tax treaties) of awards under the 2022 Plan.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">Certain Special Rules</span></p>
                <p style="text-align: justify;">The foreign earned income exclusion provisions and the foreign tax credit provisions of the Code may, under certain circumstances, reduce the U.S. federal income tax liability of a U.S. Participant with respect to participation in the Plan.&#160; U.S. Participants should consult their own financial advisor, legal counsel, or accountant regarding the foreign earned income exclusion provisions and the foreign tax credit provisions of the Code.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">Certain U.S. Federal Income Tax Consequences of Awards under the 2022 Plans</span></p>
                <p style="text-align: justify;">The following is a summary of certain anticipated material U.S. federal income tax consequences with respect to awards under the 2022 Plan.&#160; Failure to comply with Section 409A of the Code could lead to different and less favorable tax treatment.&#160; For the tax consequences of ownership and disposition of the Common Shares received pursuant to any of the aforementioned awards, see the section below under the heading "<i>Tax Consequences of the Ownership and Disposition of Common Shares</i>."&#160; The Plan is designed to permit the award of Incentive Stock Options qualified under Section 422 of the Code or non-qualified stock options for U.S. federal income tax purposes.&#160; The following discussion is subject in its entirety to the passive foreign investment company rules discussed below.</p>
                <p style="margin-bottom: 0pt; text-align: justify;"><i>Nonqualified Stock Options</i></p>
                <p style="margin-top: 0pt; text-align: justify;">A U.S. Participant will not be deemed to have received taxable income upon the grant of a nonqualified stock option. Upon the exercise of a nonqualified stock option, a U.S. Participant generally will be deemed to have received taxable ordinary income in an amount equal to the excess of the fair market value of the common stock received on the date of exercise over the option price.</p>
                <p style="text-align: justify;">Upon the exercise of a nonqualified stock option, we will ordinarily be entitled to a deduction for federal income tax purposes in an amount equal to the amount included in income by the U.S. Participant as a result of such exercise. This deduction will be available to us in the tax year in which the U.S. Participant recognizes the income.</p>
                <p style="text-align: justify;">The income arising from a U.S. Participant who is an employee exercising a nonqualified stock option will be treated as compensation income for any applicable income and payroll tax withholding purposes, and the Committee may allow the U.S. Participant to satisfy the tax withholding obligation by withholding a portion of the Common Shares that would otherwise be delivered upon exercise. The basis of Common Shares received upon the exercise of a nonqualified stock option will be the option exercise price paid plus the amount recognized by the U.S. Participant as taxable income attributable to such Common Shares as a result of the exercise. Gain or loss recognized by the U.S. Participant on a subsequent disposition of any such Common Shares will be capital gain or loss if such Common Shares constitute a capital asset in the hands of the U.S. Participant. A U.S. Participant's holding period will commence on the date of exercise.</p>
                <div>
                    <p style="text-align: center;">53</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_59_integixAnchor"></span>
                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><i>Incentive Stock Options</i></p>
                <p style="margin-top: 0pt; text-align: justify;">U.S. Participants will not be deemed to recognize taxable income upon the grant or exercise of an incentive stock option. If a U.S. Participant makes no disqualifying disposition of the common stock received upon exercise within the one-year period beginning after the transfer of such common stock to the U.S. Participant nor within two years from the date of grant of the incentive stock option, and if the U.S. Participant at all times from the date of the grant of the incentive stock option to a date three months before the date of exercise has been our employee, any gain recognized on the disposition of the common stock acquired upon exercise will be long-term capital gain. The difference between the fair market value of the common stock at the time of exercise and the exercise price will, however, be an item of tax preference, and may subject a U.S. Participant to the alternative minimum tax. We will not be entitled to any deduction with respect to the grant or exercise of the incentive stock option or the transfer of common stock acquired upon exercise.</p>
                <p style="text-align: justify;">If the U.S. Participant makes a disqualifying disposition of the common stock before the expiration of the one- or two-year holding periods described above, the U.S. Participant will be deemed to have received taxable ordinary income at the time of such disposition to the extent that the fair market value of the common stock at the time of exercise, or, if less, the amount realized on such disposition, exceeds the exercise price. To the extent that the amount realized on such disposition exceeds the fair market value of the common stock at the time of exercise, such excess will be taxed as capital gain if the common stock is otherwise a capital asset in the hands of the U.S. Participant. To the extent the U.S. Participant recognizes ordinary income on a disqualifying disposition of the common stock, we may be entitled to a deduction for federal income tax purposes in an amount equal to the ordinary income recognized by the U.S. Participant.</p>
                <p style="margin-bottom: 0pt; text-align: justify;"><i>Stock Appreciation Rights</i></p>
                <p style="margin-top: 0pt; text-align: justify;">A U.S. Participant will not be deemed to have received taxable income upon the grant or vesting of a stock appreciation right. Upon the exercise of a stock appreciation right, a U.S. Participant generally will be deemed to have received income, taxable for U.S. federal income tax purposes at ordinary income rates, equal to the fair market value at the time of exercise of any common stock received plus the amount of any cash received, and we will ordinarily be entitled to a deduction for federal income tax purposes equal to the amount of ordinary income recognized by the U.S. Participant as a result of such exercise.</p>
                <p style="text-align: justify;">The income arising from a U.S. Participant who is an employee exercising a stock appreciation right will be treated as compensation income for any applicable withholding tax purposes and the Committee may allow the U.S. Participant to satisfy the tax withholding obligation by withholding a portion of the Common Shares that would otherwise be delivered upon exercise. The basis of Common Shares received upon the exercise of a SAR will equal the fair market value of the Common Shares at the time of exercise. Gain or loss recognized by the U.S. Participant on a subsequent disposition of any such Common Shares will be capital gain or loss if such Common Shares constitute a capital asset in the hands of the U.S. Participant.</p>
                <div>
                    <p style="text-align: center;">54</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_60_integixAnchor"></span>
                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><i>Restricted Stock</i></p>
                <p style="margin-top: 0pt; text-align: justify;">Recipients of grants of restricted stock generally will be required to include as taxable ordinary income the fair market value of the restricted stock at the time it is no longer subject to a substantial risk of forfeiture. In contrast, unrestricted stock grants are taxable at grant. An award holder who makes an election under Section 83(b) of the Code (an "83(b) election") within 30 days of the date of grant of the restricted stock will incur taxable ordinary income on the date of grant equal to the fair market value of such shares of restricted stock (determined without regard to forfeiture restrictions). With respect to the sale of Common Shares after the forfeiture restrictions have expired, the holding period to determine whether the award recipient has long-term or short-term capital gain (or loss) generally begins when the restrictions expire, and the tax basis for such Common Shares will generally be based on the fair market value of the Common Shares on that date. However, if the award holder made an 83(b) election as described above, the holding period commences on the date of such election, and the tax basis will be equal to the fair market value of the Common Shares on the date of the election (determined without regard to the forfeiture restrictions on the Common Shares). If the award permits dividends to accrue while the restricted stock is subject to a substantial risk of forfeiture, such dividends will be paid if and when the underlying stock vests and will also be taxed as ordinary income. We generally will be entitled to an income tax deduction equal to amounts the award holder includes in ordinary income at the time of such income inclusion.</p>
                <p style="margin-bottom: 0pt; text-align: justify;"><i>Restricted Stock Units </i></p>
                <p style="margin-top: 0pt; text-align: justify;">Recipients of grants of restricted stock units (including performance share units) will not incur any U.S. federal income tax liability at the time the awards are granted. Award holders will recognize ordinary income equal to (i) the amount of cash received under the terms of the award or, as applicable, (ii) the fair market value of the Common Shares received (determined as of the date of receipt) under the terms of the award.&#160; We generally will be entitled to an income tax deduction equal to amounts the award holder includes in ordinary income at the time of such income inclusion.</p>
                <p style="margin-bottom: 0pt; text-align: justify;"><i>Dividends and Dividend Equivalents</i></p>
                <p style="margin-top: 0pt; text-align: justify;">If a restricted stock award permits dividends to accrue while the restricted stock is subject to a substantial risk of forfeiture, such dividends will be paid if and when the underlying stock vests and will also be taxed as ordinary income, unless the U.S. Participant has elected under Section 83(b) of the Code to accelerate income recognition and the taxability of the award to the date of grant.&#160; If a RSU permits dividend equivalent amounts to accrue while the RSU is subject to a substantial risk of forfeiture, such dividend equivalent amounts will be paid if and when the underlying stock units are paid in cash or Common Shares and will also be taxed as ordinary income.</p>
                <p style="margin-bottom: 0pt; text-align: justify;"><i>Other Stock-Based Awards or Performance Awards.</i></p>
                <p style="margin-top: 0pt; text-align: justify;">The 2022 Plan also authorizes other stock-based awards and performance awards, the terms of which are not specified in the 2022 Plan. The federal income tax consequences to recipients and to us upon the grant and exercise or settlement of these awards will depend on the terms of such awards.</p>
                <div>
                    <p style="text-align: center;">55</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_61_integixAnchor"></span>
                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><i>Special Rules for Executive Officers Subject to Section 16 of the Exchange Act</i>.</p>
                <p style="margin-top: 0pt; text-align: justify;">Special rules may apply to individuals subject to Section 16 of the Exchange Act. In particular, unless a special election is made under Section 83(b) of the Code, Common Shares received through the exercise or settlement of an award may be treated as restricted as to transferability and subject to a substantial risk of forfeiture for a period of up to six months after the date of exercise. Accordingly, the amount of any ordinary income recognized and the amount of our income tax deduction will be determined as of the end of that period.</p>
                <p style="margin-bottom: 0pt; text-align: justify;"><i>Section 409A of the Code</i></p>
                <p style="margin-top: 0pt; text-align: justify;">The foregoing discussion of tax consequences of awards under the 2022 Plan assumes that the award discussed is either not considered a "deferred compensation arrangement" subject to Section 409A of the Code, or has been structured to comply with its requirements.&#160; If an award is considered a deferred compensation arrangement subject to Section 409A but fails to comply, in operation or form, with the requirements of Section 409A, the affected U.S. Participant would generally be required to include in income when the award vests the amount deemed "deferred," would be required to pay an additional 20% income tax, and would be required to pay interest on the tax that would have been paid but for the deferral.&#160; The Committee intends to administer and interpret the 2022 Plan and all award agreements in a manner designed to satisfy the requirements of Section 409A of the Code and to avoid any adverse tax results thereunder to a holder of an award.</p>
                <p style="margin-bottom: 0pt; text-align: justify;"><i>Clawback or Recoupment</i></p>
                <p style="margin-top: 0pt; text-align: justify;">All awards under the 2022 Plan will be subject to forfeiture or other penalties pursuant to any clawback policy we may adopt or amend from time to time, as determined by the Committee.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">U.S. Federal Income Tax Consequences of Holding and Disposing of the Common Shares Received pursuant to Awards under 2022 Plan</span></p>
                <p style="margin-bottom: 0pt; text-align: justify;">The following discussion is subject, in its entirety, to the rules described below under the heading "<i>Passive Foreign Investment Company Rules</i>".</p>
                <p style="margin-top: 0pt; text-align: justify;"><i>Distributions on Common Shares</i></p>
                <p style="text-align: justify;">A U.S. Participant that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the Company's current or accumulated "earnings and profits", as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Participant at ordinary income tax rates if the Company is a PFIC for the tax year of such distribution or was a PFIC for the preceding tax year. To the extent that a distribution exceeds the Company's current and accumulated "earnings and profits", such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Participant's tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares. (See "<i>Sale or Other Taxable Disposition of Common Shares</i>" below). However, the Company does not intend to maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Participant therefore should assume that any distribution by the Company with respect to the Common Shares will constitute ordinary dividend income. Dividends received on Common Shares by corporate U.S. Participants generally will not be eligible for the "dividends received deduction". Subject to applicable limitations and provided the Company is eligible for the benefits of the Canada-U.S. Tax Convention or the Common Shares are readily tradable on a United States securities market, dividends paid by the Company to non-corporate U.S. Participants, including individuals, in respect of Common Shares generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Company not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Participant should consult its own tax advisors regarding the application of such rules.</p>
                <div>
                    <p style="text-align: center;">56</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_62_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Sale or Other Taxable Disposition of Common Shares</i></p>
                <p style="text-align: justify;">Upon the sale or other taxable disposition of Common Shares, a U.S. Participant generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Participant's tax basis in such Common Shares sold or otherwise disposed of. A U.S. Participant's tax basis in Common Shares generally will be such U.S. Participant's U.S. dollar cost for such Common Shares. Gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</p>
                <p style="text-align: justify;">Preferential tax rates currently apply to long-term capital gain of a U.S. Participant that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Participant that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.</p>
                <p style="text-align: justify;"><i>Passive Foreign Investment Company Rules </i></p>
                <p style="text-align: justify;">If the Company were to constitute a "passive foreign investment company" or "PFIC" within the meaning of Section 1297 of the Code for any year during a U.S. Participant's holding period, then certain potentially adverse rules would affect the U.S. federal income tax consequences to a U.S. Participant resulting from the acquisition, ownership and disposition of Common Shares. The Company believes that it was not a PFIC for its most recently completed tax year. The Company's anticipated PFIC status for its current tax year and future tax years is uncertain and may depend on, among other things, how quickly the Company may raise cash, the manner in which, and how quickly, the Company utilizes its cash on hand and the cash proceeds raised in certain offerings, as well as on changes in the market value of Common Shares. No opinion of legal counsel or ruling from the IRS concerning its status as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Company or any of its subsidiaries concerning its PFIC status. Each U.S. Participant should consult its own tax advisors regarding the PFIC status of the Company and each of its subsidiaries.</p>
                <div>
                    <p style="text-align: center;">57</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_63_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">In any year in which the Company is classified as a PFIC, a U.S. Participant will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Participants should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.</p>
                <p style="text-align: justify;">The Company generally will be a PFIC if, for a tax year, (a) 75% or more of its gross income is passive income (the "PFIC income test") or (b) 50% or more of the value of its assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the "PFIC asset test"). "Gross income" generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and "passive income" generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions. Active business gains arising from the sale of commodities generally are excluded from passive income if substantially all of a foreign corporation's commodities are stock in trade or inventory, depreciable property used in a trade or business, or supplies regularly used or consumed in the ordinary course of its trade or business, and certain other requirements are satisfied.</p>
                <p style="text-align: justify;">For purposes of the PFIC income test and PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, "passive income" does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain "related persons" (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</p>
                <p style="text-align: justify;">Under certain attribution rules, if the Company is a PFIC, U.S. Participants will generally be deemed to own their proportionate share of the Company's direct or indirect equity interest in any company that is also a PFIC (a "Subsidiary PFIC"), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any "excess distributions," as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Company or another Subsidiary PFIC, both as if such U.S. Participants directly held the shares of such Subsidiary PFIC. In addition, U.S. Participants may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares. Accordingly, U.S. Participants should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.<br/><br/>Under proposed Treasury Regulations, if a U.S. Participant has an option, warrant or other right to acquire stock of a PFIC (such as the options), such option, warrant or right is considered to be PFIC stock subject to the default rules of Section 1291 of the Code. Under the rules described below, the holding period for the Common Shares received upon the exercise of a stock option will begin on the date a U.S. Participant is issued such stock option. This will impact the availability of the QEF Election and Mark-to-Market Election (each as defined below) with respect to the Common Shares received upon exercise of such option.</p>
                <div>
                    <p style="text-align: center;">58</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_64_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Default PFIC Rules Under Section 1291 of the Code</i></p>
                <p style="text-align: justify;">If the Company is a PFIC for any tax year during which a U.S. Participant owns Common Shares, the U.S. federal income tax consequences to such U.S. Participant of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Participant makes an election to treat the Company and each Subsidiary PFIC, if any, as a "qualified electing fund" or "QEF" under Section 1295 of the Code (a "QEF Election") or makes a mark-to-market election under Section 1296 of the Code (a "Mark-to-Market Election"). A U.S. Participant that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a "Non-Electing U.S. Participant."</p>
                <p style="text-align: justify;">A Non-Electing U.S. Participant will be subject to the rules of Section 1291 of the Code (described below) with respect to: (a) any gain recognized on the sale or other taxable disposition of Common Shares; and (b) any "excess distribution" received on the Common Shares. A distribution generally will be an "excess distribution" to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Participant's holding period for the Common Shares, if shorter).</p>
                <p style="text-align: justify;">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any "excess distribution" received on Common Shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Participant's holding period for the respective Common Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Participant that is not a corporation must treat any such interest paid as "personal interest," which is not deductible.</p>
                <p style="text-align: justify;">If the Company is a PFIC for any tax year during which a Non-Electing U.S. Participant holds Common Shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Participant, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Participant may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if Common Shares were sold on the last day of the last tax year for which the Company was a PFIC.</p>
                <div>
                    <p style="text-align: center;">59</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_65_integixAnchor"></span>
                <p style="margin-top: 0pt; text-align: justify;"><br/><i>QEF Election</i></p>
                <p style="text-align: justify;">A U.S. Participant that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares. A U.S. Participant that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Participant's pro rata share of (a) the Company's net capital gain, which will be taxed as long-term capital gain to such U.S. Participant, and (b) the Company's ordinary earnings, which will be taxed as ordinary income to such U.S. Participant. Generally, "net capital gain" is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and "ordinary earnings" are the excess of (a) "earnings and profits" over (b) net capital gain. A U.S. Participant that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Participant by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Participants that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Participant that made a QEF Election has an income inclusion, such a U.S. Participant may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Participant is not a corporation, any such interest paid will be treated as "personal interest," which is not deductible.</p>
                <p style="text-align: justify;">A U.S. Participant that makes a timely and effective QEF Election with respect to the Company generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents the Company's "earnings and profits" that were previously included in income by the U.S. Participant because of such QEF Election and (b) will adjust such U.S. Participant's tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Participant that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</p>
                <p style="text-align: justify;">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as "timely" if such QEF Election is made for the first year in the U.S. Participant's holding period for the Common Shares in which the Company is a PFIC. A U.S. Participant may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Participant files a U.S. federal income tax return for such year. If a U.S. Participant does not make a timely and effective QEF Election for the first year in the U.S. Participant's holding period for the Common Shares, the U.S. Participant may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Participant meets certain requirements and makes a "purging" election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective. If a U.S. Participant makes a QEF Election but does not make a "purging" election to recognize gain as discussed in the preceding sentence, then such U.S. Participant shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares. If a U.S. Participant owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Participant is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs.</p>
                <p style="text-align: justify;">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Participant makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company is not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Participant will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.</p>
                <div>
                    <p style="text-align: center;">60</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_66_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">As discussed above, under proposed Treasury Regulations, if a U.S. Participant has an option, warrant or other right to acquire stock of a PFIC (such as the options), such option, warrant or right is considered to be PFIC stock subject to the default rules of Section 1291 of the Code. However, a U.S. Participant of an option, warrant or other right to acquire stock of a PFIC may not make a QEF Election that will apply to the option, warrant or other right to acquire PFIC stock. In addition, under proposed Treasury Regulations, if a U.S. Participant holds an option, warrant or other right to acquire stock of a PFIC, the holding period with respect to shares of stock of the PFIC acquired upon exercise of such option, warrant or other right will include the period that the option, warrant or other right was held.</p>
                <p style="text-align: justify;">Consequently, under the proposed Treasury Regulations, if a U.S. Participant holding Common Shares received upon exercise of options makes a QEF Election, such election generally will not be treated as a timely QEF Election with respect to such Common Shares (unless such options are exercised in the same tax year in which they are received and a QEF Election is made for such tax year) and the rules of Section 1291 of the Code discussed above will continue to apply with respect to such U.S. Participant's Common Shares. However, a U.S. Participant holding Common Shares received upon exercise of options should be eligible to make a timely QEF Election if such U.S. Participant makes a "purging" or "deemed sale" election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for fair market value. As a result of the "purging" or "deemed sale" election, the U.S. Participant will have a new tax basis and holding period in the Common Shares acquired upon the exercise of the options for purposes of the PFIC rules. In addition, gain recognized on the sale or other taxable disposition (other than by exercise) of the options by a U.S. Participant will be subject to the default rules of Section 1291 of the Code discussed above. Each U.S. Participant should consult its own tax advisor regarding the application of the PFIC rules to the Common Shares.</p>
                <p style="text-align: justify;">U.S. Participants should be aware that there can be no assurances that the Company will satisfy the record keeping requirements that apply to a QEF, or that the Company will supply U.S. Participants with information that such U.S. Participants are required to report under the QEF rules, in the event the Company is a PFIC. Thus, U.S. Participants may not be able to make a QEF Election with respect to their Common Shares. Each U.S. Participant should consult its own tax advisors regarding the availability of, and procedure for making, a QEF Election.</p>
                <p style="text-align: justify;">A U.S. Participant makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return. However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S. Participants will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Participants with respect to the taxation of gains and excess distributions.</p>
                <div>
                    <p style="text-align: center;">61</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_67_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Mark-to-Market Election</i></p>
                <p style="text-align: justify;">A U.S. Participant may make a Mark-to-Market Election only if the Common Shares are marketable stock. The Common Shares generally will be "marketable stock" if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the SEC, (b) the national market system established pursuant to section 11A of the Exchange Act, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be "regularly traded" for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Each U.S. Participant should consult its own tax advisor in this matter.</p>
                <p style="text-align: justify;">A U.S. Participant that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares. However, if a U.S. Participant does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Participant's holding period for the Common Shares for which the Company is a PFIC and such U.S. Participant has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</p>
                <p style="text-align: justify;">A U.S. Participant that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Participant's adjusted tax basis in such Common Shares. A U.S. Participant that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Participant's adjusted tax basis in the Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</p>
                <p style="text-align: justify;">A U.S. Participant that makes a Mark-to-Market Election generally also will adjust such U.S. Participant's tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Participant that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations.</p>
                <p style="text-align: justify;">A U.S. Participant makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to be "marketable stock" or the IRS consents to revocation of such election. Each U.S. Participant should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</p>
                <div>
                    <p style="text-align: center;">62</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span></span>
                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;">Although a U.S. Participant may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Participant is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</p>
                <p style="text-align: justify; margin-top: 10pt;"><i>Other PFIC Rules</i></p>
                <p style="text-align: justify;">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Participant that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations) in the event the Company is a PFIC during such U.S. Participant's holding period for the relevant shares. However, the specific U.S. federal income tax consequences to a U.S. Participant may vary based on the manner in which Common Shares are transferred.</p>
                <p style="text-align: justify;">If finalized in their current form, the proposed Treasury Regulations applicable to PFICs would be effective for transactions occurring on or after April 1, 1992. Because the proposed Treasury Regulations have not yet been adopted in final form, they are not currently effective, and there is no assurance that they will be adopted in the form and with the effective date proposed. Nevertheless, the IRS has announced that, in the absence of final Treasury Regulations, taxpayers may apply reasonable interpretations of the Code provisions applicable to PFICs and that it considers the rules set forth in the proposed Treasury Regulations to be reasonable interpretations of those Code provisions. The PFIC rules are complex, and the implementation of certain aspects of the PFIC rules requires the issuance of Treasury Regulations which in many instances have not yet been promulgated and which, when promulgated, may have retroactive effect. U.S. Participants should consult their own tax advisors about the potential applicability of the proposed Treasury Regulations.</p>
                <p style="text-align: justify;">Certain additional adverse rules may apply with respect to a U.S. Participant if the Company is a PFIC, regardless of whether such U.S. Participant makes a QEF Election. For example, under Section 1298(b)(6) of the Code, a U.S. Participant that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</p>
                <p style="text-align: justify;">In addition, a U.S. Participant who acquires Common Shares from a decedent will not receive a "step up" in tax basis of such Common Shares to fair market value unless such decedent had a timely and effective QEF Election in place.</p>
                <p style="text-align: justify;">Special rules also apply to the amount of foreign tax credit that a U.S. Participant may claim on a distribution from a PFIC. Subject to such special rules and the foreign tax credit rules described below, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Participant should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</p>
                <div>
                    <p style="text-align: center;">63</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_69_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">The PFIC rules are complex, and each U.S. Participant should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">Additional Considerations </span></p>
                <p style="text-align: justify;"><i>Receipt of Foreign Currency </i></p>
                <p style="text-align: justify;">The amount of any distribution paid to a U.S. Participant in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. Participant will have a tax basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Participant who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Participants who use the accrual method of tax accounting. Each U.S. Participant should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</p>
                <p style="text-align: justify;"><i>Foreign Tax Credit </i></p>
                <p style="text-align: justify;">Dividends paid on the Common Shares will be treated as foreign-source income, and generally will be treated as "passive category income" or "general category income" for U.S. foreign tax credit purposes. Any gain or loss recognized on a sale or other disposition of Common Shares generally will be United States source gain or loss. Certain U.S. Participants that are eligible for the benefits of Canada-U.S. Tax Convention may elect to treat such gain or loss as Canadian source gain or loss for U.S. foreign tax credit purposes. The Code applies various complex limitations on the amount of foreign taxes that may be claimed as a credit by U.S. taxpayers. In addition, Treasury Regulations that apply to foreign taxes paid or accrued (the "Foreign Tax Credit Regulations") impose additional requirements for Canadian withholding taxes to be eligible for a foreign tax credit, and there can be no assurance that those requirements will be satisfied. The Treasury Department has recently released guidance temporarily pausing the application of certain of the Foreign Tax Credit Regulations.</p>
                <p style="text-align: justify;">Subject to the PFIC rules and the Foreign Tax Credit Regulations, each as discussed above, a U.S. Participant that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Participant, to receive either a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Participant's U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Participant's income that is subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Participant during a year. The foreign tax credit rules are complex and involve the application of rules that depend on a U.S. Participant's particular circumstances. Accordingly, each U.S. Participant should consult its own U.S. tax advisor regarding the foreign tax credit rules.</p>
                <div>
                    <p style="text-align: center;">64</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_70_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Backup Withholding and Information Reporting </i></p>
                <p style="text-align: justify;">Under U.S. federal income tax law and Treasury Regulations, certain categories of U.S. Participants must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Participants that hold certain specified foreign financial assets in excess of certain threshold amounts. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a non-U.S. entity. U.S. Participants may be subject to these reporting requirements unless their Common Shares are held in an account at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Participants should consult their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</p>
                <p style="text-align: justify;">Payments made within the U.S. or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of Common Shares will generally be subject to information reporting and backup withholding tax if a U.S. Participant (a) fails to furnish such U.S. Participant's correct U.S. taxpayer identification number (generally on IRS Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Participant has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Participant has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Participant that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Participant's U.S. federal income tax liability, if any, or will be refunded, if such U.S. Participant furnishes required information to the IRS in a timely manner.</p>
                <p style="text-align: justify;">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Participant. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax, and under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Participant should consult its own tax advisors regarding the information reporting and backup withholding rules.</p>
                <p style="text-align: justify;"><b>2022 Plan Amendment Resolution</b></p>
                <p style="text-align: justify;">At the Annual Meeting, shareholders will be asked to consider and, if thought appropriate, pass, with or without variation, the following ordinary resolution to approve the 2022 Plan Amendment (the "2022 Plan Amendment Resolution"):</p>
                <div>
                    <p style="text-align: center;">65</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span id="page_71_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: justify; margin-top: 0px;">"<b>BE IT RESOLVED AS AN ORDINARY RESOLUTION THAT: </b>Section 4(a) of the 2022 Incentive Compensation Plan is hereby amended to read in its entirety as follows:</p>
                <div>
                    <div>
                        <p style="margin-left: 72pt; text-align: justify;">(a)<span style="width: 24pt; display: inline-block;">&#160;</span>Limitation on Overall Number of Shares Available for Delivery Under Plan. Subject to adjustment as provided in Section 9(c) hereof, the total number of Shares reserved and available for delivery under the Plan shall be 2,500,000. Any Shares delivered under the Plan may consist, in whole or in part, of authorized and unissued shares or treasury shares."</p>
                        <p style="text-align: justify;"><b>Vote Required.</b> For the 2022 Plan Amendment to be approved and confirmed, the 2022 Plan Amendment Resolution must be passed by the affirmative vote of a simple majority of the votes cast at the Annual Meeting are cast "FOR" approval.</p>
                        <p style="text-align: justify;"><b>THE BOARD RECOMMENDS A VOTE "FOR" THE 2022 PLAN AMENDMENT RESOLUTION AND PROXIES EXECUTED AND RETURNED WILL BE SO VOTED UNLESS A SHAREHOLDER HAS SPECIFIED CONTRARY INSTRUCTIONS IN THE PROXY.</b></p>
                        <div>
                            <p style="text-align: center;">66</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_72_integixAnchor"></span>
                        <p style="text-align: center; margin-top: 10pt;"><b>PROPOSAL NO. 4 - APPROVAL OF STOCK APPRECIATION RIGHTS PROPOSAL </b></p>
                        <p style="text-align: justify;"><b>Background</b></p>
                        <p style="text-align: justify;"><i>Clifford Starke Stock Appreciation Rights</i></p>
                        <p style="text-align: justify;">On December 15, 2023, the Company entered into a consulting agreement with Clifford Starke, Chief Executive Officer of the Company. In connection with entering into the consulting agreement, Mr. Starke was granted 1,028,665 Stock Appreciation Rights, with an exercise price of US$1.21 per Stock Appreciation Right, representing the Company's closing share price on the grant date, which vest in 12 equal tranches. The first tranche will vest upon the Company's share price increasing by 50% from US$1.21 with each tranche thereafter requiring an additional 50% increase in share price to vest in accordance with the below vesting schedule (the "December Starke Stock Appreciation Rights"). The December Starke Stock Appreciation Rights expire 10 years from the grant date with a post-termination exercise period of one year. The December Starke Stock Appreciation Rights remain unexercisable, and subject to forfeiture, unless the Company's shareholders approve the Stock Appreciation Rights Proposal at the Annual Meeting.</p>
                        <p style="text-align: justify;">On May 27, 2024, the Board authorized an award of Stock Appreciation Rights (the "May Starke Stock Appreciation Rights") to be granted as of the date of the Annual Meeting if shareholders approve the Stock Appreciation Rights Proposal (the "SAR Approval Date"). The number of May Starke Stock Appreciation Rights will equal 12% of the total issued and outstanding Common Shares as of the date of the SAR Approval Date<i> less</i> 1,028,665, with an exercise price per right equal to the Company's closing share price on Nasdaq on the SAR Approval Date (the "SAR Exercise Price"), which vest in 12 equal tranches. The first tranche will vest upon the Company's share price increasing by 50% from the SAR Exercise Price with each tranche thereafter requiring an additional 50% increase in share price to vest in accordance with the below vesting schedule (the "May Starke Stock Appreciation Rights" and together with the December Starke Stock Appreciation Rights, the "Starke Stock Appreciation Rights"). The May Starke Stock Appreciation Rights expire 10 years from the grant date with a post-termination exercise period of one year.</p>
                        <p style="text-align: justify;">The Starke Stock Appreciation Rights will vest in accordance with the following vesting schedule:</p>
                        <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><b>Tranche</b></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><b>Percentage Increase in Flora</b><br/><b>Growth Corp. Share Price From</b><br/><b>Grant Date For Tranche to Vest</b></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">1</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">50%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">2</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">100%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">3</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">150%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">4</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">200%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">5</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">250%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">6</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">300%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">7</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">350%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">8</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">400%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">9</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">450%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">10</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">500%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">11</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">550%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">12</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">600%</td>
                            </tr>
                        </table>
                        &#160;
                        <div>
                            <p style="text-align: center; margin-top: 10pt;">67</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_73_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;"><i>Dany Vaiman Stock Appreciation Rights</i></p>
                        <p style="text-align: justify;">On December 15, 2023, the Company entered into an executive employment agreement with Dany Vaiman, Chief Financial Officer of the Company. In connection with entering into the executive employment agreement, Mr. Vaiman was granted 342,888 Stock Appreciation Rights, with an exercise price of US$1.21 per Stock Appreciation Right, representing the Company's closing share price on the grant date, which vest in 8 equal tranches. The first tranche will vest upon the Company's share price increasing by 50% from US$1.21 with each tranche thereafter requiring an additional 50% increase in share price to vest in accordance with the below vesting schedule (the "December Vaiman Stock Appreciation Rights" and together with the December Starke Stock Appreciation Rights, the "December Stock Appreciation Rights"). The December Vaiman Stock Appreciation Rights expire 10 years from the grant date with a post-termination exercise period of one year. The December Vaiman Stock Appreciation Rights remain unexercisable, and subject to forfeiture, unless the Company's shareholders approve the Stock Appreciation Rights Proposal at the Annual Meeting.</p>
                        <p style="text-align: justify;">On May 27, 2024, the Board authorized an award of Stock Appreciation Rights (the "May Vaiman Stock Appreciation Rights") to be granted as of the date of the Annual Meeting if shareholders approve the Stock Appreciation Rights Proposal. The number of May Vaiman Stock Appreciation Rights will equal 4% of the total issued and outstanding Common Shares as of the date of the SAR Approval Date<i> less</i> 342,888, with an exercise price per right equal to the SAR Exercise Price, which vest in 8 equal tranches. The first tranche will vest upon the Company's share price increasing by 50% from the SAR Exercise Price with each tranche thereafter requiring an additional 50% increase in share price to vest in accordance with the below vesting schedule (the "May Vaiman Stock Appreciation Rights" and together with the December Starke Stock Appreciation Rights, the "Vaiman Stock Appreciation Rights"). The May Vaiman Stock Appreciation Rights expire 10 years from the grant date with a post-termination exercise period of one year.</p>
                        <p style="text-align: justify;">The Vaiman Stock Appreciation Rights will vest in accordance with the following vesting schedule:</p>
                        <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><b>Tranche</b></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><b>Percentage Increase in Flora</b><br/><b>Growth Corp. Share Price From</b><br/><b>Grant Date For Tranche to Vest</b></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">1</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">50%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">2</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">100%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">3</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">150%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">4</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">200%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">5</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">250%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">6</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">300%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">7</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">350%</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">8</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">400%</td>
                            </tr>
                        </table>
                        &#160;
                        <div>
                            <p style="text-align: center; margin-top: 10pt;">68</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_74_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;"><b>Reasons for the Proposed Stock Appreciation Rights</b></p>
                        <p style="text-align: justify;">The Board's main goal in designing the Starke Stock Appreciation Rights and the Vaiman Stock Appreciation Rights (together, the "Proposed Stock Appreciation Rights") is to create significant value for Flora shareholders. The Board's primarily objectives includes:</p>
                        <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify;">1)<span style="width: 10pt; text-indent: 0pt; display: inline-block;">&#160;</span><span style="text-decoration: underline;">Incentivize Mr. Starke and Mr. Vaiman, and further align their interests with those of Flora's other shareholders</span></p>
                        <p style="margin-left: 35.7pt; text-align: justify;">The board believes in compensating Mr. Starke and Mr. Vaiman fairly and providing material compensation if all other shareholders realize significant value. Under the vesting of these awards, all shareholders will benefit with the value of Flora's equity increasing by tens of millions of dollars. Flora's shareholders will realize the real-time benefits of any increases to Flora's stock price. This is a genuine pay for performance award that strongly aligns Mr. Starke's and Mr. Vaiman's interests with the interest of all shareholders and Flora.</p>
                        <p style="margin-left: 35.7pt; text-indent: -17.85pt; text-align: justify;">2)<span style="width: 7.85pt; text-indent: 0pt; display: inline-block;">&#160;</span><span style="text-decoration: underline;">Ensure the continuity of their leadership over the long-term</span></p>
                        <p style="margin-left: 35.7pt; text-align: justify;">The Board believes that securing the services of Mr. Starke and Mr. Vaiman over the long-term is in the best interests of the Flora. The Board recognizes that achieving the vesting of the award tranches will require the commitment and full engagement of the CEO and CFO. This will ensure both executives are focused on driving shareholder while leading all key aspects of Flora's business.</p>
                        <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify;">3)<span style="width: 10pt; text-indent: 0pt; display: inline-block;">&#160;</span><span style="text-decoration: underline;">Transform Flora into a Company with a market capitalization in excess of $100 million</span></p>
                        <p style="margin-left: 36pt; text-align: justify;">The board believes that these awards, if fully vested, would result in an 800% increase to Flora's share price since the respective grant dates - an ambitious and meaningful objective that will benefit all shareholders of the Company. By fully aligning the interests of the CEO and CFO with those of Flora's shareholders, Flora will be one step closer to achieving this goal.</p>
                        <p style="text-align: justify;"><b>Potential Value that Could be Realized under the Proposed Stock Appreciation Rights</b></p>
                        <p style="text-align: justify;">It is not possible to reliably estimate the value that could be realized under the Proposed Stock Appreciation Rights because the value depends on the amount of dilution that Flora experiences over the course of the term of the rights. The more dilution, the less value will be realized by the CEO and CFO. While Flora has no way of predicting how much dilution there will be, some amount of future dilution is a certainty, whether due to additional issuances of equity as part of (i) regular compensation awards to Flora employees, (ii) capital-raising activities, or (iii) mergers and acquisitions. Thus, it is not possible to know the value that the CEO and CFO will realize from the Proposed Stock Appreciation Rights even if one were to assume that the rights would fully vest.</p>
                        <p style="text-align: justify;">The table below shows the maximum theoretical value, both in dollar value and as a percentage of total value created, that could be realized by the CEO and CFO, and Flora shareholders over various vesting scenarios for the December Stock Appreciation Rights. The table below does not consider any estimated dilution. It also assumes that the CEO and CFO do not exercise any of the rights until the end of the term, which results in a significantly larger value being attributed than would be the case if the exercises were to happen as the rights vest.</p>
                        <div>
                            <p style="text-align: center;">69</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_75_integixAnchor"></span>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                        <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                            <tr>
                                <td style="width: 23%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify; white-space: nowrap;">&#160;</td>
                                <td style="width: 76%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;" colspan="4"><b>December Stock Appreciation Rights (1,371,553 SARs)</b></td>
                            </tr>
                            <tr>
                                <td style="width: 23%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify; white-space: nowrap;"><b>Total Tranches<br/>Earned</b></td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>CEO/CFO<br/>Value<br/>Realized ($M)</b></td>
                                <td style="width: 19%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Shareholder<br/>Value Realized<br/>($M)</b></td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>% of Value<br/>Realized by<br/>CEO/CFO via<br/>Rights</b></td>
                                <td style="width: 16%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center; white-space: nowrap;"><b>% of Value<br/>Realized to<br/>Shareholders</b></td>
                            </tr>
                            <tr>
                                <td style="width: 23%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">2 Tranches</td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">1.9</td>
                                <td style="width: 19%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">9.2</td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">16.9</td>
                                <td style="width: 16%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">83.1</td>
                            </tr>
                            <tr>
                                <td style="width: 23%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">4 Tranches</td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">3.7</td>
                                <td style="width: 19%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">19.0</td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">16.5</td>
                                <td style="width: 16%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">83.5</td>
                            </tr>
                            <tr>
                                <td style="width: 23%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">8 Tranches</td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">7.5</td>
                                <td style="width: 19%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">40.0</td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">15.7</td>
                                <td style="width: 16%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">84.3</td>
                            </tr>
                            <tr>
                                <td style="width: 23%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">12 Tranches</td>
                                <td style="width: 16%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">10.0</td>
                                <td style="width: 19%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">63.4</td>
                                <td style="width: 16%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center;">13.6</td>
                                <td style="width: 16%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center;">86.4</td>
                            </tr>
                        </table>
                        <p style="text-align: justify; margin-top: 10pt;">The above table does not include the May Starke Stock Appreciation Rights or the May Vaiman Stock Appreciation Rights because an exercise price for such stock appreciation rights will only be set on the SAR Approval Date.</p>
                        <p style="text-align: justify;"><b>U.S. Federal Income Tax Considerations</b></p>
                        <p style="text-align: justify;"><i>Federal Income Tax Consequences</i>.<b>&#160;</b>The following discussion is a brief summary of the principal U.S. federal income tax consequences of the Proposed Stock Appreciation Rights under the Internal Revenue Code of 1986, as amended (the "Code"), as in effect on the date of this Proxy Statement. Since neither Mr. Starke nor Mr. Vaiman are U.S. taxpayers, the discussion below is limited to the federal income tax consequences to the Company. The Code and its regulations are subject to change. This summary is not intended to be exhaustive and does not describe, among other things, state, local or non-U.S. income and other tax consequences.</p>
                        <p style="text-align: justify;"><i>Tax Effects for the Company</i>. In most cases, companies are entitled to a tax deduction in an amount equal to the ordinary income realized by a participant when the participant exercises a stock appreciation right and recognizes such income. However, Section 162(m) of the Code limits the deductibility of compensation paid to "covered employees" as defined in Section 162(m) of the Code. Under Section 162(m) of the Code, as most recently amended in December 2017, we expect that Mr. Starke and Mr. Vaiman will always be covered employees for purposes of Section 162(m) of the Code. No tax deduction is allowed for compensation paid to any covered employee to the extent that the total compensation for that executive exceeds $1,000,000 in any taxable year. Therefore, in any given year in which Mr. Starke or Mr. Vaiman exercises all or part of the Proposed Stock Appreciation Rights, we will be able to take a tax deduction of only $1,000,000 or less, regardless of the amount of compensation recognized from the exercise of the Proposed Stock Appreciation Rights.</p>
                        <div>
                            <p style="text-align: center;">70</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_76_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;"><b>Stock Appreciation Rights Proposal Resolution</b></p>
                        <p style="text-align: justify;">At the Annual Meeting, shareholders will be asked to consider and, if thought appropriate, pass, with or without variation, the following ordinary resolution to approve the Proposed Stock Appreciation Rights (the "Stock Appreciation Rights Resolution"):</p>
                        <p style="text-align: justify;">"<b>BE IT RESOLVED AS AN ORDINARY RESOLUTION THAT:</b> the Proposed Stock Appreciation Rights, as described in Proposal No. 4, hereby are, approved, confirmed and ratified in all respects."</p>
                        <p style="text-align: justify;"><b>Vote Required.</b> For the Stock Appreciation Rights Proposal to be approved and confirmed, the SARs Resolution must be passed by the affirmative vote of a simple majority of the votes cast at the Annual Meeting are cast "FOR" approval.</p>
                        <p style="text-align: justify;"><b>THE BOARD RECOMMENDS A VOTE "FOR" THE STOCK APPRECIATION RIGHTS RESOLUTION AND PROXIES EXECUTED AND RETURNED WILL BE SO VOTED UNLESS A SHAREHOLDER HAS SPECIFIED CONTRARY INSTRUCTIONS IN THE PROXY.</b></p>
                        <div>
                            <p style="text-align: center;">71</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_77_integixAnchor"></span>
                        <p style="text-align: center; margin-top: 10pt;"><b>PROPOSAL NO. 5 - APPROVAL OF SHARE ISSUANCE PROPOSAL </b></p>
                        <p style="text-align: justify;"><i>A</i><i><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">t the Annual Meeting, our shareholders are being asked to consider and vote upon the Share Issuance Resolution in connection with the issuance of 635,363 Common Shares in connection with the Acquisition of TruHC Pharma GmbH (the "Proposed Share Issuance"). Set forth below in this section and in the section entitled "The Stock Purchase Agreement" of this Proxy Statement, is a discussion of the Acquisition, including a description of the terms and conditions of the Stock Purchase Agreement (as defined below). Information about the Acquisition may be important to you in connection with your consideration of the Share Issuance Resolution. While we believe that the descriptions in this Proxy Statement cover the material terms of the Acquisition and the Stock Purchase Agreement, it may not contain all the information that is important to you. You should carefully read this entire Proxy Statement, including the Stock Purchase Agreement, and the other documents to which we have referred you.</span></i></p>
                        <p style="text-align: center;"><b>BACKGROUND AND REASONS FOR THE ACQUISITION</b></p>
                        <p style="text-align: justify;">O<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">n April 1, 2024, the Company entered into a binding letter of intent to acquire all of the issued and outstanding shares of TruHC TruHC from&#160;TruHC Holding in an all-stock deal in exchange for 2,770,562 Common Shares.</span></p>
                        <p style="text-align: justify;">O<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">n April 16, 2024, the Company entered into the Stock Purchase Agreement with TruHC Holding. The Stock Purchase Agreement provides for the acquisition of 100% of the issued and outstanding shares of TruHC, of which 100% was owned by TruHC Holding. On April 22, 2024, the Company completed the First Closing in exchange for a total of 2,135,199 Common Shares, representing approximately 77% of TruHC. The Second Closing for the balance of 635,363 Common Shares will take place after the shareholders of Flora approve the Share Issuance Resolution at this Annual Meeting</span>.</p>
                        <p style="text-align: justify;"><b>Background of the Acquisition</b></p>
                        <p style="text-align: justify;">The terms of the Acquisition were the result of arms' length negotiations between the representatives of the Company, on the one hand, and TruHC and its former parent company TruHC Holding, on the other hand. The following is a brief discussion of the background of the Acquisition, including the underlying negotiations and resulting Stock Purchase Agreement.</p>
                        <p style="text-align: justify;">As part of Flora's ongoing consideration and evaluation of its long-term prospects and strategies to enhance its shareholder value, the Board and its executive management regularly review and discuss strategic opportunities, including potential acquisitions. Among other things, these reviews and discussions focus on the opportunities and risks associated with entering transactions with other companies with complementary businesses.</p>
                        <p style="text-align: justify;">I<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">n furtherance of its evaluation of strategic acquisition opportunities, the Company determined that it is in the best of interest of shareholders to capitalize on the progressive legislative changes in the German cannabis framework. While the Company has had a presence in Germany, it has not historically had access to a EU-GMP facility in Germany. As such, the Company commenced a search for a German acquisition target with the requisite licenses and facility while adhering to the following criteria: (i) be of a size that would be transformative to the Company's business while being able to be integrated in a relatively seamless manner; (ii) be complementary to the Company's business with a solid foundation of core cannabis licenses; (iii) have a debt-free balance sheet such that a transaction would be accretive to the Company; and (iv) have an established and experienced management team in place to enable the Company to assume a strong position in the German cannabis market. The Company's executive management focused their efforts to facilitate and find a transaction that meets these criteria</span>.</p>
                        <div>
                            <p style="text-align: center;">72</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_78_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;">A<span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">s a result of a review process and utilization of the Company's network in Europe, TruHC was selected as the top candidate to pursue an acquisition transaction in Germany. Throughout the search and selection process, Flora&#8217;s management identified suitable publicly listed and privately held, to the extent available, cannabis companies globally and evaluated key information about each prospective cannabis company, including but not limited to balance sheet metrics, profit and loss summary and a qualitative assessment of the latest business developments of each company. In total, this search and evaluation process encompassed approximately 81 companies. Management selected TruHC as the top candidate primarily because of the EU-GMP licenses it holds, the track record of TruHC&#8217;s management and the relative value of TruHC, computed by TruHC&#8217;s management and corroborated by Flora&#8217;s management, compared to Flora. Prospective cannabis companies identified by management with similar licenses to TruHC with higher market capitalizations based on the most recently available trading price than Flora were deemed by management to be infeasible acquisition targets. In addition, Flora and TruHC have held productive discussions about business cooperation and the prospect of cannabis legalization in Germany prior to the Acquisition. The participants in these discussions included the CEO, CFO and Chairman of the Board of Flora, as well as the shareholders of TruHC&#8217;s parent company TruHC Holding, including Ronald D. Schmeichel and Josh Epstein and management of TruHC as represented by Hendrik Knopp. On February 29, 2024, initial discussions commenced between the Company and TruHC's management regarding the performance of due diligence procedures. On March 11, 2024, the Company received the initial drafts of the TruHC's financial records and tax accounts. On March 23, 2024, the Company obtained evidence and verifications for all TruHC's licenses, including EU-GMP processing and production license for medical cannabis, a Goods Distribution Practice ("GDP") wholesale license, and an EU-GMP certification for the operation of a medical laboratory</span>.</p>
                        <p style="text-align: justify;">At the completion of these initial verification steps, the Company's executive management presented to the Board on March 26, 2024 a proposal to acquire TruHC. Clifford Starke, Chief Executive Officer of Flora, discussed the potential acquisition of TruHC with the Board, highlighting the importance of gaining access to its EU-GMP facility as well as further strengthening the Flora team in Germany. The Board then passed a motion to enable Flora's executive team to negotiate a purchase price for a majority stake in TruHC.</p>
                        <p style="text-align: justify;">Over the next week negotiations continued and reached a mutually agreed upon level between the management of Flora and TruHC. The material terms of the proposals, subsequent proposals and counteroffers between Flora and TruHC regarding the Acquisition involved the purchase price, timing considerations and the resale restrictions of the Common Shares to be issued as consideration. Management of Flora and TruHC evaluated the aggregate costs that TruHC Holding incurred on behalf of TruHC to secure the EU-GMP and GDP licenses to inform the negotiations for the purchase price of the Acquisition. The labor component of such costs was approximately $2,500,000 as presented by a detailed schedule provided by TruHC&#8217;s Managing Director, Hendrik Knopp. Management of Flora and TruHC further negotiated the purchase price of the Acquisition by negotiating inflation adjustments, standard markups on labor, and a required return of 12% that resulted in an estimated valuation of approximately $4,100,000 for the TruHC licenses based on the replacement value method of valuation. From this position, management of Flora and TruHC evaluated Germany&#8217;s recent legislative measures related to recreational cannabis, the appreciation of Flora&#8217;s share price since acquisition negotiations commenced, and a premium for the control of TruHC. &#160;Management of Flora and TruHC negotiated and agreed on a purchase price for the Acquisition of 2,770,562 Common Shares, which occurred through verbal proposals and counterproposals between management of Flora, Ronald Schmeichel and Josh Epstein, principles of TruHC Holding who represented the shareholders of TruHC and Hendrik Knopp, Managing Director of TruHC, reflecting the matters discussed above over a period of approximately 14 days. In addition, the negotiating parties agreed that Flora would file a registration statement with the SEC upon the First Closing to register the resale of the Common Shares issued as consideration in the First Closing. The issuance of the Common Shares issuable as consideration in the Second Closing will take place if the shareholders of Flora approve the Share Issuance Resolution at this Annual Meeting in accordance with Nasdaq Listing Rule 5635(a). Throughout the negotiation process, Flora&#8217;s and TruHC&#8217;s management exchanged drafts of both a binding letter of intent and the Stock Purchase Agreement. The terms of the binding letter of intent were agreed upon by Flora and TruHC on March 31, 2024 over a negotiation period of approximately 16 days. The Board approved the Acquisition on March 31, 2024. On April 1, 2024, Flora and TruHC Holding signed a binding letter of intent encapsulating the key terms of the Acquisition. The terms of the Stock Purchase Agreement continued to be negotiated and discussed until April 16, 2024. The participants in these discussions included the CEO, CFO and Chairman of the Board of Directors of Flora, as well as the shareholders of TruHC represented by Ronald Schmeichel, and Josh Epstein and management of TruHC represented by Hendrik Knopp.</p>
                        <p style="text-align: justify;">On April 16, 2024, the company entered into the Stock Purchase Agreement with TruHC Holding pursuant to which the Company would acquire all of the issued and outstanding shares of TruHC in exchange for 2,770,562 Common Shares (the "Purchase Price") based on the closing price of the Company's Common Shares on March 28, 2024 of $2.31 per share. The Purchase Price consists of two closings. On the First Closing, which occurred on April 22, 2024, the Company issued 2,135,199 Common Shares, which is equal to 19.99% of the Company's issued and outstanding common shares prior to the signing of the Stock Purchase Agreement. On the Second Closing, the Company will issue 635,363 Common Shares after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at this Annual Meeting. It is in connection with this Second Closing that the Share Issuance Resolution is being sought.</p>
                        <p style="text-align: justify;">Under the Stock Purchase Agreement, the Company is required to take all necessary steps and commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Stock Purchase Agreement contains other customary terms, representations, warries, covenants and closing conditions for a transaction of this nature.</p>
                        <p style="text-align: justify;"><span style="font-size: 10pt; line-height: 107%; font-family: Times New Roman, serif;">Aegis Capital Corp. acted as a financial advisor to Flora in connection with the Stock Purchase Agreement.</span></p>
                        <div>
                            <p style="text-align: center;">73</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_79_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;"><b>Our Reasons for the Acquisition</b></p>
                        <p style="text-align: justify;">The Board considered and evaluated several factors, including, but not limited to, the factors discussed below, in connection with the Acquisition. In light of the number and wide variety of factors considered in connection with its evaluation of the Acquisition, the Board did not consider it practicable to, and not did not attempt to, quantify or otherwise assign relative weights to the specific factors that it considered in reaching its determination and supporting its decision. The Board viewed its decision as being based on all the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors. This explanation of the Board's reasons for the Acquisition and all other information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed in this Proxy Statement under <i>"Cautionary Note Regarding Forward-Looking Statements</i>."</p>
                        <p style="text-align: justify;">The Board considered the following factors in reaching its conclusion to approve the Acquisition, all of which the Board viewed as supporting its decision to approve the Acquisition and other aspects of the transaction:</p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The Board believes the acquisition of TruHC and its cannabis licenses will expand and accelerate the Company's ability to benefit from Germany's changing medical cannabis regime and multi-phase legalization of recreational cannabis.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The Board believes that TruHC's licenses, together with their anticipated impact, will result in a stronger market position in Germany from both a medical and recreational cannabis perspective, particularly given the phased legalization of recreational cannabis in Germany.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The Board believes that TruHC's experienced and high-reputable management team, will be important factor in achieving a foothold in Germany's cannabis industry.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The Board believes that there are synergies to be had by combining the Company's existing distribution network and infrastructure in Germany with TruHC's facility and management team.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The Board believes that the addition of TruHC will reduce our reliance on upon the success of Phatebo GmbH - the Company's current medical cannabis license holder and wholly-owned subsidiary.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The Board believes that the combined expertise and industry relationships of the Company and TruHC will broaden the distribution and future growth of our combined business, which will lead to an expanded and more diverse network, as well as greater market opportunity to launch more businesses in Germany.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The Board believes that the Company's executive management has undertaken a comprehensive and thorough process of reviewing and analyzing potential acquisition transactions and acquisitions candidates, as well as reaching out and having discussions with potential candidates to identify the opportunity that would, in the Board's view, create the most value for its shareholders.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The Board believes that the purchase price is fair and provides an opportunity to enhance shareholder value.</li>
                        </ul>
                        <div>
                            <p style="text-align: center; margin-top: 10pt;">74</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_80_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;">The Board reviewed the terms and conditions of the Stock Purchase Agreement, as well as the safeguards and protective provisions included therein intended to mitigate risks, including:</p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 30.1pt; text-align: justify; padding-left: 8.4pt;">The purchase price and two closings associated with its disbursement, including on the First Closing, by the issuance of 2,135,199 Common Shares and the Second Closing upon shareholder approval by the issuance of 635,363 Common Shares.</li>
                            <li style="margin-left: 30.1pt; text-align: justify; padding-left: 8.4pt;">The representations and warranties of TruHC, including but not limited to, no conflicts, no subsidiaries, financial statements, undisclosed liabilities, absence of certain changes, events and conditions, material contracts, legal proceedings, taxes, and brokers.</li>
                            <li style="margin-left: 30.1pt; text-align: justify; padding-left: 8.4pt;">The covenants of TruHC with regard to its conduct of business, access to information, no solicitation of other bids, notice of certain events, non-competition, non-solicitation, approvals and consents, books and records, and tax matters.</li>
                            <li style="margin-left: 30.1pt; text-align: justify; padding-left: 8.4pt;">The belief that the terms of the Stock Purchase Agreement, including the parties' representations, warranties and covenants, and the conditions to their respective obligations, are reasonable under the circumstances.</li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;">In the course of deliberations, the Board also considered a variety of risks and countervailing factors related to entering into the Stock Purchase Agreement, including:</p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">The possibility that the value of the licenses held by TruHC declines, whether due to additional grants or other factors.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The possibility volatility, at least in the short term, of the trading price of the Company's stock resulting from the announcement of the Acquisition.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The potential challenges in integrating the business of TruHC and the risk that the expected benefits of the Acquisition may not be realized to the extent anticipated or at all.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The fees and expenses to be incurred in connection with the Acquisition, including the costs associated and the time and effort management required to negotiate the terms and complete the Acquisition.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The risk that the Acquisition might not have been consummated in a timely manner or at all and the potential adverse effect of the public announcement of the Acquisition or delay or failure to complete the Acquisition may have on the reputation of the Company.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">The possibility of disruptive stockholder litigation following announcement of the Acquisition and the filing of this Proxy Statement.</li>
                            <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">The significant dilution to the Company's shareholders as a result of the Acquisition, including the Common Shares contemplated to be issued if the Share Issuance Resolution is approved at this Annual Meeting.</li>
                            <li style="margin-left: 28.52pt; text-align: justify; padding-left: 7.48pt;">The possibility that the Company's shareholders may not approve the Share Issuance Resolution at this Annual Meeting for the issuance of Common Shares in the Second Closing.</li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">Various other risks associated with the Acquisition, including those described in section titled "Risk Factors" of this Proxy Statement.</li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;">The foregoing information and factors considered by the Board are not intended to be exhaustive but are believed to be the material factors considered by the Board. The Board conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, the Company's executive management team, and the Company's legal advisors, and considered the factors overall to be favorable to, and to support, its determination. The Company has not received any reports, opinions or appraisals materially related to the Acquisition.</p>
                        <div>
                            <p style="text-align: center;">75</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_81_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;"><b>Interests of TruHC's Officers and its Managers in the Acquisition</b></p>
                        <p style="text-align: justify;"><i>Employment Agreements</i></p>
                        <p style="text-align: justify;">There was no consideration that was received by TruHC in connection with consummation of the Acquisition. Flora expects to enter into employment agreements with certain officers of TruHC, including Hendrik Knopp.</p>
                        <p style="text-align: justify;"><i>Non-Competition and Non-Solicitation</i></p>
                        <p style="text-align: justify;">Each executive officer of the TruHC is expected to enter into a non-competition agreement whereby they agree that they will not, from and after the First Closing until 6 months following the First Closing, manage, operate, carry on, engage in, join, control, or participate in the ownership, management, operation, carrying on, or control of any business or enterprise that engages in the restricted business within the applicable territory, or solicit any of the customers, suppliers or employees of TruHC or Flora.</p>
                        <p style="text-align: justify;"><b>Appraisal or Dissenters' Rights</b></p>
                        <p style="text-align: justify;">The shareholders at the Annual Meeting are not entitled to vote upon the Acquisition. In addition, no appraisal or dissenters' rights are available to our shareholders under Ontario law, our Articles of Incorporation, as amended, or our Bylaws as a result of the Acquisition or in connection with any matter to be acted upon at the Annual Meeting.</p>
                        <p style="text-align: justify;"><b>Federal Income Tax Consequences of the Acquisition</b></p>
                        <p style="text-align: justify;">The Acquisition is not expected to result in U.S. federal income tax consequences to our shareholders.</p>
                        <p style="text-align: justify;"><b>Accounting Treatment of the Acquisition</b></p>
                        <p style="text-align: justify;">The Acquisition will be accounted for under the acquisition method of accounting in accordance with the Financial Accounting Standard Board ("FASB"), Accounting Standard Codification or ASC 805-10, Business Combinations. Management has completed a preliminary allocation of the estimated Purchase Price to the tangible and intangible assets acquired and liabilities assumed based on various preliminary estimates and assumptions. These preliminary estimates and assumptions could change significantly after the Second Closing as we finalize the valuations of the net tangible assets and intangible assets. Any change could result in material variances between our future financial results and the amounts presented in the condensed combined pro forma financial statements included in this Proxy Statement, including variances in fair values recorded, as well as expenses associated with these items.</p>
                        <div>
                            <p style="text-align: center;">76</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_82_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;"><b>Regulatory Matters</b></p>
                        <p style="text-align: justify;">Neither the Company nor TruHC was required to make any filings or to obtain approvals or clearances from any antitrust regulatory authorities in the United States or other countries to consummate the Acquisition. In the United States, the Company must comply with applicable federal and state securities laws and the listing rules of the Nasdaq Stock Exchange in connection with the issuance of Common Shares in the Second Closing of the Acquisition, including the filing with the SEC of this Proxy Statement.</p>
                        <p style="text-align: center;"><b>FLORA GROWTH CORP. BUSINESS</b></p>
                        <p style="text-align: justify;"><b>Overview</b></p>
                        <p style="text-align: justify;">Flora is a prominent lifestyle brand in the United States and a player in international pharmaceutical distribution focused on therapeutics, starting with medical cannabis. The Company's approach has enabled us to develop distribution networks, build customer bases, establish operations as the regulatory framework evolves and allow for expanded access to cannabis and its derivatives.</p>
                        <p style="text-align: justify;">Just Brands LLC ("Just Brands") and High Roller Private Label LLC (together with Just Brands, "JustCBD") is Flora's leading consumer packaged goods brand. JustCBD was launched in 2017 with a mission to bring high-quality, trustworthy, and budget-friendly CBD products to market. The JustCBD offering currently consists of over 350 products across 15 categories, including CBD gummies, topicals, tinctures, and vape products and ships to over 11,500 independent retailers worldwide. JustCBD also sells direct to consumers with a customer base of approximately 350,000 people. JustCBD products are available for purchase in smoke and vape shops, clinics, spas and pet stores, as well as other independent non-traditional retail channels. JustCBD's products are both internally and third-party lab-tested to ensure quality.</p>
                        <p style="text-align: justify;">Vessel Brand Inc. ("Vessel") is Flora's cannabis accessory and technology brand currently servicing the United States and Canada through direct-to-consumer and retail sales. Vessel's products include cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herb categories, which are sold to consumers, dispensaries, smoke shops and cannabis brands. Vessel has been fully integrated into JustCBD and now benefits from operational, logistical and sales synergies with JustCBD.</p>
                        <p style="text-align: justify;">Based in Germany, <span style="background-color: #ffffff;">Phatebo GmbH ("</span>Phatebo) is a wholesale pharmaceutical distribution company with import and export capabilities of a wide range of pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, ADHD, multiple sclerosis and anti-depressants, among others. Phatebo holds a license for the Trade in Narcotic Drugs (including the cannabis sales license amendment) and a wholesale trading license, both of which are issued by BfArM (the largest drug approval authority in Europe). Phatebo is focused on distributing pharmaceutical products within 28 countries globally, primarily in Europe, but also with sales to Asia, Latin America, and North America. In November 2018, Phatebo also received a medical cannabis import and distribution license. Additionally, the Phatebo warehouse provides a logistics outpost for Flora's growing product portfolio and distribution network within the European Union.</p>
                        <div>
                            <p style="text-align: center;">77</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_83_integixAnchor"></span>
                        <p style="text-align: justify; margin-top: 10pt;"><b>Corporate Information</b></p>
                        <p style="text-align: justify;">Flora was originally incorporated on March 13, 2019, under the laws of the Province of Ontario. The Company is an early-stage company with our registered office located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1. Our principal place of business in the United States is located at 3406 SW 26th Terrace, Suite C-1, Fort Lauderdale, Florida 33312, and our phone number is (954) 842-4989. Our website address is www.floragrowth.com. The information contained on, or that can be accessed through, our website does not constitute a part of this Proxy Sttaement and is not incorporated by reference herein.</p>
                        <div>
                            <p style="text-align: center;">78</p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_84_integixAnchor"></span>
                        <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><b>FLORA GROWTH CORP. MANAGEMENT DISCUSSION AND ANALYSIS AND RESULTS OF OPERATION</b></p>
                        <p style="margin-top: 0pt; text-align: justify;"><br/>Set forth below is Flora's management discussion and analysis of financial condition and results of operations (the "Flora MD&amp;A") as reported in:</p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 28.52pt; padding-left: 7.48pt; text-align: justify;">the section entitled "<i>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</i>" in Flora's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the SEC on May 14, 2024 and attached to this Proxy Statement as Annex B; and</li>
                            <li style="margin-left: 28.52pt; padding-left: 7.48pt; text-align: justify;">the section entitled "<i>Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</i>" in Flora's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 28, 2024 and attached to this Proxy Statement as Annex C.</li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;">Flora's risk factors with respect to Flora's business (the "Flora Risk Factors") are reported in the section entitled "<i>Item 1A. Risk Factors</i>" in Flora's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 28, 2024 and attached to this Proxy Statement as Annex D.</p>
                        <p style="text-align: justify;">The Flora MD&amp;A and Flora Risk Factors should be read together with our audited financial statements for the year ended December 31, 2023 and Flora's unaudited financial statements for the three months ended March 31, 2024, which are included in this Proxy Statement. <i>Therefore, when reviewing the Flora MD&amp;A and Flora Risk Factors references to "this report" or similar wording is referencing the original Form 10-K or Form 10-Q filing cited above. Similarly, references to the Flora financial statements and the notes to such financial statements refers to the Flora financial statements included in this Proxy Statement.</i></p>
                        <p style="text-align: justify;">In addition to historical information, this discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See "<i>Cautionary Note Regarding Forward-Looking Statements</i>" for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under "Risk Factors" and elsewhere in this Proxy Statement. This information about Flora and TruHC has been included to provide shareholders in this Proxy Statement with certain historical financial information about Flora and TruHC that may be important to shareholders in connection with their evaluation of the Share Issuance Proposal.</p>
                        <div>
                            <p style="text-align: center;">79</p>
                        </div>
                    </div>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span id="page_85_integixAnchor"></span>
            </div>
            <div>
                <div>
                    <div>
                        <p style="text-align: center; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>THE TRUHC BUSINESS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Overview</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC Pharma GmbH was incorporated under the laws of Germany on February 17, 2022. TruHC engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility at a size of 7,000 square feet, located at Poppenb&#252;tteler Bogen 68 22399 Hamburg, Germany. The Company's lease on this facility expires on April 30, 2025. The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term at TruHC's option. TruHC's registered office and principal place of business in Germany is located at Hamburg, Germany. At December 31, 2023, all the Company's issued and outstanding shares were owned by TruHC Holding.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC is an early-stage, pre-revenue entity, which possesses numerous licenses including:</span></span></p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">European Union Good Manufacturing Practice ("EU-GMP") processing and production license. Its EU-GMP certified customizable modules are flexible to incorporate various production and packaging processes, which could enable license extension for future in country cultivation and supply to cannabis dispensaries. Its laboratory is EU-GMP certified for instant cannabis analysis.</span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goods Distribution Practice ("GDP") wholesale license for import and export.</span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Narcotics license with EU-GMP certified storage.</span></span></li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Recent Developments</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 1, 2024, the Company entered into a binding Letter of Intent to acquire all of the issued and outstanding shares of TruHC from TruHC Holding in an all-stock deal in exchange for 2,770,562 Common Shares.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 16, 2024, Flora entered into the Stock Purchase Agreement with TruHC Holding pursuant to which Flora will acquire all the issued and outstanding shares of the TruHC. The Purchase Price will be paid and satisfied by Flora in two closings. On the First Closing, Flora issued 2,135,199 Common Shares, which is equal to 19.99% of Flora's issued and outstanding Common Shares prior to signing the Stock Purchase Agreement. On the Second Closing, Flora will issue 635,363 Common Shares to TruHC after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at this Annual Meeting. On April 22, 2024, the First Closing of the Acquisition for 2,135,199 Common Shares was completed.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Factors Impacting TruHC's Business</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Early-stage company with limited operating history. </i>To-date TruHC has not generated any revenues, operating cash flows or profit from its activities. Formed in 2022, TruHC has a limited operating history and limited financial resources. TruHC's ability to realize its business plan continues to depend on obtaining financial support from its parent company. There can be no assurance that such funding will be available for the development of TruHC's business or that TruHC's business plan is sound. There are costs, uncertainties, delays and difficulties frequently encountered by companies in the early stage of development.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">80</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_86_integixAnchor"></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>License attainment and maintenance.</i> At this stage, a significant component of TruHC's value proposition is rooted in the licenses it holds, including EU-GMP, GDP wholesale and narcotics. The effectiveness of TruHC's quality control systems and its ability to maintain these licenses with respect to its manufacturing, processing and testing facility depend on a number of factors, including the design of its quality control procedures, training programs, and its ability to ensure its employees adhere to appropriate policies and procedures. TruHC's expects that regulatory agencies will periodically inspect its facilities to evaluate compliance with applicable requirements. Failure to comply with these requirements may subject TruHC to possible regulatory enforcement actions and suspension of termination of key licenses, which could be detrimental to TruHC's business.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Licenses, approvals, and Permits</i>. <span style="background-color: #ffffff;">TruHC has obtained the licenses to operate on a global scale including required governmental approvals, licenses and permits. A summary of such governmental approvals, licenses and permits are set forth below.</span></span></span></p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">EU-GMP processing and production license. Its EU-GMP certified customizable modules are flexible to incorporate various production and packaging processes, which could enable license extension for future in country cultivation and supply to cannabis dispensaries. Its laboratory is EU-GMP certified for instant cannabis analysis.</span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">GDP wholesale license for import and export.</span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Narcotics license with EU-GMP certified storage.</span></span></li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>German cannabis developments.<b>&#160;</b></i>TruHC's growth is embedded in the expansion, regulation and legalization of medicinal and recreational cannabis and cannabis derivative products in Germany. TruHC is focused on the most robust markets in Germany. Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require TruHC to incur substantial costs associated with compliance or alter certain aspects of TruHC's business plan. TruHC cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can it determine what effect additional government regulations or administrative policies and procedures could have on its business. A negative shift in the public's perception of the cannabis industry could affect future legislation.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Regulatory proficiency and adoption.<b>&#160;</b></i>The market in which TruHC operates is highly regulated and requires extensive experience in navigating the associated complexities. TruHC has assembled a team with deep knowledge of the regulatory and governance environments in which it operates. Fundamental expertise entails compliance with product approvals, import permits, export permits, distribution licenses and other pertinent licenses.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Integration with acquiring company.<b>&#160;</b></i>TruHC's ability to effectively execute its business plan will be heavily impacted by its integration with Flora. As a Nasdaq-listed cannabis company, Flora is subject to various risks, as detailed in its most recent Annual Report on Form 10-K filed the SEC on March 28, 2024. As a result of Flora's acquisition, TruHC has become subject to these risks. In addition, it is expected that TruHC will incur additional costs because of compliance with the regulatory requirements subject to subsidiaries of public companies, including but not limited to, the Sarbanes-Oxley Act of 2002.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">81</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_87_integixAnchor"></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Quality Control</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC has a comprehensive quality assurance program that gives it visibility into the maintenance of its licenses. Its quality control system includes the following elements:</span></span></p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">the planning and creation of site master files;</span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">the creation of standard operating procedures;</span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">the build out and retrofitting of its EU-GMP facility;</span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">the Planning, setup and audit of its EU-GMP laboratory;</span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">the audit and documentation of operating software;</span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">the mock audits, test runs and training;</span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">the planning, installation and audit of GMP production units;</span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">the planning, sourcing and installation of narcotic storage and alarm systems; and</span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">contracts with local police and service providers.</span></span></li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Seasonality</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As TruHC is an early-stage, pre-revenue entity, there are no factors pertaining to seasonality that apply to its business.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Government Regulation</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC is subject to regulation by German and European government authorities, primarily as it pertains to the obtaining and maintaining of its licenses. TruHC has developed, maintains and follows internal controls to ensure that it continues to meet the licensing requirements of Germany and the European Union for its processing, production, customizable modules, laboratory, narcotics and wholesale for import and export licenses.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Description of Property</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC is party to one lease with Ali Nahavandi, as landlord, and TruHC, as tenant, dated February 10, 2022, for 7,000 square feet of space located at Poppenbutteler Bogen 68, 22399 Hamburg, Germany, which is TruHC's headquarters and principal office. The Company's material licenses can only be utilized within this facility. The lease commenced in May 2022 and expires in April 2025. There is an optional and unilateral 5-year lease extension at TruHC's option, which TruHC intends to exercise.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Human Resources</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As of March 31, 2024, TruHC had 4 part-employees. None of the TruHC employees are represented by labor unions or covered by collective bargaining agreements. Flora intends to enter into an employment agreement with Hendrik Knopp, the Managing Director of TruHC.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">82</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_88_integixAnchor"></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Legal Proceedings</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC is from time to time subject to litigation and other proceedings. TruHC believes that there are no pending lawsuits or claims that may, individual or in the aggregate, have a material adverse effect on its business, financial condition or results of operations.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">83</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_89_integixAnchor"></span></span></span>
                        <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>TRUHC MANAGEMENT DISCUSSION AND ANALYSIS AND RESULTS OF OPERATION FOR THE QUARTER ENDED MARCH 31, 2024</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A") of the Company should be read in conjunction with (a) our unaudited condensed financial statements for the periods ended March 31, 2024 and 2023, and the accompanying notes thereto (the "Financial Statements"), which have been prepared in accordance with U.S. GAAP; (b) our audited financial statements for the periods ended December 31, 2023 and 2022, and the related Management's Discussion and Analysis. Amounts are expressed in Euro ("&#8364;" or "EUR") unless otherwise stated to be in United States dollars ("USD"). Variance, ratio, and percentage changes in this MD&amp;A are based on unrounded numbers. This MD&amp;A reports the Company's activities through December 31, 2023, unless otherwise indicated.</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Forward-looking statements are based on the Company's current expectations and assumptions regarding its business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements as a result of various factors, including, without limitation, changes in local, regional, national or global political, economic, business, competitive, market (supply and demand) and regulatory conditions. Please see "Cautionary Statement Regarding Forward-Looking Statements" in this Annual Report for more information regarding forward-looking statements. </i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Overview of our Business </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC Pharma GmbH ("TruHC") was incorporated under the laws of Germany on February 17, 2022. TruHC engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility. TruHC's registered office and principal place of business in Germany is located at Hamburg, Germany. At December 31, 2023, all the Company's issued and outstanding shares were owned by TruHC Holding GmbH ("TruHC Holding").</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC is an early-stage, pre-revenue entity, which possesses numerous licenses including:</span></span></p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">European Union Good Manufacturing Practice ("EU-GMP") processing and production license. Its EU-GMP certified customizable modules are flexible to incorporate various production and packaging processes, which could enable license extension for future in country cultivation and supply to cannabis dispensaries. Its laboratory is EU-GMP certified for instant cannabis analysis.</span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goods Distribution Practice ("GDP") wholesale license for import and export.</span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Narcotics license with EU-GMP certified storage</span></span></li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 1, 2024, Flora Growth Corp. ("Flora"), a cannabis focused consumer-packaged goods leader and pharmaceutical distributor, has entered into a binding Letter of Intent (the "LOI") to acquire all of the issued and outstanding shares of TruHC from TruHC Holding in an all-stock deal in exchange for 2,770,562 Flora common shares.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">84</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_90_integixAnchor"></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 16, 2024, Flora entered into a Stock Purchase Agreement (the "Purchase Agreement") with TruHC Holding GmbH (the "Seller") pursuant to which Flora will acquire all the issued and outstanding shares of the Company. The Purchase Price will be paid and satisfied by Flora in two closings. On the first closing, Flora issued 2,135,199 of its common shares, which is equal to 19.99% of Flora's issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the "Second Closing"), Flora will issue 635,363 of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 22, 2024, the first closing of the Transaction for 2,135,199 Flora shares was closed.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Under the Purchase Agreement, Flora is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Factors Impacting our Business </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Early-stage company with limited operating history. </i>To-date TruHC has not generated any revenues, operating cash flows or profit from its activities. Formed in 2022, TruHC has a limited operating history and limited financial resources. Our ability to realize our business plan continues to depend on obtaining financial support from its parent company. There can be no assurance that such funding will be available for the development of our business or that our business plan is sound. There are costs, uncertainties, delays and difficulties frequently encountered by companies in the early stage of development.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>License attainment and maintenance.</i> At this stage, a significant component of TruHC's value proposition is rooted in the licenses it holds, including EU-GMP, GDP wholesale and narcotics. The effectiveness of TruHC's quality control systems and its ability to maintain these licenses with respect to its manufacturing, processing and testing facility depend on a number of factors, including the design of its quality control procedures, training programs, and its ability to ensure its employees adhere to appropriate policies and procedures. We expect that regulatory agencies will periodically inspect our facilities to evaluate compliance with applicable requirements. Failure to comply with these requirements may subject us to possible regulatory enforcement actions and suspension of termination of key licenses, which could be detrimental to the business.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>German cannabis developments.<b>&#160;</b></i>TruHC's growth is embedded in the expansion, regulation and legalization of medicinal and recreational cannabis and cannabis derivative products in Germany. TruHC is focused on the most robust markets in Germany. Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require us to incur substantial costs associated with compliance or alter certain aspects of our business plan. We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional government regulations or administrative policies and procedures could have on our business. A negative shift in the public's perception of the cannabis industry could affect future legislation.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">85</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_91_integixAnchor"></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Regulatory proficiency and adoption.<b>&#160;</b></i>The market in which TruHC operates is highly regulated and requires extensive experience in navigating the associated complexities. We have assembled a team with deep knowledge of the regulatory and governance environments in which the Company operates. Fundamental expertise entails compliance with product approvals, import permits, export permits, distribution licenses and other pertinent licenses.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Integration with acquiring company.<b>&#160;</b></i>Our growth ability to effectively execute our business plan will be heavily impacted by our integration with Flora. As a NASDAQ-listed cannabis company, Flora is subject to various risks, as detailed in its most recent 10-K filed the U.S. Securities Exchange Commission on March 28, 2024. As a result of Flora's acquisition, TruHC has become subject to these risks. In addition, it is expected that TruHC will incur additional costs as a result of compliance with the regulatory requirements subject to subsidiaries of public companies, including but not limited to, the Sarbanes-Oxley Act of 2002.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Key Components of Results of Operations </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Operating Expenses</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating expenses are apportioned based on the following categories:</span></span></p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 3.78%; vertical-align: top; text-align: justify;">&#160;</td>
                                <td style="width: 3.82%; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;</span></span></td>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Professional fees</i> include legal, audit and other expenses incurred by third-party service providers.</span></span></td>
                            </tr>
                            <tr>
                                <td style="width: 3.78%; vertical-align: top; text-align: justify;">&#160;</td>
                                <td style="width: 3.82%; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;</span></span></td>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>General and administrative</i> include salaries, wages, benefits, temporary labor and subcontractor costs for TruHC's business. This category also includes the day-to-day operating costs of maintaining TruHC's facility as well as office costs.</span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify;">&#160;</td>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;</span></span></td>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Travel expenses</i> relate to flight, lodging and incidental expenses for attending conferences, events and key business meetings.</span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify;">&#160;</td>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;</span></span></td>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Operating lease expense</i> represents the cost of TruHC's operating lease, consisting of real estate.</span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify;">&#160;</td>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;</span></span></td>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Depreciation and amortization expense</i> is provided on a straight-line basis over the corresponding assets' estimated useful lives.</span></span></td>
                            </tr>
                        </table>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Interest Expense</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Interest expense</i> consists of interest on shareholder loans from TruHC Holding.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Results of Operations</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following table sets forth the TruHC's consolidated results of operations for the three months ended March 31, 2024 and 2023 (in thousands). The period-to-period comparisons of the TruHC's historical results are not necessarily indicative of the results that may be expected in the future. The results of operations data have been derived from our audited consolidated financial statements.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">86</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_92_integixAnchor"></span></span></span>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; width: 69.6408%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 13%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the<br/>three<br/>months<br/>ended<br/>March 31,<br/>2024</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 13%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the<br/>three<br/>months<br/>ended<br/>March 31,<br/>2023</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating expenses</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;<i>&#160;</i></span></span></td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,054</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">82</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">47,089</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">26,207</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Travel expenses</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">326</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">425</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29,970</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31,516</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,742</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,933</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating loss</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(100,181</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(60,163</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (recovery)</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,391</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(270</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 69.6408%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net loss for the period</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#8364; </b></span></span></td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(105,572</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 1%; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#8364;</b></span></span></td>
                                <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(59,893</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff; width: 2%; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            </tr>
                        </table>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Operating Expenses</i><span>&#160;</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating expenses totaled <i>&#8364;100,181 and &#8364;60,163</i> for the periods ended March 31, 2024 and 2023, respectively. The increase was primarily driven by increases in general and administrative and professional fees.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Professional Fees</i></span></span></p>
                        <p style="margin: 0in; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Professional fees totaled &#8364;19,054 and &#8364;82 for the periods ended March 31, 2024 and 2023 respectively. The increase is due to higher accounting, legal and consulting fees. </span></span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>General and Administrative Expenses</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative expenses totaled &#8364;47,089 and &#8364;26,207 for the periods ended March 31, 2024 and 2023, respectively. The increase is primarily due to higher salaries, wages and benefits, which contributed &#8364;15,235 to the increase. Salaries, wages and benefits for the period ended March 31, 2024 were &#8364;35,481 compared to &#8364;20,245 for the period ended March 31, 2023.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The remaining fluctuations regarding general and administrative expenses are not significant individually and in aggregate.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Travel Expenses</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Travel expenses totaled &#8364;326 and &#8364;425 for the periods ended March 31, 2024 and 2023 respectively. This fluctuation is not significant individually or in aggregate.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Operating Lease Expenses</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expenses totaled &#8364;29,970 and &#8364;31,516 for the periods ended March 31, 2024 and 2023 respectively. There have been no changes in TruHC&#8217;s leasing arrangement.<span>&#160;</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">87</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_93_integixAnchor"></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Depreciation and Amortization Expense</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization expenses totaled &#8364;3,742 and &#8364;1,933 for the periods ended March 31, 2024 and 2023, respectively. This fluctuation is not significant individually or in aggregate.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Interest Expense</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense totaled &#8364;5,391 and a recovery of &#8364;270 for the periods ended March 31, 2024 and 2023, respectively. The increase is primarily due to a higher outstanding balance on the shareholder loan TruHC Holding.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Net loss </i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC incurred a net loss of &#8364;105,572 and &#8364;59,893 for the periods ended March 31, 2024 and 2023, respectively. The increase in loss was driven primarily by higher general and administrative expenses, professional fees, and interest expense.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity and Capital Resources</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="background-color: #ffffff;">Since TruHC's inception, we have funded our operations and capital spending through shareholder loans from TruHC Holding. TruHC is a pre-revenue, early-stage company without an operating history. We have generated operating losses and negative cash flows from operations as reflected in our accumulated deficit and consolidated statements of cash flows. We expect to continue to incur operating losses and negative cash flows in the foreseeable future. Our current principal sources of liquidity are shareholder loans from our parent company. Cash and cash equivalents consist primarily of cash on deposit with banks. Cash and cash equivalents were </span>&#8364;13,899 and &#8364;13,588 <span style="background-color: #ffffff;">as of March 31, 2024, and December 31, 2023, respectively. As of March 31, 2024, the Company's current working capital, anticipated operating expenses and net losses raise substantial doubt as to whether existing cash and cash equivalents will be sufficient to meet its obligations as they come due within twelve months from the date the financial statements were issued. The financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should TruHC be unable to continue as a going concern.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC's ability to execute its operating plans through 2024 and beyond depends on its ability to obtain additional funding through funding from its parent company or other forms of financing to meet planned growth requirements and to fund future operations, which may not be available on acceptable terms, or at all. If we are unable to raise the requisite funds, we will need to curtail or cease operations. See Note 2 to the condensed interim financial statements for more information.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management has performed an analysis of our ability to continue as a going concern, and has determined that, based on our current financial position, there is a substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm has raised substantial doubt as to our ability to continue as a going concern.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. In the long term, we may be required to obtain additional financing to fund our current planned operations, which may consist of incurrence of additional indebtedness, additional equity financing or a combination of these potential sources of funds. There can be no assurance that TruHC will be able to obtain additional funds on terms acceptable to it, on a timely basis or at all. The failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the results of operations, and financial condition. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">88</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_94_integixAnchor"></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC's primary uses of cash are for working capital requirements and capital expenditures. Additionally, from time to time, it may use capital for acquisitions and other investing and financing activities. Working capital is used principally for the TruHC's personnel.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash Flows</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following table sets forth the major components of the Company's condensed statements of cash flows for the periods presented.</span></span></p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(In European Euros)</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the<br/>three<br/>months<br/>ended<br/>March 31,<br/>2024</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the<br/>three<br/>months<br/>ended<br/>March 31,<br/>2023</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash used in operating activities</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(82,189</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(11,533</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #ffffff; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash from financing activities</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #ffffff; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">82,500</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #ffffff; text-align: right;">-</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash used in investing activities</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(197</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Change in cash during the period</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">311</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(11,730</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash, beginning of period</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13,588</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">15,281</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash, end of period</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="width: 12%; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13,899</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="width: 12%; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,551</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                            </tr>
                        </table>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Cash used in Operating Activities</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net cash used in operating activities for the periods ended March 31, 2024 and 2023 totaled &#8364;82,189 and &#8364;11,533, respectively. Cash flows used in operating activities for the period ended March 31, 2024 were due primarily to general and administrative and lease expenses.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash flows used in operating activities for the period ended March 31, 2023 were also due primarily to general and administrative and lease expenses.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Cash from Financing Activities</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net cash provided from financing activities for the periods ended March 31, 2024 and 2023 totaled &#8364;82,500 and nil, respectively. Net cash flows provided from financing activities for the period ended March 31, 2024 were from cash draws on loans from TruHC Holding as well as a capital contribution from TruHC Holding.<i>&#160;</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Cash used in Investing Activities</i></span></span></p>
                        <p style="margin: 0in; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Net cash used in investing activities for the periods ended March 31, 2024 and 2023 totaled nil and &#8364;197, respectively. </span></span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Working Capital</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As of March 31, 2024, we had a working capital deficiency of <i>&#8364;68,191</i>. TruHC&#8217;s primary cash flow needs are for the development of its cannabis activities, administrative expenses and for general working capital.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Funding Requirements</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, the &#8364;250,000 (December 31, 2023 - &#8364;250,000) was outstanding under the First Loan.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">89</span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_95_integixAnchor"></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;450,000, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, &#8364;448,000 (December 31, 2023 &#8211; &#8364;378,000) was outstanding under the Second Loan.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at March 31, 2024, the amount of accrued interest on the First Loan and Second Loan totals &#8364;22,730 (December 31, 2023 &#8211; &#8364;17,339).</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan were forgiven by TruHC Holding.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Off-Balance Sheet Arrangements</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At March 31, 2024, TruHC did not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations or financial condition, including, and without limitation, such considerations as liquidity and capital resources.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Contractual Obligations</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At March 31, 2024, TruHC had the following contractual obligations to make future payments, representing contracts and other commitments that are known and committed:</span></span></p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap; width: 39.1657%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(In European Euros)</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 13%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Less than 1 Year</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1 - 3 Years</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>More than 3 Years</b></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 39.1657%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease obligations (1)</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>641,019</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">79,030</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>210,746</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;<i>&#160;</i></span></span></td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>351,243</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #ffffff; text-align: justify; width: 39.1657%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Long term debt (2)</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>720,730</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>720,730</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 39.1657%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff; border-bottom: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1,361,749</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; border-bottom: 1.5pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">79,030</span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff; border-bottom: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>931,476</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff; border-bottom: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>351,243</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff; border-bottom: 1.5pt solid #000000;">&#160;</td>
                            </tr>
                        </table>
                        <p style="margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1)<span style="display: inline-block; width: 12pt;">&#160;</span>See Note 8 of TruHC's Financial Statements for the periods March 31, 2024 and 2023.</span></span></p>
                        <p style="margin-top: 0pt; text-indent: -24pt; margin-left: 48pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2)<span style="display: inline-block; width: 12pt;">&#160;</span>See Note 7 of TruHC's Financial Statements for the periods March 31, 2024 and 2023.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Critical Accounting Estimates</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of the TruHC's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Liquidity and going concern considerations</i></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming that TruHC will continue as a going concern. Management must assess the TruHC's ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of expenses and cash flows, which requires a significant amount of management judgement.</span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">90</span></span></p>
                        </div>
                    </div>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_96_integixAnchor"></span></span></span>
            </div>
            <div>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Estimated useful lives and depreciation of long-lived assets with finite lives</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Determination of asset groups for impairment testing</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Management is required to use judgement in determining asset groups for the level at which long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the TruHC's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Impairment of long-lived assets</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions, including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>91</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_97_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Income taxes and valuation allowances for deferred tax assets</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. TruHC considers relevant tax planning opportunities that are within the TruHC's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit TruHC from realizing the tax benefits from the deferred tax assets. TruHC reassesses unrecognized income tax assets at each reporting period.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>TruHC must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by TruHC, and has concluded that as of December 31, 2023 and 2022, there were no uncertain tax positions taken.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Recently Adopted Accounting Principles</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>See Note 3, "Significant Accounting Policies", of the notes to the financial statements for a discussion of recently issued accounting standards.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>92</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_98_integixAnchor"></span></span></span></span>
                        <p style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>TRUHC MANAGEMENT DISCUSSION AND ANALYSIS AND RESULTS OF OPERATION FOR THE YEAR ENDED DECEMBER 31, 2023</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A") of the Company should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2023, and the accompanying notes thereto (the "Financial Statements"), which have been prepared in accordance with U.S. GAAP. Amounts are expressed in Euro ("&#8364;" or "EUR") unless otherwise stated to be in United States dollars ("USD"). Amounts stated in foreign currencies include approximate EUR amounts based on exchange rates on December 31, 2023. Variance, ratio, and percentage changes in this MD&amp;A are based on unrounded numbers. This MD&amp;A reports the Company's activities through December 31, 2023, unless otherwise indicated.</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Forward-looking statements are based on the Company's current expectations and assumptions regarding its business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements as a result of various factors, including, without limitation, changes in local, regional, national or global political, economic, business, competitive, market (supply and demand) and regulatory conditions. Please see "Cautionary Statement Regarding Forward-Looking Statements" in this Annual Report for more information regarding forward-looking statements. </i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Overview of our Business </b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>TruHC Pharma GmbH ("TruHC") was incorporated under the laws of Germany on February 17, 2022. TruHC engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility. TruHC's registered office and principal place of business in Germany is located at Hamburg, Germany. At December 31, 2023, all the Company's issued and outstanding shares were owned by TruHC Holding GmbH ("TruHC Holding").</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>TruHC is an early-stage, pre-revenue entity, which possesses numerous licenses including:</span></span></span></p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>European Union Good Manufacturing Practice ("EU-GMP") processing and production license. Its EU-GMP certified customizable modules are flexible to incorporate various production and packaging processes, which could enable license extension for future in country cultivation and supply to cannabis dispensaries. Its laboratory is EU-GMP certified for instant cannabis analysis.</span></span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Goods Distribution Practice ("GDP") wholesale license for import and export.</span></span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Narcotics license with EU-GMP certified storage.</span></span></span></li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>On April 1, 2024, Flora Growth Corp. ("Flora"), a cannabis focused consumer-packaged goods leader and pharmaceutical distributor, has entered into a binding Letter of Intent (the "LOI") to acquire all of the issued and outstanding shares of TruHC from TruHC Holding in an all-stock deal in exchange for 2,770,562 Flora common shares, valued at $6.4 million (in United States dollars) (the "Purchase Price") based on the closing price of the Flora shares on March 28, 2024 of $2.31 (in United States dollars) per share (the "Transaction").</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>93</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_99_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>On April 16, 2024, Flora entered into a Stock Purchase Agreement (the "Purchase Agreement") with TruHC Holding GmbH (the "Seller") pursuant to which Flora will acquire all the issued and outstanding shares of the Company. The Purchase Price will be paid and satisfied by Flora in two closings. On the first closing, Flora issued 2,135,199 of its common shares, which is equal to 19.99% of Flora's issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the "Second Closing"), Flora will issue 635,363 of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>On April 22, 2024, the first closing of the Transaction for 2,135,199 Flora shares was closed.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Under the Purchase Agreement, Flora is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Factors Impacting our Business </b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Early-stage company with limited operating history. </i>To-date TruHC has not generated any revenues, operating cash flows or profit from its activities. Formed in 2022, TruHC has a limited operating history and limited financial resources. Our ability to realize our business plan continues to depend on obtaining financial support from its parent company. There can be no assurance that such funding will be available for the development of our business or that our business plan is sound. There are costs, uncertainties, delays and difficulties frequently encountered by companies in the early stage of development.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>License attainment and maintenance.</i> At this stage, a significant component of TruHC's value proposition is rooted in the licenses it holds, including EU-GMP, GDP wholesale and narcotics. The effectiveness of TruHC's quality control systems and its ability to maintain these licenses with respect to its manufacturing, processing and testing facility depend on a number of factors, including the design of its quality control procedures, training programs, and its ability to ensure its employees adhere to appropriate policies and procedures. We expect that regulatory agencies will periodically inspect our facilities to evaluate compliance with applicable requirements. Failure to comply with these requirements may subject us to possible regulatory enforcement actions and suspension of termination of key licenses, which could be detrimental to the business.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>German cannabis developments.<b>&#160;</b></i>TruHC's growth is embedded in the expansion, regulation and legalization of medicinal and recreational cannabis and cannabis derivative products in Germany. TruHC is focused on the most robust markets in Germany. Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require us to incur substantial costs associated with compliance or alter certain aspects of our business plan. We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional government regulations or administrative policies and procedures could have on our business. A negative shift in the public's perception of the cannabis industry could affect future legislation.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>94</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_100_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Regulatory proficiency and adoption.<b>&#160;</b></i>The market in which TruHC operates is highly regulated and requires extensive experience in navigating the associated complexities. We have assembled a team with deep knowledge of the regulatory and governance environments in which the Company operates. Fundamental expertise entails compliance with product approvals, import permits, export permits, distribution licenses and other pertinent licenses.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Integration with acquiring company.<b>&#160;</b></i>Our growth ability to effectively execute our business plan will be heavily impacted by our integration with Flora. As a NASDAQ-listed cannabis company, Flora is subject to various risks, as detailed in its most recent 10-K filed the U.S. Securities Exchange Commission on March 28, 2024. As a result of Flora's acquisition, TruHC has become subject to these risks. In addition, it is expected that TruHC will incur additional costs as a result of compliance with the regulatory requirements subject to subsidiaries of public companies, including but not limited to, the Sarbanes-Oxley Act of 2002.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Key Components of Results of Operations </b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Operating Expenses</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Company's operating expenses are apportioned based on the following categories:</span></span></span></p>
                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8226;<span style="display: inline-block; width: 20pt;">&#160;</span><i>Professional fees</i> include legal, audit and other expenses incurred by third-party service providers.</span></span></span></p>
                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8226;<span style="display: inline-block; width: 20pt;">&#160;</span><i>General and administrative</i> include salaries, wages, benefits, temporary labor and subcontractor costs for TruHC's business. This category also includes the day-to-day operating costs of maintaining TruHC's facility as well as office costs.</span></span></span></p>
                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8226;<span style="display: inline-block; width: 20pt;">&#160;</span><i>Travel expenses</i> relate to flight, lodging and incidental expenses for attending conferences, events and key business meetings.</span></span></span></p>
                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8226;<span style="display: inline-block; width: 20pt;">&#160;</span><i>Operating lease expense</i> represents the cost of TruHC's operating lease, consisting of real estate.</span></span></span></p>
                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8226;<span style="display: inline-block; width: 19.5pt;">&#160;</span><i>Depreciation and amortization expense</i> is provided on a straight-line basis over the corresponding assets' estimated useful lives.</span></span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Interest Expense</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Interest expense</i> consists of interest on shareholder loans from TruHC Holding.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Results of Operations</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The following table sets forth the TruHC's consolidated results of operations for the fiscal years ended December 31, 2023 and 2022 (in thousands). The period-to-period comparisons of the TruHC's historical results are not necessarily indicative of the results that may be expected in the future. The results of operations data have been derived from our audited consolidated financial statements.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>95</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_101_integixAnchor"></span></span></span></span>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; width: 71.8424%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9.96524%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>For the year<br/>ended<br/>December<br/>31, 2023</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9351%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>For the<br/>period from<br/>February<br/>17, 2022 to<br/>December<br/>31, 2022</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; background-color: #e6efff; text-align: justify; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Operating expenses</b></span></span></span></td>
                                <td style="vertical-align: bottom; background-color: #e6efff; text-align: right; width: 1.04287%;">&#160;</td>
                                <td style="vertical-align: bottom; background-color: #e6efff; text-align: right; width: 9.96524%;">&#160;</td>
                                <td style="vertical-align: bottom; background-color: #e6efff; text-align: right; width: 1.96987%;">&#160;</td>
                                <td style="vertical-align: bottom; background-color: #e6efff; text-align: right; width: 1.04287%;">&#160;</td>
                                <td style="vertical-align: bottom; background-color: #e6efff; text-align: right; width: 11.9351%;">&#160;</td>
                                <td style="vertical-align: bottom; background-color: #e6efff; text-align: right; width: 1.96987%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; text-align: justify; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Professional fees</span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>&#8364;</i></span></span></span></td>
                                <td style="vertical-align: bottom; width: 9.96524%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>7,589</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>&#8364;</i></span></span></span></td>
                                <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>5,038</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>General and administrative</span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>210,622</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>113,458</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; text-align: justify; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Travel expenses</span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right;">&#160;</td>
                                <td style="vertical-align: bottom; width: 9.96524%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,037</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right;">&#160;</td>
                                <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>451</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Operating lease expense</span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>123,105</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>84,783</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; text-align: justify; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Depreciation and amortization</span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 9.96524%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>14,675</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>9,550</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Operating loss</b></span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(358,028</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1.96987%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(213,280</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1.96987%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; text-align: justify; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Interest expense</span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 9.96524%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>13,759</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1.96987%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>3,602</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 71.8424%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Net loss for the period</b></span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b><i>&#8364;</i></b></span></span></span></td>
                                <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(371,787</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1.96987%; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; width: 1.04287%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b><i>&#8364;</i></b></span></span></span></td>
                                <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(216,882</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1.96987%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                        </table>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Operating Expenses</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Operating expenses totaled &#8364;358,028 and &#8364;213,280 for the periods ended December 31, 2023 and 2022, respectively. The increase was primarily driven by increases in general and administrative and operating lease expenses.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Professional Fees</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Professional fees totaled &#8364;7,589 and &#8364;5,038 for the periods ended December 31, 2023 and 2022, respectively. The increase is due to higher accounting, legal and consulting fees.<i>&#160;</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>General and Administrative Expenses</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>General and administrative expenses totaled &#8364;210,622 and &#8364;113,458 for the periods ended December 31, 2023 and 2022, respectively. The increase is due to the following factors:</span></span></span></p>
                        <ul style="padding-left: 0pt; list-style-type: disc;">
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Salaries, wages and benefits contributed &#8364;60,466 to the increase. Salaries, wages and benefits for the period ended December 31, 2023 were &#8364;136,557 compared to &#8364;76,090 for the period ended December 31, 2022.</span></span></span></li>
                            <li style="margin-left: 30.77pt; text-align: justify; padding-left: 7.48pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>External work added &#8364;32,296 to the increase. External work performed on the TruHC's facility totaled<i>&#160;</i>&#8364;40,722 for the period ended December 31, 2023 compared to &#8364;8,426 for the period ended December 31, 2022.</span></span></span></li>
                        </ul>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The remaining fluctuations regarding general and administrative expenses are not significantly individually and in aggregate.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Travel Expenses</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Travel expenses totaled &#8364;2,037 and &#8364;451 for the periods ended December 31, 2023 and 2022, respectively. The increase is due to an increase in employee travel and corresponding vehicle expense.<i>&#160;</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Operating Lease Expenses</i></span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>96</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_102_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Operating lease expenses totaled &#8364;123,105 and &#8364;84,783 for the periods ended December 31, 2023 and 2022, respectively. The increase is a result of the timing of TruHC entering its facility lease in May of 2022. This entails that in the period ended December 31, 2022 there were only 8 months of lease compared to the full 12 months for the period ended December 31, 2023.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Depreciation and Amortization Expense</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Depreciation and amortization expenses totaled &#8364;14,675 and &#8364;9,550 for the periods ended December 31, 2023 and 2022, respectively. This fluctuation is not significantly individually or in aggregate.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Interest Expense</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Interest expense totaled &#8364;13,759 and &#8364;3,602 for the periods ended December 31, 2023 and 2022, respectively. The increase is due to higher amounts outstanding on the TruHC Holding loans in the period ended December 31, 2023 compared to the period ended December 31, 2022. <i><span style="font-style: normal;">&#160;</span></i></span></span></span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Net loss </i></span></span></span></p>
                        <p><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>TruHC incurred a net loss of &#8364;371,787 and &#8364;216,882 for the periods ended December 31, 2023 and 2022, respectively. The increase in loss was driven primarily by higher general and administrative expenses, operating lease expenses, and interest expense. <span><i><span style="font-style: normal;">&#160;</span></i></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Liquidity and Capital Resources</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span style="background-color: #ffffff;">Since TruHC's inception, we have funded our operations and capital spending through shareholder loans from TruHC Holding. TruHC is a pre-revenue, early-stage company without an operating history. We have generated operating losses and negative cash flows from operations as reflected in our accumulated deficit and consolidated statements of cash flows. We expect to continue to incur operating losses and negative cash flows in the foreseeable future. Our current principal sources of liquidity are shareholder loans from our parent company. Cash and cash equivalents consist primarily of cash on deposit with banks. Cash and cash equivalents were </span>&#8364;13,588<i> and </i>&#8364;15,281<i>&#160;</i><span style="background-color: #ffffff;">as of December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company's current working capital, anticipated operating expenses and net losses raise substantial doubt as to whether existing cash and cash equivalents will be sufficient to meet its obligations as they come due within twelve months from the date the financial statements were issued. The financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should TruHC be unable to continue as a going concern.</span></span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>97</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_103_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>TruHC's ability to execute its operating plans through 2024 and beyond depends on its ability to obtain additional funding through funding from its parent company or other forms of financing to meet planned growth requirements and to fund future operations, which may not be available on acceptable terms, or at all. If we are unable to raise the requisite funds, we will need to curtail or cease operations. See Note 2 to the audited financial statements for more information.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Management has performed an analysis of our ability to continue as a going concern, and has determined that, based on our current financial position, there is a substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm has raised substantial doubt as to our ability to continue as a going concern.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. In the long term, we may be required to obtain additional financing to fund our current planned operations, which may consist of incurrence of additional indebtedness, additional equity financing or a combination of these potential sources of funds. There can be no assurance that TruHC will be able to obtain additional funds on terms acceptable to it, on a timely basis or at all. The failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the results of operations, and financial condition. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>TruHC's primary uses of cash are for working capital requirements and capital expenditures. Additionally, from time to time, it may use capital for acquisitions and other investing and financing activities. Working capital is used principally for the TruHC's personnel.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Cash Flows</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The following table sets forth the major components of the Company's condensed statements of cash flows for the periods presented.</span></span></span></p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(In European Euros)</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>For the year<br/>ended<br/>December<br/>31, 2023</b></span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 12%; text-align: center; white-space: nowrap;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>For the<br/>period from<br/>February<br/>17, 2022 to<br/>December<br/>31, 2022</b></span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cash used in operating activities</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8364;</span></span></span></td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(309,956</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8364;</span></span></span></td>
                                <td style="width: 8.94%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(197,894</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #ffffff; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cash from financing activities</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #ffffff; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>313,000</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                                <td style="width: 8.94%; vertical-align: bottom; background-color: #ffffff; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>327,500</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cash used in investing activities</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(4,737</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #e6efff;">&#160;</td>
                                <td style="width: 8.94%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(114,325</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Change in cash during the period</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(1,693</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                                <td style="width: 8.94%; vertical-align: bottom; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>15,281</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; background-color: #e6efff; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cash, beginning of period</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>15,281</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                                <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: top; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cash, end of period</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8364;</span></span></span></td>
                                <td style="width: 12%; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>13,588</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#8364;</span></span></span></td>
                                <td style="width: 12%; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>15,281</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                            </tr>
                        </table>
                        <span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"> &#160;</span></span>
                        <div>
                            <p style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>98</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 5pt;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_104_integixAnchor"></span></span></span></span>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Cash used in Operating Activities</i></span></span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Net cash used in operating activities for the periods ended December 31, 2023 and 2022 totaled &#8364;309,956 and &#8364;197,894, respectively. Cash flows used in operating activities for the period ended December 31, 2023 were due primarily to general and administrative and lease expenses.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cash flows used in operating activities for the period ended December 31, 2022 were also due primarily to general and administrative and lease expenses.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Cash from Financing Activities</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Net cash provided from financing activities for the periods ended December 31, 2023 and 2022 totaled &#8364;313,000 and &#8364;327,500, respectively. Net cash flows provided from financing activities for the period ended December 31, 2023 were from cash draws on loans from TruHC Holding.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cash flows provided from financing activities for the period ended December 31, 2022 were from cash draws on loans from TruHC Holding as well as a capital contribution from TruHC Holding<i>.</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Cash used in Investing Activities</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Net cash used in investing activities for the periods ended December 31, 2023 and 2022 totaled &#8364;4,737 and &#8364;114,325, respectively. Cash flows used in investing activities for the periods ended December 31, 2023 and 2022 were related to capital expenditures related to equipment and intangible assets. </span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Working Capital</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>As of December 31, 2023, we had a working capital deficiency of &#8364;56,485. TruHC&#8217;s primary cash flow needs are for the development of its cannabis activities, administrative expenses and for general working capital. </span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Funding Requirements</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Due to the early-stage nature of our activities, our continued existence is dependent on the continued financial support of our parent company.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>In February 2022, the TruHC entered into a first loan agreement with TruHC Holding, which granted TruHC an interest-bearing loan of &#8364;250,000, in installments based on the individual installments requested by TruHC ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan was due to be repaid by December 31, 2026. TruHC was entitled to make early repayments. As at December 31, 2023, the &#8364;250,000 (December 31, 2022 - &#8364;250,000) was outstanding under the First Loan.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>99</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_105_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>In February 2022, TruHC entered into a second loan agreement with TruHC Holding, which granted TruHC an interest-bearing loan of &#8364;450,000, in installments based on the individual installments requested by TruHC (&#8220;Second Loan&#8221;). The Second Loan bears interest at 4.0% per annum. The Second Loan was due to be repaid by December 31, 2026. TruHC was entitled to make early repayments. As at December 31, 2023, &#8364;378,000 (December 31, 2022 &#8211; &#8364;65,000) was outstanding under the Second Loan.</span><i><span style="font-style: normal;">&#160;</span></i></span></span></span></p>
                        <p style="margin: 0in; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>As at December 31, 2023, the amount of accrued interest on the First Loan and Second Loan totals &#8364;17,339 (December 31, 2022 &#8211; &#8364;13,590).</span><i><span style="font-style: normal;">&#160;</span></i></span></span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>In April 2024, both the First Loan and the Second Loan were forgiven by TruHC Holding.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Off-Balance Sheet Arrangements</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>As of December 31, 2023, TruHC did not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations or financial condition, including, and without limitation, such considerations as liquidity and capital resources.</span></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Contractual Obligations</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">At December 31, 2023, TruHC had the following contractual obligations to make future payments, representing contracts and other commitments that are known and committed:</span></span></p>
                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap; width: 39.2816%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(In European Euros)</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Total</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 13%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Less than 1 Year</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>1 - 3 Years</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap; width: 9%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>More than 3 Years</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 39.2816%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Operating lease obligations (1)</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>667,362</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8364;</span></span></td>
                                        <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">105,373</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>210,746</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8364;<i>&#160;</i></span></span></td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>351,243</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="vertical-align: top; background-color: #ffffff; text-align: justify; width: 39.2816%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Long term debt (2)</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>645,339</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="width: 12%; vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">-</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>645,339</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="vertical-align: top; background-color: #e6efff; text-align: justify; width: 39.2816%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,312,701</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8364;</span></span></td>
                                        <td style="width: 12%; vertical-align: bottom; background-color: #e6efff; border-bottom: 2.25pt double #000000; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">105,373</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>856,085</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 8%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>351,243</span></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                                &#160;
                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(1)</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">See Note 8 of TruHC's Financial Statements for the periods ended December 31, 2023 and 2022.</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(2)</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">See Note 7 of TruHC's Financial Statements for the periods ended December 31, 2023 and 2022.</span></span></td>
                                    </tr>
                                </table>
                            </div>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Critical Accounting Estimates</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The preparation of the TruHC's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Liquidity and going concern considerations</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The accompanying financial statements have been prepared assuming that TruHC will continue as a going concern. Management must assess the TruHC's ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of expenses and cash flows, which requires a significant amount of management judgement.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>100</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_106_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Estimated useful lives and depreciation of long-lived assets with finite lives</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Determination of asset groups for impairment testing</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Management is required to use judgement in determining asset groups for the level at which long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the TruHC's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Impairment of long-lived assets</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions, including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>101</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_107_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>Income taxes and valuation allowances for deferred tax assets</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. TruHC considers relevant tax planning opportunities that are within the TruHC's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit TruHC from realizing the tax benefits from the deferred tax assets. TruHC reassesses unrecognized income tax assets at each reporting period.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>TruHC must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by TruHC, and has concluded that as of December 31, 2023 and 2022, there were no uncertain tax positions taken.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Recently Adopted Accounting Principles</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>See Note 3, "Significant Accounting Policies", of the notes to the financial statements for a discussion of recently issued accounting standards.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>102</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_108_integixAnchor"></span></span></span></span>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Adjustments</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="4"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>As at March 31, 2024</i></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#160;<br/>&#160;<br/>&#160;<br/>Assets</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Flora Growth<br/>Corp.</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>TruHC Pharma<br/>GmbH</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b><br/><b>&#160;</b><br/><b>Note</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b><br/><b>Acquisition of<br/>TruHC Pharma<br/>GmbH</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Consolidated</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cash and cash equivalents</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>4,156</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>15</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2b</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(138</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>3,933</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2c</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(100</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Restricted cash</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>35</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>35</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Trade and amounts receivables</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>7,281</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>23</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>7,304</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Prepaid expenses and deposits</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,049</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>22</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,071</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Inventory</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>9,246</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">-</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>9,246</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total current assets</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>21,767</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>60</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(238</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>21,589</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Plant, plant and equipment</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>786</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>98</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>884</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Right of use assets</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>710</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>496</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman, Times, serif;">-</span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,206</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Intangible assets</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>908</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>908</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Licenses</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">-</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>5,470</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>4,327</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2b</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>138</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2c</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>100</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a(iv)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(1,381</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Other assets</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>103</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman, Times, serif;">-</span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>103</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total assets</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>24,274</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>654</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>4,089</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>29,017</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Liabilities</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Trade payables and other payables</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>5,005</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>51</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>5,056</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Current portion of long-term debt</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>3,078</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>3,078</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Current portion of lease-liability</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>803</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>70</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>873</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Other accrued liabilities</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>10,433</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>13</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>10,446</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Total current liabilities</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>19,319</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>133</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>19,453</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Non-current debt</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>778</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2d</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(778</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Non-current lease liability</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,817</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>465</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,282</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Deferred tax</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,336</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>890</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a(iv)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(446</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total Liabilities</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>21,136</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>1,377</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>112</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>22,625</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Shareholders' equity</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Share capital</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>148,871</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>27</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>4,189</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>153,060</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a(v)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(27</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>AOCI</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(113</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(113</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Deficit</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(145,620</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(750</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a(v)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>750</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(146,555</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a(iv)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(1,381</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a(iv)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>446</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total shareholders' equity</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>3,138</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(723</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>3,977</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>6,392</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total liabilities &amp; shareholders' equity</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>24,274</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>654</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>4,089</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>29,017</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                        </table>
                        <p style="text-align: left; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>The accompanying notes are an integral part of these pro-forma consolidated financial statements.</i></span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>103</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_109_integixAnchor"></span></span></span></span>
                        <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Unaudited Pro Forma Consolidated Statement of Loss and Comprehensive Loss</span></span></span></p>
                        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>(Stated in Thousands of United States Dollars)</i></span></span></span></p>
                        <p style="margin-top: 0pt; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>For the three months ended March 31, 2024 </i></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: center;">&#160;</p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="10"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Adjustments</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Flora Growth<br/>Corp.</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>TruHC<br/>Pharma<br/>GmbH </b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Note</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Acquisition of TruHC<br/>Pharma GmbH</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Consolidated</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Revenue</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>18,031</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>18,031</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cost of goods sold</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>14,177</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>14,177</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Gross profit</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>3,854</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>3,854</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Expenses:</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Consulting and management fees</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,302</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,302</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Professional fees</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>453</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>21</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>474</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>General and administrative</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>442</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>51</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>493</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Promotion and communication</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,104</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,104</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Travel expenses</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>69</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>69</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Share-based compensation</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>10</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>10</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Research and development</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>47</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>47</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Operating lease expense</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>165</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>33</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>198</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Depreciation and amortization</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>74</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>4</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a(iv)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>276</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>354</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Bad debt expense</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>47</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>47</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Asset impairment</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>898</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>898</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Other expenses (income) net</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>728</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>728</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>6,339</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>109</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>276</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>6,724</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Other items</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Interest expense</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>22</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>6</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>28</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Foreign exchange loss</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>132</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>132</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Unrealized loss from changes in fair value</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>607</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>607</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Loss before income taxes</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(3,246</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(115</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(276</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(3,637</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Income tax expense (recovery)</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>128</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(89</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>39</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Net loss</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(3,374</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(115</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(187</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(3,676</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Basic and diluted loss per share attributable to Flora Growth Corp.</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(0.38</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(0.01</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(0.31</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Exchange differences on foreign operations</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(27</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(27</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Comprehensive loss</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(3,347</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(115</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(187</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(3,703</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Weighted average number of shares - basic and dilutive</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>8,916,000</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,770,562</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>11,686,562</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                        </table>
                        <p style="margin-left: 1pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>The accompanying notes are an integral part of these pro-forma consolidated financial statement</i></span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>104</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_110_integixAnchor"></span></span></span></span>
                        <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Unaudited Pro Forma Consolidated Statement of Loss and Comprehensive Loss</span></span></span></p>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>(Stated in Thousands of United States Dollars)</i></span></span></span></p>
                        <p style="margin-top: 0pt; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>For the year ended December 31, 2023</i></span></span></span></p>
                        <table style="width: 100%;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="11"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Adjustments</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap; width: 22%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Flora Growth<br/>Corp.</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>TruHC<br/>Pharma<br/>GmbH</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Note</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Acquisition of TruHC<br/>Pharma GmbH</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Consolidated</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Revenue</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>76,071</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>76,071</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Cost of goods sold</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>58,333</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>58,333</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Gross profit</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>17,738</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>17,738</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Expenses:</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Consulting and management fees</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>11,876</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman, Times, serif;">-</span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>11,876</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Professional fees</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,301</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>8</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman, Times, serif;">-</span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,309</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>General and administrative</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,646</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>228</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,874</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Promotion and communication</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>4,710</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman, Times, serif;">-</span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>4,710</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Travel expenses</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>413</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>415</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Share-based compensation</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,591</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,591</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Research and development</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>62</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>62</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Operating lease expense</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,211</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>133</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,344</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Depreciation and amortization</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,335</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>16</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2a(iv)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,105</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>3,456</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Bad debt expense</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>236</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman, Times, serif;">-</span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>236</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Asset impairment</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>39,507</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>39,507</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Other expenses (income) net</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,204</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,204</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>68,092</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>387</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>1,105</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>69,584</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: right; width: 10%;" colspan="2">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Other items</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Interest expense</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>92</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>15</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>107</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Foreign exchange gain</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(158</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(158</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Unrealized gain from changes in fair value</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(1,991</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman, Times, serif;">-</span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(1,991</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(Loss) income before income taxes</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(48,297</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(402</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(1,105</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(49,804</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Income tax (benefit) expense</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(1,628</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(357</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(1,985</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Net loss from continuing operations</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(46,669</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(402</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(748</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(47,819</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Loss from discontinued operations, net of taxes</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(9,678</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(9,678</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Net loss for the period</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(56,347</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(402</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(748</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(57,497</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Net loss attributable to Flora Growth Corp.</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(57,036</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(402</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(748</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(58,186</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Net income (loss) attributable to non-controlling interests</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>689</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>689</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Basic and diluted loss per share attributable to Flora Growth Corp.</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(7.75</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(5.75</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Exchange differences on foreign operations</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(2,592</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(2,592</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; background-color: #e6efff; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Comprehensive loss</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(53,755</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(402</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(748</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(55,594</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Comprehensive loss attributable to Flora Growth Corp.</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(54,444</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(310</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>(748</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>)</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(54,905</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Comprehensive loss attributable to non-controlling interests</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>689</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>689</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 22%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 10%;" colspan="2">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; background-color: #e6efff; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Weighted average number of shares - basic and dilutive</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>7,356,000</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>2,770,562</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 10%;" colspan="2"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>10,126,562</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            </tr>
                        </table>
                        <p style="margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><i>The accompanying notes are an integral part of these pro-forma consolidated financial statements.</i></span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>105</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span id="page_111_integixAnchor"></span></span></span></span>
                        <p style="margin-left: 29pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>1.</b><span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Basis of Presentation</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>These unaudited pro forma condensed combined financial statements (the "Pro Forma Financial Statements") are prepared to illustrate the impact of the acquisition by Flora Growth Corp. ("Flora" or the "Company") of TruHC Pharma GmbH ("TruHC") (the "Transaction").</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Company is listed on the NASDAQ and is a consumer-packaged goods leader and pharmaceutical distributor. TruHC is a German cannabis company possessing the following licenses:</span></span></span></p>
                        <p style="text-align: justify; margin-left: 54pt; text-indent: -36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>European Union Good Manufacturing Practice ("EU-GMP") processing and production license. Its EU-GMP certified customizable modules are flexible to incorporate various production and packaging processes, which could enable license extension for future in country cultivation and supply to cannabis dispensaries. Its laboratory is EU-GMP certified for instant cannabis analysis.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 54pt; text-indent: -36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Goods Distribution Practice ("GDP") wholesale license for import and export.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 54pt; text-indent: -36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(iii)<span style="width: 21.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Narcotics license with EU-GMP certified storage.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Transaction is to represent an acquisition of TruHC by Flora through two closings. On the first closing, Flora issued 2,135,199 of its common shares, which is equal to 19.99% of Flora's issued and outstanding common shares prior to signing the purchase agreement (the "First Closing"). On the second closing, Flora will issue 635,363 of its common shares after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders (the "Second Closing"). The First Closing occurred on April 22, 2024. These Pro Forma Financial Statements were prepared to illustrate impact of the occurrence of both the First Closing and the Second Closing.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Pro Forma Financial Statements are those of Flora and have been prepared for inclusion in the Proxy Statement of Flora for the upcoming general and special meeting of the shareholders of the Company.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>These Pro Forma Financial Statements are based on Flora's historical consolidated financial statements and TruHC's historical consolidated financial statements as adjusted to give effect to the acquisition of TruHC. The First Closing occurred on April 22, 2024 and the Second Closing is expected to occur in August 2024.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>These Pro Forma Financial Statements do not necessarily reflect what the combined company's financial condition or results of operations would have been had the acquisition occurred on the dates indicated. They also may not be useful in predicting the future financial condition and results of operations of the combined company. Our actual financial condition and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>There have been no adjustments made to give effect to any potential synergies or dis-synergies which may arise from the Transaction.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The accounting policies used in the preparation of the Pro Forma Financial Statements are those set out in Flora's annual audited financial statements for the year ended December 31, 2023, as well as the annual audited financial statements of TruHC for the year ended December 31, 2023, and as such should be read in conjunction with such audited financial statements.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>106</span></span></span></p>
                        </div>
                    </div>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span id="page_112_integixAnchor"></span></span></span></span></span>
            </div>
            <div>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The unaudited pro forma consolidated statement of financial position as at March 31, 2024 has been prepared from information derived from the following:</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>&#8226;<span style="display: inline-block; width: 15.0pt;">&#160;</span>Flora's unaudited condensed interim consolidated statement of financial position as at March 31, 2024;</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>&#8226;<span style="display: inline-block; width: 15.0pt;">&#160;</span>TruHC's unaudited statement of financial position as at March 31, 2024, translated to United States dollars from European Euros at the March 29, 2024 rate of 1.0797, which represents the last business day in the month of March 2024.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The unaudited pro forma consolidated statement of loss and comprehensive loss for the three months ended March 31, 2024 has been prepared from information derived from the following:</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>&#8226;<span style="display: inline-block; width: 15.0pt;">&#160;</span>Flora's unaudited condensed interim consolidated statement of loss and comprehensive loss for the three months ended March 31, 2024;</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>&#8226;<span style="display: inline-block; width: 15.0pt;">&#160;</span>TruHC's unaudited statement of operations for the three months ended March 31, 2024, translated into United States dollars from European Euros at the three-month average rate of 1.0857.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The unaudited pro forma consolidated statement of loss and comprehensive loss for the year ended December 31, 2023 has been prepared from information derived from the following:</span></span></span></p>
                        <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>&#8226;<span style="display: inline-block; width: 15.0pt;">&#160;</span>Flora's audited consolidated statement of loss and comprehensive loss for the period from January 1, 2023 to December 31, 2023;</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>&#8226;<span style="display: inline-block; width: 15.0pt;">&#160;</span>TruHC's audited statement of operations for the year ended December 31, 2023, translated to United States dollars from European Euros at the twelve-month average rate of 1.0814.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The pro forma adjustments include all those transactions attributable to the Transaction for which the complete financial effects are objectively determinable.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Pro Forma Financial Statements are not intended to reflect the results of operations or the financial position that would have actually resulted had the Transaction been effected on the dates indicated or the results which may be obtained in the future. The Pro Forma Financial Statements should be read in conjunction with the other sections of the Proxy Statement.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The pro forma adjustments are based on certain estimates and assumptions. Management believes that such assumptions provide a reasonable basis for presenting all the significant effects of the Transaction contemplated and that the Pro Forma Financial Statement adjustments give appropriate effect to those adjustments and are properly applied in the Pro Forma Financial Statements.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>107</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_113_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Pro Forma Financial Statements are based on estimates and assumptions set forth in the notes herein. The Pro Forma Financial Statements are being provided solely for informational purposes and are not necessarily indicative of any future consolidated financial position or of the consolidated financial position that might have been achieved for the periods indicated; nor is it necessarily indicative of future results that may occur.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The allocation of the purchase price to reflect the fair values of the assets acquired and liabilities assumed is based on management's estimate of such assets and liabilities and, accordingly, the adjustments that have been included in the Pro Forma Financial Statements as at March 31, 2024 may be subject to change. The preliminary purchase price allocation has been used to prepare the transaction accounting adjustments in the pro forma balance sheet and income statement. The final purchase price allocation will be determined when the Company has completed the detailed valuations and necessary calculations as described in more detail in the explanatory notes below. The final allocation is expected to be completed when the Company files its condensed interim consolidated financial statements for three and six months ended June 30, 2024, and could differ materially from the preliminary allocation used in the transaction accounting adjustments. The final allocation may include (1) changes in fair values of licenses; and (2) other changes to assets and liabilities.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>108</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_114_integixAnchor"></span></span></span></span>
                        <p style="margin-left: 11pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Pro Forma Assumptions and Adjustments</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The unaudited pro forma consolidated statement of financial position gives effect to the completion of the Transaction as if the Transaction had occurred on March 31, 2024. The unaudited pro forma consolidated statement of loss and comprehensive loss gives effect to the completion of those transactions had they occurred on January 1, 2023. The Pro Forma Financial Statements are based on the following estimates and assumptions:</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>a)<span style="width: 8.68pt; text-indent: 0pt; display: inline-block;">&#160;</span>On April 16, Flora entered into a share purchase agreement for the Transaction. Management has assessed the Arrangement under <i>ASC 805 Business Combinations </i>and concluded that it constitutes an asset acquisition. The management of Flora has made a preliminary determination of the fair value of the tangible and intangible assets acquired and liabilities assumed in the Transaction. If new information obtained within one year of the date of the Transaction about the facts and circumstances that existed at the date of the Transaction identifies adjustments to the amounts then the accounting for the Transaction is to be revised. The final allocation of the fair value of the net assets acquired and aggregate consideration may be significantly different from the preliminary allocation as presented below:</span></span></span></p>
                        <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>First Closing - 2,135,199 common shares valued at $1.56 per share (i)</span></span></span></td>
                                <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                <td style="vertical-align: bottom; width: 16.986%; text-align: right; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>3,330,910</span></span></span></td>
                                <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 79.8144%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Second Closing - 635,363 common shares value at $1.35 per share (ii)</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 16.986%; text-align: right;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>857,740</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 1.5pt solid #000000; width: 79.8144%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Total consideration</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 1.5pt solid #000000; text-align: right; width: 16.986%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>4,188,650</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%;">&#160;</td>
                                <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                <td style="vertical-align: bottom; width: 16.986%; text-align: right;" colspan="2">&#160;</td>
                                <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Purchase price allocation:</span></span></span></td>
                                <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; width: 16.986%; text-align: right; background-color: #e6efff;" colspan="2">&#160;</td>
                                <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="vertical-align: bottom; width: 79.8144%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Cash and cash equivalents</span></span></span></span></td>
                                <td style="margin-top: 0pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
                                <td style="margin-top: 0pt; text-align: right; vertical-align: bottom; width: 16.986%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>15,007</span></span></span></td>
                                <td style="margin-top: 0pt; text-align: left; vertical-align: bottom; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Receivables</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>22,870</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Prepaid expenses and other current assets</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>21,969</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Plant and equipment (iii)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>98,355</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Operating lease right of use assets</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>496,138</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade and other payables</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(51,310</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Operating lease liabilities</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(534,891</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Other accrued liabilities</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(12,546</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 79.8144%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Deferred income tax liabilities</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(1,336,392</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 79.8144%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Licenses (iv)</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 16.986%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>5,469,450</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 79.8144%;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 1.5pt solid #000000; text-align: right; width: 16.986%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>4,188,650</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                        </table>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The First Closing occurred on April 22, 2024. Flora's closing share price on April 19, 2024, representing the last available closing price at the time of this closing, is utilized to value this component. Therefore, the value of the First Closing had already occurred and will not vary based on the market price of the Company's common shares upon consummation of the Transaction.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>The value of the Second Closing within the purchase price will vary based on the market price of the Company's common shares upon the Second Closing. The Company believes that the following fluctuations in the market price of its common stock is reasonably possible based on historical volatility, and the potential effect on Second Closing component of the purchase price would be:</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>109</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_115_integixAnchor"></span></span></span></span>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif;">&#160;</p>
                        <div style="margin-left: 36pt;">
                            <table style="border-collapse: collapse; font-size: 10pt; border-color: #000000; width: 100%;" border="1" cellspacing="0" cellpadding="3">
                                <tr>
                                    <td style="width: 33%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>&#160;</b></span></span></span></td>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Company's share<br/>price</b></span></span></span></td>
                                    <td style="width: 33%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Second Closing<br/>Component of<br/>Purchase Price</b></span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>As presented</span></span></span></td>
                                    <td style="width: 33%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1.35</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$857,740</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>10% Decrease</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1.22</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$771,966</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>20% Decrease</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1.08</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$686,192</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>30% Decrease</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$0.95</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$600,418</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>40% Decrease</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$0.81</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$514,644</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>50% Decrease</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$0.68</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$428,870</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>10% Increase</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1.49</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$943,514</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>20% Increase</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1.62</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1,029,288</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>30% Increase</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1.76</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1,115,062</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>40% Increase</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1.89</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1,200,836</span></span></span></td>
                                </tr>
                                <tr>
                                    <td style="width: 33%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>50% Increase</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$2.03</span></span></span></td>
                                    <td style="width: 33%; padding-left: 5.03pt; padding-right: 5.03pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$1,286,610</span></span></span></td>
                                </tr>
                            </table>
                        </div>
                        <p style="text-align: justify; margin-left: 72pt; text-indent: -36pt; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(ii)<span style="width: 22.84pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company has not yet determined the fair value of plant and equipment acquired and is using the carrying value.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(iii)<span style="width: 20.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company has preliminarily identified and valued $5,469,450 in licenses. Since all information required to perform a detailed valuation analysis of TruHC's licenses could not be obtained as of the date of this filing, for the purposes of these pro forma financial statements, the Company used certain assumptions based on preliminary valuations concluded for these licenses. A 10% change in the valuation of licenses would cause a corresponding increase or decrease in the excess of the purchase price over the fair value of the net assets of approximately $550,000 and annual amortization expense of approximately $110,000, assuming an overall weighted average useful life of 5 years. For the purpose of the Pro Forma Financial Statements, the following are the amortization expenses for each corresponding period:</span></span></span></p>
                        <p style="text-align: justify; margin-left: 90pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>a.<span style="width: 9.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>For the three months ended March 31, 2024 - $276,170.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 90pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>b.<span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span>For the year ended December 31, 2023 - $1,104,678.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(iv)<span style="width: 20.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>Reflects the elimination of TruHC's historical equity balances.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>b)<span style="width: 10pt; text-indent: 0pt; display: inline-block;">&#160;</span>No finder's fees or commissions were paid or are payable in connection with the Transaction other than fees to certain consultants and investment banks acting as advisors to the Company. These fees would be valued at $138,000 incurred by Flora prior to the closing of the Transaction.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>110</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_116_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>c)<span style="width: 10.18pt; text-indent: 0pt; display: inline-block;">&#160;</span>Represents the accrual of legal, consulting and other professional fees in connection with the Transaction and is estimated at $100,000. These costs will not affect the Company's income statement beyond 12 months after the closing of the Transaction.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>d)<span style="width: 10pt; text-indent: 0pt; display: inline-block;">&#160;</span>In connection with the Transaction, TruHC's intercompany liabilities were forgiven.</span></span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>e)<span style="width: 10.18pt; text-indent: 0pt; display: inline-block;">&#160;</span>For all adjustments except the one described in 2)a)(iv), the Company utilized an effective income tax rate of nil for the pro forma adjustments as these adjustments net to a taxable loss for which the corresponding deferred tax asset has a full valuation allowance.</span></span></span></p>
                        <p style="margin-left: 29pt; text-indent: -18pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>2.</b><span style="width: 9pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Share Capital</b></span></span></span></p>
                        <p style="text-align: justify; margin-left: 11pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>A continuity of the pro forma consolidated share capital is as follows:</span></span></span></p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>As at March 31, 2024</b></span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; vertical-align: bottom; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Note </b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Number<br/>of shares</b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Amount </b></span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Flora common shares outstanding prior to the Transaction</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>8,981,000</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>148,871,000</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Shares issued to effect the Transaction</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2a</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,770,562</span></span></span></td>
                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>4,188,650</span></span></span></td>
                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>11,751,562</span></span></span></td>
                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>153,059,650</span></span></span></td>
                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            </tr>
                        </table>
                        <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"> &#160;</span></span>
                        <div>
                            <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>111</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_117_integixAnchor"></span></span></span></span>
                        <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>THE STOCK PURCHASE AGREEMENT</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The following summary describes the material provisions of the Stock Purchase Agreement that provides for the acquisition of TruHC, the First Closing of which took place on April 22, 2024. This summary of the Stock Purchase Agreement is subject to, and qualified in its entirety by reference to, the Stock Purchase Agreement, a copy of which is included as Annex A to this Proxy Statement. You are urged to read the Stock Purchase Agreement carefully and, in its entirety, as it is the legal document governing the Acquisition, and carefully read this entire Proxy Statement and the other documents to which we have referred you. Business and operational information regarding TruHC and us can be found elsewhere in this Proxy Statement, and with respect to us, in the other public documents that we file with the SEC. See <i>"Where to Get Additional Information" </i>in this Proxy Statement.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Stock Purchase Agreement and the following summary have been included to provide you with information regarding the terms of the Stock Purchase Agreement. The assertions embodied in the representations and warranties contained in the Stock Purchase Agreement of Flora and TruHC Holding were made solely for purposes of the Stock Purchase Agreement and may be subject to important qualifications and limitations agreed to by the parties thereto in connection with negotiating its terms. In particular, the representations and warranties contained in the Stock Purchase Agreement were made solely for the benefit of the parties to the Stock Purchase Agreement and were negotiated for the purpose of allocating risk between the parties to the Stock Purchase Agreement rather than to establish matters of fact. The assertions embodied in those representations and warranties also are qualified by information in confidential disclosure schedules that the parties have exchanged in connection with signing the Stock Purchase Agreement. Although neither Flora nor TruHC believe that the confidential disclosure schedules contain information that the federal securities laws require to be publicly disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Stock Purchase Agreement. Accordingly, neither our shareholders or investors in our Common Shares should rely on the representations and warranties as characterizations of the actual state of facts, since they were only made as of the date of the Stock Purchase Agreement and are modified in important part by the corresponding disclosure schedules. Moreover, information concerning the subject matter of the representations and warranties may have changed since the date of the Stock Purchase Agreement, which subsequent information may or may not be fully reflected in our public disclosures.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>The Acquisition and the Closing</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>On April 1, 2024, the Company entered into a binding Letter of Intent to acquire all of the issued and outstanding shares of TruHC from<span style="background-color: #ffffff;">&#160;</span>TruHC Holding in an all-stock deal in exchange for 2,770,562 Common Shares.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>On April 16, 2024, the Company entered into the Stock Purchase Agreement with TruHC Holding GmbH. The Stock Purchase Agreement provides for the acquisition of 100% of the issued and outstanding shares of TruHC Pharma GmbH, of which 100% was owned by TruHC Holding GmbH. On April 22, 2024, the Company completed the First Closing in exchange for a total of 2,135,199 Common Shares, representing approximately 77% of TruHC. The Second Closing for the balance of 635,363 Common Shares will take place after the shareholders of Flora approve the Share Issuance Resolution at this Annual Meeting - Refer to <i>Proposal No. 5 - Approval of Share Issuance Proposal </i>within this Proxy Statement<i>.</i>&#160;</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>112</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_118_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Consideration in the Acquisition</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Pursuant to the terms of the Stock Purchase Agreement, the aggregate purchase price for the Acquisition is $6.4 million and is satisfied through the issuance of Common Shares to TruHC Holding or its designees as follows:</span></span></span></p>
                        <p style="margin-left: 54pt; margin-bottom: 0pt; text-indent: -36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(i)<span style="width: 26.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>on the First Closing, by the issuance of 2,135,199 Common Shares, registered in the name of TruHC Holding, or as it may direct, at a deemed price equal to $2.31 per Common Shares; and</span></span></span></p>
                        <p style="margin-top: 0pt; margin-left: 54pt; text-indent: -36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>on the Second Closing, upon shareholder approval of the issuance at this Annual Meeting, by the issuance of 635,363 Common Shares, registered in the name of TruHC Holding, as it may direct.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The First Closing occurred on April 22, 2024.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Flora will not receive any proceeds from the issuance of Common Shares in the Second Closing, assuming the Share Issuance Resolution is approved by the shareholders at this Annual Meeting, because such issuances were in consideration for the payment of the Purchase Price.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Registration Rights</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Pursuant to Section 5.11 of the Stock Purchase Agreement, Flora shall use reasonable commercial efforts to, at Flora's expense, to file a registration statement with the SEC for the Common Shares contemplated in the First Closing and Second Closing.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Conditions to Closing</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Pursuant to the Stock Purchase Agreement, Flora, TruHC and TruHC Holding are subject to the satisfaction or waiver of agreed upon and other customary closing conditions, including the absence of injunction or the enactment of any law that would restrain, prohibit or otherwise prevent the consummation of the Acquisition. The conditions of the First Closing were satisfied. The conditions of the Second Closing are primarily subject to Flora obtaining shareholder approval for the Share Issuance Resolution at this Annual Meeting. Refer to <i>Proposal No. 5 - Approval of Share Issuance Proposal </i>within this Proxy Statement.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Representations, Warranties and Covenants</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Pursuant to the Stock Purchase Agreement, Flora, TruHC and TruHC Holding made certain customary representations and warranties relating to their respective companies, businesses, security ownership and certain other matters related to the Acquisition. Such representations and warranties generally remained accurate through the completion of the First Closing and to date in all material respects. For detailed information concerning these representations, warranties and covenants, reference is made to Articles 3, 4, 5 and 6 of the Stock Purchase Agreement.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>113</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_119_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Indemnification</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Pursuant to the Stock Purchase Agreement, Flora and TruHC Holding have agreed to indemnification provisions under certain terms, including but not limited to any inaccuracy in or breach of any of the representations or warranties or any breach or non-fulfillment of any covenant, agreement or obligation.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The maximum liability of TruHC is limited to $1.6 million.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>For detailed information concerning these indemnifications and the corresponding procedures, reference is made to Article 8 of the Stock Purchase Agreement.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Expenses</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>All costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with the Stock Purchase Agreement and the transactions contemplated thereby shall be paid by the party incurring such costs and expenses, whether or not the First Closing and Second Closing shall have occurred.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Amendments</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Stock Purchase Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Governing Law</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Stock Purchase Agreement is governed by and construed in accordance with the laws of the Province of Ontario.</span></span></span></p>
                        <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>RISK FACTORS</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Before you make a decision regarding how you will vote on the Share Issuance Resolution set forth in this Proxy Statement, you should carefully consider each of the risks described below and all of the other information in this Proxy Statement. The risk factors described below relate to the Acquisition and the integration of TruHC and its business. The risks discussed below also include forward-looking statements and actual results may differ substantially from those discussed in these forward-looking statements. See these section entitled "<i>Cautionary Note Regarding Forward-Looking Statements</i>." The risks and uncertainties described below are not the only risks and uncertainties that we face. Additional risks and uncertainties not currently known to us may also materially and adversely the Acquisition of TruHC.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>114</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_120_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Risks Related to Acquisition</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>The Acquisition involves risks associated with the acquisitions and integrating acquired businesses and the intended benefits of the Acquisition may not be realized by us. </b></i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Acquisition involves risks that are associated with acquisitions and integrating acquired businesses and their operations with existing operations, including:</span></span></span></p>
                        <ul style="padding-left: 0pt; margin-bottom: 0pt; list-style-type: disc;">
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>our senior management's attention may be diverted from the management of daily operations to the integration of TruHC's business;</span></span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>the challenges, including delays or any other unanticipated changed circumstances, and costs involved in integrating and/or developing TruHC's business;</span></span></span></li>
                            <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>failure of the assets that we acquired in the Acquisition to generate anticipated revenues or other performance in accordance with our expectations;</span></span></span></li>
                        </ul>
                        <p style="margin-top: 0pt; margin-left: 36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>failure to achieve the anticipated efficiencies and cost savings or realize other expected benefits of the Acquisition within the expected time frame or at all.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>If these risks or other unexpected costs and liabilities were to materialize, any desired benefits of the Acquisition may not be fully realized, if at all, and our future financial performance and results of operations could be negatively impacted. In addition, if the combined company does not perform as we or the market expects, then this could have an adverse effect on the price of our common stock.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>The unaudited pro forma condensed combined financial information included in this Proxy Statement may not be an indication of our financial condition or results of operations following the Acquisition.</b></i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The unaudited pro forma condensed combined financial information included in this Proxy Statement are presented for illustrative purposes only, are based on various adjustments and assumptions, many of which are preliminary, and may not be an indication of our financial condition or results of operations following the Acquisition. Our actual financial condition and results of operations following the Acquisition may not be consistent with, or evident from, these unaudited pro forma condensed combined financial information included in this Proxy Statement. In addition, the assumptions used in preparing the unaudited pro forma financial data may not prove to be accurate, and other factors may affect our financial condition or results of operations as a result of the completion of the Acquisition.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>Actual results may differ from any statements made by us concerning the anticipated impact of the Acquisition on the operating results of the combined company, and these differences could be material.</b></i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>This Proxy Statement contains a number of forward-looking statements, including statements relating to the reasons for the Acquisition and the prospects for combining TruHC's business with our Company. Although we believe that we have a reasonable basis for such forward-looking statements, these statements are based on our projections of future events that are subject to risks, uncertainties and other factors that may cause the combined company's actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements to differ in a material way. Additional risks and uncertainties that could cause actual results to differ materially from currently anticipated results include, but are not limited to, risks relating to our ability to successfully integrate TruHC; unanticipated increases in costs or expenses; our ability to realize expected cost synergies, and the other risks identified in this Proxy Statement and the documents included herein that we urge you to read. Our actual financial condition and results of operations as a result of the Acquisition may not be consistent with, or evident from, the statements provided in this sroxy statement. Consequently, actual results or developments anticipated by us may not be realized or, even if substantially realized, may not have the expected consequences to, or effects on, us. In particular, while the Acquisition is expected to be accretive to Flora, there can be no assurance with respect to the timing and scope of the accretive effect or whether it will be accretive at all. Any failure to meet expectations regarding the prospects for the combined company could have a material adverse effect on our business, financial condition, results of operation, as well as the trading price and/or volume of our Common Stock.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>115</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_121_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>Charges to earnings resulting from the application of the purchase method of accounting may adversely affect the market value of our Common Stock following the Second Closing of the Acquisition.</b></i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Acquisition will be accounted for using the purchase method of accounting, which will may in charges to earnings that could have an adverse impact on the market value of our Common Stock following as a result of us having completed the Acquisition. Under the purchase method of accounting, the total estimated Purchase Price will be allocated to TruHC's pro forma net tangible assets and identifiable intangible assets based on their respective fair values as of the Second Closing. If TruHC is determined to be a business under the meaning ascribed to it under United States Generally Accepted Accounting Principles ("U.S. GAAP"), any excess of the Purchase Price over those fair values will be recorded as goodwill. As a result of the consolidation of TruHC with our Company, we may incur additional amortization expense based on the identifiable amortizable intangible assets acquired pursuant to the Stock Purchase Agreement and their relative useful lives. Additionally, to the extent the value of goodwill or identifiable intangible assets or other long-lived assets may become impaired, we may be required to incur charges relating to the impairment. These amortization and potential impairment charges could have a material impact on the combined company's results of operations.</span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>We are required to take all necessary steps and make commercial best efforts to approve the Share Issuance Resolution at a meeting of the Company's shareholder's as soon as reasonably practicable following the execution of the Stock Purchase Agreement to approve the Second Closing and if we are unable to obtain such approval, then we may not be able to fully complete the Acquistion.</b></i></span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Pursuant to the Stock Purchase Agreement, the Company is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable following the execution of the Stock Purchase Agreement to approve the Share Issuance Resolution and to recommend the approval of the Share Issuance Resolution to the shareholders of the Company for the purpose of obtaining shareholder approval to allow for the issuance of the Common Shares in the Second Closing in accordance with Nasdaq Listing Rule 5635(a). If such shareholder approval is not received, the Company may be required to convene additional shareholder meetings thereafter until such approval is obtained, which could result in substantial costs and be a distraction to management.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>116</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_122_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Risks Related to TruHC's Business</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>TruHC is an early-stage company with limited operating history and may never generate revenue or become profitable.</b></i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>TruHC is an early-stage company and has not generated any revenues, operating cash flows or profit from its activities. Formed in 2022, TruHC has a limited operating history and limited financial resources. TruHC's ability to realize its business plan continues to depend on obtaining financial support from Flora. There can be no assurance that such funding will be available for the development of TruHC's business or that TruHC's business plan is sound. There are costs, uncertainties, delays and difficulties frequently encountered by companies in the early stage of development.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>TruHC is subject to cannabis laws, regulations, and guidelines that are dynamic and subject to changes. </b></i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require TruHC to incur substantial costs associated with compliance or alter certain aspects of its business plan. It is also possible that regulations may be enacted in the future that will be directly applicable to certain of TruHC's potential products and/or aspects of its businesses. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on TruHC's business. Management expects that the legislative and regulatory environment in the cannabis industry internationally will continue to be dynamic and will require innovative solutions to try to comply with this changing legal landscape in this nascent industry for the foreseeable future. Compliance with any such legislation may have a material adverse effect on TruHC's business, financial condition and results of operations.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Public opinion can also exert a significant influence over the regulation of the cannabis industry. A negative shift in the public's perception of the cannabis industry could affect future legislation or regulation in different jurisdictions.</span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>Demand for cannabis and derivative products could be adversely affected and significantly influenced by scientific research or findings, regulatory proceedings, litigation, media attention or other research findings.</b></i></span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The legal cannabis industry is at a relatively early stage of its development. Consumer perceptions regarding legality, morality, consumption, safety, efficacy and quality of medicinal cannabis are mixed and evolving and can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of medicinal cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the medicinal cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity, could have a material adverse effect on the demand for medicinal cannabis and on TruHC's business, results of operations, financial condition and cash flows. Further, adverse publicity reports or other media attention regarding cannabis in general or associating the consumption of medicinal cannabis with illness or other negative effects or events, could have such a material adverse effect. Public opinion and support for medicinal cannabis use has traditionally been inconsistent and varies from jurisdiction to jurisdiction. TruHC's ability to gain and increase market acceptance of its business may require substantial expenditures, strategic relationships and marketing initiatives. There can be no assurance that such initiatives will be successful and their failure to materialize into significant demand may have an adverse effect on our financial condition.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>117</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_123_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>Research regarding the medical benefits, viability, safety, efficacy, use and social acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in early stages.</b></i></span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC). Although TruHC believes that the articles, reports and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Future research studies and clinical trials may draw opposing conclusions to those stated herein or reach negative conclusions related to medical cannabis, which could have a material adverse effect on the demand for the cannabis products, which could result in a material adverse effect on TruHC's business, financial condition and results of operations or prospects.</span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>TruHC may not be able to maintain effective quality control systems.</b></i></span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span style="background-color: #ffffff;">TruHC may not be able to maintain an effective quality control system. TruHC ascribes its early successes, in part to its effective quality control system. The effectiveness of the TruHC's quality control system and its ability to obtain or maintain good manufacturing practice ("GMP") certification with respect to its manufacturing, processing and testing facility depend on a number of factors, including the design of its quality control procedures, training programs, and its ability to ensure that its employees adhere to the TruHC's policies and procedures. TruHC expects that regulatory agencies will periodically inspect its' facility to evaluate compliance with applicable GMP requirements. Failure to comply with these requirements may subject TruHC or TruHC's service providers to possible regulatory enforcement actions. Any failure or deterioration of TruHC's or its service providers' quality control systems, including loss of GMP certification, may have a material adverse effect on TruHC's business, results of operations and financial condition.</span></span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>TruHC may not be able to renew certain of its leases.</b></i></span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Several of the properties or facilities that TruHC utilizes are leased for a specific term. There is a risk that TruHC may not be able to extend the term on some or all of such leases or, if we do so, that the terms of any such lease extension will be favorable. Likewise, there is a risk that some leases may expire and TruHC will be required to relocate our operations to another location, thereby incurring costs. Further, the licenses TruHC maintains are associated with specific leased facilities.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>118</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_124_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span style="background-color: #ffffff;"><i><b>Any failure on TruHC's part to comply with applicable regulations could prevent it from being able to carry on business, and there may be additional costs associated with any such failure, including but not limited to, loss of licenses.</b></i></span></span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>TruHC's business activities are heavily regulated. TruHC's operations are subject to various laws, regulations and guidelines by governmental authorities. Any failure to comply with the applicable regulatory requirements could require extensive changes to operations, result in regulatory or agency proceedings or investigations, result in revocation of licenses and permits, increase compliance costs, result in damage awards, civil or criminal fines or penalties, result in restrictions on operations, harm TruHC's reputation or give rise to material liabilities.</span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>There can be no assurance that any future regulatory or agency proceedings, investigations or audits will not result in substantial costs, a diversion of management's attention and resources or other adverse consequences.</span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Achievement of business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all necessary regulatory approvals. Any failure to comply with the regulatory requirements applicable to TruHC's operations may lead to possible sanctions, including the revocation or imposition of additional conditions on licenses, the suspension or expulsion from a particular market or jurisdiction or of key personnel, the imposition of additional or more stringent inspection, testing and reporting requirements, and imposition of fines or censures.</span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span style="background-color: #ffffff;">In addition, changes in regulations, government or judicial interpretation of regulations, or more vigorous enforcement thereof or other unanticipated events could require extensive changes to TruHC's operations, increase compliance costs or give rise to material liabilities or a revocation of TruHC's licenses and other permits. Furthermore, governmental authorities may change their administration, application or enforcement procedures at any time, which may adversely affect TruHC's ongoing regulatory compliance costs. There is no assurance that TruHC's will be able to comply or continue to comply with applicable regulations.</span></span></span></span></p>
                        <p style="text-align: justify; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span style="background-color: #ffffff;">TruHC holds certain licenses that form an integral component of its business. There is no assurance that TruHC will be able to maintain or continue to maintain its licenses. <i><b>&#160;</b></i></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Share Issuance Resolution</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>At the Annual Meeting, shareholders will be asked to consider and, if thought appropriate, pass, with or without variation, the following ordinary resolution to approve the Share Issuance Proposal (the "Share Issuance Resolution"):</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>"<b>BE IT RESOLVED AS AN ORDINARY RESOLUTION THAT:</b> the Proposed Share Issuance, as described in Proposal No. 5, hereby is, approved, confirmed and ratified in all respects."</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>119</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_125_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Vote Required.</b> For the Share Issuance Resolution to be approved and confirmed, the Share Issuance Resolution must be passed by the affirmative vote of a simple majority of the votes cast at the Annual Meeting are cast "FOR" approval (subject to the separate tabulation of votes described in "<i>Who May Vote?</i>" set forth above).</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>THE BOARD RECOMMENDS A VOTE "FOR" THE SHARE ISSUANCE RESOLUTION AND PROXIES EXECUTED AND RETURNED WILL BE SO VOTED UNLESS A SHAREHOLDER HAS SPECIFIED CONTRARY INSTRUCTIONS IN THE PROXY.</b></span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>120</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_126_integixAnchor"></span></span></span></span>
                        <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>AUDIT COMMITTEE REPORT</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i>The following report of the Audit Committee does not constitute soliciting material and should not be deemed filed with the SEC nor shall this information be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference into a filing.</i></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Our Audit Committee consists of Chair, Kevin Taylor, and members, Edward Woo and Brendan Cahill. The Board has determined that each Audit Committee member is "independent," as independence for Audit Committee members is defined in the applicable Nasdaq listing standards and rules of the SEC and by NI 52-110. The Board also determined that all members of the Audit Committee are financially literate as such term is defined by NI 52-110, and Mr. Taylor, Mr. Woo and Mr. Cahill each qualify as an Audit Committee financial expert, as such term is defined in Item 407 of Regulation S-K. Although designated as Audit Committee financial experts, the Audit Committee Chair and members are not accountants for the Company nor, under SEC rules, an "expert" for purposes of the liability provisions of the Securities Act or for any other purpose.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The role of the Audit Committee is to (a) oversee the accounting and financial reporting processes of the Company and the audits of the Company's financial statements; (b) oversee the Company's compliance with legal and regulatory requirements; (c) oversee the performance of the Company's internal audit function; (d) take, or recommend that the Board of the Company take, appropriate action to oversee the qualifications, independence and performance of the Company's independent auditors; and (e) prepare the report required by the rules of the SEC to be included in the Company's annual proxy statement.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Audit Committee influences the overall tone for quality financial reporting, sound internal controls, and ethical behavior. Management is responsible for the preparation, presentation and integrity of the Company's financial statements, for the appropriateness of the accounting and reporting policies that are used by the Company, and for the establishment and effectiveness of internal controls and procedures designed to ensure compliance with accounting standards and applicable laws and regulations. The independent auditors are responsible for auditing the Company's consolidated financial statements in accordance with the standards of the Public Company Accounting Oversight Board ("PCAOB"), expressing an opinion as to the conformity of such financial statements with generally accepted accounting principles, expressing an opinion on the effectiveness of internal control over financial reporting (when required), and for reviewing the Company's interim consolidated financial statements.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The independent auditors report directly to the Audit Committee. The Audit Committee has the sole authority and responsibility to recommend to the Board the nomination of the independent auditors for approval by the shareholders on an annual basis. The Audit Committee is directly responsible for the appointment, retention, termination, compensation, retention, evaluation and oversight of the work of the independent auditors for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>In 2023, the Audit Committee met and held discussions with management and Davidson, the Company's independent registered public accounting firm. The Audit Committee discussed with management and Davidson the Company's audited consolidated financial statements and policies and procedures designed to reduce the likelihood of events of non-compliance with rules and regulations, including discussions of the quality, not just the acceptability, of accounting policies and principles, significant judgments and estimates, system of internal control over financial reporting, and clarity of disclosures, including items reported as Critical Auditing Matters in the report of the independent auditor. The Audit Committee reviewed the annual plan and scope of work to be performed by Davidson, and met outside of the presence of management with Davidson to discuss their respective audit results, evaluations of the Company's internal controls, and the overall quality of the Company's financial reporting. Consistent with the requirements of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder, the Audit Committee discussed with Davidson those matters required to be discussed pursuant to PCAOB Auditing Standard 1301, "Communications with Audit Committees," and the rules of the SEC, and reviewed a letter from Davidson disclosing such matters.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>121</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_127_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Audit Committee also discussed with Davidson the firm's independence from the Company and its management team and reviewed the written disclosures and letter from Davidson pursuant to applicable requirements of the PCAOB regarding the independent registered public accounting firm's communications with the Audit Committee concerning independence, and considered the compatibility of non-audit services, if any, with Davidson's independence.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Based upon the reports and discussions described above, the Audit Committee, in accordance with its responsibilities, recommended to the Board that the audited consolidated financial statements be included in the Company's Annual Report for the year ended December 31, 2023.</span></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>AUDIT COMMITTEE</b></span></span></span></p>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Kevin Taylor (Chair)</span></span></span></p>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Edward Woo</span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Brendan Cahill</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>122</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_128_integixAnchor"></span></span></span></span>
                        <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>WHERE TO GET ADDITIONAL INFORMATION</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>As a reporting company, we are subject to the informational requirements of the Exchange Act and Canadian securities laws and accordingly file our annual report (including audited consolidated financial statements), quarterly reports on Form 10-Q (management's discussion and analysis ("MD&amp;A")), current reports on Form 8-K, proxy statements, and other information with the SEC and on the System for Electronic Document Analysis and Retrieval ("SEDAR+"). As an electronic filer, our public filings are maintained on the SEC's website at http://www.sec.gov/edgar and on SEDAR+ <span style="color: #0000ff; text-decoration: underline;">https://www.sedarplus.ca</span> which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC or on SEDAR+, as applicable.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Shareholders may contact the Company to request copies of the Company's financial statements and MD&amp;A at Flora Growth Corp. Attention: Chief Financial Officer, 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309.</span></span></span></p>
                        <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>COST OF PROXY STATEMENT</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>We will bear the cost of the solicitation of proxies on behalf of the Board. In addition to the use of the mail, proxies may be solicited by us personally, or by similar means. None of our directors, officers, or employees will be specifically compensated for those activities. We do not expect to pay any compensation for the solicitation of proxies. However, we will reimburse brokerage firms, custodians, nominees, fiduciaries, and other persons holding our shares in their names, or in the names of nominees, at approved rates for their reasonable expenses in forwarding proxy materials to beneficial owners of securities held of record by them and obtaining their proxies.</span></span></span></p>
                        <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>SHAREHOLDER COMMUNICATIONS</b></span></span></span></p>
                        <p style="text-indent: 36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>General</b></i><b>.</b>&#160; All interested parties, including shareholders, may communicate with the Company or our Board by letter addressed to Flora Growth Corp. Attention: Chief Financial Officer, 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309. This centralized process assists our Board in reviewing and responding to communications in an appropriate manner. If an interested party would like the letter to be forwarded directly to the Chairman, or if no Chairman is listed, the members of the standing committees of the Board, he or she should so indicate. If no specific direction is indicated, the Chief Financial Officer of the Company will review the letter and forward it to the appropriate Board member(s).</span></span></span></p>
                        <p style="text-indent: 36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><i><b>Submission of Shareholder Proposals and Director Nominations for 2025 Annual Meeting</b></i><b>.</b> Pursuant to Rule 14a-8 under the Exchange Act, our shareholders may present proper proposals for inclusion in our proxy statement and form of proxy and for consideration at the next annual meeting by submitting their proposals to us in a timely manner. Any shareholder of the Company who wishes to present a proposal for inclusion in the proxy statement and form of proxy for action at the 2025 Annual Meeting must comply with our Bylaws and the rules and regulations of the SEC and the OBCA, each as then in effect. Such proposals must be mailed to us at our offices at Flora Growth Corp. Attention: Chief Financial Officer, 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309. Under the rules of the SEC, any shareholder proposal intended to be presented at the 2025 Annual Meeting must be received no later than 60 days prior to the one-year anniversary of the Annual Meeting in order to be considered for inclusion in our proxy statement and form of proxy relating to such meeting. Pursuant to the OBCA and the rules of the SEC, a shareholder must follow certain procedures to nominate persons for election as directors or to introduce an item of business at an annual meeting of shareholders. In order to be timely, we must receive notice of your intention to introduce a nomination or propose an item of business at our 2025 Annual Meeting between the close of business on December 31, 2024 and close of business on April 6, 2025. If we change the date of our 2025 Annual Meeting by more than thirty days before, or more than thirty days after, the one-year anniversary of the Annual Meeting, then the written notice of a shareholder proposal that is not intended to be included in our proxy statement must be delivered, or mailed and received, not later than the ninetieth day prior to our 2025 Annual Meeting or, if later, the tenth day following the day on which public announcement of the date of such meeting is first made. You are advised to review our Bylaws, the OBCA and the applicable securities laws which contain additional requirements with respect to director nominees.</span></span></span></p>
                        <div>
                            <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>123</span></span></span></p>
                        </div>
                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span id="page_129_integixAnchor"></span></span></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>If a shareholder notifies us of an intent to present a proposal at the 2025 Annual Meeting at any time after April 6, 2025 (and for any reason the proposal is voted on at that meeting), it may be considered untimely and our proxy holders will have the right to exercise discretionary voting authority with respect to the proposal, if presented at the meeting, without including information regarding the proposal in our proxy materials. Under the rules of the SEC, in the event we change the date of our 2025 Annual Meeting by more than thirty days after the one-year anniversary of the Annual Meeting, the deadline for a shareholder to submit a proposal for the 2024 Annual Meeting is a reasonable time before we begin to print and send our proxy materials.</span></span></span></p>
                        <p style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>OTHER BUSINESS</b></span></span></span></p>
                        <p style="text-indent: 36pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Board knows of no other business to be brought before the Annual Meeting. If, however, any other business should properly come before the Annual Meeting, the persons named as proxies will vote in their discretion as they may deem appropriate.</span></span></span></p>
                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="width: 50%;">&#160;</td>
                                <td style="width: 50%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>By order of the Board of Directors,</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="width: 50%;">&#160;</td>
                                <td style="width: 50%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="width: 50%;">&#160;</td>
                                <td style="width: 50%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="width: 50%;">&#160;</td>
                                <td style="width: 50%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Clifford Starke</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="width: 50%;">&#160;</td>
                                <td style="width: 50%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Chief Executive Officer</span></span></span></td>
                            </tr>
                            <tr>
                                <td style="width: 50%;">&#160;</td>
                                <td style="width: 50%;">&#160;</td>
                            </tr>
                            <tr>
                                <td style="width: 50%;">&#160;</td>
                                <td style="width: 50%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2024</span></span></span></td>
                            </tr>
                        </table>
                        <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"> &#160;</span></span>
                        <div>
                            <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>124</span></span></span></p>
                        </div>
                    </div>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="page_130_integixAnchor"></span></span></span></span></span>
            </div>
            <div>
                <div>
                    <p style="text-align: center; margin-top: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="text-decoration: underline;"><b>INDEX TO FINANCIAL STATEMENTS</b></span></span></span></p>
                </div>
                <p style="margin-bottom: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Flora Growth Corp.</b></span></span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Audited Consolidated Financial Statements as of December 31, 2023 and 2022</b></span></span></p>
                <table style="margin-left: auto; border-collapse: collapse; font-size: 10pt; width: 90%; margin-right: auto; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_67_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Report of Independent Registered Public Accounting Firm (Davidson &amp; Company LLP; Vancouver, Canada; PCAOB ID 731)</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_67_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">126</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_68_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consolidated Statements of Financial Position</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_68_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">127</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_69_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consolidated Statements of Loss and Comprehensive Loss</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_69_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">128</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_70_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Consolidated Statement of Changes in Shareholders' Equity</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_70_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">129</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><a href="#page_71_integixAnchor_integixAnchor">Consolidated Statements of Cash Flows</a></p>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_71_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">130</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_72a_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to Financial Statements</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_72a_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">131</span></span></a></td>
                    </tr>
                </table>
                &#160;
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Flora Growth Corp.</b></span></span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Unaudited Condensed Consolidated Financial Statements for the quarter ended March 31, 2024</b></span></span></p>
                <table style="width: 90%; margin-left: auto; border-collapse: collapse; font-size: 10pt; margin-right: auto; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 906px;"><a href="#page_7_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unaudited Condensed Interim Consolidated Statements of Financial Position as of March 31, 2024 and December 31, 2023</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 99px; text-align: right;"><a href="#page_7_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">177</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 906px;"><a href="#page_8_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 99px; text-align: right;"><a href="#page_8_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">178</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 906px;"><a href="#page_9_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficiency) for the Three Months Ended March 31, 2024 and 2023</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 99px; text-align: right;"><a href="#page_9_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">179</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 906px;"><a href="#page_10_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unaudited Condensed Interim Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 99px; text-align: right;"><a href="#page_10_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">180</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 906px;"><a href="#page_11_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to Unaudited Condensed Interim Consolidated Financial Statements</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 99px; text-align: right;"><a href="#page_11_integixAnchor_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">181</span></span></a></td>
                    </tr>
                </table>
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>TruHC Pharma GmbH </b></span></span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Audited Financial Statements as of December 31, 2023 and 2022</b></span></span></p>
                <table style="margin-left: auto; border-collapse: collapse; font-size: 10pt; margin-right: auto; width: 90%; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#REPORT_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Report of Independent Registered Public Accounting Firm (Davidson &amp; Company LLP; Vancouver, Canada; PCAOB ID 731)</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#REPORT_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">194</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#StatementsofFinancialPosition_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Statements of Financial Position</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#StatementsofFinancialPosition_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">195</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#StatementofLossandComprehensiveLoss_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Statements of Loss and Comprehensive Loss</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#StatementofLossandComprehensiveLoss_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">196</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#StatementofShareholdersEquityDeficiency_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Statement of Changes in Shareholders' Equity</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#StatementofShareholdersEquityDeficiency_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">197</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><a href="#StatementofCashFlows_integixAnchor">Statement of Cash Flows</a></p>
                        </td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#StatementofCashFlows_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">198</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#NotestotheFinancialStatements_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to Financial Statements</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#NotestotheFinancialStatements_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">199</span></span></a></td>
                    </tr>
                </table>
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>TruHC Pharma GmbH </b></span></span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>Unaudited Condensed Interim Financial Statements for the quarter ended March 31, 2024</b></span></span></p>
                <table style="width: 90%; margin-left: auto; border-collapse: collapse; font-size: 10pt; margin-right: auto; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page213_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unaudited Condensed Interim Statements of Financial Position as of March 31, 2024 and December 31, 2023</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page213_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">213</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_147_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unaudited Condensed Interim Statements of Loss and Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_147_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">214</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_148_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unaudited Condensed Interim Statements of Changes in Shareholders' Equity (Deficiency) for the Three Months Ended March 31, 2024 and 2023</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_148_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">215</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_149_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Unaudited Condensed Interim Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_149_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">216</span></span></a></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 90%;"><a href="#page_150_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Notes to Unaudited Condensed Interim Financial Statements</span></span></a></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 10%; text-align: right;"><a href="#page_150_integixAnchor"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">217</span></span></a></td>
                    </tr>
                </table>
                <div>
                    <p style="margin: 0pt;">&#160;</p>
                    <p style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">125</span></span></p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span id="page_131_integixAnchor"></span></span></span>
            </div>
            <div>
                <p style="text-align: center; margin-top: 0pt;"><span id="page_67_integixAnchor_integixAnchor"><img src="formprer14axz001.jpg" alt="davidson.jpg" style="width: 766px; height: 55px;"/></span></p>
                <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></span></p>
                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">To the Shareholders and Directors of</span></span></p>
                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Flora Growth Corp.</span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i><b>Opinion on the Consolidated Financial Statements</b></i></span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>W</span></span></span></span><span style="font-family: TimesNewRoman, serif; color: black; font-weight: normal; font-style: normal; font-size: 10pt; line-height: 107%;">e have audited the accompanying consolidated statements of financial position of Flora Growth Corp. (the &#8220;Company&#8221;), as of December 31, 2023 and 2022, and the related consolidated statements of loss and comprehensive loss, shareholders&#8217; equity (deficiency), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years ended December 31, 2023 and 2022 in conformity with accounting principles generally accepted in the United States of America</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>.</span></span></span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i><b>Going Concern</b></i></span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>T</span></span></span></span><span style="font-family: TimesNewRoman, serif; color: black; font-weight: normal; font-style: normal; font-size: 10pt; line-height: 107%;">he accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company&#8217;s current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>.</span></span></span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i><b>Basis for Opinion</b></i></span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>T</span></span></span></span><span style="font-family: TimesNewRoman, serif; color: black; font-weight: normal; font-style: normal; font-size: 10pt; line-height: 107%;">hese consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>.</span></span></span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>W</span></span></span></span><span style="font-family: TimesNewRoman, serif; color: black; font-weight: normal; font-style: normal; font-size: 10pt; line-height: 107%;">e conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>.</span></span></span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>O</span></span></span></span><span style="font-family: TimesNewRoman, serif; color: black; font-weight: normal; font-style: normal; font-size: 10pt; line-height: 107%;">ur audits included performing procedures to assess the risks of material misstatements of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>.</span></span></span></span></p>
                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">We have served as the Company's auditor since 2020.</span></span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                        <td style="width: 48.94%; vertical-align: middle; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>/s/</b> <b>DAVIDSON &amp; COMPANY LLP</b></span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vancouver, Canada</span></span></td>
                        <td style="width: 48.94%; vertical-align: middle; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Chartered Professional Accountants</span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                        <td style="width: 48.94%; vertical-align: middle; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">PCAOB ID: 731</span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">March 28, 2024</span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span></p>
                <p style="text-align: center;"><img src="formprer14axz006.jpg" alt="nexia.jpg" style="width: 416px; height: 104px;"/></p>
                <div>
                    <p style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">126</span></span></p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/><span id="page_68_integixAnchor"></span>
            </div>
            <div>
                <div>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span id="page_68_integixAnchor_integixAnchor"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Flora Growth Corp.</b></span></span></span></span></span></span></p>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">Consolidated Statements of Financial Position </span></span></span></span></span></p>
                    <p style="margin-top: 0pt; margin-bottom: 10pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">(in thousands of United States dollars, except share amounts which are in thousands of shares)</span></span></span></span></span></p>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>As at:</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>December 31, 2023</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>December 31, 2022</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; background-color: #ffffff; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>ASSETS</span></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Current</span></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="1">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right;" colspan="2">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Cash</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>$</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095102395" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">4,350</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>$</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055321_0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">8,935</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Restricted cash</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055322_1" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">35</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055323_2" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231" unitRef="USD">-</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Trade and amounts receivable, net of $<ix:nonFraction id="Fxbrl_20231021095048484" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">315</ix:nonFraction> allowance ($<ix:nonFraction id="F20231019113055323_3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,385</ix:nonFraction> at 2022)</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095109779" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">3,950</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055324_4" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">5,259</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Loans receivable and advances</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055325_5" name="flgc:LoansReceivableAndAdvances" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055325_6" name="flgc:LoansReceivableAndAdvances" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">271</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Prepaid expenses and other current assets</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095134387" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,368</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055326_7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">805</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Indemnification receivables</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055326_8" name="us-gaap:NontradeReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">3,153</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055327_9" name="us-gaap:NontradeReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">3,429</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Inventory</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095146651" name="us-gaap:InventoryNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">8,508</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055327_10" name="us-gaap:InventoryNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">8,747</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Current assets held for sale</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20240305094643762_xbrl_20231021095146651" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="Fxbrl_20240305094643762_20231019113055327_10" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">3,709</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Total current assets</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055328_11" name="us-gaap:AssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">21,364</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055328_12" name="us-gaap:AssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">31,155</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Non-current</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>&#160;</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Property, plant and equipment</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095346348" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">847</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055329_13" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,218</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Operating lease right of use assets</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095352475" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">389</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055329_14" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">2,118</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Intangible assets</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095358579" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">946</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055330_15" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">17,739</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Goodwill</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055330_16" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055331_17" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">23,372</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Investments</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055332_18" name="us-gaap:LongTermInvestments" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055332_19" name="us-gaap:LongTermInvestments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">730</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Other Assets</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095405923" name="us-gaap:OtherAssetsNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">80</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055321_00" name="us-gaap:OtherAssetsNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">263</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Non-current assets held for sale</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20240305094714448_xbrl_20231021095405923" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="Fxbrl_20240305094714448_20231019113055321_00" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">4,392</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Total assets</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>$</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055321_01" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">23,626</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>$</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055321_02" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">80,987</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>LIABILITIES</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Current</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>&#160;</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Trade payables</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>$</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095453324" name="us-gaap:AccountsPayableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">5,111</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>$</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055321_06" name="us-gaap:AccountsPayableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">7,831</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Contingencies</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055321_07" name="us-gaap:CommitmentsAndContingencies" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">5,500</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055321_08" name="us-gaap:CommitmentsAndContingencies" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">5,044</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Current portion of debt</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055321_09" name="us-gaap:LongTermDebtCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,931</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055322_10" name="us-gaap:LongTermDebtCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,086</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Current portion of operating lease liability</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095503090" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">799</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055322_12" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,116</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Current portion of contingent purchase considerations</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20240305094840425_xbrl_20231021095503090" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,095</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="Fxbrl_20240305094840425_20231019113055322_12" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231" unitRef="USD">-</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Other accrued liabilities</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095508499" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,844</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055322_14" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,760</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Current liabilities held for sale</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20240305094907256_xbrl_20231021095508499" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="Fxbrl_20240305094907256_20231019113055322_14" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">610</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Total current liabilities</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055322_15" name="us-gaap:LiabilitiesCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">16,280</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055322_16" name="us-gaap:LiabilitiesCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">17,447</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Non-current</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>&#160;</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Non-current operating lease liability</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20231021095538259" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">942</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055322_19" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,561</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Deferred tax</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055323_20" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055323_21" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,712</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Contingent purchase considerations</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055323_22" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055323_23" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">3,547</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Non-current liabilities held for sale</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="Fxbrl_20240305095309612_20231019113055323_22" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="Fxbrl_20240305095309612_20231019113055323_23" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">308</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Total liabilities</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055323_24" name="us-gaap:Liabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">17,222</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055323_25" name="us-gaap:Liabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">24,575</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>SHAREHOLDERS' EQUITY</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>&#160;</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Share capital, no par value, unlimited authorized, <ix:nonFraction id="Fxbrl_20231021095624190" name="us-gaap:CommonStockSharesOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="Shares"><ix:nonFraction id="Fxbrl_20231021095620114" name="us-gaap:CommonStockSharesIssued" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="Shares">8,935</ix:nonFraction></ix:nonFraction> issued and outstanding (<ix:nonFraction id="F20231019113055342_56" name="us-gaap:CommonStockSharesOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="Shares"><ix:nonFraction id="F20231019113055325_57" name="us-gaap:CommonStockSharesIssued" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="Shares">6,776</ix:nonFraction></ix:nonFraction> at 2022)</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055342_55" name="us-gaap:CommonStockValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055323_28" name="us-gaap:CommonStockValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231" unitRef="USD">-</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Additional paid-in capital</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055337_41" name="us-gaap:AdditionalPaidInCapital" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">149,093</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055337_42" name="us-gaap:AdditionalPaidInCapital" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">150,420</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Accumulated other comprehensive loss</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>(<ix:nonFraction id="F20231019113055338_43" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231" unitRef="USD">140</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>)</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>(<ix:nonFraction id="F20231019113055338_44" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231" unitRef="USD">2,732</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>)</span></span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Deficit</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>(<ix:nonFraction id="F20231019113055339_45" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231" unitRef="USD">142,549</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>)</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>(<ix:nonFraction id="F20231019113055339_46" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231" unitRef="USD">90,865</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>)</span></span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Total Flora Growth Corp. shareholders' equity</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055340_47" name="us-gaap:StockholdersEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">6,404</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055340_48" name="us-gaap:StockholdersEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">56,823</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Non-controlling interest in subsidiaries</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055341_49" name="us-gaap:MinorityInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>(<ix:nonFraction id="F20231019113055341_50" name="us-gaap:MinorityInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231" unitRef="USD">411</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>)</span></span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Total shareholders' equity</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055324_40" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">6,404</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055324_41" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">56,412</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>Total liabilities and shareholders' equity</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>$</b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b><ix:nonFraction id="F20231019113055324_42" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">23,626</ix:nonFraction></b></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>$</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><ix:nonFraction id="F20231019113055324_43" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">80,987</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        </tr>
                    </table>
                    <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><i>The accompanying notes are an integral part of these consolidated financial statements. Commitments and contingencies - see Note 19.</i></span></span></span></span></span></p>
                </div>
            </div>
            <div style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">127</span></span></div>
            <div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/>
            </div>
            <div>
                <div>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span id="page_69_integixAnchor_integixAnchor"><span><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><b>Flora Growth Corp.</b></span></span></span></span></p>
                    <p style="margin-top: 0pt; margin-bottom: 10pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Consolidated Statements of Loss and Comprehensive Loss<br/>(in thousands of United States dollars, except per share amounts which are in thousands of shares)</span></span></p>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the year ended<br/>December 31, 2023</b></span></span></td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the year ended<br/>December 31, 2022</b></span></span></td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Revenue</b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055363_0" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">76,071</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055363_1" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">33,401</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cost of sales</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055364_2" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">58,333</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055364_3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">20,150</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Gross profit</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055364_4" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">17,738</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055365_5" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">13,251</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating expenses </b></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Consulting and management fees</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055365_6" name="us-gaap:ManagementFeeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">11,876</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055365_7" name="us-gaap:ManagementFeeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">9,232</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055366_8" name="us-gaap:ProfessionalFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2,301</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055366_9" name="us-gaap:ProfessionalFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">3,884</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055366_10" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,646</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055366_11" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">3,287</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Promotion and communication</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055367_12" name="us-gaap:Communication" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">4,710</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055367_13" name="us-gaap:Communication" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">8,033</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Travel expenses</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055367_14" name="us-gaap:TravelAndEntertainmentExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">413</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055368_15" name="us-gaap:TravelAndEntertainmentExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">930</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share based compensation</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055368_16" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,591</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055368_17" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">3,404</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Research and development</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055369_18" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">62</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055369_19" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">388</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055369_20" name="us-gaap:OperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,211</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055369_21" name="us-gaap:OperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">937</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055370_22" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2,335</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055370_23" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">2,144</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Bad debt expense</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055370_24" name="us-gaap:InterestAndDebtExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">236</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055371_25" name="us-gaap:InterestAndDebtExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">941</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill impairment</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055371_26" name="us-gaap:GoodwillImpairmentLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">23,372</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055371_27" name="us-gaap:GoodwillImpairmentLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">25,072</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other asset impairments</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055372_28" name="us-gaap:OtherAssetImpairmentCharges" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">16,135</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055372_29" name="us-gaap:OtherAssetImpairmentCharges" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">709</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other expenses (income), net</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055372_30" name="us-gaap:OtherCostAndExpenseOperating" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2,204</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055372_31" name="us-gaap:OtherCostAndExpenseOperating" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,511</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total operating expenses</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055373_32" name="us-gaap:OperatingExpenses" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">68,092</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055373_33" name="us-gaap:OperatingExpenses" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">60,472</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating loss</b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055373_34" name="us-gaap:OperatingIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">50,354</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055374_35" name="us-gaap:OperatingIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">47,221</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055374_36" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">92</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055374_37" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">29</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign exchange (income) loss</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055375_38" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">158</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055375_39" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">323</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unrealized (gain) loss from changes in fair value</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055375_40" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,991</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055375_41" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">593</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss before income taxes and discontinued operations</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055376_42" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">48,297</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055376_43" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">48,108</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax benefit</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055376_44" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">1,628</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055377_45" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1,405</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss from continuing operations</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305101012018" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">46,669</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305101027542" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">46,703</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss from discontinued operations, net of taxes</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305101034337" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">9,678</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305101048224" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">5,926</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss for the period</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055377_46" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">56,347</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055377_47" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">52,629</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net income (loss) attributable to noncontrolling interest</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055379_54" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">689</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240306014913971" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">214</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net loss attributable to Flora Growth Corp </b></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055379_52" name="us-gaap:NetIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">57,036</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055379_53" name="us-gaap:NetIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">52,415</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share from continuing operations</span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305100819805" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD_Per_Share">6.34</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305100830396" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD_Per_Share">12.19</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share from continuing operations</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305100839994" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD_Per_Share">6.34</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305100851882" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD_Per_Share">12.19</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share attributable to Flora Growth Corp.</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231025124753012" name="us-gaap:EarningsPerShareBasic" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD_Per_Share">7.75</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231025124842701" name="us-gaap:EarningsPerShareBasic" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD_Per_Share">13.68</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share attributable to Flora Growth Corp.</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305100714776" name="us-gaap:EarningsPerShareDiluted" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD_Per_Share">7.75</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305100636197" name="us-gaap:EarningsPerShareDiluted" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD_Per_Share">13.68</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted average number of common shares outstanding - basic</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055381_62" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Shares">7,356</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055382_63" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Shares">3,832</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted average number of common shares outstanding - diluted</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305100737048" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Shares">7,356</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305100750101" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Shares">3,832</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Comprehensive loss:</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305102209332_20231019113055377_46" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">56,347</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305102209332_20231019113055377_47" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">52,629</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign currency translation, net of income taxes of $<ix:nonFraction id="Fxbrl_20231021102513477" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231" unitRef="USD">nil</ix:nonFraction> ($<ix:nonFraction id="Fxbrl_20231021102525336" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20220101to20221231" unitRef="USD">nil</ix:nonFraction> in 2022)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055378_48" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2,592</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055378_49" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1,624</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Comprehensive loss for the period</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055378_50" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">53,755</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055378_51" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">54,253</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Comprehensive income&#160;(loss) attributable to noncontrolling interests</span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055381_58" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">689</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055381_59" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">214</ix:nonFraction></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Comprehensive loss attributable to Flora Growth Corp.</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20231019113055380_56" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">54,444</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20231019113055380_57" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">54,039</ix:nonFraction></b></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                        </tr>
                    </table>
                    <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></span></p>
                </div>
            </div>
            <div style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">128</span></span></div>
            <div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/>
            </div>
            <div>
                <div>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span id="page_70_integixAnchor_integixAnchor"><span><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><b>Flora Growth Corp.</b></span></span></span></span></p>
                    <p style="margin-top: 0pt; margin-bottom: 10pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;">Consolidated Statement of Shareholders' Equity<br/>(in thousands of United States dollars, except share amounts which are in thousands of shares)</span></span></p>
                    <table style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="4"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Common Shares </b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Additional<br/>paid-in<br/>capital </b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Accumulated other<br/>comprehensive<br/>(loss) income </b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Accumulated<br/>Deficit </b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Non-<br/>Controlling<br/>interests in<br/>subsidiaries<br/>(Deficiency) </b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; border-top: 0.75pt solid #000000; white-space: nowrap;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; border-top: 0.75pt solid #000000; white-space: nowrap;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Shareholders'<br/>Equity</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; border-top: 0.75pt solid #000000;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b># </b></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2021</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055392_0" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">3,276</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305110235456" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055395_1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">116,810</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055396_2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">1,108</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055396_3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">38,536</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055397_4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">225</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055397_5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231" unitRef="USD">76,941</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">December unit offering</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055416_46" name="flgc:DecemberUnitOfferingShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">625</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055417_47" name="flgc:DecemberUnitOfferingAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">5,000</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055417_48" name="flgc:DecemberUnitOfferingAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">5,000</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">December unit offering issuance costs</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055417_49" name="flgc:DecemberUnitOfferingIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">415</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055418_50" name="flgc:DecemberUnitOfferingIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">415</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Share repurchase</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055418_51" name="us-gaap:StockRepurchasedDuringPeriodShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">18</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055419_52" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">255</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055419_53" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">255</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Common shares issued for business combinations</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055419_54" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">2,651</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055420_55" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">24,492</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055420_56" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">24,492</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Equity issued for other agreements</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055421_57" name="flgc:EquityIssuedForOtherAgreementsShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">40</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055421_58" name="flgc:EquityIssuedForOtherAgreementsAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">1,554</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055421_59" name="flgc:EquityIssuedForOtherAgreementsAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,554</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Acquisition of noncontrolling interest</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055422_60" name="flgc:AcquisitionOfNoncontrollingInterestShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">6</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055422_61" name="flgc:AcquisitionOfNoncontrollingInterestAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">283</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055423_62" name="flgc:AcquisitionOfNoncontrollingInterestAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">365</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055423_63" name="flgc:AcquisitionOfNoncontrollingInterestAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">28</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055423_64" name="flgc:AcquisitionOfNoncontrollingInterestAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">54</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options issued</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055424_65" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">4,003</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055424_66" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">4,003</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options exercised</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055424_67" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">27</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055425_68" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">82</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055425_69" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">82</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options expired/cancelled</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055426_70" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">1,580</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055426_71" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">451</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055426_72" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,129</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Restricted stock vesting</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055427_73" name="flgc:RestrictedStockVestingShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">146</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055427_74" name="flgc:RestrictedStockVestingAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">446</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055428_75" name="flgc:RestrictedStockVestingAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">446</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Warrants exercised</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055428_76" name="flgc:WarrantsExercisedShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">23</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055428_77" name="flgc:WarrantsExercisedAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">105</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055429_78" name="flgc:WarrantsExercisedAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">105</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Warrants expired/cancelled</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055435_91" name="flgc:WarrantsExpiredOrCancelledAmount" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Share issuance costs</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055429_79" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">105</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055430_80" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">105</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Other comprehensive loss -<br/>exchange differences on foreign operations (net of income taxes of $<ix:nonFraction id="Fxbrl_20240418094004408" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20220101to20221231" unitRef="USD">nil</ix:nonFraction>)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055430_81" name="flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">1,624</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055430_82" name="flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1,624</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Current year net loss attributable to Flora</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055432_83" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">52,415</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055433_84" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">214</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055433_85" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">52,629</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2022</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231021105708069" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">6,776</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305110318221" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055411_41" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">150,420</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055415_42" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">2,732</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055415_43" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">90,865</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055415_44" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">411</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055416_45" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">56,412</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">September unit offering</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055398_6" name="flgc:SeptemberUnitOfferingShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">1,369</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055398_7" name="flgc:SeptemberUnitOfferingAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">2,738</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055398_8" name="flgc:SeptemberUnitOfferingAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2,738</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">September unit offering issuance costs</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055399_9" name="flgc:SeptemberUnitOfferingIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">254</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055399_10" name="flgc:SeptemberUnitOfferingIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">254</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Equity issued for other agreements</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305104938392" name="flgc:EquityIssuedForOtherAgreementsShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">126</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305104947894" name="flgc:EquityIssuedForOtherAgreementsAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">590</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105000475" name="flgc:EquityIssuedForOtherAgreementsAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">590</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options issued</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105013894" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">226</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105025196" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">226</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options forfeited</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305110951286" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">5,627</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305111018527" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">5,352</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305111027165" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">275</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Restricted stock granted</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105439295_20231019113055427_73" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">838</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105439295_20231019113055427_74" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">1,989</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105439295_20231019113055428_75" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,989</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Restricted stock cancelled</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305105544611_xbrl_20240305105439295_20231019113055427_73" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">174</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305105544611_xbrl_20240305105439295_20231019113055427_74" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">844</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305105544611_xbrl_20240305105439295_20231019113055428_75" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">844</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Share issuance costs</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305105505209_20231019113055429_79" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">145</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305105505209_20231019113055430_80" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">145</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Derecognition of equity related to Colombia assets</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305111243701" name="flgc:DerecognitionOfEquityRelatedToColombiaAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">1,310</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305111259126" name="flgc:DerecognitionOfEquityRelatedToColombiaAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">278</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305111323109" name="flgc:DerecognitionOfEquityRelatedToColombiaAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,032</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Other comprehensive loss -<br/>exchange differences on foreign operations (net of income taxes of $<ix:nonFraction id="Fxbrl_20240418093944499" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231" unitRef="USD">nil</ix:nonFraction>)</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105516144_20231019113055430_81" name="flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">1,282</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105516144_20231019113055430_82" name="flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,282</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Current year net loss attributable to Flora</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305105523932_20231019113055432_83" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">57,036</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305105523932_20231019113055433_84" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">689</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240305105523932_20231019113055433_85" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">56,347</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2023</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231021105754452" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">8,935</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305110019123" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055433_86" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">149,093</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055434_87" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">140</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055434_88" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">142,549</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305110008120" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055435_90" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">6,404</ix:nonFraction></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                    </table>
                    <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></span></p>
                </div>
            </div>
            <div style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">129</span></span></div>
            <div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 10pt;"/>
            </div>
            <div>
                <div>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span id="page_71_integixAnchor_integixAnchor"><span><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Flora Growth Corp.</b></span></span></span></span></span></span></p>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">Consolidated Statements of Cash Flows</span></span></span></span></p>
                    <p style="margin-top: 0pt; margin-bottom: 10pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">(in thousands of United States dollars)</span></span></span></span></p>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2022</b></span></span></span></span></td>
                            <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Cash flows from operating activities:</b></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Net loss</span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641044_0" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">56,347</ix:nonFraction></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641044_1" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">52,629</ix:nonFraction></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Adjustments to net loss:</span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Depreciation and amortization</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641045_2" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2,484</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641045_3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">2,629</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Stock-based compensation</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641045_4" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,591</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641045_5" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">3,404</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Goodwill impairment</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641045_6" name="flgc:ImpairmentOfGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">23,372</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641046_7" name="flgc:ImpairmentOfGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">25,452</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Other asset impairments</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641046_8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">20,840</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641046_9" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">783</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Changes in fair value of investments and liabilities</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641046_10" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,991</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641047_11" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">593</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Bad debt expense</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641047_12" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">801</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641047_13" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,607</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Loss on disposal of discontinued operations</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305112654419_20240530124641047_12" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">3,132</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305112654419_20240530124641047_13" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Interest expense&#160;</span></span></span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(income) </span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641047_14" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">94</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641047_15" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">56</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Interest paid</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641048_16" name="us-gaap:InterestIncomeOperating" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">94</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641048_17" name="us-gaap:InterestIncomeOperating" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">4</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Income tax benefit</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641048_18" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">1,617</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641048_19" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1,538</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641048_20" name="us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">7,735</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641049_21" name="us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">19,759</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Net change in non-cash working capital:</span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Trade and other receivables</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641049_22" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">1,522</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641049_23" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">143</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Inventory</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641049_24" name="us-gaap:IncreaseDecreaseInInventories" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">576</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641049_25" name="us-gaap:IncreaseDecreaseInInventories" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1,219</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Prepaid expenses and other assets</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641050_26" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">419</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641050_27" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1,372</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; Trade payables and accrued liabilities</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641050_28" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">2,340</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641050_29" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,090</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Net cash used in operating activities</b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="F20240530124641050_30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">8,396</ix:nonFraction></b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="F20240530124641050_31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">15,935</ix:nonFraction></b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Cash flows from financing activities:</b></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        </tr>
                        <tr>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Units issued</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641051_32" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2,738</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641051_33" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">5,000</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Equity issue costs</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641051_34" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">396</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641051_35" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">520</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Exercise of warrants and options</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641051_36" name="flgc:ProceedsFromExerciseOfWarrantsAndOptions" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641052_37" name="flgc:ProceedsFromExerciseOfWarrantsAndOptions" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">187</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Common shares repurchased</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641052_38" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641052_39" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">255</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Loan borrowings</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641052_40" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">995</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641052_41" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">197</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Loan repayments</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641053_42" name="us-gaap:RepaymentsOfDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">187</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641053_43" name="us-gaap:RepaymentsOfDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">196</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Net cash provided by financing activities</b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20240530124641053_44" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">3,150</ix:nonFraction></b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20240530124641053_45" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">4,413</ix:nonFraction></b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Cash flows from investing activities:</b></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Purchases of property, plant and equipment and intangible assets</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641053_46" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">163</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641054_47" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,294</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Net cash on disposal</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240305112623375_20240530124641053_46" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">71</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305112623375_20240530124641054_47" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Business and asset acquisitions, net of cash acquired</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641054_48" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641054_49" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">14,508</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Net cash used in investing activities</b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="F20240530124641054_50" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">234</ix:nonFraction></b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="F20240530124641054_51" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">15,802</ix:nonFraction></b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Effect of exchange rate on changes on cash</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641054_52" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">930</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20240530124641055_53" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">755</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Change in cash during the period</b></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="F20240530124641055_54" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">4,550</ix:nonFraction></b></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="F20240530124641055_55" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">28,079</ix:nonFraction></b></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Cash and restricted cash at beginning of period</span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>8,935</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641055_57" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231" unitRef="USD">37,616</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Cash included in assets held for sale</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305112543551_20240530124641055_56" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240305112543551_20240530124641055_57" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">602</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Cash and restricted cash at end of period</b></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20240530124641056_58" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">4,385</ix:nonFraction></span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>8,935</span></span></span></span></td>
                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span><b>Supplemental disclosure of non-cash investing and financing activities</b></span></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span>Common shares issued for business combinations</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span>$</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span><ix:nonFraction id="F20240530124641060_60" name="flgc:NonCashCommonSharesIssuedForBusinessCombinations" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231" unitRef="USD">-</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span>$</span></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span><ix:nonFraction id="F20240530124641060_61" name="flgc:NonCashCommonSharesIssuedForBusinessCombinations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">24,712</ix:nonFraction></span></span></span></span></span></td>
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span>Common shares issued for other agreements</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span><ix:nonFraction id="F20240530124641060_62" name="flgc:NonCashCommonSharesIssuedForOtherAgreements" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Shares">95</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span><ix:nonFraction id="F20240530124641060_63" name="flgc:NonCashCommonSharesIssuedForOtherAgreements" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Shares">1,470</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">
                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;">Option cancellations reclassified to equity</span></p>
                            </td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529194722865_20240530124641060_62" name="flgc:NonCashOptionCancellationsReclassifiedToEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">5,352</ix:nonFraction></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529194722865_20240530124641060_63" name="flgc:NonCashOptionCancellationsReclassifiedToEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">451</ix:nonFraction></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #e6efff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span>Operating lease additions to right of use assets</span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span><ix:nonFraction id="F20240530124641061_64" name="flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Shares">245</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><span><ix:nonFraction id="F20240530124641061_65" name="flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Shares">2,919</ix:nonFraction></span></span></span></span></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        </tr>
                        <tr style="background-color: #ffffff;">
                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">
                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets acquired for contingent consideration</span></p>
                            </td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240531042636946" name="flgc:IntangibleAssetsAcquiredForContingentConsiderationNonCash" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">194</ix:nonFraction></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #ffffff;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240531042709392" name="flgc:IntangibleAssetsAcquiredForContingentConsiderationNonCash" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231" unitRef="USD">-</ix:nonFraction></span></td>
                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        </tr>
                    </table>
                    <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></span></span></span></p>
                </div>
            </div>
            <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, serif; text-align: center;"><span style="font-size: 13.3333px;">130</span></p>
            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 10pt;"/>
            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                <tr>
                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span id="page_72a_integixAnchor_integixAnchor"><span><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span></span></span></span><br/><span style="font-family: Times New Roman,Times,serif;"><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                </tr>
            </table>
            <ix:nonNumeric id="F20231019113055475_0" name="us-gaap:NatureOfOperations" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1.<span style="display: inline-block; width: 20pt;">&#160;</span></b><b>NATURE OF OPERATIONS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Flora Growth Corp. (the "Company" or "Flora") was incorporated under the laws of the Province of Ontario, Canada on March 13, 2019. The Company is manufacturer and distributor of global cannabis and pharmaceutical products and brands, building a connected, design-led collective of plant-based wellness and lifestyle brands. The Company's registered office is located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1, Canada and our principal place of business in the United States is located at 3406 SW 26th Terrace, Suite C-1, Fort Lauderdale, Florida 3312.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 23, 2022, Flora completed its acquisition of all the issued and outstanding common shares of Franchise Global Health Inc. ("FGH"), a corporation existing under the laws of the Province of British Columbia by way of a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). FGH, through its wholly-owned subsidiaries, is a multi-national distributor in the pharmaceutical and medical cannabis industry with principal operations in Germany. See Note 10 for further discussion.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On February 24, 2022, Flora Growth U.S. Holdings Corp., a wholly-owned subsidiary of the Company, completed the acquisition of 100% of the outstanding equity interests in each of (i) Just Brands LLC and (ii) High Roller Private Label LLC. JustCBD is a manufacturer and distributor of consumable cannabinoid products, including gummies, tinctures, vape cartridges, and creams with principal operations in Florida, United States. See Note 10 for further discussion.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</span></span></p>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20231019113055518_144" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" contextRef="C_20230101to20231231">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2.<span style="display: inline-block; width: 20pt;">&#160;</span></b><b>BASIS OF PRESENTATION</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements have been presented in United States dollars and are prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The Company has determined that the United States dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in United States dollars and our financial results are prepared and reviewed internally by management in United States dollars.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to January 1, 2023, Flora was a foreign private issuer reporting its financial statements under International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Boards. These consolidated financial statements, for all periods, are presented in accordance with U.S. GAAP.</span></span></p>
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Going concern</span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span></span></p>
                                    <div>
                                        <div>
                                            <ix:exclude>
                                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">131</span></span></span></div>
                                                <div>
                                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                </div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                    </tr>
                                                </table>
                                            </ix:exclude>
                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of $<ix:nonFraction id="Fxbrl_20231021114344055" name="us-gaap:Cash" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">4.4</ix:nonFraction> million at December 31, 2023, net loss of $<ix:nonFraction id="F20231019113055480_1" name="us-gaap:ProfitLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">56.3</ix:nonFraction> million for the year ended December 31, 2023, and an accumulated deficit of $<ix:nonFraction id="F20231019113055480_2" name="us-gaap:CumulativeEarningsDeficit" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231" unitRef="USD">142.5</ix:nonFraction> million at December 31, 2023. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions, through the disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. These consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                                </div>
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Presentation of comparative financial statements</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion in Note 15.</span></span></p>
                                </div>
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of consolidation</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. As at December 31, 2023, the Company had the following subsidiaries:</span></span></p>
                                    <div>
                                        <ix:nonNumeric id="Fxbrl_20240305124000279" name="flgc:ScheduleOfSubsidiariesTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                            <div style="margin-bottom: 10pt;">
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Subsidiaries</b></span></span></td>
                                                        <td style="width: 14%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Country of<br/>Incorporation</b></span></span></span></span></td>
                                                        <td style="width: 21%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Ownership %</b></span></span></td>
                                                        <td style="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Functional Currency</b></span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055480_4" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember">Kasa Wholefoods Company LLC</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055487_33" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember">United States</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055487_34" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055489_35" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember">United States Dollar (USD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055481_8" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember">Flora Beauty LLC</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055484_21" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember">United States</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055484_22" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055484_23" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember">United States Dollar (USD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055482_12" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember">Vessel Brand Inc.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055492_49" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember">United States</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055493_50" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055493_51" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember">United States Dollar (USD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055483_16" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember">Vessel Brand Canada Inc.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="Fxbrl_20240305124530374" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember">Canada</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305124542118" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="Fxbrl_20240305124553509" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember">United States Dollar (USD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055484_20" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember">Just Brands LLC</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055493_53" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember">United States</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055494_54" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055494_55" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember">United States Dollar (USD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055485_24" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember">Just Brands International LTD</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055494_57" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember">United Kingdom</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055494_58" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055495_59" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember">British Pound (GBP)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055486_28" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember">High Roller Private Label LLC</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055495_61" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember">United States</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055495_62" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055495_63" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember">United States Dollar (USD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055486_32" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember">Flora Growth US Holdings Corp.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055496_65" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember">United States</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055496_66" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055496_67" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember">United States Dollar (USD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055489_36" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember">Cardiff Brand Corp.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055498_73" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember">United States</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055498_74" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055498_75" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember">United States Dollar (USD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055491_40" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember">Franchise Global Health Inc</ix:nonNumeric>.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055502_89" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember">Canada</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055502_90" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055502_91" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember">Canadian Dollar (CAD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055491_44" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember">Harmony Health One Inc.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055503_93" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember">Canada</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055503_94" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055503_95" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember">Canadian Dollar (CAD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055492_48" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember">ACA Mueller ADAG Pharma Vertriebs GmbH</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055504_97" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember">Germany</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055504_98" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055505_99" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember">Euro (EUR)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055493_52" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember">Sativa Verwaltungs GmbH</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055505_101" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember">Germany</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055505_102" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055505_103" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember">Euro (EUR)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055494_56" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember">Sativa Verwaltungs GmbH and Co. KG</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055506_105" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember">Germany</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055506_106" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055506_107" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember">Euro (EUR)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055495_60" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember">CBD Med Therapeutics Inc.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055507_109" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember">Canada</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055507_110" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055508_111" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember">Canadian Dollar (CAD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055496_64" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember">Fayber Technologies Canada Inc.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055508_113" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember">Canada</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055509_114" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055509_115" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember">Canadian Dollar (CAD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055497_68" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember">Catalunia SAS</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055511_117" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember">Colombia</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055512_118" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055513_119" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember">Colombia Peso (COP)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055497_72" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember">Green CannaHealth SAS</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055513_121" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember">Colombia</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055514_122" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055514_123" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember">Colombia Peso (COP)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055498_76" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember">Klokken Aarhus Inc.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055514_125" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember">Canada</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055514_126" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055515_127" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember">Canadian Dollar (CAD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055499_80" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember">Rangers Pharmaceuticals A/S</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055515_129" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember">Denmark</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055515_130" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055516_131" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember">Danish Krone (DAK)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055500_84" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember">1200325 B.C. LTD.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055516_133" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember">Canada</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055516_134" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055516_135" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember">Canadian Dollar (CAD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055501_88" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember">Phatebo</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055517_137" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember">Germany</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055517_138" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055517_139" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember">Euro (EUR)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055502_92" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember">Franchise Cannabis Corp.</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055518_141" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember">Canada</ix:nonNumeric>
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055518_142" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    <ix:nonNumeric id="F20231019113055518_143" name="flgc:FunctionalCurrencyOfSubsidiary" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember">Canadian Dollar (CAD)</ix:nonNumeric>
                                                                </span></span></td>
                                                    </tr>
                                                </table>
                                            </div>
                                        </ix:nonNumeric>
                                    </div>
                                    <div>
                                        <ix:exclude>
                                            <div>
                                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">132</span></span></span></div>
                                                <div>
                                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                </div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                    </tr>
                                                </table>
                                            </div>
                                        </ix:exclude>
                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $<ix:nonFraction id="Fxbrl_20240306105805596" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD">0.8</ix:nonFraction> million (USD $<ix:nonFraction id="Fxbrl_20240306105849820" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">0.6</ix:nonFraction> million).</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company sold all of its shares and assets related to the following Colombian companies and branches:</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Growth Corp Colombia S.A.S. (formerly Hemp Textiles &amp; Co. S.A.S.)</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Lab S.A.S. (formerly Grupo Farmaceutico Cronomed S.A.S.)</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Med S.A.S. (formerly Breeze Laboratory S.A.S.)</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Labcofarm Laboratorios S.A.S</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Cosechemos Ya S.A.S.</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Kasa Wholefoods Company S.A.S.</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Growth Corp. Sucursal Colombia</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Beauty LLC Sucursal Colombia</span></span></p>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The applicable capital stock of the Colombian entities was transferred to Lisan at the date of closing. All assets underlying this sale were transferred to Lisan on an "as is where is" basis. The results of these subsidiaries are included in discontinued operations in the accompanying consolidated financial statements. See discussion in Note 5.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the fourth quarter of the year ending December 31, 2023, the Company voluntarily dissolved the following U.S. companies:</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Hemp Textiles &amp; Co. LLC</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Keel Brand Corp.</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Growth F&amp;B Corp</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Growth Management Corp.</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Masaya Holding Corp.</span></span></p>
                                </div>
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of measurement</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments that are measured at fair value as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of trade and amounts receivable, indemnification receivables, prepaids and other current assets, and trade and other payables, accrued liabilities, current portion of long term debt, and current portion of lease liability approximate their fair values due to their short periods to maturity. The Company calculates the estimated fair value of financial instruments, including investments, and contingent consideration, using quoted market prices when available. When quoted market prices are not available, fair value is determined based on valuation techniques using the best information available and may include quoted market prices, market comparable, and discounted cash flow projections.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The consolidated financial statements are presented in United States dollars ("$") unless otherwise noted.</span></span></p>
                                </div>
                            </div>
                            <div>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Use of estimates</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">133</span></span></span></div>
            <div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
            </div>
            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                <tr>
                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                </tr>
            </table>
            <div>
                <ix:nonNumeric id="F20231019113055528_37" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" contextRef="C_20230101to20231231">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3.<span style="display: inline-block; width: 20pt;">&#160;</span></b><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The significant accounting policies used by the Company are as follows:</span></span></p>
                                <ix:nonNumeric id="F20231019113055525_0" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash and restricted cash</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the consolidated statement of financial position includes cash on hand and deposits held with banks and other financial intermediaries that have a maturity of less than three months at the date they are acquired. Restricted cash in the consolidated statement of financial position includes cash required to be held in deposit accounts related to credit card accounts and merchant accounts.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055528_36" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows. Non-derivative financial assets are classified and measured as "financial assets at fair value", as either fair value through profit or loss ("FVPL"), or "financial assets at amortized cost", as appropriate.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">All financial assets are recognized initially at fair value plus, in the case of financial assets not at FVPL, directly attributable transaction costs on the trade date at which the Company becomes a party to the contractual provisions of the instrument.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets with embedded derivatives are considered in their entirety when determining their classification.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these consolidated financial statements, cash, trade and amounts receivables, indemnification receivables, and loans receivable are classified in this category.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at FVPL</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets measured at FVPL include financial assets such as the Company's equity investments in other entities, and any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial assets measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in a separate caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, trade and amounts receivables, and loans receivable.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade and note receivables are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by country and customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for trade receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the consolidated statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off. This is determined with judgment or otherwise when discharged by bankruptcy or other legal proceedings.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055526_15" name="us-gaap:InventoryPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Inventory</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Inventories </span></span><span>are comprised of raw materials and supplies, and finished goods. Inventories are initially valued at cost and subsequently at the lower of cost and net realizable value. Inventory cost is determined either on a weighted&#160;average cost or specific identification basis and any trade discounts and rebates are deducted from the purchase price</span><span><span>. Raw material costs include the purchase cost of the materials, freight-in and duty. Costs incurred during the production process are capitalized as incurred to the extent that cost is less than net realizable value. These costs include materials, labor and manufacturing overhead used in the production processes. Finished goods include the cost of direct materials and labor and a proportion of manufacturing overhead allocated based on normal production capacity.</span></span></span></span></p>
                                        <div>
                                            <div>
                                                <ix:exclude>
                                                    <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">134</span></span></span></div>
                                                    <div>
                                                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                    </div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                        </tr>
                                                    </table>
                                                </ix:exclude>
                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net realizable value represents the estimated selling price for inventories in the ordinary course of business, less all estimated costs of completion and costs necessary to make the sale. The determination of net realizable value requires significant judgment, including consideration of factors such as shrinkage, the aging of and future demand for inventory and contractual arrangements with customers. Reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The impact of changes in inventory reserves is reflected in cost of sales.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055526_16" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>
                                        <ix:nonNumeric id="F20231019113055528_38" name="flgc:ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                            <div>
                                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span><span style="font-size: 10pt; font-family: Times New Roman, Times, serif;">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20231019113055525_1" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">5</ix:nonNumeric>-<ix:nonNumeric id="F20231019113055525_2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">10</ix:nonNumeric> years
                                                        </span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vehicle&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;<ix:nonNumeric id="F20231019113055525_3" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember">5</ix:nonNumeric> years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Building&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;<ix:nonNumeric id="F20231019113055525_4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember">30</ix:nonNumeric> years</span></span></p>
                                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Lesser of useful life and remaining term of the lease</span></span></p>
                                            </div>
                                        </ix:nonNumeric>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use, including interest on borrowings when significant. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the consolidated statements of loss and comprehensive loss of the related year.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055526_17" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Intangible assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization is provided on a straight-line basis over the assets' estimated useful lives, which do not exceed the contractual period, if any. The Company's finite-lived intangible assets are amortized as follows:</span></span></p>
                                        <ix:nonNumeric id="F20231019113055528_39" name="flgc:ScheduleOfIntangibleAssetsEstimatedUsefulLives" escape="true" contextRef="C_20230101to20231231">
                                            <div>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Patents and developed technology&#160; &#160; &#160; &#160; &#160;<ix:nonNumeric id="F20231019113055525_5" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">9</ix:nonNumeric> years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Customer and supplier relationships&#160; &#160; &#160;<ix:nonNumeric id="F20231019113055526_6" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">5</ix:nonNumeric>-<ix:nonNumeric id="F20231019113055526_7" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_srtRangeAxis_srtMaximumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">10</ix:nonNumeric> years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trademarks and brands&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;<ix:nonNumeric id="F20231019113055526_8" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">8</ix:nonNumeric>-<ix:nonNumeric id="F20231019113055526_9" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_srtRangeAxis_srtMaximumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">10</ix:nonNumeric> years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Licenses&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;<ix:nonNumeric id="F20231019113055526_10" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">5</ix:nonNumeric> years</span></span></p>
                                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-compete agreements&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;<ix:nonNumeric id="F20231019113055526_12" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">3</ix:nonNumeric> years</span></span></p>
                                            </div>
                                        </ix:nonNumeric>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Amortization expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055526_18" name="us-gaap:InvestmentPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investments</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Investments include investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence and are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the "measurement alternative"). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in unrealized loss from changes in fair value on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">135</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <ix:nonNumeric id="F20231019113055526_19" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment and definite life intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_20" name="us-gaap:BusinessCombinationsPolicy" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Business combinations</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition related costs are generally recognized in the consolidated statements of loss and comprehensive loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed, are recognized at their fair value.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any noncontrolling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date. If, after assessment, the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in the consolidated statements of loss and comprehensive loss as a bargain purchase gain.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured at the fair value of the acquiree's identifiable net assets.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or liability is remeasured at subsequent reporting dates, with the corresponding gain or loss recognized in the consolidated statements of operations and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">When a business combination is achieved in stages, the Company's previously held equity interest in the acquiree is remeasured to its acquisition date fair value and the resulting gain or loss, if any, is recognized in the consolidated statements of loss and comprehensive loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to the consolidated statements of loss and comprehensive loss where such treatment would be appropriate if that interest were disposed of.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Purchase price allocations may be preliminary and, during the measurement period not to exceed one year from the date of acquisition, changes in assumptions and estimates that result in adjustments to the fair value of assets acquired and liabilities assumed are recorded in the period the adjustments are determined.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_21" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of goodwill and indefinite-lived intangible assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company operates in three operating segments which are the reporting units and goodwill is allocated at the operating segment level. The Company reviews goodwill and indefinite-lived intangible assets annually for impairment in the fourth quarter, or more frequently, if events or circumstances indicate that the carrying amount of an asset may not be recoverable.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">136</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <ix:nonNumeric id="F20231019113055527_22" name="flgc:FinancialLiabilitiesPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables and other accrued liabilities and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at FVPL</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities measured at FVPL include any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial liabilities measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in other income or expense in the consolidated statements of loss and comprehensive loss. In these consolidated financial statements, trade and other payables and other accrued liabilities, lease liability and loans payable are measured at amortized cost.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_23" name="flgc:ProvisionsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the consolidated statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_24" name="us-gaap:StockholdersEquityPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Additional proceeds from the issuance of common shares are classified as equity in additional paid in capital. Incremental costs directly attributable to the issue of common shares, stock options and warrants are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received. The fair value of options and warrants is determined using the Black Scholes model.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_25" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share based compensation</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share based compensation to employees is measured at the fair value of the instruments issued and amortized over the vesting periods. Share based compensation to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued if it is determined the fair value of the goods or services cannot be reliably measured and are recorded at the date the goods or services are received. The Company operates an equity based compensation plan. The corresponding amount is recorded to the stock option caption within shareholders&#8217; equity, and the expense to the consolidated statements of loss and comprehensive loss over the vesting period. The fair value of options is determined using the Black&#8211;Scholes pricing model which incorporates all market vesting conditions. For awards with graded vesting schedules, the Company has elected to calculate the fair value as a single award and recognize expense over the total expected vesting period rather than in tranches. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest. Upon exercise of a stock option, any amount related to the initial value of the stock option, along with the proceeds from exercise are recorded to share capital. Upon expiration of a stock option, any amount related to the initial value of the stock option is recorded to accumulated deficit. The Company also grants employees and non-employees restricted stock awards (&#8220;RSAs&#8221;). The fair value of the RSAs is determined using the fair value of the common shares on the date of the grant. The Company has elected to recognize forfeitures as they occur.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">137</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <ix:nonNumeric id="F20231019113055527_26" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Foreign currency translation</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements are presented in U.S. dollars ("USD"), which is the Company's reporting currency; however, the functional currency of the entities in these financial statements are their respective local currencies, including Canadian dollar, USD, British pound and euro.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Translation into functional currency</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Transactions in foreign currencies are recorded in the functional currency at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the period end exchange rates. Non-monetary items are translated at the exchange rates in effect on the date of the transactions. Foreign exchange gains and losses arising on translation are presented in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Translation into presentation currency</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The assets and liabilities of foreign operations are translated into USD at year-end exchange rates. Revenue, expenses, and cash flows of foreign operations are translated into USD using average exchange rates of the reporting period. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in shareholders' equity. The cumulative exchange differences are reclassified to the consolidated statements of loss and comprehensive loss upon the disposal of the foreign operation.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_27" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Research expenses</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Research expenses are expensed as they are incurred, net of any related investment tax credits, unless the criteria for capitalization of development expenses are met.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_28" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Revenue recognition</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company primarily generates revenue as a distributor of pharmaceuticals and a distributor and retailer of cannabidiol oil derived products. See disaggregation of the Company&#8217;s revenue by operating segments and sales by country in Note 24.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company uses the following five-step contract-based analysis of transactions to determine if, when and how much revenue can be recognized:</span></span></p>
                                        <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 4%; vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Identify the contract with a customer;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Identify the performance obligations in the contract;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Determine the transaction price;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Allocate the transaction price to the performance obligations in the contract; and</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Recognize revenue when or as the Company satisfies the performance obligations.</span></span></p>
                                                </td>
                                            </tr>
                                        </table>
                                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Gross revenue excludes duties and taxes collected on behalf of third parties. Revenue is presented net of expected price discounts, sales returns, customer rebates and other incentives.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's contracts with customers for the sales of products consist of one performance obligation. Revenue from product sales is recognized at the point in time when control is transferred to the customer, which is on shipment or delivery, depending on the contract terms. The Company's payment terms generally range from 0 to 30 days from the transfer of control, and sometimes up to two months.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient to not adjust the customer contract consideration for significant financing components when the period between the transfer of the Company's goods and services and customer payment is one year or less.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient to expense, as incurred, the costs of obtaining a customer contract such as sales commissions and other selling transaction costs when the amortization period of the assets otherwise would be one year or less. Accordingly, the Company has no assets recorded for costs to obtain a customer contract as at December 31, 2023 and 2022 as there are no contracts where the underlying asset would have a life exceeding one year.</span></span></p>
                                        <div>
                                            <div>
                                                <ix:exclude>
                                                    <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">138</span></span></span></div>
                                                    <div>
                                                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                    </div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                        </tr>
                                                    </table>
                                                </ix:exclude>
                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient for shipping and handling not to be a separate performance obligation.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <div>
                                    <ix:nonNumeric id="Fxbrl_20240305145803411" name="us-gaap:AdvertisingCostsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Advertising costs</b></span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Advertising costs are expensed as incurred and recorded within the promotion and communication caption on the consolidated statements of loss and comprehensive loss. Advertising costs were $<ix:nonFraction id="F20231019113055526_13" name="us-gaap:AdvertisingExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">3.4</ix:nonFraction> million in 2023 ($<ix:nonFraction id="F20231019113055526_14" name="us-gaap:AdvertisingExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">4.4</ix:nonFraction> million in 2022).</span></span></p>
                                        </div>
                                    </ix:nonNumeric>
                                </div>
                                <ix:nonNumeric id="F20231019113055527_30" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the consolidated statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the consolidated statements of loss and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable income or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                        <div>
                                            <div>
                                                <ix:exclude>
                                                    <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">139</span></span></span></div>
                                                    <div>
                                                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                    </div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                        </tr>
                                                    </table>
                                                </ix:exclude>
                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_32" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Loss per share</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share is calculated using the weighted average number of shares outstanding during the year. Diluted loss per share reflects the potential dilution of common share equivalents, such as outstanding options and warrants, in the weighted average number of common shares outstanding during the period, if dilutive. The diluted loss per share calculation excludes any potential conversion of options and warrants that would be anti-dilutive.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055527_33" name="flgc:NonControllingInterestsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Non-controlling interests</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-controlling interests of subsidiaries ("NCI") are recognized either at fair value or at the NCI's proportionate share of the net assets, determined on an acquisition-by-acquisition basis at the date of acquisition. Subsequently, the NCI's share of net loss and comprehensive loss is attributed to the NCI.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During 2023, the Company completed the sale of Cosechemos YA S.A.S. and Kasa Wholefoods Company S.A.S to Lisan. These entities each had <ix:nonFraction id="Fxbrl_20240305174603466" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtOwnershipAxis_flgcCosechemosAndKasaWholefoodsMember" unitRef="Pure">10</ix:nonFraction>% NCI which was derecognized when the Company lost control during the year ended December 31, 2023. See discussion in Note 5.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="Fxbrl_20240305170819615" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Discontinued operations and assets and liabilities held for sale</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $<ix:nonFraction id="Fxbrl_20240305174121971" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD">0.8</ix:nonFraction> million (USD $<ix:nonFraction id="Fxbrl_20240305174217121" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">0.6</ix:nonFraction> million). The assets and liabilities of these Colombian companies are reflected in the accompanying consolidated balance sheets as assets and liabilities held for sale, respectively. The results of operations of these Colombian companies are included in loss from discontinued operations, net of tax in the accompanying consolidated statements of operations and comprehensive loss. For comparative purposes, all prior periods presented have been reclassified to reflect the classifications on a consistent basis. See discussion in Note 5.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <ix:nonNumeric id="F20231019113055528_34" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ("ASU 2021-08"), which requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers ("ASC 606") rather than adjust them to fair value at the acquisition date. The effects of adoption are applied prospectively to business combinations occurring on or after the effective date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective as of January 1, 2023, and as such had no impact on the Company's consolidated financial statements.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">140</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <ix:nonNumeric id="F20231019113055528_35" name="flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2022, the FASB issued Accounting Standards Update 2022-03-Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU 2022-03"), which requires that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The effects of adoption are accounted for prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is assessing the impacts of adoption, but it is not expected to have an impact based on amounts recorded at December 31, 2023 as any changes required are for transactions occurring prospectively upon adoption.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segments Disclosures. The amendments enhance disclosures of significant segment expenses by requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM), extend certain annual disclosures to interim periods, and permit more than one measure of segment profit or loss to be reported under certain conditions. The amendments are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption of the amendment is permitted, including adoption in any interim periods for which financial statements have not been issued. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20231019113055532_1" name="us-gaap:UnusualRisksAndUncertaintiesTextBlock" escape="true" contextRef="C_20230101to20231231">
                    <div>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>4.&#160; &#160; &#160; &#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, revenues, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern considerations</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company&#8217;s ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of revenues, expenses and cash flows, which requires a significant amount of management judgement.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Determination of functional currency</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company determines the functional currency through an analysis of several indicators. Primary considerations include the currency in which the Company's goods and services are sold and the currency of the country whose competitive forces and regulations mainly determine the sales prices of its goods and services. The Company also considers the currency in which funds from financing debt and equity activities are generated and the currency in which receipts from operating activities are retained. Management judgment is applied when there are indicators supporting more than one currency for a Company subsidiary.</span></span></p>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">141</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Expected credit losses on financial assets</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Determining an allowance for expected credit losses for all financial asset receivables not held at fair value through profit or loss requires judgment. Factors that cause the estimate to be sensitive to change include historical and expected future patterns for the probability of default, the timing of collection and the amount of incurred credit losses, and management's judgment about whether economic conditions and credit terms are such that actual losses may be higher or lower than what the historical patterns suggest. These conditions are applied across each of the Company's business units to the extent the expected risk of loss differ from each other.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Inventory</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory is valued at the lower of cost and net realizable value. Determining net realizable value requires the Company to make assumptions about estimated selling prices in the ordinary course of business, the estimated costs of completion and the estimated variable costs to sell. Management judgment is applied to determine potential impairment exposure related to potential excess product inventory levels, obsolescence, and expiration.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Business combinations</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In a business combination, the Company may acquire assets and assume certain liabilities of an acquired entity. Judgement is used in determining whether an acquisition is a business combination or an asset acquisition. Estimates are made as to the fair value of the identifiable assets acquired and the liabilities assumed on the acquisition date, as well as the fair value of consideration paid and contingent consideration payable. In certain circumstances, such as the valuation of property, plant and equipment, intangible assets and goodwill acquired, the Company obtains assistance from third-party valuation specialists. The determination of these fair values involves a variety of judgment in assumptions, include revenue growth rates, expected operating income, discount rates, and earnings multiples.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Estimated useful lives and depreciation of long-lived assets with finite lives</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Determination of reporting units and asset groups for impairment testing</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining which assets or group of assets make up appropriate reporting units and asset groups for the level at which goodwill and other long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of goodwill and long-lived assets</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For reporting units to which goodwill and other long-lived assets is allocated is based on a recoverable amount, the impairment test is determined in accordance with the expected cash flow approach or another suitable model depending on the asset type. The calculation is based on assumptions including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For reporting units that test using the market based fair value approach, the fair value is determined based on guideline public companies similar to the reporting unit and considers similar financial metrics, operations and sales channels. The fair value calculation is based on assumptions including the determination of guideline public companies, determining the relevant financial metric to measure the reporting unit's recoverable value, and selecting the amount of the financial metric from the observable range of guideline public company amounts to apply to the reporting unit.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions discussed above. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.</span></span></p>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">142</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Revenue recognition</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management judgment is required to determine when the Company is acting as principal or agent in a sales contract where the Company is an intermediary, which affects whether the amount of revenue recognized is presented on a gross or net basis, respectively. The Company first considers whether it has obtained control over the product when acting as an intermediary before transferring it to the customer, and if the Company combines or transforms the product with other goods and services before transferring the good to the customer. The Company considers secondary factors, including whether the Company is primarily responsible for the fulfillment of the product obligations to the customer, whether the Company has inventory risk (acquiring and/or paying for the product prior to transferring to the customer, Company liability for damages and sales returns), and whether the Company has price discretion when selling the product to its customers. Management considers the terms of the customer and supplier contracts, as well as established business practices for the arrangements.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management judgment is required to determine the effects on the sales contract transaction price for the potential impacts of sales returns, discounts, rebates, and other customer incentives. The Company considers the terms of the contract, historical experience, as well as actual and expected customer activity after the end of the reporting period.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's primary sale of products requires management judgment to determine at what point in time control passes to the customer to recognize revenue. The Company considers the customer contract terms, logistic supplier terms, local law, and established business practices to make this determination.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share based compensation transactions</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company measures the cost of equity-settled transactions with employees and applicable non-employees by reference to the fair value of the equity instruments at the date at which they are vested. Estimating fair value for share based compensation requires judgment to determine the appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the stock price, stock option, risk-free interest rates, volatility, and dividend yield. For awards with market or performance-based features, the Company applies judgment to determine its expectation of achieving the agreement milestones. Due to the Company's limited history of publicly traded common shares, the volatility and expected term assumptions require additional judgment. The Company considers the Company's actual trading volatility to date compared to actual and expected volatility of comparable companies of similar size and industry that have been publicly traded longer than the Company's shares.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For expected term, the Company generally uses the maximum stated term in the award agreement unless there is reasonable likelihood established to shorten the expected term for potential early exercises.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes and valuation allowances for deferred tax assets</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of December 31, 2023 and 2022, there were no uncertain tax positions taken.</span></span></p>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">143</span></span></span></div>
                <div>
                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                </div>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                    </tr>
                </table>
            </div>
            <div>
                <div>
                    <ix:nonNumeric id="F20240528073307247_81" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                        <div>
                            <div>
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>5.&#160; &#160; &#160; &#160; &#160;ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS</b></span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all its shares in its Colombian related subsidiaries and its Colombian assets for a purchase price of CAD $<ix:nonFraction id="F20240528073307245_73" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD">0.8</ix:nonFraction> million (USD $<ix:nonFraction id="F20240528073307245_74" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">0.6</ix:nonFraction> million). The sale relates to all of Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab S.A.S., Flora Med S.A.S. and Flora's Colombian food and beverage and consumer products business. The Company has received proceeds of CAD $<ix:nonFraction id="F20240528073307246_79" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD">0.5</ix:nonFraction> million during the year ended December 31, 2023 which completed the sale and transfer of Flora Growth Corp Colombia S.A.S, Flora Lab S.A.S., Flora Med S.A.S., Labcofarm Laboratorios S.A.S., Kasa Wholefoods Company S.A.S., Flora Growth Corp. Sucursal Colombia and Flora Beauty LLC Sucursal Colombia. The Company and Lisan completed the sale of Cosechemos Ya S.A.S on November 1, 2023.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The sale enables the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company has presented the associated assets and liabilities of the Colombian subsidiaries as held for sale. The major classes of assets and liabilities classified as held for sale as of December 31, 2023 and December 31, 2022 were as follows:</span></span></span></span></p>
                                </div>
                            </div>
                            <div>
                                <div>
                                    <ix:nonNumeric id="F20240528073307247_82" name="flgc:ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="0" cellspacing="0" cellpadding="0">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Assets held for sale</b></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Cash</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307223_0" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307224_1" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">602</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Trade and amounts receivable</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307224_2" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307225_3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">1,592</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Prepaid expenses and other current assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307225_4" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307225_5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">174</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Inventory</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307225_6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307226_7" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">1,341</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Total current assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307226_8" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307226_9" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">3,709</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Property, plant and equipment</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307227_10" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307227_11" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">3,592</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Operating lease right of use assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307227_12" name="flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307227_13" name="flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">419</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307228_14" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307228_15" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">358</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other assets</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307228_16" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307228_17" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">23</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; Total noncurrent assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307229_18" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307229_19" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">4,392</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307229_20" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307230_21" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">8,101</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liabilities held for sale</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Current portion of operating lease liability</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307230_22" name="flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307230_23" name="flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">72</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other accrued liabilities</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307230_24" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307231_25" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">538</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; Total current liabilities held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307233_26" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307233_27" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">610</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Non-current operating lease liability</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307233_28" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307234_29" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">308</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307234_30" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307234_31" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">918</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>
                                    </ix:nonNumeric>
                                    <p style="margin: 0pt;">&#160;</p>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>The following table summarizes the major classes of line items included in loss from discontinued operations, net of tax, </span></span>for years ended December 31, 2023 and 2022:</span></span></span></span></p>
                                    <ix:nonNumeric id="F20240528073307247_83" name="flgc:ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2022</b></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue</span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307234_32" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">1,450</ix:nonFraction></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307235_33" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">3,770</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cost of sales</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307235_34" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">1,123</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307235_35" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">2,607</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross profit from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307235_36" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">327</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307236_37" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">1,163</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Consulting and management fees</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307236_38" name="flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">847</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307236_39" name="flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">2,110</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307236_40" name="flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">82</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307237_41" name="flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">514</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307237_42" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">282</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307237_43" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">1,208</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Promotion and communication</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307237_44" name="flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">14</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307238_45" name="flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">383</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307238_46" name="flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">93</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307238_47" name="flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">284</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307238_48" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">148</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307239_49" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">485</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Bad debt expense</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307239_50" name="flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">565</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307239_51" name="flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">666</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset impairment</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307239_52" name="flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">4,704</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307235_331" name="flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">454</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other (income) expense</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307240_54" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">125</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307240_55" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">1,145</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating loss from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240528073307240_56" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">6,533</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240528073307241_57" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">6,086</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307241_58" name="flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">2</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240528073307241_59" name="flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">27</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss before income taxes</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240528073307241_60" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">6,535</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240528073307242_61" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">6,059</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on disposal of discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307242_62" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">3,132</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307242_63" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense (benefit)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307243_64" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">11</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240528073307243_65" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">133</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240528073307234_328" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">9,678</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240528073307234_3211" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">5,926</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231108100011769_20240528073307234_328" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD_Per_Share">1.32</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231108100011769_20240528073307234_3211" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD_Per_Share">1.55</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231108100013814_20240528073307234_328" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD_Per_Share">1.32</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231108100013814_20240528073307234_3211" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD_Per_Share">1.55</ix:nonFraction></span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>
                                    </ix:nonNumeric>
                                    <p style="margin: 0pt;">&#160;</p>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">144</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                    <p style="margin: 0pt 0pt 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The following table summarizes the significant operating and investing items related to the Colombian subsidiaries </span></span>for the years ended December 31, 2023 and 2022</span></span></p>
                                    <ix:nonNumeric id="F20240528073307247_84" name="flgc:ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                        <div>
                                            <div>
                                                <div>
                                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year<br/>months ended<br/>December 31,<br/>2023</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year<br/>months ended<br/>December 31,<br/>2022</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating activities of discontinued operations</b></span></span></td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Depreciation and amortization</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307243_68" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">148</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307244_69" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">485</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Bad debt expense</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307245_75" name="flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">565</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307246_77" name="flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">666</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Asset impairment</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307245_76" name="flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">4,704</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307246_78" name="flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">454</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investing activities of discontinued operations</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Purchases of property, plant and equipment</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307244_70" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">92</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240528073307244_71" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">951</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>
                                        </div>
                                    </ix:nonNumeric>
                                    <div>
                                        <div>
                                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The subsidiaries sold included Cosechemos Ya S.A.S, which was part of the commercial and wholesale segment; Flora Lab S.A.S, Flora Med S.A.S. and Labcofarm Laboratories S.A.S, which were part of the pharmaceuticals segment; Flora Growth Corp Colombia S.A.S., Kasa Wholefoods Company, S.A.S. and Flora Beauty LLC Sucursal Colombia which were part of the house of brands segment; Flora Growth Corp. Sucursal Colombia which was part of the corporate segment.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company applies significant judgement in determining whether a disposal meets the criteria to present as held for sale at the reporting date, and whether the disposal represents a strategic shift that has (or will have) a major effect on its operations and financial results in order to be classified as a discontinued operation. The criteria evaluated are both quantitative and qualitative in nature, to evaluate the significance of the disposal relative to the operations of the Company as a whole. The Company has determined this disposition represents a strategic shift in operations that will have a major effect on the Company's operations and financial results, and accordingly, has been presented as discontinued operations.</span></span></p>
                                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the year ended December 31, 2023, the Company recorded a loss on disposal of $<ix:nonFraction id="F20240528073307244_72" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">3.1</ix:nonFraction> million driven by the write-off of the Company's net investment in the Colombian assets.</span></span></p>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </ix:nonNumeric>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </div>
            </div>
            <div>
                <ix:nonNumeric id="F20231019113055537_28" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.<span style="display: inline-block; width: 20pt;">&#160;</span>TRADE AND AMOUNTS RECEIVABLE </b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's trade and amounts receivable are recorded at amortized cost. The trade and other receivables balance as at December 31, 2023 and December 31, 2022 consists of trade accounts receivable, amounts recoverable from the Government of Canada for Harmonized Sales Taxes ("HST"), as well as Value Added Tax ("VAT") from various jurisdictions, and other receivables.</span></span></p>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">145</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <ix:nonNumeric id="Fxbrl_20240305114135362" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade accounts receivable</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231025124348806" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">2,299</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055535_1" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">4,288</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Allowance for expected credit losses</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231025124355398" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">315</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055535_2" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,385</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">HST/VAT receivable</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055535_3" name="us-gaap:ValueAddedTaxReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,840</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055535_4" name="us-gaap:ValueAddedTaxReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">2,294</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other receivables</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231025124405358" name="us-gaap:OtherReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">126</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055535_5" name="us-gaap:OtherReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">62</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231025124415141" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">3,950</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055535_6" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">5,259</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Changes in the trade accounts receivable allowance in the year ended December 31, 2023 relate to establishing an allowance for expected credit losses. The Company recorded $<ix:nonFraction id="F20231019113055535_7" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1.3</ix:nonFraction> million of write-offs of trade receivables during 2023 (2022 - $<ix:nonFraction id="Fxbrl_20240423112350339" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">0.2</ix:nonFraction> million), $<ix:nonFraction id="Fxbrl_20240305210028848" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapStatementOperatingActivitiesSegmentAxis_usgaapSegmentDiscontinuedOperationsMember" unitRef="USD">1.1</ix:nonFraction> million of which was related to discontinued operations. The Company has no amounts written-off that are still subject to collection enforcement activity as at December 31, 2023. The Company's aging of trade accounts receivable is as follows:</span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240305114350466" name="flgc:ScheduleOfCompanyAgingOfTradeAccountsReceivable" escape="true" contextRef="C_20230101to20231231">
                                    <table style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 80%;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 398px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">December 31, 2023</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; white-space: nowrap;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>December 31, 2022</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 9px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 112px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 13px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 6px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 118px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 12px;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055536_9" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember" unitRef="USD">218</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20240314042022094_20231019113055536_9" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember" unitRef="USD">1,202</ix:nonFraction></span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1-30 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055536_10" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember" unitRef="USD">588</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20240314042022096_20231019113055536_10" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember" unitRef="USD">838</ix:nonFraction></span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31-60 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055536_11" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember" unitRef="USD">577</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20240314042022098_20231019113055536_11" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember" unitRef="USD">660</ix:nonFraction></span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">61-90 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055536_12" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember" unitRef="USD">448</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20240314042022101_20231019113055536_12" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember" unitRef="USD">159</ix:nonFraction></span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">91-180 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055536_13" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember" unitRef="USD">401</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20240314042022104_20231019113055536_13" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember" unitRef="USD">321</ix:nonFraction></span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">180+ Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055536_14" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember" unitRef="USD">67</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20240314042022107_20231019113055536_14" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember" unitRef="USD">1,108</ix:nonFraction></span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total trade receivables</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 9px; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305114324358" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">2,299</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 6px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20240314042022108_xbrl_20240305114324358" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">4,288</ix:nonFraction></span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A continuity schedule of the allowance for expected credit losses for the years ended December 31, 2023 and 2022 is as follows:</span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240305114452403" name="us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <table style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at January 1</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055536_16" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,385</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055536_17" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231" unitRef="USD">400</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current period additions for expected credit losses</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055536_18" name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">236</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055536_19" name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,186</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Write-offs charges against allowance</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055537_20" name="us-gaap:TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,282</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055537_21" name="us-gaap:TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">151</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Recoveries collected</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055537_22" name="us-gaap:InsuranceRecoveries" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">24</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055537_23" name="us-gaap:InsuranceRecoveries" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">50</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055537_26" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">315</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055537_27" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,385</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20231019113055542_12" name="us-gaap:InventoryDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.<span style="display: inline-block; width: 20pt;">&#160;</span>INVENTORY </b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory is comprised of the following as at December 31, 2023 and 2022:</span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240305114756087" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">December 31, 2022</span></span></td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Raw materials and supplies</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20231020175304783_20231019113055541_1" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,180</ix:nonFraction></b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055541_1" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">2,363</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finished goods</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20231020175304792_20231019113055541_6" name="us-gaap:InventoryFinishedGoods" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">7,328</ix:nonFraction></b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055541_6" name="us-gaap:InventoryFinishedGoods" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">6,384</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20231020175304793_20231019113055541_01" name="us-gaap:InventoryNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">8,508</ix:nonFraction></b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055541_01" name="us-gaap:InventoryNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">8,747</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In the year ended December 31, 2023, $<ix:nonFraction id="F20231019113055541_02" name="flgc:InventoryExpensedToCostOfSales" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">54.9</ix:nonFraction> million of inventory was expensed to cost of sales (2022 - $<ix:nonFraction id="F20231019113055541_03" name="flgc:InventoryExpensedToCostOfSales" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">14.5</ix:nonFraction> million) and write-downs to cost of sales for impairment was $<ix:nonFraction id="F20231019113055541_04" name="flgc:WritedownsReversalsOfInventories" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2.7</ix:nonFraction> million (2022 - $<ix:nonFraction id="F20231019113055541_05" name="flgc:WritedownsReversalsOfInventories" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">0.5</ix:nonFraction> million), with the increase in 2023 due to write-downs related to a flooding incident at a JustCBD facility in Florida and other factors. There were no reversals of previous inventory impairments in the years ended December 31, 2023 or 2022.</span></span></p>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">146</span></span></span></div>
                <div>
                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                </div>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                    </tr>
                </table>
            </div>
            <ix:nonNumeric id="F20231019113055545_0" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>8.<span style="display: inline-block; width: 20pt;">&#160;</span>PROPERTY, PLANT AND EQUIPMENT </b></span></span></span></p>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Property, plant and equipment consist of the following:</span></span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240305115502811" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" contextRef="C_20230101to20231231">
                            <div>
                                <table style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>December 31, 2023</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>December 31, 2022</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Thousands of United States dollars</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span style="color: #ff0000;">&#160;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span style="color: #ff0000;">&#160;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Land</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20231025120459670" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember" unitRef="USD">298</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20231019113055545_2" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember" unitRef="USD">291</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Buildings</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20231025120506459" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember" unitRef="USD">78</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20231019113055545_3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Machinery and office equipment</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20231025120514730" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember" unitRef="USD">696</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20231019113055545_4" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember" unitRef="USD">1,098</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Vehicles</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20231025120524602" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember" unitRef="USD">37</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20231019113055546_5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember" unitRef="USD">37</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Total</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20231025120534594" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,109</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20231019113055545_13" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,426</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr style="background-color: #e6efff;">
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Less: accumulated depreciation</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(<ix:nonFraction id="Fxbrl_20231025120626122" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">262</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(<ix:nonFraction id="F20231019113055545_15" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">208</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Property, plant and equipment, net</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="Fxbrl_20231025120633690" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">847</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20231019113055546_10" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,218</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Depreciation expense for the year ended December 31, 2023 was $<ix:nonFraction id="F20231019113055546_11" name="us-gaap:Depreciation" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">0.2</ix:nonFraction> million (2022 - $<ix:nonFraction id="F20231019113055546_12" name="us-gaap:Depreciation" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">0.2</ix:nonFraction> million) and was recorded in depreciation and amortization in the consolidated statements of operations and comprehensive loss.</span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>During the year ended December 31, 2023, the Company recorded an impairment charge of the remaining value of the property, plant and equipment of Vessel within the House of Brands segment. The amount of $<ix:nonFraction id="F20231019113055546_13" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">0.2</ix:nonFraction> million (2022 - $<ix:nonFraction id="F20231019113055546_14" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20220101to20221231" unitRef="USD">nil</ix:nonFraction>) is included in "other asset impairments" in the consolidated statements of operations and comprehensive loss. See Note 12 for further discussion.</span></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>As at December 31, 2023, the Company's property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the year ended December 31, 2023.</span></span></span></p>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif; text-align: left;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20231019113055561_42" name="us-gaap:InvestmentTextBlock" escape="true" contextRef="C_20230101to20231231">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.<span style="display: inline-block; width: 20pt;">&#160;</span>INVESTMENTS</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023, the Company's investments consist of common shares and warrants to purchase additional common shares in an early-stage European cannabis company. The Company purchased common shares from the investee during 2021 for Euro <ix:nonFraction id="F20231019113055561_41" name="flgc:PurchaseOfCommonStock" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="EUR">2.0</ix:nonFraction> million ($<ix:nonFraction id="F20231019113055553_0" name="flgc:PurchaseOfCommonStock" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2.4</ix:nonFraction> million) and purchased its first tranche of warrants from existing investors in exchange for <ix:nonFraction id="F20231019113055553_1" name="flgc:SharesIssuedToPurchaseWarrantsFromExistingInvestors" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Shares">11,250</ix:nonFraction> common shares of the Company, and obtained a second tranche of warrants from the investee as an inducement to exercise some of the first tranche of warrants. As at December 31, 2023, <ix:nonNumeric id="F20231019113055554_2" name="flgc:InvestmentDescription" contextRef="C_20230101to20231231">the Company owns approximately 9.6% of the investee, or approximately 9% on a diluted basis including exercisable warrants of the Company and other investors.</ix:nonNumeric></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The warrants allowed the holder to purchase one common share of the investee for CAD <ix:nonFraction id="F20231019113055562_49" name="flgc:ExercisePriceOfInvestmentWarrants" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapInvestmentTypeAxis_flgcFirstTrancheMember" unitRef="CAD_Per_Share">0.30</ix:nonFraction> ($<ix:nonFraction id="F20231019113055554_3" name="flgc:ExercisePriceOfInvestmentWarrants" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapInvestmentTypeAxis_flgcFirstTrancheMember" unitRef="USD_Per_Share">0.22</ix:nonFraction>) for the first tranche, and CAD <ix:nonFraction id="F20231019113055562_50" name="flgc:ExercisePriceOfInvestmentWarrants" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapInvestmentTypeAxis_flgcSecondTrancheMember" unitRef="CAD_Per_Share">1.00</ix:nonFraction> ($<ix:nonFraction id="F20231019113055562_51" name="flgc:ExercisePriceOfInvestmentWarrants" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapInvestmentTypeAxis_flgcSecondTrancheMember" unitRef="USD_Per_Share">0.74</ix:nonFraction>) for the second tranche. The Company did not exercise the warrants and they expired on February 1, 2023.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's cost of the investments was recorded based on the fair value of the consideration exchanged as at the respective transaction dates. The investee is not a publicly listed entity and has no active quoted prices for its common shares or warrants. The Company has elected the measurement alternative to record the common share investment at cost and test for impairment. The investment had impairment indicators during 2022 and 2023, and impairments were recorded as indicated in the table below. The Company also considers observable transactions of the common shares for indicators of fair value but there have been none. Cumulative impairment related to the common shares was $<ix:nonFraction id="F20231019113055554_4" name="flgc:CumulativeImpairmentRelatedToCommonShares" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">2.9</ix:nonFraction> million and the net carrying value was $<ix:nonFraction id="F20231019113055554_5" name="us-gaap:OtherLongTermInvestments" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20231231" unitRef="USD">nil</ix:nonFraction> at December 31, 2023.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">When impairment indicators were present, <ix:nonNumeric id="Fxbrl_20240529164218324" name="flgc:DescriptionOfImpairment" contextRef="C_20230101to20231231">the investee common shares were valued considering price to book value and price to tangible book value of the investee (3.6 and 4.8, respectively) as well as comparable guideline publicly traded companies at the time of initial investment. These initial investment multiples were compared to the guideline public company multiples observed as at December 31, 2023 (negligible or nil price to book and price to tangible values), with these updated valuation multiples applied to the investee's estimated book value.</ix:nonNumeric> The Company also considered the status of the investee's milestones since the purchase date, as well as recent transactions in the European cannabis market for indicators of change in value. The impairment valuation model for the common shares uses Level 3 inputs of the fair value hierarchy.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A schedule of the Company's investments activity is as follows:</span></span></p>
                                <div>
                                    <ix:exclude>
                                        <div>
                                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">147</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                </tr>
                                            </table>
                                        </div>
                                    </ix:exclude>
                                </div>
                                <ix:nonNumeric id="Fxbrl_20240305121221185" name="flgc:ScheduleOfCompanysInvestmentsActivityTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <table style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Financial asset hierarchy level</span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Investee common<br/>shares</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Warrants CAD 0.30<br/>exercise price</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Warrants CAD 1.00<br/>exercise price</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total</span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2021</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055555_9" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember" unitRef="USD">1,987</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055555_10" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember" unitRef="USD">625</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055555_11" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember" unitRef="USD">58</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055556_12" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">2,670</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055557_21" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember" unitRef="USD">1,257</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055557_22" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055558_23" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055558_24" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">1,257</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on changes in fair value</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055558_25" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055558_26" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember" unitRef="USD">591</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055558_27" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember" unitRef="USD">58</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055559_28" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">649</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2022</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231016175253416_20231019113055555_9" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember" unitRef="USD">730</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231016175253416_20231019113055555_10" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember" unitRef="USD">34</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231016175253416_20231019113055555_11" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231016175253416_20231019113055556_12" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">764</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055559_29" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember" unitRef="USD">730</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055559_30" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055559_31" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055559_32" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">730</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on changes in fair value</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055560_33" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055560_34" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember" unitRef="USD">34</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055560_35" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055560_36" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">34</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2023</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055560_37" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055560_38" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055561_39" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055561_40" name="us-gaap:InvestmentOwnedAtFairValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The impairment of common shares and loss on changes in fair value appear in the unrealized loss on fair value of investments caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The value of the investee common shares appears in the investment line on the consolidated statement of financial position. The value of the warrants appeared in current assets within the prepaid expenses and other accrued assets line on the consolidated statement of financial position.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As a sensitivity assessment to the fair value calculations, a 10% change in the valuation multiples applied to the investee common shares results in a 10% change in the fair value as at December 31, 2023 of less than $0.1 million.</span></span></p>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div>
                <ix:nonNumeric id="Fxbrl_20240306015948787" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10.<span style="display: inline-block; width: 15pt;">&#160;</span>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS</b></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Original Hemp asset acquisition</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On March 1, 2023, the Company completed its acquisition of all the assets operating under the brand "Original Hemp". The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining Original Hemp did not meet the definition of a business as it did not have inputs, processes, and outputs in place that constituted a business under Topic 805. As a result, the transaction has been accounted for as an asset acquisition whereby all of the assets acquired and liabilities assumed are assigned a carrying amount based on relative fair values. Total purchase consideration was $<ix:nonFraction id="Fxbrl_20240305221837012" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember" unitRef="USD">0.3</ix:nonFraction> million and will consist of paying a portion of net profits not to exceed $<ix:nonFraction id="Fxbrl_20240305221843612" name="flgc:MaximumPortionOfNetProfitsPayable" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember" unitRef="USD">0.6</ix:nonFraction> million. The assets acquired included $<ix:nonFraction id="Fxbrl_20240305221846667" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember" unitRef="USD">0.1</ix:nonFraction> million of Inventory and $<ix:nonFraction id="Fxbrl_20240305221849411" name="flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember" unitRef="USD">0.2</ix:nonFraction> million of customer relationships.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Since the acquisition date through December 31, 2023, Original Hemp revenue was $<ix:nonFraction id="Fxbrl_20240305222042371" name="us-gaap:Revenues" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember" unitRef="USD">0.2</ix:nonFraction> million with net income and comprehensive income of $<ix:nonFraction id="Fxbrl_20240305222104514" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember" unitRef="USD">0.1</ix:nonFraction> million.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company was not able to obtain reliable financial records for the period from January 1, 2023 through the acquisition date, March 1, 2023. </span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Franchise Global Health Inc. ("FGH") business combination</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 23, 2022, the Company completed its acquisition of all the issued and outstanding common shares (the "Franchise Common Shares") of FGH, a corporation existing under the laws of the Province of British Columbia, by way of a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). FGH, through its wholly owned subsidiaries, is a multi-national operator in the medical cannabis and pharmaceutical industry with principal operations in Germany. The Company acquired FGH to expand its product offerings, accelerate its revenue growth, expand its customer and distribution capabilities in Germany and to improve synergies and cost savings.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pursuant to the Arrangement Agreement, at completion of the Arrangement, Flora acquired the Franchise Common Shares in exchange for <ix:nonFraction id="F20231019113055630_144" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221201to20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="Shares">2,176,297</ix:nonFraction> of Flora's common shares, no par value (the "Flora Shares"), for total purchase consideration of $<ix:nonFraction id="F20231019113055573_0" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221201to20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">9.8</ix:nonFraction> million. The issuance of the Flora Shares in exchange for the Franchise Common Shares was, subject to applicable securities laws, exempt from the registration requirements of (i) the Securities Act of 1933, as amended, pursuant to the exemption provided by Section 3(a)(10) thereof and (ii) applicable U.S. state securities laws. Notwithstanding the foregoing, in accordance with the terms set forth in the Arrangement Agreement, all Flora Shares delivered to the former shareholders of FGH bear a restrictive legend and may not be sold for a period of ninety (90) days following the closing of the Arrangement.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">148</span></span></span></div>
                                <div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                </div>
                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                    </tr>
                                </table>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240306020236137" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true" contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
                            <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055574_1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">730</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055574_2" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">2,271</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055575_3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">2,019</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Indemnity receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055575_4" name="flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">3,415</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prepaid assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055575_5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">139</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant, and equipment</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055576_6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">452</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right of use assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055576_7" name="flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">115</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055630_143" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">6,102</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055576_8" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">3,716</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055577_9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">18,959</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055577_10" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">6,245</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055577_11" name="flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">98</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current portion of debt</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055578_12" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">1,062</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Long term lease liability</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055578_13" name="flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">21</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055578_14" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">1,717</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055579_15" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">9,143</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055579_16" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">9,816</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As part of the acquisition terms, Clifford Starke, the Company's current Chief Executive Officer and a Director and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $<ix:nonFraction id="Fxbrl_20240306023257362" name="flgc:LiabilitiesAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221223_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">5.0</ix:nonFraction> million. A total of $<ix:nonFraction id="Fxbrl_20240306023300330" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">3.4</ix:nonFraction> million of liabilities were recognized in the trade payables and accrued liabilities of FGH on the date of acquisition that were subject to this indemnification obligation. The Company believes it will be fully indemnified by the current CEO of Flora, and, as such, has recorded $<ix:nonFraction id="Fxbrl_20240306023305966" name="us-gaap:NontradeReceivables" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">3.4</ix:nonFraction> million of indemnification receivables. The indemnified losses include:</span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.<span style="display: inline-block; width: 10.5pt;">&#160;</span>any losses that are related to the ownership or the operation of FGH and its Canadian subsidiaries, in each case prior to the closing of the Arrangement, that are unknown to the Company and that: (i) have not been disclosed or accounted for in FGH filings; or (ii) have not been disclosed in the FGH Disclosure Letter, in each case as at the date of the Arrangement Agreement;</span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.<span style="display: inline-block; width: 10.5pt;">&#160;</span>any losses that may arise from amounts owed or that may become owed to certain persons or in respect of certain matters identified in the indemnity agreement, as amended; and</span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3.<span style="display: inline-block; width: 10.5pt;">&#160;</span>any fraud, intentional misrepresentation, willful breach, or willful misconduct on the part of FGH or any other entity identified in the indemnity agreement of any of the foregoing in connection with the indemnity agreement or the Arrangement Agreement.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The intangible assets of $<ix:nonFraction id="F20231019113055584_22" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">6.1</ix:nonFraction> million are comprised of the following categories and estimated useful lives: supplier relationships of $<ix:nonFraction id="F20231019113055584_23" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcSupplierRelationshipsMember" unitRef="USD">2.4</ix:nonFraction> million for five years, customer relationships of $<ix:nonFraction id="F20231019113055584_24" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcCustomersRelationshipsMember" unitRef="USD">2.3</ix:nonFraction> million for five years, and licenses of $<ix:nonFraction id="F20231019113055585_25" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapLicenseMember" unitRef="USD">1.4</ix:nonFraction> million for five years. The Company does not expect the goodwill and intangible asset values to be deductible for Canadian income tax purposes. The goodwill is assigned to the commercial and wholesale segment.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">If FGH was acquired at January 1, 2022, the combined revenue and net loss of FGH and the Company would have increased approximately $<ix:nonFraction id="F20231019113055585_26" name="us-gaap:Revenues" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">40.3</ix:nonFraction> million and $<ix:nonFraction id="F20231019113055585_27" name="us-gaap:ProfitLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">19.0</ix:nonFraction> million, respectively (unaudited).</span></span></p>
                        <div>
                            <ix:exclude>
                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">149</span></span></span></div>
                                <div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                </div>
                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                    </tr>
                                </table>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company incurred acquisition related costs of $<ix:nonFraction id="F20231019113055631_145" name="us-gaap:ProfessionalFees" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">0.3</ix:nonFraction> million which were expensed as incurred in professional fees on the consolidated statements of loss and comprehensive loss.</span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Just Brands LLC and High Roller Private Label LLC (collectively "JustCBD") business combination</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On February 24, 2022, Flora Growth U.S. Holdings Corp., a wholly owned subsidiary of the Company, completed the acquisition of <ix:nonFraction id="F20231019113055586_28" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="Pure">100</ix:nonFraction>% of the outstanding equity interests in each of (i) Just Brands LLC and (ii) High Roller Private Label LLC for total purchase consideration of $<ix:nonFraction id="F20231019113055586_29" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">37.0</ix:nonFraction> million. JustCBD is a manufacturer and distributor of consumable cannabinoid products, including gummies, tinctures, vape cartridges, and creams. JustCBD is based in Florida in the United States and was formed in 2017. The Company acquired JustCBD to expand its product offerings, accelerate its revenue growth, expand its customer and distribution capabilities in the United States and for the acquisition of human capital through JustCBD's management team.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The purchase consideration was comprised of (i) $<ix:nonFraction id="F20231019113055586_30" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">16.0</ix:nonFraction> million of cash, less $<ix:nonFraction id="F20231019113055587_31" name="flgc:CashConsiderationReturned" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">0.2</ix:nonFraction> million returned to the Company in August 2022 due to final calculated closing working capital falling short of the target working capital, (ii) <ix:nonFraction id="Fxbrl_20240306024132327" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="Shares">475,000</ix:nonFraction> common shares of the Company valued at $<ix:nonFraction id="F20231019113055587_32" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">14.7</ix:nonFraction> million, inclusive of a <ix:nonFraction id="Fxbrl_20240306024325016" name="flgc:FairValueDiscount" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="Pure">15</ix:nonFraction>% fair value discount for the required six-month holding period of the shares, and (iii) $<ix:nonFraction id="F20231019113055587_33" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">4.0</ix:nonFraction> million of contingent purchase consideration. The contingent purchase consideration is based on a clause in the purchase agreement that provides that if at any time during the 24 months following the acquisition date, the five-day volume weighted average price ("VWAP") per share of the Company's common shares as quoted on the Nasdaq Capital Market fails to equal or exceed $<ix:nonFraction id="Fxbrl_20240529182337490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="CAD_Per_Share">100.00</ix:nonFraction>, then the Company shall issue a number of additional common shares to the sellers equal to the difference between (x) a fraction, the numerator of which is $<ix:nonFraction id="Fxbrl_20240529184355801" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">47.5</ix:nonFraction> million and the denominator of which is the highest five day VWAP at any point during the 24 months following the closing and (y) the <ix:nonFraction id="Fxbrl_20240529195114226" name="flgc:CommonSharesDeliveredToTheSellers" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="Shares">475,000</ix:nonFraction> common shares delivered to the sellers at the closing. <ix:nonNumeric id="Fxbrl_20240529195346798" name="flgc:DescriptionOfShares" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">In no event shall the Company be required to issue more than 182,500 common shares unless, if required by applicable law, it shall have obtained the consent of the Company's shareholders to do so. In the event the Company is required to deliver in excess of 182,500</ix:nonNumeric> shares to the sellers ("Excess Shares") and the Company shall not have obtained shareholder consent, if required, the Company may deliver cash to the sellers in lieu of such Excess Shares determined by a formula set forth in the purchase agreement. The contingent purchase consideration was classified as a financial liability within the contingent purchase considerations line on the statement of financial position as the Company may be required to settle any amounts due in cash instead of common shares if the Company's common shareholders do not provide requisite shareholder approval to issue additional common shares. It is now included in the current portion of contingent purchase consideration&#160;line on the statement of financial position as the settlement date is within the next 12 months.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of the contingent purchase consideration at February 24, 2022 was determined using a Monte Carlo simulation incorporating Brownian motion with <ix:nonFraction id="F20231019113055589_38" name="flgc:NumberOfTrials" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="Trial">100,000</ix:nonFraction> trials through a binomial model. The significant inputs to the valuation included the two-year time period, the Company's closing share price at February 24, 2022 ($<ix:nonFraction id="F20231019113055589_39" name="us-gaap:SharePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD_Per_Share">36.40</ix:nonFraction>), estimated Company common share volatility (<ix:nonFraction id="F20231019113055590_40" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="Pure">100</ix:nonFraction>%), and risk-free rate of <ix:nonFraction id="F20231019113055590_41" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="Pure">1.5</ix:nonFraction>% to discount the ending result to present value.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of the contingent purchase consideration at December 31, 2023 was determined using a simplified calculation because the end of the 24 month period after the acquisition date is within two months after the reporting date. The calculation took the expected shares to be issued (<ix:nonFraction id="F20231019113055591_42" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="Shares">632,484</ix:nonFraction>) multiplied by the Company's closing share price at December 31, 2023 ($<ix:nonFraction id="F20231019113055591_43" name="us-gaap:SharePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="CAD_Per_Share">1.35</ix:nonFraction>). The Company determined that the balance of this contingent consideration at December 31, 2023 was $<ix:nonFraction id="F20231019113055592_46" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">0.9</ix:nonFraction> million, with the $<ix:nonFraction id="F20231019113055592_47" name="flgc:UnrealizedLossesOnSecurities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">1.8</ix:nonFraction> million decrease in the balance from December 31, 2022 recorded in the unrealized (gain) loss from changes in fair value caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240306020311588" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true" contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
                            <div>
                                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055593_48" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">535</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055593_49" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">975</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055593_50" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">5,534</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055594_51" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">540</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant, and equipment</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055594_52" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">536</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                                <p style="margin-top: 0pt; margin-bottom: 10pt; font-family: Times New Roman,Times,serif; text-align: left;">&#160;</p>
                                <div>
                                    <ix:exclude>
                                        <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">150</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                            </tr>
                                        </table>
                                    </ix:exclude>
                                </div>
                                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right of use assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055594_53" name="flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">772</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other non-current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055595_54" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">127</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible asset</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055595_55" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">4,533</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055595_56" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">24,898</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055596_57" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">38,450</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055596_58" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">2,273</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current lease liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055596_59" name="flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">644</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provision for sales tax</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055597_60" name="flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">982</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055597_61" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">24</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other current liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055597_62" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">99</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055598_63" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">4,022</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055598_64" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">34,428</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of the trade receivables reflects a $<ix:nonFraction id="Fxbrl_20240306030912336" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">0.3</ix:nonFraction> million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. Since the acquisition date through December 31, 2022, JustCBD revenue was $<ix:nonFraction id="F20231019113055602_66" name="us-gaap:Revenues" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220226to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">26.4</ix:nonFraction> million with net loss and comprehensive loss of $<ix:nonFraction id="F20231019113055602_67" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220226to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">6.5</ix:nonFraction> million. The acquired provision for sales tax is discussed at Note 19 below.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The intangible assets of $<ix:nonFraction id="Fxbrl_20240306040354808" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">4.5</ix:nonFraction> million are comprised of the following categories and estimated useful lives: tradenames of $<ix:nonFraction id="F20231019113055603_68" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember" unitRef="USD">3.1</ix:nonFraction> million for eight to nine years, customer relationships of $<ix:nonFraction id="F20231019113055603_69" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcCustomersRelationshipsMember" unitRef="USD">1.2</ix:nonFraction> million for five to seven years, and know-how of $<ix:nonFraction id="F20231019113055603_70" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcKnowHowMember" unitRef="USD">0.2</ix:nonFraction> million for three years. The Company expects the goodwill and intangible asset values to be deductible for United States income tax purposes. The goodwill is assigned to the house of brands segment.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">If JustCBD was acquired at January 1, 2022, the combined revenue and net loss of JustCBD and the Company would have increased approximately $<ix:nonFraction id="F20231019113055604_71" name="us-gaap:Revenues" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">5.2</ix:nonFraction> million and $<ix:nonFraction id="F20231019113055604_72" name="us-gaap:ProfitLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">1.6</ix:nonFraction> million, respectively (unaudited).</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company incurred acquisition related costs of $<ix:nonFraction id="F20231019113055604_73" name="us-gaap:ProfessionalFees" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember" unitRef="USD">0.6</ix:nonFraction> million which were expensed as incurred in professional fees on the consolidated statements of loss and comprehensive loss.</span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>No Cap Hemp Co. ("No Cap") business combination</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 20, 2022, Just Brands LLC., a wholly owned subsidiary of the Company, acquired certain assets, assumed certain liabilities, retained certain employees and processes (together the "purchased assets") of No Cap for total purchase consideration of $<ix:nonFraction id="F20231019113055605_74" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">0.9</ix:nonFraction> million. No Cap is a manufacturer and distributor of high quality and affordable CBD products. No Cap is based in Florida in the United States and was formed in 2017. Just Brands LLC acquired No Cap to expand its product offerings and accelerate its revenue growth.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As consideration for the purchased assets of No Cap, Just Brands LLC will pay an amount equal to <ix:nonFraction id="F20231019113055605_75" name="flgc:PurchaseConsiderationPercentageOfSales" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="Pure">10</ix:nonFraction>% of the sales of No Cap until such a time that Just Brands LLC will have paid a total of $<ix:nonFraction id="F20231019113055605_76" name="flgc:PurchaseConsiderationPercentageOfSalesAmountPayable" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">2.0</ix:nonFraction> million. Also on July 20, 2022, Just Brands LLC advanced $<ix:nonFraction id="F20231019113055606_77" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">0.2</ix:nonFraction> million to the former owners of No Cap. This $<ix:nonFraction id="Fxbrl_20240306133317531" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">0.2</ix:nonFraction> million will be settled prior to and in the same manner as the consideration for the purchased assets. As these entire amounts are considered contingent consideration, it was valued using discounted cash flow models utilizing two different rates, high and low. The significant inputs to the original valuation included the estimated nine-year time period to accumulate <ix:nonNumeric id="Fxbrl_20240529202632953" name="flgc:DescriptionOfDiscountRates" contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">the $2.0 million maximum payment and discount rates of 23.5%, high, and 14.3%, low, to estimate the present value of the future cash outflows. The resulting acquisition date fair value of $0.9 million</ix:nonNumeric> contingent purchase consideration is classified within the contingent purchase considerations line on the statement of financial position.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company plans to discontinue the No Cap brand during fiscal 2024. As such, the Company determined that the balance of this contingent consideration at December 31, 2023 was $<ix:nonFraction id="Fxbrl_20240306041301302" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">nil</ix:nonFraction>, with the $<ix:nonFraction id="Fxbrl_20240306041246176" name="flgc:UnrealizedLossesOnSecurities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">0.9</ix:nonFraction> million decrease in the balance from December 31, 2022 recorded in the unrealized (gain) loss from changes in fair value caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:</span></span></p>
                        <div>
                            <ix:exclude>
                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">151</span></span></span></div>
                                <div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                </div>
                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                    </tr>
                                </table>
                            </ix:exclude>
                        </div>
                        <ix:nonNumeric id="Fxbrl_20240306020339673" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true" contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
                            <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; border-top: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055614_101" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">31</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055614_102" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">725</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055616_108" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">417</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055617_109" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">1,173</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055617_110" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">272</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055620_113" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">272</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055620_114" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">901</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of the trade receivables reflects a $<ix:nonFraction id="Fxbrl_20240306041443838" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">0.2</ix:nonFraction> million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. Since the acquisition date through December 31, 2022, No Cap revenue was $<ix:nonFraction id="Fxbrl_20240306041600591" name="us-gaap:Revenues" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">0.6</ix:nonFraction> million with net income and comprehensive loss of $<ix:nonFraction id="Fxbrl_20240306041603738" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">0.1</ix:nonFraction> million.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company expects the goodwill to be deductible for Unites States income tax purposes. The goodwill is assigned to the house of brands segment.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">If No Cap was acquired at January 1, 2022, the combined revenue of No Cap and the Company would have increased approximately $<ix:nonFraction id="Fxbrl_20240306041959666" name="us-gaap:Revenues" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">1.9</ix:nonFraction> million, and the combined net loss would have decreased by $<ix:nonFraction id="Fxbrl_20240306042004368" name="us-gaap:ProfitLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember" unitRef="USD">1.0</ix:nonFraction> million (unaudited). </span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Acquisition of Minority interests</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On January 18, 2022, the Company acquired the remaining <ix:nonFraction id="F20231019113055626_132" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember" unitRef="Pure">13</ix:nonFraction>% of the outstanding equity interests in Flora Beauty LLC from its minority shareholder in exchange for <ix:nonFraction id="F20231019113055626_133" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember" unitRef="Shares">5,000</ix:nonFraction> common shares of the Company and a stock option exercisable for up to <ix:nonFraction id="F20231019113055627_134" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember" unitRef="Shares">2,500</ix:nonFraction> common shares of the Company at an exercise price of $<ix:nonFraction id="F20231019113055627_135" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember" unitRef="USD_Per_Share">34.00</ix:nonFraction> per share that expire five years from the date of the grant. The Company dissolved Flora Beauty LLC during the year ended December 31, 2023. See Note 2.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On January 31, 2022, the Company completed its acquisition of Flora Med S.A.S by acquiring the remaining <ix:nonFraction id="F20231019113055628_136" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220131_usgaapBusinessAcquisitionAxis_flgcFloraMedSasMember" unitRef="Pure">10</ix:nonFraction>% of the equity interests in Flora Med S.A.S. from its minority shareholders in exchange for <ix:nonFraction id="F20231019113055628_137" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFloraMedSasMember" unitRef="Shares">1,514</ix:nonFraction> common shares of the Company. The Company sold Flora Med S.A.S. as part of the Share Purchase Agreement with Lisan on July 5, 2023. See Note 5.</span></span></p>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif; text-align: left;">&#160;</p>
            <ix:nonNumeric id="F20231019113055884_221" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11.<span style="display: inline-block; width: 15pt;">&#160;</span></b><b>INTANGIBLE ASSETS AND GOODWILL </b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A continuity of intangible assets for the years ended December 31, 2023 and 2022 is as follows:</span></span></p>
                            <ix:nonNumeric id="F20231019113055650_0" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>In Thousands of United States dollars</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>License</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Customer<br/>Relationships</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Patents</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Non-<br/>Compete<br/>Agreements</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Goodwill</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Total</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Cost</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2021</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055651_1" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">200</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055654_2" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">1,570</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055655_3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">2,090</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055656_4" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">4,300</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055657_5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">1,190</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055658_6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">19,675</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055659_7" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231" unitRef="USD">29,025</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Acquired through business combinations</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055671_15" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">1,397</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055672_16" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">5,945</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055673_17" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">3,063</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055673_18" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">230</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055674_19" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055675_20" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">29,031</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055676_21" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">39,666</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055677_22" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">128</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055678_23" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055679_24" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055680_25" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055681_26" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055682_27" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">25,073</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055684_28" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">25,201</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2022</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055685_29" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">1,469</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055686_30" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">7,515</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055687_31" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">5,153</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055688_32" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">4,530</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055689_33" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">1,190</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055689_34" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">23,633</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055690_35" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">43,490</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Accumulated Amortization</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2021</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055691_36" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">6</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055692_37" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">26</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055693_38" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">35</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055694_39" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">48</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055695_40" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">66</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055698_41" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055698_42" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231" unitRef="USD">181</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Additions</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055699_43" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">66</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055700_44" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">322</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055701_45" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">583</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055702_46" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">573</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055703_47" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">397</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055704_48" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055705_49" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,941</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2022</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055706_50" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">72</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055707_51" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">348</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055708_52" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">618</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055709_53" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">621</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055712_54" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">463</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055713_55" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055714_56" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">2,122</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Foreign Currency translation</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055715_57" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">5</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055716_58" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">17</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055717_59" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">18</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055718_60" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055718_61" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055719_62" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">261</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055720_63" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">257</ix:nonFraction></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Net book value at December 31, 2022</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113055721_64" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">1,402</ix:nonFraction></b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113055722_65" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">7,184</ix:nonFraction></b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113055723_66" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">4,517</ix:nonFraction></b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113055726_67" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">3,909</ix:nonFraction></b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113055727_68" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">727</ix:nonFraction></b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113055728_69" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">23,372</ix:nonFraction></b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113055728_70" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">41,111</ix:nonFraction></b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                    <div>
                                        <p style="margin: 0pt;">&#160;</p>
                                        <div>
                                            <ix:exclude>
                                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">152</span></span></span></div>
                                                <div>
                                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                </div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                    </tr>
                                                </table>
                                            </ix:exclude>
                                        </div>
                                    </div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>In Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>License</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Customer and<br/>Supplier<br/>Relationships</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Patents</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Non-<br/>Compete<br/>Agreements</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Goodwill</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Cost</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055729_71" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">1,469</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055730_72" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">7,515</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055731_73" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">5,153</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055732_74" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">4,530</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055733_75" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">1,190</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055734_76" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">23,633</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055735_77" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">43,490</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Additions</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305134234036_20231019113055744_85" name="flgc:FiniteLivedIntangibleAssetsAdditions" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305134234036_20231019113055745_86" name="flgc:FiniteLivedIntangibleAssetsAdditions" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">194</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305134234036_20231019113055746_87" name="flgc:FiniteLivedIntangibleAssetsAdditions" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305134234036_20231019113055747_88" name="flgc:FiniteLivedIntangibleAssetsAdditions" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305134234036_20231019113055747_89" name="flgc:FiniteLivedIntangibleAssetsAdditions" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305134234036_20231019113055748_90" name="flgc:FiniteLivedIntangibleAssetsAdditions" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305134234036_20231019113055749_91" name="flgc:FiniteLivedIntangibleAssetsAdditions" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">194</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Impairment</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055744_85" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">1,216</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055745_86" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">6,502</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055746_87" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">3,249</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055747_88" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">3,432</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055747_89" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">529</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055748_90" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">23,372</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055749_91" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">38,300</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2023</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20231101234452936" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">253</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20231101234457312" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">1,207</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234502607">1,904</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055750_92" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">1,098</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055753_93" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">661</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055754_94" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">261</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234536599">5,384</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Accumulated Amortization</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055755_95" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">72</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055756_96" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">348</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055756_97" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">618</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055757_98" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">621</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055758_99" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">463</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055759_100" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055760_101" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">2,122</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Additions</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055761_102" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">200</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055762_103" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">916</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055763_104" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">514</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055764_105" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">291</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055766_106" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">198</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055767_107" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055768_108" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">2,119</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2023</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20231101234559711" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">272</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20231101234603959" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">1,264</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20231101234608343" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">1,132</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20231101234612431" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">912</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20231101234617111" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">661</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055769_109" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234621352">4,241</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Foreign Currency translation</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055770_110" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">19</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055771_111" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">57</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055772_112" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">12</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055773_113" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055774_114" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055775_115" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">261</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055775_116" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">197</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Net book value at December 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055776_117" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055777_118" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055779_119" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">760</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055780_120" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">186</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055781_121" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055782_122" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember" unitRef="USD">-</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055783_123" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">946</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:nonNumeric>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's intangible asset additions in 2022 primarily consist of assets acquired as part of the February 2022 purchase of JustCBD and the December 2022 purchase of FGH (Note 10). Information regarding the significant JustCBD intangible assets within the indicated categories of the table above is as follows as at December 31, 2023:</span></span></p>
                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 4%; vertical-align: middle;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 4%; vertical-align: top;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;</span></span></td>
                                    <td style="vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Tradenames: carrying amount $<ix:nonFraction id="F20231019113055794_134" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">0.5</ix:nonFraction> million with <ix:nonNumeric id="F20231019113055795_135" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:durmonth" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember_usgaapReportingUnitAxis_flgcJustCBDMember">74</ix:nonNumeric> months of remaining amortization periods</span></span></p>
                                    </td>
                                </tr>
                            </table>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's intangible asset additions in 2023 primarily consist of customer relationships acquired as part of the March 2023 purchase of Original Hemp (Note 10). These customer relationships were fully impaired and their carrying amount at December 31, 2023 was $<ix:nonFraction id="F20231019113055785_125" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember" unitRef="USD">nil</ix:nonFraction>.</span></span></p>
                            <div>
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The gross cost of the intangible assets is amortized over their estimated useful lives, as the Company does not expect the assets to have significant residual value for any of the asset classes. The weighted average amortization period at December 31, 2023 by asset class subject to amortization is as follows:</span></span></p>
                                    <ix:nonNumeric id="Fxbrl_20240306153622550" name="flgc:ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trademarks and brands <span style="display: inline-block; width: 42.5pt;">&#160;</span>
                                                        <ix:nonNumeric id="Fxbrl_20240306153012620" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">6.1</ix:nonNumeric> years
                                                    </span></span></p>
                                            <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Patents <span style="display: inline-block; width: 107.31pt;">&#160;</span>
                                                        <ix:nonNumeric id="Fxbrl_20240306153022551" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">6.8</ix:nonNumeric> years
                                                    </span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total <span style="display: inline-block; width: 114.99pt;">&#160;</span>
                                                        <ix:nonNumeric id="Fxbrl_20240306153025916" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" contextRef="C_20231231">6.2</ix:nonNumeric>&#160;years
                                                    </span></span></p>
                                        </div>
                                    </ix:nonNumeric>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain trademarks have renewal or extension terms available, with a weighted average of <ix:nonNumeric id="F20231019113055814_153" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapTrademarksMember">6.1</ix:nonNumeric> years remaining before the next renewal or extension is due at December 31, 2023. The Company expenses such costs as incurred. The Company's trademarks and brands are registered to protect the assets from use by others, and cash flows of the related reporting units and asset groups could be negatively impact if the Company did not successfully renew them.</span></span></p>
                                </div>
                            </div>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At December 31, 2023, the estimated aggregate amortization expense for each of the next five years is as follows:</span></span></p>
                            <div>
                                <ix:exclude>
                                    <div>
                                        <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">153</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:exclude>
                            </div>
                            <ix:nonNumeric id="F20231019113055815_155" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <div>
                                    <table style="width: 20%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="text-align: left; white-space: nowrap;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$<ix:nonFraction id="F20231019113055816_156" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">152</ix:nonFraction></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                            <td style="width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$<ix:nonFraction id="F20231019113055817_157" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">152</ix:nonFraction></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$<ix:nonFraction id="F20231019113055820_158" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">152</ix:nonFraction></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                            <td style="width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$<ix:nonFraction id="F20231019113055821_159" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">152</ix:nonFraction></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$<ix:nonFraction id="F20231019113055822_160" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">152</ix:nonFraction></span></span></td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:nonNumeric>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's goodwill is assigned to the following reporting units for the years ended December 31, 2022 and 2023:</span></span></p>
                            <ix:nonNumeric id="F20231019113055823_161" name="us-gaap:ScheduleOfGoodwillTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <div>
                                    <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Vessel </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>JustCBD </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>FGH </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross goodwill recorded prior to December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055825_164" name="us-gaap:GoodwillGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapReportingUnitAxis_flgcVesselMember" unitRef="USD">19,675</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055826_165" name="us-gaap:GoodwillGross" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055827_166" name="us-gaap:GoodwillGross" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055828_167" name="us-gaap:GoodwillGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231" unitRef="USD">19,675</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment recorded prior to December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055831_170" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapReportingUnitAxis_flgcVesselMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055833_171" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055834_172" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055835_173" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net book value as at December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055838_176" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapReportingUnitAxis_flgcVesselMember" unitRef="USD">19,675</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055838_177" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055839_178" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055840_179" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231" unitRef="USD">19,675</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Acquired through business combinations</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055843_182" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapReportingUnitAxis_flgcVesselMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055844_183" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">25,315</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055846_184" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">3,716</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055847_185" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">29,031</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055850_188" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapReportingUnitAxis_flgcVesselMember" unitRef="USD">19,675</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055851_189" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">5,398</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055852_190" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055853_191" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">25,073</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign exchange impacts</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055874_211" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapReportingUnitAxis_flgcVesselMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055875_212" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">277</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055876_213" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">16</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055877_214" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">261</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net book value as at December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055856_194" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapReportingUnitAxis_flgcVesselMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055856_195" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">19,640</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055857_196" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">3,732</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055860_197" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">23,372</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055868_206" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">19,640</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055869_207" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">3,732</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113055870_208" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">23,372</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net book value as at December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055880_217" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapReportingUnitAxis_flgcVesselMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055880_218" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055881_219" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapReportingUnitAxis_usgaapFranchiseMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055882_220" name="us-gaap:Goodwill" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113055908_31" name="us-gaap:AssetImpairmentChargesTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <div>
                        <div>
                            <div>
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>12.</b></span></span><span style="padding-left: 15pt;">&#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>IMPAIRMENT OF ASSETS</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company tests its goodwill for impairment as part of its annual fourth quarter impairment test, and at interim periods when impairment indicators exist. For the year ended December 31, 2023, the Company tested its goodwill for impairment at June 30, 2023 and&#160;</span></span><span style="font-size: 10pt; font-family: Times New Roman, Times, serif;">December 31, 2023</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"> due to indicators such as a decline in the value of the Company's publicly traded common shares, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. In addition, the Company assessed its other long-lived assets for impairment at this time. The Company's goodwill was assigned to the reporting units associated with the original acquisition of those operations. Management determined the Company's reporting units for 2023 impairment testing are its reportable segments shown in Note 24, but with the house of brands segment broken down into separate reporting units for the Company's JustCBD and Vessel product groups of assets.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company may consider the results of both an income approach (discounted cash flows) and market approach (guideline public companies) when determining the recoverable amount of its reporting units. For the income approach, the significant assumptions used in the calculation of the recoverable amounts of the reporting units include forecasted revenue, expenses and net cash flows, terminal period cash flows and growth rates, and the weighted average cost of capital used as the discount rate. These assumptions are considered Level 3 inputs in the fair value hierarchy. The assumptions consider historical and projected data from internal sources as well as external industry trends and expectations. For the market approach, the significant assumptions include identifying and calibrating relevant guideline public companies, and determining the financial metric to measure against. The results of the two approaches are considered, and judgment is applied in weighting each approach to determine the recoverable amount of the reporting unit.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For long-lived assets other than goodwill, which show impairment indicators are present, the Company compares its expected undiscounted future cash flows to the carrying value of the asset group. If the undiscounted future cash flows are less than the carrying value of the assets, then the fair value of the asset group is calculated using an income or market approach as discussed in the prior paragraph. The significant assumptions used in calculating the undiscounted future cash flows include determining the primary asset of the asset group which sets the length of time to project the cash flows, and the forecasted revenue, expenses and net cash flows relating to the asset group.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023 Annual Impairment Test</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company concluded that the carrying values of its JustCBD and FGH reporting units were higher than their respective estimated fair values, and a goodwill impairment loss totaling $<ix:nonFraction id="Fxbrl_20240305182113141" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember" unitRef="USD">23.4</ix:nonFraction> million was recognized in the year ended December 31, 2023, with details of these impairment tests discussed below. The goodwill impairment loss was comprised of (i) $<ix:nonFraction id="Fxbrl_20240305184718244" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">19.6</ix:nonFraction> million related to the JustCBD reporting unit, representing the entirety of the goodwill assigned to the JustCBD reporting unit, part of the house of brands segment; and (ii) $<ix:nonFraction id="Fxbrl_20240305184742260" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember" unitRef="USD">3.7</ix:nonFraction> million related to the FGH reporting unit, part of the commercial and wholesale segment. See Note 24 for discussion of the Company's segments. Certain negative trends, including slower growth rates, resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation for the JustCBD and FGH reporting units.</span></span></p>
                                    <div>
                                        <div>
                                            <ix:exclude>
                                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">154</span></span></span></div>
                                                <div>
                                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                </div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                    </tr>
                                                </table>
                                            </ix:exclude>
                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023 Annual Goodwill Impairment Test of FGH</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At June 30, 2023, the Company's FGH reporting unit had external indicators of impairment primarily due to the Company's declining share price, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. As such, the Company tested the FGH reporting unit for impairment as at June 30, 2023 and determined that the carrying value of the reporting unit's assets exceeded the recoverable amount, resulting in goodwill impairment of $<ix:nonFraction id="Fxbrl_20240305184906107" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember" unitRef="USD">3.7</ix:nonFraction> million recorded in the first half of fiscal 2023. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">FGH's June 30, 2023 carrying value of $<ix:nonFraction id="Fxbrl_20240305185043668" name="us-gaap:Assets" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember" unitRef="USD">7.7</ix:nonFraction> million was comprised primarily of goodwill and identified intangible assets of $<ix:nonFraction id="Fxbrl_20240305185121487" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember" unitRef="USD">5.2</ix:nonFraction> million and other long-lived assets of $<ix:nonFraction id="Fxbrl_20240305185237172" name="us-gaap:OtherAssetsNoncurrent" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember" unitRef="USD">0.5</ix:nonFraction> million. The carrying value is reduced by inseparable market participant liabilities associated with the December 2022 acquisition of FGH which includes $<ix:nonFraction id="Fxbrl_20240305185248246" name="us-gaap:CapitalLeaseObligations" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember" unitRef="USD">0.1</ix:nonFraction> million of lease liability. The estimated recoverable amount of FGH at June 30, 2023 was $<ix:nonFraction id="Fxbrl_20240305185347524" name="flgc:EstimatedRecoverableAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember" unitRef="USD">1.5</ix:nonFraction> million, resulting in goodwill impairment of the remaining $<ix:nonFraction id="Fxbrl_20240305185446823" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember" unitRef="USD">3.7</ix:nonFraction> million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240305185805700" name="flgc:DescriptionOfValuation" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember">The reporting unit's fair value was determined based on an income approach discounted cash flow model. After working capital adjustments, the resulting fair value was estimated at $1.5 million. The income approach used a discount rate of 17%, operating margins of about 2%, working capital requirements of 6% revenue, and a terminal period growth rate of 2%. The revenue growth rates start at 5% in 2023 and trend down to 2% in 2028 and thereafter.</ix:nonNumeric> The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            </span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After the impairment recorded at June 30, 2023, FGH's carrying value was equal to its recoverable amount. <ix:nonNumeric id="Fxbrl_20240305185929227" name="flgc:GoodwillDescription" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $0.3 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.</ix:nonNumeric></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023 Annual Goodwill Impairment Test of JustCBD</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At June 30, 2023 and December 31, 2023, the Company&#8217;s JustCBD reporting unit had external indicators of impairment primarily due to the Company's declining share price, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. As such, the Company tested the JustCBD reporting unit for impairment as at June 30, 2023 and December 31, 2023 and determined that the carrying value of the reporting unit&#8217;s assets exceeded the recoverable amount, resulting in goodwill impairment of $<ix:nonFraction id="Fxbrl_20240327185610251" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">19.6</ix:nonFraction> million recorded in 2023. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD&#8217;s June 30, 2023 and December 31, 2023 carrying values of $<ix:nonFraction id="Fxbrl_20240328100833817" name="us-gaap:Assets" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">23.8</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20240328100849725" name="us-gaap:Assets" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">7.0</ix:nonFraction> million, respectively, were comprised primarily of goodwill and identified intangible assets of $<ix:nonFraction id="Fxbrl_20240328105107151" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">20.8</ix:nonFraction> million and $<ix:nonFraction id="Fxbrl_20240328105324896" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">3.5</ix:nonFraction> million and other long-lived assets of $<ix:nonFraction id="Fxbrl_20240328110154985" name="us-gaap:OtherAssetsNoncurrent" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">1.2</ix:nonFraction> million and $<ix:nonFraction id="Fxbrl_20240328110158581" name="us-gaap:OtherAssetsNoncurrent" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">0.7</ix:nonFraction> million. The carrying value is reduced by inseparable market participant liabilities associated with the February 2022 acquisition of JustCBD which includes $<ix:nonFraction id="Fxbrl_20240328110203533" name="us-gaap:CapitalLeaseObligations" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">1.6</ix:nonFraction> million and $<ix:nonFraction id="Fxbrl_20240328110211747" name="us-gaap:CapitalLeaseObligations" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">0.4</ix:nonFraction> million of lease liability. The estimated recoverable amount of JustCBD at June 30, 2023 and December 31, 2023 was $<ix:nonFraction id="Fxbrl_20240328110216205" name="flgc:EstimatedRecoverableAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">7.1</ix:nonFraction> million and $<ix:nonFraction id="Fxbrl_20240328110220157" name="flgc:EstimatedRecoverableAmount" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">nil</ix:nonFraction>, respectively, resulting in goodwill impairment of $<ix:nonFraction id="Fxbrl_20240328110226181" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember" unitRef="USD">19.6</ix:nonFraction> million for the year ended December 31, 2023 as the carrying value of the reporting unit&#8217;s assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240305190536851" name="flgc:DescriptionOfValuation" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember">The reporting unit&#8217;s fair value at June 30, 2023 and December 31, 2023 was determined based on an income approach discounted cash flow. After working capital adjustments, the resulting fair value was estimated at $7.1 million and $nil. The income approach used a weighted average discount rate of 28%, operating margins from 8.5% to -19.7%, weighted average working capital requirements of 1% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 17% in 2023 and taper down to 3% in 2025 and thereafter. </ix:nonNumeric> The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            </span></span></p>
                                    <div>
                                        <div>
                                            <ix:exclude>
                                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">155</span></span></span></div>
                                                <div>
                                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                </div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                    </tr>
                                                </table>
                                            </ix:exclude>
                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 1pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After the impairment recorded for the year ended December 31, 2023, JustCBD&#8217;s carrying value was equal to its recoverable amount. <ix:nonNumeric id="Fxbrl_20240305190617828" name="flgc:GoodwillDescription" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a decrease of the reporting unit fair value of approximately $1.5 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.</ix:nonNumeric></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023 Other Long-Lived Asset Impairment Tests</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For asset groups that had indicators of impairment, the Company performed a quantitative analysis as of June 30, 2023 to determine if impairment existed by comparing the carrying amount of each asset group to the future undiscounted cash flows the asset group is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of property, plant and equipment, operating lease right of use assets, customer relationships, trademarks, patents and non-compete agreements within its Vessel asset group within the house of brands segment totaling $<ix:nonFraction id="Fxbrl_20240328113101671" name="us-gaap:AssetImpairmentCharges" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember" unitRef="USD">7.4</ix:nonFraction> million. <ix:nonNumeric id="Fxbrl_20240328114109801" name="flgc:DescriptionOfValuation" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 10.7% in 2023 and tapering down to 3% thereafter, weighted average royalty rate of 1%, weighted average discount rate of 17% and a customer attrition rate of 18%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts.</ix:nonNumeric> Likewise, the Company recorded an impairment of supplier relationships, customer relationships and licenses within its FGH asset group within the commercial and wholesale segment totaling $<ix:nonFraction id="Fxbrl_20240328114710552" name="us-gaap:AssetImpairmentCharges" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember" unitRef="USD">3.7</ix:nonFraction> million. <ix:nonNumeric id="Fxbrl_20240328114807441" name="flgc:DescriptionOfValuation" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember">The key inputs included in the recoverable amount calculations are revenue growth rates starting at -2.6% in 2023, 5% in 2024 and tapering down to 4% thereafter, weighted average discount rate of 20% and customer attrition rate of 10%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.1 million decrease of the recoverable amounts.</ix:nonNumeric> Finally, the Company recorded an impairment of customer relationships, trademarks and patents within its JustCBD asset group within the house of brands segment totaling $<ix:nonFraction id="Fxbrl_20240328114912129" name="us-gaap:AssetImpairmentCharges" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">2.3</ix:nonFraction> million. <ix:nonNumeric id="Fxbrl_20240328115011657" name="flgc:DescriptionOfValuation" contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 16.5% in 2023 and tapering down to 3% thereafter, royalty rate of 1.5%, weighted average discount rate of 32.5% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.2 million decrease of the recoverable amounts.</ix:nonNumeric> These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company performed a similar analysis for its asset groups as of December 31, 2023, and determined that indicators of impairment were present. These include external indicators such as a decline in the value of the Company&#8217;s publicly traded common shares as well as internal indicators such as reduced forecasted revenue and cash flow generation. The Company performed a quantitative analysis as of December 31, 2023 to determine if impairment existed by comparing the carrying amount of each asset group to the future undiscounted cash flows the asset group is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of operating lease right of use assets, supplier relationships and licenses within its FGH asset group within the commercial and wholesale segment totaling $<ix:nonFraction id="Fxbrl_20240328115119120" name="us-gaap:AssetImpairmentCharges" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember" unitRef="USD">1.4</ix:nonFraction> million. <ix:nonNumeric id="Fxbrl_20240328115217468" name="flgc:DescriptionOfValuation" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 2.5% in 2024 and tapering down to 2.5% thereafter and a weighted average discount rate of 21%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. </ix:nonNumeric> Likewise, the Company recorded an impairment of operating lease right of use assets, customer relationships and trademarks within its JustCBD asset group within the house of brands segment totaling $<ix:nonFraction id="Fxbrl_20240328120027434" name="us-gaap:AssetImpairmentCharges" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">1.0</ix:nonFraction> million. <ix:nonNumeric id="Fxbrl_20240328120037683" name="flgc:DescriptionOfValuation" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">The key inputs included in the recoverable amount calculations are revenue growth rates starting at -37.5% in 2023 and then increasing to 2.5% thereafter, royalty rate of 1.5%, weighted average discount rate of 25% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. </ix:nonNumeric>These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2022 Annual Impairment Test</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company concluded that the carrying values of its Vessel and JustCBD reporting units were higher than their respective estimated fair values, and a goodwill impairment loss totaling $<ix:nonFraction id="F20231019113055906_0" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember" unitRef="USD">25.1</ix:nonFraction> million was recognized in the year ended December 31, 2022, with details of these impairment tests discussed below. The goodwill impairment loss was comprised of (i) $<ix:nonFraction id="F20231019113055907_1" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember" unitRef="USD">19.7</ix:nonFraction> million related to the Vessel reporting unit, representing the entirety of the goodwill assigned to the Vessel reporting unit, part of the house of brands segment; and (ii) $<ix:nonFraction id="F20231019113055907_2" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember" unitRef="USD">5.4</ix:nonFraction> million related to the JustCBD reporting unit, part of the house of brands segment. See Note 24 for discussion of the Company's segments. Certain negative trends, including slower growth rates, resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation for the Vessel reporting unit. No impairment was noted for the FGH reporting unit, as the acquisition of FGH occurred close to the end of the year and fair value calculated at the December 23, 2022 acquisition date approximates fair value as at December 31, 2022.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reconciled the sum of its reporting unit recoverable amounts discussed above plus all other net assets to the Company's market capitalization of common shares as December 31, 2022. The Company's recoverable amounts at December 31, 2022 exceeded the market capitalization of its common shares by <ix:nonFraction id="Fxbrl_20240328120708274" name="flgc:PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember" unitRef="Pure">98</ix:nonFraction>%. The Company believes the <ix:nonFraction id="Fxbrl_20240328120720070" name="flgc:PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember" unitRef="Pure">98</ix:nonFraction>% excess is due to implied equity control premium and is within an acceptable range of values based on control premiums observed in business combinations within the cannabis and wholesale industries.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022 Annual Goodwill Impairment Test of Vessel</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At June 30, 2022, the Company's Vessel reporting unit had external indicators of impairment primarily due to a decline in comparable public company share prices which would negatively impact the implied valuation of Vessel. As such, the Company tested the Vessel reporting unit for impairment as at June 30, 2022 and determined that the carrying value of the reporting unit's assets exceeded the recoverable amount, resulting in goodwill impairment of $<ix:nonFraction id="F20231019113055907_4" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" unitRef="USD">16.0</ix:nonFraction> million recorded in the first half of fiscal 2022. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <div>
                                        <div>
                                            <ix:exclude>
                                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">156</span></span></span></div>
                                                <div>
                                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                </div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                    </tr>
                                                </table>
                                            </ix:exclude>
                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vessel's December 31, 2022 carrying value of $<ix:nonFraction id="Fxbrl_20231101235532848" name="us-gaap:Assets" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" unitRef="USD">11.6</ix:nonFraction> million was comprised primarily of goodwill and identified intangible assets of $<ix:nonFraction id="Fxbrl_20231101235540020" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" unitRef="USD">11.3</ix:nonFraction> million and other long-lived assets of $<ix:nonFraction id="Fxbrl_20231101235546236" name="us-gaap:OtherAssetsNoncurrent" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" unitRef="USD">1.0</ix:nonFraction> million. The carrying value is reduced by inseparable market participant liabilities associated with the November 2021 acquisition of Vessel which includes $<ix:nonFraction id="Fxbrl_20231101235557500" name="us-gaap:CapitalLeaseObligations" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" unitRef="USD">1.1</ix:nonFraction> million of lease liability. The estimated recoverable amount of Vessel at December 31, 2022 was $<ix:nonFraction id="Fxbrl_20231101235607956" name="flgc:EstimatedRecoverableAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" unitRef="USD">7.0</ix:nonFraction> million, resulting in goodwill impairment of the remaining $<ix:nonFraction id="Fxbrl_20231101235618421" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" unitRef="USD">3.7</ix:nonFraction> million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113055907_5" name="flgc:DescriptionOfValuation" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">The reporting unit's fair value was determined based on an income approach discounted cash flow model of $7.6 million (80% weighting) and a market approach guideline public company method of $7.0 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $7.0 million. The income approach used a discount rate of 17%, operating margins from 0% to 18%, working capital requirements of 15% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 14% in 2023 and taper down to 3% in the terminal period after 2030.</ix:nonNumeric> The market approach considered guideline public companies similar to Vessel considering financial metrics such as historical revenue growth, gross margin and EBITDA profitability and with operations focused on consumer brands and similar sales channels. An enterprise value to latest twelve months revenue multiple of 1.0 was selected based on consideration of the enterprise value to latest twelve months multiples of the guideline companies. The multiple was applied to Vessel's revenue for the twelve months ended December 31, 2022. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            </span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After the impairment recorded at December 31, 2022, Vessel's carrying value was equal to its recoverable amount. <ix:nonNumeric id="Fxbrl_20231101235807075" name="flgc:GoodwillDescription" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $1.8 million. Reducing the market approach selected revenue multiple by 0.10 from 1.00 above down to 0.90 (approximately 10% change) would result in a decrease of the reporting unit fair value of approximately $0.7 million. However, there would be no impact on the goodwill impairment amount for either of these unfavorable changes in the models as the imputed fair value of the goodwill exceeded its carrying amount by $1.1 million with the goodwill impaired to zero.</ix:nonNumeric></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022 Annual Goodwill Impairment Test of JustCBD</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD's December 31, 2022 carrying value of $<ix:nonFraction id="F20231019113055907_7" name="us-gaap:Assets" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" unitRef="USD">34.4</ix:nonFraction> million was comprised primarily of goodwill and identified intangible assets of $<ix:nonFraction id="F20231019113055907_8" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" unitRef="USD">29.0</ix:nonFraction> million and other long-lived assets of $<ix:nonFraction id="F20231019113055907_9" name="us-gaap:OtherAssetsNoncurrent" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" unitRef="USD">2.0</ix:nonFraction> million. The carrying value is reduced by inseparable market participant liabilities associated with the February 2022 acquisition of JustCBD which includes $<ix:nonFraction id="F20231019113055907_10" name="us-gaap:CapitalLeaseObligations" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" unitRef="USD">1.2</ix:nonFraction> million of lease liability. The estimated recoverable amount of JustCBD at December 31, 2022 was $<ix:nonFraction id="F20231019113055907_11" name="flgc:EstimatedRecoverableAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" unitRef="USD">29.0</ix:nonFraction> million, resulting in goodwill impairment of $<ix:nonFraction id="F20231019113055907_12" name="us-gaap:GoodwillImpairmentLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" unitRef="USD">5.4</ix:nonFraction> million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113055907_13" name="flgc:DescriptionOfValuation" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember">The reporting unit's fair value was determined based on an income approach discounted cash flow model of $28.0 million (80% weighting) and a market approach guideline public company method of $21.9 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $29.0 million. The income approach used a discount rate of 32%, operating margins from 5% to 28%, working capital requirements of 10% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 21% in 2023 and taper down to 3% in the terminal period after 2030.</ix:nonNumeric> The market approach considered guideline public companies similar to JustCBD considering financial metrics such as historical revenue growth, gross margin and EBITDA profitability and with operations focused on consumer brands and similar sales channels. An enterprise value to latest twelve months revenue multiple of 0.6 was given the most weight in the valuation and was selected based on consideration of the enterprise value to latest twelve months multiples of the guideline companies. The multiple was applied to JustCBD's revenue for the twelve months ended December 31, 2022. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            </span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After the impairment recorded at December 31, 2022, JustCBD's carrying value was equal to its recoverable amount. Any change in the significant assumptions could result in additional impairment of its goodwill as at December 31, 2022. <ix:nonNumeric id="F20231019113055907_14" name="flgc:GoodwillDescription" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% from 32% above up to 35% (approximately 9% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.5 million. Reducing the market approach selected revenue multiple by 0.1 from 0.6 above down to 0.5 (approximately 17% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.7 million.</ix:nonNumeric></span></span></p>
                                    <div>
                                        <div>
                                            <ix:exclude>
                                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">157</span></span></span></div>
                                                <div>
                                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                </div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                    </tr>
                                                </table>
                                            </ix:exclude>
                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022 Other Long-Lived Asset Impairment Tests</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For asset groups that had indicators of impairment, the Company performed a quantitative analysis as of December 31, 2022 to determine if impairment existed by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of the licenses within the corporate segment totaling $<ix:nonFraction id="F20231019113055908_23" name="flgc:ImpairmentOfLicenses" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember" unitRef="USD">0.1</ix:nonFraction> million. This charge was recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the fourth quarter of 2022, the Company decided to consolidate operations and looked for subtenants for two building leases that have contractual lease obligations through 2026 and 2027. These leases are recorded on the Company's statement of financial position as operating lease right of use assets. The lease assets had indicators of impairment as they were no longer used in the asset groups' operations, but the Company was actively seeking to sublease both spaces to generate income from the spaces. The Company calculated the fair value of the two leases using an income approach on the expected sublease income. The resulting fair values were compared to the operating right of use asset values at December 31, 2022, resulting in an impairment of $<ix:nonFraction id="F20231019113055908_24" name="us-gaap:AssetImpairmentCharges" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember" unitRef="USD">0.6</ix:nonFraction> million. <ix:nonNumeric id="F20231019113055908_25" name="flgc:DescriptionOfValuation" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember">The discounted cash flow models assumed the spaces would be subleased within 2023 at 75% to 100% of the Company's cost of the leases, less upfront costs to obtain a sublease tenant. The cash flows were discounted at 8% to 9% which approximates the discount rate in the Company's right of use asset and lease liability calculations.</ix:nonNumeric> These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113055918_0" name="us-gaap:DebtDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>13.<span style="display: inline-block; width: 15pt;">&#160;</span>DEBT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Euro credit facility</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company, through FGH, has credit facilities totaling <ix:nonFraction id="F20231019113055918_1" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="EUR">4.0</ix:nonFraction> million Euro ($<ix:nonFraction id="Fxbrl_20240305140532288" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">4.4</ix:nonFraction> million USD), at two different banks in Germany. These arrangements are open ended without predetermined maturity dates. Principal and interest payments are due at the end of each term. Interest rates can change with each new amount drawn. As of December 31, 2023, the total outstanding amount on these credit facilities was <ix:nonFraction id="F20231019113055918_4" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="EUR">1.8</ix:nonFraction> million Euro ($<ix:nonFraction id="F20231019113055918_2" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1.9</ix:nonFraction> million USD) with interest rates ranging from <ix:nonFraction id="F20231019113055918_3" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember" unitRef="Pure">5.45</ix:nonFraction>% to <ix:nonFraction id="Fxbrl_20240305140617433" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember" unitRef="Pure">6.46</ix:nonFraction>% and due within the next twelve months. These credit facilities were secured by various guarantees, including joint and several guarantees of two managing directors of Phatebo, a subsidiary of FGH, and payment guarantees upon default.</span></span></p>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113055927_27" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <p style="margin: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>14.<span style="display: inline-block; width: 15pt;">&#160;</span>LEASES</b></span></span></p>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's leases primarily consist of administrative real estate leases in Germany and the United States. Management has determined all the Company's leases are operating leases through December 31, 2023. Information regarding the Company's leases is as follows:</span></span></p>
                            <ix:nonNumeric id="F20231019113055922_0" name="us-gaap:LeaseCostTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <div>
                                    <table style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Thousands of United States dollars</span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Year ended<br/>December 31, 2023 </b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Year ended<br/>December 31, 2022</span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Components of lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055923_1" name="us-gaap:OperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,211</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055923_2" name="us-gaap:OperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">937</ix:nonFraction></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Short-term lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055923_3" name="us-gaap:ShortTermLeaseCost" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">324</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055923_4" name="us-gaap:ShortTermLeaseCost" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">308</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Sublease income</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="Fxbrl_20240305194616035_20231019113055923_3" name="us-gaap:SubleaseIncome" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">71</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240305194616035_20231019113055923_4" name="us-gaap:SubleaseIncome" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231" unitRef="USD">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055923_5" name="us-gaap:LeaseCost" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,464</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055924_6" name="us-gaap:LeaseCost" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">1,245</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Other Information</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating cash outflows from operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055924_7" name="us-gaap:OperatingLeasePayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,403</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055924_8" name="us-gaap:OperatingLeasePayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">859</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU assets obtained in exchange for new operating lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055924_9" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">245</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055924_10" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">2,609</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average remaining lease term in years for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>
                                                                    <ix:nonNumeric id="F20231019113055924_11" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" contextRef="C_20231231">2.7</ix:nonNumeric>
                                                                </b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                <ix:nonNumeric id="F20231019113055925_12" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" contextRef="C_20221231">3.5</ix:nonNumeric>
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average discount rate for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055925_13" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="Pure">7.9</ix:nonFraction>%</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055925_14" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="Pure">7.9</ix:nonFraction>%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>
                                </div>
                            </ix:nonNumeric>
                            <div>
                                <div>
                                    <ix:exclude>
                                        <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">158</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                            </tr>
                                        </table>
                                    </ix:exclude>
                                </div>
                            </div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Maturities of operating lease liabilities as of December 31, 2023 are as follows:</span></span></p>
                            <ix:nonNumeric id="F20231019113055925_15" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <div>
                                    <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>Operating Leases </b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2024</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b><ix:nonFraction id="F20231019113055925_16" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">900</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2025</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b><ix:nonFraction id="F20231019113055925_17" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">460</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2026</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b><ix:nonFraction id="F20231019113055926_18" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">374</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2027</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b><ix:nonFraction id="F20231019113055926_19" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">192</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total future lease payments</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b><ix:nonFraction id="F20231019113055926_22" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,926</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Less: imputed interest</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>(<ix:nonFraction id="F20231019113055927_23" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">185</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>)</b></span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b><ix:nonFraction id="F20231019113055927_24" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,741</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Less: current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>(<ix:nonFraction id="F20231019113055927_25" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">799</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>)</b></span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total non-current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b><ix:nonFraction id="F20231019113055927_26" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">942</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:nonNumeric>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Most of the Company's leases contain renewal options to continue the leases for another term equivalent to the original term, which are generally up to two years. The lease liabilities above include renewal terms that management has executed or is reasonably certain of renewing, which only included leases that would have expired in 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating lease of warehousing and office space for Vessel Brand Inc. expires August 31, 2027. <ix:nonNumeric id="Fxbrl_20231025114759031" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20230101to20231231_srtCounterpartyNameAxis_flgcWarehousingAndOfficeSpaceMember">The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term.</ix:nonNumeric> At December 31, 2023, the renewal option is not included in the related operating right of use asset recorded. At the end of 2022, the Company decided to move Vessel's operations and to consolidate them with JustCBD's operations in Florida. See Note 11. The Company began subleasing this space to a third party during the fourth quarter of 2023. The sublease is effective through August 31, 2027 and does not contain renewal options.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating lease of retail space in Miami, FL expires November 30, 2026. <ix:nonNumeric id="Fxbrl_20231025114822932" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20230101to20231231_srtCounterpartyNameAxis_flgcRetailSpaceInMiamiMember">The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term.</ix:nonNumeric> At December 31, 2023, the renewal option is not included in the related operating right of use asset recorded. The Company began subleasing this retail space to a third party during the third quarter of 2023. The sublease agreement is effective through November 30, 2026 and contains one option to renew for five more years.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating lease of manufacturing and warehousing for High Roller Private Label LLC expires June 30, 2024. The lease does not contain a renewal option.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company&#8217;s operating lease of warehousing and office space for Just Brands LLC expires April 30, 2024. The lease does not contain a renewal option. In January 2024, the Company began leasing 14,280 sq. ft. of warehousing space in Pompano Beach, FL, for $<ix:nonFraction id="Fxbrl_20240328110246301" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_srtCounterpartyNameAxis_flgcPompanoBeachMember" unitRef="USD">20,000</ix:nonFraction> a month, pursuant to a lease agreement that expires in February 2029. In March 2024, the Company began leasing 4,184 sq. ft. of office space in Fort Lauderdale, FL, for $<ix:nonFraction id="Fxbrl_20240328110255244" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_srtCounterpartyNameAxis_flgcFortLauderdaleMember" unitRef="USD">8,000</ix:nonFraction> a month, pursuant to a lease agreement that expires in March 2028.</span></span></p>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113055950_61" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>15.<span style="display: inline-block; width: 15pt;">&#160;</span></b><b>SHARE CAPITAL &#160;</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Authorized and issued</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company is authorized to issue an unlimited number of common shares, no par value. On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion below.</span></span></span></p>
                            <div>
                                <ix:exclude>
                                    <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">159</span></span></span></div>
                                    <div>
                                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                    </div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                        </tr>
                                    </table>
                                </ix:exclude>
                            </div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company had the following significant common share transactions:</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span style="text-decoration: underline;"><b>Year ended December 31, 2023</b></span></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>SEPTEMBER 2023 UNIT OFFERING</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>On September 21, 2023, the Company closed a registered direct offering of <ix:nonFraction id="Fxbrl_20240305223350067" name="us-gaap:CommonUnitIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Shares">1,369,000</ix:nonFraction> units of the Company at a price of $<ix:nonFraction id="Fxbrl_20240305223456191" name="us-gaap:SharesIssuedPricePerShare" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD_Per_Share">2.00</ix:nonFraction> per unit for gross proceeds of $<ix:nonFraction id="Fxbrl_20240305223516630" name="us-gaap:StockIssued1" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD">2.7</ix:nonFraction> million. Each unit is comprised of one common share of the Company and one common share purchase warrant (<ix:nonFraction id="Fxbrl_20240305223536582" name="flgc:NumberOfWarrantsIssuedDuringPeriod" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Shares">1,369,000</ix:nonFraction> total warrants) to purchase one additional common share at an exercise price of $<ix:nonFraction id="Fxbrl_20240305223552680" name="flgc:WarrantsIssuedDuringPeriodExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD_Per_Share">2.50</ix:nonFraction> per warrant share through March 21, 2029. Additionally, the Company amended the exercise price with respect to <ix:nonFraction id="Fxbrl_20240305223619315" name="flgc:NumberOfWarrantsWithAmendedExercisePrice" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="Shares">61,250</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20240305224559262" name="flgc:NumberOfWarrantsWithAmendedExercisePrice" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Shares">624,995</ix:nonFraction> warrants that were previously issued in the November 2021 and December 2022 offerings, respectively, from $<ix:nonFraction id="Fxbrl_20240419113152671" name="flgc:WarrantExercisePricePriorToAmendment" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="USD_Per_Share"><ix:nonFraction id="Fxbrl_20240305223750424" name="flgc:WarrantExercisePricePriorToAmendment" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share">8.00</ix:nonFraction></ix:nonFraction> per share to $<ix:nonFraction id="Fxbrl_20240419113134669" name="flgc:WarrantAmendedExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="USD_Per_Share"><ix:nonFraction id="Fxbrl_20240305223832267" name="flgc:WarrantAmendedExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share">2.50</ix:nonFraction></ix:nonFraction> per share and recorded a $<ix:nonFraction id="Fxbrl_20240306004009208" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD">0.2</ix:nonFraction> million gain on these warrant modifications. There was no increase to the value of the additional paid-in capital as it was offset by a corresponding increase to unit issuance costs. The Company paid $<ix:nonFraction id="Fxbrl_20240305223855849" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD">0.3</ix:nonFraction> million in issuance costs relating to the September 2023 unit offering, as well as <ix:nonFraction id="Fxbrl_20240306005447893" name="flgc:NumberOfWarrantsIssuedDuringPeriod" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Shares">54,760</ix:nonFraction> warrants with a fair value of $<ix:nonFraction id="Fxbrl_20240306005553103" name="flgc:FairValueOfWarrantsIssuedDuringPeriod" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD">0.1</ix:nonFraction> million, with an exercise price of $<ix:nonFraction id="Fxbrl_20240306005624287" name="flgc:WarrantsIssuedDuringPeriodExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD_Per_Share">2.39</ix:nonFraction> per share through September 21, 2028, issued to the placement agent. See Note 17.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>REVERSE STOCK SPLIT</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>
                                            <ix:nonNumeric id="Fxbrl_20240306005828726" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_20230101to20231231">On June 7, 2023, the Company filed an amendment to its Articles of Incorporation (the "Reverse Stock Split Articles Amendment") with the Ontario Ministry of Public and Business Service Delivery to effect a reverse stock split of the Company's common shares, no par value per share (the "common shares"), at a ratio of 1-for-20, which became effective at 12:00:01 a.m. Eastern Time on June 9, 2023 (the "Reverse Stock Split").</ix:nonNumeric>
                                        </span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common shares were automatically combined and reclassified into one issued and outstanding common share. The Reverse Stock Split did not affect any shareholder's ownership percentage of the common shares, alter the par value of the common shares or modify any voting rights or other terms of the common shares. The number of authorized shares of common shares under the Company's Articles remained unchanged. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional interest as a result of the Reverse Stock Split was rounded down to the nearest whole common share.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>All common shares and per share amounts have been restated to give retroactive effect to the share consolidation.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>OTHER ISSUANCES</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>On January 31, 2023, the Company entered into a settlement agreement with a third party pursuant to which the Company issued <ix:nonFraction id="Fxbrl_20240306010115856" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230131" unitRef="Shares">16,250</ix:nonFraction> common shares of the Company, valued at $<ix:nonFraction id="Fxbrl_20240306010257734" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230131" unitRef="USD">0.1</ix:nonFraction> million, to a third party to settle a legal dispute that arose in April 2019. See Note 16.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>On April 12, 2023, Luis Merchan tendered his resignation as both Chairman of the Board of Directors of the Company and as its Chief Executive Officer. On this date, the Company entered into a separation agreement with Mr. Merchan, pursuant to which the Company issued <ix:nonFraction id="Fxbrl_20240306010352038" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230401to20230426" unitRef="Shares">80,000</ix:nonFraction> common shares of the Company, valued at $<ix:nonFraction id="Fxbrl_20240306010502366" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230401to20230426" unitRef="USD">0.4</ix:nonFraction> million, on April 26, 2023, and <ix:nonFraction id="Fxbrl_20240306010548551" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230501to20230514" unitRef="Shares">30,000</ix:nonFraction> common shares of the Company, valued at $<ix:nonFraction id="Fxbrl_20240306010630391" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230501to20230514" unitRef="USD">0.1</ix:nonFraction> million, on May 14, 2023 to Mr. Merchan.</span></span></span></p>
                        </div>
                    </div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><span style="text-decoration: underline;">Year ended December 31, 2022</span></b></span></span></span></span></p>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;">&#160;</p>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>DECEMBER 2022 PAYMENT TO FGH OWNERS</b></span></span></span></span></p>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;">&#160;</p>
                    <div>
                        <div><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>As discussed in Note 10, the Company issued <ix:nonFraction id="F20231019113055934_0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221201to20221223_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFGHOwnersMember" unitRef="Shares">2,176,297</ix:nonFraction> common shares of the Company valued at $<ix:nonFraction id="F20231019113055934_1" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221201to20221223_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFGHOwnersMember" unitRef="USD">9.8</ix:nonFraction> million, inclusive of a <ix:nonFraction id="F20231019113055935_2" name="flgc:FairValueDiscount" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20221201to20221223_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFGHOwnersMember" unitRef="Pure">7.5</ix:nonFraction>% fair value discount for the required three-month holding period of the shares, to the prior owners of FGH as part of the Company's acquisition of FGH on December 23, 2022.</span></span></span></span></div>
                    </div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>DECEMBER 2022 UNIT OFFERING</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 8, 2022, the Company closed a registered direct offering of <ix:nonFraction id="F20231019113055935_3" name="us-gaap:CommonUnitIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Shares">625,000</ix:nonFraction> units of the Company at a price of $<ix:nonFraction id="F20231019113055935_4" name="us-gaap:SharesIssuedPricePerShare" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share">8.00</ix:nonFraction> per unit for gross proceeds of $<ix:nonFraction id="F20231019113055935_5" name="us-gaap:StockIssued1" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD">5.0</ix:nonFraction> million. Each unit is comprised of one common share of the Company and one common share purchase warrant (<ix:nonFraction id="F20231019113055936_6" name="flgc:NumberOfWarrantsIssuedDuringPeriod" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Shares">625,000</ix:nonFraction> total warrants) to purchase one additional common share at an exercise price of $<ix:nonFraction id="F20231019113055936_7" name="flgc:WarrantsIssuedDuringPeriodExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share">8.00</ix:nonFraction> per warrant share through December 8, 2027. Additionally, the Company amended the exercise price with respect to <ix:nonFraction id="F20231019113055936_8" name="flgc:NumberOfWarrantsWithAmendedExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="Shares">66,250</ix:nonFraction> warrants that were previously issued in the November 2021 offering (see Note 17) from $<ix:nonFraction id="F20231019113055936_9" name="flgc:WarrantExercisePricePriorToAmendment" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="USD_Per_Share">75.00</ix:nonFraction> per share to $<ix:nonFraction id="F20231019113055936_10" name="flgc:WarrantAmendedExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="USD_Per_Share">8.00</ix:nonFraction> per share with no increase to the value of additional paid-in capital as it was offset by a corresponding increase to issuance costs. The Company paid $<ix:nonFraction id="F20231019113055937_11" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD">0.4</ix:nonFraction> million in issuance costs relating to the December 2022 unit offering, as well as<ix:nonFraction id="F20231019113055937_12" name="flgc:NumberOfWarrantsIssuedDuringPeriod" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Shares"> 25,000</ix:nonFraction> warrants issued to the placement agent as discussed in Note 17.</span></span></p>
                        </div>
                    </div>
                    <div>
                        <ix:exclude>
                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">160</span></span></span></div>
                            <div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                            </div>
                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                </tr>
                            </table>
                        </ix:exclude>
                    </div>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>FEBRUARY 2022 PAYMENT TO JUSTCBD OWNERS</b></span></span></span></span></p>
                    <div>
                        <p style="margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As discussed in Note 10, the Company issued <ix:nonFraction id="F20231019113055937_13" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220201to20220225_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustCBDOwnersMember" unitRef="Shares">475,000</ix:nonFraction> common shares of the Company valued at $<ix:nonFraction id="F20231019113055937_14" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220201to20220225_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustCBDOwnersMember" unitRef="USD">14.7</ix:nonFraction> million, inclusive of a <ix:nonFraction id="F20231019113055937_15" name="flgc:FairValueDiscount" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220201to20220225_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustCBDOwnersMember" unitRef="Pure">15</ix:nonFraction>% fair value discount for the required six-month holding period of the shares, to the prior owners of JustCBD as part of the Company's acquisition of JustCBD on February 25, 2022.</span></span></p>
                    </div>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>ACQUISITION OF NONCONTROLLING INTERESTS</b></span></span></span></span></span></span></p>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0pt 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">On January 18, 2022, the Company issued <ix:nonFraction id="F20231019113055938_16" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember" unitRef="Shares">5,000</ix:nonFraction> common shares of the Company valued at $<ix:nonFraction id="F20231019113055938_17" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember" unitRef="USD">0.2</ix:nonFraction> million to acquire the remaining <ix:nonFraction id="F20231019113055938_18" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember" unitRef="Pure">13</ix:nonFraction>% of the outstanding equity interests in Flora Beauty LLC from its minority shareholders. In addition to the common shares, the Company granted a stock option, exercisable for up to <ix:nonFraction id="F20231019113055938_19" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember" unitRef="Shares">2,500</ix:nonFraction> common shares of the Company at an exercise price of $<ix:nonFraction id="F20231019113055939_20" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember" unitRef="USD_Per_Share">34.00</ix:nonFraction> per share that expire five years from the date of the grant.&#160;</span></span></span></span>The Company dissolved Flora Beauty LLC during the year ended December 31, 2023. See Note 2.</span></span></p>
                    <div>
                        <p style="margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On January 31, 2022, the Company issued <ix:nonFraction id="F20231019113055939_21" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember" unitRef="Shares">1,514</ix:nonFraction> common shares of the Company valued at $<ix:nonFraction id="F20231019113055939_22" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" decimals="-4" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember" unitRef="USD">0.1 </ix:nonFraction>million to complete its acquisition of Flora Med S.A.S. by acquiring the remaining <ix:nonFraction id="F20231019113055939_23" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember" unitRef="Pure">10</ix:nonFraction>% of the equity interests in Flora Med S.A.S. from its minority shareholders. The Company sold Flora Med S.A.S. during the year ended December 31, 2023. See Note 2.</span></span></p>
                    </div>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>OTHER ISSUANCES</b></span></span></span></span></p>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In January 2022, the Company amended an agreement with a consultant pursuant to which the Company issued <ix:nonFraction id="F20231019113055939_24" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131" unitRef="Shares">5,555</ix:nonFraction> common shares of the Company valued at $<ix:nonFraction id="F20231019113055940_25" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131" unitRef="USD">0.2</ix:nonFraction> million and a stock option, exercisable for up to <ix:nonFraction id="F20231019113055940_26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131" unitRef="Shares">4,166</ix:nonFraction> common shares of the Company at an exercise price of $<ix:nonFraction id="F20231019113055940_27" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20220131" unitRef="USD_Per_Share">45.00</ix:nonFraction> per share that expire five years from the date of the grant.</span></span></p>
                    <div>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 5, 2022, the Company issued <ix:nonFraction id="F20231019113055940_28" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220401to20220405" unitRef="Shares">35,000</ix:nonFraction> common shares of the Company valued at $<ix:nonFraction id="F20231019113055941_29" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220401to20220405" unitRef="USD">1.3</ix:nonFraction> million as part of a settlement agreement with Boustead Securities, LLC ("Boustead") to resolve certain disputes arising under a prior underwriting agreement and engagement letter. In addition to the common shares, the Company paid Boustead $<ix:nonFraction id="F20231019113055941_30" name="us-gaap:PaymentsForLegalSettlements" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220401to20220405" unitRef="USD">0.4</ix:nonFraction> million.</span></span></p>
                    </div>
                    <div>
                        <p style="margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>SHARE REPURCHASE</b></span></span></p>
                        <p style="margin-top: 0pt; margin-bottom: 10pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company repurchased <ix:nonFraction id="F20231019113055943_31" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Shares">18,411</ix:nonFraction> common shares for $<ix:nonFraction id="F20231019113055944_32" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">0.3</ix:nonFraction> million during the year ended December 31, 2022.</span></span></p>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Any future repurchases will depend on factors such as market conditions, share price and other opportunities to invest capital for growth. From time to time when management does not possess material nonpublic information about the Company or its securities, the Company may enter a pre-defined plan with a broker to allow for the repurchase of shares at times when the Company ordinarily would not be active in the market due to internal trading blackout periods, insider trading rules or otherwise. Any such plans entered with our broker will be adopted in accordance with applicable securities laws such as the requirements of Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended. </span></span></p>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113056114_171" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <div>
                        <div>
                            <div>
                                <div>
                                    <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>16.</b></span></span><span style="padding-left: 15pt;">&#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>SHARE BASED COMPENSATION</b></span></span></p>
                                    <div>
                                        <div style="text-align: justify; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company adopted the Flora Growth Corp. 2022 Incentive Compensation Plan (the "2022 Plan") to attract, retain and motivate independent directors, executives, key employees and consultants. The 2022 Plan was approved by the Company's shareholders on July 5, 2022, and reserves an aggregate of <ix:nonFraction id="Fxbrl_20240306001336259" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220705" unitRef="Shares">300,000</ix:nonFraction> of the Company's common shares for issuance in connection with Awards (as defined in the 2022 Plan) granted under the 2022 Plan. The 2022 Plan was amended on June 6, 2023, with approval from the Company's shareholders, to increase the shares available under the 2022 Plan from <ix:nonFraction id="Fxbrl_20240306012000977" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220705" unitRef="Shares">300,000</ix:nonFraction> to <ix:nonFraction id="Fxbrl_20240306012019167" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230606" unitRef="Shares">950,000</ix:nonFraction>. Previously, the Company's shareholders had adopted a "rolling" stock option plan (the "Prior Plan") which authorized the Company to grant stock options constituting up to 10% of the Company's issued and outstanding common shares at the time of each option grant. Since the adoption of the 2022 Plan, no further grants have been made or will be made under the Prior Plan; however, any currently outstanding stock options granted prior to July 5, 2022 will remain in effect until they have been exercised or terminated or have expired in accordance with the terms of the Prior Plan. Under the 2022 Plan, the Compensation Committee of our Board of Directors (the "Committee") may grant a variety of awards including stock options, stock appreciation rights ("SAR"s), restricted stock, restricted stock units, dividend equivalents and other stock-based awards. </span></span></div>
                                    </div>
                                    <div>
                                        <div>
                                            <div>
                                                <div>
                                                    <ix:exclude>
                                                        <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">161</span></span></span></div>
                                                        <div>
                                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                        </div>
                                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                            <tr>
                                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                            </tr>
                                                        </table>
                                                    </ix:exclude>
                                                </div>
                                            </div>
                                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 15, 2023, the Company </span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>proposed to grant, upon approval by a majority of shareholders at the Company&#8217;s next annual meeting,</span></span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"> Clifford Starke, the current CEO of the Company, <ix:nonNumeric id="Fxbrl_20240419144720236" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">SARs valued at 12% of the total outstanding shares of the Company on the grant date, which vest in 12 tranches with each tranche representing 1% of the total outstanding shares of the Company</ix:nonNumeric>. The exercise price of the SARs is the closing share price of the Company's shares on the grant date. <ix:nonNumeric id="Fxbrl_20240306030227390" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">The first tranche will vest upon the Company's share price increasing by 50% from the Company's closing share price on the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest</ix:nonNumeric>. The SARs expire <ix:nonNumeric id="Fxbrl_20240306030322999" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">10 years</ix:nonNumeric> from the grant date with a post-termination exercise period of <ix:nonNumeric id="Fxbrl_20240306030408371" name="flgc:PostTerminationExercisePeriod" format="ixt-sec:durwordsen" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">one year</ix:nonNumeric>. </span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On December 15, 2023, the Company </span></span><span><span>proposed to grant, upon approval by a majority of shareholders at the Company&#8217;s next annual meeting</span>,</span></span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"> Dany Vaiman, the current CFO of the Company, <ix:nonNumeric id="Fxbrl_20240419144747220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">SARs valued at 4% of the total outstanding shares of the Company on the grant date, which vest in 8 tranches with each tranche representing 0.5% of the total outstanding shares of the Company</ix:nonNumeric>. The exercise price of the SARs is the closing share price on the grant date. <ix:nonNumeric id="Fxbrl_20240306030250514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">The first tranche will vest upon the Company's share price increasing by 50% from the closing share price as of the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest</ix:nonNumeric>. The SARs expire <ix:nonNumeric id="Fxbrl_20240306030302917" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">10 years</ix:nonNumeric> from the grant date with a post-termination exercise period of <ix:nonNumeric id="Fxbrl_20240306030421465" name="flgc:PostTerminationExercisePeriod" format="ixt-sec:durwordsen" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">one year</ix:nonNumeric>.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>All </span></span><span>SARs proposed grants to Mr. Starke and Mr. Vaiman remain unexercisable, and subject to forfeiture, unless the Company's shareholders approve such SAR grant at the Company's annual shareholder meeting</span><span><span>.</span></span></span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>OPTIONS</b></span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options granted under the Prior Plan are non-transferable and non-assignable and may be granted for a term not exceeding five years. Under the 2022 Plan, stock options may be granted with a term of up to ten years and in the case of all stock options, the exercise price may not be less than 100% of the fair market value of a Common Share on the date the award is granted. Stock option vesting terms are subject to the discretion of the Committee. Common shares are newly issued from available authorized shares upon exercise of awards.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Information relating to share options outstanding and exercisable as at December 31, 2023 and 2022 is as follows:</span></span></p>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <ix:nonNumeric id="F20231019113055964_1" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" escape="true" contextRef="C_20230101to20231231" continuedAt="F20231016185035480">
                        <div>
                            <div>
                                <div>
                                    <div>
                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="4"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Options Outstanding</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="4"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Options Exercisable</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Number of<br/>options (in<br/>thousands)</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Weighted<br/>average<br/>exercise price</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Number of<br/>options (in<br/>thousands)</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Weighted<br/>average<br/>exercise<br/>price</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Balance, December 31, 2021</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055965_2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">272</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055965_3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">39.06</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055966_4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">272</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055967_5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="USD_Per_Share">39.06</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Granted</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055968_6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">90</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055971_7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">19.15</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055972_8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">1</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055973_9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="USD_Per_Share">29.60</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Exercised</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055973_10" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">27</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055974_11" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">3.00</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="F20231019113055975_12" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">27</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055976_13" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="USD_Per_Share">3.00</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Forfeited</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240306023629637_20231019113055973_10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">45</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240306023629637_20231019113055974_11" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">52.44</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240306023629637_20231019113055975_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">34</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240306023629637_20231019113055976_13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="USD_Per_Share">54.39</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Balance, December 31, 2022</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240306014522236" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">290</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055977_15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">34.17</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113056115_172" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">212</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="F20231019113055978_16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="USD_Per_Share">41.19</ix:nonFraction></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Granted</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055979_17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">5</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055980_18" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">7.00</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113056116_173" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">14</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055980_19" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="USD_Per_Share">17.43</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Forfeited</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="Fxbrl_20240306023720045_xbrl_20240306023629637_20231019113055973_10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">246</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20240306023720045_xbrl_20240306023629637_20231019113055974_11" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">35.05</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(<ix:nonFraction id="Fxbrl_20240306023720045_xbrl_20240306023629637_20231019113055975_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">182</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20240306023720045_xbrl_20240306023629637_20231019113055976_13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="USD_Per_Share">42.31</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Balance, December 31, 2023</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20231025100527496" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">49</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20231025100557051" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">27.04</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113056118_176" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">44</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="F20231019113055988_26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="USD_Per_Share">29.30</ix:nonFraction></b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </ix:nonNumeric>
                    <ix:continuation id="F20231016185035480">
                        <div>
                            <div>
                                <div>
                                    <div>
                                        <div>&#160;
                                            <table style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Options<br/>outstanding </b></span></span></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Options<br/>exercisable</b><b>&#160;</b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Exercise<br/>price</b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 14%; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Grant date fair value<br/>vested </b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Remaining life in<br/>years </b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;" colspan="3"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands of Dollars</b></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113055989_27" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember">June 28, 2024</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055990_28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember" unitRef="Shares">17</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055991_29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember" unitRef="Shares">17</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055992_30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember" unitRef="USD_Per_Share">3.00</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 14%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055992_31" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember" unitRef="USD">13</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113055993_32" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember">0.5</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113055994_33" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember">July 15, 2025</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055995_34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember" unitRef="Shares">4</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055995_35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember" unitRef="Shares">4</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055996_36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember" unitRef="USD_Per_Share">45.00</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113055997_37" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember" unitRef="USD">83</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113055998_38" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember">1.5</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056000_39" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember">December 23, 2025</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056001_40" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember" unitRef="Shares">8</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056001_41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember" unitRef="Shares">8</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056002_42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember" unitRef="USD_Per_Share">45.00</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056003_43" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember" unitRef="USD">230</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056004_44" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember">2.0</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056005_45" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember">September 25, 2026</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056005_46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember" unitRef="Shares">2</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056006_47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember" unitRef="Shares">2</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056007_48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember" unitRef="USD_Per_Share">138.00</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056008_49" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember" unitRef="USD">205</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056008_50" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember">2.7</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056009_51" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember">December 16, 2026</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056010_52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember" unitRef="Shares">6</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056011_53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember" unitRef="Shares">6</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056012_54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember" unitRef="USD_Per_Share">40.80</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056014_55" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember" unitRef="USD">185</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056015_56" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember">3.0</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056016_57" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember">January 17, 2027</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056016_58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember" unitRef="Shares">3</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056017_59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember" unitRef="Shares">3</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056018_60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember" unitRef="USD_Per_Share">34.00</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056019_61" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember" unitRef="USD">63</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056019_62" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember">3.0</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056020_63" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember">January 26, 2027</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056021_64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember" unitRef="Shares">1</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056022_65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember" unitRef="Shares">1</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056022_66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember" unitRef="USD_Per_Share">29.60</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056023_67" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember" unitRef="USD">25</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056024_68" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember">3.1</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056025_69" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember">March 17, 2033</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056026_70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember" unitRef="Shares">5</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056028_71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember" unitRef="Shares">-</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056029_72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember" unitRef="USD_Per_Share">7.00</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056029_73" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember" unitRef="USD">26</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056030_74" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember">9.2</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056031_75" name="flgc:StockOptionDateOfExpiry" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember">July 5, 2033</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056032_76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember" unitRef="Shares">3</ix:nonFraction></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056033_77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember" unitRef="Shares">3</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056033_78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember" unitRef="USD_Per_Share">13.40</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056034_79" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember" unitRef="USD">31</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056035_80" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember">9.5</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231025100650842" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">49</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056078_131" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember" unitRef="Shares">44</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231025100717635" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">27.04</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 14%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056079_132" name="flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD">861</ix:nonFraction></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                <ix:nonNumeric id="F20231019113056080_133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">2.8</ix:nonNumeric>
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                            </table>
                                            <p style="margin: 0pt;">&#160;</p>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </ix:continuation>
                    <div>
                        <ix:exclude>
                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">162</span></span></span></div>
                            <div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                            </div>
                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                </tr>
                            </table>
                        </ix:exclude>
                    </div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of stock options issued during the years ended December 31, 2023 and 2022 was determined at the time of issuance using the Black-Scholes option pricing model with the following weighted average inputs, assumptions and results:</span></span></p>
                            <ix:nonNumeric id="F20231019113056081_134" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <div>
                                    <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2022</span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Risk-free annual interest rate</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056083_135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Pure">2.77</ix:nonFraction>%</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056084_136" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Pure">2.85</ix:nonFraction>%</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current stock price</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056085_137" name="us-gaap:SharePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">6.90</ix:nonFraction></b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056086_138" name="us-gaap:SharePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">18.95</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected annualized volatility</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056087_139" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Pure">100</ix:nonFraction>%</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056087_140" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Pure">100</ix:nonFraction>%</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected life (years)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                            <ix:nonNumeric id="F20231019113056088_141" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">10</ix:nonNumeric>
                                                        </b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                        <ix:nonNumeric id="F20231019113056089_142" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">7</ix:nonNumeric>
                                                    </span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected annual dividend yield</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056090_143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Pure">0</ix:nonFraction>%</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056090_144" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Pure">0</ix:nonFraction>%</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercise price</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240306122516749" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">7.00</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056092_146" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">19.16</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted average grant date fair value</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056093_147" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">7.00</ix:nonFraction></b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056094_148" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD_Per_Share">19.16</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total benefit related to the options granted in the year ended December 31, 2023 was less than $<ix:nonFraction id="F20231019113056094_149" name="us-gaap:StockOptionPlanExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">0.1</ix:nonFraction> million (2022 - $<ix:nonFraction id="F20231019113056095_150" name="us-gaap:StockOptionPlanExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">3.0</ix:nonFraction> million expense). This (benefit) expense is included in the share based compensation line on the statement of comprehensive loss. Generally, the options granted in 2023 and 2022 vest one to two years following the date of grant provided that the recipient is still employed or engaged by the Company.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the year ended December 31, 2023, <ix:nonFraction id="F20231019113056097_151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Shares">245,959</ix:nonFraction> (2022 - <ix:nonFraction id="Fxbrl_20231025101311550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Shares">45,187</ix:nonFraction>) unexercised stock options expired following the termination of certain employees and were charged to deficit.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The intrinsic value of options exercised for the year ended December 31, 2023 was $<ix:nonFraction id="F20231019113056098_152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231" unitRef="USD">nil</ix:nonFraction> ($<ix:nonFraction id="F20231019113056099_153" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">0.8</ix:nonFraction> million in 2022). The total fair value of options vested during the year ended December 31, 2023 was $<ix:nonFraction id="F20231019113056100_154" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">0.1</ix:nonFraction> million ($<ix:nonFraction id="F20231019113056101_155" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">4.0</ix:nonFraction> million in 2022).</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For the years ended December 31, 2023 and 2022, there has been no recognized income tax benefits associated with stock options, and no amounts capitalized as part of the cost of an asset.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At December 31, 2023 the total remaining stock option cost for nonvested awards is expected to be less than $<ix:nonFraction id="F20231019113056101_156" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">0.1</ix:nonFraction> million over a weighted average future period of<ix:nonNumeric id="F20231019113056102_157" name="flgc:RemainingWeightedAverageVestingPeriod" format="ixt-sec:duryear" contextRef="C_20230101to20231231"> 0.2</ix:nonNumeric> years until the awards vest. A total of <ix:nonFraction id="F20231019113056103_158" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="Shares">5,000</ix:nonFraction> options issued in 2023 will vest in 2024 provided if the award holder is still employed or engaged by the Company.</span></span></p>
                        </div>
                    </div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"><b>RESTRICTED STOCK AWARDS</b></p>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 10pt 0px; text-align: justify;">Restricted stock is a grant of common shares which may not be sold or disposed of, and which is subject to such risks of forfeiture and other restrictions as the Committee, in its discretion, may impose. A participant granted restricted stock generally has all of the rights of a shareholder of the Company, unless otherwise determined by the Committee. Subject to certain exceptions, the vesting of restricted stock awards is subject to the holder&#8217;s continued employment or engagement through the applicable vesting date. Unvested restricted stock awards will be forfeited if the holder&#8217;s employment or engagement ceases during the vesting period and may, in certain circumstances, be accelerated. The Company values restricted stock awards based on the closing share price of the Company&#8217;s common shares as of the date of grant. The fair value of the restricted stock award is recorded as expense over the vesting period.</p>
                    <div>
                        <ix:exclude>
                            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">163</span></span></span></div>
                            <div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                            </div>
                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                </tr>
                            </table>
                        </ix:exclude>
                    </div>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;">Information relating to restricted stock awards outstanding as at December 31, 2023 and December 31, 2022:</p>
                    <ix:nonNumeric id="F20231019113056104_160" name="flgc:ScheduleOfRestrictedStockAwards" escape="true" contextRef="C_20230101to20231231">
                        <div>
                            <div>
                                <div>
                                    <div>
                                        <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Number of<br/>restricted stock<br/>awards</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Weighted<br/>average grant<br/>date fair value</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Thousands</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2021</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056105_161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20211231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056106_162" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20211231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD_Per_Share">-</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Granted</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056107_163" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">147</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056107_164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD_Per_Share">13.64</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056108_165" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">1</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056109_166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD_Per_Share">14.62</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2022</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306020138262_20231019113056105_161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">146</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306020138262_20231019113056106_162" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD_Per_Share">13.64</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Granted</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306020147605_20231019113056107_163" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">838</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306020147605_20231019113056107_164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD_Per_Share">1.44</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240306020152741_20231019113056108_165" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">174</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240306020152741_20231019113056109_166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD_Per_Share">8.92</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240306122630213_xbrl_20240306020152741_20231019113056108_165" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">419</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240306122630213_xbrl_20240306020152741_20231019113056109_166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD_Per_Share">2.66</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2023</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306020140477_20231019113056105_161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">391</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306020140477_20231019113056106_162" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD_Per_Share">1.41</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </ix:nonNumeric>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total expense related to the restricted stock awards in the year ended December 31, 2023 was $<ix:nonFraction id="F20231019113056111_167" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD">1.1</ix:nonFraction> million (2022 - $<ix:nonFraction id="Fxbrl_20231025103311462" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD">0.4</ix:nonFraction> million). This expense is included in the share based compensation line on the consolidated statements of loss and comprehensive loss. For the years ended December 31, 2023 and 2022, there has been no recognized income tax benefits associated with restricted stock awards.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company issued <ix:nonFraction id="F20231019113056112_168" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231101to20231115_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">363,617</ix:nonFraction> restricted stock awards that vested immediately on November 15, 2023 at a total fair value of $<ix:nonFraction id="F20231019113056112_169" name="flgc:FairValueOfRestrictedStockAwardsIssued" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231101to20231115_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD">0.3</ix:nonFraction> million. The Company issued <ix:nonFraction id="Fxbrl_20240306022535429" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220901to20220928_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">1,000</ix:nonFraction> restricted stock awards that vested immediately on September 28, 2022 at a total fair value of less than $<ix:nonFraction id="Fxbrl_20240306022605807" name="flgc:FairValueOfRestrictedStockAwardsIssued" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220901to20220928_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD">0.1</ix:nonFraction> million. The remaining restricted stock awards issued in 2023 and 2022 vest over the next three years provided the award holder is still employed or engaged by the Company. As of December 31, 2023, the Company had $<ix:nonFraction id="F20231019113056113_170" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD">0.1</ix:nonFraction> million of unrecognized compensation expense related to restricted stock awards which will be recognized over the next three years.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A total of <ix:nonFraction id="Fxbrl_20240306023906700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">174,304</ix:nonFraction> restricted stock awards expired or were forfeited in the year ended December 31, 2023 (2022 - $<ix:nonFraction id="Fxbrl_20240306023917167" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" decimals="INF" format="ixt-sec:numwordsen" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">nil</ix:nonFraction>).</span></span></p>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113056133_0" name="flgc:WarrantsDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>17.<span style="display: inline-block; width: 15pt;">&#160;</span>WARRANTS</b></span></span></p>
                    </div>
                </div>
                <div>
                    <div>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On September 21, 2023, the Company issued <ix:nonFraction id="F20231019113056133_1" name="flgc:NumberOfWarrantsIssuedDuringPeriod" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Shares">1,369,000</ix:nonFraction> warrants issued as part of the September 2023 unit offering (Note 15). Each warrant permits the holder to purchase one common share of the Company through March 21, 2029 for $<ix:nonFraction id="Fxbrl_20231023113822705" name="flgc:WarrantsIssuedDuringPeriodExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD_Per_Share">2.50</ix:nonFraction>. The issue date fair value of the warrants was estimated at $<ix:nonFraction id="F20231019113056133_2" name="flgc:FairValueOfWarrantsIssuedDuringPeriod" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD">1.1</ix:nonFraction> million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of <ix:nonFraction id="F20231019113056133_3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Pure">0</ix:nonFraction>%; expected volatility of <ix:nonFraction id="F20231019113056133_4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Pure">100</ix:nonFraction>% based on comparable companies; risk-free interest rate of <ix:nonFraction id="F20231019113056134_5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Pure">4.3</ix:nonFraction>% and an expected life of <ix:nonNumeric id="F20231019113056134_6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember">5.5</ix:nonNumeric> years. The resulting grant date fair value of each warrant was $<ix:nonFraction id="F20231019113056134_7" name="flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD_Per_Share">0.82</ix:nonFraction>. Additionally, the Company amended the exercise price with respect to <ix:nonFraction id="Fxbrl_20231023114819976" name="flgc:NumberOfWarrantsWithExercisePriceAmended" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="Shares">66,245</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20240305173409286" name="flgc:NumberOfWarrantsWithExercisePriceAmended" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Shares">624,995</ix:nonFraction> warrants that (Note 15) that were previously issued in the November 2021 and December 2022 (described below) offerings, respectively, from $<ix:nonFraction id="Fxbrl_20240422110210583" name="flgc:WarrantExercisePricePriorToAmendment" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share"><ix:nonFraction id="Fxbrl_20231023114909403" name="flgc:WarrantExercisePricePriorToAmendment" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="USD_Per_Share">8.00</ix:nonFraction></ix:nonFraction> per share to $<ix:nonFraction id="Fxbrl_20240422110217028" name="flgc:WarrantAmendedExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share"><ix:nonFraction id="Fxbrl_20231023115327739" name="flgc:WarrantAmendedExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="USD_Per_Share">2.50</ix:nonFraction></ix:nonFraction> per share and recorded at $<ix:nonFraction id="Fxbrl_20240306151543863" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD">0.2</ix:nonFraction> million gain on these warrant modifications.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Related to the September 2023 unit offering, <ix:nonFraction id="F20231019113056134_8" name="flgc:NumberOfWarrantsIssuedDuringPeriod" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Shares">54,760</ix:nonFraction> warrants were issued to the placement agent and recorded as issuance costs to share capital. Each warrant permits the holder to purchase one common share of the Company after the 181st day immediately following the date of issuance through September 21, 2028 for $<ix:nonFraction id="Fxbrl_20231023114142001" name="flgc:WarrantsIssuedDuringPeriodExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD_Per_Share">2.39</ix:nonFraction>. The issue date fair value of the warrants was estimated at $<ix:nonFraction id="F20231019113056134_9" name="flgc:FairValueOfWarrantsIssuedDuringPeriod" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD">0.1</ix:nonFraction> million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of <ix:nonFraction id="F20231019113056134_10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Pure">0</ix:nonFraction>%; expected volatility of <ix:nonFraction id="F20231019113056135_11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Pure">100</ix:nonFraction>% based on comparable companies; risk-free interest rate of <ix:nonFraction id="F20231019113056135_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="Pure">4.25</ix:nonFraction>% and an expected life of <ix:nonNumeric id="F20231019113056135_13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember">5</ix:nonNumeric> years. The resulting grant date fair value of each warrant was $<ix:nonFraction id="F20231019113056135_14" name="flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember" unitRef="USD_Per_Share">1.48</ix:nonFraction>.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 8, 2022, the Company issued <ix:nonFraction id="Fxbrl_20240305172406322" name="flgc:NumberOfWarrantsIssuedDuringPeriod" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Shares">625,000</ix:nonFraction> warrants issued as part of the December 2022 unit offering (Note 15). Each warrant permits the holder to purchase one common share of the Company through December 8, 2027 for $<ix:nonFraction id="Fxbrl_20240305180159495" name="flgc:WarrantsIssuedDuringPeriodExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share">8.00</ix:nonFraction>. The issue date fair value of the warrants was estimated at $<ix:nonFraction id="Fxbrl_20240305180117817" name="flgc:FairValueOfWarrantsIssuedDuringPeriod" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD">2.0</ix:nonFraction> million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of <ix:nonFraction id="Fxbrl_20240305172439752" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Pure">0</ix:nonFraction>%; expected volatility of <ix:nonFraction id="Fxbrl_20240422111340315" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Pure">100</ix:nonFraction>%&#160;based on comparable companies; risk-free interest rate of <ix:nonFraction id="Fxbrl_20240305172456216" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Pure">3.0</ix:nonFraction>% and an expected life of <ix:nonNumeric id="Fxbrl_20240305172501272" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">5</ix:nonNumeric> years. The resulting grant date fair value of each warrant was $<ix:nonFraction id="Fxbrl_20240305172515369" name="flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share">3.25</ix:nonFraction>. Additionally, the Company amended the exercise price with respect to <ix:nonFraction id="Fxbrl_20240306151759032" name="flgc:NumberOfWarrantsWithExercisePriceAmended" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="Shares">66,250</ix:nonFraction> warrants (Note 15) that were previously issued in the November 2021 offering from $<ix:nonFraction id="Fxbrl_20240306151903741" name="flgc:WarrantExercisePricePriorToAmendment" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="USD_Per_Share">75.00</ix:nonFraction> per share to $<ix:nonFraction id="Fxbrl_20240306151926888" name="flgc:WarrantAmendedExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember" unitRef="USD_Per_Share">8.00</ix:nonFraction> per share.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">164</span></span></span></div>
                                <div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                </div>
                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                    </tr>
                                </table>
                            </ix:exclude>
                        </div>
                        <p style="margin: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Related to the December 2022 unit offering, <ix:nonFraction id="F20231019113056140_28" name="flgc:NumberOfWarrantsIssuedDuringPeriod" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Shares">25,000</ix:nonFraction> warrants were issued to the placement agent and recorded as issuance costs to share capital. Each warrant permits the holder to purchase one common share of the Company after the 180th day immediately following the date of issuance through December 8, 2027 for $<ix:nonFraction id="Fxbrl_20231023114308139" name="flgc:WarrantsIssuedDuringPeriodExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share">8.00</ix:nonFraction>. The issue date fair value of the warrants was estimated at $<ix:nonFraction id="F20231019113056140_29" name="flgc:FairValueOfWarrantsIssuedDuringPeriod" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD">0.1</ix:nonFraction> million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of <ix:nonFraction id="Fxbrl_20240305180257132" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Pure">0</ix:nonFraction>%; expected volatility of <ix:nonFraction id="F20231019113056141_31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Pure">100</ix:nonFraction>% based on comparable companies; risk-free interest rate of <ix:nonFraction id="F20231019113056141_32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="Pure">3.0</ix:nonFraction>% and an expected life of <ix:nonNumeric id="F20231019113056141_33" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">5</ix:nonNumeric> years. The resulting grant date fair value of each warrant was $<ix:nonFraction id="F20231019113056141_34" name="flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember" unitRef="USD_Per_Share">5.95</ix:nonFraction>.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The intrinsic value of warrants exercised for the year ended December 31, 2023 was less than $<ix:nonFraction id="F20231019113056141_35" name="flgc:IntrinsicValueOfWarrantsExercised" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">0.1</ix:nonFraction> million ($<ix:nonFraction id="F20231019113056142_36" name="flgc:IntrinsicValueOfWarrantsExercised" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">0.5</ix:nonFraction> million in 2022). The total fair value of warrants vested during the year ended December 31, 2023 was $<ix:nonFraction id="F20231019113056142_37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1.3</ix:nonFraction> million ($<ix:nonFraction id="F20231019113056142_38" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">2.3</ix:nonFraction> million in 2022).</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For all warrants, common shares are newly issued from available authorized shares upon exercise of awards.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>The following tables show warrants outstanding as at December 31, 2023:</b></span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240305171328631" name="flgc:ScheduleOfWarrantsOutstandingTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                            <table style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;" colspan="2">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Number of warrants</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Weighted average<br/>exercise price</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2021</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056144_47" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">438</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056144_48" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20211231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">67.46</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercised</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056142_41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">24</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056143_42" name="flgc:WeightedAverageExercisePriceOfWarrantsExercised" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">9.83</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056143_43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">103</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056143_44" name="flgc:WeightedAverageExercisePriceOfWarrantsCancelled" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">60.00</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056143_45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">650</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056143_46" name="flgc:WeightedAverageExercisePriceOfWarrantsIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">1.20</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2022</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20231023115931713" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">961</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20231023115944690" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">24.84</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercised</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056144_49" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">1</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056144_50" name="flgc:WeightedAverageExercisePriceOfWarrantsExercised" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">8.00</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056144_51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">691</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056144_52" name="flgc:WeightedAverageExercisePriceOfWarrantsCancelled" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">8.00</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056145_53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">2,115</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056145_54" name="flgc:WeightedAverageExercisePriceOfWarrantsIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">2.50</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305174120553_xbrl_20231023115931713" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">2,384</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305174120553_xbrl_20231023115944690" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="USD_Per_Share">9.90</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span>
                        <ix:nonNumeric id="Fxbrl_20240305171316951" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true" contextRef="C_20230101to20231231">
                            <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Warrants<br/>outstanding</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Exercise<br/>price</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Grant date fair<br/>value</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Remaining life<br/>in years</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113056145_55" name="flgc:WarrantsDateOfExpiry" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">November 18, 2026</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056145_56" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember" unitRef="Shares">221</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056145_57" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember" unitRef="USD_Per_Share">75.00</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056146_58" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember" unitRef="USD">6,700</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113056146_59" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">2.88</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113056146_60" name="flgc:WarrantsDateOfExpiry" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">November 18, 2027</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056146_61" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember" unitRef="Shares">23</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056146_62" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember" unitRef="USD_Per_Share">66.00</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056146_63" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember" unitRef="USD">1,055</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113056147_64" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">3.88</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113056147_65" name="flgc:WarrantsDateOfExpiry" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">December 8, 2027</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056148_71" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember" unitRef="Shares">25</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056148_72" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember" unitRef="USD_Per_Share">8.80</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056148_73" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember" unitRef="USD">149</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113056148_74" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">3.94</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240305174716627" name="flgc:WarrantsDateOfExpiry" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">September 21, 2028</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174700169_20231019113056148_71" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember" unitRef="Shares">691</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174700169_20231019113056148_72" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember" unitRef="USD_Per_Share">2.50</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174700169_20231019113056148_73" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember" unitRef="USD">522</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240305174700169_20231019113056148_74" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">4.73</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240305174720418" name="flgc:WarrantsDateOfExpiry" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">September 21, 2028</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174826721_xbrl_20240305174700169_20231019113056148_71" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember" unitRef="Shares">55</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174826721_xbrl_20240305174700169_20231019113056148_72" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember" unitRef="USD_Per_Share">2.39</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174826721_xbrl_20240305174700169_20231019113056148_73" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember" unitRef="USD">81</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240305174826721_xbrl_20240305174700169_20231019113056148_74" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">4.73</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240305174724122" name="flgc:WarrantsDateOfExpiry" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">March 21, 2029</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174829001_xbrl_20240305174700169_20231019113056148_71" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember" unitRef="Shares">1,369</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174829001_xbrl_20240305174700169_20231019113056148_72" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember" unitRef="USD_Per_Share">2.50</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305174829001_xbrl_20240305174700169_20231019113056148_73" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember" unitRef="USD">1,339</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240305174829001_xbrl_20240305174700169_20231019113056148_74" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">5.22</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231023120018738" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember" unitRef="Shares">2,384</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231023120032650" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember" unitRef="USD_Per_Share">9.90</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056149_80" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember" unitRef="USD">9,846</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20231019113056150_81" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">4.83</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113056156_13" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>18.<span style="display: inline-block; width: 15pt;">&#160;</span>RELATED PARTY DISCLOSURES</b></span></span></p>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Key management personnel compensation</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In addition to their contracted fees, directors and officers also participate in the Company's stock option program. Certain executive officers are subject to termination notices of 6 to 24 months and change of control payments (Note 19). Key management personnel compensation is comprised of the following:</span></span></p>
                            <div>
                                <div>
                                    <ix:exclude>
                                        <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">165</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                            </tr>
                                        </table>
                                    </ix:exclude>
                                </div>
                            </div>
                            <ix:nonNumeric id="Fxbrl_20240305123314560" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <div>
                                    <table style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; width: 1px; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Year ended<br/>December 31, 2022</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Directors' and officers' compensation</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056156_0" name="us-gaap:OfficersCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,862</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056156_1" name="us-gaap:OfficersCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">2,560</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share-based compensation</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056156_2" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">1,577</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056156_3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">797</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 426.4px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056156_4" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">3,439</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056156_5" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">3,357</ix:nonFraction></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:nonNumeric>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company defines key management personnel as those persons having authority and responsibility for planning, directing, and controlling the activities of the Company directly or indirectly, and was determined to be executive officers and directors (executive and non-executive) of the Company. The remuneration of directors and key executives is determined by the Board of Directors of the Company having regard to the performance of individuals and market trends.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023, $<ix:nonFraction id="Fxbrl_20240306055613042" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember" unitRef="USD">0.1</ix:nonFraction> million of the above directors' and officers' compensation was included in the trade payables and accrued liabilities (2022 - $<ix:nonFraction id="F20231019113056156_7" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember" unitRef="USD">0.2</ix:nonFraction> million). These amounts are unsecured, non-interest bearing and due on demand. The share-based compensation amount above for 2023 includes <ix:nonFraction id="F20231019113056156_8" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember" unitRef="Shares">110,000</ix:nonFraction> common shares to the former Chief Executive Officer of the Company, valued at $<ix:nonFraction id="F20231019113056156_9" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember" unitRef="USD">0.4</ix:nonFraction> million, that were recorded as share based compensation expense as part of a separation agreement.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Related party transactions</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to its acquisition by the Company, Harmony Health One, a subsidiary of FGH, entered into an Intellectual Property License Agreement with Hampstead Private Capital Limited ("Hampstead") - a corporation controlled by the CEO of the Company and former CEO of FGH. Under the terms of this agreement, Harmony is to pay Hampstead a royalty in the amount of <ix:nonFraction id="F20231019113056156_10" name="flgc:RoyaltyOnGrossRevenuesFromSaleOfProducts" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcHampsteadPrivateCapitalLimitedMember" unitRef="Pure">3.5</ix:nonFraction>% of the gross revenues from the sale of Harmony products. No royalty amounts have been recorded by the Company for the years ended December 31, 2023 and December 31, 2022, as there were no sales for the period after the Company acquired FGH.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to 2022, the Company entered into an agreement with Dr. Manalo-Morgan, a former member of the Company's board of directors, to serve in the additional capacity as Medical Advisor to the Company. In connection with this agreement, Dr. Manalo-Morgan was responsible for developing and identifying medical applications of cannabinoids for the Company for the treatment of various ailments and supporting the Company's public relations efforts and assisting the Company with its media engagements. For these services, the Company paid Dr. Manalo-Morgan $<ix:nonFraction id="F20231019113056156_11" name="flgc:MedicalServices" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcDrManaloMorganMember" unitRef="USD">0.1</ix:nonFraction> million and $<ix:nonFraction id="F20231019113056156_12" name="flgc:MedicalServices" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcDrManaloMorganMember" unitRef="USD">0.2</ix:nonFraction> million for the years ended December 31, 2023 and December 31, 2022, respectively. </span></span></p>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113056165_33" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>19.<span style="display: inline-block; width: 15pt;">&#160;</span>COMMITMENTS AND CONTINGENCIES</b></span></span></p>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An indemnification arrangement exists when one party has contractually agreed to reimburse another party for losses incurred because of circumstances that existed prior to the arrangement. The Company and its legal counsel assess whether a legal agreement exists and the maximum potential loss to be reimbursed.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's current known provisions and contingent liabilities consist of termination benefits and legal disputes.</span></span></p>
                            <ix:nonNumeric id="Fxbrl_20240305140243803" name="us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <table style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Termination benefits</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Legal disputes</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sales tax</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2022</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056160_0" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember" unitRef="USD">183</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056161_1" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">3,030</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056161_2" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">1,831</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056161_3" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">5,044</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Payments/settlements</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056162_8" name="us-gaap:LossContingencyAccrualPayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember" unitRef="USD">183</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056162_9" name="us-gaap:LossContingencyAccrualPayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">98</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056162_10" name="us-gaap:LossContingencyAccrualPayments" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056162_11" name="us-gaap:LossContingencyAccrualPayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">281</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Additional provisions</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056162_12" name="us-gaap:LossContingencyAccrualProvision" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231023111001690" name="us-gaap:LossContingencyAccrualProvision" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">8</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056163_13" name="us-gaap:LossContingencyAccrualProvision" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">707</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056163_14" name="us-gaap:LossContingencyAccrualProvision" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">715</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign currency translation</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305141410684_20231019113056162_12" name="flgc:LossContingencyAccrualForeignCurrencyTranslation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305141410684_xbrl_20231023111001690" name="flgc:LossContingencyAccrualForeignCurrencyTranslation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">22</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305141410684_20231019113056163_13" name="flgc:LossContingencyAccrualForeignCurrencyTranslation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305141410684_20231019113056163_14" name="flgc:LossContingencyAccrualForeignCurrencyTranslation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">22</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2023</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056163_15" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056163_16" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">2,962</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056163_17" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">2,538</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056163_18" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">5,500</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </ix:nonNumeric>
                            <p style="margin: 0pt;">&#160;</p>
                            <div>
                                <ix:exclude>
                                    <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">166</span></span></span></div>
                                    <div>
                                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                    </div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                        </tr>
                                    </table>
                                </ix:exclude>
                            </div>
                            <p style="margin: 0pt 0pt 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The termination benefits related to contractual termination benefits owed to a former board member of the Company, a consultant and a former member of the management team. The amounts were recorded within contingencies on the consolidated statements of financial position and $<ix:nonFraction id="F20231019113056165_38" name="us-gaap:SeveranceCosts1" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231" unitRef="USD">nil</ix:nonFraction> expense (2022 - $<ix:nonFraction id="F20231019113056163_19" name="us-gaap:SeveranceCosts1" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">0.4</ix:nonFraction> million) on the consolidated statements of loss and comprehensive loss.</span></span></p>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The legal disputes from 2022 relate to the settlement of two contractual disputes involving the Company. The first involves a third party that entered into a conditional share grant arrangement dated April 2, 2019 with Franchise Cannabis Corp and Rangers Pharmaceuticals A/S - two entities that were part of the Company's acquisition of FGH in December 2022. In January 2023, the Company entered into a settlement agreement with this third party pursuant to which the Company issued <ix:nonFraction id="F20231019113056164_23" name="us-gaap:StockIssuedDuringPeriodSharesOther" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20230131_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="Shares">16,250</ix:nonFraction> common shares of the Company, valued at $<ix:nonFraction id="F20231019113056164_24" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230131_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">0.1</ix:nonFraction> million, to the third party to settle the dispute. The provision balance as of December 31, 2022 reflected the value of the Company's shares as of the date of the settlement agreement. The second dispute involves a former shareholder of ACA Mueller, an entity that was part of the Company's acquisition of FGH in December 2022, who filed a statement of claim against a wholly-owned subsidiary of the Company in the Constance Regional Court in Germany. While the Company believes that this claim is without merit, at this time the Company believes it is probable that a liability has been incurred and the Company is able to reasonably estimate the loss of $<ix:nonFraction id="F20231019113056165_39" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">3.0</ix:nonFraction> million. As a result, without acknowledgement (explicitly or implicitly) of any amount of liability arising from this claim, the Company recognized a provision of $<ix:nonFraction id="F20231019113056165_35" name="us-gaap:LossContingencyAccrualProvision" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">3.0</ix:nonFraction> million to reflect the value of the claim. This dispute is covered under the indemnification agreement between the Company and the former Chief Executive Officer and shareholder of FGH as discussed in Note 10. The Company intends to vigorously defend itself through appropriate legal proceedings. Both of the above amounts are recorded within contingencies and $<ix:nonFraction id="F20231019113056165_36" name="flgc:IndemnificationReceivables" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">3.0</ix:nonFraction> million within indemnification receivables on the consolidated statements of financial position and $<ix:nonFraction id="Fxbrl_20240305145055134" name="us-gaap:LossContingencyLossInPeriod" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">nil</ix:nonFraction> (2022- $<ix:nonFraction id="F20231019113056164_25" name="us-gaap:LossContingencyLossInPeriod" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">0.1</ix:nonFraction> million) is recorded as expense on the consolidated statements of loss and comprehensive loss.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The additional legal dispute in 2023 related to the settlement of an action brought against the Company in the Ontario Superior Court of Justice by Gerardo Andres Garcia Mendez claiming that the Company was obligated to issue <ix:nonFraction id="F20231019113056164_26" name="flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember" unitRef="Shares">3,000,000</ix:nonFraction> common shares (pre-splits) to him for a purchase price of $<ix:nonFraction id="F20231019113056164_27" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember" unitRef="USD_Per_Share">0.05</ix:nonFraction> per share as a result of alleged consulting services he performed in 2019. <ix:nonNumeric id="Fxbrl_20240305161356715" name="us-gaap:LossContingencyTrialOrAlternativeDisputeResolution" contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute.</ix:nonNumeric> The payment was made in January 2023. The amount is recorded within contingencies on the consolidated statements of financial position and expense on the consolidated statements of loss and comprehensive loss.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Sales tax relates to estimated amounts owed to certain jurisdictions in the Unites States for sales from the Company's JustCBD operations. The opening balance was acquired during the February 24, 2022 acquisition of JustCBD, with additional provision for estimated amounts due on sales subsequent to the acquisition. The ending balance is recorded within contingencies on the consolidated statement of financial position, and additions to the provision as a reduction of revenue on the consolidated statements of loss and comprehensive loss.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For the sales tax provision and 2023 matters with accruals recorded as discussed above, it is at least reasonably possible that a change in the estimated liability could occur in the near term. Such changes in the Company's judgment could continue to change until the matters are ultimately resolved.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Legal proceedings</b></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company records liabilities for legal proceedings in those instances where it can reasonably estimate the amount of the loss and where liability is probable. The Company is engaged from time-to-time in various legal proceedings and claims that have arisen in the ordinary course of business. The outcome of all the proceedings and claims against the Company is subject to future resolution, including the uncertainties of litigation. Based on information currently known to the Company and after consultation with outside legal counsel, management believes that the probable ultimate resolution of any such proceedings and claims, individually or in the aggregate, will not have a material adverse effect on the financial condition of the Company, taken as a whole as at December 31, 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On November 1, 2023, Just Brands filed an Emergency Complaint for Declaratory Judgment and Injunctive Relief in the Southern District of Florida against the Florida Department of Agriculture and Consumer Services (the "Department") stemming from Stop Sale Orders issued by the Department whereby the Department prohibited Just Brands from selling and moving most of its products. Relying on Florida Statute Section 581.217, which includes the definition of "attractive to children," the Department determined Just Brand's product could not be sold or moved because the products were manufactured in the shape of humans, cartoons, or animals; in a form that bears a reasonable resemblance to an existing candy product; and containing color additives. The Court ruled in favor of the Department and that Order is being appealed to the Eleventh Circuit Court of Appeals. Since then, the Department has initiated an Administrative Action claiming Just Brands moved product outside the State of Florida in violation of the Stop Sale Orders. The statute provides for a penalty of up to $<ix:nonFraction id="Fxbrl_20240305145238109" name="flgc:AmountsPayablePerViolationOfStopSaleOrders" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231101" unitRef="USD">5,000</ix:nonFraction> per violation. The Department seeks to assess penalties on what they claim to be a total of <ix:nonFraction id="Fxbrl_20240422132400816" name="flgc:NumberOfViolationsInStopSaleOrders" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231101" unitRef="Pure">215,154</ix:nonFraction> violations (one for each package). The Company disputes their claim and intends to vigorously defend against this action. The Company believes that it is too early in the proceedings to determine an outcome, and, as such, has not accrued a liability as of December 31, 2023. </span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="color: black;">The total value of inventory impacted by the stop sale orders was</span><span><span>&#160;$<ix:nonFraction id="Fxbrl_20240305145430019" name="flgc:InventoryImpactedByStopSaleOrders" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1.6</ix:nonFraction>&#160;million </span></span><span style="color: black;">at December 31, 2023</span><span><span>.</span></span></span></span></p>
                            <div>
                                <ix:exclude>
                                    <div>
                                        <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">167</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:exclude>
                            </div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On May 31, 2023, Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres brought an action against the Company claiming that the Company is obligated to issue <ix:nonFraction id="Fxbrl_20240305142824112" name="flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" unitRef="Shares">500,000</ix:nonFraction> common shares (pre-splits) each for a purchase price of $<ix:nonFraction id="Fxbrl_20240305142851560" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" unitRef="USD_Per_Share">0.05</ix:nonFraction> per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of December 31, 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On May 31, 2023, Ramon Ricardo Castellanos Saenz and Miriam Ortiz brought an action against the Company claiming that the Company is obligated to issue <ix:nonFraction id="Fxbrl_20240305160420847" name="flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember" unitRef="Shares">1,500,000</ix:nonFraction> common shares (pre-splits) each for a purchase price of $<ix:nonFraction id="Fxbrl_20240305160428164" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember" unitRef="USD_Per_Share">0.05</ix:nonFraction> per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of December 31, 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In connection with the Company's acquisition of FGH, the Company's current CEO and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $<ix:nonFraction id="F20231019113056165_37" name="flgc:PotentialLiabilities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">5.0</ix:nonFraction> million. In addition to the matter regarding the former shareholder of ACA Mueller, discussed above, the following actions are pending as of the date hereof:</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On February 3, 2023, an action was brought in the Ontario Superior Court of Justice by Nathan Shantz and Liberacion e Inversiones S.A. against various parties including Clifford Starke, the Company's current CEO and FGH's former Chief Executive Officer, and FGH. The statement of claim alleges that, prior to the closing of the Arrangement, <ix:nonFraction id="F20231019113056164_28" name="flgc:WrongfullyTransferredShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="Shares">8,831,109</ix:nonFraction> FGH shares purportedly owned by the plaintiffs were wrongfully transferred to third parties, in part through alleged unauthorized steps taken by Mr. Starke. Plaintiffs seek, among other things, a declaration that they are the rightful owners of the shares or, in the alternative, damages. Against FGH, they claim a declaration that, by virtue of the alleged unauthorized transfer of shares, FGH acted oppressively and seek damages in the amount of $<ix:nonFraction id="F20231019113056164_29" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">4.0</ix:nonFraction> million. The defendants have brought motions to stay the proceedings on the grounds that the Ontario court lacks jurisdiction over the claim. In the event FGH should incur any losses in connection with this matter, such losses are to be indemnified by Mr. Starke subject to the maximum threshold of the indemnity agreement.</span></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The total amount claimed against the former entities of FGH currently exceeds the maximum $<ix:nonFraction id="F20231019113056166_40" name="flgc:PotentialLiabilities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">5.0</ix:nonFraction> million of the indemnification agreement. However, the Company is estimating the likelihood of loss in these cases will not exceed $<ix:nonFraction id="F20231019113056165_30" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">3.0</ix:nonFraction> million.</span></span></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Management contracts</b></span></span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company is party to management contracts with certain of its executive officers. As at December 31, 2023, <ix:nonNumeric id="Fxbrl_20231023111710279" name="flgc:ManagementContractsTerms" contextRef="C_20230101to20231231">these contracts would require payments totaling approximately $1.0 million to be made in the event that such executive officers are terminated (i) "without cause" or (ii) within twelve months following a "change in control" (as such terms are defined in the management contracts). The Company is also obligated to make payments to certain individuals upon termination "without cause" of approximately $1.0 million pursuant to the terms of these contracts.</ix:nonNumeric> As a triggering event has not taken place, these amounts have not been recorded in these consolidated financial statements.</span></span></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Shared services and space commitment</b></span></span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company had an agreement in 2021 and through March 2022 to share general and administrative, promotion, corporate development, consulting services, and office space with other companies with monthly payments and a minimum commitment of CAD <ix:nonFraction id="F20231019113056165_31" name="flgc:SharedServicesAndSpaceCommitment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20210101to20220314" unitRef="CAD">45,000</ix:nonFraction>. This agreement could be terminated by either party giving at least 90 days' prior written notice (or such shorter period as the parties may mutually agree upon) to the other party of termination. These services were provided by 2227929 Ontario Inc which was a related party. This agreement expired by its terms on March 14, 2022.</span></span></span></span></p>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">168</span></span></span></div>
            <div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
            </div>
            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                <tr>
                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                </tr>
            </table>
            <ix:nonNumeric id="F20231019113056195_83" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>20.<span style="display: inline-block; width: 15pt;">&#160;</span>INCOME TAXES</b></span></span></p>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The components of the income tax provision include the following. As the Company is domiciled in Canada, the Federal caption below represents the provision amount for Canada.</span></span></p>
                            <ix:nonNumeric id="Fxbrl_20240305113932630" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>For the year ended<br/>December 31, 2022</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Canada</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056173_0" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056173_1" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; U.S. federal</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056173_2" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember" unitRef="USD">17</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056174_3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160;U.S. state</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056174_4" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember" unitRef="USD">5</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056174_5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Foreign</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056175_6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember" unitRef="USD">103</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056175_7" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total current tax expense</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056175_8" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">125</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056175_9" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Canada</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20231019113056175_10" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember" unitRef="USD">1,767</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056176_11" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember" unitRef="USD">11</ix:nonFraction></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160;&#160;U.S. federal</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056176_12" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056176_13" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember" unitRef="USD">1,055</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; U.S. state</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056176_14" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056177_15" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember" unitRef="USD">316</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Foreign</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056177_16" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember" unitRef="USD">14</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056177_17" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember" unitRef="USD">23</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total deferred tax expense</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20231019113056177_18" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">1,753</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056178_19" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1,405</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 81pt;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total income tax benefit</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20231019113056179_20" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">1,628</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056180_21" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1,405</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                </table>
                            </ix:nonNumeric>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The reconciliation of the combined Canadian federal and provincial statutory income tax rate of <ix:nonFraction id="F20231019113056180_22" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Pure">26.5</ix:nonFraction>% for the year ended December 31, 2023 and 2022 to the effective rate is as follows. As the Company is domiciled in Canada, the reconciliation is to the Company's home country income tax rate rather than the applicable statutory rates in the United States. The statutory tax rate as of December 31, 2023 in other countries relevant to the Company's subsidiaries include the following: United States <ix:nonFraction id="F20231019113056181_23" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedStatesRevenueAgencyMember" unitRef="Pure">21</ix:nonFraction>%, Colombia <ix:nonFraction id="F20231019113056181_24" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember" unitRef="Pure">33</ix:nonFraction>%, Germany <ix:nonFraction id="F20231019113056181_25" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcGermanyRevenueAgencyMember" unitRef="Pure">27.73</ix:nonFraction>%, Denmark <ix:nonFraction id="F20231019113056182_26" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcDenmarkRevenueAgencyMember" unitRef="Pure">22</ix:nonFraction>%, and United Kingdom <ix:nonFraction id="F20231019113056182_27" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedKingdomRevenueAgencyMember" unitRef="Pure">19</ix:nonFraction>%. The Colombian Government lowered the corporate income tax rate from <ix:nonFraction id="F20231019113056182_28" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember" unitRef="Pure">35</ix:nonFraction>% to <ix:nonFraction id="F20231019113056182_29" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember" unitRef="Pure">33</ix:nonFraction>% during the tax year 2023.</span></span></p>
                            <div>
                                <ix:nonNumeric id="Fxbrl_20240306172218086" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>For the year ended<br/>December 31, 2022</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Statutory Canadian&#160;rate</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305115538263" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Pure">26.5</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305120029963" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Pure">26.5</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Earnings in jurisdictions taxed at different rates</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-<ix:nonFraction id="Fxbrl_20240306162335361" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" decimals="3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="Pure">1.3</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305120035782" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Pure">0.5</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairments</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-<ix:nonFraction id="Fxbrl_20240306162348472" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" decimals="3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="Pure">1.9</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-<ix:nonFraction id="Fxbrl_20240306162449610" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" decimals="3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="Pure">12.9</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-<ix:nonFraction id="Fxbrl_20240306162401633" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" decimals="3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="Pure">0.8</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-<ix:nonFraction id="Fxbrl_20240306162507127" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" decimals="3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="Pure">1.7</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on investments</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-<ix:nonFraction id="Fxbrl_20240306162415205" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" scale="-2" decimals="3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="Pure">3.0</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305120102110" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Pure">0.0</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Valuation allowance</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-<ix:nonFraction id="Fxbrl_20240306162430885" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" decimals="3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="Pure">23.8</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-<ix:nonFraction id="Fxbrl_20240306162525146" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" decimals="3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="Pure">12.3</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other permanent items</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305115627419" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Pure">1.3</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305120113652" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Pure">2.8</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior year adjustments, change in tax rates</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305131911209_xbrl_20240305115627419" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Pure">6.4</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305131911209_xbrl_20240305120113652" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Pure">0.0</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305115634786" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Pure">3.4</ix:nonFraction>%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305120121020" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Pure">2.9</ix:nonFraction>%</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                            <p style="margin: 0pt;">&#160;</p>
                            <div>
                                <ix:exclude>
                                    <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">169</span></span></span></div>
                                    <div>
                                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                    </div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                        </tr>
                                    </table>
                                </ix:exclude>
                            </div>
                            <p style="margin: 0pt 0pt 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Components of the Company's deferred income tax assets and liabilities at December 31, 2023 and 2022 are as follows:</span></span></p>
                            <ix:nonNumeric id="Fxbrl_20240305114432331" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2022</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Non-capital loss carryforwards</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b>&#160;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056185_41" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">19,725</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056185_42" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">20,240</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Share issuance costs</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056185_43" name="flgc:DeferredTaxAssetsShareIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">847</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056186_44" name="flgc:DeferredTaxAssetsShareIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,406</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Unrealized gains (losses) on investments</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056186_45" name="flgc:DeferredTaxAssetsUnrealizedGainsLossesOnInvestments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">5,858</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056186_46" name="flgc:DeferredTaxAssetsUnrealizedGainsLossesOnInvestments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">823</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Right of use assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056186_47" name="flgc:DeferredTaxAssetsRightOfUseAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">287</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056187_48" name="flgc:DeferredTaxAssetsRightOfUseAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">614</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Fixed assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305114536213_20231019113056186_47" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">77</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305114536213_20231019113056187_48" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056190_61" name="flgc:DeferredTaxAssetsIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">718</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056190_62" name="flgc:DeferredTaxAssetsIntangibleAssets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Goodwill</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305114816362_20231019113056190_61" name="flgc:DeferredTaxAssetsGoodwil" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">7,747</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305114816362_20231019113056190_62" name="flgc:DeferredTaxAssetsGoodwil" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Sec 174 - R&amp;D expense</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305114847773_xbrl_20240305114816362_20231019113056190_61" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">263</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305114847773_xbrl_20240305114816362_20231019113056190_62" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056187_49" name="us-gaap:DeferredTaxAssetsOther" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">564</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056187_50" name="us-gaap:DeferredTaxAssetsOther" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">677</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Allowance for doubtful accounts</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056188_53" name="flgc:DeferredTaxAssetsAllowanceForDoubtfulAccounts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">64</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056188_54" name="flgc:DeferredTaxAssetsAllowanceForDoubtfulAccounts" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231" unitRef="USD">-</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056188_55" name="us-gaap:DeferredTaxAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">36,150</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056188_56" name="us-gaap:DeferredTaxAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">23,760</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Valuation allowance</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20231019113056189_57" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">36,150</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056189_58" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">20,909</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056189_59" name="us-gaap:DeferredTaxAssetsNet" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056189_60" name="us-gaap:DeferredTaxAssetsNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">2,851</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240305114756861_20231019113056190_63" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305114756861_20231019113056190_64" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">4,094</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Lease obligations</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056190_63" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056190_64" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">469</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056190_65" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056191_66" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">4,563</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20231019113056191_67" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056191_68" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,712</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                </table>
                            </ix:nonNumeric>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred taxes are a result of temporary differences that arise due to the differences between the income tax values and the carrying values of assets and liabilities. The Company's deferred tax asset valuation allowances are primarily the result of uncertainties regarding the future realization of recorded tax benefits on the tax loss carryforwards from operations in various jurisdictions. Current evidence does not suggest the Company will realize sufficient taxable income of the appropriate character within the carryforward period to allow the Company to realize the deferred tax benefits. If the Company were to identify and implement tax planning strategies to recover these deferred tax assets or generate sufficient income of the appropriate character in these jurisdictions in the future, it could lead to the reversal of these valuation allowances and income tax expense.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company asserts that the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company may need to accrue and pay taxes if those earnings were repatriated to Canada. As at December 31, 2023, the amount of cash and cash equivalents related to foreign operations subject to these assertions is $<ix:nonFraction id="F20231019113056191_69" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcForeignRevenueAgencyMember" unitRef="USD">1.7</ix:nonFraction> million.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unused loss carryforwards in Canada totaling $<ix:nonFraction id="F20231019113056192_70" name="us-gaap:OperatingLossCarryforwards" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_usgaapCanadaRevenueAgencyMember" unitRef="USD">55.6</ix:nonFraction> million expire beginning 2036. Unused loss carryforwards in Columbia totaling $<ix:nonFraction id="F20231019113056192_72" name="us-gaap:OperatingLossCarryforwards" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember" unitRef="USD">0.9</ix:nonFraction> million in Colombia expire beginning 2031. Unused loss carryforwards in the United States totaling $<ix:nonFraction id="F20231019113056193_74" name="us-gaap:OperatingLossCarryforwards" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedStatesRevenueAgencyMember" unitRef="USD">13.0</ix:nonFraction> million have an indefinite carryforward period. Unused loss carryforwards in Denmark totaling $<ix:nonFraction id="F20231019113056193_75" name="us-gaap:OperatingLossCarryforwards" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcDenmarkRevenueAgencyMember" unitRef="USD">6.1</ix:nonFraction> million have an indefinite carryforward period. Unused loss carryforwards in Germany of $<ix:nonFraction id="F20231019113056193_77" name="us-gaap:OperatingLossCarryforwards" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcGermanyRevenueAgencyMember" unitRef="USD">0.7</ix:nonFraction> have an indefinite carryforward period. Unused loss carryforwards in the United Kingdom of $<ix:nonFraction id="Fxbrl_20240305114505869" name="us-gaap:OperatingLossCarryforwards" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedKingdomRevenueAgencyMember" unitRef="USD">0.7</ix:nonFraction> have an indefinite carryforward period. Deferred tax assets have not been recognized for legal entities where it is not probable that future taxable profit will be available against which the Company can use the benefits. Tax attributes are subject to review, and potential adjustment, by tax authorities. The tax years that remain subject to examination by significant tax jurisdictions of the Company as of December 31, 2023 are as follows:&#160; <ix:nonNumeric id="Fxbrl_20240529174923515" name="flgc:DescriptionOfTaxJurisdictions" contextRef="C_20230101to20231231">Canada 2020 to 2023, United States 2020 to 2023, Colombia 2020 to 2023, Germany 2019 to 2023, Denmark 2020 to 2023, and United Kingdom 2022 to 2023.</ix:nonNumeric></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The amount of current income tax expense for the year ended December 31, 2023 was $<ix:nonFraction id="F20231019113056194_79" name="flgc:CurrentTaxExpenseIncome" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">0.1</ix:nonFraction> million and deferred income tax benefit was $<ix:nonFraction id="F20231019113056194_80" name="flgc:DeferredTaxExpenseIncome" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">1.6</ix:nonFraction> million within the consolidated statements of loss and comprehensive loss. The amount of current income tax expense recorded for the year ended December 31, 2022 was $<ix:nonFraction id="Fxbrl_20240422140513526" name="flgc:CurrentTaxExpenseIncome" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20220101to20221231" unitRef="USD">nil</ix:nonFraction> and deferred income tax benefit was $<ix:nonFraction id="F20231019113056194_81" name="flgc:DeferredTaxExpenseIncome" scale="6" decimals="-4" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">1.4 </ix:nonFraction>million.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had no unrecognized income tax benefits because of uncertain income tax positions for the years ended December 31, 2023 and 2022.</span></span></p>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <div style="margin-top: 10pt;">
                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">170</span></span></span></div>
                <div>
                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                </div>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                    </tr>
                </table>
            </div>
            <ix:nonNumeric id="F20231019113056206_0" name="us-gaap:EarningsPerShareTextBlock" escape="true" contextRef="C_20230101to20231231">
                <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>21.<span style="display: inline-block; width: 15pt;">&#160;</span>LOSS PER SHARE</b></span></span></p>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive as the Company has a net loss for each period presented:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240306164033432" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" contextRef="C_20230101to20231231">
                            <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of securities</span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231021123311306" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember" unitRef="Shares">49</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056206_1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember" unitRef="Shares">290</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Warrants</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231021123318682" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember" unitRef="Shares">2,384</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056206_2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember" unitRef="Shares">961</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted stock awards</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231021123325954" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember" unitRef="Shares">391</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056206_7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember" unitRef="Shares">146</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD potential additional shares to settle contingent consideration</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231021123333073" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember" unitRef="Shares">632</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056206_8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember" unitRef="Shares">657</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total anti-dilutive</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231021123338817" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Shares">3,456</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056206_3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Shares">2,054</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113056233_89" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>22.<span style="display: inline-block; width: 15pt;">&#160;</span>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</b></span></span></span></p>
                    <div>
                        <div>
                            <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Environmental</b></span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.</span></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Fair value</b></span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company's financial instruments measured at amortized cost as at December 31, 2023 and December 31, 2022 consist of cash, restricted cash, trade and amounts receivable, loans receivable, trade payables, contingencies, accrued liabilities, contingent purchase consideration liabilities, lease liabilities, and debt and loans payable. The amounts reflected in the consolidated statements of financial position approximate fair value due to the short-term maturity of these instruments.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial instruments recorded at the reporting date at fair value are classified into one of three levels based upon the fair value hierarchy. Items are categorized based on inputs used to derive fair value based on:</span></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Level 1 - quoted prices that are unadjusted in active markets for identical assets or liabilities</span></span></span></p>
                            <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Level 2 - inputs other than quoted prices included in level 1 that are observable for the asset/liability either directly or indirectly; and</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Level 3 - inputs for the instruments are not based on any observable market data.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company&#8217;s long-term investments require significant unobservable inputs and as discussed at Note 9, are measured at FVPL and as a Level 3 fair value financial instrument within the fair value hierarchy as at December 31, 2023. As discussed in Note 10, the Company&#8217;s contingent purchase considerations consist of the estimated fair value of contingent purchase consideration from the acquisitions of JustCBD in February 2022, NoCap in July 2022 and Original Hemp in March 2023. The amount for JustCBD is measured at FVPL as a Level 2 fair value financial instrument within the fair value hierarchy as at December 31, 2023. The amounts for NoCap and Original Hemp are measured at FVPL as a Level 3 fair value financial instrument within the fair value hierarchy as at December 31, 2023. As valuations of investments for which market quotations are not readily available are inherently uncertain, may fluctuate within short periods of time and are based on estimates, determination of fair value may differ materially from the values that would have resulted if a ready market existed for the investments. Such changes may have a significant impact on the Company&#8217;s financial condition or operating results.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The following tables present information about the Company's financial instruments and their classifications as at December 31, 2023 and 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value.</span></span></span></p>
                            <ix:nonNumeric id="Fxbrl_20240306165848913" name="flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications" escape="true" contextRef="C_20230101to20231231" continuedAt="F20240306165907650">
                                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Fair value measurements at December 31, 2023 using:</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of United States Dollars</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 1</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 2</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 3</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Total</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial assets:</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Investments (Note 9)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151702254" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151717190" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151755902" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151929547" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial liabilities:</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Contingent purchase consideration from business combinations (Note 10)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306152017199_xbrl_20240306151702254" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306152017199_xbrl_20240306151717190" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member" unitRef="USD">854</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306152017199_xbrl_20240306151755902" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">241</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306152017199_xbrl_20240306151929547" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,095</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </ix:nonNumeric>
                            <p style="margin: 0pt;">&#160;</p>
                            <div>
                                <ix:exclude>
                                    <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">171</span></span></span></div>
                                    <div>
                                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                    </div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                        </tr>
                                    </table>
                                </ix:exclude>
                            </div>
                            <div>
                                <ix:continuation id="F20240306165907650">
                                    <div>
                                        <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Fair value measurements at December 31, 2022 using:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of United States Dollars</span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial assets:</span></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Investments (Note 9)</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151046156" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151100534" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151104621" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">764</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151110420" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">764</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Contingent purchase consideration from business combinations (Note 10)</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151124002_xbrl_20240306151046156" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151124002_xbrl_20240306151100534" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member" unitRef="USD">2,646</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151124002_xbrl_20240306151104621" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">901</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306151124002_xbrl_20240306151110420" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">3,547</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:continuation>
                            </div>
                        </div>
                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Risk management overview</b></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk. Further quantitative disclosures are included throughout these condensed interim consolidated financial statements.</span></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Credit risk</b></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's trade and other receivables, loans receivable and cash held with banks and other financial intermediaries.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The carrying amount of the cash, restricted cash, trade and amounts receivables, indemnification receivable, and loan receivable represents the maximum credit exposure as presented in the statement of financial position.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company has assessed that there has been no significant increase in credit risk of the loans receivable from initial recognition based on the financial position of the borrowers, and the regulatory and economic environment of the borrowers. Based on historical information, and adjusted for forward-looking expectations, the Company has assessed an insignificant loss allowance on the loans' receivable and advances as at December 31, 2023 and 2022.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company provides credit to certain customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Credit risk for customers is assessed on a case-by-case basis and an allowance for specific expected credit losses is recorded where required, in addition to an estimate of lifetime expected credit losses for the portfolio of accounts receivable. See credit risk analysis for trade receivables at Note 6.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company held cash and restricted cash of $<ix:nonFraction id="F20231019113056215_8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember" unitRef="USD">4.4</ix:nonFraction> million as at December 31, 2023 (2022 - $<ix:nonFraction id="F20231019113056215_9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember" unitRef="USD">8.9</ix:nonFraction> million), of which, $<ix:nonFraction id="F20231019113056215_10" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapCollateralAxis_flgcHeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember" unitRef="USD">4.4</ix:nonFraction> million (2022 - $<ix:nonFraction id="F20231019113056216_11" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapCollateralAxis_flgcHeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember" unitRef="USD">8.9</ix:nonFraction> million) is held with large financial institutions and national central banks. The remaining cash amount of less than $<ix:nonFraction id="F20231019113056216_12" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapCollateralAxis_flgcFinancialIntermediariesMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember" unitRef="USD">0.1</ix:nonFraction> million cash (2022 - less than $<ix:nonFraction id="F20231019113056216_13" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapCollateralAxis_flgcFinancialIntermediariesMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember" unitRef="USD">0.1</ix:nonFraction> million) are held with financial intermediaries in the United States, Canada, Germany and United Kingdom. The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has assessed an insignificant loss allowance on these cash and restricted cash balances as at December 31, 2023 and 2022.</span></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Market risk</b></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Foreign currency exchange rate risk is the risk that the fair value of future cash flows will fluctuate due to changes in foreign exchange rates. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk as management has determined that this risk is not significant. As such, the Company's financial position and financial results may be adversely affected by the unfavorable fluctuations in currency exchange rates.</span></span></span></p>
                        <div>
                            <ix:exclude>
                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">172</span></span></span></div>
                                <div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                </div>
                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                    </tr>
                                </table>
                            </ix:exclude>
                        </div>
                        <p style="margin: 0pt 0pt 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>As at December 31, 2023, the Company had the following monetary assets and liabilities denominated in foreign currencies:</span></span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240305105725907" name="flgc:ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock" escape="true" contextRef="C_20230101to20231231" continuedAt="F20240305105742093">
                            <div>
                                <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>December 31, 2023</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CAD</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>GBP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>EUR</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of foreign currencies</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Cash</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306155911469" name="us-gaap:Cash" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyCAD" unitRef="USD">969</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306155924657" name="us-gaap:Cash" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyGBP" unitRef="USD">35</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160032181" name="us-gaap:Cash" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyEUR" unitRef="USD">1</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Amounts receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160353008_xbrl_20240306155911469" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyCAD" unitRef="USD">2,995</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160353008_xbrl_20240306155924657" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyGBP" unitRef="USD">125</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160353008_xbrl_20240306160032181" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Loans receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160355367_xbrl_20240306155911469" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtCurrencyAxis_currencyCAD" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160355367_xbrl_20240306155924657" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtCurrencyAxis_currencyGBP" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160355367_xbrl_20240306160032181" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade payables</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160356878_xbrl_20240306155911469" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyCAD" unitRef="USD">6,767</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160356878_xbrl_20240306155924657" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyGBP" unitRef="USD">22</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160356878_xbrl_20240306160032181" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyEUR" unitRef="USD">18</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Accrued liabilities</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160357743_xbrl_20240306155911469" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyCAD" unitRef="USD">48</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160357743_xbrl_20240306155924657" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyGBP" unitRef="USD">69</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160357743_xbrl_20240306160032181" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Lease liability</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160400672_xbrl_20240306155911469" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyCAD" unitRef="USD">126</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160400672_xbrl_20240306155924657" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyGBP" unitRef="USD">41</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160400672_xbrl_20240306160032181" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Long term debt</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160403033_xbrl_20240306155911469" name="us-gaap:LongTermDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyCAD" unitRef="USD">2,560</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160403033_xbrl_20240306155924657" name="us-gaap:LongTermDebt" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtCurrencyAxis_currencyGBP" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160403033_xbrl_20240306160032181" name="us-gaap:LongTermDebt" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Net carrying value</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160404816_xbrl_20240306155911469" name="us-gaap:FairValueNetAssetLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_srtCurrencyAxis_currencyCAD" unitRef="USD">5,537</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306160404816_xbrl_20240306155924657" name="us-gaap:FairValueNetAssetLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtCurrencyAxis_currencyGBP" unitRef="USD">28</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306160404816_xbrl_20240306160032181" name="us-gaap:FairValueNetAssetLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_srtCurrencyAxis_currencyEUR" unitRef="USD">17</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                    </tr>
                                </table>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>As at December 31, 2022, the Company had the following monetary assets and liabilities denominated in foreign currencies:</span></span></span></p>
                        <ix:continuation id="F20240305105742093">
                            <div>
                                <table style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>December 31, 2022</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CAD</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>COP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>GBP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>EUR</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CHF</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of foreign currencies</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Cash</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153126944" name="us-gaap:Cash" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCAD" unitRef="USD">1,691</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153134098" name="us-gaap:Cash" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCOP" unitRef="USD">2,961,487</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153137016" name="us-gaap:Cash" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyGBP" unitRef="USD">64</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153140144" name="us-gaap:Cash" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyEUR" unitRef="USD">1</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153234791" name="us-gaap:Cash" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCHF" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Amounts receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153636645_xbrl_20240306153126944" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCAD" unitRef="USD">2,964</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153636645_xbrl_20240306153134098" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCOP" unitRef="USD">15,127,223</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153636645_xbrl_20240306153137016" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyGBP" unitRef="USD">61</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153636645_xbrl_20240306153140144" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153636645_xbrl_20240306153234791" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCHF" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Loans receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153641216_xbrl_20240306153126944" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCAD" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153641216_xbrl_20240306153134098" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCOP" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153641216_xbrl_20240306153137016" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyGBP" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153641216_xbrl_20240306153140144" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153641216_xbrl_20240306153234791" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCHF" unitRef="USD">250</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade payables</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153642661_xbrl_20240306153126944" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCAD" unitRef="USD">9,333</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153642661_xbrl_20240306153134098" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCOP" unitRef="USD">2,975,794</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153642661_xbrl_20240306153137016" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyGBP" unitRef="USD">56</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153642661_xbrl_20240306153140144" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyEUR" unitRef="USD">161</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153642661_xbrl_20240306153234791" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCHF" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Accrued liabilities</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153645312_xbrl_20240306153126944" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCAD" unitRef="USD">522</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153645312_xbrl_20240306153134098" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCOP" unitRef="USD">1,173,118</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153645312_xbrl_20240306153137016" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyGBP" unitRef="USD">22</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153645312_xbrl_20240306153140144" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153645312_xbrl_20240306153234791" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCHF" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Lease liability</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153646583_xbrl_20240306153126944" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCAD" unitRef="USD">153</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153646583_xbrl_20240306153134098" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCOP" unitRef="USD">1,809,970</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153646583_xbrl_20240306153137016" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyGBP" unitRef="USD">17</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153646583_xbrl_20240306153140144" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153646583_xbrl_20240306153234791" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCHF" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Long term debt</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153647813_xbrl_20240306153126944" name="us-gaap:LongTermDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCAD" unitRef="USD">1,446</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153647813_xbrl_20240306153134098" name="us-gaap:LongTermDebt" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCOP" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153647813_xbrl_20240306153137016" name="us-gaap:LongTermDebt" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyGBP" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153647813_xbrl_20240306153140144" name="us-gaap:LongTermDebt" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyEUR" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153647813_xbrl_20240306153234791" name="us-gaap:LongTermDebt" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_srtCurrencyAxis_currencyCHF" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Net carrying value</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153649767_xbrl_20240306153126944" name="us-gaap:FairValueNetAssetLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_srtCurrencyAxis_currencyCAD" unitRef="USD">6,799</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153649767_xbrl_20240306153134098" name="us-gaap:FairValueNetAssetLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCOP" unitRef="USD">12,129,828</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153649767_xbrl_20240306153137016" name="us-gaap:FairValueNetAssetLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyGBP" unitRef="USD">30</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(<ix:nonFraction id="Fxbrl_20240306153649767_xbrl_20240306153140144" name="us-gaap:FairValueNetAssetLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_srtCurrencyAxis_currencyEUR" unitRef="USD">160</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><ix:nonFraction id="Fxbrl_20240306153649767_xbrl_20240306153234791" name="us-gaap:FairValueNetAssetLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtCurrencyAxis_currencyCHF" unitRef="USD">250</ix:nonFraction></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        </ix:continuation>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Monetary assets and liabilities denominated in Canadian dollars, Colombian pesos, British pounds, Euros and Swiss Francs are subject to foreign currency risk. The Company has estimated that as at December 31, 2023, the effect of a 10% increase or decrease in Canadian dollars, British pounds, and Euros against the Unites States dollar on financial assets and liabilities would result in an increase or decrease of approximately $<ix:nonFraction id="Fxbrl_20240422151628734" name="flgc:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">0.4</ix:nonFraction> million (December 31, 2022 - $<ix:nonFraction id="Fxbrl_20240422151635777" name="flgc:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">0.1</ix:nonFraction> million) to net loss and comprehensive loss.<b> </b>Subsequent to December 31, 2023 and through the date of issuance of these financial statements, the exchange rates remained within the 10% range discussed above, and the Company does not expect significant changes in unsettled transactions from December 31, 2023.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company calculates this sensitivity analysis based on the net financial assets denominated in each currency using the December 31 exchange rate,<ix:nonNumeric id="Fxbrl_20240529162707048" name="flgc:DescriptionOfExchangeRate" contextRef="C_20230101to20230331"> then changing the rate by 10%. Management determined 10% is a 'reasonably possible' change in foreign currency rates by considering the approximate change in rates in the prior twelve months.</ix:nonNumeric></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>It is management's opinion that the Company is not subject to significant commodity or interest rate risk.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Management considers concentration risk with counterparties considering the level of purchases and sales of its business segments (Note 24). Several of the Company's business units purchase substantially all their inventory or materials from a single supplier.</span></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Liquidity risk</b></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#8217;s financial liabilities consist of trade payables and accrued liabilities, loans payable and debt, and lease liabilities as presented on the statement of financial position. The Company had cash and restricted cash as presented on the statement of financial position. As discussed in Note 13, the Company has <ix:nonFraction id="Fxbrl_20240328191947032" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_flgcGermanSubsidiariesMember" unitRef="EUR">2.2</ix:nonFraction> million Euros ($<ix:nonFraction id="Fxbrl_20240328192013262" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_flgcGermanSubsidiariesMember" unitRef="USD">2.4</ix:nonFraction> million USD) available on credit facilities through one of its German subsidiaries as of December 31, 2023. The Company has no other available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#8217;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.</span></span></span></p>
                        <div>
                            <ix:exclude>
                                <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">173</span></span></span></div>
                                <div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                </div>
                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                    </tr>
                                </table>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade payables and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials and inventory require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 14 and other commitments at Note 19.</span></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company's long-term investments in equity of other entities are not publicly traded and there is not an active market to sell the investments for cash.</span></span></span></p>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20231019113056240_0" name="flgc:CapitalManagementDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>23.<span style="display: inline-block; width: 15pt;">&#160;</span></b><b>CAPITAL MANAGEMENT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company considers the aggregate of its common shares, options, warrants and borrowings as capital. The Company's capital management objective is to ensure sufficient resources are available to meet day to day operating requirements and to safeguard its ability to continue as a going concern to provide returns for shareholders and benefits for other shareholders.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's capital management objectives were being met in 2023 primarily from the use of cash balances from the 2022 and 2023 issuances of common shares and warrants and generating increasing revenue in 2023 from the Company's reportable segments as presented in Note 24.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's officers and senior management take full responsibility for managing the Company's capital and do so through quarterly meetings and regular review of financial information. The Company's Board of Directors is responsible for overseeing this process.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company is not subject to any external capital requirements. As at December 31, 2023, there were no changes in the Company's approach to capital management.</span></span></p>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="Fxbrl_20240306053907406" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231">
                    <div>
                        <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24.<span style="display: inline-block; width: 15pt;">&#160;</span>SEGMENTED INFORMATION</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to the fourth quarter of the year ended December 31, 2022, the Company had the following <ix:nonFraction id="Fxbrl_20240306054207925" name="us-gaap:NumberOfOperatingSegments" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20220101to20221231" unitRef="Segment">four</ix:nonFraction> operating segments, which were also its reportable segments: cannabis growth and derivative production, consumer products, pharmaceuticals and nutraceuticals, and beverage and food. Since the acquisition of FGH in December 2022 (Note 10), the Company has been reporting its financial results for the following three operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH and the former Cosechemos subsidiary in Colombia), house of brands (primarily JustCBD and Vessel, as well as the former Kasa Wholefoods Company subsidiary in Colombia), and pharmaceuticals (formerly the Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries in Colombia). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As discussed in Note 2 and Note 5, on July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan to sell all its shares in its Colombian related subsidiaries and its Colombian assets. This sale was completed in full on November 1, 2023. As such, the Company has presented the associated assets and liabilities of these Colombian subsidiaries as held for sale and the results of these subsidiaries are included in discontinued operations.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operates its manufacturing and distribution business within its United States and Germany subsidiaries. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations and includes the Company's long-term investments.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following tables show information regarding the Company's segments for the years ended December 31, 2023 and 2022.</span></span></p>
                                <div>
                                    <ix:exclude>
                                        <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">174</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                            </tr>
                                        </table>
                                    </ix:exclude>
                                </div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In 2023, the Company did not have sales to a single customer exceeding <ix:nonFraction id="Fxbrl_20240530103546458" name="flgc:ConsolidatedRevenue" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="Pure">10</ix:nonFraction>% of its consolidated revenue. In 2022, the Company did not have sales to a single customer exceeding <ix:nonFraction id="Fxbrl_20240530103600498" name="flgc:ConsolidatedRevenue" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="Pure">10</ix:nonFraction>% of its consolidated revenue.</span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240305102800152" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <table style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056248_1" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">38,262</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056248_2" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">87</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056249_3" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">44,602</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056249_4" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">39,419</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056250_5" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056250_6" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056250_7" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">6,793</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056251_8" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">6,105</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056251_9" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">76,071</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056252_10" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">33,401</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Gross Profit</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056252_11" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">2,218</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056253_12" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">39</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056253_13" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">15,520</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056253_14" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">13,290</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056254_15" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056254_16" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056255_17" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056255_18" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056256_19" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">17,738</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056256_20" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">13,251</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Loss from Continuing Operations</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056256_21" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">8,763</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056257_22" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">109</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056257_23" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">31,399</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056258_24" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">29,594</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056258_25" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">81</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056259_26" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056259_27" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">6,426</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056259_28" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">17,000</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056262_29" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">46,669</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056262_30" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">46,703</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other significant items:</span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240305102839535" name="flgc:ScheduleOfOtherSignificantItemsTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Commercial &amp;<br/>Wholesale</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>House of<br/>Brands</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Pharmaceuticals</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Corporate &amp;<br/>Eliminations</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Consolidated</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056263_31" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056263_32" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056264_33" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056264_34" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">1,591</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056265_35" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">1,591</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056265_36" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">93</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056266_37" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">11</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056266_38" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056266_39" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">12</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056267_40" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">92</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income taxes</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056267_41" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">1,650</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056268_42" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">3</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056268_43" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056269_44" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">19</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056269_45" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">1,628</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056269_46" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">857</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056270_47" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">1,478</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056270_48" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056271_49" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056271_50" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">2,335</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unrealized gain from changes in fair value</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056272_51" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056272_52" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">964</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056272_53" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056273_54" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">1,027</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056273_55" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">1,991</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056274_56" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">9,096</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056274_57" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">11,608</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056275_58" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056275_59" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">2,922</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056275_60" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">23,626</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2022</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056276_61" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056276_62" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056277_63" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056277_64" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">3,404</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056278_65" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">3,404</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056280_66" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">1</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056280_67" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">27</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056281_68" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056281_69" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">3</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056282_70" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">29</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income taxes</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056282_71" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">12</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056283_72" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">1,393</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056283_73" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056284_74" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056284_75" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">1,405</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056284_76" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">1</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056285_77" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">2,077</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056285_78" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056286_79" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">66</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056286_80" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">2,144</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unrealized loss from changes in fair value</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056286_81" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056287_82" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056287_83" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056288_84" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">593</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056288_85" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">593</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056289_86" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">22,225</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056289_87" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">48,950</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056289_88" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember" unitRef="USD">3,313</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056290_89" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">6,499</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056290_90" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember" unitRef="USD">80,987</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Disaggregation of net sales and net loss before income taxes by geographic area:</span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240306165041492" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <div>
                                            <div>
                                                <table style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056291_91" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryUS" unitRef="USD">36,536</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056291_92" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryUS" unitRef="USD">32,312</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056292_93" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryDE" unitRef="USD">38,262</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056292_94" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryDE" unitRef="USD">87</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056293_97" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryGB" unitRef="USD">1,273</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056294_98" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryGB" unitRef="USD">1,002</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056295_101" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231" unitRef="USD">76,071</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056295_102" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231" unitRef="USD">33,401</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                                <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span>
                                                <div>
                                                    <ix:exclude>
                                                        <div style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">175</span></span></span></div>
                                                        <div>
                                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-bottom: 6pt;"/>
                                                        </div>
                                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                            <tr>
                                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 14pt;"><b>Flora Growth Corp.</b></span><br/><b>Notes to the consolidated financial statements</b><br/>For the years ended December 31, 2023 and 2022<br/>(United States dollars, except shares and per share amounts)</span></td>
                                                            </tr>
                                                        </table>
                                                    </ix:exclude>
                                                </div>
                                                <div>
                                                    <table style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December&#160;31,&#160;2023</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December&#160;31,&#160;2022</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Loss Before Income Taxes</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056297_103" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryUS" unitRef="USD">31,013</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056298_104" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryUS" unitRef="USD">27,867</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056298_105" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryDE" unitRef="USD">10,258</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056298_106" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryDE" unitRef="USD">121</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056300_109" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryGB" unitRef="USD">364</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056300_110" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryGB" unitRef="USD">3,120</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056301_111" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryCA" unitRef="USD">6,662</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056301_112" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryCA" unitRef="USD">17,000</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056301_113" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231" unitRef="USD">48,297</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20231019113056302_114" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220101to20221231" unitRef="USD">48,108</ix:nonFraction></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>
                                        </div>
                                    </div>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Disaggregation of property, plant and equipment and other long-lived assets by geographic area:</span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240306053921106" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" escape="true" contextRef="C_20230101to20231231">
                                    <div>
                                        <table style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, Plant and Equipment</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056302_115" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryUS" unitRef="USD">354</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056303_116" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryUS" unitRef="USD">759</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056303_117" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryDE" unitRef="USD">493</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056304_118" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryDE" unitRef="USD">459</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162914937" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">847</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20231019113056305_121" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">1,218</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                        <table style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-top: 10pt;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Long-lived Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171326826" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryUS" unitRef="USD">1,140</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171357258" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryUS" unitRef="USD">33,332</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171335271" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtStatementGeographicalAxis_countryDE" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171408598" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryDE" unitRef="USD">9,969</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Colombia</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171342307" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtStatementGeographicalAxis_countryCO" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171412791" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryCO" unitRef="USD">4,392</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171345867" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryGB" unitRef="USD">89</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171417231" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryGB" unitRef="USD">191</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171349546" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryCA" unitRef="USD">186</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171545578" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryCA" unitRef="USD">730</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171353010" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,415</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306171424607" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">48,614</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                        <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span>
                                        <table style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162335757" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryUS" unitRef="USD">11,094</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162350533" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryUS" unitRef="USD">45,341</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162401019_xbrl_20240306162335757" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryDE" unitRef="USD">9,096</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162401019_xbrl_20240306162350533" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryDE" unitRef="USD">19,382</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Colombia</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162404821_xbrl_20240306162335757" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_srtStatementGeographicalAxis_countryCO" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162404821_xbrl_20240306162350533" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryCO" unitRef="USD">8,122</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162406653_xbrl_20240306162335757" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryGB" unitRef="USD">514</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162406653_xbrl_20240306162350533" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryGB" unitRef="USD">559</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162408964_xbrl_20240306162335757" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_srtStatementGeographicalAxis_countryCA" unitRef="USD">2,922</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162408964_xbrl_20240306162350533" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_srtStatementGeographicalAxis_countryCA" unitRef="USD">7,583</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162413939_xbrl_20240306162335757" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">23,626</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240306162413939_xbrl_20240306162350533" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">80,987</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <div>
                    <ix:nonNumeric id="F20231019113056329_11" name="us-gaap:SubsequentEventsTextBlock" escape="true" contextRef="C_20230101to20231231">
                        <div>
                            <div>
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>25.&#160;</b></span></span><span style="padding-left: 15pt;">&#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>SUBSEQUENT EVENTS </b></span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>OTHER</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The contingent purchase consideration related to the acquisition of JustCBD was due on February 24, 2024. The balance of $<ix:nonFraction id="Fxbrl_20240305101445832" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240224_usgaapBusinessAcquisitionAxis_flgcJustCBDMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD">0.9</ix:nonFraction> million remains unpaid as of the date of filing these consolidated financial statements.</span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;">&#160;</p>
                                    <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On March 8, 2024, the Company entered into a settlement agreement with a third party pursuant to which the Company issued <ix:nonFraction id="Fxbrl_20240328105152872" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240301to20240308_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">50,000</ix:nonFraction> common shares of the Company, valued at $<ix:nonFraction id="Fxbrl_20240328105230084" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240301to20240308_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD">0.1</ix:nonFraction> million, to a third party to settle outstanding amounts owed.</span></span></p>
                                </div>
                            </div>
                        </div>
                    </ix:nonNumeric>
                    <div>
                        <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">176</span></span></p>
                    </div>
                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/>
                </div>
            </div>
            <div>
                <p style="margin-top: 10pt; margin-bottom: 0pt;"><span id="page_7_integixAnchor_integixAnchor"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Flora Growth Corp.</b></span></span></span></p>
                <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unaudited Condensed Interim Consolidated Statements of Financial Position<br/>(in thousands of United States dollars, except share amounts which are in thousands of shares)</span></span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at:</span></span></td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">December 31, 2023</span></span></td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">ASSETS</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728082_0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">4,156</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728083_1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">4,350</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted cash</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728091_54" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">35</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728091_55" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">35</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade and amounts receivable, net of $<ix:nonFraction id="F20240530124728090_50" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">317</ix:nonFraction> allowance ($<ix:nonFraction id="F20240530124728090_51" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">315</ix:nonFraction> at December 31, 2023)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728083_2" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">3,218</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728083_3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">3,950</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prepaid expenses and other current assets</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728083_4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">1,049</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728083_5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,368</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Indemnification receivables</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728083_6" name="us-gaap:NontradeReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">4,063</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728084_7" name="us-gaap:NontradeReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">3,153</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728084_8" name="us-gaap:InventoryNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">9,246</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728084_9" name="us-gaap:InventoryNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">8,508</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total current assets</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728084_10" name="us-gaap:AssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">21,767</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728084_11" name="us-gaap:AssetsCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">21,364</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728084_12" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">786</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728085_13" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">847</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease right of use assets</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728085_14" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">710</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728085_15" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">389</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets</span></span></td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728085_16" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">908</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728085_17" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">946</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other assets</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728085_18" name="us-gaap:OtherAssetsNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">103</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728085_19" name="us-gaap:OtherAssetsNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">80</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728086_20" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">24,274</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728086_21" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">23,626</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">LIABILITIES</span></span></td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728086_22" name="us-gaap:AccountsPayableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">5,005</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728086_23" name="us-gaap:AccountsPayableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">5,111</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies</span></span></td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728086_24" name="us-gaap:CommitmentsAndContingencies" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">6,591</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728086_25" name="us-gaap:CommitmentsAndContingencies" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">5,500</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Debt</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728086_26" name="us-gaap:LongTermDebtCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">3,078</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728087_27" name="us-gaap:LongTermDebtCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,931</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current portion of operating lease liability</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728087_28" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">803</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728087_29" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">799</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingent purchase considerations</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240507230908314_20240530124728087_28" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">1,702</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240507230908314_20240530124728087_29" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,095</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other accrued liabilities</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728087_30" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">2,140</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728087_31" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,844</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total current liabilities</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728087_32" name="us-gaap:LiabilitiesCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">19,319</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728087_33" name="us-gaap:LiabilitiesCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">16,280</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current operating lease liability</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728088_34" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">1,817</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728088_35" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">942</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728088_36" name="us-gaap:Liabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">21,136</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728088_37" name="us-gaap:Liabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">17,222</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">SHAREHOLDERS' EQUITY</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share capital, no par value, unlimited authorized, <ix:nonFraction id="F20240530124728091_58" name="us-gaap:CommonStockSharesOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="Shares"><ix:nonFraction id="F20240530124728090_52" name="us-gaap:CommonStockSharesIssued" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="Shares">8,981</ix:nonFraction></ix:nonFraction> issued and outstanding (<ix:nonFraction id="F20240530124728091_59" name="us-gaap:CommonStockSharesOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="Shares"><ix:nonFraction id="F20240530124728090_53" name="us-gaap:CommonStockSharesIssued" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="Shares">8,935</ix:nonFraction></ix:nonFraction> at December 31, 2023)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728088_38" name="us-gaap:CommonStockValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240331" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728088_39" name="us-gaap:CommonStockValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231" unitRef="USD">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Additional paid-in capital</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728088_40" name="us-gaap:AdditionalPaidInCapital" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">148,871</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728089_41" name="us-gaap:AdditionalPaidInCapital" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">149,093</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Accumulated other comprehensive loss</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20240530124728089_42" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331" unitRef="USD">113</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728089_43" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231" unitRef="USD">140</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deficit</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20240530124728089_44" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331" unitRef="USD">145,620</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728089_45" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231" unitRef="USD">142,549</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total shareholders' equity</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728089_46" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">3,138</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728089_47" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">6,404</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities and shareholders' equity</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240530124728090_48" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">24,274</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728090_49" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">23,626</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements. Commitments and<br/>contingencies - see Note 14. Going concern - see Note 2.</i></span></span></p>
                <div>
                    <p style="text-align: center; margin-bottom: 6pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">177</span></span></p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_8_integixAnchor"></span>
            </div>
            <div>
                <p style="margin-top: 10pt; margin-bottom: 0pt;"><span id="page_8_integixAnchor_integixAnchor"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Flora Growth Corp.</b></span></span></span></p>
                <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unaudited Condensed Interim Consolidated Statements of Loss and<br/>Comprehensive Loss<br/>(in thousands of United States dollars, except per share amounts which<br/>are in thousands of shares)</span></span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the three<br/>months ended<br/>March 31, 2024</b></span></span></td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the three<br/>months ended<br/>March 31, 2023</b></span></span></td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Revenue</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705218_1" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">18,031</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705217_0" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">19,319</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cost of sales</b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705219_5" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">14,177</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705219_4" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">13,973</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Gross profit</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705219_3" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">3,854</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705218_2" name="us-gaap:GrossProfit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">5,346</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating expenses </b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Consulting and management fees</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705220_7" name="us-gaap:ManagementFeeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">2,302</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705220_6" name="us-gaap:ManagementFeeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">3,671</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705220_9" name="us-gaap:ProfessionalFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">453</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705220_8" name="us-gaap:ProfessionalFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705224_11" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">442</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705221_10" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">352</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Promotion and communication</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705225_13" name="us-gaap:Communication" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">1,104</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705225_12" name="us-gaap:Communication" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">1,308</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Travel expenses</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705226_15" name="us-gaap:TravelAndEntertainmentExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">69</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705225_14" name="us-gaap:TravelAndEntertainmentExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">132</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share based compensation</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705226_17" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">10</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705226_16" name="us-gaap:ShareBasedCompensation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">654</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Research and development</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705227_19" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">47</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705227_18" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">16</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705227_21" name="us-gaap:OperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">165</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705227_20" name="us-gaap:OperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">316</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705248_59" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">74</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705228_22" name="us-gaap:DepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">864</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Bad debt expense</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705229_24" name="us-gaap:InterestAndDebtExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">47</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705228_23" name="us-gaap:InterestAndDebtExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">29</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset impairment</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705253_76" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">898</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705253_77" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20230331" unitRef="USD">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other expenses (income), net</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705229_26" name="us-gaap:OtherCostAndExpenseOperating" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">728</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705229_25" name="us-gaap:OtherCostAndExpenseOperating" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">377</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total operating expenses</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705230_28" name="us-gaap:OperatingExpenses" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">6,339</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705230_27" name="us-gaap:OperatingExpenses" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">7,716</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating loss</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705231_30" name="us-gaap:OperatingIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">2,485</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705230_29" name="us-gaap:OperatingIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">2,370</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705231_32" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">22</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705231_31" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">23</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign exchange loss (gain)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705232_34" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">132</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705232_33" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">12</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unrealized loss from changes in fair value</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705236_45" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">607</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705236_46" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">883</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss before income taxes and discontinued operations</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230807135627414_20240527045705233_36" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,246</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230807135627414_20240527045705233_35" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,264</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense (benefit)</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705233_36" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">128</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705233_35" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">78</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net loss from continuing operations </b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230807140320575_20240527045705233_36" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,374</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230807140320575_20240527045705233_35" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,186</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss from discontinued operations, net of taxes</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230807140323110_20240527045705233_36" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331" unitRef="USD">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230807140323110_20240527045705233_35" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">719</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net loss for the period</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705234_38" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,374</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705234_37" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,905</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss attributable to noncontrolling interest</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705248_60" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331" unitRef="USD">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705248_61" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">29</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net loss attributable to Flora Growth Corp.</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705235_40" name="us-gaap:NetIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,374</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705234_39" name="us-gaap:NetIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,876</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share from continuing operations</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705241_54" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="CAD_Per_Share">0.38</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705241_53" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="CAD_Per_Share">0.48</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share from continuing operations</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705247_56" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="CAD_Per_Share">0.38</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705246_55" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="CAD_Per_Share">0.48</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share attributable to Flora Growth Corp.</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705235_42" name="us-gaap:EarningsPerShareBasic" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="CAD_Per_Share">0.38</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705235_41" name="us-gaap:EarningsPerShareBasic" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="CAD_Per_Share">0.58</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share attributable to Flora Growth Corp.</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705249_62" name="us-gaap:EarningsPerShareDiluted" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="CAD_Per_Share">0.38</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705249_63" name="us-gaap:EarningsPerShareDiluted" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="CAD_Per_Share">0.58</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted average number of common shares outstanding - basic</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705236_44" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="Shares">8,916</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705236_43" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="Shares">6,640</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted average number of common shares outstanding - diluted</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705247_57" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="Shares">8,916</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705247_58" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="Shares">6,640</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other comprehensive loss</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;" colspan="1">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss for the period</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705249_64" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,374</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705250_65" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,905</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign currency translation, net of income taxes of $<ix:nonFraction id="F20240527045705252_74" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20240101to20240331" unitRef="USD">nil</ix:nonFraction> ($<ix:nonFraction id="F20240527045705253_75" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20230101to20230331" unitRef="USD">nil</ix:nonFraction> in 2023)</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705250_66" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">27</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705250_67" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">357</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Comprehensive loss for the period</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705251_68" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,347</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705251_69" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,548</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Comprehensive loss attributable to noncontrolling interests</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705252_73" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331" unitRef="USD">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705252_72" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">29</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Comprehensive loss attributable to Flora Growth Corp.</b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705251_70" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,347</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705251_71" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,519</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><i>The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.</i></span></span></span></span></p>
                <div>
                    <p style="text-align: center; margin-bottom: 6pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">178</span></span></p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_9_integixAnchor"></span>
            </div>
            <div>
                <p style="margin-top: 10pt; margin-bottom: 0pt;"><span id="page_9_integixAnchor_integixAnchor"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Flora Growth Corp.</b></span></span></span></p>
                <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unaudited Condensed Interim Consolidated Statement of<br/>Shareholders' Equity (Deficiency)<br/>(in thousands of United States dollars, except for share<br/>amounts which are in thousands of shares)</span></span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 8pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="5"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Common<br/>shares</b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Additional<br/>paid-in<br/>capital </b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Accumulated<br/>other<br/>comprehensive<br/>(loss) income </b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Accumulated<br/>deficit </b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Non-<br/>controlling<br/>interests in<br/>subsidiaries</b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Shareholders'<br/>equity<br/>(deficiency) </b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b># </b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>For the three months ended March 31, 2024</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2023</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705269_4" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">8,935</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705271_13" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705269_5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">149,093</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705269_6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">140</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705270_7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">142,549</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705270_8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705270_9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">6,404</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Equity issued for other agreements</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705280_53" name="flgc:EquityIssuedForOtherAgreementsShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">50</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705280_52" name="flgc:EquityIssuedForOtherAgreementsAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">55</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705279_51" name="flgc:EquityIssuedForOtherAgreementsAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">55</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options vested</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705268_0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">5</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705268_1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">5</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options forfeited</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705274_26" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">303</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102180402039_20240527045705273_22" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">303</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Restricted stock vested</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705275_32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">14</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705275_31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">14</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Restricted stock cancelled</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705275_30" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">4</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705275_29" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">9</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705275_28" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">9</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Share issuance costs</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705268_2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">16</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705269_3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">16</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Other comprehensive loss -<br/>exchange differences (net of income taxes of $<ix:nonFraction id="F20240527045705281_61" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20240101to20240331" unitRef="USD">nil</ix:nonFraction>)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705272_14" name="flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">27</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705272_15" name="flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">27</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Net loss</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231102180654223_20240527045705270_10" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">3,374</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231102180654223_20240527045705271_12" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,374</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Balance, March 31, 2024</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705277_40" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">8,981</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705277_41" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102180715636_20240527045705273_18" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">148,871</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705276_38" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">113</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705276_37" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">145,620</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102180715636_20240527045705272_17" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102180715636_20240527045705272_16" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">3,138</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 5%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="4">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>For the three months ended March 31, 2023</b></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="4">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2022</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102180914189_20240527045705269_4" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">6,776</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102180914189_20240527045705271_13" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102180914189_20240527045705269_5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">150,420</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">$</span></p>
                        </td>
                        <td style="vertical-align: bottom; text-align: right;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">&#160;(<ix:nonFraction id="F20240527045705280_57" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">2,732</ix:nonFraction>)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">$</span></p>
                        </td>
                        <td style="vertical-align: bottom; text-align: right;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">&#160;(<ix:nonFraction id="F20240527045705281_58" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">90,865</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">)</span></p>
                        </td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231102180914189_20240527045705270_8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">411</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102180914189_20240527045705270_9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">56,412</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Equity issued for other agreements</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240508003741968_20240527045705280_53" name="flgc:EquityIssuedForOtherAgreementsShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">16</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240508003741968_20240527045705280_52" name="flgc:EquityIssuedForOtherAgreementsAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">95</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;" colspan="2">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">-</span></p>
                        </td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240508003741968_20240527045705279_51" name="flgc:EquityIssuedForOtherAgreementsAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">95</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options vested</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705274_24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">119</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;" colspan="2">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">-</span></p>
                        </td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705274_23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">119</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Options forfeited</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705273_22" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">765</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705274_27" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">765</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Restricted stock granted</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705279_50" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">52</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102183748527_20240527045705275_32" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">534</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;" colspan="2">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">-</span></p>
                        </td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102183748527_20240527045705275_31" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">534</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Other comprehensive loss -<br/>exchange differences (net of income taxes of $<ix:nonFraction id="F20240527045705282_62" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20230101to20230331" unitRef="USD">nil</ix:nonFraction>)</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806185457906_20240527045705272_14" name="flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">357</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;" colspan="2">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">-</span></p>
                        </td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806185457906_20240527045705272_15" name="flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">357</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Net loss</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705270_10" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">3,876</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">)</span></p>
                        </td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705271_11" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">29</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 5%;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705271_12" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,905</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">Balance, March 31, 2023</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705273_19" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">6,844</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705278_42" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705273_18" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD">150,403</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">$</span></p>
                        </td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; background-color: #e6efff;"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">&#160;(<ix:nonFraction id="F20240527045705281_59" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD">2,375</ix:nonFraction>)</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; background-color: #e6efff;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">$</span></p>
                        </td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; background-color: #e6efff;" colspan="2"><span><span style="font-family: Times New Roman,Times,serif;">&#160;(<ix:nonFraction id="F20240527045705281_60" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD">93,976</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 8pt; font-family: Times New Roman, Times, serif;">)</span></p>
                        </td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705272_17" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD">440</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;" colspan="1"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 5%; background-color: #e6efff;" colspan="2"><span style="font-size: 8pt;"><span><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705272_16" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230331" unitRef="USD">53,612</ix:nonFraction></span></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 5%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 5%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 5%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 5%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 5%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 5%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 5%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom;">&#160;</td>
                    </tr>
                </table>
                <p style="margin-top: 10pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.</i></span></span></p>
                <div>
                    <p style="text-align: center; margin-bottom: 6pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">179</span></span></p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_10_integixAnchor"></span>
            </div>
            <div>
                <p style="margin-top: 10pt; margin-bottom: 0pt;"><span id="page_10_integixAnchor_integixAnchor"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Flora Growth Corp.</b></span></span></span></p>
                <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unaudited Condensed Interim Consolidated Statement of Cash Flows<br/>(in thousands of United States dollars)</span></span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the three months<br/>ended March 31, 2024</b></span></span></td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>For the three months<br/>ended March 31, 2023</b></span></span></td>
                        <td style="background-color: #ffffff; vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash flows from operating activities:</b></span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss</span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728097_0" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,374</ix:nonFraction></span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728097_1" name="us-gaap:ProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,905</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Adjustments to net loss:</span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Depreciation and amortization</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728098_2" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">74</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728098_3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">942</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Share based compensation</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728098_4" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">10</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728098_5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">654</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160; &#160;Asset impairment</span></span></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728102_54" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">898</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728102_55" name="us-gaap:AssetImpairmentCharges" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20230331" unitRef="USD">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Unrealized loss from changes in fair value</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130108415_20240530124728098_6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">607</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130108415_20240530124728098_7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">883</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Bad debt expense</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728098_6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">47</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728098_7" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">29</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Interest expense</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806125958481_20240530124728098_6" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">22</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806125958481_20240530124728098_7" name="us-gaap:InterestIncomeExpenseNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">23</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Interest paid</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728102_53" name="us-gaap:InterestIncomeOperating" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">22</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130002597_20240530124728098_7" name="us-gaap:InterestIncomeOperating" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">23</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Income tax</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130004302_20240530124728098_6" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">128</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130004302_20240530124728098_7" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">66</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130006270_20240530124728098_6" name="us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">1,610</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130006270_20240530124728098_7" name="us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">1,463</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net change in non-cash working capital:</span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Trade and other receivables</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130008464_20240530124728098_6" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">292</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130008464_20240530124728098_7" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">91</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Inventory</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130010614_20240530124728098_6" name="us-gaap:IncreaseDecreaseInInventories" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">738</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130010614_20240530124728098_7" name="us-gaap:IncreaseDecreaseInInventories" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">113</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Prepaid expenses and other assets</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130017839_20240530124728098_6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">268</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728101_47" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">920</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Trade payables and accrued liabilities</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130019118_20240530124728098_6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">1,032</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130019118_20240530124728098_7" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">1,919</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net cash used in operating activities</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20230806130020150_20240530124728098_6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">1,340</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130020150_20240530124728098_7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">4,324</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash flows from financing activities:</b></span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loan borrowings</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130029242_20240530124728098_6" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">3,078</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130029242_20240530124728098_7" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20230331" unitRef="USD">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loan repayments</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130031176_20240530124728098_6" name="us-gaap:RepaymentsOfDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">1,890</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130031176_20240530124728098_7" name="us-gaap:RepaymentsOfDebt" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">19</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net cash provided (used) by financing activities</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20230806130106020_20240530124728098_6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">1,188</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728101_46" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">19</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash flows from investing activities:</b></span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Purchases of property, plant and equipment and intangible assets</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130103950_20240530124728098_6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">88</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230806130103950_20240530124728098_7" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">102</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net cash used in investing activities</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20230806130059797_20240530124728098_6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">88</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728101_48" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">102</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Effect of exchange rate on changes on cash</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130101466_20240530124728098_6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">46</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130101466_20240530124728098_7" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">167</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #ffffff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #ffffff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Change in cash during the period</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20230806130044959_20240530124728098_6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">194</ix:nonFraction></b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240530124728101_49" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">4,278</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash and restricted cash at beginning of period</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728101_44" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">4,385</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240530115425045" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20221231" unitRef="USD">9,537</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash included in assets held for sale</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230807174133573_20240530124728101_44" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240331" unitRef="USD">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20230807174133573_20240530124728101_45" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230331" unitRef="USD">203</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash and restricted cash at end of period</b></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130043016_20240530124728098_6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">4,191</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130043016_20240530124728098_7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230331" unitRef="USD">5,056</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Supplemental disclosure of non-cash investing and financing activities</b></span></span></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;" colspan="2">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Assets acquired for contingent consideration</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130036889_20240530124728098_6" name="flgc:NonCashAssetsAcquiredForContingentConsideration" decimals="INF" format="ixt:fixed-zero" contextRef="C_20240101to20240331" unitRef="Shares">-</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130036889_20240530124728098_7" name="flgc:NonCashAssetsAcquiredForContingentConsideration" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="Shares">303</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Common shares issued for other agreements</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130035042_20240530124728098_6" name="flgc:NonCashCommonSharesIssuedForOtherAgreements" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="Shares">55</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728102_52" name="flgc:NonCashCommonSharesIssuedForOtherAgreements" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="Shares">95</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #ffffff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #ffffff;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Option cancellations reclassified to equity</span></span></p>
                        </td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728102_56" name="flgc:NonCashOptionCancellationsReclassifiedToEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">303</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #ffffff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240530124728102_57" name="flgc:NonCashOptionCancellationsReclassifiedToEquity" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">765</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #ffffff;">&#160;</td>
                    </tr>
                    <tr style="background-color: #e6efff;">
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease additions to right of use assets</span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130041094_20240530124728098_6" name="flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="Shares">1,247</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;" colspan="2"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20230806130041094_20240530124728098_7" name="flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="Shares">97</ix:nonFraction></span></span></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.</i></span></span></p>
                <div>
                    <p style="text-align: center; margin-bottom: 6pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">180</span></span></p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/>
            </div>
            <div>
                <div style="margin-bottom: 10pt;">
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;"><span id="page_11_integixAnchor_integixAnchor"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Flora Growth Corp.</b></span></span></span><br/><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></td>
                        </tr>
                    </table>
                </div>
                <ix:nonNumeric id="F20240527045705303_0" name="us-gaap:NatureOfOperations" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>NATURE OF OPERATIONS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Flora Growth Corp. (the "Company" or "Flora") was incorporated under the laws of the Province of Ontario, Canada on March 13, 2019. The Company is a manufacturer and distributor of global cannabis and pharmaceutical products and brands, building a connected, design-led collective of plant-based wellness and lifestyle brands. The Company's registered office is located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1, Canada and our principal place of business in the United States is located at 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309.</span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Presentation of comparative financial statements</b></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion in Note 11.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
            </div>
            <ix:nonNumeric id="F20240527045705307_0" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" contextRef="C_20240101to20240331">
                <div>
                    <div>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>BASIS OF PRESENTATION</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP. The Company believes that the disclosures made are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2023. These unaudited condensed interim consolidated financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements apply the same accounting policies as those used in the financial statements included in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2023.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to January 1, 2023, Flora was a foreign private issuer reporting its financial statements under International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Boards. These consolidated financial statements, for all periods, are presented in accordance with U.S. GAAP.</span></span></p>
                                <div>
                                    <ix:nonNumeric id="F20240527045705307_4" name="flgc:GoingConcernPolicyTextBlock" escape="true" contextRef="C_20240101to20240331">
                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern</b></span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying unaudited condensed interim consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these unaudited condensed interim consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of $<ix:nonFraction id="F20240527045705307_1" name="us-gaap:Cash" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">4.2</ix:nonFraction> million at March 31, 2024, net loss of $<ix:nonFraction id="F20240527045705307_2" name="us-gaap:ProfitLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3.4</ix:nonFraction> million for the three months ended March 31, 2024, and an accumulated deficit of $<ix:nonFraction id="F20240527045705307_3" name="us-gaap:CumulativeEarningsDeficit" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331" unitRef="USD">145.6</ix:nonFraction>&#160;million at March 31, 2024. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed interim consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. The unaudited condensed interim consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                                        </div>
                                    </ix:nonNumeric>
                                </div>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">181</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                                    </td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <div>
                                    <ix:nonNumeric id="F20240527045705308_5" name="us-gaap:ConsolidationPolicyTextBlock" escape="true" contextRef="C_20240101to20240331">
                                        <div>
                                            <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of consolidation</b></span></span></p>
                                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. At March 31, 2024, the Company's subsidiaries and respective ownership percentage have not changed from the year ended December 31, 2023, except as noted below.</span></span></p>
                                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the three months ended March 31, 2024, the Company voluntarily dissolved the Cardiff Brand Corp. U.S. entity. Also during the three months ended March 31, 2024, the Company signed articles of organization for Just Brands FL LLC, a United States domestic limited liability company, which is <ix:nonFraction id="F20240527045705308_6" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapBusinessAcquisitionAxis_flgcJustBrandsLLCMember" unitRef="Pure">100</ix:nonFraction>% owned by the Company and has a functional currency of the United States dollar.</span></span></p>
                                        </div>
                                    </ix:nonNumeric>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20240529105303682_42" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3.<span style="display: inline-block; width: 20pt;">&#160;</span>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all its shares in its Colombian related subsidiaries and its Colombian assets for a purchase price of CAD $<ix:nonFraction id="F20240529105303665_32" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD">0.8</ix:nonFraction> million (USD $<ix:nonFraction id="F20240529105303673_33" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">0.6</ix:nonFraction> million). The sale relates to all of Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab 2, Flora Lab 4 and Flora's Colombian food and beverage and consumer products business. The Company received proceeds of CAD $<ix:nonFraction id="F20240529105303681_34" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD">0.5</ix:nonFraction> million during the year ended December 31, 2023 which completed the sale and transfer of Flora Growth Corp Colombia S.A.S, Flora Lab S.A.S., Flora Med S.A.S., Labcofarm Laboratorios S.A.S., Kasa Wholefoods Company S.A.S., Flora Growth Corp. Sucursal Colombia and Flora Beauty LLC Sucursal Colombia. The Company and Lisan completed the sale of Cosechemos Ya S.A.S on November 1, 2023.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The sale enabled the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following table summarizes the major classes of line items included in loss from discontinued operations, net of tax, for the three months ended March 31, 2024 and 2023:</span></span></p>
                        <ix:nonNumeric id="F20240529105303682_40" name="flgc:ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                            <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span> </span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2024</b></span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2023</b></span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303657_0" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303658_1" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">788</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cost of sales</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303658_2" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303658_3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">657</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross profit from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303658_4" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303659_5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">131</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating expenses</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Consulting and management fees</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303659_6" name="flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303659_7" name="flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">369</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303659_8" name="flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303660_9" name="flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">36</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303660_10" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303660_11" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">176</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Promotion and communication</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303660_12" name="flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303661_13" name="flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">6</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303661_14" name="flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303661_15" name="flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">50</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303661_16" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303661_17" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">78</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303681_35" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303657_05" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">124</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating loss from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303662_19" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240529105303662_20" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">708</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303662_21" name="flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303662_22" name="flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss before income taxes</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303658_12" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240529105303658_15" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">708</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303683_43" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303663_25" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">11</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303663_26" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240529105303663_27" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">719</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231108100011769_20240529105303663_26" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD_Per_Share">0.00</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231108100011769_20240529105303663_27" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD_Per_Share">0.11</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231108100013814_20240529105303663_26" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD_Per_Share">0.00</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20231108100013814_20240529105303663_27" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="CAD_Per_Share">0.11</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following table summarizes the significant operating and investing items related to the Colombian subsidiaries for the three months ended March 31, 2024 and 2023</span></span></p>
                        <div>
                            <div>
                                <ix:exclude>
                                    <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">182</span></span></span></div>
                                    <div>
                                        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                    </div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                            </td>
                                        </tr>
                                    </table>
                                </ix:exclude>
                            </div>
                        </div>
                        <ix:nonNumeric id="F20240529105303682_41" name="flgc:ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span><br/><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2024</b></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2023</b></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating activities of discontinued operations</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303664_28" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303664_29" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">78</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investing activities of discontinued operations</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Purchases of property, plant and equipment</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303664_30" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240529105303664_31" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember" unitRef="USD">94</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The subsidiaries sold included Cosechemos Ya S.A.S, which was part of the commercial and wholesale segment; Flora Lab S.A.S, Flora Med S.A.S. and Labcofarm Laboratories S.A.S, which were part of the pharmaceuticals segment; Flora Growth Corp Colombia S.A.S., Kasa Wholefoods Company, S.A.S. and Flora Beauty LLC Sucursal Colombia which were part of the house of brands segment.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company applies significant judgement in determining whether a disposal meets the criteria to present as held for sale at the reporting date, and whether the disposal represents a strategic shift that has (or will have) a major effect on its operations and financial results in order to be classified as a discontinued operation. The criteria evaluated are both quantitative and qualitative in nature, to evaluate the significance of the disposal relative to the operations of the Company as a whole. The Company has determined this disposition represents a strategic shift in operations that will have a major effect on the Company's operations and financial results, and accordingly, has been presented as discontinued operations.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div>
                <ix:nonNumeric id="F20240527045705324_28" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4.<span style="display: inline-block; width: 20pt;">&#160;</span>TRADE AND AMOUNTS RECEIVABLE </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's trade and amounts receivable are recorded at amortized cost. The trade and other receivables balance as at March 31, 2024 and December 31, 2023 consists of trade accounts receivable, amounts recoverable from the Government of Canada for Harmonized Sales Taxes ("HST"), as well as Value Added Tax ("VAT") from various jurisdictions, and other receivables.</span></span></p>
                        <ix:nonNumeric id="F20240527045705324_19" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true" contextRef="C_20240101to20240331">
                            <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>March 31, 2024</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Trade accounts receivable</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="F20240527045705322_0" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">2,595</ix:nonFraction></b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705322_1" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">2,299</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Allowance for expected credit losses</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(<ix:nonFraction id="F20240527045705322_2" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">317</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(<ix:nonFraction id="F20240527045705322_3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">315</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">HST/VAT receivable</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="F20240527045705323_4" name="us-gaap:ValueAddedTaxReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">765</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705323_5" name="us-gaap:ValueAddedTaxReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,840</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Other receivables</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="F20240527045705323_6" name="us-gaap:OtherReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">175</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705323_7" name="us-gaap:OtherReceivables" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">126</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b><ix:nonFraction id="F20240527045705323_8" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">3,218</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705323_9" name="us-gaap:AccountsReceivableNetCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">3,950</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Changes in the trade accounts receivable allowance in the three months ended March 31, 2024 relate to establishing an allowance for expected credit losses and reclassification of assets held for sale. There were $<ix:nonFraction id="F20240527045705324_17" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" decimals="-6" format="ixt-sec:numwordsen" contextRef="C_20240101to20240331" unitRef="USD">nil</ix:nonFraction> and less than $<ix:nonFraction id="F20240527045705324_18" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">0.1</ix:nonFraction> million in write-offs of trade receivables during the three months ended March 31, 2024 and 2023, respectively. The Company has no amounts written-off that are still subject to collection enforcement activity as at March 31, 2024. The Company's aging of trade accounts receivable is as follows:</span></span></p>
                        <ix:nonNumeric id="F20240527045705324_27" name="flgc:ScheduleOfCompanyAgingOfTradeAccountsReceivable" escape="true" contextRef="C_20240101to20240331">
                            <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>March 31, 2024</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Current</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_20" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember" unitRef="USD">567</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705323_10" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember" unitRef="USD">218</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1-30 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_21" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember" unitRef="USD">1,314</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705323_11" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember" unitRef="USD">588</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">31-60 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_22" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember" unitRef="USD">236</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705323_12" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember" unitRef="USD">577</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">61-90 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_23" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember" unitRef="USD">173</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705323_13" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember" unitRef="USD">448</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">91-180 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_24" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember" unitRef="USD">238</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_14" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember" unitRef="USD">401</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">180+ Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_25" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember" unitRef="USD">67</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_15" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember" unitRef="USD">67</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total trade receivables</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_26" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">2,595</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><ix:nonFraction id="F20240527045705324_16" name="flgc:TradeAccountsReceivable" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">2,299</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <div>
                    <ix:nonNumeric id="F20240527045705328_6" name="us-gaap:InventoryDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>5.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>INVENTORY </b></span></span></p>
                            <div>
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory is comprised of the following:</span></span></p>
                                    <div>
                                        <ix:nonNumeric id="F20240527045705328_7" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                                            <div>
                                                <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Raw materials and supplies</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705327_0" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">1,053</ix:nonFraction></b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705327_1" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,180</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finished goods</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705327_2" name="us-gaap:InventoryFinishedGoods" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">8,193</ix:nonFraction></b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705327_3" name="us-gaap:InventoryFinishedGoods" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">7,328</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705327_4" name="us-gaap:InventoryNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">9,246</ix:nonFraction></b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705328_5" name="us-gaap:InventoryNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">8,508</ix:nonFraction></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>
                                        </ix:nonNumeric>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </ix:nonNumeric>
                </div>
            </div>
            <div style="margin-top: 15pt;">
                <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">183</span></span></span></div>
                <div>
                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                </div>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                        </td>
                    </tr>
                </table>
            </div>
            <div>
                <div>
                    <div>
                        <ix:nonNumeric id="F20240527045705331_12" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>PROPERTY, PLANT AND EQUIPMENT </b></span></span></p>
                                <div>
                                    <div>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment consist of the following:</span></span></p>
                                        <ix:nonNumeric id="F20240527045705331_15" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" contextRef="C_20240101to20240331">
                                            <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Land</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705330_0" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember" unitRef="USD">292</ix:nonFraction></b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705330_1" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember" unitRef="USD">298</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Buildings</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705331_16" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember" unitRef="USD">91</ix:nonFraction></b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705331_17" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember" unitRef="USD">78</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705330_2" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember" unitRef="USD">697</ix:nonFraction></b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705330_3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember" unitRef="USD">696</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vehicles</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705330_4" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember" unitRef="USD">37</ix:nonFraction></b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705330_5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember" unitRef="USD">37</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705330_6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">1,117</ix:nonFraction></b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705330_7" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,109</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20240527045705331_8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">331</ix:nonFraction></b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705331_9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">262</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 9px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705331_10" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">786</ix:nonFraction></b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705331_11" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">847</ix:nonFraction></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                            </table>
                                        </ix:nonNumeric>
                                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Depreciation expense for the three months ended March 3, 2024 was less than $</span><ix:nonFraction id="F20240527045705331_13" name="us-gaap:Depreciation" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">0.1</ix:nonFraction> million, (March 31, 2023 - $<ix:nonFraction id="F20240527045705331_14" name="us-gaap:Depreciation" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">0.1</ix:nonFraction><span> million) and was recorded in depreciation and amortization in the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></span></p>
                                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>See Note 8 for discussion of impairment of property, plant and equipment during the three months ended March 31, 2024.</span></span></span></p>
                                    </div>
                                </div>
                            </div>
                        </ix:nonNumeric>
                    </div>
                </div>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20240527045705334_0" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                <p style="font-size: 10pt; font-family: Times New Roman; margin: 0pt 0px 0px 0in; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>INTANGIBLE ASSETS AND GOODWILL </b></span></span></p>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A continuity of intangible assets for the three months ended March 31, 2024 is as follows:</span></span></p>
                        <ix:nonNumeric id="F20240527045705340_36" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                            <table style="width: 70%; border-collapse: collapse; font-size: 8pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; width: 311px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Patents</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Total</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Cost</b></span></span></span></span></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At December 31, 2023</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_1" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">1,892</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_2" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">1,098</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">2,990</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Additions</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_4" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">-</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331" unitRef="USD">-</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At March 31, 2024</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_7" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">1,892</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_8" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">1,098</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705335_9" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">2,990</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Accumulated Amortization</b></span></span></span></span></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At December 31, 2023</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705336_10" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">1,132</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705336_11" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">912</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705336_12" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">2,044</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Additions</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705336_13" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">31</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705336_14" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">7</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705336_15" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">38</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At March 31, 2024</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705337_16" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">1,163</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705337_17" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">919</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><ix:nonFraction id="F20240527045705337_18" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">2,082</ix:nonFraction></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Net book value at March 31, 2024</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b><ix:nonFraction id="F20240527045705338_23" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember" unitRef="USD">729</ix:nonFraction></b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b><ix:nonFraction id="F20240527045705338_24" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember" unitRef="USD">179</ix:nonFraction></b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b><ix:nonFraction id="F20240527045705338_26" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">908</ix:nonFraction></b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="background-color: #ffffff;">Amortization expense for the three months ended March 31, 2024 was less than $</span><span id="xbrl_20240530114158815">0.1</span><span style="background-color: #ffffff;"> million (March 31, 2023 - </span>$<ix:nonFraction id="F20240527045705338_27" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">0.8</ix:nonFraction>)<span style="background-color: #ffffff;"> and was recorded in depreciation and amortization in the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At March 31, 2024, the weighted average amortization period remaining for intangible assets was <ix:nonNumeric id="F20240527045705339_28" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" contextRef="C_20240331">6.0</ix:nonNumeric> years.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At March 31, 2024, the estimated future amortization expense related to intangible assets is as follows:</span></span></p>
                        <ix:nonNumeric id="F20240527045705340_37" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                            <table style="width: 30%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705339_29" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">115</ix:nonFraction></span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705339_30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">152</ix:nonFraction></span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705339_31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">152</ix:nonFraction></span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705339_32" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">152</ix:nonFraction></span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705339_33" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">152</ix:nonFraction></span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705340_34" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">185</ix:nonFraction></span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705340_35" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">908</ix:nonFraction></span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20240527045705345_1" name="us-gaap:AssetImpairmentChargesTextBlock" escape="true" contextRef="C_20240101to20240331">
                <div>
                    <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8.<span style="display: inline-block; width: 20pt;">&#160;</span>ASSET IMPAIRMENT</b></span></span></p>
                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As discussed in Note 14, on May 7, 2024, Just Brands agreed to a settlement and general release, whereby Just Brands will remove the products subject to the stop sales orders from the state of Florida and accept a five-year revocation of its food permit in the state of Florida. As a result of this settlement, the Company began negotiations to exit its current warehouse lease in Pompano Beach, FL, and searching for a new warehousing facility in a different state. The Company considered this to be an indicator of impairment and, thus, performed a quantitative analysis as of March 31, 2024 to determine if impairment existed by comparing the carrying amount of the operating lease right of use asset and related leasehold improvements to the future undiscounted cash flows the asset is expected to generate over its remaining life. This analysis indicated the asset values may not be recoverable. The Company then calculated the fair value of this asset using an income approach. As a result, the Company recorded an impairment of operating lease right of use assets and property, plant and equipment within its Vessel asset group within the house of brands segment totaling $<ix:nonFraction id="F20240527045705345_0" name="us-gaap:AssetImpairmentCharges" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">0.9</ix:nonFraction> million. These charges were recorded in the asset impairment caption on the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></p>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <ix:nonNumeric id="F20240527045705348_0" name="us-gaap:DebtDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                <div>
                    <div>
                        <div>
                            <div>
                                <div>
                                    <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.<span style="display: inline-block; width: 20pt;">&#160;</span>DEBT</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Euro credit facility</b></span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company, through FGH, has credit facilities totaling <ix:nonFraction id="F20240527045705348_1" name="us-gaap:LineOfCredit" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember" unitRef="EUR">4.3</ix:nonFraction>&#160;million Euro ($<ix:nonFraction id="F20240527045705348_3" name="us-gaap:LineOfCredit" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember" unitRef="USD">4.6</ix:nonFraction>&#160;million USD), at three different banks in Germany. These arrangements are open ended without predetermined maturity dates. Principal and interest payments are due at the end of each term. Interest rates can change with each new amount drawn. As of March 31, 2024, the total outstanding amount on these credit facilities was <ix:nonFraction id="F20240527045705348_2" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember" unitRef="EUR">2.9</ix:nonFraction> million Euro ($<ix:nonFraction id="F20240527045705348_4" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember" unitRef="USD">3.1</ix:nonFraction> million USD) with interest rates ranging from <ix:nonFraction id="F20240527045705348_5" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_srtRangeAxis_srtMinimumMember_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember" unitRef="Pure">5.45</ix:nonFraction>% to <ix:nonFraction id="F20240527045705348_6" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_srtRangeAxis_srtMaximumMember_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember" unitRef="Pure">6.44</ix:nonFraction>% and due within the next twelve months. These credit facilities were secured by various guarantees, including joint and several guarantees of two managing directors of Phatebo, a subsidiary of FGH, and payment guarantees upon default.</span></span></p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin: 0pt;">&#160;</p>
            <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">184</span></span></span></div>
            <div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
            </div>
            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                <tr>
                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                    </td>
                </tr>
            </table>
            <ix:nonNumeric id="F20240527045705352_0" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10.<span style="display: inline-block; width: 20pt;">&#160;</span>LEASES</b></span></span></p>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's leases primarily consist of administrative real estate leases in Germany and the United States. Management has determined all the Company's leases are operating leases through March 31, 2024. Information regarding the Company's leases is as follows:</span></span></p>
                        <ix:nonNumeric id="F20240527045705352_1" name="us-gaap:LeaseCostTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                            <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended March</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><b>31, 2024 </b></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">Three months</span></span><br/><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">ended March 31,</span></span> </span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">2023</span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Components of lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705353_12" name="us-gaap:OperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">165</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705353_15" name="us-gaap:OperatingLeaseExpense" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">316</ix:nonFraction></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Short-term lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705353_13" name="us-gaap:ShortTermLeaseCost" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">142</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705353_14" name="us-gaap:ShortTermLeaseCost" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">55</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sublease income</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="Fxbrl_20231102183650157_20240527045705353_13" name="us-gaap:SubleaseIncome" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">84</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20231102183650157_20240527045705353_14" name="us-gaap:SubleaseIncome" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20230101to20230331" unitRef="USD">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705354_16" name="us-gaap:LeaseCost" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">223</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705354_17" name="us-gaap:LeaseCost" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">371</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 1%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 12%; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Information</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating cash flows from operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705354_18" name="us-gaap:OperatingLeasePayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">345</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705354_20" name="us-gaap:OperatingLeasePayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">324</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">ROU assets obtained in exchange for new operating lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705354_19" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">1,247</ix:nonFraction></b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705354_21" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">97</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average remaining lease term in years for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                    <ix:nonNumeric id="F20240527045705354_22" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" contextRef="C_20240331">3.7</ix:nonNumeric>
                                                </b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="F20240527045705354_23" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" contextRef="C_20230331">2.9</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average discount rate for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705354_24" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="Pure">8.9</ix:nonFraction>%</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705354_25" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20230331" unitRef="Pure">7.7</ix:nonFraction>%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Maturities of operating lease liabilities as of March 31, 2024 are as follows:</span></span></p>
                        <ix:nonNumeric id="F20240527045705352_2" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                            <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating Leases </b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705352_3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">794</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705352_4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">766</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705352_5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">678</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705353_6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">505</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705353_7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">322</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705354_29" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">28</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total future lease payments</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705353_8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">3,093</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: imputed interest</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705353_9" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">473</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705353_10" name="us-gaap:OperatingLeaseLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">2,620</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705353_11" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">803</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total non-current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705354_26" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">1,817</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Some of the Company's leases contain renewal options to continue the leases for another term equivalent to the original term, which are generally up to five years. The lease liabilities above include renewal terms that management has executed or is reasonably certain of renewing, which only included leases that would have expired in 2024.</span></span></p>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>In April 2024, the Company began leasing 4,184 sq. ft. of office space in Fort Lauderdale, FL, for $<ix:nonFraction id="F20240527045705354_30" name="flgc:MonthlyLeasePayment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">8,000</ix:nonFraction> a month, pursuant to a lease agreement that expires in March 2028.</span></span></span></span></p>
                                <div>
                                    <ix:exclude>
                                        <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">185</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                                </td>
                                            </tr>
                                        </table>
                                    </ix:exclude>
                                </div>
                                <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company began subleasing retail space in Miami, Florida to a third party during the third quarter of 2023. The sublease agreement is effective through November 30, 2026 and contains one option to renew for five more years. The Company began subleasing warehousing and office space in Carlsbad, CA to a third party during the fourth quarter of 2023. The sublease is effective through August 31, 2027 and does not contain renewal options.</span></span></p>
                                <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">See Note 8 for discussion of impairment of operating lease right of use assets during the three months ended March 31, 2024.</span></span></p>
                            </div>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="font-size: 10pt; font-family: Times New Roman; margin: 0pt 0px; text-align: justify;">&#160;</p>
            <ix:nonNumeric id="F20240527045705357_0" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                <div>
                    <div>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>SHARE CAPITAL &#160;</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Authorized and issued</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company is authorized to issue an unlimited number of common shares, no par value. On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had the following significant common share transactions:</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="text-decoration: underline;"><b>Three months ended March 31, 2024</b></span></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>OTHER ISSUANCES</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On March 8, 2024, the Company entered into a settlement agreement with a third party pursuant to which the Company issued <ix:nonFraction id="F20240527045705357_1" name="us-gaap:StockIssuedDuringPeriodSharesOther" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240304to20240308" unitRef="Shares">50,000</ix:nonFraction> common shares of the Company, valued at $<ix:nonFraction id="F20240527045705357_2" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240304to20240308" unitRef="USD">0.1</ix:nonFraction> million, to a third party to settle outstanding amounts owed.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">See Note 18 for subsequent issuance of shares.</span></span></p>
                            </div>
                        </div>
                    </div>
                </div>
            </ix:nonNumeric>
            <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20240527045705363_28" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>12.</b><span style="display: inline-block; width: 15.5pt;">&#160;</span><b>SHARE BASED COMPENSATION</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's 2022 Incentive Compensation Plan (the "2022 Plan") and its previous "'rolling" stock option plan (the "Prior Plan") are described in the Company's 2023 Form 10-K.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>OPTIONS</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options granted under the Prior Plan are non-transferable and non-assignable and may be granted for a term not exceeding five years. Under the 2022 Plan, stock options may be granted with a term of up to ten years and in the case of all stock options, the exercise price may not be less than 100% of the fair market value of a Common Share on the date the award is granted. Stock option vesting terms are subject to the discretion of the Compensation Committee of the Company's Board of Directors. Common shares are newly issued from available authorized shares upon exercise of awards. The Company no longer makes new grants of stock options under the Prior Plan.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Information relating to share options outstanding and exercisable as at March 31, 2024 and December 31, 2023 is as follows:</span></span></p>
                                <ix:nonNumeric id="F20240527045705363_29" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" escape="true" contextRef="C_20240101to20240331">
                                    <div>
                                        <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="4"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Options Outstanding</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="4"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;" colspan="1">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Number of</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>options (in</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>thousands)</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>average</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>exercise</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted average</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>remaining life</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>(years)</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Aggregate</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>intrinsic</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>value</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Outstanding balance, December 31, 2023</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705360_0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">49</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705360_1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="CAD_Per_Share">27.04</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705360_2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">2.8</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705360_3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Forfeited</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705360_4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">11</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705360_5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="CAD_Per_Share">44.03</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705360_6" name="flgc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">2.0</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Outstanding balance, March 31, 2024</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705361_7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">38</ix:nonFraction></b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705361_8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="CAD_Per_Share">22.25</ix:nonFraction></b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                                <ix:nonNumeric id="F20240527045705361_9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">2.7</ix:nonNumeric>
                                                            </b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705361_10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Exercisable balance, March 31, 2024</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705362_18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="Shares">38</ix:nonFraction></b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705362_19" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="CAD_Per_Share">22.25</ix:nonFraction></b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                                <ix:nonNumeric id="F20240527045705362_20" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">2.7</ix:nonNumeric>
                                                            </b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705362_21" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember" unitRef="USD">-</ix:nonFraction></b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total expense related to the options granted in the three months ended March 31, 2024 was less than $<ix:nonFraction id="F20240527045705361_11" name="us-gaap:StockOptionPlanExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">0.1</ix:nonFraction> million (2023 total expense - $<ix:nonFraction id="F20240527045705362_22" name="us-gaap:StockOptionPlanExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">0.1</ix:nonFraction> million). This expense is included in the share-based compensation line on the unaudited condensed interim consolidated statements of loss and comprehensive loss. Generally, the options granted in 2023 vest one to two years following the date of grant provided that the recipient is still employed or engaged by the Company.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At March 31, 2024 the total remaining stock option cost for nonvested awards is $<ix:nonFraction id="F20240527045705363_31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" decimals="-3" format="ixt-sec:numwordsen" contextRef="C_20240331" unitRef="USD">nil</ix:nonFraction>.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>RESTRICTED STOCK AWARDS</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted stock is a grant of common shares which may not be sold or disposed of, and which is subject to such risks of forfeiture and other restrictions as the Committee, in its discretion, may impose. A participant granted restricted stock generally has all of the rights of a shareholder of the Company, unless otherwise determined by the Committee. Subject to certain exceptions, the vesting of restricted stock awards is subject to the holder's continued employment or engagement through the applicable vesting date. Unvested restricted stock awards will be forfeited if the holder's employment or engagement ceases during the vesting period and may, in certain circumstances, be accelerated. The Company values restricted stock awards based on the closing share price of the Company's common shares as of the date of grant. The fair value of the restricted stock award is recorded as expense over the vesting period.</span></span></p>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">186</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                                    </td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Information relating to restricted stock awards outstanding as at March 31, 2024 and December 31, 2023:</span></span></p>
                                <ix:nonNumeric id="F20240527045705363_30" name="flgc:ScheduleOfRestrictedStockAwards" escape="true" contextRef="C_20240101to20240331">
                                    <div>
                                        <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Number of</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>restricted stock</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>awards</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted</b></span></span></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>average grant</b></span></span></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>date fair value</b></span></span></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2023</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705361_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">391</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705361_13" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="CAD_Per_Share">1.41</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705362_23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">363</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705363_25" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="CAD_Per_Share">0.76</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705362_24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">4</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705363_26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="CAD_Per_Share">6.90</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705362_14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares">24</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705362_15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="CAD_Per_Share">10.24</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total expense related to the restricted stock awards in the three months ended March 31, 2024 was less than $<ix:nonFraction id="F20240527045705362_16" name="us-gaap:RestrictedStockExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD">0.1</ix:nonFraction> million ($<ix:nonFraction id="F20240527045705363_27" name="us-gaap:RestrictedStockExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD">0.5</ix:nonFraction> million in the three months ended March 31, 2023). This expense is included in the share based compensation line on the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The outstanding restricted stock awards vest over the next two years provided the award holder is still employed or engaged by the Company. As of March 31, 2024, the Company had $<ix:nonFraction id="F20240527045705362_17" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD">0.1</ix:nonFraction> million of unrecognized compensation expense related to restricted stock awards which will be recognized over the next two years.</span></span></p>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20240527045705370_28" name="flgc:WarrantsDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>13.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>WARRANTS</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following summarizes the number of warrants outstanding as of March 31, 2024:</span></span></p>
                                <ix:nonNumeric id="F20240527045705370_29" name="flgc:ScheduleOfWarrantsOutstandingTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                                    <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; border-top: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Number of warrants</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted average</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>exercise price</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">
                                                <p style="font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;">Balance, December 31, 2023</span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240530202721185" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xsi:nil="true" contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares"/></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705367_0" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">2,384</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705367_1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="CAD_Per_Share">9.90</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, March 31, 2024</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705368_2" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="Shares">2,384</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="Fxbrl_20240529170615653" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember" unitRef="CAD_Per_Share">9.90</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>&#160;<ix:nonNumeric id="F20240527045705371_40" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true" contextRef="C_20240101to20240331">
                                    <div>
                                        <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Warrants</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>outstanding</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Exercise</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>price</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Grant date fair</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>value</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Remaining life</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>in years</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705370_24" name="flgc:WarrantsDateOfExpiry" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">November 18, 2026</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705368_4" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember" unitRef="Shares">221</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705368_5" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember" unitRef="CAD_Per_Share">75.00</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705368_6" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember" unitRef="USD">6,729</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705368_7" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">2.64</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705370_25" name="flgc:WarrantsDateOfExpiry" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">November 18, 2027</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705368_8" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember" unitRef="Shares">23</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705368_9" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember" unitRef="CAD_Per_Share">66.00</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705368_10" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember" unitRef="USD">1,055</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705369_11" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">3.64</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705370_26" name="flgc:WarrantsDateOfExpiry" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">December 8, 2027</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705369_12" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember" unitRef="Shares">25</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705369_13" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember" unitRef="CAD_Per_Share">8.80</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705369_14" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember" unitRef="USD">149</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705369_15" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">3.69</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705370_27" name="flgc:WarrantsDateOfExpiry" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">September 21, 2028</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705369_16" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember" unitRef="Shares">691</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705369_17" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember" unitRef="CAD_Per_Share">2.50</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705369_18" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember" unitRef="USD">712</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705369_19" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">4.48</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705370_30" name="flgc:WarrantsDateOfExpiry" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">September 21, 2028</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705371_32" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember" unitRef="Shares">55</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705371_34" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember" unitRef="CAD_Per_Share">2.39</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705371_36" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember" unitRef="USD">81</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705371_38" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">4.48</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705370_31" name="flgc:WarrantsDateOfExpiry" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">March 21, 2029</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705371_33" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember" unitRef="Shares">1,369</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705371_35" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember" unitRef="CAD_Per_Share">2.50</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705371_37" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember" unitRef="USD">1,120</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705371_39" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">4.98</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705370_20" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember" unitRef="Shares">2,384</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705370_21" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember" unitRef="CAD_Per_Share">9.90</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705370_22" name="flgc:GrantDateFairValueOfWarrantsOutstanding" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember" unitRef="USD">9,846</ix:nonFraction></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            <ix:nonNumeric id="F20240527045705370_23" name="flgc:WarrantsRemainingLifeInYears" format="ixt-sec:duryear" contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">4.58</ix:nonNumeric>
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20240527045705376_3" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>14.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>COMMITMENTS AND CONTINGENCIES</b></span></span></p>
                        <div>
                            <div>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's current known provisions and contingent liabilities consist of the following as of March 31, 2024:</span></span></p>
                                <ix:nonNumeric id="F20240527045705377_4" name="us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock" escape="true" contextRef="C_20240101to20240331">
                                    <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Legal disputes</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sales tax</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2023</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705377_5" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">2,962</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705377_10" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">2,538</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705378_15" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">5,500</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Payments/Settlements</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705377_6" name="us-gaap:LossContingencyAccrualPayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">7</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705377_11" name="us-gaap:LossContingencyAccrualPayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">168</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705378_16" name="us-gaap:LossContingencyAccrualPayments" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">175</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Additional provisions</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705377_7" name="us-gaap:LossContingencyAccrualProvision" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">1,007</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705378_12" name="us-gaap:LossContingencyAccrualProvision" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">158</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705378_17" name="us-gaap:LossContingencyAccrualProvision" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">1,165</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign currency translation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305141410684_20240527045705377_7" name="flgc:LossContingencyAccrualForeignCurrencyTranslation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">101</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305141410684_20240527045705378_12" name="flgc:LossContingencyAccrualForeignCurrencyTranslation" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">-</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240305141410684_20240527045705378_17" name="flgc:LossContingencyAccrualForeignCurrencyTranslation" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">101</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance as at March 31, 2024</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705377_9" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember" unitRef="USD">4,063</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705378_14" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember" unitRef="USD">2,528</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705378_19" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">6,591</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>
                                </ix:nonNumeric>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">187</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                                    </td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The legal disputes balance as of March 31, 2024, relate to the settlement of a contractual dispute involving the Company. It involves a former shareholder of ACA Mueller, an entity that was part of the Company's acquisition of FGH in December 2022, who filed a statement of claim against a wholly owned subsidiary of the Company in the Constance Regional Court in Germany. In March 2024, the Constance Regional Court in Germany ordered the Company to pay the plaintiff $<ix:nonFraction id="F20240527045705376_0" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember" unitRef="USD">3.0</ix:nonFraction> million plus interest thereon at a <ix:nonNumeric id="F20240527045705380_34" name="flgc:LossContingencyInterestPaymentTerms" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember">rate of 5% above the prime rate since September 6, 2020 in addition to 83% of the legal fees.</ix:nonNumeric> The Company has since filed an appeal. While the Company believes that this claim is without merit, at this time the Company believes it is probable that a liability has been incurred and the Company is able to reasonably estimate the loss of $<ix:nonFraction id="F20240527045705380_32" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember" unitRef="USD">4.1</ix:nonFraction> million, including $<ix:nonFraction id="F20240527045705380_33" name="flgc:LossContingencyEstimateOfPossibleLossInterestAccrued" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember" unitRef="USD">1.0</ix:nonFraction> million of interest accrued in the three months ended March 31, 2024. As a result, without acknowledgement (explicitly or implicitly) of any amount of liability arising from this claim, the Company recognized a provision of $<ix:nonFraction id="F20240527045705376_2" name="us-gaap:LossContingencyAccrualProvision" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember" unitRef="USD">4.1</ix:nonFraction> million to reflect the value of the claim. This dispute is covered under an indemnification agreement between the Company and the former Chief Executive Officer and shareholder of FGH. The Company intends to vigorously defend itself through appropriate legal proceedings. The $<ix:nonFraction id="F20240527045705376_1" name="us-gaap:LossContingencyAccrualProvision" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember" unitRef="USD">4.1</ix:nonFraction> million is recorded within contingencies and within indemnification receivables on the&#160;unaudited condensed consolidated statements of financial position.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The settlement of legal disputes in 2024 related to the settlement of an action brought against the Company in the Ontario Superior Court of Justice by Gerardo Andres Garcia Mendez claiming that the Company was obligated to issue <ix:nonFraction id="F20240527045705379_20" name="flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember" unitRef="Shares">3,000,000</ix:nonFraction> common shares (pre-splits) to him for a purchase price of $<ix:nonFraction id="F20240527045705379_21" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember" unitRef="USD_Per_Share">0.05</ix:nonFraction> per share as a result of alleged consulting services he performed in 2019. <ix:nonNumeric id="F20240527045705379_22" name="us-gaap:LossContingencyTrialOrAlternativeDisputeResolution" contextRef="C_20240101to20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute.</ix:nonNumeric> The payment was made in January 2024. The amount was recorded within contingencies on the consolidated statements of financial position and expense on the consolidated statements of loss and comprehensive loss for the year ended December 31, 2023.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 30, 2024, a group representing the sellers of Just Brands LLC to Flora in February 2022 brought an action against the Company in the United States District Court for the Southern District of New York claiming that the Company failed to promptly issue additional shares in accordance with a specific formula set forth in the securities purchase agreement after the two-year anniversary of the closing, which occurred on February 24, 2024. The plaintiffs claim that they are entitled to <ix:nonFraction id="F20240527045705381_35" name="flgc:NumberOfSharesUnderPlaintiffClaim" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240430_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">182,889</ix:nonFraction> common shares and $<ix:nonFraction id="F20240527045705382_41" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240401to20240430_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD">38.0</ix:nonFraction> million to complete the acquisition of Just Brands LLC. The Company has assessed the claims and concluded that it is probable that a liability has been incurred and that the Company is able to reasonably estimate the loss based on the fair value of <ix:nonFraction id="F20240527045705381_36" name="flgc:LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240430_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">632,484</ix:nonFraction> common shares of the Company. As at March 31, 2024, this value is $<ix:nonFraction id="F20240527045705381_37" name="us-gaap:LossContingencyAccrualProvision" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331to20240331_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember" unitRef="USD">1.5</ix:nonFraction> million and has been recorded in the contingent purchase considerations on the unaudited condensed interim consolidated statement of financial position.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Sales tax relates to estimated amounts owed to certain jurisdictions in the Unites States for sales from the Company's JustCBD operations. The ending balance is recorded within contingencies on the unaudited condensed interim consolidated statement of financial position, and additions to the provision as a reduction of revenue on the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Legal proceedings</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company records liabilities for legal proceedings in those instances where it can reasonably estimate the amount of the loss and where liability is probable. The Company is engaged from time-to-time in various legal proceedings and claims that have arisen in the ordinary course of business. The outcome of all the proceedings and claims against the Company is subject to future resolution, including the uncertainties of litigation. Based on information currently known to the Company and after consultation with outside legal counsel, management believes that the probable ultimate resolution of any such proceedings and claims, individually or in the aggregate, will not have a material adverse effect on the financial condition of the Company, taken as a whole as at March 31, 2024.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On November 1, 2023, Just Brands filed an Emergency Complaint for Declaratory Judgment and Injunctive Relief in the Southern District of Florida against the Florida Department of Agriculture and Consumer Services (the "Department") stemming from stop sale orders issued by the Department whereby the Department prohibited Just Brands from selling and moving most of its products. Relying on Florida Statute Section 581.217, which includes the definition of "attractive to children," the Department determined Just Brand's product could not be sold or moved because the products were manufactured in the shape of humans, cartoons, or animals; in a form that bears a reasonable resemblance to an existing candy product; and containing color additives. The Court ruled in favor of the Department and that Order was being appealed to the Eleventh Circuit Court of Appeals. Since then, the Department has initiated an Administrative Action claiming Just Brands moved product outside the State of Florida in violation of the stop sale orders. The statute provides for a penalty of up to $<ix:nonFraction id="F20240527045705379_23" name="flgc:AmountsPayablePerViolationOfStopSaleOrders" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231101_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember" unitRef="USD">5,000</ix:nonFraction> per violation. The Department sought to assess penalties on what they claimed to be a total of <ix:nonFraction id="F20240527045705381_40" name="flgc:NumberOfViolationsInStopSaleOrders" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231101_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember" unitRef="Violation">215,154</ix:nonFraction> violations (one for each package). The Company disputed their claim and intended to vigorously defend against this action. The Company has not accrued a liability as of March 31, 2024. The total value of inventory impacted by the stop sale orders was $<ix:nonFraction id="F20240527045705379_24" name="flgc:InventoryImpactedByStopSaleOrders" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember" unitRef="USD">1.9</ix:nonFraction> million at March 31, 2024.&#160;On May 7, 2024, Just Brands and the Department agreed to a settlement and general release, whereby Just Brands will remove the products subject to the stop sales orders from the state of Florida, pay the Department $<ix:nonFraction id="F20240527045705382_42" name="us-gaap:LossContingencyDamagesAwardedValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240501to20240507_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD">60,500</ix:nonFraction> to reimburse the Department&#8217;s attorney&#8217;s fees, and accept a five-year revocation of its food permit in the state of Florida. By signing the release, Just Brands waived, settled and released all claims it had or might have against the Department.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On May 31, 2023, Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres brought an action against the Company in the Ontario Superior Court of Justice claiming that the Company is obligated to issue <ix:nonFraction id="F20240527045705379_25" name="flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" unitRef="Shares">500,000</ix:nonFraction> common shares (pre-splits) each for a purchase price of $<ix:nonFraction id="F20240527045705379_26" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" unitRef="USD_Per_Share">0.05</ix:nonFraction> per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.</span></span></p>
                                <div>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">188</span></span></span></div>
                                            <div>
                                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                            </div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                        <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                                    </td>
                                                </tr>
                                            </table>
                                        </ix:exclude>
                                    </div>
                                </div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On May 31, 2023, Ramon Ricardo Castellanos Saenz and Miriam Ortiz brought an action against the Company in the Ontario Superior Court of Justice claiming that the Company is obligated to issue <ix:nonFraction id="F20240527045705379_27" name="flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember" unitRef="Shares">1,500,000</ix:nonFraction> common shares (pre-splits) each for a purchase price of $<ix:nonFraction id="F20240527045705380_28" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember" unitRef="USD_Per_Share">0.05</ix:nonFraction> per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In connection with the Company's acquisition of FGH, the Company's current CEO and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $<ix:nonFraction id="F20240527045705381_39" name="flgc:PotentialLiabilities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">5.0</ix:nonFraction> million. In addition to the matter regarding the former shareholder of ACA Mueller, discussed above, the following actions are pending as of the date hereof:</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On February 3, 2023, an action was brought in the Ontario Superior Court of Justice by Nathan Shantz and Liberacion e Inversiones S.A. against various parties including Clifford Starke, the Company's current CEO and FGH's former Chief Executive Officer, and FGH. The statement of claim alleges that, prior to the closing of the Arrangement, <ix:nonFraction id="F20240527045705380_29" name="flgc:WrongfullyTransferredShares" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="Shares">8,831,109</ix:nonFraction> FGH shares purportedly owned by the plaintiffs were wrongfully transferred to third parties, in part through alleged unauthorized steps taken by Mr. Starke. Plaintiffs seek, among other things, a declaration that they are the rightful owners of the shares or, in the alternative, damages. Against FGH, they claim a declaration that, by virtue of the alleged unauthorized transfer of shares, FGH acted oppressively and seek damages in the amount of $<ix:nonFraction id="F20240527045705381_38" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">4.0</ix:nonFraction> million. The defendants have brought motions to stay the proceedings on the grounds that the Ontario court lacks jurisdiction over the claim. In the event FGH should incur any losses in connection with this matter, such losses are to be indemnified by Mr. Starke subject to the maximum threshold of the indemnity agreement. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total amount claimed against the former entities of FGH currently exceeds the maximum $<ix:nonFraction id="F20240527045705380_30" name="flgc:PotentialLiabilities" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">5.0</ix:nonFraction> million of the indemnification agreement. However, the Company is estimating the likelihood of loss in these cases will not exceed $<ix:nonFraction id="F20240527045705380_31" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240331_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember" unitRef="USD">4.1</ix:nonFraction> million.</span></span></p>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20240527045705385_0" name="us-gaap:EarningsPerShareTextBlock" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>15.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>LOSS PER SHARE</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company calculates basic earnings per share based upon the weighted average number of common shares outstanding during the period, while the calculation of diluted earnings per share includes the dilutive effect of potential common shares outstanding during the period. The calculation of diluted earnings per share excludes all potential common shares if their inclusion would have an anti-dilutive effect. Restricted stock award recipients under the 2022 Plan have a non-forfeitable right to receive dividends declared by the Company and are therefore included in computing earnings per share.</span></span></p>
                                <ix:nonNumeric id="F20240527045705385_11" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" contextRef="C_20240101to20240331">
                                    <div>
                                        <table style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705385_1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember" unitRef="Shares">38</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705385_2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember" unitRef="Shares">275</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Warrants</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705385_4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember" unitRef="Shares">2,384</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705385_3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember" unitRef="Shares">960</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted stock awards</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705385_6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember" unitRef="Shares">24</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705385_5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember" unitRef="Shares">198</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD potential additional shares to settle contingent consideration</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705385_8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember" unitRef="Shares">632</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705385_7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember" unitRef="Shares">657</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total anti-dilutive</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705385_10" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="Shares">3,078</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705385_9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="Shares">2,090</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20240527045705388_7" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>16.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>FINANCIAL INSTRUMENTS</b></span></span></span></p>
                        </div>
                        <div>
                            <div>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Fair value</b></span></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Company's financial instruments measured at amortized cost as at March 31, 2024 and December 31, 2023 consist of cash, trade and amounts receivable, loans receivable, trade payables, contingencies, accrued liabilities, lease liabilities, and debt and loans payable. The amounts reflected in the unaudited condensed interim consolidated statements of financial position approximate fair value due to the short-term maturity of these instruments.</span></span></span></p>
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Financial instruments recorded at the reporting date at fair value are classified into one of three levels based upon the fair value hierarchy. Items are categorized based on inputs used to derive fair value based on:</span></span></span></p>
                                <div>
                                    <ix:exclude>
                                        <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">189</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                                </td>
                                            </tr>
                                        </table>
                                    </ix:exclude>
                                </div>
                                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Level 1 - quoted prices that are unadjusted in active markets for identical assets or liabilities</span></span></span></p>
                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Level 2 - inputs other than quoted prices included in level 1 that are observable for the asset/liability either directly or indirectly; and</span></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Level 3 - inputs for the instruments are not based on any observable market data.</span></span></span></p>
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Company's contingent purchase considerations consist of the estimated fair value of contingent purchase consideration from the acquisitions of JustCBD in February 2022 and Original Hemp in March 2023. The amount for JustCBD is measured at FVPL as a Level 2 fair value financial instrument within the fair value hierarchy as at March 31, 2024. The fair value was determined using a simplified calculation which took the expected shares to be issued (<ix:nonFraction id="F20240527045705388_10" name="flgc:ExpectedSharesToBeIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="Shares">632,484</ix:nonFraction>) multiplied by the Company's closing share price at March 31, 2024 ($<ix:nonFraction id="F20240527045705388_11" name="us-gaap:SharePrice" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="CAD_Per_Share">2.31</ix:nonFraction>).&#160; The amount for Original Hemp is measured at FVPL as a Level 3 fair value financial instrument within the fair value hierarchy as at March 31, 2024. The fair value was determined using discounted cash flow models utilizing two different rates, high (<ix:nonFraction id="F20240527045705388_12" name="flgc:CashFlowModelHighRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="Pure">25.1</ix:nonFraction>%) and low (<ix:nonFraction id="F20240527045705388_13" name="flgc:CashFlowModelLowRate" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="Pure">18.4</ix:nonFraction>%), to estimate the present value of the future cash outflows.&#160; As valuations of investments for which market quotations are not readily available are inherently uncertain, may fluctuate within short periods of time and are based on estimates, determination of fair value may differ materially from the values that would have resulted if a ready market existed for the investments. Such changes may have a significant impact on the Company's financial condition or operating results.</span></span></span></p>
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The following tables present information about the Company's financial instruments and their classifications as at March 31, 2024 and December 31, 2023 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value.</span></span></span></p>
                                <ix:nonNumeric id="F20240527045705388_8" name="flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications" escape="true" contextRef="C_20240101to20240331">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Fair value measurements at March 31, 2024 using:</span></span></span></p>
                                        <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Contingent purchase consideration from asset acquisitions and business combinations</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b><ix:nonFraction id="F20240527045705388_0" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member" unitRef="USD">-</ix:nonFraction></b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b><ix:nonFraction id="F20240527045705388_1" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member" unitRef="USD">1,461</ix:nonFraction></b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b><ix:nonFraction id="F20240527045705388_2" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">241</ix:nonFraction></b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b><ix:nonFraction id="F20240527045705388_9" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">1,702</ix:nonFraction></b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                        <span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#160;</span></span></span>
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Fair value measurements at December 31, 2023 using:</span></span></span></p>
                                        <span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"> <span>&#160;</span></span></span>
                                        <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Contingent purchase consideration from asset acquisitions and business combinations</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20240527045705388_3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:fixed-zero" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member" unitRef="USD">-</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20240527045705388_4" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member" unitRef="USD">854</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20240527045705388_5" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="USD">241</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><ix:nonFraction id="F20240527045705388_6" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">1,095</ix:nonFraction></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin: 0pt;">&#160;</p>
            <div>
                <ix:nonNumeric id="F20240527045705394_31" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>17.<span style="display: inline-block; width: 15pt;">&#160;</span></b><b>SEGMENTED INFORMATION</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reports its financial results for the following <ix:nonFraction id="F20240527045705394_34" name="us-gaap:NumberOfOperatingSegments" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20240101to20240331" unitRef="Segment">two</ix:nonFraction> operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH subsidiaries) and house of brands (primarily JustCBD and Vessel subsidiaries). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>For the year ended December 31, 2023, the Company had <ix:nonFraction id="F20240527045705394_36" name="us-gaap:NumberOfOperatingSegments" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231" unitRef="Segment">three</ix:nonFraction> operating segments, which were also its reportable segments: commercial and wholesale, house of brands and pharmaceuticals (formerly the Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries in Colombia). Due to the sale of the Colombian subsidiaries during 2023 and the resulting reclassification into discontinued operations, the Company no longer reports a pharmaceuticals segment. &#160;</span></span></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operates its manufacturing and distribution business within its United States and Germany subsidiaries. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations and includes the Company's long-term investments.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Information regarding the Company's segments is summarized as follows:</span></span></p>
                                <ix:nonNumeric id="F20240527045705394_35" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" contextRef="C_20240101to20240331" continuedAt="F20240508012128802">
                                    <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2024</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705392_7" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">11,342</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705392_8" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">7,958</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705392_9" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">8,020</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705392_10" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">13,765</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20240527045705392_11" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">1,331</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705393_12" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">2,404</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705393_13" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">18,031</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705393_14" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">19,319</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net (Loss) Income from Continuing Operations</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20240527045705393_15" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">236</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705393_16" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">140</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20240527045705393_17" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">967</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705393_18" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">354</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20240527045705393_19" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">2,171</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705393_20" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">2,972</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(<ix:nonFraction id="F20240527045705393_21" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331" unitRef="USD">3,374</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="F20240527045705393_22" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331" unitRef="USD">3,186</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>
                                </ix:nonNumeric>
                                <div>
                                    <ix:exclude>
                                        <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">190</span></span></span></div>
                                        <div>
                                            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                        </div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                    <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                                </td>
                                            </tr>
                                        </table>
                                    </ix:exclude>
                                </div>
                                <ix:continuation id="F20240508012128802">
                                    <div>
                                        <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705392_0" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">10,473</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705392_1" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember" unitRef="USD">9,096</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705392_2" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">11,377</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705392_3" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember" unitRef="USD">11,608</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705392_4" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">2,424</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705392_5" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember" unitRef="USD">2,922</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705392_6" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240331" unitRef="USD">24,274</ix:nonFraction></b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705394_32" name="us-gaap:Assets" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20231231" unitRef="USD">23,626</ix:nonFraction></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:continuation>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Disaggregation of net sales by geographic area:</span></span></p>
                                <ix:nonNumeric id="F20240527045705394_33" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" escape="true" contextRef="C_20240101to20240331">
                                    <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2024</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705393_24" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_srtStatementGeographicalAxis_countryUS" unitRef="USD">6,518</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705393_23" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_srtStatementGeographicalAxis_countryUS" unitRef="USD">10,999</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705393_26" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_srtStatementGeographicalAxis_countryDE" unitRef="USD">11,343</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705393_25" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_srtStatementGeographicalAxis_countryDE" unitRef="USD">7,958</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705393_27" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_srtStatementGeographicalAxis_countryGB" unitRef="USD">170</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705393_28" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_srtStatementGeographicalAxis_countryGB" unitRef="USD">362</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b><ix:nonFraction id="F20240527045705393_29" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331" unitRef="USD">18,031</ix:nonFraction></b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="F20240527045705393_30" name="us-gaap:Revenues" scale="3" decimals="-3" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331" unitRef="USD">19,319</ix:nonFraction></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>
                            </div>
                        </div>
                    </div>
                </ix:nonNumeric>
            </div>
            <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;">&#160;</p>
            <div>
                <div>
                    <div>
                        <div>
                            <ix:nonNumeric id="F20240527045705397_0" name="us-gaap:SubsequentEventsTextBlock" escape="true" contextRef="C_20240101to20240331">
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>18.&#160; &#160; &#160; &#160;&#160;</b><b>SUBSEQUENT EVENTS </b></span></span></span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>ACQUISTION OF TRUHC HOLDING GMBH ("TRUHC")</b></span></span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On April 16, 2024, the Company entered into a Stock Purchase Agreement (the "Purchase Agreement") with TruHC Holding GmbH (the "Seller") pursuant to which the Company will acquire all of the issued and outstanding shares of TruHC Pharma GmbH in exchange for <ix:nonFraction id="F20240527045705397_2" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240416_usgaapBusinessAcquisitionAxis_flgcTruhcHoldingGmbhMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">2,770,562</ix:nonFraction> common shares of the Company (the "Purchase Price").</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Purchase Price will be paid and satisfied by the Company in two closings. At the first closing on April 22, 2024, the Company issued <ix:nonFraction id="F20240527045705397_4" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">2,135,199</ix:nonFraction> of its common shares, which is equal to <ix:nonFraction id="F20240527045705397_5" name="flgc:PercentageOfIssuedAndOutstandingCommonShares" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Pure">19.99</ix:nonFraction>% of the Company's issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the "Second Closing"), the Company will issue <ix:nonFraction id="F20240527045705397_6" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">635,363</ix:nonFraction> of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Under the Purchase Agreement, the Company is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Due to the timing of the closing of this transaction, purchase accounting is incomplete. The Company is evaluating the potential effects of this acquisition on the financial statements. The acquisition will be accounted for in accordance with Accounting Standards Codification ("ASC") Topic 805, "Business Combinations".</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>APRIL EQUITY OFFERING</b></span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On April 4, 2024, Flora entered into an underwriting agreement with Aegis Capital Corp. ("Aegis") as underwriter, relating to the offering, issuance and sale of up to <ix:nonFraction id="F20240527045705397_7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240402to20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">1,700,000</ix:nonFraction> of the Company's common shares ("Common Shares"), no par value per Common Share, at a public offering price of $<ix:nonFraction id="F20240527045705397_8" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD_Per_Share">1.90</ix:nonFraction> per Common Share.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The offering closed on April 8, 2024. The net proceeds to the Company for the offering was approximately $<ix:nonFraction id="F20240527045705397_9" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240407to20240408_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD">2.8</ix:nonFraction> million, after deducting the underwriting discounts and commissions and estimated offering expenses.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The offering of the securities described above was made pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-274204), filed with the Securities and Exchange Commission (the "SEC") on August 25, 2023 and amended on August 30, 2023, which was declared effective, on September 6, 2023, and the base prospectus included therein, as supplemented by the preliminary prospectus supplement filed with the SEC on April 4, 2024 and the final prospectus supplement with the SEC on April 5, 2024.</span></span></span></span></p>
                                    <div>
                                        <ix:exclude>
                                            <div style="text-align: justify; margin-bottom: 0pt;">
                                                <div style="text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="width: 34%; text-align: center;">191</span></span></span></div>
                                                <div>
                                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%; margin-top: 6pt; margin-bottom: 7pt;"/>
                                                </div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; margin-bottom: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 1.5pt solid #000000;">
                                                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Flora Growth Corp.<br/>Notes to the unaudited condensed interim consolidated financial statements</b><br/>For the three months ended March 31, 2024 and 2023<br/>(In thousands of United States dollars, except shares and per share amounts)</span></span></span></span></p>
                                                        </td>
                                                    </tr>
                                                </table>
                                            </div>
                                        </ix:exclude>
                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Aegis acted as sole underwriter for the offering. <ix:nonNumeric id="F20240527045705398_10" name="us-gaap:UnderwritingCommitments" contextRef="C_20240402to20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">The Company agreed to provide Aegis an underwriting discount of 7.0% for underwriter-introduced investors and an underwriting discount of 3.0% for Company-introduced investors.</ix:nonNumeric>&#160;The Company reimbursed Aegis for certain of its expenses, in an amount of up to $<ix:nonFraction id="F20240527045705398_11" name="us-gaap:PaymentsForUnderwritingExpense" scale="6" decimals="-5" format="ixt:num-dot-decimal" contextRef="C_20240402to20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD">0.1</ix:nonFraction> million, including legal fees.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company's CEO, Clifford Starke, subscribed to purchase <ix:nonFraction id="F20240527045705398_12" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240402to20240404_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">1,000,000</ix:nonFraction> of the Common Shares at the public offering price of $<ix:nonFraction id="F20240527045705398_13" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240404_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD_Per_Share">1.90</ix:nonFraction> per Common Share</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>AT THE MARKET ("ATM") OFFERING</b></span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On April 26, 2024, the Company entered into an ATM Issuances Sales Agreement (the "Sales Agreement") with Aegis Capital Corp. (the "Agent") pursuant to which the Company may sell from time to time, at its option, common shares through the Agent in its capacity as sales agent. The sale of common shares, if any, will be made under the Company's registration statement filed on Form S-3 (File No. 333-274204) (the "Registration Statement"), by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act").</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Subject to the terms and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market to sell on the Company's behalf all of the common shares requested to be sold by the Company. The Agent will offer the common shares, subject to the terms and conditions of the Sales Agreement, on a daily basis or as otherwise agreed upon by the Company and the Agent. The Company will designate the maximum amount of common shares to be sold through the Agent on a daily basis or otherwise determine such maximum amount, together with the Agent. The Company may instruct the Agent not to sell common shares if the sales cannot be effected at or above the price designated by the Company in any such instruction. The Company or the Agent may suspend the offering of common shares being made through the Agent under the Sales Agreement upon proper notice to the other parties.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The aggregate compensation payable to the Agent, on behalf of the Agent, shall be up to <ix:nonFraction id="F20240527045705398_14" name="flgc:PercentageOfAggregateGrossProceedsFromSaleOfCommonShares" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20240424to20240426_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Pure">3.0</ix:nonFraction>% of the aggregate gross proceeds from each sale of the common shares sold through the Agent pursuant to the Sales Agreement. In addition, the Company has agreed in the Sales Agreement to provide indemnification and contribution to the Agent against certain liabilities, including liabilities under the Securities Act.</span></span></span></span></p>
                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company is not obligated to make any sales of common shares under the Sales Agreement. The offering of common shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement by the Company or by the Agent, only with respect to itself, under the circumstances specified in the Sales Agreement. The Company has yet to sell any of its common shares under the Sales Agreement.</span></span></span></span></p>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </div>
                </div>
            </div>
            <div>
                <p style="text-align: center; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">192</span></span></p>
            </div>
            <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="color: #1f497d;">&#160;</span></p>
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="color: #1f497d;">&#160;</span></p>
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="color: #1f497d; font-size: 12pt;"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="color: #1f497d;"><b>Financial Statements</b></span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">For the periods ended December 31, 2023 and 2022</span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">&#160;</span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">&#160;</span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">&#160;</span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">&#160;</span></p>
                <div>
                    <p style="text-align: center;">193</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/>
                <p style="text-align: left; margin-top: 10pt;"><span id="REPORT_integixAnchor"><img src="formprer14axz002.jpg" alt="formpre14axu001.jpg" style="width: 828px; height: 38px;"/></span></p>
                <p style="text-align: center;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
                <p>To the Shareholders and Directors of<br/>TruHC Pharma GmbH</p>
                <p style="text-align: justify;"><b><i>Opinion on the Financial Statements</i></b></p>
                <p style="text-align: justify;">We have audited the accompanying statement of financial position of TruHC Pharma GmbH (the &#8220;Company&#8221;), as of December 31, 2023, and the related statements of loss and comprehensive loss, shareholders&#8217; equity (deficiency), and cash flows for the year ended December 31, 2023 and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.</p>
                <p style="text-align: justify;"><b><i>Going Concern</i></b></p>
                <p style="text-align: justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, events and conditions exist that raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
                <p style="text-align: justify;"><b><i>Basis for Opinion</i></b></p>
                <p style="text-align: justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
                <p style="text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
                <p style="text-align: justify;">Our audits included performing procedures to assess the risks of material misstatements of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
                <p style="text-align: justify;"><b><i>Critical Audit Matters</i></b></p>
                <p style="text-align: justify;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. In addition to the matter described in the Going Concern section, we determined that there are no other critical audit matters.</p>
                <p style="text-align: justify;">We have served as the Company&#8217;s auditor since 2024.</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 50%; text-align: right;">&#160;</td>
                        <td style="width: 50%; text-align: right;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><b>/s/ DAVIDSON &amp; COMPANY LLP</b></p>
                        </td>
                    </tr>
                    <tr>
                        <td style="width: 50%; text-align: right;">&#160;</td>
                        <td style="width: 50%; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="width: 50%; text-align: right;">
                            <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left;">Vancouver, Canada&#160;</p>
                        </td>
                        <td style="width: 50%; text-align: right;">Chartered Professional Accountants</td>
                    </tr>
                </table>
                <p style="margin-top: 10pt;">May 31, 2024</p>
                <p style="text-align: center;">&#160;<img src="formprer14axz003.jpg" alt="formpre14axu002.jpg" style="width: 438px; height: 113px;"/></p>
                <div>
                    <p style="text-align: center;">194</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_133_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span id="StatementsofFinancialPosition_integixAnchor"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Statements of Financial Position</b></p>
                <p style="margin-top: 0pt; margin-left: 9pt; margin-bottom: 0pt; text-indent: -9pt; text-align: center;"><b>As at December 31, 2023 and 2022</b></p>
                <p style="margin-top: 0pt; text-align: center;">(in Euros)</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 66.628%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 12.2827%;">December 31, 2023</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9479%;">December<b> </b>31, 2022</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%;">As at:</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12.2827%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 14.9479%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.628%;">ASSETS</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 12.2827%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 14.9479%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%;">Current</td>
                        <td style="vertical-align: bottom; text-align: right; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12.2827%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.628%;">Cash</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529000819276_42" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,588</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529000819276_45" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">15,281</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%;">Amounts receivable</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529000819276_52" name="us-gaap:AccountsReceivableNetCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">18,894</ix:nonFraction></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529000819276_55" name="us-gaap:AccountsReceivableNetCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">18,399</ix:nonFraction></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.628%;">Prepaid expenses and other current assets</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529000819276_62" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">20,347</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529000819276_65" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">20,347</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%;"><b>Total current assets</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; border-bottom: 0.75pt solid #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_72" name="us-gaap:AssetsCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">52,829</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_75" name="us-gaap:AssetsCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">54,027</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.628%;">Non-current</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%;">Property, plant and equipment</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529000819276_92" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">94,837</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529000819276_95" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">104,775</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.628%;">Operating lease right of use assets</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529000819276_102" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">478,399</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529000819276_105" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">553,936</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%;"><b>Total assets</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;"><b>&#8364;</b></td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; border-bottom: 2.25pt double #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_112" name="us-gaap:Assets" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">626,065</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;"><b>&#8364;</b></td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 2.25pt double #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_115" name="us-gaap:Assets" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">712,738</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%; background-color: #e6efff;">LIABILITIES</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%;">Current</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%; background-color: #e6efff;">Trade and amounts payable</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529000819276_142" name="us-gaap:AccountsPayableCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">34,711</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529000819276_145" name="us-gaap:AccountsPayableCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">27,341</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%;">Current portion of operating lease liability</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529000819276_152" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">63,083</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529000819276_155" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">57,805</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%; background-color: #e6efff;">Other accrued liabilities</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529000819276_162" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">11,520</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529000819276_165" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">2,720</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%;"><b>Total current liabilities</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; border-bottom: 0.75pt solid #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_172" name="us-gaap:LiabilitiesCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">109,314</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_175" name="us-gaap:LiabilitiesCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">87,866</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%; background-color: #e6efff;">Non-current</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%;">Non-current portion of debt</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529003536383" name="us-gaap:LongTermDebtNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">645,339</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529003548418" name="us-gaap:LongTermDebtNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">318,590</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%; background-color: #e6efff;">Non-current operating lease liability</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529000819276_202" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">447,581</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529000819276_205" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">510,664</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%;"><b>Total liabilities</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; border-bottom: 0.75pt solid #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_212" name="us-gaap:Liabilities" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">1,202,234</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_215" name="us-gaap:Liabilities" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">917,120</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%; background-color: #e6efff;">SHAREHOLDERS' EQUITY</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%;">Share capital</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529000819276_232" name="us-gaap:CommonStockValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529000819276_235" name="us-gaap:CommonStockValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 66.628%; background-color: #e6efff;">Accumulated deficit</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529000819276_242" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">588,669</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529000819276_245" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">216,882</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%;"><b>Total shareholders' equity</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; border-bottom: 0.75pt solid #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529000819276_252" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">576,169</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529000819276_255" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">204,382</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.628%; background-color: #e6efff;"><b>Total liabilities and shareholders' equity</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;"><b>&#8364;</b></td>
                        <td style="vertical-align: bottom; width: 12.2827%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_262" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">626,065</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;"><b>&#8364;</b></td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><b><ix:nonFraction id="Fxbrl_20240529000819276_265" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">712,738</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                </table>
                <p style="margin-left: 9.35pt; text-indent: -9.35pt; text-align: center; margin-top: 10pt;">The accompanying notes are an integral part of the financial statements.</p>
                <div>
                    <p style="text-align: center;">195</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_134_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span id="StatementofLossandComprehensiveLoss_integixAnchor"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Statement of Loss and Comprehensive Loss</b></p>
                <p style="margin-top: 0pt; margin-left: 9pt; margin-bottom: 0pt; text-indent: -9pt; text-align: center;"><b>For the Periods Ended December 31, 2023 and 2022</b></p>
                <p style="margin-top: 0pt; text-align: center;">(in Euros)</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 66.2804%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 12.6304%;"><b>For the year ended<br/>December 31, 2023</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9479%;"><b>For the period from<br/>February 17, 2022 to </b><br/><b>December 31, 2022</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.2804%;"><b>Operating expenses </b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12.6304%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 14.9479%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.2804%;">Professional fees</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529010655326_22" name="us-gaap:ProfessionalFees" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">7,589</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529010655326_25" name="us-gaap:ProfessionalFees" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">5,038</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.2804%;">General and administrative</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529010655326_32" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">210,622</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529010655326_35" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">113,458</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.2804%;">Travel expenses</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529010655326_42" name="us-gaap:TravelAndEntertainmentExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">2,037</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529010655326_45" name="us-gaap:TravelAndEntertainmentExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">451</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.2804%;">Operating lease expense</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529010655326_52" name="us-gaap:OperatingLeaseExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">123,105</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529010655326_55" name="us-gaap:OperatingLeaseExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">84,783</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.2804%;">Depreciation and amortization</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529010655326_62" name="us-gaap:DepreciationAndAmortization" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">14,675</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529010655326_65" name="us-gaap:DepreciationAndAmortization" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">9,550</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.2804%;"><b>Operating loss</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529010655326_72" name="us-gaap:OperatingIncomeLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">358,028</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529010655326_75" name="us-gaap:OperatingIncomeLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">213,280</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.2804%;">Interest expense</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529010655326_82" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,759</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529010655326_85" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">3,602</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.2804%;"><b>Net loss for the period</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right; border-bottom: 0.75pt solid #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529010655326_92" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">371,787</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529115821900" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">216,882</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.2804%;"><b>Total comprehensive loss for the period</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 12.6304%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529010655326_102" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">371,787</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529010655326_105" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">216,882</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                </table>
                <p style="text-align: center; margin-top: 10pt;">The accompanying notes are an integral part of the financial statements.</p>
                <div>
                    <p style="text-align: center;">196</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_135_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span id="StatementofShareholdersEquityDeficiency_integixAnchor"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Statement of Shareholders' Equity (Deficiency)</b></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>For the Periods Ended December 31, 2023 and 2022</b></p>
                <p style="margin-top: 0pt; text-align: center;">(in Euros)</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 41.9467%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9351%;"><b>&#160;</b><br/><b>Common<br/>Shares</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9351%;"><b>&#160;</b><br/><b>Common<br/>Shares</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9.96524%;"><b>&#160;</b><br/><b>Accumulated<br/>Deficit</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9351%;"><b>Shareholders'<br/>Equity<br/>(Deficiency)</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 41.9467%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9351%;"><b>#</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9351%;"><b>&#160;</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9.96524%;"><b>&#160;</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9351%;"><b>&#160;</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 41.9467%;">Balance, February 17, 2022</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 11.9351%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529014135623" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">25,000</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 11.9351%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529014141591" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240530130751211" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529014213084" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 41.9467%;">Net loss</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 11.9351%;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 11.9351%;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529014232753" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220218to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">216,882</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529014255896" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220218to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">216,882</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 41.9467%;"><b>Balance, December 31, 2022</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 11.9351%; background-color: #e6efff;"><b><ix:nonFraction id="Fxbrl_20240529014614051" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">25,000</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 11.9351%; background-color: #e6efff;"><b><ix:nonFraction id="Fxbrl_20240529014616292" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="EUR">12,500</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><b>(<ix:nonFraction id="Fxbrl_20240529014624909" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">216,882</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><b>(<ix:nonFraction id="Fxbrl_20240529014631025" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">204,382</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 41.9467%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 11.9351%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 11.9351%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 41.9467%;">Net loss</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 11.9351%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 11.9351%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529014659178" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">371,787</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529014705294" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">371,787</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 41.9467%;"><b>Balance, December 31, 2023</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 11.9351%;"><b><ix:nonFraction id="Fxbrl_20240529014640693" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">25,000</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 11.9351%;"><b><ix:nonFraction id="Fxbrl_20240529014648656" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="EUR">12,500</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529014906064" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">588,669</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529014917849" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">576,169</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                    </tr>
                </table>
                <p style="margin-left: 9.35pt; text-indent: -9.35pt; text-align: center; margin-top: 10pt;">The accompanying notes are an integral part of the financial statements.</p>
                <div>
                    <p style="text-align: center;">197</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_136_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span id="StatementofCashFlows_integixAnchor"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Statement of Cash Flows</b></p>
                <p style="margin-top: 0pt; margin-left: 9pt; margin-bottom: 0pt; text-indent: -9pt; text-align: center;"><b>For the Periods Ended December 31, 2023 and 2022</b></p>
                <p style="margin-top: 0pt; text-align: center;">(in Euros)</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 63.9629%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9479%;"><b>For the year ended<br/>December 31, 2023</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9479%;"><b>For the period from<br/>February 17, 2022 to </b><br/><b>December 31, 2022</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;"><b>Cash flows from operating activities:</b></td>
                        <td style="vertical-align: bottom; text-align: right; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%;">Net loss</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">(<ix:nonFraction id="Fxbrl_20240529094610771" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">371,787</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">(<ix:nonFraction id="Fxbrl_20240529094842660" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">216,882</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">Adjustments to net loss:</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%;">Depreciation and amortization</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529095002806" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">14,675</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529100715614" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">9,550</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">Interest expense</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529100738653" name="us-gaap:InterestIncomeExpenseNet" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,749</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529100825458" name="us-gaap:InterestIncomeExpenseNet" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">3,590</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%;">Operating lease expense net of cash payments</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529111753047" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">17,732</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529111829490" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">14,533</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">Net change in non-cash working capital:</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%;">Amounts receivable</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">(<ix:nonFraction id="Fxbrl_20240529120333569" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">495</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">(<ix:nonFraction id="Fxbrl_20240529120352588" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">18,399</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">Prepaid expenses and other assets</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529120517079" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529120533295" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">20,347</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%;">Trade and amounts payable</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529120545291" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">16,170</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529120601047" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">30,061</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;"><b>Net cash provided by (used in) operating activities</b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><b>(<ix:nonFraction id="Fxbrl_20240529120615904" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">309,956</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><b>(<ix:nonFraction id="Fxbrl_20240529120631302" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">197,894</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 63.9629%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;"><b>Cash flows from financing activities: </b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%;">Proceeds from issuance of debt</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529120710637" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">313,000</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529120725936" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">315,000</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">Proceeds from issuance of shares</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529120734902" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529122246087" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%;"><b>Net cash provided by (used in) financing activities </b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529121223632" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">313,000</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529121245702" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">327,500</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%;"><b>Cash flows from investing activities:</b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">Acquisition of equipment</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529121605467" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">4,737</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529121640127" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">114,325</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%;"><b>Net cash provided by (used in) investing activities</b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529121651807" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">4,737</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529121706526" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">114,325</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%;"><b>Change in cash during the period</b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529121713294" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">1,693</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529121747101" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">15,281</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">Cash at beginning of period</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529121832048" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">15,281</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529121958581" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%;"><b>Cash at end of period</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529122046678" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,588</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529122059782" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">15,281</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 14.9479%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 14.9479%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 63.9629%;"><b>Supplemental disclosure of non-cash investing and financing activities</b></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 14.9479%; text-align: right;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 14.9479%; text-align: right;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; width: 63.9629%; background-color: #e6efff;">Operating lease additions to right of use assets</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529122318943" name="flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets" decimals="INF" format="ixt:fixed-zero" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="Shares">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529122349949" name="flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="Shares">604,294</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: center; margin-top: 10pt;">The accompanying notes are an integral part of the financial statements.</p>
                <div>
                    <p style="text-align: center;">198</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_137_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;"><span id="NotestotheFinancialStatements_integixAnchor"><b>TruHC Pharma GmbH</b></span><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                        </tr>
                        <tr>
                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        </tr>
                    </table>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </div>
                <ix:nonNumeric id="Fxbrl_20240529020914405" name="us-gaap:NatureOfOperations" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1.&#160; NATURE OF OPERATIONS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC Pharma GmbH (the "Company" or "TruHC") was incorporated under the laws of Germany on February 17, 2022. The Company engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility. The Company's registered office and principal place of business in Germany is located at Poppenb&#252;tteler Bogen 68 22399 Hamburg, Germany. At December 31, 2023, all of the Company's issued and outstanding shares were owned by TruHC Holding GmbH ("TruHC Holding").</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529021555276" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>2.&#160; BASIS OF PRESENTATION</b></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>These financial statements have been presented in Euros and are prepared in accordance with United States generally accepted accounting principles (&#8220;US GAAP&#8221;). The Company has determined that the Euro is the functional and reporting currency as the majority of our operations are conducted in Euros and the financial results are prepared and reviewed internally by management in Euros.</span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue for a period of at least one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of &#8364;<ix:nonFraction id="Fxbrl_20240529021821837" name="us-gaap:Cash" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,588</ix:nonFraction> at December 31, 2023, net loss of &#8364;<ix:nonFraction id="Fxbrl_20240529021829997" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">371,787</ix:nonFraction> for the year ended December 31, 2023, and an accumulated deficit of &#8364;<ix:nonFraction id="Fxbrl_20240529021837249" name="us-gaap:CumulativeEarningsDeficit" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">588,669</ix:nonFraction> at December 31, 2023. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners or, through obtaining credit from financial institutions and the possible disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#8217;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company&#8217;s performance and investor sentiment with respect to it and its industry. These financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">199</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_138_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of measurement </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial statements have been prepared on the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of amounts receivable, prepaids and other current assets, and trade and amounts payable, accrued liabilities, and current portion of lease liability approximate their fair values due to their short periods to maturity.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial statements are presented in Euros ("&#8364;") unless otherwise noted.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Use of estimates</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529024007738" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>03.&#160; SIGNIFICANT ACCOUNTING POLICIES</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>The significant accounting policies used by the Company are as follows:</b></span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240529024256117" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash </b></span></span></p>
                                <p><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the statements of financial position includes cash on hand.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <ix:nonNumeric id="Fxbrl_20240529024304960" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">200</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_139_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        &#160;<ix:nonNumeric id="Fxbrl_20240529024249599" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>
                                <table style="border-collapse: collapse; font-size: 10pt; width: 100%;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                    <ix:nonNumeric id="Fxbrl_20240529040034874" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">5</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20240529040031186" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">10</ix:nonNumeric> years
                                                </span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">&#160;</td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets</span></span></td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Lesser of useful life and remaining term of the lease</span></span></td>
                                    </tr>
                                </table>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <ix:nonNumeric id="Fxbrl_20240529024244895" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <ix:nonNumeric id="Fxbrl_20240529024241192" name="flgc:FinancialLiabilitiesPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" continuedAt="F20240529024659560">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">201</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_140_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        &#160;<ix:continuation id="F20240529024659560">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.</span></span></p>
                            </div>
                        </ix:continuation>
                        <ix:nonNumeric id="Fxbrl_20240529024228304" name="flgc:ProvisionsPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <ix:nonNumeric id="Fxbrl_20240529024224489" name="us-gaap:StockholdersEquityPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital </b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <ix:nonNumeric id="Fxbrl_20240529024219848" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" continuedAt="F20240529024643150">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">202</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_141_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        &#160;<ix:continuation id="F20240529024643150">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                            </div>
                        </ix:continuation>
                        <ix:nonNumeric id="Fxbrl_20240529024213710" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <ix:nonNumeric id="Fxbrl_20240529024208895" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Commitments and contingencies</b></span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">203</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_142_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        &#160;<ix:nonNumeric id="Fxbrl_20240529024203998" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <ix:nonNumeric id="Fxbrl_20240529024159278" name="flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529040531693" name="us-gaap:UnusualRisksAndUncertaintiesTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4.&#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">204</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_143_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity and going concern considerations</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company's ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of expenses and cash flows, which requires a significant amount of management judgement.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining the discount rate and whether to include renewal options in the lease term. The determination of the discount rate considers the incremental borrowing rate that would be charged for a loan that is collateralized or secured by the lessee's aggregate collateral, has a term that is similar to the lease term, is for an amount similar to the lease payments, and occurs in a similar economic environment. In this instance, management utilized European corporate debt instruments compounded annually that have a similar term and economic rating. In determining the lease term, management evaluated the fact that the Company's licenses are tied to the lease facility and as such the Company is reasonably certain to exercise the renewal option.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Estimated useful lives and depreciation of long-lived assets with finite lives</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Determination of asset groups for impairment testing</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining asset groups for the level at which long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions, including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes and valuation allowances for deferred tax assets</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">205</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_144_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of December 31, 2023 and 2022, there were no uncertain tax positions taken.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529054836689" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>5.&#160; AMOUNTS RECEIVABLE</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company&#8217;s amounts receivable are recorded at amortized cost. The amounts receivable balance as at December 31, 2023 and December 31, 2022 consists of amounts recoverable from the Value Added Tax (&#8220;VAT&#8221;) from various jurisdictions, and other receivables.&#160;</span></span></span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240529054901273" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>December 31, 2023</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>December 31, 2022</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>VAT receivable</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529055438806" name="us-gaap:ValueAddedTaxReceivable" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">14,551</ix:nonFraction></span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160;<ix:nonFraction id="Fxbrl_20240529055445086" name="us-gaap:ValueAddedTaxReceivable" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">6,761</ix:nonFraction></span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Other receivables</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529055452958_xbrl_20240529055438806" name="us-gaap:OtherReceivables" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">4,343</ix:nonFraction></span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529055452958_xbrl_20240529055445086" name="us-gaap:OtherReceivables" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">11,638</ix:nonFraction></span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160;<ix:nonFraction id="Fxbrl_20240529055511014" name="us-gaap:AccountsReceivableNetCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">18,894</ix:nonFraction></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529055454951_xbrl_20240529055445086" name="us-gaap:AccountsReceivableNetCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">18,399</ix:nonFraction></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company did not record write-offs of receivables during 2023 (2022 - &#8364; <ix:nonFraction id="Fxbrl_20240529055637679" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR"><ix:nonFraction id="Fxbrl_20240529055608083" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">nil</ix:nonFraction></ix:nonFraction>).</span></span></span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529061947005" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.&#160; PROPERTY, PLANT AND EQUIPMENT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment consist of the following:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240529061953441" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529062010860" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember" unitRef="EUR">119,062</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529062016961" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember" unitRef="EUR">114,325</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529062229611_xbrl_20240529062010860" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">24,225</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529062229611_xbrl_20240529062016961" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">9,550</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529062332500" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">94,837</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529062422698" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">104,775</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation expense for the year ended December 31, 2023 was &#8364;<ix:nonFraction id="Fxbrl_20240529062021300" name="us-gaap:Depreciation" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">14,675</ix:nonFraction> (2022 - &#8364;<ix:nonFraction id="Fxbrl_20240529093210757" name="us-gaap:Depreciation" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">9,550</ix:nonFraction>) and was recorded in depreciation and amortization in the statements of loss and comprehensive loss.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023 and 2022, the Company&#8217;s property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the periods ended December 31, 2023 and 2022.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <div>
                    <p style="text-align: center; margin-top: 10pt;">206</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_145_integixAnchor"></span>
                <div style="margin-bottom: 10pt;">
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                        </tr>
                        <tr>
                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        </tr>
                    </table>
                </div>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <div>
                    <div>
                        <ix:nonNumeric id="Fxbrl_20240529144346653" name="us-gaap:DebtDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>7.&#160; DEBT</b></span></span></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;<ix:nonFraction id="Fxbrl_20240529143806633" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember" unitRef="EUR">250,000</ix:nonFraction>, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at <ix:nonFraction id="Fxbrl_20240529143852304" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember" unitRef="Pure">2.0</ix:nonFraction>% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, the &#8364;<ix:nonFraction id="Fxbrl_20240529144100216" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember" unitRef="EUR">250,000</ix:nonFraction> (December 31, 2022 - &#8364;<ix:nonFraction id="Fxbrl_20240529144154258" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember" unitRef="EUR">250,000</ix:nonFraction>) was outstanding under the First Loan.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;<ix:nonFraction id="Fxbrl_20240529143822972" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember" unitRef="EUR">450,000</ix:nonFraction>, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at <ix:nonFraction id="Fxbrl_20240529143934678" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember" unitRef="Pure">4.0</ix:nonFraction>% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, &#8364;<ix:nonFraction id="Fxbrl_20240529144126378" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember" unitRef="EUR">378,000</ix:nonFraction> (December 31, 2022 &#8211; &#8364;<ix:nonFraction id="Fxbrl_20240529144204869" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember" unitRef="EUR">65,000</ix:nonFraction>) was outstanding under the Second Loan.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023, the amount of accrued interest on the First Loan and Second Loan totals &#8364;<ix:nonFraction id="Fxbrl_20240529144215509" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">17,339</ix:nonFraction> (December 31, 2022 &#8211; &#8364;<ix:nonFraction id="Fxbrl_20240529144241460" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,590</ix:nonFraction>).</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan, including all accrued interest, were forgiven by TruHC Holding.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <p style="margin: 0pt;">&#160;</p>
                    </div>
                </div>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <div>
                    <div>
                        <ix:nonNumeric id="Fxbrl_20240529111323752" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8.&#160; LEASE</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>The Company&#8217;s lease consist of an administrative real estate lease in Germany. Management has determined the Company&#8217;s lease is an operating lease through December 31, 2023. Information regarding the Company&#8217;s lease is as follows:</span></span></span></span></span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240529111408810" name="us-gaap:LeaseCostTableTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Year ended<br/>December 31, 2023</b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>For the period from<br/>February 17, 2022 to </b><br/><b>December 31, 2022</b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Components of lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529115746952" name="us-gaap:OperatingLeaseExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">123,105</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529111710971" name="us-gaap:OperatingLeaseExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">84,783</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529111716911" name="us-gaap:LeaseCost" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">123,105</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529111732060" name="us-gaap:LeaseCost" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">84,783</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Other Information</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating cash flows from operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112047606" name="us-gaap:OperatingLeasePayments" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112101517" name="us-gaap:OperatingLeasePayments" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">70,249</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU assets obtained in exchange for new operating lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112130108" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112147037" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">604,294</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average remaining lease term in years for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                <ix:nonNumeric id="Fxbrl_20240529112153107" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">6.33</ix:nonNumeric>
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                <ix:nonNumeric id="Fxbrl_20240529112204716" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">7.33</ix:nonNumeric>
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average discount rate for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112209974" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="Pure">8.77</ix:nonFraction>%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112240566" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="Pure">8.77</ix:nonFraction>%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>
                                <div>
                                    <ix:exclude>
                                        <div>
                                            <p style="text-align: center; margin-top: 10pt;">207</p>
                                        </div>
                                        <hr style="page-break-after: always; width: 100%; color: #000000; height: 5px; background-color: #000000;"/>
                                        <div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                                </tr>
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                </tr>
                                            </table>
                                        </div>
                                    </ix:exclude>
                                </div>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Maturities of operating lease liabilities as of December 31, 2023 are as follows:</span></span></span></span></p>
                                <ix:nonNumeric id="Fxbrl_20240529111433612" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                    <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Operating Leases</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2024</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112455158" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2025</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112508047" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2026</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112536044" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2027</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112549950" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2028</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112614263" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thereafter</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112806235" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">140,497</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total future lease payments</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529112941738" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">667,362</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Less: imputed interest</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240529113031051" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">156,698</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529115142751" name="us-gaap:OperatingLeaseLiability" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">510,664</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Less: current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240529115201951" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">63,083</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total non-current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529115239372" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">447,581</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>
                                <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company's operating lease expires on April 30, 2025. <ix:nonNumeric id="Fxbrl_20240530130203871" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term.</ix:nonNumeric> At December 31, 2023, the renewal option is included in the related operating right of use asset recorded because management is reasonably certain of renewing.</span></span></span></span></p>
                            </div>
                        </ix:nonNumeric>
                        <p style="margin: 0pt;">&#160;</p>
                    </div>
                </div>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529110912216" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.&#160; RELATED PARTY DISCLOSURES</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Related party transactions</b></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span style="text-decoration: underline;">Long-term debt with TruHC Holding</span></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;<ix:nonFraction id="Fxbrl_20240529165245105" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220222_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember" unitRef="EUR">250,000</ix:nonFraction>, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at <ix:nonFraction id="Fxbrl_20240529142617020" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember" unitRef="Pure">2.0</ix:nonFraction>% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, the &#8364;<ix:nonFraction id="Fxbrl_20240529122002071" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember" unitRef="EUR">250,000</ix:nonFraction> (December 31, 2022 - &#8364;<ix:nonFraction id="Fxbrl_20240529122006058" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember" unitRef="EUR">250,000</ix:nonFraction>) was outstanding under the First Loan.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;<ix:nonFraction id="Fxbrl_20240529165346350" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember" unitRef="EUR">450,000</ix:nonFraction>, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at <ix:nonFraction id="Fxbrl_20240529142656852" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember" unitRef="Pure">4.0</ix:nonFraction>% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, &#8364;<ix:nonFraction id="Fxbrl_20240529122137633" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember" unitRef="EUR">378,000</ix:nonFraction> (December 31, 2022 &#8211; &#8364;<ix:nonFraction id="Fxbrl_20240529122656559" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember" unitRef="EUR">65,000</ix:nonFraction>) was outstanding under the Second Loan.</span></span></p>
                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023, the amount of accrued interest on the First Loan and Second Loan totals &#8364;<ix:nonFraction id="Fxbrl_20240529122635283" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">17,339</ix:nonFraction> (December 31, 2022 &#8211; &#8364;<ix:nonFraction id="Fxbrl_20240529122644695" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,590</ix:nonFraction>).</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529100939326" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10.&#160; COMMITMENTS AND CONTINGENCIES </b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company does not have commitments or contingencies as at December 31, 2023 and 2022.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529110030555" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11.&#160; INCOME TAXES </b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Components of the Company's deferred income tax assets and liabilities at December 31, 2023 and 2022 are as follows:</span></span></p>
                        <div>
                            <div>
                                <div>
                                    <ix:exclude>
                                        <div>
                                            <p style="margin-top: 10pt; margin-bottom: 0pt; text-align: center; font-size: 10pt; font-family: Times New Roman, Times, serif;">208</p>
                                        </div>
                                        <hr style="page-break-after: always; width: 100%; color: #000000; height: 5px; background-color: #000000;"/>
                                        <div>
                                            <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border: 0px;" border="0" cellspacing="0" cellpadding="0">
                                                <tr>
                                                    <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                                </tr>
                                                <tr>
                                                    <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                </tr>
                                            </table>
                                        </div>
                                    </ix:exclude>
                                </div>
                                <div>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                </div>
                            </div>
                        </div>
                        <div>
                            <div>
                                <ix:nonNumeric id="Fxbrl_20240530101316945" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                    <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Property and equipment</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529110222586" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">8,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529110229458" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">3,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU asset</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240529110236010" name="flgc:DeferredTaxAssetsRightOfUseAssets" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">154,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240529110252623" name="flgc:DeferredTaxAssetsRightOfUseAssets" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">179,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Lease liability</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529110426362" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">165,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529110926378" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">183,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Non-capital losses available for future period</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240530101541769_xbrl_20240529110426362" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">174,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240530101541769_xbrl_20240529110926378" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">64,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529110733412" name="us-gaap:DeferredTaxAssetsGross" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">193,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529110750847" name="us-gaap:DeferredTaxAssetsGross" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">71,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Unrecognized deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240529110952248" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">193,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(<ix:nonFraction id="Fxbrl_20240529111006088" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">71,000</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total net deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529111015913" name="us-gaap:DeferredTaxAssetsNet" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><ix:nonFraction id="Fxbrl_20240529111032675" name="us-gaap:DeferredTaxAssetsNet" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Net deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20240529111044455" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><ix:nonFraction id="Fxbrl_20240529111107203" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                </ix:nonNumeric>
                            </div>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred taxes are a result of temporary differences that arise due to the differences between the income tax values and the carrying values of assets and liabilities. The Company's deferred tax asset valuation allowances are primarily the result of uncertainties regarding the future realization of recorded tax benefits on the tax loss carryforwards from operations in various jurisdictions. Current evidence does not suggest the Company will realize sufficient taxable income of the appropriate character within the carryforward period to allow the Company to realize the deferred tax benefits. If the Company were to identify and implement tax planning strategies to recover these deferred tax assets or generate sufficient income of the appropriate character in these jurisdictions in the future, it could lead to the reversal of these valuation allowances and income tax expense.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unused loss carryforwards totaling &#8364;<ix:nonFraction id="Fxbrl_20240529111337957" name="us-gaap:OperatingLossCarryforwards" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">538,000</ix:nonFraction> do not have an expiry date. Deferred tax assets have not been recognized for legal entities where it is not probable that future taxable profit will be available against which the Company can use the benefits. Tax attributes are subject to review, and potential adjustment, by tax authorities. The tax years that remain subject to examination by significant tax jurisdictions of the Company as of December 31, 2023 are as follows: 2022 to 2023.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had no unrecognized income tax benefits because of uncertain income tax positions for the years ended December 31, 2023 and 2022.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529105657480" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>12.&#160; FINANCIAL INSTRUMENTS AND RISK MANAGEMENT </b></span></span></p>
                        <div>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Environmental</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Fair value</b></span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company&#8217;s financial instruments measured at amortized cost as at December 31, 2023 and December 31, 2022 consist of cash, trade and amounts payable, accrued liabilities, and debt. The amounts reflected in the statements of financial position approximate fair value for all financial instruments due to their short-term maturity, except for debt whose fair value as at December 31, 2023 is &#8364;<ix:nonFraction id="Fxbrl_20240529114245869" name="us-gaap:DebtInstrumentFairValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">504,264</ix:nonFraction> (December 31, 2022 - &#8364;<ix:nonFraction id="Fxbrl_20240529114320623" name="us-gaap:DebtInstrumentFairValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">228,704</ix:nonFraction>.</span></span></p>
                            <div>
                                <div>
                                    <ix:exclude>
                                        <div>
                                            <div>
                                                <p style="margin-top: 10pt; margin-bottom: 0pt; text-align: center; font-size: 10pt; font-family: Times New Roman, Times, serif;">209</p>
                                            </div>
                                            <hr style="page-break-after: always; width: 100%; color: #000000; height: 5px; background-color: #000000;"/>
                                            <div>
                                                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border: 0px;" border="0" cellspacing="0" cellpadding="0">
                                                    <tr>
                                                        <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>
                                        </div>
                                    </ix:exclude>
                                </div>
                            </div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Risk management overview</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Credit risk</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's amounts receivable, and cash held with banks and other financial intermediaries.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The carrying amount of the cash and represents the maximum credit exposure as presented in the statement of financial position.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company held cash of &#8364;<ix:nonFraction id="Fxbrl_20240529113023656" name="us-gaap:Cash" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,588</ix:nonFraction> as at December 31, 2023 (2022 - &#8364;<ix:nonFraction id="Fxbrl_20240529113359236" name="us-gaap:Cash" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">15,281</ix:nonFraction>). The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has not assessed a loss allowance on these cash balances as at December 31, 2023 and 2022.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Market risk</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">It is management's opinion that the Company is not subject to significant commodity or interest rate risk.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity risk</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#8217;s financial liabilities consist of trade and amounts payable, and accrued liabilities, and debt as presented on the statement of financial position. The Company had cash as presented on the statement of financial position. The Company has no available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#8217;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade and amounts payable, and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 9 and Note 2 for the Company&#8217;s assessment of the uncertainty related to the assumption of the Company continuing to operate as a going concern.</span></span></p>
                        </div>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529105442799" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>13.&#160; SHARE CAPITAL</b> </span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Authorized and issued</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company is authorized to issue an unlimited number of common shares, no par value.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">210</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Financial Statements<br/>For the periods ended December 31, 2023 and 2022<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On incorporation, the Company issued <ix:nonFraction id="Fxbrl_20240529105540508" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember" unitRef="Shares">25,000</ix:nonFraction> shares to TruHC Holding GmbH at a par value of &#8364;<ix:nonFraction id="Fxbrl_20240529110051744" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember" unitRef="Euro_Per_share">1.00</ix:nonFraction> per share. As at December 31, 2023, &#8364;<ix:nonFraction id="Fxbrl_20240529111335640" name="us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember" unitRef="EUR">12,500</ix:nonFraction> (December 31, 2022 - &#8364;<ix:nonFraction id="Fxbrl_20240529111649216" name="us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember" unitRef="EUR">12,500</ix:nonFraction>) remains receivable as been netted against the share capital balance.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529095341823" name="us-gaap:SubsequentEventsTextBlock" escape="true" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>114.&#160; SUBSEQUENT EVENTS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 16, 2024, Flora Growth Corp. (&#8220;Flora&#8221;) entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with TruHC Holding GmbH (the &#8220;Seller&#8221;) pursuant to which Flora will acquire all of the issued and outstanding shares of the Company. The Purchase Price will be paid and satisfied by Flora in two closings. On the first closing, Flora issued <ix:nonFraction id="Fxbrl_20240529102114187" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">2,135,199</ix:nonFraction> of its common shares, which is equal to <ix:nonFraction id="Fxbrl_20240529102129615" name="flgc:PercentageOfIssuedAndOutstandingCommonShares" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Pure">19.99</ix:nonFraction>% of Flora&#8217;s issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the &#8220;Second Closing&#8221;), Flora will issue <ix:nonFraction id="Fxbrl_20240529102259386" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">635,363</ix:nonFraction> of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Under the Purchase Agreement, Flora is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 22, 2024, the first closing of the Transaction for <ix:nonFraction id="Fxbrl_20240529102420565" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240422_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">2,135,199</ix:nonFraction> Flora shares was closed.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan were forgiven.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <div>
                    <p style="text-align: center; margin-top: 10pt;">211</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="color: #1f497d; font-size: 12pt;">&#160;</span></p>
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="color: #1f497d; font-size: 12pt;">&#160;</span></p>
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span style="color: #1f497d; font-size: 12pt;"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><span style="color: #1f497d;"><b>Unaudited Condensed Financial Statements</b></span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">For the Three Months Ended March 31, 2024 and 2023</span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">&#160;</span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">&#160;</span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">&#160;</span></p>
                <p style="margin-top: 0pt; text-align: center;"><span style="color: #1f497d;">&#160;</span></p>
                <div>
                    <p style="text-align: center;">212</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_151_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span id="page213_integixAnchor"><span id="page_146_integixAnchor"><b>TruHC Pharma GmbH</b></span></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Condensed Interim Statements of Financial Position</b></p>
                <p style="margin-top: 0pt; margin-left: 9pt; margin-bottom: 0pt; text-indent: -9pt; text-align: center;"><b>As at March 31, 2024 and December 31, 2023 </b></p>
                <p style="margin-top: 0pt; text-align: center;">(in Euros)</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">March 31, 2024</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">December<b> </b>31, 2023</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">As at:</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">ASSETS</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Current</td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Cash</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_42" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,899</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_45" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,588</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;">Amounts receivable</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529040601091_52" name="us-gaap:AccountsReceivableNetCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">21,182</ix:nonFraction></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529040601091_55" name="us-gaap:AccountsReceivableNetCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">18,894</ix:nonFraction></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Prepaid expenses and other current assets</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_62" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">20,347</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_65" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">20,347</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><b>Total current assets</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><b><ix:nonFraction id="Fxbrl_20240529040601091_72" name="us-gaap:AssetsCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">55,428</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><b><ix:nonFraction id="Fxbrl_20240529040601091_75" name="us-gaap:AssetsCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">52,829</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Non-current</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;">Property, plant and equipment</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><ix:nonFraction id="Fxbrl_20240529040601091_92" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">91,095</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><ix:nonFraction id="Fxbrl_20240529040601091_95" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">94,837</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Operating lease right of use assets</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_102" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">459,515</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_105" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">478,399</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><b>Total assets</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#8364;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><b><ix:nonFraction id="Fxbrl_20240529040601091_112" name="us-gaap:Assets" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">606,038</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#8364;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><b><span><ix:nonFraction id="Fxbrl_20240529040601091_115" name="us-gaap:Assets" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">626,065</ix:nonFraction></span></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">LIABILITIES</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Current</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Trade and amounts payable</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_142" name="us-gaap:AccountsPayableCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">47,522</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_145" name="us-gaap:AccountsPayableCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">34,711</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;">Current portion of operating lease liability</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><ix:nonFraction id="Fxbrl_20240529040601091_152" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">64,477</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><ix:nonFraction id="Fxbrl_20240529040601091_155" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">63,083</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Other accrued liabilities</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_162" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">11,620</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_165" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">11,520</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><b>Total current liabilities</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><b><ix:nonFraction id="Fxbrl_20240529040601091_172" name="us-gaap:LiabilitiesCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">123,619</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><b><ix:nonFraction id="Fxbrl_20240529040601091_175" name="us-gaap:LiabilitiesCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">109,314</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Non-current</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;">Non-current portion of debt</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><ix:nonFraction id="Fxbrl_20240529040601091_192" name="us-gaap:LongTermDebtNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">720,730</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><ix:nonFraction id="Fxbrl_20240529040601091_195" name="us-gaap:LongTermDebtNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">645,339</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Non-current operating lease liability</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_202" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">430,930</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529040601091_205" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">447,581</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><b>Total liabilities</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><b><ix:nonFraction id="Fxbrl_20240529040601091_212" name="us-gaap:Liabilities" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">1,275,279</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><b><ix:nonFraction id="Fxbrl_20240529040601091_215" name="us-gaap:Liabilities" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">1,202,234</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">SHAREHOLDERS' EQUITY</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;">Share capital</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><ix:nonFraction id="Fxbrl_20240529040601091_232" name="us-gaap:CommonStockValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">25,000</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><ix:nonFraction id="Fxbrl_20240529040601091_235" name="us-gaap:CommonStockValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Accumulated deficit</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529040601091_242" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">694,241</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529040601091_245" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">588,669</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><b>Total shareholders' equity</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><b>(<ix:nonFraction id="Fxbrl_20240529040601091_252" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">669,241</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><b>(<ix:nonFraction id="Fxbrl_20240529040601091_255" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">576,169</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><b>Total liabilities and shareholders' equity</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><b><ix:nonFraction id="Fxbrl_20240529040601091_262" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">606,038</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><b><ix:nonFraction id="Fxbrl_20240529040601091_265" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">626,065</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                </table>
                <p style="margin-left: 9.35pt; text-indent: -9.35pt; text-align: center; margin-top: 10pt;">The accompanying notes are an integral part of the condensed interim financial statements.</p>
                <div>
                    <p style="text-align: center;">213</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_152_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span id="page_147_integixAnchor"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Condensed Interim Statements of Loss and Comprehensive Loss</b></p>
                <p style="margin-top: 0pt; margin-left: 9pt; margin-bottom: 0pt; text-indent: -9pt; text-align: center;"><b>For the Three Months Ended March 31, 2024 and 2023</b></p>
                <p style="margin-top: 0pt; text-align: center;">(in Euros)</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 66.8598%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 11.9351%;"><b>For the Three<br/>Months Ended<br/>March 31, 2024</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 14.9479%;"><b>For the Three&#160;</b><br/><b>Months Ended </b><br/><b>March 31, 2023</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.8598%;"><b>Operating expenses </b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 11.9351%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 14.9479%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.8598%;">Professional fees</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529044251693_22" name="us-gaap:ProfessionalFees" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">19,240</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529044251693_25" name="us-gaap:ProfessionalFees" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">82</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.8598%;">General and administrative</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529044251693_32" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">47,089</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529044251693_35" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">26,207</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.8598%;">Travel expenses</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529044251693_42" name="us-gaap:TravelAndEntertainmentExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">326</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529044251693_45" name="us-gaap:TravelAndEntertainmentExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">425</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.8598%;">Operating lease expense</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529044251693_52" name="us-gaap:OperatingLeaseExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">29,970</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529044251693_55" name="us-gaap:OperatingLeaseExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">31,516</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.8598%;">Depreciation and amortization</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529044251693_62" name="us-gaap:DepreciationAndAmortization" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">3,742</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529044251693_65" name="us-gaap:DepreciationAndAmortization" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">1,933</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.8598%;"><b>Operating loss</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529044251693_72" name="us-gaap:OperatingIncomeLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">100,181</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529044251693_75" name="us-gaap:OperatingIncomeLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">60,163</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.8598%;">Interest expense (recovery)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529044251693_82" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">5,391</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529044251693_85" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">270</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.8598%;"><b>Net loss for the period</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529044251693_92" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,572</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529044251693_95" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">59,893</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.8598%;"><b>Total comprehensive loss for the period</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529044251693_102" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,572</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529044251693_105" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">59,893</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                </table>
                <p style="margin-left: 9.35pt; text-indent: -9.35pt; text-align: center; margin-top: 10pt;">The accompanying notes are an integral part of the condensed interim financial statements.</p>
                <div>
                    <p style="text-align: center;">214</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_153_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span id="page_148_integixAnchor"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Statement of Shareholders' Equity (Deficiency)</b></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>For the Periods Ended March 31, 2024 and 2023</b></p>
                <p style="margin-top: 0pt; text-align: center;">(in Euros)</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 32.9085%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9479%;"><b>&#160;</b><br/><b>Common<br/>Shares</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9479%;"><b>&#160;</b><br/><b>Common<br/>Shares</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 9.96524%;"><b>&#160;</b><br/><b>Accumulated<br/>Deficit</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9479%;"><b>Shareholders'<br/>Equity<br/>(Deficiency)</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 32.9085%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 14.9479%;"><b>#</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 14.9479%;"><b>&#160;</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 9.96524%;"><b>&#160;</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 14.9479%;"><b>&#160;</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 32.9085%;">Balance, December 31, 2022</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529045752589" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">25,000</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529045800647" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529045824870" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">216,882</ix:nonFraction></td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529045837349" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">204,382</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 32.9085%;">Net loss</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 14.9479%;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 14.9479%;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529045907542" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">59,893</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">)&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529045926382" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">59,893</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 32.9085%;"><b>Balance, March 31, 2023</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 14.9479%; background-color: #e6efff;"><b><ix:nonFraction id="Fxbrl_20240529045806800" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">25,000</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 14.9479%; background-color: #e6efff;"><b><ix:nonFraction id="Fxbrl_20240529045809400" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="EUR">12,500</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529045841740" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">276,775</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529045845111" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">264,275</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 32.9085%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 14.9479%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 14.9479%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 32.9085%;">Balance, December 31, 2023</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529045818253" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">25,000</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%; background-color: #e6efff;">&#160;<ix:nonFraction id="Fxbrl_20240529045820216" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529045847781" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">588,669</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%; background-color: #e6efff;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529045849905" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">576,169</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 32.9085%;">Contribution</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 14.9479%;"><ix:nonFraction id="Fxbrl_20240529050545606" name="flgc:Contributionamont" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529050617770" name="flgc:Contributionamont" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; text-align: left; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 32.9085%;">Net loss</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 14.9479%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 14.9479%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529045936464" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">105,572</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">(<ix:nonFraction id="Fxbrl_20240529045938816" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,572</ix:nonFraction></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1.96987%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 32.9085%;"><b>Balance, March 31, 2024</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 14.9479%;"><b><ix:nonFraction id="Fxbrl_20240529045816243" name="us-gaap:SharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares">25,000</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 14.9479%;"><b><ix:nonFraction id="Fxbrl_20240529045811671" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="EUR">25,000</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 9.96524%; text-align: right; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529045854069" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="EUR">694,241</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.04287%;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 14.9479%; text-align: right; border-bottom: 2.25pt double #000000;"><b>(<ix:nonFraction id="Fxbrl_20240529045852126" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">669,241</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.96987%;"><b>)</b></td>
                    </tr>
                </table>
                <p style="margin-left: 9.35pt; text-indent: -9.35pt; text-align: center; margin-top: 10pt;">The accompanying notes are an integral part of the condensed interim financial statements.</p>
                <div>
                    <p style="text-align: center;">215</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_154_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;"><span id="page_149_integixAnchor"><b>TruHC Pharma GmbH</b></span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Condensed Interim Statement of Cash Flows</b></p>
                <p style="margin-top: 0pt; margin-left: 9pt; margin-bottom: 0pt; text-indent: -9pt; text-align: center;"><b>For the Three Months Ended March 31, 2024 and 2023</b></p>
                <p style="margin-top: 0pt; text-align: center;">(in Euros)</p>
                <table style="font-size: 10pt; border-collapse: collapse; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 11.9351%;"><b>For the Three<br/>Months Ended<br/>March 31, 2024</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1.96987%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 1.04287%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap; width: 11.9351%;"><b>For the Three </b><br/><b>Months Ended </b><br/><b>March 31, 2023</b></td>
                        <td style="vertical-align: bottom; width: 1.96987%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; background-color: #e6efff;"><b>Cash flows from operating activities:</b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%;">Net loss</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">(<ix:nonFraction id="Fxbrl_20240529122614207" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,572</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">)</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#8364;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">(<ix:nonFraction id="Fxbrl_20240529122638032" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">59,893</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; background-color: #e6efff;">Adjustments to net loss:</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt;">Depreciation and amortization</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529122656152" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">3,742</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529122711609" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">1,933</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt; background-color: #e6efff;">Interest expense</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529122725112" name="us-gaap:InterestIncomeExpenseNet" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">5,391</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529122758272" name="us-gaap:InterestIncomeExpenseNet" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt;">Operating lease expense net of cash payments</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529122830656" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">3,627</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529122905995" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">4,903</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; background-color: #e6efff;">Net change in non-cash working capital:</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt;">Amounts receivable</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">(<ix:nonFraction id="Fxbrl_20240529122929219" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">2,288</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">)</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">(<ix:nonFraction id="Fxbrl_20240530102511699" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">2,988</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt; background-color: #e6efff;">Prepaid expenses and other assets</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529123006259" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529123104075" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt;">Trade and amounts payable</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529123151747" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">12,911</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000;"><ix:nonFraction id="Fxbrl_20240529123217114" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">44,512</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; background-color: #e6efff;"><b>Net cash provided by (used in) operating activities</b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><b>(<ix:nonFraction id="Fxbrl_20240529123229991" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">82,189</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;"><b>(<ix:nonFraction id="Fxbrl_20240529123308706" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">11,533</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; background-color: #e6efff;"><b>Cash flows from financing activities: </b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt;">Proceeds from issuance of debt</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529124416510" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">70,000</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><ix:nonFraction id="Fxbrl_20240529124534425" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt; background-color: #e6efff;">Proceeds from issuance of shares</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529124618390" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">12,500</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529124633453" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%;"><b>Net cash provided by (used in) financing activities </b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529124647581" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">82,500</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529124711004" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%;"><b>Cash flows from investing activities:</b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; padding-left: 15pt; background-color: #e6efff;">Acquisition of equipment</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529124741469" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">(<ix:nonFraction id="Fxbrl_20240529124808199" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">197</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%;"><b>Net cash provided by (used in) investing activities</b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529124906055" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529124938207" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">197</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%;"><b>Change in cash during the period</b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><b><ix:nonFraction id="Fxbrl_20240529124953287" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">311</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right;"><b>(<ix:nonFraction id="Fxbrl_20240529125452249" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">11,730</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%; background-color: #e6efff;">Cash at beginning of period</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529125550255" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,588</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><ix:nonFraction id="Fxbrl_20240529125608902" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">15,281</ix:nonFraction></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 0.75pt solid #000000; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; width: 69.8725%;"><b>Cash at end of period</b></td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 2.25pt double #000000;"><b>&#8364;</b></td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 2.25pt double #000000;"><b><ix:nonFraction id="Fxbrl_20240529125651759" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,899</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                        <td style="vertical-align: bottom; width: 1.04287%; text-align: left; border-bottom: 2.25pt double #000000;"><b>&#8364;</b></td>
                        <td style="vertical-align: bottom; width: 11.9351%; text-align: right; border-bottom: 2.25pt double #000000;"><b><ix:nonFraction id="Fxbrl_20240529125708166" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">3,551</ix:nonFraction></b></td>
                        <td style="vertical-align: bottom; width: 1.96987%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: center; margin-top: 10pt;">The accompanying notes are an integral part of the condensed interim financial statements.</p>
                <div>
                    <p style="text-align: center;">216</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_155_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;"><span id="page_150_integixAnchor"><b>TruHC Pharma GmbH</b></span><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                        </tr>
                        <tr>
                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        </tr>
                    </table>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </div>
                <ix:nonNumeric id="Fxbrl_20240529052419404" name="us-gaap:NatureOfOperations" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1.&#160; NATURE OF OPERATIONS</b></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>TruHC Pharma GmbH (the "Company" or "TruHC") was incorporated under the laws of Germany on February 17, 2022. The Company engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility. The Company's registered office and principal place of business in Germany is located at Poppenb&#252;tteler Bogen 68 22399 Hamburg, Germany. At December 31, 2023, all of the Company's issued and outstanding shares were owned by TruHC Holding GmbH ("TruHC Holding").</span></span></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>These condensed interim financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</span></span></span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529052457890" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2.&#160; BASIS OF PRESENTATION</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These financial statements have been presented in Euros and are prepared in accordance with United States generally accepted accounting principles (&#8220;US GAAP&#8221;). The Company has determined that the Euro is the functional and reporting currency as the majority of our operations are conducted in Euros and the financial results are prepared and reviewed internally by management in Euros.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue for a period of at least one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of &#8364;<ix:nonFraction id="Fxbrl_20240529052620296" name="us-gaap:Cash" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,899</ix:nonFraction> at March 31, 2024, net loss of &#8364;<ix:nonFraction id="Fxbrl_20240529052643811" name="us-gaap:ProfitLoss" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,572</ix:nonFraction> for the three months ended March 31, 2024 and an accumulated deficit of &#8364;<ix:nonFraction id="Fxbrl_20240529052708307" name="us-gaap:CumulativeEarningsDeficit" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">694,241</ix:nonFraction> at March 31, 2024. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners or, through obtaining credit from financial institutions and the possible disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#8217;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company&#8217;s performance and investor sentiment with respect to it and its industry. These financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">217</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_156_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of measurement </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial statements have been prepared on the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of amounts receivable, prepaids and other current assets, and trade and amounts payable, accrued liabilities, and current portion of lease liability approximate their fair values due to their short periods to maturity.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial statements are presented in Euros ("&#8364;") unless otherwise noted.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Use of estimates</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <div>
                    <ix:nonNumeric id="Fxbrl_20240529053143498" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                        <div>
                            <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3.&#160; SIGNIFICANT ACCOUNTING POLICIES</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>The significant accounting policies used by the Company are as follows:</b></span></span></p>
                            <div>
                                <ix:nonNumeric id="Fxbrl_20240529053159603" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash </b></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the statements of financial position includes cash on hand.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                            <div>
                                <ix:nonNumeric id="Fxbrl_20240529053206506" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.</span></span></p>
                                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                            </div>
                            <div>
                                <ix:exclude>
                                    <div>
                                        <p style="text-align: center; margin-top: 10pt;">218</p>
                                    </div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_157_integixAnchor"></span>
                                    <div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                            </tr>
                                            <tr>
                                                <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:exclude>
                            </div>
                            &#160;<ix:nonNumeric id="Fxbrl_20240529053212305" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>
                                    <table style="border-collapse: collapse; font-size: 10pt; width: 100%;" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                            <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                        <ix:nonNumeric id="Fxbrl_20240529054048347" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">5</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20240529054012546" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">10</ix:nonNumeric> years
                                                    </span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets</span></span></td>
                                            <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Lesser of useful life and remaining term of the lease</span></span></td>
                                        </tr>
                                    </table>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20240529053217099" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20240529053222366" name="flgc:FinancialLiabilitiesPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" continuedAt="F20240529053912936">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <div>
                                <ix:exclude>
                                    <div>
                                        <p style="text-align: center; margin-top: 10pt;">219</p>
                                    </div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_158_integixAnchor"></span>
                                    <div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                            </tr>
                                            <tr>
                                                <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:exclude>
                            </div>
                            &#160;<ix:continuation id="F20240529053912936">
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.</span></span></p>
                                </div>
                            </ix:continuation>
                            <ix:nonNumeric id="Fxbrl_20240529053230418" name="flgc:ProvisionsPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20240529053254826" name="us-gaap:StockholdersEquityPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                <div>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital </b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20240529053243033" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" continuedAt="F20240529053925876">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <div>
                                <ix:exclude>
                                    <div>
                                        <p style="text-align: center; margin-top: 10pt;">220</p>
                                    </div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_159_integixAnchor"></span>
                                    <div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                            </tr>
                                            <tr>
                                                <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:exclude>
                            </div>
                            &#160;<ix:continuation id="F20240529053925876">
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                                </div>
                            </ix:continuation>
                            <ix:nonNumeric id="Fxbrl_20240529053302723" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20240529053310098" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Commitments and contingencies</b></span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <div>
                                <ix:exclude>
                                    <div>
                                        <p style="text-align: center; margin-top: 10pt;">221</p>
                                    </div>
                                    <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_160_integixAnchor"></span>
                                    <div>
                                        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                            <tr>
                                                <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                            </tr>
                                            <tr>
                                                <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </ix:exclude>
                            </div>
                            &#160;<ix:nonNumeric id="Fxbrl_20240529053317265" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                            <ix:nonNumeric id="Fxbrl_20240529053328129" name="flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                                </div>
                            </ix:nonNumeric>
                        </div>
                    </ix:nonNumeric>
                    <p style="margin: 0pt;">&#160;</p>
                </div>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529054147297" name="us-gaap:UnusualRisksAndUncertaintiesTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>4.&#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">222</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_161_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity and going concern considerations</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company's ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of expenses and cash flows, which requires a significant amount of management judgement.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining the discount rate and whether to include renewal options in the lease term. The determination of the discount rate considers the incremental borrowing rate that would be charged for a loan that is collateralized or secured by the lessee's aggregate collateral, has a term that is similar to the lease term, is for an amount similar to the lease payments, and occurs in a similar economic environment. In this instance, management utilized European corporate debt instruments compounded annually that have a similar term and economic rating. In determining the lease term, management evaluated the fact that the Company's licenses are tied to the lease facility and as such the Company is reasonably certain to exercise the renewal option.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Estimated useful lives and depreciation of long-lived assets with finite lives</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Determination of asset groups for impairment testing</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining asset groups for the level at which long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions, including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes and valuation allowances for deferred tax assets</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">223</p>
                                </div>
                                <hr style="page-break-after: always; width: 100%; color: #000000; height: 5px; background-color: #000000;"/><span id="page_162_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of March 31, 2024 and December 31, 2023 there were no uncertain tax positions taken.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529055842128" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>5. AMOUNTS RECEIVABLE</b></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's amounts receivable are recorded at amortized cost. The amounts receivable balance as at December 31, 2023 and December 31, 2022 consists of amounts recoverable from the Value Added Tax ("VAT") from various jurisdictions, and other receivables.&#160;</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240529055902855" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <table style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">VAT receivable</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529060009917" name="us-gaap:ValueAddedTaxReceivable" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">19,919</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529060014530" name="us-gaap:ValueAddedTaxReceivable" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">14,551</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other receivables</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529060026716_xbrl_20240529060009917" name="us-gaap:OtherReceivables" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">1,263</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529060026716_xbrl_20240529060014530" name="us-gaap:OtherReceivables" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">4,343</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529060049044" name="us-gaap:AccountsReceivableNetCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">21,182</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529060029348_xbrl_20240529060014530" name="us-gaap:AccountsReceivableNetCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">18,894</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company did not record write-offs of receivables during the three months ended March 31, 2024 (2023 - &#8364; <ix:nonFraction id="Fxbrl_s_20240529060247712" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR"><ix:nonFraction id="Fxbrl_20240529060247712" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">nil</ix:nonFraction></ix:nonFraction>).&#160;</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529101955624" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.&#160; PROPERTY, PLANT AND EQUIPMENT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment consist of the following:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240529102112162" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <table style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 90%;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 66.9241%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9691%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9292%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529110254007" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember" unitRef="EUR">119,062</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529110321807" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember" unitRef="EUR">119,062</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529110346161" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">27,967</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529110412549" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">24,225</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529110430176" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">91,095</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529110451177" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">94,837</ix:nonFraction></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation expense for the three months ended March 31, 2024 was &#8364;<ix:nonFraction id="Fxbrl_20240529110518926" name="us-gaap:Depreciation" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">3,742</ix:nonFraction> (2023 - &#8364;<ix:nonFraction id="Fxbrl_20240529110615499" name="us-gaap:Depreciation" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">1,933</ix:nonFraction>) and was recorded in depreciation and amortization in the statements of loss and comprehensive loss.</span></span></p>
                        <p style="margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at March 31, 2024 and 2023, the Company&#8217;s property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the three months ended March 31, 2024 and 2023.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <div>
                    <p style="text-align: center; margin-top: 10pt;">224</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_163_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <div>
                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                        </tr>
                        <tr>
                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                        </tr>
                    </table>
                    <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </div>
                <ix:nonNumeric id="Fxbrl_20240529115221811" name="us-gaap:DebtDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.</b>&#160; <b>DEBT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;<ix:nonFraction id="Fxbrl_20240529115317886" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember" unitRef="EUR">250,000</ix:nonFraction>, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at <ix:nonFraction id="Fxbrl_20240529120327111" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember" unitRef="Pure">2.0</ix:nonFraction>% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, the &#8364;<ix:nonFraction id="Fxbrl_20240529141757196" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember" unitRef="EUR">250,000</ix:nonFraction> (December 31, 2023 - &#8364;<ix:nonFraction id="Fxbrl_20240529141832200" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember" unitRef="EUR">250,000</ix:nonFraction>) was outstanding under the First Loan.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;<ix:nonFraction id="Fxbrl_20240529120313216" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember" unitRef="EUR">450,000</ix:nonFraction>, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at <ix:nonFraction id="Fxbrl_20240529120357133" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember" unitRef="Pure">4.0</ix:nonFraction>% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, &#8364;<ix:nonFraction id="Fxbrl_20240529141810376" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember" unitRef="EUR">448,000</ix:nonFraction> (December 31, 2023 &#8211; &#8364;<ix:nonFraction id="Fxbrl_20240529141845864" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember" unitRef="EUR">378,000</ix:nonFraction>) was outstanding under the Second Loan.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at March 31, 2024, the amount of accrued interest on the First Loan and Second Loan totals &#8364;<ix:nonFraction id="Fxbrl_20240529141906388" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">22,730</ix:nonFraction> (December 31, 2023 &#8211; &#8364;<ix:nonFraction id="Fxbrl_20240529141931801" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">17,339</ix:nonFraction>).</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan, including all accrued interest, were forgiven by TruHC Holding.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529120116686" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8.&#160; LEASE</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Company&#8217;s lease consists of an administrative real estate lease in Germany. Management has determined the Company&#8217;s lease is an operating lease through March 31, 2024. Information regarding the Company&#8217;s lease is as follows:</span></span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240529120154546" name="us-gaap:LeaseCostTableTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <table style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the Three<br/>Months Ended<br/>March 31, 2024</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the Three </b><br/><b>Months Ended </b><br/><b>March 31, 2023</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Components of lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529120310705" name="us-gaap:OperatingLeaseExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">29,970</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529120659089" name="us-gaap:OperatingLeaseExpense" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">31,516</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529120758670" name="us-gaap:LeaseCost" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">29,970</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529120828027" name="us-gaap:LeaseCost" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">31,516</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Information</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating cash flows from operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;<ix:nonFraction id="Fxbrl_20240529120919131" name="us-gaap:OperatingLeasePayments" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">26,343</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529120937040" name="us-gaap:OperatingLeasePayments" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">26,343</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">ROU assets obtained in exchange for new operating lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;<ix:nonFraction id="Fxbrl_20240529120950072" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;<ix:nonFraction id="Fxbrl_20240529121003079" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" decimals="0" format="ixt:fixed-zero" contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">-</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average remaining lease term in years for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240529121025478" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">6.08</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                <ix:nonNumeric id="Fxbrl_20240529121045112" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">7.08</ix:nonNumeric>
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average discount rate for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121100192" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="Pure">8.77</ix:nonFraction>%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121104255" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="Pure">8.77</ix:nonFraction>%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">225</p>
                                </div>
                                <hr style="page-break-after: always; width: 100%; color: #000000; height: 5px; background-color: #000000;"/><span id="page_164_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Maturities of operating lease liabilities as of March 31, 2024 are as follows:</span></span></p>
                        <ix:nonNumeric id="Fxbrl_20240529120211464" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <table style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;" cellspacing="0" cellpadding="0">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating Leases</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121155720" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">79,030</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121206147" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121212641" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121216027" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121219012" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">105,373</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121222235" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">140,497</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total future lease payments</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121230928" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">641,019</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: imputed interest</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121234728" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">145,612</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121238744" name="us-gaap:OperatingLeaseLiability" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">495,407</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(<ix:nonFraction id="Fxbrl_20240529121243079" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">64,477</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total non-current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><ix:nonFraction id="Fxbrl_20240529121303672" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">430,930</ix:nonFraction></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        </ix:nonNumeric>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating lease expires on April 30, 2025. <ix:nonNumeric id="Fxbrl_20240530130259095" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term.</ix:nonNumeric> At March 31, 2024, the renewal option is included in the related operating right of use asset recorded because management is reasonably certain of renewing.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <div>
                    <div>
                        <div>
                            <div>
                                <ix:nonNumeric id="Fxbrl_20240529110941023" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                                    <div>
                                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>9.&#160; RELATED PARTY DISCLOSURES</b></span></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Related party transactions</b></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="text-decoration: underline;">Long-term debt with TruHC Holding</span></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;<ix:nonFraction id="Fxbrl_20240529143313709" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220222_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember" unitRef="EUR">250,000</ix:nonFraction>, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at <ix:nonFraction id="Fxbrl_20240529143322395" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember" unitRef="Pure">2.0</ix:nonFraction>% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, the &#8364;<ix:nonFraction id="Fxbrl_20240529143331545" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember" unitRef="EUR">250,000</ix:nonFraction> (December 31, 2023 - &#8364;<ix:nonFraction id="Fxbrl_20240529143342345" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember" unitRef="EUR">250,000</ix:nonFraction>) was outstanding under the First Loan.&#160;</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;<ix:nonFraction id="Fxbrl_20240529143353843" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember" unitRef="EUR">450,000</ix:nonFraction>, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at <ix:nonFraction id="Fxbrl_20240529143402687" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" decimals="3" format="ixt:num-dot-decimal" contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember" unitRef="Pure">4.0</ix:nonFraction>% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, &#8364;<ix:nonFraction id="Fxbrl_20240529143414654" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember" unitRef="EUR">448,000</ix:nonFraction> (December 31, 2023 &#8211; &#8364;<ix:nonFraction id="Fxbrl_20240529143423443" name="us-gaap:LongTermDebt" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember" unitRef="EUR">378,000</ix:nonFraction>) was outstanding under the Second Loan.</span></span></p>
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at March 31, 2024, the amount of accrued interest on the First Loan and Second Loan totals &#8364;<ix:nonFraction id="Fxbrl_20240529143433083" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">22,730</ix:nonFraction> (December 31, 2023 &#8211; &#8364;<ix:nonFraction id="Fxbrl_20240529143445054" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">17,339</ix:nonFraction>).&#160;</span></span></p>
                                    </div>
                                </ix:nonNumeric>
                                <p style="margin: 0pt;">&#160;</p>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529101519456" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10. COMMITMENTS AND CONTINGENCIES</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company does not have commitments or contingencies as at March 31, 2024 and December 31, 2023.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529115032929" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT </b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Environmental</b></span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">226</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Fair value</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company&#8217;s financial instruments measured at amortized cost as at March 31, 2024 and December&#160;31,&#160;2023 consist of cash, trade and amounts payable, accrued liabilities, and debt. The amounts reflected in the statements of financial position approximate fair value for all financial instruments due to their short-term maturity, except for debt whose fair value as at March 31, 2024 is &#8364;<ix:nonFraction id="Fxbrl_20240529115226276" name="us-gaap:DebtInstrumentFairValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">577,354</ix:nonFraction> (December 31, 2022 - &#8364;<ix:nonFraction id="Fxbrl_20240529115236799" name="us-gaap:DebtInstrumentFairValue" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">504,264</ix:nonFraction>).</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Risk management overview</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Credit risk</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's trade and amounts receivable, and cash held with banks and other financial intermediaries.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The carrying amount of the cash represents the maximum credit exposure as presented in the statement of financial position.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company held cash of &#8364;<ix:nonFraction id="Fxbrl_20240529115305781" name="us-gaap:Cash" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,899</ix:nonFraction> as at March 31, 2024 (December 31, 2023 - &#8364;<ix:nonFraction id="Fxbrl_20240529115323171" name="us-gaap:Cash" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember" unitRef="EUR">13,588</ix:nonFraction>). The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has not assessed a loss allowance on these cash balances as at March 31, 2024 and December 31, 2023.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Market risk</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">It is management's opinion that the Company is not subject to significant commodity or interest rate risk.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity risk</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#8217;s financial liabilities consist of trade and amounts payable, and accrued liabilities, and debt as presented on the statement of financial position. The Company had cash as presented on the statement of financial position. The Company has no available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#8217;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.</span></span></p>
                        <div>
                            <ix:exclude>
                                <div>
                                    <p style="text-align: center; margin-top: 10pt;">227</p>
                                </div>
                                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_166_integixAnchor"></span>
                                <div>
                                    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td style="width: 100%;"><b>TruHC Pharma GmbH</b><br/>Notes to the Condensed Interim Financial Statements<br/>For the three months ended March 31, 2024 and 2023<br/>(in Euros, except shares amount)</td>
                                        </tr>
                                        <tr>
                                            <td style="width: 100%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            </ix:exclude>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Trade and amounts payable, and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 9 and Note 2 for the Company&#8217;s assessment of the uncertainty related to the assumption of the Company continuing to operate as a going concern.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <ix:nonNumeric id="Fxbrl_20240529111804841" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                    <div style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>12.&#160; SHARE CAPITAL </b></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Authorized and issued</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company is authorized to issue an unlimited number of common shares, no par value.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On incorporation, the Company issued <ix:nonFraction id="Fxbrl_20240529111842492" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember" unitRef="Shares">25,000</ix:nonFraction> shares to TruHC Holding GmbH at a par value of &#8364;<ix:nonFraction id="Fxbrl_20240529111849179" name="us-gaap:SharesIssuedPricePerShare" scale="0" decimals="2" format="ixt:num-dot-decimal" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember" unitRef="Euro_Per_share">1.00</ix:nonFraction> per share. As at March 31, 2024, <ix:nonFraction id="Fxbrl_20240529111907258" name="us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" scale="0" decimals="0" format="ixt-sec:numwordsen" contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember" unitRef="EUR">nil</ix:nonFraction> (December 31, 2022 - &#8364;<ix:nonFraction id="Fxbrl_20240529111926731" name="us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" scale="0" decimals="0" format="ixt:num-dot-decimal" contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember" unitRef="EUR">12,500</ix:nonFraction>) remains receivable as been netted against the share capital balance.</span></span></p>
                    </div>
                </ix:nonNumeric>
                <p style="margin: 0pt;">&#160;</p>
                <span></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <div>
                    <div>
                        <ix:nonNumeric id="Fxbrl_20240529102906963" name="us-gaap:SubsequentEventsTextBlock" escape="true" contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
                            <div>
                                <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>13.&#160; SUBSEQUENT EVENTS </b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 16, 2024, Flora Growth Corp. (&#8220;Flora&#8221;) entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with TruHC Holding GmbH (the &#8220;Seller&#8221;) pursuant to which Flora will acquire all of the issued and outstanding shares of the Company. The Purchase Price will be paid and satisfied by Flora in two closings. On the first closing, Flora issued <ix:nonFraction id="Fxbrl_20240529103612377" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">2,135,199</ix:nonFraction> of its common shares, which is equal to <ix:nonFraction id="Fxbrl_20240529103639864" name="flgc:PercentageOfIssuedAndOutstandingCommonShares" scale="-2" decimals="4" format="ixt:num-dot-decimal" contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Pure">19.99</ix:nonFraction>% of Flora&#8217;s issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the &#8220;Second Closing&#8221;), Flora will issue <ix:nonFraction id="Fxbrl_20240529103713547" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">635,363</ix:nonFraction> of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Under the Purchase Agreement, Flora is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 22, 2024, the first closing of the Transaction for <ix:nonFraction id="Fxbrl_20240529103803035" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" decimals="INF" format="ixt:num-dot-decimal" contextRef="C_20240401to20240422_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares">2,135,199</ix:nonFraction> Flora shares was closed.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan were forgiven.</span></span></p>
                            </div>
                        </ix:nonNumeric>
                    </div>
                </div>
                <div>
                    <p style="text-align: center; margin-top: 10pt;">228</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_167_integixAnchor"></span>
            </div>
            <div style="font-size: 10pt; line-height: initial;">
                <p style="font-family: Times New Roman; text-align: center; margin-top: 10pt;"><span style="text-decoration: underline;"><b>ANNEX A</b></span></p>
                <p style="font-family: Times New Roman; text-align: center;"><b>STOCK PURCHASE AGREEMENT</b></p>
                <p style="font-family: Times New Roman; text-align: center;">between</p>
                <p style="font-family: Times New Roman; text-align: center;"><b>TRUHC HOLDING GMBH</b></p>
                <p style="font-family: Times New Roman; text-align: center;">and</p>
                <p style="font-family: Times New Roman; text-align: center;"><b>FLORA GROWTH CORP.</b></p>
                <p style="font-family: Times New Roman; text-align: center;">dated as of</p>
                <p style="font-family: Times New Roman; text-align: center;">April 16, 2024</p>
                <p style="font-family: Times New Roman; text-align: center;">&#160;</p>
                <p style="font-family: Times New Roman; text-align: center;">&#160;</p>
                <p style="font-family: Times New Roman; text-align: center;">&#160;</p>
                <div style="font-family: Times New Roman;">
                    <p style="text-align: center;">229</p>
                </div>
                <hr style="font-family: Times New Roman; break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman;"><span id="page_168_integixAnchor"></span></span>
                <p style="font-family: Times New Roman; text-align: center; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>TABLE OF CONTENTS</b></span></span></p>
                <div>
                    <div>
                        <table style="font-family: Times New Roman; font-size: 10pt; width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="text-align: left; padding-left: 36pt; text-indent: -36pt; background-color: #eeeeee;"><a href="#page_165_integixAnchor"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">ARTICLE I DEFINITIONS</span></span></a></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><a href="#page_165_integixAnchor"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">232</span></span></a></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 36pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_177_integixAnchor">ARTICLE II PURCHASE AND SALE</a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_177_integixAnchor">239</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_177_integixAnchor"><b>Section 2.01 Purchase and Sale.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_177_integixAnchor">239</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_177_integixAnchor"><b>Section 2.02 Purchase Price.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_177_integixAnchor">239</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_177_integixAnchor"><b>Section 2.03 Transactions to be Effected at the Closing.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_177_integixAnchor">239</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_178_integixAnchor"><b>Section 2.04 Closing.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_178_integixAnchor">240</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_178_integixAnchor"><b>Section 2.05 Withholding Tax.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_178_integixAnchor">240</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 36pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_178_integixAnchor">ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER</a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_178_integixAnchor">240</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_179_integixAnchor"><b>Section 3.01 Organization and Authority of Seller.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_179_integixAnchor">241</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_179_integixAnchor"><b>Section 3.02 Organization, Authority and Qualification of the Company.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_179_integixAnchor">241</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_179_integixAnchor"><b>Section 3.03 Capitalization.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_179_integixAnchor">241</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_179_integixAnchor"><b>Section 3.04 No Subsidiaries.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_179_integixAnchor">241</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_180_integixAnchor"><b>Section 3.05 No Conflicts; Consents.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_180_integixAnchor">242</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_180_integixAnchor"><b>Section 3.06 Financial Statements.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_180_integixAnchor">242</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_180_integixAnchor"><b>Section 3.07 Undisclosed Liabilities.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_180_integixAnchor">242</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_180_integixAnchor"><b>Section 3.08 Absence of Certain Changes, Events and Conditions.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_180_integixAnchor">242</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_182_integixAnchor"><b>Section 3.09 Material Contracts.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_182_integixAnchor">244</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_184_integixAnchor"><b>Section 3.10 Title to Assets; Real Property.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_184_integixAnchor">246</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_185_integixAnchor"><b>Section 3.11 Condition And Sufficiency of Assets.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_185_integixAnchor">247</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_185_integixAnchor"><b>Section 3.12 Intellectual Property.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_185_integixAnchor">247</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_187_integixAnchor"><b>Section 3.13 Inventory.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_187_integixAnchor">249</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_187_integixAnchor"><b>Section 3.14 Accounts Receivable.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_187_integixAnchor">249</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_188_integixAnchor"><b>Section 3.15 Customers and Suppliers.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_188_integixAnchor">250</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_188_integixAnchor"><b>Section 3.16 Insurance.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_188_integixAnchor">250</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_188_integixAnchor"><b>Section 3.17 Legal Proceedings; Governmental Orders.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_188_integixAnchor">250</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_189_integixAnchor"><b>Section 3.18 Compliance With Laws; Permits.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_189_integixAnchor">251</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_189_integixAnchor"><b>Section 3.19 Environmental Matters.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_189_integixAnchor">251</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_190_integixAnchor"><b>Section 3.20 Employee Benefit Matters.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_190_integixAnchor">252</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_192_integixAnchor"><b>Section 3.21 Employment Matters.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_192_integixAnchor">254</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_192_integixAnchor"><b>Section 3.22 Taxes.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_192_integixAnchor">254</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_193_integixAnchor"><b>Section 3.23 Books and Records.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_193_integixAnchor">255</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor"><b>Section 3.24 Brokers.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor">256</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 36pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER</a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor">256</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor"><b>Section 4.01 Organization and Authority of Buyer.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor">256</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor"><b>Section 4.02 No Conflicts; Consents.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor">256</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor"><b>Section 4.03 Authorized Capital</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor">256</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor"><b>Section 4.04 Investment Purpose.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_194_integixAnchor">256</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_195_integixAnchor"><b>Section 4.05 Compliance with Securities Laws</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_195_integixAnchor">257</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_195_integixAnchor"><b>Section 4.06 Brokers.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_195_integixAnchor">257</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_195_integixAnchor"><b>Section 4.07 Legal Proceedings.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_195_integixAnchor">257</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 36pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_196_integixAnchor">ARTICLE V COVENANTS</a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_196_integixAnchor">258</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_196_integixAnchor"><b>Section 5.01 Seller Conduct of Business Prior to the First Closing.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_196_integixAnchor">258</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_196_integixAnchor"><b>Section 5.02 Buyer Conduct of Business Prior to the Closing.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_196_integixAnchor">258</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_197_integixAnchor"><b>Section 5.03 Access to Information.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_197_integixAnchor">259</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_197_integixAnchor"><b>Section 5.04 No Solicitation of Other Bids.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_197_integixAnchor">259</a></span></span></td>
                            </tr>
                            <tr>
                                <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_198_integixAnchor"><b>Section 5.05 Notice of Certain Events.</b></a></span></span></td>
                                <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_198_integixAnchor">260</a></span></span></td>
                            </tr>
                        </table>
                        <p style="font-family: Times New Roman; margin-left: 72pt; margin-bottom: 0pt; text-indent: -36pt; margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="color: #000000;">&#160;</span></span></span></p>
                        <div>
                            <p style="text-align: center; margin-top: 10pt;"><span style="font-family: Times New Roman, Times, serif;">230</span></p>
                        </div>
                        <hr style="font-family: Times New Roman; break-after: page; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman; font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span id="page_169_integixAnchor"></span></span></span>
                        <div>
                            <div>&#160;
                                <table style="font-size: 10pt; width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0">
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_198_integixAnchor"><b>Section 5.06 Resignations.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_198_integixAnchor">260</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_198_integixAnchor"><b>Section 5.07 Confidentiality.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_198_integixAnchor">260</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_198_integixAnchor"><b>Section 5.08 Non-Competition; Non-Solicitation.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_198_integixAnchor">260</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_199_integixAnchor"><b>Section 5.09 Approvals and Consents.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_199_integixAnchor">261</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_200_integixAnchor"><b>Section 5.10 Books and Records.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_200_integixAnchor">262</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_201_integixAnchor"><b>Section 5.11 Registration Rights</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_201_integixAnchor">263</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_201_integixAnchor"><b>Section 5.12 Closing Conditions</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_201_integixAnchor">263</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_201_integixAnchor"><b>Section 5.13 Public Announcements.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_201_integixAnchor">263</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_201_integixAnchor"><b>Section 5.14 Further Assurances.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_201_integixAnchor">263</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 36pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_202_integixAnchor">ARTICLE VI TAX MATTERS</a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_202_integixAnchor">264</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_202_integixAnchor"><b>Section 6.01 Tax Covenants.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_202_integixAnchor">264</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_202_integixAnchor"><b>Section 6.02 Termination of Existing Tax Sharing Agreements.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_202_integixAnchor">264</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_202_integixAnchor"><b>Section 6.03 Tax Indemnification.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_202_integixAnchor">264</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_203_integixAnchor"><b>Section 6.04 Straddle Period.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_203_integixAnchor">265</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_203_integixAnchor"><b>Section 6.05 Contests.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_203_integixAnchor">265</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_203_integixAnchor"><b>Section 6.06 Cooperation and Exchange of Information.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_203_integixAnchor">265</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor"><b>Section 6.07 Tax Treatment of Indemnification Payments.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor">266</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor"><b>Section 6.08 Survival.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor">266</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor"><b>Section 6.09 Overlap.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor">266</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 36pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor">ARTICLE VII CONDITIONS TO CLOSING</a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor">266</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor"><b>Section 7.01 Conditions to Obligations of All Parties.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor">266</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor"><b>Section 7.02 Conditions to Obligations of Buyer.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_204_integixAnchor">266</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_206_integixAnchor"><b>Section 7.03 Conditions to Obligations of Seller.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_206_integixAnchor">268</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 36pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_207_integixAnchor">ARTICLE VIII INDEMNIFICATION</a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_207_integixAnchor">269</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_207_integixAnchor"><b>Section 8.01 Survival.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_207_integixAnchor">269</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_207_integixAnchor"><b>Section 8.02 Indemnification By Seller.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_207_integixAnchor">269</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_207_integixAnchor"><b>Section 8.03 Indemnification By Buyer.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_207_integixAnchor">269</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_208_integixAnchor"><b>Section 8.04 Certain Limitations.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_208_integixAnchor">270</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_208_integixAnchor"><b>Section 8.05 Indemnification Procedures.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_208_integixAnchor">270</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_210_integixAnchor"><b>Section 8.06 Payments</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_210_integixAnchor">272</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor"><b>Section 8.07 Tax Treatment of Indemnification Payments.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor">273</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor"><b>Section 8.08 Effect of Investigation.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor">273</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor"><b>Section 8.09 Exclusive Remedies.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor">273</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 36pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor">ARTICLE IX MISCELLANEOUS</a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor">273</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor"><b>Section 9.01 Expenses.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor">273</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor"><b>Section 9.02 Notices.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_211_integixAnchor">273</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor"><b>Section 9.03 Interpretation.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor">274</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor"><b>Section 9.04 Headings.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor">274</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor"><b>Section 9.05 Severability.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor">274</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor"><b>Section 9.06 Entire Agreement.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor">274</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor"><b>Section 9.07 Successors and Assigns.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_212_integixAnchor">274</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_213_integixAnchor"><b>Section 9.08 No Third-Party Beneficiaries.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_213_integixAnchor">275</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_213_integixAnchor"><b>Section 9.09 Amendment and Modification; Waiver.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_213_integixAnchor">275</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_213_integixAnchor"><b>Section 9.10 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_213_integixAnchor">275</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_214_integixAnchor"><b>Section 9.11 Specific Performance.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right; background-color: #eeeeee;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_214_integixAnchor">276</a></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left; padding-left: 72pt; text-indent: -36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_214_integixAnchor"><b>Section 9.12 Counterparts.</b></a></span></span></td>
                                        <td style="width: 5%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><a href="#page_214_integixAnchor">276</a></span></span></td>
                                    </tr>
                                </table>
                            </div>
                        </div>
                        <p style="font-family: Times New Roman; text-align: center; margin-top: 10pt;">&#160;</p>
                        <div>
                            <p style="text-align: center;"><span style="font-family: Times New Roman, Times, serif;">231</span></p>
                        </div>
                    </div>
                </div>
                <hr style="font-family: Times New Roman; break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span style="font-family: Times New Roman;"><span id="page_170_integixAnchor"></span></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: center; margin-top: 10pt;"><span id="page_165_integixAnchor"><span style="font-size: 12pt;"><b>STOCK PURCHASE AGREEMENT</b></span></span></p>
                <p style="text-align: justify;">This Stock Purchase Agreement (this "<b>Agreement</b>"), dated as of April 16, 2024 is entered into between TruHC Holding GmbH (the "<b>Seller</b>") and Flora Growth Corp., an Ontario corporation (the "<b>Buyer</b>").</p>
                <p style="text-align: center;"><b>RECITALS</b></p>
                <p style="text-indent: 36pt; text-align: justify;">WHEREAS, Seller owns all of the issued and outstanding 25,000 shares of common stock, par value of nominal capital of EUR 25,000.00 (the "<b>Shares</b>"), of TruHC Pharma GmbH, a German limited company (the "<b>Company</b>");</p>
                <p style="text-indent: 36pt; text-align: justify;">WHEREAS, Seller wish to sell to Buyer, and Buyer wishes to purchase from Seller, the Shares, subject to the terms and conditions set forth herein; and</p>
                <p style="text-indent: 36pt; text-align: justify;">NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</p>
                <p style="text-align: center;"><b>ARTICLE I</b><br/><b>DEFINITIONS</b></p>
                <p style="text-indent: 36pt; text-align: justify;">The following terms have the meanings specified or referred to in this <span style="background-color: transparent;">ARTICLE I</span>:</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Acquisition Proposal</b>" has the meaning set forth in <span style="background-color: transparent;">Section 5.04(a)</span>.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Action</b>" means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Affiliate</b>" of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term "control" (including the terms "controlled by" and "under common control with") means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Agreement</b>" has the meaning set forth in the preamble.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Annual Financial Statements</b>" has the meaning set forth in Section 3.06.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Applicable Securities Laws</b>" means the securities laws, the regulations, rules, rulings and orders in the United States and the Provinces of British Columbia and Ontario, the applicable policy statements issued by the securities regulators in the United States and the Provinces of British Columbia and Ontario."</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Balance Sheet</b>" has the meaning set forth in Section 3.06.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Balance Sheet Date</b>" has the meaning set forth in Section 3.06.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Basket</b>" has the meaning set forth in <span style="background-color: transparent;">Section 8.04(a)</span>.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Benefit Plan</b>" has the meaning set forth in <span style="background-color: transparent;">Section 3.20(a)</span>.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Business Day</b>" means any day except Saturday, Sunday or any other day on which commercial banks located in the Province of Ontario are authorized or required by Law to be closed for business.</p>
                <div>
                    <p style="text-align: center;">232</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_171_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;">"<b>Buyer</b>" has the meaning set forth in the preamble.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Buyer Indemnitees</b>" has the meaning set forth in <span style="background-color: transparent;">Section 8.02</span>.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Buyer's Accountants</b>" means Davidson &amp; Company LLP.</p>
                <p style="margin-left: 36pt; text-align: justify;">"<b>Certified</b>" means the certification of a business analysis (BWA) or annual financial statements (Jahresabschluss) of a German GmbH in accordance with the HGB, which contains a balance sheet and a profit and loss account for the respective financial year.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Closing</b>" means as the First Closing and the Second Closing, as the context requires..</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Closing Date</b>" means the date of Closing.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Code</b>" means the Internal Revenue Code of 1986 or any foreign equivalent, as amended.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Common Stock</b>" has the meaning set forth in Section 3.03(a).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Company</b>" has the meaning set forth in the recitals.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Company Intellectual Property</b>" means all Intellectual Property that is owned by the Company.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Company IP Agreements</b>" means all licenses, sublicenses, consent to use agreements, settlements, coexistence agreements, covenants not to sue, waivers, releases, permissions and other Contracts, whether written or oral, relating to Intellectual Property to which the Company is a party, beneficiary or otherwise bound.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Company IP Registrations</b>" means all Company Intellectual Property that is subject to any issuance, registration or application by or with any Governmental Authority or authorized private registrar in any jurisdiction, including issued patents, registered trademarks, domain names and copyrights, and pending applications for any of the foregoing.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Company IT Systems</b>" means all Software, computer hardware, servers, networks, platforms, peripherals, and similar or related items of automated, computerized, or other information technology (IT) networks and systems (including telecommunications networks and systems for voice, data and video) owned, leased, licensed, or used (including through cloud-based or other third-party service providers) by the Company.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Contracts</b>" means all contracts, leases, deeds, mortgages, licenses, instruments, notes, commitments, undertakings, indentures, joint ventures and all other agreements, commitments and legally binding arrangements, whether written or oral.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Copyrights</b>" has the meaning set forth in the definition of Intellectual Property.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Direct Claim</b>" has the meaning set forth in Section 8.05(c).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Disclosure Schedules</b>" means the Disclosure Schedules delivered by Seller and Buyer concurrently with the execution and delivery of this Agreement.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Dollars</b>"<b> </b>or<b> </b>"<b>$</b>" means the lawful currency of the United States.</p>
                <div>
                    <p style="text-align: center;">233</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_172_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;">"<b>DRS</b>" has the meaning set forth in Section 2.03(a)(i).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Encumbrance</b>" means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option, security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Environmental Claim</b>" means any Action, Governmental Order, lien, fine, penalty, or, as to each, any settlement or judgment arising therefrom, by or from any Person alleging liability of whatever kind or nature (including liability or responsibility for the costs of enforcement proceedings, investigations, cleanup, governmental response, removal or remediation, natural resources damages, property damages, personal injuries, medical monitoring, penalties, contribution, indemnification and injunctive relief) arising out of, based on or resulting from: (a) the presence of, Release of, or exposure to, any Hazardous Materials; or (b) any actual or alleged non-compliance with any Environmental Law or term or condition of any Environmental Permit.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Environmental Law</b>" means any applicable Law, and any Governmental Order or binding agreement with any Governmental Authority: (a) relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human health or safety, or the environment (including ambient or indoor air, soil, surface water or groundwater, or subsurface strata); or (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Environmental Notice</b>" means any written directive, notice of violation or infraction, or notice respecting any Environmental Claim relating to actual or alleged non-compliance with any Environmental Law or any term or condition of any Environmental Permit.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Environmental Permit</b>" means any Permit, letter, clearance, consent, waiver, closure, exemption, decision or other action required under or issued, granted, given, authorized by or made pursuant to Environmental Law.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Exchange</b>" means The NASDAQ Stock Market.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Financial Statements</b>" has the meaning set forth in Section 3.06.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>First Closing</b>" means the closing of the transaction of purchase and sale of the First Closing Shares.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>First Closing Date</b>" has the meaning set forth in Section 2.04(a)(i).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>First Closing Flora Shares</b>" has the meaning set forth in Section 2.02(b)(i).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>First Closing Shares</b>" shall mean 19,266 of the Shares of the Company.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Flora Shares</b>" has the meaning set forth in Section 2.02.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>GAAP</b>" means United States generally accepted accounting principles in effect from time to time.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Government Contracts</b>" has the meaning set forth in Section 3.09(a)(viii).</p>
                <div>
                    <p style="text-align: center;">234</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_173_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;">"<b>Governmental Authority</b>" means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Governmental Order</b>" means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Hazardous Materials</b>" means: (a) any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in each case, whether naturally occurring or manmade, that is hazardous, acutely hazardous, toxic, or words of similar import or regulatory effect under Environmental Laws; and (b) any petroleum or petroleum-derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead-containing materials, urea formaldehyde foam insulation, and polychlorinated biphenyls and per- and poly- fluoroalkyl substances (PFAS) and other emerging contaminants.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Indebtedness</b>" means, without duplication and with respect to the Company, all (a) indebtedness for borrowed money; (b) obligations for the deferred purchase price of property or services (c) long or short-term obligations evidenced by notes, bonds, debentures or other similar instruments; (d) obligations under any interest rate, currency swap or other hedging agreement or arrangement; (e) capital lease obligations; (f) reimbursement obligations under any letter of credit, banker's acceptance or similar credit transactions; (g) guarantees made by the Company on behalf of any third party in respect of obligations of the kind referred to in the foregoing clauses (a) through (f); and (h) any unpaid interest, prepayment penalties, premiums, costs and fees that would arise or become due as a result of the prepayment of any of the obligations referred to in the foregoing clauses (a) through (g).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Indemnified Party</b>" has the meaning set forth in Section 8.05.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Indemnifying Party</b>" has the meaning set forth in Section 8.05.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Insurance Policies</b>" has the meaning set forth in Section 3.16.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Intellectual Property</b>" means any and all rights in, arising out of, or associated with any of the following in any jurisdiction throughout the world: (a) issued patents and patent applications (whether provisional or non-provisional), including divisionals, continuations, continuations-in-part, substitutions, reissues, reexaminations, extensions, or restorations of any of the foregoing, and other Governmental Authority-issued indicia of invention ownership (including certificates of invention, petty patents, and patent utility models) ("<b>Patents</b>"); (b) trademarks, service marks, brands, certification marks, logos, trade dress, trade names, and other similar indicia of source or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications for registration, and renewals of, any of the foregoing ("<b>Trademarks</b>"); (c) copyrights and works of authorship, whether or not copyrightable, and all registrations, applications for registration, and renewals of any of the foregoing ("<b>Copyrights</b>"); (d) internet domain names, whether or not Trademarks, all associated web addresses, URLs, websites and web pages, social media sites and pages, and all content and data thereon or relating thereto, whether or not Copyrights<b>;</b> (g) trade secrets, know-how, inventions (whether or not patentable), discoveries, improvements, technology, business and technical information, databases, data compilations and collections, tools, methods, processes, techniques, and other confidential and proprietary information and all rights therein ("<b>Trade Secrets</b>"); (h) computer programs, operating systems, applications, firmware, and other code, including all source code, object code, application programming interfaces, data files, databases, protocols, specifications, and other documentation thereof ("<b>Software</b>"); and (j) all other intellectual or industrial property and proprietary rights.</p>
                <div>
                    <p style="text-align: center;">235</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_174_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;">"<b>Interim Balance Sheet</b>" has the meaning set forth in Section 3.06.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Interim Balance Sheet Date</b>" has the meaning set forth in Section 3.06.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Interim Financial Statements</b>" has the meaning set forth in Section 3.06.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Issue Price</b>" has the meaning of the most recent closing price of the Flora Shares available on the Exchange prior to the signing of this agreement, subject to the Exchange rules, as applicable.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>HGB</b>" means German generally accepted accounting principles in effect from time to time.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Knowledge of Seller or Seller's Knowledge</b>" or any other similar knowledge qualification, means the actual or constructive knowledge of any director or officer of Seller or the Company, after due inquiry.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Law</b>" means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Liabilities</b>" has the meaning set forth in Section 3.07.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Licensed Intellectual Property</b>" means all Intellectual Property in which the Company holds any rights or interests granted by other Persons, including the Seller.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Losses</b>" means losses, damages, Liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys' fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers; <i>provided, however,</i> that "<b>Losses</b>" shall not include punitive damages, except to the extent actually awarded to a Governmental Authority or other third party.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Material Adverse Effect</b>" means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the business, results of operations, condition (financial or otherwise) or assets of the Company, or (b) the ability of Seller to consummate the transactions contemplated hereby on a timely basis; <i>provided, however,</i> that "Material Adverse Effect" shall not include any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the industries in which the Company operates; (iii) any changes in financial or securities markets in general; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (v) any action required or permitted by this Agreement, (vi) any changes in applicable Laws or accounting rules, including HGB; or (vii) the public announcement, pendency or completion of the transactions contemplated by this Agreement; <i>provided further, however,</i> that any event, occurrence, fact, condition or change referred to in clauses (i) through (iv) immediately above shall be taken into account in determining whether a Material Adverse Effect has occurred or could reasonably be expected to occur to the extent that such event, occurrence, fact, condition or change has a disproportionate effect on the Company compared to other participants in the industries in which the Company conducts its businesses (in which case, only the incremental disproportionate adverse effect may be taken into account in determining whether a Material Adverse Effect has occurred).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Material Contracts</b>" has the meaning set forth in Section 3.09(a).</p>
                <div>
                    <p style="text-align: center;">236</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_175_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;">"<b>Material Customers</b>" has the meaning set forth in Section 3.15(a).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Material Suppliers</b>" has the meaning set forth in Section 3.15(b).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Non-U.S. Benefit Plan</b>" has the meaning set forth in Section 3.20(a).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Patents</b>" has the meaning set forth in the definition of Intellectual Property.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Permits</b>" means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Permitted Encumbrances</b>" has the meaning set forth in Section 3.10(a).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Person</b>" means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Platform Agreements</b>" has the meaning set forth in Section 3.12(h).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Post-Closing Tax Period</b>" means any taxable period beginning after the First Closing Date and, with respect to any taxable period beginning before and ending after the First Closing Date, the portion of such taxable period beginning after the First Closing Date.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Pre-Closing Tax Period</b>" means any taxable period ending on or before the First Closing Date and, with respect to any taxable period beginning before and ending after the First Closing Date, the portion of such taxable period ending on and including the First Closing Date.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Pre-Closing Taxes</b>" has the meaning set forth in Section 6.03.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Purchase Price</b>" has the meaning set forth in Section 2.02.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>"Registration Rights Agreement" </b>has the meaning set forth in Section 5.11.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Real Property</b>" means the real property owned by, or leased or subleased to, the Company, together with all buildings, structures and facilities located thereon.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Release</b>" means any actual or threatened release, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, abandonment, disposing or allowing to escape or migrate into or through the environment (including, without limitation, ambient or indoor air, surface water, groundwater, land surface or subsurface strata or within any building, structure, facility or fixture).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Representative</b>" means, with respect to any Person, any and all directors, officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Restricted Business</b>" means the development or marketing of medical cannabis products or services which are competitive with the business of the Buyer .</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Restricted Period</b>" has the meaning set forth in Section 5.08.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Second Closing</b>" means the closing of the transaction of purchase and sale of the Second Closing Shares.</p>
                <div>
                    <p style="text-align: center;">237</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_176_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;">"<b>Second Closing Date</b>" has the meaning set forth in Section 2.04(a)(ii).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Second Closing Flora Shares</b>" has the meaning set forth in Section 2.02(b)(ii).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Second Closing Shares</b>" means 5,734 Shares of the Company.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Seller</b>" has the meaning set forth in the preamble.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Seller Indemnitees</b>" has the meaning set forth in Section 8.03.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Seller's Accountants</b>" means RTS.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Shares</b>" has the meaning set forth in the recitals.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Software</b>" has the meaning set forth in the definition of Intellectual Property.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Straddle Period</b>" has the meaning set forth in Section 6.04.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Taxes</b>" means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Tax Claim</b>" has the meaning set forth in Section 6.05.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Tax Return</b>" means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Territory</b>" means Germany.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Third-Party Claim</b>" has the meaning set forth in Section 8.05(a).</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Trade Secrets</b>" has the meaning set forth in the definition of Intellectual Property.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Trademarks</b>" has the meaning set forth in the definition of Intellectual Property.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>Transaction Expenses</b>" means all fees and expenses incurred by the Company or Seller at or prior to the Closing in connection with the preparation, negotiation and execution of this Agreement, and the performance and consummation of the transactions contemplated hereby and thereby.</p>
                <p style="text-indent: 36pt; text-align: justify;">"<b>WARN Act</b>" means the federal Worker Adjustment and Retraining Notification Act of 1988, and similar state, local and foreign laws related to plant closings, relocations, mass layoffs and employment losses.</p>
                <div>
                    <p style="text-align: center;">238</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_177_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>ARTICLE II</b><br/><b>PURCHASE AND SALE</b></p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 2.01</b><span style="width: 19.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Purchase and Sale.</b> Subject to the terms and conditions set forth herein, Seller shall sell to Buyer, and Buyer shall purchase from Seller, the First Closing Shares, and the Second Closing Shares, free and clear of all Encumbrances, for the consideration specified in Section 2.02.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 2.02</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Purchase Price.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The aggregate purchase price for the Shares shall be an amount equal to <b>USD$6,400,000</b> (the "<b>Purchase Price</b>"), and shall be paid and satisfied in share consideration through the issuance of common shares of the Buyer ("<b>Flora Shares</b>").</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Purchase Price, and the transactions contemplated herein shall be completed in two tranches, and the Purchase Price shall be paid and satisfied by the Buyer as follows:</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>on the First Closing, by the issuance of 2,135,199 Flora Shares (the "<b>First Closing Flora Shares</b>"), registered in the name of the Seller, or as the Seller may direct, at a deemed price per share equal to $2.31; and</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>on the Second Closing, upon shareholder approval of the issuance of the Second Closing Flora Shares, by the issuance of 635,363 Flora Shares (the "<b>Second Closing Flora Shares</b>"), registered in the name of the Seller, or as the Seller may direct, at a deemed price per share equal to $2.31.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 2.03</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Transactions to be Effected at or after the Closings.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>on the First Closing:</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>the Buyer shall deliver to Seller</p>
                <p style="margin-left: 108pt; text-indent: 36pt; text-align: justify;">(A)<span style="width: 19.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>a direct registration system statement ("<b>DRS</b>") representing the First Closing Flora Shares in satisfaction of the First Closing Purchase Price;</p>
                <p style="margin-left: 108pt; text-indent: 36pt; text-align: justify;">(B)<span style="width: 20pt; text-indent: 0pt; display: inline-block;">&#160;</span>all other agreements, documents, instruments or certificates required to be delivered by Seller at or prior to the First Closing pursuant to Section 7.03 of this Agreement.</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>the Seller shall deliver to Buyer:</p>
                <p style="margin-left: 108pt; text-indent: 36pt; text-align: justify;">(A)<span style="width: 19.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Subject to Section 5.09(h), stock certificates evidencing the First Closing Shares, free and clear of all Encumbrances, duly endorsed in blank or accompanied by stock powers or other instruments of transfer duly executed in blank, with all required stock transfer tax stamps affixed thereto; and</p>
                <p style="margin-left: 108pt; text-indent: 36pt; text-align: justify;">(B)<span style="width: 20pt; text-indent: 0pt; display: inline-block;">&#160;</span>all other agreements, documents, instruments or certificates required to be delivered by Seller at or prior to the First Closing pursuant to Section 7.02 of this Agreement.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>on the Second Closing</p>
                <div>
                    <p style="text-align: center;">239</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_178_integixAnchor"></span>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>the Buyer shall deliver to Seller</p>
                <p style="margin-left: 108pt; text-indent: 36pt; text-align: justify;">(A)<span style="width: 19.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>a direct registration system statement ("<b>DRS</b>") representing the Second Closing Flora Shares in satisfaction of the Second Closing Purchase Price;</p>
                <p style="margin-left: 108pt; text-indent: 36pt; text-align: justify;">(B)<span style="width: 20pt; text-indent: 0pt; display: inline-block;">&#160;</span>all other agreements, documents, instruments or certificates required to be delivered by Seller at or prior to the Second Closing pursuant to Section 7.03 of this Agreement.</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>the Seller shall deliver to Buyer:</p>
                <p style="margin-left: 108pt; text-indent: 36pt; text-align: justify;">(A)<span style="width: 19.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Subject to Section 5.09(h), stock certificates evidencing the Second Closing Shares, free and clear of all Encumbrances, duly endorsed in blank or accompanied by stock powers or other instruments of transfer duly executed in blank, with all required stock transfer tax stamps affixed thereto.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 2.04</b><span style="width: 20.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Closing.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;"><b>(a)</b><span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Subject to the terms and conditions of this Agreement, the transactions of purchase and sale of the Shares contemplated hereby shall take place and be completed on the following dates:</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;"><b>(i)</b><span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>the First Closing, on or before April 22, 2024 (the "<b>First Closing Date</b>"), and in any event no later than five (5) Business Days after the last of the applicable conditions to Closing set forth in ARTICLE VII have been satisfied or waived (other than conditions which, by their nature, are to be satisfied on the applicable Closing Date), or at such other time or on such other date or at such other place as Seller and Buyer may mutually agree upon in writing; and</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;"><b>(ii)</b><span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>the Second Closing on or before August 15, 2024, and in any event no later than five (5) Business Days after the last of the applicable conditions to Closing set forth in ARTICLE VII have been satisfied or waived (other than conditions which, by their nature, are to be satisfied on the applicable Closing Date), or at such other time or on such other date or at such other place as Seller and Buyer may mutually agree upon in writing.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;"><b>(b)</b><span style="width: 21.33pt; text-indent: 0pt; display: inline-block;">&#160;</span>The First Closing and the Second Closing shall be held virtually and remotely by electronic exchange of documents and signatures.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 2.05</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Withholding Tax.</b> Buyer and the Company shall be entitled to deduct and withhold from the Purchase Price all Taxes that Buyer and the Company may be required to deduct and withhold under any provision of Tax Law. All such withheld amounts shall be treated as delivered to Seller hereunder.</p>
                <p style="text-align: center;"><b>ARTICLE III</b><br/><b>REPRESENTATIONS AND WARRANTIES OF SELLER</b></p>
                <p style="text-indent: 36pt; text-align: justify;">Except as set forth in the correspondingly numbered Section of the Disclosure Schedules, Seller represent and warrants to Buyer that the statements contained in this ARTICLE III are true and correct as of the date hereof.</p>
                <div>
                    <p style="text-align: center;">240</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_179_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 3.01</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Organization and Authority of Seller.</b> Seller is a German GmbH (limited company) duly organized, validly existing and in good standing under the Laws of Germany. Seller have full corporate power and authority to enter into this Agreement to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Seller of this Agreement and the performance by Seller of their obligations hereunder and thereunder, and the consummation by Seller of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Seller. This Agreement has been duly executed and delivered by Seller, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes a legal, valid and binding obligation of Seller enforceable against Seller in accordance with its terms. When has been duly executed and delivered by Seller (assuming due authorization, execution and delivery by each other party thereto), will constitute a legal and binding obligation of Seller enforceable against it in accordance with its terms.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.02</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Organization, Authority and Qualification of the Company.</b> The Company is a corporation duly organized, validly existing and in good standing under the Laws of Germany and has full corporate power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on its business as it has been and is currently conducted. Section 3.02 of the Disclosure Schedules sets forth each jurisdiction in which the Company is licensed or qualified to do business, and the Company is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of its business as currently conducted makes such licensing or qualification necessary. All corporate actions taken by the Company in connection with this Agreement will be duly authorized on or prior to the First Closing Date.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.03</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Capitalization.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The authorized capital stock of the Company consists of 25,000 shares of common stock, par value 1 EUR per share ("<b>Common Stock</b>"), of which 25,000 shares are issued and outstanding and constitute the Shares. All of the Shares have been duly authorized, are validly issued, fully paid and non-assessable, and are owned of record and beneficially by Seller, free and clear of all Encumbrances. Upon consummation of the transactions contemplated by this Agreement, Buyer shall own all of the Shares, free and clear of all Encumbrances.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>All of the Shares were issued in compliance with applicable Laws. None of the Shares were issued in violation of any agreement, arrangement or commitment to which Seller or the Company is a party or is subject to or in violation of any preemptive or similar rights of any Person.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>There are no outstanding or authorized options, warrants, convertible securities or other rights, agreements, arrangements or commitments of any character relating to the capital stock of the Company or obligating Seller or the Company to issue or sell any shares of capital stock of, or any other interest in, the Company. The Company does not have outstanding or authorized any stock appreciation, phantom stock, profit participation or similar rights. There are no voting trusts, stockholder agreements, proxies or other agreements or understandings in effect with respect to the voting or transfer of any of the Shares.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.04</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>No Subsidiaries.</b> The Company does not own, or have any capital stock or other equity, ownership or profit sharing interests in any other Person, or the right or obligation to acquire any capital stock or other equity, ownership or profit sharing interests in any other Person.</p>
                <div>
                    <p style="text-align: center;">241</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_180_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 3.05</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>No Conflicts; Consents.</b> The execution, delivery and performance by Seller of this Agreement, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of Seller or the Company; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Seller or the Company; (c) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel any Contract to which Seller or the Company is a party or by which Seller or the Company is bound or to which any of their respective properties and assets are subject (including any Material Contract) or any Permit affecting the properties, assets or business of the Company; or (d) result in the creation or imposition of any Encumbrance other than Permitted Encumbrances on any properties or assets of the Company. No consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Seller or the Company in connection with the execution and delivery of this Agreement and the and the consummation of the transactions contemplated hereby and thereby, except for such filings as may be required under the HSR Act.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.06</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Financial Statements.</b> Complete copies of the Company's unaudited financial statements, for the most recent fiscal year end consisting of the balance sheet of the Company as at December 31, 2023 and the related statement of income and retained earnings, stockholders' equity and cash flow for the year then ended (the "<b>Annual Financial Statements</b>"), and unaudited financial statements consisting of the balance sheet of the Company as at February 29, 2024 and the related statement of income and retained earnings, stockholders' equity and cash flow for period then ended (the "<b>Interim Financial Statements</b>" and together with the Annual Financial Statements, the "<b>Financial Statements</b>") are included in the Disclosure Schedules/have been delivered to Buyer. The Annual Financial Statements have been prepared in accordance with HGB applied on a consistent basis throughout the period involved, subject, in the case of the Interim Financial Statements, to normal and recurring year-end adjustments (the effect of which will not be materially adverse) and the absence of notes (that, if presented, would not differ materially from those presented in the Annual Financial Statements). The Financial Statements are based on the books and records of the Company, and fairly present in all material respects the financial condition of the Company as of the respective dates they were prepared and the results of the operations of the Company for the periods indicated. The balance sheet of the Company as of December 31, 2023 is referred to herein as the "<b>Balance Sheet</b>" and the date thereof as the "<b>Balance Sheet Date</b>" and the balance sheet of the Company as of March 31, 2024 is referred to herein as the "<b>Interim Balance Sheet</b>" and the date thereof as the "<b>Interim Balance Sheet Date</b>". The Company maintains a standard system of accounting established and administered in accordance with HGB.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.07</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Undisclosed Liabilities.</b> The Company has no liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise ("<b>Liabilities</b>"), except (a) those which are adequately reflected or reserved against in the Balance Sheet as of the Balance Sheet Date, and (b) those which have been incurred in the ordinary course of business consistent with past practice since the Balance Sheet Date and which are not, individually or in the aggregate, material in amount.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.08</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Absence of Certain Changes, Events and Conditions.</b> Since the Balance Sheet Date, the business of the Company has been conducted in the ordinary course of business consistent with past practice, and there has not been, with respect to the Company, any:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>event, occurrence or development that has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;</p>
                <div>
                    <p style="text-align: center;">242</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_181_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>amendment of the charter, by-laws or other organizational documents of the Company;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>split, combination or reclassification of any shares of its capital stock;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>issuance, sale or other disposition of any of its capital stock, or grant of any options, warrants or other rights to purchase or obtain (including upon conversion, exchange or exercise) any of its capital stock;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>declaration or payment of any dividends or distributions on or in respect of any of its capital stock or redemption, purchase or acquisition of its capital stock;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(f)<span style="width: 26.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>material change in any method of accounting or accounting practice of the Company, except as required by HGB or as disclosed in the notes to the Financial Statements, except in connection with the conversion to US GAAP in furtherance of the completion of the transactions contemplated herein;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>material change in the Company's cash management practices and its policies, practices and procedures with respect to collection of accounts receivable, establishment of reserves for uncollectible accounts, accrual of accounts receivable, inventory control, prepayment of expenses, payment of trade accounts payable, accrual of other expenses, deferral of revenue and acceptance of customer deposits;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>entry into any Contract that would constitute a Material Contract;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>incurrence, assumption or guarantee of any Indebtedness for borrowed money except unsecured current obligations and Liabilities incurred in the ordinary course of business consistent with past practice;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(j)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>transfer, assignment, sale or other disposition of any of the assets shown or reflected in the Balance Sheet or cancellation of any debts or entitlements;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(k)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>transfer or assignment of or grant of any license or sublicense under or with respect to any material Company Intellectual Property or Company IP Agreements, except, that the&#160; the Company acquired the EU and German trademarks TruHC and Royal Botanics and correlated domains in March 2024 from the Seller (the contract is attached to this SPA)</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(l)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>abandonment or lapse of or failure to maintain in full force and effect any material Company IP Registration;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(m)<span style="width: 21.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>material damage, destruction or loss (whether or not covered by insurance) to its property;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(n)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>capital investment in, or loan to, any other Person;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(o)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>acceleration, termination, material modification to or cancellation of any material Contract (including, but not limited to, any Material Contract) to which the Company is a party or by which it is bound;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(p)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>material capital expenditures;</p>
                <div>
                    <p style="text-align: center;">243</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_182_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(q)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>imposition of any Encumbrance upon any of the Company properties, capital stock or assets, tangible or intangible;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(r)<span style="width: 26.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>(i) grant of any bonuses, whether monetary or otherwise, or increase in any wages, salary, severance, pension or other compensation or benefits in respect of its current or former employees, officers, directors, independent contractors or consultants, other than as provided for in any written agreements or required by applicable Law, (ii) change in the terms of employment for any employee or any termination of any employees for which the aggregate costs and expenses exceed $10,000, or (iii) action to accelerate the vesting or payment of any compensation or benefit for any current or former employee, officer, director, independent contractor or consultant;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(s)<span style="width: 23.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>adoption, modification or termination of any: (i) employment, severance, retention or other agreement with any current or former employee, officer, director, independent contractor or consultant, (ii) Benefit Plan or (iii) collective bargaining or other agreement with a Union, in each case whether written or oral;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(t)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>loan to (or forgiveness of any loan to), or entry into any other transaction with, any of its stockholders or current or former directors, officers and employees, except for related party Indebtedness being forgiven in connection with the completion of the transactions contemplated herein;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(u)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>entry into a new line of business or abandonment or discontinuance of existing lines of business;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(v)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>adoption of any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar Law;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(w)<span style="width: 19.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>purchase, lease or other acquisition of the right to own, use or lease any property or assets for an amount in excess of $10,000, individually (in the case of a lease, per annum) or $10,000 in the aggregate (in the case of a lease, for the entire term of the lease, not including any option term), except for purchases of inventory or supplies in the ordinary course of business consistent with past practice;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(x)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>acquisition by merger or consolidation with, or by purchase of a substantial portion of the assets or stock of, or by any other manner, any business or any Person or any division thereof;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(y)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>action by the Company to make, change or rescind any Tax election, amend any Tax Return or take any position on any Tax Return, take any action, omit to take any action or enter into any other transaction that would have the effect of increasing the Tax liability or reducing any Tax asset of Buyer in respect of any Post-Closing Tax Period; or</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(z)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Contract to do any of the foregoing, or any action or omission that would result in any of the foregoing.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.09</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Material Contracts.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span><span style="background-color: transparent;">Section 3.09(a)</span> of the Disclosure Schedules lists each of the following Contracts of the Company (such Contracts, together with all Contracts concerning the occupancy, management or operation of any Real Property (including without limitation, brokerage contracts) listed or otherwise disclosed in <span style="background-color: transparent;">Section 3.10(b)</span> of the Disclosure Schedules and all Company IP Agreements (being "<b>Material Contracts</b>"):</p>
                <div>
                    <p style="text-align: center;">244</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_183_integixAnchor"></span>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>each Contract of the Company involving aggregate consideration in excess of $10,000 and which, in each case, cannot be cancelled by the Company without penalty or without more than 30 days' notice;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 21.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>all Contracts that require the Company to purchase its total requirements of any product or service from a third party or that contain "take or pay" provisions;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(iii)<span style="width: 18.51pt; text-indent: 0pt; display: inline-block;">&#160;</span>all Contracts that provide for the indemnification by the Company of any Person or the assumption of any Tax, environmental or other Liability of any Person;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(iv)<span style="width: 19.17pt; text-indent: 0pt; display: inline-block;">&#160;</span>all Contracts that relate to the acquisition or disposition of any business, a material amount of stock or assets of any other Person or any real property (whether by merger, sale of stock, sale of assets or otherwise);</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(v)<span style="width: 22pt; text-indent: 0pt; display: inline-block;">&#160;</span>all broker, distributor, dealer, manufacturer's representative, franchise, agency, sales promotion, market research, marketing consulting and advertising Contracts to which the Company is a party;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(vi)<span style="width: 19.17pt; text-indent: 0pt; display: inline-block;">&#160;</span>all employment agreements and Contracts with independent contractors or consultants (or similar arrangements) to which the Company is a party and which are not cancellable without material penalty or without more than 30 days' notice;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(vii)<span style="width: 16.84pt; text-indent: 0pt; display: inline-block;">&#160;</span>except for Contracts relating to trade payables, all Contracts relating to Indebtedness (including, without limitation, guarantees) of the Company;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(viii)<span style="width: 13.51pt; text-indent: 0pt; display: inline-block;">&#160;</span>all Contracts with any Governmental Authority to which the Company is a party ("<b>Government Contracts</b>");</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ix)<span style="width: 18.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>all Contracts that limit or purport to limit the ability of the Company to compete in any line of business or with any Person or in any geographic area or during any period of time;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(x)<span style="width: 21.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>any Contracts to which the Company is a party that provide for any joint venture, partnership or similar arrangement by the Company;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(xi)<span style="width: 18.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>all Contracts between or among the Company on the one hand and Seller or any Affiliate of Seller (other than the Company) on the other hand;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(xii)<span style="width: 15.84pt; text-indent: 0pt; display: inline-block;">&#160;</span>all collective bargaining agreements or Contracts with any Union to which the Company is a party; and</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(xiii)<span style="width: 13.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>any other Contract that is material to the Company and not previously disclosed pursuant to this Section 3.09.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Each Material Contract is in full force and effect and is a valid and binding agreement enforceable against the Company and, to Seller's Knowledge, the other party or parties thereto, in accordance with its terms. None of the Company or, to Seller's Knowledge, any other party thereto is in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate, any Material Contract. No event or circumstance has occurred that, with notice or lapse of time or both, would constitute an event of default under any Material Contract or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder. Complete and correct copies of each Material Contract (including all modifications, amendments and supplements thereto and waivers thereunder) have been made available to Buyer.</p>
                <div>
                    <p style="text-align: center;">245</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_184_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 3.10</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Title to Assets; Real Property.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company has good and valid (and, in the case of owned Real Property, good and marketable fee simple) title to, or a valid leasehold interest in, all Real Property and personal property and other assets reflected in the Annual Financial Statements or acquired after the Balance Sheet Date, other than properties and assets sold or otherwise disposed of in the ordinary course of business consistent with past practice since the Balance Sheet Date. All such properties and assets (including leasehold interests) are free and clear of Encumbrances except for the following (collectively referred to as "<b>Permitted Encumbrances</b>"):</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>those items set forth in Section 3.10(a) of the Disclosure Schedules;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 21.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>liens for Taxes not yet due and payable;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(iii)<span style="width: 18.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>mechanics, carriers', workmen's, repairmen's or other like liens arising or incurred in the ordinary course of business consistent with past practice or amounts that are not delinquent and which are not, individually or in the aggregate, material to the business of the Company;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(iv)<span style="width: 18.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>easements, rights of way, zoning ordinances and other similar encumbrances affecting Real Property which are not, individually or in the aggregate, material to the business of the Company; or</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(v)<span style="width: 21.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>other than with respect to owned Real Property, liens arising under original purchase price conditional sales contracts and equipment leases with third parties entered into in the ordinary course of business consistent with past practice which are not, individually or in the aggregate, material to the business of the Company.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span><span style="background-color: transparent;">Section 3.10(b)</span> of the Disclosure Schedules lists (i) the street address of each parcel of Real Property; (ii) if such property is leased or subleased by the Company, the landlord under the lease, the rental amount currently being paid, and the expiration of the term of such lease or sublease for each leased or subleased property; and (iii) the current use of such property. With respect to owned Real Property, Seller has delivered or made available to Buyer true, complete and correct copies of the deeds and other instruments (as recorded) by which the Company acquired such Real Property, and copies of all title insurance policies, opinions, abstracts and surveys in the possession of Seller or the Company and relating to the Real Property. With respect to leased Real Property, Seller has delivered or made available to Buyer true, complete and correct copies of any leases affecting the Real Property. The Company is not a sublessor or grantor under any sublease or other instrument granting to any other Person any right to the possession, lease, occupancy or enjoyment of any leased Real Property. The use and operation of the Real Property in the conduct of the Company's business do not violate in any material respect any Law, covenant, condition, restriction, easement, license, permit or agreement. No material improvements constituting a part of the Real Property encroach on real property owned or leased by a Person other than the Company. There are no Actions pending nor, to the Seller's Knowledge, threatened against or affecting the Real Property or any portion thereof or interest therein in the nature or in lieu of condemnation or eminent domain proceedings.</p>
                <div>
                    <p style="text-align: center;">246</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_185_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 3.11</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Condition and Sufficiency of Assets.</b> Except as set forth in Section 3.11 of the Disclosure Schedules, the buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles and other items of tangible personal property of the Company are structurally sound, are in good operating condition and repair, and are adequate for the uses to which they are being put, and none of such buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles and other items of tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in nature or cost.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.12</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Intellectual Property.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.12(a) of the Disclosure Schedules contains a correct, current, and complete list of: (i) all Company IP Registrations, specifying as to each, as applicable: the title, mark, or design; the record owner and inventor(s), if any; the jurisdiction by or in which it has been issued, registered, or filed; the patent, registration, or application serial number; the issue, registration, or filing date; and the current status; and (ii) all unregistered Trademarks included in the Company Intellectual Property; and (iii) all proprietary Software of the Company; and (iv) all other Company Intellectual Property used or held for use in the Company's business as currently conducted and as proposed to be conducted.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.12(b) of the Disclosure Schedules contains a correct, current, and complete list of all Company IP Agreements, specifying for each the date, title, and parties thereto, and separately identifying the Company IP Agreements: (i) under which the Company is a licensor or otherwise grants to any Person any right or interest relating to any Company Intellectual Property; (ii) under which the Company is a licensee or otherwise granted any right or interest relating to the Intellectual Property of any Person; and (iii) which otherwise relate to the Company's ownership or use of Intellectual Property, in each case identifying the Intellectual Property covered by such Company IP Agreement. Seller has provided Buyer with true and complete copies (or in the case of any oral agreements, a complete and correct written description) of all Company IP Agreements, including all modifications, amendments and supplements thereto and waivers thereunder. Each Company IP Agreement is valid and binding on the Company in accordance with its terms and is in full force and effect. Neither the Company nor any other party thereto is, or is alleged to be, in breach of or default under, or has provided or received any notice of breach of, default under, or intention to terminate (including by non-renewal), any Company IP Agreement.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company is the sole and exclusive legal and beneficial, and with respect to the Company IP Registrations, record, owner of all right, title, and interest in and to the Company Intellectual Property, and has the valid and enforceable right to use all other Intellectual Property used or held for use in or necessary for the conduct of the Company's business as currently conducted and as proposed to be conducted, in each case, free and clear of Encumbrances other than Permitted Encumbrances. The Company has entered into binding, valid and enforceable, written Contracts with each current and former employee and independent contractor who is or was involved in or has contributed to the invention, creation, or development of any Intellectual Property during the course of employment or engagement with the Company whereby such employee or independent contractor (i) acknowledges the Company's exclusive ownership of all Intellectual Property invented, created, or developed by such employee or independent contractor within the scope of his or her employment or engagement with the Company; (ii) grants to the Company a present, irrevocable assignment of any ownership interest such employee or independent contractor may have in or to such Intellectual Property, to the extent such Intellectual Property does not constitute a "work made for hire" under applicable Law; and (iii) irrevocably waives any right or interest, including any moral rights, regarding any such Intellectual Property, to the extent permitted by applicable Law. Seller has provided Buyer with true and complete copies of all such Contracts. All assignments and other instruments necessary to establish, record, and perfect the Company's ownership interest in the Company IP Registrations have been validly executed, delivered, and filed with the relevant Governmental Authorities and authorized registrars.</p>
                <div>
                    <p style="text-align: center;">247</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_186_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Neither the execution, delivery or performance of this Agreement, nor the consummation of the transactions contemplated hereunder, will result in the loss or impairment of, or require the consent of any other Person in respect of, the Company's right to own or use any Company Intellectual Property or Licensed Intellectual Property.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>All of the Company Intellectual Property and Licensed Intellectual Property is valid and enforceable, and all Company IP Registrations are subsisting and in full force and effect. The Company has taken all reasonable and necessary steps to maintain and enforce the Company Intellectual Property and Licensed Intellectual Property and to preserve the confidentiality of all Trade Secrets included in the Company Intellectual Property, including by requiring all Persons having access thereto to execute binding, written non-disclosure agreements. All required filings and fees related to the Company IP Registrations have been timely submitted with and paid to the relevant Governmental Authorities and authorized registrars. Seller has provided Buyer with true and complete copies of all file histories, documents, certificates, office actions, correspondence, assignments, and other instruments relating to the Company IP Registrations.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(f)<span style="width: 24.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>The conduct of the Company's business as currently and formerly conducted and as proposed to be conducted, including the use of the Company Intellectual Property and Licensed Intellectual Property in connection therewith, and the products, processes and services of the Company have not infringed, misappropriated or otherwise violated, and will not infringe, misappropriate or otherwise violate, the Intellectual Property or other rights of any Person. No Person has infringed, misappropriated or otherwise violated any Company Intellectual Property or Licensed Intellectual Property.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>There are no Actions (including any opposition, cancellation, revocation, review, or other proceeding), whether settled, pending, or threatened (including in the form of offers to obtain a license): (i) alleging any infringement, misappropriation, or other violation by the Company of the Intellectual Property of any Person; (ii) challenging the validity, enforceability, registrability, patentability, or ownership of any Company Intellectual Property or Licensed Intellectual Property or the Company's right, title, or interest in or to any Company Intellectual Property or Licensed Intellectual Property; or (iii) by the Company or by the owner of any Licensed Intellectual Property alleging any infringement, misappropriation, or other violation by any Person of the Company Intellectual Property or such Licensed Intellectual Property. Neither Seller nor the Company is aware of any facts or circumstances that could reasonably be expected to give rise to any such Action. The Company is not subject to any outstanding or prospective Governmental Order (including any motion or petition therefor) that does or could reasonably be expected to restrict or impair the use of any Company Intellectual Property or Licensed Intellectual Property.</p>
                <div>
                    <p style="text-align: center;">248</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_187_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.12(h) of the Disclosure Schedules contains a correct, current, and complete list of all social media accounts used in the Company's business. The Company has complied with all terms of use, terms of service, and other Contracts and all associated policies and guidelines relating to its use of any social media platforms, sites, or services (collectively, "<b>Platform Agreements</b>"). There are no Actions, whether settled, pending, or threatened, alleging any (i) breach or other violation of any Platform Agreement by the Company; or (ii) defamation, violation of publicity rights of any Person, or any other violation by the Company in connection with its use of social media.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>All Company IT Systems are in good working condition and are sufficient for the operation of the Company's business as currently conducted and as proposed to be conducted. In the past year, there has been no malfunction, failure, continued substandard performance, denial-of-service, or other cyber incident, including any cyberattack, or other impairment of the Company IT Systems that has resulted or is reasonably likely to result in disruption or damage to the business of the Company. The Company has taken all commercially reasonable steps to safeguard the confidentiality, availability, security, and integrity of the Company IT Systems, including implementing and maintaining appropriate backup, disaster recovery, and Software and hardware support arrangements.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(j)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company has complied with all applicable Laws and all internal or publicly posted policies, notices, and statements concerning the collection, use, processing, storage, transfer, and security of personal information in the conduct of the Company's business. In the past year, the Company has not (i) experienced any actual, alleged, or suspected data breach or other security incident involving personal information in its possession or control or (ii) been subject to or received any notice of any audit, investigation, complaint, or other Action by any Governmental Authority or other Person concerning the Company's collection, use, processing, storage, transfer, or protection of personal information or actual, alleged, or suspected violation of any applicable Law concerning privacy, data security, or data breach notification, and to Seller' Knowledge, there are no facts or circumstances that could reasonably be expected to give rise to any such Action.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.13</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Inventory.</b> All inventory of the Company, whether or not reflected in the Balance Sheet, consists of a quality and quantity usable and salable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. All such inventory is owned by the Company free and clear of all Encumbrances, and no inventory is held on a consignment basis. The quantities of each item of inventory (whether raw materials, work-in-process or finished goods) are not excessive, but are reasonable in the present circumstances of the Company.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.14</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Accounts Receivable.</b> The accounts receivable reflected on the Interim Balance Sheet and the accounts receivable arising after the Interim Balance Sheet Date (a) have arisen from bona fide transactions entered into by the Company involving the sale of goods or the rendering of services in the ordinary course of business consistent with past practice; and (b) constitute only valid, undisputed claims of the Company not subject to claims of set-off or other defenses or counterclaims other than normal cash discounts accrued in the ordinary course of business consistent with past practice; and (c) subject to a reserve for bad debts shown on the Interim Balance Sheet or, with respect to accounts receivable arising after the Interim Balance Sheet Date, on the accounting records of the Company, are collectible in full within 30 days after billing. The reserve for bad debts shown on the Interim Balance Sheet or, with respect to accounts receivable arising after the Interim Balance Sheet Date, on the accounting records of the Company have been determined in accordance with HGB, consistently applied, subject to normal year-end adjustments and the absence of disclosures normally made in footnotes.</p>
                <div>
                    <p style="text-align: center;">249</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_188_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 3.15</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Customers and Suppliers.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.15(a) of the Disclosure Schedules sets forth (i) each customer who has paid aggregate consideration to the Company for goods or services rendered in an amount greater than or equal to $10,000 for each of the two most recent fiscal years (collectively, the "<b>Material Customers</b>"); and (ii) the amount of consideration paid by each Material Customer during such periods. The Company has not received any notice, and has no reason to believe, that any of its Material Customers has ceased, or intends to cease after the First Closing, to use its goods or services or to otherwise terminate or materially reduce its relationship with the Company.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.15(b) of the Disclosure Schedules sets forth (i) each supplier to whom the Company has paid consideration for goods or services rendered in an amount greater than or equal to $10,000 for each of the two most recent fiscal years (collectively, the "<b>Material Suppliers</b>"); and (ii) the amount of purchases from each Material Supplier during such periods. The Company has not received any notice, and has no reason to believe, that any of its Material Suppliers has ceased, or intends to cease, to supply goods or services to the Company or to otherwise terminate or materially reduce its relationship with the Company.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.16</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Insurance.</b> Section 3.16 of the Disclosure Schedules sets forth a true and complete list of all current policies or binders of fire, liability, product liability, umbrella liability, real and personal property, workers' compensation, vehicular, directors' and officers' liability, fiduciary liability and other casualty and property insurance maintained by Seller or its Affiliates (including the Company) and relating to the assets, business, operations, employees, officers and directors of the Company (collectively, the "<b>Insurance Policies</b>") and true and complete copies of the Insurance Policies have been made available to Buyer. The Insurance Policies are in full force and effect and shall remain in full force and effect following the consummation of the transactions contemplated by this Agreement. Neither the Seller nor any of its Affiliates (including the Company) has received any written notice of cancellation of, premium increase with respect to, or alteration of coverage under, any of the Insurance Policies. All premiums due on the Insurance Policies have either been paid or, if due and payable prior to First Closing, will be paid prior to the First Closing in accordance with the payment terms of each Insurance Policy. The Insurance Policies do not provide for any retrospective premium adjustment or other experience-based liability on the part of the Company. All the Insurance Policies (a) are valid and binding in accordance with their terms; (b) are provided by carriers who are financially solvent; and (c) have not been subject to any lapse in coverage. There are no claims related to the business of the Company pending under any Insurance Policies as to which coverage has been questioned, denied or disputed or in respect of which there is an outstanding reservation of rights. None of Seller or any of its Affiliates (including the Company) is in default under, or has otherwise failed to comply with, in any material respect, any provision contained in any Insurance Policy. The Insurance Policies are of the type and in the amounts customarily carried by Persons conducting a business similar to the Company and are sufficient for compliance with all applicable Laws and Contracts to which the Company is a party or by which it is bound.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.17</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Legal Proceedings; Governmental Orders.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>There are no Actions pending or, to Seller's Knowledge, threatened (a) against or by the Company or affecting any of its properties or assets (or by or against Seller or any Affiliate thereof and relating to the Company); or (b) against or by the Company, Seller or any Affiliate of Seller that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.</p>
                <div>
                    <p style="text-align: center;">250</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_189_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>There are no outstanding Governmental Orders and no unsatisfied judgments, penalties or awards against or affecting the Company or any of its properties or assets.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.18</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Compliance With Laws; Permits.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company has complied, and is now complying, with all Laws applicable to it or its business, properties or assets.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>All Permits required for the Company to conduct its business have been obtained by it and are valid and in full force and effect. All fees and charges with respect to such Permits as of the date hereof have been paid in full. Section 3.18(b) of the Disclosure Schedules lists all current Permits issued to the Company, including the names of the Permits and their respective dates of issuance and expiration. The Company has complied and is now complying with the terms of all Permits listed on Section 3.18(b) of the Disclosure Schedules. No event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to result in the revocation, suspension, lapse or limitation of any Permit set forth in Section 3.18(b) of the Disclosure Schedules.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.19</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Environmental Matters.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company is currently and has been in compliance with all Environmental Laws and has not, and the Seller has not, received from any Person any: (i) Environmental Notice or Environmental Claim; or (ii) written request for information pursuant to Environmental Law, which, in each case, either remains pending or unresolved, or is the source of ongoing obligations or requirements as of the First Closing Date.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company has obtained and is in material compliance with all Environmental Permits (each of which is disclosed in Section 3.19(b) of the Disclosure Schedules) necessary for the ownership, lease, operation or use of the business or assets of the Company and all such Environmental Permits are in full force and effect and shall be maintained in full force and effect by Seller through the First Closing Date in accordance with Environmental Law, and neither Seller nor the Company is aware of any condition, event or circumstance that might prevent or impede, after the First Closing Date, the ownership, lease, operation or use of the business or assets of the Company as currently carried out. With respect to any such Environmental Permits, Seller has undertaken, or will undertake prior to the First Closing Date, all measures necessary to facilitate transferability of the same, and neither the Company nor the Seller is aware of any condition, event or circumstance that might prevent or impede the transferability of the same, nor have they received any Environmental Notice or written communication regarding any material adverse change in the status or terms and conditions of the same.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>There has been no Release of Hazardous Materials in contravention of Environmental Law with respect to the business or assets of the Company or any real property currently or formerly owned, operated or leased by the Company, and neither the Company nor Seller has received an Environmental Notice that any real property currently or formerly owned, operated or leased in connection with the business of the Company (including soils, groundwater, surface water, buildings and other structure located on any such real property) has been contaminated with any Hazardous Material which could reasonably be expected to result in an Environmental Claim against, or a violation of Environmental Law or term of any Environmental Permit by, Seller or the Company.</p>
                <div>
                    <p style="text-align: center;">251</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_190_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.19(d) of the Disclosure Schedules contains a complete and accurate list of all active or abandoned aboveground or underground storage tanks owned or operated by the Company.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.19(e) of the Disclosure Schedules contains a complete and accurate list of all off-site Hazardous Materials treatment, storage, or disposal facilities or locations used by the Company or Seller and any predecessors as to which the Company or Seller may retain liability.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(f)<span style="width: 26.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Neither Seller nor the Company has retained or assumed, by contract or operation of Law, any liabilities or obligations of third parties under Environmental Law.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller has provided or otherwise made available to Buyer and listed in Section 3.19(g) of the Disclosure Schedules: (i) any and all environmental reports, studies, audits, records, sampling data, site assessments, risk assessments, economic models and other similar documents with respect to the business or assets of the Company or any currently or formerly owned, operated or leased real property which are in the possession or control of the Seller or Company related to compliance with Environmental Laws, Environmental Claims or an Environmental Notice or the Release of Hazardous Materials; and (ii) any and all material documents concerning planned or anticipated capital expenditures required to reduce, offset, limit or otherwise control pollution and/or emissions, manage waste or otherwise ensure compliance with current or future Environmental Laws (including, without limitation, costs of remediation, pollution control equipment and operational changes).</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Neither the Seller nor the Company is aware of or reasonably anticipates, as of the First Closing Date, any condition, event or circumstance concerning the Release or regulation of Hazardous Materials that might, after the First Closing Date, prevent, impede or materially increase the costs associated with the ownership, lease, operation, performance or use of the business or assets of the Company as currently carried out.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller owns and controls all Environmental Attributes (a complete and accurate list of which is set forth in Section 3.19(i) of the Disclosure Schedules) and has not entered into any contract or pledge to transfer, lease, license, guarantee, sell, mortgage, pledge or otherwise dispose of or encumber any Environmental Attributes as of the date hereof. Neither Seller nor the Company is aware of any condition, event or circumstance that might prevent, impede or materially increase the costs associated with the transfer (if required) to Buyer of any Environmental Attributes after the First Closing Date.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.20</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Employee Benefit Matters.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.20(a) of the Disclosure Schedules contains a true and complete list of each pension, benefit, retirement, compensation, employment, consulting, profit-sharing, deferred compensation, incentive, bonus, performance award, phantom equity, stock or stock-based, change in control, retention, severance, vacation, paid time off (PTO), medical, vision, dental, disability, welfare, cafeteria, fringe benefit and other similar agreement, plan, policy, program or arrangement (and any amendments thereto), in each case whether or not reduced to writing and whether funded or unfunded, including each "employee benefit plan", which is or has been maintained, sponsored, contributed to, or required to be contributed to by the Company for the benefit of any current or former employee, officer, director, retiree, independent contractor or consultant of the Company or any spouse or dependent of such individual, or under which the Company or any of its affiliates has or may have any Liability, or with respect to which Buyer or any of its Affiliates would reasonably be expected to have any Liability, contingent or otherwise (as listed on Section 3.20(a) of the Disclosure Schedules, each, a "<b>Benefit Plan</b>").</p>
                <div>
                    <p style="text-align: center;">252</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_191_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>With respect to each Benefit Plan, Seller has made available to Buyer accurate, current and complete copies of each of the following: (i) where the Benefit Plan has been reduced to writing, the plan document together with all amendments; (ii) where the Benefit Plan has not been reduced to writing, a written summary of all material plan terms; (iii) where applicable, copies of any trust agreements or other funding arrangements, custodial agreements, insurance policies and contracts, administration agreements and similar agreements, and investment management or investment advisory agreements, now in effect or required in the future as a result of the transactions contemplated by this Agreement or otherwise; (iv) copies of any summary plan descriptions, summaries of material modifications, summaries of benefits and coverage, employee handbooks and any other written communications (or a description of any oral communications) relating to any Benefit Plan; (intentionally deleted; (vi) actuarial valuations and reports related to any Benefit Plans with respect to the two most recently completed plan years; (vii) copies of material notices, letters or other correspondence from any government body.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Each Benefit Plan can be amended, terminated or otherwise discontinued after the First Closing in accordance with its terms, without material liabilities to Buyer, the Company or any of their Affiliates other than ordinary administrative expenses typically incurred in a termination event. The Company has no commitment or obligation and has not made any representations to any employee, officer, director, independent contractor or consultant, whether or not legally binding, to adopt, amend, modify or terminate any Benefit Plan or any collective bargaining agreement, in connection with the consummation of the transactions contemplated by this Agreement or otherwise.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>There is no pending or, to Seller's Knowledge, threatened Action relating to a Benefit Plan (other than routine claims for benefits), and no Benefit Plan has within the three years prior to the date hereof been the subject of an examination or audit by a Governmental Authority or the subject of an application or filing under or is a participant in, an amnesty, voluntary compliance, self-correction or similar program sponsored by any Governmental Authority.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>There has been no amendment to, announcement by Seller, the Company or any of their Affiliates relating to, or change in employee participation or coverage under, any Benefit Plan or collective bargaining agreement that would increase the annual expense of maintaining such plan above the level of the expense incurred for the most recently completed fiscal year (other than on a de minimis basis) with respect to any director, officer, employee, independent contractor or consultant, as applicable. None of Seller, the Company, nor any of their Affiliates has any commitment or obligation or has made any representations to any director, officer, employee, independent contractor or consultant, whether or not legally binding, to adopt, amend, modify or terminate any Benefit Plan or any collective bargaining agreement.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(f)<span style="width: 24.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Each individual who is classified by the Company as an independent contractor has been properly classified for purposes of participation and benefit accrual under each Benefit Plan.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Neither the execution of this Agreement nor any of the transactions contemplated by this Agreement will (either alone or upon the occurrence of any additional or subsequent events): (i) entitle any current or former director, officer, employee, independent contractor or consultant of the Company to severance pay or any other payment; (ii) accelerate the time of payment, funding or vesting, or increase the amount of compensation (including stock-based compensation) due to any such individual; (iii) limit or restrict the right of the Company to merge, amend, or terminate any Benefit Plan; (iv) increase the amount payable under or result in any other material obligation pursuant to any Benefit Plan.</p>
                <div>
                    <p style="text-align: center;">253</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_192_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 3.21</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Employment Matters.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.21(a) of the Disclosure Schedules contains a list of all persons who are employees, independent contractors or consultants of the Company as of the date hereof, including any employee who is on a leave of absence of any nature, paid or unpaid, authorized or unauthorized, and sets forth for each such individual the following: (i) name; (ii) title or position (including whether full-time or part-time); (iii) hire or retention date; (iv) current annual base compensation rate or contract fee; (v) commission, bonus or other incentive-based compensation; and (vi) a description of the fringe benefits provided to each such individual as of the date hereof. As of the date hereof, all compensation, including wages, commissions, bonuses, fees and other compensation, payable to all employees, independent contractors or consultants of the Company for services performed on or prior to the date hereof have been paid in full and there are no outstanding agreements, understandings or commitments of the Company with respect to any compensation, commissions, bonuses or fees.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company is and has been in compliance with all applicable Laws pertaining to employment and employment practices to the extent they relate to employees, volunteers, interns, consultants and independent contractors of the Company, including all Laws relating to labor relations, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety, workers' compensation, leaves of absence, paid sick leave and unemployment insurance</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.22</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Taxes.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>All Tax Returns required to be filed on or before the First Closing Date by the Company have been, or will be, timely filed. Such Tax Returns are, or will be, true, complete and correct in all respects. All Taxes due and owing by the Company (whether or not shown on any Tax Return) have been, or will be, timely paid.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company has withheld and paid each Tax required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, customer, shareholder or other party, and complied with all information reporting and backup withholding provisions of applicable Law.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>No claim has been made by any taxing authority in any jurisdiction where the Company does not file Tax Returns that it is, or may be, subject to Tax by that jurisdiction.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of the Company.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The amount of the Company's Liability for unpaid Taxes for all periods ending on or before the December 31, 2023 does not, in the aggregate, exceed the amount of accruals for Taxes (excluding reserves for deferred Taxes) reflected on the Financial Statements. The amount of the Company's Liability for unpaid Taxes for all periods following the end of the recent period covered by the Financial Statements shall not, in the aggregate, exceed the amount of accruals for Taxes (excluding reserves for deferred Taxes) as adjusted for the passage of time in accordance with the past custom and practice of the Company (and which accruals shall not exceed comparable amounts incurred in similar periods in prior years).</p>
                <div>
                    <p style="text-align: center;">254</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_193_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(f)<span style="width: 24.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Section 3.22(f) of the Disclosure Schedules sets forth:</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>the taxable years of the Company as to which the applicable statutes of limitations on the assessment and collection of Taxes have not expired;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>those years for which examinations by the taxing authorities have been completed; and</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(iii)<span style="width: 21.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>those taxable years for which examinations by taxing authorities are presently being conducted.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>All deficiencies asserted, or assessments made, against the Company as a result of any examinations by any taxing authority have been fully paid.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company is not a party to any Action by any taxing authority. There are no pending or threatened Actions by any taxing authority.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller has delivered to Buyer copies of all federal, state, local and foreign income, franchise and similar Tax Returns, examination reports, and statements of deficiencies assessed against, or agreed to by, the Company for all Tax periods.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(j)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>There are no Encumbrances for Taxes (other than for current Taxes not yet due and payable) upon the assets of the Company.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(k)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company is not a party to, or bound by, any Tax indemnity, Tax sharing or Tax allocation agreement.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(l)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>No private letter rulings, technical advice memoranda or similar agreement or rulings have been requested, entered into or issued by any taxing authority with respect to the Company.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(m)<span style="width: 21.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Company will not be required to include any item of income in, or exclude any item or deduction from, taxable income for any taxable period or portion thereof ending after the First Closing Date as a result of:</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 3.23</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Books and Records.</b> The minute books and stock record books of the Company, all of which have been made available to Buyer, are complete and correct and have been maintained in accordance with sound business practices. The minute books of the Company contain accurate and complete records of all meetings, and actions taken by written consent of, the stockholders, the board of directors and any committees of the board of directors of the Company, and no meeting, or action taken by written consent, of any such stockholders, board of directors or committee has been held for which minutes have not been prepared and are not contained in such minute books. At the First Closing, all of those books and records will be in the possession of the Company.</p>
                <div>
                    <p style="text-align: center;">255</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_194_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 3.24</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Brokers.</b> No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the transactions contemplated by this Agreement or based upon arrangements made by or on behalf of Seller.</p>
                <p style="text-align: center;"><b>ARTICLE IV</b><br/><b>REPRESENTATIONS AND WARRANTIES OF BUYER</b></p>
                <p style="text-indent: 36pt; text-align: justify;">Except as set forth in the correspondingly numbered Section of the Disclosure Schedules, Buyer represents and warrants to Seller that the statements contained in this ARTICLE IV are true and correct as of the date hereof.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 4.01</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Organization and Authority of Buyer.</b> Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the Province of Ontario. Buyer has full corporate power and authority to enter into this Agreement, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Buyer of this Agreement and the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Buyer. This Agreement has been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by Seller) this Agreement constitutes a legal, valid and binding obligation of Buyer enforceable against Buyer in accordance with its terms.&#160; The Buyer has all licenses, leases, permits, authorizations and other approvals, all proprietary rights to all patents and patent applications, all copyrights, registered and unregistered, and all rights, claims and privileges pertaining thereto; software and documentation therefor, object code, source code (including all programmers' notes), procedures, methods, works of authorship, and other documentation, data and information; inventions (whether or not patentable), formulas, processes, invention disclosures, technology, technical data or information, and all rights, claims and privileges pertaining thereto, all industrial designs, trade secrets, know-how, concepts, information and all other intellectual and industrial property and other proprietary rights information and other intellectual and industrial property necessary to permit the Buyer to conduct its business as currently conducted.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 4.02</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>No Conflicts; Consents.</b> The execution, delivery and performance by Buyer of this Agreement, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of Buyer; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Buyer; or (c) except as set forth in Section 4.02 of the Disclosure Schedules, require the consent, notice or other action by any Person under any Contract to which Buyer is a party. Except as set forth in Section 4.02 of the Disclosure Schedules, no consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Buyer in connection with the execution and delivery of this Agreement and the and the consummation of the transactions contemplated hereby and thereby, except for such filings as may be required under the HSR Act.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 4.03</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Authorized Capital. </b> The authorized and issued capital of the Buyer consists of an unlimited number of common shares, of which 10,681,336 common shares have been validly issued, are outstanding as fully paid and non-assessable shares and were not issued in violation of any pre-emptive rights or other contractual rights to issue securities issued by the Buyer or of any applicable law.&#160;</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 4.04</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Investment Purpose.</b> Buyer is acquiring the Shares solely for its own account for investment purposes and not with a view to, or for offer or sale in connection with, any distribution thereof. Buyer acknowledges that the Shares are not registered under the Securities Act of 1933, as amended, or any state securities laws, and that the Shares may not be transferred or sold except pursuant to the registration provisions of the Securities Act of 1933, as amended or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable.</p>
                <div>
                    <p style="text-align: center;">256</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_195_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 4.05</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Compliance with Securities Laws.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>the issuance of Flora Shares in satisfaction of the Purchase Price hereunder, is permitted under Applicable Securities Laws, and when issued will have been validly issued, will be outstanding as fully paid and non-assessable and will not have been issued in violation of or subject to any pre-emptive rights or other contractual rights to purchase securities issued by the Buyer or in violation of any applicable law, including Applicable Securities Laws;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>the Buyer is a US reporting company or a US public company, as such term is defined in Applicable Securities Laws;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 25.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>the Flora Shares when issued will not be subject to a restricted period or to a statutory hold period under Applicable Securities Laws or to any resale restriction which extends beyond six-months of the date of issuance, subject to the terms and conditions Section 5.11.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>since December 31, 2022, the Buyer has been in compliance with its timely and continuous disclosure obligations under Applicable Securities Laws and the policies, rules and regulations of the Exchange and, without limiting the generality of the foregoing, there has not occurred any material change (actual, anticipated, contemplated or threatened, whether financial or otherwise) in the business, affairs, results, operations, assets or liabilities of the Buyer and its subsidiaries on a consolidated basis, which has not been publicly disclosed;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 25.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>all the statements set forth in the public disclosure record of the Buyer, were true, correct, and complete in all material respects and did not contain any misrepresentation as of the date of such statements and the Buyer has not filed any confidential material change reports since the date of such statements which remain confidential as at the date hereof;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;"><b>(f)</b><span style="width: 26.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>other than as disclosed in <b>public disclosure record of the Buyer</b>, no material fact or material information has arisen or has been discovered which would have been required to have been stated in <b>public disclosure record of the Buyer, </b>had the fact arisen or been discovered on, or prior to, the date of such disclosure;</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 4.06</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Brokers.</b> No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the transactions contemplated by this Agreement or based upon arrangements made by or on behalf of Buyer.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 4.07</b><span style="width: 19.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Legal Proceedings.</b> Except as set forth in Section 4.07 of the Disclosure Schedules, there are no Actions pending or, to Buyer's knowledge, threatened against or by Buyer or any Affiliate of Buyer that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise or serve as a basis for any such Action.</p>
                <div>
                    <p style="text-align: center;">257</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_196_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;"><b>ARTICLE V</b><br/><b>COVENANTS</b></p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.01</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Seller Conduct of Business Prior to the First Closing.</b> From the date hereof until the Fist Closing, except as otherwise provided in this Agreement or consented to in writing by Buyer (which consent shall not be unreasonably withheld, conditioned or delayed), Seller shall, and shall cause the Company to, (x) conduct the business of the Company in the ordinary course of business consistent with past practice; and (y) use reasonable best efforts to maintain and preserve intact the current organization, business and franchise of the Company and to preserve the rights, franchises, goodwill and relationships of its employees, customers, lenders, suppliers, regulators and others having business relationships with the Company. Without limiting the foregoing, from the date hereof until the First Closing Date, Seller shall cause the Company to:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>preserve and maintain all of its Permits;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>pay its debts, Taxes and other obligations when due;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>maintain the properties and assets owned, operated or used by the Company in the same condition as they were on the date of this Agreement, subject to reasonable wear and tear;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>continue in full force and effect without modification all Insurance Policies, except as required by applicable Law;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>defend and protect its properties and assets from infringement or usurpation;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(f)<span style="width: 26.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>perform all of its obligations under all Contracts relating to or affecting its properties, assets or business;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>maintain its books and records in accordance with past practice;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>comply in all material respects with all applicable Laws; and</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>not take or permit any action that would cause any of the changes, events or conditions described in Section 3.08 to occur.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.02</b><span style="width: 20.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Buyer Conduct of Business Prior to the Closing.</b> From the date hereof until the Second Closing, except as otherwise provided in this Agreement or consented to in writing by Seller (which consent shall not be unreasonably withheld, conditioned or delayed), the Buyer shall , (x) conduct the business of the Buyer in the ordinary course of business consistent with past practice; and (y) use reasonable best efforts to maintain and preserve intact the current organization, business and franchise of the Buyer and to preserve the rights, franchises, goodwill and relationships of its employees, customers, lenders, suppliers, regulators and others having business relationships with the Buyer. Without limiting the foregoing, from the date hereof until the Second Closing Date, Buyer shall:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>preserve and maintain all of its Permits;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>pay its debts, Taxes and other obligations when due;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>maintain the properties and assets owned, operated or used by the Buyer in the same condition as they were on the date of this Agreement, subject to reasonable wear and tear;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>continue in full force and effect without modification all Insurance Policies, except as required by applicable Law;</p>
                <div>
                    <p style="text-align: center;">258</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_197_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(e)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>defend and protect its properties and assets from infringement or usurpation;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(f)<span style="width: 26.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>perform all of its obligations under all Contracts relating to or affecting its properties, assets or business;</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>maintain its books and records in accordance with past practice; and</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>comply in all material respects with all applicable Laws.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.03</b><span style="width: 20.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Access to Information.</b> From the date hereof until the First Closing, Seller shall, and shall cause the Company to, (a) afford Buyer and its Representatives full and free access to and the right to inspect all of the Real Property, properties, assets, premises, books and records, Contracts and other documents and data related to the Company; (b) furnish Buyer and its Representatives with such financial, operating and other data and information related to the Company as Buyer or any of its Representatives may reasonably request; and (c) instruct the Representatives of Seller and the Company to cooperate with Buyer in its investigation of the Company. Any investigation pursuant to this Section 5.03 shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of Seller or the Company. No investigation by Buyer or other information received by Buyer shall operate as a waiver or otherwise affect any representation, warranty or agreement given or made by Seller in this Agreement.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.04</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>No Solicitation of Other Bids.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller shall not, and shall not authorize or permit any of its Affiliates (including the Company) or any of its or their Representatives to, directly or indirectly, (i) encourage, solicit, initiate, facilitate or continue inquiries regarding an Acquisition Proposal; (ii) enter into discussions or negotiations with, or provide any information to, any Person concerning a possible Acquisition Proposal; or (iii) enter into any agreements or other instruments (whether or not binding) regarding an Acquisition Proposal. Seller shall immediately cease and cause to be terminated, and shall cause its Affiliates (including the Company) and all of its and their Representatives to immediately cease and cause to be terminated, all existing discussions or negotiations with any Persons conducted heretofore with respect to, or that could lead to, an Acquisition Proposal. For purposes hereof, "<b>Acquisition Proposal</b>" shall mean any inquiry, proposal or offer from any Person (other than Buyer or any of its Affiliates) concerning (i) a merger, consolidation, liquidation, recapitalization, share exchange or other business combination transaction involving the Company; (ii) the issuance or acquisition of shares of capital stock or other equity securities of the Company; or (iii) the sale, lease, exchange or other disposition of any significant portion of the Company's properties or assets.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>In addition to the other obligations under this Section 5.04, Seller shall promptly (and in any event within three Business Days after receipt thereof by Seller or its Representatives) advise Buyer orally and in writing of any Acquisition Proposal, any request for information with respect to any Acquisition Proposal, or any inquiry with respect to or which could reasonably be expected to result in an Acquisition Proposal, the material terms and conditions of such request, Acquisition Proposal or inquiry, and the identity of the Person making the same.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller agrees that the rights and remedies for noncompliance with this Section 5.04 shall include having such provision specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach shall cause irreparable injury to Buyer and that money damages would not provide an adequate remedy to Buyer.</p>
                <div>
                    <p style="text-align: center;">259</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_198_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 5.05</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Notice of Certain Events.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>From the date hereof until the First Closing, Seller shall promptly notify Buyer in writing of:</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>any fact, circumstance, event or action the existence, occurrence or taking of which (A) has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, (B) has resulted in, or could reasonably be expected to result in, any representation or warranty made by Seller hereunder not being true and correct or (C) has resulted in, or could reasonably be expected to result in, the failure of any of the conditions set forth in Section 7.02 to be satisfied;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(iii)<span style="width: 21.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>any notice or other communication from any Governmental Authority in connection with the transactions contemplated by this Agreement; and</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(iv)<span style="width: 21.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>any Actions commenced or, to Seller's Knowledge, threatened against, relating to or involving or otherwise affecting Seller or the Company that, if pending on the date of this Agreement, would have been required to have been disclosed pursuant to Section 3.17 or that relates to the consummation of the transactions contemplated by this Agreement.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer's receipt of information pursuant to this Section 5.05 shall not operate as a waiver or otherwise affect any representation, warranty or agreement given or made by Seller in this Agreement (including Section 8.02) and shall not be deemed to amend or supplement the Disclosure Schedules.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.06</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Resignations.</b> Seller shall deliver to Buyer written resignations, effective as of the First Closing Date, of the officers and directors of the Company set forth on Section 5.06 of the Disclosure Schedules requested by Buyer at least five Business Days prior to the First Closing.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.07</b><span style="width: 20.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Confidentiality.</b> From and after the Closing, Seller shall, and shall cause its Affiliates to, hold, and shall use its reasonable best efforts to cause its or their respective Representatives to hold, in confidence any and all information, whether written or oral, concerning the Company, except to the extent that Seller can show that such information (a) is generally available to and known by the public through no fault of Seller, any of its Affiliates or their respective Representatives; or (b) is lawfully acquired by Seller, any of its Affiliates or their respective Representatives from and after the Closing from sources which are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If Seller or any of its Affiliates or their respective Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of Law, Seller shall promptly notify Buyer in writing and shall disclose only that portion of such information which Seller is advised by its counsel in writing is legally required to be disclosed, <i>provided that</i> Seller shall use reasonable best efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.08</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Non-Competition; </b>Non-Solicitation.<b> </b>Each executive officer of the Company shall enter into a non-competition agreement with Buyer whereby they agree that they will not, from and after the First Closing until 6 months following the First Closing (the "Restricted Period"), manage, operate, carry on, engage in, join, control, or participate in the ownership, management, operation, carrying on, or control of any business or enterprise that engages in the Restricted Business (to the extent that such person has been exposed to such business) within the Territory, or solicit any of the customers, suppliers or employees of the Company or Buyer.</p>
                <div>
                    <p style="text-align: center;">260</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_199_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 5.09</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b> Approvals and Consents.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Each party hereto shall, as promptly as possible, (i) make, or cause or be made, all filings and submissions (including those under the HSR Act) required under any Law applicable to such party or any of its Affiliates; and (ii) use reasonable best efforts to obtain, or cause to be obtained, all consents, authorizations, orders and approvals from all Governmental Authorities that may be or become necessary for its execution and delivery of this Agreement and the performance of its obligations pursuant to this Agreement. Each party shall cooperate fully with the other party and its Affiliates in promptly seeking to obtain all such consents, authorizations, orders and approvals. The parties hereto shall not willfully take any action that will have the effect of delaying, impairing or impeding the receipt of any required consents, authorizations, orders and approvals.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller and Buyer shall use reasonable best efforts to give all notices to, and obtain all consents from, all third parties that are described in Section 3.05 and Section 4.02 of the Disclosure Schedules.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Without limiting the generality of the parties' undertakings pursuant to subsections (a) and (b) above, each of the parties hereto shall use all reasonable best efforts to:</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>respond to any inquiries by any Governmental Authority regarding antitrust or other matters with respect to the transactions contemplated by this Agreement;</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>avoid the imposition of any order or the taking of any action that would restrain, alter or enjoin the transactions contemplated by this Agreement or; and</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(iii)<span style="width: 21.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>in the event any Governmental Order adversely affecting the ability of the parties to consummate the transactions contemplated by this Agreement has been issued, to have such Governmental Order vacated or lifted.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>If any consent, approval or authorization necessary to preserve any right or benefit under any Contract to which the Company is a party is not obtained prior to the First Closing, Seller shall, subsequent to the First Closing, cooperate with Buyer and the Company in attempting to obtain such consent, approval or authorization as promptly thereafter as practicable. If such consent, approval or authorization cannot be obtained, Seller shall use its reasonable best efforts to provide the Company with the rights and benefits of the affected Contract for the term thereof, and, if Seller provides such rights and benefits, the Company shall assume all obligations and burdens thereunder.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>All analyses, appearances, meetings, discussions, presentations, memoranda, briefs, filings, arguments, and proposals made by or on behalf of either party before any Governmental Authority or the staff or regulators of any Governmental Authority, in connection with the transactions contemplated hereunder (but, for the avoidance of doubt, not including any interactions between Seller or the Company with Governmental Authorities in the ordinary course of business, any disclosure which is not permitted by Law or any disclosure containing confidential information) shall be disclosed to the other party hereunder in advance of any filing, submission or attendance, it being the intent that the parties will consult and cooperate with one another, and consider in good faith the views of one another, in connection with any such analyses, appearances, meetings, discussions, presentations, memoranda, briefs, filings, arguments, and proposals. Each party shall give notice to the other party with respect to any meeting, discussion, appearance or contact with any Governmental Authority or the staff or regulators of any Governmental Authority, with such notice being sufficient to provide the other party with the opportunity to attend and participate in such meeting, discussion, appearance or contact.</p>
                <div>
                    <p style="text-align: center;">261</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_200_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(f)<span style="width: 24.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Notwithstanding the foregoing, nothing in this Section 5.09 shall require, or be construed to require, Buyer or any of its Affiliates to agree to (i) sell, hold, divest, discontinue or limit, before or after the First Closing Date, any assets, businesses or interests of Buyer, the Company or any of their respective Affiliates; (ii) any conditions relating to, or changes or restrictions in, the operations of any such assets, businesses or interests which, in either case, could reasonably be expected to result in a Material Adverse Effect or materially and adversely impact the economic or business benefits to Buyer of the transactions contemplated by this Agreement; or (iii) any material modification or waiver of the terms and conditions of this Agreement.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Flora shall add as an item to its next special or annual general meeting of shareholders seeking shareholder approval of the Second Tranche.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Following each Closing, the Company shall obtain the notarization of the SPA based on German law and registration of the buyer as new shareholder in the German trade registry (Handelsregister). Seller and Buyer are aware that notarization of the purchase agreement by a German notary is required for the sale of the company shares to be effective. Seller and Buyer will ensure that its legal representatives make the necessary declarations for the execution of the purchase agreement before a notary without delay following each Closing. This also includes the execution of a power of attorney with apostille and proof of representation of the buyer's legal representatives. Buyer and Seller are aware that formal adjustments to the contract may be necessary in the context of the execution of the notarized purchase contract due to German law. The costs of the notary shall be borne by the Buyer.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.17pt; text-indent: 0pt; display: inline-block;">&#160;</span>The Buyer shall take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the shareholders of the Buyer.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.10</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Books and Records.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>In order to facilitate the resolution of any claims made against or incurred by Seller prior to the Closing, or for any other reasonable purpose, for a period of five years after the Closing, Buyer shall:</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>retain the books and records (including personnel files) of the Company relating to periods prior to the Closing in a manner reasonably consistent with the prior practices of the Company; and</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>upon reasonable notice, afford the Representatives of Seller reasonable access (including the right to make, at Seller's expense, photocopies), during normal business hours, to such books and records;</p>
                <div>
                    <p style="text-align: center;">262</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_201_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 72pt; text-align: justify; margin-top: 10pt;"><i>provided, however</i>, that any books and records related to Tax matters shall be retained pursuant to the periods set forth in ARTICLE VI.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>In order to facilitate the resolution of any claims made by or against or incurred by Buyer or the Company after the Closing, or for any other reasonable purpose, for a period of five years following the Closing, Seller shall:</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>retain the books and records (including personnel files) of Seller which relate to the Company and its operations for periods prior to the Closing; and</p>
                <p style="margin-left: 72pt; text-indent: 36pt; text-align: justify;">(ii)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>upon reasonable notice, afford the Representatives of Buyer or the Company reasonable access (including the right to make, at Buyer's expense, photocopies), during normal business hours, to such books and records;</p>
                <p style="margin-left: 36pt; text-indent: 72pt; text-align: justify;"><i>provided, however</i>, that any books and records related to Tax matters shall be retained pursuant to the periods set forth in ARTICLE VI.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Neither Buyer nor Seller shall be obligated to provide the other party with access to any books or records (including personnel files) pursuant to this Section 5.10 where such access would violate any Law.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.11</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Registration Rights. </b>Concurrent with the First Closing, the parties shall use reasonable commercial efforts to execute and deliver a registration rights agreement ("Registration Rights Agreement") in a form acceptable to the parties. Notwithstanding the forgoing or anything contained in the Registration Rights Agreement, the Buyer covenants and agrees to use commercial best efforts to, at Buyer's sole cost and expense, file a registration rights statement with the Securities and Exchange Commission (a) on Form S-3, registering the Flora Shares for Resale within 10 days of the execution date hereof, with respect to the First Closing Shares, and within 10 days of the Second Closing, with respect to the Second Closing Shares (the "S-3 Registration(s)"); or, if despite Buyer's commercial best efforts, one or more of the S-3 Registrations cannot be obtained by Buyer, (b) on Form S-1, registering the Flora Shares for resale within 30 days of the execution date hereof, with respect to the First Closing Shares, and within 30 days of the Second Closing, with respect to the Second Closing Shares (the "S-1 Registration(s)").</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.12</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Closing Conditions</b> From the date hereof until the Closing, each party hereto shall, and Seller shall cause the Company to, use reasonable best efforts to take such actions as are necessary to expeditiously satisfy the Closing conditions set forth in ARTICLE VII hereof.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.13</b><span style="width: 20.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Public Announcements.</b> Unless otherwise required by applicable Law or stock exchange requirements (based upon the reasonable advice of counsel), no party to this Agreement shall make any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media without the prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned or delayed), and the parties shall cooperate as to the timing and contents of any such announcement.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 5.14</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Further Assurances.</b> Following the Closing, each of the parties hereto shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement.</p>
                <div>
                    <p style="text-align: center;">263</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_202_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: center; margin-top: 10pt;"><b>ARTICLE VI</b><br/><b>TAX MATTERS</b></p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 6.01</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Tax Covenants.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Without the prior written consent of Buyer, Seller shall not (and, prior to the Closing, Seller shall cause the Company, its Affiliates and their respective Representatives not to), to the extent it may affect, or relate to, the Company, make, change or rescind any Tax election, amend any Tax Return or take any position on any Tax Return, take any action, omit to take any action or enter into any other transaction that would have the effect of increasing the Tax liability or reducing any Tax asset of Buyer or the Company in respect of any Post-Closing Tax Period. Seller agrees that Buyer is to have no liability for any Tax resulting from any action of Seller, the Company, its Affiliates or any of their respective Representatives, and agrees to indemnify and hold harmless Buyer (and, after the Closing Date, the Company) against any such Tax or reduction of any Tax asset.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>All transfer, documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement (including any real property transfer Tax and any other similar Tax) shall be borne and paid by Seller when due. Seller shall, at its own expense, timely file any Tax Return or other document with respect to such Taxes or fees (and Buyer shall cooperate with respect thereto as necessary).</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer shall prepare, or cause to be prepared, all Tax Returns required to be filed by the Company after the Closing Date with respect to a Pre-Closing Tax Period. Any such Tax Return shall be prepared in a manner consistent with past practice (unless otherwise required by Law) and without a change of any election or any accounting method and shall be submitted by Buyer to Seller (together with schedules, statements and, to the extent requested by Seller, supporting documentation) at least 45 days prior to the due date (including extensions) of such Tax Return. If Seller objects to any item on any such Tax Return, it shall, within ten days after delivery of such Tax Return, notify Buyer in writing that it so objects, specifying with particularity any such item and stating the specific factual or legal basis for any such objection. If a notice of objection shall be duly delivered, Buyer and Seller shall negotiate in good faith and use their reasonable best efforts to resolve such items. If Buyer and Seller are unable to reach such agreement within ten days after receipt by Buyer of such notice, the disputed items shall be resolved by the Independent Accountant and any determination by the Independent Accountant shall be final. The Independent Accountant shall resolve any disputed items within twenty days of having the item referred to it pursuant to such procedures as it may require. If the Independent Accountant is unable to resolve any disputed items before the due date for such Tax Return, the Tax Return shall be filed as prepared by Buyer and then amended to reflect the Independent Accountant's resolution. The costs, fees and expenses of the Independent Accountant shall be borne equally by Buyer and Seller. The preparation and filing of any Tax Return of the Company that does not relate to a Pre-Closing Tax Period shall be exclusively within the control of Buyer.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 6.02</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Termination of Existing Tax Sharing Agreements.</b> Seller shall terminate or cause to be terminated any and all existing Tax sharing agreements (whether written or not) binding upon the Company as of the Closing Date. After Closing, none of the Company, Seller nor any of Seller's Affiliates and their respective Representatives shall have any further rights or liabilities thereunder.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 6.03</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Tax Indemnification.</b> Seller shall indemnify the Company, Buyer, and each Buyer Indemnitee and hold them harmless from and against (a) any Loss attributable to any breach of or inaccuracy in any representation or warranty made in Section 3.22; (b) any Loss attributable to any breach or violation of, or failure to fully perform, any covenant, agreement, undertaking or obligation in ARTICLE VI; (c) all Taxes of the Company or relating to the business of the Company for all Pre-Closing Tax Periods (""<b>Pre-Closing Taxes</b>"); (d) all Taxes of any member of an affiliated, consolidated, combined or unitary group of which the Company (or any predecessor of the Company) is or was a member on or prior to the First Closing Date; and (e) any and all Taxes of any person imposed on the Company arising under the principles of transferee or successor liability or by contract, relating to an event or transaction occurring before the First Closing Date. In each of the above cases, together with any out-of-pocket fees and expenses (including attorneys' and accountants' fees) incurred in connection therewith, Seller shall reimburse Buyer for any Taxes of the Company that are the responsibility of Seller pursuant to this Section 6.03 within ten Business Days after payment of such Taxes by Buyer or the Company.</p>
                <div>
                    <p style="text-align: center;">264</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_203_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 6.04</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Straddle Period.</b> In the case of Taxes that are payable with respect to a taxable period that begins before and ends after the First Closing Date (each such period, a "<b>Straddle Period</b>"), the portion of any such Taxes that are treated as Pre-Closing Taxes for purposes of this Agreement shall be:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 25.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>in the case of Taxes (i) based upon, or related to, income, receipts, profits, wages, capital or net worth, (ii) imposed in connection with the sale, transfer or assignment of property, or (iii) required to be withheld, deemed equal to the amount which would be payable if the taxable year ended with the Closing Date; and</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>in the case of other Taxes, deemed to be the amount of such Taxes for the entire period multiplied by a fraction the numerator of which is the number of days in the period ending on the Closing Date and the denominator of which is the number of days in the entire period.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 6.05</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Contests.</b> Buyer agrees to give written notice to Seller of the receipt of any written notice by the Company, Buyer or any of Buyer's Affiliates which involves the assertion of any claim, or the commencement of any Action, in respect of which an indemnity may be sought by Buyer pursuant to this ARTICLE VI (a "<b>Tax Claim</b>"); <i>provided, that</i> failure to comply with this provision shall not affect Buyer's right to indemnification hereunder. Buyer shall control the contest or resolution of any Tax Claim; <i>provided, however</i>, that Buyer shall obtain the prior written consent of Seller (which consent shall not be unreasonably withheld, conditioned or delayed) before entering into any settlement of a claim or ceasing to defend such claim; and, <i>provided further</i>, that Seller shall be entitled to participate in the defense of such claim and to employ counsel of its choice for such purpose, the fees and expenses of which separate counsel shall be borne solely by Seller.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 6.06</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Cooperation and Exchange of Information.</b> Seller and Buyer shall provide each other with such cooperation and information as either of them reasonably may request of the other in filing any Tax Return pursuant to this ARTICLE VI or in connection with any audit or other proceeding in respect of Taxes of the Company. Such cooperation and information shall include providing copies of relevant Tax Returns or portions thereof, together with accompanying schedules, related work papers and documents relating to rulings or other determinations by tax authorities. Each of Seller and Buyer shall retain all Tax Returns, schedules and work papers, records and other documents in its possession relating to Tax matters of the Company for any taxable period beginning before the Closing Date until the expiration of the statute of limitations of the taxable periods to which such Tax Returns and other documents relate, without regard to extensions except to the extent notified by the other party in writing of such extensions for the respective Tax periods. Prior to transferring, destroying or discarding any Tax Returns, schedules and work papers, records and other documents in its possession relating to Tax matters of the Company for any taxable period beginning before the Closing Date, Seller or Buyer (as the case may be) shall provide the other party with reasonable written notice and offer the other party the opportunity to take custody of such materials.</p>
                <div>
                    <p style="text-align: center;">265</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_204_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 6.07</b><span style="width: 22.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Tax Treatment of Indemnification Payments.</b> Any indemnification payments pursuant to this <span style="background-color: transparent;">ARTICLE VI</span> shall be treated as an adjustment to the Purchase Price by the parties for Tax purposes, unless otherwise required by Law.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 6.08</b><span style="width: 21.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Survival.</b> Notwithstanding anything in this Agreement to the contrary, the provisions of <span style="background-color: transparent;">Section 3.22</span> and this <span style="background-color: transparent;">ARTICLE VI</span> shall survive for the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof) plus 60 days.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 6.09</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Overlap.</b> To the extent that any obligation or responsibility pursuant to <span style="background-color: transparent;">ARTICLE VIII</span> may overlap with an obligation or responsibility pursuant to this <span style="background-color: transparent;">ARTICLE VI</span>, the provisions of this <span style="background-color: transparent;">ARTICLE VI</span> shall govern.</p>
                <p style="text-align: center;"><b>ARTICLE VII</b><br/><b>CONDITIONS TO CLOSING</b></p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 7.01</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Conditions to Obligations of All Parties.</b> The obligations of each party to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 26.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Governmental Order which is in effect and has the effect of making the transactions contemplated by this Agreement illegal, otherwise restraining or prohibiting consummation of such transactions or causing any of the transactions contemplated hereunder to be rescinded following completion thereof.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 26pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller shall have received all consents, authorizations, orders and approvals from the Governmental Authorities referred to in <span style="background-color: transparent;">Section 3.05</span> and Buyer shall have received all consents, authorizations, orders and approvals from the Governmental Authorities referred to in <span style="background-color: transparent;">Section 4.02</span>, in each case, in form and substance reasonably satisfactory to Buyer and Seller, and no such consent, authorization, order and approval shall have been revoked.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 7.02</b><span style="width: 20.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Conditions to Obligations of Buyer.</b> The obligations of Buyer to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Buyer's waiver, at or prior to each Closing, of each of the following conditions:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>With respect only to the consummation of the Second Closing, but not the First Closing, approval of the acquisition of the Company by the Buyer's shareholders.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Other than the representations and warranties of Seller contained in <span style="background-color: transparent;">Section 3.01</span>, <span style="background-color: transparent;">Section 3.02</span>, <span style="background-color: transparent;">Section 3.03</span>, <span style="background-color: transparent;">Section 3.04</span>, <span style="background-color: transparent;">Section 3.05</span> and <span style="background-color: transparent;">Section 3.24</span>, the representations and warranties of Seller contained in this Agreement, and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality or Material Adverse Effect) or in all material respects (in the case of any representation or warranty not qualified by materiality or Material Adverse Effect) on and as of the date hereof and on and as of the First Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects). The representations and warranties of Seller contained in <span style="background-color: transparent;">Section 3.01</span>, <span style="background-color: transparent;">Section 3.02</span>, <span style="background-color: transparent;">Section 3.03</span>, <span style="background-color: transparent;">Section 3.04</span>, <span style="background-color: transparent;">Section 3.05</span> and <span style="background-color: transparent;">Section 3.24</span> shall be true and correct in all respects on and as of the date hereof and on and as of the First Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects).</p>
                <div>
                    <p style="text-align: center;">266</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_205_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(c)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement to be performed or complied with by it prior to or on the Closing Date; <i>provided, that</i>, with respect to agreements, covenants and conditions that are qualified by materiality, Seller shall have performed such agreements, covenants and conditions, as so qualified, in all respects.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>No Action shall have been commenced against Buyer, Seller or the Company, which would prevent the Closing. No injunction or restraining order shall have been issued by any Governmental Authority, and be in effect, which restrains or prohibits any transaction contemplated hereby.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>All approvals, consents and waivers that are listed on <span style="background-color: transparent;">Section 3.05</span> of the Disclosure Schedules shall have been received, and executed counterparts thereof shall have been delivered to Buyer at or prior to the Closing.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(f)<span style="width: 26.01pt; text-indent: 0pt; display: inline-block;">&#160;</span>Intentionally deleted.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer shall have received resignations of the directors and officers of the Company pursuant to Section 5.06.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Intentionally deleted.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(i)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>Intentionally deleted.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(j)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>Intentionally deleted.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(k)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Intentionally deleted.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(l)<span style="width: 26.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer shall have received a certificate, dated the Closing Date and signed by a duly authorized officer of Seller, that each of the conditions set forth in Section 7.02(a) and Section 7.02(c) have been satisfied.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(m)<span style="width: 21.67pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Seller certifying that attached thereto are true and complete copies of all resolutions adopted by the board of directors of Seller authorizing the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(n)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Seller certifying the names and signatures of the officers of Seller authorized to sign this Agreement, and the other documents to be delivered hereunder and thereunder.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(o)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller shall have delivered to Buyer such other documents or instruments as Buyer reasonably requests and are reasonably necessary to consummate the transactions contemplated by this Agreement.</p>
                <div>
                    <p style="text-align: center;">267</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_206_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 7.03</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Conditions to Obligations of Seller.</b> The obligations of Seller to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Seller's waiver, at or prior to the First Closing, of each of the following conditions:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 25pt; text-indent: 0pt; display: inline-block;">&#160;</span>Other than the representations and warranties of Buyer contained in <span style="background-color: transparent;">Section 4.01</span><span style="color: #0000ff;"><span style="text-decoration: underline;">, </span></span><span style="background-color: transparent;">Section 4.02</span><span style="color: #0000ff;">&#160;</span>and <span style="background-color: transparent;">Section 4.06</span>, the representations and warranties of Buyer contained in this Agreement, and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality or Material Adverse Effect) or in all material respects (in the case of any representation or warranty not qualified by materiality or material adverse effect) on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects). The representations and warranties of Buyer contained in Section 4.01<span style="color: #0000ff;"><span style="text-decoration: underline;">, </span></span>Section 4.02 and Section 4.06 shall be true and correct in all respects on and as of the date hereof and on and as of the Closing Date with the same effect as though made at and as of such date.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and to be performed or complied with by it prior to or on the Closing Date; <i>provided, that</i>, with respect to agreements, covenants and conditions that are qualified by materiality, Buyer shall have performed such agreements, covenants and conditions, as so qualified, in all respects.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>No injunction or restraining order shall have been issued by any Governmental Authority, and be in effect, which restrains or prohibits any material transaction contemplated hereby.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>All approvals, consents and waivers that are listed on <span style="background-color: transparent;">Section 4.02</span> of the Disclosure Schedules shall have been received, and executed counterparts thereof shall have been delivered to Seller at or prior to the Closing.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer shall have delivered to holders of outstanding Indebtedness, if any, by wire transfer of immediately available funds that amount of money due and owing from the Company to such holder of outstanding Indebtedness as set forth on the Closing Indebtedness Certificate.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(f)<span style="width: 25.51pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller shall have received a certificate, dated the Closing Date and signed by a duly authorized officer of Buyer, that each of the conditions set forth in <span style="background-color: transparent;">Section 7.03(a)</span> and <span style="background-color: transparent;">Section 7.03(b)</span> have been satisfied.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(g)<span style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Buyer certifying that attached thereto are true and complete copies of all resolutions adopted by the board of directors of Buyer authorizing the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(h)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Buyer certifying the names and signatures of the officers of Buyer authorized to sign this Agreement, and the other documents to be delivered hereunder and thereunder.</p>
                <div>
                    <p style="text-align: center;">268</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_207_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(i)<span style="width: 24.67pt; text-indent: 0pt; display: inline-block;">&#160;</span> Buyer shall have delivered to Seller such other documents or instruments as Seller reasonably requests and are reasonably necessary to consummate the transactions contemplated by this Agreement.</p>
                <p style="text-align: center;"><b>ARTICLE VIII</b><br/><b>INDEMNIFICATION</b></p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 8.01</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Survival.</b> Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein (other than any representations or warranties contained in <span style="background-color: transparent;">Section 3.22</span> which are subject to <span style="background-color: transparent;">ARTICLE VI</span>) shall survive the Closing and shall remain in full force and effect until the date that is eighteen (18) months from the Closing Date; <i>provided, that</i> the representations and warranties in <span style="background-color: transparent;">Section 3.01</span>, <span style="background-color: transparent;">Section 3.02</span>, <span style="background-color: transparent;">Section 3.03</span>, <span style="background-color: transparent;">Section 3.04</span>, <span style="background-color: transparent;">Section 3.24</span>, <span style="background-color: transparent;">Section 4.01</span><span style="color: #0000ff;"><span style="text-decoration: underline;">, </span></span><span style="background-color: transparent;">Section 4.02</span> and <span style="background-color: transparent;">Section 4.06</span> shall survive indefinitely. All covenants and agreements of the parties contained herein (other than any covenants or agreements contained in <span style="background-color: transparent;">ARTICLE VI</span> which are subject to <span style="background-color: transparent;">ARTICLE VI</span>) shall survive the Closing indefinitely or for the period explicitly specified therein. Notwithstanding the foregoing, any claims asserted in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the non-breaching party to the breaching party prior to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of the relevant representation or warranty and such claims shall survive until finally resolved.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 8.02</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Indemnification By Seller.</b> Subject to the other terms and conditions of this <span style="background-color: transparent;">ARTICLE VIII</span>, from and after Closing, Seller shall indemnify and defend each of Buyer and its Affiliates (including the Company) and their respective Representatives (collectively, the "<b>Buyer Indemnitees</b>") against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Buyer Indemnitees based upon, arising out of, with respect to or by reason of:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>any inaccuracy in or breach of any of the representations or warranties of Seller contained in this Agreement or in any certificate or instrument delivered by or on behalf of Seller pursuant to this Agreement (other than in respect of <span style="background-color: transparent;">Section 3.22</span>, it being understood that the sole remedy for any such inaccuracy in or breach thereof shall be pursuant to <span style="background-color: transparent;">ARTICLE VI</span>), as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller pursuant to this Agreement (other than any breach or non-fulfillment of any covenant, agreement or obligation in <span style="background-color: transparent;">ARTICLE VI</span>, it being understood that the sole remedy for any such breach or non-fulfillment shall be pursuant to <span style="background-color: transparent;">ARTICLE VI</span>).</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 8.03</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Indemnification By Buyer.</b> Subject to the other terms and conditions of this <span style="background-color: transparent;">ARTICLE VIII</span>, from and after Closing, Buyer shall indemnify and defend each of Seller and its Affiliates and their respective Representatives (collectively, the "<b>Seller Indemnitees</b>") against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Seller Indemnitees based upon, arising out of, with respect to or by reason of:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>any inaccuracy in or breach of any of the representations or warranties of Buyer contained in this Agreement or in any certificate or instrument delivered by or on behalf of Buyer pursuant to this Agreement, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date); or</p>
                <div>
                    <p style="text-align: center;">269</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_208_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Buyer pursuant to this Agreement (other than any breach or non-fulfillments of any covenant, agreement or obligation in <span style="background-color: transparent;">ARTICLE VI</span>, it being understood that the sole remedy for any such breach or non-fulfillment thereof shall be pursuant to <span style="background-color: transparent;">ARTICLE VI</span>).</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 8.04</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Certain Limitations.</b> The indemnification provided for in <span style="background-color: transparent;">Section 8.02</span> and <span style="background-color: transparent;">Section 8.03</span> shall be subject to the following limitations:</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Seller shall not be liable to the Buyer Indemnitees for indemnification under <span style="background-color: transparent;">Section 8.02(a)</span> until the aggregate amount of all Losses in respect of indemnification under Section 8.02(a) exceeds $50,000 (the "<b>Basket</b>"), in which event Seller shall be required to pay or be liable for all such Losses from the first dollar.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Buyer shall not be liable to the Seller Indemnitees for indemnification under <span style="background-color: transparent;">Section 8.03(a)</span> until the aggregate amount of all Losses in respect of indemnification under <span style="background-color: transparent;">Section 8.03(a)</span> exceeds the Basket, in which event Buyer shall be required to pay or be liable for all such Losses from the first dollar.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Notwithstanding the foregoing, the limitations set forth in <span style="background-color: transparent;">Section 8.04(a)</span> and <span style="background-color: transparent;">Section 8.04(b)</span> shall not apply to Losses based upon, arising out of, with respect to or by reason of any inaccuracy in or breach of any representation or warranty in <span style="background-color: transparent;">Section 3.01</span>, <span style="background-color: transparent;">Section 3.02</span>, <span style="background-color: transparent;">Section 3.03</span>, <span style="background-color: transparent;">Section 3.04</span>, <span style="background-color: transparent;">Section 3.05</span>, <span style="background-color: transparent;">Section 3.24</span>, <span style="background-color: transparent;">Section 4.01</span><span style="color: #0000ff;"><span style="text-decoration: underline;">, </span></span><span style="background-color: transparent;">Section 4.02</span>, Section 4.03, and <span style="background-color: transparent;">Section 4.06</span>.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>For purposes of this <span style="background-color: transparent;">ARTICLE VIII</span> (including for purposes of determining the existence of any inaccuracy in, or breach of, any representation or warranty and for calculating the amount of any Loss with respect thereto), any inaccuracy in or breach of any representation or warranty shall be determined without regard to any materiality, Material Adverse Effect or other similar qualification contained in or otherwise applicable to such representation or warranty.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(e)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Notwithstanding anything to the contrary, the maximum liability of the Seller all claims arising from this contract is limited to a liability sum of USD$1,600,000.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 8.05</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Indemnification Procedures.</b> The party making a claim under this ARTICLE VIII is referred to as the "<b>Indemnified Party</b>", and the party against whom such claims are asserted under this ARTICLE VIII is referred to as the "<b>Indemnifying Party</b>".</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Third-Party Claims. If any Indemnified Party receives notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing (a "<b>Third-Party Claim</b>") against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than 30 calendar days after receipt of such notice of such Third-Party Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Third-Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right to participate in, or by giving written notice to the Indemnified Party, to assume the defense of any Third-Party Claim at the Indemnifying Party's expense and by the Indemnifying Party's own counsel, and the Indemnified Party shall cooperate in good faith in such defense; <i>provided, that</i> if the Indemnifying Party is Seller, such Indemnifying Party shall not have the right to defend or direct the defense of any such Third-Party Claim that (x) is asserted directly by or on behalf of a Person that is a supplier or customer of the Company, or (y) seeks an injunction or other equitable relief against the Indemnified Party. In the event that the Indemnifying Party assumes the defense of any Third-Party Claim, subject to <span style="background-color: transparent;">Section 8.05(b)</span>, it shall have the right to take such action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Third-Party Claim in the name and on behalf of the Indemnified Party. The Indemnified Party shall have the right to participate in the defense of any Third-Party Claim with counsel selected by it subject to the Indemnifying Party's right to control the defense thereof. The fees and disbursements of such counsel shall be at the expense of the Indemnified Party, <i>provided, that</i> if in the reasonable opinion of counsel to the Indemnified Party, (A) there are legal defenses available to an Indemnified Party that are different from or additional to those available to the Indemnifying Party; or (B) there exists a conflict of interest between the Indemnifying Party and the Indemnified Party that cannot be waived, the Indemnifying Party shall be liable for the reasonable fees and expenses of counsel to the Indemnified Party in each jurisdiction for which the Indemnified Party determines counsel is required. If the Indemnifying Party elects not to compromise or defend such Third-Party Claim, fails to promptly notify the Indemnified Party in writing of its election to defend as provided in this Agreement, or fails to diligently prosecute the defense of such Third-Party Claim, the Indemnified Party may, subject to <span style="background-color: transparent;">Section 8.05(b)</span>, pay, compromise, defend such Third-Party Claim and seek indemnification for any and all Losses based upon, arising from or relating to such Third-Party Claim. Seller and Buyer shall cooperate with each other in all reasonable respects in connection with the defense of any Third-Party Claim, including making available (subject to the provisions of <span style="background-color: transparent;">Section 5.07</span>) records relating to such Third-Party Claim and furnishing, without expense (other than reimbursement of actual out-of-pocket expenses) to the defending party, management employees of the non-defending party as may be reasonably necessary for the preparation of the defense of such Third-Party Claim.</p>
                <div>
                    <p style="text-align: center;">270</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_209_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Settlement of Third-Party Claims. Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into settlement of any Third-Party Claim without the prior written consent of the Indemnified Party, except as provided in this <span style="background-color: transparent;">Section 8.05(b)</span>. If a firm offer is made to settle a Third-Party Claim without leading to liability or the creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of each Indemnified Party from all liabilities and obligations in connection with such Third-Party Claim and the Indemnifying Party desires to accept and agree to such offer, the Indemnifying Party shall give written notice to that effect to the Indemnified Party. If the Indemnified Party fails to consent to such firm offer within 10 days after its receipt of such notice, the Indemnified Party may continue to contest or defend such Third-Party Claim and in such event, the maximum liability of the Indemnifying Party as to such Third-Party Claim shall not exceed the amount of such settlement offer. If the Indemnified Party fails to consent to such firm offer and also fails to assume defense of such Third-Party Claim, the Indemnifying Party may settle the Third-Party Claim upon the terms set forth in such firm offer to settle such Third-Party Claim. If the Indemnified Party has assumed the defense pursuant to <span style="background-color: transparent;">Section 8.05(a)</span>, it shall not agree to any settlement without the written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed).</p>
                <div>
                    <p style="text-align: center;">271</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_210_integixAnchor"></span>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Direct Claims. Any Action by an Indemnified Party on account of a Loss which does not result from a Third-Party Claim (a "<b>Direct Claim</b>") shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than 30 days after the Indemnified Party becomes aware of such Direct Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have 30 days after its receipt of such notice to respond in writing to such Direct Claim. The Indemnified Party shall allow the Indemnifying Party and its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount is payable in respect of the Direct Claim and the Indemnified Party shall assist the Indemnifying Party's investigation by giving such information and assistance (including access to the Company's premises and personnel and the right to examine and copy any accounts, documents or records) as the Indemnifying Party or any of its professional advisors may reasonably request. If the Indemnifying Party does not so respond within such 30-day period, the Indemnifying Party shall be deemed to have rejected such claim, in which case the Indemnified Party shall be free to pursue such remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(d)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Tax Claims. Notwithstanding any other provision of this Agreement, the control of any claim, assertion, event or proceeding in respect of Taxes of the Company (including, but not limited to, any such claim in respect of a breach of the representations and warranties in <span style="background-color: transparent;">Section 3.22</span> hereof or any breach or violation of or failure to fully perform any covenant, agreement, undertaking or obligation in <span style="background-color: transparent;">ARTICLE VI</span>) shall be governed exclusively by <span style="background-color: transparent;">ARTICLE VI</span> hereof.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 8.06</b><span style="width: 20.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Payments</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;"><b>(a)</b><span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>Once a Loss is agreed to by the Indemnifying Party or finally adjudicated to be payable pursuant to this <span style="background-color: transparent;">ARTICLE VIII</span>, the Indemnifying Party shall satisfy its obligations within 15 Business Days of such final, non-appealable adjudication by wire transfer of immediately available funds. The parties hereto agree that should an Indemnifying Party not make full payment of any such obligations within such 15 Business Day period, any amount payable shall accrue interest from and including the date of agreement of the Indemnifying Party or final, non-appealable adjudication to the date such payment has been made at a rate per annum equal to 5%. Such interest shall be calculated daily on the basis of a 365/366-day year and the actual number of days elapsed.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;"><b>(b)</b><span style="width: 21.33pt; text-indent: 0pt; display: inline-block;">&#160;</span>The parties acknowledge and agree that for the purposes of satisfying claims for indemnity,&#160; hereunder, the Seller shall be entitled to satisfy such claims in its sole and absolute discretion, by payment of cash, or by surrender of Flora Shares, and in connection with such surrender, the Flor Shares shall be deemed to have a per share value equal to the greater of (i) $2.31; or (ii) the 10 day volume weighted average trading price of the Flora Shares on the Exchange.</p>
                <div>
                    <p style="text-align: center;">272</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_211_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 8.07</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Tax Treatment of Indemnification Payments.</b> All indemnification payments made under this Agreement shall be treated by the parties as an adjustment to the Purchase Price for Tax purposes, unless otherwise required by Law.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 8.08</b><span style="width: 21.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Effect of Investigation.</b> The representations, warranties and covenants of the Indemnifying Party, and the Indemnified Party's right to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of the Indemnified Party (including by any of its Representatives) or by reason of the fact that the Indemnified Party or any of its Representatives knew or should have known that any such representation or warranty is, was or might be inaccurate or by reason of the Indemnified Party's waiver of any condition set forth in <span style="background-color: transparent;">Section 7.02</span> or <span style="background-color: transparent;">Section 7.03</span>, as the case may be.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 8.09</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Exclusive Remedies.</b> Subject to <span style="background-color: transparent;">Section 5.08</span> and <span style="background-color: transparent;">Section 9.11</span>, the parties acknowledge and agree that from and after Closing their sole and exclusive remedy with respect to any and all claims (other than claims arising from fraud on the part of a party hereto in connection with the transactions contemplated by this Agreement) for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in <span style="background-color: transparent;">ARTICLE VI</span> and this <span style="background-color: transparent;">ARTICLE VIII</span>. In furtherance of the foregoing, except with respect to <span style="background-color: transparent;">Section 5.08</span> and <span style="background-color: transparent;">Section 9.11</span>, each party hereby waives, from and after Closing, to the fullest extent permitted under Law, any and all rights, claims and causes of action for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement it may have against the other parties hereto and their Affiliates and each of their respective Representatives arising under or based upon any Law, except pursuant to the indemnification provisions set forth in <span style="background-color: transparent;">ARTICLE VI</span> and this <span style="background-color: transparent;">ARTICLE VIII</span>. Nothing in this <span style="background-color: transparent;">Section 8.09</span> shall limit any Person's right to seek and obtain any equitable relief to which any Person shall be entitled or to seek any remedy on account of any party's fraud or willful misconduct.</p>
                <p style="text-align: center;"><b>ARTICLE IX</b><br/><b>MISCELLANEOUS</b></p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.01</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Expenses.</b> Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.02</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Notices.</b> All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this <span style="background-color: transparent;">Section 9.02</span>):</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">If to Seller:</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">TruHC Holding GmbH<br/>Sternstrasse 97, 20357 Hamburg, Germany<br/>E-mail: Hendrik.knopp@gmail.com<br/>Attention:<span style="width: 23.34pt; display: inline-block;">&#160;</span>Managing Director</td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">273</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_212_integixAnchor"></span>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; width: 50%;">If to Buyer:</td>
                        <td style="margin-bottom: 0pt; vertical-align: top; width: 50%;">Flora Growth Corp.<br/>3406 SW 26th Terrace, Fort Lauderdale, Florida 33315, US<br/>E-mail: Clifford.Starke@floragrowth.com<br/>Attention:<span style="width: 23.34pt; display: inline-block;">&#160;</span>Chief Executive Officer</td>
                    </tr>
                </table>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 9.03</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Interpretation.</b> For purposes of this Agreement, (a) the words "include," "includes" and "including" shall be deemed to be followed by the words "without limitation"; (b) the word "or" is not exclusive; and (c) the words "herein," "hereof," "hereby," "hereto" and "hereunder" refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Disclosure Schedules and Exhibits mean the Articles and Sections of, and Disclosure Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.04</b><span style="width: 21.67pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Headings.</b> The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.05</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Severability.</b> If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.06</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Entire Agreement.</b> This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and those in the Exhibits and Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of this Agreement will control.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.07</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Successors and Assigns.</b> This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed. No assignment shall relieve the assigning party of any of its obligations hereunder.</p>
                <div>
                    <p style="text-align: center;">274</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_213_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 9.08</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>No Third-Party Beneficiaries.</b> Except as provided in <span style="background-color: transparent;">Section 6.03</span> and <span style="background-color: transparent;">ARTICLE VIII</span>, this Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.09</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Amendment and Modification; Waiver.</b> This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.10</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.</b></p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(a)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>This Agreement shall be governed by and construed in accordance with the internal laws of the Province of Ontario and the federal laws of Canada applicable therein, without giving effect to any choice or conflict of law provision or rule (whether of the Province of Ontario or any other jurisdiction).</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(b)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY MAY BE INSTITUTED IN THE FEDERAL COURTS OF CANADA OR THE COURTS OF THE PROVINCE OF ONTARIO, AND EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING. SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER DOCUMENT BY MAIL TO SUCH PARTY'S ADDRESS SET FORTH HEREIN SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY SUIT, ACTION OR OTHER PROCEEDING BROUGHT IN ANY SUCH COURT. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.</p>
                <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify;">(c)<span style="width: 24pt; text-indent: 0pt; display: inline-block;">&#160;</span>EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.10(c).</p>
                <div>
                    <p style="text-align: center;">275</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_214_integixAnchor"></span>
                <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt;"><b>Section 9.11</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Specific Performance.</b> The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.</p>
                <p style="text-indent: 36pt; text-align: justify;"><b>Section 9.12</b><span style="width: 20.17pt; text-indent: 0pt; display: inline-block;">&#160;</span><b>Counterparts.</b> This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</p>
                <p style="text-align: center;">[SIGNATURE PAGE FOLLOWS]</p>
                <div>
                    <p style="text-align: center;">276</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_215_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their duly authorized officers/representatives.</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">SELLER: TruHC Holding GmbH</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top; border-bottom: 0.75pt solid #000000;">By<i>&#160; "Hendrik Knopp"</i></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">Name: Hendrik Knopp<br/>Title: Managing Director</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">BUYER: Flora Growth Corp.</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top; border-bottom: 0.75pt solid #000000;">By<i> &#160; "Clifford Starke"</i></td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                        <td style="margin-bottom: 0pt; width: 50%; vertical-align: top;">Name: Clifford Starke<br/>Title: Chief Executive Officer</td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">277</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_216_integixAnchor"></span>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: center; margin-top: 10pt;"><span style="text-decoration: underline;"><b>ANNEX B </b></span></p>
                <p style="text-align: justify;"><b>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations for the Quarter Ended March 31, 2024</b></p>
                <p style="text-align: justify;"><i>The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations, financial condition, liquidity and cash flows for the periods presented. This discussion should be read in conjunction with (a) our unaudited condensed consolidated financial statements and related notes contained elsewhere in Part I, Item 1, "Financial Statements" of this Quarterly Report, and (b) Part I, Item 1A "Risk Factors", Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our audited consolidated financial statements and related notes in our 2023 Annual Report. As discussed in the section above titled "Cautionary Statement Regarding Forward-Looking Statements," the following discussion contains forward-looking statements that are based upon our current expectations, including with respect to our future revenues and operating results. Our actual results may differ materially from those anticipated in such forward-looking statements as a result of various factors. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled "Risk Factors" included under Part II, Item 1A below and included under Part I, Item 1A in our 2023 Annual Report.</i></p>
                <p style="text-align: justify;"><i>Amounts are expressed in United States dollars ("$" or "USD") unless otherwise stated to be in Canadian dollars ("CAD"), Euro ("&#8364;" or "EUR"), or Colombia pesos ("COP"). Amounts stated in foreign currencies include approximate USD amounts based on exchange rates on March 31, 2024. Variance, ratio, and percentage changes in this section are based on unrounded numbers. This section reports the Company's activities through March 31, 2024, unless otherwise indicated.</i></p>
                <p style="text-align: justify;"><b>Overview of our Business </b></p>
                <p style="text-align: justify;">We are a multi-national cannabis company that manufactures and distributes consumer packaged goods and distributes medicinal cannabis and pharmaceutical products. Flora exists to create a world where the benefits of cannabis are accessible to everyone. Our primary businesses include JustCBD, Vessel and Phatebo.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i>JustCBD</i></p>
                <p style="text-align: justify; background-color: #ffffff;">JustCBD is Flora's leading consumer packaged goods brand. JustCBD was launched in 2017 with a mission to bring high-quality, trustworthy and budget-friendly CBD products to market. The JustCBD offering currently consists of over 350 products across 15 categories, including CBD gummies, topicals, tinctures, and vape products and ships to over 11,500 independent retailers worldwide. JustCBD also sells direct to consumers with a customer base of approximately 350,000 people. JustCBD products are available for purchase in smoke and vape shops, clinics, spas and pet stores, as well as other independent non-traditional retail channels. JustCBD's products are both internally and third-party lab-tested to ensure quality.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i>Vessel</i></p>
                <p style="text-align: justify; background-color: #ffffff;">Vessel is Flora's cannabis accessory and technology brand currently servicing the United States and Canada through direct-to-consumer and retail sales. Vessel's products include cannabis consumption accessories, personal storage and travel accessories for the vape and dry herb categories, which are sold to consumers, dispensaries, smoke shops and cannabis brands. Vessel has positioned itself as a lifestyle brand, developing products for consumers interested in "elevating" the consumption experience, focusing primarily on the direct-to-consumer business and have garnered a customer base of approximately 150,000 people. Since our acquisition of Vessel in November 2021, Vessel has been fully integrated into JustCBD and now benefits from operational, logistical and sales synergies with JustCBD.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i>Phatebo</i></p>
                <p style="text-align: justify; background-color: #ffffff;">Based in Germany, Phatebo is a wholesale pharmaceutical distribution company with import and export capabilities of a wide range of pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, multiple sclerosis and anti-depressants, among others. Phatebo holds a <i>License for the Trade in Narcotic Drugs </i>(including the cannabis sales license amendment) and a <i>Wholesale Trading License</i>, both of which are issued by BfArM (the largest drug approval authority in Europe). Phatebo is focused on distributing pharmaceutical products within 28 countries globally, primarily in Europe, but also with sales to Asia, Latin America, and North America. In November 2018, Phatebo also received a medical cannabis import and distribution license. The Phatebo warehouse provides a logistics outpost for Flora's growing product portfolio and distribution network within the European Union.</p>
                <div>
                    <p style="text-align: center;">278</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_217_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i>Colombian Related Subsidiaries</i></p>
                <p style="text-align: justify; background-color: #ffffff;">On July 5, 2023, the Company entered into a share purchase agreement with Lisan, a Delaware limited liability company, to sell all its shares in certain of its Colombian subsidiaries and its Colombian assets for a purchase price of CAD $0.8 million (USD $0.6 million). The sale relates to Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab 2, Flora Lab 4 and Flora's Colombian food and beverage and consumer products business (collectively "Colombia Assets"). The sale enables the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations. The Company received proceeds of CAD $0.5 million during the quarter ended September 30, 2023. The Company and Lisan completed the sale of Cosechemos Ya S.A.S on November 1, 2023.</p>
                <p style="text-align: justify;"><b>Factors Impacting our Business </b></p>
                <p style="text-align: justify;"><i>Challenges in realization of overhead reductions.</i> Management has taken, and continues to implement, various cost-saving initiatives to lower overhead costs. However, the Company has not yet reached the critical balance in reducing overhead to meet both the existing and potential market demand in aggregate. The Company strives to attain sufficient growth to cover its overhead to reach profitability. If the Company fails to grow its business or reduce its operating expenses further in the long term, it will continue to face significant cash flow deficiencies in the future and continue to be reliant on debt and/or equity financing to fund operations.</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;"><i>Consistent profitability and positive operating cash flows.</i> A key determinant of the Company's success is to deliver profitable results and positive cashflows from operating activities. The Company's results have not yet achieved the prerequisite consistency to achieve self-sufficiency. Since its inception, only the third quarter of 2023 yielded net income and positive cashflows from operating activities. There is no assurance that the Company will be able to produce adequate levels of sustained profitability and cash flow positive, or at all. These factors, amongst others, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are described in Note 2 of the Company's unaudited condensed interim consolidated financial statements for the three months ended March 31, 2024. For more information, see Item 1A "Risk Factors" in the Company's 2023 Annual Report.</span></p>
                <p style="text-align: justify;"><i>Acquisition strategy disadvantages include significant transaction costs and liabilities of our acquirees.</i> The Company has historically been opportunistic and pursues acquisitions from time to time that management believes will be complementary to or synergistic to the Company's existing business. However, any such acquisitions require the Company to incur heightened upfront transaction costs and require the Company to assume certain liabilities from the acquired companies. In addition, while the Company believes such acquisitions will provide enhanced value in the long term, it is possible that the anticipated synergies from the acquisition may never be realized.</p>
                <p style="text-align: justify;"><i>Diversification of cashflows.<b> </b></i>Our sources of cash are diversified across geographic and product lines. Revenues are concentrated primarily in Germany and the United States, spanning pharmaceuticals, hemp and non-hemp consumer products and medicinal cannabis.</p>
                <p style="text-align: justify;"><i>International cannabis developments.<b> </b></i>Flora's growth is embedded in the expansion, regulation and legalization of medicinal and recreational cannabis and cannabis derivative products across the world. While medicinal cannabis has been regulated at the federal level in multiple countries, the Company is focused on the most robust markets in Germany and the European Union. We remain tuned to international developments as potentially lucrative medicinal cannabis markets open.</p>
                <p style="text-align: justify;"><i>Product evolution and brand acceptance.<b> </b></i>As the cannabis industry continues to change, divergent regulations and the corresponding resources required to introduce high-quality products are expected to impact our market share. Gaining access to continuously evolving and superior products remains a critical success factor. Our ultimate ability to produce and acquire products meeting stringent quality control standards drives the extent of consumer acceptance. Furthermore, the intrinsic value within our brands, including JustCBD and Vessel, is subject to evolving consumer sentiment.</p>
                <p style="text-align: justify;"><i>Regulatory proficiency and adoption.<b> </b></i>The markets in which Flora operates are highly regulated and require extensive experience in navigating the associated complexities. We have assembled a team with deep knowledge of the regulatory and governance environments in which the Company operates. Fundamental expertise entails compliance with product approvals, import permits, export permits, distribution licenses and other pertinent licenses.</p>
                <div>
                    <p style="text-align: center;">279</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_218_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Integration of acquired companies.<b> </b></i>Our growth has been fueled substantially by the acquisition of JustCBD, Vessel and FGH. Our continued ability to extract incremental synergies from a group of diversified entities is a key determinant of our ability to expand organically.</p>
                <p style="text-align: justify;"><b>Public Company Costs</b></p>
                <p style="text-align: justify;">We are a public company, which requires additional staff and the implementation of processes and procedures to address public company regulatory requirements and customary practices. We expect to continue to incur substantial additional annual expenses for, among other things, directors' and officers' liability insurance and additional internal and external costs for investor relations, accounting, audit, legal, and other functions.</p>
                <p style="text-align: justify;"><b>Audit Committee Requirement</b></p>
                <p style="text-align: justify;">On December 6, 2023, the Company received a notification from Nasdaq, confirming that, due to having less than three independent audit committee members, the Company no longer complies with Nasdaq's audit committee requirements contained in Nasdaq Listing Rule 5605(c)(2)(A). As set forth in such notification, Nasdaq advised the Company that, under Nasdaq Rule 5605(c)(4), the Company was afforded a cure period in order to regain compliance (i) until the earlier of the Company's next annual shareholders' meeting or November 30, 2024, or (ii) if the next annual shareholders' meeting is held before May 28, 2024, then the Company must evidence compliance no later than May 28, 2024.</p>
                <p style="text-align: justify;">On May 2, 2024, the Board appointed Mr. Brendan Cahill as a director and member of each of the Company's audit committee, compensation committee and nominating and corporate governance committee.</p>
                <p style="text-align: justify;">After giving effect to Mr. Cahill's appointment, the audit committee of the Board has three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A). As a result of the foregoing, the Company has regained compliance with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A).</p>
                <p style="text-align: justify;"><b>Key Components of Results of Operations </b></p>
                <p style="text-align: justify;"><i>Revenue<b> </b></i></p>
                <p style="text-align: justify;">The Company primarily generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products. The Company has two major revenue groups, which are also its two reportable segments:</p>
                <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(1)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>House of Brands; and</p>
                <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;">(2)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Commercial and Wholesale.</p>
                <p style="text-align: justify;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.</p>
                <p style="text-align: justify;">The Company's operates its manufacturing and distribution business through its subsidiaries in the United States and Germany. Until the sale of the Colombia Assets, the Company also was engaged in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products in Colombia.</p>
                <p style="text-align: justify;">The Company uses the following five-step contract-based analysis of transactions to determine if, when and how much revenue can be recognized:</p>
                <p style="margin-bottom: 0pt; text-align: justify;">1.<span style="width: 26.5pt; display: inline-block;">&#160;</span>Identify the contract with a customer;</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">2.<span style="width: 26.5pt; display: inline-block;">&#160;</span>Identify the performance obligations in the contract;</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">3.<span style="width: 26.5pt; display: inline-block;">&#160;</span>Determine the transaction price;</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">4.<span style="width: 26.5pt; display: inline-block;">&#160;</span>Allocate the transaction price to the performance obligations in the contract; and</p>
                <p style="margin-top: 0pt; text-align: justify;">5.<span style="width: 26.5pt; display: inline-block;">&#160;</span>Recognize revenue when or as the Company satisfies the performance obligations.</p>
                <div>
                    <p style="text-align: center;">280</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_219_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Gross revenue excludes duties and taxes collected on behalf of third parties. Revenue is presented net of expected price discounts, sales returns, customer rebates and other incentives. The Company's cannabis consumption accessory products include a six-month warranty, which the Company accrues for the estimated liability based on historical and expected claim costs.</p>
                <p style="text-align: justify;">The Company's contracts with customers for the sales of products consist of one performance obligation. Revenue from product sales is recognized at the point in time when control is transferred to the customer, which is on shipment or delivery, depending on the contract terms. The Company's payment terms generally range from 0 to 30 days from the transfer of control, and sometimes up to six months.</p>
                <p style="text-align: justify;"><i>Cost of sales</i>&#160;</p>
                <p style="text-align: justify;">The Company includes the cost of raw materials and supplies, purchased finished goods and changes in inventory reserves in cost of sales for each of its two reportable segments. Raw materials include the purchase cost of the materials, freight-in and duty. Finished goods include the cost of direct materials and labor and a proportion of manufacturing overhead allocated based on normal production capacity. Inventory reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The primary factors that can impact cost of goods sold on a period-to-period basis include the volume of products sold, the mix of products sold, third-party quality costs, transportation, overhead allocations and changes in inventory provisions.</p>
                <p style="text-align: justify;"><i>Operating Expenses</i></p>
                <p style="text-align: justify;">The Company's operating expenses are apportioned based on the following categories:</p>
                <ul style="padding-left: 0pt; list-style-type: disc;">
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Consulting and management fees</i> include salary and benefit expenses for employees, directors and consultants for the Company's corporate activities, other than those included in one of general and administrative, share-based compensation, and research and development.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Professional fees</i> include legal, audit and other expenses incurred by third-party service providers.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>General and administrative</i> include certain public company costs, merchant fees and temporary labor and subcontractor costs for the Company's operating subsidiaries.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Promotion and communication expenses</i> consist primarily of services engaged in marketing and promotion of our products and costs associated with initiatives and development programs and salary and benefit expenses for certain employees.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Travel expenses</i> relate to flight, lodging and incidental expenses for attending conferences, events and key business meetings.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Share-based compensation</i> includes the cost of vesting of the Company's equity awards, including share options and restricted share awards.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Research and development</i> <i>expenses</i> primarily consist of salary and benefit expenses for employees engaged in research and development activities, as well as other general costs associated with R&amp;D activities.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Operating lease expense</i> represents the cost of the Company's operating leases, primarily consisting of real estate and equipment.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Depreciation and amortization expense</i> is provided on a straight-line basis over the corresponding assets' estimated useful lives.&#160;</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Bad debt expense</i> consists of changes in the provision for the Company's expected credit losses. The Company utilizes a provision matrix to estimate lifetime expected credit losses.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Asset impairment</i> includes the difference between the fair value and carrying amount of the asset group. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of an asset group.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;"><i>Other expenses (income), net</i> include miscellaneous expenses that do not fit the criteria for recognition in another category.</li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;"><i>Non-Operating (Income) Expenses<b> </b></i></p>
                <p style="text-align: justify;">Non-operating expenses include interest income and expenses, foreign exchange losses and unrealized losses from changes in fair value. Interest is primarily related to the Company's lease liabilities and operating lines of credit. Foreign exchange is largely related to the revaluation of balances denominated in foreign currencies to U.S. dollars. Unrealized losses from changes in fair value pertain to fluctuations in the fair values of the Company's investments and liabilities.</p>
                <div>
                    <p style="text-align: center;">281</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_220_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Income Tax<b> </b></i></p>
                <p style="text-align: justify;">Income tax<b> </b>consists primarily of income taxes related to U.S. federal and state income taxes and income taxes in foreign jurisdictions in which we conduct business.</p>
                <p style="text-align: justify;"><i>Loss from Discontinued Operations</i></p>
                <p style="text-align: justify;">Loss from discontinued operations includes the net income (loss), net of tax, of the Colombian subsidiaries sold on July 5, 2023 and on November 1, 2023. It also includes an expected loss on the disposal as the carrying value of the assets being sold exceeded the expected sale price.</p>
                <p style="text-align: justify;"><b>Results of Operations</b></p>
                <p style="text-align: justify;">The following tables provide sets forth the Company's consolidated results of operations for the three months ended March 31, 2024 and 2023 (in thousands).<span style="background-color: #ffffff;">&#160;</span>The period-to-period comparisons of the Company's historical results are not necessarily indicative of the results that may be expected in the future. The results of operations data have been derived from our unaudited condensed interim consolidated financial statements for the three months ended March 31, 2024 and 2023 included elsewhere in this Quarterly Report.&#160;</p>
                <table style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>For the three<br/>months ended<br/>March 31, 2024</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>For the three<br/>months ended<br/>March 31, 2023</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Revenue</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">18,031</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">19,319</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Cost of sales</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;">14,177</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;">13,973</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Gross profit</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">3,854</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">5,346</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Consulting and management fees</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">2,302</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">3,671</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Professional fees</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">453</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">(3</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">General and administrative</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">442</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">352</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Promotion and communication</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">1,104</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">1,308</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Travel expenses</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">69</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">132</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Share based compensation</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">10</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">654</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Research and development</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">47</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">16</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Operating lease expense</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">165</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">316</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Depreciation and amortization</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">74</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">864</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Bad debt expense</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">47</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">29</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Asset impairment</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">898</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Other expenses, net</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">728</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">377</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Operating loss</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;">(2,485</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;">(2,370</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Non-operating expenses</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">761</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">894</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Net loss before taxes and discontinued operations</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;">(3,246</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;">(3,264</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Income tax</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">128</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">(78</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Net loss from continuing operations</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;">(3,374</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;">(3,186</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Loss from discontinued operations</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">(719</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Net loss for the period</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 22%;">(3,374</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 22%;">(3,905</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">)</td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;"><span style="text-decoration: underline;">For the Three Months Ended March 31, 2024, and 2023</span></p>
                <p style="text-align: justify; background-color: #ffffff;"><i>Stop Sale Order by Florida Department of Agriculture and Consumer Services Division of Food Safety (the "Department")</i></p>
                <p style="text-align: justify; background-color: #ffffff;">On October 31, 2023, the Department issued 340 stop sale orders on hemp extract products distributed by Just Brands primarily on the basis that such products were determined to be attractive to children with the product and/or labels in the shape of an animal, human, or cartoon; or bears any reasonable resemblance to an existing candy product, or branded food product. As a result, Just Brands has stopped distributing these products in the State of Florida. There is no assurance that these products can be sold in another jurisdiction, or at all.</p>
                <p style="text-align: justify; background-color: #ffffff;">On January 22, 2024, the Department issued a stop sale order on 231 hemp extract and other products distributed by Just Brands primarily on the basis that such products were determined to be attractive to children with the product and/or labels in the shape of an animal, human, or cartoon; or bears any reasonable resemblance to an existing candy product, or branded food product. As a result, Just Brands has stopped distributing these products in the State of Florida. There is no assurance that these products can be sold in another jurisdiction, or at all.</p>
                <div>
                    <p style="text-align: center;">282</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_221_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">On April 2, 2024, the Department issued a stop sale order on 84 hemp extract and other products distributed by High Roller primarily on the basis that such products were determined to be attractive to children with the product and/or labels in the shape of an animal, human, or cartoon; or bears any reasonable resemblance to an existing candy product, or branded food product. As a result, Higher Roller has stopped distributing these products in the State of Florida. There is no assurance that these products can be sold in another jurisdiction, or at all.</p>
                <p style="text-align: justify;">On May 7, 2024, Just Brands and the Department agreed to a settlement and general release, whereby Just Brands will remove the products subject to the Stop Sales Orders from the state of Florida, pay the Department $60,500 to reimburse the Department's attorney's fees, and accept a five-year revocation of its food permit in the state of Florida. By signing the release, Just Brands waived, settled and released all claims it had or might have against the Department.</p>
                <p style="text-align: justify; background-color: #ffffff;">The Company estimates that the disruption from these stop sale orders had an unfavorable impact of $0.7 million on revenue during the three months ended March 31, 2024. The total value of inventory impacted by the stop sale orders was $1.9 million at March 31, 2024.</p>
                <p style="text-align: justify;"><i>Revenue</i></p>
                <p style="margin-bottom: 0pt; text-align: justify;">Revenue totaled $18.0 million and $19.3 million for the three months ended March 31, 2024 and 2023, respectively. The decrease was primarily driven by the following:</p>
                <ul style="padding-left: 0pt; margin-top: 0pt; list-style-type: disc;">
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">JustCBD contributed $5.4 million in the three months ended March 31, 2024 compared to $9.8 million in the three months ended March 31, 2023. The decrease was driven by the Company's decision to discontinue several unprofitable product lines during 2023, as well as the stop sales orders discussed above.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">Vessel contributed $1.3 million in the three months ended March 31, 2024, compared to $1.6 million in the three months ended March 31, 2023.</li>
                    <li style="margin-left: 27.6pt; text-align: justify; padding-left: 8.4pt;">This was partially offset by an increase at FGH, which contributed $11.3 million in the three months ended March 31, 2024, compared to $8.0 million in the three months ended March 31, 2023.</li>
                </ul>
                <p style="text-align: justify; margin-top: 10pt;"><i>Gross Profit</i></p>
                <p style="text-align: justify;">Gross profit totaled $3.9 million and $5.3 million for the three months ended March 31, 2024 and 2023, respectively. The decrease was primarily driven by the decreased sales at JustCBD, which contributed $2.7 million in the three months ended March 31, 2024 compared to $4.0 million in the three months ended March 31, 2023. The remaining fluctuation is due to decreased gross margins at Vessel with $0.5 million in the three months ended March 31, 2024 compared to $0.7 million in the three months ended March 31, 2023. As a percentage of net sales, or gross margin, the Company reported 21% and 28% for the three months ended March 31, 2024 and 2024, respectively. The decrease is primarily due to unfavorable mix, with increased Sales at FGH which distributes relatively lower margin pharmaceuticals.</p>
                <p style="text-align: justify;"><i>Operating Expenses</i></p>
                <p style="text-align: justify;">Operating expenses totaled $6.3 million and $7.7 million for the three months ended March 31, 2024 and March 31, 2023, respectively. The decrease is seen across multiple expense categories and is due to management's cost-cutting initiatives implemented during the second half of 2023.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Consulting and Management Fees</i></span></p>
                <p style="text-align: justify;">Consulting and management fees were $2.3 million for the three months ended March 31, 2024 compared to $3.7 million for the three months ended March 31, 2023. These fees are related to employment and consulting contracts with most of the Company's management, as well as directors. The decrease is primarily due a substantial reduction in the Company's corporate office headcount that resulted in $1.2 million lower expenses in the quarter.</p>
                <div>
                    <p style="text-align: center;">283</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_222_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="text-decoration: underline;"><i>Professional Fees</i></span></p>
                <p style="text-align: justify;">Professional fees totaled $0.5 million for the three months ended March 31, 2024 compared to less than $0.1 million for the three months ended March 31, 2023. These expenses are associated with legal, accounting and audit services. In the three months ended March 31, 2023, the Company received credit notes from certain service providers.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>General and Administrative Expenses</i></span></p>
                <p style="text-align: justify;">General and administrative expenses totaled $0.4 million for both the three months ended March 31, 2024 and the three months ended March 31, 2023. The primary expenses included in both periods were filing services and shareholder communications, as well as professional dues and subscriptions.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Promotion and Communication Expenses</i> </span></p>
                <p style="text-align: justify;">Promotion and communication expenses totaled $1.1 million for the three months ended March 31, 2024 compared to $1.3 million for the three months ended March 31, 2023. The decrease is due to reduced sales as well as cost-cutting initiatives by the Company aimed at the minimization of corporate overhead. Promotion expenses incurred in the period largely relate to the nature of JustCBD's business model, which is centered around promoting its products as a method for stimulating revenue growth.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Travel Expenses</i></span></p>
                <p style="text-align: justify;">Travel expenses totaled $0.1 million for both the three months ended March 31, 2024 and the three months ended March 31, 2023. These expenses were for various trips related to the subsidiaries and the Company's promotional activities.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Share-based Compensation Expenses </i></span></p>
                <p style="text-align: justify;">Share based compensation expenses totaled less than $0.1 million for the three months ended March 31, 2024 compared to $0.7 million for the three months ended March 31, 2023. These expenses represent the amortization of the fair value of share-based payments. The decrease is primarily due to the granting of fewer stock based compensation awards during 2023 than in 2022.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Research and Development Expenses</i></span></p>
                <p style="text-align: justify;">Research and development expenses totaled less than $0.1 million for both the three months ended March 31, 2024 and the three months ended March 31, 2023. Research and development expenses consist primarily of contract research fees, manufacturing, consultant fees, and costs related to the launch of new brands for the Vessel business.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Operating Lease Expenses</i></span></p>
                <p style="text-align: justify;">Operating lease expenses totaled $0.2 million for the three months ended March 31, 2024 compared to $0.3 million for three months ended March 31, 2023. The decrease is due to the impairment of the right-of-use operating lease assets during 2023.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Depreciation and Amortization Expense</i></span></p>
                <p style="text-align: justify;">Depreciation and amortization expenses totaled $0.1 million for the three months ended March 31, 2024 compared to $0.9 million for the three months ended March 31, 2023. The decrease is primarily due to the impairment recorded on the Company's long-lived assets during 2023.&#160;</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Bad Debt Expense</i></span></p>
                <p style="text-align: justify;">Bad debt expense totaled less than $0.1 million for both the three months ended March 31, 2024 and the three months ended March 31, 2023. The amounts reflect the Company's estimate of lifetime expected losses related to outstanding trade receivables.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;"><i>Asset Impairment</i></span></p>
                <p style="text-align: justify;">Asset impairment totaled $0.9 million for the three months ended March 31, 2024 compared to $nil for the three months ended March 31, 2023. The amount in 2024 represents impairment of the operating lease right of use assets and property, plant and equipment at Vessel.</p>
                <div>
                    <p style="text-align: center;">284</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_223_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><span style="text-decoration: underline;"><i>Other Expenses</i></span></p>
                <p style="text-align: justify;">Other expenses totaled $0.7 million for the three months ended March 31, 2024 compared to $0.4 million for the three months ended March 31, 2023. For both periods, these expenses consist mainly of insurance, repairs and maintenance and royalties partially offset by miscellaneous incomes. The increase is due to higher royalty fees.</p>
                <p style="text-align: justify;"><i>Non-operating Expenses</i></p>
                <p style="text-align: justify;">Flora realized $0.8 million in non-operating expenses for the three months ended March 31, 2024 compared to non-operating expense of $0.9 million for the three months ended March 31, 2023. These expenses consist of unrealized losses from changes in fair value, interest (income) expense and foreign exchange loss (gain). The decrease in expense is primarily due to a $0.6 million loss on the value of the contingent consideration related to the JustCBD acquisition during the three months ended March 31, 2024 compared to a $0.8 million loss during the three months ended March 31, 2023.</p>
                <p style="text-align: justify;"><i>Income Tax Benefit</i></p>
                <p style="text-align: justify;">We recognized $0.1 million expense and $0.1 million in income tax benefit for the three months ended March 31, 2024 and 2023, respectively. Our effective tax rate during the periods ended March 31, 2024 and 2023 was<span style="background-color: #ffffff;"> -3.9% and 2.4%, respectively</span>. We maintain valuation allowances when it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. In determining whether a valuation allowance is required, we consider such factors as prior earnings history, expected future earnings, carry-back and carry-forward periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset. We continue to believe our deferred tax assets are not more-likely-than-not to be realized and a full valuation allowance remains recorded against net deferred taxes as of March 31, 2024 and 2023. The income tax benefit in the three months ended March 31, 2023 is primarily related to the tax effect of the amortization on the intangible assets at FGH.</p>
                <p style="text-align: justify;"><i>Loss from Discontinued Operations</i></p>
                <p style="text-align: justify;">Loss from discontinued operations totaled $nil in the three months ended March 31, 2024 compared to loss from discontinued operations of $0.7 million in the three months ended March 31, 2023. The sale of the Colombian entities was completed during the third and fourth quarters of 2023.</p>
                <p style="text-align: justify;"><i>Net Loss </i></p>
                <p style="text-align: justify;">Flora recorded a net loss of $3.4 million for the three months ended March 31, 2024 compared to a net loss of $3.9 million for the three months ended March 31, 2023. This decrease in net loss is driven by lower operating expenses of $1.4 million and the $0.7 million loss from the disposed Colombia operations in 2023 partially offset by lower gross profit of $1.5 million.</p>
                <p style="text-align: justify;"><span style="text-decoration: underline;">EBITDA and Adjusted EBITDA </span></p>
                <p style="text-align: justify;">EBITDA and Adjusted EBITDA are non-U.S. GAAP financial measures that do not have any standardized meaning prescribed by U.S. GAAP and may not be comparable to similar measures presented by other companies. We calculate EBITDA as total net income (loss) from continuing operations, plus (minus) income taxes (recovery), plus (minus) interest expense (income), plus depreciation and amortization. We calculate Adjusted EBITDA as EBITDA plus (minus) non-operating expense (income), plus share based compensation expense, plus asset impairment charges, plus (minus) unrealized loss (gain) from changes in fair value, plus charges related to the flow-through of inventory step-up on business combinations, plus other acquisition and transaction costs. Management believes that EBITDA and Adjusted EBITDA provide meaningful and useful financial information as these measures demonstrate the operating performance of the business.</p>
                <p style="text-align: justify;">The reconciliation of the Company's Adjusted EBITDA, a non-U.S. GAAP financial measure, to net income (loss) from continuing operations, the most directly comparable U.S. GAAP financial measure, for the three months ended March 31, 2024 is presented in the table below:</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-top: 0.75pt solid #000000; white-space: nowrap;">(In thousands of United States dollars)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>JustCBD</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Vessel</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Phatebo</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Corporate &amp;<br/>Other</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Consolidated</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><b>Net income (loss) from continuing operations</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>110</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(1,077</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(6</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(2,401</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(3,374</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Income tax expense</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">64</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">64</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">128</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Interest expense (income)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">36</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">(14</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">22</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">Depreciation and amortization</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">48</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">17</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">6</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">3</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">74</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><b>EBITDA</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>158</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(1,060</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>100</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(2,348</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(3,150</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">285</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_224_integixAnchor"></span>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;">Non-operating loss (1)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">1</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">131</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">132</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Share based compensation</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">10</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">10</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Asset impairment</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">864</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">34</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">898</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">Unrealized loss from changes in fair value (2)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">607</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">607</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify;"><b>Adjusted EBITDA</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>159</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>(196</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>100</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>(1,566</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>(1,503</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><b>)</b></td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;">The reconciliation of the Company's Adjusted EBITDA, a non-U.S. GAAP financial measure, to net income (loss) from continuing operations, the most directly comparable U.S. GAAP financial measure, for the three months ended March 31, 2023 is presented in the table below:</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;">(In thousands of United States dollars)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>JustCBD</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Vessel</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Phatebo</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Corporate &amp;<br/>Other</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Consolidated</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><b>Net income (loss) from continuing operations</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>246</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(557</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>54</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(2,929</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(3,186</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Income tax expense (recovery)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">25</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">(103</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">(78</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Interest expense (income)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">3</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">21</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">(1</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">23</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">Depreciation and amortization</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">196</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">352</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">7</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">309</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;">864</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><b>EBITDA</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>445</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(205</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>107</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(2,724</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><b>(2,377</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><b>)</b></td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;">Non-operating (gain) (1)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">(2</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">(10</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%;">(12</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Share based compensation</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">654</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;">654</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Unrealized loss from changes in fair value (2)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">883</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 10%;">883</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">Charges related to the flow-through of inventory step-up on business combinations</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">45</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;">45</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify;"><b>Adjusted EBITDA</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>443</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>(205</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>152</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>(1,197</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><b>)</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><b>$</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><b>(807</b></td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><b>)</b></td>
                    </tr>
                </table>
                <div style="margin-left: 18pt; background-color: #ffffff;">
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-bottom: 0pt;">(1)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Non-operating loss (gain) includes foreign exchange losses.</p>
                </div>
                <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 0pt;">(2)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Unrealized loss from changes in fair value includes changes in the value of the Company's contingent consideration associated with its acquisition of JustCBD.</p>
                <p style="text-align: justify;"><b>Liquidity and Capital Resources</b></p>
                <p style="text-align: justify;">Since the Company's inception, we have funded our operations and capital spending through cash flows from product sales and proceeds from the sale of our capital stock. The Company is generating cash from sales and is deploying its capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term to support our business growth and expansion. We have generated significant operating losses and negative cash flows from operations as reflected in our accumulated deficit and unaudited condensed interim consolidated statements of cash flows. We expect to continue to incur operating losses and negative cash flows in the foreseeable future. Our current principal sources of liquidity are cash and cash equivalents provided by our operations and prior equity offerings. Cash consists primarily of cash on deposit with banks. Cash was $4.2 million and $4.4 million as of March 31, 2024, and December 31, 2023, respectively. <span style="background-color: #ffffff;">As of March 31, 2024, the Company's current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, raise substantial doubt as to whether existing cash and cash equivalents will be sufficient to meet its obligations as they come due within twelve months from the date the unaudited condensed interim consolidated financial statements were issued. The unaudited condensed interim consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. </span></p>
                <p style="text-align: justify;">The Company's ability to execute its operating plans depends on its ability to obtain additional funding through equity offerings, debt financing, or other forms of financing to meet planned growth requirements and to fund future operations, which may not be available on acceptable terms, or at all. If we are unable to raise the requisite funds, we will need to curtail or cease operations. See Note 2 to the Company's unaudited condensed interim consolidated financial statements included elsewhere in this Quarterly Report and to the Company's audited consolidated financial statements for the years ended December 31, 2023, and 2022, included in the 2023 Annual Report, for more information, and "Part I., Item IA Risk Factors - Management has performed an analysis of our ability to continue as a going concern, and has determined that, based on our current financial position, there is a substantial doubt about our ability to continue as a going concern" in the Company's 2023 Annual Report. We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. In the long term, we will be required to obtain additional financing to fund our current planned operations, which may consist of incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds. There can be no assurance that the Company will be able to obtain additional funds on terms acceptable to it, on a timely basis or at all. The failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the results of operations, and financial condition. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing shareholders will be diluted. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</p>
                <div>
                    <p style="text-align: center;">286</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_225_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">The Company's primary uses of cash are for working capital requirements and capital expenditures. Additionally, from time to time, it may use capital for acquisitions and other investing and financing activities. Working capital is used principally for the Company's personnel as well as costs related to the manufacture and production of its products. The Company's capital expenditures consist primarily of additional facilities, improvements in existing facilities and product development.</p>
                <p style="text-align: justify;"><b>Cash Flows</b></p>
                <p style="text-align: justify; background-color: #ffffff;">The following table sets forth the major components of the Company's unaudited condensed interim consolidated statements of cash flows for the periods presented.</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;">(In thousands of United States dollars)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>For the three<br/>months ended<br/>March 31,<br/>2024</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>For the three<br/>months ended<br/>March 31,<br/>2023</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Cash used in operating activities</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">(1,340</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">(4,324</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Cash from (used in) financing activities</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">1,188</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">(19</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Cash used in investing activities</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">(88</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">(102</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">Effect of exchange rate change</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;">46</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;">167</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">Change in cash during the period</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">(194</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">(4,278</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Cash, beginning of period</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">4,385</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 22%;">9,537</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">Cash included in assets held for sale</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;">(203</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;">Cash, end of period</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">$</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 22%; text-align: right;">4,191</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 22%;">5,056</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i>Cash used in Operating Activities</i></p>
                <p style="text-align: justify; background-color: #ffffff;">Net cash used in operating activities in the three months ended March 31, 2024 was $1.3 million compared to net cash used in operating activities of $4.3 million for the three months ended March 31, 2023. Cash flows used in operating activities for the periods ended March 31, 2024 and 2023 were due primarily to operating expenses exceeding the gross profit for the periods.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i>Cash provided by (used in) Financing Activities</i></p>
                <p style="text-align: justify; background-color: #ffffff;">Net cash provided by financing activities for the three months ended March 31, 2024 totaled $1.2 million compared to net cash used in financing activities of less than $0.1 million for the three months ended March 31, 2023. Cash flows provided from financing activities for the period ending March 31, 2024 were due to net borrowings on the credit facilities in Germany through the Company's Phatebo subsidiary. Cash flows used in financing activities for the period ended March 31, 2023 were related to loan repayments through the Company's JustCBD subsidiary.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i>Cash used in Investing Activities</i></p>
                <p style="text-align: justify; background-color: #ffffff;">Net cash used in investing activities for the three months ended March 31, 2024 and 2023 totaled $0.1 million for both periods. Cash flows used in investing activities for the period ended March 31, 2024 were primarily related to the purchases of property, plant and equipment. Cash flows used in investing activities for the period ended March 31, 2023 were primarily related to the purchases of property, plant and equipment, and intangible assets.</p>
                <p style="text-align: justify;"><i>Working Capital</i></p>
                <p style="text-align: justify;">As of March 31, 2024, we had working capital of $2.4 million, including $4.2 million of cash. The Company's primary cash flow needs are for the development of its operating activities, administrative expenses and for general working capital to support growing sales with related receivables and payables.</p>
                <div>
                    <p style="text-align: center;">287</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_226_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><b>Funding Requirements</b></p>
                <p style="text-align: justify;">Our continued existence is dependent on our ability to generate positive cash flows through synergies within our operations, expanding our production capacity and geographic footprint, exploring strategic partnerships, and pursuing accretive acquisitions to supplement our organic growth. We are committed to attaining a level of sustained growth that will effectively offset our overhead costs, thereby paving the path to achieving profitability. We will be required in the future to raise additional capital through either equity or debt financings. To date, we have raised capital through multiple equity offerings. There were no equity offerings in the periods ended March 31, 2024 and March 31, 2023. On April 8, 2024, the Company closed a registered direct offering of 1,700,000 common shares of the Company at a price of $1.90 per common share for gross proceeds of $2.8 million. On April 26, 2024, the Company entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. (the "Agent") pursuant to which the Company may sell from time to time, at its option, common shares through the Agent in its capacity as sales agent, common shares with an aggregate value of up to $3.8 million.</p>
                <p style="text-align: justify;"><i><b>Debt</b></i></p>
                <p style="text-align: justify;">In addition to the equity offerings described above, the Company also has access to credit facilities through its FGH subsidiary. The credit facilities total 4.3 million Euros with three different German banks and are secured by either joint and several guarantees or default guarantees. On March 31, 2024, the outstanding amount was 2.9 million Euros ($3.1 million USD) and was due within the next twelve months. The credit facilities have interest rates ranging from 5.45% to 6.44% per year and does not have a set maturity date. The interest rate is reset every time a new amount is drawn.</p>
                <p style="text-align: justify;"><b>Off-Balance Sheet Arrangements</b></p>
                <p style="text-align: justify;">As of March 31, 2024, the Company did not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations or financial condition, including, and without limitation, such considerations as liquidity and capital resources.</p>
                <p style="text-align: justify;"><b>Contractual Obligations</b></p>
                <p style="text-align: justify;">At March 31, 2024, the Company had the following contractual obligations to make future payments, representing contracts and other commitments that are known and committed:</p>
                <table style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;">(In thousands of United States dollars)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Total</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Less than 1<br/>Year</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>1 - 3 Years</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>More than<br/>Years</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Legal disputes (1)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">4,063</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">4,063</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Sales tax (1)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">2,528</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">2,528</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Contingent purchase consideration (2)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">1,702</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">1,702</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Operating lease obligations (3)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">3,093</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">794</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">1,444</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">855</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">Debt (4)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">3,078</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">3,078</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">Total</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">14,464</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">12,165</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">1,444</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">855</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                </table>
                <p style="margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify; margin-top: 10pt;">(1)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>See Note 14 of the Company's unaudited condensed interim consolidated financial statements, included elsewhere in this Quarterly Report.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(2)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>Contingent purchase consideration related to the February 2022 acquisition of JustCBD and the March 2023 acquisition of Original Hemp.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; margin-bottom: 0pt; text-indent: -18pt; text-align: justify;">(3)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>See Note 10 of the Company's unaudited condensed interim consolidated financial statements, included elsewhere in this Quarterly Report.</p>
                <p style="margin-top: 0pt; margin-left: 36pt; text-indent: -18pt; text-align: justify;">(4)<span style="width: 6.34pt; text-indent: 0pt; display: inline-block;">&#160;</span>See Note 9 of the Company's unaudited condensed interim consolidated financial statements, included elsewhere in this Quarterly Report.</p>
                <p style="text-align: justify;"><b>Critical Accounting Estimates</b></p>
                <p style="text-align: justify;">For information regarding our critical accounting policies and estimates, see "Critical Accounting Estimates" included in Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2023 Annual Report.</p>
                <p style="text-align: justify;"><b>Recently Adopted Accounting Principles</b></p>
                <p style="text-align: justify;">There were no new accounting standards issued during the three months ended March 31, 2024 that impacted the Company. See Note 3, Significant Accounting Policies, of the notes to the consolidated financial statements for the year ended December 31, 2023 for a discussion of recently issued accounting standards.</p>
                <div>
                    <p style="text-align: center;">288</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_227_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: center; margin-top: 10pt;"><span style="text-decoration: underline;"><b>ANNEX C</b></span></p>
                <p style="text-align: justify;"><b>Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations for the Year Ended December 31, 2023</b></p>
                <p style="text-align: justify;"><i>The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A") of the Company should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2023, and the accompanying notes thereto (the "Financial Statements") included in this Annual Report, which have been prepared in accordance with U.S. GAAP. Amounts are expressed in USD unless otherwise stated to be in Canadian dollars ("CAD"), Euro ("&#8364;" or "EUR"), or Colombia pesos ("COP"). Amounts stated in foreign currencies include approximate USD amounts based on exchange rates on December 31, 2023. Variance, ratio, and percentage changes in this MD&amp;A are based on unrounded numbers. This MD&amp;A reports the Company's activities through December 31, 2023, unless otherwise indicated.</i></p>
                <p style="text-align: justify;"><i>Forward-looking statements are based on the Company's current expectations and assumptions regarding its business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements as a result of various factors, including, without limitation, changes in local, regional, national or global political, economic, business, competitive, market (supply and demand) and regulatory conditions. Please see "Cautionary Statement Regarding Forward-Looking Statements" in this Annual Report for more information regarding forward-looking statements. </i></p>
                <p style="text-align: justify;"><b>Overview of our Business </b></p>
                <p style="text-align: justify;">We are a multi-national cannabis company that manufactures and distributes consumer packaged goods and distributes medicinal cannabis and pharmaceutical products. Flora exists to create a world where the benefits of cannabis are accessible to everyone. Our business strategy is built on two core pillars: House of Brands and Commercial &amp; Wholesale. This strategy was devised to allow us optimal access to markets around the globe based on the legal standing of cannabis in each of the geographical locations in which we operate. Our approach has enabled us to develop distribution networks, build customer bases, establish operations as the regulatory framework evolves and allow for expanded access to cannabis and its derivatives.</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">Our brand portfolio consists of a mix of products across multiple categories, including food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness. Consumer brands allow Flora to move assertively into nascent markets, develop customer bases and distribution channels, and gather consumer insights which would not be possible with traditional cannabis sales alone. Through this channel we seek to build loyalty, credibility and enjoy healthy margins that help to support the rapid growth of our business.</span></p>
                <p style="text-align: justify;"><i>House of Brands</i></p>
                <p style="text-align: justify; background-color: #ffffff;">JustCBD is Flora's leading consumer packaged goods brand. JustCBD was launched in 2017 with a mission to bring high-quality, trustworthy, and budget-friendly CBD products to market. The JustCBD offering currently consists of over 350 products across 15 categories, including CBD gummies, topicals, tinctures, and vape products and ships to over 11,500 independent retailers worldwide. JustCBD also sells direct to consumers with a customer base of approximately 350,000 people. JustCBD products are available for purchase in smoke and vape shops, clinics, spas and pet stores, as well as other independent non-traditional retail channels. JustCBD's products are both internally and third-party lab-tested to ensure quality.</p>
                <p style="text-align: justify; background-color: #ffffff;">Vessel is Flora's cannabis accessory and technology brand currently servicing the United States and Canada through direct-to-consumer and retail sales. Vessel's products include cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herb categories, which are sold to consumers, dispensaries, smoke shops and cannabis brands. Vessel has been fully integrated into JustCBD and now benefits from operational, logistical and sales synergies with JustCBD.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i>Commercial &amp; Wholesale</i></p>
                <p style="text-align: justify; background-color: #ffffff;"><span style="background-color: #ffffff;">The Company's Commercial and Wholesale pillar encompasses the distribution of pharmaceutical products to international markets. This pillar is anchored by Flora's wholly owned subsidiary, Phatebo, a multi-national operator in pharmaceutical and medical cannabis distribution, with principal operations in Germany. </span>Phatebo is a wholesale pharmaceutical distribution company with import and export capabilities of a wide range of pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, ADHD, multiple sclerosis and anti-depressants, among others. Phatebo holds a license for the Trade in Narcotic Drugs (including the cannabis sales license amendment) and a wholesale trading license, both of which are issued by BfArM (the largest drug approval authority in Europe). Phatebo is focused on distributing pharmaceutical products within 28 countries globally, primarily in Europe, but also with sales to Asia, Latin America, and North America. In November 2018, Phatebo also received a medical cannabis import and distribution license. We intend to leverage Phatebo's existing network of approximately 1,200 pharmacies as Flora begins to move medicinal cannabis from third parties into Germany. Additionally, the Phatebo warehouse provides a logistics outpost for Flora's growing product portfolio and distribution network within the European Union.</p>
                <div>
                    <p style="text-align: center;">289</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_228_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i>Colombian Related Subsidiaries</i></p>
                <p style="text-align: justify;">On July 5, 2023, the Company entered into a share purchase agreement with Lisan, a Delaware limited liability company, to sell all its shares in certain of its Colombian subsidiaries and its Colombian assets for a purchase price of CAD $0.8 million (USD $0.6 million). The sale relates to Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab 2, Flora Lab 4 and Flora's Colombian food and beverage and consumer products business (collectively "Colombia Assets").&#160; The sale enables the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations. The Company received proceeds of CAD $0.5 million during the quarter ended September 30, 2023. The Company and Lisan completed the sale of Cosechemos Ya S.A.S on November 1, 2023.</p>
                <p style="text-align: justify;"><b>Factors Impacting our Business </b></p>
                <p style="text-align: justify;"><i>Challenges in realization of overhead reductions.</i> Management has taken, and continues to implement, various cost-saving initiatives to lower overhead costs. However, the Company has not yet reached the critical balance in reducing overhead to meet both the existing and potential market demand in aggregate. The Company strives to attain sufficient growth to cover its overhead to reach profitability. If the Company fails to grow its business or reduce its operating expenses further in the long term, it will continue to face significant cash flow deficiencies in the future and continue to be reliant on debt and/or equity financing to fund operations.</p>
                <p style="text-align: justify;"><i>Consistent profitability and positive operating cash flows.</i> A key determinant of the Company's success is to deliver profitable results and positive cashflows from operating activities. The Company's results have not yet achieved the prerequisite consistency to achieve self-sufficiency. Since its inception, only the third quarter of 2023 yielded net income and positive cashflows from operating activities. There is no assurance that the Company would be able to produce adequate levels of sustained profitability and cash flow positive, or at all. These factors, amongst others, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are described in Note 2 of the Company's audited consolidated financial statements for the year ended December 31, 2023. For more information, see Item 1A "Risk Factors."</p>
                <p style="text-align: justify;"><i>Acquisition strategy disadvantages include significant transaction costs and liabilities of our acquirees.</i> The Company has historically been opportunistic and pursues acquisitions from time to time that management believes will be complementary to or synergistic to the Company's existing business. However, any such acquisitions require the Company to incur heightened upfront transaction costs and require the Company to assume certain liabilities from the acquired companies. In addition, while the Company believes such acquisitions will provide enhanced value in the long term, it is possible that the anticipated synergies from the acquisition may never be realized. For example, the Company acquired JustCBD in February 2022 and FGH in December 2022. In connection with the acquisition of JustCBD, the Company incurred $0.6 million in transaction costs in the first quarter of 2022, which included legal and consulting fees incurred by the Company. In addition, we assumed $4.0 million in liabilities, which included $0.6 million of lease liabilities and other ordinary course operating liabilities. In connection with the acquisition of FGH, the Company incurred $0.5 million in transaction costs in the fourth quarter of 2022, which included legal and consulting fees incurred by the Company. In addition, we assumed $9.1 million in liabilities, which included $1.3 million of outstanding legal fees of FGH prior to the acquisition, $1.1 million of debt, $3.4 million of indemnified liabilities and other ordinary course operating liabilities.</p>
                <p style="text-align: justify;"><i>Diversification of cashflows.<b> </b></i>Our sources of cash are diversified across geographic and product lines. Revenues are concentrated primarily in Germany and the United States, spanning pharmaceuticals, hemp and non-hemp consumer products and medicinal cannabis.</p>
                <div>
                    <p style="text-align: center;">290</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_229_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>International cannabis developments.<b> </b></i>Flora's growth is embedded in the expansion, regulation and legalization of medicinal and recreational cannabis and cannabis derivative products across the world. While medicinal cannabis has been regulated at the federal level in multiple countries, the Company is focused on the most robust markets in Germany and the European Union. We remain tuned to international developments as potentially lucrative medicinal cannabis markets open.</p>
                <p style="text-align: justify;"><i>Product evolution and brand acceptance.<b> </b></i>As the cannabis industry continues to change, divergent regulations and the corresponding resources required to introduce high-quality products are expected to impact our market share. Gaining access to continuously evolving and superior products remains a critical success factor. Our ultimate ability to produce and acquire products meeting stringent quality control standards drives the extent of consumer acceptance. Furthermore, the intrinsic value within our brands, including JustCBD and Vessel, is subject to evolving consumer sentiment.</p>
                <p style="text-align: justify;"><i>Regulatory proficiency and adoption.<b> </b></i>The markets in which Flora operates are highly regulated and require extensive experience in navigating the associated complexities. We have assembled a team with deep knowledge of the regulatory and governance environments in which the Company operates. Fundamental expertise entails compliance with product approvals, import permits, export permits, distribution licenses and other pertinent licenses.</p>
                <p style="text-align: justify;"><i>Integration of acquired companies.<b> </b></i>Our growth has been fueled substantially by the acquisition of JustCBD, Vessel and FGH. Our continued ability to extract incremental synergies from a group of diversified entities is a key determinant of our ability to expand organically.</p>
                <p style="text-align: justify;"><b>Public Company Costs</b></p>
                <p style="text-align: justify;">Following the consummation of our initial public offering, we became a public company, which has required the hiring of additional staff and implementation of processes and procedures to address public company regulatory requirements and customary practices. We expect to continue to incur substantial additional annual expenses for, among other things, directors' and officers' liability insurance and additional internal and external costs for investor relations, accounting, audit, legal, and other functions.</p>
                <p style="text-align: justify; background-color: #ffffff;"><b>Audit Committee Requirement</b></p>
                <p style="text-align: justify;">On December 6, 2023, the Company received a notification from Nasdaq, confirming that, due to having less than three independent audit committee members, the Company no longer complies with Nasdaq's audit committee requirements contained in Nasdaq Listing Rule 5605(c)(2)(A). As set forth in such notification, Nasdaq advised the Company that, under Nasdaq Rule 5605(c)(4), the Company was afforded a cure period in order to regain compliance (i) until the earlier of the Company's next annual shareholders' meeting or November 30, 2024, or (ii) if the next annual shareholders' meeting is held before May 28, 2024, then the Company must evidence compliance no later than May 28, 2024.</p>
                <p style="text-align: justify;"><b>Key Components of Results of Operations </b></p>
                <p style="text-align: justify;"><i>Revenue<b> </b></i></p>
                <p style="text-align: justify;">The Company primarily generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products. The Company has two major revenue groups, which are also two of its three reportable segments:</p>
                <p style="margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">(1)<span style="display: inline-block; width: 16.5pt;">&#160;</span>House of Brands; and</p>
                <p style="text-indent: -24pt; margin-left: 48pt; margin-top: 0pt;">(2)<span style="display: inline-block; width: 16.5pt;">&#160;</span>commercial and wholesale.</p>
                <p style="text-align: justify;">The third reportable segment is pharmaceuticals.</p>
                <p style="text-align: justify;">These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.</p>
                <p style="text-align: justify;">The Company's operates its manufacturing and distribution business through its subsidiaries in the United States and Germany. Until the sale of the Colombia Assets, the Company also was engaged in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products in Colombia.</p>
                <div>
                    <p style="text-align: center;">291</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_230_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">The Company uses the following five-step contract-based analysis of transactions to determine if, when and how much revenue can be recognized:</p>
                <p style="text-indent: -24pt; margin-left: 24pt; margin-bottom: 0pt;">1.<span style="display: inline-block; width: 12pt;">&#160;</span>Identify the contract with a customer;</p>
                <p style="text-indent: -24pt; margin-left: 24pt; margin-bottom: 0pt; margin-top: 0pt;">2.<span style="display: inline-block; width: 12pt;">&#160;</span>Identify the performance obligations in the contract;</p>
                <p style="text-indent: -24pt; margin-left: 24pt; margin-bottom: 0pt; margin-top: 0pt;">3.<span style="display: inline-block; width: 12pt;">&#160;</span>Determine the transaction price;</p>
                <p style="text-indent: -24pt; margin-left: 24pt; margin-bottom: 0pt; margin-top: 0pt;">4.<span style="display: inline-block; width: 12pt;">&#160;</span>Allocate the transaction price to the performance obligations in the contract; and</p>
                <p style="text-indent: -24pt; margin-left: 24pt; margin-top: 0pt;">5.<span style="display: inline-block; width: 12pt;">&#160;</span>Recognize revenue when or as the Company satisfies the performance obligations.</p>
                <p style="text-align: justify;">Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Gross revenue excludes duties and taxes collected on behalf of third parties. Revenue is presented net of expected price discounts, sales returns, customer rebates and other incentives. The Company's cannabis consumption accessory products include a six-month warranty, which the Company accrues for the estimated liability based on historical and expected claim costs.</p>
                <p style="text-align: justify;">The Company's contracts with customers for the sales of products consist of one performance obligation. Revenue from product sales is recognized at the point in time when control is transferred to the customer, which is on shipment or delivery, depending on the contract terms. The Company's payment terms generally range from 0 to 30 days from the transfer of control, and sometimes up to six months.</p>
                <p style="text-align: justify;"><i>Cost of sales</i>&#160;</p>
                <p style="text-align: justify;">The Company includes the cost of raw materials and supplies, purchased finished goods and changes in inventory reserves in cost of sales for each of its three reportable segments. Raw materials include the purchase cost of the materials, freight-in and duty. Finished goods include the cost of direct materials and labor and a proportion of manufacturing overhead allocated based on normal production capacity. Inventory reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The primary factors that can impact cost of goods sold on a period-to-period basis include the volume of products sold, the mix of products sold, third-party quality costs, transportation, overhead allocations and changes in inventory provisions.</p>
                <p style="text-align: justify;"><i>Operating Expenses</i></p>
                <p style="text-align: justify;">The Company's operating expenses are apportioned based on the following categories:</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="width: 2.5%; vertical-align: top; text-align: justify;">&#160;</td>
                        <td style="width: 2.5%; vertical-align: top; text-align: justify;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Consulting and management fees</i> include salary and benefit expenses for employees, directors and consultants for the Company's corporate activities, other than those included in one of general and administrative, share-based compensation, and research and development.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Professional fees</i> include legal, audit and other expenses incurred by third-party service providers.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>General and administrative</i> include certain public company costs, merchant fees and temporary labor and subcontractor costs for the Company's operating subsidiaries.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Promotion and communication expenses</i> consist primarily of services engaged in marketing and promotion of our products and costs associated with initiatives and development programs and salary and benefit expenses for certain employees.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Travel expenses</i> relate to flight, lodging and incidental expenses for attending conferences, events and key business meetings.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Share-based compensation</i> includes the cost of vesting of the Company's equity awards, including share options and restricted share awards.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Research and development</i> <i>expenses</i> primarily consist of salary and benefit expenses for employees engaged in research and development activities, as well as other general costs associated with R&amp;D activities.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Operating lease expense</i> represents the cost of the Company's operating leases, primarily consisting of real estate and equipment.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Depreciation and amortization expense</i> is provided on a straight-line basis over the corresponding assets' estimated useful lives.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify; width: 2.5%;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Bad debt expense</i> consists of changes in the provision for the Company's expected credit losses. The Company utilizes a provision matrix to estimate lifetime expected credit losses.</td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">292</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_231_integixAnchor"></span>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="vertical-align: top; width: 2.5%; text-align: justify;">&#160;</td>
                        <td style="vertical-align: top; width: 2.5%; text-align: justify;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Asset impairment</i> includes the difference between the fair value and carrying amount of the asset group. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of an asset group.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; width: 2.5%; text-align: justify;">&#160;</td>
                        <td style="vertical-align: top; width: 2.5%; text-align: justify;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;"><i>Other expenses (income), net</i> include miscellaneous expenses that do not fit the criteria for recognition in another category.</td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;"><i>Non-Operating Expenses<b> </b></i></p>
                <p style="text-align: justify;">Non-operating expenses include interest income and expenses, foreign exchange losses and unrealized losses from changes in fair value. Interest is primarily related to the Company's lease liabilities and operating lines of credit. Foreign exchange is largely related to the revaluation of balances denominated in foreign currencies to U.S. dollars. Unrealized losses from changes in fair value pertain to fluctuations in the fair values of the Company's investments and liabilities.</p>
                <p style="text-align: justify;"><i>Income Tax<b> </b></i></p>
                <p style="text-align: justify;">Income tax<b> </b>consists primarily of income taxes related to U.S. federal and state income taxes and income taxes in foreign jurisdictions in which we conduct business.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i>Loss from Discontinued Operations</i></p>
                <p style="text-align: justify; background-color: #ffffff;">Loss from discontinued operations includes the net income (loss), net of tax, of the Colombian subsidiaries sold on July 5, 2023 and on November 1, 2023. It also includes an expected loss on the disposal as the carrying value of the assets being sold exceeded the expected sale price.</p>
                <p style="text-align: justify;"><b>Results of Operations</b></p>
                <p style="text-align: justify;">The following table sets forth the Company's consolidated results of operations for the fiscal years ended December 31, 2023 and 2022 (in thousands). The period-to-period comparisons of the Company's historical results are not necessarily indicative of the results that may be expected in the future. The results of operations data have been derived from our audited consolidated financial statements included elsewhere in this Annual Report.&#160;</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1"><b>For the<br/>year ended<br/>December<br/>31, 2023</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;" colspan="1"><b>For the<br/>year ended<br/>December<br/>31, 2022</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center; white-space: nowrap;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Revenue</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">76,071</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">33,401</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;">&#160;</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Gross profit</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">17,738</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">13,251</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Consulting and management fees</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">11,876</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">9,232</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Professional fees</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">2,301</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">3,884</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">General and administrative</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">1,646</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">3,287</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Promotion and communication</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">4,710</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">8,033</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Travel expenses</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">413</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">930</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Share based compensation</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">1,591</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">3,404</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Research and development</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">62</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">388</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Operating lease expense</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">1,211</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">937</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Depreciation and amortization</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">2,335</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">2,144</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Bad debt expense</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">236</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">941</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Other expenses, net</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">2,204</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">1,511</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Goodwill and other asset impairments</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">39,507</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">25,781</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Operating loss</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">(50,354</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">(47,221</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Non-operating expenses</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">(2,057</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">887</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Net loss before taxes and discontinued operations</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">(48,297</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">(48,108</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Income tax benefit</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">(1,628</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">(1,405</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Net loss from continuing operations</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">(46,669</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid transparent; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">(46,703</td>
                        <td style="vertical-align: bottom; border-top: 0.75pt solid transparent; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Loss from discontinued operations</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">(9,678</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">(5,926</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Net loss for the period</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">(56,347</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double transparent; text-align: left; width: 2%;">)</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">(52,629</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double transparent; text-align: left; width: 2%;">)</td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">293</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_232_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Stop Sale Order by Florida Department of Agriculture and Consumer Services Division of Food Safety</i></p>
                <p style="text-align: justify;">On October 31, 2023, the Department issued 340 stop sale orders on hemp extract products distributed by Just Brands primarily on the basis that such products were determined to be attractive to children with the product and/or labels in the shape of an animal, human, or cartoon; or bears any reasonable resemblance to an existing candy product, or branded food product. As a result, Just Brands has stopped distributing these products in the State of Florida. There is no assurance that these products can be sold in another jurisdiction, or at all. The Company estimates that the disruption from this stop sale order had an unfavorable impact of $0.5 million on revenue and $0.2 million on consulting and management fees during the year ended December 31, 2023.</p>
                <p style="text-align: justify;">In late January 2024, and in early February 2024, the Department issued a stop sale order on 231 hemp extract and other products distributed by Just Brands primarily on the basis that such products were determined to be attractive to children with the product and/or labels in the shape of an animal, human, or cartoon; or bears any reasonable resemblance to an existing candy product, or branded food product. As a result, Just Brands has stopped distributing these products in the State of Florida. There is no assurance that these products can be sold in another jurisdiction, or at all. The Company estimates that the disruption from this stop sale order is expected to have an unfavorable impact of $0.3 million on revenue during the quarter ended March 31, 2024.</p>
                <p style="text-align: justify;">The total value of inventory impacted by the stop sale orders was $1.6 million at December 31, 2023.</p>
                <p style="text-align: justify;"><i>Revenue</i></p>
                <p style="text-align: justify;">Revenue totaled $76.1 million and $33.4 million for the years ended December 31, 2023 and 2022, respectively. The increase was primarily driven by the following:</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="vertical-align: top; text-align: justify;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;">FGH contributed $38.3 million for the year ended December 31, 2023 compared to $0.1 million for the year ended December 31, 2022.</td>
                    </tr>
                    <tr>
                        <td style="width: 3.84%; vertical-align: top; text-align: justify;">&#160;</td>
                        <td style="width: 3.86%; vertical-align: top; text-align: justify;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;">JustCBD contributed $31.1 million for the year ended December 31, 2023 compared to $26.4 million for the year ended December 31, 2022.</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: top; text-align: justify;">&#160;</td>
                        <td style="vertical-align: top; text-align: justify;">&#8226;</td>
                        <td style="vertical-align: top; text-align: justify;">Vessel contributed $6.7 million for the year ended December 31, 2023, compared to $7.0 million for the year ended December 31, 2022.</td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;">Revenues generated for the year ended December 31, 2023 by the Company`s Colombian entities are included separately within<i> Loss from Discontinued Operations</i>.</p>
                <p style="text-align: justify;">Revenues generated for the year ended December 31, 2023 by the House of Brands segment were $37.8 million compared to revenues generated for the year ended December 31, 2022 of $33.3 million. The increase was primarily due to JustCBD being encompassed in our business for the full 2023 fiscal year, which contributed $31.1 million for the year ended December 31, 2023, compared to $26.4 million for the year ended December 31, 2022. The Vessel brand generated revenues of $6.7 million for year ended December 31, 2023, a decrease of $0.3 million from the year ended December 31, 2022, primarily due to supply chain issues that occurred early in fiscal 2023.</p>
                <p style="text-align: justify;">Revenues generated for the year ended December 31, 2023 by the commercial and wholesale segment were $38.3 million compared to revenues generated for the year ended December 31, 2022 of $0.1 million. The revenue was entirely generated by FGH, which was acquired on December 23, 2022.</p>
                <p style="text-align: justify;">Revenues from the pharmaceuticals segment were formerly generated by the Company's Colombian entities. These results are included separately within <i>Loss from Discontinued Operations</i>.</p>
                <p style="text-align: justify;"><i>Gross Profit</i></p>
                <p style="text-align: justify;">Gross profit totaled $17.7 million and $13.3 million for the years ended December 31, 2023 and 2022, respectively. The increase was primarily driven by the acquisitions of FGH and JustCBD, which contributed $2.2 million and $12.7 million, respectively, in the year ended December 31, 2023. In the comparative period in the year ended December 31, 2022, JustCBD contributed $11.2 million and FGH contributed less than $0.1 million as it was not acquired until December 2022. Vessel contributed $3.0 million in the year ended December 31, 2023 compared to $2.0 million in the year ended December 31, 2022. The remaining $0.2 million decrease was due to the discontinuance of the U.S. brands during the second half of 2023. As a percentage of net sales, or gross margin, the Company reported 23% and 40% for the year ended December 31, 2023 and 2022, respectively. The decrease is primarily due to the acquisition of FGH, which distributes relatively lower margin pharmaceuticals.</p>
                <div>
                    <p style="text-align: center;">294</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_233_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Operating Expenses</i></p>
                <p style="text-align: justify;">Operating expenses totaled $68.1 million and $60.5 million for the years ended December 31, 2023 and 2022, respectively. The increase was primarily driven by asset impairments of $39.5 million and the acquisition of FGH, which increased expenses by $3.2 million. This was partially offset by reduced promotion and communication, professional fees, general and administrative and share-based compensation expenses.</p>
                <p style="text-align: justify;"><i>Consulting and Management Fees</i></p>
                <p style="text-align: justify;">Consulting and management fees were $11.9 million for the year ended December 31, 2023 compared to $9.2 million for the year ended December 31, 2022. These fees are related to employment and consulting contracts with most of the Company's management, as well as directors. The $2.6 million increase in 2023 is primarily related to the acquisition of FGH, which contributed $2.5 million, and a severance payment made to the Company's former chief executive officer. These increases were partially offset by significant corporate office headcount reductions, the impact of which was only reflected in the last half of the 2023 fiscal period.</p>
                <p style="text-align: justify;"><i>Professional Fees</i></p>
                <p style="text-align: justify;">Professional fees totaled $2.3 million for the year ended December 31, 2023 compared to $3.9 million for the year ended December 31, 2022. These expenses are associated with legal, accounting and audit services. In the period ended December 31, 2023, the Company reduced professional fees and received credit notes from certain service providers. In the period ended December 31, 2022, professional fees included one-time acquisition and transaction related costs relating to the Company's acquisitions of JustCBD and FGH.</p>
                <p style="text-align: justify;"><i>General and Administrative Expenses</i></p>
                <p style="text-align: justify;">General and administrative expenses totaled $1.6 million for the year ended December 31, 2023 compared to $3.3 million for the year ended December 31, 2022. The $1.6 million decrease in 2023 is primarily due to the Company's efforts to reduce general and administrative expenses.</p>
                <p style="text-align: justify;"><i>Promotion and Communication Expenses</i></p>
                <p style="text-align: justify;">Promotion and communication expenses totaled $4.7 million for the year ended December 31, 2023 compared to $8.0 million for the year ended December 31, 2022. The $3.3 million decrease in 2023 is primarily due to cost-cutting initiatives by the Company aimed at minimizing corporate overhead. Promotion expenses incurred in the period largely relate to the nature of JustCBD's business model, which is centered around promoting its products as a method for stimulating revenue growth.</p>
                <p style="text-align: justify;"><i>Travel Expenses</i></p>
                <p style="text-align: justify;">Travel expenses totaled $0.4 million for the year ended December 31, 2023 compared to $0.9 million for the year ended December 31, 2022. These expenses were for various trips related to the subsidiaries' and the Company's promotional activities. The decrease of $0.5 million in 2023 is due to the Company's efforts to minimize overhead expenses.</p>
                <p style="text-align: justify;"><i>Share-based Compensation Expenses </i></p>
                <p style="text-align: justify;">Share based compensation expenses totaled $1.6 million for the year ended December 31, 2023 compared to $3.4 million for the year ended December 31, 2022. These expenses represent the amortization of the fair value of share-based payments. The $1.8 million decrease in 2023 is primarily due to the cancellation of restricted stock awards, a result of employee terminations during 2023.</p>
                <p style="text-align: justify;"><i>Research and Development Expenses</i></p>
                <p style="text-align: justify;">Research and development expenses totaled $0.1 million for the year ended December 31, 2023 compared to $0.4 million for the year ended December 31, 2022. Research and development expenses have been minimized in the period ended December 31, 2023 whereas in the period ended December 31, 2022 they consisted primarily of contract research fees, manufacturing, consultant fees, and costs related to the launch of new brands for the Vessel business.</p>
                <div>
                    <p style="text-align: center;">295</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_234_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Operating Lease Expenses</i></p>
                <p style="text-align: justify;">Operating lease expenses totaled $1.2 million for the year ended December 31, 2023 compared to $0.9 million for the year ended December 31, 2022. The increase is primarily due to the acquisition of FGH and its accompanying facility and vehicle leases.</p>
                <p style="text-align: justify;"><i>Depreciation and Amortization Expense</i></p>
                <p style="text-align: justify;">Depreciation and amortization expenses totaled $2.3 million for the year ended December 31, 2023 compared to $2.1 million for the year ended December 31, 2022. The $0.2 million increase is primarily due to the acquisition of FGH, and the corresponding amortization of the intangible assets acquired, and partially offset by long lived asset impairments taken over the past year requiring less amortization to be recorded.</p>
                <p style="text-align: justify;"><i>Bad Debt Expense</i></p>
                <p style="text-align: justify;">Bad debt expense totaled $0.2 million for the year ended December 31, 2023 compared to $0.9 million for the year ended December 31, 2022. The amounts reflect the Company's estimate of lifetime expected losses related to outstanding trade receivables. The $0.7 million decrease in 2023 is driven by the Company's exit from the Colombian related businesses.</p>
                <p style="text-align: justify;"><i>Other Expenses</i></p>
                <p style="text-align: justify;">Other expenses totaled $2.2 million for the year ended December 31, 2023 compared to $1.5 million for the year ended December 31, 2022. These expenses consist mainly of insurance, repairs and maintenance and royalties partially offset by miscellaneous incomes. The $0.7 million increase in 2023 is due to an increase of $0.6 million in insurance costs, partially offset by a number of refunds and balance sheet adjustments at FGH in 2023.</p>
                <p style="text-align: justify;"><i>Goodwill and other asset impairments</i></p>
                <p style="text-align: justify;">Goodwill and other asset impairments totaled $39.5 million and $25.8 million in asset impairments for the years ended December 31, 2023 and 2022, respectively. The Company tests its goodwill and indefinite-lived intangibles for impairment as part of its annual fourth quarter impairment test, and at interim periods when impairment indicators exist. At June 30, 2023 and December 31, 2023, Flora determined that the decline in the share price of the Company's publicly traded Common Shares, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital were indicators of impairment. Flora then concluded that the carrying values of its JustCBD and FGH reporting units were higher than their respective estimated fair values, and a cumulative goodwill impairment loss totaling $23.4 million was recognized for the year ended December 31, 2023.</p>
                <p style="text-align: justify;">The factors listed above representing goodwill impairment indicators were also indicators of impairment for certain other of our long-lived assets. The Company performed a quantitative analysis as of June 30, 2023 to determine if impairment existed by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over their remaining lives. This analysis resulted in impairments of property, plant and equipment, operating lease right of use assets and certain intangibles assets totaling $13.4 million for the quarter ended June 30, 2023.</p>
                <p style="text-align: justify;">The Company performed a similar analysis for its asset groups as of December 31, 2023, and determined that indicators of impairment were present. These include external indicators such as a decline in the share price of the Company's publicly traded Common Shares as well as internal indicators such as reduced forecasted revenue and cash flow generation. The Company performed a quantitative analysis as of December 31, 2023 to determine if impairment existed by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over their remaining lives. This analysis resulted in impairments operating lease right of use assets and certain intangibles assets totaling $2.7 million.</p>
                <p style="text-align: justify;">During the fourth quarter of 2022, the Company determined that the decline in the share price of its publicly traded Common Shares, declines in comparable public company share prices, as well as negative operating cash flows were indicators of impairment. Flora then concluded that the carrying values of its Vessel and JustCBD reporting units were higher than their respective estimated fair values, and a goodwill impairment loss totaling $25.1 million was recognized in the year ended December 31, 2022.</p>
                <p style="text-align: justify;">Also during the fourth quarter of 2022, the Company decided to consolidate operations and looked for subtenants for two building leases that have contractual lease obligations through 2026 and 2027. These leases are recorded on the statement of financial position as operating lease right of use assets. The lease assets had indicators of impairment as they were no longer used in the asset groups' operations, but the Company was actively seeking to sublease both spaces to generate income from the spaces. The resulting analysis resulted in an impairment of $0.7 million of operating lease right of use assets for the year ended December 31, 2022.</p>
                <div>
                    <p style="text-align: center;">296</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_235_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: justify; margin-top: 10pt;"><i>Non-operating (Income) Expenses</i></p>
                <p style="text-align: justify;">Flora realized $2.1 million in non-operating income for the year ended December 31, 2023 compared to non-operating expense of $0.9 million for the year ended December 31, 2022. This (income) expense consists of unrealized (gains) losses from changes in fair value, interest (income) expense and foreign exchange loss. The increase in income is primarily due to a $2.0 million gain on the value of the contingent consideration related to the JustCBD, No Cap Hemp and Original Hemp acquisitions during the year ended December 31, 2023, compared to a $0.6 million loss during the year ended December 31, 2022.</p>
                <p style="text-align: justify;"><i>Income Tax Benefit</i></p>
                <p style="text-align: justify;">The Company recognized $1.6 million and $1.4 million in income tax benefit for the years ended December 31, 2023 and 2022, respectively. Our effective tax rate during the year ended December 31, 2023 and 2022 was 3.4% and 2.9%, respectively. The Company maintains valuation allowances when it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. In determining whether a valuation allowance is required, the Company considers such factors as prior earnings history, expected future earnings, carry-back and carry-forward periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset. Flora continues to believe its deferred tax assets are not more-likely-than-not to be realized and a full valuation allowance remains recorded against net deferred taxes as of December 31, 2023 and 2022.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i>Loss from Discontinued Operations</i></p>
                <p style="text-align: justify; background-color: #ffffff;">Loss from discontinued operations totaled $9.7 million in the year ended December 31, 2023 compared to $5.9 million in the year ended December 31, 2022. The increase is primarily due to impairment charges and losses on disposal in relation to the Company`s Colombian operations.</p>
                <p style="text-align: justify;"><i>Net loss </i></p>
                <p style="text-align: justify;">The Company incurred a net loss of $56.3 million and $52.6 million for the years ended December 31, 2023 and 2022, respectively. The increase in loss was driven by higher asset impairments of $13.7 million and an increase of $3.8 million in relation to the loss from discontinued operations for the Company`s Colombian operations, partially offset by increased gross profit of $4.5 million, decreased operating expenses of $6.1 million and increased non-operating income of $2.9 million.</p>
                <p style="text-align: justify; background-color: #ffffff;"><b>EBITDA and Adjusted EBITDA</b></p>
                <p style="text-align: justify; background-color: #ffffff;">EBITDA and Adjusted EBITDA are non-U.S. GAAP financial measures that do not have any standardized meaning prescribed by U.S. GAAP and may not be comparable to similar measures presented by other companies. Flora calculates EBITDA as total net (loss) income from continuing operations, plus (minus) income taxes (recovery), plus (minus) interest expense (income), plus depreciation and amortization. Flora calculates Adjusted EBITDA as EBITDA plus (minus) non-operating expense (income), plus share based compensation expense, plus asset impairment charges, plus (minus) unrealized loss (gain) from changes in fair value, plus charges related to the flow-through of inventory step-up on business combinations, plus other acquisition and transaction costs. Management believes that EBITDA and Adjusted EBITDA provide meaningful and useful financial information as these measures demonstrate the operating performance of the business.</p>
                <p style="text-align: justify; background-color: #ffffff;"><span style="background-color: #ffffff;">The reconciliation of the Company's EBITDA and Adjusted EBITDA, non-U.S. GAAP financial measures, to net (loss) income from continuing operations, the most directly comparable U.S. GAAP financial measure, for the year ended December 31, 2023 is presented in the table below:</span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap;">&#160;(In thousands of United States dollars)</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center; white-space: nowrap;"><b>JustCBD</b></td>
                        <td style="width: 10%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center; white-space: nowrap;"><b>Vessel</b></td>
                        <td style="width: 7%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center; white-space: nowrap;"><b>Phatebo</b></td>
                        <td style="width: 10%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: center; white-space: nowrap;"><b>Corporate &amp;<br/>Other</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Consolidated</b></td>
                    </tr>
                    <tr>
                        <td style="width: 39%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;"><b>Net (loss) income from continuing operations</b></td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; (22,790)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; &#160; (8,372)</b></td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; 274</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (15,781)</b></td>
                        <td style="width: 10%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: right;"><b>$ &#160; &#160; (46,669)</b></td>
                    </tr>
                    <tr>
                        <td style="width: 39%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">Income tax expense (recovery)</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">3</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">101</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(1,732)</td>
                        <td style="width: 10%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: right;">(1,628)</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: justify;">Interest expense (income)</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">9</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">2</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">92</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(11)</td>
                        <td style="width: 10%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: right;">92</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Depreciation and amortization</td>
                        <td style="width: 9%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: right;">742</td>
                        <td style="width: 10%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: right;">736</td>
                        <td style="width: 7%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: right;">28</td>
                        <td style="width: 10%; vertical-align: top; padding-right: 5.03pt; padding-left: 5.03pt; text-align: right;">829</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">2,335</td>
                    </tr>
                </table>
                &#160;
                <div>
                    <p style="text-align: center; margin-top: 10pt;">297</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_236_integixAnchor"></span>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;"><b>EBITDA</b></td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(22,039)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(7,631)</b></td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>495</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(16,695)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(45,870)</b></td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Non-operating loss (income) (1)</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">2</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">14</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(174)</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(158)</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Share based compensation</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">1,591</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">1,591</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Asset impairment</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">22,892</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">7,402</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">9,213</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">39,507</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Unrealized gain from changes in fair value (2)</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(964)</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(1,027)</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(1,991)</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Charges related to the flow-through of inventory step-up on business combinations</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">45</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">45</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;"><b>Adjusted EBITDA</b></td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; &#160; (109)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (215)</b></td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; 495</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; &#160; (7,047)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (6,876)</b></td>
                    </tr>
                </table>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><span style="background-color: #ffffff;">The reconciliation of the Company's EBITDA and Adjusted EBITDA, non-U.S. GAAP financial measures, to net income (loss) from continuing operations, the most directly comparable U.S. GAAP financial measure, for the year ended December 31, 2022 is presented in the table below:</span></p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="1" cellspacing="0" cellpadding="3">
                    <tr>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap;">&#160;(In thousands of United States dollars)</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>JustCBD</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Vessel</b></td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Phatebo</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Corporate &amp;<br/>Other</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: center; white-space: nowrap;"><b>Consolidated</b></td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;"><b>Net loss from continuing operations</b></td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; (7,001)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (21,985)</b></td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; (109)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (17,608)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (46,703)</b></td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Income tax recovery</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(21)</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(1,372)</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(12)</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(1,405)</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Interest expense (income)</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">17</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(35)</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">2</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(13)</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(29)</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Depreciation and amortization</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">643</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">1,434</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">1</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">66</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">2,144</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;"><b>EBITDA</b></td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(6,362)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(21,958)</b></td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(118)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(17,555)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>(45,993)</b></td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Non-operating loss (income) (1)</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">56</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">4</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">(13)</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">276</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">323</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Share based compensation</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">3,404</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">3,404</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Asset impairment</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">5,397</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">20,139</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">245</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">25,781</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Unrealized loss from changes in fair value (2)</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">593</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">593</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top;">Charges related to the flow-through of inventory step-up on business combinations</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">1,631</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">1,631</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;">Other acquisition and transaction costs</td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">614</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">81</td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">-</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">353</td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;">1,048</td>
                    </tr>
                    <tr>
                        <td style="width: 39%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: justify;"><b>Adjusted EBITDA</b></td>
                        <td style="width: 9%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; &#160; 1,336</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (1,734)</b></td>
                        <td style="width: 7%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; (131)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (12,684)</b></td>
                        <td style="width: 10%; padding-right: 5.03pt; padding-left: 5.03pt; vertical-align: top; text-align: right;"><b>$&#160; &#160; &#160; (13,213)</b></td>
                    </tr>
                </table>
                <p style="margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt; margin-top: 10pt;">(1)<span style="display: inline-block; width: 12pt;">&#160;</span>Non-operating expense includes foreign exchange gain (loss).</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">(2)<span style="display: inline-block; width: 12pt;">&#160;</span>Unrealized loss from changes in fair value includes changes in the value of the Company's long-term investment in an early-stage European cannabis company and the value of the Company's contingent consideration associated with its acquisition of JustCBD.</p>
                <p style="text-align: justify; margin-top: 10pt;"><b>Liquidity and Capital Resources</b></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">Since the Company's inception, we have funded our operations and capital spending through cash flows from product sales and proceeds from the sale of our capital stock. The Company is generating cash from sales and is deploying its capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term to support our business growth and expansion. We have generated significant operating losses and negative cash flows from operations as reflected in our accumulated deficit and consolidated statements of cash flows. We expect to continue to incur operating losses and negative cash flows for the foreseeable future. Our current, principal sources of liquidity are cash and cash equivalents provided by our operations and prior equity offerings. Cash and cash equivalents consist primarily of cash on deposit with banks. Cash and cash equivalents were $4.4 million and $8.9 million as of December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company's current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, raise substantial doubt as to whether existing cash and cash equivalents will be sufficient to meet its obligations as they come due within twelve months from the date the consolidated financial statements were issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>
                <p style="text-align: justify;">The Company's ability to execute its operating plans through 2024 and beyond depends on its ability to obtain additional funding through equity offerings, debt financing, or other forms of financing to meet planned growth requirements and to fund future operations, which may not be available on acceptable terms, or at all. If we are unable to raise the requisite funds, we will need to curtail or cease operations. See Note 2 to the audited consolidated financial statements for more information and Item 1A "Risk Factors - Management has performed an analysis of our ability to continue as a going concern, and has determined that, based on our current financial position, there is a substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm has raised substantial doubt as to our ability to continue as a going concern" in this Annual Report. We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. In the long-term, we may be required to obtain additional financing to fund our current planned operations, which may consist of incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds. There can be no assurance that the Company will be able to obtain additional funds on terms acceptable to it, on a timely basis or at all. The failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the results of operations, and financial condition. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing shareholders will be diluted. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>
                <div>
                    <p style="text-align: center;">298</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_237_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">The Company's primary uses of cash are for working capital requirements and capital expenditures. Additionally, from time to time, it may use capital for acquisitions and other investing and financing activities. Working capital is used principally for the Company's personnel as well as costs related to the growth, manufacture, and production of its products. The Company's capital expenditures consist primarily of additional facilities, improvements in existing facilities and product development.</p>
                <p style="text-align: justify;"><b>Cash Flows</b></p>
                <p style="text-align: justify;">The following table sets forth the major components of the Company's condensed consolidated statements of cash flows for the periods presented.</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">(In thousands of United States dollars)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1"><b>For the<br/>year ended<br/>December<br/>31, 2023</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;" colspan="1"><b>For the<br/>year ended<br/>December<br/>31, 2022</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center;" colspan="1">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Cash used in operating activities</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">(8,396</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">$</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">(15,935</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Cash from financing activities</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">3,150</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">4,413</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Cash used in investing activities</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">(234</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">(15,802</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Effect of exchange rate change</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;">930</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;">(755</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Change in cash during the period</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">(4,550</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">(28,079</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">)</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Cash, beginning of period</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">8,935</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">37,616</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Cash included in assets held for sale</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">(602))</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Cash, end of period</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">4,385</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double transparent; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">8,935</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double transparent; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                </table>
                <p style="text-align: justify; margin-top: 10pt;"><i>Cash used in Operating Activities</i></p>
                <p style="text-align: justify;">Net cash used in operating activities for the years ended December 31, 2023 and 2022 totaled $8.4 million and $15.9 million, respectively. Cash flows used in operating activities for the year ended December 31, 2023 were due primarily to operating expenses exceeding the gross profit for the year.</p>
                <p style="text-align: justify;">Cash flows used in operating activities for the year ended December 31, 2022 were also due primarily to operating expenses exceeding the gross profit for the year.</p>
                <p style="text-align: justify;"><i>Cash from Financing Activities</i></p>
                <p style="text-align: justify;">Net cash provided from financing activities for the years ended December 31, 2023 and 2022 totaled $3.2 million and $4.4 million, respectively. Cash flows provided from financing activities for the year ended December 31, 2023 were primarily related to the Company's September 2023 unit offering (as described below) and borrowings on a credit facility through its FGH subsidiary (as described below), partially offset by amounts used for equity issuances costs and loan repayments.</p>
                <p style="text-align: justify;">Cash flows provided from financing activities for the year ended December 31, 2022 were primarily related to the Company's December 2022 unit offering (as described below) as well as from proceeds received from warrant and stock option exercises, partially offset by amounts used for equity issuances costs and for the Company's share repurchase program. Under the repurchase program, the Company repurchased 18,411 Common Shares at an average price of $13.84 per share.</p>
                <div>
                    <p style="text-align: center;">299</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_238_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><i>Cash used in Investing Activities</i></p>
                <p style="text-align: justify;">Net cash used in investing activities for the years ended December 31, 2023 and 2022 totaled $0.2 million and $15.8 million, respectively. Cash flows used in investing activities for the year ended December 31, 2023 were primarily related to capital expenditures related to equipment in the House of Brands segment.</p>
                <p style="text-align: justify;">Cash flows used in investing activities for the year ended December 31, 2022 were primarily related to the cash portion of the consideration paid with respect to the acquisition of JustCBD in February 2022.</p>
                <p style="text-align: justify;"><i>Working Capital</i></p>
                <p style="text-align: justify;">As of December 31, 2023, we had working capital of $5.1 million. The Company's primary cash flow needs are for the development of its cannabis and pharmaceutical activities, administrative expenses and for general working capital to support growing sales and production with related receivables and payables.</p>
                <p style="text-align: justify;"><b>Funding Requirements</b></p>
                <p style="text-align: justify;">Our continued existence is dependent on our ability to generate positive cash flows through synergies within our operations, expanding our production capacity and geographic footprint, exploring strategic partnerships, and pursuing accretive acquisitions to supplement our organic growth. We are committed to attaining a level of sustained growth that will effectively offset our overhead costs, thereby paving the path to achieving profitability. We will be required in the future to raise additional capital through either equity or debt financings. To date, we have raised capital through multiple equity offerings. Our equity offerings in 2022 and 2023 are described below.</p>
                <p style="text-align: justify;"><i>September 2023 Unit Offering</i></p>
                <p style="text-align: justify;">In September 2023, we closed a registered direct offering of 1,369,000 units of the Company at a price of $2.00 per unit for gross proceeds of $2.7 million. Each unit is comprised of one Common Share of the Company and one Common Share purchase warrant (1,369,000 total warrants) to purchase one additional Common Share at an exercise price of $2.50 per share. The warrants expire on March 21, 2029. We paid $0.3 million in issuance costs relating to the September 2023 unit offering and issued 54,760 warrants issued to the placement agent. As of December 31, 2023, all of the warrants issued in connection with the September 2023 unit offering remain outstanding.</p>
                <p style="text-align: justify;"><i>December 2022 Unit Offering</i></p>
                <p style="text-align: justify;">In December 2022, we closed an offering of 625,000 units of the Company at a price of $8.00 per unit for gross proceeds of $5.0 million. Each unit is comprised of one Common Share of the Company and one Common Share purchase warrant (625,000 total warrants) to purchase one additional common share at an exercise price of $8.00 per share. The warrants expire on December 8, 2027. We paid $0.4 million in issuance costs relating to the December 2022 unit offering and issued 25,000 warrants issued to the placement agent.</p>
                <p style="text-align: justify;">In September 2023, the Company repriced 624,995 warrants issued in the December 2022 unit offering to certain investors to $2.50 per share in connection with such investors' participation in the September 2023 unit offering.</p>
                <p style="text-align: justify;">As of December 31, 2023, 624,995 warrants issued in connection with the December 2022 Unit Offering remain outstanding.</p>
                <p style="text-align: justify;"><i><b>Debt</b></i></p>
                <p style="text-align: justify;">In addition to the equity offerings described above, <span style="background-color: #ffffff;">the Company also has access to credit facilities through its FGH subsidiary. The credit facilities total 4.0 million Euros with two different German banks, Hypoverinsbank and Volksbank, secured by either joint and several guarantees or default guarantees. On December 31, 2023, the outstanding amount was 1.8 million Euros ($1.9 million USD) and was due within three months. The credit facilities have interest rates ranging from 5.45% to 6.46% per year and does not have a set maturity date. The interest rate is reset every time a new amount is drawn.</span></p>
                <p style="text-align: justify;"><b>Off-Balance Sheet Arrangements</b></p>
                <p style="text-align: justify;">As of December 31, 2023, the Company did not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations or financial condition, including, and without limitation, such considerations as liquidity and capital resources.</p>
                <div>
                    <p style="text-align: center;">300</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_239_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;"><b>Contractual Obligations</b></p>
                <p style="text-align: justify;">At December 31, 2023, the Company had the following contractual obligations to make future payments, representing contracts and other commitments that are known and committed:</p>
                <table style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;">(In thousands of United States dollars)</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center; width: 2%; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Total</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>Less than 1<br/>Year</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>1 - 3 Years</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><b>More than<br/>3 Years</b></td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid transparent; text-align: center; white-space: nowrap;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Legal disputes (1)</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">2,962</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">2,962</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Sales tax (1)</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">2,538</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">2,538</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Contingent purchase consideration (2)</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">1,095</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">921</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">52</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">122</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Operating lease obligations (3)</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">1,926</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">900</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">834</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                        <td style="vertical-align: bottom; text-align: right; width: 12%;">192</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">Long term debt (4)</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">1,931</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">1,931</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">-</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                    </tr>
                    <tr>
                        <td style="vertical-align: bottom; text-align: justify;">Total</td>
                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">10,452</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">9,252</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">886</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">$</td>
                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 12%;">314</td>
                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                    </tr>
                </table>
                <p style="margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt; margin-top: 10pt;">(1)<span style="display: inline-block; width: 12pt;">&#160;</span>See Note 19 of the Company's Consolidated Financial Statements for the year ended December 31, 2023.</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">(2)<span style="display: inline-block; width: 12pt;">&#160;</span>See Note 10 of the Company's Consolidated Financial Statements for the year ended December 31, 2023.</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">(3)<span style="display: inline-block; width: 12pt;">&#160;</span>See Note 14 of the Company's Consolidated Financial Statements for the year ended December 31, 2023.</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">(4)<span style="display: inline-block; width: 12pt;">&#160;</span>See Note 13 of the Company's Consolidated Financial Statements for the year ended December 31, 2023.</p>
                <p style="text-align: justify; margin-top: 10pt;"><b>Critical Accounting Estimates</b></p>
                <p style="text-align: justify;">The preparation of financial statements and related disclosures in conformity with U.S. GAAP and the Company's discussion and analysis of its financial condition and operating results require management to make judgments, assumptions and estimates that affect the amounts reported in the Company's consolidated financial statements and accompanying notes. Note 3, Significant Accounting Policies, of the Company's notes to the consolidated financial statements describes the significant accounting policies and methods used in the preparation of its consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</p>
                <p style="text-align: justify;">The Company believes that the following critical accounting policies involve the more significant judgments and estimates used in the preparation of its consolidated financial statements and are the most critical to aid the reader in fully understanding and evaluating the Company's reported financial results. Management considers these policies critical because they are both important to the portrayal of the Company's financial condition and operating results, and they require management to make judgments and estimates about inherently uncertain matters.</p>
                <p style="text-align: justify;"><i>Inventories</i></p>
                <p style="text-align: justify;">Inventories are comprised of raw materials and supplies, internally produced work in progress, and finished goods. Inventories are initially valued at cost and subsequently at the lower of cost and net realizable value. Inventory cost is determined either on a weighted average cost or specific identification basis and any trade discounts and rebates are deducted from the purchase price. Raw material costs include the purchase cost of the materials, freight-in and duty. Finished goods include the cost of direct materials and labor and a proportion of manufacturing overhead allocated based on normal production capacity.</p>
                <p style="text-align: justify;">Net realizable value represents the estimated selling price for inventories in the ordinary course of business, less all estimated costs of completion and costs necessary to make the sale. The determination of net realizable value requires significant judgment, including consideration of factors such as shrinkage, the aging of and future demand for inventory and contractual arrangements with customers. Reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The impact of changes in inventory reserves is reflected in cost of sales.</p>
                <p style="text-align: justify;"><i>Business combinations</i></p>
                <p style="text-align: justify;">Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition related costs are generally recognized in profit or loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed, are recognized at their fair value.</p>
                <div>
                    <p style="text-align: center;">301</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_240_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any noncontrolling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date. If, after assessment, the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain.</p>
                <p style="text-align: justify;">Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured at the fair value of the acquiree's identifiable net assets.</p>
                <p style="text-align: justify;">Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or liability is remeasured at subsequent reporting dates, with the corresponding gain or loss recognized in the consolidated statements of operations and comprehensive income.</p>
                <p style="text-align: justify;">When a business combination is achieved in stages, the Company's previously held equity interest in the acquiree is remeasured to its acquisition date fair value and the resulting gain or loss, if any, is recognized in profit or loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to profit or loss where such treatment would be appropriate if that interest were disposed of.</p>
                <p style="text-align: justify;">Purchase price allocations may be preliminary and, during the measurement period not to exceed one year from the date of acquisition, changes in assumptions and estimates that result in adjustments to the fair value of assets acquired and liabilities assumed are recorded in the period the adjustments are determined.</p>
                <p style="text-align: justify;"><i>Intangible Assets</i></p>
                <p style="text-align: justify;">Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization is provided on a straight-line basis over the assets' estimated useful lives, which do not exceed the contractual period, if any.</p>
                <p style="text-align: justify;">The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Amortization expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.</p>
                <p style="text-align: justify;">Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.</p>
                <p style="text-align: justify;"><i>Impairment of goodwill and indefinite-lived intangible assets</i></p>
                <p style="text-align: justify;">Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company reviews goodwill and indefinite lived intangible assets annually for impairment in the fourth quarter, or sooner, if events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company may elect to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If factors indicate this is the case, then a quantitative test is performed and an impairment is recorded for any excess carrying value above the reporting unit's fair value, not to exceed the amount of goodwill. The Company performs a one-step test to calculate the fair value of the asset and record goodwill impairment to the extent the fair value of the reporting unit exceeds its carrying amount. Several factors, including historical results, business plans, forecasts, market data and the weighting of valuation model results when multiple are developed, are used to determine the fair value.</p>
                <p style="text-align: justify;"><i>Income taxes</i></p>
                <p style="text-align: justify;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.</p>
                <div>
                    <p style="text-align: center;">302</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_241_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</p>
                <p style="text-align: justify;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</p>
                <p style="text-align: justify;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p>
                <p style="text-align: justify;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</p>
                <p style="text-align: justify;">Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense.</p>
                <p style="text-align: justify;"><b>Recently Adopted Accounting Principles</b></p>
                <p style="text-align: justify;">See Note 3, "Significant Accounting Policies", of the notes to the consolidated financial statements for a discussion of recently issued accounting standards.</p>
                <div>
                    <p style="text-align: center;">303</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_242_integixAnchor"></span>
                <p style="text-align: center; margin-top: 10pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: center; margin-top: 10pt;"><span style="text-decoration: underline;"><b>ANNEX D</b></span></p>
                <p style="text-align: justify;"><b>ITEM 1A. RISK FACTORS.</b></p>
                <p style="text-align: justify;">You should carefully consider the risks described below, as well as other information contained in this report, including the consolidated financial statements and the notes thereto and Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations." The occurrence of any of the events discussed below could significantly and adversely affect our business, prospects, results of operations, financial condition, and cash flows.</p>
                <p style="text-align: justify;"><b>RISKS RELATED TO OUR BUSINESS AND INDUSTRY </b></p>
                <p style="text-align: justify;"><i><b>We are an early-stage company with limited operating history and may never become profitable.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We are an early-stage company focused on supplying natural, medicinal-grade cannabis flower and high-quality cannabis derived medical and wellness products to large channel distributors and retailers globally. Formed in March 2019, we have a limited operating history. We have limited financial resources and minimal operating cash flow. For the years ended December 31, 2023 and 2022, we had losses of $56.3 million and $52.6 million, respectively, and as of December 31, 2023 an accumulated deficit of $142.5 million.</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">Additionally, there can be no assurance that additional funding will be available to us for the development of our business, which will require the commitment of substantial resources. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development. Potential investors should carefully consider the risks and uncertainties that a company with a limited operating history will face. In particular, potential investors should consider that we may be unable to:</span></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">&#8226;<span style="display: inline-block; width: 16.5pt;">&#160;</span>successfully implement or execute our business plan, or that our business plan is sound;</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">&#8226;<span style="display: inline-block; width: 16.5pt;">&#160;</span>adjust to changing conditions or keep pace with increased demand;</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">&#8226;<span style="display: inline-block; width: 16.5pt;">&#160;</span>attract and retain an experienced management team;</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">&#8226;<span style="display: inline-block; width: 16.5pt;">&#160;</span>successfully integrate businesses that we acquire; or</p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: -24pt; margin-left: 48pt;">&#8226;<span style="display: inline-block; width: 16.5pt;">&#160;</span>raise sufficient funds in the capital markets to effectuate our business plan, including product development, licensing and approvals.</p>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>Recent and future acquisitions and strategic investments could be difficult to integrate, divert the attention of key management personnel, disrupt our business, dilute shareholder value, may subject us to liability, and harm our results of operations and financial condition.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We have recently acquired Just Brands and FGH and have a history of acquisitive activity, and we may in the future seek to acquire or invest in businesses, products, or technologies that we believe could complement our operations or expand our breadth, enhance our capabilities, or otherwise offer growth opportunities. Our diversity of product offerings may not be successful. While our growth strategy includes broadening our service and product offerings, implementing an aggressive marketing plan and employing product diversification, there can be no assurance that our systems, procedures and controls will be adequate to support our operations as they expand. We cannot assure you that our existing personnel, systems, procedures or controls will be adequate to support our operations in the future or that we will be able to successfully implement appropriate measures consistent with our growth strategy. As part of our planned growth and diversified product offerings, we may have to implement new operational and financial systems, procedures and controls to expand, train and manage our employee base, and maintain close coordination among our staff. We cannot guarantee that we will be able to do so, or that if we are able to do so, we will be able to effectively integrate them into our existing staff and systems. Additionally, the integration of our acquisitions and pursuit of potential future acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. Any acquisition, investment or business relationship may result in unforeseen operating difficulties and expenditures. In addition, we have limited experience in acquiring other businesses. Specifically, we may not successfully evaluate or utilize the acquired products, assets or personnel, or accurately forecast the financial impact of an acquisition transaction, including accounting charges.</p>
                <p style="text-align: justify; background-color: #ffffff;">We may not be able to find and identify desirable acquisition targets or we may not be successful in entering into an agreement with any one target. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could harm our results of operations. In addition, if an acquired business fails to meet our expectations, our business, results of operations, and financial condition may suffer. In some cases, minority shareholders may exist in certain of our non-wholly-owned acquisitions (for businesses we do not purchase as an 100% owned subsidiary) and may retain minority shareholder rights which could make a future change of control or corporate approvals for actions more difficult to achieve and/or more costly.</p>
                <div>
                    <p style="text-align: center;">304</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_243_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">We also make strategic investments in early-stage companies developing products or technologies that we believe could complement our business or expand our breadth, enhance our technical capabilities, or otherwise offer growth opportunities. These investments may be in early-stage private companies for restricted stock. Such investments are generally illiquid and may never generate value. Further, the companies in which we invest may not succeed, and our investments would lose their value.</p>
                <p style="text-align: justify; background-color: #ffffff;">Moreover, the anticipated benefits of any acquisition, investment, or business relationship may not be realized, or we may be exposed to unknown risks or liabilities of our acquisitions. Furthermore, we may be subject to unknown liabilities of the businesses we acquire. In addition, we may become subject to legal proceedings in connection with the businesses of, or resulting from, our acquisitions. For example, we have become party to certain litigation as a result of our acquisition of FGH, which falls under certain indemnification protections obtained in the acquisition. For more information, see Item 3 "Legal Proceedings."</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Certain conditions or events could disrupt the Company's supply chains, disrupt operations, and increase operating expenses.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Conditions or events including, but not limited to, the following could disrupt the Company's supply chains and in particular its ability to deliver its products, interrupt operations at its facilities, increase operating expenses, resulting in loss of sales, delayed performance of contractual obligations or require additional expenditures to be incurred: (i) extraordinary weather conditions or natural disasters such as hurricanes, tornadoes, floods, fires, extreme heat, earthquakes, etc.; (ii) a local, regional, national or international outbreak of a contagious disease, including the COVID-19 coronavirus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome, H1N1 influenza virus, avian flu, or any other similar illness could result in a general or acute decline in economic activity; (iii) political instability, social and labor unrest, war or terrorism, including the current conflict between Russia and Ukraine; or (iv) interruptions in the availability of basic commercial and social services and infrastructure including power and water shortages, and shipping and freight forwarding services including via air, sea, rail and road.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Cannabis laws, regulations, and guidelines are dynamic and subject to changes.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require us to incur substantial costs associated with compliance or alter certain aspects of our business plan. It is also possible that regulations may be enacted in the future that will be directly applicable to certain of our products and/or aspects of our businesses. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business. Management expects that the legislative and regulatory environment in the cannabis industry internationally will continue to be dynamic and will require innovative solutions to try to comply with this changing legal landscape in this nascent industry for the foreseeable future. Compliance with any such legislation may have a material adverse effect on our business, financial condition and results of operations.</p>
                <p style="text-align: justify; background-color: #ffffff;">Public opinion can also exert a significant influence over the regulation of the cannabis industry. A negative shift in the public's perception of the cannabis industry could affect future legislation or regulation in different jurisdictions.<i><b> </b></i></p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Demand for cannabis and derivative products could be adversely affected and significantly influenced by scientific research or findings, regulatory proceedings, litigation, media attention or other research findings.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The legal cannabis industry is at a relatively early stage of its development. Consumer perceptions regarding legality, morality, consumption, safety, efficacy and quality of medicinal cannabis are mixed and evolving and can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of medicinal cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the medicinal cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity, could have a material adverse effect on the demand for medicinal cannabis and on our business, results of operations, financial condition and cash flows. Further, adverse publicity reports or other media attention regarding cannabis in general or associating the consumption of medicinal cannabis with illness or other negative effects or events, could have such a material adverse effect. Public opinion and support for medicinal cannabis use has traditionally been inconsistent and varies from jurisdiction to jurisdiction. Our ability to gain and increase market acceptance of our business may require substantial expenditures on investor relations, strategic relationships and marketing initiatives. There can be no assurance that such initiatives will be successful and their failure to materialize into significant demand may have an adverse effect on our financial condition.</p>
                <div>
                    <p style="text-align: center;">305</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_244_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>Damage to the Company's reputation can be the result of the actual or perceived occurrence of any number of events, and could include any negative publicity, whether such publicity is accurate or not.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The increased usage of social media and other web-based tools used to generate, publish and discuss user-generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share opinions and views regarding the Company and its activities, whether true or not. Although the Company believes that it operates in a manner that is respectful to all stakeholders and that it takes pride in protecting its image and reputation, it does not ultimately have direct control over how it is perceived by others. Reputational loss may result in decreased ability to enter into new customer, distributor or supplier relationships, retain existing customers, distributors or suppliers, reduced investor confidence and access to capital, increased challenges in developing and maintaining community relations and an impediment to our overall ability to advance our projects, thereby having a material adverse effect on our financial performance, financial condition, cash flows and growth prospects.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We are subject to the inherent risk of exposure to product liability claims, actions and litigation.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">As a distributor of products designed to be ingested by humans, we face an inherent risk of exposure to product liability claims, regulatory action and litigation if our products are alleged to have caused bodily harm or injury. In addition, the sale of our products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Adverse reactions resulting from human consumption of our products alone or in combination with other medications or substances could occur. We may be subject to various product liability claims, including, among others, that our products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning health risks, possible side effects or interactions with other substances. Product liability claims or regulatory actions against us could result in increased costs, could adversely affect our reputation with our clients and consumers generally, and could have a material adverse effect on our results of operations and financial condition. There can be no assurances that we will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of our potential products.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We are subject to the inherent risks involved with product recalls.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of our products are recalled due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. We may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin, or at all. In addition, a product recall may require significant management attention. There can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if our products are subject to recall, our reputation could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for our products and could have a material adverse effect on our results of operations and financial condition. Additionally, product recalls may lead to increased scrutiny of our operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses, and potential legal fees and other expenses.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The Company's products could have unknown side effects.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">If the products the Company sells are not perceived to have the effects intended by the end user, its business may suffer and the business may be subject to products liability or other legal actions. Many of the Company's products contain innovative ingredients or combinations of ingredients. There is little long-term data available with respect to efficacy, unknown side effects and/or interaction with individual human biochemistry, or interaction with other drugs. Moreover, there is little long-term data available with respect to efficacy, unknown side effects and/or its interaction with individual animal biochemistry. As a result, the Company's products could have certain side effects if not taken as directed or if taken by an end user that has certain known or unknown medical conditions.</p>
                <div>
                    <p style="text-align: center;">306</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_245_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">The Company may be unable to anticipate changes in its potential client requirements that could make the Company's existing products and services obsolete. The Company's success will depend, in part, on its ability to continue to enhance its product and service offerings so as to address the increasing sophistication and varied needs of the market and respond to technological and regulatory changes and emerging industry standards and practices on a timely and cost-effective basis.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Research regarding the medical benefits, viability, safety, efficacy, use and social acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in early stages.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC). Although the Company believes that the articles, reports and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Given these risks, uncertainties and assumptions, investors should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions to those stated herein or reach negative conclusions related to medical cannabis, which could have a material adverse effect on the demand for the Company's products, which could result in a material adverse effect on our business, financial condition and results of operations or prospects.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Our growth depends, in part, on expanding into additional consumer markets, and we may not be successful in doing so.</b></i></p>
                <p style="text-align: justify;">We believe that our future growth depends not only on continuing to provide our current customers with new products, but also continuing to enlarge our customer base. The growth of our business will depend, in part, on our ability to continue to expand in the United States, as well as into international markets. We are investing significant resources in these areas, and although we hope that our products will gain popularity, we may face challenges that are different from those we currently encounter, including competitive merchandising, distribution, hiring, and other difficulties. We may also encounter difficulties in attracting customers due to a lack of consumer familiarity with or acceptance of our brand, or a resistance to paying for premium products, particularly in international markets. In addition, although we are investing in sales and marketing activities to further penetrate newer regions, including expansion of our dedicated sales force, we may not be successful. If we are not successful, our business and results of operations may be harmed.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Fluctuations in the cost and availability of raw materials, equipment, labor, and transportation could cause manufacturing delays or increase our costs.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The price and availability of key components used to manufacture our products has been increasing and may continue to fluctuate significantly. In addition, the cost of labor within our company or at our third-party manufacturers could increase significantly due to regulation or inflationary pressures. Additionally, the cost of logistics and transportation fluctuates in large part due to the price of oil, and availability can be limited due to political and economic issues. Any fluctuations in the cost and availability of any of our raw materials, packaging, or other sourcing or transportation costs could harm our gross margins and our ability to meet customer demand. If we are unable to successfully mitigate a significant portion of these product cost increases or fluctuations, our results of operations could be harmed.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We rely on third-parties for raw materials and to manufacture and compound some of our products. We have no control over these third parties and if these relationships are disrupted our results of operations in future periods will be adversely impacted.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We currently hold short term supply contracts with unaffiliated third-party vendors for our critical raw materials. In addition, some of our products are manufactured or compounded by unaffiliated third parties and the use of these third-party co-packers changes from time to time due to customer demand and the composition of our product mix and product portfolio. We do not have any long-term contracts with any of these third parties, and we expect to compete with other companies for raw materials, production and imported packaging material capacity. If we experience significant increased demand or need to replace an existing raw material supplier or third-party manufacturer, there can be no assurances that replacements for these third-party vendors will be available when required on terms that are acceptable to us, or at all, or that any manufacturer or compounder would allocate sufficient capacity to us in order to meet our requirements. In addition, even if we are able to expand existing or find new sources, we may encounter delays in production and added costs as a result of the time it takes to engage third parties. Any delays, interruption or increased costs in raw materials and/or the manufacturing or compounding of our products could have an adverse effect on our ability to meet retail customer and consumer demand for our products and result in lower revenues and net income both in the short and long-term.</p>
                <div>
                    <p style="text-align: center;">307</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_246_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>The Company's inventory has a shelf life and may reach its expiration and not be sold.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The Company holds finished goods in inventory and its inventory has a shelf life. Finished goods in the Company's inventory may include cannabis flower, cannabis oil products and cosmeceuticals. The Company's inventory may reach its expiration and not be sold. Although management regularly reviews the quantity and remaining shelf life of inventory on hand, and estimates manufacturing and sales lead times in order to manage its inventory, write-downs of inventory may still be required. Any such write-down of inventory could have a material adverse effect on the Company's business, financial condition, and results of operations.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The seasonal trends in our business create variability in our financial and operating results.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Our financial and operating results are subject to seasonal and quarterly variations in our net revenue and operating income and, as a result, our quarterly results may fluctuate and could be below expectations. Our business has realized a disproportionate amount of our net revenue and earnings for prior fiscal years in the third and fourth quarter as a result of the holiday season, and we expect this seasonal impact on our operations to continue in the future. If we experience lower than expected net revenue during any third or fourth quarter, it may have disproportionately large effects on our operating results and financial condition for that year. Any factors that harm our third or fourth quarter operating results, including disruptions in our brands or our supply chains or unfavorable economic conditions, could have a disproportionate effect on our results of operations and our financial condition for our entire fiscal year.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The Company may not be able to maintain effective quality control systems.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The Company may not be able to maintain an effective quality control system. The Company ascribes its early successes, in part, on its commitment to product quality and its effective quality control system. The effectiveness of the Company's quality control system and its ability to obtain or maintain good manufacturing practice ("GMP") certification with respect to its manufacturing, processing and testing facilities depend on a number of factors, including the design of its quality control procedures, training programs, and its ability to ensure that its employees adhere to the Company's policies and procedures. The Company also depends on service providers such as toll manufacturers and contract laboratories to manufacture, process or test its products that are subject to GMP certification requirements.</p>
                <p style="text-align: justify; background-color: #ffffff;">We expect that regulatory agencies will periodically inspect our and our service providers' facilities to evaluate compliance with applicable GMP requirements. Failure to comply with these requirements may subject us or our service providers to possible regulatory enforcement actions. Any failure or deterioration of the Company's or its service providers' quality control systems, including loss of GMP certification, may have a material adverse effect on the Company's business, results of operations and financial condition.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The cannabinoid industry faces strong opposition and may face similar opposition in other jurisdictions in which we operate.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Many political and social organizations oppose hemp and cannabis and their legalization, and many people, even those who support legalization, oppose the sale of hemp and cannabis in their geographies. Our business will need support from local governments, industry participants, consumers and residents to be successful. Additionally, there are large, well-funded businesses that may have a strong opposition to the cannabis industry. For example, the pharmaceutical and alcohol industries have traditionally opposed cannabis legalization. Any efforts by these or other industries to halt or impede the cannabis industry could have detrimental effects on our business.</p>
                <p style="text-align: justify; background-color: #ffffff;"><span style="background-color: #ffffff;"><i><b>The Company is subject to wholesale price volatility that could expose the Company to lower than anticipated revenues, gross margins, net income and cash flows.</b></i></span></p>
                <p style="text-align: justify; background-color: #ffffff;">The pharmaceutical distribution and cannabis industries are margin-based businesses in which gross profits depend on the excess of sales prices over costs. Consequently, profitability is sensitive to fluctuations in wholesale and retail prices caused by changes in supply (which itself depends on other factors such as weather, fuel, equipment and labor costs, shipping costs, economic situation, government regulations and demand), taxes, government programs and policies for the pharmaceutical distribution and cannabis industries (including price controls and wholesale price restrictions that may be imposed by government agencies responsible for the sale of pharmaceuticals and cannabis), and other market conditions, all of which are factors beyond our control. The Company's operating income may be significantly and adversely affected by a decline in the price of pharmaceuticals and cannabis and will be sensitive to changes in the price of cannabis and the overall condition of the cannabis industry, as our profitability is directly related to the price of pharmaceuticals and cannabis. These prices affected by numerous factors beyond our control. Any price decline may have a material adverse effect on the Company's business, financial condition and results of operations.</p>
                <div>
                    <p style="text-align: center;">308</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_247_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>The Company could face competitive risks from the development and distribution of synthetic cannabis.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The pharmaceutical industry and others may attempt to enter the cannabis industry and, in particular, the medical cannabis industry through the development and distribution of synthetic products that emulate the effects of and treatment provided by naturally occurring cannabis. If synthetic cannabis products are widely adopted, the widespread popularity of such synthetic cannabis products could change the demand, volume and profitability of the botanical cannabinoid industry. This could adversely affect our ability to secure long-term profitability and success through the sustainable and profitable operation of our business.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The legalization of adult-use, recreational cannabis may reduce sales of medical cannabis.</b></i></p>
                <p style="text-align: justify;">Legalization of the sale to adults of recreational, non-medical cannabis in any country may increase competition in the medical cannabis market. We may not be able to achieve our business plan in a highly competitive market where recreational, adult-use cannabis is legal, or the market may experience a drop in the price of cannabis and cannabis products over time, decreasing our profit margins.</p>
                <p style="text-align: justify;"><i><b>The Company is reliant on third party transportation services and importation services to deliver its products to customers.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The Company relies on third party transportation services and importation services to deliver its products to its customers. The Company is exposed to the inherent risks associated with relying on third party transportation service-providers, including logistical problems, delays, loss or theft of product and increased shipping and insurance costs. Any delay in transporting the product, breach of security or loss of product, could have a material adverse effect on the Company's business, financial performance and results of operations.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We may not be able to establish and maintain bank accounts in certain countries.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">There is a risk that banking institutions in countries where we operate will not open accounts for us or will not accept payments or deposits from proceeds related to the cannabis industry. Such risks could increase our costs or prevent us from expanding into certain jurisdictions.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We may not be able to renew certain of our leases.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Several of the properties or facilities that we utilize in our operations are leased for a specific term. There is a risk that we may not be able to extend the term on some or all of such leases or, if we do so, that the terms of any such lease extension will be favorable. Likewise, there is a risk that some leases may expire and we will be required to relocate our operations to another location, thereby incurring costs.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The Company may be subject to cyber-security and privacy risks that could disrupt its operations and expose the Company to financial losses, contractual losses, liability, reputational damage and additional expense.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The Company may be subject to risks related to our information technology systems, including cyber-attacks, malware, ransomware and phishing attacks that could target our intellectual property, trade secrets, financial information, personal information of our employees, customers and patients, including sensitive personal health information. The occurrence of such an attack could disrupt our operations and expose the Company to financial losses, contractual damages, liability under labor and privacy laws, reputational damage and additional expenses. We have implemented security measures to protect our data and information technology systems; however, such measures may not be effective in preventing cyber-attacks. We may be required to allocate additional resources to implement additional preventative measures including significant investments in information technology systems. A serious cyber-security breach could have a material adverse effect on our business, financial condition and results of operations.</p>
                <p style="text-align: justify; background-color: #ffffff;">The Company may collect and store certain personal information about customers and is responsible for protecting such information from privacy breaches. A privacy breach may occur through procedural or process failure, information technology malfunction, or deliberate unauthorized intrusions. In addition, theft of data is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such privacy breach or theft could have a material adverse effect on the Company's business, financial condition and results of operations. If the Company were found to be in violation of privacy or security rules or other laws protecting the confidentiality of information, the Company could be subject to sanctions and civil or criminal penalties, which could increase its liabilities, harm its reputation and have a material adverse effect on the Company's business, financial condition and results of operations.</p>
                <div>
                    <p style="text-align: center;">309</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_248_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>The Company may incur significant costs to defend its intellectual property and other proprietary rights.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;"><span style="background-color: #ffffff;">The ownership and protection of trademarks, patents, trade secrets and intellectual property rights are significant aspects of the Company's future success. Unauthorized parties may attempt to replicate or otherwise obtain and use the Company's products and technology. Policing the unauthorized use of the Company's current or future trademarks, patents, trade secrets or intellectual property rights could be difficult, expensive, time-consuming and unpredictable, as may be enforcing these rights against unauthorized use by others.</span></p>
                <p style="text-align: justify; background-color: #ffffff;"><span style="background-color: #ffffff;">In addition, other parties may claim that the Company's products infringe on their proprietary and perhaps patent protected rights. Such claims, regardless of their merit, may result in the expenditure of significant financial and managerial resources, legal fees, injunctions, temporary restraining orders and/or require the payment of damages. As well, the Company may need to obtain licenses from third parties who allege that the Company has infringed on their lawful rights. Such licenses may not be available on terms acceptable to the Company or at all. In addition, the Company may not be able to obtain or utilize on terms that are favorable to it, or at all, licenses or other rights with respect to intellectual property that it does not own.</span></p>
                <p style="text-align: justify;"><b>RISKS RELATED TO OUR REGULATORY FRAMEWORK</b></p>
                <p style="text-align: justify;"><i><b>Marijuana remains illegal under U.S. federal law, and the enforcement of U.S. cannabis laws could change.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">There are significant legal restrictions and regulations that govern the cannabis industry in the United States. Marijuana remains a Schedule I drug under the Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. In those states in which the use of marijuana has been legalized, its use remains a violation of federal law pursuant to the Controlled Substances Act. The Controlled Substances Act classifies marijuana as a Schedule I controlled substance, and as such, medical and adult cannabis use is illegal under U.S. federal law. Unless and until the U.S. Congress amends the Controlled Substances Act with respect to marijuana (and the President approves such amendment), there is a risk that federal authorities may enforce current federal law. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis regulatory programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve us of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against us. Since U.S. federal law criminalizing the use of marijuana pre-empts state laws that legalize its use, enforcement of federal law regarding marijuana is a significant risk and would greatly harm our business, prospects, revenue, results of operation and financial condition. The enforcement of federal laws in the United States is a risk to our business and any proceedings brought against us thereunder may materially, adversely affect our operations and financial performance.</p>
                <p style="text-align: justify; background-color: #ffffff;">Our activities are, and will continue to be, subject to evolving regulation by governmental authorities. The legality of the production, cultivation, extraction, distribution, retail sales, transportation and use of cannabis differs among states in the United States. Due to the current regulatory environment in the United States, new risks may emerge; Management may not be able to predict all such risks.</p>
                <p style="text-align: justify; background-color: #ffffff;">Due to the conflicting views between state legislatures and the federal government regarding cannabis, cannabis businesses are subject to inconsistent laws and regulations. There can be no assurance that the federal government will not enforce federal laws relating to marijuana and seek to prosecute cases involving marijuana businesses that are otherwise compliant with state laws in the future.</p>
                <p style="text-align: justify; background-color: #ffffff;">The uncertainty of U.S. federal enforcement practices going forward and the inconsistency between U.S. federal and state laws and regulations present major risks for the Company.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Changes to federal or state laws pertaining to industrial hemp could slow the use of industrial hemp which would materially impact our revenues in future periods.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">As of the date hereof, most states and the District of Columbia have authorized industrial hemp programs pursuant to the United States of the 2018 Farm Bill, or under prior programs authorized under the 2014 Farm Bill or have plans under review by the USDA. Effective January 1, 2022, several states without an approved plan under the Farm Bill, or a plan under review, will default to the USDA Hemp Producer License. Continued development of the industrial hemp industry will be dependent upon new legislative authorization of industrial hemp at the state level, and further amendment or supplementation of legislation at the federal level. Any number of events or occurrences could slow or halt progress all together in this space. While progress within the industrial hemp industry is currently encouraging, growth is not assured. While there appears to be ample public support for favorable legislative action, numerous factors may impact or negatively affect the legislative process(es) within the various states where we have business interests. Any one of these factors could slow or halt use of industrial hemp, which could negatively impact the business up to possibly causing us to discontinue operations as a whole. In addition, changes in Federal or state laws could require us to alter the way we conduct our business in order to remain compliant with applicable state laws in ways we are presently unable to foresee. These possible changes, if necessary, could be costly and may adversely impact our results of operations in future periods.</p>
                <div>
                    <p style="text-align: center;">310</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_249_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>Uncertainty caused by potential changes to legal regulations could impact the use of CBD products.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">There is substantial uncertainty and different interpretations among federal, state and local regulatory agencies, legislators, academics and businesses as to the scope of operation of Farm Bill-compliant hemp programs relative to the emerging regulation of cannabinoids. These different opinions include, but are not limited to, the regulation of cannabinoids by the FDA and the extent to which manufacturers of products containing Farm Bill-compliant cultivators and processors may engage in interstate commerce. The uncertainties cannot be resolved without further federal, and perhaps even state-level, legislation, regulation or a definitive judicial interpretation of existing legislation and rules. If these uncertainties continue, they may have an adverse effect upon the introduction of our products in different markets.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Our business activities are heavily regulated in all jurisdictions where we do business. Our operations are subject to various laws, regulations and guidelines by governmental authorities relating to the cultivation, processing, manufacture, marketing, management, distribution, transportation, storage, sale, packaging, labeling, pricing and disposal of cannabis and cannabis products. In addition, we are subject to laws and regulations relating to employee health and safety, insurance coverage and the environment. Laws and regulations, applied generally, grant government agencies and self-regulatory bodies broad administrative discretion over our activities, including the power to limit or restrict business activities as well as impose additional disclosure requirements on our products and services.</p>
                <p style="text-align: justify; background-color: #ffffff;">Any failure by us to comply with the applicable regulatory requirements could</p>
                <div style="margin-top: 14pt; margin-left: 45.6pt; margin-bottom: 14pt; background-color: #ffffff;">
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>require extensive changes to our operations;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>result in regulatory or agency proceedings or investigations;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>result in the revocation of our licenses and permits, increased compliance costs;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>result in damage awards, civil or criminal fines or penalties;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>result in restrictions on our operations;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>harm our reputation&#894; or</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>give rise to material liabilities.</p>
                </div>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">There can be no assurance that any future regulatory or agency proceedings, investigations or audits will not result in substantial costs, a diversion of management's attention and resources or other adverse consequences to our business.</p>
                <p style="text-align: justify; background-color: #ffffff;">Achievement of our business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all necessary regulatory approvals for the cultivation, processing, production, storage, distribution, transportation, sale, import and export, as applicable, of our products. Any failure to comply with the regulatory requirements applicable to our operations may lead to possible sanctions, including:</p>
                <div style="margin-top: 14pt; margin-left: 45.6pt; margin-bottom: 14pt; background-color: #ffffff;">
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>the revocation or imposition of additional conditions on licenses to operate our business;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>the suspension or expulsion from a particular market or jurisdiction or of our key personnel;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>the imposition of additional or more stringent inspection, testing and reporting requirements;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>product recalls or seizures; and</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>the imposition of fines and censures.</p>
                </div>
                <div>
                    <p style="text-align: center; margin-top: 10pt;">311</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_250_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">In addition, changes in regulations, government or judicial interpretation of regulations, or more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increase compliance costs or give rise to material liabilities or a revocation of our licenses and other permits. Furthermore, governmental authorities may change their administration, application or enforcement procedures at any time, which may adversely affect our ongoing regulatory compliance costs. There is no assurance that we will be able to comply or continue to comply with applicable regulations.</p>
                <p style="text-align: justify;"><i><b>The FDA limits the ability to discuss the medical benefits of CBD.</b></i></p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">Under FDA rules it is illegal for companies to make "health claims" or claim that a product has a specific medical benefit. The FDA has not recognized any medical benefits derived from CBD, which means that we are not legally permitted to advertise any potential health claims related to our CBD products. Because of the perception among many consumers that CBD is a health/medicinal product, the inability to make such health claims about its CBD products may limit our ability to market and sell products to consumers, which would negatively affect our revenues and profits.</span></p>
                <p style="text-align: justify; background-color: #ffffff;"><span style="background-color: #ffffff;"><i><b>The legal cannabis market is a relatively new industry. As a result, the size of our target market is difficult to quantify, and investors will be reliant on their own estimates on the accuracy of market data.</b></i></span></p>
                <p style="text-align: justify; background-color: #ffffff;">Because the cannabis industry is in a nascent stage, there is a lack of information about comparable companies available for potential investors to review and to decide whether to invest in us and, few, if any, established companies whose business model we can follow or upon whose success we can build. Accordingly, investors should rely on their own estimates regarding the potential size, economics and risks of the cannabis market in deciding whether to invest in our Common Shares. We are an early-stage company that has not generated net income. There can be no assurance that our growth estimates are accurate or that the cannabis market will be large enough for our business to grow as projected.</p>
                <p style="text-align: justify; background-color: #ffffff;">Although we are committed to researching and developing new markets and products and improving existing products, there can be no assurances that such research and market development activities will prove profitable or that the resulting markets or products, if any, will be commercially viable or successfully produced and marketed. We must rely largely on our own market research to forecast sales and design products as detailed forecasts and consumer research are not generally obtainable from reliable third-party sources in Canada and in other international jurisdictions.</p>
                <p style="text-align: justify; background-color: #ffffff;">In addition, there is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated or function and evolve in the manner consistent with management's expectations and assumptions. We could also be subject to other events or circumstances that adversely affect the cannabis industry, such as the imposition of further restrictions on sales and marketing or further restrictions on sales in certain areas and markets.</p>
                <p style="text-align: justify;"><b>RISKS RELATED TO FINANCIALS AND ACCOUNTING</b></p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Management has performed an analysis of our ability to continue as a going concern, and has determined that, based on our current financial position, there is a substantial doubt about our ability to continue as a going concern</b></i><b>. </b><i><b>In addition, our independent registered public accounting firm has raised substantial doubt as to our ability to continue as a going concern.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Based on its assessment, management has raised substantial doubt about our ability to continue as a going concern. The Company had cash and cash equivalents of $4.4 million at December 31, 2023, a loss of $56.3 million for the year ended December 31, 2023, and an accumulated deficit of $142.5 million at December 31, 2023. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash and cash equivalents are not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding our ability to continue as a going concern. In an effort to alleviate these conditions, management continues to evaluate various cost reduction, asset sales, and other alternatives and may seek to raise additional funds through the issuance of equity, mezzanine or debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions or otherwise.</p>
                <p style="text-align: justify; background-color: #ffffff;">Our independent registered public accounting firm has raised substantial doubt as to our ability to continue as a going concern. A going concern opinion in the report of our independent registered public accounting firm could impair our ability to finance our operations through public or private equity offerings or debt financings, or a combination of one or more of these funding sources. Any additional equity or equity-linked debt financing could be extremely dilutive to our current stockholders. Additional capital may not be available on reasonable terms, or at all, and we may be required to terminate or significantly curtail our operations, or enter into arrangements with collaborative partners or others that may require us to relinquish rights to certain aspects of our product candidates, or potential markets that we would not otherwise relinquish. If we are unable to obtain capital, our business would be jeopardized, and we may not be able to continue operations.</p>
                <div>
                    <p style="text-align: center;">312</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_251_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>We may increase our foreign sales in the future, and such sales may be subject to unexpected regulatory requirements and other barriers.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Our functional currency is denominated in U.S. dollars. We currently expect that a portion of our sales will be denominated in European euros and we may, in the future, have sales denominated in the currencies of additional countries in which we establish operations or distribution. In addition, we incur a portion of our operating expenses in European euros. In the future, the proportion of our sales that are international may increase. Such sales may be subject to unexpected regulatory requirements and other barriers. Any fluctuation in the exchange rates of foreign currencies may negatively affect our business, financial condition and results of operations. We have not previously engaged in foreign currency hedging. If we decide to hedge our foreign currency exposure, we may not be able to hedge effectively due to lack of experience, unreasonable costs or illiquid markets. In addition, those activities may be limited in the protection they provide from foreign currency fluctuations and can themselves result in losses.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Assumptions, estimates and judgments related to critical accounting matters could significantly affect our reported financial results or financial condition.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (" U.S. GAAP") requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on limited historical experience and on various other assumptions that we believe to be reasonable under the circumstances, as provided in the notes to our financial statements, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. Our operating results may be adversely affected if the assumptions change or if actual circumstances differ from those in the assumptions, which could cause our operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the price of our Common Shares. Significant assumptions and estimates used in preparing the financial statements include those related to the credit quality of accounts receivable, income tax credits receivable, share based payments, impairment of non-financial assets, as well as revenue and cost recognition.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>There are tax risks the Company may be subject to in carrying on business in multiple jurisdictions.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We and our subsidiaries will operate and, accordingly, will be subject to income tax and other forms of taxation in multiple jurisdictions. We may be subject to income taxes and non-income taxes in a variety of jurisdictions and our tax structure may be subject to review by both domestic and foreign taxation authorities. Those tax authorities may disagree with our interpretation and/or application of relevant tax rules. A challenge by a tax authority in these circumstances might require us to incur costs in connection with litigation against the relevant tax authority or reaching a settlement with the tax authority and, if the tax authority's challenge is successful, could result in additional taxes (perhaps together with interest and penalties) being assessed on us, and as a result an increase in the amount of tax payable by us.</p>
                <p style="text-align: justify; background-color: #ffffff;">Taxation laws and rates which determine taxation expenses may vary significantly in different jurisdictions, and legislation governing taxation laws and rates are also subject to change. Therefore, our earnings may be affected by changes in the proportion of earnings taxed in different jurisdictions, changes in taxation rates, changes in estimates of liabilities and changes in the amount of other forms of taxation. The determination of our provision for income taxes and other tax liabilities will require significant judgment (including based on external advice) as to the interpretation and application of these rules. We may have exposure to greater than anticipated tax liabilities or expenses.</p>
                <p style="text-align: justify; background-color: #ffffff;">Additionally, dividends and other intra-group payments made by our subsidiaries or international branches may expose the recipients of such payments to taxes in their jurisdictions of organization and operation and such dividends and other intra-group payments may also be subject to withholding taxes imposed by the jurisdiction in which the entity making the payment is organized or tax resident. Unless such withholding taxes are fully creditable or refundable, dividends and other intra-group payments may increase the amount of tax paid by us. Although the Company and its subsidiaries arrange themselves and their affairs with a view to minimizing the incurrence of such taxes, there can be no assurance that we will succeed.</p>
                <div>
                    <p style="text-align: center;">313</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_252_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>Restrictions on Deduction of Certain Expenses for U.S. Federal Income Tax Purposes.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Section 280E of the Internal Revenue Code of 1986, as amended (the "Code"), prohibits businesses from deducting certain expenses associated with trafficking-controlled substances for United States federal income tax purposes. The Internal Revenue Service (the "IRS") has invoked Code Section 280E in tax audits against various cannabis businesses in the U.S. that are permitted under applicable state laws. Section 280E of the Code prohibits cannabis businesses that are deemed to be trafficking in controlled substances from deducting certain ordinary and necessary business expenses, forcing them to pay higher effective federal tax rates than similar companies in other industries. The effective tax rate on a cannabis business depends on how large its ratio of non-deductible expenses is to its total revenues. Therefore, businesses in the U.S. legal cannabis industry may be less profitable than they would otherwise be.</p>
                <p style="text-align: justify; background-color: #ffffff;">Although the IRS issued a clarification allowing the deduction of certain expenses, the scope of such items is interpreted very narrowly and the bulk of operating costs and general administrative costs are not permitted to be deducted. While there are currently several pending cases before various administrative bodies and federal courts challenging these restrictions, there is no guarantee that these authorities will issue an interpretation of Code Section 280E favorable to cannabis businesses.</p>
                <p style="text-align: justify; background-color: #ffffff;">Although the IRS issued a clarification allowing the deduction of certain expenses, the scope of such items is interpreted very narrowly and the bulk of operating costs and general administrative costs are not permitted to be deducted. While there are currently several pending cases before various administrative bodies and federal courts challenging these restrictions, there is no guarantee that these authorities will issue an interpretation of Code Section 280E favorable to cannabis businesses.</p>
                <p style="text-align: justify;">If our tax filing positions were to be challenged by federal, state and local or foreign tax jurisdictions, we may not be wholly successful in defending our tax filing positions. We record reserves for unrecognized tax benefits based on our assessment of the probability of successfully sustaining tax filing positions. We, therefore, analyze and consider the appropriateness of recording reserves for unrecognized tax benefits each quarter. Management exercises significant judgment when assessing the probability of successfully sustaining tax filing positions, and in determining whether a contingent tax liability should be recorded and, if so, estimating the amount. If our tax filing positions are successfully challenged, payments could be required that are in excess of reserved amounts or we may be required to reduce the carrying amount of our net deferred tax asset, either of which result could be significant to our financial condition or results of operations.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The Company may be at a higher risk of IRS audit.</b></i></p>
                <p style="text-align: justify;">The Company believes there is a greater likelihood that the IRS will audit the tax returns of cannabis-related businesses. Any such audit of our tax returns could result in us being required to pay additional tax, interest and penalties, as well as incremental accounting and legal expenses, which could be material.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The Company will likely be a "passive foreign investment company" for its current tax year, which may have adverse U.S. federal income tax consequences for U.S. investors.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The Company believes it was a PFIC within the meaning of Section 1297 of the Code for its most recently completed tax year, and based on current business plans and financial expectations, it believes that it will likely be a PFIC for its current tax year and may be a PFIC in subsequent tax years. If the Company is a PFIC for any year during a U.S. taxpayer's holding period of Common Shares, then such U.S. taxpayer generally will be required to treat any gain realized upon a disposition of the Common Shares or any so-called "excess distribution" received on its Common Shares as ordinary income, and to pay an interest charge on a portion of such gain or distribution. In certain circumstances, the sum of the tax and the interest charge may exceed the total amount of proceeds realized on the disposition, or the amount of excess distribution received, by the U.S. taxpayer. Subject to certain limitations, these tax consequences may be mitigated if a U.S. taxpayer makes a timely and effective "QEF election" under Code Section 1295 ("QEF Election") or a "mark-to-market" election under Section 1296 of the Code ("Mark-to-Market Election"). U.S. taxpayers should be aware that there can be no assurances that the Company will satisfy the record keeping requirements that apply to a qualified electing fund (a "QEF"), or that the Company will supply U.S. taxpayers with information that such U.S. taxpayers are required to report under the QEF rules, in the event the Company is a PFIC. Thus, U.S. Holders may not be able to make a QEF Election with respect to their Common Shares. A U.S. taxpayer who makes a Mark-to-Market Election generally must include as ordinary income each year the excess of the fair market value of the Common Shares over the taxpayer's basis therein. This paragraph is qualified in its entirety by the discussion below under the heading of "<i>Certain United States Federal Income Taxation Considerations - Passive Foreign Investment Company Rules.</i>" Each potential investor who is a U.S. taxpayer should consult its own tax advisor regarding the tax consequences of the PFIC rules and the acquisition, ownership, and disposition of the Common Shares.</p>
                <div>
                    <p style="text-align: center;">314</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_253_integixAnchor"></span>
                <p style="text-align: justify; margin-top: 10pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: justify; margin-top: 10pt;"><i><b>The Company's ability to use its U.S. net operating loss carryforwards to offset its future U.S. taxable income may be subject to limitations.</b></i></p>
                <p style="text-align: justify;">The Company's U.S. federal net operating loss carryforwards ("NOLs") generated in taxable years beginning before January 1, 2018 may be carried forward for 20 years. The Company's U.S. federal NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the utilization of such NOLs is limited. In addition, under Section 382 of the Code, a corporation that undergoes an "ownership change" (generally defined as a greater than 50% change (by value) in its stock ownership over a three-year period) is subject to limitations on its ability to utilize its pre-change U.S. federal NOLs to offset its future U.S. taxable income. If the Company has undergone an ownership change in the past, or if future changes in its stock ownership, some of which are outside its control, results in an ownership change, its ability to utilize its U.S. federal NOLs may be limited by Section 382 of the Code. It is uncertain if and to what extent U.S. states will conform to U.S. federal income tax law with respect to the treatment of NOLs. As a result, the Company's ability to use its U.S. NOLs to offset its future U.S. taxable income may be subject to limitations, which could increase its tax liability and decrease its cash flow.</p>
                <p style="text-align: justify;"><i><b>Changes in global and local tax laws and regulations in jurisdictions in which the Company operates may adversely impact the Company and the value of the Common Shares.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Changes to tax laws in the U.S. or in any jurisdiction in which the Company conducts business (which changes may have retroactive application) could adversely affect the Company or holders of the Common Shares. In recent years, many changes to U.S. federal income tax laws have been proposed and made, and additional changes to U.S. federal income tax laws are likely to continue to occur in the future.</p>
                <p style="text-align: justify; background-color: #ffffff;">The U.S. Congress is currently considering numerous items of legislation which may be enacted prospectively or with retroactive effect, which legislation could adversely impact the Company's financial performance and the value of the Common Shares. Additionally, states in which the Company operates or owns assets may impose new or increased taxes. If enacted, most of the proposals would be effective for the current or later years. The proposed legislation remains subject to change, and its impact on the Company and purchasers of the Common Shares is uncertain.</p>
                <p style="text-align: justify; background-color: #ffffff;">In addition, the Inflation Reduction Act of 2022 includes provisions that impact the U.S. federal income taxation of corporations. Among other items, this legislation includes provisions that impose a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that is imposed on the corporation purchasing such stock. It is unclear how this legislation will be implemented by the U.S. Department of the Treasury and the Company cannot predict how this legislation or any future changes in tax laws might affect the Company or purchasers of the Common Shares.</p>
                <p style="text-align: justify;"><span style="background-color: #ffffff;">A number of international legislative and regulatory bodies have proposed legislation and begun investigations of the tax practices of multinational companies and, in the European Union, the tax policies of certain European Union member states. One of these efforts has been led by the Organization for Economic Co-operation and Development (OECD), which has finalized recommendations to revise corporate tax, transfer pricing, and tax treaty provisions in member countries. On December 15, 2022, European Union member states unanimously adopted the Minimum Tax Directive ensuring a global minimum level of taxation for multinational companies. Member states had until December 31, 2023, to transpose the Minimum Tax Directive into national legislation. The enactment of this and the heightened interest in and taxation of large multinational companies increase tax uncertainty and could ultimately have a material effect on our effective tax rate, income tax expense, net income, or cash flows.</span></p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Failure to develop our internal controls over financial reporting as we grow could have an adverse effect on our operations.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">As we mature we will need to continue to develop and improve our current internal control systems and procedures to manage our growth. We are required to establish and maintain appropriate internal controls over financial reporting. Failure to establish appropriate controls, or any failure of those controls once established, could adversely affect our public disclosures regarding our business, financial condition or results of operations. In addition, management's assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for investors. In connection with the audit of our financials for the year ended December 31, 2021, the Company's auditors noted material weaknesses and made certain recommendations to management regarding material weaknesses related to goodwill impairment testing and purchase price allocations, contract receivables and corresponding revenue and inventory procedures (the "2021 Material Weaknesses"). In connection with the 2021 Material Weaknesses, the Company allocated resources to its remediation plan, including (i) continuing to enhance our impairment testing procedures with the assistance of our third party experts (ii) implementing enhanced credit assessment over the creditworthiness of certain contract receivables and their corresponding revenue and (iii) implementing regularly scheduled physical inventory counts in all company locations and reconciling with internal accounting records. As of December 31, 2022, management believed the 2021 Material Weaknesses relating to its contract receivables and corresponding revenue and investor procedures have been fully remediated.</p>
                <div>
                    <p style="text-align: center;">315</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_254_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">However, in connection with the audit of our financials for the year ended December 31, 2022, our auditors noted that the material weakness with respect to goodwill impairment testing and purchase price allocations remains un-remediated (the "2022 Material Weakness"). In connection with the 2022 Material Weakness, management has, and will continue to, allocate resources to its remediation plan, which include (i) the establishment of additional internal procedures with respect to the documentation of budget and forecasting process with respect to material assumptions or determinations, (ii) the implementation of a new validation process to bolster accuracy of underlying assumptions and (iii) the assessment of our third party experts engaged to assist in the accuracy of our impairment testing. As of December 31, 2023, management believes the 2022 Material Weaknesses relating to its goodwill impairment testing and purchase price allocations have been fully remediated.</p>
                <p style="text-align: justify; background-color: #ffffff;">Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting, disclosure of management's assessment of our internal controls over financial reporting or disclosure of our public accounting firm's attestation to or report on management's assessment of our internal controls over financial reporting may have an adverse effect on the price of our Common Shares.&#160;</p>
                <p style="text-align: justify;"><b>RISKS RELATED TO OUR COMMON SHARES</b></p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We will need, but may be unable to, obtain additional funding on satisfactory terms, which could dilute our shareholders or impose burdensome financial restrictions on our business.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">In the future, we hope to rely on revenues generated from operations to fund all of the cash requirements of our activities. However, there can be no assurance that we will be able to generate any significant cash from our operating activities in the future. Future financings may not be available on a timely basis, in sufficient amounts or on terms acceptable to us, if at all. Any debt financing or other financing of securities senior to the Common Shares will likely include financial and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a material adverse effect on our business, prospects, financial condition and results of operations because we could lose our existing sources of funding and impair our ability to secure new sources of funding. There can be no assurance that we will be able to generate any investor interest in our securities. If we do not obtain additional financing, our business may never commence, in which case you would likely lose the entirety of your investment in the Company.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Holders of our Common Shares are subject to dilution resulting from the issuance of equity-based compensation by us.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We have awarded stock options and restricted common shares to our management and key employees to incentivize their performance and retention. Any additional equity grants and any exercise of existing warrants will cause our shareholders to be diluted and may negatively affect the price of the Common Shares.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We continue to incur increased costs as a result of operating as a public company and our management is required to devote substantial time to new compliance initiatives.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">As a public company, particularly after we are no longer an emerging growth company, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2022 ("Sarbanes-Oxley Act"), and rules implemented by the SEC and Nasdaq, impose various requirements on public companies, including requirements to file annual, quarterly and event-driven reports with respect to our business and financial condition and operations and establish and maintain effective disclosure and financial controls and corporate governance practices. Our existing management team will continue to devote a substantial amount of time to these compliance initiatives, and we may need to hire additional personnel to assist us with complying with these requirements. Moreover, these rules and regulations will continue to increase our legal and financial compliance costs and will make some activities more time consuming and costly.</p>
                <p style="text-align: justify; background-color: #ffffff;">Pursuant to Section 404 of the Sarbanes-Oxley Act ("Section 404"), we will be required to furnish a report by our management on our internal controls over financial reporting, which, after we are no longer an emerging growth company, must be accompanied by an attestation report on internal controls over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will document and evaluate our internal controls over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal controls over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal controls over financial reporting.</p>
                <div>
                    <p style="text-align: center;">316</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_255_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some public company required activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We continue to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and divert management's time and attention from revenue generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>If we fail to meet applicable listing requirements, Nasdaq may delist our Common Shares from trading, in which case the liquidity and market price of our Common Shares could decline.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We cannot assure you that we will be able to meet the continued listing standards of Nasdaq currently or in the future. Nasdaq imposes, among other requirements, continued listing standards including a minimum bid requirement.</p>
                <p style="text-align: justify; background-color: #ffffff;">The price of our Common Shares must trade at or above $1.00 to comply with the minimum bid requirement for continued listing on the Nasdaq Capital Market. On July 8, 2022, the Company was notified by the Nasdaq Stock Market, LLC that it was not in compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive business days as set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq provided a 180-calendar day period following the date of the notice to regain compliance. To regain compliance with the Minimum Bid Price Requirement, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. From June 9, 2023 through June 23, 2023, a period of 10 consecutive trading days, the closing bid price of the Company's Common Shares was greater than $1.00 per share. Accordingly, on June 26, 2023, the Company received formal notice from Nasdaq that it had regained compliance with the Minimum Bid Price Requirement and that the matter has been closed.</p>
                <p style="text-align: justify; background-color: #ffffff;">The audit committee of the Board of Directors of the Company must include three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A). With the resignation of Director Thomas Solomon, the Company informed Nasdaq of the foregoing on December 4, 2023. On December 6, 2023, the Company received a notification from Nasdaq, confirming that, for the reasons described above, the Company no longer complies with Nasdaq's audit committee requirements contained in Nasdaq Listing Rule 5605(c)(2)(A). As set forth in such notification, Nasdaq advised the Company that, under Nasdaq Rule 5605(c)(4), Nasdaq will provide the Company a cure period in order to regain compliance (i) until the earlier of the Company's next annual shareholders' meeting or November 30, 2024, or (ii) if the next annual shareholders' meeting is held before May 28, 2024, then the Company must evidence compliance no later than May 28, 2024.</p>
                <p style="text-align: justify; background-color: #ffffff;">If the Company fails to regain compliance with the audit committee requirement, or if we otherwise fail to meet any other applicable requirements of the Nasdaq and we are unable to regain compliance, Nasdaq may make a determination to delist our Common Shares. Any delisting of our Common Shares would likely adversely affect the market liquidity and market price of our Common Shares and our ability to obtain financing for the continuation of our operations or result in the loss of confidence by investors.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Ownership of our Common Shares may be considered unlawful in some jurisdictions and holders of our Common Shares may consequently be subject to liability in such jurisdictions.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Cannabis-related financial transactions, including investment in the securities of cannabis companies and receipt of any associated benefits, such as dividends, are currently subject to anti-money laundering and a variety of other laws that vary by jurisdiction, many of which are unsettled and still developing. While the interpretation of these laws is unclear, in some jurisdictions, financial benefit directly or indirectly arising from conduct that would be considered unlawful in such jurisdiction may be viewed to be within the purview of these laws, and persons receiving any such benefit, including investors in an applicable jurisdiction, may be subject to liability under such laws. Each prospective investor should therefore contact his, her or its own legal advisor regarding the ownership of our Common Shares and any related potential liability.</p>
                <div>
                    <p style="text-align: center;">317</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_256_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>The Company's directors and officers may have a conflict of interest in conducting their duties.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We may be subject to various potential conflicts of interest because of the fact that some of our officers and directors may be engaged in a range of business activities. In addition, our executive officers and directors may devote time to their outside business interests, so long as such activities do not materially or adversely interfere with their duties to the Company. In some cases, our executive officers and directors may have fiduciary obligations associated with these business interests that interfere with their ability to devote time to our business and affairs and that could adversely affect our operations. These business interests could require significant time and attention of our executive officers and directors.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>As of January 1, 2023, we were required to report as a U.S. domestic issuer and the benefits of a "foreign private issuer" are no longer available to us, which will likely result in additional costs and expenses for us.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">On January 1, 2023, we lost our status as a "foreign private issuer" (within the meaning of Rule 3b-4 of the Exchange Act). Complying with these additional requirements increases our legal and audit fees which in turn, could have a material adverse effect on our business, financial condition and results of operations. As a result of being considered a "domestic issuer" for reporting and disclosure requirements. We were required to adjust our disclosure and reporting to comply with the requirements for domestic U.S. companies, including that:</p>
                <div style="margin-top: 14pt; margin-left: 45.6pt; margin-bottom: 14pt; background-color: #ffffff;">
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>we are required to prepare and report on forms that are applicable to U.S. domestic issuers, such as Forms 10-K, 10-Q and 8-K, rather than the forms formerly used by us, such as Forms 20-F and 6-K&#894;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>we are required to prepare and file proxy statements in accordance with SEC rules&#894;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>we are no longer exempt from certain requirements of U.S. securities laws such as (i) Regulation FD, which restricts the selective disclosure of material information, (ii) exemptions for filing beneficial ownership reports under Section 16(a) of the Exchange Act for executive officers, directors and 10% shareholders (Forms 3, 4, and 5), and (iii) the Section 16(b) short swing profit rules&#894;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>we are no longer permitted to disclose compensation information for our executive officers on an aggregate rather than an individual basis, although such exemption may still be available to us as long as we remain an "emerging growth company"; and</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>we have lost the ability to rely upon exemptions from U.S. stock exchange rules related to corporate governance requirements that are available to foreign private issuers.</p>
                </div>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">We expect that complying with these additional requirements would increase our legal and audit fees which in turn, could have a material adverse effect on our business, financial condition and results of operations. In addition, as a result of being considered a "domestic issuer" for reporting and disclosure requirements:</p>
                <div style="margin-top: 14pt; margin-left: 45.6pt; margin-bottom: 14pt; background-color: #ffffff;">
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>we are no longer exempt from certain requirements of U.S. securities laws such as (i) Regulation FD, which restricts the selective disclosure of material information, (ii) exemptions for filing beneficial ownership reports under Section 16(a) of the Exchange Act for executive officers, directors and 10% shareholders (Forms 3, 4, and 5), and (iii) the Section 16(b) short swing profit rules&#894;</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>we are no longer permitted to disclose compensation information for our executive officers on an aggregate rather than an individual basis, although such exemption may still be available to us as long as we remain an "emerging growth company"; and</p>
                    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#8226;<span style="width: 13.4pt; text-indent: 0pt; display: inline-block;">&#160;</span>we have lost the ability to rely upon exemptions from Nasdaq corporate governance requirements that are available to foreign private issuers.</p>
                </div>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">As a foreign private issuer, we were permitted to follow, and had followed through December 31, 2022, certain home country corporate governance practices instead of those otherwise required under Nasdaq rules for domestic U.S. issuers. For instance, we followed home country practice in Canada with regard to the lack of need to obtain shareholder approval for certain dilutive events such as (i) the establishment or amendment of certain equity-based compensation plans and (ii) certain transactions other than a public offering involving issuances of a 20% or more interest in the company.</p>
                <div>
                    <p style="text-align: center;">318</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_257_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>The regulated nature of our business may impede or discourage a takeover, which could reduce the market price of our Common Shares.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We require and hold various government licenses to operate our business. These licensing requirements could impede a merger, amalgamation, takeover or other business combination involving us or discourage a potential acquirer from making a tender offer for our Common Shares, which, under certain circumstances, could reduce the market price of our Common Shares.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We do not intend to pay dividends on our Common Shares in the near future, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our Common Shares.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We have never declared or paid any cash dividend on our Common Shares and do not currently intend to do so in the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. Therefore, the success of an investment in the Common Shares will depend upon any future appreciation in their value. There is no guarantee that the Common Shares will appreciate in value or even maintain the price at which you purchased them.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We are an emerging growth company and a smaller reporting company, and our compliance with the reduced reporting and disclosure requirements applicable to emerging growth companies and smaller reporting companies could make our Common Shares less attractive to investors and may make it more difficult to raise capital as and when we need it.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We are an "emerging growth company", as defined in the Jumpstart our Business Startups Act of 2012, referred to as the JOBS Act, and we expect to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved and extended adoption period for accounting pronouncements.</p>
                <p style="text-align: justify; background-color: #ffffff;">Even after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company," which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 and reduced disclosure obligations regarding executive compensation in this Annual Report and our periodic reports and proxy statements.</p>
                <p style="text-align: justify; background-color: #ffffff;">We cannot predict whether investors will find our Common Shares less attractive as a result of our reliance on these exemptions. If some investors find our Common Shares less attractive as a result, there may be a less active trading market for our Common Shares and our stock price may be more volatile.</p>
                <p style="text-align: justify; background-color: #ffffff;">Additionally, because of the exemptions from various reporting requirements provided to us as an emerging growth company, we may be less attractive to investors and it may be difficult for us to raise additional capital as and when we need it. Investors may be unable to compare our business with other companies in our industry if they believe that our reporting is not as transparent as the reporting of other companies in our industry. If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially and adversely affected.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>Future issuances of debt securities, which would rank senior to our Common Shares upon our bankruptcy or liquidation, and future issuances of preferred stock, which could rank senior to our Common Shares for the purposes of dividends and liquidating distributions, may adversely affect the level of return you may be able to achieve from an investment in our Common Shares.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">In the future, we may attempt to increase our capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of our debt securities, and lenders with respect to other borrowings we may make, would receive distributions of our available assets prior to any distributions being made to holders of our Common Shares. Moreover, if we issue preferred stock, the holders of such preferred stock could be entitled to preferences over holders of Common Shares in respect of the payment of dividends and the payment of liquidating distributions. Because our decision to issue debt or preferred stock in any future offering, or borrow money from lenders, will depend in part on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any such future offerings or borrowings. Holders of our Common Shares must bear the risk that any future offerings we conduct or borrowings we make may adversely affect the level of return, if any, they may be able to achieve from an investment in our Common Shares.</p>
                <div>
                    <p style="text-align: center;">319</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_258_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>If the price of our Common Shares fluctuates, you could lose a significant part of your investment.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The market price of our Common Shares could be subject to wide fluctuations in response to, among other things, the risk factors described in this section of this Annual Report, and other factors beyond our control, such as fluctuations in the valuation of companies perceived by investors to be comparable to us. Furthermore, the stock markets have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political, and market conditions, such as recessions, interest rate changes or international currency fluctuations, may negatively affect the market price of our Common Shares. In the past, many companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management's attention from other business concerns, which could seriously harm our business.</p>
                <p style="text-align: justify; background-color: #ffffff;">Volatility in the market price of our Common Shares may prevent investors from being able to sell their shares at or above the public offering price. As a result, you may suffer a loss on your investment.</p>
                <p style="text-align: justify;"><b>GENERAL RISK FACTORS</b></p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The Company may become involved in legal proceedings from time to time, which could adversely affect the Company.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">From time to time, we may be a party to legal and regulatory proceedings, including matters involving governmental agencies, entities with whom it does business and other proceedings arising in the ordinary course of business. We will evaluate our exposure to these legal and regulatory proceedings and establish reserves for the estimated liabilities in accordance with generally accepted accounting principles. For more information, see Item 3 "Legal Proceedings." Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management's evaluations or predictions and accompanying changes in established reserves, could have an adverse impact on our financial results.</p>
                <p style="text-align: justify; background-color: #ffffff;">Our participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by third parties, other companies and/or various governmental authorities against us. Litigation, complaints, and enforcement actions involving us could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on our future cash flows, earnings, results of operations and financial condition.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>The Company's success will depend, in part, on its ability to continue to enhance its product and service offerings to respond to technological and regulatory changes and emerging industry standards and practices.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Rapidly changing markets, technology, emerging industry and regulatory standards and frequent introduction of new products characterize the Company's business. The introduction of new products embodying new technologies and regulatory developments may render the Company's equipment obsolete and its products and services less competitive or less marketable. The process of developing the Company's products and services is complex and requires significant continuing costs, development efforts, third-party commitments and regulatory approvals. The Company may not be successful in developing or effectively commercializing such new products and services, or obtaining any required regulatory approvals, which, together with any capital expenditures made in the course of developing such products and services, may have a material adverse effect on the Company's business, financial condition and operating results.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We are dependent upon our management and key employees, and the loss of any member of our management team or key employees could have a material adverse effect on our operations.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The Company's success is dependent upon the ability, expertise, judgment, discretion and good faith of its senior management and key employees. The loss of any member of our management team or key employees could have a material adverse effect on our business and results of operations. While employment agreements and incentive programs are customarily used as primary methods of retaining the services of key employees, these agreements and incentive programs cannot assure the continued services of such employees. Any loss of the services of such individuals, or an inability to attract other suitably qualified persons when needed, could have a material adverse effect on the Company's business, operating results or financial condition. We do not currently maintain key-person insurance on the lives of any of our key employees. Competition for qualified technical, sales and marketing staff, as well as officers and directors can be intense, and no assurance can be provided that the Company will be able to attract or retain key employees in the future, which may adversely affect the Company's operations.</p>
                <div>
                    <p style="text-align: center;">320</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_259_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;">&#160;</p>
            </div>
            <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>Our inability to retain and acquire skilled personnel could impair our business and operations.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The loss of any member of our management team could have a material adverse effect on our business and results of operations. In addition, the inability to hire or the increased costs of hiring new personnel, including members of executive management, could have a material adverse effect on our business and operating results. The expansion of marketing and sales of our products will require us to find, hire and retain additional capable employees who can understand, explain, market and sell our products. There is intense competition for capable personnel in all of these areas and we may not be successful in attracting, training, integrating, motivating, or retaining new personnel, vendors, or subcontractors for these required functions. New employees often require significant training and, in many cases, take a significant amount of time before they achieve full productivity. As a result, we may incur significant costs to attract and retain employees, including significant expenditures related to salaries and benefits and compensation expenses issued in connection to equity awards, and we may lose new employees to our competitors or other companies before we realize the benefit of our investment in recruiting and training them. In addition, as we move into new jurisdictions, we will need to attract and recruit skilled employees in those new areas.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We will need to grow the size of our organization, and we may experience difficulties in managing any growth we may achieve.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">As our development and commercialization plans and strategies develop, we expect to need additional research, development, managerial, operational, sales, marketing, financial, accounting, legal and other resources. Future growth would impose significant added responsibilities on members of management. In order to manage growth and changes in strategy effectively, the Company must: (a) maintain adequate systems to meet customer demand; (b) expand sales and marketing, distribution capabilities, and administrative functions; (c) expand the skills and capabilities of its current management team; and (d) attract and retain qualified employees. Our management may not be able to accommodate those added responsibilities, and our failure to do so could prevent us from effectively managing future growth and successfully growing our Company.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about us, our share price and trading volume could decline.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">The trading market for our Common Shares will depend, in part, on the research and reports that securities or industry analysts publish about us or our operations. We do not have any control over these analysts and their research and reports. If one or more of the analysts who cover us downgrade our shares or publish inaccurate or unfavorable research about our business, our share price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our shares could decrease, which might cause our share price and trading volume to decline.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>We expect to incur significant ongoing costs and obligations related to our investment in infrastructure, growth, regulatory compliance and operations.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">We expect to incur significant ongoing costs and obligations related to our investment in infrastructure and growth and regulatory compliance, which could have a material adverse effect on our results of operations, financial condition and cash flows. In addition, future changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on our business, results of operations and financial condition. Our efforts to grow our business may be costlier than we expect, and we may not be able to generate sufficient revenue to offset such higher operating expenses. We may incur significant losses in the future for a number of reasons, including unforeseen expenses, difficulties, complications and delays, and other unknown events.</p>
                <p style="text-align: justify; background-color: #ffffff;"><i><b>There is no assurance that the Company's insurance coverage will be sufficient to cover all claims to which the Company may become subject.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Our production is, in general, subject to different risks and hazards, including adverse weather conditions, fires, plant diseases and pest infestations, other natural phenomena, industrial accidents, labor disputes, changes in the legal and regulatory framework applicable to us and environmental contingencies.</p>
                <p style="text-align: justify; background-color: #ffffff;">We may not be able to maintain or obtain insurance of the type and amount desired at a reasonable cost. If we were to incur significant liability for which we were not fully insured, it could have an adverse effect on our business, financial condition and results of operations.</p>
                <p style="text-align: justify; background-color: #ffffff;">We do not currently maintain key-person insurance on the lives of any of our key employees.</p>
                <div>
                    <p style="text-align: center;">321</p>
                </div>
                <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><span id="page_260_integixAnchor"></span>
                <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt;"><i><b>We may be unable to implement our business strategy, which could have negative financial and reputational effects on our business.</b></i></p>
                <p style="margin-bottom: 0pt; text-align: justify; background-color: #ffffff;">The growth and expansion of our business is heavily dependent upon the successful implementation of our business strategy. There can be no assurance that we will be successful in the implementation of our business strategy. A failure to do so could have negative financial and reputational effects on us. Future clinical research studies may lead to conclusions that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis.</p>
                <p style="margin-top: 0pt; text-align: justify; background-color: #ffffff;"><br/><i><b>The Company could be subject to a security breach that could result in significant damage or theft of products and equipment.</b></i></p>
                <p style="text-align: justify; background-color: #ffffff;">Breaches of security at our facilities may occur and could result in damage to or theft of products and equipment. A security breach at our facilities could result in a significant loss of inventory or work in process, expose us to liability under applicable regulations and increase expenses relating to the investigation of the breach and implementation of additional preventative security measures, any of which could have an adverse effect on our business, financial condition and results of operations.</p>
                <div>
                    <p style="text-align: center;">322</p>
                </div>
                <hr style="height: 5px; color: #000000; background-color: #000000; width: 100%;"/>
            </div>
            <div>
                <div>
                    <div><br/></div>
                    <span id="page_261_integixAnchor"></span>
                    <p style="text-align: center; background-color: #ffffff; margin-top: 10pt;"><img src="formprer14axz004.jpg" alt="formpre14axu003.jpg" style="width: 757px; height: 980px;"/></p>
                    <hr style="page-break-after: always; width: 100%; color: #000000; height: 5px; background-color: #000000;"/><span id="page_262_integixAnchor"></span>
                    <p style="text-align: center; background-color: #ffffff; margin-top: 10pt;"><img src="formprer14axz005.jpg" alt="formpre14axu004.jpg"/></p>
                </div>
            </div>
            <hr style="height: 5px; color: #000000; background-color: #000000; width: 100%;"/>
        </div>
    </div>

</body>

</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>flgc-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:flgc="http://www.floragrowth.com/20240331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://www.floragrowth.com/20240331" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.floragrowth.com/role/Cover" id="Cover">
        <link:definition>0001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition" id="CondensedInterimConsolidatedStatementsOfFinancialPosition">
        <link:definition>0002 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical" id="CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical">
        <link:definition>0003 - Statement - Consolidated Statements of Financial Position (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" id="ConsolidatedStatementsOfLossAndComprehensiveLoss">
        <link:definition>0004 - Statement - Consolidated Statements of Loss and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLossParenthetical" id="ConsolidatedStatementsOfLossAndComprehensiveLossParenthetical">
        <link:definition>0005 - Statement - Consolidated Statements of Loss and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity" id="ConsolidatedStatementOfStockholdersEquity">
        <link:definition>0006 - Statement - Consolidated Statement of Shareholders' Equity (Deficiency)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/UnauditedCondensedInterimConsolidatedStatementOfShareholdersEquityDeficiencyParentheticals" id="UnauditedCondensedInterimConsolidatedStatementOfShareholdersEquityDeficiencyParentheticals">
        <link:definition>0007 - Statement - Unaudited Condensed Interim Consolidated Statement of Shareholders' Equity (Deficiency) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows" id="ConsolidatedStatementOfCashFlows">
        <link:definition>0008 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>0009 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>0010 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>0011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties" id="CriticalJudgmentsAndEstimationUncertainties">
        <link:definition>0012 - Disclosure - CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS" id="ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS">
        <link:definition>0013 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivable" id="TradeAndAmountsReceivable">
        <link:definition>0014 - Disclosure - TRADE AND AMOUNTS RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/INVENTORY" id="INVENTORY">
        <link:definition>0015 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
        <link:definition>0016 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/INVESTMENTS" id="INVESTMENTS">
        <link:definition>0017 - Disclosure - INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinations" id="AssetAcquisitionsAndBusinessCombinations">
        <link:definition>0018 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
        <link:definition>0019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IMPAIRMENTOFASSETS" id="IMPAIRMENTOFASSETS">
        <link:definition>0020 - Disclosure - IMPAIRMENT OF ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/DEBT" id="DEBT">
        <link:definition>0021 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LEASES" id="LEASES">
        <link:definition>0022 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ShareCapital" id="ShareCapital">
        <link:definition>0023 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
        <link:definition>0024 - Disclosure - SHARE BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/WARRANTS" id="WARRANTS">
        <link:definition>0025 - Disclosure - WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosures" id="RelatedPartyDisclosures">
        <link:definition>0026 - Disclosure - RELATED PARTY DISCLOSURES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>0027 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0028 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LossPerShare" id="LossPerShare">
        <link:definition>0029 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/FinancialInstruments" id="FinancialInstruments">
        <link:definition>0030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/CapitalManagement" id="CapitalManagement">
        <link:definition>0031 - Disclosure - CAPITAL MANAGEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SegmentedInformation" id="SegmentedInformation">
        <link:definition>0032 - Disclosure - SEGMENTED INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0033 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <link:definition>0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/BasisOfPresentationTables" id="BasisOfPresentationTables">
        <link:definition>0035 - Disclosure - BASIS OF PRESENTATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
        <link:definition>0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables" id="ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables">
        <link:definition>0037 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableTables" id="TradeAndAmountsReceivableTables">
        <link:definition>0038 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/InventoryTables" id="InventoryTables">
        <link:definition>0039 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
        <link:definition>0040 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/InvestmentsTables" id="InvestmentsTables">
        <link:definition>0041 - Disclosure - INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables" id="AssetAcquisitionsAndBusinessCombinationsTables">
        <link:definition>0042 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
        <link:definition>0043 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LeasesTables" id="LeasesTables">
        <link:definition>0044 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
        <link:definition>0045 - Disclosure - SHARE BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/WarrantsTables" id="WarrantsTables">
        <link:definition>0046 - Disclosure - WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresTables" id="RelatedPartyDisclosuresTables">
        <link:definition>0047 - Disclosure - RELATED PARTY DISCLOSURES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>0048 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>0049 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LossPerShareTables" id="LossPerShareTables">
        <link:definition>0050 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/FinancialInstrumentsTables" id="FinancialInstrumentsTables">
        <link:definition>0051 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SegmentedInformationTables" id="SegmentedInformationTables">
        <link:definition>0052 - Disclosure - SEGMENTED INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
        <link:definition>0053 - Disclosure - BASIS OF PRESENTATION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/BasisOfPresentationDetails" id="BasisOfPresentationDetails">
        <link:definition>0054 - Disclosure - BASIS OF PRESENTATION (Schedule of subsidiaries) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
        <link:definition>0055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
        <link:definition>0056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of assets estimated useful lives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1" id="SignificantAccountingPoliciesDetails1">
        <link:definition>0057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of intangible assets estimated useful lives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails" id="ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails">
        <link:definition>0058 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails" id="ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails">
        <link:definition>0059 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of major classes of assets and liabilities held for sale) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1" id="ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1">
        <link:definition>0060 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of loss from discontinued operations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2" id="ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2">
        <link:definition>0061 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of significant operating and investing items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails" id="TRADEANDAMOUNTSRECEIVABLENarrativeDetails">
        <link:definition>0062 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails" id="TradeAndAmountsReceivableDetails">
        <link:definition>0063 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of trade and other receivables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1" id="TradeAndAmountsReceivableDetails1">
        <link:definition>0064 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of aging of trade accounts receivable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2" id="TradeAndAmountsReceivableDetails2">
        <link:definition>0065 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of allowance for expected credit losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/InventoryDetailsNarrative" id="InventoryDetailsNarrative">
        <link:definition>0066 - Disclosure - INVENTORY (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/InventoryDetails" id="InventoryDetails">
        <link:definition>0067 - Disclosure - INVENTORY (Schedule of inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative" id="PropertyPlantAndEquipmentDetailsNarrative">
        <link:definition>0068 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails" id="PropertyPlantAndEquipmentDetails">
        <link:definition>0069 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Schedule of property, plant and equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/InvestmentsDetailsNarrative" id="InvestmentsDetailsNarrative">
        <link:definition>0070 - Disclosure - INVESTMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/InvestmentsDetails" id="InvestmentsDetails">
        <link:definition>0071 - Disclosure - INVESTMENTS (Schedule of investments activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative" id="AssetAcquisitionsAndBusinessCombinationsDetailsNarrative">
        <link:definition>0072 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1" id="AssetAcquisitionsAndBusinessCombinationsDetails1">
        <link:definition>0073 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Schedule of major class of assets acquired and liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" id="IntangibleAssetsAndGoodwillDetailsNarrative">
        <link:definition>0074 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails" id="IntangibleAssetsAndGoodwillDetails">
        <link:definition>0075 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of intangible assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/DummyDetails" id="DummyDetails">
        <link:definition>0076 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of amortization) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1" id="IntangibleAssetsAndGoodwillDetails1">
        <link:definition>0077 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of estimation of amortization expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2" id="IntangibleAssetsAndGoodwillDetails2">
        <link:definition>0078 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of goodwill) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative" id="ImpairmentOfAssetsDetailsNarrative">
        <link:definition>0079 - Disclosure - IMPAIRMENT OF ASSETS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
        <link:definition>0080 - Disclosure - DEBT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LEASESNarrativeDetails" id="LEASESNarrativeDetails">
        <link:definition>0081 - Disclosure - LEASES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LeasesDetails" id="LeasesDetails">
        <link:definition>0082 - Disclosure - LEASES (Schedule of leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LeasesDetails1" id="LeasesDetails1">
        <link:definition>0083 - Disclosure - LEASES (Schedule of maturities of operating lease liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1" id="SHARECAPITALDetailsNarrative1">
        <link:definition>0084 - Disclosure - SHARE CAPITAL (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative" id="ShareBasedCompensationDetailsNarrative">
        <link:definition>0085 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails" id="ShareBasedCompensationDetails">
        <link:definition>0086 - Disclosure - SHARE BASED COMPENSATION (Schedule of stock options roll forward) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable" id="SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable">
        <link:definition>0087 - Disclosure - SHARE BASED COMPENSATION (Schedule of stock options outstanding and exercisable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails2" id="ShareBasedCompensationDetails2">
        <link:definition>0088 - Disclosure - SHARE BASED COMPENSATION (Schedule of weighted average inputs and assumptions)  (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails1" id="ShareBasedCompensationDetails1">
        <link:definition>0089 - Disclosure - SHARE BASED COMPENSATION (Schedule of restricted stock awards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
        <link:definition>0090 - Disclosure - WARRANTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/WarrantsDetails" id="WarrantsDetails">
        <link:definition>0091 - Disclosure - WARRANTS (Schedule of warrants outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/WarrantsDetails1" id="WarrantsDetails1">
        <link:definition>0092 - Disclosure - WARRANTS (Schedule of warrants outstanding by date of expiry) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative" id="RelatedPartyDisclosuresDetailsNarrative">
        <link:definition>0093 - Disclosure - RELATED PARTY DISCLOSURES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails" id="RelatedPartyDisclosuresDetails">
        <link:definition>0094 - Disclosure - RELATED PARTY DISCLOSURES (Schedule of key management personnel compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>0095 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>0096 - Disclosure - COMMITMENTS AND CONTINGENCIES (Schedule of provisions and contingent liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
        <link:definition>0097 - Disclosure - INCOME TAXES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>0098 - Disclosure - INCOME TAXES (Schedule of components of the income tax provision) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>0099 - Disclosure - INCOME TAXES  (Schedule of corporate income tax rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
        <link:definition>0100 - Disclosure - INCOME TAXES (Schedule of deferred income tax assets and liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LossPerShareDetailsNarrative" id="LossPerShareDetailsNarrative">
        <link:definition>0101 - Disclosure - LOSS PER SHARE (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/LossPerShareDetails" id="LossPerShareDetails">
        <link:definition>0102 - Disclosure - LOSS PER SHARE (Schedule of anti-dilutive shares) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" id="FinancialInstrumentsAndRiskManagementDetailsNarrative">
        <link:definition>0103 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails" id="FinancialInstrumentsAndRiskManagementDetails">
        <link:definition>0105 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of information about the financial instruments and their classifications) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1" id="FinancialInstrumentsAndRiskManagementDetails1">
        <link:definition>0106 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of assets and liabilities denominated in foreign currencies) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SegmentedInformationDetailsNarrative" id="SegmentedInformationDetailsNarrative">
        <link:definition>0107 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails" id="SegmentedInformationDetails">
        <link:definition>0108 - Disclosure - SEGMENTED INFORMATION (Schedule of operation segments information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SegmentDetails" id="SegmentDetails">
        <link:definition>0109 - Disclosure - SEGMENTED INFORMATION (Schedule of other significant items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails1" id="SegmentedInformationDetails1">
        <link:definition>0110 - Disclosure - SEGMENTED INFORMATION (Schedule of disaggregation of net sales by geographic area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails3" id="SegmentedInformationDetails3">
        <link:definition>0111 - Disclosure - SEGMENTED INFORMATION  (Schedule of disaggregation of property, plant and equipment and other long-lived assets by geographic area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>0112 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="flgc-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="flgc-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="flgc-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="flgc-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="ACAMullerMember" id="flgc_ACAMullerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" id="flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AcquisitionOfNoncontrollingInterestAmount" id="flgc_AcquisitionOfNoncontrollingInterestAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AcquisitionOfNoncontrollingInterestMember" id="flgc_AcquisitionOfNoncontrollingInterestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AcquisitionOfNoncontrollingInterestShares" id="flgc_AcquisitionOfNoncontrollingInterestShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdditionalLegalDisputesMember" id="flgc_AdditionalLegalDisputesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdditionalPaidAmount" id="flgc_AdditionalPaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdditonalyCancelledSharesValue" id="flgc_AdditonalyCancelledSharesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AegisCapitalCorpMember" id="flgc_AegisCapitalCorpMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementAxis" id="flgc_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="AgreementDomain" id="flgc_AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountPayableOfProfitsForAdditionalAmount" id="flgc_AmountPayableOfProfitsForAdditionalAmount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountsPayablePerViolationOfStopSaleOrders" id="flgc_AmountsPayablePerViolationOfStopSaleOrders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AnnualGoodwillImpairmentTestOfFghMember" id="flgc_AnnualGoodwillImpairmentTestOfFghMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualGoodwillImpairmentTestOfJustCBDMember" id="flgc_AnnualGoodwillImpairmentTestOfJustCBDMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualGoodwillImpairmentTestOfPharmaceuticalsMember" id="flgc_AnnualGoodwillImpairmentTestOfPharmaceuticalsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent" id="flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BasisOfAccountingAxis" id="flgc_BasisOfAccountingAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="BasisOfAccountingLineItems" id="flgc_BasisOfAccountingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BasisOfAccountingTable" id="flgc_BasisOfAccountingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="BasisOfMeasurementPolicyTextBlock" id="flgc_BasisOfMeasurementPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BearsInterestRate" id="flgc_BearsInterestRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BousteadSecuritiesLLCMember" id="flgc_BousteadSecuritiesLLCMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BreezeAcquisitionMember" id="flgc_BreezeAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BreezeLaboratorySasMember" id="flgc_BreezeLaboratorySasMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" id="flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" id="flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables" id="flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships" id="flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax" id="flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" id="flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CanadaIncomeTaxAuthorityMember" id="flgc_CanadaIncomeTaxAuthorityMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CancelledShares" id="flgc_CancelledShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CapitalManagementAbstract" id="flgc_CapitalManagementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CapitalManagementDisclosureTextBlock" id="flgc_CapitalManagementDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashConsiderationReturned" id="flgc_CashConsiderationReturned" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashEquivalentsAtCarryingValue1" id="flgc_CashEquivalentsAtCarryingValue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashFlowModelHighRate" id="flgc_CashFlowModelHighRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashFlowModelLowRate" id="flgc_CashFlowModelLowRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashPaid" id="flgc_CashPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ClassicPlanPremiumFinancingMember" id="flgc_ClassicPlanPremiumFinancingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ColombianRelatedSubsidiariesAndColombianAssetsMember" id="flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ColombiaRevenueAgencyMember" id="flgc_ColombiaRevenueAgencyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommercialAndWholesaleMember" id="flgc_CommercialAndWholesaleMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommercialAndWholesaleSegmentMember" id="flgc_CommercialAndWholesaleSegmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonSharesDeliveredToTheSellers" id="flgc_CommonSharesDeliveredToTheSellers" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonSharesIssuedForInvestmentsAmount" id="flgc_CommonSharesIssuedForInvestmentsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CommonSharesIssuedForInvestmentsShares" id="flgc_CommonSharesIssuedForInvestmentsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonSharesIssuedForOtherAgreementsAmount" id="flgc_CommonSharesIssuedForOtherAgreementsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CommonSharesIssuedForOtherAgreementsShares" id="flgc_CommonSharesIssuedForOtherAgreementsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockIssuedForRsusVested" id="flgc_CommonStockIssuedForRsusVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CompanyValued" id="flgc_CompanyValued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConsolidatedMember" id="flgc_ConsolidatedMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsolidatedRevenue" id="flgc_ConsolidatedRevenue" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Contributionamont" id="flgc_Contributionamont" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="Contributionshares" id="flgc_Contributionshares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CorporateAndEliminationsMember" id="flgc_CorporateAndEliminationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CorporateIncomeTax" id="flgc_CorporateIncomeTax" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CosechemosAndKasaWholefoodsMember" id="flgc_CosechemosAndKasaWholefoodsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CreditFacilityDue" id="flgc_CreditFacilityDue" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CriticalJudgmentsAndEstimationUncertaintiesAbstract" id="flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CumulativeImpairmentRelatedToCommonShares" id="flgc_CumulativeImpairmentRelatedToCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrentPortionOfContingentPurchaseConsideration" id="flgc_CurrentPortionOfContingentPurchaseConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrentTaxExpenseIncome" id="flgc_CurrentTaxExpenseIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CustomersRelationshipsMember" id="flgc_CustomersRelationshipsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DecemberTwoThousandTwentyTwoUnitOfferingMember" id="flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DecemberUnitOfferingAmount" id="flgc_DecemberUnitOfferingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DecemberUnitOfferingIssuanceCosts" id="flgc_DecemberUnitOfferingIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DecemberUnitOfferingShares" id="flgc_DecemberUnitOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DeferredTaxAssetsAllowanceForDoubtfulAccounts" id="flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsGoodwil" id="flgc_DeferredTaxAssetsGoodwil" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsIntangibleAssets" id="flgc_DeferredTaxAssetsIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsRightOfUseAssets" id="flgc_DeferredTaxAssetsRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsShareIssuanceCosts" id="flgc_DeferredTaxAssetsShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsUnrealizedGainsLossesOnInvestments" id="flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxExpenseIncome" id="flgc_DeferredTaxExpenseIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxLiabilitiesAmount" id="flgc_DeferredTaxLiabilitiesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeferredTaxLiabilitiesNet" id="flgc_DeferredTaxLiabilitiesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DenmarkRevenueAgencyMember" id="flgc_DenmarkRevenueAgencyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerecognitionOfEquityRelatedToColombiaAssets" id="flgc_DerecognitionOfEquityRelatedToColombiaAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DescriptionOfDiscountRates" id="flgc_DescriptionOfDiscountRates" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfExchangeRate" id="flgc_DescriptionOfExchangeRate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfExpectedVolatilityShareOptionsGranted" id="flgc_DescriptionOfExpectedVolatilityShareOptionsGranted" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfImpairment" id="flgc_DescriptionOfImpairment" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfRevenueGrowth" id="flgc_DescriptionOfRevenueGrowth" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfRiskFreeInterestRateShareOptionsGranted" id="flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfSensitivityAnalysis" id="flgc_DescriptionOfSensitivityAnalysis" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfShares" id="flgc_DescriptionOfShares" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfTaxJurisdictions" id="flgc_DescriptionOfTaxJurisdictions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfValuation" id="flgc_DescriptionOfValuation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DiscountRate" id="flgc_DiscountRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationAssetImpairment" id="flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" id="flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" id="flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" id="flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationLongTermDebt" id="flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" id="flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" id="flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" id="flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationProfessionalFees" id="flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" id="flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DrManaloMorganMember" id="flgc_DrManaloMorganMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate" id="flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityIssuedForOtherAgreementsAmount" id="flgc_EquityIssuedForOtherAgreementsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EquityIssuedForOtherAgreementsShares" id="flgc_EquityIssuedForOtherAgreementsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EstimatedImpactOfPotentialExchangeRateFluctuations" id="flgc_EstimatedImpactOfPotentialExchangeRateFluctuations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EstimatedLossOnPotentialLiabilities" id="flgc_EstimatedLossOnPotentialLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EstimatedRecoverableAmount" id="flgc_EstimatedRecoverableAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EuroCreditFacilityMember" id="flgc_EuroCreditFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceOfInvestmentWarrants" id="flgc_ExercisePriceOfInvestmentWarrants" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpectedDividendAsPercentageShareOptionsGranted" id="flgc_ExpectedDividendAsPercentageShareOptionsGranted" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpectedLife" id="flgc_ExpectedLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpectedOptionLifeInYears" id="flgc_ExpectedOptionLifeInYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExpectedSharesToBeIssued" id="flgc_ExpectedSharesToBeIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss" id="flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueDiscount" id="flgc_FairValueDiscount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfNonemployeeStockWarrantsGranted" id="flgc_FairValueOfNonemployeeStockWarrantsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfRestrictedStockAwardsIssued" id="flgc_FairValueOfRestrictedStockAwardsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantsIssuedDuringPeriod" id="flgc_FairValueOfWarrantsIssuedDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FGHMember" id="flgc_FGHMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FGHOwnersMember" id="flgc_FGHOwnersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" id="flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FinancialInstrumentsAbstract" id="flgc_FinancialInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialInstrumentsAndRiskManagementAbstract" id="flgc_FinancialInstrumentsAndRiskManagementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialIntermediariesMember" id="flgc_FinancialIntermediariesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialLiabilitiesPolicyTextBlock" id="flgc_FinancialLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancingReceivables180PlusDaysPastDueMember" id="flgc_FinancingReceivables180PlusDaysPastDueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FiniteLivedIntangibleAssetsAdditions" id="flgc_FiniteLivedIntangibleAssetsAdditions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FirstClosingMember" id="flgc_FirstClosingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FirstLoanAgreementMember" id="flgc_FirstLoanAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FirstLoanMember" id="flgc_FirstLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FirstTrancheMember" id="flgc_FirstTrancheMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FixedAssets" id="flgc_FixedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FloraBeautyMember" id="flgc_FloraBeautyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FloraBreezeLaboratoryMember" id="flgc_FloraBreezeLaboratoryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FloraGrowthCorpMember" id="flgc_FloraGrowthCorpMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FloraMedSasMember" id="flgc_FloraMedSasMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FoodAndBeveragesMember" id="flgc_FoodAndBeveragesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ForeignExchangeImpacts" id="flgc_ForeignExchangeImpacts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ForeignIncomeTaxAuthorityMember" id="flgc_ForeignIncomeTaxAuthorityMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ForeignRevenueAgencyMember" id="flgc_ForeignRevenueAgencyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FortLauderdaleMember" id="flgc_FortLauderdaleMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FranchiseGlobalHealthIncMember" id="flgc_FranchiseGlobalHealthIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FunctionalCurrencyOfSubsidiary" id="flgc_FunctionalCurrencyOfSubsidiary" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GerardoAndresGarciaMendezMember" id="flgc_GerardoAndresGarciaMendezMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GermanSubsidiariesMember" id="flgc_GermanSubsidiariesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GermanyRevenueAgencyMember" id="flgc_GermanyRevenueAgencyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GoingConcernPolicyTextBlock" id="flgc_GoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GoodwillAndIdentifiedIntangibleAssets" id="flgc_GoodwillAndIdentifiedIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="GoodwillDescription" id="flgc_GoodwillDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrantDateFairValueOfWarrantsOutstanding" id="flgc_GrantDateFairValueOfWarrantsOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GrupoFarmaceuticoCronomedSasMember" id="flgc_GrupoFarmaceuticoCronomedSasMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HampsteadPrivateCapitalLimitedMember" id="flgc_HampsteadPrivateCapitalLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HarvestedCannabis" id="flgc_HarvestedCannabis" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember" id="flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HouseOfBrandsMember" id="flgc_HouseOfBrandsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HouseOfBrandsSegmentMember" id="flgc_HouseOfBrandsSegmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HypoverinsbankMember" id="flgc_HypoverinsbankMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ImpairmentOfAssetsAbstract" id="flgc_ImpairmentOfAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ImpairmentOfGoodwill" id="flgc_ImpairmentOfGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ImpairmentOfLicenses" id="flgc_ImpairmentOfLicenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ImpairmentOfPatents" id="flgc_ImpairmentOfPatents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ImpairmentOfPropertyPlantAndEquipment" id="flgc_ImpairmentOfPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseInCarryingValueOfAssets" id="flgc_IncreaseInCarryingValueOfAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IndemnificationReceivables" id="flgc_IndemnificationReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InitialPublicOfferingAmount" id="flgc_InitialPublicOfferingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="InitialPublicOfferingIssuanceCostsAmount" id="flgc_InitialPublicOfferingIssuanceCostsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="InitialPublicOfferingIssuanceCostsShares" id="flgc_InitialPublicOfferingIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InitialPublicOfferingMember" id="flgc_InitialPublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InitialPublicOfferingShares" id="flgc_InitialPublicOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IntangibleAssetsAcquiredForContingentConsiderationNonCash" id="flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IntrinsicValueOfWarrantsExercised" id="flgc_IntrinsicValueOfWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="InventoryAbstract" id="flgc_InventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InventoryExpensedToCostOfSales" id="flgc_InventoryExpensedToCostOfSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InventoryImpactedByStopSaleOrders" id="flgc_InventoryImpactedByStopSaleOrders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="InvesteeCommonSharesMember" id="flgc_InvesteeCommonSharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InvestingActivitiesOfDiscontinuedOperationsAbstract" id="flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InvestmentDescription" id="flgc_InvestmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InvestmentExercisePrice" id="flgc_InvestmentExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceCosts" id="flgc_IssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="JustBrandsLlcAndHighRollerPrivateLabelLlcMember" id="flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="JustBrandsLLCMember" id="flgc_JustBrandsLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="JustCBDInsurancePremiumLoanMember" id="flgc_JustCBDInsurancePremiumLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="JustCBDMember" id="flgc_JustCBDMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="JustCBDOwnersMember" id="flgc_JustCBDOwnersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="KnowHowMember" id="flgc_KnowHowMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeaseLiabilities" id="flgc_LeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LeaseObligations" id="flgc_LeaseObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LeasesMonthlyAmount" id="flgc_LeasesMonthlyAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LegalDisputesMember" id="flgc_LegalDisputesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiabilitiesAmount" id="flgc_LiabilitiesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" id="flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent" id="flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LicensesAndTrademarksMember" id="flgc_LicensesAndTrademarksMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicensesMember" id="flgc_LicensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LisanFarmaColombiaLLCMember" id="flgc_LisanFarmaColombiaLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanAgreementsAxis" id="flgc_LoanAgreementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="LoanAgreementsDomain" id="flgc_LoanAgreementsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanRepaymentsReceived" id="flgc_LoanRepaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LoansProvided" id="flgc_LoansProvided" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LoansReceivableAndAdvances" id="flgc_LoansReceivableAndAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossContingencyAccrualForeignCurrencyTranslation" id="flgc_LossContingencyAccrualForeignCurrencyTranslation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" id="flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares" id="flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LossContingencyEstimateOfPossibleLossInterestAccrued" id="flgc_LossContingencyEstimateOfPossibleLossInterestAccrued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossContingencyInterestPaymentTerms" id="flgc_LossContingencyInterestPaymentTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MachineryAndOfficeEquipmentMember" id="flgc_MachineryAndOfficeEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ManagementContractsTerms" id="flgc_ManagementContractsTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" id="flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumLimitOfIndemnificationAgreement" id="flgc_MaximumLimitOfIndemnificationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MaximumPaymentAccumulatedForValuation" id="flgc_MaximumPaymentAccumulatedForValuation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MaximumPortionOfNetProfitsPayable" id="flgc_MaximumPortionOfNetProfitsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MedicalServices" id="flgc_MedicalServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonthlyLeasePayment" id="flgc_MonthlyLeasePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NameOfSubsidiary" id="flgc_NameOfSubsidiary" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndGoingConcernAbstract" id="flgc_NatureOfOperationsAndGoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NetDeferredTaxLiabilities" id="flgc_NetDeferredTaxLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NoCapHempCoMember" id="flgc_NoCapHempCoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonCapitalLossCarryforwards" id="flgc_NonCapitalLossCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonCashAssetsAcquiredForContingentConsideration" id="flgc_NonCashAssetsAcquiredForContingentConsideration" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonCashCommonSharesIssuedForBusinessCombinations" id="flgc_NonCashCommonSharesIssuedForBusinessCombinations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonCashCommonSharesIssuedForOtherAgreements" id="flgc_NonCashCommonSharesIssuedForOtherAgreements" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonCashOperatingLeaseAdditionsToRightOfUseAssets" id="flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonCashOptionCancellationsReclassifiedToEquity" id="flgc_NonCashOptionCancellationsReclassifiedToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonControllingInterestsPolicyTextBlock" id="flgc_NonControllingInterestsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonVestedShares" id="flgc_NonVestedShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NovemberTwoThousandTwentyOneUnitOfferingMember" id="flgc_NovemberTwoThousandTwentyOneUnitOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfSharesUnderPlaintiffClaim" id="flgc_NumberOfSharesUnderPlaintiffClaim" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfTrials" id="flgc_NumberOfTrials" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfViolationsClaimed" id="flgc_NumberOfViolationsClaimed" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfViolationsInStopSaleOrders" id="flgc_NumberOfViolationsInStopSaleOrders" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsCancelledExpired" id="flgc_NumberOfWarrantsCancelledExpired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsIssuedDuringPeriod" id="flgc_NumberOfWarrantsIssuedDuringPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsWithAmendedExercisePrice" id="flgc_NumberOfWarrantsWithAmendedExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsWithExercisePriceAmended" id="flgc_NumberOfWarrantsWithExercisePriceAmended" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingActivitiesOfDiscontinuedOperationsAbstract" id="flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionsExercisableMember" id="flgc_OptionsExercisableMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionsExpiredCancelled" id="flgc_OptionsExpiredCancelled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" id="flgc_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OriginalHempAssetAcquisitionMember" id="flgc_OriginalHempAssetAcquisitionMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" id="flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" id="flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="OtherEquityIssuanceCosts" id="flgc_OtherEquityIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="OtherInformationAbstract" id="flgc_OtherInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherIssuanceMember" id="flgc_OtherIssuanceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherLongLivedAssetImpairmentTestsMember" id="flgc_OtherLongLivedAssetImpairmentTestsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherLongLivedAssets" id="flgc_OtherLongLivedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OtherOfferingMember" id="flgc_OtherOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaidAmountToBreezeVendor" id="flgc_PaidAmountToBreezeVendor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PatentAndDevelopedTechnologyMember" id="flgc_PatentAndDevelopedTechnologyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAcquisition" id="flgc_PercentageOfAcquisition" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAggregateGrossProceedsFromSaleOfCommonShares" id="flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfIssuedAndOutstandingCommonShares" id="flgc_PercentageOfIssuedAndOutstandingCommonShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" id="flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PharmaceuticalsMember" id="flgc_PharmaceuticalsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlacementAgentMember" id="flgc_PlacementAgentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PompanoBeachMember" id="flgc_PompanoBeachMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PostTerminationExercisePeriod" id="flgc_PostTerminationExercisePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PotentialLiabilities" id="flgc_PotentialLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PresentationOfComparativeFinancialStatementsPolicyTextBlock" id="flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreviouslyIssuedWarrant" id="flgc_PreviouslyIssuedWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PriceToBookValue" id="flgc_PriceToBookValue" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PriceToTangibleBookValue" id="flgc_PriceToTangibleBookValue" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromExerciseOfWarrantsAndOptions" id="flgc_ProceedsFromExerciseOfWarrantsAndOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PropertyInSantanderMember" id="flgc_PropertyInSantanderMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProvisionsPolicyTextBlock" id="flgc_ProvisionsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseConsideration" id="flgc_PurchaseConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PurchaseConsiderationComprised" id="flgc_PurchaseConsiderationComprised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PurchaseConsiderationComprisedShare" id="flgc_PurchaseConsiderationComprisedShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseConsiderationDiscountRate" id="flgc_PurchaseConsiderationDiscountRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseConsiderationPercentageOfSales" id="flgc_PurchaseConsiderationPercentageOfSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseConsiderationPercentageOfSalesAmountPayable" id="flgc_PurchaseConsiderationPercentageOfSalesAmountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PurchaseOfCommonStock" id="flgc_PurchaseOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RamonRicardoCastellanosSaenzAndMiriamOrtizMember" id="flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsEighteenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsEightMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsElevenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsFifteenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsFiveMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsFourMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsFourteenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsNineMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsOneMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsSevenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsSixMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsSixteenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsTenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsThirteenMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsThreeMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsTwelveMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RangesOfExercisePricesForOutstandingShareOptionsTwoMember" id="flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RealEstateAssetsMember" id="flgc_RealEstateAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RegulationAAndOtherOfferingsAmount" id="flgc_RegulationAAndOtherOfferingsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RegulationAAndOtherOfferingsShares" id="flgc_RegulationAAndOtherOfferingsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyDisclosuresAbstract" id="flgc_RelatedPartyDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RemainingPercentageOfAcquisition" id="flgc_RemainingPercentageOfAcquisition" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RemainingWeightedAverageVestingPeriod" id="flgc_RemainingWeightedAverageVestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedStockAwardsMember" id="flgc_RestrictedStockAwardsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedStockVestingAmount" id="flgc_RestrictedStockVestingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RestrictedStockVestingShares" id="flgc_RestrictedStockVestingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RetailSpaceInMiamiMember" id="flgc_RetailSpaceInMiamiMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyOnGrossRevenuesFromSaleOfProducts" id="flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SalesTaxesMember" id="flgc_SalesTaxesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock" id="flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock" id="flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfCommitmentsAndContingenciesLineItems" id="flgc_ScheduleOfCommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfCommitmentsAndContingenciesTable" id="flgc_ScheduleOfCommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="ScheduleOfCompanyAgingOfTradeAccountsReceivable" id="flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfCompanysInvestmentsActivityTableTextBlock" id="flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfFairValueOfWarrantsTableTextBlock" id="flgc_ScheduleOfFairValueOfWarrantsTableTextBlock" type="dtr-types:textBlockItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications" id="flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfIntangibleAssetsEstimatedUsefulLives" id="flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" id="flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" id="flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfOtherSignificantItemsTableTextBlock" id="flgc_ScheduleOfOtherSignificantItemsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock" id="flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRestrictedStockAwards" id="flgc_ScheduleOfRestrictedStockAwards" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock" id="flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfSubsidiariesTableTextBlock" id="flgc_ScheduleOfSubsidiariesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWarrantsOutstandingTableTextBlock" id="flgc_ScheduleOfWarrantsOutstandingTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock" id="flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondClosingMember" id="flgc_SecondClosingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondLoanAgreementMember" id="flgc_SecondLoanAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondLoanMember" id="flgc_SecondLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondTrancheMember" id="flgc_SecondTrancheMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeparationAgreementMember" id="flgc_SeparationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeptemberTwoThousandTwentyThreeUnitOfferingMember" id="flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeptemberUnitOfferingAmount" id="flgc_SeptemberUnitOfferingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SeptemberUnitOfferingIssuanceCosts" id="flgc_SeptemberUnitOfferingIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeptemberUnitOfferingShares" id="flgc_SeptemberUnitOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SettlementAgreementMember" id="flgc_SettlementAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares" id="flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm" id="flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" id="flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationConsideration" id="flgc_ShareBasedCompensationConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationOptionsVestedGrantDateFairValue" id="flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" id="flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharedServicesAndSpaceCommitment" id="flgc_SharedServicesAndSpaceCommitment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SharePurchaseAgreementMember" id="flgc_SharePurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareRepurchaseMember" id="flgc_ShareRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareRepurchaseShares" id="flgc_ShareRepurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesIssuedDuringPeriodSharesWarrantsExpired" id="flgc_SharesIssuedDuringPeriodSharesWarrantsExpired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesIssuedToPurchaseWarrantsFromExistingInvestors" id="flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantAccountingPoliciesLineItems" id="flgc_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantAccountingPoliciesTable" id="flgc_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="StockOptionDateOfExpiry" id="flgc_StockOptionDateOfExpiry" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockOptionExercisable" id="flgc_StockOptionExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockOptionsMember" id="flgc_StockOptionsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockRepurchasedDuringPeriodAmount" id="flgc_StockRepurchasedDuringPeriodAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockWarrantMember" id="flgc_StockWarrantMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryEighteenMember" id="flgc_SubsidiaryEighteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryEightMember" id="flgc_SubsidiaryEightMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryElevenMember" id="flgc_SubsidiaryElevenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryFifteenMember" id="flgc_SubsidiaryFifteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryFiveMember" id="flgc_SubsidiaryFiveMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryFourMember" id="flgc_SubsidiaryFourMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryFourteenMember" id="flgc_SubsidiaryFourteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryNineMember" id="flgc_SubsidiaryNineMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryNineteenMember" id="flgc_SubsidiaryNineteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryOneMember" id="flgc_SubsidiaryOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiarySevenMember" id="flgc_SubsidiarySevenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiarySeventeenMember" id="flgc_SubsidiarySeventeenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiarySixMember" id="flgc_SubsidiarySixMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiarySixteenMember" id="flgc_SubsidiarySixteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTenMember" id="flgc_SubsidiaryTenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryThirteenMember" id="flgc_SubsidiaryThirteenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryThirtyFiveMember" id="flgc_SubsidiaryThirtyFiveMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryThirtyFourMember" id="flgc_SubsidiaryThirtyFourMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryThirtyMember" id="flgc_SubsidiaryThirtyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryThirtyOneMember" id="flgc_SubsidiaryThirtyOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryThirtyThreeMember" id="flgc_SubsidiaryThirtyThreeMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryThirtyTwoMember" id="flgc_SubsidiaryThirtyTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryThreeMember" id="flgc_SubsidiaryThreeMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwelveMember" id="flgc_SubsidiaryTwelveMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentyEightMember" id="flgc_SubsidiaryTwentyEightMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentyFiveMember" id="flgc_SubsidiaryTwentyFiveMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentyFourMember" id="flgc_SubsidiaryTwentyFourMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentyMember" id="flgc_SubsidiaryTwentyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentyNineMember" id="flgc_SubsidiaryTwentyNineMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentyOneMember" id="flgc_SubsidiaryTwentyOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentySevenMember" id="flgc_SubsidiaryTwentySevenMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentySixMember" id="flgc_SubsidiaryTwentySixMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentyThreeMember" id="flgc_SubsidiaryTwentyThreeMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwentyTwoMember" id="flgc_SubsidiaryTwentyTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsidiaryTwoMember" id="flgc_SubsidiaryTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplierRelationshipsMember" id="flgc_SupplierRelationshipsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TerminationBenefitsMember" id="flgc_TerminationBenefitsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThresholdLimitOfEstimateOfLoss" id="flgc_ThresholdLimitOfEstimateOfLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalAmountClaimedUnderIndemnificationAgreement" id="flgc_TotalAmountClaimedUnderIndemnificationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalAmountPayableInViolationOfStopSaleOrders" id="flgc_TotalAmountPayableInViolationOfStopSaleOrders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalCarryingValue" id="flgc_TotalCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TradeAccountsReceivable" id="flgc_TradeAccountsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TradeAndOtherReceivablesAbstract" id="flgc_TradeAndOtherReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TrademarksAndBrandsMember" id="flgc_TrademarksAndBrandsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TradenamesMember" id="flgc_TradenamesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TradeReceivable" id="flgc_TradeReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TradeReceivableBeginningBalance" id="flgc_TradeReceivableBeginningBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TruhcHoldingGmbhMember" id="flgc_TruhcHoldingGmbhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TruhcPharmaGmbhMember" id="flgc_TruhcPharmaGmbhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTwentyOneAnnualImpairmentTestMember" id="flgc_TwoThousandTwentyOneAnnualImpairmentTestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTwentyThreeAnnualImpairmentTestMember" id="flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember" id="flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" id="flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" id="flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTwentyTwoImpairmentTestMember" id="flgc_TwoThousandTwentyTwoImpairmentTestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember" id="flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTwentyTwoPlanMember" id="flgc_TwoThousandTwentyTwoPlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnitedKingdomRevenueAgencyMember" id="flgc_UnitedKingdomRevenueAgencyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnitedStatesRevenueAgencyMember" id="flgc_UnitedStatesRevenueAgencyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnitOfferingMember" id="flgc_UnitOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnrealizedLossesOnSecurities" id="flgc_UnrealizedLossesOnSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="UnusedLossCarryforwards" id="flgc_UnusedLossCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="UnvestedRsusGrantedToExecutiveOfficers" id="flgc_UnvestedRsusGrantedToExecutiveOfficers" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="USFederalIncomeTaxAuthorityMember" id="flgc_USFederalIncomeTaxAuthorityMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="USStateIncomeTaxAuthorityMember" id="flgc_USStateIncomeTaxAuthorityMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VesselAssetGroupMember" id="flgc_VesselAssetGroupMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VesselMember" id="flgc_VesselMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VesselOwnersMember" id="flgc_VesselOwnersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VesselsMember" id="flgc_VesselsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VestInOneYearMember" id="flgc_VestInOneYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VestInThreeYearsMember" id="flgc_VestInThreeYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarehousingAndOfficeSpaceMember" id="flgc_WarehousingAndOfficeSpaceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantAmendedExercisePrice" id="flgc_WarrantAmendedExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantExercisePricePriorToAmendment" id="flgc_WarrantExercisePricePriorToAmendment" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantIssued" id="flgc_WarrantIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantOneMember" id="flgc_WarrantOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantPurchase" id="flgc_WarrantPurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAbstract" id="flgc_WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsCadOnePointZeroZeroMember" id="flgc_WarrantsCadOnePointZeroZeroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsCadZeroPointThreeZeroMember" id="flgc_WarrantsCadZeroPointThreeZeroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsDateOfExpiry" id="flgc_WarrantsDateOfExpiry" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsDisclosureTextBlock" id="flgc_WarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsExercisedAmount" id="flgc_WarrantsExercisedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsExercisedShares" id="flgc_WarrantsExercisedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsExpiredOrCancelledAmount" id="flgc_WarrantsExpiredOrCancelledAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsFiveMember" id="flgc_WarrantsFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsFourMember" id="flgc_WarrantsFourMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedDuringPeriodExercisePrice" id="flgc_WarrantsIssuedDuringPeriodExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedToPlacementAgent" id="flgc_WarrantsIssuedToPlacementAgent" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsLineItems" id="flgc_WarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsMember" id="flgc_WarrantsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsOneMember" id="flgc_WarrantsOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsRemainingLifeInYears" id="flgc_WarrantsRemainingLifeInYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsSixMember" id="flgc_WarrantsSixMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsTable" id="flgc_WarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="WarrantsThreeMember" id="flgc_WarrantsThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsTwoMember" id="flgc_WarrantsTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceOfWarrantsCancelled" id="flgc_WeightedAverageExercisePriceOfWarrantsCancelled" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceOfWarrantsExercised" id="flgc_WeightedAverageExercisePriceOfWarrantsExercised" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceOfWarrantsIssued" id="flgc_WeightedAverageExercisePriceOfWarrantsIssued" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WritedownsReversalsOfInventories" id="flgc_WritedownsReversalsOfInventories" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="WriterMember" id="flgc_WriterMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WrongfullyTransferredShares" id="flgc_WrongfullyTransferredShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>flgc-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CondensedInterimConsolidatedStatementsOfFinancialPosition" roleURI="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementOfCashFlows" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivableDetails" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InventoryDetails" roleURI="http://www.floragrowth.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LeasesDetails" roleURI="http://www.floragrowth.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosuresDetails" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoansReceivableAndAdvances" xlink:label="loc_flgc_LoansReceivableAndAdvances_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivables" xlink:label="loc_us-gaap_NontradeReceivables_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_InventoryNet_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_flgc_LoansReceivableAndAdvances_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_NontradeReceivables_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_11" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_Goodwill_12" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_LongTermInvestments_13" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_16" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_17" xlink:to="loc_us-gaap_Liabilities_18" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_18" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18" xlink:to="loc_us-gaap_LiabilitiesCurrent_19" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_19" xlink:to="loc_us-gaap_LongTermDebtCurrent_19" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_19" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_19" xlink:to="loc_us-gaap_AccountsPayableCurrent_22" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_23" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_19" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_24" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_19" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_25" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_27" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_28" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_29" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_30" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_17" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32" xlink:to="loc_us-gaap_MinorityInterest_32" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32" xlink:to="loc_us-gaap_StockholdersEquity_33" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_33" xlink:to="loc_us-gaap_CommonStockValue_33" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_33" xlink:to="loc_us-gaap_AdditionalPaidInCapital_34" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_33" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_35" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_33" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Communication" xlink:label="loc_us-gaap_Communication_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_33"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_10" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_10" xlink:to="loc_us-gaap_ProfitLoss_11" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_11" xlink:to="loc_us-gaap_OperatingIncomeLoss_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_11" xlink:to="loc_us-gaap_OperatingExpenses_11" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_Communication_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_OperatingLeaseExpense_12" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_AssetImpairmentCharges_13" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_14" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_InterestAndDebtExpense_15" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_DepreciationAndAmortization_16" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_17" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_18" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_ShareBasedCompensation_19" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_20" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_TravelAndEntertainmentExpense_21" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_22" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_ManagementFeeExpense_23" order="120" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11" xlink:to="loc_us-gaap_ProfessionalFees_24" order="130" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_11" xlink:to="loc_us-gaap_GrossProfit_26" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_26" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_26" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_26" xlink:to="loc_us-gaap_Revenues_27" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_11" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_30" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_33" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfGoodwill" xlink:label="loc_flgc_ImpairmentOfGoodwill_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProceedsFromExerciseOfWarrantsAndOptions" xlink:label="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_34"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_AssetImpairmentCharges_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_10" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_11" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_12" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_13" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_14" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_ShareBasedCompensation_15" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_16" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_17" order="110" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_18" order="120" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_InterestIncomeOperating_19" order="130" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_flgc_ImpairmentOfGoodwill_20" order="140" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_ProfitLoss_21" order="150" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_22" order="160" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_23" order="170" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_24" order="180" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_25" order="190" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_27" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_28" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_29" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_30" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_31" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" xlink:to="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_32" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" xlink:to="loc_us-gaap_RepaymentsOfDebt_33" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_34" order="60" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivable" xlink:label="loc_us-gaap_ValueAddedTaxReceivable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_0" xlink:to="loc_us-gaap_ValueAddedTaxReceivable_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_0" xlink:to="loc_us-gaap_OtherReceivables_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_0" xlink:to="loc_flgc_TradeAccountsReceivable_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InventoryDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HarvestedCannabis" xlink:label="loc_flgc_HarvestedCannabis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_us-gaap_InventoryFinishedGoods_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_flgc_HarvestedCannabis_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_us-gaap_InventoryWorkInProcess_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_6"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_6" order="50" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0" xlink:to="loc_us-gaap_ShortTermLeaseCost_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0" xlink:to="loc_us-gaap_OperatingLeaseExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0" xlink:to="loc_us-gaap_SubleaseIncome_3" order="20" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_0" xlink:to="loc_us-gaap_OfficersCompensation_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_15"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_3" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_4" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_7" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_7" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_7" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_9" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_10" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_12" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_12" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_12" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_12" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_14" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_12" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_15" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_13"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_5" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_6" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_9" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_9" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_12" order="90" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_13" order="100" use="optional" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>flgc-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#Cover" roleURI="http://www.floragrowth.com/role/Cover"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CondensedInterimConsolidatedStatementsOfFinancialPosition" roleURI="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementOfStockholdersEquity" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementOfCashFlows" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#NatureOfOperations" roleURI="http://www.floragrowth.com/role/NatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#BasisOfPresentation" roleURI="http://www.floragrowth.com/role/BasisOfPresentation"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#PropertyPlantAndEquipment" roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#DEBT" roleURI="http://www.floragrowth.com/role/DEBT"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LEASES" roleURI="http://www.floragrowth.com/role/LEASES"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareCapital" roleURI="http://www.floragrowth.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CommitmentsAndContingencies" roleURI="http://www.floragrowth.com/role/CommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstruments" roleURI="http://www.floragrowth.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SubsequentEvents" roleURI="http://www.floragrowth.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivableTables" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#PropertyPlantAndEquipmentTables" roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#AssetAcquisitionsAndBusinessCombinationsTables" roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LeasesTables" roleURI="http://www.floragrowth.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstrumentsTables" roleURI="http://www.floragrowth.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#BasisOfPresentationDetailsNarrative" roleURI="http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivableDetails" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivableDetails1" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#PropertyPlantAndEquipmentDetails" roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#PropertyPlantAndEquipmentDetailsNarrative" roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InvestmentsDetails" roleURI="http://www.floragrowth.com/role/InvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InvestmentsDetailsNarrative" roleURI="http://www.floragrowth.com/role/InvestmentsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#AssetAcquisitionsAndBusinessCombinationsDetails1" roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#AssetAcquisitionsAndBusinessCombinationsDetailsNarrative" roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillDetails2" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#DebtDetailsNarrative" roleURI="http://www.floragrowth.com/role/DebtDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LeasesDetails" roleURI="http://www.floragrowth.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LeasesDetails1" roleURI="http://www.floragrowth.com/role/LeasesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationDetails" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationDetails1" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationDetailsNarrative" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#WarrantsDetails" roleURI="http://www.floragrowth.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#WarrantsDetails1" roleURI="http://www.floragrowth.com/role/WarrantsDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LossPerShareDetails" roleURI="http://www.floragrowth.com/role/LossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstrumentsAndRiskManagementDetails" roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformationDetails" roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformationDetails1" roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SubsequentEventsDetailsNarrative" roleURI="http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TRADEANDAMOUNTSRECEIVABLENarrativeDetails" roleURI="http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LEASESNarrativeDetails" roleURI="http://www.floragrowth.com/role/LEASESNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformationDetails3" roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails3"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentDetails" roleURI="http://www.floragrowth.com/role/SegmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstrumentsAndRiskManagementDetails1" roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstrumentsAndRiskManagementDetailsNarrative" roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LossPerShareDetailsNarrative" roleURI="http://www.floragrowth.com/role/LossPerShareDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosures" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosuresTables" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosuresDetails" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosuresDetailsNarrative" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#BasisOfPresentationDetails" roleURI="http://www.floragrowth.com/role/BasisOfPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPolicies" roleURI="http://www.floragrowth.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesTables" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesDetails" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesDetails1" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ImpairmentOfAssetsDetailsNarrative" roleURI="http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CriticalJudgmentsAndEstimationUncertainties" roleURI="http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxes" roleURI="http://www.floragrowth.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesTables" roleURI="http://www.floragrowth.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesDetails" roleURI="http://www.floragrowth.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesDetails2" roleURI="http://www.floragrowth.com/role/IncomeTaxesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivable" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#WarrantsDetailsNarrative" roleURI="http://www.floragrowth.com/role/WarrantsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SHARECAPITALDetailsNarrative1" roleURI="http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationDetails2" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable" roleURI="http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillDetails" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#DummyDetails" roleURI="http://www.floragrowth.com/role/DummyDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/Cover">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_47"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityRegistrantName_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentType_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AmendmentFlag_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AmendmentDescription_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_16" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentQuarterlyReport_17" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_18" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityFilerCategory_19" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_20" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityFileNumber_21" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_22" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_23" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_24" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_25" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressStateOrProvince_26" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_27" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_CityAreaCode_28" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_29" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_Security12bTitle_30" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_TradingSymbol_31" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_SecurityExchangeName_32" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_33" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_34" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntitySmallBusiness_35" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_36" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_37" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_ContactPersonnelName_38" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityShellCompany_39" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_40" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_41" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_EntityPublicFloat_42" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_43" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_44" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AuditorName_45" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AuditorLocation_46" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_0" xlink:to="loc_dei_AuditorFirmId_47" order="420" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoansReceivableAndAdvances" xlink:label="loc_flgc_LoansReceivableAndAdvances_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivables" xlink:label="loc_us-gaap_NontradeReceivables_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_51"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_flgc_LoansReceivableAndAdvances_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_NontradeReceivables_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_InventoryNet_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_AssetsCurrent_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_16" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_16" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_16" xlink:to="loc_us-gaap_Goodwill_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_16" xlink:to="loc_us-gaap_LongTermInvestments_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_16" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_21" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_16" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_22" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_Assets_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAbstract_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccountsPayableCurrent_26" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_CommitmentsAndContingencies_27" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LongTermDebtCurrent_28" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_29" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_30" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_31" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_32" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrent_33" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_26" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_35" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_35" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_35" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_35" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_36" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_35" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_37" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_38" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_35" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_39" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_26" xlink:to="loc_us-gaap_Liabilities_41" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_43" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_CommonStockValue_43" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_AdditionalPaidInCapital_44" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_45" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_46" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_StockholdersEquity_47" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_MinorityInterest_48" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_51" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Communication" xlink:label="loc_us-gaap_Communication_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_45"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Revenues_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_GrossProfit_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_ManagementFeeExpense_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_ProfessionalFees_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_Communication_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_TravelAndEntertainmentExpense_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensation_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_OperatingLeaseExpense_16" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_DepreciationAndAmortization_17" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_InterestAndDebtExpense_18" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_AssetImpairmentCharges_19" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_20" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_21" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_22" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_OperatingExpenses_23" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_OperatingIncomeLoss_24" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_27" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_30" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_31" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_32" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_33" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_34" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_35" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_36" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_37" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_38" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_39" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_41" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_42" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_42" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_42" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_42" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_43" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_42" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_44" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_42" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_45" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingShares" xlink:label="loc_flgc_SeptemberUnitOfferingShares_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingAmount" xlink:label="loc_flgc_SeptemberUnitOfferingAmount_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_SeptemberUnitOfferingIssuanceCosts_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingShares" xlink:label="loc_flgc_DecemberUnitOfferingShares_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingAmount" xlink:label="loc_flgc_DecemberUnitOfferingAmount_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_DecemberUnitOfferingIssuanceCosts_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingShares" xlink:label="loc_flgc_InitialPublicOfferingShares_24"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingAmount" xlink:label="loc_flgc_InitialPublicOfferingAmount_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingIssuanceCostsShares" xlink:label="loc_flgc_InitialPublicOfferingIssuanceCostsShares_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingIssuanceCostsAmount" xlink:label="loc_flgc_InitialPublicOfferingIssuanceCostsAmount_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RegulationAAndOtherOfferingsShares" xlink:label="loc_flgc_RegulationAAndOtherOfferingsShares_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RegulationAAndOtherOfferingsAmount" xlink:label="loc_flgc_RegulationAAndOtherOfferingsAmount_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForInvestmentsShares" xlink:label="loc_flgc_CommonSharesIssuedForInvestmentsShares_32"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForInvestmentsAmount" xlink:label="loc_flgc_CommonSharesIssuedForInvestmentsAmount_33"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForOtherAgreementsShares" xlink:label="loc_flgc_CommonSharesIssuedForOtherAgreementsShares_34"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForOtherAgreementsAmount" xlink:label="loc_flgc_CommonSharesIssuedForOtherAgreementsAmount_35"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EquityIssuedForOtherAgreementsShares" xlink:label="loc_flgc_EquityIssuedForOtherAgreementsShares_36"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EquityIssuedForOtherAgreementsAmount" xlink:label="loc_flgc_EquityIssuedForOtherAgreementsAmount_37"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AcquisitionOfNoncontrollingInterestShares" xlink:label="loc_flgc_AcquisitionOfNoncontrollingInterestShares_38"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AcquisitionOfNoncontrollingInterestAmount" xlink:label="loc_flgc_AcquisitionOfNoncontrollingInterestAmount_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_44"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockVestingShares" xlink:label="loc_flgc_RestrictedStockVestingShares_45"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockVestingAmount" xlink:label="loc_flgc_RestrictedStockVestingAmount_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_47"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExercisedShares" xlink:label="loc_flgc_WarrantsExercisedShares_48"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExercisedAmount" xlink:label="loc_flgc_WarrantsExercisedAmount_49"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedDuringPeriodSharesWarrantsExpired" xlink:label="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_50"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExpiredOrCancelledAmount" xlink:label="loc_flgc_WarrantsExpiredOrCancelledAmount_51"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherEquityIssuanceCosts" xlink:label="loc_flgc_OtherEquityIssuanceCosts_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_57"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DerecognitionOfEquityRelatedToColombiaAssets" xlink:label="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_58"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" xlink:label="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_59"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" xlink:label="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_61"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionshares" xlink:label="loc_flgc_Contributionshares_62"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionamont" xlink:label="loc_flgc_Contributionamont_63"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_64"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_flgc_TruhcPharmaGmbhMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesIssued_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_SeptemberUnitOfferingShares_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_SeptemberUnitOfferingAmount_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_SeptemberUnitOfferingIssuanceCosts_18" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_DecemberUnitOfferingShares_19" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_DecemberUnitOfferingAmount_20" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_DecemberUnitOfferingIssuanceCosts_21" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_22" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_23" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_InitialPublicOfferingShares_24" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_InitialPublicOfferingAmount_25" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_InitialPublicOfferingIssuanceCostsShares_26" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_InitialPublicOfferingIssuanceCostsAmount_27" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_RegulationAAndOtherOfferingsShares_28" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_RegulationAAndOtherOfferingsAmount_29" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_30" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_31" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_CommonSharesIssuedForInvestmentsShares_32" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_CommonSharesIssuedForInvestmentsAmount_33" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_CommonSharesIssuedForOtherAgreementsShares_34" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_CommonSharesIssuedForOtherAgreementsAmount_35" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_EquityIssuedForOtherAgreementsShares_36" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_EquityIssuedForOtherAgreementsAmount_37" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_AcquisitionOfNoncontrollingInterestShares_38" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_AcquisitionOfNoncontrollingInterestAmount_39" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_40" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_41" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_42" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_43" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_44" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_RestrictedStockVestingShares_45" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_RestrictedStockVestingAmount_46" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_47" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_WarrantsExercisedShares_48" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_WarrantsExercisedAmount_49" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_50" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_WarrantsExpiredOrCancelledAmount_51" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_OtherEquityIssuanceCosts_52" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_53" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_54" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_55" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_56" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_57" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_58" order="450" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_59" order="460" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_60" order="470" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_61" order="480" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_Contributionshares_62" order="490" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_Contributionamont_63" order="500" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_64" order="510" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfGoodwill" xlink:label="loc_flgc_ImpairmentOfGoodwill_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_38"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProceedsFromExerciseOfWarrantsAndOptions" xlink:label="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashAssetsAcquiredForContingentConsideration" xlink:label="loc_flgc_NonCashAssetsAcquiredForContingentConsideration_50"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashCommonSharesIssuedForBusinessCombinations" xlink:label="loc_flgc_NonCashCommonSharesIssuedForBusinessCombinations_51"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashCommonSharesIssuedForOtherAgreements" xlink:label="loc_flgc_NonCashCommonSharesIssuedForOtherAgreements_52"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashOptionCancellationsReclassifiedToEquity" xlink:label="loc_flgc_NonCashOptionCancellationsReclassifiedToEquity_53"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets" xlink:label="loc_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_54"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash" xlink:label="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_55"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_ProfitLoss_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_AssetImpairmentCharges_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_ShareBasedCompensation_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_flgc_ImpairmentOfGoodwill_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_15" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_16" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_17" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_InterestIncomeOperating_18" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_19" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_20" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_32" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_33" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_34" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_37" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_38" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_39" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_40" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_41" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_42" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_RepaymentsOfDebt_43" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_46" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_47" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_49" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50" xlink:to="loc_flgc_NonCashAssetsAcquiredForContingentConsideration_50" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50" xlink:to="loc_flgc_NonCashCommonSharesIssuedForBusinessCombinations_51" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50" xlink:to="loc_flgc_NonCashCommonSharesIssuedForOtherAgreements_52" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50" xlink:to="loc_flgc_NonCashOptionCancellationsReclassifiedToEquity_53" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50" xlink:to="loc_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_54" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50" xlink:to="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_55" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/NatureOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NatureOfOperations_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/BasisOfPresentation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/PropertyPlantAndEquipment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/DEBT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LEASES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstruments">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivableTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable" xlink:label="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_8" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NoCapHempCoMember" xlink:label="loc_flgc_NoCapHempCoMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FranchiseGlobalHealthIncMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_NoCapHempCoMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications" xlink:label="loc_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock" xlink:label="loc_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_7" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLLCMember" xlink:label="loc_flgc_JustBrandsLLCMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeEarningsDeficit" xlink:label="loc_us-gaap_CumulativeEarningsDeficit_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_19"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_flgc_TruhcPharmaGmbhMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_10" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10" xlink:to="loc_flgc_JustBrandsLLCMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_10" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_Cash_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_CumulativeEarningsDeficit_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_19" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivable" xlink:label="loc_us-gaap_ValueAddedTaxReceivable_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_TradeAccountsReceivable_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ValueAddedTaxReceivable_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherReceivables_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_10" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivablesPastDueTable" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialAssetNotPastDueMember" xlink:label="loc_us-gaap_FinancialAssetNotPastDueMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables1To29DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables1To29DaysPastDueMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables30To59DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables30To59DaysPastDueMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables60To89DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables60To89DaysPastDueMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancingReceivables180PlusDaysPastDueMember" xlink:label="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancialAssetNotPastDueMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancingReceivables1To29DaysPastDueMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancingReceivables30To59DaysPastDueMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancingReceivables60To89DaysPastDueMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_0" xlink:to="loc_flgc_TradeAccountsReceivable_11" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_LandMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_BuildingMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_VehiclesMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_ConstructionInProgressMember_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_ProductOrServiceAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_13" xlink:to="loc_srt_ProductsAndServicesDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_13" xlink:to="loc_us-gaap_LandMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_13" xlink:to="loc_srt_ProductsAndServicesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_20" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Depreciation_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_7" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InvestmentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInAffiliateActivityLineItems" xlink:label="loc_us-gaap_InvestmentInAffiliateActivityLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesTable" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvesteeCommonSharesMember" xlink:label="loc_flgc_InvesteeCommonSharesMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadZeroPointThreeZeroMember" xlink:label="loc_flgc_WarrantsCadZeroPointThreeZeroMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadOnePointZeroZeroMember" xlink:label="loc_flgc_WarrantsCadOnePointZeroZeroMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_0" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1" xlink:to="loc_us-gaap_InvestmentTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5" xlink:to="loc_flgc_InvesteeCommonSharesMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5" xlink:to="loc_flgc_WarrantsCadZeroPointThreeZeroMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5" xlink:to="loc_flgc_WarrantsCadOnePointZeroZeroMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_0" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_0" xlink:to="loc_us-gaap_AssetImpairmentCharges_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_0" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_16" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InvestmentsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstTrancheMember" xlink:label="loc_flgc_FirstTrancheMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondTrancheMember" xlink:label="loc_flgc_SecondTrancheMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseOfCommonStock" xlink:label="loc_flgc_PurchaseOfCommonStock_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors" xlink:label="loc_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestmentDescription" xlink:label="loc_flgc_InvestmentDescription_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExercisePriceOfInvestmentWarrants" xlink:label="loc_flgc_ExercisePriceOfInvestmentWarrants_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CumulativeImpairmentRelatedToCommonShares" xlink:label="loc_flgc_CumulativeImpairmentRelatedToCommonShares_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PriceToBookValue" xlink:label="loc_flgc_PriceToBookValue_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PriceToTangibleBookValue" xlink:label="loc_flgc_PriceToTangibleBookValue_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfSensitivityAnalysis" xlink:label="loc_flgc_DescriptionOfSensitivityAnalysis_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfImpairment" xlink:label="loc_flgc_DescriptionOfImpairment_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1" xlink:to="loc_us-gaap_InvestmentTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_flgc_FirstTrancheMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_flgc_SecondTrancheMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_PurchaseOfCommonStock_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_InvestmentDescription_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_ExercisePriceOfInvestmentWarrants_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_CumulativeImpairmentRelatedToCommonShares_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_us-gaap_OtherLongTermInvestments_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_PriceToBookValue_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_PriceToTangibleBookValue_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_DescriptionOfSensitivityAnalysis_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_0" xlink:to="loc_flgc_DescriptionOfImpairment_16" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NoCapHempCoMember" xlink:label="loc_flgc_NoCapHempCoMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_24"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_31"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FranchiseGlobalHealthIncMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_NoCapHempCoMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_8" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_15" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_15" xlink:to="loc_us-gaap_Goodwill_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_22" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_25" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_26" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_27" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_28" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_30" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_31" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OriginalHempAssetAcquisitionMember" xlink:label="loc_flgc_OriginalHempAssetAcquisitionMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NoCapHempCoMember" xlink:label="loc_flgc_NoCapHempCoMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBeautyMember" xlink:label="loc_flgc_FloraBeautyMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraMedSasMember" xlink:label="loc_flgc_FloraMedSasMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradenamesMember" xlink:label="loc_flgc_TradenamesMember_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SupplierRelationshipsMember" xlink:label="loc_flgc_SupplierRelationshipsMember_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CustomersRelationshipsMember" xlink:label="loc_flgc_CustomersRelationshipsMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_KnowHowMember" xlink:label="loc_flgc_KnowHowMember_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PatentAndDevelopedTechnologyMember" xlink:label="loc_flgc_PatentAndDevelopedTechnologyMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumPortionOfNetProfitsPayable" xlink:label="loc_flgc_MaximumPortionOfNetProfitsPayable_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_33"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesAmount" xlink:label="loc_flgc_LiabilitiesAmount_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivables" xlink:label="loc_us-gaap_NontradeReceivables_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_41"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashConsiderationReturned" xlink:label="loc_flgc_CashConsiderationReturned_42"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueDiscount" xlink:label="loc_flgc_FairValueDiscount_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_46"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesDeliveredToTheSellers" xlink:label="loc_flgc_CommonSharesDeliveredToTheSellers_47"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfShares" xlink:label="loc_flgc_DescriptionOfShares_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_49"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfTrials" xlink:label="loc_flgc_NumberOfTrials_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_53"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationPercentageOfSales" xlink:label="loc_flgc_PurchaseConsiderationPercentageOfSales_54"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationPercentageOfSalesAmountPayable" xlink:label="loc_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_55"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfDiscountRates" xlink:label="loc_flgc_DescriptionOfDiscountRates_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_57"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnrealizedLossesOnSecurities" xlink:label="loc_flgc_UnrealizedLossesOnSecurities_58"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationDiscountRate" xlink:label="loc_flgc_PurchaseConsiderationDiscountRate_59"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_61"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_63"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_OriginalHempAssetAcquisitionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FranchiseGlobalHealthIncMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_NoCapHempCoMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FloraBeautyMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FloraMedSasMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_srt_RangeAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MaximumMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MinimumMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15" xlink:to="loc_flgc_TradenamesMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15" xlink:to="loc_flgc_SupplierRelationshipsMember_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15" xlink:to="loc_flgc_CustomersRelationshipsMember_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15" xlink:to="loc_us-gaap_LicenseMember_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15" xlink:to="loc_flgc_KnowHowMember_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15" xlink:to="loc_flgc_PatentAndDevelopedTechnologyMember_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_21" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_26" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_MaximumPortionOfNetProfitsPayable_27" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_28" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_29" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_Revenues_30" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_31" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_32" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_33" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_LiabilitiesAmount_34" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_35" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_NontradeReceivables_36" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_37" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_38" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ProfessionalFees_39" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_40" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_41" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_CashConsiderationReturned_42" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_FairValueDiscount_43" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_44" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_45" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_46" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_CommonSharesDeliveredToTheSellers_47" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_DescriptionOfShares_48" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_49" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_NumberOfTrials_50" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_SharePrice_51" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_52" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_53" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_PurchaseConsiderationPercentageOfSales_54" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_55" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_DescriptionOfDiscountRates_56" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_Capital_57" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_UnrealizedLossesOnSecurities_58" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_flgc_PurchaseConsiderationDiscountRate_59" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_60" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_61" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_63" order="380" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FoodAndBeveragesMember" xlink:label="loc_flgc_FoodAndBeveragesMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselMember" xlink:label="loc_flgc_VesselMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FranchiseMember" xlink:label="loc_us-gaap_FranchiseMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PharmaceuticalsMember" xlink:label="loc_flgc_PharmaceuticalsMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_ReportingUnitAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_1" xlink:to="loc_us-gaap_ReportingUnitDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1" xlink:to="loc_flgc_FoodAndBeveragesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1" xlink:to="loc_flgc_VesselMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1" xlink:to="loc_flgc_JustCBDMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1" xlink:to="loc_us-gaap_FranchiseMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_1" xlink:to="loc_us-gaap_ReportingUnitDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8" xlink:to="loc_flgc_PharmaceuticalsMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_GoodwillGross_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_16" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_Goodwill_17" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradenamesMember" xlink:label="loc_flgc_TradenamesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaap_TrademarksMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHMember" xlink:label="loc_flgc_FGHMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_TradenamesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_TrademarksMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_ReportingUnitAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_7" xlink:to="loc_us-gaap_ReportingUnitDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_7" xlink:to="loc_flgc_JustCBDMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_7" xlink:to="loc_flgc_FGHMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_7" xlink:to="loc_us-gaap_ReportingUnitDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_16" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/DebtDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HypoverinsbankMember" xlink:label="loc_flgc_HypoverinsbankMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ClassicPlanPremiumFinancingMember" xlink:label="loc_flgc_ClassicPlanPremiumFinancingMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstLoanMember" xlink:label="loc_flgc_FirstLoanMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondLoanMember" xlink:label="loc_flgc_SecondLoanMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EuroCreditFacilityMember" xlink:label="loc_flgc_EuroCreditFacilityMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDInsurancePremiumLoanMember" xlink:label="loc_flgc_JustCBDInsurancePremiumLoanMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_33"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CreditFacilityDue" xlink:label="loc_flgc_CreditFacilityDue_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_38"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5" xlink:to="loc_flgc_HypoverinsbankMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5" xlink:to="loc_flgc_ClassicPlanPremiumFinancingMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5" xlink:to="loc_flgc_FirstLoanMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5" xlink:to="loc_flgc_SecondLoanMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_us-gaap_CreditFacilityAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_12" xlink:to="loc_us-gaap_CreditFacilityDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_12" xlink:to="loc_flgc_EuroCreditFacilityMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_12" xlink:to="loc_flgc_JustCBDInsurancePremiumLoanMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_12" xlink:to="loc_us-gaap_CreditFacilityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_srt_RangeAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_25" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LineOfCredit_26" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_27" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_28" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_29" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LoansPayable_30" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_32" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_33" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_flgc_CreditFacilityDue_34" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_35" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_36" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_LongTermDebt_37" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_38" order="160" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherInformationAbstract" xlink:label="loc_flgc_OtherInformationAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseExpense_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_ShortTermLeaseCost_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_SubleaseIncome_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LeaseCost_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_flgc_OtherInformationAbstract_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_OtherInformationAbstract_10" xlink:to="loc_us-gaap_OperatingLeasePayments_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_OtherInformationAbstract_10" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_OtherInformationAbstract_10" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_OtherInformationAbstract_10" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_13" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LeasesDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16" order="110" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OptionsExercisableMember" xlink:label="loc_flgc_OptionsExercisableMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_StockOptionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_OptionsExercisableMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_17" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_19" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_20" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_22" order="160" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14" order="90" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PostTerminationExercisePeriod" xlink:label="loc_flgc_PostTerminationExercisePeriod_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RemainingWeightedAverageVestingPeriod" xlink:label="loc_flgc_RemainingWeightedAverageVestingPeriod_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonVestedShares" xlink:label="loc_flgc_NonVestedShares_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfRestrictedStockAwardsIssued" xlink:label="loc_flgc_FairValueOfRestrictedStockAwardsIssued_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_31"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_ChiefExecutiveOfficerMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_ChiefFinancialOfficerMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_flgc_PostTerminationExercisePeriod_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockOptionPlanExpense_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_RestrictedStockExpense_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_20" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_21" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_flgc_RemainingWeightedAverageVestingPeriod_22" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_23" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_26" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_flgc_NonVestedShares_27" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_28" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_29" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_flgc_FairValueOfRestrictedStockAwardsIssued_30" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_31" order="210" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/WarrantsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsMember" xlink:label="loc_flgc_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsExercised_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsCancelled" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsIssued" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsIssued_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_flgc_WarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_flgc_WeightedAverageExercisePriceOfWarrantsExercised_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_flgc_WeightedAverageExercisePriceOfWarrantsIssued_13" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/WarrantsDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsOneMember" xlink:label="loc_flgc_WarrantsOneMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsTwoMember" xlink:label="loc_flgc_WarrantsTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsThreeMember" xlink:label="loc_flgc_WarrantsThreeMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsFourMember" xlink:label="loc_flgc_WarrantsFourMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsFiveMember" xlink:label="loc_flgc_WarrantsFiveMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsSixMember" xlink:label="loc_flgc_WarrantsSixMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsMember" xlink:label="loc_flgc_WarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsDateOfExpiry" xlink:label="loc_flgc_WarrantsDateOfExpiry_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GrantDateFairValueOfWarrantsOutstanding" xlink:label="loc_flgc_GrantDateFairValueOfWarrantsOutstanding_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsRemainingLifeInYears" xlink:label="loc_flgc_WarrantsRemainingLifeInYears_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsTwoMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsThreeMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsFourMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsFiveMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsSixMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_flgc_WarrantsDateOfExpiry_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_flgc_GrantDateFairValueOfWarrantsOutstanding_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_flgc_WarrantsRemainingLifeInYears_16" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesLineItems" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TerminationBenefitsMember" xlink:label="loc_flgc_TerminationBenefitsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LegalDisputesMember" xlink:label="loc_flgc_LegalDisputesMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SalesTaxesMember" xlink:label="loc_flgc_SalesTaxesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyAccrualForeignCurrencyTranslation" xlink:label="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1" xlink:to="loc_flgc_TerminationBenefitsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1" xlink:to="loc_flgc_LegalDisputesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1" xlink:to="loc_flgc_SalesTaxesMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_12" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesLineItems" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLLCMember" xlink:label="loc_flgc_JustBrandsLLCMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GerardoAndresGarciaMendezMember" xlink:label="loc_flgc_GerardoAndresGarciaMendezMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" xlink:label="loc_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember" xlink:label="loc_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ACAMullerMember" xlink:label="loc_flgc_ACAMullerMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LegalDisputesMember" xlink:label="loc_flgc_LegalDisputesMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TerminationBenefitsMember" xlink:label="loc_flgc_TerminationBenefitsMember_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AdditionalLegalDisputesMember" xlink:label="loc_flgc_AdditionalLegalDisputesMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IndemnificationReceivables" xlink:label="loc_flgc_IndemnificationReceivables_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" xlink:label="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyTrialOrAlternativeDisputeResolution" xlink:label="loc_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_33"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AmountsPayablePerViolationOfStopSaleOrders" xlink:label="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_34"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfViolationsInStopSaleOrders" xlink:label="loc_flgc_NumberOfViolationsInStopSaleOrders_35"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryImpactedByStopSaleOrders" xlink:label="loc_flgc_InventoryImpactedByStopSaleOrders_36"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PotentialLiabilities" xlink:label="loc_flgc_PotentialLiabilities_37"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WrongfullyTransferredShares" xlink:label="loc_flgc_WrongfullyTransferredShares_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_39"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentPortionOfContingentPurchaseConsideration" xlink:label="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_40"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedLossOnPotentialLiabilities" xlink:label="loc_flgc_EstimatedLossOnPotentialLiabilities_41"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_42"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfSharesUnderPlaintiffClaim" xlink:label="loc_flgc_NumberOfSharesUnderPlaintiffClaim_43"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountPayableInViolationOfStopSaleOrders" xlink:label="loc_flgc_TotalAmountPayableInViolationOfStopSaleOrders_44"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfViolationsClaimed" xlink:label="loc_flgc_NumberOfViolationsClaimed_45"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossInterestAccrued" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_46"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyInterestPaymentTerms" xlink:label="loc_flgc_LossContingencyInterestPaymentTerms_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_48"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ManagementContractsTerms" xlink:label="loc_flgc_ManagementContractsTerms_49"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumLimitOfIndemnificationAgreement" xlink:label="loc_flgc_MaximumLimitOfIndemnificationAgreement_50"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountClaimedUnderIndemnificationAgreement" xlink:label="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_51"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ThresholdLimitOfEstimateOfLoss" xlink:label="loc_flgc_ThresholdLimitOfEstimateOfLoss_52"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharedServicesAndSpaceCommitment" xlink:label="loc_flgc_SharedServicesAndSpaceCommitment_53"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_flgc_JustBrandsLLCMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_flgc_GerardoAndresGarciaMendezMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_flgc_FranchiseGlobalHealthIncMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_12" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_12" xlink:to="loc_flgc_ACAMullerMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_12" xlink:to="loc_flgc_LegalDisputesMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_12" xlink:to="loc_flgc_TerminationBenefitsMember_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_12" xlink:to="loc_flgc_AdditionalLegalDisputesMember_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_12" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_19" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19" xlink:to="loc_us-gaap_SubsequentEventMember_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_19" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_SeveranceCosts1_24" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_25" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_26" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_27" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_28" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_IndemnificationReceivables_29" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_30" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_31" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_32" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_33" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_34" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_NumberOfViolationsInStopSaleOrders_35" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_InventoryImpactedByStopSaleOrders_36" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_PotentialLiabilities_37" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_WrongfullyTransferredShares_38" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_39" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_40" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_EstimatedLossOnPotentialLiabilities_41" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_42" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_NumberOfSharesUnderPlaintiffClaim_43" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_TotalAmountPayableInViolationOfStopSaleOrders_44" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_NumberOfViolationsClaimed_45" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_46" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_LossContingencyInterestPaymentTerms_47" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_48" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_ManagementContractsTerms_49" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_MaximumLimitOfIndemnificationAgreement_50" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_51" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_ThresholdLimitOfEstimateOfLoss_52" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xlink:to="loc_flgc_SharedServicesAndSpaceCommitment_53" order="300" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LossPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockAwardsMember" xlink:label="loc_flgc_RestrictedStockAwardsMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_flgc_StockOptionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_flgc_RestrictedStockAwardsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_flgc_JustCBDMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_9" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleMember" xlink:label="loc_flgc_CommercialAndWholesaleMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsMember" xlink:label="loc_flgc_HouseOfBrandsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PharmaceuticalsMember" xlink:label="loc_flgc_PharmaceuticalsMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CorporateAndEliminationsMember" xlink:label="loc_flgc_CorporateAndEliminationsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_CommercialAndWholesaleMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_HouseOfBrandsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_PharmaceuticalsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_CorporateAndEliminationsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_Revenues_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_GrossProfit_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_Assets_12" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformationDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ReportableGeographicalComponentsMember" xlink:label="loc_srt_ReportableGeographicalComponentsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="loc_country_DE_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CO" xlink:label="loc_country_CO_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="loc_country_GB_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_srt_ConsolidationItemsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1" xlink:to="loc_srt_ConsolidationItemsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1" xlink:to="loc_srt_ReportableGeographicalComponentsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1" xlink:to="loc_srt_ConsolidationItemsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_srt_StatementGeographicalAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_US_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_DE_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_CO_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_GB_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_CA_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_Revenues_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcHoldingGmbhMember" xlink:label="loc_flgc_TruhcHoldingGmbhMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AegisCapitalCorpMember" xlink:label="loc_flgc_AegisCapitalCorpMember_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraGrowthCorpMember" xlink:label="loc_flgc_FloraGrowthCorpMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstClosingMember" xlink:label="loc_flgc_FirstClosingMember_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondClosingMember" xlink:label="loc_flgc_SecondClosingMember_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares" xlink:label="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingCommitments" xlink:label="loc_us-gaap_UnderwritingCommitments_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_33"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfIssuedAndOutstandingCommonShares" xlink:label="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_37"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5" xlink:to="loc_us-gaap_SubsequentEventMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" xlink:to="loc_flgc_JustCBDMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" xlink:to="loc_flgc_TruhcHoldingGmbhMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" xlink:to="loc_flgc_AegisCapitalCorpMember_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" xlink:to="loc_flgc_FloraGrowthCorpMember_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_16" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_16" xlink:to="loc_srt_ChiefExecutiveOfficerMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_16" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_20" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_20" xlink:to="loc_flgc_FirstClosingMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_20" xlink:to="loc_flgc_SecondClosingMember_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_20" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_26" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_27" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_29" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_30" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_UnderwritingCommitments_31" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_33" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_34" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_35" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_36" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_37" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivablesPastDueTable" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_5" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_5" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_5" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LEASESNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarehousingAndOfficeSpaceMember" xlink:label="loc_flgc_WarehousingAndOfficeSpaceMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RetailSpaceInMiamiMember" xlink:label="loc_flgc_RetailSpaceInMiamiMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PompanoBeachMember" xlink:label="loc_flgc_PompanoBeachMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FortLauderdaleMember" xlink:label="loc_flgc_FortLauderdaleMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MonthlyLeasePayment" xlink:label="loc_flgc_MonthlyLeasePayment_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CounterpartyNameAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5" xlink:to="loc_flgc_WarehousingAndOfficeSpaceMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5" xlink:to="loc_flgc_RetailSpaceInMiamiMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5" xlink:to="loc_flgc_PompanoBeachMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5" xlink:to="loc_flgc_FortLauderdaleMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_flgc_MonthlyLeasePayment_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_15" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformationDetails3">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="loc_country_DE_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CO" xlink:label="loc_country_CO_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="loc_country_GB_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_srt_StatementGeographicalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_US_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_DE_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_CO_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_GB_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_CA_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_Assets_12" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleMember" xlink:label="loc_flgc_CommercialAndWholesaleMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsMember" xlink:label="loc_flgc_HouseOfBrandsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PharmaceuticalsMember" xlink:label="loc_flgc_PharmaceuticalsMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CorporateAndEliminationsMember" xlink:label="loc_flgc_CorporateAndEliminationsMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ConsolidatedMember" xlink:label="loc_flgc_ConsolidatedMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_CommercialAndWholesaleMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_HouseOfBrandsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_PharmaceuticalsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_CorporateAndEliminationsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_ConsolidatedMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_DepreciationAndAmortization_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0" xlink:to="loc_us-gaap_Assets_15" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_COP" xlink:label="loc_currency_COP_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP" xlink:label="loc_currency_GBP_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF" xlink:label="loc_currency_CHF_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableFairValueDisclosure" xlink:label="loc_us-gaap_LoansReceivableFairValueDisclosure_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_CAD_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_COP_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_GBP_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_EUR_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_CHF_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_Cash_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_LoansReceivableFairValueDisclosure_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_LongTermDebt_16" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_FairValueNetAssetLiability_17" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditRiskMember" xlink:label="loc_us-gaap_CreditRiskMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GermanSubsidiariesMember" xlink:label="loc_flgc_GermanSubsidiariesMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember" xlink:label="loc_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialIntermediariesMember" xlink:label="loc_flgc_FinancialIntermediariesMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfExchangeRate" xlink:label="loc_flgc_DescriptionOfExchangeRate_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashFlowModelHighRate" xlink:label="loc_flgc_CashFlowModelHighRate_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedSharesToBeIssued" xlink:label="loc_flgc_ExpectedSharesToBeIssued_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashFlowModelLowRate" xlink:label="loc_flgc_CashFlowModelLowRate_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_5" xlink:to="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_5" xlink:to="loc_us-gaap_CreditRiskMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_5" xlink:to="loc_flgc_GermanSubsidiariesMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_5" xlink:to="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_us-gaap_CollateralAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_10" xlink:to="loc_us-gaap_CollateralDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_10" xlink:to="loc_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_10" xlink:to="loc_flgc_FinancialIntermediariesMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_10" xlink:to="loc_us-gaap_CollateralDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_flgc_DescriptionOfExchangeRate_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_Cash_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFairValue_21" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_flgc_CashFlowModelHighRate_22" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_flgc_ExpectedSharesToBeIssued_23" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_flgc_CashFlowModelLowRate_24" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xlink:to="loc_us-gaap_SharePrice_25" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LossPerShareDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoPlanMember" xlink:label="loc_flgc_TwoThousandTwentyTwoPlanMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoPlanMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosures">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosuresTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OfficersCompensation_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_8" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HampsteadPrivateCapitalLimitedMember" xlink:label="loc_flgc_HampsteadPrivateCapitalLimitedMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DrManaloMorganMember" xlink:label="loc_flgc_DrManaloMorganMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsAxis" xlink:label="loc_flgc_LoanAgreementsAxis_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsDomain" xlink:label="loc_flgc_LoanAgreementsDomain_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstLoanAgreementMember" xlink:label="loc_flgc_FirstLoanAgreementMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondLoanAgreementMember" xlink:label="loc_flgc_SecondLoanAgreementMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsDomain" xlink:label="loc_flgc_LoanAgreementsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts" xlink:label="loc_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MedicalServices" xlink:label="loc_flgc_MedicalServices_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_srt_DirectorMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_srt_ChiefExecutiveOfficerMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_flgc_HampsteadPrivateCapitalLimitedMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_flgc_DrManaloMorganMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_flgc_LoanAgreementsAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_flgc_LoanAgreementsAxis_12" xlink:to="loc_flgc_LoanAgreementsDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_LoanAgreementsDomain_12" xlink:to="loc_flgc_FirstLoanAgreementMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_LoanAgreementsDomain_12" xlink:to="loc_flgc_SecondLoanAgreementMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_flgc_LoanAgreementsAxis_12" xlink:to="loc_flgc_LoanAgreementsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_flgc_MedicalServices_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_LongTermDebt_23" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_24" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_25" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/BasisOfPresentationDetails">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfAccountingLineItems" xlink:label="loc_flgc_BasisOfAccountingLineItems_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfAccountingTable" xlink:label="loc_flgc_BasisOfAccountingTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryOneMember" xlink:label="loc_flgc_SubsidiaryOneMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwoMember" xlink:label="loc_flgc_SubsidiaryTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThreeMember" xlink:label="loc_flgc_SubsidiaryThreeMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFourMember" xlink:label="loc_flgc_SubsidiaryFourMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFiveMember" xlink:label="loc_flgc_SubsidiaryFiveMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySixMember" xlink:label="loc_flgc_SubsidiarySixMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySevenMember" xlink:label="loc_flgc_SubsidiarySevenMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryEightMember" xlink:label="loc_flgc_SubsidiaryEightMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryNineMember" xlink:label="loc_flgc_SubsidiaryNineMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTenMember" xlink:label="loc_flgc_SubsidiaryTenMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryElevenMember" xlink:label="loc_flgc_SubsidiaryElevenMember_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwelveMember" xlink:label="loc_flgc_SubsidiaryTwelveMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirteenMember" xlink:label="loc_flgc_SubsidiaryThirteenMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFourteenMember" xlink:label="loc_flgc_SubsidiaryFourteenMember_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFifteenMember" xlink:label="loc_flgc_SubsidiaryFifteenMember_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySixteenMember" xlink:label="loc_flgc_SubsidiarySixteenMember_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySeventeenMember" xlink:label="loc_flgc_SubsidiarySeventeenMember_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryEighteenMember" xlink:label="loc_flgc_SubsidiaryEighteenMember_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryNineteenMember" xlink:label="loc_flgc_SubsidiaryNineteenMember_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyMember" xlink:label="loc_flgc_SubsidiaryTwentyMember_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyOneMember" xlink:label="loc_flgc_SubsidiaryTwentyOneMember_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyTwoMember" xlink:label="loc_flgc_SubsidiaryTwentyTwoMember_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyThreeMember" xlink:label="loc_flgc_SubsidiaryTwentyThreeMember_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyFourMember" xlink:label="loc_flgc_SubsidiaryTwentyFourMember_24"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyFiveMember" xlink:label="loc_flgc_SubsidiaryTwentyFiveMember_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentySixMember" xlink:label="loc_flgc_SubsidiaryTwentySixMember_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentySevenMember" xlink:label="loc_flgc_SubsidiaryTwentySevenMember_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyEightMember" xlink:label="loc_flgc_SubsidiaryTwentyEightMember_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyNineMember" xlink:label="loc_flgc_SubsidiaryTwentyNineMember_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyMember" xlink:label="loc_flgc_SubsidiaryThirtyMember_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyOneMember" xlink:label="loc_flgc_SubsidiaryThirtyOneMember_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyTwoMember" xlink:label="loc_flgc_SubsidiaryThirtyTwoMember_32"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyThreeMember" xlink:label="loc_flgc_SubsidiaryThirtyThreeMember_33"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyFourMember" xlink:label="loc_flgc_SubsidiaryThirtyFourMember_34"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyFiveMember" xlink:label="loc_flgc_SubsidiaryThirtyFiveMember_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_42"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FunctionalCurrencyOfSubsidiary" xlink:label="loc_flgc_FunctionalCurrencyOfSubsidiary_43"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_flgc_BasisOfAccountingLineItems_0" xlink:to="loc_flgc_BasisOfAccountingTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_BasisOfAccountingTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwoMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThreeMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryFourMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryFiveMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiarySixMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiarySevenMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryEightMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryNineMember_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTenMember_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryElevenMember_11" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwelveMember_12" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirteenMember_13" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryFourteenMember_14" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryFifteenMember_15" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiarySixteenMember_16" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiarySeventeenMember_17" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryEighteenMember_18" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryNineteenMember_19" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyMember_20" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyOneMember_21" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyTwoMember_22" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyThreeMember_23" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyFourMember_24" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyFiveMember_25" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentySixMember_26" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentySevenMember_27" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyEightMember_28" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyNineMember_29" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyMember_30" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyOneMember_31" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyTwoMember_32" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyThreeMember_33" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyFourMember_34" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyFiveMember_35" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_BasisOfAccountingLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_40" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_BasisOfAccountingLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_41" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_BasisOfAccountingLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_42" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_BasisOfAccountingLineItems_0" xlink:to="loc_flgc_FunctionalCurrencyOfSubsidiary_43" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialLiabilitiesPolicyTextBlock" xlink:label="loc_flgc_FinancialLiabilitiesPolicyTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProvisionsPolicyTextBlock" xlink:label="loc_flgc_ProvisionsPolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonControllingInterestsPolicyTextBlock" xlink:label="loc_flgc_NonControllingInterestsPolicyTextBlock_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoingConcernPolicyTextBlock" xlink:label="loc_flgc_GoingConcernPolicyTextBlock_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_32"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_FinancialLiabilitiesPolicyTextBlock_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_ProvisionsPolicyTextBlock_16" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_17" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_18" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_19" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_20" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_21" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_22" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_23" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_24" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_25" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_NonControllingInterestsPolicyTextBlock_26" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_27" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_28" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_29" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_30" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_GoingConcernPolicyTextBlock_31" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_32" order="270" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock" xlink:label="loc_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives" xlink:label="loc_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_7" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesLineItems" xlink:label="loc_flgc_SignificantAccountingPoliciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesTable" xlink:label="loc_flgc_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_flgc_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_flgc_SignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_VehiclesMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_BuildingMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_srt_RangeAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_11" xlink:to="loc_srt_RangeMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11" xlink:to="loc_srt_MinimumMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11" xlink:to="loc_srt_MaximumMember_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_11" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesLineItems" xlink:label="loc_flgc_SignificantAccountingPoliciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesTable" xlink:label="loc_flgc_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesMember" xlink:label="loc_flgc_LicensesMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_flgc_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_flgc_SignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_PatentsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_TrademarksAndBrandsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_LicensesMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_srt_RangeAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_15" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CosechemosAndKasaWholefoodsMember" xlink:label="loc_flgc_CosechemosAndKasaWholefoodsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_srt_OwnershipAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1" xlink:to="loc_srt_OwnershipDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1" xlink:to="loc_flgc_CosechemosAndKasaWholefoodsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1" xlink:to="loc_srt_OwnershipDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_flgc_SharePurchaseAgreementMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_AdvertisingExpense_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_16" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfFghMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfFghMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfJustCBDMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyTwoImpairmentTestMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" xlink:label="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" xlink:label="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember" xlink:label="loc_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselAssetGroupMember" xlink:label="loc_flgc_VesselAssetGroupMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHMember" xlink:label="loc_flgc_FGHMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsSegmentMember" xlink:label="loc_flgc_HouseOfBrandsSegmentMember_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedRecoverableAmount" xlink:label="loc_flgc_EstimatedRecoverableAmount_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfValuation" xlink:label="loc_flgc_DescriptionOfValuation_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoodwillDescription" xlink:label="loc_flgc_GoodwillDescription_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" xlink:label="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_32"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfLicenses" xlink:label="loc_flgc_ImpairmentOfLicenses_33"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_AnnualGoodwillImpairmentTestOfFghMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoImpairmentTestMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_ReportingUnitAxis_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_12" xlink:to="loc_us-gaap_ReportingUnitDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_12" xlink:to="loc_flgc_VesselAssetGroupMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_12" xlink:to="loc_flgc_FGHMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_12" xlink:to="loc_flgc_JustCBDMember_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_12" xlink:to="loc_us-gaap_ReportingUnitDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_18" xlink:to="loc_us-gaap_SegmentDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_18" xlink:to="loc_flgc_HouseOfBrandsSegmentMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_18" xlink:to="loc_us-gaap_SegmentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_Assets_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_25" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_26" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_CapitalLeaseObligations_27" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_flgc_EstimatedRecoverableAmount_28" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_us-gaap_AssetImpairmentCharges_29" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_flgc_DescriptionOfValuation_30" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_flgc_GoodwillDescription_31" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_32" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0" xlink:to="loc_flgc_ImpairmentOfLicenses_33" order="110" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CanadaIncomeTaxAuthorityMember" xlink:label="loc_flgc_CanadaIncomeTaxAuthorityMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_USFederalIncomeTaxAuthorityMember" xlink:label="loc_flgc_USFederalIncomeTaxAuthorityMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_USStateIncomeTaxAuthorityMember" xlink:label="loc_flgc_USStateIncomeTaxAuthorityMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignIncomeTaxAuthorityMember" xlink:label="loc_flgc_ForeignIncomeTaxAuthorityMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_flgc_CanadaIncomeTaxAuthorityMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_flgc_USFederalIncomeTaxAuthorityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_flgc_USStateIncomeTaxAuthorityMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_flgc_ForeignIncomeTaxAuthorityMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsShareIssuanceCosts" xlink:label="loc_flgc_DeferredTaxAssetsShareIssuanceCosts_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments" xlink:label="loc_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_flgc_DeferredTaxAssetsRightOfUseAssets_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsIntangibleAssets" xlink:label="loc_flgc_DeferredTaxAssetsIntangibleAssets_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsGoodwil" xlink:label="loc_flgc_DeferredTaxAssetsGoodwil_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts" xlink:label="loc_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_flgc_DeferredTaxAssetsShareIssuanceCosts_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_flgc_DeferredTaxAssetsRightOfUseAssets_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_flgc_DeferredTaxAssetsIntangibleAssets_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_flgc_DeferredTaxAssetsGoodwil_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_16" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_17" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_18" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_19" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_19" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_19" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_19" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_19" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_22" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitedStatesRevenueAgencyMember" xlink:label="loc_flgc_UnitedStatesRevenueAgencyMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombiaRevenueAgencyMember" xlink:label="loc_flgc_ColombiaRevenueAgencyMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GermanyRevenueAgencyMember" xlink:label="loc_flgc_GermanyRevenueAgencyMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DenmarkRevenueAgencyMember" xlink:label="loc_flgc_DenmarkRevenueAgencyMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitedKingdomRevenueAgencyMember" xlink:label="loc_flgc_UnitedKingdomRevenueAgencyMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignRevenueAgencyMember" xlink:label="loc_flgc_ForeignRevenueAgencyMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentTaxExpenseIncome" xlink:label="loc_flgc_CurrentTaxExpenseIncome_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxExpenseIncome" xlink:label="loc_flgc_DeferredTaxExpenseIncome_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfTaxJurisdictions" xlink:label="loc_flgc_DescriptionOfTaxJurisdictions_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5" xlink:to="loc_flgc_UnitedStatesRevenueAgencyMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5" xlink:to="loc_flgc_ColombiaRevenueAgencyMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5" xlink:to="loc_flgc_GermanyRevenueAgencyMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5" xlink:to="loc_flgc_DenmarkRevenueAgencyMember_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5" xlink:to="loc_flgc_UnitedKingdomRevenueAgencyMember_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5" xlink:to="loc_flgc_ForeignRevenueAgencyMember_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_flgc_CurrentTaxExpenseIncome_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_flgc_DeferredTaxExpenseIncome_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_flgc_DescriptionOfTaxJurisdictions_21" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivable">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/WarrantsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsLineItems" xlink:label="loc_flgc_WarrantsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsTable" xlink:label="loc_flgc_WarrantsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember" xlink:label="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NovemberTwoThousandTwentyOneUnitOfferingMember" xlink:label="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember" xlink:label="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PlacementAgentMember" xlink:label="loc_flgc_PlacementAgentMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsIssuedDuringPeriodExercisePrice" xlink:label="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" xlink:label="loc_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsWithExercisePriceAmended" xlink:label="loc_flgc_NumberOfWarrantsWithExercisePriceAmended_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantExercisePricePriorToAmendment" xlink:label="loc_flgc_WarrantExercisePricePriorToAmendment_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantAmendedExercisePrice" xlink:label="loc_flgc_WarrantAmendedExercisePrice_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IntrinsicValueOfWarrantsExercised" xlink:label="loc_flgc_IntrinsicValueOfWarrantsExercised_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_WarrantsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_WarrantsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_flgc_WarrantsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_flgc_PlacementAgentMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_16" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_17" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_18" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_19" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_NumberOfWarrantsWithExercisePriceAmended_20" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_WarrantExercisePricePriorToAmendment_21" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_WarrantAmendedExercisePrice_22" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_23" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_flgc_IntrinsicValueOfWarrantsExercised_24" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_WarrantsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_25" order="140" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHOwnersMember" xlink:label="loc_flgc_FGHOwnersMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDOwnersMember" xlink:label="loc_flgc_JustCBDOwnersMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselOwnersMember" xlink:label="loc_flgc_VesselOwnersMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBeautyMember" xlink:label="loc_flgc_FloraBeautyMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraMedSasMember" xlink:label="loc_flgc_FloraMedSasMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcHoldingGmbhMember" xlink:label="loc_flgc_TruhcHoldingGmbhMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember" xlink:label="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember" xlink:label="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NovemberTwoThousandTwentyOneUnitOfferingMember" xlink:label="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PlacementAgentMember" xlink:label="loc_flgc_PlacementAgentMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsIssuedDuringPeriodExercisePrice" xlink:label="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsWithAmendedExercisePrice" xlink:label="loc_flgc_NumberOfWarrantsWithAmendedExercisePrice_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantExercisePricePriorToAmendment" xlink:label="loc_flgc_WarrantExercisePricePriorToAmendment_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantAmendedExercisePrice" xlink:label="loc_flgc_WarrantAmendedExercisePrice_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_34"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_40"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueDiscount" xlink:label="loc_flgc_FairValueDiscount_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_50"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_flgc_FGHOwnersMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_flgc_JustCBDOwnersMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_flgc_VesselOwnersMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_flgc_FloraBeautyMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_flgc_FloraMedSasMember_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_flgc_TruhcHoldingGmbhMember_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_14" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_14" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_20" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20" xlink:to="loc_flgc_PlacementAgentMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_20" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_CommonUnitIssued_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssued1_27" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_28" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_29" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_flgc_NumberOfWarrantsWithAmendedExercisePrice_30" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_flgc_WarrantExercisePricePriorToAmendment_31" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_flgc_WarrantAmendedExercisePrice_32" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_33" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_34" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_35" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_36" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_37" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_38" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_39" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_40" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_flgc_FairValueDiscount_41" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_42" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_44" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_45" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_47" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_48" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_49" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_50" order="260" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_StockOptionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharePrice_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_12" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OptionsExercisableMember" xlink:label="loc_flgc_OptionsExercisableMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionDateOfExpiry" xlink:label="loc_flgc_StockOptionDateOfExpiry_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue" xlink:label="loc_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_33"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_StockOptionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_OptionsExercisableMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_16" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_17" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_18" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_19" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_20" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_21" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_22" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_23" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_flgc_StockOptionDateOfExpiry_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_33" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember" xlink:label="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_35"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9" xlink:to="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_13" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_13" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_13" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_20" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_21" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_22" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_23" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_24" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_25" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_26" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_27" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_18" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_28" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_30" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_30" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_30" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_30" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_31" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_32" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_30" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_33" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_34" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_30" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_35" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember" xlink:label="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_24"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_37"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13" xlink:to="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_23" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_24" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_25" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_26" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_27" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_28" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_29" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_30" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_31" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_32" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_33" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_34" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_35" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_36" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_37" order="200" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_11" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract" xlink:label="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract" xlink:label="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_10" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_10" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_10" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xlink:to="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_14" xlink:to="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_14" order="0" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesMember" xlink:label="loc_flgc_LicensesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaap_GoodwillMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FiniteLivedIntangibleAssetsAdditions" xlink:label="loc_flgc_FiniteLivedIntangibleAssetsAdditions_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_LicensesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_TrademarksAndBrandsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_PatentsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_GoodwillMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_flgc_FiniteLivedIntangibleAssetsAdditions_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_18" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/DummyDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesMember" xlink:label="loc_flgc_LicensesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_TrademarksAndBrandsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_PatentsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_LicensesMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_10" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>flgc-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CO" xlink:label="loc_country_CO_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CO" xlink:label="loc_country_CO_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="loc_country_DE_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="loc_country_DE_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="loc_country_GB_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="loc_country_GB_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF" xlink:label="loc_currency_CHF_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF" xlink:label="loc_currency_CHF_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_COP" xlink:label="loc_currency_COP_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_COP" xlink:label="loc_currency_COP_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP" xlink:label="loc_currency_GBP_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP" xlink:label="loc_currency_GBP_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_59"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_61"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_62"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_63"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_64"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_65"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_66"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_67"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_68"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_69"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_71"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ACAMullerMember" xlink:label="loc_flgc_ACAMullerMember_72"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ACAMullerMember" xlink:label="loc_flgc_ACAMullerMember_73"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ACAMullerMember" xlink:label="loc_flgc_ACAMullerMember_74"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_75"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_76"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AcquisitionOfNoncontrollingInterestAmount" xlink:label="loc_flgc_AcquisitionOfNoncontrollingInterestAmount_77"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AcquisitionOfNoncontrollingInterestMember" xlink:label="loc_flgc_AcquisitionOfNoncontrollingInterestMember_78"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AcquisitionOfNoncontrollingInterestMember" xlink:label="loc_flgc_AcquisitionOfNoncontrollingInterestMember_79"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AcquisitionOfNoncontrollingInterestShares" xlink:label="loc_flgc_AcquisitionOfNoncontrollingInterestShares_80"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AdditionalLegalDisputesMember" xlink:label="loc_flgc_AdditionalLegalDisputesMember_81"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AdditionalPaidAmount" xlink:label="loc_flgc_AdditionalPaidAmount_82"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AdditonalyCancelledSharesValue" xlink:label="loc_flgc_AdditonalyCancelledSharesValue_83"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AdditonalyCancelledSharesValue" xlink:label="loc_flgc_AdditonalyCancelledSharesValue_84"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AegisCapitalCorpMember" xlink:label="loc_flgc_AegisCapitalCorpMember_85"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AegisCapitalCorpMember" xlink:label="loc_flgc_AegisCapitalCorpMember_86"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AgreementAxis" xlink:label="loc_flgc_AgreementAxis_87"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AgreementDomain" xlink:label="loc_flgc_AgreementDomain_88"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AmountPayableOfProfitsForAdditionalAmount" xlink:label="loc_flgc_AmountPayableOfProfitsForAdditionalAmount_89"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AmountPayableOfProfitsForAdditionalAmount" xlink:label="loc_flgc_AmountPayableOfProfitsForAdditionalAmount_90"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AmountPayableOfProfitsForAdditionalAmount" xlink:label="loc_flgc_AmountPayableOfProfitsForAdditionalAmount_91"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AmountsPayablePerViolationOfStopSaleOrders" xlink:label="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_92"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AmountsPayablePerViolationOfStopSaleOrders" xlink:label="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_93"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AmountsPayablePerViolationOfStopSaleOrders" xlink:label="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_94"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfFghMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfFghMember_95"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfFghMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfFghMember_96"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfJustCBDMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_97"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfJustCBDMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_98"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfPharmaceuticalsMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfPharmaceuticalsMember_99"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent" xlink:label="loc_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_100"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent" xlink:label="loc_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_101"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent" xlink:label="loc_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_102"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfAccountingAxis" xlink:label="loc_flgc_BasisOfAccountingAxis_103"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfAccountingLineItems" xlink:label="loc_flgc_BasisOfAccountingLineItems_104"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfAccountingTable" xlink:label="loc_flgc_BasisOfAccountingTable_105"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfMeasurementPolicyTextBlock" xlink:label="loc_flgc_BasisOfMeasurementPolicyTextBlock_106"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfMeasurementPolicyTextBlock" xlink:label="loc_flgc_BasisOfMeasurementPolicyTextBlock_107"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfMeasurementPolicyTextBlock" xlink:label="loc_flgc_BasisOfMeasurementPolicyTextBlock_108"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BearsInterestRate" xlink:label="loc_flgc_BearsInterestRate_109"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BearsInterestRate" xlink:label="loc_flgc_BearsInterestRate_110"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BousteadSecuritiesLLCMember" xlink:label="loc_flgc_BousteadSecuritiesLLCMember_111"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BousteadSecuritiesLLCMember" xlink:label="loc_flgc_BousteadSecuritiesLLCMember_112"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BreezeAcquisitionMember" xlink:label="loc_flgc_BreezeAcquisitionMember_113"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BreezeLaboratorySasMember" xlink:label="loc_flgc_BreezeLaboratorySasMember_114"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BreezeLaboratorySasMember" xlink:label="loc_flgc_BreezeLaboratorySasMember_115"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_116"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_117"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_118"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_119"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_120"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_121"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_122"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_123"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_124"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_125"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_126"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_127"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_128"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_129"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_130"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_131"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_132"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_133"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_134"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_135"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_136"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CanadaIncomeTaxAuthorityMember" xlink:label="loc_flgc_CanadaIncomeTaxAuthorityMember_137"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CanadaIncomeTaxAuthorityMember" xlink:label="loc_flgc_CanadaIncomeTaxAuthorityMember_138"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CancelledShares" xlink:label="loc_flgc_CancelledShares_139"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CancelledShares" xlink:label="loc_flgc_CancelledShares_140"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CapitalManagementAbstract" xlink:label="loc_flgc_CapitalManagementAbstract_141"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CapitalManagementAbstract" xlink:label="loc_flgc_CapitalManagementAbstract_142"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CapitalManagementDisclosureTextBlock" xlink:label="loc_flgc_CapitalManagementDisclosureTextBlock_143"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CapitalManagementDisclosureTextBlock" xlink:label="loc_flgc_CapitalManagementDisclosureTextBlock_144"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashConsiderationReturned" xlink:label="loc_flgc_CashConsiderationReturned_145"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashEquivalentsAtCarryingValue1" xlink:label="loc_flgc_CashEquivalentsAtCarryingValue1_146"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashEquivalentsAtCarryingValue1" xlink:label="loc_flgc_CashEquivalentsAtCarryingValue1_147"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashFlowModelHighRate" xlink:label="loc_flgc_CashFlowModelHighRate_148"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashFlowModelLowRate" xlink:label="loc_flgc_CashFlowModelLowRate_149"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashPaid" xlink:label="loc_flgc_CashPaid_150"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ClassicPlanPremiumFinancingMember" xlink:label="loc_flgc_ClassicPlanPremiumFinancingMember_151"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ClassicPlanPremiumFinancingMember" xlink:label="loc_flgc_ClassicPlanPremiumFinancingMember_152"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ClassicPlanPremiumFinancingMember" xlink:label="loc_flgc_ClassicPlanPremiumFinancingMember_153"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember" xlink:label="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_154"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember" xlink:label="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_155"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember" xlink:label="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_156"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombiaRevenueAgencyMember" xlink:label="loc_flgc_ColombiaRevenueAgencyMember_157"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombiaRevenueAgencyMember" xlink:label="loc_flgc_ColombiaRevenueAgencyMember_158"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleMember" xlink:label="loc_flgc_CommercialAndWholesaleMember_159"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleMember" xlink:label="loc_flgc_CommercialAndWholesaleMember_160"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleMember" xlink:label="loc_flgc_CommercialAndWholesaleMember_161"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleSegmentMember" xlink:label="loc_flgc_CommercialAndWholesaleSegmentMember_162"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleSegmentMember" xlink:label="loc_flgc_CommercialAndWholesaleSegmentMember_163"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleSegmentMember" xlink:label="loc_flgc_CommercialAndWholesaleSegmentMember_164"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesDeliveredToTheSellers" xlink:label="loc_flgc_CommonSharesDeliveredToTheSellers_165"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForInvestmentsAmount" xlink:label="loc_flgc_CommonSharesIssuedForInvestmentsAmount_166"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForInvestmentsShares" xlink:label="loc_flgc_CommonSharesIssuedForInvestmentsShares_167"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForOtherAgreementsAmount" xlink:label="loc_flgc_CommonSharesIssuedForOtherAgreementsAmount_168"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForOtherAgreementsShares" xlink:label="loc_flgc_CommonSharesIssuedForOtherAgreementsShares_169"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonStockIssuedForRsusVested" xlink:label="loc_flgc_CommonStockIssuedForRsusVested_170"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CompanyValued" xlink:label="loc_flgc_CompanyValued_171"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ConsolidatedMember" xlink:label="loc_flgc_ConsolidatedMember_172"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ConsolidatedMember" xlink:label="loc_flgc_ConsolidatedMember_173"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ConsolidatedRevenue" xlink:label="loc_flgc_ConsolidatedRevenue_174"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ConsolidatedRevenue" xlink:label="loc_flgc_ConsolidatedRevenue_175"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ConsolidatedRevenue" xlink:label="loc_flgc_ConsolidatedRevenue_176"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionamont" xlink:label="loc_flgc_Contributionamont_177"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionamont" xlink:label="loc_flgc_Contributionamont_178"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionamont" xlink:label="loc_flgc_Contributionamont_179"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionshares" xlink:label="loc_flgc_Contributionshares_180"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionshares" xlink:label="loc_flgc_Contributionshares_181"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionshares" xlink:label="loc_flgc_Contributionshares_182"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CorporateAndEliminationsMember" xlink:label="loc_flgc_CorporateAndEliminationsMember_183"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CorporateAndEliminationsMember" xlink:label="loc_flgc_CorporateAndEliminationsMember_184"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CorporateAndEliminationsMember" xlink:label="loc_flgc_CorporateAndEliminationsMember_185"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CorporateIncomeTax" xlink:label="loc_flgc_CorporateIncomeTax_186"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CosechemosAndKasaWholefoodsMember" xlink:label="loc_flgc_CosechemosAndKasaWholefoodsMember_187"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CosechemosAndKasaWholefoodsMember" xlink:label="loc_flgc_CosechemosAndKasaWholefoodsMember_188"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CosechemosAndKasaWholefoodsMember" xlink:label="loc_flgc_CosechemosAndKasaWholefoodsMember_189"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CreditFacilityDue" xlink:label="loc_flgc_CreditFacilityDue_190"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract" xlink:label="loc_flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract_191"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CumulativeImpairmentRelatedToCommonShares" xlink:label="loc_flgc_CumulativeImpairmentRelatedToCommonShares_192"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentPortionOfContingentPurchaseConsideration" xlink:label="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_193"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentPortionOfContingentPurchaseConsideration" xlink:label="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_194"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentPortionOfContingentPurchaseConsideration" xlink:label="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_195"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentTaxExpenseIncome" xlink:label="loc_flgc_CurrentTaxExpenseIncome_196"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentTaxExpenseIncome" xlink:label="loc_flgc_CurrentTaxExpenseIncome_197"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CustomersRelationshipsMember" xlink:label="loc_flgc_CustomersRelationshipsMember_198"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CustomersRelationshipsMember" xlink:label="loc_flgc_CustomersRelationshipsMember_199"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember" xlink:label="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_200"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember" xlink:label="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_201"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingAmount" xlink:label="loc_flgc_DecemberUnitOfferingAmount_202"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_DecemberUnitOfferingIssuanceCosts_203"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_DecemberUnitOfferingIssuanceCosts_204"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingShares" xlink:label="loc_flgc_DecemberUnitOfferingShares_205"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingShares" xlink:label="loc_flgc_DecemberUnitOfferingShares_206"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts" xlink:label="loc_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_207"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts" xlink:label="loc_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_208"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsGoodwil" xlink:label="loc_flgc_DeferredTaxAssetsGoodwil_209"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsGoodwil" xlink:label="loc_flgc_DeferredTaxAssetsGoodwil_210"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsGoodwil" xlink:label="loc_flgc_DeferredTaxAssetsGoodwil_211"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsIntangibleAssets" xlink:label="loc_flgc_DeferredTaxAssetsIntangibleAssets_212"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsIntangibleAssets" xlink:label="loc_flgc_DeferredTaxAssetsIntangibleAssets_213"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsIntangibleAssets" xlink:label="loc_flgc_DeferredTaxAssetsIntangibleAssets_214"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_flgc_DeferredTaxAssetsRightOfUseAssets_215"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_flgc_DeferredTaxAssetsRightOfUseAssets_216"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsShareIssuanceCosts" xlink:label="loc_flgc_DeferredTaxAssetsShareIssuanceCosts_217"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsShareIssuanceCosts" xlink:label="loc_flgc_DeferredTaxAssetsShareIssuanceCosts_218"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments" xlink:label="loc_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_219"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments" xlink:label="loc_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_220"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxExpenseIncome" xlink:label="loc_flgc_DeferredTaxExpenseIncome_221"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxExpenseIncome" xlink:label="loc_flgc_DeferredTaxExpenseIncome_222"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxLiabilitiesAmount" xlink:label="loc_flgc_DeferredTaxLiabilitiesAmount_223"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxLiabilitiesAmount" xlink:label="loc_flgc_DeferredTaxLiabilitiesAmount_224"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxLiabilitiesNet" xlink:label="loc_flgc_DeferredTaxLiabilitiesNet_225"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxLiabilitiesNet" xlink:label="loc_flgc_DeferredTaxLiabilitiesNet_226"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DenmarkRevenueAgencyMember" xlink:label="loc_flgc_DenmarkRevenueAgencyMember_227"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DenmarkRevenueAgencyMember" xlink:label="loc_flgc_DenmarkRevenueAgencyMember_228"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DerecognitionOfEquityRelatedToColombiaAssets" xlink:label="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_229"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DerecognitionOfEquityRelatedToColombiaAssets" xlink:label="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_230"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DerecognitionOfEquityRelatedToColombiaAssets" xlink:label="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_231"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfDiscountRates" xlink:label="loc_flgc_DescriptionOfDiscountRates_232"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfExchangeRate" xlink:label="loc_flgc_DescriptionOfExchangeRate_233"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfExchangeRate" xlink:label="loc_flgc_DescriptionOfExchangeRate_234"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfExchangeRate" xlink:label="loc_flgc_DescriptionOfExchangeRate_235"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_flgc_DescriptionOfExpectedVolatilityShareOptionsGranted_236"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_flgc_DescriptionOfExpectedVolatilityShareOptionsGranted_237"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfImpairment" xlink:label="loc_flgc_DescriptionOfImpairment_238"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfImpairment" xlink:label="loc_flgc_DescriptionOfImpairment_239"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfImpairment" xlink:label="loc_flgc_DescriptionOfImpairment_240"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfRevenueGrowth" xlink:label="loc_flgc_DescriptionOfRevenueGrowth_241"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfRevenueGrowth" xlink:label="loc_flgc_DescriptionOfRevenueGrowth_242"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted_243"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted_244"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfSensitivityAnalysis" xlink:label="loc_flgc_DescriptionOfSensitivityAnalysis_245"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfSensitivityAnalysis" xlink:label="loc_flgc_DescriptionOfSensitivityAnalysis_246"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfShares" xlink:label="loc_flgc_DescriptionOfShares_247"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfShares" xlink:label="loc_flgc_DescriptionOfShares_248"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfTaxJurisdictions" xlink:label="loc_flgc_DescriptionOfTaxJurisdictions_249"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfTaxJurisdictions" xlink:label="loc_flgc_DescriptionOfTaxJurisdictions_250"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfValuation" xlink:label="loc_flgc_DescriptionOfValuation_251"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfValuation" xlink:label="loc_flgc_DescriptionOfValuation_252"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DiscountRate" xlink:label="loc_flgc_DiscountRate_253"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_254"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_255"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_256"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_257"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_258"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_259"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_260"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_261"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_262"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_263"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_264"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_265"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_266"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_267"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_268"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_269"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_270"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_271"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_272"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_273"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_274"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_275"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_276"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_277"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_278"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_279"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_280"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_281"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_282"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_283"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DrManaloMorganMember" xlink:label="loc_flgc_DrManaloMorganMember_284"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DrManaloMorganMember" xlink:label="loc_flgc_DrManaloMorganMember_285"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate" xlink:label="loc_flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate_286"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate" xlink:label="loc_flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate_287"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EquityIssuedForOtherAgreementsAmount" xlink:label="loc_flgc_EquityIssuedForOtherAgreementsAmount_288"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EquityIssuedForOtherAgreementsAmount" xlink:label="loc_flgc_EquityIssuedForOtherAgreementsAmount_289"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EquityIssuedForOtherAgreementsShares" xlink:label="loc_flgc_EquityIssuedForOtherAgreementsShares_290"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedImpactOfPotentialExchangeRateFluctuations" xlink:label="loc_flgc_EstimatedImpactOfPotentialExchangeRateFluctuations_291"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedLossOnPotentialLiabilities" xlink:label="loc_flgc_EstimatedLossOnPotentialLiabilities_292"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedLossOnPotentialLiabilities" xlink:label="loc_flgc_EstimatedLossOnPotentialLiabilities_293"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedLossOnPotentialLiabilities" xlink:label="loc_flgc_EstimatedLossOnPotentialLiabilities_294"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedRecoverableAmount" xlink:label="loc_flgc_EstimatedRecoverableAmount_295"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedRecoverableAmount" xlink:label="loc_flgc_EstimatedRecoverableAmount_296"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EuroCreditFacilityMember" xlink:label="loc_flgc_EuroCreditFacilityMember_297"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EuroCreditFacilityMember" xlink:label="loc_flgc_EuroCreditFacilityMember_298"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExercisePriceOfInvestmentWarrants" xlink:label="loc_flgc_ExercisePriceOfInvestmentWarrants_299"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExercisePriceOfInvestmentWarrants" xlink:label="loc_flgc_ExercisePriceOfInvestmentWarrants_300"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_flgc_ExpectedDividendAsPercentageShareOptionsGranted_301"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_flgc_ExpectedDividendAsPercentageShareOptionsGranted_302"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedLife" xlink:label="loc_flgc_ExpectedLife_303"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedLife" xlink:label="loc_flgc_ExpectedLife_304"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedOptionLifeInYears" xlink:label="loc_flgc_ExpectedOptionLifeInYears_305"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedOptionLifeInYears" xlink:label="loc_flgc_ExpectedOptionLifeInYears_306"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedSharesToBeIssued" xlink:label="loc_flgc_ExpectedSharesToBeIssued_307"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss" xlink:label="loc_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_308"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss" xlink:label="loc_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_309"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss" xlink:label="loc_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_310"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueDiscount" xlink:label="loc_flgc_FairValueDiscount_311"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueDiscount" xlink:label="loc_flgc_FairValueDiscount_312"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfNonemployeeStockWarrantsGranted" xlink:label="loc_flgc_FairValueOfNonemployeeStockWarrantsGranted_313"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfNonemployeeStockWarrantsGranted" xlink:label="loc_flgc_FairValueOfNonemployeeStockWarrantsGranted_314"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfRestrictedStockAwardsIssued" xlink:label="loc_flgc_FairValueOfRestrictedStockAwardsIssued_315"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_316"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_317"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHMember" xlink:label="loc_flgc_FGHMember_318"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHMember" xlink:label="loc_flgc_FGHMember_319"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHMember" xlink:label="loc_flgc_FGHMember_320"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHMember" xlink:label="loc_flgc_FGHMember_321"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHOwnersMember" xlink:label="loc_flgc_FGHOwnersMember_322"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHOwnersMember" xlink:label="loc_flgc_FGHOwnersMember_323"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_324"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_325"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_326"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialInstrumentsAbstract" xlink:label="loc_flgc_FinancialInstrumentsAbstract_327"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_flgc_FinancialInstrumentsAndRiskManagementAbstract_328"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_flgc_FinancialInstrumentsAndRiskManagementAbstract_329"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialIntermediariesMember" xlink:label="loc_flgc_FinancialIntermediariesMember_330"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialIntermediariesMember" xlink:label="loc_flgc_FinancialIntermediariesMember_331"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialIntermediariesMember" xlink:label="loc_flgc_FinancialIntermediariesMember_332"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialLiabilitiesPolicyTextBlock" xlink:label="loc_flgc_FinancialLiabilitiesPolicyTextBlock_333"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialLiabilitiesPolicyTextBlock" xlink:label="loc_flgc_FinancialLiabilitiesPolicyTextBlock_334"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancingReceivables180PlusDaysPastDueMember" xlink:label="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_335"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancingReceivables180PlusDaysPastDueMember" xlink:label="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_336"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancingReceivables180PlusDaysPastDueMember" xlink:label="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_337"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FiniteLivedIntangibleAssetsAdditions" xlink:label="loc_flgc_FiniteLivedIntangibleAssetsAdditions_338"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FiniteLivedIntangibleAssetsAdditions" xlink:label="loc_flgc_FiniteLivedIntangibleAssetsAdditions_339"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstClosingMember" xlink:label="loc_flgc_FirstClosingMember_340"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstClosingMember" xlink:label="loc_flgc_FirstClosingMember_341"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstLoanAgreementMember" xlink:label="loc_flgc_FirstLoanAgreementMember_342"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstLoanAgreementMember" xlink:label="loc_flgc_FirstLoanAgreementMember_343"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstLoanMember" xlink:label="loc_flgc_FirstLoanMember_344"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstLoanMember" xlink:label="loc_flgc_FirstLoanMember_345"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstTrancheMember" xlink:label="loc_flgc_FirstTrancheMember_346"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FixedAssets" xlink:label="loc_flgc_FixedAssets_347"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FixedAssets" xlink:label="loc_flgc_FixedAssets_348"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FixedAssets" xlink:label="loc_flgc_FixedAssets_349"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBeautyMember" xlink:label="loc_flgc_FloraBeautyMember_350"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBeautyMember" xlink:label="loc_flgc_FloraBeautyMember_351"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBeautyMember" xlink:label="loc_flgc_FloraBeautyMember_352"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBreezeLaboratoryMember" xlink:label="loc_flgc_FloraBreezeLaboratoryMember_353"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBreezeLaboratoryMember" xlink:label="loc_flgc_FloraBreezeLaboratoryMember_354"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraGrowthCorpMember" xlink:label="loc_flgc_FloraGrowthCorpMember_355"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraGrowthCorpMember" xlink:label="loc_flgc_FloraGrowthCorpMember_356"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraMedSasMember" xlink:label="loc_flgc_FloraMedSasMember_357"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraMedSasMember" xlink:label="loc_flgc_FloraMedSasMember_358"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraMedSasMember" xlink:label="loc_flgc_FloraMedSasMember_359"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FoodAndBeveragesMember" xlink:label="loc_flgc_FoodAndBeveragesMember_360"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FoodAndBeveragesMember" xlink:label="loc_flgc_FoodAndBeveragesMember_361"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignExchangeImpacts" xlink:label="loc_flgc_ForeignExchangeImpacts_362"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignIncomeTaxAuthorityMember" xlink:label="loc_flgc_ForeignIncomeTaxAuthorityMember_363"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignIncomeTaxAuthorityMember" xlink:label="loc_flgc_ForeignIncomeTaxAuthorityMember_364"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignRevenueAgencyMember" xlink:label="loc_flgc_ForeignRevenueAgencyMember_365"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignRevenueAgencyMember" xlink:label="loc_flgc_ForeignRevenueAgencyMember_366"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FortLauderdaleMember" xlink:label="loc_flgc_FortLauderdaleMember_367"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FortLauderdaleMember" xlink:label="loc_flgc_FortLauderdaleMember_368"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_369"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_370"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FunctionalCurrencyOfSubsidiary" xlink:label="loc_flgc_FunctionalCurrencyOfSubsidiary_371"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FunctionalCurrencyOfSubsidiary" xlink:label="loc_flgc_FunctionalCurrencyOfSubsidiary_372"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GerardoAndresGarciaMendezMember" xlink:label="loc_flgc_GerardoAndresGarciaMendezMember_373"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GerardoAndresGarciaMendezMember" xlink:label="loc_flgc_GerardoAndresGarciaMendezMember_374"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GermanSubsidiariesMember" xlink:label="loc_flgc_GermanSubsidiariesMember_375"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GermanyRevenueAgencyMember" xlink:label="loc_flgc_GermanyRevenueAgencyMember_376"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GermanyRevenueAgencyMember" xlink:label="loc_flgc_GermanyRevenueAgencyMember_377"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoingConcernPolicyTextBlock" xlink:label="loc_flgc_GoingConcernPolicyTextBlock_378"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoingConcernPolicyTextBlock" xlink:label="loc_flgc_GoingConcernPolicyTextBlock_379"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoodwillAndIdentifiedIntangibleAssets" xlink:label="loc_flgc_GoodwillAndIdentifiedIntangibleAssets_380"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoodwillAndIdentifiedIntangibleAssets" xlink:label="loc_flgc_GoodwillAndIdentifiedIntangibleAssets_381"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoodwillDescription" xlink:label="loc_flgc_GoodwillDescription_382"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GrantDateFairValueOfWarrantsOutstanding" xlink:label="loc_flgc_GrantDateFairValueOfWarrantsOutstanding_383"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GrupoFarmaceuticoCronomedSasMember" xlink:label="loc_flgc_GrupoFarmaceuticoCronomedSasMember_384"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GrupoFarmaceuticoCronomedSasMember" xlink:label="loc_flgc_GrupoFarmaceuticoCronomedSasMember_385"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HampsteadPrivateCapitalLimitedMember" xlink:label="loc_flgc_HampsteadPrivateCapitalLimitedMember_386"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HarvestedCannabis" xlink:label="loc_flgc_HarvestedCannabis_387"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember" xlink:label="loc_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_388"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember" xlink:label="loc_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_389"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsMember" xlink:label="loc_flgc_HouseOfBrandsMember_390"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsMember" xlink:label="loc_flgc_HouseOfBrandsMember_391"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsSegmentMember" xlink:label="loc_flgc_HouseOfBrandsSegmentMember_392"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsSegmentMember" xlink:label="loc_flgc_HouseOfBrandsSegmentMember_393"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsSegmentMember" xlink:label="loc_flgc_HouseOfBrandsSegmentMember_394"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HypoverinsbankMember" xlink:label="loc_flgc_HypoverinsbankMember_395"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfAssetsAbstract" xlink:label="loc_flgc_ImpairmentOfAssetsAbstract_396"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfGoodwill" xlink:label="loc_flgc_ImpairmentOfGoodwill_397"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfGoodwill" xlink:label="loc_flgc_ImpairmentOfGoodwill_398"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfGoodwill" xlink:label="loc_flgc_ImpairmentOfGoodwill_399"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfLicenses" xlink:label="loc_flgc_ImpairmentOfLicenses_400"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfPatents" xlink:label="loc_flgc_ImpairmentOfPatents_401"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfPatents" xlink:label="loc_flgc_ImpairmentOfPatents_402"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfPropertyPlantAndEquipment" xlink:label="loc_flgc_ImpairmentOfPropertyPlantAndEquipment_403"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IncreaseInCarryingValueOfAssets" xlink:label="loc_flgc_IncreaseInCarryingValueOfAssets_404"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IncreaseInCarryingValueOfAssets" xlink:label="loc_flgc_IncreaseInCarryingValueOfAssets_405"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IndemnificationReceivables" xlink:label="loc_flgc_IndemnificationReceivables_406"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IndemnificationReceivables" xlink:label="loc_flgc_IndemnificationReceivables_407"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IndemnificationReceivables" xlink:label="loc_flgc_IndemnificationReceivables_408"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingAmount" xlink:label="loc_flgc_InitialPublicOfferingAmount_409"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingIssuanceCostsAmount" xlink:label="loc_flgc_InitialPublicOfferingIssuanceCostsAmount_410"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingIssuanceCostsShares" xlink:label="loc_flgc_InitialPublicOfferingIssuanceCostsShares_411"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingMember" xlink:label="loc_flgc_InitialPublicOfferingMember_412"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingMember" xlink:label="loc_flgc_InitialPublicOfferingMember_413"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingShares" xlink:label="loc_flgc_InitialPublicOfferingShares_414"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash" xlink:label="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_415"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash" xlink:label="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_416"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash" xlink:label="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_417"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IntrinsicValueOfWarrantsExercised" xlink:label="loc_flgc_IntrinsicValueOfWarrantsExercised_418"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryAbstract" xlink:label="loc_flgc_InventoryAbstract_419"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryExpensedToCostOfSales" xlink:label="loc_flgc_InventoryExpensedToCostOfSales_420"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryExpensedToCostOfSales" xlink:label="loc_flgc_InventoryExpensedToCostOfSales_421"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryImpactedByStopSaleOrders" xlink:label="loc_flgc_InventoryImpactedByStopSaleOrders_422"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryImpactedByStopSaleOrders" xlink:label="loc_flgc_InventoryImpactedByStopSaleOrders_423"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvesteeCommonSharesMember" xlink:label="loc_flgc_InvesteeCommonSharesMember_424"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract" xlink:label="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_425"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract" xlink:label="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_426"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestmentDescription" xlink:label="loc_flgc_InvestmentDescription_427"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestmentDescription" xlink:label="loc_flgc_InvestmentDescription_428"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestmentExercisePrice" xlink:label="loc_flgc_InvestmentExercisePrice_429"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestmentExercisePrice" xlink:label="loc_flgc_InvestmentExercisePrice_430"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IssuanceCosts" xlink:label="loc_flgc_IssuanceCosts_431"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IssuanceCosts" xlink:label="loc_flgc_IssuanceCosts_432"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_433"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_434"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_435"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLLCMember" xlink:label="loc_flgc_JustBrandsLLCMember_436"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLLCMember" xlink:label="loc_flgc_JustBrandsLLCMember_437"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLLCMember" xlink:label="loc_flgc_JustBrandsLLCMember_438"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLLCMember" xlink:label="loc_flgc_JustBrandsLLCMember_439"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDInsurancePremiumLoanMember" xlink:label="loc_flgc_JustCBDInsurancePremiumLoanMember_440"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDInsurancePremiumLoanMember" xlink:label="loc_flgc_JustCBDInsurancePremiumLoanMember_441"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDInsurancePremiumLoanMember" xlink:label="loc_flgc_JustCBDInsurancePremiumLoanMember_442"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_443"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_444"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_445"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_446"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_447"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDOwnersMember" xlink:label="loc_flgc_JustCBDOwnersMember_448"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDOwnersMember" xlink:label="loc_flgc_JustCBDOwnersMember_449"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_KnowHowMember" xlink:label="loc_flgc_KnowHowMember_450"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_KnowHowMember" xlink:label="loc_flgc_KnowHowMember_451"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LeaseLiabilities" xlink:label="loc_flgc_LeaseLiabilities_452"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LeaseLiabilities" xlink:label="loc_flgc_LeaseLiabilities_453"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LeaseObligations" xlink:label="loc_flgc_LeaseObligations_454"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LeasesMonthlyAmount" xlink:label="loc_flgc_LeasesMonthlyAmount_455"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LegalDisputesMember" xlink:label="loc_flgc_LegalDisputesMember_456"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LegalDisputesMember" xlink:label="loc_flgc_LegalDisputesMember_457"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesAmount" xlink:label="loc_flgc_LiabilitiesAmount_458"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesAmount" xlink:label="loc_flgc_LiabilitiesAmount_459"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_460"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_461"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_462"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent" xlink:label="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_463"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent" xlink:label="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_464"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent" xlink:label="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_465"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesAndTrademarksMember" xlink:label="loc_flgc_LicensesAndTrademarksMember_466"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesMember" xlink:label="loc_flgc_LicensesMember_467"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesMember" xlink:label="loc_flgc_LicensesMember_468"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_469"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_470"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_471"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsAxis" xlink:label="loc_flgc_LoanAgreementsAxis_472"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsAxis" xlink:label="loc_flgc_LoanAgreementsAxis_473"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsDomain" xlink:label="loc_flgc_LoanAgreementsDomain_474"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsDomain" xlink:label="loc_flgc_LoanAgreementsDomain_475"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanRepaymentsReceived" xlink:label="loc_flgc_LoanRepaymentsReceived_476"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanRepaymentsReceived" xlink:label="loc_flgc_LoanRepaymentsReceived_477"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoansProvided" xlink:label="loc_flgc_LoansProvided_478"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoansProvided" xlink:label="loc_flgc_LoansProvided_479"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoansReceivableAndAdvances" xlink:label="loc_flgc_LoansReceivableAndAdvances_480"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyAccrualForeignCurrencyTranslation" xlink:label="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_481"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyAccrualForeignCurrencyTranslation" xlink:label="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_482"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyAccrualForeignCurrencyTranslation" xlink:label="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_483"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" xlink:label="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_484"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" xlink:label="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_485"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" xlink:label="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_486"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_487"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_488"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_489"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossInterestAccrued" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_490"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossInterestAccrued" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_491"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossInterestAccrued" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_492"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyInterestPaymentTerms" xlink:label="loc_flgc_LossContingencyInterestPaymentTerms_493"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyInterestPaymentTerms" xlink:label="loc_flgc_LossContingencyInterestPaymentTerms_494"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyInterestPaymentTerms" xlink:label="loc_flgc_LossContingencyInterestPaymentTerms_495"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MachineryAndOfficeEquipmentMember" xlink:label="loc_flgc_MachineryAndOfficeEquipmentMember_496"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MachineryAndOfficeEquipmentMember" xlink:label="loc_flgc_MachineryAndOfficeEquipmentMember_497"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ManagementContractsTerms" xlink:label="loc_flgc_ManagementContractsTerms_498"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ManagementContractsTerms" xlink:label="loc_flgc_ManagementContractsTerms_499"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" xlink:label="loc_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_500"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" xlink:label="loc_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_501"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumLimitOfIndemnificationAgreement" xlink:label="loc_flgc_MaximumLimitOfIndemnificationAgreement_502"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumLimitOfIndemnificationAgreement" xlink:label="loc_flgc_MaximumLimitOfIndemnificationAgreement_503"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumLimitOfIndemnificationAgreement" xlink:label="loc_flgc_MaximumLimitOfIndemnificationAgreement_504"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumPaymentAccumulatedForValuation" xlink:label="loc_flgc_MaximumPaymentAccumulatedForValuation_505"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumPaymentAccumulatedForValuation" xlink:label="loc_flgc_MaximumPaymentAccumulatedForValuation_506"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumPaymentAccumulatedForValuation" xlink:label="loc_flgc_MaximumPaymentAccumulatedForValuation_507"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumPortionOfNetProfitsPayable" xlink:label="loc_flgc_MaximumPortionOfNetProfitsPayable_508"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumPortionOfNetProfitsPayable" xlink:label="loc_flgc_MaximumPortionOfNetProfitsPayable_509"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumPortionOfNetProfitsPayable" xlink:label="loc_flgc_MaximumPortionOfNetProfitsPayable_510"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MedicalServices" xlink:label="loc_flgc_MedicalServices_511"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MonthlyLeasePayment" xlink:label="loc_flgc_MonthlyLeasePayment_512"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NameOfSubsidiary" xlink:label="loc_flgc_NameOfSubsidiary_513"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NatureOfOperationsAndGoingConcernAbstract" xlink:label="loc_flgc_NatureOfOperationsAndGoingConcernAbstract_514"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NatureOfOperationsAndGoingConcernAbstract" xlink:label="loc_flgc_NatureOfOperationsAndGoingConcernAbstract_515"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NetDeferredTaxLiabilities" xlink:label="loc_flgc_NetDeferredTaxLiabilities_516"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NetDeferredTaxLiabilities" xlink:label="loc_flgc_NetDeferredTaxLiabilities_517"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NoCapHempCoMember" xlink:label="loc_flgc_NoCapHempCoMember_518"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NoCapHempCoMember" xlink:label="loc_flgc_NoCapHempCoMember_519"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCapitalLossCarryforwards" xlink:label="loc_flgc_NonCapitalLossCarryforwards_520"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCapitalLossCarryforwards" xlink:label="loc_flgc_NonCapitalLossCarryforwards_521"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashAssetsAcquiredForContingentConsideration" xlink:label="loc_flgc_NonCashAssetsAcquiredForContingentConsideration_522"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashAssetsAcquiredForContingentConsideration" xlink:label="loc_flgc_NonCashAssetsAcquiredForContingentConsideration_523"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashCommonSharesIssuedForBusinessCombinations" xlink:label="loc_flgc_NonCashCommonSharesIssuedForBusinessCombinations_524"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashCommonSharesIssuedForBusinessCombinations" xlink:label="loc_flgc_NonCashCommonSharesIssuedForBusinessCombinations_525"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashCommonSharesIssuedForOtherAgreements" xlink:label="loc_flgc_NonCashCommonSharesIssuedForOtherAgreements_526"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashCommonSharesIssuedForOtherAgreements" xlink:label="loc_flgc_NonCashCommonSharesIssuedForOtherAgreements_527"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets" xlink:label="loc_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_528"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets" xlink:label="loc_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_529"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashOptionCancellationsReclassifiedToEquity" xlink:label="loc_flgc_NonCashOptionCancellationsReclassifiedToEquity_530"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashOptionCancellationsReclassifiedToEquity" xlink:label="loc_flgc_NonCashOptionCancellationsReclassifiedToEquity_531"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonControllingInterestsPolicyTextBlock" xlink:label="loc_flgc_NonControllingInterestsPolicyTextBlock_532"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonControllingInterestsPolicyTextBlock" xlink:label="loc_flgc_NonControllingInterestsPolicyTextBlock_533"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonVestedShares" xlink:label="loc_flgc_NonVestedShares_534"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NovemberTwoThousandTwentyOneUnitOfferingMember" xlink:label="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_535"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NovemberTwoThousandTwentyOneUnitOfferingMember" xlink:label="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_536"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfSharesUnderPlaintiffClaim" xlink:label="loc_flgc_NumberOfSharesUnderPlaintiffClaim_537"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfSharesUnderPlaintiffClaim" xlink:label="loc_flgc_NumberOfSharesUnderPlaintiffClaim_538"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfSharesUnderPlaintiffClaim" xlink:label="loc_flgc_NumberOfSharesUnderPlaintiffClaim_539"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfTrials" xlink:label="loc_flgc_NumberOfTrials_540"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfTrials" xlink:label="loc_flgc_NumberOfTrials_541"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfTrials" xlink:label="loc_flgc_NumberOfTrials_542"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfViolationsClaimed" xlink:label="loc_flgc_NumberOfViolationsClaimed_543"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfViolationsClaimed" xlink:label="loc_flgc_NumberOfViolationsClaimed_544"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfViolationsClaimed" xlink:label="loc_flgc_NumberOfViolationsClaimed_545"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfViolationsInStopSaleOrders" xlink:label="loc_flgc_NumberOfViolationsInStopSaleOrders_546"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsCancelledExpired" xlink:label="loc_flgc_NumberOfWarrantsCancelledExpired_547"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsCancelledExpired" xlink:label="loc_flgc_NumberOfWarrantsCancelledExpired_548"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_549"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_550"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_551"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsWithAmendedExercisePrice" xlink:label="loc_flgc_NumberOfWarrantsWithAmendedExercisePrice_552"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsWithExercisePriceAmended" xlink:label="loc_flgc_NumberOfWarrantsWithExercisePriceAmended_553"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract" xlink:label="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_554"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract" xlink:label="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_555"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OptionsExercisableMember" xlink:label="loc_flgc_OptionsExercisableMember_556"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OptionsExercisableMember" xlink:label="loc_flgc_OptionsExercisableMember_557"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OptionsExpiredCancelled" xlink:label="loc_flgc_OptionsExpiredCancelled_558"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_flgc_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_559"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OriginalHempAssetAcquisitionMember" xlink:label="loc_flgc_OriginalHempAssetAcquisitionMember_560"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" xlink:label="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_561"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" xlink:label="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_562"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" xlink:label="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_563"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" xlink:label="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_564"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherEquityIssuanceCosts" xlink:label="loc_flgc_OtherEquityIssuanceCosts_565"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherInformationAbstract" xlink:label="loc_flgc_OtherInformationAbstract_566"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherInformationAbstract" xlink:label="loc_flgc_OtherInformationAbstract_567"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherIssuanceMember" xlink:label="loc_flgc_OtherIssuanceMember_568"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherLongLivedAssetImpairmentTestsMember" xlink:label="loc_flgc_OtherLongLivedAssetImpairmentTestsMember_569"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherLongLivedAssets" xlink:label="loc_flgc_OtherLongLivedAssets_570"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherLongLivedAssets" xlink:label="loc_flgc_OtherLongLivedAssets_571"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherOfferingMember" xlink:label="loc_flgc_OtherOfferingMember_572"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherOfferingMember" xlink:label="loc_flgc_OtherOfferingMember_573"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PaidAmountToBreezeVendor" xlink:label="loc_flgc_PaidAmountToBreezeVendor_574"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PaidAmountToBreezeVendor" xlink:label="loc_flgc_PaidAmountToBreezeVendor_575"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PaidAmountToBreezeVendor" xlink:label="loc_flgc_PaidAmountToBreezeVendor_576"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PatentAndDevelopedTechnologyMember" xlink:label="loc_flgc_PatentAndDevelopedTechnologyMember_577"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PatentAndDevelopedTechnologyMember" xlink:label="loc_flgc_PatentAndDevelopedTechnologyMember_578"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfAcquisition" xlink:label="loc_flgc_PercentageOfAcquisition_579"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfAcquisition" xlink:label="loc_flgc_PercentageOfAcquisition_580"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares" xlink:label="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_581"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares" xlink:label="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_582"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares" xlink:label="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_583"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfIssuedAndOutstandingCommonShares" xlink:label="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_584"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfIssuedAndOutstandingCommonShares" xlink:label="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_585"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfIssuedAndOutstandingCommonShares" xlink:label="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_586"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" xlink:label="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_587"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" xlink:label="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_588"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" xlink:label="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_589"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PharmaceuticalsMember" xlink:label="loc_flgc_PharmaceuticalsMember_590"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PlacementAgentMember" xlink:label="loc_flgc_PlacementAgentMember_591"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PompanoBeachMember" xlink:label="loc_flgc_PompanoBeachMember_592"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PompanoBeachMember" xlink:label="loc_flgc_PompanoBeachMember_593"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PostTerminationExercisePeriod" xlink:label="loc_flgc_PostTerminationExercisePeriod_594"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PostTerminationExercisePeriod" xlink:label="loc_flgc_PostTerminationExercisePeriod_595"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PostTerminationExercisePeriod" xlink:label="loc_flgc_PostTerminationExercisePeriod_596"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PotentialLiabilities" xlink:label="loc_flgc_PotentialLiabilities_597"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PotentialLiabilities" xlink:label="loc_flgc_PotentialLiabilities_598"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock" xlink:label="loc_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_599"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock" xlink:label="loc_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_600"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock" xlink:label="loc_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_601"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PreviouslyIssuedWarrant" xlink:label="loc_flgc_PreviouslyIssuedWarrant_602"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PreviouslyIssuedWarrant" xlink:label="loc_flgc_PreviouslyIssuedWarrant_603"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PriceToBookValue" xlink:label="loc_flgc_PriceToBookValue_604"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PriceToTangibleBookValue" xlink:label="loc_flgc_PriceToTangibleBookValue_605"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProceedsFromExerciseOfWarrantsAndOptions" xlink:label="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_606"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProceedsFromExerciseOfWarrantsAndOptions" xlink:label="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_607"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PropertyInSantanderMember" xlink:label="loc_flgc_PropertyInSantanderMember_608"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PropertyInSantanderMember" xlink:label="loc_flgc_PropertyInSantanderMember_609"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProvisionsPolicyTextBlock" xlink:label="loc_flgc_ProvisionsPolicyTextBlock_610"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProvisionsPolicyTextBlock" xlink:label="loc_flgc_ProvisionsPolicyTextBlock_611"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsideration" xlink:label="loc_flgc_PurchaseConsideration_612"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationComprised" xlink:label="loc_flgc_PurchaseConsiderationComprised_613"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationComprisedShare" xlink:label="loc_flgc_PurchaseConsiderationComprisedShare_614"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationDiscountRate" xlink:label="loc_flgc_PurchaseConsiderationDiscountRate_615"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationDiscountRate" xlink:label="loc_flgc_PurchaseConsiderationDiscountRate_616"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationPercentageOfSales" xlink:label="loc_flgc_PurchaseConsiderationPercentageOfSales_617"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationPercentageOfSalesAmountPayable" xlink:label="loc_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_618"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationPercentageOfSalesAmountPayable" xlink:label="loc_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_619"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseOfCommonStock" xlink:label="loc_flgc_PurchaseOfCommonStock_620"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember" xlink:label="loc_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_621"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember" xlink:label="loc_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_622"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_623"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_624"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_625"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_626"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_627"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_628"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_629"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_630"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_631"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_632"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_633"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_634"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_635"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_636"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_637"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_638"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_639"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_640"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_641"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_642"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_643"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_644"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_645"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_646"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_647"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_648"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_649"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_650"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_651"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_652"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_653"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_654"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_655"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_656"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_657"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_658"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RealEstateAssetsMember" xlink:label="loc_flgc_RealEstateAssetsMember_659"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RealEstateAssetsMember" xlink:label="loc_flgc_RealEstateAssetsMember_660"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RealEstateAssetsMember" xlink:label="loc_flgc_RealEstateAssetsMember_661"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RegulationAAndOtherOfferingsAmount" xlink:label="loc_flgc_RegulationAAndOtherOfferingsAmount_662"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RegulationAAndOtherOfferingsShares" xlink:label="loc_flgc_RegulationAAndOtherOfferingsShares_663"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RelatedPartyDisclosuresAbstract" xlink:label="loc_flgc_RelatedPartyDisclosuresAbstract_664"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RelatedPartyDisclosuresAbstract" xlink:label="loc_flgc_RelatedPartyDisclosuresAbstract_665"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RemainingPercentageOfAcquisition" xlink:label="loc_flgc_RemainingPercentageOfAcquisition_666"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RemainingWeightedAverageVestingPeriod" xlink:label="loc_flgc_RemainingWeightedAverageVestingPeriod_667"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockAwardsMember" xlink:label="loc_flgc_RestrictedStockAwardsMember_668"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockVestingAmount" xlink:label="loc_flgc_RestrictedStockVestingAmount_669"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockVestingAmount" xlink:label="loc_flgc_RestrictedStockVestingAmount_670"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockVestingShares" xlink:label="loc_flgc_RestrictedStockVestingShares_671"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockVestingShares" xlink:label="loc_flgc_RestrictedStockVestingShares_672"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RetailSpaceInMiamiMember" xlink:label="loc_flgc_RetailSpaceInMiamiMember_673"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RetailSpaceInMiamiMember" xlink:label="loc_flgc_RetailSpaceInMiamiMember_674"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts" xlink:label="loc_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_675"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts" xlink:label="loc_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_676"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SalesTaxesMember" xlink:label="loc_flgc_SalesTaxesMember_677"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock" xlink:label="loc_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_678"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock" xlink:label="loc_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_679"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock" xlink:label="loc_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_680"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock" xlink:label="loc_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_681"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesLineItems" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_682"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesLineItems" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_683"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_684"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_685"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable" xlink:label="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_686"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable" xlink:label="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_687"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable" xlink:label="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_688"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock" xlink:label="loc_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_689"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock" xlink:label="loc_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_690"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:label="loc_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_691"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:label="loc_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_692"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications" xlink:label="loc_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_693"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications" xlink:label="loc_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_694"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives" xlink:label="loc_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_695"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives" xlink:label="loc_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_696"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" xlink:label="loc_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_697"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" xlink:label="loc_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_698"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" xlink:label="loc_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_699"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_700"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_701"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_702"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfOtherSignificantItemsTableTextBlock" xlink:label="loc_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_703"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfOtherSignificantItemsTableTextBlock" xlink:label="loc_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_704"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock" xlink:label="loc_flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock_705"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock" xlink:label="loc_flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock_706"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfRestrictedStockAwards" xlink:label="loc_flgc_ScheduleOfRestrictedStockAwards_707"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfRestrictedStockAwards" xlink:label="loc_flgc_ScheduleOfRestrictedStockAwards_708"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock" xlink:label="loc_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_709"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock" xlink:label="loc_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_710"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock" xlink:label="loc_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_711"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfSubsidiariesTableTextBlock" xlink:label="loc_flgc_ScheduleOfSubsidiariesTableTextBlock_712"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfSubsidiariesTableTextBlock" xlink:label="loc_flgc_ScheduleOfSubsidiariesTableTextBlock_713"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_714"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_715"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock" xlink:label="loc_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_716"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock" xlink:label="loc_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_717"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondClosingMember" xlink:label="loc_flgc_SecondClosingMember_718"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondClosingMember" xlink:label="loc_flgc_SecondClosingMember_719"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondLoanAgreementMember" xlink:label="loc_flgc_SecondLoanAgreementMember_720"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondLoanAgreementMember" xlink:label="loc_flgc_SecondLoanAgreementMember_721"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondLoanMember" xlink:label="loc_flgc_SecondLoanMember_722"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondLoanMember" xlink:label="loc_flgc_SecondLoanMember_723"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondTrancheMember" xlink:label="loc_flgc_SecondTrancheMember_724"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeparationAgreementMember" xlink:label="loc_flgc_SeparationAgreementMember_725"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeparationAgreementMember" xlink:label="loc_flgc_SeparationAgreementMember_726"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember" xlink:label="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_727"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember" xlink:label="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_728"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingAmount" xlink:label="loc_flgc_SeptemberUnitOfferingAmount_729"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingAmount" xlink:label="loc_flgc_SeptemberUnitOfferingAmount_730"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_SeptemberUnitOfferingIssuanceCosts_731"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_SeptemberUnitOfferingIssuanceCosts_732"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_SeptemberUnitOfferingIssuanceCosts_733"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingShares" xlink:label="loc_flgc_SeptemberUnitOfferingShares_734"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingShares" xlink:label="loc_flgc_SeptemberUnitOfferingShares_735"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SettlementAgreementMember" xlink:label="loc_flgc_SettlementAgreementMember_736"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SettlementAgreementMember" xlink:label="loc_flgc_SettlementAgreementMember_737"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares_738"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares_739"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_740"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_741"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_742"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_743"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_744"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_745"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_746"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_747"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_748"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationConsideration" xlink:label="loc_flgc_ShareBasedCompensationConsideration_749"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationConsideration" xlink:label="loc_flgc_ShareBasedCompensationConsideration_750"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue" xlink:label="loc_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_751"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue" xlink:label="loc_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_752"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" xlink:label="loc_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_753"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" xlink:label="loc_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_754"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharedServicesAndSpaceCommitment" xlink:label="loc_flgc_SharedServicesAndSpaceCommitment_755"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_756"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_757"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareRepurchaseMember" xlink:label="loc_flgc_ShareRepurchaseMember_758"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareRepurchaseShares" xlink:label="loc_flgc_ShareRepurchaseShares_759"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareRepurchaseShares" xlink:label="loc_flgc_ShareRepurchaseShares_760"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedDuringPeriodSharesWarrantsExpired" xlink:label="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_761"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedDuringPeriodSharesWarrantsExpired" xlink:label="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_762"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedDuringPeriodSharesWarrantsExpired" xlink:label="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_763"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors" xlink:label="loc_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_764"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors" xlink:label="loc_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_765"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesLineItems" xlink:label="loc_flgc_SignificantAccountingPoliciesLineItems_766"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesLineItems" xlink:label="loc_flgc_SignificantAccountingPoliciesLineItems_767"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesTable" xlink:label="loc_flgc_SignificantAccountingPoliciesTable_768"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionDateOfExpiry" xlink:label="loc_flgc_StockOptionDateOfExpiry_769"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionDateOfExpiry" xlink:label="loc_flgc_StockOptionDateOfExpiry_770"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionExercisable" xlink:label="loc_flgc_StockOptionExercisable_771"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionExercisable" xlink:label="loc_flgc_StockOptionExercisable_772"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_773"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_774"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockRepurchasedDuringPeriodAmount" xlink:label="loc_flgc_StockRepurchasedDuringPeriodAmount_775"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockRepurchasedDuringPeriodAmount" xlink:label="loc_flgc_StockRepurchasedDuringPeriodAmount_776"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockWarrantMember" xlink:label="loc_flgc_StockWarrantMember_777"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryEighteenMember" xlink:label="loc_flgc_SubsidiaryEighteenMember_778"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryEighteenMember" xlink:label="loc_flgc_SubsidiaryEighteenMember_779"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryEightMember" xlink:label="loc_flgc_SubsidiaryEightMember_780"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryEightMember" xlink:label="loc_flgc_SubsidiaryEightMember_781"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryElevenMember" xlink:label="loc_flgc_SubsidiaryElevenMember_782"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryElevenMember" xlink:label="loc_flgc_SubsidiaryElevenMember_783"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFifteenMember" xlink:label="loc_flgc_SubsidiaryFifteenMember_784"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFifteenMember" xlink:label="loc_flgc_SubsidiaryFifteenMember_785"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFiveMember" xlink:label="loc_flgc_SubsidiaryFiveMember_786"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFiveMember" xlink:label="loc_flgc_SubsidiaryFiveMember_787"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFourMember" xlink:label="loc_flgc_SubsidiaryFourMember_788"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFourMember" xlink:label="loc_flgc_SubsidiaryFourMember_789"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFourteenMember" xlink:label="loc_flgc_SubsidiaryFourteenMember_790"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFourteenMember" xlink:label="loc_flgc_SubsidiaryFourteenMember_791"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryNineMember" xlink:label="loc_flgc_SubsidiaryNineMember_792"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryNineMember" xlink:label="loc_flgc_SubsidiaryNineMember_793"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryNineteenMember" xlink:label="loc_flgc_SubsidiaryNineteenMember_794"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryNineteenMember" xlink:label="loc_flgc_SubsidiaryNineteenMember_795"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryOneMember" xlink:label="loc_flgc_SubsidiaryOneMember_796"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryOneMember" xlink:label="loc_flgc_SubsidiaryOneMember_797"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySevenMember" xlink:label="loc_flgc_SubsidiarySevenMember_798"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySevenMember" xlink:label="loc_flgc_SubsidiarySevenMember_799"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySeventeenMember" xlink:label="loc_flgc_SubsidiarySeventeenMember_800"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySeventeenMember" xlink:label="loc_flgc_SubsidiarySeventeenMember_801"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySixMember" xlink:label="loc_flgc_SubsidiarySixMember_802"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySixMember" xlink:label="loc_flgc_SubsidiarySixMember_803"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySixteenMember" xlink:label="loc_flgc_SubsidiarySixteenMember_804"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySixteenMember" xlink:label="loc_flgc_SubsidiarySixteenMember_805"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTenMember" xlink:label="loc_flgc_SubsidiaryTenMember_806"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTenMember" xlink:label="loc_flgc_SubsidiaryTenMember_807"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirteenMember" xlink:label="loc_flgc_SubsidiaryThirteenMember_808"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirteenMember" xlink:label="loc_flgc_SubsidiaryThirteenMember_809"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyFiveMember" xlink:label="loc_flgc_SubsidiaryThirtyFiveMember_810"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyFiveMember" xlink:label="loc_flgc_SubsidiaryThirtyFiveMember_811"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyFourMember" xlink:label="loc_flgc_SubsidiaryThirtyFourMember_812"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyFourMember" xlink:label="loc_flgc_SubsidiaryThirtyFourMember_813"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyMember" xlink:label="loc_flgc_SubsidiaryThirtyMember_814"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyMember" xlink:label="loc_flgc_SubsidiaryThirtyMember_815"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyOneMember" xlink:label="loc_flgc_SubsidiaryThirtyOneMember_816"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyOneMember" xlink:label="loc_flgc_SubsidiaryThirtyOneMember_817"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyThreeMember" xlink:label="loc_flgc_SubsidiaryThirtyThreeMember_818"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyThreeMember" xlink:label="loc_flgc_SubsidiaryThirtyThreeMember_819"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyTwoMember" xlink:label="loc_flgc_SubsidiaryThirtyTwoMember_820"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyTwoMember" xlink:label="loc_flgc_SubsidiaryThirtyTwoMember_821"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThreeMember" xlink:label="loc_flgc_SubsidiaryThreeMember_822"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThreeMember" xlink:label="loc_flgc_SubsidiaryThreeMember_823"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwelveMember" xlink:label="loc_flgc_SubsidiaryTwelveMember_824"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwelveMember" xlink:label="loc_flgc_SubsidiaryTwelveMember_825"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyEightMember" xlink:label="loc_flgc_SubsidiaryTwentyEightMember_826"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyEightMember" xlink:label="loc_flgc_SubsidiaryTwentyEightMember_827"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyFiveMember" xlink:label="loc_flgc_SubsidiaryTwentyFiveMember_828"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyFiveMember" xlink:label="loc_flgc_SubsidiaryTwentyFiveMember_829"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyFourMember" xlink:label="loc_flgc_SubsidiaryTwentyFourMember_830"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyFourMember" xlink:label="loc_flgc_SubsidiaryTwentyFourMember_831"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyMember" xlink:label="loc_flgc_SubsidiaryTwentyMember_832"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyMember" xlink:label="loc_flgc_SubsidiaryTwentyMember_833"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyNineMember" xlink:label="loc_flgc_SubsidiaryTwentyNineMember_834"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyNineMember" xlink:label="loc_flgc_SubsidiaryTwentyNineMember_835"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyOneMember" xlink:label="loc_flgc_SubsidiaryTwentyOneMember_836"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyOneMember" xlink:label="loc_flgc_SubsidiaryTwentyOneMember_837"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentySevenMember" xlink:label="loc_flgc_SubsidiaryTwentySevenMember_838"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentySevenMember" xlink:label="loc_flgc_SubsidiaryTwentySevenMember_839"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentySixMember" xlink:label="loc_flgc_SubsidiaryTwentySixMember_840"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentySixMember" xlink:label="loc_flgc_SubsidiaryTwentySixMember_841"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyThreeMember" xlink:label="loc_flgc_SubsidiaryTwentyThreeMember_842"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyThreeMember" xlink:label="loc_flgc_SubsidiaryTwentyThreeMember_843"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyTwoMember" xlink:label="loc_flgc_SubsidiaryTwentyTwoMember_844"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyTwoMember" xlink:label="loc_flgc_SubsidiaryTwentyTwoMember_845"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwoMember" xlink:label="loc_flgc_SubsidiaryTwoMember_846"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwoMember" xlink:label="loc_flgc_SubsidiaryTwoMember_847"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SupplierRelationshipsMember" xlink:label="loc_flgc_SupplierRelationshipsMember_848"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SupplierRelationshipsMember" xlink:label="loc_flgc_SupplierRelationshipsMember_849"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TerminationBenefitsMember" xlink:label="loc_flgc_TerminationBenefitsMember_850"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TerminationBenefitsMember" xlink:label="loc_flgc_TerminationBenefitsMember_851"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TerminationBenefitsMember" xlink:label="loc_flgc_TerminationBenefitsMember_852"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ThresholdLimitOfEstimateOfLoss" xlink:label="loc_flgc_ThresholdLimitOfEstimateOfLoss_853"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ThresholdLimitOfEstimateOfLoss" xlink:label="loc_flgc_ThresholdLimitOfEstimateOfLoss_854"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountClaimedUnderIndemnificationAgreement" xlink:label="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_855"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountClaimedUnderIndemnificationAgreement" xlink:label="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_856"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountClaimedUnderIndemnificationAgreement" xlink:label="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_857"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountPayableInViolationOfStopSaleOrders" xlink:label="loc_flgc_TotalAmountPayableInViolationOfStopSaleOrders_858"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountPayableInViolationOfStopSaleOrders" xlink:label="loc_flgc_TotalAmountPayableInViolationOfStopSaleOrders_859"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalCarryingValue" xlink:label="loc_flgc_TotalCarryingValue_860"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalCarryingValue" xlink:label="loc_flgc_TotalCarryingValue_861"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_862"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_863"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_864"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_865"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_866"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAndOtherReceivablesAbstract" xlink:label="loc_flgc_TradeAndOtherReceivablesAbstract_867"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAndOtherReceivablesAbstract" xlink:label="loc_flgc_TradeAndOtherReceivablesAbstract_868"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_869"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_870"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_871"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradenamesMember" xlink:label="loc_flgc_TradenamesMember_872"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeReceivable" xlink:label="loc_flgc_TradeReceivable_873"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeReceivable" xlink:label="loc_flgc_TradeReceivable_874"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeReceivable" xlink:label="loc_flgc_TradeReceivable_875"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeReceivableBeginningBalance" xlink:label="loc_flgc_TradeReceivableBeginningBalance_876"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeReceivableBeginningBalance" xlink:label="loc_flgc_TradeReceivableBeginningBalance_877"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcHoldingGmbhMember" xlink:label="loc_flgc_TruhcHoldingGmbhMember_878"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcHoldingGmbhMember" xlink:label="loc_flgc_TruhcHoldingGmbhMember_879"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcHoldingGmbhMember" xlink:label="loc_flgc_TruhcHoldingGmbhMember_880"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_881"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_882"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyOneAnnualImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyOneAnnualImpairmentTestMember_883"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyOneAnnualImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyOneAnnualImpairmentTestMember_884"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_885"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_886"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_887"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_888"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_889"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" xlink:label="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_890"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" xlink:label="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_891"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" xlink:label="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_892"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" xlink:label="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_893"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyTwoImpairmentTestMember_894"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyTwoImpairmentTestMember_895"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember" xlink:label="loc_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_896"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember" xlink:label="loc_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_897"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoPlanMember" xlink:label="loc_flgc_TwoThousandTwentyTwoPlanMember_898"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoPlanMember" xlink:label="loc_flgc_TwoThousandTwentyTwoPlanMember_899"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitedKingdomRevenueAgencyMember" xlink:label="loc_flgc_UnitedKingdomRevenueAgencyMember_900"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitedKingdomRevenueAgencyMember" xlink:label="loc_flgc_UnitedKingdomRevenueAgencyMember_901"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitedStatesRevenueAgencyMember" xlink:label="loc_flgc_UnitedStatesRevenueAgencyMember_902"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitedStatesRevenueAgencyMember" xlink:label="loc_flgc_UnitedStatesRevenueAgencyMember_903"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitOfferingMember" xlink:label="loc_flgc_UnitOfferingMember_904"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitOfferingMember" xlink:label="loc_flgc_UnitOfferingMember_905"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnrealizedLossesOnSecurities" xlink:label="loc_flgc_UnrealizedLossesOnSecurities_906"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnrealizedLossesOnSecurities" xlink:label="loc_flgc_UnrealizedLossesOnSecurities_907"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnusedLossCarryforwards" xlink:label="loc_flgc_UnusedLossCarryforwards_908"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnvestedRsusGrantedToExecutiveOfficers" xlink:label="loc_flgc_UnvestedRsusGrantedToExecutiveOfficers_909"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_USFederalIncomeTaxAuthorityMember" xlink:label="loc_flgc_USFederalIncomeTaxAuthorityMember_910"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_USFederalIncomeTaxAuthorityMember" xlink:label="loc_flgc_USFederalIncomeTaxAuthorityMember_911"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_USStateIncomeTaxAuthorityMember" xlink:label="loc_flgc_USStateIncomeTaxAuthorityMember_912"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_USStateIncomeTaxAuthorityMember" xlink:label="loc_flgc_USStateIncomeTaxAuthorityMember_913"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselAssetGroupMember" xlink:label="loc_flgc_VesselAssetGroupMember_914"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselAssetGroupMember" xlink:label="loc_flgc_VesselAssetGroupMember_915"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselMember" xlink:label="loc_flgc_VesselMember_916"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselOwnersMember" xlink:label="loc_flgc_VesselOwnersMember_917"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselOwnersMember" xlink:label="loc_flgc_VesselOwnersMember_918"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselsMember" xlink:label="loc_flgc_VesselsMember_919"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselsMember" xlink:label="loc_flgc_VesselsMember_920"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VestInOneYearMember" xlink:label="loc_flgc_VestInOneYearMember_921"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VestInOneYearMember" xlink:label="loc_flgc_VestInOneYearMember_922"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VestInThreeYearsMember" xlink:label="loc_flgc_VestInThreeYearsMember_923"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VestInThreeYearsMember" xlink:label="loc_flgc_VestInThreeYearsMember_924"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarehousingAndOfficeSpaceMember" xlink:label="loc_flgc_WarehousingAndOfficeSpaceMember_925"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarehousingAndOfficeSpaceMember" xlink:label="loc_flgc_WarehousingAndOfficeSpaceMember_926"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantAmendedExercisePrice" xlink:label="loc_flgc_WarrantAmendedExercisePrice_927"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantExercisePricePriorToAmendment" xlink:label="loc_flgc_WarrantExercisePricePriorToAmendment_928"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantIssued" xlink:label="loc_flgc_WarrantIssued_929"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantIssued" xlink:label="loc_flgc_WarrantIssued_930"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantOneMember" xlink:label="loc_flgc_WarrantOneMember_931"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantPurchase" xlink:label="loc_flgc_WarrantPurchase_932"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantPurchase" xlink:label="loc_flgc_WarrantPurchase_933"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsAbstract" xlink:label="loc_flgc_WarrantsAbstract_934"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadOnePointZeroZeroMember" xlink:label="loc_flgc_WarrantsCadOnePointZeroZeroMember_935"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadOnePointZeroZeroMember" xlink:label="loc_flgc_WarrantsCadOnePointZeroZeroMember_936"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadOnePointZeroZeroMember" xlink:label="loc_flgc_WarrantsCadOnePointZeroZeroMember_937"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadZeroPointThreeZeroMember" xlink:label="loc_flgc_WarrantsCadZeroPointThreeZeroMember_938"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadZeroPointThreeZeroMember" xlink:label="loc_flgc_WarrantsCadZeroPointThreeZeroMember_939"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadZeroPointThreeZeroMember" xlink:label="loc_flgc_WarrantsCadZeroPointThreeZeroMember_940"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsDateOfExpiry" xlink:label="loc_flgc_WarrantsDateOfExpiry_941"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsDateOfExpiry" xlink:label="loc_flgc_WarrantsDateOfExpiry_942"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsDateOfExpiry" xlink:label="loc_flgc_WarrantsDateOfExpiry_943"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsDisclosureTextBlock" xlink:label="loc_flgc_WarrantsDisclosureTextBlock_944"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsDisclosureTextBlock" xlink:label="loc_flgc_WarrantsDisclosureTextBlock_945"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExercisedAmount" xlink:label="loc_flgc_WarrantsExercisedAmount_946"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExercisedShares" xlink:label="loc_flgc_WarrantsExercisedShares_947"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExpiredOrCancelledAmount" xlink:label="loc_flgc_WarrantsExpiredOrCancelledAmount_948"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExpiredOrCancelledAmount" xlink:label="loc_flgc_WarrantsExpiredOrCancelledAmount_949"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExpiredOrCancelledAmount" xlink:label="loc_flgc_WarrantsExpiredOrCancelledAmount_950"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsFiveMember" xlink:label="loc_flgc_WarrantsFiveMember_951"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsFiveMember" xlink:label="loc_flgc_WarrantsFiveMember_952"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsFourMember" xlink:label="loc_flgc_WarrantsFourMember_953"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsFourMember" xlink:label="loc_flgc_WarrantsFourMember_954"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsIssuedDuringPeriodExercisePrice" xlink:label="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_955"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsIssuedToPlacementAgent" xlink:label="loc_flgc_WarrantsIssuedToPlacementAgent_956"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsIssuedToPlacementAgent" xlink:label="loc_flgc_WarrantsIssuedToPlacementAgent_957"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsIssuedToPlacementAgent" xlink:label="loc_flgc_WarrantsIssuedToPlacementAgent_958"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsLineItems" xlink:label="loc_flgc_WarrantsLineItems_959"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsMember" xlink:label="loc_flgc_WarrantsMember_960"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsOneMember" xlink:label="loc_flgc_WarrantsOneMember_961"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsOneMember" xlink:label="loc_flgc_WarrantsOneMember_962"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsRemainingLifeInYears" xlink:label="loc_flgc_WarrantsRemainingLifeInYears_963"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsRemainingLifeInYears" xlink:label="loc_flgc_WarrantsRemainingLifeInYears_964"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsSixMember" xlink:label="loc_flgc_WarrantsSixMember_965"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsSixMember" xlink:label="loc_flgc_WarrantsSixMember_966"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsTable" xlink:label="loc_flgc_WarrantsTable_967"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsThreeMember" xlink:label="loc_flgc_WarrantsThreeMember_968"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsThreeMember" xlink:label="loc_flgc_WarrantsThreeMember_969"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsTwoMember" xlink:label="loc_flgc_WarrantsTwoMember_970"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsTwoMember" xlink:label="loc_flgc_WarrantsTwoMember_971"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsCancelled" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_972"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsCancelled" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_973"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsExercised_974"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsExercised_975"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsIssued" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsIssued_976"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsIssued" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsIssued_977"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WritedownsReversalsOfInventories" xlink:label="loc_flgc_WritedownsReversalsOfInventories_978"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WritedownsReversalsOfInventories" xlink:label="loc_flgc_WritedownsReversalsOfInventories_979"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WriterMember" xlink:label="loc_flgc_WriterMember_980"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WriterMember" xlink:label="loc_flgc_WriterMember_981"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WrongfullyTransferredShares" xlink:label="loc_flgc_WrongfullyTransferredShares_982"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WrongfullyTransferredShares" xlink:label="loc_flgc_WrongfullyTransferredShares_983"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_984"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_985"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_986"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_987"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_988"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_989"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_990"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_991"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_992"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_993"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_994"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_995"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_996"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_997"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_998"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_999"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1000"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1001"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1002"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1003"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1004"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1005"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1006"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1007"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1008"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ReportableGeographicalComponentsMember" xlink:label="loc_srt_ReportableGeographicalComponentsMember_1009"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1010"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1011"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1012"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1013"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1014"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1015"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_1016"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1017"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1018"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1019"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1020"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1021"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1022"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1023"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1024"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1025"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1026"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1027"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1028"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1029"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1030"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1031"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1032"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1033"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1034"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1035"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1036"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1037"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1038"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1039"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1040"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1041"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1042"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1043"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1044"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1045"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1046"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1047"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1048"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1049"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1050"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1051"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1052"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1053"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_1054"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_1055"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1056"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1057"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1058"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_1059"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_1060"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1061"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1062"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1063"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1064"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1065"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_1066"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_1067"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1068"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1069"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1070"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1071"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1072"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1073"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1074"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1075"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1076"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_1077"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_1078"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_1079"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_1080"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_1081"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_1082"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_1083"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_1084"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesTextBlock" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock_1085"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesTextBlock" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock_1086"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1087"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1088"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1089"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1090"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1091"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1092"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1093"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1094"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1095"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1096"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1097"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_1098"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_1099"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_1100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_1101"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_1102"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1103"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1104"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_1105"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_1106"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1107"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1108"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1109"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1111"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_1112"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_1113"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1114"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1115"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_1116"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_1117"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1118"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1119"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1121"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1122"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_1123"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_1124"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1125"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1126"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1127"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1128"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1129"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1131"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_1132"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_1133"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1134"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1135"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1136"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1137"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1138"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1139"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1147"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1148"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1149"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1151"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1153"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1154"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1155"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1156"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1157"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1158"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_1165"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_1166"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_1167"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_1168"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1169"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1171"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1172"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1173"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1174"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1175"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1176"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1177"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1178"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1179"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_1180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_1181"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1182"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1183"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1184"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1185"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1186"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1187"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1188"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1189"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1191"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1192"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1193"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1194"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1195"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1196"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1197"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_1198"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_1199"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_1200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_1201"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_1202"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_1203"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_1204"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1205"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1206"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1207"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1208"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1209"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1211"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1212"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1213"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1214"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1215"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1216"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1217"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1218"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1219"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1221"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_1222"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_1223"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_1224"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1225"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1226"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1227"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1228"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1229"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_1239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_1240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_1256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_1257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Communication" xlink:label="loc_us-gaap_Communication_1258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_1265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_1266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_1274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_1275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_1276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditRiskMember" xlink:label="loc_us-gaap_CreditRiskMember_1279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditRiskMember" xlink:label="loc_us-gaap_CreditRiskMember_1280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeEarningsDeficit" xlink:label="loc_us-gaap_CumulativeEarningsDeficit_1281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeEarningsDeficit" xlink:label="loc_us-gaap_CumulativeEarningsDeficit_1282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_1305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_1306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_1307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_1344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_1345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_1346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_1347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_1377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_1378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_1391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_1392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_1393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_1394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_1395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_1396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_1403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_1404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_1409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_1410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_1432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_1433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_1434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_1435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_1437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_1440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue_1463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue_1464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_1470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_1471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_1472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialAssetNotPastDueMember" xlink:label="loc_us-gaap_FinancialAssetNotPastDueMember_1477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialAssetNotPastDueMember" xlink:label="loc_us-gaap_FinancialAssetNotPastDueMember_1478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_1480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_1481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_1482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_1483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables1To29DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables1To29DaysPastDueMember_1484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables1To29DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables1To29DaysPastDueMember_1485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables30To59DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables30To59DaysPastDueMember_1486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables30To59DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables30To59DaysPastDueMember_1487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables60To89DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables60To89DaysPastDueMember_1488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables60To89DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables60To89DaysPastDueMember_1489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_1490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_1491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_1503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_1504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_1505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_1506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_1507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_1508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_1509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_1510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_1511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_1512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_1524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_1525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_1541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_1542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_1543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_1544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:label="loc_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_1547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:label="loc_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_1548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FranchiseMember" xlink:label="loc_us-gaap_FranchiseMember_1549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FranchiseMember" xlink:label="loc_us-gaap_FranchiseMember_1550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_1566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_1571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaap_GoodwillMember_1572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaap_GoodwillMember_1573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_1604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_1611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_1613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_1614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_1615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaap_InsuranceRecoveries_1641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_1642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_1643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_1652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_1653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_1654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_1655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_1666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_1667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_1668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_1669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_1674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_1675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_1679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_1680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_1687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_1688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInAffiliateActivityLineItems" xlink:label="loc_us-gaap_InvestmentInAffiliateActivityLineItems_1689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_1690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_1691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_1692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAbstract_1695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAbstract_1696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesTable" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaap_InvestmentTextBlock_1701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaap_InvestmentTextBlock_1702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaap_InvestmentTextBlock_1703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_1706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_1742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1746"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1747"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1748"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1749"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_1750"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_1751"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1752"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1753"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_1754"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_1755"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1756"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1757"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1758"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1759"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1760"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1761"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_1762"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_1763"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_1764"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_1765"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1766"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1767"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_1768"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_1769"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1770"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1771"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_1772"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1773"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1774"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_1775"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_1776"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_1777"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1778"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1779"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1780"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1781"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1782"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable_1783"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable_1784"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableFairValueDisclosure" xlink:label="loc_us-gaap_LoansReceivableFairValueDisclosure_1785"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableFairValueDisclosure" xlink:label="loc_us-gaap_LoansReceivableFairValueDisclosure_1786"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_1787"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_1788"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1789"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1790"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1791"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1792"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1793"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_1794"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1795"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1796"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_1797"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_1798"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_1799"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1800"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1801"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1802"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_1803"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_1804"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_1805"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_1806"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_1807"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_1808"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_1809"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1810"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1811"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1812"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1813"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_1814"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_1815"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyTrialOrAlternativeDisputeResolution" xlink:label="loc_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_1816"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyTrialOrAlternativeDisputeResolution" xlink:label="loc_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_1817"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1818"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1819"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1820"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_1821"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_1822"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_1823"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_1824"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1825"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1826"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1827"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1828"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1829"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1830"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1831"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1832"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1833"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1834"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1835"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1836"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1837"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1838"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1839"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1840"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1841"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1842"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1843"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1844"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1845"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1846"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_1847"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_1848"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_1849"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1850"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1851"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivables" xlink:label="loc_us-gaap_NontradeReceivables_1852"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivables" xlink:label="loc_us-gaap_NontradeReceivables_1853"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivables" xlink:label="loc_us-gaap_NontradeReceivables_1854"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1855"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1856"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_1857"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_1858"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1859"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1860"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1861"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1862"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1863"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1864"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1865"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_1866"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_1867"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1868"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1869"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1870"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1871"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1872"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1873"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1874"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1875"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1876"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1877"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1878"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1879"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1880"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1881"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1882"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1883"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1884"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1885"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1886"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1887"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1888"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1889"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1890"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1891"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1892"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1893"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1894"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1895"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1896"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1897"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1898"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_1899"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_1900"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_1901"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1902"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1903"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1904"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1905"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1906"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1907"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1908"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1909"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1910"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1911"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1912"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1913"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1914"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1915"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_1916"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_1917"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1918"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1919"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_1920"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_1921"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables_1922"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables_1923"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_1924"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_1925"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1926"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1927"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_1928"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_1929"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_1930"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_1931"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1932"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1933"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1934"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1935"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1936"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1937"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_1938"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_1939"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1940"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1941"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1942"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1943"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1944"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1945"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_1946"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_1947"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1948"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1949"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1950"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1951"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1952"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1953"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1954"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1955"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1956"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1957"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1958"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1959"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1960"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1961"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1962"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_1963"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_1964"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1965"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1966"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1967"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1968"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1969"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1970"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1971"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1972"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1973"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1974"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1975"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1976"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1977"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1978"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1979"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1980"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1981"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1982"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1983"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1984"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1985"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1986"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1987"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1988"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1989"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1990"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_1991"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1992"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_1993"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_1994"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_1995"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_1996"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1997"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1998"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1999"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2000"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_2001"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2002"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2003"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2004"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2005"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2006"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2007"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2008"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_2009"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2010"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2011"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2012"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2013"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_2014"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_2015"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_2016"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_2017"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_2018"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2019"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2020"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2021"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2022"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2023"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2024"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2025"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2026"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2027"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2028"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2029"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2030"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2031"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2032"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_2033"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2034"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2035"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2036"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2037"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2038"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2039"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2040"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2041"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2042"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2043"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2044"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2045"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2046"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2047"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivablesPastDueTable" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_2048"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2049"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2050"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2051"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_2052"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_2053"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_2054"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2055"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2056"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_2057"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_2058"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_2059"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_2060"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2061"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2062"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2063"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2064"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2065"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2066"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_2067"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_2068"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2069"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_2070"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_2071"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2072"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2073"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2074"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2075"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2076"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2077"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2078"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2079"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2080"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2081"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionAxis_2082"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_2083"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_2084"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_2085"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_2086"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_2087"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_2088"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_2089"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_2090"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2091"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2092"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2093"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2094"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2095"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2096"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2097"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_2098"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2099"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2101"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2102"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_2103"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_2104"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2105"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2106"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2107"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2108"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2109"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2111"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2112"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2113"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2114"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2115"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2116"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2117"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2118"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2119"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2121"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2122"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2123"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2124"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2125"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2126"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2127"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2128"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2129"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2131"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2132"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2133"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2134"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2135"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2136"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2137"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2138"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2139"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2147"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2148"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2149"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2151"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2153"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2154"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2155"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2156"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2157"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2158"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2165"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2166"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2167"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2168"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2169"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2171"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2172"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2173"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2174"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2175"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2176"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2177"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2178"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2179"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_2181"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_2182"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2183"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2184"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2185"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2186"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2187"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2188"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2189"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2191"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2192"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2193"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2194"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2195"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2196"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2197"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2198"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_2199"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_2200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2201"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2202"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2203"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2204"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2205"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2206"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2207"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2208"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2209"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_2210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_2211"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2212"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2213"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_2214"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_2215"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_2216"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_2217"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_2218"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_2219"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_2220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2221"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2222"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2223"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2224"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2225"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2226"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2227"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2228"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_2229"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_2230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_2241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_2242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_2243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_2244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_2245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_2257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_2258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_2261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_2262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_2300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_2301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_2308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_2309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_2310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_2315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_2318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_2319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_2320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance" xlink:label="loc_us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance_2321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaap_TrademarksMember_2322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense_2324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingCommitments" xlink:label="loc_us-gaap_UnderwritingCommitments_2326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingCommitments" xlink:label="loc_us-gaap_UnderwritingCommitments_2327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_2328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_2329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivable" xlink:label="loc_us-gaap_ValueAddedTaxReceivable_2332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivable" xlink:label="loc_us-gaap_ValueAddedTaxReceivable_2333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_2334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_2335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_2336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2342"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CA_0" xml:lang="en-US">CANADA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CA_1" xml:lang="en-US">Canada [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CO_0" xml:lang="en-US">COLOMBIA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CO_1" xml:lang="en-US">Colombia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_DE_0" xml:lang="en-US">GERMANY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_DE_1" xml:lang="en-US">Germany [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_GB_0" xml:lang="en-US">UNITED KINGDOM</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_GB_1" xml:lang="en-US">United Kingdom [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US_1" xml:lang="en-US">United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain_0" xml:lang="en-US">All Currencies [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_CAD_0" xml:lang="en-US">Canada, Dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_CAD_1" xml:lang="en-US">CAD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_CHF_0" xml:lang="en-US">Switzerland, Francs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_CHF_1" xml:lang="en-US">CHF [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_COP_0" xml:lang="en-US">Colombia, Pesos</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_COP_1" xml:lang="en-US">COP [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR_0" xml:lang="en-US">Euro Member Countries, Euro</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_EUR_1" xml:lang="en-US">EUR [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_GBP_0" xml:lang="en-US">United Kingdom, Pounds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_GBP_1" xml:lang="en-US">GBP [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain_0" xml:lang="en-US">Address Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm Id</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember_0" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName_0" xml:lang="en-US">Contact Personnel Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag_0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport_0" xml:lang="en-US">Document Quarterly Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address Address Line 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address Address Line 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address City Or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_0" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesLineItems_0" xml:lang="en-US">Entity Addresses [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesTable_0" xml:lang="en-US">Entity Addresses [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince_0" xml:lang="en-US">Entity Address State Or Province</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation State Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">Icfr Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Security 12b Title</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ACAMullerMember_0" xml:lang="en-US">This member stands for ACA Muller.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ACAMullerMember_1" xml:lang="en-US">A C A Muller [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ACAMullerMember_2" xml:lang="en-US">ACA Muller [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_0" xml:lang="en-US">Accounting Pronouncements Not Yet Adopted Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_1" xml:lang="en-US">Accounting pronouncements not yet adopted [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AcquisitionOfNoncontrollingInterestAmount_0" xml:lang="en-US">Acquisition of noncontrolling interest, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AcquisitionOfNoncontrollingInterestMember_0" xml:lang="en-US">Acquisition Of Noncontrolling Interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_AcquisitionOfNoncontrollingInterestMember_1" xml:lang="en-US">Acquisition of noncontrolling interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AcquisitionOfNoncontrollingInterestShares_0" xml:lang="en-US">Acquisition of noncontrolling interest, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AdditionalLegalDisputesMember_0" xml:lang="en-US">Additional Legal Disputes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AdditionalPaidAmount_0" xml:lang="en-US">Additional paid amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AdditonalyCancelledSharesValue_0" xml:lang="en-US">Additonaly Cancelled Shares Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_AdditonalyCancelledSharesValue_1" xml:lang="en-US">Additionally cancelled shares, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_AegisCapitalCorpMember_0" xml:lang="en-US">This member represents about aegis capital corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AegisCapitalCorpMember_1" xml:lang="en-US">Aegis Capital Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AgreementAxis_0" xml:lang="en-US">Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AgreementDomain_0" xml:lang="en-US">Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_AmountPayableOfProfitsForAdditionalAmount_0" xml:lang="en-US">Amount payable of profits for additional amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AmountPayableOfProfitsForAdditionalAmount_1" xml:lang="en-US">Amount Payable Of Profits For Additional Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_AmountPayableOfProfitsForAdditionalAmount_2" xml:lang="en-US">Amount payable of profits for additional amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_AmountsPayablePerViolationOfStopSaleOrders_0" xml:lang="en-US">Represents the amount of amounts payable per violation of stop sale orders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AmountsPayablePerViolationOfStopSaleOrders_1" xml:lang="en-US">Amounts Payable Per Violation Of Stop Sale Orders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_AmountsPayablePerViolationOfStopSaleOrders_2" xml:lang="en-US">Amounts payable per violation of stop sale orders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AnnualGoodwillImpairmentTestOfFghMember_0" xml:lang="en-US">Annual Goodwill Impairment Test Of Fgh [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_AnnualGoodwillImpairmentTestOfFghMember_1" xml:lang="en-US">2023 Annual Goodwill Impairment Test of FGH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_0" xml:lang="en-US">Annual Goodwill Impairment Test of Just C B D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_1" xml:lang="en-US">2023 Annual Goodwill Impairment Test of JustCBD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AnnualGoodwillImpairmentTestOfPharmaceuticalsMember_0" xml:lang="en-US">Annual Goodwill Impairment Test of Pharmaceuticals [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_0" xml:lang="en-US">The amount represents assets held for sale not part of disposal group non current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_1" xml:lang="en-US">Assets Held For Sale Not Part Of Disposal Group Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_2" xml:lang="en-US">Noncurrent assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BasisOfAccountingAxis_0" xml:lang="en-US">Basis Of Accounting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BasisOfAccountingLineItems_0" xml:lang="en-US">Basis Of Accounting [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BasisOfAccountingTable_0" xml:lang="en-US">Basis Of Accounting [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_BasisOfMeasurementPolicyTextBlock_0" xml:lang="en-US">Accounting policy for basis of measurement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BasisOfMeasurementPolicyTextBlock_1" xml:lang="en-US">Basis Of Measurement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_BasisOfMeasurementPolicyTextBlock_2" xml:lang="en-US">Basis of measurement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_BearsInterestRate_0" xml:lang="en-US">Bears Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BearsInterestRate_1" xml:lang="en-US">Bears Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BousteadSecuritiesLLCMember_0" xml:lang="en-US">Boustead Securities L l c [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_BousteadSecuritiesLLCMember_1" xml:lang="en-US">Boustead Securities, LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BreezeAcquisitionMember_0" xml:lang="en-US">Breeze acquisition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BreezeLaboratorySasMember_0" xml:lang="en-US">Breeze Laboratory Sas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_BreezeLaboratorySasMember_1" xml:lang="en-US">Breeze Laboratory S.A.S. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_0" xml:lang="en-US">Amount of current lease liabilities assumed in business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_1" xml:lang="en-US">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_2" xml:lang="en-US">Business Combination Recognized Identifiable Asset Acquired And Liability Assumed Current Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_3" xml:lang="en-US">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_0" xml:lang="en-US">Amount of noncurrent lease liabilities assumed in business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_1" xml:lang="en-US">Long term lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_2" xml:lang="en-US">Business Combination Recognized Identifiable Asset Acquired And Liability Assumed Noncurrent Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_3" xml:lang="en-US">Operating Lease, Liability, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_4" xml:lang="en-US">Total lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_0" xml:lang="en-US">The amount of indemnity receivables recognized as of the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Indemnity Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_2" xml:lang="en-US">Indemnity receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_1" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Customer Relationships</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_2" xml:lang="en-US">Customer relationships acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_0" xml:lang="en-US">Amount of provision for sales tax attributable at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_1" xml:lang="en-US">Provision for sales tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_2" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Provision For Sales Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_0" xml:lang="en-US">Amount of right of use assets acquired at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2" xml:lang="en-US">Right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CanadaIncomeTaxAuthorityMember_0" xml:lang="en-US">Canada Income Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_CanadaIncomeTaxAuthorityMember_1" xml:lang="en-US">Canada [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CancelledShares_0" xml:lang="en-US">Cancelled Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_CancelledShares_1" xml:lang="en-US">Additionally cancelled shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CapitalManagementAbstract_0" xml:lang="en-US">Capital Management [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_CapitalManagementAbstract_1" xml:lang="en-US">Capital Management [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CapitalManagementDisclosureTextBlock_0" xml:lang="en-US">Capital Management disclosure text block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_CapitalManagementDisclosureTextBlock_1" xml:lang="en-US">CAPITAL MANAGEMENT [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CashConsiderationReturned_0" xml:lang="en-US">Cash consideration returned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CashEquivalentsAtCarryingValue1_0" xml:lang="en-US">Cash equivalents at carrying value1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_CashEquivalentsAtCarryingValue1_1" xml:lang="en-US">Net carrying value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CashFlowModelHighRate_0" xml:lang="en-US">Cash flow model, high rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CashFlowModelLowRate_0" xml:lang="en-US">Cash flow model, low rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CashPaid_0" xml:lang="en-US">Cash paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ClassicPlanPremiumFinancingMember_0" xml:lang="en-US">This member stands for classic plan premium financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ClassicPlanPremiumFinancingMember_1" xml:lang="en-US">Classic Plan Premium Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ClassicPlanPremiumFinancingMember_2" xml:lang="en-US">ClassicPlan Premium Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_0" xml:lang="en-US">This member stands for Colombian related subsidiaries and Colombian assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_1" xml:lang="en-US">Colombian Related Subsidiaries And Colombian Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_2" xml:lang="en-US">Colombian related subsidiaries and Colombian assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ColombiaRevenueAgencyMember_0" xml:lang="en-US">Colombia Revenue Agency [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ColombiaRevenueAgencyMember_1" xml:lang="en-US">Colombia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CommercialAndWholesaleMember_0" xml:lang="en-US">Commercial And Wholesale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_CommercialAndWholesaleMember_1" xml:lang="en-US">Commercial &amp; Wholesale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_CommercialAndWholesaleMember_2" xml:lang="en-US">Commercial &amp; Wholesale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_CommercialAndWholesaleSegmentMember_0" xml:lang="en-US">This member stands for commercial and wholesale segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CommercialAndWholesaleSegmentMember_1" xml:lang="en-US">Commercial And Wholesale Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_CommercialAndWholesaleSegmentMember_2" xml:lang="en-US">Commercial and Wholesale Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CommonSharesDeliveredToTheSellers_0" xml:lang="en-US">Common shares delivered to the sellers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CommonSharesIssuedForInvestmentsAmount_0" xml:lang="en-US">Common shares issued for Investments, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CommonSharesIssuedForInvestmentsShares_0" xml:lang="en-US">Common shares issued for investments, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CommonSharesIssuedForOtherAgreementsAmount_0" xml:lang="en-US">Common shares issued for other agreements, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CommonSharesIssuedForOtherAgreementsShares_0" xml:lang="en-US">Common shares issued for other agreements, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CommonStockIssuedForRsusVested_0" xml:lang="en-US">Common Stock Issued For Rsus Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CompanyValued_0" xml:lang="en-US">Company Valued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ConsolidatedMember_0" xml:lang="en-US">Consolidated [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ConsolidatedMember_1" xml:lang="en-US">Consolidated [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ConsolidatedRevenue_0" xml:lang="en-US">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ConsolidatedRevenue_1" xml:lang="en-US">Consolidated Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ConsolidatedRevenue_2" xml:lang="en-US">Consolidated revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_Contributionamont_0" xml:lang="en-US">The amount represents Contribution.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_Contributionamont_1" xml:lang="en-US">Contributionamont</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_Contributionamont_2" xml:lang="en-US">Contribution,Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_Contributionshares_0" xml:lang="en-US">The value represents contribution shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_Contributionshares_1" xml:lang="en-US">Contributionshares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_Contributionshares_2" xml:lang="en-US">Contribution,Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CorporateAndEliminationsMember_0" xml:lang="en-US">Corporate And Eliminations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_CorporateAndEliminationsMember_1" xml:lang="en-US">Corporate &amp; Eliminations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_CorporateAndEliminationsMember_2" xml:lang="en-US">Corp &amp; Eliminations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CorporateIncomeTax_0" xml:lang="en-US">Corporate income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_CosechemosAndKasaWholefoodsMember_0" xml:lang="en-US">This member represents about Cosechemos YA S.A.S. and Kasa Wholefoods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CosechemosAndKasaWholefoodsMember_1" xml:lang="en-US">Cosechemos And Kasa Wholefoods [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_CosechemosAndKasaWholefoodsMember_2" xml:lang="en-US">Cosechemos YA S.A.S. and Kasa Wholefoods Company S.A.S [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CreditFacilityDue_0" xml:lang="en-US">Credit Facility due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract_0" xml:lang="en-US">Critical Judgments and Estimation Uncertainties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CumulativeImpairmentRelatedToCommonShares_0" xml:lang="en-US">Cumulative impairment related to common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_CurrentPortionOfContingentPurchaseConsideration_0" xml:lang="en-US">Amount of current portion of contingent purchase consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CurrentPortionOfContingentPurchaseConsideration_1" xml:lang="en-US">Current Portion Of Contingent Purchase Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_CurrentPortionOfContingentPurchaseConsideration_2" xml:lang="en-US">Current portion of contingent purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CurrentTaxExpenseIncome_0" xml:lang="en-US">Current tax expense income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_CurrentTaxExpenseIncome_1" xml:lang="en-US">Current income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_CustomersRelationshipsMember_0" xml:lang="en-US">Customers Relationships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_CustomersRelationshipsMember_1" xml:lang="en-US">Customer relationships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_0" xml:lang="en-US">December Two Thousand Twenty Two Unit Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_1" xml:lang="en-US">December 2022 unit offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DecemberUnitOfferingAmount_0" xml:lang="en-US">December unit offering, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_DecemberUnitOfferingIssuanceCosts_0" xml:lang="en-US">December unit offering issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DecemberUnitOfferingIssuanceCosts_1" xml:lang="en-US">December unit offering issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DecemberUnitOfferingShares_0" xml:lang="en-US">December Unit offering shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DecemberUnitOfferingShares_1" xml:lang="en-US">December unit offering, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_0" xml:lang="en-US">Deferred Tax Assets, Allowance For Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_1" xml:lang="en-US">Allowance for doubtful accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DeferredTaxAssetsGoodwil_0" xml:lang="en-US">The amount of goodwill.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxAssetsGoodwil_1" xml:lang="en-US">Deferred Tax Assets, Goodwil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DeferredTaxAssetsGoodwil_2" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DeferredTaxAssetsIntangibleAssets_0" xml:lang="en-US">The amount of intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxAssetsIntangibleAssets_1" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DeferredTaxAssetsIntangibleAssets_2" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxAssetsRightOfUseAssets_0" xml:lang="en-US">Deferred Tax Assets, Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DeferredTaxAssetsRightOfUseAssets_1" xml:lang="en-US">Right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxAssetsShareIssuanceCosts_0" xml:lang="en-US">Deferred Tax Assets, Share Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DeferredTaxAssetsShareIssuanceCosts_1" xml:lang="en-US">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_0" xml:lang="en-US">Deferred Tax Assets, Unrealized Gains (Losses) On Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_1" xml:lang="en-US">Unrealized gains (losses) on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_DeferredTaxExpenseIncome_0" xml:lang="en-US">Deferred income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxExpenseIncome_1" xml:lang="en-US">Deferred tax expense income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxLiabilitiesAmount_0" xml:lang="en-US">Deferred tax liabilities amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DeferredTaxLiabilitiesAmount_1" xml:lang="en-US">Total deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DeferredTaxLiabilitiesNet_0" xml:lang="en-US">Deferred tax liabilities net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DeferredTaxLiabilitiesNet_1" xml:lang="en-US">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DenmarkRevenueAgencyMember_0" xml:lang="en-US">Denmark Revenue Agency [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DenmarkRevenueAgencyMember_1" xml:lang="en-US">Denmark [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DerecognitionOfEquityRelatedToColombiaAssets_0" xml:lang="en-US">Represents the amount of derecognition of equity related to Colombia assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DerecognitionOfEquityRelatedToColombiaAssets_1" xml:lang="en-US">Derecognition Of Equity Related To Colombia Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DerecognitionOfEquityRelatedToColombiaAssets_2" xml:lang="en-US">Derecognition of equity related to Colombia assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfDiscountRates_0" xml:lang="en-US">Description of discount rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DescriptionOfExchangeRate_0" xml:lang="en-US">Represent Description Of Exchange Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfExchangeRate_1" xml:lang="en-US">Description Of Exchange Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DescriptionOfExchangeRate_2" xml:lang="en-US">Description of exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfExpectedVolatilityShareOptionsGranted_0" xml:lang="en-US">Description Of Expected Volatility Share Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DescriptionOfExpectedVolatilityShareOptionsGranted_1" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DescriptionOfImpairment_0" xml:lang="en-US">Represents the information related to Impairment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfImpairment_1" xml:lang="en-US">Description Of Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DescriptionOfImpairment_2" xml:lang="en-US">Description of impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfRevenueGrowth_0" xml:lang="en-US">Description Of Revenue Growth</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DescriptionOfRevenueGrowth_1" xml:lang="en-US">Description of revenue growth</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted_0" xml:lang="en-US">Description Of Risk Free Interest Rate Share Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DescriptionOfSensitivityAnalysis_0" xml:lang="en-US">Description of sensitivity analysis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfSensitivityAnalysis_1" xml:lang="en-US">Description of sensitivity analysis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfShares_0" xml:lang="en-US">Description of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DescriptionOfShares_1" xml:lang="en-US">Description of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfTaxJurisdictions_0" xml:lang="en-US">Description Of Tax Jurisdictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DescriptionOfTaxJurisdictions_1" xml:lang="en-US">Description of tax jurisdictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DescriptionOfValuation_0" xml:lang="en-US">Description Of Valuation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DescriptionOfValuation_1" xml:lang="en-US">Description of valuation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DiscountRate_0" xml:lang="en-US">Discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_0" xml:lang="en-US">Amount of Asset impairment attributable to disposal group, including, but not limited to, discontinued operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Asset Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_2" xml:lang="en-US">Asset impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_0" xml:lang="en-US">Amount of Bad debt expense attributable to disposal group, including, but not limited to, discontinued operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Bad Debt Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_2" xml:lang="en-US">Bad debt expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_0" xml:lang="en-US">Amount of consulting and management fees attributable to disposal group, including, but not limited to, discontinued operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consulting And Management Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_2" xml:lang="en-US">Consulting and management fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_0" xml:lang="en-US">Amount of interest income (expense) attributable to disposal group, including, but not limited to, discontinued operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_1" xml:lang="en-US">Disposal Group Including Discontinued Operation Interest Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_2" xml:lang="en-US">Interest (income) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_0" xml:lang="en-US">Amount classified as long-term debt attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_2" xml:lang="en-US">Current portion of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_0" xml:lang="en-US">Amount of operating lease expense attributable to disposal group, including, but not limited to, discontinued operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_1" xml:lang="en-US">"Disposal Group, Including Discontinued Operation, Operating Lease Expense"</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_2" xml:lang="en-US">Operating lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Amount classified as operating lease liability attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_2" xml:lang="en-US">Current portion of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_0" xml:lang="en-US">Amount classified as operating lease right of use assets attributable to disposal group held for sale or disposed of.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_1" xml:lang="en-US">"Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Assets"</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_2" xml:lang="en-US">Operating lease right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_0" xml:lang="en-US">Amount of professional fees attributable to disposal group, including, but not limited to, discontinued operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_2" xml:lang="en-US">Professional fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_0" xml:lang="en-US">Amount of promotion and communication attributable to disposal group, including, but not limited to, discontinued operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Promotion And Communication</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_2" xml:lang="en-US">Promotion and communication</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_DrManaloMorganMember_0" xml:lang="en-US">Dr. Manalo Morgan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_DrManaloMorganMember_1" xml:lang="en-US">Dr. Manalo-Morgan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation At Federal Statutory U S Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate_1" xml:lang="en-US">Statutory Canadian rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_EquityIssuedForOtherAgreementsAmount_0" xml:lang="en-US">Equity issued for other agreements, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_EquityIssuedForOtherAgreementsAmount_1" xml:lang="en-US">Equity issued for other agreements, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_EquityIssuedForOtherAgreementsShares_0" xml:lang="en-US">Equity issued for other agreements, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_EstimatedImpactOfPotentialExchangeRateFluctuations_0" xml:lang="en-US">Estimated impact of potential exchange rate fluctuations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_EstimatedLossOnPotentialLiabilities_0" xml:lang="en-US">Amount of estimated loss on potential liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_EstimatedLossOnPotentialLiabilities_1" xml:lang="en-US">Estimated Loss On Potential Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_EstimatedLossOnPotentialLiabilities_2" xml:lang="en-US">Estimated loss on potential liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_EstimatedRecoverableAmount_0" xml:lang="en-US">Estimated Recoverable Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_EstimatedRecoverableAmount_1" xml:lang="en-US">Estimated recoverable amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_EuroCreditFacilityMember_0" xml:lang="en-US">This member stands for Euro credit facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_EuroCreditFacilityMember_1" xml:lang="en-US">Euro Credit Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ExercisePriceOfInvestmentWarrants_0" xml:lang="en-US">Exercise price of investment warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ExercisePriceOfInvestmentWarrants_1" xml:lang="en-US">Exercise price of investment warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ExpectedDividendAsPercentageShareOptionsGranted_0" xml:lang="en-US">Expected Dividend As Percentage Share Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ExpectedDividendAsPercentageShareOptionsGranted_1" xml:lang="en-US">Expected dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ExpectedLife_0" xml:lang="en-US">Expected life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ExpectedLife_1" xml:lang="en-US">Expected life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ExpectedOptionLifeInYears_0" xml:lang="en-US">Expected option life in years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ExpectedOptionLifeInYears_1" xml:lang="en-US">Expected life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ExpectedSharesToBeIssued_0" xml:lang="en-US">Expected shares to be issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_0" xml:lang="en-US">Unrealized gain from changes in fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_1" xml:lang="en-US">Fair Value Assets Measured On Recurring Basis Changes In Unrealized Gain Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_2" xml:lang="en-US">Unrealized gain (loss) from changes in fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FairValueDiscount_0" xml:lang="en-US">Fair value discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FairValueDiscount_1" xml:lang="en-US">Fair value discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FairValueOfNonemployeeStockWarrantsGranted_0" xml:lang="en-US">Fair value of nonemployee stock warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FairValueOfNonemployeeStockWarrantsGranted_1" xml:lang="en-US">Fair value of non-employee stock warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FairValueOfRestrictedStockAwardsIssued_0" xml:lang="en-US">Fair value of restricted stock awards issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FairValueOfWarrantsIssuedDuringPeriod_0" xml:lang="en-US">Fair Value Of Warrants Issued During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FairValueOfWarrantsIssuedDuringPeriod_1" xml:lang="en-US">Fair value of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FGHMember_0" xml:lang="en-US">This member stands for FGH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FGHMember_1" xml:lang="en-US">F G H [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_FGHMember_2" xml:lang="en-US">FGH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FGHMember_3" xml:lang="en-US">FGH asset group [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FGHOwnersMember_0" xml:lang="en-US">F G H Owners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FGHOwnersMember_1" xml:lang="en-US">FGH owners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_0" xml:lang="en-US">Represent the amount for Financial Assets Pledged As Collateral For Liabilities Or Contingent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_1" xml:lang="en-US">Financial Assets Pledged As Collateral For Liabilities Or Contingent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_2" xml:lang="en-US">Financial assets and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FinancialInstrumentsAbstract_0" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FinancialInstrumentsAndRiskManagementAbstract_0" xml:lang="en-US">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_FinancialInstrumentsAndRiskManagementAbstract_1" xml:lang="en-US">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FinancialIntermediariesMember_0" xml:lang="en-US">This member represents about financial intermediaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FinancialIntermediariesMember_1" xml:lang="en-US">Financial Intermediaries [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FinancialIntermediariesMember_2" xml:lang="en-US">Held with financial intermediaries [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FinancialLiabilitiesPolicyTextBlock_0" xml:lang="en-US">Financial Liabilities [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_FinancialLiabilitiesPolicyTextBlock_1" xml:lang="en-US">Financial liabilities [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FinancingReceivables180PlusDaysPastDueMember_0" xml:lang="en-US">Financial assets more than 180 days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FinancingReceivables180PlusDaysPastDueMember_1" xml:lang="en-US">Financing Receivables180 Plus Days Past Due [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_FinancingReceivables180PlusDaysPastDueMember_2" xml:lang="en-US">180+ Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FiniteLivedIntangibleAssetsAdditions_0" xml:lang="en-US">Finite Lived Intangible Assets Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FiniteLivedIntangibleAssetsAdditions_1" xml:lang="en-US">Intangible assets, Cost, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FirstClosingMember_0" xml:lang="en-US">First Closing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FirstClosingMember_1" xml:lang="en-US">First Closing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FirstLoanAgreementMember_0" xml:lang="en-US">First Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FirstLoanAgreementMember_1" xml:lang="en-US">First Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FirstLoanMember_0" xml:lang="en-US">This member stands for First Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FirstLoanMember_1" xml:lang="en-US">First Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FirstTrancheMember_0" xml:lang="en-US">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FixedAssets_0" xml:lang="en-US">Represents the amount of fixed assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FixedAssets_1" xml:lang="en-US">Fixed Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FixedAssets_2" xml:lang="en-US">Fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FloraBeautyMember_0" xml:lang="en-US">Flora Beauty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FloraBeautyMember_1" xml:lang="en-US">Flora Beauty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_FloraBeautyMember_2" xml:lang="en-US">Flora Beauty LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FloraBreezeLaboratoryMember_0" xml:lang="en-US">Flora Breeze Laboratory [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FloraBreezeLaboratoryMember_1" xml:lang="en-US">FLORA Breeze Laboratory [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FloraGrowthCorpMember_0" xml:lang="en-US">This member stands for Flora Growth Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FloraGrowthCorpMember_1" xml:lang="en-US">Flora Growth Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_FloraMedSasMember_0" xml:lang="en-US">Flora Med SAS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FloraMedSasMember_1" xml:lang="en-US">Flora Med Sas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_FloraMedSasMember_2" xml:lang="en-US">Flora Med S.A.S [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FoodAndBeveragesMember_0" xml:lang="en-US">Food And Beverages [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FoodAndBeveragesMember_1" xml:lang="en-US">Food and beverage [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ForeignExchangeImpacts_0" xml:lang="en-US">Foreign exchange impacts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ForeignIncomeTaxAuthorityMember_0" xml:lang="en-US">Foreign Income Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ForeignIncomeTaxAuthorityMember_1" xml:lang="en-US">Foreign [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ForeignRevenueAgencyMember_0" xml:lang="en-US">Foreign Revenue Agency [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ForeignRevenueAgencyMember_1" xml:lang="en-US">Foreign [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FortLauderdaleMember_0" xml:lang="en-US">Fort Lauderdale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FortLauderdaleMember_1" xml:lang="en-US">Fort Lauderdale, FL [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FranchiseGlobalHealthIncMember_0" xml:lang="en-US">Franchise Global Health Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_FranchiseGlobalHealthIncMember_1" xml:lang="en-US">Franchise Global Health Inc. ("FGH") business combination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_FunctionalCurrencyOfSubsidiary_0" xml:lang="en-US">Functional Currency Of Subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_FunctionalCurrencyOfSubsidiary_1" xml:lang="en-US">Functional Currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_GerardoAndresGarciaMendezMember_0" xml:lang="en-US">Gerardo Andres Garcia Mendez.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_GerardoAndresGarciaMendezMember_1" xml:lang="en-US">Gerardo Andres Garcia Mendez [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_GermanSubsidiariesMember_0" xml:lang="en-US">German subsidiaries [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_GermanyRevenueAgencyMember_0" xml:lang="en-US">Germany Revenue Agency [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_GermanyRevenueAgencyMember_1" xml:lang="en-US">Germany [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_GoingConcernPolicyTextBlock_0" xml:lang="en-US">Going concern [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_GoingConcernPolicyTextBlock_1" xml:lang="en-US">Going concern [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_GoodwillAndIdentifiedIntangibleAssets_0" xml:lang="en-US">Goodwill And Identified Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_GoodwillAndIdentifiedIntangibleAssets_1" xml:lang="en-US">Goodwill and identified intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_GoodwillDescription_0" xml:lang="en-US">Goodwill description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_GrantDateFairValueOfWarrantsOutstanding_0" xml:lang="en-US">Grant Date Fair Value Of Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_GrupoFarmaceuticoCronomedSasMember_0" xml:lang="en-US">Grupo Farmaceutico Cronomed Sas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_GrupoFarmaceuticoCronomedSasMember_1" xml:lang="en-US">Grupo Farmaceutico Cronomed S.A.S [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_HampsteadPrivateCapitalLimitedMember_0" xml:lang="en-US">Hampstead Private Capital Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_HarvestedCannabis_0" xml:lang="en-US">Harvested Cannabis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_0" xml:lang="en-US">This member represents about amount held With Large Financial Institutions And National Central Banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_1" xml:lang="en-US">Held with large financial institutions and national central banks [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_HouseOfBrandsMember_0" xml:lang="en-US">House of Brands [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_HouseOfBrandsMember_1" xml:lang="en-US">House of Brands [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_HouseOfBrandsSegmentMember_0" xml:lang="en-US">This member stands for house of brands segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_HouseOfBrandsSegmentMember_1" xml:lang="en-US">House Of Brands Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_HouseOfBrandsSegmentMember_2" xml:lang="en-US">House of Brands Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_HypoverinsbankMember_0" xml:lang="en-US">Hypoverinsbank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ImpairmentOfAssetsAbstract_0" xml:lang="en-US">Impairment Of Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ImpairmentOfGoodwill_0" xml:lang="en-US">Impairment of goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ImpairmentOfGoodwill_1" xml:lang="en-US">Impairment of goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ImpairmentOfGoodwill_2" xml:lang="en-US">Goodwill impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ImpairmentOfLicenses_0" xml:lang="en-US">Impairment of licenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ImpairmentOfPatents_0" xml:lang="en-US">Represents the amount of impairment of patents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ImpairmentOfPatents_1" xml:lang="en-US">Impairment of patents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ImpairmentOfPropertyPlantAndEquipment_0" xml:lang="en-US">Impairment of property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_IncreaseInCarryingValueOfAssets_0" xml:lang="en-US">Increase In Carrying Value Of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_IncreaseInCarryingValueOfAssets_1" xml:lang="en-US">Increase in carrying value of assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_IndemnificationReceivables_0" xml:lang="en-US">Amount of indemnification receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_IndemnificationReceivables_1" xml:lang="en-US">Indemnification Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_IndemnificationReceivables_2" xml:lang="en-US">Indemnification receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InitialPublicOfferingAmount_0" xml:lang="en-US">Initial public offering, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InitialPublicOfferingIssuanceCostsAmount_0" xml:lang="en-US">Initial public offering issuance costs, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InitialPublicOfferingIssuanceCostsShares_0" xml:lang="en-US">Initial public offering issuance costs, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InitialPublicOfferingMember_0" xml:lang="en-US">Initial Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_InitialPublicOfferingMember_1" xml:lang="en-US">Initial Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InitialPublicOfferingShares_0" xml:lang="en-US">Initial public offering, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_0" xml:lang="en-US">The amount represents Intangible assets acquired for contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_1" xml:lang="en-US">Intangible Assets Acquired For Contingent Consideration Non Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_2" xml:lang="en-US">Intangible assets acquired for contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_IntrinsicValueOfWarrantsExercised_0" xml:lang="en-US">Intrinsic value of warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InventoryAbstract_0" xml:lang="en-US">Inventory [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InventoryExpensedToCostOfSales_0" xml:lang="en-US">Inventory Expensed To Cost Of Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_InventoryExpensedToCostOfSales_1" xml:lang="en-US">Inventory expensed to cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_InventoryImpactedByStopSaleOrders_0" xml:lang="en-US">Represents the amount of Inventory impacted by stop sale orders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InventoryImpactedByStopSaleOrders_1" xml:lang="en-US">Inventory impacted by stop sale orders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InvesteeCommonSharesMember_0" xml:lang="en-US">Investee common shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_0" xml:lang="en-US">Investing Activities Of Discontinued Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_1" xml:lang="en-US">Investing activities of discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InvestmentDescription_0" xml:lang="en-US">Investment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_InvestmentDescription_1" xml:lang="en-US">Investment description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_InvestmentExercisePrice_0" xml:lang="en-US">Investment Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_InvestmentExercisePrice_1" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_IssuanceCosts_0" xml:lang="en-US">Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_IssuanceCosts_1" xml:lang="en-US">Issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_0" xml:lang="en-US">Just Brands Llc And High Roller Private Label Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_1" xml:lang="en-US">Just Brands LLC and High Roller Private Label LLC business combination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2" xml:lang="en-US">Just Brands LLC and High Roller Private Label LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_JustBrandsLLCMember_0" xml:lang="en-US">Just Brands L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_JustBrandsLLCMember_1" xml:lang="en-US">Just Brands L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_JustBrandsLLCMember_2" xml:lang="en-US">Just Brands LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_JustBrandsLLCMember_3" xml:lang="en-US">Just Brands FL LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_JustCBDInsurancePremiumLoanMember_0" xml:lang="en-US">This member stands for JustCBD insurance premium loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_JustCBDInsurancePremiumLoanMember_1" xml:lang="en-US">Just C B D Insurance Premium Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_JustCBDInsurancePremiumLoanMember_2" xml:lang="en-US">JustCBD insurance premium loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_JustCBDMember_0" xml:lang="en-US">Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_flgc_JustCBDMember_1" xml:lang="en-US">JustCBD potential additional shares to settle contingent consideration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_JustCBDMember_2" xml:lang="en-US">Just C B D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_JustCBDMember_3" xml:lang="en-US">JustCBD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_JustCBDMember_4" xml:lang="en-US">JustCBD asset group [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_JustCBDOwnersMember_0" xml:lang="en-US">Just C B D Owners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_JustCBDOwnersMember_1" xml:lang="en-US">JustCBD owners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_KnowHowMember_0" xml:lang="en-US">Know How [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_KnowHowMember_1" xml:lang="en-US">Know-how [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LeaseLiabilities_0" xml:lang="en-US">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LeaseLiabilities_1" xml:lang="en-US">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LeaseObligations_0" xml:lang="en-US">Lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LeasesMonthlyAmount_0" xml:lang="en-US">Leases, monthly amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LegalDisputesMember_0" xml:lang="en-US">Legal Disputes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LegalDisputesMember_1" xml:lang="en-US">Legal disputes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LiabilitiesAmount_0" xml:lang="en-US">Liabilities Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_LiabilitiesAmount_1" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_0" xml:lang="en-US">The amount represent liabilities held for sale not part of disposal group current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_1" xml:lang="en-US">Liabilities Held For Sale Not Part Of Disposal Group Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_2" xml:lang="en-US">Current liabilities held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_0" xml:lang="en-US">The amount represents liabilities held for sale not part of disposal group non current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_1" xml:lang="en-US">Liabilities Held For Sale Not Part Of Disposal Group Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_2" xml:lang="en-US">Noncurrent liabilities held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LicensesAndTrademarksMember_0" xml:lang="en-US">Licenses and trademarks [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LicensesMember_0" xml:lang="en-US">Licenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_LicensesMember_1" xml:lang="en-US">Licenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LisanFarmaColombiaLLCMember_0" xml:lang="en-US">Lisan Farma Colombia L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LisanFarmaColombiaLLCMember_1" xml:lang="en-US">Lisan Farma Colombia L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LisanFarmaColombiaLLCMember_2" xml:lang="en-US">Lisan Farma Colombia LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LoanAgreementsAxis_0" xml:lang="en-US">Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LoanAgreementsAxis_1" xml:lang="en-US">Loan Agreements [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LoanAgreementsDomain_0" xml:lang="en-US">Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LoanAgreementsDomain_1" xml:lang="en-US">Loan Agreements [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LoanRepaymentsReceived_0" xml:lang="en-US">Loan repayments received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LoanRepaymentsReceived_1" xml:lang="en-US">Loan repayments received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_LoansProvided_0" xml:lang="en-US">Loans Provided</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LoansProvided_1" xml:lang="en-US">Loans Provided</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LoansReceivableAndAdvances_0" xml:lang="en-US">Loans receivable and advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LossContingencyAccrualForeignCurrencyTranslation_0" xml:lang="en-US">Amount of foreign currency translation affecting the loss contingency liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LossContingencyAccrualForeignCurrencyTranslation_1" xml:lang="en-US">Loss Contingency Accrual, Foreign Currency Translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LossContingencyAccrualForeignCurrencyTranslation_2" xml:lang="en-US">Foreign currency translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_0" xml:lang="en-US">Number of shares that the company is obligated to issue pre-one-for three reverse stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_1" xml:lang="en-US">Loss Contingency Damages Sought Share To Be Issued Pre One For Three Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_2" xml:lang="en-US">Number of shares to be issued pre-one-for three reverse stock split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_0" xml:lang="en-US">Represents about loss contingency estimate of possible loss based on number of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_1" xml:lang="en-US">Loss Contingency Estimate Of Possible Loss Based On Number Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_2" xml:lang="en-US">Number of shares loss estimate is based on</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_0" xml:lang="en-US">Amount of loss contingency, estimate of possible loss, interest accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_1" xml:lang="en-US">Loss Contingency, Estimate Of Possible Loss, Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_2" xml:lang="en-US">Loss contingency, estimate of possible loss, interest accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_LossContingencyInterestPaymentTerms_0" xml:lang="en-US">Represents about loss contingency interest payment terms.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_LossContingencyInterestPaymentTerms_1" xml:lang="en-US">Loss Contingency Interest Payment Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_LossContingencyInterestPaymentTerms_2" xml:lang="en-US">Loss contingency interest payment terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_MachineryAndOfficeEquipmentMember_0" xml:lang="en-US">Machinery and office equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_MachineryAndOfficeEquipmentMember_1" xml:lang="en-US">Machinery and office equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ManagementContractsTerms_0" xml:lang="en-US">Represents about management contracts terms.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ManagementContractsTerms_1" xml:lang="en-US">Management contracts terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_0" xml:lang="en-US">This member is stand for Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_1" xml:lang="en-US">Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_MaximumLimitOfIndemnificationAgreement_0" xml:lang="en-US">Reprsents the value of maximum limit of the indemnification agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_MaximumLimitOfIndemnificationAgreement_1" xml:lang="en-US">Maximum Limit Of Indemnification Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_MaximumLimitOfIndemnificationAgreement_2" xml:lang="en-US">Maximum limit of indemnification agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_MaximumPaymentAccumulatedForValuation_0" xml:lang="en-US">Maximum payment accumulated for valuation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_MaximumPaymentAccumulatedForValuation_1" xml:lang="en-US">Maximum Payment Accumulated For Valuation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_MaximumPaymentAccumulatedForValuation_2" xml:lang="en-US">Maximum payment accumulated for valuation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_MaximumPortionOfNetProfitsPayable_0" xml:lang="en-US">Maximum portion of net profits payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_MaximumPortionOfNetProfitsPayable_1" xml:lang="en-US">Maximum Portion Of Net Profits Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_MaximumPortionOfNetProfitsPayable_2" xml:lang="en-US">Maximum portion of net profits payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_MedicalServices_0" xml:lang="en-US">Medical services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_MonthlyLeasePayment_0" xml:lang="en-US">Monthly lease payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NameOfSubsidiary_0" xml:lang="en-US">Name Of Subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NatureOfOperationsAndGoingConcernAbstract_0" xml:lang="en-US">Nature Of Operations And Going Concern [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NatureOfOperationsAndGoingConcernAbstract_1" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NetDeferredTaxLiabilities_0" xml:lang="en-US">Net deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NetDeferredTaxLiabilities_1" xml:lang="en-US">Net deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NoCapHempCoMember_0" xml:lang="en-US">No Cap Hemp Co [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NoCapHempCoMember_1" xml:lang="en-US">No Cap Hemp Co. business combination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NonCapitalLossCarryforwards_0" xml:lang="en-US">Non-capital Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NonCapitalLossCarryforwards_1" xml:lang="en-US">Non-capital loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NonCashAssetsAcquiredForContingentConsideration_0" xml:lang="en-US">Non Cash Assets Acquired For Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NonCashAssetsAcquiredForContingentConsideration_1" xml:lang="en-US">Assets acquired for contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NonCashCommonSharesIssuedForBusinessCombinations_0" xml:lang="en-US">Non Cash Common Shares Issued For Business Combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NonCashCommonSharesIssuedForBusinessCombinations_1" xml:lang="en-US">Common shares issued for business combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NonCashCommonSharesIssuedForOtherAgreements_0" xml:lang="en-US">Non Cash Common Shares Issued For Other Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NonCashCommonSharesIssuedForOtherAgreements_1" xml:lang="en-US">Common shares issued for other agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_0" xml:lang="en-US">Non Cash Operating Lease Additions To Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_1" xml:lang="en-US">Operating lease additions to right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NonCashOptionCancellationsReclassifiedToEquity_0" xml:lang="en-US">Non Cash Option Cancellations Reclassified To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NonCashOptionCancellationsReclassifiedToEquity_1" xml:lang="en-US">Option cancellations reclassified to equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NonControllingInterestsPolicyTextBlock_0" xml:lang="en-US">Non-controlling interests [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_NonControllingInterestsPolicyTextBlock_1" xml:lang="en-US">Non-controlling interests [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NonVestedShares_0" xml:lang="en-US">Non-vested shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_0" xml:lang="en-US">November Two Thousand Twenty One Unit Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_1" xml:lang="en-US">November 2021 offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_NumberOfSharesUnderPlaintiffClaim_0" xml:lang="en-US">Represents about number of shares under plaintiff claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NumberOfSharesUnderPlaintiffClaim_1" xml:lang="en-US">Number Of Shares Under Plaintiff Claim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_NumberOfSharesUnderPlaintiffClaim_2" xml:lang="en-US">Number of shares under plaintiff claim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_NumberOfTrials_0" xml:lang="en-US">Number of trials.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NumberOfTrials_1" xml:lang="en-US">Number Of Trials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_NumberOfTrials_2" xml:lang="en-US">Number of trials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_NumberOfViolationsClaimed_0" xml:lang="en-US">Represents about number of violations claimed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NumberOfViolationsClaimed_1" xml:lang="en-US">Number Of Violations Claimed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_NumberOfViolationsClaimed_2" xml:lang="en-US">Number of violations claimed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NumberOfViolationsInStopSaleOrders_0" xml:lang="en-US">Number of violations in stop sale orders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_NumberOfWarrantsCancelledExpired_0" xml:lang="en-US">Cancelled/Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NumberOfWarrantsCancelledExpired_1" xml:lang="en-US">Number Of Warrants, Cancelled/expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NumberOfWarrantsIssuedDuringPeriod_0" xml:lang="en-US">Number Of Warrants Issued During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_NumberOfWarrantsIssuedDuringPeriod_1" xml:lang="en-US">Warrant issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_NumberOfWarrantsIssuedDuringPeriod_2" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NumberOfWarrantsWithAmendedExercisePrice_0" xml:lang="en-US">Number of warrants with amended exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_NumberOfWarrantsWithExercisePriceAmended_0" xml:lang="en-US">Number of warrants with exercise price amended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_0" xml:lang="en-US">Operating Activities Of Discontinued Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_1" xml:lang="en-US">Operating activities of discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OptionsExercisableMember_0" xml:lang="en-US">Options Exercisable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_OptionsExercisableMember_1" xml:lang="en-US">Options exercisable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OptionsExpiredCancelled_0" xml:lang="en-US">Options expired/cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_0" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OriginalHempAssetAcquisitionMember_0" xml:lang="en-US">Original Hemp asset acquisition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_0" xml:lang="en-US">Other Comprehensive Loss Exchange Differences On Foreign Operations Net Of Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_1" xml:lang="en-US">Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_0" xml:lang="en-US">Other comprehensive loss- exchange differences on foreign operations (net of income taxes of $nil)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_1" xml:lang="en-US">Other comprehensive loss -exchange differences (net of income taxes of $nil)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OtherEquityIssuanceCosts_0" xml:lang="en-US">Other equity issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OtherInformationAbstract_0" xml:lang="en-US">Other Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_OtherInformationAbstract_1" xml:lang="en-US">Other Information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OtherIssuanceMember_0" xml:lang="en-US">Other issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OtherLongLivedAssetImpairmentTestsMember_0" xml:lang="en-US">Other Long-Lived Asset Impairment Tests [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OtherLongLivedAssets_0" xml:lang="en-US">Other Long-lived Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_OtherLongLivedAssets_1" xml:lang="en-US">Other long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_OtherOfferingMember_0" xml:lang="en-US">Other Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_OtherOfferingMember_1" xml:lang="en-US">Other offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_PaidAmountToBreezeVendor_0" xml:lang="en-US">Represent the amount paid to Breeze Vendor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PaidAmountToBreezeVendor_1" xml:lang="en-US">Paid Amount To Breeze Vendor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_PaidAmountToBreezeVendor_2" xml:lang="en-US">Breeze vendors payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PatentAndDevelopedTechnologyMember_0" xml:lang="en-US">Patent And Developed Technology [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_PatentAndDevelopedTechnologyMember_1" xml:lang="en-US">Patents and developed technology [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PercentageOfAcquisition_0" xml:lang="en-US">Percentage Of Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_PercentageOfAcquisition_1" xml:lang="en-US">Percentage of acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_0" xml:lang="en-US">Represents about percentage of aggregate gross proceeds from sale of common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_1" xml:lang="en-US">Percentage Of Aggregate Gross Proceeds From Sale Of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_2" xml:lang="en-US">Percentage of aggregate gross proceeds from sale of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_PercentageOfIssuedAndOutstandingCommonShares_0" xml:lang="en-US">Represents about percentage of issued and outstanding common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PercentageOfIssuedAndOutstandingCommonShares_1" xml:lang="en-US">Percentage Of Issued And Outstanding Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_PercentageOfIssuedAndOutstandingCommonShares_2" xml:lang="en-US">Percentage of issued and outstanding common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_0" xml:lang="en-US">Percentage of Recoverable amounts exceeded the market capitalization of common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_1" xml:lang="en-US">Percentage Of Recoverable Amounts Exceeded Market Capitalization Of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_2" xml:lang="en-US">Percentage of recoverable amounts exceeded market capitalization of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PharmaceuticalsMember_0" xml:lang="en-US">Pharmaceuticals [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PlacementAgentMember_0" xml:lang="en-US">Placement agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PompanoBeachMember_0" xml:lang="en-US">Pompano Beach [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_PompanoBeachMember_1" xml:lang="en-US">Pompano Beach, FL [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_PostTerminationExercisePeriod_0" xml:lang="en-US">Post Termination Exercise Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PostTerminationExercisePeriod_1" xml:lang="en-US">Post Termination Exercise Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_PostTerminationExercisePeriod_2" xml:lang="en-US">Post-termination exercise period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_PotentialLiabilities_0" xml:lang="en-US">Amount of potential liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PotentialLiabilities_1" xml:lang="en-US">Potential liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_0" xml:lang="en-US">Accounting policy for presentation of comparative financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_1" xml:lang="en-US">Presentation Of Comparative Financial Statements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_2" xml:lang="en-US">Presentation of comparative financial statements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PreviouslyIssuedWarrant_0" xml:lang="en-US">Previously Issued Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_PreviouslyIssuedWarrant_1" xml:lang="en-US">Previously issued warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PriceToBookValue_0" xml:lang="en-US">Price to book value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PriceToTangibleBookValue_0" xml:lang="en-US">Price to tangible book value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ProceedsFromExerciseOfWarrantsAndOptions_0" xml:lang="en-US">Proceeds From Exercise Of Warrants And Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ProceedsFromExerciseOfWarrantsAndOptions_1" xml:lang="en-US">Exercise of warrants and options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_PropertyInSantanderMember_0" xml:lang="en-US">Property In Santander, [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PropertyInSantanderMember_1" xml:lang="en-US">Property In Santander [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ProvisionsPolicyTextBlock_0" xml:lang="en-US">Provisions [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ProvisionsPolicyTextBlock_1" xml:lang="en-US">Provisions [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PurchaseConsideration_0" xml:lang="en-US">Purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PurchaseConsiderationComprised_0" xml:lang="en-US">Purchase Consideration Comprised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PurchaseConsiderationComprisedShare_0" xml:lang="en-US">Purchase Consideration Comprised Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PurchaseConsiderationDiscountRate_0" xml:lang="en-US">Purchase Consideration, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_PurchaseConsiderationDiscountRate_1" xml:lang="en-US">Discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PurchaseConsiderationPercentageOfSales_0" xml:lang="en-US">Purchase consideration, percentage of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_0" xml:lang="en-US">Purchase Consideration, Percentage Of Sales Amount Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_1" xml:lang="en-US">Purchase consideration, percentage of sales, amount payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_PurchaseOfCommonStock_0" xml:lang="en-US">Purchase of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_0" xml:lang="en-US">This member is stand for Ramon Ricardo Castellanos Saenz and Miriam Ortiz.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_1" xml:lang="en-US">Ramon Ricardo Castellanos Saenz and Miriam Ortiz [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Eighteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_1" xml:lang="en-US">July 5, 2033 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_1" xml:lang="en-US">June 3, 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Eleven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_1" xml:lang="en-US">September 25, 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_1" xml:lang="en-US">May 16, 2027 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_1" xml:lang="en-US">September 8, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_1" xml:lang="en-US">July 15, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Fourteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_1" xml:lang="en-US">January 26, 2027 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Nine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_1" xml:lang="en-US">June 10, 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_1" xml:lang="en-US">June 28, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_1" xml:lang="en-US">December 23, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Seventeen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_1" xml:lang="en-US">August 18, 2032 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_1" xml:lang="en-US">November 4, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Sixteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_1" xml:lang="en-US">December 31, 2029 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Ten [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_1" xml:lang="en-US">September 21, 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Thirteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_1" xml:lang="en-US">January 17, 2027 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_1" xml:lang="en-US">July 6, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Twelve [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_1" xml:lang="en-US">December 16, 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_0" xml:lang="en-US">Ranges Of Exercise Prices For Outstanding Share Options Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_1" xml:lang="en-US">April 23, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_RealEstateAssetsMember_0" xml:lang="en-US">This member stands for Real estate assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RealEstateAssetsMember_1" xml:lang="en-US">Real estate assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_RealEstateAssetsMember_2" xml:lang="en-US">Real Estate Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RegulationAAndOtherOfferingsAmount_0" xml:lang="en-US">Regulation A and other offerings, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RegulationAAndOtherOfferingsShares_0" xml:lang="en-US">Regulation A and other offerings, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RelatedPartyDisclosuresAbstract_0" xml:lang="en-US">Related Party Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_RelatedPartyDisclosuresAbstract_1" xml:lang="en-US">Related Party Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RemainingPercentageOfAcquisition_0" xml:lang="en-US">Remaining percentage of acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RemainingWeightedAverageVestingPeriod_0" xml:lang="en-US">Remaining weighted average vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RestrictedStockAwardsMember_0" xml:lang="en-US">Restricted stock awards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RestrictedStockVestingAmount_0" xml:lang="en-US">Restricted stock vesting amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_RestrictedStockVestingAmount_1" xml:lang="en-US">Restricted stock vesting, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RestrictedStockVestingShares_0" xml:lang="en-US">Restricted stock vesting shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_RestrictedStockVestingShares_1" xml:lang="en-US">Restricted stock vesting, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_RetailSpaceInMiamiMember_0" xml:lang="en-US">Retail space in Miami [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RetailSpaceInMiamiMember_1" xml:lang="en-US">Retail space In Miami [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_0" xml:lang="en-US">Royalty on gross revenues from sale of products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_1" xml:lang="en-US">Payment of royalty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SalesTaxesMember_0" xml:lang="en-US">Sales taxes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_0" xml:lang="en-US">Schedule Of Assets And Liabilities Denominated In Foreign Currencies [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_1" xml:lang="en-US">Schedule of assets and liabilities denominated in foreign currencies [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_0" xml:lang="en-US">Schedule of assets estimated useful life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_1" xml:lang="en-US">Schedule of assets estimated useful lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_1" xml:lang="en-US">Schedule Of Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ScheduleOfCommitmentsAndContingenciesTable_0" xml:lang="en-US">Schdeule Of Commitments And Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xml:lang="en-US">Schedule Of Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_0" xml:lang="en-US">Schedule of company aging of trade accounts receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_1" xml:lang="en-US">Schedule Of Company Aging Of Trade Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_2" xml:lang="en-US">Schedule of aging of trade accounts receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_0" xml:lang="en-US">Schedule Of Companys Investments Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_1" xml:lang="en-US">Schedule of investments activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_0" xml:lang="en-US">Schedule Of Fair Value Of Warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_1" xml:lang="en-US">Schedule of fair value of warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_0" xml:lang="en-US">Schedule Of Information About Companys Financial Instruments And Their Classifications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_1" xml:lang="en-US">Schedule of information about the financial instruments and their classifications [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_0" xml:lang="en-US">Schedule Of Intangible Assets Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_1" xml:lang="en-US">Schedule of intangible assets estimated useful lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_0" xml:lang="en-US">Tabular disclosure of information related to&#160;loss net of tax discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_1" xml:lang="en-US">Schedule Of Loss From Discontinued Operations [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_2" xml:lang="en-US">Schedule of loss from discontinued operations [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_0" xml:lang="en-US">Tabular disclosure of information related to assets and liabilities&#160;held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1" xml:lang="en-US">Schedule Of Major Classes Of Assets And Liabilities Held For Sale [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_2" xml:lang="en-US">Schedule of major classes of assets and liabilities held for sale [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_0" xml:lang="en-US">Schedule of other significant items [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_1" xml:lang="en-US">Schedule of other significant items [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule Of Provisions And Contingent Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of provisions and contingent liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfRestrictedStockAwards_0" xml:lang="en-US">Schedule Of Restricted Stock Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfRestrictedStockAwards_1" xml:lang="en-US">Schedule of restricted stock awards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_0" xml:lang="en-US">Tabular disclosure of information related to&#160;operating and investing items&#160;discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_1" xml:lang="en-US">Schedule Of Significant Operating And Investing Items [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_2" xml:lang="en-US">Schedule of significant operating and investing items [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfSubsidiariesTableTextBlock_0" xml:lang="en-US">Schedule of subsidiaries [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfSubsidiariesTableTextBlock_1" xml:lang="en-US">Schedule of subsidiaries [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_0" xml:lang="en-US">Schedule of warrants outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_1" xml:lang="en-US">Schedule of warrants outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_0" xml:lang="en-US">Schedule Of Weighted Average Amortization Period Of Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_1" xml:lang="en-US">Schedule of weighted average amortization period of intangible assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SecondClosingMember_0" xml:lang="en-US">Second Closing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SecondClosingMember_1" xml:lang="en-US">Second Closing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SecondLoanAgreementMember_0" xml:lang="en-US">Second Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SecondLoanAgreementMember_1" xml:lang="en-US">Second Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SecondLoanMember_0" xml:lang="en-US">This member stands for Second Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SecondLoanMember_1" xml:lang="en-US">Second Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SecondTrancheMember_0" xml:lang="en-US">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SeparationAgreementMember_0" xml:lang="en-US">This member stands for separation agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SeparationAgreementMember_1" xml:lang="en-US">Separation Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_0" xml:lang="en-US">September Two Thousand Twenty Three Unit Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_1" xml:lang="en-US">September 2023 unit offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SeptemberUnitOfferingAmount_0" xml:lang="en-US">September Unit Offering Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SeptemberUnitOfferingAmount_1" xml:lang="en-US">September unit offering, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_SeptemberUnitOfferingIssuanceCosts_0" xml:lang="en-US">September unit offering issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SeptemberUnitOfferingIssuanceCosts_1" xml:lang="en-US">September Unit Offering Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SeptemberUnitOfferingIssuanceCosts_2" xml:lang="en-US">September unit offering issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SeptemberUnitOfferingShares_0" xml:lang="en-US">September Unit Offering Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SeptemberUnitOfferingShares_1" xml:lang="en-US">September unit offering shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SettlementAgreementMember_0" xml:lang="en-US">This member stands for settlement agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SettlementAgreementMember_1" xml:lang="en-US">Settlement Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares_0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Per Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares_1" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_0" xml:lang="en-US">Weighted average remaining contractual term for option awards cancelled, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_2" xml:lang="en-US">Weighted average remaining life, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_0" xml:lang="en-US">Weighted average remaining contractual term for option awards Exercises in Period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_2" xml:lang="en-US">Weighted average remaining life, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_0" xml:lang="en-US">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_2" xml:lang="en-US">Weighted average remaining life, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareBasedCompensationConsideration_0" xml:lang="en-US">Share Based Compensation Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ShareBasedCompensationConsideration_1" xml:lang="en-US">Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_0" xml:lang="en-US">Share Based Compensation , Options, Vested, Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_1" xml:lang="en-US">Grant date fair value vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_0" xml:lang="en-US">Share Based Compensation , Warrants, Grant Date Fair Value Per Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_1" xml:lang="en-US">Warrants issued, grant date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SharedServicesAndSpaceCommitment_0" xml:lang="en-US">Shared services and space commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SharePurchaseAgreementMember_0" xml:lang="en-US">Share Purchase Agreement [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SharePurchaseAgreementMember_1" xml:lang="en-US">Share Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareRepurchaseMember_0" xml:lang="en-US">Share repurchase [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_ShareRepurchaseShares_0" xml:lang="en-US">Share repurchase, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ShareRepurchaseShares_1" xml:lang="en-US">Share repurchase shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_0" xml:lang="en-US">Shares issued during period warrants expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_1" xml:lang="en-US">Shares Issued During Period Shares Warrants Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_2" xml:lang="en-US">Warrants expired/cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_0" xml:lang="en-US">Shares issued to purchase warrants from existing investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_1" xml:lang="en-US">Shares issued to purchase warrants from existing investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SignificantAccountingPoliciesLineItems_0" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SignificantAccountingPoliciesLineItems_1" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SignificantAccountingPoliciesTable_0" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_StockOptionDateOfExpiry_0" xml:lang="en-US">Stock Option Date Of Expiry</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_StockOptionDateOfExpiry_1" xml:lang="en-US">Date of expiry</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_StockOptionExercisable_0" xml:lang="en-US">Stock Option Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_StockOptionExercisable_1" xml:lang="en-US">Maximum stock option, exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_StockOptionsMember_0" xml:lang="en-US">Stock options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_StockOptionsMember_1" xml:lang="en-US">Stock options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_flgc_StockRepurchasedDuringPeriodAmount_0" xml:lang="en-US">Share repurchase, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_StockRepurchasedDuringPeriodAmount_1" xml:lang="en-US">Stock Repurchased During Period, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_StockWarrantMember_0" xml:lang="en-US">Stock Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryEighteenMember_0" xml:lang="en-US">Subsidiary eighteen [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryEighteenMember_1" xml:lang="en-US">Subsidiary 18 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryEightMember_0" xml:lang="en-US">Subsidiary eight [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryEightMember_1" xml:lang="en-US">Subsidiary 8 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryElevenMember_0" xml:lang="en-US">Subsidiary eleven [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryElevenMember_1" xml:lang="en-US">Subsidiary 11 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryFifteenMember_0" xml:lang="en-US">Subsidiary fifteen [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryFifteenMember_1" xml:lang="en-US">Subsidiary 15 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryFiveMember_0" xml:lang="en-US">Subsidiary five [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryFiveMember_1" xml:lang="en-US">Subsidiary 5 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryFourMember_0" xml:lang="en-US">Subsidiary four [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryFourMember_1" xml:lang="en-US">Subsidiary 4 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryFourteenMember_0" xml:lang="en-US">Subsidiary fourteen [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryFourteenMember_1" xml:lang="en-US">Subsidiary 14 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryNineMember_0" xml:lang="en-US">Subsidiary nine [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryNineMember_1" xml:lang="en-US">Subsidiary 9 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryNineteenMember_0" xml:lang="en-US">Subsidiary nineteen [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryNineteenMember_1" xml:lang="en-US">Subsidiary 19 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryOneMember_0" xml:lang="en-US">Subsidiary one [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryOneMember_1" xml:lang="en-US">Subsidiary 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiarySevenMember_0" xml:lang="en-US">Subsidiary seven [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiarySevenMember_1" xml:lang="en-US">Subsidiary 7 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiarySeventeenMember_0" xml:lang="en-US">Subsidiary seventeen [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiarySeventeenMember_1" xml:lang="en-US">Subsidiary 17 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiarySixMember_0" xml:lang="en-US">Subsidiary six [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiarySixMember_1" xml:lang="en-US">Subsidiary 6 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiarySixteenMember_0" xml:lang="en-US">Subsidiary sixteen [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiarySixteenMember_1" xml:lang="en-US">Subsidiary 16 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTenMember_0" xml:lang="en-US">Subsidiary ten [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTenMember_1" xml:lang="en-US">Subsidiary 10 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryThirteenMember_0" xml:lang="en-US">Subsidiary thirteen [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryThirteenMember_1" xml:lang="en-US">Subsidiary 13 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryThirtyFiveMember_0" xml:lang="en-US">Subsidiary thirty five [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryThirtyFiveMember_1" xml:lang="en-US">Subsidiary 35 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryThirtyFourMember_0" xml:lang="en-US">Subsidiary thirty four [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryThirtyFourMember_1" xml:lang="en-US">Subsidiary 34 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryThirtyMember_0" xml:lang="en-US">Subsidiary thirty [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryThirtyMember_1" xml:lang="en-US">Subsidiary 30 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryThirtyOneMember_0" xml:lang="en-US">Subsidiary thirty one [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryThirtyOneMember_1" xml:lang="en-US">Subsidiary 31 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryThirtyThreeMember_0" xml:lang="en-US">Subsidiary thirty three [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryThirtyThreeMember_1" xml:lang="en-US">Subsidiary 33 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryThirtyTwoMember_0" xml:lang="en-US">Subsidiary thirty two [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryThirtyTwoMember_1" xml:lang="en-US">Subsidiary 32 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryThreeMember_0" xml:lang="en-US">Subsidiary three [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryThreeMember_1" xml:lang="en-US">Subsidiary 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwelveMember_0" xml:lang="en-US">Subsidiary twelve [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwelveMember_1" xml:lang="en-US">Subsidiary 12 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentyEightMember_0" xml:lang="en-US">Subsidiary twenty eight [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentyEightMember_1" xml:lang="en-US">Subsidiary 28 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentyFiveMember_0" xml:lang="en-US">Subsidiary twenty five [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentyFiveMember_1" xml:lang="en-US">Subsidiary 25 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentyFourMember_0" xml:lang="en-US">Subsidiary twenty four [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentyFourMember_1" xml:lang="en-US">Subsidiary 24 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentyMember_0" xml:lang="en-US">Subsidiary twenty [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentyMember_1" xml:lang="en-US">Subsidiary 20 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentyNineMember_0" xml:lang="en-US">Subsidiary twenty nine [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentyNineMember_1" xml:lang="en-US">Subsidiary 29 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentyOneMember_0" xml:lang="en-US">Subsidiary twenty one [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentyOneMember_1" xml:lang="en-US">Subsidiary 21 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentySevenMember_0" xml:lang="en-US">Subsidiary twenty seven [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentySevenMember_1" xml:lang="en-US">Subsidiary 27 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentySixMember_0" xml:lang="en-US">Subsidiary twenty six [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentySixMember_1" xml:lang="en-US">Subsidiary 26 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentyThreeMember_0" xml:lang="en-US">Subsidiary twenty three [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentyThreeMember_1" xml:lang="en-US">Subsidiary 23 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwentyTwoMember_0" xml:lang="en-US">Subsidiary twenty two [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwentyTwoMember_1" xml:lang="en-US">Subsidiary 22 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SubsidiaryTwoMember_0" xml:lang="en-US">Subsidiary two [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_SubsidiaryTwoMember_1" xml:lang="en-US">Subsidiary 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_SupplierRelationshipsMember_0" xml:lang="en-US">This member stands for supplier relationships.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_SupplierRelationshipsMember_1" xml:lang="en-US">Supplier relationships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TerminationBenefitsMember_0" xml:lang="en-US">Termination Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_TerminationBenefitsMember_1" xml:lang="en-US">Termination Benefits [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TerminationBenefitsMember_2" xml:lang="en-US">Termination Benefits [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_ThresholdLimitOfEstimateOfLoss_0" xml:lang="en-US">Threshold Limit Of Estimate Of Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_ThresholdLimitOfEstimateOfLoss_1" xml:lang="en-US">Threshold limit of estimate of loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_TotalAmountClaimedUnderIndemnificationAgreement_0" xml:lang="en-US">Represents the total amount claimed under the indemnification agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TotalAmountClaimedUnderIndemnificationAgreement_1" xml:lang="en-US">Total Amount Claimed Under Indemnification Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TotalAmountClaimedUnderIndemnificationAgreement_2" xml:lang="en-US">Amount claimed under the indemnification agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_TotalAmountPayableInViolationOfStopSaleOrders_0" xml:lang="en-US">Represents the amount of total amount payable in violation of stop sale orders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TotalAmountPayableInViolationOfStopSaleOrders_1" xml:lang="en-US">Total Amount Payable In Violation Of Stop Sale Orders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TotalCarryingValue_0" xml:lang="en-US">Total Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_TotalCarryingValue_1" xml:lang="en-US">Total carrying value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_TradeAccountsReceivable_0" xml:lang="en-US">Amount of trade accounts receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TradeAccountsReceivable_1" xml:lang="en-US">Trade Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_TradeAccountsReceivable_2" xml:lang="en-US">Total trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_flgc_TradeAccountsReceivable_3" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TradeAccountsReceivable_4" xml:lang="en-US">Trade accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TradeAndOtherReceivablesAbstract_0" xml:lang="en-US">Trade and Other Receivables [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TradeAndOtherReceivablesAbstract_1" xml:lang="en-US">Trade and Amount Receivable [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TrademarksAndBrandsMember_0" xml:lang="en-US">Trademarks and brands [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_TrademarksAndBrandsMember_1" xml:lang="en-US">Trademarks and Brands [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TrademarksAndBrandsMember_2" xml:lang="en-US">Trademarks and brands [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TradenamesMember_0" xml:lang="en-US">Tradenames [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_flgc_TradeReceivable_0" xml:lang="en-US">Trade Receivable, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_flgc_TradeReceivable_1" xml:lang="en-US">Trade receivable beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TradeReceivable_2" xml:lang="en-US">Trade receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_flgc_TradeReceivableBeginningBalance_0" xml:lang="en-US">Trade receivable beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TradeReceivableBeginningBalance_1" xml:lang="en-US">[Trade receivable beginning balance]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_TruhcHoldingGmbhMember_0" xml:lang="en-US">This member represents about TruHC Holding GmbH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TruhcHoldingGmbhMember_1" xml:lang="en-US">TruHC Holding GmbH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_TruhcHoldingGmbhMember_2" xml:lang="en-US">TruHC Holding GmbH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_TruhcPharmaGmbhMember_0" xml:lang="en-US">Represents information about TruHC Pharma GmbH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TruhcPharmaGmbhMember_1" xml:lang="en-US">TruHC Pharma GmbH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TwoThousandTwentyOneAnnualImpairmentTestMember_0" xml:lang="en-US">Two Thousand Twenty One Annual Impairment Test [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TwoThousandTwentyOneAnnualImpairmentTestMember_1" xml:lang="en-US">2021 Annual Impairment Test [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_0" xml:lang="en-US">Two Thousand Twenty Three Annual Impairment Test [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_1" xml:lang="en-US">2023 Annual Impairment Test [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_0" xml:lang="en-US">December 31, 2023 Other Long-Lived Asset Impairment Test</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_1" xml:lang="en-US">Two Thousand Twenty Three Other Longlived Asset Impairment Test [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_2" xml:lang="en-US">December 31, 2023 Other Long-Lived Asset Impairment Test [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_0" xml:lang="en-US">Two Thousand Twenty Two Annual Goodwill Impairment Test Of Justcbd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_1" xml:lang="en-US">December 31, 2022 Annual Goodwill Impairment Test of JustCBD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_0" xml:lang="en-US">Two Thousand Twenty Two Annual Goodwill Impairment Test Of Vessel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_1" xml:lang="en-US">December 31, 2022 Annual Goodwill Impairment Test of Vessel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TwoThousandTwentyTwoImpairmentTestMember_0" xml:lang="en-US">Two Thousand Twenty Two Impairment Test [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_TwoThousandTwentyTwoImpairmentTestMember_1" xml:lang="en-US">2022 Annual Impairment Test [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_0" xml:lang="en-US">Two Thousand Twenty Two Other Longlived Asset Impairment Tests [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_1" xml:lang="en-US">December 31, 2022 Other Long-Lived Asset Impairment Tests [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_TwoThousandTwentyTwoPlanMember_0" xml:lang="en-US">Two Thousand Twenty Two Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_TwoThousandTwentyTwoPlanMember_1" xml:lang="en-US">2022 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_UnitedKingdomRevenueAgencyMember_0" xml:lang="en-US">United Kingdom Revenue Agency [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_UnitedKingdomRevenueAgencyMember_1" xml:lang="en-US">United Kingdom [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_UnitedStatesRevenueAgencyMember_0" xml:lang="en-US">United States Revenue Agency [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_UnitedStatesRevenueAgencyMember_1" xml:lang="en-US">United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_UnitOfferingMember_0" xml:lang="en-US">Unit Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_UnitOfferingMember_1" xml:lang="en-US">Unit offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_UnrealizedLossesOnSecurities_0" xml:lang="en-US">Unrealized losses on securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_UnrealizedLossesOnSecurities_1" xml:lang="en-US">Unrealized loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_UnusedLossCarryforwards_0" xml:lang="en-US">Unused loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_UnvestedRsusGrantedToExecutiveOfficers_0" xml:lang="en-US">Unvested RSUs granted to executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_USFederalIncomeTaxAuthorityMember_0" xml:lang="en-US">U.S. federal Income Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_USFederalIncomeTaxAuthorityMember_1" xml:lang="en-US">U.S. federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_USStateIncomeTaxAuthorityMember_0" xml:lang="en-US">U S State Income Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_USStateIncomeTaxAuthorityMember_1" xml:lang="en-US">U.S. state [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_VesselAssetGroupMember_0" xml:lang="en-US">This member stands for vessel asset group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_VesselAssetGroupMember_1" xml:lang="en-US">Vessel Asset Group [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_VesselMember_0" xml:lang="en-US">Vessel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_VesselOwnersMember_0" xml:lang="en-US">Vessel Owners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_VesselOwnersMember_1" xml:lang="en-US">Vessel owners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_VesselsMember_0" xml:lang="en-US">Vessels [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_VesselsMember_1" xml:lang="en-US">Vessel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_VestInOneYearMember_0" xml:lang="en-US">This member represents about vest in one year .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_VestInOneYearMember_1" xml:lang="en-US">Vest In One Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_VestInThreeYearsMember_0" xml:lang="en-US">This member represents about vest in three years.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_VestInThreeYearsMember_1" xml:lang="en-US">Vest In Three Years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_WarehousingAndOfficeSpaceMember_0" xml:lang="en-US">Warehousing And Office Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarehousingAndOfficeSpaceMember_1" xml:lang="en-US">Warehousing and office space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantAmendedExercisePrice_0" xml:lang="en-US">Warrant amended exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantExercisePricePriorToAmendment_0" xml:lang="en-US">Warrant exercise price prior to amendment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantIssued_0" xml:lang="en-US">Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantIssued_1" xml:lang="en-US">Warrant issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantOneMember_0" xml:lang="en-US">Warrant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantPurchase_0" xml:lang="en-US">Warrant Purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantPurchase_1" xml:lang="en-US">Purchase warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsAbstract_0" xml:lang="en-US">Warrants [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_WarrantsCadOnePointZeroZeroMember_0" xml:lang="en-US">This member stands for Warrants CAD 1.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsCadOnePointZeroZeroMember_1" xml:lang="en-US">Warrants Cad One Point Zero Zero [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WarrantsCadOnePointZeroZeroMember_2" xml:lang="en-US">Warrants CAD 1.00 exercise price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_WarrantsCadZeroPointThreeZeroMember_0" xml:lang="en-US">This member stands for Warrants CAD 0.30.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsCadZeroPointThreeZeroMember_1" xml:lang="en-US">Warrants Cad Zero Point Three Zero [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WarrantsCadZeroPointThreeZeroMember_2" xml:lang="en-US">Warrants CAD 0.30 exercise price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsDateOfExpiry_0" xml:lang="en-US">Warrants Date of expiry</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantsDateOfExpiry_1" xml:lang="en-US">Date of expiry</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WarrantsDateOfExpiry_2" xml:lang="en-US">Date of expiry</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsDisclosureTextBlock_0" xml:lang="en-US">Warrants Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantsDisclosureTextBlock_1" xml:lang="en-US">WARRANTS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsExercisedAmount_0" xml:lang="en-US">Warrants exercised, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsExercisedShares_0" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_WarrantsExpiredOrCancelledAmount_0" xml:lang="en-US">Shares issued during period warrants expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsExpiredOrCancelledAmount_1" xml:lang="en-US">Warrants Expired Or Cancelled Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantsExpiredOrCancelledAmount_2" xml:lang="en-US">Warrants expired/cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsFiveMember_0" xml:lang="en-US">Warrants Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WarrantsFiveMember_1" xml:lang="en-US">September 21, 2028 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsFourMember_0" xml:lang="en-US">Warrants Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantsFourMember_1" xml:lang="en-US">September 21, 2028 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsIssuedDuringPeriodExercisePrice_0" xml:lang="en-US">Warrants issued during period, exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_WarrantsIssuedToPlacementAgent_0" xml:lang="en-US">Information about warrants issued to placement agent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsIssuedToPlacementAgent_1" xml:lang="en-US">Warrants Issued To Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantsIssuedToPlacementAgent_2" xml:lang="en-US">Warrants issued to placement agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsLineItems_0" xml:lang="en-US">Warrants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsMember_0" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsOneMember_0" xml:lang="en-US">Warrants One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantsOneMember_1" xml:lang="en-US">November 18, 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsRemainingLifeInYears_0" xml:lang="en-US">Warrants Remaining Life In Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WarrantsRemainingLifeInYears_1" xml:lang="en-US">Remaining life in years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsSixMember_0" xml:lang="en-US">Warrants Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WarrantsSixMember_1" xml:lang="en-US">March 21, 2029 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsTable_0" xml:lang="en-US">Warrants [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsThreeMember_0" xml:lang="en-US">Warrants Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WarrantsThreeMember_1" xml:lang="en-US">December 8, 2027 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WarrantsTwoMember_0" xml:lang="en-US">Warrants Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WarrantsTwoMember_1" xml:lang="en-US">November 18, 2027 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_0" xml:lang="en-US">Weighted Average Exercise Price Of Warrants Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_1" xml:lang="en-US">Weighted average exercise price, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WeightedAverageExercisePriceOfWarrantsExercised_0" xml:lang="en-US">Weighted Average Exercise Price Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WeightedAverageExercisePriceOfWarrantsExercised_1" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WeightedAverageExercisePriceOfWarrantsIssued_0" xml:lang="en-US">Weighted Average Exercise Price Of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WeightedAverageExercisePriceOfWarrantsIssued_1" xml:lang="en-US">Weighted average exercise price, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WritedownsReversalsOfInventories_0" xml:lang="en-US">Writedowns reversals of inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_flgc_WritedownsReversalsOfInventories_1" xml:lang="en-US">Write-downs to cost of sales for impairment of inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WriterMember_0" xml:lang="en-US">Writer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_flgc_WriterMember_1" xml:lang="en-US">Writer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_flgc_WrongfullyTransferredShares_0" xml:lang="en-US">Represents the number of wrongfully transferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_flgc_WrongfullyTransferredShares_1" xml:lang="en-US">Wrongfully transferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_1" xml:lang="en-US">Board of Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefExecutiveOfficerMember_0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_1" xml:lang="en-US">Clifford Starke [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_2" xml:lang="en-US">Clifford Starke [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefFinancialOfficerMember_0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_1" xml:lang="en-US">Dany Vaiman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis_0" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain_0" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsAxis_0" xml:lang="en-US">Consolidation Items [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsDomain_0" xml:lang="en-US">Consolidation Items [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis_0" xml:lang="en-US">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis_0" xml:lang="en-US">Currency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember_0" xml:lang="en-US">Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember_1" xml:lang="en-US">Directors and officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember_1" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember_1" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis_0" xml:lang="en-US">Ownership [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain_0" xml:lang="en-US">Ownership [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis_0" xml:lang="en-US">Product and Service [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain_0" xml:lang="en-US">Product and Service [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ReportableGeographicalComponentsMember_0" xml:lang="en-US">Reportable Geographical Components [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0" xml:lang="en-US">Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain_0" xml:lang="en-US">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title of Individual [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_0" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_0" xml:lang="en-US">[Accounts Payable]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_1" xml:lang="en-US">Trade payables and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1" xml:lang="en-US">Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_2" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_1" xml:lang="en-US">Trade and amounts receivable, net of allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_2" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_3" xml:lang="en-US">Amounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_0" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1" xml:lang="en-US">Other accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2" xml:lang="en-US">Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_3" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Less: accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US">Net income and comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0" xml:lang="en-US">Accumulated other comprehensive (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US">Additional common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net income (loss) to cash provided by (Used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net income (loss) to cash provided by (Used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1" xml:lang="en-US">Restricted stock vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1" xml:lang="en-US">Options vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0" xml:lang="en-US">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments to net loss:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_0" xml:lang="en-US">Advertising costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_1" xml:lang="en-US">Advertising costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingExpense_0" xml:lang="en-US">[Advertising Expense]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdvertisingExpense_1" xml:lang="en-US">Advertising costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_2" xml:lang="en-US">Share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_0" xml:lang="en-US">Allowance for expected credit losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_1" xml:lang="en-US">Schedule of allowance for expected credit losses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0" xml:lang="en-US">Allowance for expected credit losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1" xml:lang="en-US">Allowance for expected credit losses, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2" xml:lang="en-US">Allowance for expected credit losses, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4" xml:lang="en-US">Trade and amounts receivable, allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_1" xml:lang="en-US">Write-offs of trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_1" xml:lang="en-US">Intangible assets, Accumulated Amortization, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_2" xml:lang="en-US">Amortization expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Total anti-dilutive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred_0" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred_1" xml:lang="en-US">Total purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_0" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_1" xml:lang="en-US">Contingent purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability_0" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability_1" xml:lang="en-US">Contingent purchase consideration from asset acquisitions and business combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges_0" xml:lang="en-US">Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges_1" xml:lang="en-US">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges_2" xml:lang="en-US">Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges_3" xml:lang="en-US">Asset impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock_0" xml:lang="en-US">Asset Impairment Charges [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock_1" xml:lang="en-US">IMPAIRMENT OF ASSETS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Total Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Assets_2" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_3" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets_4" xml:lang="en-US">Purchased assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">[Assets, Current]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_2" xml:lang="en-US">Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_0" xml:lang="en-US">Asset, Held-for-Sale, Not Part of Disposal Group, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_1" xml:lang="en-US">Current assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_1" xml:lang="en-US">Non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_2" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1" xml:lang="en-US">Total assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_1" xml:lang="en-US">Assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1" xml:lang="en-US">Current assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2" xml:lang="en-US">Total current assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis_1" xml:lang="en-US">Award Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BuildingMember_0" xml:lang="en-US">Building [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BuildingMember_1" xml:lang="en-US">Buildings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_0" xml:lang="en-US">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_0" xml:lang="en-US">Business Acquisition, Description of Acquired Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_1" xml:lang="en-US">Country of Incorporation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1" xml:lang="en-US">Value of common shares in purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1" xml:lang="en-US">Number of common shares in purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_0" xml:lang="en-US">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_0" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_1" xml:lang="en-US">Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1" xml:lang="en-US">Net asset acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2" xml:lang="en-US">Ownership %</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_0" xml:lang="en-US">Business Acquisition, Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_1" xml:lang="en-US">Common shares issued, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_0" xml:lang="en-US">Acquired through business combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_0" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_1" xml:lang="en-US">Description of contingent purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1" xml:lang="en-US">Contingent purchase consideration unpaid balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1" xml:lang="en-US">Current portion of contingent purchase considerations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1" xml:lang="en-US">Contingent purchase considerations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0" xml:lang="en-US">Asset Acquisitions And Business Combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1" xml:lang="en-US">ASSET ACQUISITIONS AND BUSINESS COMBINATIONS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2" xml:lang="en-US">Total net assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3" xml:lang="en-US">Total Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1" xml:lang="en-US">Prepaid assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1" xml:lang="en-US">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_2" xml:lang="en-US">Nontrade Receivables, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3" xml:lang="en-US">Trade Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_0" xml:lang="en-US">Trade Payables And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1" xml:lang="en-US">Trade payables and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_3" xml:lang="en-US">Trade payables and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_0" xml:lang="en-US">Current portion of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_1" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_0" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_1" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0" xml:lang="en-US">Deferred Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2" xml:lang="en-US">Inventory acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0" xml:lang="en-US">Total Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_1" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1" xml:lang="en-US">Other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_2" xml:lang="en-US">Other Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_3" xml:lang="en-US">Other non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1" xml:lang="en-US">Property, Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3" xml:lang="en-US">Property, plant, and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1" xml:lang="en-US">Total net assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2" xml:lang="en-US">Total net assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3" xml:lang="en-US">Total Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_0" xml:lang="en-US">Business Combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_1" xml:lang="en-US">Business combinations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0" xml:lang="en-US">Basis Of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1" xml:lang="en-US">BASIS OF PRESENTATION [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember_0" xml:lang="en-US">Canada Revenue Agency [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember_1" xml:lang="en-US">Canada [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Capital_0" xml:lang="en-US">Working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_0" xml:lang="en-US">Capital Expenditure, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_1" xml:lang="en-US">Purchases of property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeaseObligations_0" xml:lang="en-US">Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeaseObligations_1" xml:lang="en-US">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash_0" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash_1" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Cash_2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash_3" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and restricted cash [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Cash and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Change in cash during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_0" xml:lang="en-US">[Cash Equivalents, at Carrying Value]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems_0" xml:lang="en-US">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Weighted average exercise price, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Weighted average exercise price, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_0" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Number of warrants, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US">Number of warrants, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3" xml:lang="en-US">Warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollateralAxis_0" xml:lang="en-US">Collateral Held [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollateralDomain_0" xml:lang="en-US">Collateral Held [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1" xml:lang="en-US">Commitments and contingencies [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common stock, shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US">Share capital, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_2" xml:lang="en-US">Issued Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Share capital, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Share capital, no par value, unlimited authorized, 135,573 issued and outstanding (65,517 at 2021)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Share capital, no par value, unlimited authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_2" xml:lang="en-US">Common stock value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonUnitIssued_0" xml:lang="en-US">Common Unit, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonUnitIssued_1" xml:lang="en-US">Offering unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Communication_0" xml:lang="en-US">Promotion and communication</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US">Comprehensive loss attributable to Flora Growth Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2" xml:lang="en-US">Net income and comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_1" xml:lang="en-US">Comprehensive loss:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US">Non-controlling interests in subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2" xml:lang="en-US">Comprehensive loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_1" xml:lang="en-US">Basis of consolidation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember_0" xml:lang="en-US">Construction in progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_0" xml:lang="en-US">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_0" xml:lang="en-US">[Related Party Costs]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_1" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_2" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis_0" xml:lang="en-US">Credit Facility [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain_0" xml:lang="en-US">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditRiskMember_0" xml:lang="en-US">Credit Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditRiskMember_1" xml:lang="en-US">Credit risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CumulativeEarningsDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CumulativeEarningsDeficit_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0" xml:lang="en-US">Total current tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerRelationshipsMember_0" xml:lang="en-US">Customer Relationships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CustomerRelationshipsMember_1" xml:lang="en-US">Customer and supplier relationships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CustomerRelationshipsMember_2" xml:lang="en-US">Customer relationships [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_0" xml:lang="en-US">Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_1" xml:lang="en-US">DEBT [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis_0" xml:lang="en-US">Debt Instrument Axis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_0" xml:lang="en-US">Long-Term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_1" xml:lang="en-US">Interest-bearing loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0" xml:lang="en-US">Current stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1" xml:lang="en-US">Loan agreement, face amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue_0" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue_1" xml:lang="en-US">Fair value of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_0" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_1" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_2" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US">Loan agreement, interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_0" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_1" xml:lang="en-US">Principal and interest payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_2" xml:lang="en-US">Leases, monthly amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable_0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1" xml:lang="en-US">Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0" xml:lang="en-US">Total deferred tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_1" xml:lang="en-US">Total deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0" xml:lang="en-US">Deferred Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1" xml:lang="en-US">Deferred tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis_0" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain_0" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xml:lang="en-US">Sec 174 - R&amp;D expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xml:lang="en-US">Net deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_2" xml:lang="en-US">Deferred Tax Assets, Net, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_3" xml:lang="en-US">Net deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Total Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Total net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_0" xml:lang="en-US">Deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xml:lang="en-US">Non-capital loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">[Deferred Tax Assets, Other]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_0" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1" xml:lang="en-US">Fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">[Deferred Tax Assets, Valuation Allowance]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_1" xml:lang="en-US">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1" xml:lang="en-US">Lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization_0" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization_1" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_0" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_1" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_0" xml:lang="en-US">[Depreciation, Depletion and Amortization]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_1" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_0" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US">SHARE BASED COMPENSATION [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xml:lang="en-US">Share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_0" xml:lang="en-US">Loss on disposal of discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_2" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_3" xml:lang="en-US">Loss on disposal of discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1" xml:lang="en-US">Net loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_2" xml:lang="en-US">Net loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_0" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1" xml:lang="en-US">Basic loss per share from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_2" xml:lang="en-US">Basic loss per share from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_0" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1" xml:lang="en-US">Diluted loss per share from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_2" xml:lang="en-US">Diluted loss per share from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_0" xml:lang="en-US">Discontinued Operations, Held-for-Sale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_0" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_1" xml:lang="en-US">Discontinued operations and assets and liabilities held for sale [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1" xml:lang="en-US">Income tax expense (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_0" xml:lang="en-US">Disposal Group Classification [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_0" xml:lang="en-US">Disposal Group Classification [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_1" xml:lang="en-US">Trade and amounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1" xml:lang="en-US">Noncurrent assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2" xml:lang="en-US">Total noncurrent assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_0" xml:lang="en-US">Cash included in assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1" xml:lang="en-US">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_1" xml:lang="en-US">Gross profit from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_1" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_1" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1" xml:lang="en-US">Operating loss from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1" xml:lang="en-US">Other accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1" xml:lang="en-US">Other (income) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_1" xml:lang="en-US">Other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1" xml:lang="en-US">Non-current operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_1" xml:lang="en-US">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1" xml:lang="en-US">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_0" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1" xml:lang="en-US">ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0" xml:lang="en-US">Disposal Group Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per share attributable to Flora Growth Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted loss per share attributable to Flora Growth Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">Loss per share [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_1" xml:lang="en-US">LOSS PER SHARE [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1" xml:lang="en-US">Effective income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Statutory Canadian rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1" xml:lang="en-US">Earnings in jurisdictions taxed at different rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_0" xml:lang="en-US">Impairments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_1" xml:lang="en-US">Prior year adjustments, change in tax rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_0" xml:lang="en-US">Stock based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0" xml:lang="en-US">Earnings in jurisdictions taxed at different rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_0" xml:lang="en-US">Loss on investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1" xml:lang="en-US">Other permanent items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_0" xml:lang="en-US">Legal settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" xml:lang="en-US">Effect of exchange rate on changes on cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1" xml:lang="en-US">Effect of exchange rate on changes on cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1" xml:lang="en-US">Share based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US">Period for recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1" xml:lang="en-US">Unrecognized compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Remaining cost for nonvested awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1" xml:lang="en-US">Ownership %</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_1" xml:lang="en-US">Gain on warrant modifications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level Axis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0" xml:lang="en-US">Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_0" xml:lang="en-US">Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_1" xml:lang="en-US">Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue_0" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Planned Sale, Investments Not Identified, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue_1" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0" xml:lang="en-US">Unrealized (gain) loss from changes in fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" xml:lang="en-US">Changes in fair value of investments and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2" xml:lang="en-US">Unrealized (gain) loss from changes in fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetAssetLiability_0" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability_1" xml:lang="en-US">Fair Value, Net Asset (Liability), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability_2" xml:lang="en-US">Net carrying value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0" xml:lang="en-US">Financial Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_1" xml:lang="en-US">Financial assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_0" xml:lang="en-US">Loss on changes in fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1" xml:lang="en-US">Loss on changes in fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialAssetNotPastDueMember_0" xml:lang="en-US">Financial Asset, Not Past Due [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialAssetNotPastDueMember_1" xml:lang="en-US">Current [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis_0" xml:lang="en-US">Financial Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_0" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_1" xml:lang="en-US">FINANCIAL INSTRUMENTS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2" xml:lang="en-US">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_0" xml:lang="en-US">Financing Receivable, Past Due [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivables1To29DaysPastDueMember_0" xml:lang="en-US">Financial Asset, 1 to 29 Days Past Due [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancingReceivables1To29DaysPastDueMember_1" xml:lang="en-US">1-30 Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivables30To59DaysPastDueMember_0" xml:lang="en-US">Financial Asset, 30 to 59 Days Past Due [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancingReceivables30To59DaysPastDueMember_1" xml:lang="en-US">31-60 Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivables60To89DaysPastDueMember_0" xml:lang="en-US">Financial Asset, 60 to 89 Days Past Due [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancingReceivables60To89DaysPastDueMember_1" xml:lang="en-US">61-90 Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_0" xml:lang="en-US">Financial Asset, Equal to or Greater than 90 Days Past Due [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_1" xml:lang="en-US">91-180 Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_0" xml:lang="en-US">Financial Asset, Aging [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_0" xml:lang="en-US">Financial Asset, Aging [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0" xml:lang="en-US">Intangible assets, Accumulated Amortization, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1" xml:lang="en-US">Intangible assets, Accumulated Amortization, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2" xml:lang="en-US">[Finite-Lived Intangible Assets, Accumulated Amortization]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_0" xml:lang="en-US">Intangible assets, Cost, Acquired through business combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_1" xml:lang="en-US">Intangible assets, Cost, Acquired through business combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_1" xml:lang="en-US">Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_1" xml:lang="en-US">2028</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_1" xml:lang="en-US">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_1" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_0" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1" xml:lang="en-US">Schedule of estimation of amortization expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1" xml:lang="en-US">2028</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1" xml:lang="en-US">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_0" xml:lang="en-US">Intangible assets, Foreign Currency translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_1" xml:lang="en-US">[Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0" xml:lang="en-US">Intangible assets, Cost, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_1" xml:lang="en-US">Intangible assets, Cost, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_2" xml:lang="en-US">[Finite-Lived Intangible Assets, Gross]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3" xml:lang="en-US">Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1" xml:lang="en-US">Weighted average amortization period remaining for intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1" xml:lang="en-US">Weighted average amortization period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_0" xml:lang="en-US">Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_1" xml:lang="en-US">Weighted average period before next renewal or extension</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_0" xml:lang="en-US">Foreign exchange (income) loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_1" xml:lang="en-US">Foreign exchange (gain) loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Foreign Currency Translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US">Foreign currency translation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_0" xml:lang="en-US">Forward Contract Indexed to Equity, Settlement, Share, Fair Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_1" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FranchiseMember_0" xml:lang="en-US">Franchise [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FranchiseMember_1" xml:lang="en-US">FGH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_Goodwill_0" xml:lang="en-US">Carrying value of goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Goodwill_1" xml:lang="en-US">Net book value as at June 30, 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Goodwill_2" xml:lang="en-US">Net book value as at December 31, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill_3" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill_4" xml:lang="en-US">Net book value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Goodwill_5" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_0" xml:lang="en-US">Goodwill, Acquired During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_1" xml:lang="en-US">Acquired through business combinations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_0" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1" xml:lang="en-US">Foreign currency translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillGross_0" xml:lang="en-US">Gross goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0" xml:lang="en-US">Impairment recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1" xml:lang="en-US">[Goodwill, Impaired, Accumulated Impairment Loss]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_0" xml:lang="en-US">Goodwill impairment loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_1" xml:lang="en-US">Goodwill impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillLineItems_0" xml:lang="en-US">Goodwill [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillMember_0" xml:lang="en-US">Goodwill [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GoodwillMember_1" xml:lang="en-US">Goodwill [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit_0" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit_1" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1" xml:lang="en-US">Other asset impairments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3" xml:lang="en-US">Other asset impairments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1" xml:lang="en-US">Intangible assets, Cost, Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_0" xml:lang="en-US">Impairment of goodwill and indefinite-lived intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1" xml:lang="en-US">Impairment of goodwill and indefinite-lived intangible assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0" xml:lang="en-US">Impairment of long lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xml:lang="en-US">Impairment of long-lived assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_0" xml:lang="en-US">Net Loss from Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_1" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_2" xml:lang="en-US">Flora Growth Corp. continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_3" xml:lang="en-US">Net loss from continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_4" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Net loss before income taxes and discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Net Loss Before Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1" xml:lang="en-US">Basic loss per share from continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1" xml:lang="en-US">Diluted loss per share from continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1" xml:lang="en-US">Loss from discontinued operations, net of taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2" xml:lang="en-US">Loss from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3" xml:lang="en-US">Loss from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1" xml:lang="en-US">Flora Growth Corp. discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0" xml:lang="en-US">Disposal Group Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis_0" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_0" xml:lang="en-US">Income Tax Contingency [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_0" xml:lang="en-US">Income Tax Contingency [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments_0" xml:lang="en-US">Income Tax Credits and Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments_1" xml:lang="en-US">Income Tax Expense (Benefit), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments_2" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US">INCOME TAXES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Total income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_1" xml:lang="en-US">Income taxes [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0" xml:lang="en-US">Trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1" xml:lang="en-US">Trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Trade payables and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Trade payables and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1" xml:lang="en-US">Trade and amounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Amounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_1" xml:lang="en-US">[Increase (Decrease) in Inventories]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_2" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0" xml:lang="en-US">Net change in non-cash working capital:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InsuranceRecoveries_0" xml:lang="en-US">Recoveries collected</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_1" xml:lang="en-US">Intangible assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0" xml:lang="en-US">Carrying value of identified intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3" xml:lang="en-US">Carrying amount of intangible asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_0" xml:lang="en-US">Intangible assets, Net book value, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_1" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_2" xml:lang="en-US">Goodwill and identified intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndDebtExpense_0" xml:lang="en-US">Interest and Debt Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestAndDebtExpense_1" xml:lang="en-US">Bad debt expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestAndDebtExpense_2" xml:lang="en-US">Interest and Debt Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestAndDebtExpense_3" xml:lang="en-US">Bad debt expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_0" xml:lang="en-US">Interest expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_1" xml:lang="en-US">Interest expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_2" xml:lang="en-US">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_3" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_4" xml:lang="en-US">Interest Income (Expense), Net, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_5" xml:lang="en-US">Interest expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_0" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_2" xml:lang="en-US">Interest Income (Expense), Net, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_3" xml:lang="en-US">Interest expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeOperating_0" xml:lang="en-US">Interest paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOperating_1" xml:lang="en-US">Interest Income, Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestIncomeOperating_2" xml:lang="en-US">Interest Income, Operating, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestIncomeOperating_3" xml:lang="en-US">Interest paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeOther_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_InterestIncomeOther_1" xml:lang="en-US">Interest expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther_2" xml:lang="en-US">Interest Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOther_3" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_0" xml:lang="en-US">Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_1" xml:lang="en-US">Accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_0" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1" xml:lang="en-US">INVENTORY [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoods_0" xml:lang="en-US">Finished Goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoods_1" xml:lang="en-US">Finished goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet_0" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet_1" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet_2" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryNet_3" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_0" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_1" xml:lang="en-US">Inventories [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies_0" xml:lang="en-US">Raw Materials And Supplies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies_1" xml:lang="en-US">Raw materials and supplies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentInAffiliateActivityLineItems_0" xml:lang="en-US">Investments in and Advances to Affiliates, Activity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue_0" xml:lang="en-US">Investments, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue_1" xml:lang="en-US">Investments, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue_2" xml:lang="en-US">Investment Owned, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_1" xml:lang="en-US">Investments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsAbstract_0" xml:lang="en-US">Investments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsAbstract_1" xml:lang="en-US">INVESTMENTS [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_0" xml:lang="en-US">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_1" xml:lang="en-US">Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_2" xml:lang="en-US">Investments, Fair Value Disclosure, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_0" xml:lang="en-US">Investments in and Advances to Affiliates [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTextBlock_0" xml:lang="en-US">Investment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTextBlock_1" xml:lang="en-US">INVESTMENTS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentTextBlock_2" xml:lang="en-US">Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis_0" xml:lang="en-US">Investment Type Axis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_0" xml:lang="en-US">Investments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LandMember_0" xml:lang="en-US">Land [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost_0" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost_1" xml:lang="en-US">Total lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_1" xml:lang="en-US">Schedule of leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract_0" xml:lang="en-US">Leases [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_0" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_1" xml:lang="en-US">LEASES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_0" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_0" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Maturities of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of maturities of operating lease liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total future lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1" xml:lang="en-US">Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1" xml:lang="en-US">2028</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1" xml:lang="en-US">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less: imputed interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1" xml:lang="en-US">Lessee, operating lease, option to extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Total Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">[Liabilities]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_2" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract_0" xml:lang="en-US">LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">[Liabilities and Equity]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">[Liabilities, Current]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_2" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US">Non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1" xml:lang="en-US">Total liabilities held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_1" xml:lang="en-US">Liabilities held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1" xml:lang="en-US">Current liabilities held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2" xml:lang="en-US">Total current liabilities held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1" xml:lang="en-US">Noncurrent liabilities held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_2" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember_0" xml:lang="en-US">License [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LicenseMember_1" xml:lang="en-US">Licenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit_0" xml:lang="en-US">Long-Term Line of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit_1" xml:lang="en-US">Credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0" xml:lang="en-US">Outstanding amount of Credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1" xml:lang="en-US">Outstanding amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDescription_0" xml:lang="en-US">Line of Credit Facility, Interest Rate Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDescription_1" xml:lang="en-US">Line of credit facility, interest rate description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_0" xml:lang="en-US">Credit facility rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1" xml:lang="en-US">Credit facility interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems_0" xml:lang="en-US">Line of Credit Facility [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xml:lang="en-US">Available credit facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment_0" xml:lang="en-US">Credit Facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_0" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_1" xml:lang="en-US">Principal and interest payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1" xml:lang="en-US">Available credit facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityTable_0" xml:lang="en-US">Line of Credit Facility [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_0" xml:lang="en-US">Trade And Amounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1" xml:lang="en-US">TRADE AND AMOUNTS RECEIVABLE [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansPayable_0" xml:lang="en-US">Loans Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LoansPayable_1" xml:lang="en-US">Loans payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansReceivableFairValueDisclosure_0" xml:lang="en-US">Loans Receivable, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LoansReceivableFairValueDisclosure_1" xml:lang="en-US">Loans receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0" xml:lang="en-US">Disaggregation of long-lived assets by geographic area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_1" xml:lang="en-US">Schedule of disaggregation of long-lived assets by geographic area [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebt_0" xml:lang="en-US">Long term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_LongTermDebt_1" xml:lang="en-US">Outstanding debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt_2" xml:lang="en-US">Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebt_3" xml:lang="en-US">Long-Term Debt, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebt_4" xml:lang="en-US">Long term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent_0" xml:lang="en-US">Current portion of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_0" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_1" xml:lang="en-US">Non-current portion of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermInvestments_0" xml:lang="en-US">Long-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermInvestments_1" xml:lang="en-US">Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermInvestments_2" xml:lang="en-US">Long-Term Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_0" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_1" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2" xml:lang="en-US">Loss Contingency Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LossContingencyAccrualPayments_0" xml:lang="en-US">Payments/settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualPayments_1" xml:lang="en-US">Loss Contingency Accrual, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualProvision_0" xml:lang="en-US">Loss Contingency Accrual, Provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualProvision_1" xml:lang="en-US">Additional provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualProvision_2" xml:lang="en-US">Loss contingency provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_0" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_1" xml:lang="en-US">Damages awarded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_0" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_1" xml:lang="en-US">Value of damages sought</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_0" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_1" xml:lang="en-US">Estimate of possible loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyLossInPeriod_0" xml:lang="en-US">Loss Contingency, Loss in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LossContingencyLossInPeriod_1" xml:lang="en-US">Loss recorded within contingencies and within indemnification receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_0" xml:lang="en-US">Loss Contingency, Trial or Alternative Dispute Resolution</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_1" xml:lang="en-US">Description of settlement of disputes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_1" xml:lang="en-US">Machinery and office equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_2" xml:lang="en-US">Machinery and office equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ManagementFeeExpense_0" xml:lang="en-US">Consulting and management fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_0" xml:lang="en-US">Servicing Assets and Servicing Liabilities Risk [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest_0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest_1" xml:lang="en-US">Non-controlling interest in subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1" xml:lang="en-US">Percentage of non-controlling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations_0" xml:lang="en-US">Nature Of Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations_1" xml:lang="en-US">NATURE OF OPERATIONS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss attributable to Flora Growth Corp</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0" xml:lang="en-US">Net income (loss) attributable to noncontrolling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2" xml:lang="en-US">Net income (loss) attributable to noncontrolling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">Adoption Of Accounting Standards And Amendments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Adoption of accounting standards and amendments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_0" xml:lang="en-US">Noncompete Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_1" xml:lang="en-US">Non-Compete Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_2" xml:lang="en-US">Non-compete agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember_0" xml:lang="en-US">Noncontrolling Interest in subsidiaries (deficiency)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember_1" xml:lang="en-US">Non-controlling interests in subsidiaries (deficiency)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NontradeReceivables_0" xml:lang="en-US">Nontrade Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NontradeReceivables_1" xml:lang="en-US">Nontrade Receivables, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NontradeReceivables_2" xml:lang="en-US">Indemnification receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments_0" xml:lang="en-US">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments_1" xml:lang="en-US">Number of operating segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation_0" xml:lang="en-US">Directors' And Officers' Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OfficersCompensation_1" xml:lang="en-US">Directors' and officers' compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">[Operating Expenses]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">[Operating Income (Loss)]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense_0" xml:lang="en-US">Operating lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense_1" xml:lang="en-US">Operating lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_0" xml:lang="en-US">Operating Lease, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_1" xml:lang="en-US">Operating lease expense net of cash payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Operating Lease, Liability, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_3" xml:lang="en-US">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_4" xml:lang="en-US">Operating Lease, Liability, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_5" xml:lang="en-US">Total lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Less: current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_2" xml:lang="en-US">Current portion of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Non-current operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2" xml:lang="en-US">Total non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3" xml:lang="en-US">Total non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments_0" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments_1" xml:lang="en-US">Operating cash flows from operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1" xml:lang="en-US">Weighted-average discount rate for operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1" xml:lang="en-US">Weighted-average remaining lease term in years for operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards_1" xml:lang="en-US">Non-capital loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2" xml:lang="en-US">Unused loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Trade payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Trade payables and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1" xml:lang="en-US">Other accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2" xml:lang="en-US">Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges_0" xml:lang="en-US">Other Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges_1" xml:lang="en-US">Other asset impairments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges_2" xml:lang="en-US">Asset Impairment Charges, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_1" xml:lang="en-US">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_2" xml:lang="en-US">Other long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0" xml:lang="en-US">Foreign currency translation, net of income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2" xml:lang="en-US">Foreign currency translation, net of income taxes of $nil ($nil in 2022)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1" xml:lang="en-US">Foreign currency translation, tax amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3" xml:lang="en-US">Foreign currency translation, tax amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating_0" xml:lang="en-US">Other Cost and Expense, Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating_1" xml:lang="en-US">Other expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_0" xml:lang="en-US">Other long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_1" xml:lang="en-US">Other Long-lived Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermInvestments_0" xml:lang="en-US">Other Long-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLongTermInvestments_1" xml:lang="en-US">Net carrying value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherReceivables_0" xml:lang="en-US">Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherReceivables_1" xml:lang="en-US">Other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_0" xml:lang="en-US">Current period additions for expected credit losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_1" xml:lang="en-US">[Other than Temporary Impairment, Credit Losses Recognized in Earnings, Additions, Additional Credit Losses]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PatentsMember_0" xml:lang="en-US">Patents and developed technology [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PatentsMember_1" xml:lang="en-US">Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_0" xml:lang="en-US">Payments/Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_1" xml:lang="en-US">Payments for Legal Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_2" xml:lang="en-US">Settlement payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_3" xml:lang="en-US">Payments/Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0" xml:lang="en-US">Net cash on disposal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0" xml:lang="en-US">Common shares repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants_0" xml:lang="en-US">Payments for Repurchase of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants_1" xml:lang="en-US">Exercise of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense_0" xml:lang="en-US">Payments for Underwriting Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense_1" xml:lang="en-US">Underwriting expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Equity issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Payment of stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_0" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_1" xml:lang="en-US">Cash consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0" xml:lang="en-US">Business and asset acquisitions, net of cash acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1" xml:lang="en-US">[Payments to Acquire Businesses, Net of Cash Acquired]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_0" xml:lang="en-US">Acquisition of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_1" xml:lang="en-US">Payments to Acquire Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchases of property, plant and equipment and intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">September units issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_0" xml:lang="en-US">Loan borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_1" xml:lang="en-US">Proceeds from issuance of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1" xml:lang="en-US">Warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_0" xml:lang="en-US">Proceeds from Sale, Property, Held-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1" xml:lang="en-US">Proceeds from property held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_2" xml:lang="en-US">Purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees_0" xml:lang="en-US">Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfessionalFees_1" xml:lang="en-US">Professional fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProfitLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss_1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss_2" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss_3" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">Property, Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">[Property, Plant and Equipment, Gross]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_1" xml:lang="en-US">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2" xml:lang="en-US">Property, Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3" xml:lang="en-US">Property, plant and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4" xml:lang="en-US">Property, plant and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xml:lang="en-US">Property, plant and equipment [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US">Schedule of property, plant and equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0" xml:lang="en-US">Estimated useful lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_1" xml:lang="en-US">Bad debt expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_2" xml:lang="en-US">Bad debt expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_0" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_0" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_0" xml:lang="en-US">Receivable from Shareholders or Affiliates for Issuance of Capital Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_1" xml:lang="en-US">Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_0" xml:lang="en-US">Receivable with Imputed Interest, Effective Yield (Interest Rate)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_1" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_0" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_0" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_0" xml:lang="en-US">Purchases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_1" xml:lang="en-US">Related Party Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Party Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">RELATED PARTY DISCLOSURES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt_0" xml:lang="en-US">Loan repayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebt_1" xml:lang="en-US">[Repayments of Debt]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReportingUnitAxis_0" xml:lang="en-US">Reporting Unit [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReportingUnitDomain_0" xml:lang="en-US">Reporting Unit [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research expenses [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_0" xml:lang="en-US">Restricted Cash and Investments, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_2" xml:lang="en-US">Restricted Cash and Investments, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockExpense_0" xml:lang="en-US">Restricted Stock or Unit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockExpense_1" xml:lang="en-US">Restricted stock awards expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_1" xml:lang="en-US">Restricted stock awards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1" xml:lang="en-US">Revenue recognition [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues_1" xml:lang="en-US">Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Revenues_2" xml:lang="en-US">Revenues, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues_3" xml:lang="en-US">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1" xml:lang="en-US">ROU assets obtained in exchange for new operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_0" xml:lang="en-US">Risks Inherent in Servicing Assets and Servicing Liabilities, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1" xml:lang="en-US">Schedule of trade and amounts receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2" xml:lang="en-US">Schedule of trade and amounts receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of anti-dilutive shares [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0" xml:lang="en-US">Schedule Of Income Tax Provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" xml:lang="en-US">Schedule of components of the income tax provision [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Deferred Income Tax Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of deferred income tax assets and liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of corporate income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of corporate income tax rate [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_0" xml:lang="en-US">Financing Receivable, Past Due [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" xml:lang="en-US">Schedule of intangible assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_0" xml:lang="en-US">Schedule of Goodwill [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_0" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_1" xml:lang="en-US">Schedule of goodwill [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0" xml:lang="en-US">Schedule Of Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xml:lang="en-US">Schedule of inventory [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems_0" xml:lang="en-US">Schedule of Investments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable_0" xml:lang="en-US">Schedule of Investments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_0" xml:lang="en-US">Schedule of Loss Contingencies by Contingency [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_1" xml:lang="en-US">Schedule of provisions and contingent liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0" xml:lang="en-US">Schedule Of Major Class Of Assets Acquired And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1" xml:lang="en-US">Schedule of major class of assets acquired and liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of related party transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0" xml:lang="en-US">Disaggregation of net sales and net loss before income taxes by geographic area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1" xml:lang="en-US">Schedule of disaggregation of net sales by geographic area [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_0" xml:lang="en-US">Schedule of operation segment information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1" xml:lang="en-US">Schedule of operation segment information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_0" xml:lang="en-US">Schedule Of Share Options Outstanding And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1" xml:lang="en-US">Schedule of stock options outstanding and exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of weighted average inputs and assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_0" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xml:lang="en-US">Schedule of warrants outstanding by date of expiry [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1" xml:lang="en-US">Schedule of stock options roll forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuritiesFinancingTransactionAxis_0" xml:lang="en-US">Securities Financing Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuritiesFinancingTransactionTypeDomain_0" xml:lang="en-US">Securities Financing Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_0" xml:lang="en-US">Discontinued Operations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_1" xml:lang="en-US">Discontinued operations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain_0" xml:lang="en-US">Segments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_0" xml:lang="en-US">Operating Activities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract_0" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_1" xml:lang="en-US">SEGMENTED INFORMATION [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_0" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeveranceCosts1_1" xml:lang="en-US">Termination benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_2" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_3" xml:lang="en-US">Share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract_0" xml:lang="en-US">SHARE BASED COMPENSATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US">Vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_1" xml:lang="en-US">Award vesting rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1" xml:lang="en-US">Terms of share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0" xml:lang="en-US">Number of restricted stock awards, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xml:lang="en-US">Number of restricted stock awards, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average grant date fair value, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US">Number of restricted stock awards, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted average grant date fair value, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xml:lang="en-US">Number of restricted stock awards, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US">Number of restricted stock awards, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average grant date fair value, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted average grant date fair value, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0" xml:lang="en-US">Vested (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2" xml:lang="en-US">Number of restricted stock awards, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1" xml:lang="en-US">Fair value of warrants vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average grant date fair value, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Weighted Average Exercise Price, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xml:lang="en-US">Award expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US">Expected dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" xml:lang="en-US">Expected life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_0" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_0" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_0" xml:lang="en-US">Cancelled/Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2" xml:lang="en-US">Non-option equity instruments, forfeitures and expirations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_1" xml:lang="en-US">Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2" xml:lang="en-US">Non-option equity instruments granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xml:lang="en-US">Number of shares authorized under compensation plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Aggregate intrinsic value, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Number of options exercisable, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US">Number of options exercisable, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3" xml:lang="en-US">Options exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average exercise price, exercisable, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price, exercisable, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3" xml:lang="en-US">Stock options exercisable price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4" xml:lang="en-US">Weighted average exercise price, Exercisable balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Weighted average remaining life (years) Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1" xml:lang="en-US">Options, exercises in period, intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Options expired in period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Number of options, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US">Number of options, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1" xml:lang="en-US">Options unvested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average grant date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xml:lang="en-US">Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Number of options, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Number of options, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average exercise price, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Weighted average remaining life, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xml:lang="en-US">Remaining life in years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xml:lang="en-US">Options, vested in period, fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_1" xml:lang="en-US">Weighted average price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">All Award Types</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xml:lang="en-US">All Award Types</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price, Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Stock options granted, exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_0" xml:lang="en-US">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_1" xml:lang="en-US">Share based compensation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_0" xml:lang="en-US">[Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_1" xml:lang="en-US">Common share volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice_1" xml:lang="en-US">Current stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice_2" xml:lang="en-US">Closing share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued_0" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued_1" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued_2" xml:lang="en-US">[Shares, Issued]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued_3" xml:lang="en-US">Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Offering price per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_2" xml:lang="en-US">Purchase price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_3" xml:lang="en-US">Price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost_0" xml:lang="en-US">Short-term lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost_1" xml:lang="en-US">Short-term lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_0" xml:lang="en-US">Segments [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Unaudited Condensed Interim Consolidated Statement of Cash Flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Unaudited Condensed Interim Consolidated Statements of Financial Position</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_0" xml:lang="en-US">Operating Activities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_1" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_2" xml:lang="en-US">Options expired/cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_0" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, before Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_1" xml:lang="en-US">Options issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Total Flora Growth Corp. shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xml:lang="en-US">Balance, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US">Balance, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xml:lang="en-US">[Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US">SHARE CAPITAL [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock_0" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock_1" xml:lang="en-US">Share capital [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit_0" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit_1" xml:lang="en-US">Reverse stock split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1_0" xml:lang="en-US">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssued1_1" xml:lang="en-US">Gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0" xml:lang="en-US">Stock issued during period, acquisitions (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1" xml:lang="en-US">Common shares issued for business combinations shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2" xml:lang="en-US">Common shares issued for business combinations, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3" xml:lang="en-US">Common share issued for acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_1" xml:lang="en-US">Stock issued during period, other (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_0" xml:lang="en-US">Restricted stock cancelled, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_1" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2" xml:lang="en-US">Restricted stock cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_3" xml:lang="en-US">Number of restricted shares forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0" xml:lang="en-US">Restricted Stock awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1" xml:lang="en-US">Restricted units granted, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2" xml:lang="en-US">Restricted Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1" xml:lang="en-US">Common shares in purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2" xml:lang="en-US">Share-based compensation, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Number of options, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Options exercised shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3" xml:lang="en-US">Number of stock option exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1" xml:lang="en-US">Common shares issued for business combinations, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2" xml:lang="en-US">Stock issued during period, acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Stock issued value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_1" xml:lang="en-US">Stock issued during period, other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_0" xml:lang="en-US">Restricted stock cancelled, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_1" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xml:lang="en-US">Restricted units granted, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US">Options exercised, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionPlanExpense_0" xml:lang="en-US">Expense Related To Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockOptionPlanExpense_1" xml:lang="en-US">Expense (benefit) related to options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_0" xml:lang="en-US">Share repurchase, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_1" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares_2" xml:lang="en-US">Stock repurchased (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_0" xml:lang="en-US">Share repurchase, amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_1" xml:lang="en-US">Stock Repurchased During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue_2" xml:lang="en-US">Stock repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SubleaseIncome_0" xml:lang="en-US">Sublease Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubleaseIncome_1" xml:lang="en-US">Sublease Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">SUBSEQUENT EVENTS [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges_0" xml:lang="en-US">Tangible Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges_1" xml:lang="en-US">Impairment of property plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_0" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance_0" xml:lang="en-US">Write-offs charges against allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TrademarksMember_0" xml:lang="en-US">Trademarks [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xml:lang="en-US">Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TravelAndEntertainmentExpense_0" xml:lang="en-US">Travel expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnderwritingCommitments_0" xml:lang="en-US">Underwriting Commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnderwritingCommitments_1" xml:lang="en-US">Underwriting commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnusualRisksAndUncertaintiesTextBlock_0" xml:lang="en-US">Critical Judgments And Estimation Uncertainties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnusualRisksAndUncertaintiesTextBlock_1" xml:lang="en-US">CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates_1" xml:lang="en-US">Use of estimates [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValueAddedTaxReceivable_0" xml:lang="en-US">Value Added Tax Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValueAddedTaxReceivable_1" xml:lang="en-US">HST/VAT receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VehiclesMember_0" xml:lang="en-US">Vehicle [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VehiclesMember_1" xml:lang="en-US">Vehicles [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain_0" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of common shares outstanding - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of common shares outstanding - basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA_1" xlink:to="lab_country_CA_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA_2" xlink:to="lab_country_CA_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CO_3" xlink:to="lab_country_CO_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CO_4" xlink:to="lab_country_CO_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_5" xlink:to="lab_country_DE_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_6" xlink:to="lab_country_DE_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB_7" xlink:to="lab_country_GB_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB_8" xlink:to="lab_country_GB_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_9" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_10" xlink:to="lab_country_US_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_11" xlink:to="lab_currency_AllCurrenciesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_12" xlink:to="lab_currency_CAD_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_13" xlink:to="lab_currency_CAD_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_14" xlink:to="lab_currency_CHF_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_15" xlink:to="lab_currency_CHF_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_COP_16" xlink:to="lab_currency_COP_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_COP_17" xlink:to="lab_currency_COP_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_18" xlink:to="lab_currency_EUR_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_19" xlink:to="lab_currency_EUR_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_20" xlink:to="lab_currency_GBP_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_21" xlink:to="lab_currency_GBP_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain_22" xlink:to="lab_dei_AddressTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_23" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_24" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_25" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_26" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_27" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember_28" xlink:to="lab_dei_BusinessContactMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_29" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName_30" xlink:to="lab_dei_ContactPersonnelName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_31" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_32" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_33" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag_34" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_35" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_36" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_37" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_38" xlink:to="lab_dei_DocumentQuarterlyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_39" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_40" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_41" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_42" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_43" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_44" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems_45" xlink:to="lab_dei_EntityAddressesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable_46" xlink:to="lab_dei_EntityAddressesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_47" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_48" xlink:to="lab_dei_EntityAddressStateOrProvince_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_49" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_50" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_51" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_52" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_53" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_54" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_55" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_56" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_57" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_58" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_59" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_60" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_61" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_62" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_63" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_64" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_65" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_66" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_67" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_68" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_69" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_70" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_71" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ACAMullerMember_72" xlink:to="lab_flgc_ACAMullerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ACAMullerMember_73" xlink:to="lab_flgc_ACAMullerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ACAMullerMember_74" xlink:to="lab_flgc_ACAMullerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_75" xlink:to="lab_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_76" xlink:to="lab_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AcquisitionOfNoncontrollingInterestAmount_77" xlink:to="lab_flgc_AcquisitionOfNoncontrollingInterestAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AcquisitionOfNoncontrollingInterestMember_78" xlink:to="lab_flgc_AcquisitionOfNoncontrollingInterestMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AcquisitionOfNoncontrollingInterestMember_79" xlink:to="lab_flgc_AcquisitionOfNoncontrollingInterestMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AcquisitionOfNoncontrollingInterestShares_80" xlink:to="lab_flgc_AcquisitionOfNoncontrollingInterestShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AdditionalLegalDisputesMember_81" xlink:to="lab_flgc_AdditionalLegalDisputesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AdditionalPaidAmount_82" xlink:to="lab_flgc_AdditionalPaidAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AdditonalyCancelledSharesValue_83" xlink:to="lab_flgc_AdditonalyCancelledSharesValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AdditonalyCancelledSharesValue_84" xlink:to="lab_flgc_AdditonalyCancelledSharesValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AegisCapitalCorpMember_85" xlink:to="lab_flgc_AegisCapitalCorpMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AegisCapitalCorpMember_86" xlink:to="lab_flgc_AegisCapitalCorpMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AgreementAxis_87" xlink:to="lab_flgc_AgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AgreementDomain_88" xlink:to="lab_flgc_AgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AmountPayableOfProfitsForAdditionalAmount_89" xlink:to="lab_flgc_AmountPayableOfProfitsForAdditionalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AmountPayableOfProfitsForAdditionalAmount_90" xlink:to="lab_flgc_AmountPayableOfProfitsForAdditionalAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AmountPayableOfProfitsForAdditionalAmount_91" xlink:to="lab_flgc_AmountPayableOfProfitsForAdditionalAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_92" xlink:to="lab_flgc_AmountsPayablePerViolationOfStopSaleOrders_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_93" xlink:to="lab_flgc_AmountsPayablePerViolationOfStopSaleOrders_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_94" xlink:to="lab_flgc_AmountsPayablePerViolationOfStopSaleOrders_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AnnualGoodwillImpairmentTestOfFghMember_95" xlink:to="lab_flgc_AnnualGoodwillImpairmentTestOfFghMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AnnualGoodwillImpairmentTestOfFghMember_96" xlink:to="lab_flgc_AnnualGoodwillImpairmentTestOfFghMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_97" xlink:to="lab_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_98" xlink:to="lab_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AnnualGoodwillImpairmentTestOfPharmaceuticalsMember_99" xlink:to="lab_flgc_AnnualGoodwillImpairmentTestOfPharmaceuticalsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_100" xlink:to="lab_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_101" xlink:to="lab_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_102" xlink:to="lab_flgc_AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BasisOfAccountingAxis_103" xlink:to="lab_flgc_BasisOfAccountingAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BasisOfAccountingLineItems_104" xlink:to="lab_flgc_BasisOfAccountingLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BasisOfAccountingTable_105" xlink:to="lab_flgc_BasisOfAccountingTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BasisOfMeasurementPolicyTextBlock_106" xlink:to="lab_flgc_BasisOfMeasurementPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BasisOfMeasurementPolicyTextBlock_107" xlink:to="lab_flgc_BasisOfMeasurementPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BasisOfMeasurementPolicyTextBlock_108" xlink:to="lab_flgc_BasisOfMeasurementPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BearsInterestRate_109" xlink:to="lab_flgc_BearsInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BearsInterestRate_110" xlink:to="lab_flgc_BearsInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BousteadSecuritiesLLCMember_111" xlink:to="lab_flgc_BousteadSecuritiesLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BousteadSecuritiesLLCMember_112" xlink:to="lab_flgc_BousteadSecuritiesLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BreezeAcquisitionMember_113" xlink:to="lab_flgc_BreezeAcquisitionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BreezeLaboratorySasMember_114" xlink:to="lab_flgc_BreezeLaboratorySasMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BreezeLaboratorySasMember_115" xlink:to="lab_flgc_BreezeLaboratorySasMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_116" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_117" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_118" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_119" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_120" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_121" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_122" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_123" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_124" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_125" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_126" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_127" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_128" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_129" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_130" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_131" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_132" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_133" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_134" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_135" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_136" xlink:to="lab_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CanadaIncomeTaxAuthorityMember_137" xlink:to="lab_flgc_CanadaIncomeTaxAuthorityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CanadaIncomeTaxAuthorityMember_138" xlink:to="lab_flgc_CanadaIncomeTaxAuthorityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CancelledShares_139" xlink:to="lab_flgc_CancelledShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CancelledShares_140" xlink:to="lab_flgc_CancelledShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CapitalManagementAbstract_141" xlink:to="lab_flgc_CapitalManagementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CapitalManagementAbstract_142" xlink:to="lab_flgc_CapitalManagementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CapitalManagementDisclosureTextBlock_143" xlink:to="lab_flgc_CapitalManagementDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CapitalManagementDisclosureTextBlock_144" xlink:to="lab_flgc_CapitalManagementDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CashConsiderationReturned_145" xlink:to="lab_flgc_CashConsiderationReturned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CashEquivalentsAtCarryingValue1_146" xlink:to="lab_flgc_CashEquivalentsAtCarryingValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CashEquivalentsAtCarryingValue1_147" xlink:to="lab_flgc_CashEquivalentsAtCarryingValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CashFlowModelHighRate_148" xlink:to="lab_flgc_CashFlowModelHighRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CashFlowModelLowRate_149" xlink:to="lab_flgc_CashFlowModelLowRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CashPaid_150" xlink:to="lab_flgc_CashPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ClassicPlanPremiumFinancingMember_151" xlink:to="lab_flgc_ClassicPlanPremiumFinancingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ClassicPlanPremiumFinancingMember_152" xlink:to="lab_flgc_ClassicPlanPremiumFinancingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ClassicPlanPremiumFinancingMember_153" xlink:to="lab_flgc_ClassicPlanPremiumFinancingMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_154" xlink:to="lab_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_155" xlink:to="lab_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_156" xlink:to="lab_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ColombiaRevenueAgencyMember_157" xlink:to="lab_flgc_ColombiaRevenueAgencyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ColombiaRevenueAgencyMember_158" xlink:to="lab_flgc_ColombiaRevenueAgencyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommercialAndWholesaleMember_159" xlink:to="lab_flgc_CommercialAndWholesaleMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommercialAndWholesaleMember_160" xlink:to="lab_flgc_CommercialAndWholesaleMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommercialAndWholesaleMember_161" xlink:to="lab_flgc_CommercialAndWholesaleMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommercialAndWholesaleSegmentMember_162" xlink:to="lab_flgc_CommercialAndWholesaleSegmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommercialAndWholesaleSegmentMember_163" xlink:to="lab_flgc_CommercialAndWholesaleSegmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommercialAndWholesaleSegmentMember_164" xlink:to="lab_flgc_CommercialAndWholesaleSegmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommonSharesDeliveredToTheSellers_165" xlink:to="lab_flgc_CommonSharesDeliveredToTheSellers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommonSharesIssuedForInvestmentsAmount_166" xlink:to="lab_flgc_CommonSharesIssuedForInvestmentsAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommonSharesIssuedForInvestmentsShares_167" xlink:to="lab_flgc_CommonSharesIssuedForInvestmentsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommonSharesIssuedForOtherAgreementsAmount_168" xlink:to="lab_flgc_CommonSharesIssuedForOtherAgreementsAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommonSharesIssuedForOtherAgreementsShares_169" xlink:to="lab_flgc_CommonSharesIssuedForOtherAgreementsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommonStockIssuedForRsusVested_170" xlink:to="lab_flgc_CommonStockIssuedForRsusVested_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CompanyValued_171" xlink:to="lab_flgc_CompanyValued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ConsolidatedMember_172" xlink:to="lab_flgc_ConsolidatedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ConsolidatedMember_173" xlink:to="lab_flgc_ConsolidatedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ConsolidatedRevenue_174" xlink:to="lab_flgc_ConsolidatedRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ConsolidatedRevenue_175" xlink:to="lab_flgc_ConsolidatedRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ConsolidatedRevenue_176" xlink:to="lab_flgc_ConsolidatedRevenue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_Contributionamont_177" xlink:to="lab_flgc_Contributionamont_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_Contributionamont_178" xlink:to="lab_flgc_Contributionamont_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_Contributionamont_179" xlink:to="lab_flgc_Contributionamont_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_Contributionshares_180" xlink:to="lab_flgc_Contributionshares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_Contributionshares_181" xlink:to="lab_flgc_Contributionshares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_Contributionshares_182" xlink:to="lab_flgc_Contributionshares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CorporateAndEliminationsMember_183" xlink:to="lab_flgc_CorporateAndEliminationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CorporateAndEliminationsMember_184" xlink:to="lab_flgc_CorporateAndEliminationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CorporateAndEliminationsMember_185" xlink:to="lab_flgc_CorporateAndEliminationsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CorporateIncomeTax_186" xlink:to="lab_flgc_CorporateIncomeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CosechemosAndKasaWholefoodsMember_187" xlink:to="lab_flgc_CosechemosAndKasaWholefoodsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CosechemosAndKasaWholefoodsMember_188" xlink:to="lab_flgc_CosechemosAndKasaWholefoodsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CosechemosAndKasaWholefoodsMember_189" xlink:to="lab_flgc_CosechemosAndKasaWholefoodsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CreditFacilityDue_190" xlink:to="lab_flgc_CreditFacilityDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract_191" xlink:to="lab_flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CumulativeImpairmentRelatedToCommonShares_192" xlink:to="lab_flgc_CumulativeImpairmentRelatedToCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_193" xlink:to="lab_flgc_CurrentPortionOfContingentPurchaseConsideration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_194" xlink:to="lab_flgc_CurrentPortionOfContingentPurchaseConsideration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_195" xlink:to="lab_flgc_CurrentPortionOfContingentPurchaseConsideration_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CurrentTaxExpenseIncome_196" xlink:to="lab_flgc_CurrentTaxExpenseIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CurrentTaxExpenseIncome_197" xlink:to="lab_flgc_CurrentTaxExpenseIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CustomersRelationshipsMember_198" xlink:to="lab_flgc_CustomersRelationshipsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CustomersRelationshipsMember_199" xlink:to="lab_flgc_CustomersRelationshipsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_200" xlink:to="lab_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_201" xlink:to="lab_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DecemberUnitOfferingAmount_202" xlink:to="lab_flgc_DecemberUnitOfferingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DecemberUnitOfferingIssuanceCosts_203" xlink:to="lab_flgc_DecemberUnitOfferingIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DecemberUnitOfferingIssuanceCosts_204" xlink:to="lab_flgc_DecemberUnitOfferingIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DecemberUnitOfferingShares_205" xlink:to="lab_flgc_DecemberUnitOfferingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DecemberUnitOfferingShares_206" xlink:to="lab_flgc_DecemberUnitOfferingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_207" xlink:to="lab_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_208" xlink:to="lab_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsGoodwil_209" xlink:to="lab_flgc_DeferredTaxAssetsGoodwil_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsGoodwil_210" xlink:to="lab_flgc_DeferredTaxAssetsGoodwil_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsGoodwil_211" xlink:to="lab_flgc_DeferredTaxAssetsGoodwil_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsIntangibleAssets_212" xlink:to="lab_flgc_DeferredTaxAssetsIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsIntangibleAssets_213" xlink:to="lab_flgc_DeferredTaxAssetsIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsIntangibleAssets_214" xlink:to="lab_flgc_DeferredTaxAssetsIntangibleAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsRightOfUseAssets_215" xlink:to="lab_flgc_DeferredTaxAssetsRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsRightOfUseAssets_216" xlink:to="lab_flgc_DeferredTaxAssetsRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsShareIssuanceCosts_217" xlink:to="lab_flgc_DeferredTaxAssetsShareIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsShareIssuanceCosts_218" xlink:to="lab_flgc_DeferredTaxAssetsShareIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_219" xlink:to="lab_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_220" xlink:to="lab_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxExpenseIncome_221" xlink:to="lab_flgc_DeferredTaxExpenseIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxExpenseIncome_222" xlink:to="lab_flgc_DeferredTaxExpenseIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxLiabilitiesAmount_223" xlink:to="lab_flgc_DeferredTaxLiabilitiesAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxLiabilitiesAmount_224" xlink:to="lab_flgc_DeferredTaxLiabilitiesAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxLiabilitiesNet_225" xlink:to="lab_flgc_DeferredTaxLiabilitiesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DeferredTaxLiabilitiesNet_226" xlink:to="lab_flgc_DeferredTaxLiabilitiesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DenmarkRevenueAgencyMember_227" xlink:to="lab_flgc_DenmarkRevenueAgencyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DenmarkRevenueAgencyMember_228" xlink:to="lab_flgc_DenmarkRevenueAgencyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_229" xlink:to="lab_flgc_DerecognitionOfEquityRelatedToColombiaAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_230" xlink:to="lab_flgc_DerecognitionOfEquityRelatedToColombiaAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_231" xlink:to="lab_flgc_DerecognitionOfEquityRelatedToColombiaAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfDiscountRates_232" xlink:to="lab_flgc_DescriptionOfDiscountRates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfExchangeRate_233" xlink:to="lab_flgc_DescriptionOfExchangeRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfExchangeRate_234" xlink:to="lab_flgc_DescriptionOfExchangeRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfExchangeRate_235" xlink:to="lab_flgc_DescriptionOfExchangeRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfExpectedVolatilityShareOptionsGranted_236" xlink:to="lab_flgc_DescriptionOfExpectedVolatilityShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfExpectedVolatilityShareOptionsGranted_237" xlink:to="lab_flgc_DescriptionOfExpectedVolatilityShareOptionsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfImpairment_238" xlink:to="lab_flgc_DescriptionOfImpairment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfImpairment_239" xlink:to="lab_flgc_DescriptionOfImpairment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfImpairment_240" xlink:to="lab_flgc_DescriptionOfImpairment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfRevenueGrowth_241" xlink:to="lab_flgc_DescriptionOfRevenueGrowth_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfRevenueGrowth_242" xlink:to="lab_flgc_DescriptionOfRevenueGrowth_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted_243" xlink:to="lab_flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted_244" xlink:to="lab_flgc_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfSensitivityAnalysis_245" xlink:to="lab_flgc_DescriptionOfSensitivityAnalysis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfSensitivityAnalysis_246" xlink:to="lab_flgc_DescriptionOfSensitivityAnalysis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfShares_247" xlink:to="lab_flgc_DescriptionOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfShares_248" xlink:to="lab_flgc_DescriptionOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfTaxJurisdictions_249" xlink:to="lab_flgc_DescriptionOfTaxJurisdictions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfTaxJurisdictions_250" xlink:to="lab_flgc_DescriptionOfTaxJurisdictions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfValuation_251" xlink:to="lab_flgc_DescriptionOfValuation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DescriptionOfValuation_252" xlink:to="lab_flgc_DescriptionOfValuation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DiscountRate_253" xlink:to="lab_flgc_DiscountRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_254" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_255" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_256" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_257" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_258" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_259" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_260" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_261" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_262" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_263" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_264" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_265" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_266" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_267" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_268" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_269" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_270" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_271" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_272" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_273" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_274" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_275" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_276" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_277" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_278" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_279" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_280" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_281" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_282" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_283" xlink:to="lab_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DrManaloMorganMember_284" xlink:to="lab_flgc_DrManaloMorganMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_DrManaloMorganMember_285" xlink:to="lab_flgc_DrManaloMorganMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate_286" xlink:to="lab_flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate_287" xlink:to="lab_flgc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryUSIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EquityIssuedForOtherAgreementsAmount_288" xlink:to="lab_flgc_EquityIssuedForOtherAgreementsAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EquityIssuedForOtherAgreementsAmount_289" xlink:to="lab_flgc_EquityIssuedForOtherAgreementsAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EquityIssuedForOtherAgreementsShares_290" xlink:to="lab_flgc_EquityIssuedForOtherAgreementsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EstimatedImpactOfPotentialExchangeRateFluctuations_291" xlink:to="lab_flgc_EstimatedImpactOfPotentialExchangeRateFluctuations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EstimatedLossOnPotentialLiabilities_292" xlink:to="lab_flgc_EstimatedLossOnPotentialLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EstimatedLossOnPotentialLiabilities_293" xlink:to="lab_flgc_EstimatedLossOnPotentialLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EstimatedLossOnPotentialLiabilities_294" xlink:to="lab_flgc_EstimatedLossOnPotentialLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EstimatedRecoverableAmount_295" xlink:to="lab_flgc_EstimatedRecoverableAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EstimatedRecoverableAmount_296" xlink:to="lab_flgc_EstimatedRecoverableAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EuroCreditFacilityMember_297" xlink:to="lab_flgc_EuroCreditFacilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_EuroCreditFacilityMember_298" xlink:to="lab_flgc_EuroCreditFacilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExercisePriceOfInvestmentWarrants_299" xlink:to="lab_flgc_ExercisePriceOfInvestmentWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExercisePriceOfInvestmentWarrants_300" xlink:to="lab_flgc_ExercisePriceOfInvestmentWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExpectedDividendAsPercentageShareOptionsGranted_301" xlink:to="lab_flgc_ExpectedDividendAsPercentageShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExpectedDividendAsPercentageShareOptionsGranted_302" xlink:to="lab_flgc_ExpectedDividendAsPercentageShareOptionsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExpectedLife_303" xlink:to="lab_flgc_ExpectedLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExpectedLife_304" xlink:to="lab_flgc_ExpectedLife_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExpectedOptionLifeInYears_305" xlink:to="lab_flgc_ExpectedOptionLifeInYears_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExpectedOptionLifeInYears_306" xlink:to="lab_flgc_ExpectedOptionLifeInYears_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ExpectedSharesToBeIssued_307" xlink:to="lab_flgc_ExpectedSharesToBeIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_308" xlink:to="lab_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_309" xlink:to="lab_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_310" xlink:to="lab_flgc_FairValueAssetsMeasuredOnRecurringBasisChangesInUnrealizedGainLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueDiscount_311" xlink:to="lab_flgc_FairValueDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueDiscount_312" xlink:to="lab_flgc_FairValueDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueOfNonemployeeStockWarrantsGranted_313" xlink:to="lab_flgc_FairValueOfNonemployeeStockWarrantsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueOfNonemployeeStockWarrantsGranted_314" xlink:to="lab_flgc_FairValueOfNonemployeeStockWarrantsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueOfRestrictedStockAwardsIssued_315" xlink:to="lab_flgc_FairValueOfRestrictedStockAwardsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_316" xlink:to="lab_flgc_FairValueOfWarrantsIssuedDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_317" xlink:to="lab_flgc_FairValueOfWarrantsIssuedDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FGHMember_318" xlink:to="lab_flgc_FGHMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FGHMember_319" xlink:to="lab_flgc_FGHMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FGHMember_320" xlink:to="lab_flgc_FGHMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FGHMember_321" xlink:to="lab_flgc_FGHMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FGHOwnersMember_322" xlink:to="lab_flgc_FGHOwnersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FGHOwnersMember_323" xlink:to="lab_flgc_FGHOwnersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_324" xlink:to="lab_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_325" xlink:to="lab_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_326" xlink:to="lab_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialInstrumentsAbstract_327" xlink:to="lab_flgc_FinancialInstrumentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialInstrumentsAndRiskManagementAbstract_328" xlink:to="lab_flgc_FinancialInstrumentsAndRiskManagementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialInstrumentsAndRiskManagementAbstract_329" xlink:to="lab_flgc_FinancialInstrumentsAndRiskManagementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialIntermediariesMember_330" xlink:to="lab_flgc_FinancialIntermediariesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialIntermediariesMember_331" xlink:to="lab_flgc_FinancialIntermediariesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialIntermediariesMember_332" xlink:to="lab_flgc_FinancialIntermediariesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialLiabilitiesPolicyTextBlock_333" xlink:to="lab_flgc_FinancialLiabilitiesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancialLiabilitiesPolicyTextBlock_334" xlink:to="lab_flgc_FinancialLiabilitiesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_335" xlink:to="lab_flgc_FinancingReceivables180PlusDaysPastDueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_336" xlink:to="lab_flgc_FinancingReceivables180PlusDaysPastDueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_337" xlink:to="lab_flgc_FinancingReceivables180PlusDaysPastDueMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FiniteLivedIntangibleAssetsAdditions_338" xlink:to="lab_flgc_FiniteLivedIntangibleAssetsAdditions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FiniteLivedIntangibleAssetsAdditions_339" xlink:to="lab_flgc_FiniteLivedIntangibleAssetsAdditions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FirstClosingMember_340" xlink:to="lab_flgc_FirstClosingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FirstClosingMember_341" xlink:to="lab_flgc_FirstClosingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FirstLoanAgreementMember_342" xlink:to="lab_flgc_FirstLoanAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FirstLoanAgreementMember_343" xlink:to="lab_flgc_FirstLoanAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FirstLoanMember_344" xlink:to="lab_flgc_FirstLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FirstLoanMember_345" xlink:to="lab_flgc_FirstLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FirstTrancheMember_346" xlink:to="lab_flgc_FirstTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FixedAssets_347" xlink:to="lab_flgc_FixedAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FixedAssets_348" xlink:to="lab_flgc_FixedAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FixedAssets_349" xlink:to="lab_flgc_FixedAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraBeautyMember_350" xlink:to="lab_flgc_FloraBeautyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraBeautyMember_351" xlink:to="lab_flgc_FloraBeautyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraBeautyMember_352" xlink:to="lab_flgc_FloraBeautyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraBreezeLaboratoryMember_353" xlink:to="lab_flgc_FloraBreezeLaboratoryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraBreezeLaboratoryMember_354" xlink:to="lab_flgc_FloraBreezeLaboratoryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraGrowthCorpMember_355" xlink:to="lab_flgc_FloraGrowthCorpMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraGrowthCorpMember_356" xlink:to="lab_flgc_FloraGrowthCorpMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraMedSasMember_357" xlink:to="lab_flgc_FloraMedSasMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraMedSasMember_358" xlink:to="lab_flgc_FloraMedSasMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FloraMedSasMember_359" xlink:to="lab_flgc_FloraMedSasMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FoodAndBeveragesMember_360" xlink:to="lab_flgc_FoodAndBeveragesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FoodAndBeveragesMember_361" xlink:to="lab_flgc_FoodAndBeveragesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ForeignExchangeImpacts_362" xlink:to="lab_flgc_ForeignExchangeImpacts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ForeignIncomeTaxAuthorityMember_363" xlink:to="lab_flgc_ForeignIncomeTaxAuthorityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ForeignIncomeTaxAuthorityMember_364" xlink:to="lab_flgc_ForeignIncomeTaxAuthorityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ForeignRevenueAgencyMember_365" xlink:to="lab_flgc_ForeignRevenueAgencyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ForeignRevenueAgencyMember_366" xlink:to="lab_flgc_ForeignRevenueAgencyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FortLauderdaleMember_367" xlink:to="lab_flgc_FortLauderdaleMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FortLauderdaleMember_368" xlink:to="lab_flgc_FortLauderdaleMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FranchiseGlobalHealthIncMember_369" xlink:to="lab_flgc_FranchiseGlobalHealthIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FranchiseGlobalHealthIncMember_370" xlink:to="lab_flgc_FranchiseGlobalHealthIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FunctionalCurrencyOfSubsidiary_371" xlink:to="lab_flgc_FunctionalCurrencyOfSubsidiary_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_FunctionalCurrencyOfSubsidiary_372" xlink:to="lab_flgc_FunctionalCurrencyOfSubsidiary_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GerardoAndresGarciaMendezMember_373" xlink:to="lab_flgc_GerardoAndresGarciaMendezMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GerardoAndresGarciaMendezMember_374" xlink:to="lab_flgc_GerardoAndresGarciaMendezMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GermanSubsidiariesMember_375" xlink:to="lab_flgc_GermanSubsidiariesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GermanyRevenueAgencyMember_376" xlink:to="lab_flgc_GermanyRevenueAgencyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GermanyRevenueAgencyMember_377" xlink:to="lab_flgc_GermanyRevenueAgencyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GoingConcernPolicyTextBlock_378" xlink:to="lab_flgc_GoingConcernPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GoingConcernPolicyTextBlock_379" xlink:to="lab_flgc_GoingConcernPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GoodwillAndIdentifiedIntangibleAssets_380" xlink:to="lab_flgc_GoodwillAndIdentifiedIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GoodwillAndIdentifiedIntangibleAssets_381" xlink:to="lab_flgc_GoodwillAndIdentifiedIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GoodwillDescription_382" xlink:to="lab_flgc_GoodwillDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GrantDateFairValueOfWarrantsOutstanding_383" xlink:to="lab_flgc_GrantDateFairValueOfWarrantsOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GrupoFarmaceuticoCronomedSasMember_384" xlink:to="lab_flgc_GrupoFarmaceuticoCronomedSasMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_GrupoFarmaceuticoCronomedSasMember_385" xlink:to="lab_flgc_GrupoFarmaceuticoCronomedSasMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HampsteadPrivateCapitalLimitedMember_386" xlink:to="lab_flgc_HampsteadPrivateCapitalLimitedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HarvestedCannabis_387" xlink:to="lab_flgc_HarvestedCannabis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_388" xlink:to="lab_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_389" xlink:to="lab_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HouseOfBrandsMember_390" xlink:to="lab_flgc_HouseOfBrandsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HouseOfBrandsMember_391" xlink:to="lab_flgc_HouseOfBrandsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HouseOfBrandsSegmentMember_392" xlink:to="lab_flgc_HouseOfBrandsSegmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HouseOfBrandsSegmentMember_393" xlink:to="lab_flgc_HouseOfBrandsSegmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HouseOfBrandsSegmentMember_394" xlink:to="lab_flgc_HouseOfBrandsSegmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_HypoverinsbankMember_395" xlink:to="lab_flgc_HypoverinsbankMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ImpairmentOfAssetsAbstract_396" xlink:to="lab_flgc_ImpairmentOfAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ImpairmentOfGoodwill_397" xlink:to="lab_flgc_ImpairmentOfGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ImpairmentOfGoodwill_398" xlink:to="lab_flgc_ImpairmentOfGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ImpairmentOfGoodwill_399" xlink:to="lab_flgc_ImpairmentOfGoodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ImpairmentOfLicenses_400" xlink:to="lab_flgc_ImpairmentOfLicenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ImpairmentOfPatents_401" xlink:to="lab_flgc_ImpairmentOfPatents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ImpairmentOfPatents_402" xlink:to="lab_flgc_ImpairmentOfPatents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ImpairmentOfPropertyPlantAndEquipment_403" xlink:to="lab_flgc_ImpairmentOfPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IncreaseInCarryingValueOfAssets_404" xlink:to="lab_flgc_IncreaseInCarryingValueOfAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IncreaseInCarryingValueOfAssets_405" xlink:to="lab_flgc_IncreaseInCarryingValueOfAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IndemnificationReceivables_406" xlink:to="lab_flgc_IndemnificationReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IndemnificationReceivables_407" xlink:to="lab_flgc_IndemnificationReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IndemnificationReceivables_408" xlink:to="lab_flgc_IndemnificationReceivables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InitialPublicOfferingAmount_409" xlink:to="lab_flgc_InitialPublicOfferingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InitialPublicOfferingIssuanceCostsAmount_410" xlink:to="lab_flgc_InitialPublicOfferingIssuanceCostsAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InitialPublicOfferingIssuanceCostsShares_411" xlink:to="lab_flgc_InitialPublicOfferingIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InitialPublicOfferingMember_412" xlink:to="lab_flgc_InitialPublicOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InitialPublicOfferingMember_413" xlink:to="lab_flgc_InitialPublicOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InitialPublicOfferingShares_414" xlink:to="lab_flgc_InitialPublicOfferingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_415" xlink:to="lab_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_416" xlink:to="lab_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_417" xlink:to="lab_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IntrinsicValueOfWarrantsExercised_418" xlink:to="lab_flgc_IntrinsicValueOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InventoryAbstract_419" xlink:to="lab_flgc_InventoryAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InventoryExpensedToCostOfSales_420" xlink:to="lab_flgc_InventoryExpensedToCostOfSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InventoryExpensedToCostOfSales_421" xlink:to="lab_flgc_InventoryExpensedToCostOfSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InventoryImpactedByStopSaleOrders_422" xlink:to="lab_flgc_InventoryImpactedByStopSaleOrders_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InventoryImpactedByStopSaleOrders_423" xlink:to="lab_flgc_InventoryImpactedByStopSaleOrders_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InvesteeCommonSharesMember_424" xlink:to="lab_flgc_InvesteeCommonSharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_425" xlink:to="lab_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_426" xlink:to="lab_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InvestmentDescription_427" xlink:to="lab_flgc_InvestmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InvestmentDescription_428" xlink:to="lab_flgc_InvestmentDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InvestmentExercisePrice_429" xlink:to="lab_flgc_InvestmentExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_InvestmentExercisePrice_430" xlink:to="lab_flgc_InvestmentExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IssuanceCosts_431" xlink:to="lab_flgc_IssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_IssuanceCosts_432" xlink:to="lab_flgc_IssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_433" xlink:to="lab_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_434" xlink:to="lab_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_435" xlink:to="lab_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustBrandsLLCMember_436" xlink:to="lab_flgc_JustBrandsLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustBrandsLLCMember_437" xlink:to="lab_flgc_JustBrandsLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustBrandsLLCMember_438" xlink:to="lab_flgc_JustBrandsLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustBrandsLLCMember_439" xlink:to="lab_flgc_JustBrandsLLCMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDInsurancePremiumLoanMember_440" xlink:to="lab_flgc_JustCBDInsurancePremiumLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDInsurancePremiumLoanMember_441" xlink:to="lab_flgc_JustCBDInsurancePremiumLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDInsurancePremiumLoanMember_442" xlink:to="lab_flgc_JustCBDInsurancePremiumLoanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDMember_443" xlink:to="lab_flgc_JustCBDMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDMember_444" xlink:to="lab_flgc_JustCBDMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDMember_445" xlink:to="lab_flgc_JustCBDMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDMember_446" xlink:to="lab_flgc_JustCBDMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDMember_447" xlink:to="lab_flgc_JustCBDMember_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDOwnersMember_448" xlink:to="lab_flgc_JustCBDOwnersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_JustCBDOwnersMember_449" xlink:to="lab_flgc_JustCBDOwnersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_KnowHowMember_450" xlink:to="lab_flgc_KnowHowMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_KnowHowMember_451" xlink:to="lab_flgc_KnowHowMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LeaseLiabilities_452" xlink:to="lab_flgc_LeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LeaseLiabilities_453" xlink:to="lab_flgc_LeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LeaseObligations_454" xlink:to="lab_flgc_LeaseObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LeasesMonthlyAmount_455" xlink:to="lab_flgc_LeasesMonthlyAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LegalDisputesMember_456" xlink:to="lab_flgc_LegalDisputesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LegalDisputesMember_457" xlink:to="lab_flgc_LegalDisputesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LiabilitiesAmount_458" xlink:to="lab_flgc_LiabilitiesAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LiabilitiesAmount_459" xlink:to="lab_flgc_LiabilitiesAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_460" xlink:to="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_461" xlink:to="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_462" xlink:to="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_463" xlink:to="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_464" xlink:to="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_465" xlink:to="lab_flgc_LiabilitiesHeldForSaleNotPartOfDisposalGroupNonCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LicensesAndTrademarksMember_466" xlink:to="lab_flgc_LicensesAndTrademarksMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LicensesMember_467" xlink:to="lab_flgc_LicensesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LicensesMember_468" xlink:to="lab_flgc_LicensesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LisanFarmaColombiaLLCMember_469" xlink:to="lab_flgc_LisanFarmaColombiaLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LisanFarmaColombiaLLCMember_470" xlink:to="lab_flgc_LisanFarmaColombiaLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LisanFarmaColombiaLLCMember_471" xlink:to="lab_flgc_LisanFarmaColombiaLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoanAgreementsAxis_472" xlink:to="lab_flgc_LoanAgreementsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoanAgreementsAxis_473" xlink:to="lab_flgc_LoanAgreementsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoanAgreementsDomain_474" xlink:to="lab_flgc_LoanAgreementsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoanAgreementsDomain_475" xlink:to="lab_flgc_LoanAgreementsDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoanRepaymentsReceived_476" xlink:to="lab_flgc_LoanRepaymentsReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoanRepaymentsReceived_477" xlink:to="lab_flgc_LoanRepaymentsReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoansProvided_478" xlink:to="lab_flgc_LoansProvided_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoansProvided_479" xlink:to="lab_flgc_LoansProvided_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LoansReceivableAndAdvances_480" xlink:to="lab_flgc_LoansReceivableAndAdvances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_481" xlink:to="lab_flgc_LossContingencyAccrualForeignCurrencyTranslation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_482" xlink:to="lab_flgc_LossContingencyAccrualForeignCurrencyTranslation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_483" xlink:to="lab_flgc_LossContingencyAccrualForeignCurrencyTranslation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_484" xlink:to="lab_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_485" xlink:to="lab_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_486" xlink:to="lab_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_487" xlink:to="lab_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_488" xlink:to="lab_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_489" xlink:to="lab_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_490" xlink:to="lab_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_491" xlink:to="lab_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_492" xlink:to="lab_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyInterestPaymentTerms_493" xlink:to="lab_flgc_LossContingencyInterestPaymentTerms_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyInterestPaymentTerms_494" xlink:to="lab_flgc_LossContingencyInterestPaymentTerms_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_LossContingencyInterestPaymentTerms_495" xlink:to="lab_flgc_LossContingencyInterestPaymentTerms_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MachineryAndOfficeEquipmentMember_496" xlink:to="lab_flgc_MachineryAndOfficeEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MachineryAndOfficeEquipmentMember_497" xlink:to="lab_flgc_MachineryAndOfficeEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ManagementContractsTerms_498" xlink:to="lab_flgc_ManagementContractsTerms_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ManagementContractsTerms_499" xlink:to="lab_flgc_ManagementContractsTerms_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_500" xlink:to="lab_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_501" xlink:to="lab_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumLimitOfIndemnificationAgreement_502" xlink:to="lab_flgc_MaximumLimitOfIndemnificationAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumLimitOfIndemnificationAgreement_503" xlink:to="lab_flgc_MaximumLimitOfIndemnificationAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumLimitOfIndemnificationAgreement_504" xlink:to="lab_flgc_MaximumLimitOfIndemnificationAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumPaymentAccumulatedForValuation_505" xlink:to="lab_flgc_MaximumPaymentAccumulatedForValuation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumPaymentAccumulatedForValuation_506" xlink:to="lab_flgc_MaximumPaymentAccumulatedForValuation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumPaymentAccumulatedForValuation_507" xlink:to="lab_flgc_MaximumPaymentAccumulatedForValuation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumPortionOfNetProfitsPayable_508" xlink:to="lab_flgc_MaximumPortionOfNetProfitsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumPortionOfNetProfitsPayable_509" xlink:to="lab_flgc_MaximumPortionOfNetProfitsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MaximumPortionOfNetProfitsPayable_510" xlink:to="lab_flgc_MaximumPortionOfNetProfitsPayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MedicalServices_511" xlink:to="lab_flgc_MedicalServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_MonthlyLeasePayment_512" xlink:to="lab_flgc_MonthlyLeasePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NameOfSubsidiary_513" xlink:to="lab_flgc_NameOfSubsidiary_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NatureOfOperationsAndGoingConcernAbstract_514" xlink:to="lab_flgc_NatureOfOperationsAndGoingConcernAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NatureOfOperationsAndGoingConcernAbstract_515" xlink:to="lab_flgc_NatureOfOperationsAndGoingConcernAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NetDeferredTaxLiabilities_516" xlink:to="lab_flgc_NetDeferredTaxLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NetDeferredTaxLiabilities_517" xlink:to="lab_flgc_NetDeferredTaxLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NoCapHempCoMember_518" xlink:to="lab_flgc_NoCapHempCoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NoCapHempCoMember_519" xlink:to="lab_flgc_NoCapHempCoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCapitalLossCarryforwards_520" xlink:to="lab_flgc_NonCapitalLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCapitalLossCarryforwards_521" xlink:to="lab_flgc_NonCapitalLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashAssetsAcquiredForContingentConsideration_522" xlink:to="lab_flgc_NonCashAssetsAcquiredForContingentConsideration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashAssetsAcquiredForContingentConsideration_523" xlink:to="lab_flgc_NonCashAssetsAcquiredForContingentConsideration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashCommonSharesIssuedForBusinessCombinations_524" xlink:to="lab_flgc_NonCashCommonSharesIssuedForBusinessCombinations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashCommonSharesIssuedForBusinessCombinations_525" xlink:to="lab_flgc_NonCashCommonSharesIssuedForBusinessCombinations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashCommonSharesIssuedForOtherAgreements_526" xlink:to="lab_flgc_NonCashCommonSharesIssuedForOtherAgreements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashCommonSharesIssuedForOtherAgreements_527" xlink:to="lab_flgc_NonCashCommonSharesIssuedForOtherAgreements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_528" xlink:to="lab_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_529" xlink:to="lab_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashOptionCancellationsReclassifiedToEquity_530" xlink:to="lab_flgc_NonCashOptionCancellationsReclassifiedToEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonCashOptionCancellationsReclassifiedToEquity_531" xlink:to="lab_flgc_NonCashOptionCancellationsReclassifiedToEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonControllingInterestsPolicyTextBlock_532" xlink:to="lab_flgc_NonControllingInterestsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonControllingInterestsPolicyTextBlock_533" xlink:to="lab_flgc_NonControllingInterestsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NonVestedShares_534" xlink:to="lab_flgc_NonVestedShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_535" xlink:to="lab_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_536" xlink:to="lab_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfSharesUnderPlaintiffClaim_537" xlink:to="lab_flgc_NumberOfSharesUnderPlaintiffClaim_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfSharesUnderPlaintiffClaim_538" xlink:to="lab_flgc_NumberOfSharesUnderPlaintiffClaim_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfSharesUnderPlaintiffClaim_539" xlink:to="lab_flgc_NumberOfSharesUnderPlaintiffClaim_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfTrials_540" xlink:to="lab_flgc_NumberOfTrials_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfTrials_541" xlink:to="lab_flgc_NumberOfTrials_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfTrials_542" xlink:to="lab_flgc_NumberOfTrials_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfViolationsClaimed_543" xlink:to="lab_flgc_NumberOfViolationsClaimed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfViolationsClaimed_544" xlink:to="lab_flgc_NumberOfViolationsClaimed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfViolationsClaimed_545" xlink:to="lab_flgc_NumberOfViolationsClaimed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfViolationsInStopSaleOrders_546" xlink:to="lab_flgc_NumberOfViolationsInStopSaleOrders_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfWarrantsCancelledExpired_547" xlink:to="lab_flgc_NumberOfWarrantsCancelledExpired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfWarrantsCancelledExpired_548" xlink:to="lab_flgc_NumberOfWarrantsCancelledExpired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_549" xlink:to="lab_flgc_NumberOfWarrantsIssuedDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_550" xlink:to="lab_flgc_NumberOfWarrantsIssuedDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_551" xlink:to="lab_flgc_NumberOfWarrantsIssuedDuringPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfWarrantsWithAmendedExercisePrice_552" xlink:to="lab_flgc_NumberOfWarrantsWithAmendedExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_NumberOfWarrantsWithExercisePriceAmended_553" xlink:to="lab_flgc_NumberOfWarrantsWithExercisePriceAmended_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_554" xlink:to="lab_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_555" xlink:to="lab_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OptionsExercisableMember_556" xlink:to="lab_flgc_OptionsExercisableMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OptionsExercisableMember_557" xlink:to="lab_flgc_OptionsExercisableMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OptionsExpiredCancelled_558" xlink:to="lab_flgc_OptionsExpiredCancelled_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_559" xlink:to="lab_flgc_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OriginalHempAssetAcquisitionMember_560" xlink:to="lab_flgc_OriginalHempAssetAcquisitionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_561" xlink:to="lab_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_562" xlink:to="lab_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_563" xlink:to="lab_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_564" xlink:to="lab_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherEquityIssuanceCosts_565" xlink:to="lab_flgc_OtherEquityIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherInformationAbstract_566" xlink:to="lab_flgc_OtherInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherInformationAbstract_567" xlink:to="lab_flgc_OtherInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherIssuanceMember_568" xlink:to="lab_flgc_OtherIssuanceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherLongLivedAssetImpairmentTestsMember_569" xlink:to="lab_flgc_OtherLongLivedAssetImpairmentTestsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherLongLivedAssets_570" xlink:to="lab_flgc_OtherLongLivedAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherLongLivedAssets_571" xlink:to="lab_flgc_OtherLongLivedAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherOfferingMember_572" xlink:to="lab_flgc_OtherOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_OtherOfferingMember_573" xlink:to="lab_flgc_OtherOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PaidAmountToBreezeVendor_574" xlink:to="lab_flgc_PaidAmountToBreezeVendor_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PaidAmountToBreezeVendor_575" xlink:to="lab_flgc_PaidAmountToBreezeVendor_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PaidAmountToBreezeVendor_576" xlink:to="lab_flgc_PaidAmountToBreezeVendor_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PatentAndDevelopedTechnologyMember_577" xlink:to="lab_flgc_PatentAndDevelopedTechnologyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PatentAndDevelopedTechnologyMember_578" xlink:to="lab_flgc_PatentAndDevelopedTechnologyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfAcquisition_579" xlink:to="lab_flgc_PercentageOfAcquisition_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfAcquisition_580" xlink:to="lab_flgc_PercentageOfAcquisition_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_581" xlink:to="lab_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_582" xlink:to="lab_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_583" xlink:to="lab_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_584" xlink:to="lab_flgc_PercentageOfIssuedAndOutstandingCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_585" xlink:to="lab_flgc_PercentageOfIssuedAndOutstandingCommonShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_586" xlink:to="lab_flgc_PercentageOfIssuedAndOutstandingCommonShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_587" xlink:to="lab_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_588" xlink:to="lab_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_589" xlink:to="lab_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PharmaceuticalsMember_590" xlink:to="lab_flgc_PharmaceuticalsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PlacementAgentMember_591" xlink:to="lab_flgc_PlacementAgentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PompanoBeachMember_592" xlink:to="lab_flgc_PompanoBeachMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PompanoBeachMember_593" xlink:to="lab_flgc_PompanoBeachMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PostTerminationExercisePeriod_594" xlink:to="lab_flgc_PostTerminationExercisePeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PostTerminationExercisePeriod_595" xlink:to="lab_flgc_PostTerminationExercisePeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PostTerminationExercisePeriod_596" xlink:to="lab_flgc_PostTerminationExercisePeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PotentialLiabilities_597" xlink:to="lab_flgc_PotentialLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PotentialLiabilities_598" xlink:to="lab_flgc_PotentialLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_599" xlink:to="lab_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_600" xlink:to="lab_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_601" xlink:to="lab_flgc_PresentationOfComparativeFinancialStatementsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PreviouslyIssuedWarrant_602" xlink:to="lab_flgc_PreviouslyIssuedWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PreviouslyIssuedWarrant_603" xlink:to="lab_flgc_PreviouslyIssuedWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PriceToBookValue_604" xlink:to="lab_flgc_PriceToBookValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PriceToTangibleBookValue_605" xlink:to="lab_flgc_PriceToTangibleBookValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_606" xlink:to="lab_flgc_ProceedsFromExerciseOfWarrantsAndOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_607" xlink:to="lab_flgc_ProceedsFromExerciseOfWarrantsAndOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PropertyInSantanderMember_608" xlink:to="lab_flgc_PropertyInSantanderMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PropertyInSantanderMember_609" xlink:to="lab_flgc_PropertyInSantanderMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ProvisionsPolicyTextBlock_610" xlink:to="lab_flgc_ProvisionsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ProvisionsPolicyTextBlock_611" xlink:to="lab_flgc_ProvisionsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseConsideration_612" xlink:to="lab_flgc_PurchaseConsideration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseConsiderationComprised_613" xlink:to="lab_flgc_PurchaseConsiderationComprised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseConsiderationComprisedShare_614" xlink:to="lab_flgc_PurchaseConsiderationComprisedShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseConsiderationDiscountRate_615" xlink:to="lab_flgc_PurchaseConsiderationDiscountRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseConsiderationDiscountRate_616" xlink:to="lab_flgc_PurchaseConsiderationDiscountRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseConsiderationPercentageOfSales_617" xlink:to="lab_flgc_PurchaseConsiderationPercentageOfSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_618" xlink:to="lab_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_619" xlink:to="lab_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_PurchaseOfCommonStock_620" xlink:to="lab_flgc_PurchaseOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_621" xlink:to="lab_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_622" xlink:to="lab_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_623" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_624" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_625" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_626" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_627" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_628" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_629" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_630" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_631" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_632" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_633" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_634" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_635" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_636" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_637" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_638" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_639" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_640" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_641" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_642" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_643" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_644" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_645" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_646" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_647" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_648" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_649" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_650" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_651" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_652" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_653" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_654" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_655" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_656" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_657" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_658" xlink:to="lab_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RealEstateAssetsMember_659" xlink:to="lab_flgc_RealEstateAssetsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RealEstateAssetsMember_660" xlink:to="lab_flgc_RealEstateAssetsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RealEstateAssetsMember_661" xlink:to="lab_flgc_RealEstateAssetsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RegulationAAndOtherOfferingsAmount_662" xlink:to="lab_flgc_RegulationAAndOtherOfferingsAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RegulationAAndOtherOfferingsShares_663" xlink:to="lab_flgc_RegulationAAndOtherOfferingsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RelatedPartyDisclosuresAbstract_664" xlink:to="lab_flgc_RelatedPartyDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RelatedPartyDisclosuresAbstract_665" xlink:to="lab_flgc_RelatedPartyDisclosuresAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RemainingPercentageOfAcquisition_666" xlink:to="lab_flgc_RemainingPercentageOfAcquisition_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RemainingWeightedAverageVestingPeriod_667" xlink:to="lab_flgc_RemainingWeightedAverageVestingPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RestrictedStockAwardsMember_668" xlink:to="lab_flgc_RestrictedStockAwardsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RestrictedStockVestingAmount_669" xlink:to="lab_flgc_RestrictedStockVestingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RestrictedStockVestingAmount_670" xlink:to="lab_flgc_RestrictedStockVestingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RestrictedStockVestingShares_671" xlink:to="lab_flgc_RestrictedStockVestingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RestrictedStockVestingShares_672" xlink:to="lab_flgc_RestrictedStockVestingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RetailSpaceInMiamiMember_673" xlink:to="lab_flgc_RetailSpaceInMiamiMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RetailSpaceInMiamiMember_674" xlink:to="lab_flgc_RetailSpaceInMiamiMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_675" xlink:to="lab_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_676" xlink:to="lab_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SalesTaxesMember_677" xlink:to="lab_flgc_SalesTaxesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_678" xlink:to="lab_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_679" xlink:to="lab_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_680" xlink:to="lab_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_681" xlink:to="lab_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_682" xlink:to="lab_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_683" xlink:to="lab_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_684" xlink:to="lab_flgc_ScheduleOfCommitmentsAndContingenciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_685" xlink:to="lab_flgc_ScheduleOfCommitmentsAndContingenciesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_686" xlink:to="lab_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_687" xlink:to="lab_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_688" xlink:to="lab_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_689" xlink:to="lab_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_690" xlink:to="lab_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_691" xlink:to="lab_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_692" xlink:to="lab_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_693" xlink:to="lab_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_694" xlink:to="lab_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_695" xlink:to="lab_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_696" xlink:to="lab_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_697" xlink:to="lab_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_698" xlink:to="lab_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_699" xlink:to="lab_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_700" xlink:to="lab_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_701" xlink:to="lab_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_702" xlink:to="lab_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_703" xlink:to="lab_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_704" xlink:to="lab_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock_705" xlink:to="lab_flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock_706" xlink:to="lab_flgc_ScheduleOfProvisionsAndContingentLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfRestrictedStockAwards_707" xlink:to="lab_flgc_ScheduleOfRestrictedStockAwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfRestrictedStockAwards_708" xlink:to="lab_flgc_ScheduleOfRestrictedStockAwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_709" xlink:to="lab_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_710" xlink:to="lab_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_711" xlink:to="lab_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfSubsidiariesTableTextBlock_712" xlink:to="lab_flgc_ScheduleOfSubsidiariesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfSubsidiariesTableTextBlock_713" xlink:to="lab_flgc_ScheduleOfSubsidiariesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_714" xlink:to="lab_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_715" xlink:to="lab_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_716" xlink:to="lab_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_717" xlink:to="lab_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SecondClosingMember_718" xlink:to="lab_flgc_SecondClosingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SecondClosingMember_719" xlink:to="lab_flgc_SecondClosingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SecondLoanAgreementMember_720" xlink:to="lab_flgc_SecondLoanAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SecondLoanAgreementMember_721" xlink:to="lab_flgc_SecondLoanAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SecondLoanMember_722" xlink:to="lab_flgc_SecondLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SecondLoanMember_723" xlink:to="lab_flgc_SecondLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SecondTrancheMember_724" xlink:to="lab_flgc_SecondTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeparationAgreementMember_725" xlink:to="lab_flgc_SeparationAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeparationAgreementMember_726" xlink:to="lab_flgc_SeparationAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_727" xlink:to="lab_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_728" xlink:to="lab_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberUnitOfferingAmount_729" xlink:to="lab_flgc_SeptemberUnitOfferingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberUnitOfferingAmount_730" xlink:to="lab_flgc_SeptemberUnitOfferingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberUnitOfferingIssuanceCosts_731" xlink:to="lab_flgc_SeptemberUnitOfferingIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberUnitOfferingIssuanceCosts_732" xlink:to="lab_flgc_SeptemberUnitOfferingIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberUnitOfferingIssuanceCosts_733" xlink:to="lab_flgc_SeptemberUnitOfferingIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberUnitOfferingShares_734" xlink:to="lab_flgc_SeptemberUnitOfferingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SeptemberUnitOfferingShares_735" xlink:to="lab_flgc_SeptemberUnitOfferingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SettlementAgreementMember_736" xlink:to="lab_flgc_SettlementAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SettlementAgreementMember_737" xlink:to="lab_flgc_SettlementAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares_738" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares_739" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePerShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_740" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_741" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_742" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_743" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_744" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_745" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_746" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_747" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_748" xlink:to="lab_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationConsideration_749" xlink:to="lab_flgc_ShareBasedCompensationConsideration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationConsideration_750" xlink:to="lab_flgc_ShareBasedCompensationConsideration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_751" xlink:to="lab_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_752" xlink:to="lab_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_753" xlink:to="lab_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_754" xlink:to="lab_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SharedServicesAndSpaceCommitment_755" xlink:to="lab_flgc_SharedServicesAndSpaceCommitment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SharePurchaseAgreementMember_756" xlink:to="lab_flgc_SharePurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SharePurchaseAgreementMember_757" xlink:to="lab_flgc_SharePurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareRepurchaseMember_758" xlink:to="lab_flgc_ShareRepurchaseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareRepurchaseShares_759" xlink:to="lab_flgc_ShareRepurchaseShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ShareRepurchaseShares_760" xlink:to="lab_flgc_ShareRepurchaseShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_761" xlink:to="lab_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_762" xlink:to="lab_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_763" xlink:to="lab_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_764" xlink:to="lab_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_765" xlink:to="lab_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SignificantAccountingPoliciesLineItems_766" xlink:to="lab_flgc_SignificantAccountingPoliciesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SignificantAccountingPoliciesLineItems_767" xlink:to="lab_flgc_SignificantAccountingPoliciesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_768" xlink:to="lab_flgc_SignificantAccountingPoliciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockOptionDateOfExpiry_769" xlink:to="lab_flgc_StockOptionDateOfExpiry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockOptionDateOfExpiry_770" xlink:to="lab_flgc_StockOptionDateOfExpiry_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockOptionExercisable_771" xlink:to="lab_flgc_StockOptionExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockOptionExercisable_772" xlink:to="lab_flgc_StockOptionExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockOptionsMember_773" xlink:to="lab_flgc_StockOptionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockOptionsMember_774" xlink:to="lab_flgc_StockOptionsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockRepurchasedDuringPeriodAmount_775" xlink:to="lab_flgc_StockRepurchasedDuringPeriodAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockRepurchasedDuringPeriodAmount_776" xlink:to="lab_flgc_StockRepurchasedDuringPeriodAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_StockWarrantMember_777" xlink:to="lab_flgc_StockWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryEighteenMember_778" xlink:to="lab_flgc_SubsidiaryEighteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryEighteenMember_779" xlink:to="lab_flgc_SubsidiaryEighteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryEightMember_780" xlink:to="lab_flgc_SubsidiaryEightMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryEightMember_781" xlink:to="lab_flgc_SubsidiaryEightMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryElevenMember_782" xlink:to="lab_flgc_SubsidiaryElevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryElevenMember_783" xlink:to="lab_flgc_SubsidiaryElevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryFifteenMember_784" xlink:to="lab_flgc_SubsidiaryFifteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryFifteenMember_785" xlink:to="lab_flgc_SubsidiaryFifteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryFiveMember_786" xlink:to="lab_flgc_SubsidiaryFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryFiveMember_787" xlink:to="lab_flgc_SubsidiaryFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryFourMember_788" xlink:to="lab_flgc_SubsidiaryFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryFourMember_789" xlink:to="lab_flgc_SubsidiaryFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryFourteenMember_790" xlink:to="lab_flgc_SubsidiaryFourteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryFourteenMember_791" xlink:to="lab_flgc_SubsidiaryFourteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryNineMember_792" xlink:to="lab_flgc_SubsidiaryNineMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryNineMember_793" xlink:to="lab_flgc_SubsidiaryNineMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryNineteenMember_794" xlink:to="lab_flgc_SubsidiaryNineteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryNineteenMember_795" xlink:to="lab_flgc_SubsidiaryNineteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryOneMember_796" xlink:to="lab_flgc_SubsidiaryOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryOneMember_797" xlink:to="lab_flgc_SubsidiaryOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiarySevenMember_798" xlink:to="lab_flgc_SubsidiarySevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiarySevenMember_799" xlink:to="lab_flgc_SubsidiarySevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiarySeventeenMember_800" xlink:to="lab_flgc_SubsidiarySeventeenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiarySeventeenMember_801" xlink:to="lab_flgc_SubsidiarySeventeenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiarySixMember_802" xlink:to="lab_flgc_SubsidiarySixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiarySixMember_803" xlink:to="lab_flgc_SubsidiarySixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiarySixteenMember_804" xlink:to="lab_flgc_SubsidiarySixteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiarySixteenMember_805" xlink:to="lab_flgc_SubsidiarySixteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTenMember_806" xlink:to="lab_flgc_SubsidiaryTenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTenMember_807" xlink:to="lab_flgc_SubsidiaryTenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirteenMember_808" xlink:to="lab_flgc_SubsidiaryThirteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirteenMember_809" xlink:to="lab_flgc_SubsidiaryThirteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyFiveMember_810" xlink:to="lab_flgc_SubsidiaryThirtyFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyFiveMember_811" xlink:to="lab_flgc_SubsidiaryThirtyFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyFourMember_812" xlink:to="lab_flgc_SubsidiaryThirtyFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyFourMember_813" xlink:to="lab_flgc_SubsidiaryThirtyFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyMember_814" xlink:to="lab_flgc_SubsidiaryThirtyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyMember_815" xlink:to="lab_flgc_SubsidiaryThirtyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyOneMember_816" xlink:to="lab_flgc_SubsidiaryThirtyOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyOneMember_817" xlink:to="lab_flgc_SubsidiaryThirtyOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyThreeMember_818" xlink:to="lab_flgc_SubsidiaryThirtyThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyThreeMember_819" xlink:to="lab_flgc_SubsidiaryThirtyThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyTwoMember_820" xlink:to="lab_flgc_SubsidiaryThirtyTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThirtyTwoMember_821" xlink:to="lab_flgc_SubsidiaryThirtyTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThreeMember_822" xlink:to="lab_flgc_SubsidiaryThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryThreeMember_823" xlink:to="lab_flgc_SubsidiaryThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwelveMember_824" xlink:to="lab_flgc_SubsidiaryTwelveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwelveMember_825" xlink:to="lab_flgc_SubsidiaryTwelveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyEightMember_826" xlink:to="lab_flgc_SubsidiaryTwentyEightMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyEightMember_827" xlink:to="lab_flgc_SubsidiaryTwentyEightMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyFiveMember_828" xlink:to="lab_flgc_SubsidiaryTwentyFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyFiveMember_829" xlink:to="lab_flgc_SubsidiaryTwentyFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyFourMember_830" xlink:to="lab_flgc_SubsidiaryTwentyFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyFourMember_831" xlink:to="lab_flgc_SubsidiaryTwentyFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyMember_832" xlink:to="lab_flgc_SubsidiaryTwentyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyMember_833" xlink:to="lab_flgc_SubsidiaryTwentyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyNineMember_834" xlink:to="lab_flgc_SubsidiaryTwentyNineMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyNineMember_835" xlink:to="lab_flgc_SubsidiaryTwentyNineMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyOneMember_836" xlink:to="lab_flgc_SubsidiaryTwentyOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyOneMember_837" xlink:to="lab_flgc_SubsidiaryTwentyOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentySevenMember_838" xlink:to="lab_flgc_SubsidiaryTwentySevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentySevenMember_839" xlink:to="lab_flgc_SubsidiaryTwentySevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentySixMember_840" xlink:to="lab_flgc_SubsidiaryTwentySixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentySixMember_841" xlink:to="lab_flgc_SubsidiaryTwentySixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyThreeMember_842" xlink:to="lab_flgc_SubsidiaryTwentyThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyThreeMember_843" xlink:to="lab_flgc_SubsidiaryTwentyThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyTwoMember_844" xlink:to="lab_flgc_SubsidiaryTwentyTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwentyTwoMember_845" xlink:to="lab_flgc_SubsidiaryTwentyTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwoMember_846" xlink:to="lab_flgc_SubsidiaryTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SubsidiaryTwoMember_847" xlink:to="lab_flgc_SubsidiaryTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SupplierRelationshipsMember_848" xlink:to="lab_flgc_SupplierRelationshipsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_SupplierRelationshipsMember_849" xlink:to="lab_flgc_SupplierRelationshipsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TerminationBenefitsMember_850" xlink:to="lab_flgc_TerminationBenefitsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TerminationBenefitsMember_851" xlink:to="lab_flgc_TerminationBenefitsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TerminationBenefitsMember_852" xlink:to="lab_flgc_TerminationBenefitsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ThresholdLimitOfEstimateOfLoss_853" xlink:to="lab_flgc_ThresholdLimitOfEstimateOfLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_ThresholdLimitOfEstimateOfLoss_854" xlink:to="lab_flgc_ThresholdLimitOfEstimateOfLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_855" xlink:to="lab_flgc_TotalAmountClaimedUnderIndemnificationAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_856" xlink:to="lab_flgc_TotalAmountClaimedUnderIndemnificationAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_857" xlink:to="lab_flgc_TotalAmountClaimedUnderIndemnificationAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TotalAmountPayableInViolationOfStopSaleOrders_858" xlink:to="lab_flgc_TotalAmountPayableInViolationOfStopSaleOrders_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TotalAmountPayableInViolationOfStopSaleOrders_859" xlink:to="lab_flgc_TotalAmountPayableInViolationOfStopSaleOrders_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TotalCarryingValue_860" xlink:to="lab_flgc_TotalCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TotalCarryingValue_861" xlink:to="lab_flgc_TotalCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeAccountsReceivable_862" xlink:to="lab_flgc_TradeAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeAccountsReceivable_863" xlink:to="lab_flgc_TradeAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeAccountsReceivable_864" xlink:to="lab_flgc_TradeAccountsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeAccountsReceivable_865" xlink:to="lab_flgc_TradeAccountsReceivable_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeAccountsReceivable_866" xlink:to="lab_flgc_TradeAccountsReceivable_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_867" xlink:to="lab_flgc_TradeAndOtherReceivablesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_868" xlink:to="lab_flgc_TradeAndOtherReceivablesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TrademarksAndBrandsMember_869" xlink:to="lab_flgc_TrademarksAndBrandsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TrademarksAndBrandsMember_870" xlink:to="lab_flgc_TrademarksAndBrandsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TrademarksAndBrandsMember_871" xlink:to="lab_flgc_TrademarksAndBrandsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradenamesMember_872" xlink:to="lab_flgc_TradenamesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeReceivable_873" xlink:to="lab_flgc_TradeReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeReceivable_874" xlink:to="lab_flgc_TradeReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeReceivable_875" xlink:to="lab_flgc_TradeReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeReceivableBeginningBalance_876" xlink:to="lab_flgc_TradeReceivableBeginningBalance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TradeReceivableBeginningBalance_877" xlink:to="lab_flgc_TradeReceivableBeginningBalance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TruhcHoldingGmbhMember_878" xlink:to="lab_flgc_TruhcHoldingGmbhMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TruhcHoldingGmbhMember_879" xlink:to="lab_flgc_TruhcHoldingGmbhMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TruhcHoldingGmbhMember_880" xlink:to="lab_flgc_TruhcHoldingGmbhMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TruhcPharmaGmbhMember_881" xlink:to="lab_flgc_TruhcPharmaGmbhMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TruhcPharmaGmbhMember_882" xlink:to="lab_flgc_TruhcPharmaGmbhMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyOneAnnualImpairmentTestMember_883" xlink:to="lab_flgc_TwoThousandTwentyOneAnnualImpairmentTestMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyOneAnnualImpairmentTestMember_884" xlink:to="lab_flgc_TwoThousandTwentyOneAnnualImpairmentTestMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_885" xlink:to="lab_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_886" xlink:to="lab_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_887" xlink:to="lab_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_888" xlink:to="lab_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_889" xlink:to="lab_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_890" xlink:to="lab_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_891" xlink:to="lab_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_892" xlink:to="lab_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_893" xlink:to="lab_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoImpairmentTestMember_894" xlink:to="lab_flgc_TwoThousandTwentyTwoImpairmentTestMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoImpairmentTestMember_895" xlink:to="lab_flgc_TwoThousandTwentyTwoImpairmentTestMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_896" xlink:to="lab_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_897" xlink:to="lab_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoPlanMember_898" xlink:to="lab_flgc_TwoThousandTwentyTwoPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_TwoThousandTwentyTwoPlanMember_899" xlink:to="lab_flgc_TwoThousandTwentyTwoPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnitedKingdomRevenueAgencyMember_900" xlink:to="lab_flgc_UnitedKingdomRevenueAgencyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnitedKingdomRevenueAgencyMember_901" xlink:to="lab_flgc_UnitedKingdomRevenueAgencyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnitedStatesRevenueAgencyMember_902" xlink:to="lab_flgc_UnitedStatesRevenueAgencyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnitedStatesRevenueAgencyMember_903" xlink:to="lab_flgc_UnitedStatesRevenueAgencyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnitOfferingMember_904" xlink:to="lab_flgc_UnitOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnitOfferingMember_905" xlink:to="lab_flgc_UnitOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnrealizedLossesOnSecurities_906" xlink:to="lab_flgc_UnrealizedLossesOnSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnrealizedLossesOnSecurities_907" xlink:to="lab_flgc_UnrealizedLossesOnSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnusedLossCarryforwards_908" xlink:to="lab_flgc_UnusedLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_UnvestedRsusGrantedToExecutiveOfficers_909" xlink:to="lab_flgc_UnvestedRsusGrantedToExecutiveOfficers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_USFederalIncomeTaxAuthorityMember_910" xlink:to="lab_flgc_USFederalIncomeTaxAuthorityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_USFederalIncomeTaxAuthorityMember_911" xlink:to="lab_flgc_USFederalIncomeTaxAuthorityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_USStateIncomeTaxAuthorityMember_912" xlink:to="lab_flgc_USStateIncomeTaxAuthorityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_USStateIncomeTaxAuthorityMember_913" xlink:to="lab_flgc_USStateIncomeTaxAuthorityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VesselAssetGroupMember_914" xlink:to="lab_flgc_VesselAssetGroupMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VesselAssetGroupMember_915" xlink:to="lab_flgc_VesselAssetGroupMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VesselMember_916" xlink:to="lab_flgc_VesselMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VesselOwnersMember_917" xlink:to="lab_flgc_VesselOwnersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VesselOwnersMember_918" xlink:to="lab_flgc_VesselOwnersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VesselsMember_919" xlink:to="lab_flgc_VesselsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VesselsMember_920" xlink:to="lab_flgc_VesselsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VestInOneYearMember_921" xlink:to="lab_flgc_VestInOneYearMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VestInOneYearMember_922" xlink:to="lab_flgc_VestInOneYearMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VestInThreeYearsMember_923" xlink:to="lab_flgc_VestInThreeYearsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_VestInThreeYearsMember_924" xlink:to="lab_flgc_VestInThreeYearsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarehousingAndOfficeSpaceMember_925" xlink:to="lab_flgc_WarehousingAndOfficeSpaceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarehousingAndOfficeSpaceMember_926" xlink:to="lab_flgc_WarehousingAndOfficeSpaceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantAmendedExercisePrice_927" xlink:to="lab_flgc_WarrantAmendedExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantExercisePricePriorToAmendment_928" xlink:to="lab_flgc_WarrantExercisePricePriorToAmendment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantIssued_929" xlink:to="lab_flgc_WarrantIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantIssued_930" xlink:to="lab_flgc_WarrantIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantOneMember_931" xlink:to="lab_flgc_WarrantOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantPurchase_932" xlink:to="lab_flgc_WarrantPurchase_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantPurchase_933" xlink:to="lab_flgc_WarrantPurchase_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsAbstract_934" xlink:to="lab_flgc_WarrantsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsCadOnePointZeroZeroMember_935" xlink:to="lab_flgc_WarrantsCadOnePointZeroZeroMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsCadOnePointZeroZeroMember_936" xlink:to="lab_flgc_WarrantsCadOnePointZeroZeroMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsCadOnePointZeroZeroMember_937" xlink:to="lab_flgc_WarrantsCadOnePointZeroZeroMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsCadZeroPointThreeZeroMember_938" xlink:to="lab_flgc_WarrantsCadZeroPointThreeZeroMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsCadZeroPointThreeZeroMember_939" xlink:to="lab_flgc_WarrantsCadZeroPointThreeZeroMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsCadZeroPointThreeZeroMember_940" xlink:to="lab_flgc_WarrantsCadZeroPointThreeZeroMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsDateOfExpiry_941" xlink:to="lab_flgc_WarrantsDateOfExpiry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsDateOfExpiry_942" xlink:to="lab_flgc_WarrantsDateOfExpiry_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsDateOfExpiry_943" xlink:to="lab_flgc_WarrantsDateOfExpiry_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsDisclosureTextBlock_944" xlink:to="lab_flgc_WarrantsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsDisclosureTextBlock_945" xlink:to="lab_flgc_WarrantsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsExercisedAmount_946" xlink:to="lab_flgc_WarrantsExercisedAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsExercisedShares_947" xlink:to="lab_flgc_WarrantsExercisedShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsExpiredOrCancelledAmount_948" xlink:to="lab_flgc_WarrantsExpiredOrCancelledAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsExpiredOrCancelledAmount_949" xlink:to="lab_flgc_WarrantsExpiredOrCancelledAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsExpiredOrCancelledAmount_950" xlink:to="lab_flgc_WarrantsExpiredOrCancelledAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsFiveMember_951" xlink:to="lab_flgc_WarrantsFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsFiveMember_952" xlink:to="lab_flgc_WarrantsFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsFourMember_953" xlink:to="lab_flgc_WarrantsFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsFourMember_954" xlink:to="lab_flgc_WarrantsFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_955" xlink:to="lab_flgc_WarrantsIssuedDuringPeriodExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsIssuedToPlacementAgent_956" xlink:to="lab_flgc_WarrantsIssuedToPlacementAgent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsIssuedToPlacementAgent_957" xlink:to="lab_flgc_WarrantsIssuedToPlacementAgent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsIssuedToPlacementAgent_958" xlink:to="lab_flgc_WarrantsIssuedToPlacementAgent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsLineItems_959" xlink:to="lab_flgc_WarrantsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsMember_960" xlink:to="lab_flgc_WarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsOneMember_961" xlink:to="lab_flgc_WarrantsOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsOneMember_962" xlink:to="lab_flgc_WarrantsOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsRemainingLifeInYears_963" xlink:to="lab_flgc_WarrantsRemainingLifeInYears_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsRemainingLifeInYears_964" xlink:to="lab_flgc_WarrantsRemainingLifeInYears_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsSixMember_965" xlink:to="lab_flgc_WarrantsSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsSixMember_966" xlink:to="lab_flgc_WarrantsSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsTable_967" xlink:to="lab_flgc_WarrantsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsThreeMember_968" xlink:to="lab_flgc_WarrantsThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsThreeMember_969" xlink:to="lab_flgc_WarrantsThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsTwoMember_970" xlink:to="lab_flgc_WarrantsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WarrantsTwoMember_971" xlink:to="lab_flgc_WarrantsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_972" xlink:to="lab_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_973" xlink:to="lab_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WeightedAverageExercisePriceOfWarrantsExercised_974" xlink:to="lab_flgc_WeightedAverageExercisePriceOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WeightedAverageExercisePriceOfWarrantsExercised_975" xlink:to="lab_flgc_WeightedAverageExercisePriceOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WeightedAverageExercisePriceOfWarrantsIssued_976" xlink:to="lab_flgc_WeightedAverageExercisePriceOfWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WeightedAverageExercisePriceOfWarrantsIssued_977" xlink:to="lab_flgc_WeightedAverageExercisePriceOfWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WritedownsReversalsOfInventories_978" xlink:to="lab_flgc_WritedownsReversalsOfInventories_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WritedownsReversalsOfInventories_979" xlink:to="lab_flgc_WritedownsReversalsOfInventories_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WriterMember_980" xlink:to="lab_flgc_WriterMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WriterMember_981" xlink:to="lab_flgc_WriterMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WrongfullyTransferredShares_982" xlink:to="lab_flgc_WrongfullyTransferredShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_WrongfullyTransferredShares_983" xlink:to="lab_flgc_WrongfullyTransferredShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_984" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_985" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_986" xlink:to="lab_srt_ChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_987" xlink:to="lab_srt_ChiefExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_988" xlink:to="lab_srt_ChiefExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_989" xlink:to="lab_srt_ChiefFinancialOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_990" xlink:to="lab_srt_ChiefFinancialOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis_991" xlink:to="lab_srt_ConsolidatedEntitiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain_992" xlink:to="lab_srt_ConsolidatedEntitiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis_993" xlink:to="lab_srt_ConsolidationItemsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain_994" xlink:to="lab_srt_ConsolidationItemsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_995" xlink:to="lab_srt_CounterpartyNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_996" xlink:to="lab_srt_CurrencyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_997" xlink:to="lab_srt_DirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_998" xlink:to="lab_srt_DirectorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_999" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_1000" xlink:to="lab_srt_MaximumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_1001" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_1002" xlink:to="lab_srt_MinimumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis_1003" xlink:to="lab_srt_OwnershipAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain_1004" xlink:to="lab_srt_OwnershipDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_1005" xlink:to="lab_srt_ProductOrServiceAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_1006" xlink:to="lab_srt_ProductsAndServicesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_1007" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_1008" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ReportableGeographicalComponentsMember_1009" xlink:to="lab_srt_ReportableGeographicalComponentsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1010" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_1011" xlink:to="lab_srt_SegmentGeographicalDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_1012" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_1013" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1014" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1015" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_1016" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_1017" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1018" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1019" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1020" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1021" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1022" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1023" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1024" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1025" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1026" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1027" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1028" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1029" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1030" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1031" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1032" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1033" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1034" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1035" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1036" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_1037" xlink:to="lab_us-gaap_AdditionalPaidInCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1038" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1039" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_1040" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_1041" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1042" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1043" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_1044" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1045" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1046" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1047" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1048" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1049" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1050" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1051" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1052" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1053" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_1054" xlink:to="lab_us-gaap_AdvertisingExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_1055" xlink:to="lab_us-gaap_AdvertisingExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_1056" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_1057" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_1058" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_1059" xlink:to="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_1060" xlink:to="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1061" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1062" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1063" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1064" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1065" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_1066" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_1067" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_1068" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_1069" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_1070" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1071" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1072" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1073" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1074" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1075" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1076" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_1077" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_1078" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_1079" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_1080" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_1081" xlink:to="lab_us-gaap_AssetImpairmentCharges_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_1082" xlink:to="lab_us-gaap_AssetImpairmentCharges_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_1083" xlink:to="lab_us-gaap_AssetImpairmentCharges_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_1084" xlink:to="lab_us-gaap_AssetImpairmentCharges_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentChargesTextBlock_1085" xlink:to="lab_us-gaap_AssetImpairmentChargesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentChargesTextBlock_1086" xlink:to="lab_us-gaap_AssetImpairmentChargesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_1087" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_1088" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_1089" xlink:to="lab_us-gaap_Assets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_1090" xlink:to="lab_us-gaap_Assets_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_1091" xlink:to="lab_us-gaap_Assets_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_1092" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_1093" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_1094" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1095" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1096" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1097" xlink:to="lab_us-gaap_AssetsCurrentAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_1098" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_1099" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1100" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1101" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1102" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1103" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1104" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_1105" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_1106" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1107" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1108" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1109" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_1110" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_1111" xlink:to="lab_us-gaap_AwardTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_1112" xlink:to="lab_us-gaap_BuildingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_1113" xlink:to="lab_us-gaap_BuildingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1114" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1115" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_1116" xlink:to="lab_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_1117" xlink:to="lab_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1118" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1119" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1120" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1121" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1122" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_1123" xlink:to="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_1124" xlink:to="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1125" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1126" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1127" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_1128" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_1129" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1130" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1131" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_1132" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_1133" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1134" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1135" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1136" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1137" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1138" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1139" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1140" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1141" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1142" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1143" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1144" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1145" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1146" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1147" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1148" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1149" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1150" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1151" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1152" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1153" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1154" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1155" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1156" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1157" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1158" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1159" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1160" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1161" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1162" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1163" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1164" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_1165" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_1166" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_1167" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_1168" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1169" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1170" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1171" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1172" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1173" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1174" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1175" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1176" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1177" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1178" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1179" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_1180" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_1181" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1182" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1183" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1184" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1185" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1186" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1187" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1188" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1189" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1190" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1191" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1192" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1193" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_1194" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_1195" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1196" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1197" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CanadaRevenueAgencyMember_1198" xlink:to="lab_us-gaap_CanadaRevenueAgencyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CanadaRevenueAgencyMember_1199" xlink:to="lab_us-gaap_CanadaRevenueAgencyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Capital_1200" xlink:to="lab_us-gaap_Capital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_1201" xlink:to="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_1202" xlink:to="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligations_1203" xlink:to="lab_us-gaap_CapitalLeaseObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligations_1204" xlink:to="lab_us-gaap_CapitalLeaseObligations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_1205" xlink:to="lab_us-gaap_Cash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_1206" xlink:to="lab_us-gaap_Cash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_1207" xlink:to="lab_us-gaap_Cash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_1208" xlink:to="lab_us-gaap_Cash_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1209" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1210" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1211" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1212" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1213" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1214" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1215" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1216" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1217" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1218" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1219" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1220" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1221" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_1222" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_1223" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_1224" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_1225" xlink:to="lab_us-gaap_ClassOfStockLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1226" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1227" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1228" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1229" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1230" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1231" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1232" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1233" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1234" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1235" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1236" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1237" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1238" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis_1239" xlink:to="lab_us-gaap_CollateralAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain_1240" xlink:to="lab_us-gaap_CollateralDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_1241" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1242" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1243" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1244" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1245" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1246" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_1247" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_1248" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_1249" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_1250" xlink:to="lab_us-gaap_CommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_1251" xlink:to="lab_us-gaap_CommonStockSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_1252" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_1253" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_1254" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_1255" xlink:to="lab_us-gaap_CommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitIssued_1256" xlink:to="lab_us-gaap_CommonUnitIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitIssued_1257" xlink:to="lab_us-gaap_CommonUnitIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Communication_1258" xlink:to="lab_us-gaap_Communication_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1259" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1260" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1261" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1262" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1263" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1264" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_1265" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_1266" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1267" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1268" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1269" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_1270" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_1271" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_1272" xlink:to="lab_us-gaap_ConstructionInProgressMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_1273" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_1274" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_1275" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_1276" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_1277" xlink:to="lab_us-gaap_CreditFacilityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_1278" xlink:to="lab_us-gaap_CreditFacilityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditRiskMember_1279" xlink:to="lab_us-gaap_CreditRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditRiskMember_1280" xlink:to="lab_us-gaap_CreditRiskMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEarningsDeficit_1281" xlink:to="lab_us-gaap_CumulativeEarningsDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEarningsDeficit_1282" xlink:to="lab_us-gaap_CumulativeEarningsDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1283" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember_1284" xlink:to="lab_us-gaap_CustomerRelationshipsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember_1285" xlink:to="lab_us-gaap_CustomerRelationshipsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember_1286" xlink:to="lab_us-gaap_CustomerRelationshipsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1287" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_1288" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_1289" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_1290" xlink:to="lab_us-gaap_DebtInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1291" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1292" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1293" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_1294" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_1295" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_1296" xlink:to="lab_us-gaap_DebtInstrumentFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_1297" xlink:to="lab_us-gaap_DebtInstrumentFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1298" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1299" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1300" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1301" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1302" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1303" xlink:to="lab_us-gaap_DebtInstrumentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1304" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment_1305" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment_1306" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment_1307" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_1308" xlink:to="lab_us-gaap_DebtInstrumentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1309" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1310" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1311" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1312" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1313" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1314" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1315" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1316" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1317" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1318" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1319" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1320" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1321" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1322" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1323" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1324" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1325" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1326" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1327" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1328" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1329" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_1330" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_1331" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1332" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1333" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1334" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1335" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1336" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1337" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1338" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1339" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1340" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1341" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_1342" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_1343" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_1344" xlink:to="lab_us-gaap_DepreciationAndAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_1345" xlink:to="lab_us-gaap_DepreciationAndAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_1346" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_1347" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_1348" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_1349" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_1350" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1351" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1352" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1353" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1354" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1355" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1356" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1357" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1358" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1359" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1360" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1361" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1362" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1363" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1364" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1365" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1366" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1367" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1368" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1369" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1370" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1371" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1372" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1373" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1374" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1375" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1376" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_1377" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_1378" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1379" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1380" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1381" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1382" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1383" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1384" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1385" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1386" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1387" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1388" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1389" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1390" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_1391" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_1392" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_1393" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_1394" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_1395" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_1396" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1397" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1398" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1399" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1400" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1401" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1402" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_1403" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_1404" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1405" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1406" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1407" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1408" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_1409" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_1410" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1411" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1412" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1413" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1414" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1415" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1416" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_1417" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_1418" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_1419" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_1420" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_1421" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_1422" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_1423" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_1424" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1425" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1426" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1427" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1428" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1429" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1430" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1431" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_1432" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_1433" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_1434" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_1435" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1436" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_1437" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1438" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1439" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_1440" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1441" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1442" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1443" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1444" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1445" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1446" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1447" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1448" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1449" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1450" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_1451" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1452" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1453" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_1454" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_1455" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1456" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1457" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1458" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_1459" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_1460" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_1461" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_1462" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue_1463" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue_1464" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1465" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1466" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1467" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1468" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1469" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability_1470" xlink:to="lab_us-gaap_FairValueNetAssetLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability_1471" xlink:to="lab_us-gaap_FairValueNetAssetLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability_1472" xlink:to="lab_us-gaap_FairValueNetAssetLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1473" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1474" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1475" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1476" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialAssetNotPastDueMember_1477" xlink:to="lab_us-gaap_FinancialAssetNotPastDueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialAssetNotPastDueMember_1478" xlink:to="lab_us-gaap_FinancialAssetNotPastDueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1479" xlink:to="lab_us-gaap_FinancialInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_1480" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_1481" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_1482" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_1483" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivables1To29DaysPastDueMember_1484" xlink:to="lab_us-gaap_FinancingReceivables1To29DaysPastDueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivables1To29DaysPastDueMember_1485" xlink:to="lab_us-gaap_FinancingReceivables1To29DaysPastDueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivables30To59DaysPastDueMember_1486" xlink:to="lab_us-gaap_FinancingReceivables30To59DaysPastDueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivables30To59DaysPastDueMember_1487" xlink:to="lab_us-gaap_FinancingReceivables30To59DaysPastDueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivables60To89DaysPastDueMember_1488" xlink:to="lab_us-gaap_FinancingReceivables60To89DaysPastDueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivables60To89DaysPastDueMember_1489" xlink:to="lab_us-gaap_FinancingReceivables60To89DaysPastDueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_1490" xlink:to="lab_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_1491" xlink:to="lab_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1492" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1493" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1494" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1495" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1496" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1497" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1498" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1499" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1500" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1501" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1502" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_1503" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_1504" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_1505" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_1506" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_1507" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_1508" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_1509" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_1510" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_1511" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_1512" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1513" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1514" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1515" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1516" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1517" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1518" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1519" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1520" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1521" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1522" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1523" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_1524" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_1525" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1526" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1527" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1528" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1529" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1530" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1531" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1532" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1533" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1534" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1535" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1536" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1537" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1538" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1539" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1540" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_1541" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_1542" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_1543" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_1544" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1545" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1546" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_1547" xlink:to="lab_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_1548" xlink:to="lab_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FranchiseMember_1549" xlink:to="lab_us-gaap_FranchiseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FranchiseMember_1550" xlink:to="lab_us-gaap_FranchiseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_1551" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_1552" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1553" xlink:to="lab_us-gaap_Goodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1554" xlink:to="lab_us-gaap_Goodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1555" xlink:to="lab_us-gaap_Goodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1556" xlink:to="lab_us-gaap_Goodwill_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1557" xlink:to="lab_us-gaap_Goodwill_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1558" xlink:to="lab_us-gaap_Goodwill_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_1559" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_1560" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1561" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1562" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1563" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1564" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1565" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross_1566" xlink:to="lab_us-gaap_GoodwillGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1567" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1568" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_1569" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_1570" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_1571" xlink:to="lab_us-gaap_GoodwillLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillMember_1572" xlink:to="lab_us-gaap_GoodwillMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillMember_1573" xlink:to="lab_us-gaap_GoodwillMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_1574" xlink:to="lab_us-gaap_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_1575" xlink:to="lab_us-gaap_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1576" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1577" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1578" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1579" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1580" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1581" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1582" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1583" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1584" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1585" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_1586" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_1587" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_1588" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_1589" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_1590" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1591" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1592" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1593" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1594" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1595" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1596" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1597" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1598" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1599" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1600" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1601" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1602" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1603" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_1604" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1605" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1606" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1607" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1608" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1609" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1610" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1611" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1612" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments_1613" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments_1614" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments_1615" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1616" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1617" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1618" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1619" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1620" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1621" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1622" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1623" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_1624" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_1625" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1626" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1627" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1628" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1629" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1630" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1631" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1632" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1633" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_1634" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_1635" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_1636" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1637" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1638" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1639" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1640" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries_1641" xlink:to="lab_us-gaap_InsuranceRecoveries_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_1642" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_1643" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1644" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1645" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1646" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1647" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1648" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1649" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1650" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1651" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_1652" xlink:to="lab_us-gaap_InterestAndDebtExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_1653" xlink:to="lab_us-gaap_InterestAndDebtExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_1654" xlink:to="lab_us-gaap_InterestAndDebtExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_1655" xlink:to="lab_us-gaap_InterestAndDebtExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_1656" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_1657" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_1658" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_1659" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_1660" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_1661" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1662" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1663" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1664" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1665" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_1666" xlink:to="lab_us-gaap_InterestIncomeOperating_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_1667" xlink:to="lab_us-gaap_InterestIncomeOperating_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_1668" xlink:to="lab_us-gaap_InterestIncomeOperating_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_1669" xlink:to="lab_us-gaap_InterestIncomeOperating_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_1670" xlink:to="lab_us-gaap_InterestIncomeOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_1671" xlink:to="lab_us-gaap_InterestIncomeOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_1672" xlink:to="lab_us-gaap_InterestIncomeOther_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_1673" xlink:to="lab_us-gaap_InterestIncomeOther_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_1674" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_1675" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1676" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_1677" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_1678" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_1679" xlink:to="lab_us-gaap_InventoryFinishedGoods_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_1680" xlink:to="lab_us-gaap_InventoryFinishedGoods_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_1681" xlink:to="lab_us-gaap_InventoryNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_1682" xlink:to="lab_us-gaap_InventoryNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_1683" xlink:to="lab_us-gaap_InventoryNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_1684" xlink:to="lab_us-gaap_InventoryNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_1685" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_1686" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSupplies_1687" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSupplies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSupplies_1688" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSupplies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_1689" xlink:to="lab_us-gaap_InvestmentInAffiliateActivityLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtFairValue_1690" xlink:to="lab_us-gaap_InvestmentOwnedAtFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtFairValue_1691" xlink:to="lab_us-gaap_InvestmentOwnedAtFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtFairValue_1692" xlink:to="lab_us-gaap_InvestmentOwnedAtFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_1693" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_1694" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract_1695" xlink:to="lab_us-gaap_InvestmentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract_1696" xlink:to="lab_us-gaap_InvestmentsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_1697" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_1698" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_1699" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1700" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock_1701" xlink:to="lab_us-gaap_InvestmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock_1702" xlink:to="lab_us-gaap_InvestmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock_1703" xlink:to="lab_us-gaap_InvestmentTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_1704" xlink:to="lab_us-gaap_InvestmentTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1705" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_1706" xlink:to="lab_us-gaap_LandMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_1707" xlink:to="lab_us-gaap_LeaseCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_1708" xlink:to="lab_us-gaap_LeaseCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_1709" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_1710" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_1711" xlink:to="lab_us-gaap_LeasesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1712" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1713" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1714" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1715" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1716" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_1717" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_1718" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1719" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1720" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1721" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1722" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1723" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1724" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1725" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1726" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1727" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1728" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1729" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1730" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1731" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1732" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1733" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1734" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1735" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1736" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1737" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1738" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_1739" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_1740" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_1741" xlink:to="lab_us-gaap_Liabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_1742" xlink:to="lab_us-gaap_LiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1743" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1744" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_1745" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_1746" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_1747" xlink:to="lab_us-gaap_LiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1748" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1749" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_1750" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_1751" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1752" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1753" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_1754" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_1755" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1756" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1757" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1758" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1759" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1760" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1761" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_1762" xlink:to="lab_us-gaap_LicenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_1763" xlink:to="lab_us-gaap_LicenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit_1764" xlink:to="lab_us-gaap_LineOfCredit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit_1765" xlink:to="lab_us-gaap_LineOfCredit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1766" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1767" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_1768" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_1769" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1770" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1771" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1772" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1773" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1774" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_1775" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_1776" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_1777" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1778" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1779" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1780" xlink:to="lab_us-gaap_LineOfCreditFacilityTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1781" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1782" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayable_1783" xlink:to="lab_us-gaap_LoansPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayable_1784" xlink:to="lab_us-gaap_LoansPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansReceivableFairValueDisclosure_1785" xlink:to="lab_us-gaap_LoansReceivableFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansReceivableFairValueDisclosure_1786" xlink:to="lab_us-gaap_LoansReceivableFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_1787" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_1788" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_1789" xlink:to="lab_us-gaap_LongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_1790" xlink:to="lab_us-gaap_LongTermDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_1791" xlink:to="lab_us-gaap_LongTermDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_1792" xlink:to="lab_us-gaap_LongTermDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_1793" xlink:to="lab_us-gaap_LongTermDebt_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_1794" xlink:to="lab_us-gaap_LongTermDebtCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1795" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1796" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_1797" xlink:to="lab_us-gaap_LongTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_1798" xlink:to="lab_us-gaap_LongTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_1799" xlink:to="lab_us-gaap_LongTermInvestments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1800" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1801" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1802" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments_1803" xlink:to="lab_us-gaap_LossContingencyAccrualPayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments_1804" xlink:to="lab_us-gaap_LossContingencyAccrualPayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision_1805" xlink:to="lab_us-gaap_LossContingencyAccrualProvision_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision_1806" xlink:to="lab_us-gaap_LossContingencyAccrualProvision_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision_1807" xlink:to="lab_us-gaap_LossContingencyAccrualProvision_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue_1808" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue_1809" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_1810" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_1811" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1812" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1813" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod_1814" xlink:to="lab_us-gaap_LossContingencyLossInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod_1815" xlink:to="lab_us-gaap_LossContingencyLossInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_1816" xlink:to="lab_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_1817" xlink:to="lab_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_1818" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_1819" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_1820" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense_1821" xlink:to="lab_us-gaap_ManagementFeeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_1822" xlink:to="lab_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_1823" xlink:to="lab_us-gaap_MinorityInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_1824" xlink:to="lab_us-gaap_MinorityInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1825" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1826" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_1827" xlink:to="lab_us-gaap_NatureOfOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_1828" xlink:to="lab_us-gaap_NatureOfOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1829" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1830" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1831" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1832" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1833" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1834" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1835" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1836" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1837" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1838" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1839" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1840" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1841" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1842" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1843" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1844" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1845" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1846" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember_1847" xlink:to="lab_us-gaap_NoncompeteAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember_1848" xlink:to="lab_us-gaap_NoncompeteAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember_1849" xlink:to="lab_us-gaap_NoncompeteAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_1850" xlink:to="lab_us-gaap_NoncontrollingInterestMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_1851" xlink:to="lab_us-gaap_NoncontrollingInterestMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivables_1852" xlink:to="lab_us-gaap_NontradeReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivables_1853" xlink:to="lab_us-gaap_NontradeReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivables_1854" xlink:to="lab_us-gaap_NontradeReceivables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_1855" xlink:to="lab_us-gaap_NumberOfOperatingSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_1856" xlink:to="lab_us-gaap_NumberOfOperatingSegments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_1857" xlink:to="lab_us-gaap_OfficersCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_1858" xlink:to="lab_us-gaap_OfficersCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_1859" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_1860" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1861" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_1862" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_1863" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_1864" xlink:to="lab_us-gaap_OperatingLeaseExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_1865" xlink:to="lab_us-gaap_OperatingLeaseExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_1866" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_1867" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1868" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1869" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1870" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1871" xlink:to="lab_us-gaap_OperatingLeaseLiability_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1872" xlink:to="lab_us-gaap_OperatingLeaseLiability_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1873" xlink:to="lab_us-gaap_OperatingLeaseLiability_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_1874" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_1875" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_1876" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1877" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1878" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1879" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1880" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_1881" xlink:to="lab_us-gaap_OperatingLeasePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_1882" xlink:to="lab_us-gaap_OperatingLeasePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_1883" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_1884" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1885" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1886" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1887" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1888" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1889" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1890" xlink:to="lab_us-gaap_OperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1891" xlink:to="lab_us-gaap_OperatingLossCarryforwards_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1892" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1893" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1894" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1895" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1896" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1897" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1898" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges_1899" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges_1900" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges_1901" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1902" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1903" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1904" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1905" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1906" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1907" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1908" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1909" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1910" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1911" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1912" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1913" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1914" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1915" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating_1916" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating_1917" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1918" xlink:to="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1919" xlink:to="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments_1920" xlink:to="lab_us-gaap_OtherLongTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments_1921" xlink:to="lab_us-gaap_OtherLongTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables_1922" xlink:to="lab_us-gaap_OtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables_1923" xlink:to="lab_us-gaap_OtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_1924" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_1925" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember_1926" xlink:to="lab_us-gaap_PatentsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember_1927" xlink:to="lab_us-gaap_PatentsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_1928" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_1929" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_1930" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_1931" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1932" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1933" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1934" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1935" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1936" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1937" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense_1938" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense_1939" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_1940" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_1941" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_1942" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_1943" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1944" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1945" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_1946" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_1947" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1948" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1949" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_1950" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_1951" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1952" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1953" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1954" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1955" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_1956" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_1957" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1958" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1959" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1960" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1961" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_1962" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_1963" xlink:to="lab_us-gaap_ProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_1964" xlink:to="lab_us-gaap_ProfessionalFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1965" xlink:to="lab_us-gaap_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1966" xlink:to="lab_us-gaap_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1967" xlink:to="lab_us-gaap_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1968" xlink:to="lab_us-gaap_ProfitLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1969" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1970" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1971" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1972" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1973" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_1974" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_1975" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1976" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1977" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1978" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1979" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1980" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1981" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1982" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1983" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1984" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1985" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1986" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1987" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_1988" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_1989" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_1990" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_1991" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_1992" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_1993" xlink:to="lab_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_1994" xlink:to="lab_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_1995" xlink:to="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_1996" xlink:to="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_1997" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1998" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1999" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2000" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_2001" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2002" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2003" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2004" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2005" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2006" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_2007" xlink:to="lab_us-gaap_RepaymentsOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_2008" xlink:to="lab_us-gaap_RepaymentsOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis_2009" xlink:to="lab_us-gaap_ReportingUnitAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain_2010" xlink:to="lab_us-gaap_ReportingUnitDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_2011" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2012" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2013" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_2014" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_2015" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_2016" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_2017" xlink:to="lab_us-gaap_RestrictedStockExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_2018" xlink:to="lab_us-gaap_RestrictedStockExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_2019" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_2020" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2021" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2022" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_2023" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_2024" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2025" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2026" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_2027" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_2028" xlink:to="lab_us-gaap_Revenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_2029" xlink:to="lab_us-gaap_Revenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_2030" xlink:to="lab_us-gaap_Revenues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2031" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2032" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_2033" xlink:to="lab_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2034" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2035" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2036" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2037" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2038" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2039" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2040" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2041" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2042" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2043" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2044" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2045" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2046" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2047" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_2048" xlink:to="lab_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2049" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2050" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2051" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_2052" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_2053" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_2054" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2055" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2056" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2057" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_2058" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_2059" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_2060" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2061" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2062" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2063" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2064" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2065" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2066" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_2067" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_2068" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2069" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_2070" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_2071" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2072" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2073" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2074" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2075" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2076" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2077" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2078" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2079" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2080" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2081" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionAxis_2082" xlink:to="lab_us-gaap_SecuritiesFinancingTransactionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_2083" xlink:to="lab_us-gaap_SecuritiesFinancingTransactionTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember_2084" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember_2085" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_2086" xlink:to="lab_us-gaap_SegmentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_2087" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_2088" xlink:to="lab_us-gaap_SegmentReportingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_2089" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_2090" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2091" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_2092" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_2093" xlink:to="lab_us-gaap_SeveranceCosts1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_2094" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_2095" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_2096" xlink:to="lab_us-gaap_ShareBasedCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_2097" xlink:to="lab_us-gaap_ShareBasedCompensation_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_2098" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2099" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2100" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2101" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2102" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_2103" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_2104" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2105" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2106" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2107" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2108" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2109" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2110" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2111" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2112" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2113" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2114" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2115" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2116" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2117" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2118" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2119" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2120" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2121" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2122" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2123" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2124" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2125" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2126" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2127" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2128" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2129" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2130" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2131" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2132" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2133" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2134" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2135" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2136" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2137" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2138" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2139" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2140" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2141" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2142" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2143" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2144" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2145" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2146" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2147" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2148" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2149" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2150" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2151" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2152" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2153" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2154" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2155" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2156" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2157" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2158" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2159" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2160" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2161" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2162" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2163" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2164" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2165" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2166" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2167" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2168" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2169" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2170" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2171" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2172" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2173" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2174" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2175" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2176" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2177" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2178" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2179" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2180" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_2181" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_2182" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2183" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2184" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2185" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2186" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2187" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2188" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2189" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2190" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2191" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2192" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2193" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2194" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2195" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2196" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2197" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2198" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_2199" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_2200" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2201" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2202" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2203" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2204" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2205" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2206" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2207" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2208" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2209" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_2210" xlink:to="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_2211" xlink:to="lab_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2212" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2213" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_2214" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_2215" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_2216" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_2217" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_2218" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_2219" xlink:to="lab_us-gaap_SharePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_2220" xlink:to="lab_us-gaap_SharePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_2221" xlink:to="lab_us-gaap_SharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_2222" xlink:to="lab_us-gaap_SharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_2223" xlink:to="lab_us-gaap_SharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_2224" xlink:to="lab_us-gaap_SharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_2225" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_2226" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_2227" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_2228" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost_2229" xlink:to="lab_us-gaap_ShortTermLeaseCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost_2230" xlink:to="lab_us-gaap_ShortTermLeaseCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2231" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2232" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2233" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2234" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_2235" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2236" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2237" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2238" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2239" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_2240" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_2241" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_2242" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_2243" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_2244" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_2245" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2246" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2247" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2248" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2249" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2250" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2251" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2252" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2253" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2254" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2255" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2256" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock_2257" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock_2258" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit_2259" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit_2260" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_2261" xlink:to="lab_us-gaap_StockIssued1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_2262" xlink:to="lab_us-gaap_StockIssued1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2263" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2264" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2265" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2266" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2267" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2268" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2269" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2270" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2271" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2272" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2273" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2274" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2275" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2276" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2277" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2278" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2279" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2280" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2281" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2282" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2283" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2284" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2285" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2286" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2287" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2288" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2289" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_2290" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_2291" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2292" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_2293" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2294" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2295" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2296" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2297" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2298" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2299" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense_2300" xlink:to="lab_us-gaap_StockOptionPlanExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense_2301" xlink:to="lab_us-gaap_StockOptionPlanExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares_2302" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares_2303" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares_2304" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue_2305" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue_2306" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue_2307" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_2308" xlink:to="lab_us-gaap_SubleaseIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_2309" xlink:to="lab_us-gaap_SubleaseIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_2310" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_2311" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2312" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_2313" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_2314" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_2315" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2316" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2317" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges_2318" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges_2319" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_2320" xlink:to="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance_2321" xlink:to="lab_us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember_2322" xlink:to="lab_us-gaap_TrademarksMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2323" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TravelAndEntertainmentExpense_2324" xlink:to="lab_us-gaap_TravelAndEntertainmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2325" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnderwritingCommitments_2326" xlink:to="lab_us-gaap_UnderwritingCommitments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnderwritingCommitments_2327" xlink:to="lab_us-gaap_UnderwritingCommitments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_2328" xlink:to="lab_us-gaap_UnusualRisksAndUncertaintiesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_2329" xlink:to="lab_us-gaap_UnusualRisksAndUncertaintiesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_2330" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_2331" xlink:to="lab_us-gaap_UseOfEstimates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivable_2332" xlink:to="lab_us-gaap_ValueAddedTaxReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivable_2333" xlink:to="lab_us-gaap_ValueAddedTaxReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember_2334" xlink:to="lab_us-gaap_VehiclesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember_2335" xlink:to="lab_us-gaap_VehiclesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_2336" xlink:to="lab_us-gaap_VestingDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_2337" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_2338" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2339" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2340" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2341" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2342" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>flgc-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#Cover" roleURI="http://www.floragrowth.com/role/Cover"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CondensedInterimConsolidatedStatementsOfFinancialPosition" roleURI="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical" roleURI="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementOfStockholdersEquity" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementOfCashFlows" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#NatureOfOperations" roleURI="http://www.floragrowth.com/role/NatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#BasisOfPresentation" roleURI="http://www.floragrowth.com/role/BasisOfPresentation"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#INVENTORY" roleURI="http://www.floragrowth.com/role/INVENTORY"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#PropertyPlantAndEquipment" roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#INVESTMENTS" roleURI="http://www.floragrowth.com/role/INVESTMENTS"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#AssetAcquisitionsAndBusinessCombinations" roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinations"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#DEBT" roleURI="http://www.floragrowth.com/role/DEBT"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LEASES" roleURI="http://www.floragrowth.com/role/LEASES"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareCapital" roleURI="http://www.floragrowth.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensation" roleURI="http://www.floragrowth.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#WARRANTS" roleURI="http://www.floragrowth.com/role/WARRANTS"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CommitmentsAndContingencies" roleURI="http://www.floragrowth.com/role/CommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LossPerShare" roleURI="http://www.floragrowth.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstruments" roleURI="http://www.floragrowth.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformation" roleURI="http://www.floragrowth.com/role/SegmentedInformation"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SubsequentEvents" roleURI="http://www.floragrowth.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivableTables" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InventoryTables" roleURI="http://www.floragrowth.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#PropertyPlantAndEquipmentTables" roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InvestmentsTables" roleURI="http://www.floragrowth.com/role/InvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#AssetAcquisitionsAndBusinessCombinationsTables" roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillTables" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LeasesTables" roleURI="http://www.floragrowth.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationTables" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#WarrantsTables" roleURI="http://www.floragrowth.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.floragrowth.com/role/CommitmentsAndContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LossPerShareTables" roleURI="http://www.floragrowth.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstrumentsTables" roleURI="http://www.floragrowth.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformationTables" roleURI="http://www.floragrowth.com/role/SegmentedInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#BasisOfPresentationDetailsNarrative" roleURI="http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivableDetails" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivableDetails1" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InventoryDetails" roleURI="http://www.floragrowth.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#PropertyPlantAndEquipmentDetails" roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#PropertyPlantAndEquipmentDetailsNarrative" roleURI="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InvestmentsDetails" roleURI="http://www.floragrowth.com/role/InvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InvestmentsDetailsNarrative" roleURI="http://www.floragrowth.com/role/InvestmentsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#AssetAcquisitionsAndBusinessCombinationsDetails1" roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#AssetAcquisitionsAndBusinessCombinationsDetailsNarrative" roleURI="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillDetails2" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#DebtDetailsNarrative" roleURI="http://www.floragrowth.com/role/DebtDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LeasesDetails" roleURI="http://www.floragrowth.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LeasesDetails1" roleURI="http://www.floragrowth.com/role/LeasesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationDetails" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationDetails1" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationDetailsNarrative" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#WarrantsDetails" roleURI="http://www.floragrowth.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#WarrantsDetails1" roleURI="http://www.floragrowth.com/role/WarrantsDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LossPerShareDetails" roleURI="http://www.floragrowth.com/role/LossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstrumentsAndRiskManagementDetails" roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformationDetails" roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformationDetails1" roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SubsequentEventsDetailsNarrative" roleURI="http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IMPAIRMENTOFASSETS" roleURI="http://www.floragrowth.com/role/IMPAIRMENTOFASSETS"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TRADEANDAMOUNTSRECEIVABLENarrativeDetails" roleURI="http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LEASESNarrativeDetails" roleURI="http://www.floragrowth.com/role/LEASESNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformationDetails3" roleURI="http://www.floragrowth.com/role/SegmentedInformationDetails3"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentedInformationDetailsNarrative" roleURI="http://www.floragrowth.com/role/SegmentedInformationDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SegmentDetails" roleURI="http://www.floragrowth.com/role/SegmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CapitalManagement" roleURI="http://www.floragrowth.com/role/CapitalManagement"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstrumentsAndRiskManagementDetails1" roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#FinancialInstrumentsAndRiskManagementDetailsNarrative" roleURI="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#LossPerShareDetailsNarrative" roleURI="http://www.floragrowth.com/role/LossPerShareDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosures" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosuresTables" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosuresDetails" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#RelatedPartyDisclosuresDetailsNarrative" roleURI="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#BasisOfPresentationDetails" roleURI="http://www.floragrowth.com/role/BasisOfPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#BasisOfPresentationTables" roleURI="http://www.floragrowth.com/role/BasisOfPresentationTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPolicies" roleURI="http://www.floragrowth.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesTables" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesDetails" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesDetails1" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ImpairmentOfAssetsDetailsNarrative" roleURI="http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#CriticalJudgmentsAndEstimationUncertainties" roleURI="http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivableDetails2" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxes" roleURI="http://www.floragrowth.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesTables" roleURI="http://www.floragrowth.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesDetails" roleURI="http://www.floragrowth.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesDetails1" roleURI="http://www.floragrowth.com/role/IncomeTaxesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesDetails2" roleURI="http://www.floragrowth.com/role/IncomeTaxesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#TradeAndAmountsReceivable" roleURI="http://www.floragrowth.com/role/TradeAndAmountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#WarrantsDetailsNarrative" roleURI="http://www.floragrowth.com/role/WarrantsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#InventoryDetailsNarrative" roleURI="http://www.floragrowth.com/role/InventoryDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SHARECAPITALDetailsNarrative1" roleURI="http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ShareBasedCompensationDetails2" roleURI="http://www.floragrowth.com/role/ShareBasedCompensationDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable" roleURI="http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ConsolidatedStatementsOfLossAndComprehensiveLossParenthetical" roleURI="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLossParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables" roleURI="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwillDetails" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#DummyDetails" roleURI="http://www.floragrowth.com/role/DummyDetails"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#IntangibleAssetsAndGoodwill" roleURI="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwill"/>
  <roleRef xlink:type="simple" xlink:href="flgc-20240331.xsd#UnauditedCondensedInterimConsolidatedStatementOfShareholdersEquityDeficiencyParentheticals" roleURI="http://www.floragrowth.com/role/UnauditedCondensedInterimConsolidatedStatementOfShareholdersEquityDeficiencyParentheticals"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/Cover">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_1" xlink:to="loc_dei_EntityAddressesLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityTaxIdentificationNumber_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityRegistrantName_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentType_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AmendmentFlag_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AmendmentDescription_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentQuarterlyReport_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentTransitionReport_16" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityFilerCategory_17" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_18" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityFileNumber_19" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_20" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine1_21" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine2_22" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressCityOrTown_23" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressStateOrProvince_24" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityAddressPostalZipCode_25" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_CityAreaCode_26" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_LocalPhoneNumber_27" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_Security12bTitle_28" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_TradingSymbol_29" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_SecurityExchangeName_30" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_31" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityInteractiveDataCurrent_32" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntitySmallBusiness_33" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityEmergingGrowthCompany_34" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityExTransitionPeriod_35" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_ContactPersonnelName_36" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityShellCompany_37" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_38" order="340" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_39" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_EntityPublicFloat_40" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_DocumentAnnualReport_41" order="370" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_42" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AuditorName_43" order="390" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AuditorLocation_44" order="400" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_4" xlink:to="loc_dei_AuditorFirmId_45" order="410" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoansReceivableAndAdvances" xlink:label="loc_flgc_LoansReceivableAndAdvances_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivables" xlink:label="loc_us-gaap_NontradeReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_49"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AssetsAbstract_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_flgc_LoansReceivableAndAdvances_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_us-gaap_NontradeReceivables_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_us-gaap_InventoryNet_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4" xlink:to="loc_us-gaap_AssetsCurrent_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_14" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_14" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_14" xlink:to="loc_us-gaap_Goodwill_17" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_14" xlink:to="loc_us-gaap_LongTermInvestments_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_14" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_14" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4" xlink:to="loc_us-gaap_Assets_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_LiabilitiesAbstract_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_24" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24" xlink:to="loc_us-gaap_AccountsPayableCurrent_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24" xlink:to="loc_us-gaap_CommitmentsAndContingencies_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24" xlink:to="loc_us-gaap_LongTermDebtCurrent_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24" xlink:to="loc_us-gaap_LiabilitiesCurrent_31" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_24" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_33" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_33" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_33" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_33" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_36" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_33" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_24" xlink:to="loc_us-gaap_Liabilities_39" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_41" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_CommonStockValue_41" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_AdditionalPaidInCapital_42" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_43" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_StockholdersEquity_45" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_MinorityInterest_46" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_41" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_47" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_49" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Communication" xlink:label="loc_us-gaap_Communication_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_44"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_Revenues_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_GrossProfit_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ManagementFeeExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ProfessionalFees_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_Communication_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_TravelAndEntertainmentExpense_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ShareBasedCompensation_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OperatingLeaseExpense_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_DepreciationAndAmortization_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_InterestAndDebtExpense_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_AssetImpairmentCharges_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_18" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OperatingExpenses_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OperatingIncomeLoss_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_30" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ProfitLoss_31" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_NetIncomeLoss_33" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_34" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_35" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_EarningsPerShareBasic_36" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_37" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_38" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_40" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_40" xlink:to="loc_us-gaap_ProfitLoss_40" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_41" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_40" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_42" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_40" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_43" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_40" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_44" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingShares" xlink:label="loc_flgc_SeptemberUnitOfferingShares_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingAmount" xlink:label="loc_flgc_SeptemberUnitOfferingAmount_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_SeptemberUnitOfferingIssuanceCosts_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingShares" xlink:label="loc_flgc_DecemberUnitOfferingShares_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingAmount" xlink:label="loc_flgc_DecemberUnitOfferingAmount_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberUnitOfferingIssuanceCosts" xlink:label="loc_flgc_DecemberUnitOfferingIssuanceCosts_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingShares" xlink:label="loc_flgc_InitialPublicOfferingShares_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingAmount" xlink:label="loc_flgc_InitialPublicOfferingAmount_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingIssuanceCostsShares" xlink:label="loc_flgc_InitialPublicOfferingIssuanceCostsShares_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InitialPublicOfferingIssuanceCostsAmount" xlink:label="loc_flgc_InitialPublicOfferingIssuanceCostsAmount_24"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RegulationAAndOtherOfferingsShares" xlink:label="loc_flgc_RegulationAAndOtherOfferingsShares_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RegulationAAndOtherOfferingsAmount" xlink:label="loc_flgc_RegulationAAndOtherOfferingsAmount_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForInvestmentsShares" xlink:label="loc_flgc_CommonSharesIssuedForInvestmentsShares_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForInvestmentsAmount" xlink:label="loc_flgc_CommonSharesIssuedForInvestmentsAmount_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForOtherAgreementsShares" xlink:label="loc_flgc_CommonSharesIssuedForOtherAgreementsShares_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesIssuedForOtherAgreementsAmount" xlink:label="loc_flgc_CommonSharesIssuedForOtherAgreementsAmount_32"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EquityIssuedForOtherAgreementsShares" xlink:label="loc_flgc_EquityIssuedForOtherAgreementsShares_33"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EquityIssuedForOtherAgreementsAmount" xlink:label="loc_flgc_EquityIssuedForOtherAgreementsAmount_34"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AcquisitionOfNoncontrollingInterestShares" xlink:label="loc_flgc_AcquisitionOfNoncontrollingInterestShares_35"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AcquisitionOfNoncontrollingInterestAmount" xlink:label="loc_flgc_AcquisitionOfNoncontrollingInterestAmount_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_41"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockVestingShares" xlink:label="loc_flgc_RestrictedStockVestingShares_42"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockVestingAmount" xlink:label="loc_flgc_RestrictedStockVestingAmount_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_44"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExercisedShares" xlink:label="loc_flgc_WarrantsExercisedShares_45"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExercisedAmount" xlink:label="loc_flgc_WarrantsExercisedAmount_46"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedDuringPeriodSharesWarrantsExpired" xlink:label="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_47"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsExpiredOrCancelledAmount" xlink:label="loc_flgc_WarrantsExpiredOrCancelledAmount_48"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherEquityIssuanceCosts" xlink:label="loc_flgc_OtherEquityIssuanceCosts_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_54"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DerecognitionOfEquityRelatedToColombiaAssets" xlink:label="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_55"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes" xlink:label="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_56"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil" xlink:label="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_58"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionshares" xlink:label="loc_flgc_Contributionshares_59"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_Contributionamont" xlink:label="loc_flgc_Contributionamont_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_61"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_62"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8" xlink:to="loc_flgc_TruhcPharmaGmbhMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_SharesIssued_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_SeptemberUnitOfferingShares_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_SeptemberUnitOfferingAmount_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_SeptemberUnitOfferingIssuanceCosts_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_DecemberUnitOfferingShares_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_DecemberUnitOfferingAmount_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_DecemberUnitOfferingIssuanceCosts_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_InitialPublicOfferingShares_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_InitialPublicOfferingAmount_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_InitialPublicOfferingIssuanceCostsShares_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_InitialPublicOfferingIssuanceCostsAmount_24" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_RegulationAAndOtherOfferingsShares_25" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_RegulationAAndOtherOfferingsAmount_26" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_27" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_28" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_CommonSharesIssuedForInvestmentsShares_29" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_CommonSharesIssuedForInvestmentsAmount_30" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_CommonSharesIssuedForOtherAgreementsShares_31" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_CommonSharesIssuedForOtherAgreementsAmount_32" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_EquityIssuedForOtherAgreementsShares_33" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_EquityIssuedForOtherAgreementsAmount_34" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_AcquisitionOfNoncontrollingInterestShares_35" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_AcquisitionOfNoncontrollingInterestAmount_36" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_37" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_38" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_40" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_41" order="300" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_RestrictedStockVestingShares_42" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_RestrictedStockVestingAmount_43" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_44" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_WarrantsExercisedShares_45" order="340" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_WarrantsExercisedAmount_46" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_SharesIssuedDuringPeriodSharesWarrantsExpired_47" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_WarrantsExpiredOrCancelledAmount_48" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_OtherEquityIssuanceCosts_49" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_51" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_52" order="410" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_53" order="420" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_54" order="430" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_DerecognitionOfEquityRelatedToColombiaAssets_55" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes_56" order="450" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil_57" order="460" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_58" order="470" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_Contributionshares_59" order="480" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_flgc_Contributionamont_60" order="490" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_ProfitLoss_61" order="500" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_SharesIssued_62" order="510" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63" order="520" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfGoodwill" xlink:label="loc_flgc_ImpairmentOfGoodwill_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_36"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProceedsFromExerciseOfWarrantsAndOptions" xlink:label="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_49"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashAssetsAcquiredForContingentConsideration" xlink:label="loc_flgc_NonCashAssetsAcquiredForContingentConsideration_49"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashCommonSharesIssuedForBusinessCombinations" xlink:label="loc_flgc_NonCashCommonSharesIssuedForBusinessCombinations_50"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashCommonSharesIssuedForOtherAgreements" xlink:label="loc_flgc_NonCashCommonSharesIssuedForOtherAgreements_51"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashOptionCancellationsReclassifiedToEquity" xlink:label="loc_flgc_NonCashOptionCancellationsReclassifiedToEquity_52"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets" xlink:label="loc_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_53"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash" xlink:label="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_54"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_ProfitLoss_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AssetImpairmentCharges_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_flgc_ImpairmentOfGoodwill_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_InterestIncomeOperating_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_18" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" xlink:to="loc_flgc_ProceedsFromExerciseOfWarrantsAndOptions_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_38" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_39" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_40" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" xlink:to="loc_us-gaap_RepaymentsOfDebt_41" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_44" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_47" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_49" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_49" xlink:to="loc_flgc_NonCashAssetsAcquiredForContingentConsideration_49" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_49" xlink:to="loc_flgc_NonCashCommonSharesIssuedForBusinessCombinations_50" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_49" xlink:to="loc_flgc_NonCashCommonSharesIssuedForOtherAgreements_51" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_49" xlink:to="loc_flgc_NonCashOptionCancellationsReclassifiedToEquity_52" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_49" xlink:to="loc_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets_53" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_49" xlink:to="loc_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash_54" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/NatureOfOperations">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NatureOfOperationsAndGoingConcernAbstract" xlink:label="loc_flgc_NatureOfOperationsAndGoingConcernAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_NatureOfOperationsAndGoingConcernAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_NatureOfOperations_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/BasisOfPresentation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/INVENTORY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/PropertyPlantAndEquipment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/INVESTMENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaap_InvestmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_0" xlink:to="loc_us-gaap_InvestmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/DEBT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LEASES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/WARRANTS">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsAbstract" xlink:label="loc_flgc_WarrantsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsDisclosureTextBlock" xlink:label="loc_flgc_WarrantsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsAbstract_0" xlink:to="loc_flgc_WarrantsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LossPerShare">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstruments">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialInstrumentsAbstract" xlink:label="loc_flgc_FinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_FinancialInstrumentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivableTables">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAndOtherReceivablesAbstract" xlink:label="loc_flgc_TradeAndOtherReceivablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable" xlink:label="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InvestmentsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:label="loc_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock" xlink:label="loc_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_0" xlink:to="loc_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_0" xlink:to="loc_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NoCapHempCoMember" xlink:label="loc_flgc_NoCapHempCoMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FranchiseGlobalHealthIncMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_NoCapHempCoMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock" xlink:label="loc_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfRestrictedStockAwards" xlink:label="loc_flgc_ScheduleOfRestrictedStockAwards_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_flgc_ScheduleOfRestrictedStockAwards_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/WarrantsTables">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsAbstract" xlink:label="loc_flgc_WarrantsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsAbstract_0" xlink:to="loc_flgc_ScheduleOfWarrantsOutstandingTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CommitmentsAndContingenciesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialInstrumentsAbstract" xlink:label="loc_flgc_FinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications" xlink:label="loc_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock" xlink:label="loc_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_FinancialInstrumentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformationTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfOtherSignificantItemsTableTextBlock" xlink:label="loc_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_flgc_ScheduleOfOtherSignificantItemsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLLCMember" xlink:label="loc_flgc_JustBrandsLLCMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeEarningsDeficit" xlink:label="loc_us-gaap_CumulativeEarningsDeficit_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_flgc_TruhcPharmaGmbhMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8" xlink:to="loc_flgc_JustBrandsLLCMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_us-gaap_Cash_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_us-gaap_ProfitLoss_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_us-gaap_CumulativeEarningsDeficit_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAndOtherReceivablesAbstract" xlink:label="loc_flgc_TradeAndOtherReceivablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivable" xlink:label="loc_us-gaap_ValueAddedTaxReceivable_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_TradeAccountsReceivable_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ValueAddedTaxReceivable_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_OtherReceivables_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAndOtherReceivablesAbstract" xlink:label="loc_flgc_TradeAndOtherReceivablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivablesPastDueTable" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialAssetNotPastDueMember" xlink:label="loc_us-gaap_FinancialAssetNotPastDueMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables1To29DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables1To29DaysPastDueMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables30To59DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables30To59DaysPastDueMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivables60To89DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivables60To89DaysPastDueMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember" xlink:label="loc_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancingReceivables180PlusDaysPastDueMember" xlink:label="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAccountsReceivable" xlink:label="loc_flgc_TradeAccountsReceivable_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_1" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancialAssetNotPastDueMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancingReceivables1To29DaysPastDueMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancingReceivables30To59DaysPastDueMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancingReceivables60To89DaysPastDueMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_1" xlink:to="loc_flgc_FinancingReceivables180PlusDaysPastDueMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems_9" xlink:to="loc_flgc_TradeAccountsReceivable_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InventoryDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_InventoryFinishedGoods_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_InventoryNet_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_LandMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_BuildingMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_VehiclesMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_ConstructionInProgressMember_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_ProductOrServiceAxis_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_11" xlink:to="loc_srt_ProductsAndServicesDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_11" xlink:to="loc_us-gaap_LandMember_11" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_Depreciation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InvestmentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesTable" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvesteeCommonSharesMember" xlink:label="loc_flgc_InvesteeCommonSharesMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadZeroPointThreeZeroMember" xlink:label="loc_flgc_WarrantsCadZeroPointThreeZeroMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsCadOnePointZeroZeroMember" xlink:label="loc_flgc_WarrantsCadOnePointZeroZeroMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInAffiliateActivityLineItems" xlink:label="loc_us-gaap_InvestmentInAffiliateActivityLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_0" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1" xlink:to="loc_us-gaap_InvestmentTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4" xlink:to="loc_flgc_InvesteeCommonSharesMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4" xlink:to="loc_flgc_WarrantsCadZeroPointThreeZeroMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4" xlink:to="loc_flgc_WarrantsCadOnePointZeroZeroMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesTable_1" xlink:to="loc_us-gaap_InvestmentInAffiliateActivityLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_9" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_9" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_9" xlink:to="loc_us-gaap_AssetImpairmentCharges_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_9" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentInAffiliateActivityLineItems_9" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InvestmentsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstTrancheMember" xlink:label="loc_flgc_FirstTrancheMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondTrancheMember" xlink:label="loc_flgc_SecondTrancheMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseOfCommonStock" xlink:label="loc_flgc_PurchaseOfCommonStock_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors" xlink:label="loc_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestmentDescription" xlink:label="loc_flgc_InvestmentDescription_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExercisePriceOfInvestmentWarrants" xlink:label="loc_flgc_ExercisePriceOfInvestmentWarrants_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CumulativeImpairmentRelatedToCommonShares" xlink:label="loc_flgc_CumulativeImpairmentRelatedToCommonShares_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PriceToBookValue" xlink:label="loc_flgc_PriceToBookValue_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PriceToTangibleBookValue" xlink:label="loc_flgc_PriceToTangibleBookValue_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfSensitivityAnalysis" xlink:label="loc_flgc_DescriptionOfSensitivityAnalysis_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfImpairment" xlink:label="loc_flgc_DescriptionOfImpairment_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1" xlink:to="loc_us-gaap_InvestmentTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_flgc_FirstTrancheMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_flgc_SecondTrancheMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_PurchaseOfCommonStock_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_InvestmentDescription_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_ExercisePriceOfInvestmentWarrants_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_CumulativeImpairmentRelatedToCommonShares_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_us-gaap_OtherLongTermInvestments_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_PriceToBookValue_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_PriceToTangibleBookValue_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_DescriptionOfSensitivityAnalysis_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5" xlink:to="loc_flgc_DescriptionOfImpairment_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NoCapHempCoMember" xlink:label="loc_flgc_NoCapHempCoMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FranchiseGlobalHealthIncMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_NoCapHempCoMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_6" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_13" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_13" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract_13" xlink:to="loc_us-gaap_Goodwill_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OriginalHempAssetAcquisitionMember" xlink:label="loc_flgc_OriginalHempAssetAcquisitionMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember" xlink:label="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NoCapHempCoMember" xlink:label="loc_flgc_NoCapHempCoMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBeautyMember" xlink:label="loc_flgc_FloraBeautyMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraMedSasMember" xlink:label="loc_flgc_FloraMedSasMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradenamesMember" xlink:label="loc_flgc_TradenamesMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SupplierRelationshipsMember" xlink:label="loc_flgc_SupplierRelationshipsMember_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CustomersRelationshipsMember" xlink:label="loc_flgc_CustomersRelationshipsMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_KnowHowMember" xlink:label="loc_flgc_KnowHowMember_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PatentAndDevelopedTechnologyMember" xlink:label="loc_flgc_PatentAndDevelopedTechnologyMember_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumPortionOfNetProfitsPayable" xlink:label="loc_flgc_MaximumPortionOfNetProfitsPayable_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_24"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships" xlink:label="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LiabilitiesAmount" xlink:label="loc_flgc_LiabilitiesAmount_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivables" xlink:label="loc_us-gaap_NontradeReceivables_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_37"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashConsiderationReturned" xlink:label="loc_flgc_CashConsiderationReturned_38"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueDiscount" xlink:label="loc_flgc_FairValueDiscount_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_42"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommonSharesDeliveredToTheSellers" xlink:label="loc_flgc_CommonSharesDeliveredToTheSellers_43"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfShares" xlink:label="loc_flgc_DescriptionOfShares_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_45"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfTrials" xlink:label="loc_flgc_NumberOfTrials_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_49"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationPercentageOfSales" xlink:label="loc_flgc_PurchaseConsiderationPercentageOfSales_50"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationPercentageOfSalesAmountPayable" xlink:label="loc_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_51"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfDiscountRates" xlink:label="loc_flgc_DescriptionOfDiscountRates_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_53"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnrealizedLossesOnSecurities" xlink:label="loc_flgc_UnrealizedLossesOnSecurities_54"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PurchaseConsiderationDiscountRate" xlink:label="loc_flgc_PurchaseConsiderationDiscountRate_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_59"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_OriginalHempAssetAcquisitionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FranchiseGlobalHealthIncMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_NoCapHempCoMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FloraBeautyMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_flgc_FloraMedSasMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_srt_RangeAxis_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13" xlink:to="loc_flgc_TradenamesMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13" xlink:to="loc_flgc_SupplierRelationshipsMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13" xlink:to="loc_flgc_CustomersRelationshipsMember_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13" xlink:to="loc_us-gaap_LicenseMember_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13" xlink:to="loc_flgc_KnowHowMember_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13" xlink:to="loc_flgc_PatentAndDevelopedTechnologyMember_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_22" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_MaximumPortionOfNetProfitsPayable_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_Revenues_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_LiabilitiesAmount_30" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_31" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_NontradeReceivables_32" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_33" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_ProfitLoss_34" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_ProfessionalFees_35" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_36" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_37" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_CashConsiderationReturned_38" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_FairValueDiscount_39" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_40" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_41" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_42" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_CommonSharesDeliveredToTheSellers_43" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_DescriptionOfShares_44" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_45" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_NumberOfTrials_46" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_SharePrice_47" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_48" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_49" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_PurchaseConsiderationPercentageOfSales_50" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable_51" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_DescriptionOfDiscountRates_52" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_Capital_53" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_UnrealizedLossesOnSecurities_54" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_flgc_PurchaseConsiderationDiscountRate_55" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_56" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_57" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_58" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_59" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FoodAndBeveragesMember" xlink:label="loc_flgc_FoodAndBeveragesMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselMember" xlink:label="loc_flgc_VesselMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FranchiseMember" xlink:label="loc_us-gaap_FranchiseMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PharmaceuticalsMember" xlink:label="loc_flgc_PharmaceuticalsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_ReportingUnitAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_1" xlink:to="loc_us-gaap_ReportingUnitDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1" xlink:to="loc_flgc_FoodAndBeveragesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1" xlink:to="loc_flgc_VesselMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1" xlink:to="loc_flgc_JustCBDMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1" xlink:to="loc_us-gaap_FranchiseMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" xlink:to="loc_flgc_PharmaceuticalsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_GoodwillLineItems_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_10" xlink:to="loc_us-gaap_GoodwillGross_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_10" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_10" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_10" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_10" xlink:to="loc_us-gaap_Goodwill_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradenamesMember" xlink:label="loc_flgc_TradenamesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaap_TrademarksMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHMember" xlink:label="loc_flgc_FGHMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_TradenamesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_TrademarksMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_ReportingUnitAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_6" xlink:to="loc_us-gaap_ReportingUnitDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_6" xlink:to="loc_flgc_JustCBDMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_6" xlink:to="loc_flgc_FGHMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/DebtDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HypoverinsbankMember" xlink:label="loc_flgc_HypoverinsbankMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ClassicPlanPremiumFinancingMember" xlink:label="loc_flgc_ClassicPlanPremiumFinancingMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstLoanMember" xlink:label="loc_flgc_FirstLoanMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondLoanMember" xlink:label="loc_flgc_SecondLoanMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EuroCreditFacilityMember" xlink:label="loc_flgc_EuroCreditFacilityMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDInsurancePremiumLoanMember" xlink:label="loc_flgc_JustCBDInsurancePremiumLoanMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CreditFacilityDue" xlink:label="loc_flgc_CreditFacilityDue_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4" xlink:to="loc_flgc_HypoverinsbankMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4" xlink:to="loc_flgc_ClassicPlanPremiumFinancingMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4" xlink:to="loc_flgc_FirstLoanMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4" xlink:to="loc_flgc_SecondLoanMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_us-gaap_CreditFacilityAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_10" xlink:to="loc_us-gaap_CreditFacilityDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_10" xlink:to="loc_flgc_EuroCreditFacilityMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_10" xlink:to="loc_flgc_JustCBDInsurancePremiumLoanMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_srt_RangeAxis_14" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LineOfCredit_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LoansPayable_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_28" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_flgc_CreditFacilityDue_29" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_LongTermDebt_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_18" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OtherInformationAbstract" xlink:label="loc_flgc_OtherInformationAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseExpense_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_ShortTermLeaseCost_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_SubleaseIncome_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LeaseCost_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_flgc_OtherInformationAbstract_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_OtherInformationAbstract_8" xlink:to="loc_us-gaap_OperatingLeasePayments_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_OtherInformationAbstract_8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_OtherInformationAbstract_8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_OtherInformationAbstract_8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LeasesDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseLiability_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OptionsExercisableMember" xlink:label="loc_flgc_OptionsExercisableMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm" xlink:label="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_StockOptionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_OptionsExercisableMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm_22" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PostTerminationExercisePeriod" xlink:label="loc_flgc_PostTerminationExercisePeriod_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RemainingWeightedAverageVestingPeriod" xlink:label="loc_flgc_RemainingWeightedAverageVestingPeriod_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonVestedShares" xlink:label="loc_flgc_NonVestedShares_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfRestrictedStockAwardsIssued" xlink:label="loc_flgc_FairValueOfRestrictedStockAwardsIssued_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_srt_ChiefExecutiveOfficerMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_srt_ChiefFinancialOfficerMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_flgc_PostTerminationExercisePeriod_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_StockOptionPlanExpense_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_RestrictedStockExpense_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_flgc_RemainingWeightedAverageVestingPeriod_19" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_23" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_flgc_NonVestedShares_24" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_25" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_26" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_flgc_FairValueOfRestrictedStockAwardsIssued_27" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_28" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/WarrantsDetails">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsAbstract" xlink:label="loc_flgc_WarrantsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsMember" xlink:label="loc_flgc_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsExercised_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsCancelled" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WeightedAverageExercisePriceOfWarrantsIssued" xlink:label="loc_flgc_WeightedAverageExercisePriceOfWarrantsIssued_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_flgc_WarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_flgc_WeightedAverageExercisePriceOfWarrantsExercised_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_flgc_WeightedAverageExercisePriceOfWarrantsCancelled_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_flgc_WeightedAverageExercisePriceOfWarrantsIssued_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/WarrantsDetails1">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsAbstract" xlink:label="loc_flgc_WarrantsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsOneMember" xlink:label="loc_flgc_WarrantsOneMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsTwoMember" xlink:label="loc_flgc_WarrantsTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsThreeMember" xlink:label="loc_flgc_WarrantsThreeMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsFourMember" xlink:label="loc_flgc_WarrantsFourMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsFiveMember" xlink:label="loc_flgc_WarrantsFiveMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsSixMember" xlink:label="loc_flgc_WarrantsSixMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsMember" xlink:label="loc_flgc_WarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsDateOfExpiry" xlink:label="loc_flgc_WarrantsDateOfExpiry_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GrantDateFairValueOfWarrantsOutstanding" xlink:label="loc_flgc_GrantDateFairValueOfWarrantsOutstanding_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsRemainingLifeInYears" xlink:label="loc_flgc_WarrantsRemainingLifeInYears_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsOneMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsTwoMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsThreeMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsFourMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsFiveMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsSixMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_flgc_WarrantsMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_10" xlink:to="loc_flgc_WarrantsDateOfExpiry_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_10" xlink:to="loc_flgc_GrantDateFairValueOfWarrantsOutstanding_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_10" xlink:to="loc_flgc_WarrantsRemainingLifeInYears_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TerminationBenefitsMember" xlink:label="loc_flgc_TerminationBenefitsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LegalDisputesMember" xlink:label="loc_flgc_LegalDisputesMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SalesTaxesMember" xlink:label="loc_flgc_SalesTaxesMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesLineItems" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyAccrualForeignCurrencyTranslation" xlink:label="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1" xlink:to="loc_flgc_TerminationBenefitsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1" xlink:to="loc_flgc_LegalDisputesMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1" xlink:to="loc_flgc_SalesTaxesMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_6" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_6" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_6" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_6" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_6" xlink:to="loc_flgc_LossContingencyAccrualForeignCurrencyTranslation_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_6" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustBrandsLLCMember" xlink:label="loc_flgc_JustBrandsLLCMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GerardoAndresGarciaMendezMember" xlink:label="loc_flgc_GerardoAndresGarciaMendezMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember" xlink:label="loc_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember" xlink:label="loc_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FranchiseGlobalHealthIncMember" xlink:label="loc_flgc_FranchiseGlobalHealthIncMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ACAMullerMember" xlink:label="loc_flgc_ACAMullerMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LegalDisputesMember" xlink:label="loc_flgc_LegalDisputesMember_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TerminationBenefitsMember" xlink:label="loc_flgc_TerminationBenefitsMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AdditionalLegalDisputesMember" xlink:label="loc_flgc_AdditionalLegalDisputesMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfCommitmentsAndContingenciesLineItems" xlink:label="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IndemnificationReceivables" xlink:label="loc_flgc_IndemnificationReceivables_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit" xlink:label="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyTrialOrAlternativeDisputeResolution" xlink:label="loc_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AmountsPayablePerViolationOfStopSaleOrders" xlink:label="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfViolationsInStopSaleOrders" xlink:label="loc_flgc_NumberOfViolationsInStopSaleOrders_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryImpactedByStopSaleOrders" xlink:label="loc_flgc_InventoryImpactedByStopSaleOrders_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PotentialLiabilities" xlink:label="loc_flgc_PotentialLiabilities_32"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WrongfullyTransferredShares" xlink:label="loc_flgc_WrongfullyTransferredShares_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_34"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentPortionOfContingentPurchaseConsideration" xlink:label="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_35"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedLossOnPotentialLiabilities" xlink:label="loc_flgc_EstimatedLossOnPotentialLiabilities_36"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_37"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfSharesUnderPlaintiffClaim" xlink:label="loc_flgc_NumberOfSharesUnderPlaintiffClaim_38"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountPayableInViolationOfStopSaleOrders" xlink:label="loc_flgc_TotalAmountPayableInViolationOfStopSaleOrders_39"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfViolationsClaimed" xlink:label="loc_flgc_NumberOfViolationsClaimed_40"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyEstimateOfPossibleLossInterestAccrued" xlink:label="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_41"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LossContingencyInterestPaymentTerms" xlink:label="loc_flgc_LossContingencyInterestPaymentTerms_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_43"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ManagementContractsTerms" xlink:label="loc_flgc_ManagementContractsTerms_44"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MaximumLimitOfIndemnificationAgreement" xlink:label="loc_flgc_MaximumLimitOfIndemnificationAgreement_45"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TotalAmountClaimedUnderIndemnificationAgreement" xlink:label="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_46"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ThresholdLimitOfEstimateOfLoss" xlink:label="loc_flgc_ThresholdLimitOfEstimateOfLoss_47"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharedServicesAndSpaceCommitment" xlink:label="loc_flgc_SharedServicesAndSpaceCommitment_48"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_flgc_JustBrandsLLCMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_flgc_GerardoAndresGarciaMendezMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_flgc_FranchiseGlobalHealthIncMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_10" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_10" xlink:to="loc_flgc_ACAMullerMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_10" xlink:to="loc_flgc_LegalDisputesMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_10" xlink:to="loc_flgc_TerminationBenefitsMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_10" xlink:to="loc_flgc_AdditionalLegalDisputesMember_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_16" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_16" xlink:to="loc_us-gaap_SubsequentEventMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesTable_1" xlink:to="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_SeveranceCosts1_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_IndemnificationReceivables_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_AmountsPayablePerViolationOfStopSaleOrders_29" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_NumberOfViolationsInStopSaleOrders_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_InventoryImpactedByStopSaleOrders_31" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_PotentialLiabilities_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_WrongfullyTransferredShares_33" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_CurrentPortionOfContingentPurchaseConsideration_35" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_EstimatedLossOnPotentialLiabilities_36" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares_37" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_NumberOfSharesUnderPlaintiffClaim_38" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_TotalAmountPayableInViolationOfStopSaleOrders_39" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_NumberOfViolationsClaimed_40" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued_41" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_LossContingencyInterestPaymentTerms_42" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_43" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_ManagementContractsTerms_44" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_MaximumLimitOfIndemnificationAgreement_45" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_TotalAmountClaimedUnderIndemnificationAgreement_46" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_ThresholdLimitOfEstimateOfLoss_47" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ScheduleOfCommitmentsAndContingenciesLineItems_19" xlink:to="loc_flgc_SharedServicesAndSpaceCommitment_48" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LossPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RestrictedStockAwardsMember" xlink:label="loc_flgc_RestrictedStockAwardsMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionAxis_1" xlink:to="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_flgc_StockOptionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_flgc_RestrictedStockAwardsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuritiesFinancingTransactionTypeDomain_1" xlink:to="loc_flgc_JustCBDMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialInstrumentsAbstract" xlink:label="loc_flgc_FinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_FinancialInstrumentsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleMember" xlink:label="loc_flgc_CommercialAndWholesaleMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsMember" xlink:label="loc_flgc_HouseOfBrandsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PharmaceuticalsMember" xlink:label="loc_flgc_PharmaceuticalsMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CorporateAndEliminationsMember" xlink:label="loc_flgc_CorporateAndEliminationsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_CommercialAndWholesaleMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_HouseOfBrandsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_PharmaceuticalsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_CorporateAndEliminationsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7" xlink:to="loc_us-gaap_Revenues_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7" xlink:to="loc_us-gaap_GrossProfit_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7" xlink:to="loc_us-gaap_Assets_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformationDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ReportableGeographicalComponentsMember" xlink:label="loc_srt_ReportableGeographicalComponentsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="loc_country_DE_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CO" xlink:label="loc_country_CO_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="loc_country_GB_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_srt_ConsolidationItemsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1" xlink:to="loc_srt_ConsolidationItemsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1" xlink:to="loc_srt_ReportableGeographicalComponentsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_srt_StatementGeographicalAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4" xlink:to="loc_srt_SegmentGeographicalDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_US_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_DE_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_CO_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_GB_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_CA_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_11" xlink:to="loc_us-gaap_Revenues_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcHoldingGmbhMember" xlink:label="loc_flgc_TruhcHoldingGmbhMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AegisCapitalCorpMember" xlink:label="loc_flgc_AegisCapitalCorpMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraGrowthCorpMember" xlink:label="loc_flgc_FloraGrowthCorpMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstClosingMember" xlink:label="loc_flgc_FirstClosingMember_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondClosingMember" xlink:label="loc_flgc_SecondClosingMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares" xlink:label="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingCommitments" xlink:label="loc_us-gaap_UnderwritingCommitments_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfIssuedAndOutstandingCommonShares" xlink:label="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_flgc_JustCBDMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_flgc_TruhcHoldingGmbhMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_flgc_AegisCapitalCorpMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_flgc_FloraGrowthCorpMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_13" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13" xlink:to="loc_srt_ChiefExecutiveOfficerMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_16" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_16" xlink:to="loc_flgc_FirstClosingMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_16" xlink:to="loc_flgc_SecondClosingMember_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_UnderwritingCommitments_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_flgc_PercentageOfIssuedAndOutstandingCommonShares_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_30" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_31" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IMPAIRMENTOFASSETS">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfAssetsAbstract" xlink:label="loc_flgc_ImpairmentOfAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesTextBlock" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ImpairmentOfAssetsAbstract_0" xlink:to="loc_us-gaap_AssetImpairmentChargesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAndOtherReceivablesAbstract" xlink:label="loc_flgc_TradeAndOtherReceivablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivablesPastDueTable" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_4" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_4" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivablesPastDueTable_1" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LEASESNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarehousingAndOfficeSpaceMember" xlink:label="loc_flgc_WarehousingAndOfficeSpaceMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RetailSpaceInMiamiMember" xlink:label="loc_flgc_RetailSpaceInMiamiMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PompanoBeachMember" xlink:label="loc_flgc_PompanoBeachMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FortLauderdaleMember" xlink:label="loc_flgc_FortLauderdaleMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MonthlyLeasePayment" xlink:label="loc_flgc_MonthlyLeasePayment_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CounterpartyNameAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4" xlink:to="loc_flgc_WarehousingAndOfficeSpaceMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4" xlink:to="loc_flgc_RetailSpaceInMiamiMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4" xlink:to="loc_flgc_PompanoBeachMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4" xlink:to="loc_flgc_FortLauderdaleMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_10" xlink:to="loc_flgc_MonthlyLeasePayment_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_10" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_10" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformationDetails3">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="loc_country_DE_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CO" xlink:label="loc_country_CO_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="loc_country_GB_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_srt_StatementGeographicalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_US_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_DE_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_CO_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_GB_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_CA_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_Assets_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentedInformationDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ConsolidatedRevenue" xlink:label="loc_flgc_ConsolidatedRevenue_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_flgc_ConsolidatedRevenue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SegmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CommercialAndWholesaleMember" xlink:label="loc_flgc_CommercialAndWholesaleMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsMember" xlink:label="loc_flgc_HouseOfBrandsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PharmaceuticalsMember" xlink:label="loc_flgc_PharmaceuticalsMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CorporateAndEliminationsMember" xlink:label="loc_flgc_CorporateAndEliminationsMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ConsolidatedMember" xlink:label="loc_flgc_ConsolidatedMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_CommercialAndWholesaleMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_HouseOfBrandsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_PharmaceuticalsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_CorporateAndEliminationsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_ConsolidatedMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensation_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_DepreciationAndAmortization_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8" xlink:to="loc_us-gaap_Assets_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CapitalManagement">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CapitalManagementAbstract" xlink:label="loc_flgc_CapitalManagementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CapitalManagementDisclosureTextBlock" xlink:label="loc_flgc_CapitalManagementDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_CapitalManagementAbstract_0" xlink:to="loc_flgc_CapitalManagementDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_flgc_FinancialInstrumentsAndRiskManagementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_COP" xlink:label="loc_currency_COP_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP" xlink:label="loc_currency_GBP_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF" xlink:label="loc_currency_CHF_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableFairValueDisclosure" xlink:label="loc_us-gaap_LoansReceivableFairValueDisclosure_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_FinancialInstrumentsAndRiskManagementAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_CAD_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_COP_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_GBP_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_EUR_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_CHF_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" xlink:to="loc_us-gaap_Cash_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" xlink:to="loc_us-gaap_LoansReceivableFairValueDisclosure_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" xlink:to="loc_us-gaap_OperatingLeaseLiability_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" xlink:to="loc_us-gaap_LongTermDebt_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8" xlink:to="loc_us-gaap_FairValueNetAssetLiability_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_flgc_FinancialInstrumentsAndRiskManagementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditRiskMember" xlink:label="loc_us-gaap_CreditRiskMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GermanSubsidiariesMember" xlink:label="loc_flgc_GermanSubsidiariesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember" xlink:label="loc_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialIntermediariesMember" xlink:label="loc_flgc_FinancialIntermediariesMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfExchangeRate" xlink:label="loc_flgc_DescriptionOfExchangeRate_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashFlowModelHighRate" xlink:label="loc_flgc_CashFlowModelHighRate_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ExpectedSharesToBeIssued" xlink:label="loc_flgc_ExpectedSharesToBeIssued_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CashFlowModelLowRate" xlink:label="loc_flgc_CashFlowModelLowRate_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_FinancialInstrumentsAndRiskManagementAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_4" xlink:to="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_4" xlink:to="loc_us-gaap_CreditRiskMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_4" xlink:to="loc_flgc_GermanSubsidiariesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_us-gaap_CollateralAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_8" xlink:to="loc_us-gaap_CollateralDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_8" xlink:to="loc_flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_8" xlink:to="loc_flgc_FinancialIntermediariesMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_flgc_DescriptionOfExchangeRate_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_us-gaap_Cash_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentFairValue_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_flgc_CashFlowModelHighRate_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_flgc_ExpectedSharesToBeIssued_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_flgc_CashFlowModelLowRate_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_12" xlink:to="loc_us-gaap_SharePrice_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/LossPerShareDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoPlanMember" xlink:label="loc_flgc_TwoThousandTwentyTwoPlanMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoPlanMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosures">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosuresTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_OfficersCompensation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HampsteadPrivateCapitalLimitedMember" xlink:label="loc_flgc_HampsteadPrivateCapitalLimitedMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DrManaloMorganMember" xlink:label="loc_flgc_DrManaloMorganMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsAxis" xlink:label="loc_flgc_LoanAgreementsAxis_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LoanAgreementsDomain" xlink:label="loc_flgc_LoanAgreementsDomain_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FirstLoanAgreementMember" xlink:label="loc_flgc_FirstLoanAgreementMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SecondLoanAgreementMember" xlink:label="loc_flgc_SecondLoanAgreementMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts" xlink:label="loc_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_MedicalServices" xlink:label="loc_flgc_MedicalServices_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" xlink:to="loc_us-gaap_RelatedPartyDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_srt_DirectorMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_srt_ChiefExecutiveOfficerMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_flgc_HampsteadPrivateCapitalLimitedMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_flgc_DrManaloMorganMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_flgc_LoanAgreementsAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_LoanAgreementsAxis_10" xlink:to="loc_flgc_LoanAgreementsDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_LoanAgreementsDomain_10" xlink:to="loc_flgc_FirstLoanAgreementMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_LoanAgreementsDomain_10" xlink:to="loc_flgc_SecondLoanAgreementMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_14" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_14" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_14" xlink:to="loc_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_14" xlink:to="loc_flgc_MedicalServices_18" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_14" xlink:to="loc_us-gaap_LongTermDebt_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_14" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_14" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/BasisOfPresentationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfAccountingTable" xlink:label="loc_flgc_BasisOfAccountingTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryOneMember" xlink:label="loc_flgc_SubsidiaryOneMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwoMember" xlink:label="loc_flgc_SubsidiaryTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThreeMember" xlink:label="loc_flgc_SubsidiaryThreeMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFourMember" xlink:label="loc_flgc_SubsidiaryFourMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFiveMember" xlink:label="loc_flgc_SubsidiaryFiveMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySixMember" xlink:label="loc_flgc_SubsidiarySixMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySevenMember" xlink:label="loc_flgc_SubsidiarySevenMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryEightMember" xlink:label="loc_flgc_SubsidiaryEightMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryNineMember" xlink:label="loc_flgc_SubsidiaryNineMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTenMember" xlink:label="loc_flgc_SubsidiaryTenMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryElevenMember" xlink:label="loc_flgc_SubsidiaryElevenMember_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwelveMember" xlink:label="loc_flgc_SubsidiaryTwelveMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirteenMember" xlink:label="loc_flgc_SubsidiaryThirteenMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFourteenMember" xlink:label="loc_flgc_SubsidiaryFourteenMember_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryFifteenMember" xlink:label="loc_flgc_SubsidiaryFifteenMember_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySixteenMember" xlink:label="loc_flgc_SubsidiarySixteenMember_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiarySeventeenMember" xlink:label="loc_flgc_SubsidiarySeventeenMember_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryEighteenMember" xlink:label="loc_flgc_SubsidiaryEighteenMember_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryNineteenMember" xlink:label="loc_flgc_SubsidiaryNineteenMember_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyMember" xlink:label="loc_flgc_SubsidiaryTwentyMember_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyOneMember" xlink:label="loc_flgc_SubsidiaryTwentyOneMember_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyTwoMember" xlink:label="loc_flgc_SubsidiaryTwentyTwoMember_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyThreeMember" xlink:label="loc_flgc_SubsidiaryTwentyThreeMember_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyFourMember" xlink:label="loc_flgc_SubsidiaryTwentyFourMember_24"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyFiveMember" xlink:label="loc_flgc_SubsidiaryTwentyFiveMember_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentySixMember" xlink:label="loc_flgc_SubsidiaryTwentySixMember_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentySevenMember" xlink:label="loc_flgc_SubsidiaryTwentySevenMember_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyEightMember" xlink:label="loc_flgc_SubsidiaryTwentyEightMember_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryTwentyNineMember" xlink:label="loc_flgc_SubsidiaryTwentyNineMember_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyMember" xlink:label="loc_flgc_SubsidiaryThirtyMember_30"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyOneMember" xlink:label="loc_flgc_SubsidiaryThirtyOneMember_31"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyTwoMember" xlink:label="loc_flgc_SubsidiaryThirtyTwoMember_32"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyThreeMember" xlink:label="loc_flgc_SubsidiaryThirtyThreeMember_33"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyFourMember" xlink:label="loc_flgc_SubsidiaryThirtyFourMember_34"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SubsidiaryThirtyFiveMember" xlink:label="loc_flgc_SubsidiaryThirtyFiveMember_35"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_BasisOfAccountingLineItems" xlink:label="loc_flgc_BasisOfAccountingLineItems_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_40"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FunctionalCurrencyOfSubsidiary" xlink:label="loc_flgc_FunctionalCurrencyOfSubsidiary_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_flgc_BasisOfAccountingTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_BasisOfAccountingTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryOneMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwoMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThreeMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryFourMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryFiveMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiarySixMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiarySevenMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryEightMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryNineMember_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTenMember_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryElevenMember_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwelveMember_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirteenMember_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryFourteenMember_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryFifteenMember_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiarySixteenMember_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiarySeventeenMember_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryEighteenMember_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryNineteenMember_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyMember_20" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyOneMember_21" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyTwoMember_22" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyThreeMember_23" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyFourMember_24" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyFiveMember_25" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentySixMember_26" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentySevenMember_27" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyEightMember_28" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryTwentyNineMember_29" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyMember_30" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyOneMember_31" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyTwoMember_32" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyThreeMember_33" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyFourMember_34" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_flgc_SubsidiaryThirtyFiveMember_35" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_BasisOfAccountingTable_1" xlink:to="loc_flgc_BasisOfAccountingLineItems_38" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_BasisOfAccountingLineItems_38" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_BasisOfAccountingLineItems_38" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_39" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_BasisOfAccountingLineItems_38" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_40" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_BasisOfAccountingLineItems_38" xlink:to="loc_flgc_FunctionalCurrencyOfSubsidiary_41" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/BasisOfPresentationTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfSubsidiariesTableTextBlock" xlink:label="loc_flgc_ScheduleOfSubsidiariesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_flgc_ScheduleOfSubsidiariesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FinancialLiabilitiesPolicyTextBlock" xlink:label="loc_flgc_FinancialLiabilitiesPolicyTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ProvisionsPolicyTextBlock" xlink:label="loc_flgc_ProvisionsPolicyTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NonControllingInterestsPolicyTextBlock" xlink:label="loc_flgc_NonControllingInterestsPolicyTextBlock_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoingConcernPolicyTextBlock" xlink:label="loc_flgc_GoingConcernPolicyTextBlock_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_30"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_FinancialLiabilitiesPolicyTextBlock_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_ProvisionsPolicyTextBlock_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_16" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_17" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_18" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_19" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_20" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_21" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_22" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_23" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_NonControllingInterestsPolicyTextBlock_24" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_25" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_26" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_27" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_28" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_GoingConcernPolicyTextBlock_29" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_30" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock" xlink:label="loc_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives" xlink:label="loc_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesTable" xlink:label="loc_flgc_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaap_VehiclesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesLineItems" xlink:label="loc_flgc_SignificantAccountingPoliciesLineItems_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_flgc_SignificantAccountingPoliciesTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_VehiclesMember_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_BuildingMember_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_srt_RangeAxis_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_flgc_SignificantAccountingPoliciesLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesTable" xlink:label="loc_flgc_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesMember" xlink:label="loc_flgc_LicensesMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SignificantAccountingPoliciesLineItems" xlink:label="loc_flgc_SignificantAccountingPoliciesLineItems_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_flgc_SignificantAccountingPoliciesTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_PatentsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_TrademarksAndBrandsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_LicensesMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_srt_RangeAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8" xlink:to="loc_srt_RangeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8" xlink:to="loc_srt_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8" xlink:to="loc_srt_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesTable_1" xlink:to="loc_flgc_SignificantAccountingPoliciesLineItems_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_SignificantAccountingPoliciesLineItems_12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_12" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CosechemosAndKasaWholefoodsMember" xlink:label="loc_flgc_CosechemosAndKasaWholefoodsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_srt_OwnershipAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1" xlink:to="loc_srt_OwnershipDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1" xlink:to="loc_flgc_CosechemosAndKasaWholefoodsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_flgc_SharePurchaseAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10" xlink:to="loc_us-gaap_AdvertisingExpense_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfAssetsAbstract" xlink:label="loc_flgc_ImpairmentOfAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfFghMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfFghMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_AnnualGoodwillImpairmentTestOfJustCBDMember" xlink:label="loc_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoImpairmentTestMember" xlink:label="loc_flgc_TwoThousandTwentyTwoImpairmentTestMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember" xlink:label="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember" xlink:label="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember" xlink:label="loc_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselAssetGroupMember" xlink:label="loc_flgc_VesselAssetGroupMember_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHMember" xlink:label="loc_flgc_FGHMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDMember" xlink:label="loc_flgc_JustCBDMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_HouseOfBrandsSegmentMember" xlink:label="loc_flgc_HouseOfBrandsSegmentMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_EstimatedRecoverableAmount" xlink:label="loc_flgc_EstimatedRecoverableAmount_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfValuation" xlink:label="loc_flgc_DescriptionOfValuation_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GoodwillDescription" xlink:label="loc_flgc_GoodwillDescription_27"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares" xlink:label="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ImpairmentOfLicenses" xlink:label="loc_flgc_ImpairmentOfLicenses_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_ImpairmentOfAssetsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_AnnualGoodwillImpairmentTestOfFghMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_AnnualGoodwillImpairmentTestOfJustCBDMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoImpairmentTestMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_ReportingUnitAxis_11" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_11" xlink:to="loc_us-gaap_ReportingUnitDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_11" xlink:to="loc_flgc_VesselAssetGroupMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_11" xlink:to="loc_flgc_FGHMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_11" xlink:to="loc_flgc_JustCBDMember_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16" xlink:to="loc_us-gaap_SegmentDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_16" xlink:to="loc_flgc_HouseOfBrandsSegmentMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1" xlink:to="loc_us-gaap_GoodwillLineItems_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_us-gaap_Assets_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_us-gaap_CapitalLeaseObligations_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_flgc_EstimatedRecoverableAmount_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_us-gaap_AssetImpairmentCharges_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_flgc_DescriptionOfValuation_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_flgc_GoodwillDescription_27" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_19" xlink:to="loc_flgc_ImpairmentOfLicenses_29" order="100" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract" xlink:label="loc_flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAndOtherReceivablesAbstract" xlink:label="loc_flgc_TradeAndOtherReceivablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance" xlink:label="loc_us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaap_InsuranceRecoveries_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignExchangeImpacts" xlink:label="loc_flgc_ForeignExchangeImpacts_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_InsuranceRecoveries_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_flgc_ForeignExchangeImpacts_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CanadaIncomeTaxAuthorityMember" xlink:label="loc_flgc_CanadaIncomeTaxAuthorityMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_USFederalIncomeTaxAuthorityMember" xlink:label="loc_flgc_USFederalIncomeTaxAuthorityMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_USStateIncomeTaxAuthorityMember" xlink:label="loc_flgc_USStateIncomeTaxAuthorityMember_3"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignIncomeTaxAuthorityMember" xlink:label="loc_flgc_ForeignIncomeTaxAuthorityMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_flgc_CanadaIncomeTaxAuthorityMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_flgc_USFederalIncomeTaxAuthorityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_flgc_USStateIncomeTaxAuthorityMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_flgc_ForeignIncomeTaxAuthorityMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsShareIssuanceCosts" xlink:label="loc_flgc_DeferredTaxAssetsShareIssuanceCosts_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments" xlink:label="loc_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_flgc_DeferredTaxAssetsRightOfUseAssets_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsIntangibleAssets" xlink:label="loc_flgc_DeferredTaxAssetsIntangibleAssets_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsGoodwil" xlink:label="loc_flgc_DeferredTaxAssetsGoodwil_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts" xlink:label="loc_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_flgc_DeferredTaxAssetsShareIssuanceCosts_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_flgc_DeferredTaxAssetsRightOfUseAssets_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_flgc_DeferredTaxAssetsIntangibleAssets_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_flgc_DeferredTaxAssetsGoodwil_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_14" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_16" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_17" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_17" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_17" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_17" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_17" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitedStatesRevenueAgencyMember" xlink:label="loc_flgc_UnitedStatesRevenueAgencyMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombiaRevenueAgencyMember" xlink:label="loc_flgc_ColombiaRevenueAgencyMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_GermanyRevenueAgencyMember" xlink:label="loc_flgc_GermanyRevenueAgencyMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DenmarkRevenueAgencyMember" xlink:label="loc_flgc_DenmarkRevenueAgencyMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_UnitedKingdomRevenueAgencyMember" xlink:label="loc_flgc_UnitedKingdomRevenueAgencyMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ForeignRevenueAgencyMember" xlink:label="loc_flgc_ForeignRevenueAgencyMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_CurrentTaxExpenseIncome" xlink:label="loc_flgc_CurrentTaxExpenseIncome_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DeferredTaxExpenseIncome" xlink:label="loc_flgc_DeferredTaxExpenseIncome_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DescriptionOfTaxJurisdictions" xlink:label="loc_flgc_DescriptionOfTaxJurisdictions_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_4" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4" xlink:to="loc_flgc_UnitedStatesRevenueAgencyMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4" xlink:to="loc_flgc_ColombiaRevenueAgencyMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4" xlink:to="loc_flgc_GermanyRevenueAgencyMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4" xlink:to="loc_flgc_DenmarkRevenueAgencyMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4" xlink:to="loc_flgc_UnitedKingdomRevenueAgencyMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4" xlink:to="loc_flgc_ForeignRevenueAgencyMember_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_13" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_13" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_13" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_13" xlink:to="loc_us-gaap_OperatingLossCarryforwards_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_13" xlink:to="loc_flgc_CurrentTaxExpenseIncome_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_13" xlink:to="loc_flgc_DeferredTaxExpenseIncome_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_13" xlink:to="loc_flgc_DescriptionOfTaxJurisdictions_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/TradeAndAmountsReceivable">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TradeAndOtherReceivablesAbstract" xlink:label="loc_flgc_TradeAndOtherReceivablesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_TradeAndOtherReceivablesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/WarrantsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsAbstract" xlink:label="loc_flgc_WarrantsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsTable" xlink:label="loc_flgc_WarrantsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember" xlink:label="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NovemberTwoThousandTwentyOneUnitOfferingMember" xlink:label="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember" xlink:label="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PlacementAgentMember" xlink:label="loc_flgc_PlacementAgentMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsLineItems" xlink:label="loc_flgc_WarrantsLineItems_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsIssuedDuringPeriodExercisePrice" xlink:label="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant" xlink:label="loc_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsWithExercisePriceAmended" xlink:label="loc_flgc_NumberOfWarrantsWithExercisePriceAmended_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantExercisePricePriorToAmendment" xlink:label="loc_flgc_WarrantExercisePricePriorToAmendment_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantAmendedExercisePrice" xlink:label="loc_flgc_WarrantAmendedExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_IntrinsicValueOfWarrantsExercised" xlink:label="loc_flgc_IntrinsicValueOfWarrantsExercised_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsAbstract_0" xlink:to="loc_flgc_WarrantsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1" xlink:to="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_flgc_PlacementAgentMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsTable_1" xlink:to="loc_flgc_WarrantsLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_flgc_NumberOfWarrantsWithExercisePriceAmended_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_flgc_WarrantExercisePricePriorToAmendment_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_flgc_WarrantAmendedExercisePrice_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_20" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_flgc_IntrinsicValueOfWarrantsExercised_21" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_WarrantsLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_22" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/InventoryDetailsNarrative">
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryAbstract" xlink:label="loc_flgc_InventoryAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InventoryExpensedToCostOfSales" xlink:label="loc_flgc_InventoryExpensedToCostOfSales_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WritedownsReversalsOfInventories" xlink:label="loc_flgc_WritedownsReversalsOfInventories_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_InventoryAbstract_0" xlink:to="loc_flgc_InventoryExpensedToCostOfSales_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_InventoryAbstract_0" xlink:to="loc_flgc_WritedownsReversalsOfInventories_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcPharmaGmbhMember" xlink:label="loc_flgc_TruhcPharmaGmbhMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FGHOwnersMember" xlink:label="loc_flgc_FGHOwnersMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_JustCBDOwnersMember" xlink:label="loc_flgc_JustCBDOwnersMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_VesselOwnersMember" xlink:label="loc_flgc_VesselOwnersMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraBeautyMember" xlink:label="loc_flgc_FloraBeautyMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FloraMedSasMember" xlink:label="loc_flgc_FloraMedSasMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TruhcHoldingGmbhMember" xlink:label="loc_flgc_TruhcHoldingGmbhMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember" xlink:label="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember" xlink:label="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NovemberTwoThousandTwentyOneUnitOfferingMember" xlink:label="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_PlacementAgentMember" xlink:label="loc_flgc_PlacementAgentMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_23"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantsIssuedDuringPeriodExercisePrice" xlink:label="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_24"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_NumberOfWarrantsWithAmendedExercisePrice" xlink:label="loc_flgc_NumberOfWarrantsWithAmendedExercisePrice_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantExercisePricePriorToAmendment" xlink:label="loc_flgc_WarrantExercisePricePriorToAmendment_26"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_WarrantAmendedExercisePrice" xlink:label="loc_flgc_WarrantAmendedExercisePrice_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_29"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueOfWarrantsIssuedDuringPeriod" xlink:label="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_35"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FairValueDiscount" xlink:label="loc_flgc_FairValueDiscount_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_flgc_TruhcPharmaGmbhMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" xlink:to="loc_us-gaap_RelatedPartyDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_flgc_FGHOwnersMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_flgc_JustCBDOwnersMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_flgc_VesselOwnersMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_flgc_FloraBeautyMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_flgc_FloraMedSasMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_flgc_TruhcHoldingGmbhMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_12" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_12" xlink:to="loc_flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_12" xlink:to="loc_flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_12" xlink:to="loc_flgc_NovemberTwoThousandTwentyOneUnitOfferingMember_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_17" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_17" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_17" xlink:to="loc_flgc_PlacementAgentMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_20" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_CommonUnitIssued_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockIssued1_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_flgc_NumberOfWarrantsIssuedDuringPeriod_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_flgc_WarrantsIssuedDuringPeriodExercisePrice_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_flgc_NumberOfWarrantsWithAmendedExercisePrice_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_flgc_WarrantExercisePricePriorToAmendment_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_flgc_WarrantAmendedExercisePrice_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_flgc_FairValueOfWarrantsIssuedDuringPeriod_30" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_31" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_33" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_34" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_35" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_flgc_FairValueDiscount_36" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_37" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_40" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_41" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_42" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_43" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_44" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_20" xlink:to="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_45" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ShareBasedCompensationDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_StockOptionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_SharePrice_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_10" order="60" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionsMember" xlink:label="loc_flgc_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OptionsExercisableMember" xlink:label="loc_flgc_OptionsExercisableMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_5"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_6"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_11"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_12"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_13"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_14"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_17"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_20"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember" xlink:label="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_StockOptionDateOfExpiry" xlink:label="loc_flgc_StockOptionDateOfExpiry_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue" xlink:label="loc_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_StockOptionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_flgc_OptionsExercisableMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember_18" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember_19" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember_20" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember_21" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5" xlink:to="loc_flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember_22" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25" xlink:to="loc_flgc_StockOptionDateOfExpiry_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25" xlink:to="loc_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLossParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember" xlink:label="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_30"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7" xlink:to="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_10" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_10" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_22" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_13" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_25" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_25" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_25" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_25" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_25" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_25" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember" xlink:label="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_15"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_16"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_18"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_19"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_21"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_22"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_25"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_10" xlink:to="loc_flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_22" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_24" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_25" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_26" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_27" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_28" order="150" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_29" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_30" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_31" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_13" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_32" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyHeldForSale_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_SharePurchaseAgreementMember" xlink:label="loc_flgc_SharePurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LisanFarmaColombiaLLCMember" xlink:label="loc_flgc_LisanFarmaColombiaLLCMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract" xlink:label="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_7"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_8"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment" xlink:label="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract" xlink:label="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_flgc_SharePurchaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_flgc_LisanFarmaColombiaLLCMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7" xlink:to="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_7" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_7" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract_7" xlink:to="loc_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7" xlink:to="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract_11" xlink:to="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" xlink:label="loc_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock" xlink:label="loc_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesMember" xlink:label="loc_flgc_LicensesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaap_GoodwillMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_FiniteLivedIntangibleAssetsAdditions" xlink:label="loc_flgc_FiniteLivedIntangibleAssetsAdditions_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_LicensesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_TrademarksAndBrandsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_PatentsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_GoodwillMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_flgc_FiniteLivedIntangibleAssetsAdditions_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/DummyDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_2"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_TrademarksAndBrandsMember" xlink:label="loc_flgc_TrademarksAndBrandsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_4"/>
    <loc xlink:type="locator" xlink:href="flgc-20240331.xsd#flgc_LicensesMember" xlink:label="loc_flgc_LicensesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_TrademarksAndBrandsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_us-gaap_PatentsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:to="loc_flgc_LicensesMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/IntangibleAssetsAndGoodwill">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.floragrowth.com/role/UnauditedCondensedInterimConsolidatedStatementOfShareholdersEquityDeficiencyParentheticals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>formprer14axz001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formprer14axz001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  W OX# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS7\4/"UW\2_^"E7[$?QX\16L]MKWQU^(VM:QI]O<*5ETOP[;:;%'HMH1_"3
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M7^)M'OO!/PP\3:;#J'@;P)J/B1]"\-NUS?OI_B076N0L3$RO>-;;&,#!I+@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>formprer14axz002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formprer14axz002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #__@ [0U)%051/4CH@9V0M:G!E9R!V,2XP
M("AU<VEN9R!)2D<@2E!%1R!V.3 I+"!Q=6%L:71Y(#T@.3 *_]L 0P # @(#
M @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3
M%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@
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M*?Z;#9]O+#<N%^57(  YKZXH *AO+R#3[2:ZNIX[:VA0R2S3.$2- ,EF8\
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M@#5N@ HHHH ***0G R>E "T4@((R#D>HI&=5906 +' !/7Z4 .HHHH ****
M"BFI(LJAD8.I[J<BE+!>I ^M "T444 %%%% !112=* %HI 0PR#D>HI: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVYT_1Y'<VMM)-!;M(R1[MHR6;C&!N.,5]YZQXNTK0=;T+2+VY\K4-;GDM["
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M_P"M1_PWA^S[_P!%:\-?^!7_ -:@#WFBO!O^&\/V??\ HK7AK_P*_P#K4?\
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M#B_@_P#LM^$?@IX U3P/HE[K=]X1OX)+<Z1J]Z+F&!)-WFB+*@KOWG(R1GG
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M^H;_ .$OI'_R+110 ?\ #(/A7_J&_P#A+Z1_\BU[G:6ZV=K# F-L2*@PH48
*QT' ^@HHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>formprer14axz003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formprer14axz003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #__@ [0U)%051/4CH@9V0M:G!E9R!V,2XP
M("AU<VEN9R!)2D<@2E!%1R!V.3 I+"!Q=6%L:71Y(#T@.3 *_]L 0P # @(#
M @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3
M%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;)>:+-.V?M%JZ"0(&[X4[E_V<C^&HOV>+L0_M<_&MYY]D$0=F:1\*@$PR>>
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M@  \9^)'C+2/@A^SW;> =#\0+;>+X;;3;?[!)?--J$,%W?0033'>QD^43O\
M,3QCKQ7*R>)=1N?BKXC\%ZM<WUOX T_6-6TRWNX6DVVMS+IUG<6J,Z\KL,EX
M8R3PQ4#D+7U3XZ\"Z5\0O"^I:%JL1-K?1A'DCP)$*L'1U./O*ZJP]U%<Q+\)
M/)\+^(-#L[YHV\4W<UUKNJ8"S2>:BQR")0,*3&BQJ<_(%!Y- 'AO@K]IB34O
M#/P&?7[[3I-:U;^S+;4[>\G$<PN;FR>4S[,]0H3!/!-QZJ*]-^&W[/\ X/\
MAU\7M0U?PW'JT<\-@ZW7VW6KR\B:6XEWX6.65E0J(R> .)5QQ78>*_@WHWB=
M_!GERS:/#X4OHK^Q@L8XMC-%$T4:/O1CL5'8 *1VYX%=5I&B+I5UJEP93/-?
MW/VAV90"H"*BI[@!?U- 'C'[1&GPZE\5_@7:7(>2TN_$%W!<0"1ECF0:?<.%
M=00& 9%;G/(%><Z-^T'XL^&/PO\ &Y:R_MVT\'^)-7TF'5M6G+&6"">'[/;\
M'S'D*7#J'Y"K;,6R>OT+\1?A/!\0_$'A'67UO4='O?#-Y)?61L5A*M*\30G>
M)(WR-CN,#'7/:N \:?LAZ'XJT"QT:U\2:UHME%::E;W0@,4CWLM[(DLMS(70
M_O?-0-N&,@LG"G% &%XX^-VJ:GHVKVMYHEI(VA>+K?2[ZVBOI[:2-1J5E':3
MADY/F+<QRF,X!4,N2 <\OXZ^+VI:MXY\!?$2QT--3L]/7Q6FEZ?91L]Y=1VR
M"+=D'G>8G<(HSC:.37M.M_L[Z+KO_"02S:IJ$%_K]WI-]J-Y;B)7GET]HWA.
MTH5&YHU+8 ST&!7.+^RG%9:M9W6E^.=>TFVTV_U+4-+M;9(,637K"2:,.4+,
MF_<0I/"L5SB@#&N?VKI9?#U]J^A'1?%&GZ5X<NO%MY?6#2)'-8QW+QQQ(K'=
M'.8XIF8/G8\>TCG*Z6F?M(:G<?%=M'O;#2[/PG_:USI*WWG/YX$>E1:DMPY8
M!54H[*RXR#@[B <Z^H_LK^&;Y-5\J[N;!]<@O+36_LBJBW\%U<">9-N#L^;>
MH(R0LCCDG<-:R_9[T:Q\=Q^*4U74C<1ZU-K:V9$ MQ+)8K8^7@1Y\L0HH SG
M/))Z4 9ES\=YO&GBE-'^&;Z+XD2+2(=;FOI;DM!/ ]VT'EQ,AP&Q#<-N.0"B
MC'S$B+X0_M!3_$?7O#MM=:;#9V/BG0KCQ#H\D3,76WBN$B\N7/!<I-#)D8 R
MRXX!/4^)?@_#K'Q%TWQEIFMWOA[4X-/;2+R.R2-H[ZS,GFK&P=3L97+%77!'
MF..XQAZ#^SEIWA6+_B2Z]J6FW%GI<NC:-<Q+&SZ7:27 G=(]RD,=RHN6'"1H
M.H)(!@^(?VB-:TO1_&GBVST>PNO!WA>^U'2;A'F9+R6YME1$*G[H5[@M%C&0
M &SSBJ]]^T#XJ3Q]#\/[?3-&'BG^UCIT]Y.\WV6.-]*DOXI1&/F;F)XRN\?=
MR#\W'3W/[..E7<OCJR?6M2'A;QA+-=WV@IY8BCNY8PDLT<FW>N2JR;<D!QN]
MJ?;?L\:<GBFR\43Z[J,OB.#4FU.6^1(5$[FQ-BB,I0X1(6; !'S,S'KB@#*^
M 'QVUOXKZA:PZQI=A81ZAX6TWQ-;"QD=C$MR\T;PN6^\0T.X, .&P1QD^WUY
ME\+?@-I/PHO["ZT[5M3OOL7A^U\.11WIA*_9[>21XV.R-3OS*X)S@C''>O3:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>formprer14axz004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formprer14axz004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #__@ [0U)%051/4CH@9V0M:G!E9R!V,2XP
M("AU<VEN9R!)2D<@2E!%1R!V.3 I+"!Q=6%L:71Y(#T@.3 *_]L 0P # @(#
M @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3
M%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@#
MU +U P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _5.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[?O+)HV8H%SE#\O 'S9&:FG[_+V:B_\ P)M+UV_1:Z%3]R_=.2_\!2;]-_\
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M F7 ._#DA<?D2'OR<5T5_P"OZ\MPE[D5-[-V-#_A07QY_P"AY\;_ /A96O\
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M /(-<[_P3J^*/A/1?&OBGX5^&?%!\3:++9VVN:=>2PS0L;KRHTOX]LJ*W^L
M<8&,$\]:\[^,G@?^Q?B!X^^(7B32;OXB^'(];>>'XA>!O&*QZEX;C5UQ:FV+
M-&&C^[M*<?WAQC::4)Q3>C5[_.WYWU=D]-;M(SC[ZDUNGMZJZ_"UTKO?31GL
MW_"@OCS_ -#SXW_\+*U_^0:/^%!?'G_H>?&__A96O_R#7H7[3?A7_A)OA-X?
M^+WA&],?BOP1:+XBTK4;I=K7=IY0>>WFP!\LL6<C ^;T!-:'['O@BYF\*7OQ
M8\1R17GC3XA^7J]S,F2MK:,N;6TC)Y"I&5SZD\YP*%%WG%Z<NC_3[[2OVMUN
MB>;W8R7VMOS?W75N]^EF>6_\*"^//_0\^-__  LK7_Y!H_X4%\>?^AY\;_\
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MI7*>/_V5_P!GV/P_H%UXP\-:+8Z1X?ABL+"\U+4I;:.*/?\ NXGE,J^:"S8
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M)-Y'V+=Y:;-_G?)G=C&>^,<UY%H/CGP9\/T^/UQX5UW6/#OPIOM>TC3]'O\
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M;OYK1O[S]%+_ ,%:%JGB2VU^]TRWO-7MK62S@N9UWF**0@R*@/"[L ,0,D
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MA@?4&KE>._L>?\FN?##_ + 5M_Z#7L5;U8>SFX+H84Y<\%+N%%%%9&@4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVH/._:SG^"?_  C./*TW^T/[=^W]?W0DV>1Y7OC._P#"O*_^"4G_ ":_<?\
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M-]:LK4$F;5V>)I=.CF'0^3&&'IG P170_#?]H+XM6U]\(_%GB+QIH7B?P_\
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M_"[PO=:+J-Y'IM@_@71WLK62]U)@FFZ?)'Y;>:'DVE&2/&^4'[IYZUE_#O\
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MW8T3Q'J?@G4M>DTJYT^#PB!I>F6WF&-9AJ2,7:1#M+AU"CYN1Q7T+^V#X_\
M&W@3PYX#C\!ZO;Z+K6N^+;+16N+JU2XB,4RR@AE8'C(4_*0W'!&:Z73?V5/A
M/H_Q-?X@V?@FP@\7-,US]O5Y=JS-UD6(OY:ODD[@H.3G.:[3QI\._#WQ"&B_
M\)!I_P#:']C:E#J]A^^DC\FZBSY<GR,-V-Q^5LJ<\@T)+DIQ?1J_FM+Z^>OW
M_<Y/WYRCL[V\M';[KK[K^OR7IGQN^(NA:/\ $OP5XL^*5K:^*]$\2V.BZ3XG
MMO"T=S<7K7,)D2".S5TCWG'#,2 -V<\$<AI_[1_QJO\ P;9Z%%XMMX_%T7Q+
MB\(MK5[H]HIFMY("W[Z")GC5E;DB-\\ ;NM?6GB_]E[X7^/8_$B:_P"%(=2'
MB*\@U#4C+=3@RW$,9CCD4B0&,A"5_=[<@G.<U#H?[*GPK\,I9QZ5X2BT^&SU
M6WURWAM[NX2..]@C\N*8()-N0O!&,,>6!/-.&Z]I_=O\K7^_7U%)Z/D\[?.]
MOT]+'RC<?'?X]^%M*\0:KJ'CO1]5L/ WC6'PU?H-"BBEUQ)944NY!Q"%5UP(
MP"<G+''+_!?[6_QH\8?'-YM/T+Q)JW@R/Q0^B7.D6/A'S=.M;-9?+:=M11C(
M)UX9D9-@YY XKZ]U']G;X>ZMIFOZ?=>'_-L]>U=->U&/[;<#S[U&5EER),K@
MHORJ0O'3K6<W[*GPG;XGCXAGP38?\)>)_M7V_?)M\[KYOD[_ "M^>=VW.><Y
MYITVU*+GK;?[E?[VGZ7NK!4LU)0TOM][M]R:];6>A\4_$KXD?$;XN^#-)\9:
MWXRT=?"=S\1[72K;P6FGQI<6?D7>$?SP=[/A<LC C#9&.@^NOVT/B5XE^$WP
M-NO$'A+5(-'UI-2L;=+NYA26)4DN$1PX=2-I!.3U Z$'FKFJ_L:_!G6O&ESX
MLN_ MF?$%Q=I?27D5Q/$?/1Q() J2!58L 3@#=SNSDU;_:E^#NI?'7X3R>%-
M+DT^.>74;*ZD_M-G6%XHIU>13M1B254@#&#GDBHBFJ48=>:-_P#R1/7?6TF_
M)VZ%-IU7/I:5O_)VM-M+I>;5^I\U^,_C[\7OA/I7QC\,ZIX[TWQ;KFA>';/Q
M#I7B33]*MX/LIFN$C:!X0&C;ALJ6!)'.>1CHM4\8_'"+Q;X#^&!^*6DZ;XD\
M1Z=<^(KGQ5/H%OMAB4)LL;> G8Y4[R7;YBN#QC!]PT/]D?X1^&O!OB/PKI?@
MNUL=#\1%?[4MXKF</<A6W*OF^9O50>0JL .<#DTGQ8^''P8^+NEW&B>.HM!U
M:'PG&DES'<:EY,VDHZ J99$D62%650?F(#!0><4WHONOTT2E?[FX^O+K:XEK
M^/WOEM^4M.CEIL?+GBO]L#XE^%_@3H7Q(_MW2+N^TCQ!?^%]3TA;>,6NOL@8
M1WENP0R+M(#%48*0#P.E=!XJ^+/BCX>:Q\)?$&J:QIGC_53X%U[7I]4&E6@-
MQ*ENLR)!*D2O%$,A2$*[@,MDU]$^%/@K\(/$.F^$M8\.:1H^K:/H5M<6NB2:
M=>-<6$4<N4G*(KF)V;Y@SL&;.><U<\-?LT_#?PBV@G3/#GEKH5O=VFG1W%]<
MW$<$%U_Q\1[))&5D;^ZP(&3C&:))ZJ^O?_MUKY7;YO*_*M$@3CH[:=O^WD_P
M2Y?/=ZGRE^S]^T7^T-X]75D.B:[K_P#:WAVXU#2-0UOPDNDZ?::@J[H88;A'
M*3PN"0&D*DD+T&:]4_91^*7C?5/&NJ>$OB9XOU6]\5_V>NH)X?USPA#I$L"!
MPCR07$$SQSQ!CMY 8\'C!%>B>$/V/O@WX$DUQ]%\ Z;;'6K=[2^$K2SK)"_W
MHU$CL$4X'";>@]!6I\)/V9?AC\"]0OK_ ,#^$[;0[Z]3RI[D3S3R,F<[ TKL
M57(!VK@<#T%:)I2O;2UOGK;]-=W8B2;C;K?_ "_X.AZ?1114#"BBB@ HHHH
M**** "BBB@ HHHH *\)_:)_9?_X7YXX^&GB+_A)?["_X0S43?_9OL'VC[9F2
M%]F[S4\O_4XSAOO=..?=J*%I*,NJ=UZH.CCT::?H]PKY&^/'["FN_%KXX7/Q
M+\.?%S4?A]JDMI%:*-+T^0S1JB;&Q.ES&V&'48_.OKFBI:3:EU7^5OR*4FDU
MW_X<^9O@)^RI\0OA'\08O$'B3X^>)OB'IB6\L)T355N!"S, %<[[N497M\OX
MBL7XR_\ !/K2/'?Q%NO'O@7QOK/PL\5WK,]Y=:.&:.5V^\X5)(V1FZMA\$\X
MSDGZSHJG[UF^FWS$G:]NI\P?L^_L(Z!\&_'4GCOQ%XHU3XC>.2"(M7U<$"$D
M;2ZJ7=B^W(W,[8!X KJ=8_9?_M;]K'1OC7_PDWE?V=IIT_\ L/[!GS,QRIO\
M_P WC_6YQL/3KS7NU%5=WC+^6]O*Z:?X-DVTDG]K?Y:K\CYS_:6_8ZM?CQXS
M\*>--$\3OX%\:>'Y5:/5X+$71F1&WQJR>9'RK9(.3PS @Y&+J_LM76J?M1:=
M\9/$7BU-8ETS318V&B1:688[=_+*-()#,^<L\K;=O&\<G;D^_P!%3'W+<O1M
MKU:L_O7^>Y4GSWOU27R3NOQ_RV/'OVIOV=+']ISX7MX3N=4_L*ZBO(KVTU,6
MWV@P2)D'Y-Z9#*S+]X=0>U>B^!]#U#PSX-T32-5U7^W-1L+.*VGU+R/)-TR*
M%,A3<VTMC)&X\FMRBA>ZFEU=_G:WY"?O6;Z:??J?-'[0O[#/ASXV>,X?&^B^
M(M4^'WCN-55M:T<_ZW:-JLZAE;>!QN5U..#G QR'@+_@G!I-GXVT_P 5_$KX
MB^(_BGJVGR++:C4Y'BB#*0R[]TDCL 0#@.!Z@CBOL:BB'[MIQZ;>7IV^0YOG
M5I?\/Z]SPGXI_LO_ /"R_P!H;X>_%'_A)O[-_P"$20)_97V#S?M7SLW^M\U=
MGWL?<;I57]J[]D72_P!IRST"YCUM_"7BG1+@2V>NP6OVAUCSDQE=Z$_,%8'=
M\I!QU-?0%%*UDHKH[KU;O<?,[N7=6^6UOQ/)OBG^SOHOQW^$EEX,^(5R=9O+
M>*-O[;LH1:S+=*NTW$:DN$+<Y4EA@D>E?-:?\$PM1U&"UT3Q!\=?%>L^"+9U
M,?AXQ.J(H/"J7G>-2/41?A7W;13TYG+OKY?=L)-J*CV_K?<YOP5\._#_ ,//
M ]AX0T'3X['0+&W^S16J\C8<[BQ/+%B223R22:\"_9._8:T[]EOQIXG\11>)
MSXCFU: 6MM&VG?9C9P^9O9=WFOO)P@SA?N>_'U#13N^=U.K5ODR;+D]GTO?[
MCY=@_86TJW_:X?XVKXC_ '1N&O!X>_L[@7!@\LOY_F_WB9,>7UXSWKZ0\2:/
M_P )#X=U32O.^S_;K66V\W;NV;T*[L9&<9SC(K2HJ'%.FJ+^&S5O7<M2:J>U
M^UI^&QXU^RE^SM_PS%\+Y/!__"0?\)+OU":^^V_8OLF-ZH-FSS'Z;.N[OTK.
MA_9?\G]K.?XV?\)-GS=-_L_^POL'3]T(]_G^;[9QL_&O=J*T<FYJH]U_ER_E
MH0DE%P6S_P [_F>&?&[]F+_A<GQ?^%WCK_A)?[(_X0B]%Y]@^P>?]MQ+%)M\
MSS%\O_5XSM;KG'%>YT45*]U<JVNW]^Y3;D[OT^X^6?CG^P9I/Q-^(4GC[P=X
MSUCX7^-+@8N]1T7<5N#C!<JLD;*Y  )5P#C)&<DV_P!G?]AK1?@GXZN/'>O>
M*]5^(?CF5&C36-6!7R@PVLRJ7=BY7Y=S.>"0,9-?3=%$/W?P_P##7WMV^03?
M/\7]6[]_F?-'[1?[#7ASXZ>+[;QKI/B'4O /CJ!57^V])&?-VC"LZ!D.\#@,
MKJ<<'.!CF_A3_P $\=,\+_$2Q\<?$/Q]K?Q7\0:<RR63ZP&6*-U.49@\DKOM
M/(&\*#V-?7=%$/W>L?\ AO3M\@F^=6E_7KW/"?C=^R__ ,+D^,7PS\=_\)-_
M9'_"%W/VG^S_ +!Y_P!L_>I)M\SS5\O[F,[6ZTG[6'[)VC_M2>&=+M9M4;PW
MX@TFX\ZPUN*V\]XE.-\93>FY6P#]X8*@^H/N]%39<JCT3O\ -M._X#YGS<W6
MUOEV_$^</CS^R5JOQ_\ ACX#\,ZWX]6+5O#=U'=7.M+I&_\ M!TC*9,7GCRR
MW4G<W.>.>/HU%V(JYS@8S3J*N[U\W?YNR_0BRT\E9>FYY7\$?A#XD^%NH>,+
MCQ!\1-5\>1:WJ!O+*'4A*%TN/+GR(]\TGR_,!\H4?*./3U2BBET2[)+[M![M
MON[_ 'A1110 4444 %%%% !7$_&W1CX@^#WC33Q>WFGF?2+I1<Z?+Y4Z8B8_
M*V#C.,=.A-=M3719$964,K#!4C((K.K#VE.4.Z:_ TIRY)QGV:9^9'P[\61Z
M7\(_@-X./QBUKP=X'U^*^N-<\1VNKHDUC>11QE-.CN2,6L:Y#!&_O\]17UA^
MQ;XSUOXA?"GQ%#K&OW?BG3M-UZ^TC2/$TQ*3ZG8Q[1'.7&"S99AO')V]<BO7
M/^%1>!/^$;D\/?\ "%>'?[ DF-R^E?V5!]E:4]9#%LVEO]K&:Z+2M)L="TZW
MT_3;.WT^PMT$<-K:Q+%%$HZ*JJ  /85O*2ESW7Q?\#\DG%6MH]=3%*RBET_X
M/YW3=[ZK30^&/A?X[^(>O_$_1/A#<ZWKMWJ?PXU#5M3UR^>]F$VKVL>#IL<T
MF[,BR&=<JQ((09KA/AQ\7/$>L77PR\06OQHUWQ#\0/&'B%M)\1> OM:F#3K1
MVD61XK8#-LT*A6$G?J. <_HS:>%]&T_7;_6[72+"VUF_1([O48;9$N+E4&$6
M20#<X4= 2<=JX[X:_P#"L_&NI:MXQ\&Z3HTNJ)>W&FWVLV^DBVNFGB;;*C2-
M&KO@]\D'L340W7-K9:^>MG\I*T7\[6;-)O1\NEWI]S_%-N2^2=TC\W-'\9ZY
M\)OV=WL/"/C;79KK5/'=QIFN1_\ "20V4VG0H\_EA+B52MD]QM+M*XPQCSTR
M*^UOV'_$WB_QI\(-7@\8:FNJ&VU.:TL-0A\26>M7)M2B,JRWEHQ5I4+,-Q"M
MC:<#BO:6^%?@I[76+9O!^@M;:S*)M3A.F0%+Z0$D/.-N)&R2<MD\U3O_ !!X
M)^#%IX:T$1V7A>UUB_72M(L-/L"D+W+@LL:I$FU,X)R=H]Z(Z0<):MJ*^Y16
MGW.W^)BGK)2CI9M_>V_U5_\ "O,^/OA;\0?'^O?$OPY\(I]=UR]UGX=ZEK.H
MZ]=O>S";5;6+']G)-)NS(DAG7*L2"$&17'_"GXS^([G6/A5XJM?C%K'BKX@>
M*O$O]F^(OAY/<J]I96C/()"MH!FW\I54[^_;@'/V=\*/@9-X$^(7C;QWKFN0
M^(?%7BIK=)Y[73_L5O;P0IMCBCC,DC>Y8N<D#IBNWT_X=^%-)\27/B*Q\,Z-
M9^(+D$3ZK;V$4=U*#UW2A=S9]S3A>/(Y:NROZWU\M4DGIWL%2TN=1T5W;TM]
M^C;:^2>B/@CPK^T1>7G@3X5>'&^(5_/XY?XI_9=3L3JTK7S6(NIE\N<;MQAP
MT8"M\IP !QQ[7^Q7HWB+Q/?>,_'/B#Q[XHUOR_$&K:-::'?:BTNGV\*7 *N(
MVR2X^902<!3@ 8KVY_ 7P[;QTZ-X&TMO$4FS6'U,^&\JTJOA9#>>3Y9G#<A=
M_F ?,!CFNMT+PUI'A:UFMM&TJRTBWFG>YEAL+=($DE<Y>1@H +,>2QY/>E3]
MR*OO:W_I"_\ ;'\Y/U94?.[+17O][D__ &Y?)+T/A#]H?XCZE\.?V@=8U_6_
MBIJUSX<L[JU%KX?\%>-K&UN]/7"!XKC29HV-R2Q+<'.T\CTYWXH6/B2U\2_M
M1>//#GCOQ!X3G\,ZCIE];V6D3+!%>2FWC'^D_+N=0I("9 R22#TK[]U7X8>#
MM=\16_B#4O"6AZCKUN5,.J7>FPRW46W[NV5E+#';!XJ6[^'GA6_BUN*Y\,Z/
M<1ZX5;54EL(F&H%0 IG!7][@  ;\XQ413C!)/5)V?KR_?L]^^Q;DG.[6CM?Y
M7^[<_/K]IWX^S1^(=5UGPQ\3/%>B^+?#QTQ)=$D\006>FS22+$SK!IZPF2Y4
M*Q+M(P4$GD@!3V.MZOX]?QA^TAXYT[QUXH+>!#NT;PW!?,VG[Y+'+O)"<AE3
M(D5!A0RDD')KZE\4Z-\)/^%@Z3X<U[PWX>N?%?B2QFBM8KK1$F>[M;=5+QM+
MY14(HVX1V X& <5W6E^$]#T.XU&XTW1M/T^?4F5[V6UM4B:Z95VJ92H!<A>
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M>GO??W5%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+CUD16.F;9!>I&U_$LI0L(&(1W ).=N>?TT\0?$WP?X3U>TTK7/%FAZ-JEX
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *BN;:*\MI;>>-9894,;HPR&4C!!_"I:HZ[K=EX:T
M34-7U*;[-I]A;R75S-L9O+C12S-A02< $X )J9<O*^;8J-[KEW/@'X/_ +/7
MQ&/Q;U+P5J5C?:;X-^&\.LR>#]7N8)$@N)[WBV9)"-KF(,S94G:1CBLKX/\
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M=>6<>7C8H)Y).,<Y7Q>^&6IZAX[^/%E<_ GQ#XOUGQ3=6UMX9\3PZ7NALI!
M@+^<^#$@8@F1?E)4JQ&#7Z(^'/'WA[Q?X-@\6:+JL&I^'I[=KJ._MB61HUSN
M.,9R,$%<9!!&,UY=I_[;?P2U3PWJVOV_CVU;2=*\@7=P]I<IL:8,8T56B#.Y
M"/\ (H+#:<@8-9J*@N271:]':T8_+9*ZZFG.Y/GCU=UVO>_S]#YB^(W[.&J^
M(+WXZ7>O>"KOQ-K]IX)T:TT74VTV2X,][':A9VM'VG?)O1<E,L,X/4UE?$[]
MGO5?#=MXFM?!_P /]4MX-2^$UG!<KINE3'[7J?VV)I$?:OSW&U2S Y? )-?:
M%W^U%\*['X86_P 0YO&E@O@^XE\B+40LC%Y><QB(+YF\8)*;=P SC%5]3_:R
M^$>C_#C3O'EWXWL(_"VH3&WM;U8Y7>60?>00JADW+W!7(XSC-5+7FOIW^?-^
M?-?Y(F#MRM:]OER?ER?BSY2^*7P4O+WXE_$FW_X51>:U+XF^'T":5J\6BI+!
M;:C#;N7WRD?NYV9$48^<L%]C7FGQ/^#?B_Q!IWPQUBP^'WBC0O#,?A(:'-I-
MIX#M-7N[*^65OM$C6,TB"'SB?,%P"'.<G!)K[UUK]IKP=I[^"[VSUG3=0\/>
M);2_OH;^)[J25H;6'S9##%%;2!RH!W*[Q,,8 =OE&_'\>? <P\(%/$,3+XLM
M);[1V$$NVXMXXQ+)(QV8B54.29-N.G7BG)7O?N_SJ:?=*2_[=OT8H/E22[?I
M!7_\D3^=NI\3^(/@SK'@?7O"LWB_X6>(_C+HTW@&+P_IJ_V9%)<:9>J[D?:(
MA-(EN=C*/,$C;<<$D$#ZI_8I\.ZKX3_9>\!:3K>F7>CZI:VLJ3V-_ T,T1,\
MA 9& (X(/(Z$5M_#[]J/X5?%.77(_#'C73]2?1(6N+_<'@$,*_>ES(JAHQW=
M<J,CGD5QWA']M?P'\3/C!X7\$>!KR#Q3#JT5Z]UJ44DD!L6MT#JIADB!</DX
M8$#Y3C-6I-MQZRU^5Y2_5ZO>R1#5DI/:.GSM&/\ EHO-GR-J?[._Q"F_:@UH
M:E9>*;>6[\8C6[#7=)\%V>H6YA\T/$SZK)<12P*% 5H@2!M^ZQ.*D^+?P0^(
MVK:1XBU&S\-ZXVF6GQ2UG4Y[*+PZFJ37%O+'&L%U%8W!6.ZCR' Y(^?(Z&OL
M#XH_MA>#O@K\8#X-\;2Q:#I1T--736Y)9)3)(TYB%NMO'$S$X4MN!Z \=Z[K
M0?CWX!\3ZL--TOQ);WETVC#Q"I2.01O8%BOGK(5V, P((!+*0<@5A!)4HV>B
M6_H[Z_*#O_X$;RDW4DVM7;\;[?.7Y(^&M-^"'B'P?\./A3K.M>!_%7Q(\&:3
MXAU34=3\'W?ANWL[U4N8D6%ETR.>5-B2+*P3*XWXV*.3TUY\-(K'7/@1XMM?
MV?M4T;P]9:YJ?VGPY% =6N[2&<#[--.D@_T=!*6E\K.V(Y(^8XK[+T_XO>%M
M7^%Q^(=A?37GA3[')?I=I9S*\D*9RRQ,@D.=IP-O/&.HKR_P!^V#IGC#P5XX
M\3ZAX2US1+7PWK(T>+3?(:XU*\D81^6/LZJ#'(S2!=A)QW8<XVYN2;?6+3_)
M6\[Z6ZKIT,FN:'DTX_?S?=;6_1VU/GJW_9FUK4_V9OBO-IO@F6#Q[J?BN]F=
M+FU-K?:EIBWL<AMTD<!O+D2/*@':QZ9S7.^*?A9K7C30OBYX@\!_!OQ!\-?#
M%UX.@T8>&I]+-O=:IJ"W<;^;':1Y+;$##>!\W7J3CZ\^&O[5&@>+?@=!\3O$
M]G)X+TJ34)-.:WE9[QXY!<FWC#>7'G+-C("X7/)P,URGQ<_:^UKP+\:Y?AQX
M8\!:=XLOX;>UEEFOO%]GHS&2?=MBCCN%_>MM4'"$GGH.,YJ&U+NE%?\ @$5^
M,;.VR;;-.=W=3LVW_P"!M_A+2^]E8\4^(_[/EQX.\0>,K7P/X O;#2]0^#TE
MG(ND:7)Y=UJ/G#]V=BX>X*@$KRYQFH/&OPYO= \;6NJ>-?@AKOQ=T?6/ FEZ
M1I-K8VAD;2[N*$"6&4GYK0ECDS ;ER<9.<>T>)/VXX_#?CS5+*3P'?2^!M&U
MR+PYJOBT:E OV6^? VBU/[QT!;EP1P"<=C[9\5/C7X*^">G6%_XVUV+0+._G
M:VMYYH99%>0(7*DHK;?E4]<9Z#D@53DI+VCV;_/GT^Z>GDDUN1%./N=4E^'+
MK]\?>7FTSX0_:=\$^,?%R:_X;C^!%Y!<V^@:?_8^JZ'HL&JS$QPH9HKC59E,
MS-'M,:+$!(^WT;G9^*GPV\9ZU=?&>>U\):_=#5+KP7+:%-,G)N1"D?GE!LRW
MEX._'W<'=BOMSX6_&#P=\:_#9U[P3KL&O:6LI@>:)'C:.08)5T=593@@X(&0
M0:X2?]M'X*6GBN;PU=>/["SUF"ZGLIK>ZAGA6*6$D2*[M&$7!! )(#?PDU2;
MA/7>]_Q3_1:_,37-%I;6Y?T_I'SM\7OAYJC_ +7<?PSLX0W@WXBZEI_B_4E#
M?*@L1)]I0KZ2M' 2?4BOKKXZ^&=:\9?!GQKH7AN;[/KNH:1<VUDX?9^\:,A5
MW?PYZ9[9KE?@I?\ P@^*WB36?B9X OE\1ZU(3IMWJLUS=RR0+D.88X[@_N8R
M2&"QJJGJ,U[+64H?N%1EY_CM]T;(M3M6]JNEOO6_WO4_/?X+_!=O&OQ$\ V=
MC\%]7^%VE:%X=OM(\97^J6:VL>M&:W$(C0@YN?GR_F'G\AF'X?? +XJ>*_!W
MQ*L=<T^\L]:\)>%9_ GA.:Z1H1J$?F2.\\3, "'B$,0<'&">>#7K_@;]K7XN
M?$^WN-2\)?L]_P!L^'XM0GT\:G_PFMI!N:*0H[>5)$K#&,XQ]":]3\0_M8_"
M;PG\1HO >K^-+*R\6/+' ; Q3,J2OC:CRJAC1CD<,PZBKE^^7^-/[Y>]=+TD
MTELE*PE^Z?\ A:_\ETLWYM:O?W5V/@OX8? ;QM;_  X^*-R-!\8VNH-X*FT9
MM'N/ 5KHT-Y-N0HL36\[27<@*MB0PDL"<L,@']#?@'\.M&^&7PH\-Z5I&@V_
MA]FL+:6]MX;80.]SY*"1Y1@$R$KABW.1S6//^UE\)+;XF_\ "OI?&UBGB[[2
M+/[ 8I=HGSCRC-L\K?GC;NSGCKQ7*_#_ /;F^%_CF#Q]=RZN-#T[PA=>5<75
M_'(HF@)").HV?QR;E6/ESM!*C(%5[3F3:ZI/Y*]_E>7Y$.#35^CM\W:WSM$^
M>/BW\*M4L/$G[4VG:;\+M6N+WQ+86MWHFMZ7HGF0S)^Y-Q!'*@W&220[RB@[
MC&S-R!E_Q0_9EUNQ\2>)='^&G@Z?08-4^%4=K)+96;6]O=7RWD;20R2X"FX>
M)&!#'<<\^M?547[7'PBG^'4?CN/QK:/X5:^333J"V\Y\NX896.2/R]\>0,Y=
M0,<YQ6+J7[=/P,TBSL[J]\>0VT-Y:I>V_F:?>!I87=XU=5\G)^:-P>,C&3@$
M$Y<EH^S[)+_R627X2OYVOZ:\[<N?U?XQ;_&-O*[7KXI_P3]^%7B#PGXV\1:]
MJEEXGT:&32(M.FL=8\$V?ARVDE20,KQB"X8SLH\P>8T0R'R7S@'US]I+POK.
MN_&OX"7VFZ1?ZA9:;K5[+?7-K;/+':HUMM5I64$("> 6QDUZKXH\=:DWPT/B
MCX?Z'%\0;NX@AN=-T^'4H[)+V-V7YA/("J@(Q;D<XQU-?/G@?]M'QYXIM?%F
MJ:I\&[;PQX:\*RWUIK6N7GBV.>&QNK:(NT;QPVSS."VQ=\22 ;L@-@BJJOG=
MI:<N_P"/?SE]]D1"/NOEUYM/O2_1?/7L>.?"S]FZ;P]X _9XU<?#F\LO%@\9
M3/XAN9-(D6[2S9YU_P!*RFY8=@C WX7!_P!KGB]<^!7C/_A2MQH6C_#;6M%N
M_#GCJ>_U4P>&(+O^U+1FF%O);V\A5+Y(5.-C?*!(,<9Q]P>)?VR?A)X#;3[7
MQ9XPM-%U2ZL+34/LHM[J53'<+NC9&\D%EX/)52!@L%SBMGP[^U+\)_%FK>(-
M-TGQUI5Y<Z!:M>ZB5=EBA@7&Z02D!'5<C)1FQD9JI+67E?Y6<7]R<-?5]BN:
M[YN_Z\WY\^GHNY\9^#/V==9O?!WPHTS6/#OB36_#]W\1&U6^TW7/"<6EK9VQ
MM\.9+."::.&!G7HWECDC;@@GI?B?^S/9Z[XE_:=O!\-WO#!H&FV_A%X](9E#
M1V6"MCA<%E9(U(CY&-O?%?7/PD_: ^'WQUAU"7P+XFMM?&GN$NHXXY(I(LYV
MDI(JMM.#A@,'!YKKO$_BC2?!?A^^US7=0M]*TBQB,US>73A(XD'<G],=22 *
MFHO==]+I_BH*_P E#1^;%3;4M-7I^#D[?-RU]$?E[\6_V>OB)K?Q#635=%\5
MSV&O:#HT%I>:/X+M=<EMFCM8TDB>:XGA>P=)%8DJRDYR37U#\%?A]=?#_P#;
M#\<SZGX&OI_[:T;3I++Q@FDHML)8[?;>;YP2(Y9I""RJS%BN23P3ZIX>_:]^
M$'BSP;XA\4Z3XUM;W1/#Z+)J<J6UP);9&;:K&$QB0J2<!E4BM?X7?M(_#7XU
M:SJ>D^"O%EIK^H::@DN8(8Y4*IG&]2ZJ'7) W(2.1SR*U4GS.R_F?RE?\K[]
M;:]3-KW;/;1?.+C_ )+3I?3H>E4445F4%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ROQ6T2]\
M2_"_Q?I&FP_:=0O](N[6VAWJOF2/"RJN6( R2!DD"NJHJ)P52+@^NA<).$E-
M='?[CX_^'?[-_B30_%_P"O-0\*VT5GX7\&W>FZNQEMW%M>R1J N Y+DL9/F3
M<.2<\UQ?@7X$_&7X2:%\$-?T7P19Z[K_ (6M=9T[4M!N=9M[;RENIV:*43 L
MA4 @D+D]L>GJ7P[_ &N-6\7_ +1][X2O-*L+;X?ZA=7^E>'-:C#^?>7UDL9N
M%=BY0H=TFW"C[O4UW.O?M7^$O#WA7XB:_<Z=K3V?@;5TT74DB@A,DTS/&H:$
M&4!DS*O+%3P>/73FY[5%]J[^^3_6HEZ2CZD\O+>DUM9?A9?^DOYQ:[H^:]*_
M9X^)_A?X->$8V^&EWJ7C[3-0U64:AX<\<1:+>Z>MQ<%_D<H\<L3C!*LV1C!4
M9-=YI?PR^-^G>*OV?_%OB#3+;QGK^@QZC8^(G&I00/:PW3*J2EB )FCC^]L&
M69/?=7<?$?\ ;G^'_P -/$/B+2KO2_%&K+X>B5M3U+2-*\^RM9F4,EN\Q=56
M1L@#.%SQNS772?M,>%X[WQO;&PU?S/".@0>(KXB&+$EO+"TRI%^\YD"J00VT
M9Q\QZTHR44IK9:^6D6OQ5[]_N8-.;Y>K_P#;FK?BU;SZ'!_M0^ _B%JGQ>^$
MOC7P+X-LO&8\*_VE+=V5]J$-HA,L<:(JM(<ASABK!2 5&<5\[^(OV-/BW-X<
MT7Q=::=<V/B=O$VK:Y=^%O"OB.+2[FQCO%B54M[UD>)2OD_-@$$/@=Z^F[S]
MM;PHNJZ-IVD^$/'7BJ\O]+M-7GB\.Z$;XZ=!<H'B-SL<[25.<)O^IJ?PG^T_
M=>*/VH-<^%8\&:W;:=I]A'<)K,MBZIO9"^^4L1Y<3#"(2"6<$'&*48-/D6]Y
M?@^:2_#\-&-STYGM9?CHOS_'5%G]GOX/ZC\,?V=;GPQ/I]_8ZK>)>W#6&I:S
M%JDT4LVX[6N4AA1B2<G"X!8_,W6O _%?[)7C^_\ V2_A!H6DZ=<:=XS\'WGV
M^]TG3-7AL+J5F,N[R;P!XTE!<$.<CEN_%=5^TE^VIXG^$/Q/\0Z#HUIX/@TS
MPQ86M_>P^)K^6WO]8$W)CT]5^5F4<'(;G/%?6/A/Q%;^+_"VC:]9JRVFJ64-
M]"K_ '@DB!US[X84_P"*G577E^7*VU^3^[IH&M-J#_O/_P "2O\ FOOZZGP[
MH?[+'Q%\'>"O!_BO1_"]YJ?BW1?%DWB*[\)^*O%=OJ4U[YD"Q,YO%MXHEER@
M89WXZ[B?EI/B]^SC\7OB)HWA'QE;>$-/\*>)-/U?4;NX\+^ -:BT:]$5RL86
M5K]E>)[G,9\R0* RL !UKTWX]_M)?%KX8^)?$>I:-X%TEOA]X:N+&VN+G6VN
M(;W6I+AE!&GE<(VTMM.0W([]*R?'?[8_C?P[X[\2W^F^&-%F^%_A/7++0-:N
M+J:4:HT\^P/)" ?+"QLX!# D\8/)VD?WEK=7IY?"ON?NK7NM$#O"[?9W\]W]
MZUV[;NQ1^%_[,'BCP=XA^!<K^'[Z+2]&N=?N]=BU77K?4Y;,WD"JBM*L4'F[
MV!R$C;!8Y8CFL[X9_L<>,[6Y^)VCZ_-'::+::%?^%O MTTZ2;;2[EFF:5@K%
ME(WQQG< =H( Q79>//VEOBUX/^(HG;P'I=K\.?\ A*;?PM!'J)N(M9U)Y"!]
MJM5.(VBY)'!R >>I'0>-/VJ;NR_:6\&?#3PUIEMJ&D7=_)I^NZU.K,L-R(&F
M6V@*L!YBJ%9R0P =1@&E954DOM77WI/Y66SZ<UMW8&W3O?[-G]S?WW;U76WE
M<^=_A-^Q3\1+S2?$&G>*K#Q%HNH1>%KOP_I^IZMXVM]3L',J!0D%I';!X8<@
M'!E&W X:O0_@]\+?B[<?&[X1ZWXL^&ND^#]$\&:%=Z'->:?JMO</<$P!$E*(
M051B/E0;BI+EL9K[3HK12:DI?U>TE?\ \F?D0TG%Q_JWNZ?^2H^3?C?X%^*6
MF_M-?\+"\$_#K3/'NEGPA_8;PZCJ=O:8E>=V;9YA)X4KG( 968!LUX7\8?@1
MXI^"7P0^"^F:=J%I#X]OFO/!MY# ^X20ZHTCM&G=A"QX(X!.:_2:L2\\$>'-
M0\36GB.ZT#2[GQ#:1^3;:M-91O=PIS\J2E=ZK\S< XY/K648I)1>JNK^EY-K
MY\S3\F:.;;<EO;\;))_*R?JAW@WPO9^"/"6B^'M.01V.E6<-E H[)&@4?H*\
ML_9X^'7B'P+XH^,-WKFG_8;?7_%L^IZ:_G1R>?;-&BJ^$8E<E3PV#QTKVRBK
M;<I.;W::^]IO\C-)1@H+96_"_P#F?.7[/_A;X@? W]G2/3CX*_MKQ7'K-U*-
M$_M6W@S!->LWF^?ET^6-]^W.3C;P:\N_:<_9N\:_$KQ_XPM]&^$_A+6(_%"V
M2VWQ EU$Q7NCB(*&:2*1V)8!<#[.J KC<&/ ^WJ*FRNF^EON2BO_ &U/2SO?
MIH7S-<S76[^;;?\ [<UKI:W74^!OC1^Q]XL^)GQ9DME^&WAI+6YO+%W^)<&I
MO%<BUB"&99;,R$/<L4(\U4 (.">21Z9^W7_:HU?X'OH>E6>N:O'XRCDM=-U"
M01PW,BP2,(V<@A<XP&(P#@U]6UFZMX:TC7KG3KC4]*LM1N-.G%U92W=NDKVL
MP! DB+ E'P2-RX/-/7W5VDI?G\OPL+37SCR_A]_XGS;\$/"?Q1^'<OCOQQJ/
MP\LTU_QQXDM)I?"EEK4"KI=FJ>7)<M/@I(_)<JO+>Q.!P.H_LN^,[_P/K-A+
MX3@GO;WXO#Q*R/<VQ,NE>:#YQ)?&-I;]V3OY(V\U]Q44U[K372R7I%Q:_&/X
MORLG=II];W]6I+\I?@O._P V^!/"'C[X4?$KXNZ[IO@5=:LO$_B;3I+*)-5M
MK4?8_("7%UR6_P!6<GRR%9NWK7K7PN^(5_\ $)/%#WN@_P!AII&N76D6[B[6
MY6]CB*@7"LJ@+DD@ISM*D$Y! [BBDM(J+Z))?+^G]X/5M]W?^OP^X_,SP-^R
MKXK\'ZM<7NN_LK?\)OKL>LSW]OXA_P"%B1:?E#,7B_T=)2ORC'7KW%>D_M!?
M"K]H/XI^)/$NG3>'1K/AR'6K/4M$N(/$4-M!':QR1DP"TROF3?>8R3-@8;;S
MMK[JHHA[B@E]FUOERV_])6OKW'-\[FW]J]_GS7_]*?X=CXPU[X4_&#2?CS+>
M?#KPE>>!]&OM>74-4UF'QG'=:/?Q,X,TDFF20AUED4<[,8/<_>KE_B'^S!\5
MO%>@?%SPU::&MK:W?C<>--%U6WUJ*!]1!(5K9>"8'51N$CC&X#C S7WO14J-
MHJ/;_.+7W.*LMM_E3DW)R[__ &R_%2=^I^?VB?LF>/+CX=,;[POKQUW5?&FC
M:IJEGXG\7VFMW#VMJ9!),TRPPK]U\;-TC,%& ,8/M?C'X(:]KGQ_^)'B5?#\
M%SHVJ?#XZ%IUR\L'[R[9Y"T04MN7(9?F("\]:^EJ*<TIIQ[W7WPY/RV\Q1DX
MM/M;\)<_Y_@>:_LU^$-7\ ? 3P)X<U^T^PZUIFE0VUW;>:DGER*,%=R$J?J"
M17B6E_ KQQ;? G]H_P .R:)MUCQ=KVLWNB6WVN _:X9T00MNW[4W$'ARI'<"
MOK>BG5_?.;E]I6?WI_HA4_W2BH]&G]U__DF?&%W^SAXTO+[Q_<2^&HYGU'X5
M6?AK3W>YMR7U!("LD(R_RX8+\YPAP/FKG/'_ .Q[XW\9Z/X7T?3M)M]$6#X7
MKX?NKK[3"J1ZBLT4H@<(Q9@Q1@74,OS$Y-?>5%$_?O?KK_Z7_P#+']R\[D'R
M6MT_R@O_ &Q?>_*WPE\#/AYX\_9OTGQM\3O$_@_Q->:]I^AQ:9;6/B'Q[:ZF
M=0031D)#Y=J/) P=BEV/S;0A+9KZ&_:A^%NM_'3X!ZCH&CK!:ZY,;6_AL[YS
MY,LD4B2F"0XZ-M*YQC.,XKV>BG-N:U\K>5G?\]?Z8H^X[KS_ !T_+3Y^2/@S
MQY\ OB]\9[/XE>+-6\ Z9X,UN_\ "4/AC3/#.GZK;W#WS+=1S-/),"L:@!-J
MAB"!@=N?;O!_P>USP[^T]HGBF+0XK+PQ;?#V'0I;F&2%0MXERK>5Y:MN.$'W
M@NWC&:^A:*$^5W7]:27_ +<WZ^0GJK/T_&+_  Y4OO"BBBD,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K \?VFOW_ ((UVU\+36EOXCGLI8M/GOG9((IV4A'<JK'"DYX4]*WZ
M*F45.+B]F5&3BU)=#X;C_P""=>M>$_ WA*Y\+?$K7KCQWX<N[?5+6QUK52WA
M^.[#A[@QQ+ 7C#9?#<DY^;J<6OBI^R#\7_$\OQ-T?PYXE\(6O@_QOJT&NW$&
MH)<_;([A#&S0AU0JL>Z,'=@D[1PN37VU16EWS<WG?R^S^'NQ?R0D[?UZ_C[T
MOO9^5O[2?B?6_ GCOXW_  RT?4&LK+QC<6]ZNDW^A3S7VI7;K&"MC+$6C,1*
MC<\NUA]U5)!-?1WQ%_9<^*VKZ]XCO_!'B#PSIFG^,/"5KX?UJ#78IVN(&BA,
M?[DQ@K\P)!9NF3A20*^Q**S45[/D>O\ E9QM]S_!?-\S4N:.B_6\7?[XH^*/
MB7^QU\1?%7AOP9I.DQ_#B&[TC0;/2G\23QZC;ZS9211*C/!<0.HE4,"R"1%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:OJ_[2NJ+8>+K^RLQ\,+EYM,MH%D^6)MQ.QQD_*, *5XHB^;EMU3?W/E_/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:28)]%-TUG.]S-)('N<?:'D9G)E=R 2\FYL]ZF/=]W_P/EY=2I-;+LOOUO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO1ZS?Z>MSJ,>GW&E"5Y'Q]EG9&EC* [2&,:<D9&.",G/.1_ #X?QZ#H^B_\
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M;4-$\3Z]K6B7?BR+0IQ_85I;:&L3W!@:..60?:9)4((\Q'=&=&^4+P/8-<^
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M7^37YM._R,M7"SWT_.+_ $>GG<[>BBBI*"BBB@ HHHH **** "BBB@ HHHH
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MZ&IA[G+Y)?@H[?=KW+F^9R\V_P 6]_OT[!11102%%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M0^)OCV;X?:+87=KH\VNWM]J-OIMO90SI"6DE;:"7?@ =377UYI\</^/?P/\
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M@,VZ6)5X+#C.>::3;<5NO^'$W9<SV_I&M_PGWQ"_Z)9-_P"#ZTH_X3[XA?\
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MG-W&1GT->C5YIK__ "<EX$_[%/Q#_P"EFC5Z72 **** "BBB@ HHHH ****
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M/,D_)QM_Z5=_]O/T(E[_ #2>CE:_JI77_DNG_;J,GXG_ /)_?P7_ .Q>U?\
M] -8W[8]AJGP'\2:;^T1X.MX9=1TR(:1XBTZ1_+CU&SE(2)F(_BCD*<]<;>R
MUUGB+]B/1?$P\*7%S\3?B9#K?ANWN+:U\00:^BZE*DTA=Q+<&$LV,[1C V@
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MVK?_ "51_P ,[^#?[_B;_P *[5O_ )*KTNB@#S3_ (9W\&_W_$W_ (5VK?\
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M?!GPKX+\1KKVFP:E)JR6LMDEQJ.M7M\8X9'C>1%6>9PNYH8B2 #\@YKMZ**
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MIZ:=?G3M/U!'CMK#PZ=;TY%2%T1+O3XF$DL'( $8)5@AX S7NE%5+5<OG?\
M+_+?NV^HD[._E;\6_P!;6[)+H?G[)X&U6\UWX>W7B7X>VFGZ;:>&;ZS$&K>
M=5\6V4+_ -H9BVVRR&:V9XQO59')C4[,#@#MM7_9MN?BY\7O%MU]DL?#6A+I
M.@&QUB3PE+'>QB*-F9--D>1#9LNU59-DC+E5(!'/V913NTTUNFW\WU^7]:">
MJ:[V7W'Q_P##32_B3I/QGM?B;JOA2:WTCQS>W6GW\,<ES+?VMJ0/[.:YM#;J
M+=8A!M9O,;_CY)(6N ^!?PU\3_![4/AUXJU?P+)!;V^C:I/GPKX8F@U6:[VN
M1:ZK@N\H91F)]JC?M! X)^_Z*E+E5HZ65EZ:_C=M^O1E-\S?,MW=_A^B2]%N
MCXN^%GPG\7Z3?:OI/Q'\#Z?K>D>/=)FUF\1!)JL,6LQLTN^X26V1+=V298U7
M+\VR@,3BN9U'X*Q:!\*/V=XA\/K2S\F*2X\10W7@.XUN-+AK )YE[8VP65Y"
M^%W,00V">F*^]Z*>G16V^Y.5E]SM\D*[>_G][23?X7^;/(XM$\277[/"Z;\,
MKG2/"7B0VI339Y/#4VC65O()3O/]GSJ\D /SX#*W+!L,#SF_%WP[XDU"S^"J
M74$FM:MIWBBQGU>ZTZV8Q*5LKE99R /W<9=AR< ;E'>O;J*)>\[^:?W7_P Q
M+16\FOO/AWX8?#SQCX8L?@WI-UX>\2/I45EJ]_(]M T=SILTMG,DEN3)M$+,
M[*\1<J"TC#("BN:/PYURU^$OQ/T'0O!.H7=G<^%[>)-0_P"$5OM)OKJY6X7_
M $>XLV=H[V?:69KF!?FP1N((Q^@]%#UO_7;_ "1?-[W-YW_/_,^'?$'PK7Q9
MX/\ "^C>'/"'AWS#XQT^>^2/X3:AH>GB$6]R-]W:W$@-U&I."P=0NX XW#++
MKX'SZE^R?\0M$UGX?BX\9V.M7,UKID&A%K6U=YH03HZE6(MVC4-\A)!+ANAK
M[EHI]_/]'%_^VV^?3K"TMY?Y2_S_  Z]/$/V@/A]#8?L\S^&_!WAI+>&*_TQ
MX-(T.P"JBC4;>20K#$N   [L0.S$]Z\=\*^ /&'A_5O!,?\ 8.KS:3??$O4=
M9N@]M(?[.*SWRB9@1E(9HGA*MPN5SG]X*^T:*(MQDY^:?W6_R0FKP4.R?XW_
M ,V?)?[3'@YM9_:#\.:E?^'+35M#B\,SVYNM6^'][XMLTG-TC!!#;%3'(5#$
M.3TR,<UR'Q*^'WBB/3_C#JOAOPUJMU8:U!HVFIIEEI,]JL]N+.V\N:WM6&Y?
M)D#(T8Y17<-S'BON.BE#W+>3?XM/]+%R?-?T2^Y-?K<^1O%7PL\43?M!3>";
M71KN3X9>)]8L_&>HZBL3&U@FMT/G6CMC ::>&UDVD\@OQUKD/@/X".C>']=M
M[[PA:6?BF:VUQ(V?X8:C;ZH6D:X*9UECY+AD(  4;@RH"3U^Z**S<+P<.Z:^
M^Z7W+1>2*4[24NS3^[_-ZOS/DM+_ %7Q3^RMX4\):3H7BQ-4T6ST5?$&DSZ%
M?Z;-<V43PB]MX9)XHUE8HK@I&Y+#(&<UQOQ"^&5]XHTKQA;> ?!%]HOP_O[W
MPY';:'?^'9X;:2[2_P!UW<#37$;B$1&(2';&'V$YX+5]S45M*7/4=1]7?\OP
MTT71W>YE%<L%!=%;\_QUWZK0^)/BK^SC<?#O0/!UFEI9>)-/N/&<NKW]G9>"
M+G4M%TV)K&6,*FDV\CN(MP7@2???=GM7HWQ*\+-K/[%GB70O#&@1M<36;Q0Z
M7HWA&ZT1)'-P"WEZ;+F5 >202=W+ X-?2M%1]EQ?5W^[ET_\E_$M.TE-=/\
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MZD1\#BOO&BI<;JW];6?WNS?FET+4K._];IK[M4O5GP)\0_AQ<:GX-\;K\/?
M>JZ-X1G\/Z/;W>D'PO=6L=[J::C&\DD>GM'')+LA#>8RH-PP,G&1TGB?P7H=
MSX'\(0+X$M-2T.U\<6=YK-AX?^%.I:-"]J+:=2\MA*DKW !(!=00-RC /7[7
MHK2^M_-/[FW;TUVZ*W8S2LE'LK?@E]^F_5W/#_V<M/N_!G@WQO=OHVIZ1X5.
MN7=[X>T6:RE2Y@L/+C^2.U(\R,-(LK)%M! 8#:,@5\M_ #XU?'"3]KC6]?\
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M?_\ 2S1J]+KS37O^3DO _P#V*6O_ /I9HU>EU(@HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!Y3\>)?$5BGA&]TKQ ^D:8GB'3(;VTMH<2WHDO88]C2[OECVLVY
M0N6R 6"Y5O5JS-?\.:=XGM;>VU.W^TPV]U!>QKO9-LT,BR1ME2,X=5.#P<8(
M(J>TTN&RO;VZC>Y:6\=7D6:YDDC4JH4>6C,5C& ,A H)R2"221:*WFW^"_R8
M/5W\OU9<KY;TJWO/$_Q.^(8OO#?Q+\2Q6GB0VMO>Z!XS?3["TB%M;MY?V?\
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M%64<D;OPH^+OB'XE?$N;%A:V?A"Y\*:9K-O%)=;KJ&:>2X#!E$.#_JBI_>8
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MM F)$VR 94.%P!QC>/ ]L(?$?Q&\1Z5J-MX29M$BM]5FB>^U".^OH8F*J?\
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MB3JFE:??ZE=ZF+(:993+"]Q,TSJK/$6(W.V,DFKG_"N?'?\ T5K5/_!-I_\
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MM]]G\EYHS3]WF_K2S?W77S?D?:E[>V^FV<]W=SQ6MK!&TLT\SA$C11EF9CP
M "23TKC/#WQV^&OB[6+?2="^(?A36M5N21#8Z?K=M//*0"3M1'+' !/ Z UC
M_!J&?1?$7Q#\._VGJ6I:;I&K0)9'5KZ6]GB22RMY63SI6:1EWNY&YCC=@<
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M;'P<\(ZCX#^&7A_0=7>UDU.RM]EPUD[/#O+%CL9E4D<]2H/M6/\ \-$^"O\
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MV[0F/8H62<YE$C%E7&P$DTI7Y=-]?Z^6_GL+3?\ KK_P%Y;D/A+]J=/$&A^
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M/[OQ=I'B*QLO$-U/I>K>$WNY5;Q3<:W-'=+>6:AI1)$D-I<JLS;[>#Y5)&5
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M^'M3\'>)O#=S)>R66O:A/JDLPE59[:YD<2"2!POR&-U5D)!((&2:6JES=/\
M@Q_1/?TZW*35K?UL_P!;;-'$Z'\<M?U#7=6\/:3X?/B#Q%%JVH1FVO\ 5([:
M""VM5MA(4D2VSR]PBHC*Q))+2@#CF[#]ICQ7<3:GXEB\*I<^%[;POIFOWMA/
MJ*0RZ<LKW7GB(B%C<2;8E.QBB_NSA@3ST/BSX :MI"QWO@:_NG\13W]U=W6L
M7^M)8S!;A(5FCPEA.DB.8(V*[$967*NO;:\*?LX:1HGP[NO#-[J5]<R:CX:M
M/#=_<0.JYC@68>9$&5BK$SR'YBW1>.#FH]WT_':_RM?SOU)TM;O^7^?]6..N
M_P!HSQ+X+?QC<:_IFBMI\'BMM'TZ^O-7>TLK2 6B39NIQ:-Y0.5VDA\O*5+*
M%#-V7Q2^)7B:R^#FA^)_"UE8Q:KJ-_I,;07>H(T21W%U#&ZB:*.9'#>9LWJ"
M K%QDJ%.K=_!*(W^MW>E^,/$WA^75+]=1==.FMC'%+Y AD CE@=75T5,K*'
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M>C.\KR7X3^']+U#Q%\4IKK3;.YF/BR4&2:!'8C[%9]R*]:KS3X-_\AOXH_\
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M_:\C7XH3>$Y?#<!@:34X+6]M-5%RQELXFE99PD1ABWJAPJS/(O&]$/ Q]/\
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M@713J)L/!N@6?]HE6O/(TR%/M!#[QOPOS8?YAG^+GK41M]K7_AU_E_5V-O\
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M#\.06.N&Y1+G2-3N)Y8GBA,G*26Z @@$9W<>E>J5YI\0?^2O_"K_ *^=2_\
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M%?!O@?5/[2T;27MK_?/*UQ)>W$[N\R0I,[&21MS.+>'+'))4G.68FE<_L^^
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M!\OW?:N$^$?[/"?#7QE<^)+K4[2\N19/IME:Z=;74%O:6[R+(45;B[N2H!1
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MJS0 44A.!D]*KZ;J=GK-A;WVGW<%]97""2&YMI!)'*IZ,K*2"#ZB@"S1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
M5S;0WEO+;W$23P2H8Y(I%#*ZD8((/!!':I:*-PVU0R&".VA2&*-8HHU")&@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM]Y[_P" _&^E?$CPCIGB319))--OXS)'YT9CD0@E61U/*LK*RD=B#6_7GGP
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M_P#PJKS_ .5M']L_&+_H4/ __A57G_RMKTNB@#S3^V?C%_T*'@?_ ,*J\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\T\#?\EK^)_P#USTK_ -$25Z77FG@;_DM?Q/\
M^N>E?^B)* /2Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQQ_X#V7_ ,E4?\+DU+_HEWCC_P ![+_Y*KTNB@#S3_A<FI?]$N\<?^ ]E_\
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M+R"Q71]4M](6&T2YN[N6XF@25(?(2#+2D/PL)F&T9W Y5>2^.OPK_P"%O?\
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M<;S7WPI\6VEHLJPBZGU#0HXF=W"1@%M2'+NRJH."2P&,FDU#XTZUI-J+B_\
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MP"70]8339;>XE^S^1([M(A>(-&691NR%Y1_N-/\ ".?7-0\>^*XK[7&U?1=
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M+75FNHH[:9I[*TEF,K"1Y]QBD?>XVA0[L!D_2U%*WZ?@DOT7],&[[^?XMO\
M5_TD?/MI\,/B)8:E'J<6O:S+J\<D=NKW.LR26!B.E%9)&MC(4/\ INT\J7&/
MEPI.<3X7?#+XH2V>@6OB_5O$B6T6NK=W\0U%[9_*2SG!/G)J5U)+"]P8#Y>Z
M,<?ZI5+"OIVBJ6CNOZUO_7HA/WE9_P!:6/$O@G#XR\%W&IV'BC3/$-_;:CJP
MBL=1U&X^T7"KY4LCRSJ+ZYCBA_=HJF+R@6D \A.IB\>^"_%UW\;[?6M#L=7C
MMI8=*B75;75T@L84AN;A[M+FV\P--NADVI^[<!GR-F"U>Y44OY?+3\+#;OS>
M?^=SY=TCX9>/KW4]!NM;T[Q/,NF:MI]W?)<^)A*+NZ4S+/=VRK<@1VV)$)@.
MS*@@0Y&&]#^ WP[U_P"'D<=MJ,VI-92Z)8B2WOM2-U'!?*TPF2%"[")0AA&$
M 0X!&6W$^OT4T[?U_7;^D$GS;GS+I'PI\<Z_K]Y8Z\/$*Z /$BWT>IW.M/!?
M>08+M7\LQ7\PBC!DA4&$6[$.?W0V[JT='\'_ !.CU_PL;_\ M^6Z@MK!)-4_
MMU!801)'B\BNK82_OYY&W%91&^"RD.FTY^B:*BVBC_6UOR_KJ.3YKO\ K>Y\
MQQ^#OBOXEN?"<UYI=[IEUHILD$^I:G!<J+B+3=4@FO,+*^0\T]L<XWL""RC:
MP7L_@GX.\0Z'8>+I=4T[Q!HT^H10+ =7UB+4[UI$A99'27S9  7)9%9@ ".$
M'R+[3152]Z]^J:^_?^O3LA7V\OT;?Z_U=GR;'H/Q9\,?#H7%U)K6FII8U>:>
M[O-4DENY839?N9)D^V7GS>;NVB-V52 _EQ]*B\&Z3XB^+GA34]0\-:MXMAT*
M%]3;26'BUII6G%I9"U1KJ.X99T$RW/\ RTDCR&#,<D'ZWHII[_UV_P M 3LT
MU_7]=?(P+FQ;Q;X<U?1M6T^>VAN('L96G:,K<H\(#.FQVPN79?F"ME#QC:3X
M?X1^#_BX:YHFL:U8(EYK$IN?$P^T1MMDL\_V?C#'=GY2=N<8YQ7T?1422E?S
M_P"#_G^"["6D5'M_P/\ (^4+[X0_%/PU\-;#1?#5]K>%L]'>]M7U9[B<RI#<
M)=PVS"^MC$H86AVQW$,>%;;G+*W:^'/AWX]@US0=9U/6=?O+VQ&EP2+)J7V>
MVFB$<BWC2V:7$D3/\R9):0Y4%&/)/O5%:.3<N;SN)ZJQX;\0O#7C^X^+TFH>
M'TUBYT:;1I[=F?4/L]G;2^3*$:%4O5W2F0Q_ZVU;&<B9-H%>3PZSXPN?'9\&
MKJGB&3QW%ISK-''X@Q L?]B,(P;?S<AQ=L#]I*[&=EQ*Q&U/LJBH2MITU_\
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>formprer14axz005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formprer14axz005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #__@ [0U)%051/4CH@9V0M:G!E9R!V,2XP
M("AU<VEN9R!)2D<@2E!%1R!V.3 I+"!Q=6%L:71Y(#T@.3 *_]L 0P # @(#
M @(# P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3
M%!45%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@#
MU@+S P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _5.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1O"?B/5QI.D^)]&U35#:K>BQL]0BFG-N<;9MBL6V'(PV,<CFJ0^,/@(^)/\
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M "GY6P>#QQ7QO^QY\*/"?CG]I+]HG6O$6@6&MWNE>+&%@]_ LWV5S<SN7C#
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M2MS&>=I)R157Q-\7='E^$WBWQ?X,UO1O$PT?3+J[BFLKM+NV,L4+.JN8GZ9
MR 0<=Q3JM0YY2UMJ_EJ*FG+DC'2^B^>AB^&OV3_A/X-N=9FT+P?;Z0VL:2VB
M7Z6=U<1QSVC !D*"3:&( S( 'SD[LDUH3_LX?#JY^$$?PND\.[O D>"NE?;;
MD8Q+YH_>^9YOW^?O^W3BL3]GGX\_\+$_9Q\,_$GQQ=Z-X<DU".9[N82_9;*(
MK<21+@RN=N0@ZL>2?I7I/A/QWX:\>V<EWX9\1:5XCM8VV//I-[%=(K>A:-B
M:N<6FX2Z;_)W7XNZ\V).UI+Y?=;\E;T..^(W[,_PS^+6AZ#I'BSPK!K%AH48
MATU7N)XWMT"JNT2(ZN1A%R&)S@$\UW\NAV,VA/HSP9TUK8VA@W,/W179MSG/
MW>,YS7C?[7_[2D'[,_PKGURU&FWWB6YD6'3-*O[D(9R6 >38"'=4!!;;ZC)&
M:UO@C\5M2USX01^+_B'XB\"H'E9O[3\+ZB6TN.+"@*TLKD"0-O5ANP" *BZJ
M1G?:^OFW^;UU_P ]!V<'#OT]%^7E_3.I\%?!KP;\//AXW@70=$CM/";)-&VF
M2S2W",LI)D4M*S,0VYNI[U4^'/P$\ _"?P5J'A'PQX<@LO#6H2R2W6FW$TMW
M',SJ$?=YS.2"J@;<XXZ5TOA?QKX>\;Z<VH>'->TS7[!6VM=:7>1W,0/H61B,
M_C6/I7QH^'VNW=A:Z;X[\-:A=:A(T5G!:ZQ;RO<NIPRQJKDN0>H&<53NVT]W
MOYKH):)6V3O\_P#,XSP1^QU\&OASXO3Q/X>\!:?8:W&_F17+233+"W]Z..1V
M2,CL548[5M^,/V<?AQX^^(>D>.M=\+P7OBS2FB>TU-9YHG1HVW1EE1U5]IZ;
MP:R/VI?VB],_9H^%]UXFNH8-1U.1Q!IVE272PO=2D@$C/S%4!#-M!('IG->>
M_%']KB]\/:S\"1X3G\.:YHWCO4A8ZG>I(URD !A600R1RA593(X.[=@J,C@T
MHOF:4>C27DVF_EHM6.2LFWU3;\TM_7T/:/!OP.\#^ /^$J&B:!%;IXIN7N]9
MBGFEN8[R1]V\LLK, #O;*J O/2N/\(?L7_!7P'XOA\4:'X T^SUJ&7SH9WFF
MF2%\Y#1Q2.R(0>A51CMBO2_"_P 0O"OC>6[B\.>)='U^2S;;<II=_%<F ^CA
M&.T_6H9OB?X-M_%"^&I?%NAQ>(V(5='?4H1=DGH!"6W_ *4+W6N7>UEZ+:WD
M)ZII[=?7S.&^)?[(_P (?B_XF'B'Q;X(L]4UK"A[Q)IK=Y=HP/,\IU$F  /F
M!X '2O4-!T'3?"VC6>D:/8V^F:79Q+#;VEK&(XXD'154< 5?KX[_ &SOVU?$
MW[/OCK1O#G@O0]-U^:&P.KZ]]NBED-M:F58T*F.1-I/S9+;A\R<5*DHVAM=_
M+U^75]"N5SO+>R_K]$CZ.L/@QX.TOXJ:C\2+;1_*\::A:"QNM3^U3'S(1L 3
MRB_EC_5IR%!XZ\FJGB+X!> _%7Q-T?XA:CH._P 9:2JI::M;W<]NZJ,X#+'(
MJR#YF&'#9!(Z<5O6/Q!\/W?@.S\92ZM:6'ANYLH]0&HWLZPP1PNH96=V(51A
MAU-5K7XN>!;[5K#2[;QIX>N-3OXTFL[*+58&FN8W 9'C0/EU8$$$ @@\5IRN
M$E'K'\-_^#^)',IQ<NDE]ZT_X'X' ^)OV,/@IXP\9R^*]7^'^G7>MRR^?+*)
M)HXII,Y+/"KB-R3R=RG/?-</^V)\)O%GQ 'A6UT3X5>$OB?X3L<_:=(O[R33
M-2@/3_1KI9HTC0J%!&#RHX(QCW_5_B1X2\/ZO+I6J>*=%TW5(K4WTEE>:A#%
M.EN#@S%&8,$SQN(Q[T:=\2?".L>&;KQ'8>*=%O?#UJK-<:M;:C#):0A1EB\H
M8HH Y.3Q65ERI+9:^7;T_KY&B;4FWN]/,^6_V3?V8==\)?%KQ=X^\2^!=(^'
M6DZCI,>B:=X.LKU+\10_)YC2RKE7+>6,DY+%FS[^D?\ #!/P#\K4X_\ A7%@
M%U''GD75R&7#!OW1\W,/('^KV\<="17K-[\3O!VF^%+;Q/=^+-#M?#5R5$&L
MSZE"EG+N)"[9BVQLD'&#SBIO%'Q"\*^!["WOO$?B71_#]E<<0W.J7\5M')QG
MY6=@#P1TK23VOTT_7\W<A7U:ZZ_=I^%K&'I_P,\$:7\0;#QQ;:,R^*;'3%T>
MWU![VX<K:*,",HTA1CC^(@L>YJK\7/V=OAS\=A8GQUX6M=>DL<_9YVDDAEC!
M.2OF1,K%<\[2<>U<_P#M"?'G_A7O[.GB3XD>![S1O$;V$<3VDQE^U64I:=(V
MR8G&[ 8]&'.*[_X6^)[KQO\ #+PCXBOHX8KW5]'L]0GCMU*QK)+"DC! 22%!
M8XR2<=S2^*]_LO\ %WE_F_5^8TN5)KK^EE_DO^&.,\/_ +*/PH\*VGBBUT?P
M?!IMKXFL5TW5H+:ZN$CN+=5VA HDQ'P3EDVL2222>:M77[,WPUO/#O@S0IO#
M>_2O!URMWH=O]NN1]CE#;@VX2;I.><.6'M71^(_B[X%\'ZNFE:]XT\/:)JC@
M%;+4=5@MYVSTPCN&.?I6EK?C?PYX9?3%UC7]+TIM4E%O8"^O(X3=R'&$BW,-
M['(P%R>133V:\OO5[?<V[=KL36Z?G]S5G]Z2OY&-J_P=\(:[\3-'^(5[I'G>
M,-'MGM+'4?M,R^3$P<,OEAQ&V?,?EE)YZ\"OB/XC?LZ?$K7O&GC.]OOV<? W
MB37]5,\.G^,-(UPV-O")%91<S64\[B249#;@JD,,\GFON[PU\1O"?C.^O++P
M_P"*-&UV\L_^/FWTW4(KB2#G'SJC$KSZUSWQ+^,_AWP3H_B2VM_$>@GQ?I^E
MW-];Z)<WT?VAVCA:1<P!Q(5.!G&..]8SY8QYI;)/[GJ[=?N_X)M!R<N5;W7X
M:*_W]?\ @.C^S'\)+GX&? OPGX*OKF*[O]-MV^U2P9,9EDD:1PI(!(!<@$@9
MQG J?QA^SC\./'WQ#TCQUKOA>"]\6:4T3VFIK/-$Z-&VZ,LJ.JOM/3>#69^R
M?\7M8^.WP&\-^-M?MK&TU74OM'G0Z;&Z0+LGDC&T.[L.$&<L><UY%\</VL/B
M=;_&^_\ A5\%? -AXM\1:19QWFIW.K3;(8U=58!1YL0  =/F+\EL <9/35<E
M6][XKWTZ::OY(YZ23IOE^'K?UM^+/?O"'P,\$> X_%D>A:)]A3Q7<276LC[7
M/)]JDD#!V^=SLSO;A-HYXJEI?[.7PWTCX5M\-X/"MK)X)+/)_9-W++<*&9RY
M8/([.&W'((;([8KS+]EK]K'5?BUJ/C+PK\1/#L'@CQOX1 EU.!9<6QAYW2 L
MQV!<#.68896#8/'L-O\ &[X=7;Z8L'C[PQ,VI_\ '@(]9MF-W\Q7]UA_G^8%
M?ESR"*AQ5DMTTK>:Z?)6=O->17,[MO1IO[^OSL]?)F+\)/V9?AC\"[R[O/ _
MA&UT2]ND\N6Z\V6XF*9SM$DKNRKD [00#@>E=+\3/AAX9^,/A"Z\+^+],_M?
M0KIT>:T\^6#<R,&4[XV5A@@'@UK>)/%6B^#=+?4]?UBPT/38R ]YJ5REO"I/
M0%W( _.G>'O$ND>+=+BU/0]5LM:TV7/EWFGW"3POCKAT)!_.D_?5GK8%[KNM
M+G)7'P'\"W7BKPAXDET/=K7A*T^Q:+<_:YQ]DAV;-NW?M?Y3C+AC[U:L?@SX
M.TWXF:M\0;?1@GB[5K-;"]U!KF9A-  @"&(N8Q_JTY"@\=>35O3?BOX(UKQ$
M^@:?XQT"^UY"5?2[;5()+I2.H,2L6!'TKGM!\:>(+[XZ^(O#=SKO@>X\.V>G
M1W%MI%A>2-XB@E/E9>YA)V+"=S8(&?FC]31?F:\^9_?\7W]>_4=K)^5E]VWW
M=.W0I^"OV5OA1\/$\21Z!X+LK*W\1Q>1JML\DL\%S'DG88Y'9%7+'A0!5?X:
M_LC?"'X0^)SXB\)^"+/2]:PP2\:::X:+<,'RQ*["/()'R@<$CI786GQA\!7_
M (C_ .$?M?&_ARYU[>8O[+AU:W>ZWCJOE!]V?;%>767[0'B&Y_;0U#X1-9Z8
M/#=OX>&K+="*3[8924^4MYFS;\QXV9]Z(OWHJ.[3MZ)-[^E_Z82^&3ELK-^K
M:7YV/3? GP=\(?#/7/$^L>&](_LW4?$UY]OU:;[3-+]IGRQW[7=@G+MP@4<]
M.E,\'_!?P;X"UKQ9JV@Z/]AU#Q7<?:M9F^U32?:I,N=V'<A/]8_"!1S["N0_
M:[^,NM? +X$ZYXU\/6MA>:K8RVZ1PZG&[P$23(C;@CHW1CC##FO*OA/^VKJO
MB[]D7QO\3]?T_2[+Q3X8>ZMI;"VCD2V,X"_9P4:1GPQD0'Y^<'&*SO'EF^D%
M9^CMHO+;0OEE>*_G>GJNK_'4]LT;]FCX9:#\,;KX>6OA.U?P;=3M<RZ7=S2W
M*F5B"7#RNSJV0""&&,<8I/A)^S+\,?@7>7=YX'\(VNB7MTGERW7FRW$Q3.=H
MDE=V5<@':" <#TKRC]A/]J/Q?^TQH?C*[\9:9H^E7.B7<$$::5!-",.CLV\2
M2R<C:.F*^@?#GQ-\'^,=3N=.T#Q9H>N:A;9\^TTW48;B6+!P=R(Q*\^HK=J4
M9>;2^ZW^7^1BFI1\D_QO_F<UX'_9Q^''PU\>ZOXS\,^%X-'\2:JLB7EW!/-M
MD5W#N!$7,:Y90?E4=*T;[X(^"M3^*MC\2;O1?M'C2QMC9VNI274Q$,1##:L6
M_P L<._.W/S'FM3Q+\3/!_@S4+:P\0>*]#T*^NAF"UU+48;>6;G'R*[ MSZ5
MY7^T_P#M6:-^SK!X6MG^PWVK:_J$-LD5Q>I$MK;,V)+J09W>6HR,\#/5A6:=
MG!+O9>5]++MOKV5^A;N^9OM=^:6OSV^^QZ+\5_@WX.^.'AJ/0/&VBIKFDQW"
MW20-/+ 4E4$!@\3*PX8C@\YJAXU_9]^'_P 1;_PG>^)/#R:M=^%7632)I[J?
M= 5*$;B''F\QH<2;@<<]3G,F^)FHZG\8O"6FZ%XK^'UWX,U?3'O&LWU%GUR]
M.V4I+9HC>7)!\JDM@\+)@\"NBN_C9\.["WNI[KQ[X8MH+2Z:QN)9M8MT6&X'
MWH7)?"R#NIY]J:TLUIK?YK2_KTO_ ,,#5_/2WR>MO\U_PY7^+7P+\"?'72;7
M3?'7AVWU^UM)#+;^9))%)"Q&#MDC974' R <' STK \(?LG_  G\ ZO/J?AS
MP?;Z->3Z6^C3/9W5PBRVK_>1T$FUF/=R"_ ^;BO2;KQ+I%EH3:W<:K96^C+$
M)SJ,MPBVXC/1_,)V[>1SG%8>F?%[P)K4^E0:?XU\.W\VK,Z:?';:K!(UXR<N
M(0KGS"N1D+G&>:5EK&V^_P TU^*NOO#F=D[[?IK^#LSDI_V4/A7<_##3OAY)
MX6W>#M.O?[1M=-_M"Z'ESY8[_,\WS#R[<%B.>G2G?$3]E+X3?%CQA#XI\6>"
MK'6-=B"K]KDDEC\T+]T2(CA9<#CYPW QTKUFN7TGXI^"]>\02:%IGB_0=1UR
M+(DTRTU.&6Y3'7,2L6&/I3WE?KO^%K_<DO0-HVZ?\&_YZ^IQ"?LD_">+P#K?
M@F/PFL7A76;\:G>Z9%?W21O< J0ZXES&/E7Y4*KP!C%-\)_LA?!WP/XXC\7Z
M'X#TZP\01-OBN5>5TB;^\D3.8T;_ &E4'WKR?]I']LG5_ /QJ\/?#/P)?^!(
M]2NH'FU/5O%^I-'96#C<5@E,3@QR$+D!LD[T^7G-?2_B'Q8G@CX?:CXEU[8R
MZ5IKW]\+($J?+B+R>6#R1P<9]J2DHP]M>R77T5OP2M^0W%N:I/5OIZN_XO7\
MS%M/@7X'L/&7BOQ7!HFS7_%-K]BUB[^USG[5#M"[=A?:G"@90*>.M8$_[*'P
MKN?AAIWP\D\+;O!VG7O]HVNF_P!H70\N?+'?YGF^8>7;@L1STZ5\I#]N?]H>
M^\&R_%"Q^#>CO\*$9I?M#7+-=>0KE6;<)@V 007\C:,$]!7KWC_]L:^M)OV?
M=0\)V6G/H'Q)O1#>G58W::UCW0JP0I(JJZF1P2P894<>M1BU9+1WBO3>4;]M
M4VNS);W=[Z2=^]E:5N[M9>FA[!\0?V<?AQ\4_&.C^*O%'A>#4_$.D%#9W_GS
M0O'L?>@/ENH<!LD!@0,FOGWQ'\"_B)^T'^U?X1\8^.? ^G>#O!O@IY#;2KJD
M5[/JY24O"V$P47<$;8X&T;ADDU]6>%_B%X5\;RW<7ASQ+H^OR6;;;E-+OXKD
MP'T<(QVGZU0U/XP^ M$\0#0=1\;^'+#7"P0:9=:M;QW.X]!Y3.&R?3%*/NRB
MUTU2\WU]=1R?-&2?56;\NWH=?7EOQ7_9@^%OQOU&#4/&O@ZRUG4(5"+>"26W
MG*CHK21.C,HYP&) S77^(?B1X2\(ZC%I^N^*=%T6_F@>ZCM=1U"&"5X4!+R!
M78$HH!RPX&#GI4=S\4?!EGX6@\33^+M"@\-SG$.L2:E"MG(<D868ML/((X/8
MTG9ZOH-76BZF:?@AX&'PPN/AW%X<M;3P9<0FWETJT+P(Z$Y.61@^21DMNR>Y
MKHO"/A/2O GAC2_#VAVOV'1],MTM;2V\QY/+B485=SDL<#N237 _&[XS#P3^
MS]XI^(?@Z[TG7VTZQ-U9S>9]ILYB& Y,3C<.3]UA47P6^/VA^/\ P+X(GUSQ
M#X>L/&FOZ7;WSZ'!>QQS%Y$#$1P/(9-O/'7ZU2O)R[Z7_&WKHGZ$-**B^FMO
ME:_INO4Z33_@QX-TKXJ:E\1[71_*\::C:"QNM3^U3'S(1LPOE%_+'^K3D*#Q
MUY-=5K&DVFOZ1?:9?Q>?8WL#VT\6XKOC=2K+D$$9!(R"#5#Q5XX\.>!+)+SQ
M+X@TOP]:.VQ+C5;V.UC9O0-(P!-<O\5/BBGAGX'>*O'?A:ZTW6SINDW&H64R
MR?:+29HT+#+1L-RY'.UA]:RFXJF^;X5_5OQ_$U@I2FK?$_Z7W6-KX<_#'PS\
M)?!EIX4\*:8-+\/VID,-F9I)PN]B[_-*S,<LQ/)/6O.[?]BKX(6GC%?%$7PY
MTI-767SU(,OV=7SG<+??Y(YY^Y6K\#/C1_PG/[/?A?XB^,KK2= ;4++[3>S>
M9]FLX3YC+PTKG:.!]YCS7"Z[^U-=2_M2_#7X?^%[GP]KW@SQ1IMQ>3ZK:2&Y
MEWQK.0(I8Y?+QF)<Y5CR>?3>2DJRB_BV_!O?T1BFG2<E\-K_ (V_4]7U/X'>
M"=9^*.G?$6_T3[9XPTZ#[/9W\]W.ZVZ8882$OY2GYFY"9R2<YKE[OX2:5\#X
MO&/C7X5?#Y=7\:ZVZS7>DIK<EE#J#F7+-^]9H8V7<[ A!W (W5WM_P#$_P &
MZ5XEB\.WOBW0[/Q!*0(])GU*%+MR>F(BVXY[<4_Q%\2/"7A#48M/UWQ3HNBW
M\T#W4=KJ.H0V\KPH"7D"NP)50#E@,#!STK+9:.V_XZO[[:_U;3KJK[?AM]U]
M#Y[_ &)_V</$/PIO_'OCGQOIECH_B[QAJ+W!TNPE66.PMR[2>6'4E>7<\ D8
M5><YQ]3UR5]\7O FF>';/7[SQKX=M-"O21:ZI/JL"6LY!P0DI?:V"#T)K<T#
MQ%I7BK2X=2T34[/6-.FSY=Y87"3POCKM="0?P-:/912LHI+T2V(ZN3>LFWZF
MC1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYHFKIX>U W?A5+FUMO'OG'2;N\(D7-P(_F=S&L& <Y9E!X8YZZU\ ^/?@O\
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M]KW6FBT5M[[GRAIWA'P[\(?^"E.E:?X5TFT\-:+>>#)9[NRTN$0PN0)"6\M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L6T\9Z'?\ BF]\-VVJVMQK
MUC ES=6$4@:6"-R0C.!]W.#@'D]>E;5?GA^S?H?B_0?VV?C?J%_\0#+;:$4N
M]>(T6 '6(=C%$X/[CR^#E,EMO/6I4ES\LM%:3O\ X5?_ (?\"G%\CDM7>*MZ
MNW_#>9^A]%?!WA+XN_M#?'3X8>*/C)X4\7:)X4\.:;+=2:7X0ET>.Y^W06X)
M?SKAOG1B 1\O!(/W1BOJ/]FSXRI\?O@OX<\;BT%A<:A$ZW-JA)6.:-VCD"D\
M[=RDC/."*T479WT:LVNMGM_73J0VDUU3;5^EUO\ UUZ'>>)?$6G^$/#VIZ[J
M]Q]DTK3;:2\N[C8S^7%&I9VVJ"QP 3@ GT%4/A_X_P! ^*7A#3O%'AB__M/0
MM15GM;OR9(O,"L5)V2*K#YE(Y Z5S/[27_)O7Q,_[%K4?_2:2OA+X5^)OCO\
M*_V*?#GQ,\.>+M$MO"F@HQ3PG+I*2M>6OVIE>26Y8[PV]F^5-HV@<YXK.,E>
M?-HH\NOJVM?N7XFG*VH\N[;7W)/3\3]-**^"OC[^W=>Q:S\.-"T+Q79_"ZP\
M1:!!XAU/Q->:2^K26BS*3'!' JMN.5()([CE<'/H_P"P]^U)J7QTO/&OAC6M
M:LO%=WX<FC>T\2V%B]BFIVLA8!V@95,;@KR, <].,G2,7)R7:_\ Y*[/\?OW
M6AFVDE+O;\=OZZ=3WOQU\8O"'PUU_P +Z+XCU?\ L[4_$UT;+28/LTTOVF;*
MC;N1&"<NO+E1SUZUV=?#W_!1!M77XK_LY_\ "/BV_MP^(919&]!, F+VP0R!
M2"5!P2 <XK8\'_&WXG?"3]I[4_AO\2O%EEXZT67PW-XA@U"UTF.PDMA&KNR!
M$SD8CD'S%B?E.1R*SC).%Y::S^Z*4OOM=_AN:2BTTHZZ1?\ X%)Q_.Q]DUQG
MB+XQ>$/"GQ!\/>"-5U?[+XH\0(\FF6'V:9_M"H"6/F*A1<;3]YATK\X9?^"B
MWC2]TF^\;Q?$_0]-U".]/V;X72>&9I4FM0X W:@(^'*Y;[X''4'Y:]F^)7B^
MW\??ME?LL^)[6-H;;6-$FU".-CDHLD+N%)]MV*N*;E"^S=GY7C*7IT\[:IZD
M2M&,^Z3:\[.*_7Y[K0^X]0OX-+L+F]NG\JVMHFFE?!.U%!+' Y/ /2N;^&/Q
M3\+_ !D\)0>)_!^I_P!KZ'/(\4=U]GE@W,C;6&V5588(]*^.?#7Q9^./[2FE
M?%3QEX3\4:+X>\$^'Y[S3;'PS=:4EP=36.(E_,GR)(F*,I#*<;FQM &3Z)_P
M3&_Y-)T+_L(7W_HXTJ?OJ3>GNQ:[^\^ORM^HZBY++^\T_DO\_P#@'U=17RE\
M6/C'\1_'O[3"?!/X8:W8^#'T[2QJVL^)+RP2^EC!V[8XH7^0\21YSUW'D;>>
M/TW]IOXE>%M,^._P\\7:G97?Q \"Z%-J^E^)M/LTC2ZB\M61W@(*!QYD9QC'
M)!!QDQSKDY_)M>:B[.W_  =];%<CYN7S2?ES;7_K2ZN?;M%?G%K7[0'[17A'
M]F[P7\<;WQSHUYIES/!!<>&O[#A4W,3.R>=). "'<IRL80 ,,=,5^B>EWPU/
M3+2\5=BW$*3!3V#*#C]:V<6KWZ.S];7_ ",E).WFKK[[/\3@OB7^T3\._@_X
MDT'0?%_B6+1M6UQ@MA;O;S2^9EP@+-&C+&-S 9<J.O/!QZ/7Y._'/4_"/[2O
MQ/\ C[XCUKQ=HND2>%]-32?"-MJ.IPV\ES-!)YCM"KL"^XQ2J, _Z\5]*W_[
M46OZQ_P3L?XF^&M5%AXPT^SMK2XN_)CF,=TEQ%#*2DBLIWJ2W(/#BL8S7L'5
M>^C_ .W9-J/S[^J-I0?ME376Z_[>23?RUT]&?9M%?&_[0?[0'C[P/\!/@5XC
MT37OL6L^)K[2X=6N?L=O)]I2:WWRC:\95,MS\@&.V*O>._BU\4_BK^U5J_PD
M^&OB>P\!Z;X8TU+_ %36;G2X]0EN)'$9$:QR<!?WJ#@@\,<]!6KBU-PZJ4H_
M^ I-OTL_7R,DTXJ?1I/[W9+UN?75%?GSH'[37QEB\$_M.OXA\16B>(O GV>'
M3'L+" 06LGF2)(R!HR75M@($N\C-==\<_P!HKXA>#OV,/A1X[T?Q#]C\5ZY/
MIB:A?_8K=_/$L$CR#RVC*+EE!^51C'&*F/O6MUY/_)[V_+4III\KW][_ ,E2
M;_/0^V*HZYKNG>&=(N]5U>^M],TRTC,MQ=W<HCBB0=69CP!7Q'^U+^U'XS\"
M_'ZV\%2^/$^#OA+^RX[NW\2/X:&L?VA.V-RE6!VH#E<J,@J<]1CGOVE/$GC7
MXE?L":KK6J?$+PMXA%EJ,(O+WPG%Y\&K6_G1B-)=Z(;697978(/X . QK*4G
M[)U(]/\ Y+E_/IO8N$4YQ@^O^7-^7RN??^D:M::]I-EJ=A,+FQO8$N+>900)
M(W4,K#//((/-8?Q)^)OACX0^$;OQ/XOU:/1M#M619;J2-Y/F9@JJJ(K,Q)/1
M03U/0&N0_9:T/Q!H/P(\(0^(_$W_  E-U+IUO/!<_8([/R+=H4,5OM0D-L'&
M\\MU-?*G_!2SX)>(-:\(^*OB+K7C"YF\.:0ME%H7AB#B&&5Y(XYII>Q8[GQ@
M$\CY@/EK7$_N9N*V3MZ:V^_IVO?IO&'_ 'T4WU7W_P# Z^GF?>^D:K:Z]I-E
MJ=C+Y]E>P)<P2[2N^-U#*V" 1D$'! -<IX;^-/@OQ?\ $/7_  -H^NQW_BC0
M4$FI6,4,N+<$@<R%?+8Y8 A6)!X(&#7DOQ*^.$GP3_9?\&S:1#_:'C/6]+L-
M*\/::@W/<7DD"*IV]U3.X_@.]>#?L(?#>_\ A-^UU\5?#6K:B^K:S!H5I/J%
MY(VXRW,WDS3'/<;Y& )Y(&:U<5]8G37PQYOFXZV^2LWZI&:D_81J/=\OW.RO
M]^B]&?H37G_Q:^/OP_\ @796ESXZ\3VN@)=DBWCD5Y9I<8R5BC5G(&1D@8&1
M7H%>0?&G3/A7\/-1B^-'CNS@CU;PW:M;VFIS2R,ZAMV(HH=VQI&+L!\N<G.1
MC(YY/EU;LNO]>MOZT-HKF=DKOI_7WG5^ /C-X(^*7A";Q3X7\2V.JZ#!O\^]
M5S&MOM&YO-5PK1X7GY@..>E<W\-_VK/A/\7?%,WAOPEXUL=7UN(,WV18Y8C(
M%^\8S(BB3 Y^0MQSTK\^K*?Q'??LM?M+_%J'39/#6@^.]2M5TVP4;1Y!N]LK
M@# ((EV%AP2'KT3XNZ5:>!;']B?5-#MHK._CGL;;S(%"M)'(MJ9%)'7<7?.?
M[[>IK:"YII25KN"MU3G%O\++[_(SEI&3B[VYW?HU"WYW?W>9]<?$7]KWX/\
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M$V(8LL"&R<-U'S'MZ915)M)+LK?C?[_,EZMON[_A;[O(****0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=EW.(I#B-"N2[@'#)D$YK-37LO:OM=>:;MZ7UVW^YFC@_:>S6][>FE_N\_\
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M#P9\6+W7M+MK37/#GB;1+=KN]\.>([#[%J"0@9WB,L01R/XN,C.,BDW;FO\
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MAE1AF4XR<U^FU%9J'[N4.K5OQ3NUU>F^G7N:.?OQFEL[_GHGT6OGT1^;UO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBY)17_#[7_/JKK9;G5_&3]J/PM\&?$VF^&9])\1>+?%-_;M=Q:%X4TTWUV(
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M6DY];2?W6_KOUV1^BGPQ_::\)_%"W\>/;V^IZ'-X)NI;76;;68HXY(?+#%I
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M@ HHHH **** "BBO$?VTO'.N_#;]FCQGXC\-:C)I.MV4=NUO>1*K-&6N(E.
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M]HKS_P",WQW\%_ /PY#K/C/5?[/@N)?(M8(HFFGN9.NV.-02?<]!QDC-<O\
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MP95(7! P@[YK[XH2;A&?>_X.P/W9N':WXA1112 **** "BBB@ HHHH ****
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MW[0G[.G@S1/ %G/INE^/?%UKH(MI;9+9Q'',)+A]B$C'R+SGO7?^%;:/QO\
MMW>(KF) =,^'OA6VTB!0/ECN;IO,./?RAMKZ9FM(+B2*26&.22([HW= 2A]0
M>U$5I!!+++%#''+,09'1 &<CID]_QI)J,KKNW]\5%?<N;_P+RU)7E'E\DO\
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M5'T J7%.,H=/>:_[>M>_>UO+S!2?-&?7W4_^W6]NV_GWW/R-\%_$W5/!%_\
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M8CUVK7[(T54DFY6V=ODDE&7KS123!2>C>]VWYW;DO3ED[H_-?]IOX5R?!O\
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M!&21O>!=+\.?'']DCQ'\+?V:+Z72I[2>VBUB_P#$*-:/>I,',K,Z!R6<18.
M %^7@5]^T4/WU/GU<G=_?=+T7;YL$^3DY?LJR^ZS?J^_3H?E:W@GXW^ ?VLO
M@YX;D'@:R\3:=HDEOHL6G+/]@CLE$PD$F5W&0CS2#@Y)!)ZU^J(Z<TM%5S-Q
M47O=O[W?^N[U\C.RYKKLE]P4445)04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?*/[=O[8DG
M[,^D^'=.T 07?BO4[J.Y>WF 98[*-P9"P[>9@Q@_[Y'*BO5]8^,-OXL_9GUK
MXC^#;[8)?#EUJ=A<;5=H)D@=@&5@5+(ZX(((RI!KI?%7P7^'WCK53J?B7P)X
M9\0ZD4$9O-5T>WN9B@Z+O="<#/ S6GH_P_\ "_A[PU/X=TKPWI&F>'YUD672
M;.PBBM) XPX:)5"$,.#D<]ZS<6Z4X-^\]GVZ6_7UN:*252$DM%NN^M_^!Z'S
MC:?$KX@Z%\)/#FKZCJ_BBPOO$VIZ1IKZOXL@T1H=/BN1F2ZMEL5 P20JBYZ%
MDROW@4\0?&'QKX/\8:CX1A\4OX@@TSQ5X<LO[<GM+47$D-Z[BXLYA'&L6]0B
MG<B(P65>_)^GKKP[I5]H;:+<Z99W&CM"+<Z?+;HUN8@,!/+(V[0 !C&.*P6^
M$'@-O"O_  C#>"?#I\->:)_[&.DP?8_,[/Y.S9N]\9K>4DYN26E]O*ZT^5GM
MO?70Q2]Q1;UMOYZZ_BM^U]SSWXLZYXGN_C=X2\):1XTOO!VE7F@ZGJ=U/8VM
ME*SRP26ZQES<P2X0"5\A=I/J*Y?5_CGXOF_8OT_XBV[BV\52K9@R6D$9$^;Z
M.!FC27* 2IDC/ WC!& :]:F_9_\ A?<:?9V,OPW\(RV-DSO:VSZ%:F.!G(+E
M%\O"EBJY(QG STKK+_PUI&JZ,ND7NE65YI*B,"PN+='@ 0AD_=D;?E*J1QP5
M&.E1'16\T_\ R:_Y>[;:Q;=W?R_]M:_/7N?(WQ%_:!^)#>)_%NGV,'B#PF8-
M=\-Z=::0(=(EU&.*[\X3B-V>:W+2;5VF20A<#[HS6[\2O'GQ$\'6_P .=.AO
MOB*ESK&H:C]OMC:^')M<EAAM3(BQ!$-IM!4M@?O""PY.T5]$^(/AEX/\6+?+
MKGA30]96_:)KL:AIT,XN#$"(C)O4[R@9@N<[<G&,TSP_\+?!?A*.S30_"&@Z
M,EE/)<VJZ?ID, @ED0))(@11M9D 4L,$@ 'BDEI;T_7_ ( VU>_D_P!/^"?*
M'ASXS?$_QFGPNM[;7O$.IIKVEZOJ$P\(0:(M_*D-U$EN9S?(($D1'*R)'M^?
M@#@U]%_$/Q]XD^%OPFLM:TWP?K_Q!UR,6T,NE*8%OW+D!Y)?LZ-%N7DMY2[,
M],+R-75_@;\-_$"*FJ?#[PMJ2)-+<*MYHMM*!+*099!N0_,Y +'JQ SFNKTC
M1[#P_I=KINEV5MING6L8BM[2TB6*&% ,!410 H'8 8JK^[;SO^6GZ?.^A/VK
M]/\ A_\ @?<>1?&CQ%XE;Q]\*?#FB^)+_P 'V_B*YOEU":QM[2:<+%:&5%!N
M(94&&'.%Y&>:\V\!?&7QM\2=;\+>$+KQ9_PCB3G7?,\56%G;>=JYL+Q8(A"L
MT<D*ED8R/A#G8=NT9Q](^,/AWX4^(=O;0>*O#.C>)H+9S)!'K%A%=K$Q&"RB
M12%)'<4S5_AKX0U_P]:Z!JGA71-2T*UV_9]+N].AEMH<<+LB92JX[8%2M+W[
M_P!?=]SZC>R7E_7W_AT/&+;XR>*-1_9(\<>,4U"'_A(M%@UB"RUNVMT\J[-K
M++'%=K&P9,.(PQ&"N<X&,"N+\6?M)>-_#=UXDL6OK6+4]%\/:7'>^=:H8+2[
MGU V\FH$ !O+,#QS!"VT# /1J^K9O#6D7&@/H4NE64NB/!]E;37MT-L8<8\L
MQXV[,<;<8Q4;^$M"EO[N^?1=/>]N[5;&XN6M8S)-;C)$+MC+1C<V%/')XYI_
M:ONM/P5NFUW=NW?35(.GW_B[_.RT5_GHV>&)KOBZ+QWXL\!1_$74]4BL_#D/
MB"'Q%;V>G"]LIC)(OV9P+8P,DBH'7,6\ -\QX(Z/X#Z_XBU']G32?%^O^+I-
M8UK5=$35GO=<CM;>ULY&@W$?Z/#$%A#<DMN8#/S5Z/X9\ >%_!6G7&G^'O#>
MD:#87#%IK73+&*VBE)&"65% )(]16GIFC:?HNE6^EZ?8VUAIEM$((;*VA6.&
M*,# 144 !0., 8I-7C)+=JW_ *5^C2T_EN">L6^CO^$?U3?;4^,]0^/'Q%\+
M_#CQVNI^)=43QA:>&+?6[(SV&EW%LVZX6-[FQN;8F.2!MX"QW$>\9!W'G'7>
M/_&?Q(\&?#33[J+4/B!::OJ?B;2],0:W%X:>^>"5RLBVGV93;@MD#-QT('09
MS[W8_!WP%I>F:KIUGX(\.6FGZL,:A:0:3;I%>#.?WR!,2<\_,#3="^#/P_\
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M#\/O$?Q)\5_M$:%X>^!V@_$"YU#Q7?VL?B_5-1M+:;1I&X&Q9%\T[<[_ )&
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M5).&YJ+P%^VIJ4/P*^(GCKQOI&E7DGA+4/[.@O?"D[OIFM2,55/LTDF3MWL
M6R< Y]JA23BYK97_  ?+^;2[OH6XM24>KM^*;7X)^G4^M**^0]6_:/\ CG\(
MM)T7QK\4_!/A.#X?ZA<P0W<>@75P=2TA9B CSB0F-\$@$)W[BNF_:P_:=\2_
M!G4M"TSP/HEAXCU#[%<:_K45XLC?9]*@*AY$V.N'8L=I.1\AX-4_=M?O;T>^
MO:RU;VMJ0O>^'M?U6VGST]6NY]+45\X_M#?M!^+O#-E\)Q\+H_#FH7/CZ_2U
MM;CQ''.ULJ21"2-\PNK#[PR<-]*Y/3_VGOBGX,\7^//!'Q"TCP=-XFT;PA<^
M*=/O?"\ER]D?*!Q%.DK!QD@=UX^H-)OEYN;2W-_Y*KO[D5%<W+RZWM_Y,[+[
MV?75%?$FE_M6_'+PA\.?"7Q5\>^'? M_\,]9:V-T?#;7D6HV,4[!5E=9F9#@
MD952<],CK7TW\<OC%IGP.^$^M^.=0@>^MM/A5H;6%MK7$KL$B0'MN9ER<' R
M<'%5->S3<NCL_733U=U;O<F/OM*/75>FWZ:GH%%?(>K?M'_'/X1:3HOC7XI^
M"?"<'P_U"Y@ANX] NK@ZEI"S$!'G$A,;X) (3OW%8WCW]K7XDV_QT\>>#- \
M1_!SPII'AV2U6WG^(-]<V4UV)H1(?+9)=K[3G.%& R]<TGH[==?E:S=_O7<%
MJKK;3YW=M/F?:M%>>:[XQ\1>%?@)J?BK43HM[XGT[P_-J4ITPR2:;+<) TF8
M]Q#M$2!C)!(/6OF?2_VK?CEX0^'/A+XJ^/?#O@6_^&>LM;&Z/AMKR+4;&*=@
MJRNLS,AP2,JI.>F1UIV]]P[67E=NR^]Z!O!376_KHKO\#[;HKY'^(G[77B[P
MIIO[1%UI^GZ'-_PKR;24T@SP3$3K= &0SXE&[&?EV;,=\TVU_:%^-OPY\<_#
M6R^)NE> +_0?'%]'I]LWA&2\6\MGD4%7=)R05&X9V@_4<94/?:2ZV^]IM+UT
M8YKD3;\W\E:[]-4?75%?!]E^V+\5_$OB;QE:V/BWX$>$;+1-=N](@M/&VI7=
ME?2I$^%EV"8AE((&X8!(;@8KUOQQ\??B1=^/="^&/PYT?PMK/CS^PHM;US5M
M3N)UT:S5L+B,)^]<.YRO.=I7.<DA1?-&,EUV^[F_+5ZCE'EE*+Z;_?;\]$?2
MM%?._A_QU^T-XQ^'FH1V_@SPGX2\?:5JQM)I/$4ET^DZA:A&S-:^23*#NV ;
MLKC)SG@>9_"C]K+XMWOPJUKXN>/K'P)%\.](6[AFM-#2]CU66YB?RHT3S'>(
M*TI49)S@YQ0VE>[V5_ET^]NW>^E@46[6ZNWS_K7TU/M2BOCO5/VE?CQ\-_!^
MF_$OQ[X#\)Q_#BY:"2[L='O+@ZQIMO,RA))-_P"[<C>N549R<';SC4UWXY_&
MSQG\>_&G@GX70?#PZ/X>L;&_%UXJ2^669+B%7&&@<J>2>JK@8ZU333L]];^5
ME=W^7]:$JS5[Z:?.[MI\SZPHKXHNOV\O$D'[/]AXI?P]HEEXJE\5/X3N;J[N
M)?[$M9D!8W+.N7\K&. ?4Y..?</V?/'OQ0\8/J*>/M%\*S:8(HY],\5>"M3%
MSINH _>14=S*"O\ >("GGT&1+FO;I_DG^33Z>5]0?NVO_5FU^:?<]GHHHI %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5X/X=^&?B6Q_;.\6>.Y]-V>%;[PK;:;;W_ )\1WW"3*S)Y
M8;>, $Y*@>]>\44+22EVO^*L#UBX][?@[GR/\//V48+F^^.NH^./AWH6J:EK
MNOW]YX>N]4M;.\F>"2,^6R.=QBRYSABI!YP*Y_X)?L[?$7P?K?[-USJ6@K8K
MX0TC7+769'N[>5;.:X$GD JDN9 Q9?\ 5YQW(K[8HI17*DET27_@*DK^OO._
MR+<FVV^K;^_E_#W5^)^>7Q;_ &=_B[\6O$$4L_P9\,^&?'L5^LJ?%'PSXC%E
M!M$F?-:SR9G;:.K$MGIZ5]0?M;?#CQ)\3/V9/%7A'P]:G7/$=[;6T441EC@\
M]TGB9SN=E5>%8\D5[;12<4Z?LNE[_E\EMT!2:J*KU7]>OW['B'P5_9#^%WP7
MDL]<\.^"[;2_%'V-8I;R6ZFNI(W9 )-AED<)DY!*8X)'2OE#0/\ @G1?Q_!*
M#Q"_A6VMOC+IFJ3WZZ;J5W'=66K0B8F.WF3S&A :/H05P<;B.H_1ZBKDVYN:
MT?3R][FT^>GIH1'W8J&ZZ^>G+K\OQU/E#QO\/OBIH_Q0\)_&SP-X-LKK79/#
MRZ%K_@2_U*&W=$#[P(+E2T65;C.<84<') K^%O WQC/CGQS\<-?\'6,/CB70
M1H7AKP38ZG#-Y2;P^^>Y9DC/SX8X/(W8 .!7UO12>M[>=O+FWM][M>]KNPUT
MOY7\^7:_W+:U[*Y\1_"7]FWXK?L_^/O"GC[3Y9_&>K>*BZ?$336O((PCRN9%
MN(3(ZJWDEBN 23@[1ACCUGQ1\&]7U3]M;P=\1(M!@F\.Z?X:N;*YU4O"&CNB
M[^6-A;S"=KD!@I !(S7T'157LXM+X;V\DTU;T5W8EZJ5_M)7\[-._J[*YY/^
MU7X'UOXD_L\^./#/ARR_M'7-2L?)M;7S4B\Q]ZG&YV51P#U(KQ?XS_#+XA:]
MX8\+^';_ ."OA?XM^%;;0K6V%K)JR:7JVF7BQ*LI%T[E2F5X\K!/<D 9^P**
MRY5JN[3^Y-?K]YHI-6\K_BT_T^X\*_8R^%/BWX.?!B/0/&$NV].H7%S::<+P
MW8TRU?;Y=KYO1MN&.1Q\W%?/7[0_P'^*GQ?UC5;:_P#@CX6U#Q)]I/\ 9'Q*
M\/\ B :6UO$"/*>>W9FEE=1C.20#]WH,_?5%7/WY*3_K;KO?3>]]^Y,7R)I?
MUOTVMKM:Q\DZ[\(?BW\(?BCH7Q+\%:?8_$K5+CPQ:>'_ !+I-YJ*V,UW-"J_
MZ5%-(-H+%<G=SUX.>.9UO]GCXJ?$CPW\;?'/BG1;'3_'/C#04T/1_"FGW\<H
MM;=&5MLEPQ6,NQ4'.<<'IG ^W**4ESII];_+F=W;[WZ)M(<9.+37E\^565_P
MVM>RN?*G@CQ%\<K_ .'UM\/=<^!']@:<OAZ32&U[_A,+&YPZ6;1QMY"#/SNJ
MKC=\N_). :XOP]^SE\4OAYX'^!GC+PYH=E>^/O VFW.F:GX6O[^.);NWF9\J
MEPI:-77<2#G'/M@_;]%7*3E-U/M.SO\ .3]/M->C(BE&*AT6EO5)>OV4_5'R
M+XY\-?M _&SX,?%JQ\4^&=*T'^V+"*U\/>$+6^@N+F.0.I=I+O<L9# ="?\
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MOJ*I2?,YO=K]$OTOV3O:W167*H+9?YM_K:^[6]PHHHJ0"BBB@ HHHH ****
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M[REQ$[?/)"JC"JQY(Z5G*2Y)2CK:5K?*+O\ B_N*C!N<8RT35[]M6OTO\S]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK2*<ODC++O!SQ7Z"454G*7/).TG)23[65ON_KS%%I<B>J2::[W=_Z_I'P/\
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MY\)>,- _T2'6]#N?#-WY:\-&HX0_5)2!_N>U?IO16"A:E"G_ "N_JK-6_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$3Q%:>/Y?#WAOQ-K-G+::2M[)IWA7P_%J-TLCNX22ZEN5,$41"85=RNV'.0
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MV$X(SD9'@+XJ_$[XPW7A'3K7QC%X7:Z\%2ZU?W=GI4$TDUW%>-;AE$JLJ*V
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M()8BW.Q\CD\<G+J7DDH]I+[TTG\KK[B(Z-W\OPM?[[/[SP;X<?$?XF?&*_\
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M.U51!@ !$55 ' JH/W?>WLOO]W;_ ,F_JULY[KEVO^'O?_:_=ZW^>/CA\/\
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M;\Q3RK@C( W9RO(Z5]*>(/AWIOB3QQX4\4W,]TFH>&_M7V2*)U$3_:(Q&_F
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M1[E$<:!054?*!M& %"CBN]INUEZ*_KU)6[]7]P4445(PHHHH **** "BBB@
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M_P"WONZ2Z_:;\,VFKW,9TK7I/#UKJ8T>X\5I9J=+AN_,$1C+[_,($A"&01E
MW!:J)_:P\,#5+B$Z#XF&DVNN-X=N]?-@@L+:]$_D!'?S-Q4N5&]491O7<5.0
M/+5_8\U.PU74-)A\.^#]3T>\UR34U\2ZG=W37L-M)<&=X&L@GER2 LRK)YJC
M&"5R,'N[[]GSQ#<_"'Q-X52\TL:AJ?C)_$4,IED\I;<ZHEV%8^7D2>6A& "-
MV!NQS13UY7/RO\W!/[DY/_MWKU)V3DH^=ONE;[[1^_[NK^"WQ;U;XD^*/B+I
MVI:%=:7!X>UQ].M)Y(D5'C$43;6(D8F3+,QX VNG?('DWB+]JGQ19W6LLVA:
MAI]KI/Q"L_#V(K&.:2[LWC4M"JB1RTS,<Y 48=.0<X]C^%W@7Q#X(\=?$6:]
M739O#^OZO_;%C<P7$ANE=H8HGBEB,84 >5D,'.=W05P%[\!?&5QXWU25)-$_
MX1^;QW8^,8;EKJ87)2.)(YH&B\HJ&'E@J0^#GG;BE#>%^ROZWC>_RYARM:=N
M[MZ6E;\;'5Q_M/\ AJ/2=6FO]&\0Z3K>FZA;Z6_AN[LD.HS7,Z[X$B2.1D?>
MN2"'P K%B,&H]1_:F\+Z'X<U;4=7T?Q#I.H:3?6FGWN@W%DK:A%)<L%MR$CD
M99%<GAD=LX(Z@BN,^+W[+>K_ !$\7>*?$$<FCW9GU32-5TW3M0EF6&X^RV\T
M$T-PR)F,.)CM=-Y! )':J>D_LP:XVGW5PFB^%/"5U<^(=%U(:=IEU<70CM;*
MX$KB2Z>-6ED;+[5\M57(&>2:</>^+3;Y:K_@^GYDK1VUW_)Z?EZG>77[4>DV
MPN5'@SQE/<:=:K>ZU;0Z;$TFBQMN*_:1YW+%%+[(C(VT@XY%7]?_ &D_#NG7
MOV;1-(U_QL8].AU>ZE\-V:7"6EI*I:*20NZ9+J"P1-SD#.VO-OB?^S!JVK?$
MOQAXDTCP[X6\4Q^*(X#O\1:A=6DFEW$<(A+A(8W%Q$556V$H<@C.#QN:1\'?
M'OPCU;4IO $'AC5;76=(L+"XAU2XFL$L+FU@,*S1)'%+OB*8_=$J05X;DXB[
MY+VU_6ST]+VU_I-I*5NGZ::^N^GE]\7A_P"-NM?$[]H[2M'\.7>IP> 8_#]O
MK(N+>QMG@U'SVEVO))(QECCP@4!%5MX8, ,&OHNO ?A7^S_X@^#E^]SH]]IF
MJ-:>"[30;,WKR1":^AFN)6>4*C;(6:9?NEF SQP,^ZZ:;QM.M3J"P)?F)/M"
MVS%HA)@;@A8 E<YP2 <5LU%)*/2_YR_2WX=S/5MM^7Y+]?QOV+-%%%0,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQM0.UE.",BWP>1VKUSPS\7O"7C'4?$ECH^K?;+KPZL+:I']FF3[.)8O-CY9
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M5[)HPQ?*E 7 "/@H&!VD DU^<_[*OQ]MO WAOPQI%[^TI_PB%G;ZI(9O _\
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MC/R%O?FN:A_:2^&\_P .=7\=CQ-''X7TBY>RO[N:UGCDMYU<(T30-&)=^YE
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M.<8(.0:\M_;8\=:MX1^ TGAS0$>]\9>,9HO#6EV\+A7EEF&V0@D@#Y _S$@
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M !1110 4444 %%%% '+S?%+P7;PRS2^+]!BABU'^R))'U.$*E]_SZD[N)O\
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M.I:9>_!34=.NO#^F36]W\5I5EL)D*9#6;J2&8CJ0<;<5%[\EOM)_*W-I^'_
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M:?\ "X/^$M_:B_X5_P#\(1_PC?\ ;%W_ &M_PDOVS[9_QZ?-]G\GY/N9QO\
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M67@NY(W\O<MQ;M@&,*>JCMU)SQD](WDK;+YV<K?+OM=[;LIZ-V=[7?R32O\
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M/!5AXF_9^_:G\*_#_P#X6#XG\?>%O%NCWET8?%MZ+VZL9[?#!UEV@[6&5VX
MZ]<"M5'WN7;HO5PYVO+3?S,Y/1RWZ_)2Y;^>I]'6_P ,O!]IX9O?#D'A30X?
M#UZ[2W6DQZ="MI<.Q!9I(@NQB2 22#G KH;>WBM((X((TAAB4(D<:A510,
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M$9!\N5O**LC%5+ *OW1@BL?7?V)-&U3QKXE\3:9\3_B;X1NO$-ZU_?6GAKQ
MEE;-*1C(18<G &!N)/O7,_LE?'KX@>*_%VI>'OB=<Q-?Z]HT/B[PVB6\</E6
M$K,IM_D5=Q3]V<MEL$Y->B_L;?$;Q%\5O@)H_B/Q3J']J:S<7=[%)<^1'#N6
M.YD1!MC55&%4#@<XYJVFVV]_B?JWROYWC9^AG=)66U[+Y)R3]+-M>IS_ (@_
M8CT;7/%"^([?XH?$[0M;;3;72[F^T;Q EO->1P($1YW$):1SC<Q)P6)( K1U
M_P#8V\.>(]$\-0W7C;Q\OB/0(YH+7QC#KQ36WAED+M%+<;,.H)P 5X  SUS[
M7XD\1Z;X0\/ZCK>L7D=AI6GP/<W-S,<+'&HR2:^<_P!FCXY^.OBQ\;OB'9^)
M+<Z/X<ATW3]2T+1)(46:WMYS)LDE8+O\R1%5RI8A=P QS4KWI<B\W^;_ !N]
M%Y]"G[L>=^2^^R_#3?RZGKOP8^"'AWX%^'KS2]!DU"^EO[MKZ_U/5[HW-Y>S
ML #)+(0,G  X 'XDU8T/X0:-H'Q7\3_$&WN;Z36?$-G;65U;RNAMD2 $(44(
M&!.><L1Z 5E?M*?%.7X.?!GQ#XBLL/K0B6STJ':&,M[,PC@ 4_>P[!B/137A
M_A;X\_$#3_V<_C-8^*-8B;XL_#R.Z2;4H[6%1*K1&6UN!$$$>"I(QMP=G(YJ
M93^*;^ROPLDTO1-7\FBE!OEC_,_QO=-_-.WFCJ=7_8"^'.IZEJ'DZQXOTGPU
MJ-R;N]\(:;K;PZ/<2$[F+0!<X)[!ACMC KZ*TK2;/0]*M--T^VCL["TA2WM[
M>%=J11J JJH[   5\7>#OVL/&GB3PW\(=,U"]72?&S^+[#1?%-M]FA/VVTGM
MWFBF4%"$29-C;DVX(8# XKF?#_Q-_:#NO@MXG^,UO\5+'4=,\/ZC?"3PAJ'A
MRU2.:VMYRK+]JC"ODJ.. >.M6U[-.#TBM^VG+&_?[27E9[6)5ZC4MV_OUN_3
M[-_.ZU=SZ>L_V6?"EC\"]=^%,>H:R?#NL2W$L]RTT7VM3--YK;&\K8 &X&4/
M'KUK?\1_ S0?$^J_#K4+J[U&.;P--Y^FK#)&%F;R1%B;*'<-HS\NWG\JZWP;
MXCB\8^$-#UZ&,PPZI8P7R1L<E%DC5P#]-U?G!X\_:^^(VD>./B7:V7QI-EK^
MB>);O3]"\ #P9'>_VC DNV-?M:1Y7/S+@DM\N<\BD[TZGLWNK?\ DONKS=KV
M5N@1_>P]HMG_ .W>\_2]KNY],Z9^P7HWA][E=#^+WQ:\/64]U+>'3](\3);6
MRR2.6<K&D  R3]?4UZ;\<_V?='^/>C:!8:KKWB'0)=#OUU*RU#P]>);7:3JC
M(&\QHWQC<3E<'..:^1OC-^U%XS\/_&N[T'7OC1_PI/3X_#^FWZ6'_"(1ZWNO
M)8@T\.1&73:V>68CL*Z3PM^T5\:O'GA+X5^"[:6S\/>/?&5QJ,A\4:EI>T+I
MUKRMRMHV!YD@/"D8XZ -D"C>*@NCT]4W'?RY&]_A5[#<M>=O=7?HTI/3SYDM
MMW8]R^'W['O@WP3JFO:GJNK^)OB%JFM::VCW5[XTU3^T)?L;'+0*=JX4G!]>
M.".:PO#G[!?P]T#6M(N+C6O%^OZ)H]P+K3/"^M:VUQI-E(IRAC@V@_*>@9B/
M7-<3J'QA^+'P:U[Q]\/_ !GXJL?%VJ1^";[Q1X?\56FEQ6<R20JX,<UN-T?#
M#<."..<YP/)?@3^UU\0=>\<_#V*#XJM\5TU1?,\3^'5\'+I_]AQ"+?(_VI$4
M2;#D9'RG'3D41DN923V6_IS?DXRUMH];ZW%*+Y6FMWMWTC^::5KZ[6T/K?1O
MV/?A;92>);G6O#5EXSU3Q!J$^HW>J>)K*VN[M'EZI%)Y0,:+_"%Y'KFD^&G[
M*'A;X7:[X0U73]9U_4;CPMI=SH^GIJ5Q#(GV::4R%7VPJ25)PN",# .:\+T+
MX@_M#_$KX0ZC\<-#\<Z#H6A)'=:CI_@>718YXYK2!G!66[)$BR,(V^[QG'*Y
MP,3XO?M=^-KV[\":I;^+F^#7@?7_  Y;ZI#K[>&O[:AN+YR=]K(Q!\M5P.54
MM@Y(P1A+W+*UFK*W;1V\MKKO>ZU;&USWUNG?7OJK^?9]K*^R/=->_8A\$ZSX
M>\2Z#;:[XGT/1=;UN+Q#]ATJ\@BCT^\3)WVN86,88D$C)Y4;=N*Z+X1_LM>&
M_A+XMNO%1U_Q3XU\4S6WV)=9\8:J;^Y@@SN,<;;5"@D#MGWY-<)XP^._BW2?
MV6?#.J6.O>'M9^)'BJYM]#TC5/#A-Q837<TI03HLJ#[L:LS*RX#*01BN2U;]
MI/QQ;?L6>.->DU9++XJ>#+\Z)JMXEK"?])CNXXS*(F0QX>)P?NXR3C&*I?NW
M)+[-E_Z3'3T4HI];-($G5Y;_ &K_ )MZ^K3:[M-GLWQ<_95\*?%OQ9;^*CJ_
MB3P=XJBM_L;ZWX2U,V%U/!G(CD;:P8#Z9[9P!5*Q_8X^'^E>#/#OANP.JV=M
MH_B&#Q0;Q;I9+J_OHLX>YD=&WAL\@!>@P17M&DSO=:5932MNDDA1V;&,DJ":
M\ _;<^+'BOX6_#[PVO@J^U#3M?UK7H-/%QI6DQZI=+"4D>3RK:0;9&^4 +D9
MSU'6I?[EV7=???\ SU_&UR8/VZ4O*_RY?\G;YVN?15?,%S_P3^\&7M_K)N?&
M_P 0I=!UC4IM4O\ PPNNK%I5Q++)O<-#'$N03@?>S@#GBNS_ &1?'][\1OA.
MVHZIXTO?&VJPZA/;7=QJ>A1:-=V<B;<VTMM$S*K)UR"<[O:O7M<UFS\.:+?Z
MMJ$RV]A8V\ES<3.<!(T4LS'Z &G-*DW.71;^6C_X/7RZ#@W-<J[_ ([?UMN>
M0^-_V2/!7CG4/$MU<7.K:<FO>'(/"\UMI\L,<5O:12K(GDAHF*N"H&26&/X>
M];GB7]GGPYXC\2> O$*WNJ:3KW@U1%8ZCITL:2SP; K6\^Z-@\; <@ 'DX(R
M:\2_99_:)\>^,/B'/IGQ"N(Q8>,M)?Q/X0A%O'$;:U6>1#;%E4&1O+\J3+9.
M._->2>%?VU_B/+^S3XWGU[5EL_']M"NK>'M:^QVX6]L3?K;2XC\ORR\3!U(V
MYPZGKS35[I=='\^9QMZIRE==G+<?+S:=+\OE9I._HU%6?DMMSWK3/V"]&\/O
M<KH?Q>^+7AZRGNI;PZ?I'B9+:V621RSE8T@ &2?KZFM_XD_L5>"/B/XIU/7O
M[:\5^%[K6(UBUJ'PWJYM(-751M'VF/:P?(X.,9YSR<UYW?:Q\;?BM^T+\3_#
M/@WXLQ>"]+\+6NES6MA/X=M+Z.X>XM=[!I&4.@WJ3GYOO< 8Q7LO[*OQ>U/X
MV?!G2_$.N6\%MKL<]QI^H+:@B)IX)&C9T!Z!L X[9-*,4XI=DG;R^'[O=M;T
MT)<W?F[_ )M*?W^]>_>^I<\8?LX^#_%OPATWX:K'=Z)X7TZ2U>VBTN15D3R)
M!(@W2*^<L/F)&3D\Y.:E^-7[/7A;XZ6^DMK<FIZ5J^CRM-INN:'>&TO[)F #
M>7* < X&00>@KP;]HWX_^/? ?Q"^+NF:%KWV&RT'P';:SIT7V.WD\B\>[6-I
M<O&2V5)&UB5]LU'X/_:E\7^*K[X+:+>72Z/XHE\0S:%XRTW[/$?/9+1I8Y%R
MI*)*-LBLFWJ0#@41_?:]6T_FW*-_ERZ^37=CDO9+T37R2C*WSYOO3/2],_8H
M\!Z=X&\9^'IM1\1ZK?>+X5M]7\2ZKJ(NM5FC5@542NA4 $#^#GOG QUWB?\
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MC?!S3-<L=%N;ZZBUC6+K6YVOY$=EGG(+JFU%P@P, Y/J37RC\#_CYJ?BZ_\
M$3V/[3?_  LN\T[P[?:C_8'_  @*Z3L=(OEE\\Q@'8Y7Y>=V>F*Q?!O[9'Q
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M>&Z;^Q/X#T_P+XS\/3:EXCU6^\7PI;ZOXEU741=:K-&K!E42NA4 $#^#GOG
MQ[CI6C6^D:'9Z5'NFM;6V2U7SL,615"C=P <@<\5\<>%_'G[0/QQ\ ZY\6_"
M?CK1/"GAZ":\?2/",^BQW(O(+=F7_2+ECO1F*-]WC_=KSWXB_MI^(M?\2?#R
M\'Q8'P4\,Z_X/35[B1?#,>N*;\7,L3QJIC:0*?+;!S@!!QDT[W]U];77E9M>
M6UU;N[-:ARV;?:^OFFD_/>WW:;'O]Q_P3\^&T][-"FK>+[;PG-=?;)?!4&N.
MFB/)NW',&W.,\X#_ $KH?B'^QSX1\=>*I_$.G^(/%O@+4;JUBL[W_A#=7.GQ
MWL,2[(TE38P(5 %&,<"N[^!6HW>L_";PYJ-[XR_X6!+>VYN4\1_V6--^VQNQ
M9&^S#'EX4JN, G;D\FOG;X_R?''PI\;/!6BZ!\;O[+T7QUJUS:VEG_PB=C-_
M9,<<7F ;WRT_IDE3WIRCRR5*W6WSM:VNNVFM]%;:PHRYHNI?I?Y7O^>O>_F>
MFZ#^Q+\*M%UO2+VXT0:]8Z1I']CV&BZ['#>V-NAE,KS".2,DS.[,6=F/WB !
M6;X@_84^'NKZ=XKTW3K[7/"ND^(=0L]4DTWP]-;VMO97-L"$>U7R#Y1;.6Z\
M@8VXKS]?VLX_V?OC[X@\%?&3XD_;-)LM T]K2\_L+9]IO6!,\NRUB=DW#!VE
MBH[5Y1K7[7_CZX^"_P ./$<OQ2_X1&VU[Q5JUC>^)O\ A'K>]\JRB.8#]F\K
M+8! ^4!CGDFE=2M)._GZSMKMKS1OKTMY(=FKIZ?\"-_/H[>K?F?9WP>^ G_"
MH-3U"\_X6+X_\:_;(5A^S^,-<^WQ08;.Z-=B[6/0GTKU2OG?]CSXAS_$?1O$
ME^?C5_PN2V@N(H%G_P"$4&A?86VL67;M4R;@5.>VWWKZ(K22:LGV,XM.]NX4
M445!04444 %%%% !1110 4444 %%%% !1110 4444 ?,<G[%!F^(D>H2?$+5
MG\ Q^(O^$K3P8;6,HNH9W;OM.=_E[N?+VX]\\U[+\)++QG9:#J@\<:B-2U"3
M5KN2R8P0Q-%9&0_9XV$/RY"CKDD@C)SD#YX\1_MS^+]$N/'NIVOP8EU3P/X,
MUJXT?4_$,/B>WC=3$X4N+9X@Y)#*=H)'.-W!K?UO]KGQGJOQ(N?"OPV^$#_$
M!(-'L=:>[D\2V^ELL-U&'CS'-&1D9QPQ^@I0?N)1V:T^Y23[_"E9O[*L5-/F
M;ENO\[6_\">J[NYZIK/P9_M?]H#P[\3O[8\K^R-&N-(_LO[+N\WS7W>9YN\;
M<=-NTY]11\4O@P/B7XY^''B(ZO\ V>/!^IRZB;4VOF_;-\7E[-V]=F.N<-]*
M\T\<?M1?$;PCJ/P]\.P_!7^T?'7BNUO;E_#O_"56T7V+[.PR/M!B,4F4._.5
MQTY-8X_;QCTCP5XQN_$_P_OM!\8^&M4M-'G\.+JD%Q')<7()A_TL 1JN%;<Q
M&%P.N:%HE;[+;7KS*]N_O27WB:;O?[22?I9VOVTB_N.L_P"&/M%&I_$?3DU=
MXOAUXY@#7GA**UVK:7V03=6TV_$9) 8IY9&X YP *Y[2?V,O$.HZAX:M/'WQ
MAUKQYX,\.745WIWAR?38;4,\7^J^T3JQ:<+_ +0&?:NH\%_M/:HVA>+-2^)7
MPWU?X;0>']/&J/>-<IJ5A=P8Z0W<2B-Y.G[L'/(]\<A8_MLZ_IT&A^(O&7P<
MUSPA\.-:GBAM/%,VI07#1B4XBDGME >%&R.23UXSQFH)QDHQW7+;[WR^5]U&
M^O1;(4GS1;>SO^2YO.S5F[:/=ZMGK_P6^#/_  J"Z\>3?VQ_:W_"4^)+KQ!M
M^R^3]E\X+^Y^^V_;M^]\N<]!7(?%']F35O$7Q+F^(/P^^(M_\,_%=[:)8ZG-
M!I\6H6U]$GW"\$I WJ. V>@& .2:GA;]L+2O$'Q1^*/@2XT5M.UCP;%//:%[
MS<NK1PINDV_NQY;+E,K\_#9[&N>U#]MJ^N=%^&T?ACX=2>(_%_C32#K,6AMK
MD%E%;P@[2/M,R@2/G.%"@G%0K-0:[*WHTXK\(M/TU+=TYI]W?U7*W^<6O70V
M-*_8^N/#/P^NM.\/_$[Q-HWCB]U?^W;_ ,8Q.#+?76""L]OD))#@\1,2 ><G
MG/(W?[!6J:_IOBZ3Q%\4Y]7\2>*_LMIJVK0Z#!9)+812B1X$@AD55>0JH,I+
M<#[IR:^A_A#\0[[XF^"X-9U/PGK'@K4A+);W.CZW T<L3H<$JQ $D9ZJX&"*
M\7\*_MQZ5XFT+XPS'PZUGKGP\^V2_P!E27^1J=O SIYJ2>4-F70JPVMMRO)S
M3DU%N_17^2Y5IY?#=+=;K<4>:25NKM\W??SO>S>SZ[$FE_L$^ OA]\0?"/C#
MX9;_  )J6C73O>KYESJ":E;.A1X&$L_[LD$X=<XSRIXQ2^$G[*7Q6^#D.E:1
MHOQ\V>$+*^-T^A_\(;:'S8WF,DL7GO*TB[MS#=DD9XZ8KI?C1^UE'\)/A)X-
M\76_A67Q#K'B>".ZM_#]O>^6Z1?9C<SOYGEME8D')VC.1TK/^/\ ^VAIWP6\
M%_#WQ3IWAQO%FD>+LS))%??9S;6XB64R8\M]^%8DK\OW3S5ZPE;JI<OS;V[6
MNO1:^9/QQ5NJYODD]>][/U_ ]R\>>!-"^)OA'4O#'B6Q_M+0]1C$5U:^=)%Y
MBA@P&^-E8<@="*\5^#G[#_@#X&_&/5/'/ABV^R03626FGZ7ON'^PM@B=_-DF
M<R>9QPR_+CCK3M4_:^M+;]J'0_A!8>'#J,&H6@N)?$"W^U('-M)<+&(O+._*
M(ASO'W^G'/,_"W]K/XN?%[2M-UWP]^SW]J\+7MRT U;_ (36T3:J2F.1_*>)
M7.TJW&!G''6E!>]S1W=_S<=?G=:^;"3]VTMM']ZYE;Y*^AZ7^T#^SC8?M%W?
MA&R\1ZHX\'Z/>27VH:#'$ZG4W\LI$#.DBM&$W,> 2<]1UKS63_@G]X8\-7OB
MN/X>ZP_@GP_XG\-SZ#J.CM#-J"/(Y)2Z626XW!DSC9T(S@KDFJ^H_MJ>.(M2
M\>76E? ^[U[P;X,U>ZTO4]=L?$<'FJ+<YDD%JT0<_(0V 2!G[W!KZ9\%>,-,
M\?\ A#1_$NCS&;2M5M([RVD8;28W4,,CL1G!'8YJ(Q4H.2V>_P#V\NO6S2TO
MVT+E*49)/=?^VN^GFF]>NNIX=XH_8TTKQ!X\^$OB^WUYM.UCP/'9P73)9[EU
M>.W4",./,'EL#OPWSX#D<X%<1IW["/C"'PYJ/@N[^-]ZWPWU*_FO;WPY8>'+
M>WDF667S'C^U&1Y ">#U'MVKT;X'_M;:;\:OBEXI\'PZ%+I,.GK+/H^IR7/F
M)K5M%.]O+-&NQ=@610,9;(.>,5RL'[:VNZWXHUM?#/P?UOQ7X-T75FTB^UK2
MM0AFODD1]CNNG*IF9 ><\<<\5:?/)/?FO+R]Z2;OT^*V^S[$V<$X_P MEYZ)
MI6ZWY;[=/0^G=*TRUT33+/3K*%;>SM(4MX(EZ(BJ%51]  *\^^"WP9_X5!=>
M/)O[8_M;_A*?$EUX@V_9?)^R^<%_<_?;?MV_>^7.>@J+]HWXUR? /X47OC.#
M0CXCE@N+:W33C=_9#(9I5C'[PH^W&[/*_E7ENF?ME>(-+USQ/X=\>_"JX\%>
M)M+\-77B:SL1KT&H17L,"DLAEB3$1.,#(;OQT!GGUE-O75/_ -*?J]+]P4/=
MC%+1VM]_*OE=V^9Z#=?LWZ3K7Q6\?>*]=N8=9TGQ?HUMHUQH4]G\L:19R_F;
MSN)SQ\H*D9!KS\?L67X\#>%]*3XFZG;^)O!M[/+X6\406*BYL+20 ?9)D:1E
MN$ &,_)D #&,@Y7AS]MOQ@!X$U7QE\%[CPIX.\97=K9Z;KMOXFMK\LUP,PDV
MZHK@$<G."!VSQ6_X@_:[\1WWBKQ/8?#?X1:O\1M%\+W+V6KZU!J<-G&LZ#,D
M<$;J6G9>A"X.>V""1KDTVM^'*V]>UG)ZOI*VSL--RUWO^-URZ=[\MK=U?=7)
MM!_9 O7C\<:MXS^(E]XW\=>)M!G\.KK]UIT=M#I]K(I&(;6-MH^8AC\PSCMD
MD^S?#'P&GPZ^&/AKP?)=C58]'TR#36NFA\H7 CC"%MFYMN<=,G&>IKQS4/VU
M= L?#OP]\:-H\R?#7Q4[VEUXCFN-CZ-=C<!%<0!#\I967>'P"#P1@FD/VQ]4
MC^%ME\3[CX<SV_P]N=:%D=1;4S]JBTXOL34FM_(^X6_@WYQ@Y(-5;>#VT3[;
MV7EJY?.]]5JIWM+U:[[:^>BC:W2UK)Z/)G_8;UVQTG4_!WASXS:]X>^%>I32
M//X3CTZ"62.*1BTD,5VQWQQG)&W:1@G.[)SU7C;]EKQ%(UC!\.?BMJWP_P!%
M@TJ'2)=!N=/BUC3GAB7:K)!.VV-RH&Y@,MC)YSGK_AU\>H_BI\4O%?A[PYI"
M7WA7P[''%<>*DO<Q37K@,;:&,(0X53EGW\' QR#5OP=\:/\ A+/C)\1O 7]C
M_9?^$/AL)?[0^U;_ +7]IB,F/+V#9MQC[S9]JAV44GM9OY)6UZO39/IMW*N[
MN79V^;:>GFW:[77?L>.0?\$]/"=YI/@3PWX@UNZ\0>"?#$5Y++HDL;V[7]]<
MON:X::&52BKP%C5>,<L<G,.I_P#!/?1-.T/XB>&_!'B9_"'A'QA8V<+Z-):2
M7XL[FWF607"227 9@P#*4/\ >SNP M06/[=7B;Q3I7PY/A#X1_\ "2:[XR34
MY(=)_P"$EBM?(%G,8V_>R0!6W*"W.W'3FNG\:_M0_$;X<_#C3-;\2_!7^S/$
MNJ^([?P_I_AW_A*K:;[1YR,4E^T1Q,B9=2FU@/4D"J=_O=O5MQ7SUY;=K*UK
M#UC*W5?A;F=_+:3??6^YV7P?^%GQ5\#:_P#:/&7QG_X3[0TM3!'I/_"+6FF[
M),KMD\V)BQP 1M/!W>U=!\:/AGK_ ,2=&TY/#'CW5OA[KFG70N8-1TY!/%)P
M08Y[=F"3)SG:W0@'U%>2:3^V+X@T[6/%WA_QW\*[CP5XIT3PS<^*+;3QKL&H
M17D$(.5,T28B)(P,ANYQT!O_  F_:,^+GQ,_X1S5+CX"?V-X.UB*.Z_M_P#X
M3&TG\JW=-RR^0(UD;(Q\N >:)/F5WTUO]_7Y/[K$)<FWI;Y+IZ-;%_X>? CQ
M;\&KKPI8^'O%=SJ]O?ZY?:UXVU.]M+=3JDDL7! .6B/F*F%CSP&W,, 'T#X\
M_"^\^,_PLUGP99Z^WAI=65(;F^2U^T/Y&\&2-5WI@NH*YR< G@UX1_P\&TS3
MO"'PG\2ZUX2?3=*\;WU]:7,R:EYO]E);S"+S6_<CS5.0Q^YM&?O5[AX)^,2^
M,OB_X_\  Z:6+=/"L.GS+J2W7F"\%U$T@PFP;-NW&=S9SGBFX\ZY6N__ )+R
MNWHERV6UK^8[NG+FV?\ FY*_K>^ODO(\FB_X)]_#WP9XJ\(^)_AH)/ FOZ%J
M"7,UV9;G4%O[?:5EMW26?";PQ^9>F3P>V9XL_P""?VE>+?V?/#'PYG\5-!K'
MAZ[GN;3Q)'IV&*33/)+"T/F\HP91C?U16]J[3XB?M0:WIGQ+U/P)\./AIJ'Q
M-UW18([C66AU*'3[:Q$@W(AEE!#2%>=HQ[9P<<?XG_X*!Z%X;^&NA>+G\):B
M'E\1-X<UW2+J817>C3(C/,Q4(WF[57('RY!ZJ012C*]FGU37_@6C7ES?+?HQ
MV<7Z+_VU[^?*]GK\[&MXK_92\>S_ !7\7>,O!/QGE\"Q>)X+.WO[&'PW!>.5
MMX!$NV:27*G[QRJJ1N[X!KV/X+_"72/@?\.-)\'Z+)/<6EBKL]U=$&6XE=B\
MDKD=V9B?;@=JQ_#WQQM/$WQLG\!V%C'<6(\,P>)(-;BNMR3QRS>6J"/9TQAM
M^XYSC'>N>_:@_:=@_9OTO0Y8_#D_BS4M3EF?^S[:Y\AXK2",R7%R3L?(1<<8
M&<]1BB_)%)Z7T_&2MY)/F\EJR5'G>G3_ .17X\MEWZ=3+^+W[)G_  M7Q;X^
MUO\ X2K^R_\ A*O"\/AOR/[.\[[+Y=P)O.W>:N_.-NS"^N[M4GB7]D32M;^.
M'P]^)EIK3:9JGAF%(;ZV2TWIJHCB,<3,=X\MU#,-V'R"!VIWQL_:^T#X+ZC\
M,)+G3SJ?AOQJ[DZU%<[%L8 L3+.4V'>N)03\RX )YZ5%XX_:EU3PWJ_Q4LM%
M\"GQ*/ -OIU[<&'5?+DO+:YC:222-?)8 Q*N=N3N&>5Q@I?N[-:<K?R<;WOZ
M<[O?37RT;O4\^9+YJ327WN"\[^NOH7QY^%]Y\9_A9K/@RSU]O#2ZLJ0W-\EK
M]H?R-X,D:KO3!=05SDX!/!KR"V_X)^_#WP3XM\'^*/AJLG@77]!U%+J>Z,MS
MJ"W]OM*RV[I+/A-X8C<O3)X/;M/"'[3VF_$[XIZ-X5\#Z8OB/29M&36M6UY;
MORXM,CE&8(BFQM\K]T++M&3S@@)\9?VC[SP!XZTOP'X-\$7WQ&\=7UHVHG2K
M2\CLHK:U#;?-FGD!5,L" "/Q&1EV]G).VK?STNONT?DU=ZK4+\\7'HE\K.S^
M_5>:T1Y_JO[#NK(-8\/^&?B]KOA;X9ZQ?-?7GA.UL8I&5G</(D%V2'B0G^$
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MBT3^W[?5/M8.[><PJ-FW"]>N[CI7H]:2OI<S74****D84444 %%%% !1110
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MWA[PZEY:B>)L, ZS?0@$ X(.!FMIWDVG_>5OFN9>BE:W5-V3:VSBM$]](O\
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M[X^\ VUEJOBCP3?SW$>C7\_D1W\$\8CEC$AX1\ 8)XY/T/0O^TWX-C^/Z?"
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MAXRMOAIXG\$^'O"/AG6K<-XGLOLU]J5U=VCPK#% "S,H)W \@GT) /E_A?\
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M]M6_F_ZO8\^_:$TR\UKX$?$/3]/M)[^_NM OH;>UMHVDEFD:!PJ(J@EF)(
MY-?-7Q>^%GB7Q;^RI^SQX8@TSQ%9ZC;:MX?343I5O+'?Z7&MNR2S'"DPM&3G
M>PPI S7VM1222=WWB_\ P&_YW!MV5NBE_P"3*WX'P)XO_9Q\2> /BW\0(M.O
M_B!\0["_^%6I6L.L>))I=3D-V\I"V<4RQ@;B &$0RV6)[UG?$#P%>VG@GX13
M:I\,OB?::SIG@ZRM(/%OPVE;^U;2=8UWV=S9E5**K9.XMG+$<<U^AE%%G9*_
M;\.;_P"2_#K=COK>W]6BO_;?^&T/&/V1Y/B++\%M/;XG?;/^$@^T3" ZFBI>
MFTW?N3<*O EQG/?&,\YKYZ^"G[&,7Q*M?'MSX^U;X@:+IESXSU*8>$QJ$ECI
M6H0><KQS-;M'EP_]]6&0HP>*^[**MM.;J6Z6_%._KIVZW(5U#DOUO^#5OQ[]
M#X0\=?LQ>-?B)\>?CC>^&/$7B_X=O'I^DIH5QI=Q-8Z;JS):;6AD90/-52H3
M*M\A<Y!Z52T#PEXB\&>'O@9\1O#7PDU^*/P*-1TS7O!A@E&H))<#$EW;B;!G
M!8LX8$Y# 9X)7[\HJ(W@E9[6^]<WYJ3NMNJLRI6E>ZT_2T5^'*FGONM5H?&.
MF^*/%_BKXV:[\=Y?A;XLT'0?#OA231M.T2_TYAK&LW+S;PHMH]S*@)QDY ZY
MZXPOV5/AGX^_9U^+4&I^)/"0NM/^*,#7=_-H>ENP\-WOF/(EM,4!\N$K( 2<
M*&'HI)^ZZ*J%H--=%;Y-MO[VT[]+)+2]U*\TT^MG\TDH_<K^MW?I;Y3^&'P+
MM?#_ .W#\1_$_P#PC-Y:Z0NG07FE7LL$@LA>W( O'@8C9YC;!NV\C)SUKJ/V
MU_#&L^*_A[X0MM$TF^UBX@\8:3=2PV%L\[QPI*2\C! 2%4<ECP.]?0E%*/NJ
MG'^2WX2YO\EZ)#;YI3E_,FOOCR_\'U/SN^/GAGQ1I/Q7\8ZOX)^'_P 6?!GC
MV[NR]EJO@><7V@:T0 (Y[P$((BW&Y.0.2<GFOM"ZMO$>H? A[?Q#H%IXG\4S
MZ!Y>I:']I%O!?7+08F@$@#! S%ES@@9]*]!HJ>7]TZ7];-;;==>GDBG*]15.
MW_ Z[]-.J[L_/'X!:%\0/#GQ>\(Z;X \.?%GPAX1,K+XCT+QXJR:+9V^PY6R
MF8@L0>%(4,>,\9%;O@'7_B#^SU\(O$?P8N/@QXJ\5ZP9;^#2];TBT6;2K^.Y
M=RDMQ/G]UC?R""<  XK[QHIR7/%Q>S33\U>^^ZMTWW?E91?++F6Z::\FDU\[
MWUVV7S_/SPEH'BK]E#XH_#&ZU7P%XS\<6NF?#PZ/>2^#M'?41#=R7KS&,ME4
MPHX^]G&TXP:[/Q-I>O\ [1'QPTC6[+P?XL\(:7J_P]UG16F\2:3):265Q)*T
M:";&Y4+??4;LE<'%?:%%.?[SX_[W_DW-?_TK\%YBB^3X>T?_ "7E:_\ 23XH
M^%WQ%^)'AOP+\/\ X2_\*#U>Y\0Z%/:V5[JFM6JC08X(6P;J*Z!(,FT;A@9!
M)QN/!ZCX;^"_$-CIW[5*W.A:G;MK.L:A+IBRV<BF^1K0JK097]X"W *YR>*^
MKZ*53]ZI<V\E)-_XK?Y?B_))P:IN/+M%Q:7^%M_K_6Y\'?%;X?>*;C_@GQ\+
M="B\->)Y=<T^XTJ2\TS1K"4ZK;+&6,C+$%W(ZCH2!@XS6?H]M?ZW\*/B]H.E
MZ3^T;JVHZCX5NEMX_BE;--;,XP!';!<DSMO^Z 20I]*_0&BG4_>.HW]O\-$O
MT_X(H/V:@E]G_-O]3X2L+_Q;\?;'X$^![+X6^-?",/@O4M,U/6->\5Z5_9\"
MK9P[62 LQ,A<Y X!Z9'7'N/[9GPY\2>/OAMH=YX5TU=<U?PQX@LO$*Z,SA/M
MZ0%MT()XR0V0#UQCKBO?**J<G-\RT?-S7_O73^[1:$P2C9=%'EMY6:_5ZGQQ
MJNM^,/VI?C#\+KFV^%_BKP%H7@S4)-8U+5/%EF+1Y'\O:MO;KDF16/!8=N2!
MCGYZ\0?LY?$+P[^RCI>K^&/"FL?VUKD<VC>*?#0T^87<T2ZB\UK=B#;O+IC;
MG',<@[#-?J914JT7==[_ /DR;^3LE;LD]S12?7^K)I?--MW[^1Y/^TGHNH:[
M^S-X^TO3;"YU#4[GP_<0P65I"TLTLAB("*B@EF)XP!FOA_X1>#/&+?$'X.2Z
M'X;^-EWJFB7ENNIK\4+0'0=/M_*V7#6>\9B*C(CZ'  Z\5^G%%.+Y:CJ=VG]
MU_\ /_@HSM^Z5+LFOOM_E_P&?E]X6\/:SX.\5^-QK6B_M.:;+-XKU"^@@^'=
MJ\6D7$#3923:P&YFP<L."NW!KURP_9QUSXI?&GXZ>(;O7_B9\/;*YDLIM.CT
M&\?3(M4!LOF$@,;"8HPV':>"S#O7W+167)^[5/M'EO\ ]NQC?U]U/MY&KFW-
MS[N_XMV_'U\S\Y/#'P_^,/B3X7_L]_#[PYX2&EW/AF*?Q-J<OC6PO+;35N8[
MJ46UO,43<7^9G\L<X*D\52USP!\6/"7[/7Q6^%FN>"[W5;RSUVPU[2'\)Z==
M75A/#/=1RSP6C,FYA$P)V'YAN;/ S7Z445LY/F<ENW?Y\T9+[G!?CW,U:R7;
M3\))_?S,^*_VAOBYJ_[1/[.GC_PIH?PB^*&B:J+.UGA&N^&GMQ<[;RW#1P['
M=G< EL ?=1CVKWSX&? MOA#%<W#^/O'7C![^WA0VWB_6?MT=J5R?W*[%V$YP
M>O 'I7K%%)/EYK=?\K">JBNBO^:?Z'RO\7;?Q5\'/VH[?XM6/@?6O'_AC4O#
M8T&\M_#< N=0L)4F\Q76$D%U88'!'?)'&?%_B9\./B!\4_AU^T+\0W\!ZWH$
MOC"/2++1_##VS2:I-';3Q;IY((P65B!G&,@!NP!/Z(45"BDDGTO;T;3?^7DG
MWLUKSVES+R;\[*R].GW>M_)_@9\"V^$,5S</X^\=>,'O[>%#;>+]9^W1VI7)
M_<KL783G!Z\ >E<I^VKX8UCQ5X \'6^B:3?:Q<0>,=)NI8K"V>=XX4E)>1@@
M)"J.2QX'>OH.BM')RDI=FG]S3M^!C&/+%Q[IK[XN-_Q/DW]H#X):Q\6_VM/
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MXOE"[(WV+M3C.,=2:[VBBJ;;W(2L%%%%(84444 %%%% !1110 4444 %%%%
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MR:*?N<M^T?6\>?\ /FOZ]&.H^;F7KZ:J._IRV].Q^>S?&[Q29I?&P^+NL?\
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MC1M4AF\0:?=I:31YV$(L[@B+<0!N_#O7UOH'P[\*>%=5O=4T3PSHVCZG>_\
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MK[DUMU1^97QO\<7/C30O'NH>)_BSJL'BV'QTND0_#B2[06@LHKI/+=;8C<"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>formprer14axz006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formprer14axz006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !H : # 2(  A$! Q$!_\0
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M#&>2!CN/A7\'=$^$_P ++;PCI]I9KHT"SJ;6. 1V^)I'DD18^0L>Z1@$Y 7
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MI7P\\):3I?A"X\/>*+JXO=7N$-[8:YJ\7A1;G33+ IBR([68L%+_ '[-2/\
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M!P?5!H]H((HOLMOY5NP>)/*&V-AT*C'!^E316T<#NR1HC2MN<JN"YP!D^IP
M/P% 'YE?%OX"^,?CUX]\6> /$L:>'?%OCWXS1:I=G2;M[V/3M'G^'@L9[BWF
M>.%Y+=)$N+996BBW2+M*J6Q6QJ_@CXJ^'=,^/OBB/_A$)HM(\.Z'X?U:[77+
MG2[.ZO=&TN^FEN;.46TK%A/>60*G: ]H\)<[6-?HQ=:7!=[RT8#O&8C(GRR!
M3U 88(_ U%H7AZQ\,Z3#8Z?:06=G;@B.&% JKDY/'J222>Y))H \*_9AU_4/
MB9\&O@1%JCPSWL7A:U\0ZI)%>-?+)*EI'!&LDC*I9GDG>7<R@[[5NI!(P/\
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002966507328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Flora Growth Corp.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001790169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">PRER14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment No. 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959843360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade and amounts receivable, net of allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LoansReceivableAndAdvances', window );">Loans receivable and advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivables', window );">Indemnification receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent purchase considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent purchase considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Noncurrent liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share capital, no par value, unlimited authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145,620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,865)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Flora Growth Corp. shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash | &#8364;</a></td>
<td class="nump">&#8364; 13,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade and amounts receivable, net of allowance | &#8364;</a></td>
<td class="nump">21,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets | &#8364;</a></td>
<td class="nump">20,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets | &#8364;</a></td>
<td class="nump">55,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment | &#8364;</a></td>
<td class="nump">91,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets | &#8364;</a></td>
<td class="nump">459,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets | &#8364;</a></td>
<td class="nump">606,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables | &#8364;</a></td>
<td class="nump">47,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability | &#8364;</a></td>
<td class="nump">64,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities | &#8364;</a></td>
<td class="nump">11,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities | &#8364;</a></td>
<td class="nump">123,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt | &#8364;</a></td>
<td class="nump">720,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability | &#8364;</a></td>
<td class="nump">430,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities | &#8364;</a></td>
<td class="nump">1,275,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,202,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share capital, no par value, unlimited authorized | &#8364;</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | &#8364;</a></td>
<td class="num">(694,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(588,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity | &#8364;</a></td>
<td class="num">(669,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(576,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(204,382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity | &#8364;</a></td>
<td class="nump">&#8364; 606,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 626,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 712,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LoansReceivableAndAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LoansReceivableAndAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amounts due as of the balance sheet date of the sum of amounts receivable other than from customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960003680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position (Parenthetical) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Unaudited Condensed Interim Consolidated Statements of Financial Position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Trade and amounts receivable, allowance</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 1,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Share capital, shares issued</a></td>
<td class="nump">8,981<span></span>
</td>
<td class="nump">8,935<span></span>
</td>
<td class="nump">6,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Share capital, shares outstanding</a></td>
<td class="nump">8,981<span></span>
</td>
<td class="nump">8,935<span></span>
</td>
<td class="nump">6,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003083176880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Loss and Comprehensive Loss<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,071<span></span>
</td>
<td class="nump">$ 33,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,333<span></span>
</td>
<td class="nump">20,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,738<span></span>
</td>
<td class="nump">13,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Consulting and management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,876<span></span>
</td>
<td class="nump">9,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
<td class="nump">3,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Communication', window );">Promotion and communication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,710<span></span>
</td>
<td class="nump">8,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">3,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,372<span></span>
</td>
<td class="nump">25,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Other asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,135<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other expenses (income), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,092<span></span>
</td>
<td class="nump">60,472<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,354)<span></span>
</td>
<td class="num">(47,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign exchange (income) loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gain) loss from changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,991)<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes and discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,297)<span></span>
</td>
<td class="num">(48,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,628)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,669)<span></span>
</td>
<td class="num">(46,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,678)<span></span>
</td>
<td class="num">(5,926)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,347)<span></span>
</td>
<td class="num">(52,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Flora Growth Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (57,036)<span></span>
</td>
<td class="num">$ (52,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic loss per share from continuing operations | (per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6.34)<span></span>
</td>
<td class="num">$ (12.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted loss per share from continuing operations | (per share)</a></td>
<td class="num">(0.38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.34)<span></span>
</td>
<td class="num">(12.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Flora Growth Corp. | (per share)</a></td>
<td class="num">(0.38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.75)<span></span>
</td>
<td class="num">(13.68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Flora Growth Corp. | (per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7.75)<span></span>
</td>
<td class="num">$ (13.68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,916<span></span>
</td>
<td class="nump">8,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,640<span></span>
</td>
<td class="nump">6,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding - diluted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,916<span></span>
</td>
<td class="nump">8,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,640<span></span>
</td>
<td class="nump">6,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (56,347)<span></span>
</td>
<td class="num">$ (52,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation, net of income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,755)<span></span>
</td>
<td class="num">(54,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Flora Growth Corp.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (54,444)<span></span>
</td>
<td class="num">$ (54,039)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,038<span></span>
</td>
<td class="nump">&#8364; 7,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,458<span></span>
</td>
<td class="nump">210,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,783<span></span>
</td>
<td class="nump">123,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
<td class="nump">14,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213,280)<span></span>
</td>
<td class="num">(358,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,602<span></span>
</td>
<td class="nump">13,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,882)<span></span>
</td>
<td class="num">(371,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,882)<span></span>
</td>
<td class="num">(371,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss for the period | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (105,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (59,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (216,882)<span></span>
</td>
<td class="num">&#8364; (371,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Communication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense incurred in the period for communication, which is the exchange of information by several methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Communication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959184560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Loss and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation, tax amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960166768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Shareholders' Equity (Deficiency)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Common shares </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Common shares </div>
<div>TruHC Pharma GmbH [Member] </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Accumulated other comprehensive (loss) income </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Accumulated deficit </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Accumulated deficit </div>
<div>TruHC Pharma GmbH [Member] </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Non-controlling interests in subsidiaries (deficiency) </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>TruHC Pharma GmbH [Member] </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021 | shares</a></td>
<td class="nump">3,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,810<span></span>
</td>
<td class="num">$ (1,108)<span></span>
</td>
<td class="num">$ (38,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (225)<span></span>
</td>
<td class="nump">$ 76,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DecemberUnitOfferingShares', window );">December unit offering, shares | shares</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DecemberUnitOfferingAmount', window );">December unit offering, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DecemberUnitOfferingIssuanceCosts', window );">December unit offering issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Share repurchase, shares | shares</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Share repurchase, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common shares issued for business combinations, shares | shares</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Common shares issued for business combinations, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EquityIssuedForOtherAgreementsShares', window );">Equity issued for other agreements, shares | shares</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EquityIssuedForOtherAgreementsAmount', window );">Equity issued for other agreements, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_AcquisitionOfNoncontrollingInterestShares', window );">Acquisition of noncontrolling interest, shares | shares</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_AcquisitionOfNoncontrollingInterestAmount', window );">Acquisition of noncontrolling interest, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised shares | shares</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_RestrictedStockVestingShares', window );">Restricted stock vesting, shares | shares</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_RestrictedStockVestingAmount', window );">Restricted stock vesting, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsExercisedShares', window );">Warrants exercised, shares | shares</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsExercisedAmount', window );">Warrants exercised, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsExpiredOrCancelledAmount', window );">Warrants expired/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes', window );">Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation, tax amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="num">(52,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022 | shares</a></td>
<td class="nump">6,776<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="nump">150,420<span></span>
</td>
<td class="num">(2,732)<span></span>
</td>
<td class="num">(90,865)<span></span>
</td>
<td class="num">&#8364; (216,882)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="nump">56,412<span></span>
</td>
<td class="num">&#8364; (204,382)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Feb. 17, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Feb. 17, 2022 | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,882)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022 | shares</a></td>
<td class="nump">6,776<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="nump">150,420<span></span>
</td>
<td class="num">(2,732)<span></span>
</td>
<td class="num">(90,865)<span></span>
</td>
<td class="num">(216,882)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="nump">56,412<span></span>
</td>
<td class="num">(204,382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EquityIssuedForOtherAgreementsShares', window );">Equity issued for other agreements, shares | shares</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EquityIssuedForOtherAgreementsAmount', window );">Equity issued for other agreements, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted units granted, shares | shares</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted units granted, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil', window );">Other comprehensive loss -exchange differences (net of income taxes of $nil)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation, tax amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,876)<span></span>
</td>
<td class="num">(59,893)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(3,905)<span></span>
</td>
<td class="num">(59,893)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2023 | shares</a></td>
<td class="nump">6,844<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Mar. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="nump">150,403<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(93,976)<span></span>
</td>
<td class="num">(276,775)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
<td class="nump">53,612<span></span>
</td>
<td class="num">(264,275)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022 | shares</a></td>
<td class="nump">6,776<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="nump">150,420<span></span>
</td>
<td class="num">(2,732)<span></span>
</td>
<td class="num">(90,865)<span></span>
</td>
<td class="num">(216,882)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="nump">56,412<span></span>
</td>
<td class="num">(204,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SeptemberUnitOfferingShares', window );">September unit offering shares | shares</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SeptemberUnitOfferingAmount', window );">September unit offering, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SeptemberUnitOfferingIssuanceCosts', window );">September unit offering issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EquityIssuedForOtherAgreementsShares', window );">Equity issued for other agreements, shares | shares</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EquityIssuedForOtherAgreementsAmount', window );">Equity issued for other agreements, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted units granted, shares | shares</a></td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted units granted, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock cancelled, shares | shares</a></td>
<td class="num">(174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted stock cancelled, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DerecognitionOfEquityRelatedToColombiaAssets', window );">Derecognition of equity related to Colombia assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes', window );">Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation, tax amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,036)<span></span>
</td>
<td class="num">(371,787)<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="num">(56,347)<span></span>
</td>
<td class="num">(371,787)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023 | shares</a></td>
<td class="nump">8,935<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="nump">149,093<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="num">(142,549)<span></span>
</td>
<td class="num">(588,669)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
<td class="num">(576,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EquityIssuedForOtherAgreementsShares', window );">Equity issued for other agreements, shares | shares</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EquityIssuedForOtherAgreementsAmount', window );">Equity issued for other agreements, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock cancelled, shares | shares</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted stock cancelled, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil', window );">Other comprehensive loss -exchange differences (net of income taxes of $nil)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation, tax amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_Contributionamont', window );">Contribution,Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,374)<span></span>
</td>
<td class="num">(105,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,374)<span></span>
</td>
<td class="num">(105,572)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2024 | shares</a></td>
<td class="nump">8,981<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, amount at Mar. 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="nump">$ 148,871<span></span>
</td>
<td class="num">$ (113)<span></span>
</td>
<td class="num">$ (145,620)<span></span>
</td>
<td class="num">&#8364; (694,241)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,138<span></span>
</td>
<td class="num">&#8364; (669,241)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_AcquisitionOfNoncontrollingInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_AcquisitionOfNoncontrollingInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_AcquisitionOfNoncontrollingInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_AcquisitionOfNoncontrollingInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_Contributionamont">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represents Contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_Contributionamont</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DecemberUnitOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DecemberUnitOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DecemberUnitOfferingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DecemberUnitOfferingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DecemberUnitOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DecemberUnitOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DerecognitionOfEquityRelatedToColombiaAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of derecognition of equity related to Colombia assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DerecognitionOfEquityRelatedToColombiaAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_EquityIssuedForOtherAgreementsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_EquityIssuedForOtherAgreementsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_EquityIssuedForOtherAgreementsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_EquityIssuedForOtherAgreementsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_RestrictedStockVestingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_RestrictedStockVestingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_RestrictedStockVestingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_RestrictedStockVestingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_SeptemberUnitOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_SeptemberUnitOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_SeptemberUnitOfferingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_SeptemberUnitOfferingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_SeptemberUnitOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_SeptemberUnitOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsExercisedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsExercisedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsExpiredOrCancelledAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued during period warrants expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsExpiredOrCancelledAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002950202752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Interim Consolidated Statement of Shareholders' Equity (Deficiency) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation, tax amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953470688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (56,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (52,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ImpairmentOfGoodwill', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Other asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of investments and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on disposal of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Net income (loss) to cash provided by (Used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net change in non-cash working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Trade payables and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,919)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment and intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Net cash on disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business and asset acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,508)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ProceedsFromExerciseOfWarrantsAndOptions', window );">Exercise of warrants and options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Loan repayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash included in assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(602)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,079)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate on changes on cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NonCashAssetsAcquiredForContingentConsideration', window );">Assets acquired for contingent consideration | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NonCashCommonSharesIssuedForBusinessCombinations', window );">Common shares issued for business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NonCashCommonSharesIssuedForOtherAgreements', window );">Common shares issued for other agreements | shares</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NonCashOptionCancellationsReclassifiedToEquity', window );">Option cancellations reclassified to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets', window );">Operating lease additions to right of use assets | shares</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">2,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash', window );">Intangible assets acquired for contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss | &#8364;</a></td>
<td class="num">&#8364; (105,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (59,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (216,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (371,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization | &#8364;</a></td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense (income) | &#8364;</a></td>
<td class="nump">5,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease expense net of cash payments | &#8364;</a></td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net change in non-cash working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Amounts receivable | &#8364;</a></td>
<td class="num">(2,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets | &#8364;</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade and amounts payable | &#8364;</a></td>
<td class="nump">12,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities | &#8364;</a></td>
<td class="num">(82,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(309,956)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Acquisition of equipment | &#8364;</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities | &#8364;</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt | &#8364;</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares | &#8364;</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities | &#8364;</a></td>
<td class="nump">82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash during the period | &#8364;</a></td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at beginning of period | &#8364;</a></td>
<td class="nump">13,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at end of period | &#8364;</a></td>
<td class="nump">&#8364; 13,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets', window );">Operating lease additions to right of use assets | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,294<span></span>
</td>
<td class="nump">604,294<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ImpairmentOfGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ImpairmentOfGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represents Intangible assets acquired for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NonCashAssetsAcquiredForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NonCashAssetsAcquiredForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NonCashCommonSharesIssuedForBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NonCashCommonSharesIssuedForBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NonCashCommonSharesIssuedForOtherAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NonCashCommonSharesIssuedForOtherAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NonCashOptionCancellationsReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NonCashOptionCancellationsReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ProceedsFromExerciseOfWarrantsAndOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ProceedsFromExerciseOfWarrantsAndOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480228/946-830-45-39<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002949758000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>NATURE OF OPERATIONS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Flora Growth Corp. (the "Company" or "Flora") was incorporated under the laws of the Province of Ontario, Canada on March 13, 2019. The Company is a manufacturer and distributor of global cannabis and pharmaceutical products and brands, building a connected, design-led collective of plant-based wellness and lifestyle brands. The Company's registered office is located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1, Canada and our principal place of business in the United States is located at 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309.</span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Presentation of comparative financial statements</b></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion in Note 11.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1.<span style="display: inline-block; width: 20pt;">&#160;</span></b><b>NATURE OF OPERATIONS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Flora Growth Corp. (the "Company" or "Flora") was incorporated under the laws of the Province of Ontario, Canada on March 13, 2019. The Company is manufacturer and distributor of global cannabis and pharmaceutical products and brands, building a connected, design-led collective of plant-based wellness and lifestyle brands. The Company's registered office is located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1, Canada and our principal place of business in the United States is located at 3406 SW 26th Terrace, Suite C-1, Fort Lauderdale, Florida 3312.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 23, 2022, Flora completed its acquisition of all the issued and outstanding common shares of Franchise Global Health Inc. ("FGH"), a corporation existing under the laws of the Province of British Columbia by way of a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). FGH, through its wholly-owned subsidiaries, is a multi-national distributor in the pharmaceutical and medical cannabis industry with principal operations in Germany. See Note 10 for further discussion.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On February 24, 2022, Flora Growth U.S. Holdings Corp., a wholly-owned subsidiary of the Company, completed the acquisition of 100% of the outstanding equity interests in each of (i) Just Brands LLC and (ii) High Roller Private Label LLC. JustCBD is a manufacturer and distributor of consumable cannabinoid products, including gummies, tinctures, vape cartridges, and creams with principal operations in Florida, United States. See Note 10 for further discussion.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</span></span></p>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1.&#160; NATURE OF OPERATIONS</b></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>TruHC Pharma GmbH (the "Company" or "TruHC") was incorporated under the laws of Germany on February 17, 2022. The Company engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility. The Company's registered office and principal place of business in Germany is located at Poppenb&#252;tteler Bogen 68 22399 Hamburg, Germany. At December 31, 2023, all of the Company's issued and outstanding shares were owned by TruHC Holding GmbH ("TruHC Holding").</span></span></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>These condensed interim financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</span></span></span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1.&#160; NATURE OF OPERATIONS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">TruHC Pharma GmbH (the "Company" or "TruHC") was incorporated under the laws of Germany on February 17, 2022. The Company engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility. The Company's registered office and principal place of business in Germany is located at Poppenb&#252;tteler Bogen 68 22399 Hamburg, Germany. At December 31, 2023, all of the Company's issued and outstanding shares were owned by TruHC Holding GmbH ("TruHC Holding").</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002952796480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION [Text Block]</a></td>
<td class="text">
                <div>
                    <div>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>BASIS OF PRESENTATION</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP. The Company believes that the disclosures made are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2023. These unaudited condensed interim consolidated financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements apply the same accounting policies as those used in the financial statements included in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2023.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to January 1, 2023, Flora was a foreign private issuer reporting its financial statements under International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Boards. These consolidated financial statements, for all periods, are presented in accordance with U.S. GAAP.</span></span></p>
                                <div>

                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern</b></span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying unaudited condensed interim consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these unaudited condensed interim consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of $4.2 million at March 31, 2024, net loss of $3.4 million for the three months ended March 31, 2024, and an accumulated deficit of $145.6&#160;million at March 31, 2024. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed interim consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. The unaudited condensed interim consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                                        </div>

                                </div>
                                <div>
                                    <div>

                                    </div>
                                </div>
                                <div>

                                        <div>
                                            <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of consolidation</b></span></span></p>
                                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. At March 31, 2024, the Company's subsidiaries and respective ownership percentage have not changed from the year ended December 31, 2023, except as noted below.</span></span></p>
                                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the three months ended March 31, 2024, the Company voluntarily dissolved the Cardiff Brand Corp. U.S. entity. Also during the three months ended March 31, 2024, the Company signed articles of organization for Just Brands FL LLC, a United States domestic limited liability company, which is 100% owned by the Company and has a functional currency of the United States dollar.</span></span></p>
                                        </div>

                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2.<span style="display: inline-block; width: 20pt;">&#160;</span></b><b>BASIS OF PRESENTATION</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements have been presented in United States dollars and are prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The Company has determined that the United States dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in United States dollars and our financial results are prepared and reviewed internally by management in United States dollars.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to January 1, 2023, Flora was a foreign private issuer reporting its financial statements under International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Boards. These consolidated financial statements, for all periods, are presented in accordance with U.S. GAAP.</span></span></p>
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Going concern</span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span></span></p>
                                    <div>
                                        <div>

                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of $4.4 million at December 31, 2023, net loss of $56.3 million for the year ended December 31, 2023, and an accumulated deficit of $142.5 million at December 31, 2023. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions, through the disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. These consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                                </div>
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Presentation of comparative financial statements</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion in Note 15.</span></span></p>
                                </div>
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of consolidation</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. As at December 31, 2023, the Company had the following subsidiaries:</span></span></p>
                                    <div>

                                            <div style="margin-bottom: 10pt;">
                                                <table border="1" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                    <tr>
                                                        <td style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Subsidiaries</b></span></span></td>
                                                        <td style="width: 14%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Country of<br/>Incorporation</b></span></span></span></span></td>
                                                        <td style="width: 21%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Ownership %</b></span></span></td>
                                                        <td style="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Functional Currency</b></span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Kasa Wholefoods Company LLC
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Flora Beauty LLC
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Vessel Brand Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Vessel Brand Canada Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Just Brands LLC
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Just Brands International LTD
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United Kingdom
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    British Pound (GBP)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    High Roller Private Label LLC
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Flora Growth US Holdings Corp.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Cardiff Brand Corp.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Franchise Global Health Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Harmony Health One Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    ACA Mueller ADAG Pharma Vertriebs GmbH
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Germany
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Euro (EUR)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Sativa Verwaltungs GmbH
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Germany
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Euro (EUR)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Sativa Verwaltungs GmbH and Co. KG
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Germany
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Euro (EUR)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    CBD Med Therapeutics Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Fayber Technologies Canada Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Catalunia SAS
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Colombia
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Colombia Peso (COP)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Green CannaHealth SAS
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Colombia
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Colombia Peso (COP)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Klokken Aarhus Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Rangers Pharmaceuticals A/S
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Denmark
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Danish Krone (DAK)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    1200325 B.C. LTD.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Phatebo
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Germany
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Euro (EUR)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Franchise Cannabis Corp.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                </table>
                                            </div>

                                    </div>
                                    <div>

                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $0.8 million (USD $0.6 million).</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company sold all of its shares and assets related to the following Colombian companies and branches:</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Growth Corp Colombia S.A.S. (formerly Hemp Textiles &amp; Co. S.A.S.)</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Lab S.A.S. (formerly Grupo Farmaceutico Cronomed S.A.S.)</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Med S.A.S. (formerly Breeze Laboratory S.A.S.)</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Labcofarm Laboratorios S.A.S</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Cosechemos Ya S.A.S.</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Kasa Wholefoods Company S.A.S.</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Growth Corp. Sucursal Colombia</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Beauty LLC Sucursal Colombia</span></span></p>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The applicable capital stock of the Colombian entities was transferred to Lisan at the date of closing. All assets underlying this sale were transferred to Lisan on an "as is where is" basis. The results of these subsidiaries are included in discontinued operations in the accompanying consolidated financial statements. See discussion in Note 5.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the fourth quarter of the year ending December 31, 2023, the Company voluntarily dissolved the following U.S. companies:</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Hemp Textiles &amp; Co. LLC</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Keel Brand Corp.</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Growth F&amp;B Corp</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Flora Growth Management Corp.</span></span></p>
                                    <p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;<span style="display: inline-block; width: 10pt;">&#160;</span>Masaya Holding Corp.</span></span></p>
                                </div>
                                <div>
                                    <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of measurement</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments that are measured at fair value as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of trade and amounts receivable, indemnification receivables, prepaids and other current assets, and trade and other payables, accrued liabilities, current portion of long term debt, and current portion of lease liability approximate their fair values due to their short periods to maturity. The Company calculates the estimated fair value of financial instruments, including investments, and contingent consideration, using quoted market prices when available. When quoted market prices are not available, fair value is determined based on valuation techniques using the best information available and may include quoted market prices, market comparable, and discounted cash flow projections.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The consolidated financial statements are presented in United States dollars ("$") unless otherwise noted.</span></span></p>
                                </div>
                            </div>
                            <div>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Use of estimates</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>
                            </div>
                        </div>
                    </div>
                <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2.&#160; BASIS OF PRESENTATION</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These financial statements have been presented in Euros and are prepared in accordance with United States generally accepted accounting principles (&#8220;US GAAP&#8221;). The Company has determined that the Euro is the functional and reporting currency as the majority of our operations are conducted in Euros and the financial results are prepared and reviewed internally by management in Euros.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue for a period of at least one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of &#8364;13,899 at March 31, 2024, net loss of &#8364;105,572 for the three months ended March 31, 2024 and an accumulated deficit of &#8364;694,241 at March 31, 2024. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners or, through obtaining credit from financial institutions and the possible disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#8217;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company&#8217;s performance and investor sentiment with respect to it and its industry. These financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of measurement </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial statements have been prepared on the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of amounts receivable, prepaids and other current assets, and trade and amounts payable, accrued liabilities, and current portion of lease liability approximate their fair values due to their short periods to maturity.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial statements are presented in Euros ("&#8364;") unless otherwise noted.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Use of estimates</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>2.&#160; BASIS OF PRESENTATION</b></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>These financial statements have been presented in Euros and are prepared in accordance with United States generally accepted accounting principles (&#8220;US GAAP&#8221;). The Company has determined that the Euro is the functional and reporting currency as the majority of our operations are conducted in Euros and the financial results are prepared and reviewed internally by management in Euros.</span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue for a period of at least one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of &#8364;13,588 at December 31, 2023, net loss of &#8364;371,787 for the year ended December 31, 2023, and an accumulated deficit of &#8364;588,669 at December 31, 2023. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners or, through obtaining credit from financial institutions and the possible disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#8217;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company&#8217;s performance and investor sentiment with respect to it and its industry. These financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of measurement </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial statements have been prepared on the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of amounts receivable, prepaids and other current assets, and trade and amounts payable, accrued liabilities, and current portion of lease liability approximate their fair values due to their short periods to maturity.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The financial statements are presented in Euros ("&#8364;") unless otherwise noted.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Use of estimates</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958785008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES [Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3.<span style="display: inline-block; width: 20pt;">&#160;</span></b><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The significant accounting policies used by the Company are as follows:</span></span></p>

                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash and restricted cash</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the consolidated statement of financial position includes cash on hand and deposits held with banks and other financial intermediaries that have a maturity of less than three months at the date they are acquired. Restricted cash in the consolidated statement of financial position includes cash required to be held in deposit accounts related to credit card accounts and merchant accounts.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows. Non-derivative financial assets are classified and measured as "financial assets at fair value", as either fair value through profit or loss ("FVPL"), or "financial assets at amortized cost", as appropriate.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">All financial assets are recognized initially at fair value plus, in the case of financial assets not at FVPL, directly attributable transaction costs on the trade date at which the Company becomes a party to the contractual provisions of the instrument.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets with embedded derivatives are considered in their entirety when determining their classification.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these consolidated financial statements, cash, trade and amounts receivables, indemnification receivables, and loans receivable are classified in this category.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at FVPL</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets measured at FVPL include financial assets such as the Company's equity investments in other entities, and any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial assets measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in a separate caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, trade and amounts receivables, and loans receivable.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade and note receivables are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by country and customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for trade receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the consolidated statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off. This is determined with judgment or otherwise when discharged by bankruptcy or other legal proceedings.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Inventory</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Inventories </span></span><span>are comprised of raw materials and supplies, and finished goods. Inventories are initially valued at cost and subsequently at the lower of cost and net realizable value. Inventory cost is determined either on a weighted&#160;average cost or specific identification basis and any trade discounts and rebates are deducted from the purchase price</span><span><span>. Raw material costs include the purchase cost of the materials, freight-in and duty. Costs incurred during the production process are capitalized as incurred to the extent that cost is less than net realizable value. These costs include materials, labor and manufacturing overhead used in the production processes. Finished goods include the cost of direct materials and labor and a proportion of manufacturing overhead allocated based on normal production capacity.</span></span></span></span></p>
                                        <div>
                                            <div>

                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net realizable value represents the estimated selling price for inventories in the ordinary course of business, less all estimated costs of completion and costs necessary to make the sale. The determination of net realizable value requires significant judgment, including consideration of factors such as shrinkage, the aging of and future demand for inventory and contractual arrangements with customers. Reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The impact of changes in inventory reserves is reflected in cost of sales.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>

                                            <div>
                                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span><span style="font-size: 10pt; font-family: Times New Roman, Times, serif;">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            5-10 years
                                                        </span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vehicle&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;5 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Building&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;30 years</span></span></p>
                                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Lesser of useful life and remaining term of the lease</span></span></p>
                                            </div>

                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use, including interest on borrowings when significant. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the consolidated statements of loss and comprehensive loss of the related year.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Intangible assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization is provided on a straight-line basis over the assets' estimated useful lives, which do not exceed the contractual period, if any. The Company's finite-lived intangible assets are amortized as follows:</span></span></p>

                                            <div>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Patents and developed technology&#160; &#160; &#160; &#160; &#160;9 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Customer and supplier relationships&#160; &#160; &#160;5-10 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trademarks and brands&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;8-10 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Licenses&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;5 years</span></span></p>
                                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-compete agreements&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;3 years</span></span></p>
                                            </div>

                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Amortization expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investments</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Investments include investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence and are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the "measurement alternative"). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in unrealized loss from changes in fair value on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>

                                <div>
                                    <div>

                                    </div>
                                </div>

                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment and definite life intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Business combinations</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition related costs are generally recognized in the consolidated statements of loss and comprehensive loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed, are recognized at their fair value.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any noncontrolling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date. If, after assessment, the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in the consolidated statements of loss and comprehensive loss as a bargain purchase gain.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured at the fair value of the acquiree's identifiable net assets.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or liability is remeasured at subsequent reporting dates, with the corresponding gain or loss recognized in the consolidated statements of operations and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">When a business combination is achieved in stages, the Company's previously held equity interest in the acquiree is remeasured to its acquisition date fair value and the resulting gain or loss, if any, is recognized in the consolidated statements of loss and comprehensive loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to the consolidated statements of loss and comprehensive loss where such treatment would be appropriate if that interest were disposed of.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Purchase price allocations may be preliminary and, during the measurement period not to exceed one year from the date of acquisition, changes in assumptions and estimates that result in adjustments to the fair value of assets acquired and liabilities assumed are recorded in the period the adjustments are determined.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of goodwill and indefinite-lived intangible assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company operates in three operating segments which are the reporting units and goodwill is allocated at the operating segment level. The Company reviews goodwill and indefinite-lived intangible assets annually for impairment in the fourth quarter, or more frequently, if events or circumstances indicate that the carrying amount of an asset may not be recoverable.</span></span></p>
                                    </div>

                                <div>
                                    <div>

                                    </div>
                                </div>

                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables and other accrued liabilities and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at FVPL</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities measured at FVPL include any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial liabilities measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in other income or expense in the consolidated statements of loss and comprehensive loss. In these consolidated financial statements, trade and other payables and other accrued liabilities, lease liability and loans payable are measured at amortized cost.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the consolidated statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Additional proceeds from the issuance of common shares are classified as equity in additional paid in capital. Incremental costs directly attributable to the issue of common shares, stock options and warrants are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received. The fair value of options and warrants is determined using the Black Scholes model.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share based compensation</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share based compensation to employees is measured at the fair value of the instruments issued and amortized over the vesting periods. Share based compensation to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued if it is determined the fair value of the goods or services cannot be reliably measured and are recorded at the date the goods or services are received. The Company operates an equity based compensation plan. The corresponding amount is recorded to the stock option caption within shareholders&#8217; equity, and the expense to the consolidated statements of loss and comprehensive loss over the vesting period. The fair value of options is determined using the Black&#8211;Scholes pricing model which incorporates all market vesting conditions. For awards with graded vesting schedules, the Company has elected to calculate the fair value as a single award and recognize expense over the total expected vesting period rather than in tranches. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest. Upon exercise of a stock option, any amount related to the initial value of the stock option, along with the proceeds from exercise are recorded to share capital. Upon expiration of a stock option, any amount related to the initial value of the stock option is recorded to accumulated deficit. The Company also grants employees and non-employees restricted stock awards (&#8220;RSAs&#8221;). The fair value of the RSAs is determined using the fair value of the common shares on the date of the grant. The Company has elected to recognize forfeitures as they occur.</span></span></p>
                                    </div>

                                <div>
                                    <div>

                                    </div>
                                </div>

                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Foreign currency translation</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements are presented in U.S. dollars ("USD"), which is the Company's reporting currency; however, the functional currency of the entities in these financial statements are their respective local currencies, including Canadian dollar, USD, British pound and euro.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Translation into functional currency</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Transactions in foreign currencies are recorded in the functional currency at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the period end exchange rates. Non-monetary items are translated at the exchange rates in effect on the date of the transactions. Foreign exchange gains and losses arising on translation are presented in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Translation into presentation currency</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The assets and liabilities of foreign operations are translated into USD at year-end exchange rates. Revenue, expenses, and cash flows of foreign operations are translated into USD using average exchange rates of the reporting period. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in shareholders' equity. The cumulative exchange differences are reclassified to the consolidated statements of loss and comprehensive loss upon the disposal of the foreign operation.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Research expenses</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Research expenses are expensed as they are incurred, net of any related investment tax credits, unless the criteria for capitalization of development expenses are met.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Revenue recognition</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company primarily generates revenue as a distributor of pharmaceuticals and a distributor and retailer of cannabidiol oil derived products. See disaggregation of the Company&#8217;s revenue by operating segments and sales by country in Note 24.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company uses the following five-step contract-based analysis of transactions to determine if, when and how much revenue can be recognized:</span></span></p>
                                        <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt;">
                                            <tr>
                                                <td style="width: 4%; vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Identify the contract with a customer;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Identify the performance obligations in the contract;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Determine the transaction price;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Allocate the transaction price to the performance obligations in the contract; and</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Recognize revenue when or as the Company satisfies the performance obligations.</span></span></p>
                                                </td>
                                            </tr>
                                        </table>
                                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Gross revenue excludes duties and taxes collected on behalf of third parties. Revenue is presented net of expected price discounts, sales returns, customer rebates and other incentives.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's contracts with customers for the sales of products consist of one performance obligation. Revenue from product sales is recognized at the point in time when control is transferred to the customer, which is on shipment or delivery, depending on the contract terms. The Company's payment terms generally range from 0 to 30 days from the transfer of control, and sometimes up to two months.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient to not adjust the customer contract consideration for significant financing components when the period between the transfer of the Company's goods and services and customer payment is one year or less.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient to expense, as incurred, the costs of obtaining a customer contract such as sales commissions and other selling transaction costs when the amortization period of the assets otherwise would be one year or less. Accordingly, the Company has no assets recorded for costs to obtain a customer contract as at December 31, 2023 and 2022 as there are no contracts where the underlying asset would have a life exceeding one year.</span></span></p>
                                        <div>
                                            <div>

                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient for shipping and handling not to be a separate performance obligation.</span></span></p>
                                    </div>

                                <div>

                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Advertising costs</b></span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Advertising costs are expensed as incurred and recorded within the promotion and communication caption on the consolidated statements of loss and comprehensive loss. Advertising costs were $3.4 million in 2023 ($4.4 million in 2022).</span></span></p>
                                        </div>

                                </div>

                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the consolidated statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the consolidated statements of loss and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable income or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                        <div>
                                            <div>

                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Loss per share</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share is calculated using the weighted average number of shares outstanding during the year. Diluted loss per share reflects the potential dilution of common share equivalents, such as outstanding options and warrants, in the weighted average number of common shares outstanding during the period, if dilutive. The diluted loss per share calculation excludes any potential conversion of options and warrants that would be anti-dilutive.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Non-controlling interests</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-controlling interests of subsidiaries ("NCI") are recognized either at fair value or at the NCI's proportionate share of the net assets, determined on an acquisition-by-acquisition basis at the date of acquisition. Subsequently, the NCI's share of net loss and comprehensive loss is attributed to the NCI.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During 2023, the Company completed the sale of Cosechemos YA S.A.S. and Kasa Wholefoods Company S.A.S to Lisan. These entities each had 10% NCI which was derecognized when the Company lost control during the year ended December 31, 2023. See discussion in Note 5.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Discontinued operations and assets and liabilities held for sale</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $0.8 million (USD $0.6 million). The assets and liabilities of these Colombian companies are reflected in the accompanying consolidated balance sheets as assets and liabilities held for sale, respectively. The results of operations of these Colombian companies are included in loss from discontinued operations, net of tax in the accompanying consolidated statements of operations and comprehensive loss. For comparative purposes, all prior periods presented have been reclassified to reflect the classifications on a consistent basis. See discussion in Note 5.</span></span></p>
                                    </div>


                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ("ASU 2021-08"), which requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers ("ASC 606") rather than adjust them to fair value at the acquisition date. The effects of adoption are applied prospectively to business combinations occurring on or after the effective date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective as of January 1, 2023, and as such had no impact on the Company's consolidated financial statements.</span></span></p>
                                    </div>

                                <div>
                                    <div>

                                    </div>
                                </div>

                                    <div>
                                        <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2022, the FASB issued Accounting Standards Update 2022-03-Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU 2022-03"), which requires that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The effects of adoption are accounted for prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is assessing the impacts of adoption, but it is not expected to have an impact based on amounts recorded at December 31, 2023 as any changes required are for transactions occurring prospectively upon adoption.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segments Disclosures. The amendments enhance disclosures of significant segment expenses by requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM), extend certain annual disclosures to interim periods, and permit more than one measure of segment profit or loss to be reported under certain conditions. The amendments are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption of the amendment is permitted, including adoption in any interim periods for which financial statements have not been issued. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                                    </div>

                            </div>
                        </div>
                    </div>
                <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3.&#160; SIGNIFICANT ACCOUNTING POLICIES</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>The significant accounting policies used by the Company are as follows:</b></span></span></p>
                            <div>

                                    <div>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash </b></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the statements of financial position includes cash on hand.</span></span></p>
                                    </div>

                            </div>
                            <div>

                                    <div>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.</span></span></p>
                                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.</span></span></p>
                                    </div>

                            </div>
                            <div>

                            </div>
                            &#160;
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>
                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;">
                                        <tr>
                                            <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                            <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                        5-10 years
                                                    </span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets</span></span></td>
                                            <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Lesser of useful life and remaining term of the lease</span></span></td>
                                        </tr>
                                    </table>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.</span></span></p>
                                </div>


                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                                </div>


                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                                </div>

                            <div>

                            </div>
                            &#160;
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.</span></span></p>
                                </div>


                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.</span></span></p>
                                </div>


                                <div>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital </b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.</span></span></p>
                                </div>


                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                </div>

                            <div>

                            </div>
                            &#160;
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                                </div>


                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                                </div>


                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Commitments and contingencies</b></span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.</span></span></p>
                                </div>

                            <div>

                            </div>
                            &#160;
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                </div>


                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                                </div>

                        </div>
                    <span></span>
</td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>03.&#160; SIGNIFICANT ACCOUNTING POLICIES</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>The significant accounting policies used by the Company are as follows:</b></span></span></p>

                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash </b></span></span></p>
                                <p><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the statements of financial position includes cash on hand.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.</span></span></p>
                            </div>

                        <div>

                        </div>
                        &#160;
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;">
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                    5-10 years
                                                </span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">&#160;</td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets</span></span></td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Lesser of useful life and remaining term of the lease</span></span></td>
                                    </tr>
                                </table>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                            </div>

                        <div>

                        </div>
                        &#160;
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital </b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                            </div>

                        <div>

                        </div>
                        &#160;
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Commitments and contingencies</b></span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.</span></span></p>
                            </div>

                        <div>

                        </div>
                        &#160;
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                            </div>


                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                            </div>

                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002952467552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock', window );">CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES [Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                    <div>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>4.&#160; &#160; &#160; &#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, revenues, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern considerations</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company&#8217;s ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of revenues, expenses and cash flows, which requires a significant amount of management judgement.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Determination of functional currency</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company determines the functional currency through an analysis of several indicators. Primary considerations include the currency in which the Company's goods and services are sold and the currency of the country whose competitive forces and regulations mainly determine the sales prices of its goods and services. The Company also considers the currency in which funds from financing debt and equity activities are generated and the currency in which receipts from operating activities are retained. Management judgment is applied when there are indicators supporting more than one currency for a Company subsidiary.</span></span></p>
                                <div>
                                    <div>

                                    </div>
                                </div>
                                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Expected credit losses on financial assets</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Determining an allowance for expected credit losses for all financial asset receivables not held at fair value through profit or loss requires judgment. Factors that cause the estimate to be sensitive to change include historical and expected future patterns for the probability of default, the timing of collection and the amount of incurred credit losses, and management's judgment about whether economic conditions and credit terms are such that actual losses may be higher or lower than what the historical patterns suggest. These conditions are applied across each of the Company's business units to the extent the expected risk of loss differ from each other.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Inventory</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory is valued at the lower of cost and net realizable value. Determining net realizable value requires the Company to make assumptions about estimated selling prices in the ordinary course of business, the estimated costs of completion and the estimated variable costs to sell. Management judgment is applied to determine potential impairment exposure related to potential excess product inventory levels, obsolescence, and expiration.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Business combinations</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In a business combination, the Company may acquire assets and assume certain liabilities of an acquired entity. Judgement is used in determining whether an acquisition is a business combination or an asset acquisition. Estimates are made as to the fair value of the identifiable assets acquired and the liabilities assumed on the acquisition date, as well as the fair value of consideration paid and contingent consideration payable. In certain circumstances, such as the valuation of property, plant and equipment, intangible assets and goodwill acquired, the Company obtains assistance from third-party valuation specialists. The determination of these fair values involves a variety of judgment in assumptions, include revenue growth rates, expected operating income, discount rates, and earnings multiples.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Estimated useful lives and depreciation of long-lived assets with finite lives</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Determination of reporting units and asset groups for impairment testing</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining which assets or group of assets make up appropriate reporting units and asset groups for the level at which goodwill and other long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of goodwill and long-lived assets</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For reporting units to which goodwill and other long-lived assets is allocated is based on a recoverable amount, the impairment test is determined in accordance with the expected cash flow approach or another suitable model depending on the asset type. The calculation is based on assumptions including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For reporting units that test using the market based fair value approach, the fair value is determined based on guideline public companies similar to the reporting unit and considers similar financial metrics, operations and sales channels. The fair value calculation is based on assumptions including the determination of guideline public companies, determining the relevant financial metric to measure the reporting unit's recoverable value, and selecting the amount of the financial metric from the observable range of guideline public company amounts to apply to the reporting unit.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions discussed above. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.</span></span></p>
                                <div>
                                    <div>

                                    </div>
                                </div>
                                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Revenue recognition</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management judgment is required to determine when the Company is acting as principal or agent in a sales contract where the Company is an intermediary, which affects whether the amount of revenue recognized is presented on a gross or net basis, respectively. The Company first considers whether it has obtained control over the product when acting as an intermediary before transferring it to the customer, and if the Company combines or transforms the product with other goods and services before transferring the good to the customer. The Company considers secondary factors, including whether the Company is primarily responsible for the fulfillment of the product obligations to the customer, whether the Company has inventory risk (acquiring and/or paying for the product prior to transferring to the customer, Company liability for damages and sales returns), and whether the Company has price discretion when selling the product to its customers. Management considers the terms of the customer and supplier contracts, as well as established business practices for the arrangements.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management judgment is required to determine the effects on the sales contract transaction price for the potential impacts of sales returns, discounts, rebates, and other customer incentives. The Company considers the terms of the contract, historical experience, as well as actual and expected customer activity after the end of the reporting period.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's primary sale of products requires management judgment to determine at what point in time control passes to the customer to recognize revenue. The Company considers the customer contract terms, logistic supplier terms, local law, and established business practices to make this determination.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share based compensation transactions</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company measures the cost of equity-settled transactions with employees and applicable non-employees by reference to the fair value of the equity instruments at the date at which they are vested. Estimating fair value for share based compensation requires judgment to determine the appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the stock price, stock option, risk-free interest rates, volatility, and dividend yield. For awards with market or performance-based features, the Company applies judgment to determine its expectation of achieving the agreement milestones. Due to the Company's limited history of publicly traded common shares, the volatility and expected term assumptions require additional judgment. The Company considers the Company's actual trading volatility to date compared to actual and expected volatility of comparable companies of similar size and industry that have been publicly traded longer than the Company's shares.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For expected term, the Company generally uses the maximum stated term in the award agreement unless there is reasonable likelihood established to shorten the expected term for potential early exercises.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes and valuation allowances for deferred tax assets</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of December 31, 2023 and 2022, there were no uncertain tax positions taken.</span></span></p>
                            </div>
                        </div>
                    </div>
                <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock', window );">CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>4.&#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity and going concern considerations</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company's ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of expenses and cash flows, which requires a significant amount of management judgement.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining the discount rate and whether to include renewal options in the lease term. The determination of the discount rate considers the incremental borrowing rate that would be charged for a loan that is collateralized or secured by the lessee's aggregate collateral, has a term that is similar to the lease term, is for an amount similar to the lease payments, and occurs in a similar economic environment. In this instance, management utilized European corporate debt instruments compounded annually that have a similar term and economic rating. In determining the lease term, management evaluated the fact that the Company's licenses are tied to the lease facility and as such the Company is reasonably certain to exercise the renewal option.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Estimated useful lives and depreciation of long-lived assets with finite lives</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Determination of asset groups for impairment testing</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining asset groups for the level at which long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions, including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes and valuation allowances for deferred tax assets</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of March 31, 2024 and December 31, 2023 there were no uncertain tax positions taken.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4.&#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity and going concern considerations</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company's ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of expenses and cash flows, which requires a significant amount of management judgement.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining the discount rate and whether to include renewal options in the lease term. The determination of the discount rate considers the incremental borrowing rate that would be charged for a loan that is collateralized or secured by the lessee's aggregate collateral, has a term that is similar to the lease term, is for an amount similar to the lease payments, and occurs in a similar economic environment. In this instance, management utilized European corporate debt instruments compounded annually that have a similar term and economic rating. In determining the lease term, management evaluated the fact that the Company's licenses are tied to the lease facility and as such the Company is reasonably certain to exercise the renewal option.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Estimated useful lives and depreciation of long-lived assets with finite lives</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Determination of asset groups for impairment testing</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Management is required to use judgement in determining asset groups for the level at which long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions, including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes and valuation allowances for deferred tax assets</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of December 31, 2023 and 2022, there were no uncertain tax positions taken.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003065971568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3.<span style="display: inline-block; width: 20pt;">&#160;</span>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all its shares in its Colombian related subsidiaries and its Colombian assets for a purchase price of CAD $0.8 million (USD $0.6 million). The sale relates to all of Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab 2, Flora Lab 4 and Flora's Colombian food and beverage and consumer products business. The Company received proceeds of CAD $0.5 million during the year ended December 31, 2023 which completed the sale and transfer of Flora Growth Corp Colombia S.A.S, Flora Lab S.A.S., Flora Med S.A.S., Labcofarm Laboratorios S.A.S., Kasa Wholefoods Company S.A.S., Flora Growth Corp. Sucursal Colombia and Flora Beauty LLC Sucursal Colombia. The Company and Lisan completed the sale of Cosechemos Ya S.A.S on November 1, 2023.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The sale enabled the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following table summarizes the major classes of line items included in loss from discontinued operations, net of tax, for the three months ended March 31, 2024 and 2023:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span> </span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2024</b></span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2023</b></span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">788</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cost of sales</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">657</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross profit from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">131</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating expenses</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Consulting and management fees</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">369</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">36</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">176</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Promotion and communication</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">50</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">78</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">124</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating loss from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(708</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss before income taxes</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(708</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(719</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.00</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(0.11</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.00</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(0.11</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                            </table>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following table summarizes the significant operating and investing items related to the Colombian subsidiaries for the three months ended March 31, 2024 and 2023</span></span></p>
                        <div>
                            <div>

                            </div>
                        </div>

                            <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span><br/><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2024</b></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2023</b></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating activities of discontinued operations</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">78</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investing activities of discontinued operations</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Purchases of property, plant and equipment</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">94</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The subsidiaries sold included Cosechemos Ya S.A.S, which was part of the commercial and wholesale segment; Flora Lab S.A.S, Flora Med S.A.S. and Labcofarm Laboratories S.A.S, which were part of the pharmaceuticals segment; Flora Growth Corp Colombia S.A.S., Kasa Wholefoods Company, S.A.S. and Flora Beauty LLC Sucursal Colombia which were part of the house of brands segment.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company applies significant judgement in determining whether a disposal meets the criteria to present as held for sale at the reporting date, and whether the disposal represents a strategic shift that has (or will have) a major effect on its operations and financial results in order to be classified as a discontinued operation. The criteria evaluated are both quantitative and qualitative in nature, to evaluate the significance of the disposal relative to the operations of the Company as a whole. The Company has determined this disposition represents a strategic shift in operations that will have a major effect on the Company's operations and financial results, and accordingly, has been presented as discontinued operations.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                        <div>
                            <div>
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>5.&#160; &#160; &#160; &#160; &#160;ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS</b></span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all its shares in its Colombian related subsidiaries and its Colombian assets for a purchase price of CAD $0.8 million (USD $0.6 million). The sale relates to all of Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab S.A.S., Flora Med S.A.S. and Flora's Colombian food and beverage and consumer products business. The Company has received proceeds of CAD $0.5 million during the year ended December 31, 2023 which completed the sale and transfer of Flora Growth Corp Colombia S.A.S, Flora Lab S.A.S., Flora Med S.A.S., Labcofarm Laboratorios S.A.S., Kasa Wholefoods Company S.A.S., Flora Growth Corp. Sucursal Colombia and Flora Beauty LLC Sucursal Colombia. The Company and Lisan completed the sale of Cosechemos Ya S.A.S on November 1, 2023.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The sale enables the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company has presented the associated assets and liabilities of the Colombian subsidiaries as held for sale. The major classes of assets and liabilities classified as held for sale as of December 31, 2023 and December 31, 2022 were as follows:</span></span></span></span></p>
                                </div>
                            </div>
                            <div>
                                <div>

                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Assets held for sale</b></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Cash</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">602</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Trade and amounts receivable</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,592</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Prepaid expenses and other current assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">174</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Inventory</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,341</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Total current assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,709</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Property, plant and equipment</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,592</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Operating lease right of use assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">419</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">358</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other assets</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; Total noncurrent assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,392</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8,101</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liabilities held for sale</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Current portion of operating lease liability</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">72</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other accrued liabilities</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">538</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; Total current liabilities held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">610</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Non-current operating lease liability</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">308</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">918</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>

                                    <p style="margin: 0pt;">&#160;</p>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>The following table summarizes the major classes of line items included in loss from discontinued operations, net of tax, </span></span>for years ended December 31, 2023 and 2022:</span></span></span></span></p>

                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2022</b></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue</span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,450</span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,770</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cost of sales</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,123</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,607</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross profit from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">327</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,163</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Consulting and management fees</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">847</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,110</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">82</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">514</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">282</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,208</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Promotion and communication</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">14</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">383</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">93</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">284</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">148</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">485</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Bad debt expense</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">565</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">666</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset impairment</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,704</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">454</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other (income) expense</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">125</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,145</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating loss from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,533</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,086</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(27</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss before income taxes</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,535</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,059</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on disposal of discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,132</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense (benefit)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(133</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(9,678</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(5,926</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1.32</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1.55</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1.32</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1.55</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>

                                    <p style="margin: 0pt;">&#160;</p>
                                    <div>

                                    </div>
                                    <p style="margin: 0pt 0pt 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The following table summarizes the significant operating and investing items related to the Colombian subsidiaries </span></span>for the years ended December 31, 2023 and 2022</span></span></p>

                                        <div>
                                            <div>
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year<br/>months ended<br/>December 31,<br/>2023</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year<br/>months ended<br/>December 31,<br/>2022</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating activities of discontinued operations</b></span></span></td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Depreciation and amortization</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">148</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">485</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Bad debt expense</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">565</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">666</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Asset impairment</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,704</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">454</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investing activities of discontinued operations</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Purchases of property, plant and equipment</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">92</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">951</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>
                                        </div>

                                    <div>
                                        <div>
                                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The subsidiaries sold included Cosechemos Ya S.A.S, which was part of the commercial and wholesale segment; Flora Lab S.A.S, Flora Med S.A.S. and Labcofarm Laboratories S.A.S, which were part of the pharmaceuticals segment; Flora Growth Corp Colombia S.A.S., Kasa Wholefoods Company, S.A.S. and Flora Beauty LLC Sucursal Colombia which were part of the house of brands segment; Flora Growth Corp. Sucursal Colombia which was part of the corporate segment.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company applies significant judgement in determining whether a disposal meets the criteria to present as held for sale at the reporting date, and whether the disposal represents a strategic shift that has (or will have) a major effect on its operations and financial results in order to be classified as a discontinued operation. The criteria evaluated are both quantitative and qualitative in nature, to evaluate the significance of the disposal relative to the operations of the Company as a whole. The Company has determined this disposition represents a strategic shift in operations that will have a major effect on the Company's operations and financial results, and accordingly, has been presented as discontinued operations.</span></span></p>
                                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the year ended December 31, 2023, the Company recorded a loss on disposal of $3.1 million driven by the write-off of the Company's net investment in the Colombian assets.</span></span></p>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002957295840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRADE AND AMOUNTS RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">TRADE AND AMOUNTS RECEIVABLE [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>4.<span style="display: inline-block; width: 20pt;">&#160;</span>TRADE AND AMOUNTS RECEIVABLE </b></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">The Company's trade and amounts receivable are recorded at amortized cost. The trade and other receivables balance as at March 31, 2024 and December 31, 2023 consists of trade accounts receivable, amounts recoverable from the Government of Canada for Harmonized Sales Taxes ("HST"), as well as Value Added Tax ("VAT") from various jurisdictions, and other receivables.</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>March 31, 2024</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Trade accounts receivable</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2,595</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2,299</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Allowance for expected credit losses</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(317</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(315</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">HST/VAT receivable</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>765</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1,840</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Other receivables</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>175</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">126</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3,218</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">3,950</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Changes in the trade accounts receivable allowance in the three months ended March 31, 2024 relate to establishing an allowance for expected credit losses and reclassification of assets held for sale. There were $nil and less than $0.1 million in write-offs of trade receivables during the three months ended March 31, 2024 and 2023, respectively. The Company has no amounts written-off that are still subject to collection enforcement activity as at March 31, 2024. The Company's aging of trade accounts receivable is as follows:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>March 31, 2024</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Current</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">567</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">218</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1-30 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1,314</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">588</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">31-60 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">236</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">577</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">61-90 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">173</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">448</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">91-180 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">238</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">401</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">180+ Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">67</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">67</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total trade receivables</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2,595</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2,299</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.<span style="display: inline-block; width: 20pt;">&#160;</span>TRADE AND AMOUNTS RECEIVABLE </b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's trade and amounts receivable are recorded at amortized cost. The trade and other receivables balance as at December 31, 2023 and December 31, 2022 consists of trade accounts receivable, amounts recoverable from the Government of Canada for Harmonized Sales Taxes ("HST"), as well as Value Added Tax ("VAT") from various jurisdictions, and other receivables.</span></span></p>
                                <div>
                                    <div>

                                    </div>
                                </div>

                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade accounts receivable</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,299</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,288</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Allowance for expected credit losses</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(315</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,385</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">HST/VAT receivable</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,840</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,294</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other receivables</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">126</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">62</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,950</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,259</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Changes in the trade accounts receivable allowance in the year ended December 31, 2023 relate to establishing an allowance for expected credit losses. The Company recorded $1.3 million of write-offs of trade receivables during 2023 (2022 - $0.2 million), $1.1 million of which was related to discontinued operations. The Company has no amounts written-off that are still subject to collection enforcement activity as at December 31, 2023. The Company's aging of trade accounts receivable is as follows:</span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 80%;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 398px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">December 31, 2023</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; white-space: nowrap;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>December 31, 2022</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 9px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 112px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 13px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 6px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 118px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 12px;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">218</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,202</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1-30 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">588</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>838</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31-60 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">577</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>660</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">61-90 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">448</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>159</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">91-180 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">401</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>321</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">180+ Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">67</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,108</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total trade receivables</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 9px; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,299</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 6px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>4,288</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                    </table>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A continuity schedule of the allowance for expected credit losses for the years ended December 31, 2023 and 2022 is as follows:</span></span></p>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at January 1</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,385</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(400</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current period additions for expected credit losses</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(236</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,186</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Write-offs charges against allowance</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,282</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">151</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Recoveries collected</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">24</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">50</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(315</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,385</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                        </table>
                                    </div>

                            </div>
                        </div>
                    </div>
                <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">TRADE AND AMOUNTS RECEIVABLE [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>5. AMOUNTS RECEIVABLE</b></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's amounts receivable are recorded at amortized cost. The amounts receivable balance as at December 31, 2023 and December 31, 2022 consists of amounts recoverable from the Value Added Tax ("VAT") from various jurisdictions, and other receivables.&#160;</span></span></p>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">VAT receivable</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,919</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">14,551</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other receivables</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,263</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,343</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">21,182</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">18,894</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company did not record write-offs of receivables during the three months ended March 31, 2024 (2023 - &#8364; nil).&#160;</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>5.&#160; AMOUNTS RECEIVABLE</b></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company&#8217;s amounts receivable are recorded at amortized cost. The amounts receivable balance as at December 31, 2023 and December 31, 2022 consists of amounts recoverable from the Value Added Tax (&#8220;VAT&#8221;) from various jurisdictions, and other receivables.&#160;</span></span></span></span></p>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>December 31, 2023</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>December 31, 2022</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>VAT receivable</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>14,551</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160;6,761</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Other receivables</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>4,343</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>11,638</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160;18,894</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>18,399</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company did not record write-offs of receivables during 2023 (2022 - &#8364; nil).</span></span></span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002950220480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY [Text Block]</a></td>
<td class="text">
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>5.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>INVENTORY </b></span></span></p>
                            <div>
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory is comprised of the following:</span></span></p>
                                    <div>

                                            <div>
                                                <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Raw materials and supplies</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1,053</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,180</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finished goods</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8,193</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7,328</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9,246</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8,508</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>

                                    </div>
                                </div>
                            </div>
                        </div>
                    <span></span>
</td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.<span style="display: inline-block; width: 20pt;">&#160;</span>INVENTORY </b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory is comprised of the following as at December 31, 2023 and 2022:</span></span></p>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">December 31, 2022</span></span></td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Raw materials and supplies</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1,180</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,363</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finished goods</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>7,328</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,384</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>8,508</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8,747</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                                <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In the year ended December 31, 2023, $54.9 million of inventory was expensed to cost of sales (2022 - $14.5 million) and write-downs to cost of sales for impairment was $2.7 million (2022 - $0.5 million), with the increase in 2023 due to write-downs related to a flooding incident at a JustCBD facility in Florida and other factors. There were no reversals of previous inventory impairments in the years ended December 31, 2023 or 2022.</span></span></p>
                            </div>
                        </div>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958586384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT [Text Block]</a></td>
<td class="text">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>PROPERTY, PLANT AND EQUIPMENT </b></span></span></p>
                                <div>
                                    <div>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment consist of the following:</span></span></p>

                                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Land</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>292</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">298</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Buildings</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>91</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">78</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>697</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">696</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vehicles</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>37</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">37</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1,117</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,109</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(331</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(262</span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 9px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>786</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">847</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                            </table>

                                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Depreciation expense for the three months ended March 3, 2024 was less than $</span>0.1 million, (March 31, 2023 - $0.1<span> million) and was recorded in depreciation and amortization in the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></span></p>
                                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>See Note 8 for discussion of impairment of property, plant and equipment during the three months ended March 31, 2024.</span></span></span></p>
                                    </div>
                                </div>
                            </div>
                        <span></span>
</td>
<td class="text">
                <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>8.<span style="display: inline-block; width: 20pt;">&#160;</span>PROPERTY, PLANT AND EQUIPMENT </b></span></span></span></p>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Property, plant and equipment consist of the following:</span></span></span></p>

                            <div>
                                <table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>December 31, 2023</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>December 31, 2022</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Thousands of United States dollars</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span style="color: #ff0000;">&#160;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span style="color: #ff0000;">&#160;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Land</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>298</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>291</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Buildings</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>78</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Machinery and office equipment</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>696</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,098</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Vehicles</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>37</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>37</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Total</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,109</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,426</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr style="background-color: #e6efff;">
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Less: accumulated depreciation</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(262</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(208</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Property, plant and equipment, net</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>847</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,218</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Depreciation expense for the year ended December 31, 2023 was $0.2 million (2022 - $0.2 million) and was recorded in depreciation and amortization in the consolidated statements of operations and comprehensive loss.</span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>During the year ended December 31, 2023, the Company recorded an impairment charge of the remaining value of the property, plant and equipment of Vessel within the House of Brands segment. The amount of $0.2 million (2022 - $nil) is included in "other asset impairments" in the consolidated statements of operations and comprehensive loss. See Note 12 for further discussion.</span></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>As at December 31, 2023, the Company's property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the year ended December 31, 2023.</span></span></span></p>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.&#160; PROPERTY, PLANT AND EQUIPMENT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment consist of the following:</span></span></p>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 90%;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 66.9241%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9691%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9292%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">119,062</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">119,062</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">27,967</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">24,225</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">91,095</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">94,837</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation expense for the three months ended March 31, 2024 was &#8364;3,742 (2023 - &#8364;1,933) and was recorded in depreciation and amortization in the statements of loss and comprehensive loss.</span></span></p>
                        <p style="margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at March 31, 2024 and 2023, the Company&#8217;s property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the three months ended March 31, 2024 and 2023.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.&#160; PROPERTY, PLANT AND EQUIPMENT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment consist of the following:</span></span></p>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">119,062</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">114,325</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">24,225</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,550</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">94,837</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">104,775</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation expense for the year ended December 31, 2023 was &#8364;14,675 (2022 - &#8364;9,550) and was recorded in depreciation and amortization in the statements of loss and comprehensive loss.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023 and 2022, the Company&#8217;s property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the periods ended December 31, 2023 and 2022.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003097650800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">INVESTMENTS [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.<span style="display: inline-block; width: 20pt;">&#160;</span>INVESTMENTS</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023, the Company's investments consist of common shares and warrants to purchase additional common shares in an early-stage European cannabis company. The Company purchased common shares from the investee during 2021 for Euro 2.0 million ($2.4 million) and purchased its first tranche of warrants from existing investors in exchange for 11,250 common shares of the Company, and obtained a second tranche of warrants from the investee as an inducement to exercise some of the first tranche of warrants. As at December 31, 2023, the Company owns approximately 9.6% of the investee, or approximately 9% on a diluted basis including exercisable warrants of the Company and other investors.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The warrants allowed the holder to purchase one common share of the investee for CAD 0.30 ($0.22) for the first tranche, and CAD 1.00 ($0.74) for the second tranche. The Company did not exercise the warrants and they expired on February 1, 2023.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's cost of the investments was recorded based on the fair value of the consideration exchanged as at the respective transaction dates. The investee is not a publicly listed entity and has no active quoted prices for its common shares or warrants. The Company has elected the measurement alternative to record the common share investment at cost and test for impairment. The investment had impairment indicators during 2022 and 2023, and impairments were recorded as indicated in the table below. The Company also considers observable transactions of the common shares for indicators of fair value but there have been none. Cumulative impairment related to the common shares was $2.9 million and the net carrying value was $nil at December 31, 2023.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">When impairment indicators were present, the investee common shares were valued considering price to book value and price to tangible book value of the investee (3.6 and 4.8, respectively) as well as comparable guideline publicly traded companies at the time of initial investment. These initial investment multiples were compared to the guideline public company multiples observed as at December 31, 2023 (negligible or nil price to book and price to tangible values), with these updated valuation multiples applied to the investee's estimated book value. The Company also considered the status of the investee's milestones since the purchase date, as well as recent transactions in the European cannabis market for indicators of change in value. The impairment valuation model for the common shares uses Level 3 inputs of the fair value hierarchy.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A schedule of the Company's investments activity is as follows:</span></span></p>
                                <div>

                                </div>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Financial asset hierarchy level</span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Investee common<br/>shares</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Warrants CAD 0.30<br/>exercise price</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Warrants CAD 1.00<br/>exercise price</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total</span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2021</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,987</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">625</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">58</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,670</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,257</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,257</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on changes in fair value</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(591</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(58</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(649</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2022</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">730</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">34</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">764</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(730</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(730</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on changes in fair value</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(34</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(34</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2023</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The impairment of common shares and loss on changes in fair value appear in the unrealized loss on fair value of investments caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The value of the investee common shares appears in the investment line on the consolidated statement of financial position. The value of the warrants appeared in current assets within the prepaid expenses and other accrued assets line on the consolidated statement of financial position.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As a sensitivity assessment to the fair value calculations, a 10% change in the valuation multiples applied to the investee common shares results in a 10% change in the fair value as at December 31, 2023 of less than $0.1 million.</span></span></p>
                            </div>
                        </div>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org//325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002950616288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ASSET ACQUISITIONS AND BUSINESS COMBINATIONS [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10.<span style="display: inline-block; width: 15pt;">&#160;</span>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS</b></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Original Hemp asset acquisition</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On March 1, 2023, the Company completed its acquisition of all the assets operating under the brand "Original Hemp". The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining Original Hemp did not meet the definition of a business as it did not have inputs, processes, and outputs in place that constituted a business under Topic 805. As a result, the transaction has been accounted for as an asset acquisition whereby all of the assets acquired and liabilities assumed are assigned a carrying amount based on relative fair values. Total purchase consideration was $0.3 million and will consist of paying a portion of net profits not to exceed $0.6 million. The assets acquired included $0.1 million of Inventory and $0.2 million of customer relationships.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Since the acquisition date through December 31, 2023, Original Hemp revenue was $0.2 million with net income and comprehensive income of $0.1 million.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company was not able to obtain reliable financial records for the period from January 1, 2023 through the acquisition date, March 1, 2023. </span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Franchise Global Health Inc. ("FGH") business combination</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 23, 2022, the Company completed its acquisition of all the issued and outstanding common shares (the "Franchise Common Shares") of FGH, a corporation existing under the laws of the Province of British Columbia, by way of a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). FGH, through its wholly owned subsidiaries, is a multi-national operator in the medical cannabis and pharmaceutical industry with principal operations in Germany. The Company acquired FGH to expand its product offerings, accelerate its revenue growth, expand its customer and distribution capabilities in Germany and to improve synergies and cost savings.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pursuant to the Arrangement Agreement, at completion of the Arrangement, Flora acquired the Franchise Common Shares in exchange for 2,176,297 of Flora's common shares, no par value (the "Flora Shares"), for total purchase consideration of $9.8 million. The issuance of the Flora Shares in exchange for the Franchise Common Shares was, subject to applicable securities laws, exempt from the registration requirements of (i) the Securities Act of 1933, as amended, pursuant to the exemption provided by Section 3(a)(10) thereof and (ii) applicable U.S. state securities laws. Notwithstanding the foregoing, in accordance with the terms set forth in the Arrangement Agreement, all Flora Shares delivered to the former shareholders of FGH bear a restrictive legend and may not be sold for a period of ninety (90) days following the closing of the Arrangement.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">730</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,271</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,019</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Indemnity receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,415</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prepaid assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">139</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant, and equipment</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">452</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right of use assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">115</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,102</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,716</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">18,959</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,245</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(98</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current portion of debt</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,062</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Long term lease liability</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(21</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,717</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(9,143</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,816</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As part of the acquisition terms, Clifford Starke, the Company's current Chief Executive Officer and a Director and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $5.0 million. A total of $3.4 million of liabilities were recognized in the trade payables and accrued liabilities of FGH on the date of acquisition that were subject to this indemnification obligation. The Company believes it will be fully indemnified by the current CEO of Flora, and, as such, has recorded $3.4 million of indemnification receivables. The indemnified losses include:</span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.<span style="display: inline-block; width: 10.5pt;">&#160;</span>any losses that are related to the ownership or the operation of FGH and its Canadian subsidiaries, in each case prior to the closing of the Arrangement, that are unknown to the Company and that: (i) have not been disclosed or accounted for in FGH filings; or (ii) have not been disclosed in the FGH Disclosure Letter, in each case as at the date of the Arrangement Agreement;</span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.<span style="display: inline-block; width: 10.5pt;">&#160;</span>any losses that may arise from amounts owed or that may become owed to certain persons or in respect of certain matters identified in the indemnity agreement, as amended; and</span></span></p>
                        <p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3.<span style="display: inline-block; width: 10.5pt;">&#160;</span>any fraud, intentional misrepresentation, willful breach, or willful misconduct on the part of FGH or any other entity identified in the indemnity agreement of any of the foregoing in connection with the indemnity agreement or the Arrangement Agreement.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The intangible assets of $6.1 million are comprised of the following categories and estimated useful lives: supplier relationships of $2.4 million for five years, customer relationships of $2.3 million for five years, and licenses of $1.4 million for five years. The Company does not expect the goodwill and intangible asset values to be deductible for Canadian income tax purposes. The goodwill is assigned to the commercial and wholesale segment.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">If FGH was acquired at January 1, 2022, the combined revenue and net loss of FGH and the Company would have increased approximately $40.3 million and $19.0 million, respectively (unaudited).</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company incurred acquisition related costs of $0.3 million which were expensed as incurred in professional fees on the consolidated statements of loss and comprehensive loss.</span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Just Brands LLC and High Roller Private Label LLC (collectively "JustCBD") business combination</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On February 24, 2022, Flora Growth U.S. Holdings Corp., a wholly owned subsidiary of the Company, completed the acquisition of 100% of the outstanding equity interests in each of (i) Just Brands LLC and (ii) High Roller Private Label LLC for total purchase consideration of $37.0 million. JustCBD is a manufacturer and distributor of consumable cannabinoid products, including gummies, tinctures, vape cartridges, and creams. JustCBD is based in Florida in the United States and was formed in 2017. The Company acquired JustCBD to expand its product offerings, accelerate its revenue growth, expand its customer and distribution capabilities in the United States and for the acquisition of human capital through JustCBD's management team.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The purchase consideration was comprised of (i) $16.0 million of cash, less $0.2 million returned to the Company in August 2022 due to final calculated closing working capital falling short of the target working capital, (ii) 475,000 common shares of the Company valued at $14.7 million, inclusive of a 15% fair value discount for the required six-month holding period of the shares, and (iii) $4.0 million of contingent purchase consideration. The contingent purchase consideration is based on a clause in the purchase agreement that provides that if at any time during the 24 months following the acquisition date, the five-day volume weighted average price ("VWAP") per share of the Company's common shares as quoted on the Nasdaq Capital Market fails to equal or exceed $100.00, then the Company shall issue a number of additional common shares to the sellers equal to the difference between (x) a fraction, the numerator of which is $47.5 million and the denominator of which is the highest five day VWAP at any point during the 24 months following the closing and (y) the 475,000 common shares delivered to the sellers at the closing. In no event shall the Company be required to issue more than 182,500 common shares unless, if required by applicable law, it shall have obtained the consent of the Company's shareholders to do so. In the event the Company is required to deliver in excess of 182,500 shares to the sellers ("Excess Shares") and the Company shall not have obtained shareholder consent, if required, the Company may deliver cash to the sellers in lieu of such Excess Shares determined by a formula set forth in the purchase agreement. The contingent purchase consideration was classified as a financial liability within the contingent purchase considerations line on the statement of financial position as the Company may be required to settle any amounts due in cash instead of common shares if the Company's common shareholders do not provide requisite shareholder approval to issue additional common shares. It is now included in the current portion of contingent purchase consideration&#160;line on the statement of financial position as the settlement date is within the next 12 months.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of the contingent purchase consideration at February 24, 2022 was determined using a Monte Carlo simulation incorporating Brownian motion with 100,000 trials through a binomial model. The significant inputs to the valuation included the two-year time period, the Company's closing share price at February 24, 2022 ($36.40), estimated Company common share volatility (100%), and risk-free rate of 1.5% to discount the ending result to present value.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of the contingent purchase consideration at December 31, 2023 was determined using a simplified calculation because the end of the 24 month period after the acquisition date is within two months after the reporting date. The calculation took the expected shares to be issued (632,484) multiplied by the Company's closing share price at December 31, 2023 ($1.35). The Company determined that the balance of this contingent consideration at December 31, 2023 was $0.9 million, with the $1.8 million decrease in the balance from December 31, 2022 recorded in the unrealized (gain) loss from changes in fair value caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:</span></span></p>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">535</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">975</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,534</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">540</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant, and equipment</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">536</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                                <p style="margin-top: 0pt; margin-bottom: 10pt; font-family: Times New Roman,Times,serif; text-align: left;">&#160;</p>
                                <div>

                                </div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right of use assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">772</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other non-current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">127</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible asset</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,533</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">24,898</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">38,450</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2,273</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current lease liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(644</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provision for sales tax</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(982</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(24</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other current liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(99</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(4,022</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">34,428</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of the trade receivables reflects a $0.3 million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. Since the acquisition date through December 31, 2022, JustCBD revenue was $26.4 million with net loss and comprehensive loss of $6.5 million. The acquired provision for sales tax is discussed at Note 19 below.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The intangible assets of $4.5 million are comprised of the following categories and estimated useful lives: tradenames of $3.1 million for eight to nine years, customer relationships of $1.2 million for five to seven years, and know-how of $0.2 million for three years. The Company expects the goodwill and intangible asset values to be deductible for United States income tax purposes. The goodwill is assigned to the house of brands segment.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">If JustCBD was acquired at January 1, 2022, the combined revenue and net loss of JustCBD and the Company would have increased approximately $5.2 million and $1.6 million, respectively (unaudited).</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company incurred acquisition related costs of $0.6 million which were expensed as incurred in professional fees on the consolidated statements of loss and comprehensive loss.</span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>No Cap Hemp Co. ("No Cap") business combination</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 20, 2022, Just Brands LLC., a wholly owned subsidiary of the Company, acquired certain assets, assumed certain liabilities, retained certain employees and processes (together the "purchased assets") of No Cap for total purchase consideration of $0.9 million. No Cap is a manufacturer and distributor of high quality and affordable CBD products. No Cap is based in Florida in the United States and was formed in 2017. Just Brands LLC acquired No Cap to expand its product offerings and accelerate its revenue growth.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As consideration for the purchased assets of No Cap, Just Brands LLC will pay an amount equal to 10% of the sales of No Cap until such a time that Just Brands LLC will have paid a total of $2.0 million. Also on July 20, 2022, Just Brands LLC advanced $0.2 million to the former owners of No Cap. This $0.2 million will be settled prior to and in the same manner as the consideration for the purchased assets. As these entire amounts are considered contingent consideration, it was valued using discounted cash flow models utilizing two different rates, high and low. The significant inputs to the original valuation included the estimated nine-year time period to accumulate the $2.0 million maximum payment and discount rates of 23.5%, high, and 14.3%, low, to estimate the present value of the future cash outflows. The resulting acquisition date fair value of $0.9 million contingent purchase consideration is classified within the contingent purchase considerations line on the statement of financial position.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company plans to discontinue the No Cap brand during fiscal 2024. As such, the Company determined that the balance of this contingent consideration at December 31, 2023 was $nil, with the $0.9 million decrease in the balance from December 31, 2022 recorded in the unrealized (gain) loss from changes in fair value caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:</span></span></p>
                        <div>

                        </div>

                            <table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; border-top: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">725</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">417</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,173</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(272</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(272</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">901</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of the trade receivables reflects a $0.2 million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. Since the acquisition date through December 31, 2022, No Cap revenue was $0.6 million with net income and comprehensive loss of $0.1 million.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company expects the goodwill to be deductible for Unites States income tax purposes. The goodwill is assigned to the house of brands segment.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">If No Cap was acquired at January 1, 2022, the combined revenue of No Cap and the Company would have increased approximately $1.9 million, and the combined net loss would have decreased by $1.0 million (unaudited). </span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Acquisition of Minority interests</i></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On January 18, 2022, the Company acquired the remaining 13% of the outstanding equity interests in Flora Beauty LLC from its minority shareholder in exchange for 5,000 common shares of the Company and a stock option exercisable for up to 2,500 common shares of the Company at an exercise price of $34.00 per share that expire five years from the date of the grant. The Company dissolved Flora Beauty LLC during the year ended December 31, 2023. See Note 2.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On January 31, 2022, the Company completed its acquisition of Flora Med S.A.S by acquiring the remaining 10% of the equity interests in Flora Med S.A.S. from its minority shareholders in exchange for 1,514 common shares of the Company. The Company sold Flora Med S.A.S. as part of the Share Purchase Agreement with Lisan on July 5, 2023. See Note 5.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953408832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL [Text Block]</a></td>
<td class="text">
                <p style="font-size: 10pt; font-family: Times New Roman; margin: 0pt 0px 0px 0in; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.</b><span style="display: inline-block; width: 20pt;">&#160;</span><b>INTANGIBLE ASSETS AND GOODWILL </b></span></span></p>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A continuity of intangible assets for the three months ended March 31, 2024 is as follows:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 8pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; width: 311px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Patents</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Total</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Cost</b></span></span></span></span></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At December 31, 2023</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,892</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,098</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>2,990</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Additions</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>-</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>-</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>-</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At March 31, 2024</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,892</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,098</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>2,990</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Accumulated Amortization</b></span></span></span></span></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At December 31, 2023</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,132</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>912</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>2,044</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Additions</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>31</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>7</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>38</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At March 31, 2024</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,163</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>919</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>2,082</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Net book value at March 31, 2024</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>729</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>179</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>908</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="background-color: #ffffff;">Amortization expense for the three months ended March 31, 2024 was less than $</span><span id="xbrl_20240530114158815">0.1</span><span style="background-color: #ffffff;"> million (March 31, 2023 - </span>$0.8)<span style="background-color: #ffffff;"> and was recorded in depreciation and amortization in the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At March 31, 2024, the weighted average amortization period remaining for intangible assets was 6.0 years.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At March 31, 2024, the estimated future amortization expense related to intangible assets is as follows:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 30%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">115</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">152</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">152</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">152</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">152</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">185</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">908</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                </tr>
                            </table>

                    </div>
                </div>
            <span></span>
</td>
<td class="text">
                <div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11.<span style="display: inline-block; width: 15pt;">&#160;</span></b><b>INTANGIBLE ASSETS AND GOODWILL </b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A continuity of intangible assets for the years ended December 31, 2023 and 2022 is as follows:</span></span></p>

                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>In Thousands of United States dollars</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>License</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Customer<br/>Relationships</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Patents</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Non-<br/>Compete<br/>Agreements</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Goodwill</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Total</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Cost</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2021</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">200</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,570</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">2,090</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">4,300</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,190</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">29,025</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Acquired through business combinations</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,397</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">5,945</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">3,063</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">230</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">29,031</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">39,666</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(128</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(25,073</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(25,201</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2022</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,469</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">7,515</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">5,153</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">4,530</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,190</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">23,633</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">43,490</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Accumulated Amortization</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2021</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">6</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">26</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">35</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">48</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">66</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">181</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Additions</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">66</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">322</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">583</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">573</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">397</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,941</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2022</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">72</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">348</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">618</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">621</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">463</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">2,122</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Foreign Currency translation</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">5</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">17</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(18</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(261</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(257</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Net book value at December 31, 2022</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>1,402</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>7,184</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>4,517</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>3,909</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>727</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>23,372</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>41,111</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                    <div>
                                        <p style="margin: 0pt;">&#160;</p>
                                        <div>

                                        </div>
                                    </div>
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>In Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>License</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Customer and<br/>Supplier<br/>Relationships</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Patents</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Non-<br/>Compete<br/>Agreements</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Goodwill</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Cost</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,469</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>7,515</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>5,153</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>4,530</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,190</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>23,633</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>43,490</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Additions</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>194</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>194</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Impairment</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(1,216</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(6,502</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(3,249</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(3,432</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(529</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(23,372</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(38,300</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2023</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>253</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,207</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234502607">1,904</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,098</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>661</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>261</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234536599">5,384</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Accumulated Amortization</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>72</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>348</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>618</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>621</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>463</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2,122</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Additions</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>200</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>916</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>514</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>291</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>198</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2,119</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2023</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>272</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,264</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,132</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>912</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>661</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234621352">4,241</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Foreign Currency translation</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>19</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>57</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(12</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(261</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(197</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Net book value at December 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>760</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>186</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>946</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>

                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's intangible asset additions in 2022 primarily consist of assets acquired as part of the February 2022 purchase of JustCBD and the December 2022 purchase of FGH (Note 10). Information regarding the significant JustCBD intangible assets within the indicated categories of the table above is as follows as at December 31, 2023:</span></span></p>
                            <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt;">
                                <tr>
                                    <td style="width: 4%; vertical-align: middle;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                    </td>
                                    <td style="width: 4%; vertical-align: top;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8226;</span></span></td>
                                    <td style="vertical-align: top;">
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Tradenames: carrying amount $0.5 million with 74 months of remaining amortization periods</span></span></p>
                                    </td>
                                </tr>
                            </table>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's intangible asset additions in 2023 primarily consist of customer relationships acquired as part of the March 2023 purchase of Original Hemp (Note 10). These customer relationships were fully impaired and their carrying amount at December 31, 2023 was $nil.</span></span></p>
                            <div>
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The gross cost of the intangible assets is amortized over their estimated useful lives, as the Company does not expect the assets to have significant residual value for any of the asset classes. The weighted average amortization period at December 31, 2023 by asset class subject to amortization is as follows:</span></span></p>

                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trademarks and brands <span style="display: inline-block; width: 42.5pt;">&#160;</span>
                                                        6.1 years
                                                    </span></span></p>
                                            <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Patents <span style="display: inline-block; width: 107.31pt;">&#160;</span>
                                                        6.8 years
                                                    </span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total <span style="display: inline-block; width: 114.99pt;">&#160;</span>
                                                        6.2&#160;years
                                                    </span></span></p>
                                        </div>

                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain trademarks have renewal or extension terms available, with a weighted average of 6.1 years remaining before the next renewal or extension is due at December 31, 2023. The Company expenses such costs as incurred. The Company's trademarks and brands are registered to protect the assets from use by others, and cash flows of the related reporting units and asset groups could be negatively impact if the Company did not successfully renew them.</span></span></p>
                                </div>
                            </div>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At December 31, 2023, the estimated aggregate amortization expense for each of the next five years is as follows:</span></span></p>
                            <div>

                            </div>

                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 20%; border-collapse: collapse; font-size: 10pt;">
                                        <tr>
                                            <td colspan="2" style="text-align: left; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                            <td style="width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                            <td style="width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                    </table>
                                </div>

                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's goodwill is assigned to the following reporting units for the years ended December 31, 2022 and 2023:</span></span></p>

                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Vessel </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>JustCBD </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>FGH </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross goodwill recorded prior to December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment recorded prior to December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net book value as at December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Acquired through business combinations</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">25,315</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,716</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29,031</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(19,675</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(5,398</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(25,073</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign exchange impacts</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(277</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">16</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(261</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net book value as at December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,640</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,732</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,372</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(19,640</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3,732</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(23,372</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net book value as at December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>

                        </div>
                    </div>
                </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960756896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT OF ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ImpairmentOfAssetsAbstract', window );"><strong>Impairment Of Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesTextBlock', window );">IMPAIRMENT OF ASSETS [Text Block]</a></td>
<td class="text">
                <div>
                    <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8.<span style="display: inline-block; width: 20pt;">&#160;</span>ASSET IMPAIRMENT</b></span></span></p>
                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As discussed in Note 14, on May 7, 2024, Just Brands agreed to a settlement and general release, whereby Just Brands will remove the products subject to the stop sales orders from the state of Florida and accept a five-year revocation of its food permit in the state of Florida. As a result of this settlement, the Company began negotiations to exit its current warehouse lease in Pompano Beach, FL, and searching for a new warehousing facility in a different state. The Company considered this to be an indicator of impairment and, thus, performed a quantitative analysis as of March 31, 2024 to determine if impairment existed by comparing the carrying amount of the operating lease right of use asset and related leasehold improvements to the future undiscounted cash flows the asset is expected to generate over its remaining life. This analysis indicated the asset values may not be recoverable. The Company then calculated the fair value of this asset using an income approach. As a result, the Company recorded an impairment of operating lease right of use assets and property, plant and equipment within its Vessel asset group within the house of brands segment totaling $0.9 million. These charges were recorded in the asset impairment caption on the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></p>
                </div>
            <span></span>
</td>
<td class="text">
                <div>
                    <div>
                        <div>
                            <div>
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>12.</b></span></span><span style="padding-left: 15pt;">&#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>IMPAIRMENT OF ASSETS</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company tests its goodwill for impairment as part of its annual fourth quarter impairment test, and at interim periods when impairment indicators exist. For the year ended December 31, 2023, the Company tested its goodwill for impairment at June 30, 2023 and&#160;</span></span><span style="font-size: 10pt; font-family: Times New Roman, Times, serif;">December 31, 2023</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"> due to indicators such as a decline in the value of the Company's publicly traded common shares, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. In addition, the Company assessed its other long-lived assets for impairment at this time. The Company's goodwill was assigned to the reporting units associated with the original acquisition of those operations. Management determined the Company's reporting units for 2023 impairment testing are its reportable segments shown in Note 24, but with the house of brands segment broken down into separate reporting units for the Company's JustCBD and Vessel product groups of assets.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company may consider the results of both an income approach (discounted cash flows) and market approach (guideline public companies) when determining the recoverable amount of its reporting units. For the income approach, the significant assumptions used in the calculation of the recoverable amounts of the reporting units include forecasted revenue, expenses and net cash flows, terminal period cash flows and growth rates, and the weighted average cost of capital used as the discount rate. These assumptions are considered Level 3 inputs in the fair value hierarchy. The assumptions consider historical and projected data from internal sources as well as external industry trends and expectations. For the market approach, the significant assumptions include identifying and calibrating relevant guideline public companies, and determining the financial metric to measure against. The results of the two approaches are considered, and judgment is applied in weighting each approach to determine the recoverable amount of the reporting unit.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For long-lived assets other than goodwill, which show impairment indicators are present, the Company compares its expected undiscounted future cash flows to the carrying value of the asset group. If the undiscounted future cash flows are less than the carrying value of the assets, then the fair value of the asset group is calculated using an income or market approach as discussed in the prior paragraph. The significant assumptions used in calculating the undiscounted future cash flows include determining the primary asset of the asset group which sets the length of time to project the cash flows, and the forecasted revenue, expenses and net cash flows relating to the asset group.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023 Annual Impairment Test</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company concluded that the carrying values of its JustCBD and FGH reporting units were higher than their respective estimated fair values, and a goodwill impairment loss totaling $23.4 million was recognized in the year ended December 31, 2023, with details of these impairment tests discussed below. The goodwill impairment loss was comprised of (i) $19.6 million related to the JustCBD reporting unit, representing the entirety of the goodwill assigned to the JustCBD reporting unit, part of the house of brands segment; and (ii) $3.7 million related to the FGH reporting unit, part of the commercial and wholesale segment. See Note 24 for discussion of the Company's segments. Certain negative trends, including slower growth rates, resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation for the JustCBD and FGH reporting units.</span></span></p>
                                    <div>
                                        <div>

                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023 Annual Goodwill Impairment Test of FGH</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At June 30, 2023, the Company's FGH reporting unit had external indicators of impairment primarily due to the Company's declining share price, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. As such, the Company tested the FGH reporting unit for impairment as at June 30, 2023 and determined that the carrying value of the reporting unit's assets exceeded the recoverable amount, resulting in goodwill impairment of $3.7 million recorded in the first half of fiscal 2023. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">FGH's June 30, 2023 carrying value of $7.7 million was comprised primarily of goodwill and identified intangible assets of $5.2 million and other long-lived assets of $0.5 million. The carrying value is reduced by inseparable market participant liabilities associated with the December 2022 acquisition of FGH which includes $0.1 million of lease liability. The estimated recoverable amount of FGH at June 30, 2023 was $1.5 million, resulting in goodwill impairment of the remaining $3.7 million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                The reporting unit's fair value was determined based on an income approach discounted cash flow model. After working capital adjustments, the resulting fair value was estimated at $1.5 million. The income approach used a discount rate of 17%, operating margins of about 2%, working capital requirements of 6% revenue, and a terminal period growth rate of 2%. The revenue growth rates start at 5% in 2023 and trend down to 2% in 2028 and thereafter. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            </span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After the impairment recorded at June 30, 2023, FGH's carrying value was equal to its recoverable amount. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $0.3 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023 Annual Goodwill Impairment Test of JustCBD</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At June 30, 2023 and December 31, 2023, the Company&#8217;s JustCBD reporting unit had external indicators of impairment primarily due to the Company's declining share price, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. As such, the Company tested the JustCBD reporting unit for impairment as at June 30, 2023 and December 31, 2023 and determined that the carrying value of the reporting unit&#8217;s assets exceeded the recoverable amount, resulting in goodwill impairment of $19.6 million recorded in 2023. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD&#8217;s June 30, 2023 and December 31, 2023 carrying values of $23.8 and $7.0 million, respectively, were comprised primarily of goodwill and identified intangible assets of $20.8 million and $3.5 million and other long-lived assets of $1.2 million and $0.7 million. The carrying value is reduced by inseparable market participant liabilities associated with the February 2022 acquisition of JustCBD which includes $1.6 million and $0.4 million of lease liability. The estimated recoverable amount of JustCBD at June 30, 2023 and December 31, 2023 was $7.1 million and $nil, respectively, resulting in goodwill impairment of $19.6 million for the year ended December 31, 2023 as the carrying value of the reporting unit&#8217;s assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                The reporting unit&#8217;s fair value at June 30, 2023 and December 31, 2023 was determined based on an income approach discounted cash flow. After working capital adjustments, the resulting fair value was estimated at $7.1 million and $nil. The income approach used a weighted average discount rate of 28%, operating margins from 8.5% to -19.7%, weighted average working capital requirements of 1% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 17% in 2023 and taper down to 3% in 2025 and thereafter.  The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            </span></span></p>
                                    <div>
                                        <div>

                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 1pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After the impairment recorded for the year ended December 31, 2023, JustCBD&#8217;s carrying value was equal to its recoverable amount. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a decrease of the reporting unit fair value of approximately $1.5 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023 Other Long-Lived Asset Impairment Tests</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For asset groups that had indicators of impairment, the Company performed a quantitative analysis as of June 30, 2023 to determine if impairment existed by comparing the carrying amount of each asset group to the future undiscounted cash flows the asset group is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of property, plant and equipment, operating lease right of use assets, customer relationships, trademarks, patents and non-compete agreements within its Vessel asset group within the house of brands segment totaling $7.4 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at 10.7% in 2023 and tapering down to 3% thereafter, weighted average royalty rate of 1%, weighted average discount rate of 17% and a customer attrition rate of 18%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. Likewise, the Company recorded an impairment of supplier relationships, customer relationships and licenses within its FGH asset group within the commercial and wholesale segment totaling $3.7 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at -2.6% in 2023, 5% in 2024 and tapering down to 4% thereafter, weighted average discount rate of 20% and customer attrition rate of 10%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.1 million decrease of the recoverable amounts. Finally, the Company recorded an impairment of customer relationships, trademarks and patents within its JustCBD asset group within the house of brands segment totaling $2.3 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at 16.5% in 2023 and tapering down to 3% thereafter, royalty rate of 1.5%, weighted average discount rate of 32.5% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.2 million decrease of the recoverable amounts. These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company performed a similar analysis for its asset groups as of December 31, 2023, and determined that indicators of impairment were present. These include external indicators such as a decline in the value of the Company&#8217;s publicly traded common shares as well as internal indicators such as reduced forecasted revenue and cash flow generation. The Company performed a quantitative analysis as of December 31, 2023 to determine if impairment existed by comparing the carrying amount of each asset group to the future undiscounted cash flows the asset group is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of operating lease right of use assets, supplier relationships and licenses within its FGH asset group within the commercial and wholesale segment totaling $1.4 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at 2.5% in 2024 and tapering down to 2.5% thereafter and a weighted average discount rate of 21%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts.  Likewise, the Company recorded an impairment of operating lease right of use assets, customer relationships and trademarks within its JustCBD asset group within the house of brands segment totaling $1.0 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at -37.5% in 2023 and then increasing to 2.5% thereafter, royalty rate of 1.5%, weighted average discount rate of 25% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2022 Annual Impairment Test</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company concluded that the carrying values of its Vessel and JustCBD reporting units were higher than their respective estimated fair values, and a goodwill impairment loss totaling $25.1 million was recognized in the year ended December 31, 2022, with details of these impairment tests discussed below. The goodwill impairment loss was comprised of (i) $19.7 million related to the Vessel reporting unit, representing the entirety of the goodwill assigned to the Vessel reporting unit, part of the house of brands segment; and (ii) $5.4 million related to the JustCBD reporting unit, part of the house of brands segment. See Note 24 for discussion of the Company's segments. Certain negative trends, including slower growth rates, resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation for the Vessel reporting unit. No impairment was noted for the FGH reporting unit, as the acquisition of FGH occurred close to the end of the year and fair value calculated at the December 23, 2022 acquisition date approximates fair value as at December 31, 2022.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reconciled the sum of its reporting unit recoverable amounts discussed above plus all other net assets to the Company's market capitalization of common shares as December 31, 2022. The Company's recoverable amounts at December 31, 2022 exceeded the market capitalization of its common shares by 98%. The Company believes the 98% excess is due to implied equity control premium and is within an acceptable range of values based on control premiums observed in business combinations within the cannabis and wholesale industries.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022 Annual Goodwill Impairment Test of Vessel</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At June 30, 2022, the Company's Vessel reporting unit had external indicators of impairment primarily due to a decline in comparable public company share prices which would negatively impact the implied valuation of Vessel. As such, the Company tested the Vessel reporting unit for impairment as at June 30, 2022 and determined that the carrying value of the reporting unit's assets exceeded the recoverable amount, resulting in goodwill impairment of $16.0 million recorded in the first half of fiscal 2022. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <div>
                                        <div>

                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vessel's December 31, 2022 carrying value of $11.6 million was comprised primarily of goodwill and identified intangible assets of $11.3 million and other long-lived assets of $1.0 million. The carrying value is reduced by inseparable market participant liabilities associated with the November 2021 acquisition of Vessel which includes $1.1 million of lease liability. The estimated recoverable amount of Vessel at December 31, 2022 was $7.0 million, resulting in goodwill impairment of the remaining $3.7 million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                The reporting unit's fair value was determined based on an income approach discounted cash flow model of $7.6 million (80% weighting) and a market approach guideline public company method of $7.0 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $7.0 million. The income approach used a discount rate of 17%, operating margins from 0% to 18%, working capital requirements of 15% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 14% in 2023 and taper down to 3% in the terminal period after 2030. The market approach considered guideline public companies similar to Vessel considering financial metrics such as historical revenue growth, gross margin and EBITDA profitability and with operations focused on consumer brands and similar sales channels. An enterprise value to latest twelve months revenue multiple of 1.0 was selected based on consideration of the enterprise value to latest twelve months multiples of the guideline companies. The multiple was applied to Vessel's revenue for the twelve months ended December 31, 2022. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            </span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After the impairment recorded at December 31, 2022, Vessel's carrying value was equal to its recoverable amount. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $1.8 million. Reducing the market approach selected revenue multiple by 0.10 from 1.00 above down to 0.90 (approximately 10% change) would result in a decrease of the reporting unit fair value of approximately $0.7 million. However, there would be no impact on the goodwill impairment amount for either of these unfavorable changes in the models as the imputed fair value of the goodwill exceeded its carrying amount by $1.1 million with the goodwill impaired to zero.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022 Annual Goodwill Impairment Test of JustCBD</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD's December 31, 2022 carrying value of $34.4 million was comprised primarily of goodwill and identified intangible assets of $29.0 million and other long-lived assets of $2.0 million. The carrying value is reduced by inseparable market participant liabilities associated with the February 2022 acquisition of JustCBD which includes $1.2 million of lease liability. The estimated recoverable amount of JustCBD at December 31, 2022 was $29.0 million, resulting in goodwill impairment of $5.4 million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                The reporting unit's fair value was determined based on an income approach discounted cash flow model of $28.0 million (80% weighting) and a market approach guideline public company method of $21.9 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $29.0 million. The income approach used a discount rate of 32%, operating margins from 5% to 28%, working capital requirements of 10% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 21% in 2023 and taper down to 3% in the terminal period after 2030. The market approach considered guideline public companies similar to JustCBD considering financial metrics such as historical revenue growth, gross margin and EBITDA profitability and with operations focused on consumer brands and similar sales channels. An enterprise value to latest twelve months revenue multiple of 0.6 was given the most weight in the valuation and was selected based on consideration of the enterprise value to latest twelve months multiples of the guideline companies. The multiple was applied to JustCBD's revenue for the twelve months ended December 31, 2022. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            </span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After the impairment recorded at December 31, 2022, JustCBD's carrying value was equal to its recoverable amount. Any change in the significant assumptions could result in additional impairment of its goodwill as at December 31, 2022. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% from 32% above up to 35% (approximately 9% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.5 million. Reducing the market approach selected revenue multiple by 0.1 from 0.6 above down to 0.5 (approximately 17% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.7 million.</span></span></p>
                                    <div>
                                        <div>

                                        </div>
                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022 Other Long-Lived Asset Impairment Tests</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For asset groups that had indicators of impairment, the Company performed a quantitative analysis as of December 31, 2022 to determine if impairment existed by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of the licenses within the corporate segment totaling $0.1 million. This charge was recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the fourth quarter of 2022, the Company decided to consolidate operations and looked for subtenants for two building leases that have contractual lease obligations through 2026 and 2027. These leases are recorded on the Company's statement of financial position as operating lease right of use assets. The lease assets had indicators of impairment as they were no longer used in the asset groups' operations, but the Company was actively seeking to sublease both spaces to generate income from the spaces. The Company calculated the fair value of the two leases using an income approach on the expected sublease income. The resulting fair values were compared to the operating right of use asset values at December 31, 2022, resulting in an impairment of $0.6 million. The discounted cash flow models assumed the spaces would be subleased within 2023 at 75% to 100% of the Company's cost of the leases, less upfront costs to obtain a sublease tenant. The cash flows were discounted at 8% to 9% which approximates the discount rate in the Company's right of use asset and lease liability calculations. These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ImpairmentOfAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ImpairmentOfAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002954638176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT [Text Block]</a></td>
<td class="text">
                <div>
                    <div>
                        <div>
                            <div>
                                <div>
                                    <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.<span style="display: inline-block; width: 20pt;">&#160;</span>DEBT</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Euro credit facility</b></span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company, through FGH, has credit facilities totaling 4.3&#160;million Euro ($4.6&#160;million USD), at three different banks in Germany. These arrangements are open ended without predetermined maturity dates. Principal and interest payments are due at the end of each term. Interest rates can change with each new amount drawn. As of March 31, 2024, the total outstanding amount on these credit facilities was 2.9 million Euro ($3.1 million USD) with interest rates ranging from 5.45% to 6.44% and due within the next twelve months. These credit facilities were secured by various guarantees, including joint and several guarantees of two managing directors of Phatebo, a subsidiary of FGH, and payment guarantees upon default.</span></span></p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
<td class="text">
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>13.<span style="display: inline-block; width: 15pt;">&#160;</span>DEBT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Euro credit facility</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company, through FGH, has credit facilities totaling 4.0 million Euro ($4.4 million USD), at two different banks in Germany. These arrangements are open ended without predetermined maturity dates. Principal and interest payments are due at the end of each term. Interest rates can change with each new amount drawn. As of December 31, 2023, the total outstanding amount on these credit facilities was 1.8 million Euro ($1.9 million USD) with interest rates ranging from 5.45% to 6.46% and due within the next twelve months. These credit facilities were secured by various guarantees, including joint and several guarantees of two managing directors of Phatebo, a subsidiary of FGH, and payment guarantees upon default.</span></span></p>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.</b>&#160; <b>DEBT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, the &#8364;250,000 (December 31, 2023 - &#8364;250,000) was outstanding under the First Loan.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;450,000, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, &#8364;448,000 (December 31, 2023 &#8211; &#8364;378,000) was outstanding under the Second Loan.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at March 31, 2024, the amount of accrued interest on the First Loan and Second Loan totals &#8364;22,730 (December 31, 2023 &#8211; &#8364;17,339).</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan, including all accrued interest, were forgiven by TruHC Holding.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>7.&#160; DEBT</b></span></span></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, the &#8364;250,000 (December 31, 2022 - &#8364;250,000) was outstanding under the First Loan.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;450,000, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, &#8364;378,000 (December 31, 2022 &#8211; &#8364;65,000) was outstanding under the Second Loan.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023, the amount of accrued interest on the First Loan and Second Loan totals &#8364;17,339 (December 31, 2022 &#8211; &#8364;13,590).</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan, including all accrued interest, were forgiven by TruHC Holding.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002950220352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES [Text Block]</a></td>
<td class="text">
                <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10.<span style="display: inline-block; width: 20pt;">&#160;</span>LEASES</b></span></span></p>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's leases primarily consist of administrative real estate leases in Germany and the United States. Management has determined all the Company's leases are operating leases through March 31, 2024. Information regarding the Company's leases is as follows:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended March</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><b>31, 2024 </b></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">Three months</span></span><br/><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">ended March 31,</span></span> </span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">2023</span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Components of lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>165</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">316</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Short-term lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>142</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">55</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sublease income</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(84</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>223</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">371</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 1%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 12%; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Information</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating cash flows from operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>345</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">324</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">ROU assets obtained in exchange for new operating lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1,247</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">97</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average remaining lease term in years for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                    3.7
                                                </b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                2.9
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average discount rate for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8.9%</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7.7%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Maturities of operating lease liabilities as of March 31, 2024 are as follows:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating Leases </b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">794</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">766</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">678</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">505</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">322</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">28</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total future lease payments</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,093</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: imputed interest</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(473</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,620</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(803</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total non-current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,817</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Some of the Company's leases contain renewal options to continue the leases for another term equivalent to the original term, which are generally up to five years. The lease liabilities above include renewal terms that management has executed or is reasonably certain of renewing, which only included leases that would have expired in 2024.</span></span></p>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>In April 2024, the Company began leasing 4,184 sq. ft. of office space in Fort Lauderdale, FL, for $8,000 a month, pursuant to a lease agreement that expires in March 2028.</span></span></span></span></p>
                                <div>

                                </div>
                                <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company began subleasing retail space in Miami, Florida to a third party during the third quarter of 2023. The sublease agreement is effective through November 30, 2026 and contains one option to renew for five more years. The Company began subleasing warehousing and office space in Carlsbad, CA to a third party during the fourth quarter of 2023. The sublease is effective through August 31, 2027 and does not contain renewal options.</span></span></p>
                                <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif;"><span style="font-size: 13.3333px;">See Note 8 for discussion of impairment of operating lease right of use assets during the three months ended March 31, 2024.</span></span></p>
                            </div>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
<td class="text">
                <div>
                    <p style="margin: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>14.<span style="display: inline-block; width: 15pt;">&#160;</span>LEASES</b></span></span></p>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's leases primarily consist of administrative real estate leases in Germany and the United States. Management has determined all the Company's leases are operating leases through December 31, 2023. Information regarding the Company's leases is as follows:</span></span></p>

                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Thousands of United States dollars</span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Year ended<br/>December 31, 2023 </b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Year ended<br/>December 31, 2022</span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Components of lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1,211</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>937</span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Short-term lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>324</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>308</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Sublease income</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(71</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1,464</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,245</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Other Information</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating cash outflows from operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1,403</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>859</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU assets obtained in exchange for new operating lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>245</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2,609</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average remaining lease term in years for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>
                                                                    2.7
                                                                </b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                3.5
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average discount rate for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>7.9%</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>7.9%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>
                                </div>

                            <div>
                                <div>

                                </div>
                            </div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Maturities of operating lease liabilities as of December 31, 2023 are as follows:</span></span></p>

                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>Operating Leases </b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2024</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>900</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2025</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>460</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2026</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>374</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2027</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>192</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total future lease payments</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>1,926</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Less: imputed interest</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>(185</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>)</b></span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>1,741</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Less: current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>(799</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>)</b></span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total non-current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>942</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>

                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Most of the Company's leases contain renewal options to continue the leases for another term equivalent to the original term, which are generally up to two years. The lease liabilities above include renewal terms that management has executed or is reasonably certain of renewing, which only included leases that would have expired in 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating lease of warehousing and office space for Vessel Brand Inc. expires August 31, 2027. The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term. At December 31, 2023, the renewal option is not included in the related operating right of use asset recorded. At the end of 2022, the Company decided to move Vessel's operations and to consolidate them with JustCBD's operations in Florida. See Note 11. The Company began subleasing this space to a third party during the fourth quarter of 2023. The sublease is effective through August 31, 2027 and does not contain renewal options.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating lease of retail space in Miami, FL expires November 30, 2026. The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term. At December 31, 2023, the renewal option is not included in the related operating right of use asset recorded. The Company began subleasing this retail space to a third party during the third quarter of 2023. The sublease agreement is effective through November 30, 2026 and contains one option to renew for five more years.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating lease of manufacturing and warehousing for High Roller Private Label LLC expires June 30, 2024. The lease does not contain a renewal option.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company&#8217;s operating lease of warehousing and office space for Just Brands LLC expires April 30, 2024. The lease does not contain a renewal option. In January 2024, the Company began leasing 14,280 sq. ft. of warehousing space in Pompano Beach, FL, for $20,000 a month, pursuant to a lease agreement that expires in February 2029. In March 2024, the Company began leasing 4,184 sq. ft. of office space in Fort Lauderdale, FL, for $8,000 a month, pursuant to a lease agreement that expires in March 2028.</span></span></p>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8.&#160; LEASE</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Company&#8217;s lease consists of an administrative real estate lease in Germany. Management has determined the Company&#8217;s lease is an operating lease through March 31, 2024. Information regarding the Company&#8217;s lease is as follows:</span></span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the Three<br/>Months Ended<br/>March 31, 2024</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the Three </b><br/><b>Months Ended </b><br/><b>March 31, 2023</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Components of lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29,970</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31,516</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29,970</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31,516</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Information</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating cash flows from operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;26,343</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">26,343</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">ROU assets obtained in exchange for new operating lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average remaining lease term in years for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                6.08
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                7.08
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average discount rate for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.77%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.77%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Maturities of operating lease liabilities as of March 31, 2024 are as follows:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating Leases</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">79,030</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">105,373</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">105,373</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">105,373</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">105,373</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">140,497</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total future lease payments</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">641,019</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: imputed interest</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">145,612</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">495,407</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(64,477</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total non-current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">430,930</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operating lease expires on April 30, 2025. The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term. At March 31, 2024, the renewal option is included in the related operating right of use asset recorded because management is reasonably certain of renewing.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8.&#160; LEASE</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>The Company&#8217;s lease consist of an administrative real estate lease in Germany. Management has determined the Company&#8217;s lease is an operating lease through December 31, 2023. Information regarding the Company&#8217;s lease is as follows:</span></span></span></span></span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Year ended<br/>December 31, 2023</b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>For the period from<br/>February 17, 2022 to </b><br/><b>December 31, 2022</b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Components of lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>123,105</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>84,783</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>123,105</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>84,783</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Other Information</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating cash flows from operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>70,249</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU assets obtained in exchange for new operating lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>604,294</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average remaining lease term in years for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                6.33
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                7.33
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average discount rate for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>8.77%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>8.77%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>

                                <div>

                                </div>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Maturities of operating lease liabilities as of December 31, 2023 are as follows:</span></span></span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Operating Leases</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2024</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2025</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2026</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2027</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2028</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thereafter</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>140,497</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total future lease payments</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>667,362</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Less: imputed interest</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(156,698</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>510,664</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Less: current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(63,083</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total non-current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>447,581</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>

                                <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company's operating lease expires on April 30, 2025. The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term. At December 31, 2023, the renewal option is included in the related operating right of use asset recorded because management is reasonably certain of renewing.</span></span></span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//840/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002952377248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL [Text Block]</a></td>
<td class="text">
                <div>
                    <div>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>SHARE CAPITAL &#160;</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Authorized and issued</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company is authorized to issue an unlimited number of common shares, no par value. On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had the following significant common share transactions:</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="text-decoration: underline;"><b>Three months ended March 31, 2024</b></span></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>OTHER ISSUANCES</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On March 8, 2024, the Company entered into a settlement agreement with a third party pursuant to which the Company issued 50,000 common shares of the Company, valued at $0.1 million, to a third party to settle outstanding amounts owed.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">See Note 18 for subsequent issuance of shares.</span></span></p>
                            </div>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
<td class="text">
                <div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>15.<span style="display: inline-block; width: 15pt;">&#160;</span></b><b>SHARE CAPITAL &#160;</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Authorized and issued</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company is authorized to issue an unlimited number of common shares, no par value. On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion below.</span></span></span></p>
                            <div>

                            </div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company had the following significant common share transactions:</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span style="text-decoration: underline;"><b>Year ended December 31, 2023</b></span></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>SEPTEMBER 2023 UNIT OFFERING</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>On September 21, 2023, the Company closed a registered direct offering of 1,369,000 units of the Company at a price of $2.00 per unit for gross proceeds of $2.7 million. Each unit is comprised of one common share of the Company and one common share purchase warrant (1,369,000 total warrants) to purchase one additional common share at an exercise price of $2.50 per warrant share through March 21, 2029. Additionally, the Company amended the exercise price with respect to 61,250 and 624,995 warrants that were previously issued in the November 2021 and December 2022 offerings, respectively, from $8.00 per share to $2.50 per share and recorded a $0.2 million gain on these warrant modifications. There was no increase to the value of the additional paid-in capital as it was offset by a corresponding increase to unit issuance costs. The Company paid $0.3 million in issuance costs relating to the September 2023 unit offering, as well as 54,760 warrants with a fair value of $0.1 million, with an exercise price of $2.39 per share through September 21, 2028, issued to the placement agent. See Note 17.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>REVERSE STOCK SPLIT</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>
                                            On June 7, 2023, the Company filed an amendment to its Articles of Incorporation (the "Reverse Stock Split Articles Amendment") with the Ontario Ministry of Public and Business Service Delivery to effect a reverse stock split of the Company's common shares, no par value per share (the "common shares"), at a ratio of 1-for-20, which became effective at 12:00:01 a.m. Eastern Time on June 9, 2023 (the "Reverse Stock Split").
                                        </span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common shares were automatically combined and reclassified into one issued and outstanding common share. The Reverse Stock Split did not affect any shareholder's ownership percentage of the common shares, alter the par value of the common shares or modify any voting rights or other terms of the common shares. The number of authorized shares of common shares under the Company's Articles remained unchanged. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional interest as a result of the Reverse Stock Split was rounded down to the nearest whole common share.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>All common shares and per share amounts have been restated to give retroactive effect to the share consolidation.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>OTHER ISSUANCES</b></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>On January 31, 2023, the Company entered into a settlement agreement with a third party pursuant to which the Company issued 16,250 common shares of the Company, valued at $0.1 million, to a third party to settle a legal dispute that arose in April 2019. See Note 16.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>On April 12, 2023, Luis Merchan tendered his resignation as both Chairman of the Board of Directors of the Company and as its Chief Executive Officer. On this date, the Company entered into a separation agreement with Mr. Merchan, pursuant to which the Company issued 80,000 common shares of the Company, valued at $0.4 million, on April 26, 2023, and 30,000 common shares of the Company, valued at $0.1 million, on May 14, 2023 to Mr. Merchan.</span></span></span></p>
                        </div>
                    </div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b><span style="text-decoration: underline;">Year ended December 31, 2022</span></b></span></span></span></span></p>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;">&#160;</p>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>DECEMBER 2022 PAYMENT TO FGH OWNERS</b></span></span></span></span></p>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;">&#160;</p>
                    <div>
                        <div><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>As discussed in Note 10, the Company issued 2,176,297 common shares of the Company valued at $9.8 million, inclusive of a 7.5% fair value discount for the required three-month holding period of the shares, to the prior owners of FGH as part of the Company's acquisition of FGH on December 23, 2022.</span></span></span></span></div>
                    </div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>DECEMBER 2022 UNIT OFFERING</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 8, 2022, the Company closed a registered direct offering of 625,000 units of the Company at a price of $8.00 per unit for gross proceeds of $5.0 million. Each unit is comprised of one common share of the Company and one common share purchase warrant (625,000 total warrants) to purchase one additional common share at an exercise price of $8.00 per warrant share through December 8, 2027. Additionally, the Company amended the exercise price with respect to 66,250 warrants that were previously issued in the November 2021 offering (see Note 17) from $75.00 per share to $8.00 per share with no increase to the value of additional paid-in capital as it was offset by a corresponding increase to issuance costs. The Company paid $0.4 million in issuance costs relating to the December 2022 unit offering, as well as 25,000 warrants issued to the placement agent as discussed in Note 17.</span></span></p>
                        </div>
                    </div>
                    <div>

                    </div>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>FEBRUARY 2022 PAYMENT TO JUSTCBD OWNERS</b></span></span></span></span></p>
                    <div>
                        <p style="margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As discussed in Note 10, the Company issued 475,000 common shares of the Company valued at $14.7 million, inclusive of a 15% fair value discount for the required six-month holding period of the shares, to the prior owners of JustCBD as part of the Company's acquisition of JustCBD on February 25, 2022.</span></span></p>
                    </div>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>ACQUISITION OF NONCONTROLLING INTERESTS</b></span></span></span></span></span></span></p>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0pt 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">On January 18, 2022, the Company issued 5,000 common shares of the Company valued at $0.2 million to acquire the remaining 13% of the outstanding equity interests in Flora Beauty LLC from its minority shareholders. In addition to the common shares, the Company granted a stock option, exercisable for up to 2,500 common shares of the Company at an exercise price of $34.00 per share that expire five years from the date of the grant.&#160;</span></span></span></span>The Company dissolved Flora Beauty LLC during the year ended December 31, 2023. See Note 2.</span></span></p>
                    <div>
                        <p style="margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On January 31, 2022, the Company issued 1,514 common shares of the Company valued at $0.1 million to complete its acquisition of Flora Med S.A.S. by acquiring the remaining 10% of the equity interests in Flora Med S.A.S. from its minority shareholders. The Company sold Flora Med S.A.S. during the year ended December 31, 2023. See Note 2.</span></span></p>
                    </div>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>OTHER ISSUANCES</b></span></span></span></span></p>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In January 2022, the Company amended an agreement with a consultant pursuant to which the Company issued 5,555 common shares of the Company valued at $0.2 million and a stock option, exercisable for up to 4,166 common shares of the Company at an exercise price of $45.00 per share that expire five years from the date of the grant.</span></span></p>
                    <div>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 5, 2022, the Company issued 35,000 common shares of the Company valued at $1.3 million as part of a settlement agreement with Boustead Securities, LLC ("Boustead") to resolve certain disputes arising under a prior underwriting agreement and engagement letter. In addition to the common shares, the Company paid Boustead $0.4 million.</span></span></p>
                    </div>
                    <div>
                        <p style="margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>SHARE REPURCHASE</b></span></span></p>
                        <p style="margin-top: 0pt; margin-bottom: 10pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company repurchased 18,411 common shares for $0.3 million during the year ended December 31, 2022.</span></span></p>
                        <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Any future repurchases will depend on factors such as market conditions, share price and other opportunities to invest capital for growth. From time to time when management does not possess material nonpublic information about the Company or its securities, the Company may enter a pre-defined plan with a broker to allow for the repurchase of shares at times when the Company ordinarily would not be active in the market due to internal trading blackout periods, insider trading rules or otherwise. Any such plans entered with our broker will be adopted in accordance with applicable securities laws such as the requirements of Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended. </span></span></p>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL [Text Block]</a></td>
<td class="text">
                    <div style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>12.&#160; SHARE CAPITAL </b></span></span>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Authorized and issued</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company is authorized to issue an unlimited number of common shares, no par value.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On incorporation, the Company issued 25,000 shares to TruHC Holding GmbH at a par value of &#8364;1.00 per share. As at March 31, 2024, nil (December 31, 2022 - &#8364;12,500) remains receivable as been netted against the share capital balance.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>13.&#160; SHARE CAPITAL</b> </span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Authorized and issued</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company is authorized to issue an unlimited number of common shares, no par value.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On incorporation, the Company issued 25,000 shares to TruHC Holding GmbH at a par value of &#8364;1.00 per share. As at December 31, 2023, &#8364;12,500 (December 31, 2022 - &#8364;12,500) remains receivable as been netted against the share capital balance.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003068722256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE BASED COMPENSATION [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>12.</b><span style="display: inline-block; width: 15.5pt;">&#160;</span><b>SHARE BASED COMPENSATION</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's 2022 Incentive Compensation Plan (the "2022 Plan") and its previous "'rolling" stock option plan (the "Prior Plan") are described in the Company's 2023 Form 10-K.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>OPTIONS</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options granted under the Prior Plan are non-transferable and non-assignable and may be granted for a term not exceeding five years. Under the 2022 Plan, stock options may be granted with a term of up to ten years and in the case of all stock options, the exercise price may not be less than 100% of the fair market value of a Common Share on the date the award is granted. Stock option vesting terms are subject to the discretion of the Compensation Committee of the Company's Board of Directors. Common shares are newly issued from available authorized shares upon exercise of awards. The Company no longer makes new grants of stock options under the Prior Plan.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Information relating to share options outstanding and exercisable as at March 31, 2024 and December 31, 2023 is as follows:</span></span></p>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Options Outstanding</b></span></span></td>
                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Number of</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>options (in</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>thousands)</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>average</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>exercise</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted average</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>remaining life</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>(years)</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Aggregate</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>intrinsic</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>value</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Outstanding balance, December 31, 2023</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">49</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">27.04</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            2.8
                                                        </span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Forfeited</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(11</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">44.03</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            2.0
                                                        </span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Outstanding balance, March 31, 2024</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>38</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>22.25</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                                2.7
                                                            </b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Exercisable balance, March 31, 2024</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>38</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>22.25</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                                2.7
                                                            </b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total expense related to the options granted in the three months ended March 31, 2024 was less than $0.1 million (2023 total expense - $0.1 million). This expense is included in the share-based compensation line on the unaudited condensed interim consolidated statements of loss and comprehensive loss. Generally, the options granted in 2023 vest one to two years following the date of grant provided that the recipient is still employed or engaged by the Company.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At March 31, 2024 the total remaining stock option cost for nonvested awards is $nil.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>RESTRICTED STOCK AWARDS</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted stock is a grant of common shares which may not be sold or disposed of, and which is subject to such risks of forfeiture and other restrictions as the Committee, in its discretion, may impose. A participant granted restricted stock generally has all of the rights of a shareholder of the Company, unless otherwise determined by the Committee. Subject to certain exceptions, the vesting of restricted stock awards is subject to the holder's continued employment or engagement through the applicable vesting date. Unvested restricted stock awards will be forfeited if the holder's employment or engagement ceases during the vesting period and may, in certain circumstances, be accelerated. The Company values restricted stock awards based on the closing share price of the Company's common shares as of the date of grant. The fair value of the restricted stock award is recorded as expense over the vesting period.</span></span></p>
                                <div>
                                    <div>

                                    </div>
                                </div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Information relating to restricted stock awards outstanding as at March 31, 2024 and December 31, 2023:</span></span></p>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Number of</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>restricted stock</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>awards</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted</b></span></span></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>average grant</b></span></span></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>date fair value</b></span></span></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2023</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">391</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.41</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(363</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(0.76</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(4</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6.90</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10.24</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total expense related to the restricted stock awards in the three months ended March 31, 2024 was less than $0.1 million ($0.5 million in the three months ended March 31, 2023). This expense is included in the share based compensation line on the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The outstanding restricted stock awards vest over the next two years provided the award holder is still employed or engaged by the Company. As of March 31, 2024, the Company had $0.1 million of unrecognized compensation expense related to restricted stock awards which will be recognized over the next two years.</span></span></p>
                            </div>
                        </div>
                    </div>
                <span></span>
</td>
<td class="text">
                <div>
                    <div>
                        <div>
                            <div>
                                <div>
                                    <p style="margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>16.</b></span></span><span style="padding-left: 15pt;">&#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>SHARE BASED COMPENSATION</b></span></span></p>
                                    <div>
                                        <div style="text-align: justify; margin-bottom: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company adopted the Flora Growth Corp. 2022 Incentive Compensation Plan (the "2022 Plan") to attract, retain and motivate independent directors, executives, key employees and consultants. The 2022 Plan was approved by the Company's shareholders on July 5, 2022, and reserves an aggregate of 300,000 of the Company's common shares for issuance in connection with Awards (as defined in the 2022 Plan) granted under the 2022 Plan. The 2022 Plan was amended on June 6, 2023, with approval from the Company's shareholders, to increase the shares available under the 2022 Plan from 300,000 to 950,000. Previously, the Company's shareholders had adopted a "rolling" stock option plan (the "Prior Plan") which authorized the Company to grant stock options constituting up to 10% of the Company's issued and outstanding common shares at the time of each option grant. Since the adoption of the 2022 Plan, no further grants have been made or will be made under the Prior Plan; however, any currently outstanding stock options granted prior to July 5, 2022 will remain in effect until they have been exercised or terminated or have expired in accordance with the terms of the Prior Plan. Under the 2022 Plan, the Compensation Committee of our Board of Directors (the "Committee") may grant a variety of awards including stock options, stock appreciation rights ("SAR"s), restricted stock, restricted stock units, dividend equivalents and other stock-based awards. </span></span></div>
                                    </div>
                                    <div>
                                        <div>
                                            <div>
                                                <div>

                                                </div>
                                            </div>
                                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 15, 2023, the Company </span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>proposed to grant, upon approval by a majority of shareholders at the Company&#8217;s next annual meeting,</span></span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"> Clifford Starke, the current CEO of the Company, SARs valued at 12% of the total outstanding shares of the Company on the grant date, which vest in 12 tranches with each tranche representing 1% of the total outstanding shares of the Company. The exercise price of the SARs is the closing share price of the Company's shares on the grant date. The first tranche will vest upon the Company's share price increasing by 50% from the Company's closing share price on the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest. The SARs expire 10 years from the grant date with a post-termination exercise period of one year. </span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On December 15, 2023, the Company </span></span><span><span>proposed to grant, upon approval by a majority of shareholders at the Company&#8217;s next annual meeting</span>,</span></span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"> Dany Vaiman, the current CFO of the Company, SARs valued at 4% of the total outstanding shares of the Company on the grant date, which vest in 8 tranches with each tranche representing 0.5% of the total outstanding shares of the Company. The exercise price of the SARs is the closing share price on the grant date. The first tranche will vest upon the Company's share price increasing by 50% from the closing share price as of the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest. The SARs expire 10 years from the grant date with a post-termination exercise period of one year.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>All </span></span><span>SARs proposed grants to Mr. Starke and Mr. Vaiman remain unexercisable, and subject to forfeiture, unless the Company's shareholders approve such SAR grant at the Company's annual shareholder meeting</span><span><span>.</span></span></span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>OPTIONS</b></span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options granted under the Prior Plan are non-transferable and non-assignable and may be granted for a term not exceeding five years. Under the 2022 Plan, stock options may be granted with a term of up to ten years and in the case of all stock options, the exercise price may not be less than 100% of the fair market value of a Common Share on the date the award is granted. Stock option vesting terms are subject to the discretion of the Committee. Common shares are newly issued from available authorized shares upon exercise of awards.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Information relating to share options outstanding and exercisable as at December 31, 2023 and 2022 is as follows:</span></span></p>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>

                        <div>
                            <div>
                                <div>
                                    <div>
                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                                <td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Options Outstanding</b></span></span></span></span></span></span></td>
                                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Options Exercisable</b></span></span></span></span></span></span></td>
                                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Number of<br/>options (in<br/>thousands)</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Weighted<br/>average<br/>exercise price</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Number of<br/>options (in<br/>thousands)</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Weighted<br/>average<br/>exercise<br/>price</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Balance, December 31, 2021</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>272</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>39.06</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>272</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>39.06</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Granted</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>90</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>19.15</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>29.60</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Exercised</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(27</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>3.00</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(27</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>3.00</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Forfeited</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(45</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>52.44</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(34</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>54.39</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Balance, December 31, 2022</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>290</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>34.17</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>212</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>41.19</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Granted</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>5</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>7.00</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>14</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>17.43</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Forfeited</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(246</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>35.05</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(182</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>42.31</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Balance, December 31, 2023</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>49</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>27.04</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>44</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>29.30</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>


                        <div>
                            <div>
                                <div>
                                    <div>
                                        <div>&#160;
                                            <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Options<br/>outstanding </b></span></span></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Options<br/>exercisable</b><b>&#160;</b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Exercise<br/>price</b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 14%; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Grant date fair value<br/>vested </b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Remaining life in<br/>years </b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                                    <td colspan="3" style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands of Dollars</b></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                June 28, 2024
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">17</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">17</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 14%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                0.5
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                July 15, 2025
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">45.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">83</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                1.5
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                December 23, 2025
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">45.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">230</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                2.0
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                September 25, 2026
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">138.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">205</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                2.7
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                December 16, 2026
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">40.80</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">185</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                3.0
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                January 17, 2027
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">34.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">63</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                3.0
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                January 26, 2027
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29.60</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">25</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                3.1
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                March 17, 2033
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">26</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                9.2
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                July 5, 2033
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13.40</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                9.5
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">49</span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">44</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">27.04</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 14%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">861</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                2.8
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                            </table>
                                            <p style="margin: 0pt;">&#160;</p>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>

                    <div>

                    </div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The fair value of stock options issued during the years ended December 31, 2023 and 2022 was determined at the time of issuance using the Black-Scholes option pricing model with the following weighted average inputs, assumptions and results:</span></span></p>

                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2022</span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Risk-free annual interest rate</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2.77%</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.85%</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current stock price</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.90</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">18.95</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected annualized volatility</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>100%</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected life (years)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                            10
                                                        </b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                        7
                                                    </span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected annual dividend yield</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>0%</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0%</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercise price</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.00</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19.16</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted average grant date fair value</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.00</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19.16</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>

                        </div>
                    </div>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total benefit related to the options granted in the year ended December 31, 2023 was less than $0.1 million (2022 - $3.0 million expense). This (benefit) expense is included in the share based compensation line on the statement of comprehensive loss. Generally, the options granted in 2023 and 2022 vest one to two years following the date of grant provided that the recipient is still employed or engaged by the Company.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the year ended December 31, 2023, 245,959 (2022 - 45,187) unexercised stock options expired following the termination of certain employees and were charged to deficit.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The intrinsic value of options exercised for the year ended December 31, 2023 was $nil ($0.8 million in 2022). The total fair value of options vested during the year ended December 31, 2023 was $0.1 million ($4.0 million in 2022).</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For the years ended December 31, 2023 and 2022, there has been no recognized income tax benefits associated with stock options, and no amounts capitalized as part of the cost of an asset.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At December 31, 2023 the total remaining stock option cost for nonvested awards is expected to be less than $0.1 million over a weighted average future period of 0.2 years until the awards vest. A total of 5,000 options issued in 2023 will vest in 2024 provided if the award holder is still employed or engaged by the Company.</span></span></p>
                        </div>
                    </div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"><b>RESTRICTED STOCK AWARDS</b></p>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 10pt 0px; text-align: justify;">Restricted stock is a grant of common shares which may not be sold or disposed of, and which is subject to such risks of forfeiture and other restrictions as the Committee, in its discretion, may impose. A participant granted restricted stock generally has all of the rights of a shareholder of the Company, unless otherwise determined by the Committee. Subject to certain exceptions, the vesting of restricted stock awards is subject to the holder&#8217;s continued employment or engagement through the applicable vesting date. Unvested restricted stock awards will be forfeited if the holder&#8217;s employment or engagement ceases during the vesting period and may, in certain circumstances, be accelerated. The Company values restricted stock awards based on the closing share price of the Company&#8217;s common shares as of the date of grant. The fair value of the restricted stock award is recorded as expense over the vesting period.</p>
                    <div>

                    </div>
                    <p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;">Information relating to restricted stock awards outstanding as at December 31, 2023 and December 31, 2022:</p>

                        <div>
                            <div>
                                <div>
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Number of<br/>restricted stock<br/>awards</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Weighted<br/>average grant<br/>date fair value</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Thousands</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2021</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Granted</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">147</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13.64</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">14.62</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2022</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">146</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13.64</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Granted</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">838</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.44</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(174</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(8.92</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(419</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2.66</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2023</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">391</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.41</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </div>
                            </div>
                        </div>

                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total expense related to the restricted stock awards in the year ended December 31, 2023 was $1.1 million (2022 - $0.4 million). This expense is included in the share based compensation line on the consolidated statements of loss and comprehensive loss. For the years ended December 31, 2023 and 2022, there has been no recognized income tax benefits associated with restricted stock awards.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company issued 363,617 restricted stock awards that vested immediately on November 15, 2023 at a total fair value of $0.3 million. The Company issued 1,000 restricted stock awards that vested immediately on September 28, 2022 at a total fair value of less than $0.1 million. The remaining restricted stock awards issued in 2023 and 2022 vest over the next three years provided the award holder is still employed or engaged by the Company. As of December 31, 2023, the Company had $0.1 million of unrecognized compensation expense related to restricted stock awards which will be recognized over the next three years.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A total of 174,304 restricted stock awards expired or were forfeited in the year ended December 31, 2023 (2022 - $nil).</span></span></p>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002951794560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsDisclosureTextBlock', window );">WARRANTS [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>13.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>WARRANTS</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following summarizes the number of warrants outstanding as of March 31, 2024:</span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; border-top: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Number of warrants</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted average</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>exercise price</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">
                                                <p style="font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;">Balance, December 31, 2023</span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,384</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9.90</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, March 31, 2024</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,384</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.90</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                &#160;
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Warrants</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>outstanding</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Exercise</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>price</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Grant date fair</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>value</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Remaining life</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>in years</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            November 18, 2026
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">221</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">75.00</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,729</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            2.64
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            November 18, 2027
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">66.00</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,055</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            3.64
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            December 8, 2027
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">25</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.80</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">149</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            3.69
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            September 21, 2028
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">691</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">712</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            4.48
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            September 21, 2028
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">55</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.39</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">81</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            4.48
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            March 21, 2029
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,369</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,120</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            4.98
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,384</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9.90</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,846</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            4.58
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                            </div>
                        </div>
                    </div>
                <span></span>
</td>
<td class="text">
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>17.<span style="display: inline-block; width: 15pt;">&#160;</span>WARRANTS</b></span></span></p>
                    </div>
                </div>
                <div>
                    <div>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On September 21, 2023, the Company issued 1,369,000 warrants issued as part of the September 2023 unit offering (Note 15). Each warrant permits the holder to purchase one common share of the Company through March 21, 2029 for $2.50. The issue date fair value of the warrants was estimated at $1.1 million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 100% based on comparable companies; risk-free interest rate of 4.3% and an expected life of 5.5 years. The resulting grant date fair value of each warrant was $0.82. Additionally, the Company amended the exercise price with respect to 66,245 and 624,995 warrants that (Note 15) that were previously issued in the November 2021 and December 2022 (described below) offerings, respectively, from $8.00 per share to $2.50 per share and recorded at $0.2 million gain on these warrant modifications.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Related to the September 2023 unit offering, 54,760 warrants were issued to the placement agent and recorded as issuance costs to share capital. Each warrant permits the holder to purchase one common share of the Company after the 181st day immediately following the date of issuance through September 21, 2028 for $2.39. The issue date fair value of the warrants was estimated at $0.1 million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 100% based on comparable companies; risk-free interest rate of 4.25% and an expected life of 5 years. The resulting grant date fair value of each warrant was $1.48.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On December 8, 2022, the Company issued 625,000 warrants issued as part of the December 2022 unit offering (Note 15). Each warrant permits the holder to purchase one common share of the Company through December 8, 2027 for $8.00. The issue date fair value of the warrants was estimated at $2.0 million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 100%&#160;based on comparable companies; risk-free interest rate of 3.0% and an expected life of 5 years. The resulting grant date fair value of each warrant was $3.25. Additionally, the Company amended the exercise price with respect to 66,250 warrants (Note 15) that were previously issued in the November 2021 offering from $75.00 per share to $8.00 per share.</span></span></p>
                        <div>

                        </div>
                        <p style="margin: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Related to the December 2022 unit offering, 25,000 warrants were issued to the placement agent and recorded as issuance costs to share capital. Each warrant permits the holder to purchase one common share of the Company after the 180th day immediately following the date of issuance through December 8, 2027 for $8.00. The issue date fair value of the warrants was estimated at $0.1 million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 100% based on comparable companies; risk-free interest rate of 3.0% and an expected life of 5 years. The resulting grant date fair value of each warrant was $5.95.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The intrinsic value of warrants exercised for the year ended December 31, 2023 was less than $0.1 million ($0.5 million in 2022). The total fair value of warrants vested during the year ended December 31, 2023 was $1.3 million ($2.3 million in 2022).</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For all warrants, common shares are newly issued from available authorized shares upon exercise of awards.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>The following tables show warrants outstanding as at December 31, 2023:</b></span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Number of warrants</b></span></span></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Weighted average<br/>exercise price</b></span></span></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: center;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2021</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>438</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>67.46</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercised</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(24</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9.83</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(103</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">60.00</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">650</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.20</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2022</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>961</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24.84</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercised</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.00</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(691</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.00</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,115</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2023</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,384</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.90</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span>

                            <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Warrants<br/>outstanding</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Exercise<br/>price</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Grant date fair<br/>value</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Remaining life<br/>in years</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                November 18, 2026
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">221</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">75.00</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,700</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                2.88
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                November 18, 2027
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">66.00</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,055</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                3.88
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                December 8, 2027
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">25</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.80</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">149</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                3.94
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                September 21, 2028
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">691</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">522</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                4.73
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                September 21, 2028
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">55</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.39</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">81</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                4.73
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                March 21, 2029
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,369</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,339</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                5.22
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,384</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9.90</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,846</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                4.83
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                    </div>
                </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002954121328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY DISCLOSURES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY DISCLOSURES [Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                <div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>18.<span style="display: inline-block; width: 15pt;">&#160;</span>RELATED PARTY DISCLOSURES</b></span></span></p>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Key management personnel compensation</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In addition to their contracted fees, directors and officers also participate in the Company's stock option program. Certain executive officers are subject to termination notices of 6 to 24 months and change of control payments (Note 19). Key management personnel compensation is comprised of the following:</span></span></p>
                            <div>
                                <div>

                                </div>
                            </div>

                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; width: 1px; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Year ended<br/>December 31, 2022</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Directors' and officers' compensation</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,862</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,560</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share-based compensation</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,577</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">797</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 426.4px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,439</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,357</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>

                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company defines key management personnel as those persons having authority and responsibility for planning, directing, and controlling the activities of the Company directly or indirectly, and was determined to be executive officers and directors (executive and non-executive) of the Company. The remuneration of directors and key executives is determined by the Board of Directors of the Company having regard to the performance of individuals and market trends.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023, $0.1 million of the above directors' and officers' compensation was included in the trade payables and accrued liabilities (2022 - $0.2 million). These amounts are unsecured, non-interest bearing and due on demand. The share-based compensation amount above for 2023 includes 110,000 common shares to the former Chief Executive Officer of the Company, valued at $0.4 million, that were recorded as share based compensation expense as part of a separation agreement.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Related party transactions</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to its acquisition by the Company, Harmony Health One, a subsidiary of FGH, entered into an Intellectual Property License Agreement with Hampstead Private Capital Limited ("Hampstead") - a corporation controlled by the CEO of the Company and former CEO of FGH. Under the terms of this agreement, Harmony is to pay Hampstead a royalty in the amount of 3.5% of the gross revenues from the sale of Harmony products. No royalty amounts have been recorded by the Company for the years ended December 31, 2023 and December 31, 2022, as there were no sales for the period after the Company acquired FGH.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to 2022, the Company entered into an agreement with Dr. Manalo-Morgan, a former member of the Company's board of directors, to serve in the additional capacity as Medical Advisor to the Company. In connection with this agreement, Dr. Manalo-Morgan was responsible for developing and identifying medical applications of cannabinoids for the Company for the treatment of various ailments and supporting the Company's public relations efforts and assisting the Company with its media engagements. For these services, the Company paid Dr. Manalo-Morgan $0.1 million and $0.2 million for the years ended December 31, 2023 and December 31, 2022, respectively. </span></span></p>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY DISCLOSURES [Text Block]</a></td>
<td class="text">
                                    <div>
                                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>9.&#160; RELATED PARTY DISCLOSURES</b></span></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Related party transactions</b></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="text-decoration: underline;">Long-term debt with TruHC Holding</span></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, the &#8364;250,000 (December 31, 2023 - &#8364;250,000) was outstanding under the First Loan.&#160;</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;450,000, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, &#8364;448,000 (December 31, 2023 &#8211; &#8364;378,000) was outstanding under the Second Loan.</span></span></p>
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at March 31, 2024, the amount of accrued interest on the First Loan and Second Loan totals &#8364;22,730 (December 31, 2023 &#8211; &#8364;17,339).&#160;</span></span></p>
                                    </div>
                                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.&#160; RELATED PARTY DISCLOSURES</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Related party transactions</b></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span style="text-decoration: underline;">Long-term debt with TruHC Holding</span></span></span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, the &#8364;250,000 (December 31, 2022 - &#8364;250,000) was outstanding under the First Loan.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#8364;450,000, in installments based on the individual installments requested by the Company (&#8220;Second Loan&#8221;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, &#8364;378,000 (December 31, 2022 &#8211; &#8364;65,000) was outstanding under the Second Loan.</span></span></p>
                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at December 31, 2023, the amount of accrued interest on the First Loan and Second Loan totals &#8364;17,339 (December 31, 2022 &#8211; &#8364;13,590).</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003051431808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>14.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>COMMITMENTS AND CONTINGENCIES</b></span></span></p>
                        <div>
                            <div>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's current known provisions and contingent liabilities consist of the following as of March 31, 2024:</span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Legal disputes</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sales tax</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2023</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,962</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,538</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,500</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Payments/Settlements</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(7</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(168</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(175</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Additional provisions</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,007</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">158</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,165</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign currency translation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">101</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">101</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance as at March 31, 2024</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>4,063</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,528</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6,591</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>

                                <div>
                                    <div>

                                    </div>
                                </div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The legal disputes balance as of March 31, 2024, relate to the settlement of a contractual dispute involving the Company. It involves a former shareholder of ACA Mueller, an entity that was part of the Company's acquisition of FGH in December 2022, who filed a statement of claim against a wholly owned subsidiary of the Company in the Constance Regional Court in Germany. In March 2024, the Constance Regional Court in Germany ordered the Company to pay the plaintiff $3.0 million plus interest thereon at a rate of 5% above the prime rate since September 6, 2020 in addition to 83% of the legal fees. The Company has since filed an appeal. While the Company believes that this claim is without merit, at this time the Company believes it is probable that a liability has been incurred and the Company is able to reasonably estimate the loss of $4.1 million, including $1.0 million of interest accrued in the three months ended March 31, 2024. As a result, without acknowledgement (explicitly or implicitly) of any amount of liability arising from this claim, the Company recognized a provision of $4.1 million to reflect the value of the claim. This dispute is covered under an indemnification agreement between the Company and the former Chief Executive Officer and shareholder of FGH. The Company intends to vigorously defend itself through appropriate legal proceedings. The $4.1 million is recorded within contingencies and within indemnification receivables on the&#160;unaudited condensed consolidated statements of financial position.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The settlement of legal disputes in 2024 related to the settlement of an action brought against the Company in the Ontario Superior Court of Justice by Gerardo Andres Garcia Mendez claiming that the Company was obligated to issue 3,000,000 common shares (pre-splits) to him for a purchase price of $0.05 per share as a result of alleged consulting services he performed in 2019. In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute. The payment was made in January 2024. The amount was recorded within contingencies on the consolidated statements of financial position and expense on the consolidated statements of loss and comprehensive loss for the year ended December 31, 2023.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 30, 2024, a group representing the sellers of Just Brands LLC to Flora in February 2022 brought an action against the Company in the United States District Court for the Southern District of New York claiming that the Company failed to promptly issue additional shares in accordance with a specific formula set forth in the securities purchase agreement after the two-year anniversary of the closing, which occurred on February 24, 2024. The plaintiffs claim that they are entitled to 182,889 common shares and $38.0 million to complete the acquisition of Just Brands LLC. The Company has assessed the claims and concluded that it is probable that a liability has been incurred and that the Company is able to reasonably estimate the loss based on the fair value of 632,484 common shares of the Company. As at March 31, 2024, this value is $1.5 million and has been recorded in the contingent purchase considerations on the unaudited condensed interim consolidated statement of financial position.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Sales tax relates to estimated amounts owed to certain jurisdictions in the Unites States for sales from the Company's JustCBD operations. The ending balance is recorded within contingencies on the unaudited condensed interim consolidated statement of financial position, and additions to the provision as a reduction of revenue on the unaudited condensed interim consolidated statements of loss and comprehensive loss.</span></span></p>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Legal proceedings</b></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company records liabilities for legal proceedings in those instances where it can reasonably estimate the amount of the loss and where liability is probable. The Company is engaged from time-to-time in various legal proceedings and claims that have arisen in the ordinary course of business. The outcome of all the proceedings and claims against the Company is subject to future resolution, including the uncertainties of litigation. Based on information currently known to the Company and after consultation with outside legal counsel, management believes that the probable ultimate resolution of any such proceedings and claims, individually or in the aggregate, will not have a material adverse effect on the financial condition of the Company, taken as a whole as at March 31, 2024.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On November 1, 2023, Just Brands filed an Emergency Complaint for Declaratory Judgment and Injunctive Relief in the Southern District of Florida against the Florida Department of Agriculture and Consumer Services (the "Department") stemming from stop sale orders issued by the Department whereby the Department prohibited Just Brands from selling and moving most of its products. Relying on Florida Statute Section 581.217, which includes the definition of "attractive to children," the Department determined Just Brand's product could not be sold or moved because the products were manufactured in the shape of humans, cartoons, or animals; in a form that bears a reasonable resemblance to an existing candy product; and containing color additives. The Court ruled in favor of the Department and that Order was being appealed to the Eleventh Circuit Court of Appeals. Since then, the Department has initiated an Administrative Action claiming Just Brands moved product outside the State of Florida in violation of the stop sale orders. The statute provides for a penalty of up to $5,000 per violation. The Department sought to assess penalties on what they claimed to be a total of 215,154 violations (one for each package). The Company disputed their claim and intended to vigorously defend against this action. The Company has not accrued a liability as of March 31, 2024. The total value of inventory impacted by the stop sale orders was $1.9 million at March 31, 2024.&#160;On May 7, 2024, Just Brands and the Department agreed to a settlement and general release, whereby Just Brands will remove the products subject to the stop sales orders from the state of Florida, pay the Department $60,500 to reimburse the Department&#8217;s attorney&#8217;s fees, and accept a five-year revocation of its food permit in the state of Florida. By signing the release, Just Brands waived, settled and released all claims it had or might have against the Department.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On May 31, 2023, Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres brought an action against the Company in the Ontario Superior Court of Justice claiming that the Company is obligated to issue 500,000 common shares (pre-splits) each for a purchase price of $0.05 per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.</span></span></p>
                                <div>
                                    <div>

                                    </div>
                                </div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On May 31, 2023, Ramon Ricardo Castellanos Saenz and Miriam Ortiz brought an action against the Company in the Ontario Superior Court of Justice claiming that the Company is obligated to issue 1,500,000 common shares (pre-splits) each for a purchase price of $0.05 per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In connection with the Company's acquisition of FGH, the Company's current CEO and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $5.0 million. In addition to the matter regarding the former shareholder of ACA Mueller, discussed above, the following actions are pending as of the date hereof:</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On February 3, 2023, an action was brought in the Ontario Superior Court of Justice by Nathan Shantz and Liberacion e Inversiones S.A. against various parties including Clifford Starke, the Company's current CEO and FGH's former Chief Executive Officer, and FGH. The statement of claim alleges that, prior to the closing of the Arrangement, 8,831,109 FGH shares purportedly owned by the plaintiffs were wrongfully transferred to third parties, in part through alleged unauthorized steps taken by Mr. Starke. Plaintiffs seek, among other things, a declaration that they are the rightful owners of the shares or, in the alternative, damages. Against FGH, they claim a declaration that, by virtue of the alleged unauthorized transfer of shares, FGH acted oppressively and seek damages in the amount of $4.0 million. The defendants have brought motions to stay the proceedings on the grounds that the Ontario court lacks jurisdiction over the claim. In the event FGH should incur any losses in connection with this matter, such losses are to be indemnified by Mr. Starke subject to the maximum threshold of the indemnity agreement. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The total amount claimed against the former entities of FGH currently exceeds the maximum $5.0 million of the indemnification agreement. However, the Company is estimating the likelihood of loss in these cases will not exceed $4.1 million.</span></span></p>
                            </div>
                        </div>
                    </div>
                <span></span>
</td>
<td class="text">
                <div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>19.<span style="display: inline-block; width: 15pt;">&#160;</span>COMMITMENTS AND CONTINGENCIES</b></span></span></p>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An indemnification arrangement exists when one party has contractually agreed to reimburse another party for losses incurred because of circumstances that existed prior to the arrangement. The Company and its legal counsel assess whether a legal agreement exists and the maximum potential loss to be reimbursed.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's current known provisions and contingent liabilities consist of termination benefits and legal disputes.</span></span></p>

                                <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Termination benefits</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Legal disputes</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sales tax</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2022</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">183</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,030</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,831</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,044</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Payments/settlements</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(183</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(98</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(281</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Additional provisions</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">707</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">715</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign currency translation</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">22</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">22</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2023</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,962</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,538</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,500</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>

                            <p style="margin: 0pt;">&#160;</p>
                            <div>

                            </div>
                            <p style="margin: 0pt 0pt 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The termination benefits related to contractual termination benefits owed to a former board member of the Company, a consultant and a former member of the management team. The amounts were recorded within contingencies on the consolidated statements of financial position and $nil expense (2022 - $0.4 million) on the consolidated statements of loss and comprehensive loss.</span></span></p>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The legal disputes from 2022 relate to the settlement of two contractual disputes involving the Company. The first involves a third party that entered into a conditional share grant arrangement dated April 2, 2019 with Franchise Cannabis Corp and Rangers Pharmaceuticals A/S - two entities that were part of the Company's acquisition of FGH in December 2022. In January 2023, the Company entered into a settlement agreement with this third party pursuant to which the Company issued 16,250 common shares of the Company, valued at $0.1 million, to the third party to settle the dispute. The provision balance as of December 31, 2022 reflected the value of the Company's shares as of the date of the settlement agreement. The second dispute involves a former shareholder of ACA Mueller, an entity that was part of the Company's acquisition of FGH in December 2022, who filed a statement of claim against a wholly-owned subsidiary of the Company in the Constance Regional Court in Germany. While the Company believes that this claim is without merit, at this time the Company believes it is probable that a liability has been incurred and the Company is able to reasonably estimate the loss of $3.0 million. As a result, without acknowledgement (explicitly or implicitly) of any amount of liability arising from this claim, the Company recognized a provision of $3.0 million to reflect the value of the claim. This dispute is covered under the indemnification agreement between the Company and the former Chief Executive Officer and shareholder of FGH as discussed in Note 10. The Company intends to vigorously defend itself through appropriate legal proceedings. Both of the above amounts are recorded within contingencies and $3.0 million within indemnification receivables on the consolidated statements of financial position and $nil (2022- $0.1 million) is recorded as expense on the consolidated statements of loss and comprehensive loss.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The additional legal dispute in 2023 related to the settlement of an action brought against the Company in the Ontario Superior Court of Justice by Gerardo Andres Garcia Mendez claiming that the Company was obligated to issue 3,000,000 common shares (pre-splits) to him for a purchase price of $0.05 per share as a result of alleged consulting services he performed in 2019. In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute. The payment was made in January 2023. The amount is recorded within contingencies on the consolidated statements of financial position and expense on the consolidated statements of loss and comprehensive loss.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Sales tax relates to estimated amounts owed to certain jurisdictions in the Unites States for sales from the Company's JustCBD operations. The opening balance was acquired during the February 24, 2022 acquisition of JustCBD, with additional provision for estimated amounts due on sales subsequent to the acquisition. The ending balance is recorded within contingencies on the consolidated statement of financial position, and additions to the provision as a reduction of revenue on the consolidated statements of loss and comprehensive loss.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For the sales tax provision and 2023 matters with accruals recorded as discussed above, it is at least reasonably possible that a change in the estimated liability could occur in the near term. Such changes in the Company's judgment could continue to change until the matters are ultimately resolved.</span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Legal proceedings</b></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company records liabilities for legal proceedings in those instances where it can reasonably estimate the amount of the loss and where liability is probable. The Company is engaged from time-to-time in various legal proceedings and claims that have arisen in the ordinary course of business. The outcome of all the proceedings and claims against the Company is subject to future resolution, including the uncertainties of litigation. Based on information currently known to the Company and after consultation with outside legal counsel, management believes that the probable ultimate resolution of any such proceedings and claims, individually or in the aggregate, will not have a material adverse effect on the financial condition of the Company, taken as a whole as at December 31, 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On November 1, 2023, Just Brands filed an Emergency Complaint for Declaratory Judgment and Injunctive Relief in the Southern District of Florida against the Florida Department of Agriculture and Consumer Services (the "Department") stemming from Stop Sale Orders issued by the Department whereby the Department prohibited Just Brands from selling and moving most of its products. Relying on Florida Statute Section 581.217, which includes the definition of "attractive to children," the Department determined Just Brand's product could not be sold or moved because the products were manufactured in the shape of humans, cartoons, or animals; in a form that bears a reasonable resemblance to an existing candy product; and containing color additives. The Court ruled in favor of the Department and that Order is being appealed to the Eleventh Circuit Court of Appeals. Since then, the Department has initiated an Administrative Action claiming Just Brands moved product outside the State of Florida in violation of the Stop Sale Orders. The statute provides for a penalty of up to $5,000 per violation. The Department seeks to assess penalties on what they claim to be a total of 215,154 violations (one for each package). The Company disputes their claim and intends to vigorously defend against this action. The Company believes that it is too early in the proceedings to determine an outcome, and, as such, has not accrued a liability as of December 31, 2023. </span></span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="color: black;">The total value of inventory impacted by the stop sale orders was</span><span><span>&#160;$1.6&#160;million </span></span><span style="color: black;">at December 31, 2023</span><span><span>.</span></span></span></span></p>
                            <div>

                            </div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On May 31, 2023, Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres brought an action against the Company claiming that the Company is obligated to issue 500,000 common shares (pre-splits) each for a purchase price of $0.05 per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of December 31, 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On May 31, 2023, Ramon Ricardo Castellanos Saenz and Miriam Ortiz brought an action against the Company claiming that the Company is obligated to issue 1,500,000 common shares (pre-splits) each for a purchase price of $0.05 per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of December 31, 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In connection with the Company's acquisition of FGH, the Company's current CEO and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $5.0 million. In addition to the matter regarding the former shareholder of ACA Mueller, discussed above, the following actions are pending as of the date hereof:</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On February 3, 2023, an action was brought in the Ontario Superior Court of Justice by Nathan Shantz and Liberacion e Inversiones S.A. against various parties including Clifford Starke, the Company's current CEO and FGH's former Chief Executive Officer, and FGH. The statement of claim alleges that, prior to the closing of the Arrangement, 8,831,109 FGH shares purportedly owned by the plaintiffs were wrongfully transferred to third parties, in part through alleged unauthorized steps taken by Mr. Starke. Plaintiffs seek, among other things, a declaration that they are the rightful owners of the shares or, in the alternative, damages. Against FGH, they claim a declaration that, by virtue of the alleged unauthorized transfer of shares, FGH acted oppressively and seek damages in the amount of $4.0 million. The defendants have brought motions to stay the proceedings on the grounds that the Ontario court lacks jurisdiction over the claim. In the event FGH should incur any losses in connection with this matter, such losses are to be indemnified by Mr. Starke subject to the maximum threshold of the indemnity agreement.</span></span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The total amount claimed against the former entities of FGH currently exceeds the maximum $5.0 million of the indemnification agreement. However, the Company is estimating the likelihood of loss in these cases will not exceed $3.0 million.</span></span></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Management contracts</b></span></span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company is party to management contracts with certain of its executive officers. As at December 31, 2023, these contracts would require payments totaling approximately $1.0 million to be made in the event that such executive officers are terminated (i) "without cause" or (ii) within twelve months following a "change in control" (as such terms are defined in the management contracts). The Company is also obligated to make payments to certain individuals upon termination "without cause" of approximately $1.0 million pursuant to the terms of these contracts. As a triggering event has not taken place, these amounts have not been recorded in these consolidated financial statements.</span></span></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Shared services and space commitment</b></span></span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company had an agreement in 2021 and through March 2022 to share general and administrative, promotion, corporate development, consulting services, and office space with other companies with monthly payments and a minimum commitment of CAD 45,000. This agreement could be terminated by either party giving at least 90 days' prior written notice (or such shorter period as the parties may mutually agree upon) to the other party of termination. These services were provided by 2227929 Ontario Inc which was a related party. This agreement expired by its terms on March 14, 2022.</span></span></span></span></p>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10. COMMITMENTS AND CONTINGENCIES</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company does not have commitments or contingencies as at March 31, 2024 and December 31, 2023.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10.&#160; COMMITMENTS AND CONTINGENCIES </b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company does not have commitments or contingencies as at December 31, 2023 and 2022.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002954113312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES [Text Block]</a></td>
<td class="text">
                <div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>20.<span style="display: inline-block; width: 15pt;">&#160;</span>INCOME TAXES</b></span></span></p>
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The components of the income tax provision include the following. As the Company is domiciled in Canada, the Federal caption below represents the provision amount for Canada.</span></span></p>

                                <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>For the year ended<br/>December 31, 2022</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Canada</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; U.S. federal</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>17</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160;U.S. state</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>5</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Foreign</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>103</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total current tax expense</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>125</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Canada</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(1,767</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(11</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160;&#160;U.S. federal</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,055</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; U.S. state</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(316</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Foreign</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>14</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(23</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total deferred tax expense</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(1,753</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,405</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 81pt;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total income tax benefit</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(1,628</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,405</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                </table>

                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 26.5% for the year ended December 31, 2023 and 2022 to the effective rate is as follows. As the Company is domiciled in Canada, the reconciliation is to the Company's home country income tax rate rather than the applicable statutory rates in the United States. The statutory tax rate as of December 31, 2023 in other countries relevant to the Company's subsidiaries include the following: United States 21%, Colombia 33%, Germany 27.73%, Denmark 22%, and United Kingdom 19%. The Colombian Government lowered the corporate income tax rate from 35% to 33% during the tax year 2023.</span></span></p>
                            <div>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>For the year ended<br/>December 31, 2022</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Statutory Canadian&#160;rate</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>26.5%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">26.5%</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Earnings in jurisdictions taxed at different rates</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-1.3%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.5%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairments</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-1.9%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-12.9%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-0.8%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-1.7%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on investments</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-3.0%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.0%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Valuation allowance</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-23.8%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-12.3%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other permanent items</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1.3%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.8%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior year adjustments, change in tax rates</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.4%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.0%</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3.4%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.9%</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                            </div>
                            <p style="margin: 0pt;">&#160;</p>
                            <div>

                            </div>
                            <p style="margin: 0pt 0pt 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Components of the Company's deferred income tax assets and liabilities at December 31, 2023 and 2022 are as follows:</span></span></p>

                                <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2022</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Non-capital loss carryforwards</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b>&#160;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>19,725</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">20,240</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Share issuance costs</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>847</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,406</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Unrealized gains (losses) on investments</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>5,858</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">823</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Right of use assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>287</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">614</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Fixed assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>77</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>718</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Goodwill</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7,747</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Sec 174 - R&amp;D expense</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>263</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>564</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">677</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Allowance for doubtful accounts</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>64</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>36,150</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,760</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Valuation allowance</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(36,150</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(20,909</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,851</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,094</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Lease obligations</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">469</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,563</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,712</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                </table>

                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred taxes are a result of temporary differences that arise due to the differences between the income tax values and the carrying values of assets and liabilities. The Company's deferred tax asset valuation allowances are primarily the result of uncertainties regarding the future realization of recorded tax benefits on the tax loss carryforwards from operations in various jurisdictions. Current evidence does not suggest the Company will realize sufficient taxable income of the appropriate character within the carryforward period to allow the Company to realize the deferred tax benefits. If the Company were to identify and implement tax planning strategies to recover these deferred tax assets or generate sufficient income of the appropriate character in these jurisdictions in the future, it could lead to the reversal of these valuation allowances and income tax expense.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company asserts that the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company may need to accrue and pay taxes if those earnings were repatriated to Canada. As at December 31, 2023, the amount of cash and cash equivalents related to foreign operations subject to these assertions is $1.7 million.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unused loss carryforwards in Canada totaling $55.6 million expire beginning 2036. Unused loss carryforwards in Columbia totaling $0.9 million in Colombia expire beginning 2031. Unused loss carryforwards in the United States totaling $13.0 million have an indefinite carryforward period. Unused loss carryforwards in Denmark totaling $6.1 million have an indefinite carryforward period. Unused loss carryforwards in Germany of $0.7 have an indefinite carryforward period. Unused loss carryforwards in the United Kingdom of $0.7 have an indefinite carryforward period. Deferred tax assets have not been recognized for legal entities where it is not probable that future taxable profit will be available against which the Company can use the benefits. Tax attributes are subject to review, and potential adjustment, by tax authorities. The tax years that remain subject to examination by significant tax jurisdictions of the Company as of December 31, 2023 are as follows:&#160; Canada 2020 to 2023, United States 2020 to 2023, Colombia 2020 to 2023, Germany 2019 to 2023, Denmark 2020 to 2023, and United Kingdom 2022 to 2023.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The amount of current income tax expense for the year ended December 31, 2023 was $0.1 million and deferred income tax benefit was $1.6 million within the consolidated statements of loss and comprehensive loss. The amount of current income tax expense recorded for the year ended December 31, 2022 was $nil and deferred income tax benefit was $1.4 million.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had no unrecognized income tax benefits because of uncertain income tax positions for the years ended December 31, 2023 and 2022.</span></span></p>
                        </div>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11.&#160; INCOME TAXES </b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Components of the Company's deferred income tax assets and liabilities at December 31, 2023 and 2022 are as follows:</span></span></p>
                        <div>
                            <div>
                                <div>

                                </div>
                                <div>
                                    <p style="margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                                </div>
                            </div>
                        </div>
                        <div>
                            <div>

                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Property and equipment</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>8,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>3,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU asset</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(154,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(179,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Lease liability</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>165,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>183,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Non-capital losses available for future period</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>174,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>64,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>193,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>71,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Unrecognized deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(193,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(71,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total net deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Net deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>

                            </div>
                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred taxes are a result of temporary differences that arise due to the differences between the income tax values and the carrying values of assets and liabilities. The Company's deferred tax asset valuation allowances are primarily the result of uncertainties regarding the future realization of recorded tax benefits on the tax loss carryforwards from operations in various jurisdictions. Current evidence does not suggest the Company will realize sufficient taxable income of the appropriate character within the carryforward period to allow the Company to realize the deferred tax benefits. If the Company were to identify and implement tax planning strategies to recover these deferred tax assets or generate sufficient income of the appropriate character in these jurisdictions in the future, it could lead to the reversal of these valuation allowances and income tax expense.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unused loss carryforwards totaling &#8364;538,000 do not have an expiry date. Deferred tax assets have not been recognized for legal entities where it is not probable that future taxable profit will be available against which the Company can use the benefits. Tax attributes are subject to review, and potential adjustment, by tax authorities. The tax years that remain subject to examination by significant tax jurisdictions of the Company as of December 31, 2023 are as follows: 2022 to 2023.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had no unrecognized income tax benefits because of uncertain income tax positions for the years ended December 31, 2023 and 2022.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002951748464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>15.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>LOSS PER SHARE</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company calculates basic earnings per share based upon the weighted average number of common shares outstanding during the period, while the calculation of diluted earnings per share includes the dilutive effect of potential common shares outstanding during the period. The calculation of diluted earnings per share excludes all potential common shares if their inclusion would have an anti-dilutive effect. Restricted stock award recipients under the 2022 Plan have a non-forfeitable right to receive dividends declared by the Company and are therefore included in computing earnings per share.</span></span></p>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>38</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">275</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Warrants</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,384</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">960</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted stock awards</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">198</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD potential additional shares to settle contingent consideration</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>632</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">657</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total anti-dilutive</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3,078</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,090</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                            </div>
                        </div>
                    </div>
                <span></span>
</td>
<td class="text">
                <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>21.<span style="display: inline-block; width: 15pt;">&#160;</span>LOSS PER SHARE</b></span></span></p>
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive as the Company has a net loss for each period presented:</span></span></p>

                            <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of securities</span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">49</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">290</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Warrants</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,384</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">961</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted stock awards</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">391</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">146</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD potential additional shares to settle contingent consideration</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">632</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">657</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total anti-dilutive</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,456</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,054</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>

                    </div>
                </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960748304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [Text Block]</a></td>
<td class="text">
                    <div>
                        <div>
                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>16.</b><span style="display: inline-block; width: 15pt;">&#160;</span><b>FINANCIAL INSTRUMENTS</b></span></span></span></p>
                        </div>
                        <div>
                            <div>
                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Fair value</b></span></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Company's financial instruments measured at amortized cost as at March 31, 2024 and December 31, 2023 consist of cash, trade and amounts receivable, loans receivable, trade payables, contingencies, accrued liabilities, lease liabilities, and debt and loans payable. The amounts reflected in the unaudited condensed interim consolidated statements of financial position approximate fair value due to the short-term maturity of these instruments.</span></span></span></p>
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Financial instruments recorded at the reporting date at fair value are classified into one of three levels based upon the fair value hierarchy. Items are categorized based on inputs used to derive fair value based on:</span></span></span></p>
                                <div>

                                </div>
                                <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Level 1 - quoted prices that are unadjusted in active markets for identical assets or liabilities</span></span></span></p>
                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Level 2 - inputs other than quoted prices included in level 1 that are observable for the asset/liability either directly or indirectly; and</span></span></span></p>
                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Level 3 - inputs for the instruments are not based on any observable market data.</span></span></span></p>
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The Company's contingent purchase considerations consist of the estimated fair value of contingent purchase consideration from the acquisitions of JustCBD in February 2022 and Original Hemp in March 2023. The amount for JustCBD is measured at FVPL as a Level 2 fair value financial instrument within the fair value hierarchy as at March 31, 2024. The fair value was determined using a simplified calculation which took the expected shares to be issued (632,484) multiplied by the Company's closing share price at March 31, 2024 ($2.31).&#160; The amount for Original Hemp is measured at FVPL as a Level 3 fair value financial instrument within the fair value hierarchy as at March 31, 2024. The fair value was determined using discounted cash flow models utilizing two different rates, high (25.1%) and low (18.4%), to estimate the present value of the future cash outflows.&#160; As valuations of investments for which market quotations are not readily available are inherently uncertain, may fluctuate within short periods of time and are based on estimates, determination of fair value may differ materially from the values that would have resulted if a ready market existed for the investments. Such changes may have a significant impact on the Company's financial condition or operating results.</span></span></span></p>
                                <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>The following tables present information about the Company's financial instruments and their classifications as at March 31, 2024 and December 31, 2023 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value.</span></span></span></p>

                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Fair value measurements at March 31, 2024 using:</span></span></span></p>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Contingent purchase consideration from asset acquisitions and business combinations</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>1,461</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>241</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>1,702</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                        <span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#160;</span></span></span>
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Fair value measurements at December 31, 2023 using:</span></span></span></p>
                                        <span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"> <span>&#160;</span></span></span>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Contingent purchase consideration from asset acquisitions and business combinations</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>854</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>241</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,095</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                            </div>
                        </div>
                    </div>
                <span></span>
</td>
<td class="text">
                <div>
                    <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>22.<span style="display: inline-block; width: 15pt;">&#160;</span>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</b></span></span></span></p>
                    <div>
                        <div>
                            <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Environmental</b></span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.</span></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Fair value</b></span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company's financial instruments measured at amortized cost as at December 31, 2023 and December 31, 2022 consist of cash, restricted cash, trade and amounts receivable, loans receivable, trade payables, contingencies, accrued liabilities, contingent purchase consideration liabilities, lease liabilities, and debt and loans payable. The amounts reflected in the consolidated statements of financial position approximate fair value due to the short-term maturity of these instruments.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial instruments recorded at the reporting date at fair value are classified into one of three levels based upon the fair value hierarchy. Items are categorized based on inputs used to derive fair value based on:</span></span></span></p>
                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Level 1 - quoted prices that are unadjusted in active markets for identical assets or liabilities</span></span></span></p>
                            <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Level 2 - inputs other than quoted prices included in level 1 that are observable for the asset/liability either directly or indirectly; and</span></span></span></p>
                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Level 3 - inputs for the instruments are not based on any observable market data.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company&#8217;s long-term investments require significant unobservable inputs and as discussed at Note 9, are measured at FVPL and as a Level 3 fair value financial instrument within the fair value hierarchy as at December 31, 2023. As discussed in Note 10, the Company&#8217;s contingent purchase considerations consist of the estimated fair value of contingent purchase consideration from the acquisitions of JustCBD in February 2022, NoCap in July 2022 and Original Hemp in March 2023. The amount for JustCBD is measured at FVPL as a Level 2 fair value financial instrument within the fair value hierarchy as at December 31, 2023. The amounts for NoCap and Original Hemp are measured at FVPL as a Level 3 fair value financial instrument within the fair value hierarchy as at December 31, 2023. As valuations of investments for which market quotations are not readily available are inherently uncertain, may fluctuate within short periods of time and are based on estimates, determination of fair value may differ materially from the values that would have resulted if a ready market existed for the investments. Such changes may have a significant impact on the Company&#8217;s financial condition or operating results.</span></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The following tables present information about the Company's financial instruments and their classifications as at December 31, 2023 and 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value.</span></span></span></p>

                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Fair value measurements at December 31, 2023 using:</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of United States Dollars</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 1</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 2</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 3</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Total</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial assets:</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Investments (Note 9)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial liabilities:</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Contingent purchase consideration from business combinations (Note 10)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>854</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>241</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1,095</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>

                            <p style="margin: 0pt;">&#160;</p>
                            <div>

                            </div>
                            <div>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Fair value measurements at December 31, 2022 using:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of United States Dollars</span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial assets:</span></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Investments (Note 9)</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>764</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>764</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Contingent purchase consideration from business combinations (Note 10)</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,646</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>901</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>3,547</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                            </div>
                        </div>
                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Risk management overview</b></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk. Further quantitative disclosures are included throughout these condensed interim consolidated financial statements.</span></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Credit risk</b></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's trade and other receivables, loans receivable and cash held with banks and other financial intermediaries.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The carrying amount of the cash, restricted cash, trade and amounts receivables, indemnification receivable, and loan receivable represents the maximum credit exposure as presented in the statement of financial position.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company has assessed that there has been no significant increase in credit risk of the loans receivable from initial recognition based on the financial position of the borrowers, and the regulatory and economic environment of the borrowers. Based on historical information, and adjusted for forward-looking expectations, the Company has assessed an insignificant loss allowance on the loans' receivable and advances as at December 31, 2023 and 2022.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company provides credit to certain customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Credit risk for customers is assessed on a case-by-case basis and an allowance for specific expected credit losses is recorded where required, in addition to an estimate of lifetime expected credit losses for the portfolio of accounts receivable. See credit risk analysis for trade receivables at Note 6.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company held cash and restricted cash of $4.4 million as at December 31, 2023 (2022 - $8.9 million), of which, $4.4 million (2022 - $8.9 million) is held with large financial institutions and national central banks. The remaining cash amount of less than $0.1 million cash (2022 - less than $0.1 million) are held with financial intermediaries in the United States, Canada, Germany and United Kingdom. The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has assessed an insignificant loss allowance on these cash and restricted cash balances as at December 31, 2023 and 2022.</span></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Market risk</b></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Foreign currency exchange rate risk is the risk that the fair value of future cash flows will fluctuate due to changes in foreign exchange rates. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk as management has determined that this risk is not significant. As such, the Company's financial position and financial results may be adversely affected by the unfavorable fluctuations in currency exchange rates.</span></span></span></p>
                        <div>

                        </div>
                        <p style="margin: 0pt 0pt 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>As at December 31, 2023, the Company had the following monetary assets and liabilities denominated in foreign currencies:</span></span></span></p>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>December 31, 2023</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CAD</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>GBP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>EUR</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of foreign currencies</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Cash</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>969</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>35</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Amounts receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,995</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>125</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Loans receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade payables</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(6,767</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(22</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(18</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Accrued liabilities</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(48</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(69</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Lease liability</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(126</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(41</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Long term debt</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(2,560</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Net carrying value</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(5,537</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>28</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(17</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                    </tr>
                                </table>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>As at December 31, 2022, the Company had the following monetary assets and liabilities denominated in foreign currencies:</span></span></span></p>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>December 31, 2022</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CAD</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>COP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>GBP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>EUR</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CHF</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of foreign currencies</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Cash</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1,691</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,961,487</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>64</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Amounts receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,964</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>15,127,223</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>61</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Loans receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>250</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade payables</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(9,333</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(2,975,794</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(56</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(161</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Accrued liabilities</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(522</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(1,173,118</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(22</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Lease liability</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(153</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(1,809,970</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(17</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Long term debt</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(1,446</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Net carrying value</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(6,799</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>12,129,828</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>30</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(160</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>250</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>

                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Monetary assets and liabilities denominated in Canadian dollars, Colombian pesos, British pounds, Euros and Swiss Francs are subject to foreign currency risk. The Company has estimated that as at December 31, 2023, the effect of a 10% increase or decrease in Canadian dollars, British pounds, and Euros against the Unites States dollar on financial assets and liabilities would result in an increase or decrease of approximately $0.4 million (December 31, 2022 - $0.1 million) to net loss and comprehensive loss.<b> </b>Subsequent to December 31, 2023 and through the date of issuance of these financial statements, the exchange rates remained within the 10% range discussed above, and the Company does not expect significant changes in unsettled transactions from December 31, 2023.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company calculates this sensitivity analysis based on the net financial assets denominated in each currency using the December 31 exchange rate, then changing the rate by 10%. Management determined 10% is a 'reasonably possible' change in foreign currency rates by considering the approximate change in rates in the prior twelve months.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>It is management's opinion that the Company is not subject to significant commodity or interest rate risk.</span></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Management considers concentration risk with counterparties considering the level of purchases and sales of its business segments (Note 24). Several of the Company's business units purchase substantially all their inventory or materials from a single supplier.</span></span></span></p>
                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Liquidity risk</b></span></span></span></p>
                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#8217;s financial liabilities consist of trade payables and accrued liabilities, loans payable and debt, and lease liabilities as presented on the statement of financial position. The Company had cash and restricted cash as presented on the statement of financial position. As discussed in Note 13, the Company has 2.2 million Euros ($2.4 million USD) available on credit facilities through one of its German subsidiaries as of December 31, 2023. The Company has no other available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#8217;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.</span></span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade payables and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials and inventory require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 14 and other commitments at Note 19.</span></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>The Company's long-term investments in equity of other entities are not publicly traded and there is not an active market to sell the investments for cash.</span></span></span></p>
                    </div>
                </div>
            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT </b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Environmental</b></span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Fair value</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company&#8217;s financial instruments measured at amortized cost as at March 31, 2024 and December&#160;31,&#160;2023 consist of cash, trade and amounts payable, accrued liabilities, and debt. The amounts reflected in the statements of financial position approximate fair value for all financial instruments due to their short-term maturity, except for debt whose fair value as at March 31, 2024 is &#8364;577,354 (December 31, 2022 - &#8364;504,264).</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Risk management overview</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Credit risk</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's trade and amounts receivable, and cash held with banks and other financial intermediaries.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The carrying amount of the cash represents the maximum credit exposure as presented in the statement of financial position.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company held cash of &#8364;13,899 as at March 31, 2024 (December 31, 2023 - &#8364;13,588). The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has not assessed a loss allowance on these cash balances as at March 31, 2024 and December 31, 2023.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Market risk</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">It is management's opinion that the Company is not subject to significant commodity or interest rate risk.</span></span></p>
                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity risk</b></span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#8217;s financial liabilities consist of trade and amounts payable, and accrued liabilities, and debt as presented on the statement of financial position. The Company had cash as presented on the statement of financial position. The Company has no available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#8217;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.</span></span></p>
                        <div>

                        </div>
                        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Trade and amounts payable, and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 9 and Note 2 for the Company&#8217;s assessment of the uncertainty related to the assumption of the Company continuing to operate as a going concern.</span></span></p>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>12.&#160; FINANCIAL INSTRUMENTS AND RISK MANAGEMENT </b></span></span></p>
                        <div>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Environmental</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Fair value</b></span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company&#8217;s financial instruments measured at amortized cost as at December 31, 2023 and December 31, 2022 consist of cash, trade and amounts payable, accrued liabilities, and debt. The amounts reflected in the statements of financial position approximate fair value for all financial instruments due to their short-term maturity, except for debt whose fair value as at December 31, 2023 is &#8364;504,264 (December 31, 2022 - &#8364;228,704.</span></span></p>
                            <div>
                                <div>

                                </div>
                            </div>
                            <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Risk management overview</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Credit risk</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's amounts receivable, and cash held with banks and other financial intermediaries.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The carrying amount of the cash and represents the maximum credit exposure as presented in the statement of financial position.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company held cash of &#8364;13,588 as at December 31, 2023 (2022 - &#8364;15,281). The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has not assessed a loss allowance on these cash balances as at December 31, 2023 and 2022.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Market risk</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">It is management's opinion that the Company is not subject to significant commodity or interest rate risk.</span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liquidity risk</b></span></span></p>
                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#8217;s financial liabilities consist of trade and amounts payable, and accrued liabilities, and debt as presented on the statement of financial position. The Company had cash as presented on the statement of financial position. The Company has no available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#8217;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.</span></span></p>
                            <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade and amounts payable, and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 9 and Note 2 for the Company&#8217;s assessment of the uncertainty related to the assumption of the Company continuing to operate as a going concern.</span></span></p>
                        </div>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002951700704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_CapitalManagementAbstract', window );"><strong>Capital Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_CapitalManagementDisclosureTextBlock', window );">CAPITAL MANAGEMENT [Text Block]</a></td>
<td class="text">
                <div>
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>23.<span style="display: inline-block; width: 15pt;">&#160;</span></b><b>CAPITAL MANAGEMENT</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company considers the aggregate of its common shares, options, warrants and borrowings as capital. The Company's capital management objective is to ensure sufficient resources are available to meet day to day operating requirements and to safeguard its ability to continue as a going concern to provide returns for shareholders and benefits for other shareholders.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's capital management objectives were being met in 2023 primarily from the use of cash balances from the 2022 and 2023 issuances of common shares and warrants and generating increasing revenue in 2023 from the Company's reportable segments as presented in Note 24.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's officers and senior management take full responsibility for managing the Company's capital and do so through quarterly meetings and regular review of financial information. The Company's Board of Directors is responsible for overseeing this process.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company is not subject to any external capital requirements. As at December 31, 2023, there were no changes in the Company's approach to capital management.</span></span></p>
                    </div>
                </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_CapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_CapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_CapitalManagementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_CapitalManagementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958487216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTED INFORMATION [Text Block]</a></td>
<td class="text">
                    <div>
                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>17.<span style="display: inline-block; width: 15pt;">&#160;</span></b><b>SEGMENTED INFORMATION</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reports its financial results for the following two operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH subsidiaries) and house of brands (primarily JustCBD and Vessel subsidiaries). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>For the year ended December 31, 2023, the Company had three operating segments, which were also its reportable segments: commercial and wholesale, house of brands and pharmaceuticals (formerly the Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries in Colombia). Due to the sale of the Colombian subsidiaries during 2023 and the resulting reclassification into discontinued operations, the Company no longer reports a pharmaceuticals segment. &#160;</span></span></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operates its manufacturing and distribution business within its United States and Germany subsidiaries. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations and includes the Company's long-term investments.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Information regarding the Company's segments is summarized as follows:</span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2024</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11,342</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7,958</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8,020</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13,765</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(1,331</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2,404</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>18,031</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,319</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net (Loss) Income from Continuing Operations</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(236</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">140</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(967</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(354</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(2,171</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2,972</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(3,374</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3,186</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>

                                <div>

                                </div>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10,473</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,096</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11,377</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11,608</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,424</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,922</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24,274</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,626</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Disaggregation of net sales by geographic area:</span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2024</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6,518</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">10,999</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11,343</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7,958</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>170</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">362</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>18,031</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,319</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>

                            </div>
                        </div>
                    </div>
                <span></span>
</td>
<td class="text">
                    <div>
                        <p style="font-size: 10pt; font-family: times new roman; margin: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24.<span style="display: inline-block; width: 15pt;">&#160;</span>SEGMENTED INFORMATION</b></span></span></p>
                        <div>
                            <div>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior to the fourth quarter of the year ended December 31, 2022, the Company had the following four operating segments, which were also its reportable segments: cannabis growth and derivative production, consumer products, pharmaceuticals and nutraceuticals, and beverage and food. Since the acquisition of FGH in December 2022 (Note 10), the Company has been reporting its financial results for the following three operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH and the former Cosechemos subsidiary in Colombia), house of brands (primarily JustCBD and Vessel, as well as the former Kasa Wholefoods Company subsidiary in Colombia), and pharmaceuticals (formerly the Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries in Colombia). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As discussed in Note 2 and Note 5, on July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan to sell all its shares in its Colombian related subsidiaries and its Colombian assets. This sale was completed in full on November 1, 2023. As such, the Company has presented the associated assets and liabilities of these Colombian subsidiaries as held for sale and the results of these subsidiaries are included in discontinued operations.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's operates its manufacturing and distribution business within its United States and Germany subsidiaries. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations and includes the Company's long-term investments.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The following tables show information regarding the Company's segments for the years ended December 31, 2023 and 2022.</span></span></p>
                                <div>

                                </div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In 2023, the Company did not have sales to a single customer exceeding 10% of its consolidated revenue. In 2022, the Company did not have sales to a single customer exceeding 10% of its consolidated revenue.</span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">38,262</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">87</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">44,602</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">39,419</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,793</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,105</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">76,071</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">33,401</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Gross Profit</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,218</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(39</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">15,520</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13,290</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">17,738</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13,251</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Loss from Continuing Operations</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(8,763</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(109</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(31,399</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(29,594</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(81</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,426</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(17,000</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(46,669</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(46,703</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                    </table>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other significant items:</span></span></p>

                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Commercial &amp;<br/>Wholesale</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>House of<br/>Brands</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Pharmaceuticals</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Corporate &amp;<br/>Eliminations</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Consolidated</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,591</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,591</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">93</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(12</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">92</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income taxes</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,650</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,628</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">857</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,478</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,335</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unrealized gain from changes in fair value</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(964</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,027</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,991</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,096</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11,608</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,922</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,626</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2022</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,404</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,404</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(27</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(29</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income taxes</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(12</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,393</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,405</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,077</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">66</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,144</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unrealized loss from changes in fair value</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">593</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">593</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">22,225</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">48,950</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,313</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,499</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">80,987</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Disaggregation of net sales and net loss before income taxes by geographic area:</span></span></p>

                                    <div>
                                        <div>
                                            <div>
                                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">36,536</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">32,312</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">38,262</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">87</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,273</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,002</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">76,071</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">33,401</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                                <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span>
                                                <div>

                                                </div>
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December&#160;31,&#160;2023</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December&#160;31,&#160;2022</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Loss Before Income Taxes</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(31,013</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(27,867</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(10,258</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(121</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(364</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3,120</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,662</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(17,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(48,297</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(48,108</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>
                                        </div>
                                    </div>

                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Disaggregation of property, plant and equipment and other long-lived assets by geographic area:</span></span></p>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, Plant and Equipment</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">354</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">759</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">493</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">459</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">847</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,218</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-top: 10pt;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Long-lived Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,140</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">33,332</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,969</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Colombia</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,392</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">89</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">191</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">186</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">730</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,415</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">48,614</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                        <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11,094</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">45,341</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,096</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,382</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Colombia</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8,122</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">514</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">559</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,922</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7,583</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,626</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">80,987</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>

                            </div>
                        </div>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002957703408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS [Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>18.&#160; &#160; &#160; &#160;&#160;</b><b>SUBSEQUENT EVENTS </b></span></span></span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>ACQUISTION OF TRUHC HOLDING GMBH ("TRUHC")</b></span></span></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On April 16, 2024, the Company entered into a Stock Purchase Agreement (the "Purchase Agreement") with TruHC Holding GmbH (the "Seller") pursuant to which the Company will acquire all of the issued and outstanding shares of TruHC Pharma GmbH in exchange for 2,770,562 common shares of the Company (the "Purchase Price").</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Purchase Price will be paid and satisfied by the Company in two closings. At the first closing on April 22, 2024, the Company issued 2,135,199 of its common shares, which is equal to 19.99% of the Company's issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the "Second Closing"), the Company will issue 635,363 of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Under the Purchase Agreement, the Company is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Due to the timing of the closing of this transaction, purchase accounting is incomplete. The Company is evaluating the potential effects of this acquisition on the financial statements. The acquisition will be accounted for in accordance with Accounting Standards Codification ("ASC") Topic 805, "Business Combinations".</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>APRIL EQUITY OFFERING</b></span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On April 4, 2024, Flora entered into an underwriting agreement with Aegis Capital Corp. ("Aegis") as underwriter, relating to the offering, issuance and sale of up to 1,700,000 of the Company's common shares ("Common Shares"), no par value per Common Share, at a public offering price of $1.90 per Common Share.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The offering closed on April 8, 2024. The net proceeds to the Company for the offering was approximately $2.8 million, after deducting the underwriting discounts and commissions and estimated offering expenses.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The offering of the securities described above was made pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-274204), filed with the Securities and Exchange Commission (the "SEC") on August 25, 2023 and amended on August 30, 2023, which was declared effective, on September 6, 2023, and the base prospectus included therein, as supplemented by the preliminary prospectus supplement filed with the SEC on April 4, 2024 and the final prospectus supplement with the SEC on April 5, 2024.</span></span></span></span></p>
                                    <div>

                                    </div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Aegis acted as sole underwriter for the offering. The Company agreed to provide Aegis an underwriting discount of 7.0% for underwriter-introduced investors and an underwriting discount of 3.0% for Company-introduced investors.&#160;The Company reimbursed Aegis for certain of its expenses, in an amount of up to $0.1 million, including legal fees.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company's CEO, Clifford Starke, subscribed to purchase 1,000,000 of the Common Shares at the public offering price of $1.90 per Common Share</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>AT THE MARKET ("ATM") OFFERING</b></span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>On April 26, 2024, the Company entered into an ATM Issuances Sales Agreement (the "Sales Agreement") with Aegis Capital Corp. (the "Agent") pursuant to which the Company may sell from time to time, at its option, common shares through the Agent in its capacity as sales agent. The sale of common shares, if any, will be made under the Company's registration statement filed on Form S-3 (File No. 333-274204) (the "Registration Statement"), by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act").</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Subject to the terms and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market to sell on the Company's behalf all of the common shares requested to be sold by the Company. The Agent will offer the common shares, subject to the terms and conditions of the Sales Agreement, on a daily basis or as otherwise agreed upon by the Company and the Agent. The Company will designate the maximum amount of common shares to be sold through the Agent on a daily basis or otherwise determine such maximum amount, together with the Agent. The Company may instruct the Agent not to sell common shares if the sales cannot be effected at or above the price designated by the Company in any such instruction. The Company or the Agent may suspend the offering of common shares being made through the Agent under the Sales Agreement upon proper notice to the other parties.</span></span></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The aggregate compensation payable to the Agent, on behalf of the Agent, shall be up to 3.0% of the aggregate gross proceeds from each sale of the common shares sold through the Agent pursuant to the Sales Agreement. In addition, the Company has agreed in the Sales Agreement to provide indemnification and contribution to the Agent against certain liabilities, including liabilities under the Securities Act.</span></span></span></span></p>
                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>The Company is not obligated to make any sales of common shares under the Sales Agreement. The offering of common shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement by the Company or by the Agent, only with respect to itself, under the circumstances specified in the Sales Agreement. The Company has yet to sell any of its common shares under the Sales Agreement.</span></span></span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                        <div>
                            <div>
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>25.&#160;</b></span></span><span style="padding-left: 15pt;">&#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>SUBSEQUENT EVENTS </b></span></span></p>
                                    <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>OTHER</b></span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The contingent purchase consideration related to the acquisition of JustCBD was due on February 24, 2024. The balance of $0.9 million remains unpaid as of the date of filing these consolidated financial statements.</span></span></p>
                                    <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;">&#160;</p>
                                    <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On March 8, 2024, the Company entered into a settlement agreement with a third party pursuant to which the Company issued 50,000 common shares of the Company, valued at $0.1 million, to a third party to settle outstanding amounts owed.</span></span></p>
                                </div>
                            </div>
                        </div>
                    <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS [Text Block]</a></td>
<td class="text">
                            <div>
                                <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>13.&#160; SUBSEQUENT EVENTS </b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 16, 2024, Flora Growth Corp. (&#8220;Flora&#8221;) entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with TruHC Holding GmbH (the &#8220;Seller&#8221;) pursuant to which Flora will acquire all of the issued and outstanding shares of the Company. The Purchase Price will be paid and satisfied by Flora in two closings. On the first closing, Flora issued 2,135,199 of its common shares, which is equal to 19.99% of Flora&#8217;s issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the &#8220;Second Closing&#8221;), Flora will issue 635,363 of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Under the Purchase Agreement, Flora is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 22, 2024, the first closing of the Transaction for 2,135,199 Flora shares was closed.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan were forgiven.</span></span></p>
                            </div>
                        <span></span>
</td>
<td class="text">
                    <div>
                        <p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>114.&#160; SUBSEQUENT EVENTS</b></span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 16, 2024, Flora Growth Corp. (&#8220;Flora&#8221;) entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with TruHC Holding GmbH (the &#8220;Seller&#8221;) pursuant to which Flora will acquire all of the issued and outstanding shares of the Company. The Purchase Price will be paid and satisfied by Flora in two closings. On the first closing, Flora issued 2,135,199 of its common shares, which is equal to 19.99% of Flora&#8217;s issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the &#8220;Second Closing&#8221;), Flora will issue 635,363 of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Under the Purchase Agreement, Flora is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.</span></span></p>
                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On April 22, 2024, the first closing of the Transaction for 2,135,199 Flora shares was closed.</span></span></p>
                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In April 2024, both the First Loan and the Second Loan were forgiven.</span></span></p>
                    </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953925136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and restricted cash [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash and restricted cash</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the consolidated statement of financial position includes cash on hand and deposits held with banks and other financial intermediaries that have a maturity of less than three months at the date they are acquired. Restricted cash in the consolidated statement of financial position includes cash required to be held in deposit accounts related to credit card accounts and merchant accounts.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial assets [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows. Non-derivative financial assets are classified and measured as "financial assets at fair value", as either fair value through profit or loss ("FVPL"), or "financial assets at amortized cost", as appropriate.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">All financial assets are recognized initially at fair value plus, in the case of financial assets not at FVPL, directly attributable transaction costs on the trade date at which the Company becomes a party to the contractual provisions of the instrument.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets with embedded derivatives are considered in their entirety when determining their classification.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these consolidated financial statements, cash, trade and amounts receivables, indemnification receivables, and loans receivable are classified in this category.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at FVPL</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets measured at FVPL include financial assets such as the Company's equity investments in other entities, and any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial assets measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in a separate caption in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, trade and amounts receivables, and loans receivable.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade and note receivables are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by country and customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for trade receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the consolidated statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off. This is determined with judgment or otherwise when discharged by bankruptcy or other legal proceedings.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Inventory</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Inventories </span></span><span>are comprised of raw materials and supplies, and finished goods. Inventories are initially valued at cost and subsequently at the lower of cost and net realizable value. Inventory cost is determined either on a weighted&#160;average cost or specific identification basis and any trade discounts and rebates are deducted from the purchase price</span><span><span>. Raw material costs include the purchase cost of the materials, freight-in and duty. Costs incurred during the production process are capitalized as incurred to the extent that cost is less than net realizable value. These costs include materials, labor and manufacturing overhead used in the production processes. Finished goods include the cost of direct materials and labor and a proportion of manufacturing overhead allocated based on normal production capacity.</span></span></span></span></p>
                                        <div>
                                            <div>

                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net realizable value represents the estimated selling price for inventories in the ordinary course of business, less all estimated costs of completion and costs necessary to make the sale. The determination of net realizable value requires significant judgment, including consideration of factors such as shrinkage, the aging of and future demand for inventory and contractual arrangements with customers. Reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The impact of changes in inventory reserves is reflected in cost of sales.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>

                                            <div>
                                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span><span style="font-size: 10pt; font-family: Times New Roman, Times, serif;">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            5-10 years
                                                        </span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vehicle&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;5 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Building&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;30 years</span></span></p>
                                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Lesser of useful life and remaining term of the lease</span></span></p>
                                            </div>

                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use, including interest on borrowings when significant. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the consolidated statements of loss and comprehensive loss of the related year.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Intangible assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization is provided on a straight-line basis over the assets' estimated useful lives, which do not exceed the contractual period, if any. The Company's finite-lived intangible assets are amortized as follows:</span></span></p>

                                            <div>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Patents and developed technology&#160; &#160; &#160; &#160; &#160;9 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Customer and supplier relationships&#160; &#160; &#160;5-10 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trademarks and brands&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;8-10 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Licenses&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;5 years</span></span></p>
                                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-compete agreements&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;3 years</span></span></p>
                                            </div>

                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Amortization expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investments</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Investments include investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence and are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the "measurement alternative"). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in unrealized loss from changes in fair value on the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment and definite life intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business combinations [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Business combinations</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition related costs are generally recognized in the consolidated statements of loss and comprehensive loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed, are recognized at their fair value.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any noncontrolling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date. If, after assessment, the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in the consolidated statements of loss and comprehensive loss as a bargain purchase gain.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured at the fair value of the acquiree's identifiable net assets.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or liability is remeasured at subsequent reporting dates, with the corresponding gain or loss recognized in the consolidated statements of operations and comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">When a business combination is achieved in stages, the Company's previously held equity interest in the acquiree is remeasured to its acquisition date fair value and the resulting gain or loss, if any, is recognized in the consolidated statements of loss and comprehensive loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to the consolidated statements of loss and comprehensive loss where such treatment would be appropriate if that interest were disposed of.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Purchase price allocations may be preliminary and, during the measurement period not to exceed one year from the date of acquisition, changes in assumptions and estimates that result in adjustments to the fair value of assets acquired and liabilities assumed are recorded in the period the adjustments are determined.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of goodwill and indefinite-lived intangible assets [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of goodwill and indefinite-lived intangible assets</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company operates in three operating segments which are the reporting units and goodwill is allocated at the operating segment level. The Company reviews goodwill and indefinite-lived intangible assets annually for impairment in the fourth quarter, or more frequently, if events or circumstances indicate that the carrying amount of an asset may not be recoverable.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FinancialLiabilitiesPolicyTextBlock', window );">Financial liabilities [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables and other accrued liabilities and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at FVPL</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities measured at FVPL include any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial liabilities measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in other income or expense in the consolidated statements of loss and comprehensive loss. In these consolidated financial statements, trade and other payables and other accrued liabilities, lease liability and loans payable are measured at amortized cost.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ProvisionsPolicyTextBlock', window );">Provisions [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the consolidated statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Share capital [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Additional proceeds from the issuance of common shares are classified as equity in additional paid in capital. Incremental costs directly attributable to the issue of common shares, stock options and warrants are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received. The fair value of options and warrants is determined using the Black Scholes model.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Share based compensation [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share based compensation</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share based compensation to employees is measured at the fair value of the instruments issued and amortized over the vesting periods. Share based compensation to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued if it is determined the fair value of the goods or services cannot be reliably measured and are recorded at the date the goods or services are received. The Company operates an equity based compensation plan. The corresponding amount is recorded to the stock option caption within shareholders&#8217; equity, and the expense to the consolidated statements of loss and comprehensive loss over the vesting period. The fair value of options is determined using the Black&#8211;Scholes pricing model which incorporates all market vesting conditions. For awards with graded vesting schedules, the Company has elected to calculate the fair value as a single award and recognize expense over the total expected vesting period rather than in tranches. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest. Upon exercise of a stock option, any amount related to the initial value of the stock option, along with the proceeds from exercise are recorded to share capital. Upon expiration of a stock option, any amount related to the initial value of the stock option is recorded to accumulated deficit. The Company also grants employees and non-employees restricted stock awards (&#8220;RSAs&#8221;). The fair value of the RSAs is determined using the fair value of the common shares on the date of the grant. The Company has elected to recognize forfeitures as they occur.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Foreign currency translation</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These consolidated financial statements are presented in U.S. dollars ("USD"), which is the Company's reporting currency; however, the functional currency of the entities in these financial statements are their respective local currencies, including Canadian dollar, USD, British pound and euro.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Translation into functional currency</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Transactions in foreign currencies are recorded in the functional currency at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the period end exchange rates. Non-monetary items are translated at the exchange rates in effect on the date of the transactions. Foreign exchange gains and losses arising on translation are presented in the consolidated statements of loss and comprehensive loss.</span></span></p>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Translation into presentation currency</i></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The assets and liabilities of foreign operations are translated into USD at year-end exchange rates. Revenue, expenses, and cash flows of foreign operations are translated into USD using average exchange rates of the reporting period. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in shareholders' equity. The cumulative exchange differences are reclassified to the consolidated statements of loss and comprehensive loss upon the disposal of the foreign operation.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research expenses [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Research expenses</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Research expenses are expensed as they are incurred, net of any related investment tax credits, unless the criteria for capitalization of development expenses are met.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Revenue recognition</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company primarily generates revenue as a distributor of pharmaceuticals and a distributor and retailer of cannabidiol oil derived products. See disaggregation of the Company&#8217;s revenue by operating segments and sales by country in Note 24.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company uses the following five-step contract-based analysis of transactions to determine if, when and how much revenue can be recognized:</span></span></p>
                                        <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt;">
                                            <tr>
                                                <td style="width: 4%; vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Identify the contract with a customer;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Identify the performance obligations in the contract;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Determine the transaction price;</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Allocate the transaction price to the performance obligations in the contract; and</span></span></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="vertical-align: middle;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5.</span></span></p>
                                                </td>
                                                <td style="vertical-align: top;">
                                                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Recognize revenue when or as the Company satisfies the performance obligations.</span></span></p>
                                                </td>
                                            </tr>
                                        </table>
                                        <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Gross revenue excludes duties and taxes collected on behalf of third parties. Revenue is presented net of expected price discounts, sales returns, customer rebates and other incentives.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's contracts with customers for the sales of products consist of one performance obligation. Revenue from product sales is recognized at the point in time when control is transferred to the customer, which is on shipment or delivery, depending on the contract terms. The Company's payment terms generally range from 0 to 30 days from the transfer of control, and sometimes up to two months.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient to not adjust the customer contract consideration for significant financing components when the period between the transfer of the Company's goods and services and customer payment is one year or less.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient to expense, as incurred, the costs of obtaining a customer contract such as sales commissions and other selling transaction costs when the amortization period of the assets otherwise would be one year or less. Accordingly, the Company has no assets recorded for costs to obtain a customer contract as at December 31, 2023 and 2022 as there are no contracts where the underlying asset would have a life exceeding one year.</span></span></p>
                                        <div>
                                            <div>

                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company elected as a permitted practical expedient for shipping and handling not to be a separate performance obligation.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising costs [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Advertising costs</b></span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Advertising costs are expensed as incurred and recorded within the promotion and communication caption on the consolidated statements of loss and comprehensive loss. Advertising costs were $3.4 million in 2023 ($4.4 million in 2022).</span></span></p>
                                        </div>
                                    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the consolidated statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the consolidated statements of loss and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable income or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                        <div>
                                            <div>

                                            </div>
                                        </div>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Loss per share</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share is calculated using the weighted average number of shares outstanding during the year. Diluted loss per share reflects the potential dilution of common share equivalents, such as outstanding options and warrants, in the weighted average number of common shares outstanding during the period, if dilutive. The diluted loss per share calculation excludes any potential conversion of options and warrants that would be anti-dilutive.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NonControllingInterestsPolicyTextBlock', window );">Non-controlling interests [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Non-controlling interests</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-controlling interests of subsidiaries ("NCI") are recognized either at fair value or at the NCI's proportionate share of the net assets, determined on an acquisition-by-acquisition basis at the date of acquisition. Subsequently, the NCI's share of net loss and comprehensive loss is attributed to the NCI.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During 2023, the Company completed the sale of Cosechemos YA S.A.S. and Kasa Wholefoods Company S.A.S to Lisan. These entities each had 10% NCI which was derecognized when the Company lost control during the year ended December 31, 2023. See discussion in Note 5.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued operations and assets and liabilities held for sale [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Discontinued operations and assets and liabilities held for sale</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $0.8 million (USD $0.6 million). The assets and liabilities of these Colombian companies are reflected in the accompanying consolidated balance sheets as assets and liabilities held for sale, respectively. The results of operations of these Colombian companies are included in loss from discontinued operations, net of tax in the accompanying consolidated statements of operations and comprehensive loss. For comparative purposes, all prior periods presented have been reclassified to reflect the classifications on a consistent basis. See discussion in Note 5.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of accounting standards and amendments [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                        <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ("ASU 2021-08"), which requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers ("ASC 606") rather than adjust them to fair value at the acquisition date. The effects of adoption are applied prospectively to business combinations occurring on or after the effective date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective as of January 1, 2023, and as such had no impact on the Company's consolidated financial statements.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Accounting pronouncements not yet adopted [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                        <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2022, the FASB issued Accounting Standards Update 2022-03-Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU 2022-03"), which requires that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The effects of adoption are accounted for prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is assessing the impacts of adoption, but it is not expected to have an impact based on amounts recorded at December 31, 2023 as any changes required are for transactions occurring prospectively upon adoption.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segments Disclosures. The amendments enhance disclosures of significant segment expenses by requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM), extend certain annual disclosures to interim periods, and permit more than one measure of segment profit or loss to be reported under certain conditions. The amendments are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption of the amendment is permitted, including adoption in any interim periods for which financial statements have not been issued. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GoingConcernPolicyTextBlock', window );">Going concern [Policy Text Block]</a></td>
<td class="text">
                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Going concern</b></span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The accompanying unaudited condensed interim consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these unaudited condensed interim consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></span></p>
                                            <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company had cash of $4.2 million at March 31, 2024, net loss of $3.4 million for the three months ended March 31, 2024, and an accumulated deficit of $145.6&#160;million at March 31, 2024. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed interim consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. The unaudited condensed interim consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></span></p>
                                        </div>
                                    <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation [Policy Text Block]</a></td>
<td class="text">
                                        <div>
                                            <p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Basis of consolidation</b></span></span></p>
                                            <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">These unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. At March 31, 2024, the Company's subsidiaries and respective ownership percentage have not changed from the year ended December 31, 2023, except as noted below.</span></span></p>
                                            <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">During the three months ended March 31, 2024, the Company voluntarily dissolved the Cardiff Brand Corp. U.S. entity. Also during the three months ended March 31, 2024, the Company signed articles of organization for Just Brands FL LLC, a United States domestic limited liability company, which is 100% owned by the Company and has a functional currency of the United States dollar.</span></span></p>
                                        </div>
                                    <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and restricted cash [Policy Text Block]</a></td>
<td class="text">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash </b></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the statements of financial position includes cash on hand.</span></span></p>
                                    </div>
                                <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Cash </b></span></span></p>
                                <p><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash in the statements of financial position includes cash on hand.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial assets [Policy Text Block]</a></td>
<td class="text">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                        <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.</span></span></p>
                                        <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.</span></span></p>
                                    </div>
                                <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial assets</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial assets at amortized cost</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Impairment of financial assets</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>
                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;">
                                        <tr>
                                            <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                            <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                        5-10 years
                                                    </span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets</span></span></td>
                                            <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Lesser of useful life and remaining term of the lease</span></span></td>
                                        </tr>
                                    </table>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, plant and equipment</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:</span></span></p>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;">
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                    5-10 years
                                                </span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">&#160;</td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets</span></span></td>
                                        <td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Lesser of useful life and remaining term of the lease</span></span></td>
                                    </tr>
                                </table>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Impairment of long-lived assets</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company reviews long-lived assets, including property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FinancialLiabilitiesPolicyTextBlock', window );">Financial liabilities [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                                </div>

                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Financial liabilities</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Initial recognition and measurement</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Subsequent measurement - Financial liabilities at amortized cost</i></span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.</span></span></p>
                            </div>

                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><i>Derecognition</i></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ProvisionsPolicyTextBlock', window );">Provisions [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Provisions</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Share capital [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital </b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Share capital </b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                                </div>

                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Leases</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.</span></span></p>
                            </div>

                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                    <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Income taxes</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and contingencies [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Commitments and contingencies</b></span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Commitments and contingencies</b></span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of accounting standards and amendments [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Adoption of accounting standards and amendments</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                                <p style="text-align: justify; margin-top: 10pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Accounting pronouncements not yet adopted [Policy Text Block]</a></td>
<td class="text">
                                <div>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                    <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                    <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                                </div>
                            <span></span>
</td>
<td class="text">
                            <div>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Accounting pronouncements not yet adopted</b></span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:</span></span></p>
                                <p style="text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.</span></span></p>
                                <p style="text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.</span></span></p>
                            </div>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FinancialLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FinancialLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NonControllingInterestsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NonControllingInterestsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ProvisionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ProvisionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002951777344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfSubsidiariesTableTextBlock', window );">Schedule of subsidiaries [Table Text Block]</a></td>
<td class="text">
                                            <div style="margin-bottom: 10pt;">
                                                <table border="1" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                    <tr>
                                                        <td style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Subsidiaries</b></span></span></td>
                                                        <td style="width: 14%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Country of<br/>Incorporation</b></span></span></span></span></td>
                                                        <td style="width: 21%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Ownership %</b></span></span></td>
                                                        <td style="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Functional Currency</b></span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Kasa Wholefoods Company LLC
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Flora Beauty LLC
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Vessel Brand Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Vessel Brand Canada Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Just Brands LLC
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Just Brands International LTD
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United Kingdom
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    British Pound (GBP)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    High Roller Private Label LLC
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Flora Growth US Holdings Corp.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Cardiff Brand Corp.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    United States Dollar (USD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Franchise Global Health Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Harmony Health One Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    ACA Mueller ADAG Pharma Vertriebs GmbH
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Germany
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Euro (EUR)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Sativa Verwaltungs GmbH
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Germany
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Euro (EUR)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Sativa Verwaltungs GmbH and Co. KG
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Germany
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Euro (EUR)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    CBD Med Therapeutics Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Fayber Technologies Canada Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Catalunia SAS
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Colombia
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Colombia Peso (COP)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Green CannaHealth SAS
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Colombia
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Colombia Peso (COP)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Klokken Aarhus Inc.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Rangers Pharmaceuticals A/S
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Denmark
                                                                </span></span></td>
                                                        <td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Danish Krone (DAK)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    1200325 B.C. LTD.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Phatebo
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Germany
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Euro (EUR)
                                                                </span></span></td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Franchise Cannabis Corp.
                                                                </span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canada
                                                                </span></span></td>
                                                        <td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                    Canadian Dollar (CAD)
                                                                </span></span></td>
                                                    </tr>
                                                </table>
                                            </div>
                                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003090996832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock', window );">Schedule of assets estimated useful lives [Table Text Block]</a></td>
<td class="text">
                                            <div>
                                                <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span><span style="font-size: 10pt; font-family: Times New Roman, Times, serif;">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            5-10 years
                                                        </span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vehicle&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;5 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Building&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;30 years</span></span></p>
                                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right-of-use assets&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Lesser of useful life and remaining term of the lease</span></span></p>
                                            </div>
                                        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives', window );">Schedule of intangible assets estimated useful lives [Table Text Block]</a></td>
<td class="text">
                                            <div>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Patents and developed technology&#160; &#160; &#160; &#160; &#160;9 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Customer and supplier relationships&#160; &#160; &#160;5-10 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trademarks and brands&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;8-10 years</span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Licenses&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;5 years</span></span></p>
                                                <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-compete agreements&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;3 years</span></span></p>
                                            </div>
                                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003068803952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock', window );">Schedule of major classes of assets and liabilities held for sale [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Assets held for sale</b></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Cash</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">602</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Trade and amounts receivable</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,592</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Prepaid expenses and other current assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">174</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Inventory</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,341</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Total current assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,709</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Property, plant and equipment</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,592</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Operating lease right of use assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">419</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">358</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other assets</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; Total noncurrent assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,392</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8,101</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Liabilities held for sale</b></span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; &#160;Current portion of operating lease liability</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">72</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other accrued liabilities</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">538</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; Total current liabilities held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">610</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Non-current operating lease liability</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">308</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities held for sale</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">918</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>
                                    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock', window );">Schedule of loss from discontinued operations [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span> </span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2024</b></span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2023</b></span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">788</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cost of sales</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">657</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross profit from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">131</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating expenses</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Consulting and management fees</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">369</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">36</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">176</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Promotion and communication</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">50</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">78</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">124</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating loss from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(708</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss before income taxes</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(708</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(719</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.00</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(0.11</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share from discontinued operations</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.00</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(0.11</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2022</b></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Revenue</span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,450</span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,770</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cost of sales</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,123</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,607</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross profit from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">327</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,163</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Consulting and management fees</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">847</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,110</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Professional fees</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">82</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">514</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">General and administrative</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">282</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,208</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Promotion and communication</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">14</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">383</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">93</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">284</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">148</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">485</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Bad debt expense</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">565</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">666</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Asset impairment</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,704</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">454</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other (income) expense</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">125</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,145</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating loss from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,533</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,086</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(27</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net loss before income taxes</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,535</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,059</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on disposal of discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,132</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income tax expense (benefit)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(133</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(9,678</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(5,926</span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Basic loss per share from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1.32</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1.55</span></span></td>
                                                                <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Diluted loss per share from discontinued operations</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1.32</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1.55</span></span></td>
                                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>
                                    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock', window );">Schedule of significant operating and investing items [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span><br/><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2024</b></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>March 31, 2023</b></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating activities of discontinued operations</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">78</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investing activities of discontinued operations</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Purchases of property, plant and equipment</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">94</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                        <div>
                                            <div>
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year<br/>months ended<br/>December 31,<br/>2023</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year<br/>months ended<br/>December 31,<br/>2022</b></span></span></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating activities of discontinued operations</b></span></span></td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Depreciation and amortization</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">148</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">485</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Bad debt expense</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">565</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">666</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Asset impairment</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,704</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">454</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Investing activities of discontinued operations</b></span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Purchases of property, plant and equipment</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">92</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">951</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>
                                        </div>
                                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to&#160;loss net of tax discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to assets and liabilities&#160;held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to&#160;operating and investing items&#160;discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953236320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRADE AND AMOUNTS RECEIVABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of trade and amounts receivable [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>March 31, 2024</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Trade accounts receivable</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>2,595</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2,299</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Allowance for expected credit losses</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>(317</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>)</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">(315</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">HST/VAT receivable</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>765</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1,840</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Other receivables</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>175</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">126</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>3,218</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">3,950</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade accounts receivable</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,299</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,288</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Allowance for expected credit losses</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(315</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,385</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">HST/VAT receivable</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,840</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,294</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other receivables</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">126</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">62</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,950</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,259</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable', window );">Schedule of aging of trade accounts receivable [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>March 31, 2024</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Current</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">567</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">218</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1-30 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">1,314</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">588</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">31-60 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">236</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">577</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">61-90 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">173</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">448</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">91-180 Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">238</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">401</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">180+ Days</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">67</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">67</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">Total trade receivables</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2,595</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">2,299</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 80%;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 398px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">December 31, 2023</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; white-space: nowrap;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>December 31, 2022</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 9px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 112px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 13px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 6px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 118px;">&#160;</td>
                                            <td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 12px;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">218</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,202</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1-30 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">588</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>838</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31-60 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">577</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>660</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">61-90 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">448</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>159</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">91-180 Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">401</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>321</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">180+ Days</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">67</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,108</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 398px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total trade receivables</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 9px; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 112px; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,299</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 13px; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 6px;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 118px; text-align: right;">
                                                <p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>4,288</span></span></span></p>
                                            </td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 12px; text-align: right;">&#160;</td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock', window );">Schedule of allowance for expected credit losses [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at January 1</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,385</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(400</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current period additions for expected credit losses</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(236</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,186</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Write-offs charges against allowance</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,282</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">151</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Recoveries collected</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">24</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">50</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(315</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,385</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of trade and amounts receivable [Table Text Block]</a></td>
<td class="text">
                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">VAT receivable</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,919</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">14,551</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other receivables</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,263</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,343</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">21,182</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">18,894</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        <span></span>
</td>
<td class="text">
                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>December 31, 2023</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>December 31, 2022</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>VAT receivable</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>14,551</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160; &#160;6,761</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Other receivables</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>4,343</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>11,638</span></span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#160;18,894</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>18,399</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of company aging of trade accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003065978304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory [Table Text Block]</a></td>
<td class="text">
                                            <div>
                                                <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Raw materials and supplies</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1,053</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,180</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finished goods</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8,193</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7,328</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9,246</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8,508</span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                            </div>
                                        <span></span>
</td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">December 31, 2022</span></span></td>
                                                <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                                <td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Raw materials and supplies</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1,180</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,363</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Finished goods</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>7,328</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,384</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>8,508</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8,747</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960632128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment [Table Text Block]</a></td>
<td class="text">
                                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Land</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>292</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">298</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Buildings</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>91</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">78</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>697</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">696</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vehicles</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>37</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">37</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1,117</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,109</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 9px;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 91px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(331</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(262</span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 9px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 91px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>786</b></span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">847</span></span></td>
                                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                            </table>
                                        <span></span>
</td>
<td class="text">
                            <div>
                                <table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>December 31, 2023</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>December 31, 2022</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Thousands of United States dollars</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span style="color: #ff0000;">&#160;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span style="color: #ff0000;">&#160;</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Land</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>298</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>291</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Buildings</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>78</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Machinery and office equipment</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>696</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,098</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Vehicles</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>37</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>37</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Total</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,109</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,426</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr style="background-color: #e6efff;">
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Less: accumulated depreciation</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(262</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>(208</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>)</span></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Property, plant and equipment, net</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>847</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,218</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment [Table Text Block]</a></td>
<td class="text">
                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 90%;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 66.9241%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9691%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9292%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">119,062</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">119,062</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">27,967</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1.0296%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">24,225</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2.0592%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">91,095</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">94,837</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        <span></span>
</td>
<td class="text">
                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Machinery and office equipment</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">119,062</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">114,325</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: accumulated depreciation</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">24,225</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,550</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant and equipment, net</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">94,837</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">104,775</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002951746000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock', window );"><strong>Schedule of fair value of warrants [Table Text Block]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock', window );">Schedule of investments activity [Table Text Block]</a></td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Financial asset hierarchy level</span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Investee common<br/>shares</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Warrants CAD 0.30<br/>exercise price</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Warrants CAD 1.00<br/>exercise price</span></span></span></span></td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total</span></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Level 3</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2021</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,987</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">625</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">58</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,670</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,257</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,257</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on changes in fair value</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(591</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(58</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(649</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2022</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">730</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">34</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">764</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(730</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(730</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on changes in fair value</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(34</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(34</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance at December 31, 2023</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfFairValueOfWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfFairValueOfWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958266144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember', window );">Franchise Global Health Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of major class of assets acquired and liabilities [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">730</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,271</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,019</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Indemnity receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,415</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prepaid assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">139</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant, and equipment</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">452</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right of use assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">115</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,102</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,716</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">18,959</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,245</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(98</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current portion of debt</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,062</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Long term lease liability</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(21</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,717</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(9,143</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,816</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember', window );">Just Brands LLC and High Roller Private Label LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of major class of assets acquired and liabilities [Table Text Block]</a></td>
<td class="text">
                            <div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cash</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">535</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">975</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,534</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">540</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Property, plant, and equipment</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">536</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                                <p style="margin-top: 0pt; margin-bottom: 10pt; font-family: Times New Roman,Times,serif; text-align: left;">&#160;</p>
                                <div>

                                </div>
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Right of use assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">772</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other non-current assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">127</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Intangible asset</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,533</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">24,898</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">38,450</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2,273</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current lease liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(644</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Provision for sales tax</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(982</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(24</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other current liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(99</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(4,022</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">34,428</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember', window );">No Cap Hemp Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of major class of assets acquired and liabilities [Table Text Block]</a></td>
<td class="text">
                            <table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; border-top: 1.5pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(Thousands of United States dollars)</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-top: 1.5pt solid #000000;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade receivables</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Inventory</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">725</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Non-current assets</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Goodwill</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">417</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,173</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trade payables and accrued liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(272</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(272</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr style="background-color: #e6efff;">
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net assets acquired</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">901</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002957034432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 8pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; width: 311px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Patents</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Total</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Cost</b></span></span></span></span></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At December 31, 2023</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,892</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,098</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>2,990</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Additions</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>-</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>-</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>-</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At March 31, 2024</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,892</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,098</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>2,990</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Accumulated Amortization</b></span></span></span></span></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At December 31, 2023</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,132</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>912</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>2,044</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Additions</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>31</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>7</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>38</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>At March 31, 2024</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>1,163</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>919</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>$</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>2,082</span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 12px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 124px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 13px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 93px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 10px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 75px;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Net book value at March 31, 2024</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 12px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 124px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>729</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 18px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 13px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 93px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>179</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 45px;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 10px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>$</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 75px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>908</b></span></span></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span>In Thousands of United States dollars</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>License</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Customer<br/>Relationships</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Patents</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Non-<br/>Compete<br/>Agreements</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Goodwill</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><b>Total</b></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Cost</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2021</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">200</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,570</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">2,090</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">4,300</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,190</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">29,025</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Acquired through business combinations</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,397</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">5,945</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">3,063</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">230</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">29,031</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">39,666</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(128</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(25,073</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(25,201</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2022</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,469</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">7,515</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">5,153</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">4,530</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,190</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">23,633</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">43,490</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Accumulated Amortization</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2021</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">6</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">26</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">35</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">48</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">66</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">181</span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Additions</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">66</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">322</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">583</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">573</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">397</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">1,941</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">At December 31, 2022</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">72</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">348</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">618</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">621</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">463</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">$</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">2,122</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">Foreign Currency translation</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">5</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">17</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(18</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">-</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(261</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">(257</span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;">)</span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>Net book value at December 31, 2022</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>1,402</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>7,184</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>4,517</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>3,909</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>727</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>23,372</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span><span style="font-family: Times New Roman,Times,serif;"><b>41,111</b></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                    <div>
                                        <p style="margin: 0pt;">&#160;</p>
                                        <div>

                                        </div>
                                    </div>
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>In Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>License</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Customer and<br/>Supplier<br/>Relationships</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Trademarks<br/>and Brands</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Patents</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Non-<br/>Compete<br/>Agreements</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Goodwill</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Cost</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,469</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>7,515</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>5,153</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>4,530</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,190</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>23,633</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>43,490</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Additions</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>194</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>194</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Impairment</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(1,216</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(6,502</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(3,249</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(3,432</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(529</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(23,372</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(38,300</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2023</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>253</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,207</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234502607">1,904</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,098</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>661</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>261</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234536599">5,384</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Accumulated Amortization</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>72</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>348</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>618</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>621</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>463</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2,122</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Additions</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>200</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>916</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>514</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>291</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>198</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2,119</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>At December 31, 2023</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>272</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,264</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,132</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>912</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>661</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span id="xbrl_20231101234621352">4,241</span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Foreign Currency translation</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>19</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>57</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(12</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(261</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(197</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Net book value at December 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>760</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>186</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 9pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>946</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock', window );">Schedule of weighted average amortization period of intangible assets [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                        <div>
                                            <p style="margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Trademarks and brands <span style="display: inline-block; width: 42.5pt;">&#160;</span>
                                                        6.1 years
                                                    </span></span></p>
                                            <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Patents <span style="display: inline-block; width: 107.31pt;">&#160;</span>
                                                        6.8 years
                                                    </span></span></p>
                                            <p style="margin-top: 0pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total <span style="display: inline-block; width: 114.99pt;">&#160;</span>
                                                        6.2&#160;years
                                                    </span></span></p>
                                        </div>
                                    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of estimation of amortization expense [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 30%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">115</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">152</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">152</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">152</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">152</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">185</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">908</span></span></td>
                                    <td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 20%; border-collapse: collapse; font-size: 10pt;">
                                        <tr>
                                            <td colspan="2" style="text-align: left; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                            <td style="width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                            <td style="width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                            <td style="width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$152</span></span></td>
                                        </tr>
                                    </table>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">In Thousands of United States dollars</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Vessel </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>JustCBD </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>FGH </b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross goodwill recorded prior to December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment recorded prior to December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net book value as at December 31, 2021</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,675</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Acquired through business combinations</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">25,315</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,716</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29,031</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(19,675</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(5,398</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(25,073</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign exchange impacts</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(277</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">16</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(261</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net book value as at December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,640</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,732</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,372</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairment</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(19,640</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3,732</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(23,372</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net book value as at December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002950607408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of leases [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended March</b></span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><b>31, 2024 </b></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">Three months</span></span><br/><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">ended March 31,</span></span> </span></span></span></span></p>
                                        <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;">2023</span></span></span></span></span></span></p>
                                    </td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Components of lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>165</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">316</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Short-term lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>142</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">55</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sublease income</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(84</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>223</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">371</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 1%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 12%; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Information</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating cash flows from operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>345</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">324</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">ROU assets obtained in exchange for new operating lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1,247</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">97</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average remaining lease term in years for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                    3.7
                                                </b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                2.9
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average discount rate for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8.9%</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7.7%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Thousands of United States dollars</span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Year ended<br/>December 31, 2023 </b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span>Year ended<br/>December 31, 2022</span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Components of lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1,211</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>937</span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Short-term lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>324</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>308</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Sublease income</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(71</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1,464</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1,245</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Other Information</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating cash outflows from operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>1,403</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>859</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU assets obtained in exchange for new operating lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>245</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2,609</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average remaining lease term in years for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>
                                                                    2.7
                                                                </b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                3.5
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average discount rate for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>7.9%</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>7.9%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating lease liabilities [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating Leases </b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">794</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">766</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">678</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">505</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">322</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">28</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total future lease payments</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,093</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: imputed interest</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(473</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,620</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(803</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total non-current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,817</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>Operating Leases </b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2024</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>900</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2025</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>460</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2026</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>374</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>2027</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>192</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total future lease payments</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>1,926</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Less: imputed interest</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>(185</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>)</b></span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>1,741</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Less: current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>(799</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>)</b></span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-indent: 18pt; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span>Total non-current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>$</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><span><b>942</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of leases [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the Three<br/>Months Ended<br/>March 31, 2024</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the Three </b><br/><b>Months Ended </b><br/><b>March 31, 2023</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Components of lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating lease expense</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29,970</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31,516</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total lease expense</b></span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29,970</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31,516</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Information</b></span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Operating cash flows from operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;26,343</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">26,343</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">ROU assets obtained in exchange for new operating lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;-</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average remaining lease term in years for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                6.08
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                7.08
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted-average discount rate for operating leases</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.77%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.77%</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Year ended<br/>December 31, 2023</b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>For the period from<br/>February 17, 2022 to </b><br/><b>December 31, 2022</b></span></span></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Components of lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating lease expense</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>123,105</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>84,783</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Total lease expense</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>123,105</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>84,783</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Other Information</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Operating cash flows from operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>70,249</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU assets obtained in exchange for new operating lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>604,294</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average remaining lease term in years for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                6.33
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>
                                                                7.33
                                                            </span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Weighted-average discount rate for operating leases</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>8.77%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>8.77%</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating lease liabilities [Table Text Block]</a></td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Operating Leases</b></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2024</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">79,030</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2025</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">105,373</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2026</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">105,373</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2027</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">105,373</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2028</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">105,373</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thereafter</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">140,497</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total future lease payments</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">641,019</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: imputed interest</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">145,612</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">495,407</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Less: current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(64,477</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                </tr>
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total non-current lease liabilities</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#8364;</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">430,930</span></span></td>
                                    <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Operating Leases</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2024</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2025</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2026</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2027</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2028</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>105,373</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thereafter</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>140,497</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total future lease payments</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>667,362</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Less: imputed interest</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(156,698</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>510,664</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Less: current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(63,083</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total non-current lease liabilities</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>447,581</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953155168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of stock options roll forward [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                        <div>
                            <div>
                                <div>
                                    <div>
                                        <div>
                                            <div>
                                                <div>
                                                    <div>
                                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                                <td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Options Outstanding</b></span></span></span></span></span></span></td>
                                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Options Exercisable</b></span></span></span></span></span></span></td>
                                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Number of<br/>options (in<br/>thousands)</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Weighted<br/>average<br/>exercise price</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Number of<br/>options (in<br/>thousands)</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><span><span><b>Weighted<br/>average<br/>exercise<br/>price</b></span></span></span></span></span></span></td>
                                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Balance, December 31, 2021</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>272</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>39.06</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>272</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>$</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>39.06</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Granted</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>90</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>19.15</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>1</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>29.60</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Exercised</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(27</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>3.00</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(27</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>3.00</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Forfeited</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(45</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>52.44</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(34</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>54.39</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Balance, December 31, 2022</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>290</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>34.17</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>212</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>41.19</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Granted</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>5</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>7.00</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>14</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>17.43</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Forfeited</span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(246</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>35.05</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>(182</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>)</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>42.31</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                            </tr>
                                                            <tr>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Balance, December 31, 2023</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>49</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>27.04</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>44</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>29.30</b></span></span></span></span></td>
                                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                            </tr>
                                                        </table>
                                                    </div>
                                                </div>
                                            </div>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div>
                            <div>
                                <div>
                                    <div>
                                        <div>&#160;
                                            <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Options<br/>outstanding </b></span></span></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Options<br/>exercisable</b><b>&#160;</b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Exercise<br/>price</b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 14%; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Grant date fair value<br/>vested </b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Remaining life in<br/>years </b></span></span></span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                                    <td colspan="3" style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands of Dollars</b></span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                June 28, 2024
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">17</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">17</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 14%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                0.5
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                July 15, 2025
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">45.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">83</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                1.5
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                December 23, 2025
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">45.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">230</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                2.0
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                September 25, 2026
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">138.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">205</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                2.7
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                December 16, 2026
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">40.80</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">185</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                3.0
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                January 17, 2027
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">34.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">63</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                3.0
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                January 26, 2027
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">29.60</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">25</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                3.1
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                March 17, 2033
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7.00</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; width: 14%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">26</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                9.2
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                July 5, 2033
                                                            </span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13.40</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 1%; background-color: #e6efff;">&#160;</td>
                                                    <td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; width: 14%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">31</span></span></td>
                                                    <td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                9.5
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                </tr>
                                                <tr>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;">&#160;</td>
                                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">49</span></span></td>
                                                    <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">44</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">27.04</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 14%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">861</span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                                2.8
                                                            </span></span></td>
                                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                </tr>
                                            </table>
                                            <p style="margin: 0pt;">&#160;</p>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of stock options outstanding and exercisable [Table Text Block]</a></td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Options Outstanding</b></span></span></td>
                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Number of</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>options (in</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>thousands)</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>average</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>exercise</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted average</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>remaining life</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>(years)</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Aggregate</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>intrinsic</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>value</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Outstanding balance, December 31, 2023</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">49</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">27.04</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            2.8
                                                        </span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Forfeited</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(11</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">44.03</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            2.0
                                                        </span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Outstanding balance, March 31, 2024</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>38</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>22.25</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                                2.7
                                                            </b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Exercisable balance, March 31, 2024</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>38</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>22.25</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                                2.7
                                                            </b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average inputs and assumptions [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2022</span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Risk-free annual interest rate</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2.77%</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.85%</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current stock price</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.90</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">18.95</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected annualized volatility</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>100%</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">100%</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected life (years)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>
                                                            10
                                                        </b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                        7
                                                    </span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Expected annual dividend yield</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>0%</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0%</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercise price</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.00</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19.16</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Weighted average grant date fair value</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7.00</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19.16</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfRestrictedStockAwards', window );">Schedule of restricted stock awards [Table Text Block]</a></td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Number of</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>restricted stock</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>awards</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted</b></span></span></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>average grant</b></span></span></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>date fair value</b></span></span></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Thousands</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2023</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">391</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.41</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(363</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(0.76</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(4</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6.90</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10.24</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
<td class="text">
                        <div>
                            <div>
                                <div>
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Number of<br/>restricted stock<br/>awards</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Weighted<br/>average grant<br/>date fair value</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Thousands</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>$</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2021</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Granted</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">147</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13.64</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">14.62</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2022</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">146</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13.64</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Granted</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">838</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.44</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(174</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(8.92</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Vested</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(419</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2.66</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance, December 31, 2023</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">391</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.41</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                </div>
                            </div>
                        </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002949598288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfWarrantsOutstandingTableTextBlock', window );">Schedule of warrants outstanding [Table Text Block]</a></td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; border-top: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Number of warrants</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted average</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>exercise price</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">
                                                <p style="font-family: Times New Roman, Times, serif;"><span style="font-size: 10pt;">Balance, December 31, 2023</span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,384</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9.90</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, March 31, 2024</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,384</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.90</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Number of warrants</b></span></span></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Weighted average<br/>exercise price</b></span></span></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: center;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2021</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>438</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>67.46</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercised</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(24</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9.83</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(103</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">60.00</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">650</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1.20</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2022</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>961</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24.84</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Exercised</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.00</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Cancelled</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(691</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.00</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Issued</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,115</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance, December 31, 2023</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,384</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                    <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>9.90</b></span></span></td>
                                    <td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding by date of expiry [Table Text Block]</a></td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Warrants</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>outstanding</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Exercise</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>price</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Grant date fair</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>value</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Remaining life</b></span></span></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>in years</b></span></span></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            November 18, 2026
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">221</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">75.00</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,729</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            2.64
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            November 18, 2027
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">66.00</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,055</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            3.64
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            December 8, 2027
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">25</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.80</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">149</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            3.69
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            September 21, 2028
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">691</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">712</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            4.48
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            September 21, 2028
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">55</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.39</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">81</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            4.48
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            March 21, 2029
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,369</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,120</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            4.98
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,384</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9.90</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,846</span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                            4.58
                                                        </span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Date of expiry</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Warrants<br/>outstanding</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Exercise<br/>price</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Grant date fair<br/>value</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Remaining life<br/>in years</b></span></span></span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands</span></span></td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                November 18, 2026
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">221</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">75.00</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,700</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                2.88
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                November 18, 2027
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">66.00</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,055</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                3.88
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                December 8, 2027
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">25</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8.80</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">149</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                3.94
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                September 21, 2028
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">691</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">522</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                4.73
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                September 21, 2028
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">55</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.39</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">81</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                4.73
                                            </span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                March 21, 2029
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,369</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.50</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,339</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                5.22
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,384</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9.90</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,846</span></span></td>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">
                                                4.83
                                            </span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002955090016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY DISCLOSURES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transactions [Table Text Block]</a></td>
<td class="text">
                                <div>
                                    <table cellpadding="0" cellspacing="0" style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; width: 1px; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Year ended<br/>December 31, 2022</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Directors' and officers' compensation</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,862</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,560</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Share-based compensation</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,577</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">797</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 426.4px;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,439</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,357</span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                </div>
                            <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002954140288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock', window );">Schedule of provisions and contingent liabilities [Table Text Block]</a></td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Legal disputes</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sales tax</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2023</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,962</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,538</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,500</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Payments/Settlements</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(7</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(168</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(175</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Additional provisions</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,007</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">158</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,165</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign currency translation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">101</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">101</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Balance as at March 31, 2024</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>4,063</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,528</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6,591</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;">&#160;</td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>
                                <span></span>
</td>
<td class="text">
                                <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Termination benefits</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Legal disputes</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Sales tax</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2022</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">183</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,030</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,831</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,044</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Payments/settlements</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(183</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(98</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(281</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Additional provisions</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">707</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">715</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Foreign currency translation</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">22</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">22</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Balance as at December 31, 2023</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,962</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,538</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">5,500</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003068870080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred income tax assets and liabilities [Table Text Block]</a></td>
<td class="text">
                                <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of United States dollars</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2022</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Non-capital loss carryforwards</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b>&#160;</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>19,725</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">20,240</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Share issuance costs</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>847</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,406</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Unrealized gains (losses) on investments</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>5,858</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">823</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Right of use assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>287</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">614</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Fixed assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>77</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>718</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Goodwill</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>7,747</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Sec 174 - R&amp;D expense</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>263</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Other</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>564</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">677</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Allowance for doubtful accounts</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>64</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Gross deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>36,150</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,760</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Valuation allowance</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(36,150</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(20,909</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total net deferred tax assets</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,851</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Intangible assets</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,094</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Lease obligations</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">469</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,563</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Net deferred tax liabilities</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,712</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                </table>
                            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of corporate income tax rate [Table Text Block]</a></td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>For the year ended<br/>December 31, 2022</span></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Statutory Canadian&#160;rate</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>26.5%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">26.5%</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;">&#160;</td>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Earnings in jurisdictions taxed at different rates</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-1.3%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.5%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Impairments</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-1.9%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-12.9%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-0.8%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-1.7%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Loss on investments</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-3.0%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.0%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Valuation allowance</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-23.8%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-12.3%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Other permanent items</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>1.3%</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.8%</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Prior year adjustments, change in tax rates</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6.4%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">0.0%</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3.4%</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2.9%</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of the income tax provision [Table Text Block]</a></td>
<td class="text">
                                <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Thousands of United States dollars</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>For the year ended<br/>December 31, 2023</b></span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>For the year ended<br/>December 31, 2022</span></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Current</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Canada</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; U.S. federal</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>17</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160;U.S. state</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>5</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Foreign</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>103</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total current tax expense</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>125</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Deferred</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Canada</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(1,767</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(11</span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160;&#160;U.S. federal</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,055</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; U.S. state</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>-</b></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(316</span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160; &#160; Foreign</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>14</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(23</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total deferred tax expense</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(1,753</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,405</span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 81pt;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;">&#160;</td>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total income tax benefit</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(1,628</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,405</span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                    </tr>
                                </table>
                            <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred income tax assets and liabilities [Table Text Block]</a></td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>2022</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: center; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Property and equipment</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>8,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>3,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>ROU asset</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(154,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(179,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Lease liability</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>165,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>183,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Non-capital losses available for future period</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="width: 15%; text-align: right;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>174,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>64,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>193,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>71,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Unrecognized deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(193,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>(71,000</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>)</span></span></span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Total net deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>-</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>Net deferred tax assets</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span>&#8364;</span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>-</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002951741328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive shares [Table Text Block]</a></td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>Three months</b></span></span></span></span></p>
                                                    <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>ended</b></span></span></span></span></p>
                                                </td>
                                                <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>38</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">275</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Warrants</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,384</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">960</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted stock awards</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">198</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD potential additional shares to settle contingent consideration</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>632</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">657</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total anti-dilutive</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>3,078</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,090</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
<td class="text">
                            <table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Thousands of securities</span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;">&#160;</td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                    <td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock options</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">49</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">290</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Warrants</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,384</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">961</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Restricted stock awards</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">391</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">146</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">JustCBD potential additional shares to settle contingent consideration</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">632</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                    <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">657</span></span></td>
                                    <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                </tr>
                                <tr>
                                    <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total anti-dilutive</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,456</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,054</span></span></td>
                                    <td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                </tr>
                            </table>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002951788080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications', window );">Schedule of information about the financial instruments and their classifications [Table Text Block]</a></td>
<td class="text">
                                    <div>
                                        <p style="text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Fair value measurements at March 31, 2024 using:</span></span></span></p>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>&#160;</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Contingent purchase consideration from asset acquisitions and business combinations</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>-</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>1,461</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>241</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>$</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>1,702</b></span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                        <span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>&#160;</span></span></span>
                                        <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Fair value measurements at December 31, 2023 using:</span></span></span></p>
                                        <span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"> <span>&#160;</span></span></span>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>Contingent purchase consideration from asset acquisitions and business combinations</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>-</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>854</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>241</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-family: Times New Roman,Times,serif;"><span style="font-size: 10pt;"><span>1,095</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
<td class="text">
                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Fair value measurements at December 31, 2023 using:</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of United States Dollars</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 1</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 2</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 3</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Total</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial assets:</span></span></span></td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Investments (Note 9)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial liabilities:</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Contingent purchase consideration from business combinations (Note 10)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>854</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>241</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1,095</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Fair value measurements at December 31, 2022 using:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: justify;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of United States Dollars</span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 1</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 2</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Level 3</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>Total</b></span></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial assets:</span></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Investments (Note 9)</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>764</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>764</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Financial liabilities:</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Contingent purchase consideration from business combinations (Note 10)</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,646</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>901</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>$</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>3,547</span></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock', window );">Schedule of assets and liabilities denominated in foreign currencies [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                            <div>
                                <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>December 31, 2023</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CAD</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>GBP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>EUR</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of foreign currencies</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Cash</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>969</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>35</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Amounts receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,995</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>125</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Loans receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade payables</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(6,767</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(22</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(18</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Accrued liabilities</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(48</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(69</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Lease liability</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(126</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(41</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Long term debt</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(2,560</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Net carrying value</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(5,537</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>28</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(17</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                    </tr>
                                </table>
                            </div>

                            <div>
                                <table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>December 31, 2022</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CAD</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>COP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>GBP</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>EUR</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>CHF</b></span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Thousands of foreign currencies</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Cash</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1,691</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,961,487</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>64</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>1</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Amounts receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>2,964</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>15,127,223</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>61</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Loans receivable</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>250</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Trade payables</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(9,333</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(2,975,794</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(56</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(161</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Accrued liabilities</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(522</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(1,173,118</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(22</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Lease liability</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(153</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(1,809,970</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(17</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Long term debt</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(1,446</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>-</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                    </tr>
                                    <tr>
                                        <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>Net carrying value</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(6,799</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>12,129,828</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>30</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>(160</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>)</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span>250</span></span></span></td>
                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                    </tr>
                                </table>
                            </div>
                        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959862352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of operation segment information [Table Text Block]</a></td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2024</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11,342</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7,958</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>8,020</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13,765</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(1,331</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2,404</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>18,031</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,319</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net (Loss) Income from Continuing Operations</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(236</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">140</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(967</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(354</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(2,171</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(2,972</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>(3,374</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>)</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3,186</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                    </table>
                                    <p style="margin: 0pt;">&#160;</p>

                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">As at</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>March 31, 2024</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>10,473</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,096</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11,377</b></span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11,608</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2,424</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,922</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>24,274</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,626</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">38,262</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">87</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">44,602</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">39,419</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,793</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,105</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">76,071</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">33,401</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Gross Profit</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,218</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(39</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">15,520</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13,290</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">17,738</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">13,251</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Loss from Continuing Operations</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Commercial &amp; Wholesale</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(8,763</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(109</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">House of Brands</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(31,399</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(29,594</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Pharmaceuticals</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(81</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Corp &amp; Eliminations</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,426</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(17,000</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(46,669</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(46,703</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfOtherSignificantItemsTableTextBlock', window );">Schedule of other significant items [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>&#160;</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Commercial &amp;<br/>Wholesale</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>House of<br/>Brands</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Pharmaceuticals</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Corporate &amp;<br/>Eliminations</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>Consolidated</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2023</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,591</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,591</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">93</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(12</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">92</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income taxes</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,650</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,628</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">857</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,478</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,335</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unrealized gain from changes in fair value</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(964</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,027</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,991</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,096</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11,608</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,922</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,626</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>2022</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Stock based compensation</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,404</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,404</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Interest expense (income)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(27</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(29</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Income taxes</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(12</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,393</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(1,405</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Depreciation and amortization</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,077</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">66</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,144</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Unrealized loss from changes in fair value</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">593</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">593</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Total assets</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">22,225</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">48,950</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">3,313</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">6,499</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">80,987</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of disaggregation of net sales by geographic area [Table Text Block]</a></td>
<td class="text">
                                    <table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;">
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;">
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>For the three</b></span></span></span></span></span></span></span></span></p>
                                                <p style="margin-top: 0pt; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><span style="margin-top: 0pt; margin-bottom: 0pt;"><b>months ended</b></span></span></span></span></span></span></span></span></p>
                                            </td>
                                            <td style="vertical-align: bottom; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2024</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><span><b>March 31, 2023</b></span></span></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>6,518</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">10,999</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>11,343</b></span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7,958</span></span></td>
                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>170</b></span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">362</span></span></td>
                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                        </tr>
                                        <tr>
                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>$</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>18,031</b></span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,319</span></span></td>
                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                        </tr>
                                    </table>
                                <span></span>
</td>
<td class="text">
                                    <div>
                                        <div>
                                            <div>
                                                <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                                    <tr>
                                                        <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Sales</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">36,536</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">32,312</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">38,262</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">87</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,273</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                        <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,002</span></span></td>
                                                        <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                    </tr>
                                                    <tr>
                                                        <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">76,071</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">33,401</span></span></td>
                                                        <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                    </tr>
                                                </table>
                                                <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span>
                                                <div>

                                                </div>
                                                <div>
                                                    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                                        <tr>
                                                            <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December&#160;31,&#160;2023</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December&#160;31,&#160;2022</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Net Loss Before Income Taxes</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(31,013</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(27,867</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(10,258</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(121</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(364</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                            <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(3,120</span></span></td>
                                                            <td style="vertical-align: bottom; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(6,662</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(17,000</span></span></td>
                                                            <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                        <tr>
                                                            <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(48,297</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">(48,108</span></span></td>
                                                            <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">)</span></span></td>
                                                        </tr>
                                                    </table>
                                                </div>
                                            </div>
                                        </div>
                                    </div>
                                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of disaggregation of long-lived assets by geographic area [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
                                    <div>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Property, Plant and Equipment</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">354</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">759</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">493</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">459</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">847</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,218</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                        </table>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-top: 10pt;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Other Long-lived Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,140</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">33,332</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,969</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Colombia</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">4,392</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">89</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">191</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">186</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">730</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">1,415</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">48,614</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                        <span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">&#160;</span></span>
                                        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;">
                                            <tr>
                                                <td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2023</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>December 31, 2022</b></span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Total Assets</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>&#160;</b></span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United States</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">11,094</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">45,341</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Germany</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">9,096</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">19,382</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Colombia</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">-</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">8,122</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">United Kingdom</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">514</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">559</span></span></td>
                                                <td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">Canada</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">2,922</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;">&#160;</td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">7,583</span></span></td>
                                                <td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;">&#160;</td>
                                            </tr>
                                            <tr>
                                                <td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">23,626</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">$</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">80,987</span></span></td>
                                                <td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;">&#160;</td>
                                            </tr>
                                        </table>
                                    </div>
                                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfOtherSignificantItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfOtherSignificantItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959580672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Narrative) (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 05, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jul. 05, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (56,347)<span></span>
</td>
<td class="num">$ (52,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeEarningsDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (145,600)<span></span>
</td>
<td class="num">$ (142,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLLCMember', window );">Just Brands FL LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Ownership %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,281<span></span>
</td>
<td class="nump">&#8364; 15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (59,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (216,882)<span></span>
</td>
<td class="num">&#8364; (216,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(371,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeEarningsDeficit', window );">Accumulated deficit | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (694,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (588,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member] | Lisan Farma Colombia LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale', window );">Purchase price</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEarningsDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative earnings (deficits) for relevant time periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEarningsDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002966390672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Schedule of subsidiaries) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryOneMember', window );">Subsidiary 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Kasa Wholefoods Company LLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">United States Dollar (USD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwoMember', window );">Subsidiary 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Flora Beauty LLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">United States Dollar (USD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryThreeMember', window );">Subsidiary 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Vessel Brand Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">United States Dollar (USD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFourMember', window );">Subsidiary 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Vessel Brand Canada Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">United States Dollar (USD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFiveMember', window );">Subsidiary 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Just Brands LLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">United States Dollar (USD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySixMember', window );">Subsidiary 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Just Brands International LTD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">United Kingdom<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">British Pound (GBP)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySevenMember', window );">Subsidiary 7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">High Roller Private Label LLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">United States Dollar (USD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryEightMember', window );">Subsidiary 8 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Flora Growth US Holdings Corp.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">United States Dollar (USD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryNineMember', window );">Subsidiary 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Cardiff Brand Corp.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">United States<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">United States Dollar (USD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTenMember', window );">Subsidiary 10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Franchise Global Health Inc<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Canadian Dollar (CAD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryElevenMember', window );">Subsidiary 11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Harmony Health One Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Canadian Dollar (CAD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwelveMember', window );">Subsidiary 12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">ACA Mueller ADAG Pharma Vertriebs GmbH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Germany<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Euro (EUR)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryThirteenMember', window );">Subsidiary 13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Sativa Verwaltungs GmbH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Germany<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Euro (EUR)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFourteenMember', window );">Subsidiary 14 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Sativa Verwaltungs GmbH and Co. KG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Germany<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Euro (EUR)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFifteenMember', window );">Subsidiary 15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">CBD Med Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Canadian Dollar (CAD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySixteenMember', window );">Subsidiary 16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Fayber Technologies Canada Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Canadian Dollar (CAD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySeventeenMember', window );">Subsidiary 17 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Catalunia SAS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Colombia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Colombia Peso (COP)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryEighteenMember', window );">Subsidiary 18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Green CannaHealth SAS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Colombia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Colombia Peso (COP)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryNineteenMember', window );">Subsidiary 19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Klokken Aarhus Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Canadian Dollar (CAD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyMember', window );">Subsidiary 20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Rangers Pharmaceuticals A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Denmark<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Danish Krone (DAK)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyOneMember', window );">Subsidiary 21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">1200325 B.C. LTD.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Canadian Dollar (CAD)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyTwoMember', window );">Subsidiary 22 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Phatebo<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Germany<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Euro (EUR)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyThreeMember', window );">Subsidiary 23 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BasisOfAccountingLineItems', window );"><strong>Basis Of Accounting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Subsidiaries</a></td>
<td class="text">Franchise Cannabis Corp.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FunctionalCurrencyOfSubsidiary', window );">Functional Currency</a></td>
<td class="text">Canadian Dollar (CAD)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_BasisOfAccountingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_BasisOfAccountingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FunctionalCurrencyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FunctionalCurrencyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionNameOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiarySeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=flgc_SubsidiaryTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953293488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 05, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jul. 05, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member] | Lisan Farma Colombia LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale', window );">Proceeds from property held for sale</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=flgc_CosechemosAndKasaWholefoodsMember', window );">Cosechemos YA S.A.S. and Kasa Wholefoods Company S.A.S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=flgc_CosechemosAndKasaWholefoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=flgc_CosechemosAndKasaWholefoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003090939696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of assets estimated useful lives) (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | Machinery and office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | Machinery and office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003051550336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of intangible assets estimated useful lives) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer and supplier relationships [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer and supplier relationships [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember', window );">Trademarks and brands [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember', window );">Trademarks and brands [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_LicensesMember', window );">Licenses [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002957266592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Narrative) (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 05, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jul. 05, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on disposal of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,132<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member] | Lisan Farma Colombia LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale', window );">Proceeds from property held for sale</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on disposal of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959986464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of major classes of assets and liabilities held for sale) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total noncurrent assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member] | Lisan Farma Colombia LLC [Member] | Colombian related subsidiaries and Colombian assets [Member] | Discontinued Operations, Held-for-Sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Trade and amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total noncurrent assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Non-current operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as operating lease liability attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as operating lease right of use assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002954755248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of loss from discontinued operations) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on disposal of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,926)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member] | Lisan Farma Colombia LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees', window );">Consulting and management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication', window );">Promotion and communication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment', window );">Asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense', window );">Interest (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on disposal of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Basic loss per share from discontinued operations | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted loss per share from discontinued operations | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member] | Lisan Farma Colombia LLC [Member] | Discontinued Operations, Held-for-Sale [Member] | Colombian related subsidiaries and Colombian assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,607<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees', window );">Consulting and management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication', window );">Promotion and communication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment', window );">Asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense', window );">Interest (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on disposal of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,926)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Asset impairment attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Bad debt expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consulting and management fees attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of professional fees attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of promotion and communication attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953215184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of significant operating and investing items) (Details) - Share Purchase Agreement [Member] - Lisan Farma Colombia LLC [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract', window );"><strong>Operating activities of discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment', window );">Asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,704<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract', window );"><strong>Investing activities of discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Purchases of property, plant and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Asset impairment attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Bad debt expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=flgc_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_LisanFarmaColombiaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959648864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRADE AND AMOUNTS RECEIVABLE (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs of trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs of trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs of trade receivables | &#8364;</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953323520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TRADE AND AMOUNTS RECEIVABLE (Schedule of trade and other receivables) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for expected credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,385)<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivable', window );">HST/VAT receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivable', window );">HST/VAT receivable | &#8364;</a></td>
<td class="nump">&#8364; 19,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables | &#8364;</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total | &#8364;</a></td>
<td class="nump">&#8364; 21,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_TradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of trade accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_TradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002950255488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TRADE AND AMOUNTS RECEIVABLE (Schedule of aging of trade accounts receivable) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems', window );"><strong>Financing Receivable, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAccountsReceivable', window );">Total trade receivables</a></td>
<td class="nump">$ 2,595<span></span>
</td>
<td class="nump">$ 2,299<span></span>
</td>
<td class="nump">$ 4,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancialAssetNotPastDueMember', window );">Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems', window );"><strong>Financing Receivable, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAccountsReceivable', window );">Total trade receivables</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables1To29DaysPastDueMember', window );">1-30 Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems', window );"><strong>Financing Receivable, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAccountsReceivable', window );">Total trade receivables</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables30To59DaysPastDueMember', window );">31-60 Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems', window );"><strong>Financing Receivable, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAccountsReceivable', window );">Total trade receivables</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables60To89DaysPastDueMember', window );">61-90 Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems', window );"><strong>Financing Receivable, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAccountsReceivable', window );">Total trade receivables</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember', window );">91-180 Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems', window );"><strong>Financing Receivable, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAccountsReceivable', window );">Total trade receivables</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=flgc_FinancingReceivables180PlusDaysPastDueMember', window );">180+ Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems', window );"><strong>Financing Receivable, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAccountsReceivable', window );">Total trade receivables</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 1,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_TradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of trade accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_TradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 80<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479294/326-20-55-80<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancialAssetNotPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancialAssetNotPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables1To29DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables1To29DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables30To59DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables30To59DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables60To89DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivables60To89DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=flgc_FinancingReceivables180PlusDaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=flgc_FinancingReceivables180PlusDaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960097568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRADE AND AMOUNTS RECEIVABLE (Schedule of allowance for expected credit losses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for expected credit losses, beginning balance</a></td>
<td class="num">$ (1,385)<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses', window );">Current period additions for expected credit losses</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(1,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance', window );">Write-offs charges against allowance</a></td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Recoveries collected</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for expected credit losses, ending balance</a></td>
<td class="num">$ (315)<span></span>
</td>
<td class="num">$ (1,385)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an increase to the cumulative amount of credit losses recognized in earnings for an other than temporary impairment (OTTI) of a debt security held for which a previous OTTI was recognized and the investor does not intend to sell the debt security and it is not more likely than not that the investor will be required to sell the debt security before recovery of its amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-8B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the allowance for uncollectible accounts, for time sharing transactions, from direct write-offs charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 978<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482707/978-310-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953131616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_InventoryExpensedToCostOfSales', window );">Inventory expensed to cost of sales</a></td>
<td class="nump">$ 54.9<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WritedownsReversalsOfInventories', window );">Write-downs to cost of sales for impairment of inventory</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_InventoryExpensedToCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_InventoryExpensedToCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WritedownsReversalsOfInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WritedownsReversalsOfInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959840720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Schedule of inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials and supplies</a></td>
<td class="nump">$ 1,053<span></span>
</td>
<td class="nump">$ 1,180<span></span>
</td>
<td class="nump">$ 2,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">8,193<span></span>
</td>
<td class="nump">7,328<span></span>
</td>
<td class="nump">6,384<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 9,246<span></span>
</td>
<td class="nump">$ 8,508<span></span>
</td>
<td class="nump">$ 8,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959714944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense | &#8364;</a></td>
<td class="nump">&#8364; 3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958743344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Schedule of property, plant and equipment) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation | &#8364;</a></td>
<td class="num">&#8364; (27,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (24,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (9,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net | &#8364;</a></td>
<td class="nump">91,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | Machinery and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment | &#8364;</a></td>
<td class="nump">&#8364; 119,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 119,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 114,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959772016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS (Narrative) (Details) - 12 months ended Dec. 31, 2023<br> $ / shares in Units, &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>$ / shares</div></th>
<th class="th">
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PurchaseOfCommonStock', window );">Purchase of common stock</a></td>
<td class="nump">&#8364; 2.0<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors', window );">Shares issued to purchase warrants from existing investors | shares</a></td>
<td class="nump">11,250<span></span>
</td>
<td class="nump">11,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_InvestmentDescription', window );">Investment description</a></td>
<td class="text">the Company owns approximately 9.6% of the investee, or approximately 9% on a diluted basis including exercisable warrants of the Company and other investors.<span></span>
</td>
<td class="text">the Company owns approximately 9.6% of the investee, or approximately 9% on a diluted basis including exercisable warrants of the Company and other investors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_CumulativeImpairmentRelatedToCommonShares', window );">Cumulative impairment related to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfImpairment', window );">Description of impairment</a></td>
<td class="text">the investee common shares were valued considering price to book value and price to tangible book value of the investee (3.6 and 4.8, respectively) as well as comparable guideline publicly traded companies at the time of initial investment. These initial investment multiples were compared to the guideline public company multiples observed as at December 31, 2023 (negligible or nil price to book and price to tangible values), with these updated valuation multiples applied to the investee's estimated book value.<span></span>
</td>
<td class="text">the investee common shares were valued considering price to book value and price to tangible book value of the investee (3.6 and 4.8, respectively) as well as comparable guideline publicly traded companies at the time of initial investment. These initial investment multiples were compared to the guideline public company multiples observed as at December 31, 2023 (negligible or nil price to book and price to tangible values), with these updated valuation multiples applied to the investee's estimated book value.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=flgc_FirstTrancheMember', window );">First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ExercisePriceOfInvestmentWarrants', window );">Exercise price of investment warrants | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=flgc_SecondTrancheMember', window );">Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ExercisePriceOfInvestmentWarrants', window );">Exercise price of investment warrants | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_CumulativeImpairmentRelatedToCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_CumulativeImpairmentRelatedToCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DescriptionOfImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information related to Impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DescriptionOfImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ExercisePriceOfInvestmentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price of investment warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ExercisePriceOfInvestmentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_InvestmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_InvestmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_PurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_PurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued to purchase warrants from existing investors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=flgc_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=flgc_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=flgc_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=flgc_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958036064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS (Schedule of investments activity) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInAffiliateActivityLineItems', window );"><strong>Investments in and Advances to Affiliates, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="num">$ (898)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInAffiliateActivityLineItems', window );"><strong>Investments in and Advances to Affiliates, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investments, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">$ 2,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(730)<span></span>
</td>
<td class="num">(1,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Loss on changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investments, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Investee common shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInAffiliateActivityLineItems', window );"><strong>Investments in and Advances to Affiliates, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investments, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(730)<span></span>
</td>
<td class="num">(1,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Loss on changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investments, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Warrants CAD 0.30 exercise price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInAffiliateActivityLineItems', window );"><strong>Investments in and Advances to Affiliates, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investments, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Loss on changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investments, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Warrants CAD 1.00 exercise price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInAffiliateActivityLineItems', window );"><strong>Investments in and Advances to Affiliates, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investments, beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Loss on changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investments, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInAffiliateActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column C)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column C)(Footnote 6)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 6)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInAffiliateActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in security owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=flgc_InvesteeCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=flgc_InvesteeCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=flgc_WarrantsCadZeroPointThreeZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=flgc_WarrantsCadZeroPointThreeZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=flgc_WarrantsCadOnePointZeroZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=flgc_WarrantsCadOnePointZeroZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002962629280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 23, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 20, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2022 </div>
<div>USD ($) </div>
<div>Trial </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 24, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,031<span></span>
</td>
<td class="nump">$ 19,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,071<span></span>
</td>
<td class="nump">$ 33,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net income and comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,347)<span></span>
</td>
<td class="num">(3,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,444)<span></span>
</td>
<td class="num">(54,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivables', window );">Indemnification receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,374)<span></span>
</td>
<td class="num">(3,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,347)<span></span>
</td>
<td class="num">(52,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 453<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,301<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_OriginalHempAssetAcquisitionMember', window );">Original Hemp asset acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_MaximumPortionOfNetProfitsPayable', window );">Maximum portion of net profits payable</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory acquired</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships', window );">Customer relationships acquired</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net income and comprehensive income</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember', window );">Franchise Global Health Inc. ("FGH") business combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common shares in purchase consideration | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,176,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Trade payables and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivables', window );">Indemnification receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember', window );">Franchise Global Health Inc. ("FGH") business combination [Member] | Supplier relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember', window );">Franchise Global Health Inc. ("FGH") business combination [Member] | Customer relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember', window );">Franchise Global Health Inc. ("FGH") business combination [Member] | Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember', window );">Franchise Global Health Inc. ("FGH") business combination [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LiabilitiesAmount', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember', window );">Just Brands LLC and High Roller Private Label LLC business combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net income and comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common shares in purchase consideration | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Value of common shares in purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Net asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_CashConsiderationReturned', window );">Cash consideration returned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueDiscount', window );">Fair value discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Weighted average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_CommonSharesDeliveredToTheSellers', window );">Common shares delivered to the sellers | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfShares', window );">Description of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In no event shall the Company be required to issue more than 182,500 common shares unless, if required by applicable law, it shall have obtained the consent of the Company's shareholders to do so. In the event the Company is required to deliver in excess of 182,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfTrials', window );">Number of trials | Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing share price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Common share volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_UnrealizedLossesOnSecurities', window );">Unrealized losses on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember', window );">Just Brands LLC and High Roller Private Label LLC business combination [Member] | Tradenames [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember', window );">Just Brands LLC and High Roller Private Label LLC business combination [Member] | Customer relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember', window );">Just Brands LLC and High Roller Private Label LLC business combination [Member] | Know How [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember', window );">No Cap Hemp Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net income and comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PurchaseConsiderationPercentageOfSales', window );">Purchase consideration, percentage of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable', window );">Purchase consideration, percentage of sales, amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfDiscountRates', window );">Description of discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the $2.0 million maximum payment and discount rates of 23.5%, high, and 14.3%, low, to estimate the present value of the future cash outflows. The resulting acquisition date fair value of $0.9 million<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_UnrealizedLossesOnSecurities', window );">Unrealized losses on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FloraBeautyMember', window );">Flora Beauty LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Net asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common share issued for acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FloraMedSasMember', window );">Flora Med S.A.S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Net asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common share issued for acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_CashConsiderationReturned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_CashConsiderationReturned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_CommonSharesDeliveredToTheSellers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_CommonSharesDeliveredToTheSellers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DescriptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DescriptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DescriptionOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DescriptionOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FairValueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FairValueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LiabilitiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LiabilitiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_MaximumPortionOfNetProfitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum portion of net profits payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_MaximumPortionOfNetProfitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NumberOfTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NumberOfTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_PurchaseConsiderationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_PurchaseConsiderationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_PurchaseConsiderationPercentageOfSalesAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_PurchaseConsiderationPercentageOfSalesAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_UnrealizedLossesOnSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_UnrealizedLossesOnSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amounts due as of the balance sheet date of the sum of amounts receivable other than from customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_OriginalHempAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_OriginalHempAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_SupplierRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_SupplierRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_CustomersRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_CustomersRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TradenamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TradenamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_KnowHowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_KnowHowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_FloraBeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_FloraBeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_FloraMedSasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_FloraMedSasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959263264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Schedule of major class of assets acquired and liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Jul. 20, 2022</div></th>
<th class="th"><div>Feb. 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember', window );">Franchise Global Health Inc. ("FGH") business combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables', window );">Indemnity receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant, and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Trade payables and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Current portion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities', window );">Long term lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember', window );">Just Brands LLC and High Roller Private Label LLC business combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant, and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Trade payables and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax', window );">Provision for sales tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember', window );">No Cap Hemp Co. business combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Trade payables and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current lease liabilities assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent lease liabilities assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of indemnity receivables recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of provision for sales tax attributable at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right of use assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_FranchiseGlobalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_NoCapHempCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958348448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Carrying amount of intangible asset</a></td>
<td class="nump">$ 908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 17,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average amortization period remaining for intangible assets</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TradenamesMember', window );">Tradenames [Member] | JustCBD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Carrying amount of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average amortization period remaining for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">74 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Carrying amount of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Weighted average period before next renewal or extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TradenamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TradenamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=flgc_JustCBDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=flgc_JustCBDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002962388832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Schedule of intangible assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Beginning balance</a></td>
<td class="nump">$ 2,990<span></span>
</td>
<td class="nump">$ 43,490<span></span>
</td>
<td class="nump">$ 43,490<span></span>
</td>
<td class="nump">$ 29,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FiniteLivedIntangibleAssetsAdditions', window );">Intangible assets, Cost, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets, Cost, Acquired through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets, Cost, Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,300)<span></span>
</td>
<td class="num">(25,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Ending balance</a></td>
<td class="nump">2,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,990<span></span>
</td>
<td class="nump">43,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Beginning balance</a></td>
<td class="nump">2,044<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, Accumulated Amortization, Additions</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Ending balance</a></td>
<td class="nump">2,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Intangible assets, Foreign Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="num">(257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, Net book value, Ending balance</a></td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="nump">41,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_LicensesMember', window );">Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Beginning balance</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FiniteLivedIntangibleAssetsAdditions', window );">Intangible assets, Cost, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets, Cost, Acquired through business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets, Cost, Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,216)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Beginning balance</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, Accumulated Amortization, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Intangible assets, Foreign Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, Net book value, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Beginning balance</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">7,515<span></span>
</td>
<td class="nump">7,515<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FiniteLivedIntangibleAssetsAdditions', window );">Intangible assets, Cost, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets, Cost, Acquired through business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets, Cost, Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,502)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">7,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Beginning balance</a></td>
<td class="nump">1,264<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, Accumulated Amortization, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Intangible assets, Foreign Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, Net book value, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember', window );">Trademarks and Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Beginning balance</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">5,153<span></span>
</td>
<td class="nump">5,153<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FiniteLivedIntangibleAssetsAdditions', window );">Intangible assets, Cost, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets, Cost, Acquired through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets, Cost, Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,249)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Ending balance</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">5,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Beginning balance</a></td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, Accumulated Amortization, Additions</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Ending balance</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Intangible assets, Foreign Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, Net book value, Ending balance</a></td>
<td class="nump">729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="nump">4,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Beginning balance</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">4,530<span></span>
</td>
<td class="nump">4,530<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FiniteLivedIntangibleAssetsAdditions', window );">Intangible assets, Cost, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets, Cost, Acquired through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets, Cost, Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,432)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Ending balance</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">4,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Beginning balance</a></td>
<td class="nump">912<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, Accumulated Amortization, Additions</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Ending balance</a></td>
<td class="nump">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Intangible assets, Foreign Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, Net book value, Ending balance</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-Compete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Beginning balance</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FiniteLivedIntangibleAssetsAdditions', window );">Intangible assets, Cost, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets, Cost, Acquired through business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets, Cost, Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(529)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Beginning balance</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, Accumulated Amortization, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Intangible assets, Foreign Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, Net book value, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Beginning balance</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">23,633<span></span>
</td>
<td class="nump">23,633<span></span>
</td>
<td class="nump">19,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FiniteLivedIntangibleAssetsAdditions', window );">Intangible assets, Cost, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets, Cost, Acquired through business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets, Cost, Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,372)<span></span>
</td>
<td class="num">(25,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Cost, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">23,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, Accumulated Amortization, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Intangible assets, Foreign Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, Net book value, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FiniteLivedIntangibleAssetsAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FiniteLivedIntangibleAssetsAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960758608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Schedule of amortization) (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average amortization period remaining for intangible assets</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember', window );">Trademarks and brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average amortization period remaining for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average amortization period remaining for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flgc_TrademarksAndBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002952876464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Schedule of estimation of amortization expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2024</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2025</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2026</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2027</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2028</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958035696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Schedule of goodwill) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Gross goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquired through business combinations</a></td>
<td class="nump">$ 29,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Impairment recorded</a></td>
<td class="num">(25,073)<span></span>
</td>
<td class="num">$ (23,372)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Net book value</a></td>
<td class="nump">23,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=flgc_VesselMember', window );">Vessel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Gross goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquired through business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Impairment recorded</a></td>
<td class="num">(19,675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Net book value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=flgc_JustCBDMember', window );">JustCBD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Gross goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquired through business combinations</a></td>
<td class="nump">25,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Impairment recorded</a></td>
<td class="num">(5,398)<span></span>
</td>
<td class="num">(19,640)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="num">(277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Net book value</a></td>
<td class="nump">19,640<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=us-gaap_FranchiseMember', window );">FGH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Gross goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquired through business combinations</a></td>
<td class="nump">3,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Impairment recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,732)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Net book value</a></td>
<td class="nump">$ 3,732<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=flgc_VesselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=flgc_VesselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=flgc_JustCBDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=flgc_JustCBDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=us-gaap_FranchiseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=us-gaap_FranchiseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959478512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT OF ASSETS (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,372<span></span>
</td>
<td class="nump">$ 25,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Purchased assets</a></td>
<td class="nump">$ 24,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,626<span></span>
</td>
<td class="nump">80,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and identified intangible assets</a></td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="nump">41,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-lived assets</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="nump">$ 898<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember', window );">2023 Annual Impairment Test [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember', window );">2023 Annual Impairment Test [Member] | FGH asset group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember', window );">2023 Annual Impairment Test [Member] | JustCBD asset group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_AnnualGoodwillImpairmentTestOfFghMember', window );">2023 Annual Goodwill Impairment Test of FGH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Purchased assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and identified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EstimatedRecoverableAmount', window );">Estimated recoverable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfValuation', window );">Description of valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The reporting unit's fair value was determined based on an income approach discounted cash flow model. After working capital adjustments, the resulting fair value was estimated at $1.5 million. The income approach used a discount rate of 17%, operating margins of about 2%, working capital requirements of 6% revenue, and a terminal period growth rate of 2%. The revenue growth rates start at 5% in 2023 and trend down to 2% in 2028 and thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GoodwillDescription', window );">Goodwill description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $0.3 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_AnnualGoodwillImpairmentTestOfJustCBDMember', window );">2023 Annual Goodwill Impairment Test of JustCBD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Purchased assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and identified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EstimatedRecoverableAmount', window );">Estimated recoverable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfValuation', window );">Description of valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The reporting unit&#8217;s fair value at June 30, 2023 and December 31, 2023 was determined based on an income approach discounted cash flow. After working capital adjustments, the resulting fair value was estimated at $7.1 million and $nil. The income approach used a weighted average discount rate of 28%, operating margins from 8.5% to -19.7%, weighted average working capital requirements of 1% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 17% in 2023 and taper down to 3% in 2025 and thereafter. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GoodwillDescription', window );">Goodwill description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a decrease of the reporting unit fair value of approximately $1.5 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember', window );">December 31, 2023 Other Long-Lived Asset Impairment Test [Member] | Vessel Asset Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfValuation', window );">Description of valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 10.7% in 2023 and tapering down to 3% thereafter, weighted average royalty rate of 1%, weighted average discount rate of 17% and a customer attrition rate of 18%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember', window );">December 31, 2023 Other Long-Lived Asset Impairment Test [Member] | FGH asset group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfValuation', window );">Description of valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The key inputs included in the recoverable amount calculations are revenue growth rates starting at -2.6% in 2023, 5% in 2024 and tapering down to 4% thereafter, weighted average discount rate of 20% and customer attrition rate of 10%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.1 million decrease of the recoverable amounts.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 2.5% in 2024 and tapering down to 2.5% thereafter and a weighted average discount rate of 21%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember', window );">December 31, 2023 Other Long-Lived Asset Impairment Test [Member] | JustCBD asset group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfValuation', window );">Description of valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 16.5% in 2023 and tapering down to 3% thereafter, royalty rate of 1.5%, weighted average discount rate of 32.5% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.2 million decrease of the recoverable amounts.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The key inputs included in the recoverable amount calculations are revenue growth rates starting at -37.5% in 2023 and then increasing to 2.5% thereafter, royalty rate of 1.5%, weighted average discount rate of 25% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoImpairmentTestMember', window );">2022 Annual Impairment Test [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares', window );">Percentage of recoverable amounts exceeded market capitalization of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoImpairmentTestMember', window );">2022 Annual Impairment Test [Member] | Vessel Asset Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoImpairmentTestMember', window );">2022 Annual Impairment Test [Member] | JustCBD asset group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember', window );">December 31, 2022 Annual Goodwill Impairment Test of Vessel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Purchased assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and identified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EstimatedRecoverableAmount', window );">Estimated recoverable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfValuation', window );">Description of valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The reporting unit's fair value was determined based on an income approach discounted cash flow model of $7.6 million (80% weighting) and a market approach guideline public company method of $7.0 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $7.0 million. The income approach used a discount rate of 17%, operating margins from 0% to 18%, working capital requirements of 15% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 14% in 2023 and taper down to 3% in the terminal period after 2030.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GoodwillDescription', window );">Goodwill description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $1.8 million. Reducing the market approach selected revenue multiple by 0.10 from 1.00 above down to 0.90 (approximately 10% change) would result in a decrease of the reporting unit fair value of approximately $0.7 million. However, there would be no impact on the goodwill impairment amount for either of these unfavorable changes in the models as the imputed fair value of the goodwill exceeded its carrying amount by $1.1 million with the goodwill impaired to zero.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember', window );">December 31, 2022 Annual Goodwill Impairment Test of JustCBD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Purchased assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and identified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_EstimatedRecoverableAmount', window );">Estimated recoverable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfValuation', window );">Description of valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The reporting unit's fair value was determined based on an income approach discounted cash flow model of $28.0 million (80% weighting) and a market approach guideline public company method of $21.9 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $29.0 million. The income approach used a discount rate of 32%, operating margins from 5% to 28%, working capital requirements of 10% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 21% in 2023 and taper down to 3% in the terminal period after 2030.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GoodwillDescription', window );">Goodwill description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% from 32% above up to 35% (approximately 9% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.5 million. Reducing the market approach selected revenue multiple by 0.1 from 0.6 above down to 0.5 (approximately 17% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.7 million.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember', window );">December 31, 2022 Other Long-Lived Asset Impairment Tests [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfValuation', window );">Description of valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The discounted cash flow models assumed the spaces would be subleased within 2023 at 75% to 100% of the Company's cost of the leases, less upfront costs to obtain a sublease tenant. The cash flows were discounted at 8% to 9% which approximates the discount rate in the Company's right of use asset and lease liability calculations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ImpairmentOfLicenses', window );">Impairment of licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DescriptionOfValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DescriptionOfValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_EstimatedRecoverableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_EstimatedRecoverableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_GoodwillDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_GoodwillDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ImpairmentOfLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ImpairmentOfLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Recoverable amounts exceeded the market capitalization of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481161/840-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=flgc_FGHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=flgc_FGHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=flgc_JustCBDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=flgc_JustCBDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_AnnualGoodwillImpairmentTestOfFghMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_AnnualGoodwillImpairmentTestOfFghMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_AnnualGoodwillImpairmentTestOfJustCBDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_AnnualGoodwillImpairmentTestOfJustCBDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=flgc_VesselAssetGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=flgc_VesselAssetGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoImpairmentTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoImpairmentTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002950333920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Available credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,800,000<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Credit facility interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Credit facility interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.46%<span></span>
</td>
<td class="nump">6.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=flgc_EuroCreditFacilityMember', window );">Euro Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,900,000<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=flgc_EuroCreditFacilityMember', window );">Euro Credit Facility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Credit facility interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=flgc_EuroCreditFacilityMember', window );">Euro Credit Facility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Credit facility interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.44%<span></span>
</td>
<td class="nump">6.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 22,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | First Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Interest-bearing loan</a></td>
<td class="nump">&#8364; 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | Second Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Interest-bearing loan</a></td>
<td class="nump">&#8364; 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 448,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 378,000<span></span>
</td>
<td class="nump">&#8364; 65,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=flgc_EuroCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=flgc_EuroCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=flgc_FirstLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=flgc_FirstLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=flgc_SecondLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=flgc_SecondLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002955562064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_MonthlyLeasePayment', window );">Monthly lease payment</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=flgc_WarehousingAndOfficeSpaceMember', window );">Warehousing and office space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=flgc_RetailSpaceInMiamiMember', window );">Retail space In Miami [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=flgc_PompanoBeachMember', window );">Pompano Beach, FL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Leases, monthly amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=flgc_FortLauderdaleMember', window );">Fort Lauderdale, FL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Leases, monthly amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term.<span></span>
</td>
<td class="text">The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_MonthlyLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_MonthlyLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=flgc_WarehousingAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=flgc_WarehousingAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=flgc_RetailSpaceInMiamiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=flgc_RetailSpaceInMiamiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=flgc_PompanoBeachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=flgc_PompanoBeachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=flgc_FortLauderdaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=flgc_FortLauderdaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002954721328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Schedule of leases) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_OtherInformationAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">$ 2,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term in years for operating leases</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate for operating leases</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense | &#8364;</a></td>
<td class="nump">&#8364; 29,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 84,783<span></span>
</td>
<td class="nump">&#8364; 123,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense | &#8364;</a></td>
<td class="nump">29,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,783<span></span>
</td>
<td class="nump">123,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_OtherInformationAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases | &#8364;</a></td>
<td class="nump">26,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,249<span></span>
</td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for new operating lease liabilities | &#8364;</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 604,294<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term in years for operating leases</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">7 years 29 days<span></span>
</td>
<td class="text">7 years 29 days<span></span>
</td>
<td class="text">7 years 3 months 29 days<span></span>
</td>
<td class="text">6 years 3 months 29 days<span></span>
</td>
<td class="text">6 years 3 months 29 days<span></span>
</td>
<td class="text">7 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate for operating leases</a></td>
<td class="nump">8.77%<span></span>
</td>
<td class="nump">8.77%<span></span>
</td>
<td class="nump">8.77%<span></span>
</td>
<td class="nump">8.77%<span></span>
</td>
<td class="nump">8.77%<span></span>
</td>
<td class="nump">8.77%<span></span>
</td>
<td class="nump">8.77%<span></span>
</td>
<td class="nump">8.77%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002955525168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of maturities of operating lease liabilities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024 | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025 | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026 | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027 | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028 | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Total non-current lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024 | &#8364;</a></td>
<td class="nump">&#8364; 79,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025 | &#8364;</a></td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026 | &#8364;</a></td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027 | &#8364;</a></td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028 | &#8364;</a></td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter | &#8364;</a></td>
<td class="nump">140,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments | &#8364;</a></td>
<td class="nump">641,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest | &#8364;</a></td>
<td class="num">(145,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,698)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities | &#8364;</a></td>
<td class="nump">495,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current lease liabilities | &#8364;</a></td>
<td class="num">(64,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (57,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Total non-current lease liabilities | &#8364;</a></td>
<td class="nump">&#8364; 430,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 447,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 510,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002954987760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Narrative) (Details)<br> &#8364; / shares in Units, $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 14, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 08, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 21, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 26, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 23, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 25, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 7, 2023, the Company filed an amendment to its Articles of Incorporation (the "Reverse Stock Split Articles Amendment") with the Ontario Ministry of Public and Business Service Delivery to effect a reverse stock split of the Company's common shares, no par value per share (the "common shares"), at a ratio of 1-for-20, which became effective at 12:00:01 a.m. Eastern Time on June 9, 2023 (the "Reverse Stock Split").<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued during period, other (shares) | shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued during period, other</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember', window );">September 2023 unit offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Offering unit | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsIssuedDuringPeriodExercisePrice', window );">Warrants issued during period, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain on warrant modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfWarrantsIssuedDuringPeriod', window );">Fair value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember', window );">September 2023 unit offering [Member] | Placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsIssuedDuringPeriodExercisePrice', window );">Warrants issued during period, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfWarrantsIssuedDuringPeriod', window );">Fair value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember', window );">December 2022 unit offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Offering unit | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsIssuedDuringPeriodExercisePrice', window );">Warrants issued during period, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsWithAmendedExercisePrice', window );">Number of warrants with amended exercise price | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantExercisePricePriorToAmendment', window );">Warrant exercise price prior to amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantAmendedExercisePrice', window );">Warrant amended exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfWarrantsIssuedDuringPeriod', window );">Fair value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember', window );">December 2022 unit offering [Member] | Placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsIssuedDuringPeriodExercisePrice', window );">Warrants issued during period, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfWarrantsIssuedDuringPeriod', window );">Fair value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_NovemberTwoThousandTwentyOneUnitOfferingMember', window );">November 2021 offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsWithAmendedExercisePrice', window );">Number of warrants with amended exercise price | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantExercisePricePriorToAmendment', window );">Warrant exercise price prior to amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantAmendedExercisePrice', window );">Warrant amended exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FGHOwnersMember', window );">FGH owners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,176,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueDiscount', window );">Fair value discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_JustCBDOwnersMember', window );">JustCBD owners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueDiscount', window );">Fair value discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FloraBeautyMember', window );">Flora Beauty LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Net asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FloraMedSasMember', window );">Flora Med S.A.S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Net asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | TruHC Holding GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock', window );">Receivable | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FairValueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FairValueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FairValueOfWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FairValueOfWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NumberOfWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NumberOfWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NumberOfWarrantsWithAmendedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NumberOfWarrantsWithAmendedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantAmendedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantAmendedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantExercisePricePriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantExercisePricePriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsIssuedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsIssuedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from owner or affiliate of reporting entity for issuance of shares. Includes, but is not limited to, amount due for award under share-based payment arrangement. Excludes amount due from officer or director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=flgc_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=flgc_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_NovemberTwoThousandTwentyOneUnitOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_NovemberTwoThousandTwentyOneUnitOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FGHOwnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FGHOwnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_JustCBDOwnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_JustCBDOwnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FloraBeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FloraBeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FloraMedSasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_FloraMedSasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_TruhcHoldingGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_TruhcHoldingGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953903504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 15, 2023</div></th>
<th class="th"><div>Sep. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Jul. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Expense (benefit) related to options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,959<span></span>
</td>
<td class="nump">45,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercises in period, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options, vested in period, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining cost for nonvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_RemainingWeightedAverageVestingPeriod', window );">Remaining weighted average vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Options unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Clifford Starke [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Terms of share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">SARs valued at 12% of the total outstanding shares of the Company on the grant date, which vest in 12 tranches with each tranche representing 1% of the total outstanding shares of the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Award vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The first tranche will vest upon the Company's share price increasing by 50% from the Company's closing share price on the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PostTerminationExercisePeriod', window );">Post-termination exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Dany Vaiman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Terms of share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">SARs valued at 4% of the total outstanding shares of the Company on the grant date, which vest in 8 tranches with each tranche representing 0.5% of the total outstanding shares of the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Award vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The first tranche will vest upon the Company's share price increasing by 50% from the closing share price as of the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PostTerminationExercisePeriod', window );">Post-termination exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock awards expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining cost for nonvested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Non-option equity instruments granted</a></td>
<td class="nump">363,617<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfRestrictedStockAwardsIssued', window );">Fair value of restricted stock awards issued</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Non-option equity instruments, forfeitures and expirations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,304<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FairValueOfRestrictedStockAwardsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FairValueOfRestrictedStockAwardsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_PostTerminationExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post Termination Exercise Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_PostTerminationExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_RemainingWeightedAverageVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_RemainingWeightedAverageVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958839664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Schedule of stock options roll forward) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="nump">4,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance</a></td>
<td class="nump">272,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246,000)<span></span>
</td>
<td class="num">(246,000)<span></span>
</td>
<td class="num">(45,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | (per share)</a></td>
<td class="nump">$ 39.06<span></span>
</td>
<td class="nump">$ 27.04<span></span>
</td>
<td class="nump">$ 27.04<span></span>
</td>
<td class="nump">$ 34.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.17<span></span>
</td>
<td class="nump">$ 39.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">19.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Cancelled | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, Forfeited | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.05<span></span>
</td>
<td class="nump">52.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.04<span></span>
</td>
<td class="nump">$ 27.04<span></span>
</td>
<td class="nump">$ 34.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable, ending balance | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining life (years) Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_OptionsExercisableMember', window );">Options exercisable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, beginning balance</a></td>
<td class="nump">272,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">212,000<span></span>
</td>
<td class="nump">212,000<span></span>
</td>
<td class="nump">212,000<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182,000)<span></span>
</td>
<td class="num">(182,000)<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">212,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable, beginning balance | $ / shares</a></td>
<td class="nump">$ 39.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="nump">$ 41.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.19<span></span>
</td>
<td class="nump">$ 39.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.43<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, Forfeited | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.31<span></span>
</td>
<td class="nump">54.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable, ending balance | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="nump">$ 41.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards cancelled, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_OptionsExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_OptionsExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002955205696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Schedule of stock options outstanding and exercisable) (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 22.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.04<span></span>
</td>
<td class="nump">$ 27.04<span></span>
</td>
<td class="nump">$ 34.17<span></span>
</td>
<td class="nump">$ 39.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | June 28, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June 28, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | April 23, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">July 15, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | July 6, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 23, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | July 15, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September 25, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | September 8, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 16, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | November 4, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 17, 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | December 23, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 26, 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | June 3, 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">March 17, 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member] | June 10, 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_StockOptionDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">July 5, 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue', window );">Grant date fair value vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_OptionsExercisableMember', window );">Options exercisable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_StockOptionDateOfExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_StockOptionDateOfExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_OptionsExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_OptionsExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958499712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Schedule of weighted average inputs and assumptions)  (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Current stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Current stock price</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="nump">$ 18.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 19.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 19.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002956925440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Schedule of restricted stock awards) (Details) - Restricted stock awards [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted stock awards, Beginning Balance</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stock awards, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of restricted stock awards, Cancelled</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in dollars per share)</a></td>
<td class="num">(363)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted stock awards, Ending Balance</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning balance | (per share)</a></td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.64<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.44<span></span>
</td>
<td class="nump">13.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Cancelled | (per share)</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Vested | (per share)</a></td>
<td class="num">(0.76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.66)<span></span>
</td>
<td class="num">(14.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending balance | (per share)</a></td>
<td class="nump">$ 10.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 13.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002950334736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 08, 2022</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_IntrinsicValueOfWarrantsExercised', window );">Intrinsic value of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of warrants vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember', window );">September 2023 unit offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsIssuedDuringPeriodExercisePrice', window );">Warrants issued during period, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfWarrantsIssuedDuringPeriod', window );">Fair value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant', window );">Warrants issued, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain on warrant modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember', window );">September 2023 unit offering [Member] | Placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsIssuedDuringPeriodExercisePrice', window );">Warrants issued during period, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfWarrantsIssuedDuringPeriod', window );">Fair value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant', window );">Warrants issued, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_NovemberTwoThousandTwentyOneUnitOfferingMember', window );">November 2021 offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsWithExercisePriceAmended', window );">Number of warrants with exercise price amended</a></td>
<td class="nump">66,250<span></span>
</td>
<td class="nump">66,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantExercisePricePriorToAmendment', window );">Warrant exercise price prior to amendment</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantAmendedExercisePrice', window );">Warrant amended exercise price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember', window );">December 2022 unit offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsIssuedDuringPeriodExercisePrice', window );">Warrants issued during period, exercise price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfWarrantsIssuedDuringPeriod', window );">Fair value of warrants issued</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant', window );">Warrants issued, grant date fair value</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsWithExercisePriceAmended', window );">Number of warrants with exercise price amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantExercisePricePriorToAmendment', window );">Warrant exercise price prior to amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantAmendedExercisePrice', window );">Warrant amended exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember', window );">December 2022 unit offering [Member] | Placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsIssuedDuringPeriodExercisePrice', window );">Warrants issued during period, exercise price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FairValueOfWarrantsIssuedDuringPeriod', window );">Fair value of warrants issued</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant', window );">Warrants issued, grant date fair value</a></td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FairValueOfWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FairValueOfWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_IntrinsicValueOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_IntrinsicValueOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NumberOfWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NumberOfWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NumberOfWarrantsWithExercisePriceAmended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NumberOfWarrantsWithExercisePriceAmended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantAmendedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantAmendedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantExercisePricePriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantExercisePricePriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsIssuedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsIssuedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=flgc_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=flgc_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_NovemberTwoThousandTwentyOneUnitOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_NovemberTwoThousandTwentyOneUnitOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002958731088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Schedule of warrants outstanding) (Details) - Warrants [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants, beginning balance</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(691)<span></span>
</td>
<td class="num">(691)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants, ending balance</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, beginning balance | (per share)</a></td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.84<span></span>
</td>
<td class="nump">$ 67.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WeightedAverageExercisePriceOfWarrantsExercised', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">9.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WeightedAverageExercisePriceOfWarrantsCancelled', window );">Weighted average exercise price, Cancelled | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WeightedAverageExercisePriceOfWarrantsIssued', window );">Weighted average exercise price, Issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, ending balance | (per share)</a></td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 24.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WeightedAverageExercisePriceOfWarrantsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WeightedAverageExercisePriceOfWarrantsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WeightedAverageExercisePriceOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WeightedAverageExercisePriceOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WeightedAverageExercisePriceOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WeightedAverageExercisePriceOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=flgc_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=flgc_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002957528192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Schedule of warrants outstanding by date of expiry) (Details)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsOneMember', window );">November 18, 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">November 18, 2026<span></span>
</td>
<td class="text">November 18, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GrantDateFairValueOfWarrantsOutstanding', window );">Grant Date Fair Value Of Warrants Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 6,729,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsRemainingLifeInYears', window );">Remaining life in years</a></td>
<td class="text">2 years 7 months 20 days<span></span>
</td>
<td class="text">2 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsTwoMember', window );">November 18, 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">November 18, 2027<span></span>
</td>
<td class="text">November 18, 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GrantDateFairValueOfWarrantsOutstanding', window );">Grant Date Fair Value Of Warrants Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,055<span></span>
</td>
<td class="nump">$ 1,055,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsRemainingLifeInYears', window );">Remaining life in years</a></td>
<td class="text">3 years 7 months 20 days<span></span>
</td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsThreeMember', window );">December 8, 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">December 8, 2027<span></span>
</td>
<td class="text">December 8, 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GrantDateFairValueOfWarrantsOutstanding', window );">Grant Date Fair Value Of Warrants Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsRemainingLifeInYears', window );">Remaining life in years</a></td>
<td class="text">3 years 8 months 8 days<span></span>
</td>
<td class="text">3 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsFourMember', window );">September 21, 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">September 21, 2028<span></span>
</td>
<td class="text">September 21, 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GrantDateFairValueOfWarrantsOutstanding', window );">Grant Date Fair Value Of Warrants Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 712,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsRemainingLifeInYears', window );">Remaining life in years</a></td>
<td class="text">4 years 5 months 23 days<span></span>
</td>
<td class="text">4 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsFiveMember', window );">September 21, 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">September 21, 2028<span></span>
</td>
<td class="text">September 21, 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GrantDateFairValueOfWarrantsOutstanding', window );">Grant Date Fair Value Of Warrants Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsRemainingLifeInYears', window );">Remaining life in years</a></td>
<td class="text">4 years 5 months 23 days<span></span>
</td>
<td class="text">4 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsSixMember', window );">March 21, 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsDateOfExpiry', window );">Date of expiry</a></td>
<td class="text">March 21, 2029<span></span>
</td>
<td class="text">March 21, 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GrantDateFairValueOfWarrantsOutstanding', window );">Grant Date Fair Value Of Warrants Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="nump">$ 1,120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsRemainingLifeInYears', window );">Remaining life in years</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">5 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | (per share)</a></td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_GrantDateFairValueOfWarrantsOutstanding', window );">Grant Date Fair Value Of Warrants Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,846<span></span>
</td>
<td class="nump">$ 9,846,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WarrantsRemainingLifeInYears', window );">Remaining life in years</a></td>
<td class="text">4 years 6 months 29 days<span></span>
</td>
<td class="text">4 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_GrantDateFairValueOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_GrantDateFairValueOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsDateOfExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsDateOfExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WarrantsRemainingLifeInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WarrantsRemainingLifeInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=flgc_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959991728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY DISCLOSURES (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 22, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Directors and officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Trade payables and accrued liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_HampsteadPrivateCapitalLimitedMember', window );">Hampstead Private Capital Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts', window );">Royalty on gross revenues from sale of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_DrManaloMorganMember', window );">Dr. Manalo-Morgan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_MedicalServices', window );">Medical services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 22,730<span></span>
</td>
<td class="nump">&#8364; 17,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | First Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | Second Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt | &#8364;</a></td>
<td class="nump">&#8364; 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 448,000<span></span>
</td>
<td class="nump">&#8364; 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_MedicalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_MedicalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_HampsteadPrivateCapitalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_HampsteadPrivateCapitalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_DrManaloMorganMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_DrManaloMorganMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LoanAgreementsAxis=flgc_FirstLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LoanAgreementsAxis=flgc_FirstLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LoanAgreementsAxis=flgc_SecondLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LoanAgreementsAxis=flgc_SecondLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953393792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY DISCLOSURES (Schedule of key management personnel compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Directors' and officers' compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,862<span></span>
</td>
<td class="nump">$ 2,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,439<span></span>
</td>
<td class="nump">$ 3,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003050182240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 14, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 03, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 26, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 14, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2023 </div>
<div>USD ($) </div>
<div>Violation</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Termination benefits expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued during period, other (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
<td class="nump">5,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued during period, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,165,000<span></span>
</td>
<td class="nump">715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_AmountsPayablePerViolationOfStopSaleOrders', window );">Amounts payable per violation of stop sale orders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfViolationsInStopSaleOrders', window );">Number of violations in stop sale orders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_InventoryImpactedByStopSaleOrders', window );">Inventory impacted by stop sale orders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ManagementContractsTerms', window );">Management contracts terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">these contracts would require payments totaling approximately $1.0 million to be made in the event that such executive officers are terminated (i) "without cause" or (ii) within twelve months following a "change in control" (as such terms are defined in the management contracts). The Company is also obligated to make payments to certain individuals upon termination "without cause" of approximately $1.0 million pursuant to the terms of these contracts.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_SharedServicesAndSpaceCommitment', window );">Shared services and space commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_ACAMullerMember', window );">ACA Muller [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued', window );">Loss contingency, estimate of possible loss, interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyInterestPaymentTerms', window );">Loss contingency interest payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">rate of 5% above the prime rate since September 6, 2020 in addition to 83% of the legal fees.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_LegalDisputesMember', window );">Legal disputes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued during period, other (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued during period, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,007,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_IndemnificationReceivables', window );">Indemnification receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Loss recorded within contingencies and within indemnification receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_TerminationBenefitsMember', window );">Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=flgc_GerardoAndresGarciaMendezMember', window );">Gerardo Andres Garcia Mendez [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit', window );">Number of shares to be issued pre-one-for three reverse stock split | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution', window );">Description of settlement of disputes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute.<span></span>
</td>
<td class="text">In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember', window );">Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit', window );">Number of shares to be issued pre-one-for three reverse stock split | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember', window );">Ramon Ricardo Castellanos Saenz and Miriam Ortiz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit', window );">Number of shares to be issued pre-one-for three reverse stock split | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=flgc_FranchiseGlobalHealthIncMember', window );">Franchise Global Health Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PotentialLiabilities', window );">Potential liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_WrongfullyTransferredShares', window );">Wrongfully transferred shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,831,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Value of damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_JustBrandsLLCMember', window );">Just Brands LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_AmountsPayablePerViolationOfStopSaleOrders', window );">Amounts payable per violation of stop sale orders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfViolationsInStopSaleOrders', window );">Number of violations in stop sale orders | Violation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_InventoryImpactedByStopSaleOrders', window );">Inventory impacted by stop sale orders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_JustBrandsLLCMember', window );">Just Brands LLC [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Value of damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares', window );">Number of shares loss estimate is based on | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_NumberOfSharesUnderPlaintiffClaim', window );">Number of shares under plaintiff claim | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="nump">$ 60,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_AmountsPayablePerViolationOfStopSaleOrders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of amounts payable per violation of stop sale orders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_AmountsPayablePerViolationOfStopSaleOrders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_IndemnificationReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of indemnification receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_IndemnificationReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_InventoryImpactedByStopSaleOrders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of Inventory impacted by stop sale orders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_InventoryImpactedByStopSaleOrders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that the company is obligated to issue pre-one-for three reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about loss contingency estimate of possible loss based on number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LossContingencyEstimateOfPossibleLossInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency, estimate of possible loss, interest accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LossContingencyEstimateOfPossibleLossInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LossContingencyInterestPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about loss contingency interest payment terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LossContingencyInterestPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ManagementContractsTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about management contracts terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ManagementContractsTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NumberOfSharesUnderPlaintiffClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about number of shares under plaintiff claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NumberOfSharesUnderPlaintiffClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_NumberOfViolationsInStopSaleOrders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_NumberOfViolationsInStopSaleOrders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_PotentialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of potential liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_PotentialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfCommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_SharedServicesAndSpaceCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_SharedServicesAndSpaceCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_WrongfullyTransferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of wrongfully transferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_WrongfullyTransferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyTrialOrAlternativeDisputeResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies whether the action is pursued in a court of law, an arbitration or mediation, and whether a decision by the Trier of fact in a nontrial proceeding is binding or nonbinding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyTrialOrAlternativeDisputeResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_ACAMullerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=flgc_ACAMullerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_LegalDisputesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=flgc_LegalDisputesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_TerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=flgc_TerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=flgc_GerardoAndresGarciaMendezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=flgc_GerardoAndresGarciaMendezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=flgc_FranchiseGlobalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=flgc_FranchiseGlobalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_JustBrandsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flgc_JustBrandsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002954744976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Schedule of provisions and contingent liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Beginning balance</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="nump">$ 5,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payments/settlements</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Additional provisions</a></td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyAccrualForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Ending balance</a></td>
<td class="nump">6,591<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">$ 5,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_TerminationBenefitsMember', window );">Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payments/settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Additional provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyAccrualForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_LegalDisputesMember', window );">Legal disputes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Beginning balance</a></td>
<td class="nump">2,962<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payments/settlements</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Additional provisions</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyAccrualForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Ending balance</a></td>
<td class="nump">4,063<span></span>
</td>
<td class="nump">2,962<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_SalesTaxesMember', window );">Sales taxes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems', window );"><strong>Schedule Of Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Beginning balance</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payments/settlements</a></td>
<td class="num">(168)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Additional provisions</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_LossContingencyAccrualForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Ending balance</a></td>
<td class="nump">$ 2,528<span></span>
</td>
<td class="nump">$ 2,538<span></span>
</td>
<td class="nump">$ 1,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_LossContingencyAccrualForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation affecting the loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_LossContingencyAccrualForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ScheduleOfCommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ScheduleOfCommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_TerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=flgc_TerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_LegalDisputesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=flgc_LegalDisputesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=flgc_SalesTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=flgc_SalesTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003050283280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Canadian rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_CurrentTaxExpenseIncome', window );">Current income tax expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DeferredTaxExpenseIncome', window );">Deferred income tax benefit</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfTaxJurisdictions', window );">Description of tax jurisdictions</a></td>
<td class="text">Canada 2020 to 2023, United States 2020 to 2023, Colombia 2020 to 2023, Germany 2019 to 2023, Denmark 2020 to 2023, and United Kingdom 2022 to 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember', window );">Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Unused loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_UnitedStatesRevenueAgencyMember', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Canadian rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Unused loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_ColombiaRevenueAgencyMember', window );">Colombia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Canadian rate</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Unused loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_GermanyRevenueAgencyMember', window );">Germany [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Canadian rate</a></td>
<td class="nump">27.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Unused loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_DenmarkRevenueAgencyMember', window );">Denmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Canadian rate</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Unused loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_UnitedKingdomRevenueAgencyMember', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Canadian rate</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Unused loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_ForeignRevenueAgencyMember', window );">Foreign Revenue Agency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Unused loss carryforwards | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DescriptionOfTaxJurisdictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DescriptionOfTaxJurisdictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_UnitedStatesRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=flgc_UnitedStatesRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_ColombiaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=flgc_ColombiaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_GermanyRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=flgc_GermanyRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_DenmarkRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=flgc_DenmarkRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_UnitedKingdomRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=flgc_UnitedKingdomRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=flgc_ForeignRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=flgc_ForeignRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002955479792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Schedule of components of the income tax provision) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,753)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
<td class="num">(1,628)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=flgc_CanadaIncomeTaxAuthorityMember', window );">Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,767)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=flgc_USFederalIncomeTaxAuthorityMember', window );">U.S. federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,055)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=flgc_USStateIncomeTaxAuthorityMember', window );">U.S. state [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=flgc_ForeignIncomeTaxAuthorityMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=flgc_CanadaIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=flgc_CanadaIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=flgc_USFederalIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=flgc_USFederalIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=flgc_USStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=flgc_USStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=flgc_ForeignIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=flgc_ForeignIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960681328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES  (Schedule of corporate income tax rate) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Canadian rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Earnings in jurisdictions taxed at different rates</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Impairments</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(12.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock based compensation</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment', window );">Loss on investments</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(23.80%)<span></span>
</td>
<td class="num">(12.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other permanent items</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year adjustments, change in tax rates</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to investment tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959296144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Schedule of deferred income tax assets and liabilities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DeferredTaxAssetsShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments', window );">Unrealized gains (losses) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DeferredTaxAssetsRightOfUseAssets', window );">Right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DeferredTaxAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DeferredTaxAssetsGoodwil', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Sec 174 - R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,909)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,712)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital loss carryforwards | &#8364;</a></td>
<td class="nump">&#8364; 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DeferredTaxAssetsRightOfUseAssets', window );">Right of use assets | &#8364;</a></td>
<td class="num">(154,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets | &#8364;</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets | &#8364;</a></td>
<td class="nump">193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance | &#8364;</a></td>
<td class="num">(193,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets | &#8364;</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease obligations | &#8364;</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liabilities | &#8364;</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DeferredTaxAssetsGoodwil">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DeferredTaxAssetsGoodwil</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DeferredTaxAssetsRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DeferredTaxAssetsRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DeferredTaxAssetsShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DeferredTaxAssetsShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960190144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Schedule of anti-dilutive shares) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">3,078<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=flgc_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=flgc_RestrictedStockAwardsMember', window );">Restricted stock awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=flgc_JustCBDMember', window );">JustCBD potential additional shares to settle contingent consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=flgc_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=flgc_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=flgc_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=flgc_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=flgc_JustCBDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=flgc_JustCBDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003051406384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,385<span></span>
</td>
<td class="nump">$ 5,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Financial assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_DescriptionOfExchangeRate', window );">Description of exchange rate</a></td>
<td class="text"> then changing the rate by 10%. Management determined 10% is a 'reasonably possible' change in foreign currency rates by considering the approximate change in rates in the prior twelve months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_CashFlowModelHighRate', window );">Cash flow model, high rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ExpectedSharesToBeIssued', window );">Expected shares to be issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,484<span></span>
</td>
<td class="nump">632,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_CashFlowModelLowRate', window );">Cash flow model, low rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=us-gaap_CreditRiskMember', window );">Credit risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=us-gaap_CreditRiskMember', window );">Credit risk [Member] | Held with large financial institutions and national central banks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=us-gaap_CreditRiskMember', window );">Credit risk [Member] | Held with financial intermediaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=flgc_GermanSubsidiariesMember', window );">German subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Available credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,200,000<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash | &#8364;</a></td>
<td class="nump">&#8364; 3,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 577,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 504,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 228,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_CashFlowModelHighRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_CashFlowModelHighRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_CashFlowModelLowRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_CashFlowModelLowRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_DescriptionOfExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent Description Of Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_DescriptionOfExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ExpectedSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ExpectedSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount for Financial Assets Pledged As Collateral For Liabilities Or Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=us-gaap_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=us-gaap_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=flgc_FinancialIntermediariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=flgc_FinancialIntermediariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=flgc_GermanSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=flgc_GermanSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002952565280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of information about the financial instruments and their classifications) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent purchase consideration from asset acquisitions and business combinations</a></td>
<td class="nump">$ 1,702<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">3,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent purchase consideration from asset acquisitions and business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent purchase consideration from asset acquisitions and business combinations</a></td>
<td class="nump">1,461<span></span>
</td>
<td class="nump">854<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent purchase consideration from asset acquisitions and business combinations</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002953376384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of assets and liabilities denominated in foreign currencies) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="nump">3,218<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
<td class="nump">$ 5,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">$ (2,620)<span></span>
</td>
<td class="num">(1,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">CAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,995<span></span>
</td>
<td class="nump">2,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableFairValueDisclosure', window );">Loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,767)<span></span>
</td>
<td class="num">(9,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,560)<span></span>
</td>
<td class="num">(1,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,537)<span></span>
</td>
<td class="num">(6,799)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_COP', window );">COP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,961,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,127,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableFairValueDisclosure', window );">Loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,975,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,173,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,809,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,129,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">GBP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableFairValueDisclosure', window );">Loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableFairValueDisclosure', window );">Loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableFairValueDisclosure', window );">Loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_COP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_COP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003090896288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION (Narrative) (Details) - Segment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_ConsolidatedRevenue', window );">Consolidated revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_ConsolidatedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_ConsolidatedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002960850080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION (Schedule of operation segments information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 18,031<span></span>
</td>
<td class="nump">$ 19,319<span></span>
</td>
<td class="nump">$ 76,071<span></span>
</td>
<td class="nump">$ 33,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">3,854<span></span>
</td>
<td class="nump">5,346<span></span>
</td>
<td class="nump">17,738<span></span>
</td>
<td class="nump">13,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Loss from Continuing Operations</a></td>
<td class="num">(3,374)<span></span>
</td>
<td class="num">(3,186)<span></span>
</td>
<td class="num">(46,669)<span></span>
</td>
<td class="num">(46,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">24,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,626<span></span>
</td>
<td class="nump">80,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_CommercialAndWholesaleMember', window );">Commercial &amp; Wholesale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">11,342<span></span>
</td>
<td class="nump">7,958<span></span>
</td>
<td class="nump">38,262<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Loss from Continuing Operations</a></td>
<td class="num">(236)<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(8,763)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">10,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,096<span></span>
</td>
<td class="nump">22,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_HouseOfBrandsMember', window );">House of Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">8,020<span></span>
</td>
<td class="nump">13,765<span></span>
</td>
<td class="nump">44,602<span></span>
</td>
<td class="nump">39,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,520<span></span>
</td>
<td class="nump">13,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Loss from Continuing Operations</a></td>
<td class="num">(967)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
<td class="num">(31,399)<span></span>
</td>
<td class="num">(29,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">11,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,608<span></span>
</td>
<td class="nump">48,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_PharmaceuticalsMember', window );">Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Loss from Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_CorporateAndEliminationsMember', window );">Corp &amp; Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="num">(1,331)<span></span>
</td>
<td class="num">(2,404)<span></span>
</td>
<td class="num">(6,793)<span></span>
</td>
<td class="num">(6,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Loss from Continuing Operations</a></td>
<td class="num">(2,171)<span></span>
</td>
<td class="num">$ (2,972)<span></span>
</td>
<td class="num">(6,426)<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 2,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,922<span></span>
</td>
<td class="nump">$ 6,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_CommercialAndWholesaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_CommercialAndWholesaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_HouseOfBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_HouseOfBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_PharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_PharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_CorporateAndEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_CorporateAndEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002959479872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION (Schedule of other significant items) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">$ 1,591<span></span>
</td>
<td class="nump">$ 3,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense (income)</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">128<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(1,628)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gain) loss from changes in fair value</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">$ 883<span></span>
</td>
<td class="num">(1,991)<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">24,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,626<span></span>
</td>
<td class="nump">80,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_CommercialAndWholesaleMember', window );">Commercial &amp; Wholesale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,650)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gain) loss from changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">10,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,096<span></span>
</td>
<td class="nump">22,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_HouseOfBrandsMember', window );">House of Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(1,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">2,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gain) loss from changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(964)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">11,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,608<span></span>
</td>
<td class="nump">48,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_PharmaceuticalsMember', window );">Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gain) loss from changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_CorporateAndEliminationsMember', window );">Corporate &amp; Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">3,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gain) loss from changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 2,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
<td class="nump">6,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=flgc_ConsolidatedMember', window );">Consolidated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">3,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,628)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gain) loss from changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,991)<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,626<span></span>
</td>
<td class="nump">$ 80,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_CommercialAndWholesaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_CommercialAndWholesaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_HouseOfBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_HouseOfBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_PharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_PharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_CorporateAndEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_CorporateAndEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=flgc_ConsolidatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=flgc_ConsolidatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002956881440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION (Schedule of disaggregation of net sales by geographic area) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 18,031<span></span>
</td>
<td class="nump">$ 19,319<span></span>
</td>
<td class="nump">$ 76,071<span></span>
</td>
<td class="nump">$ 33,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Loss Before Income Taxes</a></td>
<td class="num">(3,246)<span></span>
</td>
<td class="num">(3,264)<span></span>
</td>
<td class="num">(48,297)<span></span>
</td>
<td class="num">(48,108)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">6,518<span></span>
</td>
<td class="nump">10,999<span></span>
</td>
<td class="nump">36,536<span></span>
</td>
<td class="nump">32,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Loss Before Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,013)<span></span>
</td>
<td class="num">(27,867)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">11,343<span></span>
</td>
<td class="nump">7,958<span></span>
</td>
<td class="nump">38,262<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Loss Before Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,258)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Loss Before Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="num">(3,120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Loss Before Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,662)<span></span>
</td>
<td class="num">$ (17,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140002957293728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SEGMENTED INFORMATION  (Schedule of disaggregation of property, plant and equipment and other long-lived assets by geographic area) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant And Equipment</a></td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Other Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
<td class="nump">48,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">$ 24,274<span></span>
</td>
<td class="nump">23,626<span></span>
</td>
<td class="nump">80,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant And Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Other Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">33,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,094<span></span>
</td>
<td class="nump">45,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant And Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Other Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,096<span></span>
</td>
<td class="nump">19,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CO', window );">Colombia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Other Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Other Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Other Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,922<span></span>
</td>
<td class="nump">$ 7,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140003083151856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 08, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 04, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 16, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,738<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares', window );">Percentage of aggregate gross proceeds from sale of common shares</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | First Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PercentageOfIssuedAndOutstandingCommonShares', window );">Percentage of issued and outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common shares in purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,135,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Second Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common shares in purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Clifford Starke [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per common share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common shares in purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | JustCBD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent purchase consideration unpaid balance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | TruHC Holding GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common shares in purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,770,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Aegis Capital Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnderwritingCommitments', window );">Underwriting commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company agreed to provide Aegis an underwriting discount of 7.0% for underwriter-introduced investors and an underwriting discount of 3.0% for Company-introduced investors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per common share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 12,500<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | Subsequent Event [Member] | Flora Growth Corp [Member] | First Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flgc_PercentageOfIssuedAndOutstandingCommonShares', window );">Percentage of issued and outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common shares in purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,135,199<span></span>
</td>
<td class="nump">2,135,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember', window );">TruHC Pharma GmbH [Member] | Subsequent Event [Member] | Flora Growth Corp [Member] | Second Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common shares in purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about percentage of aggregate gross proceeds from sale of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flgc_PercentageOfIssuedAndOutstandingCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about percentage of issued and outstanding common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flgc_PercentageOfIssuedAndOutstandingCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flgc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderwritingCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclose the effect on the financial statements of underwriting commitments open at year-end and subsequently settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481804/940-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderwritingCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=flgc_FirstClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=flgc_FirstClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=flgc_SecondClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=flgc_SecondClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_JustCBDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_JustCBDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_TruhcHoldingGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_TruhcHoldingGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_AegisCapitalCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_AegisCapitalCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flgc_TruhcPharmaGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flgc_FloraGrowthCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flgc_FloraGrowthCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M9D1.4M=I Z9LE9Z;LF]\..+R4!N;F(X2<&2>=C:(,!UCTS%P1RZ!P7. @37
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M-\SQ5@9E ;B^EM(\3VP?;^_YY ]02P,$%     @ .8#56"'1?J9:$    :<
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M*:.,2::/_?5BGCVASPL^.)/<[$QNSXLW,\?Z4)3S:IU__X-5YN18RHP[]^2
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M:[7Z,=0\\?A3ZI;?U\4A!QW6WQ]53M]LH-].MI_):/<B:0F4ED)I#$KC4)J
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M<VZL#;JLJ?KHY.%_ S,T&1#_E-?/&9IO?_Z?F0I%LT ;)BV(4E1 ;#_1T<Y
MTE(HC4%I'$H34%J&HJGFEMEB8,\6B8!8,3?IZ?!B0'PL<BD@#HA(,IP&QD:8
M1+F)Y\>A/OXDBLW]N=D]4;@XBG4@IPH&^B;]@B@5^I$1$).J4>"=J*H?H@S%
M GLH]D536 (S&R&FL!"ER!X*NF(*2DNA- :E<2A-0&D9BJ::6P9C@3T8>\D4
MEB/2VD/%PWHH(GNAIK 0Y:@I+%0Q:@H+B:.FL% %S2DL1"EJ"@NI:IG"$LAX
M*+CPN+?BL:4>PSGD"<IF2.+ZT5S_.*%A$)260&DIE,:@- ZE"2@M0]'4%B#3
MI<">+IUI =9;Z\AL80&E+0/B:76Q/]-[16BJ!*4Q*(U#:6)0[68H3?7IX#(M
M"NUIT;D^_?(V+W;P6&-#:<O0C#4FGO'8'ZAF"J4Q*(U#:6)0[68H3=78,C4*
M_R_/=PNIM3?Z=97]5$:;%YKY0&DIE,:@- ZE"2@M0]'4QB!3I/!K/N#-#A_=
MTT-SI-!,,,*Y?ET'E4RA- :E<2A-#*G<#"6I6EL&1*$](+K\""$[8+1]H3%1
M2"PJT[]>$JAD"J4Q*(U#:6)(Y68H2=6^,I<*[;G4H"FW=L9H!R-IR]!,O29A
MI#_/*(&*IH1HZ.M3-1E4DT-I@JHV3X\N,I2F:DZ9*X7V7.F+)M.&9E(RTZ]^
M%_83&.U%Z%(U*"V%TAB4QJ$T :5E*)K:!&0J%]I3N9?,IK4C1W?7T 5JH1D!
MNO.9OL@'JIE":0Q*XU":&%2[&4I3M;3,XD)[%O=.?Z+*\\[EP_IU(E]R8WTR
MC/T<1KL6NL<AE)9":0Q*XU":@-(R%$UM!3+,#.UAIJT56+IVZ.(W*&T9$HO?
MC%EJ"50SA=(8E,:A-#&H=C.4IFIJF4^&%_+)@5OTVS&C;0P-)4-BUT,WT-=P
M0C53*(U!:1Q*$X-J-T-I*C:.9"@9V4/)95$7J^I^]_R4^N+I_G5=;/*^PVXK
M9U%MJNUMF3MYTQ2TR>TB8TT.I2VAM"0R SG7=[4;M2E4DT%IG'@'$R_6'VE/
MO<^I/CTK0YV9:EX9/$8O7:[V59\O83^KT6Z')II06A)1D:P^IRZ%:C(HC4-I
M8E!]9"A-M57(!#+Z>NO8[.C1UH;FCU!: J6E4!J#TCB4)J++Z]A0@JK_94P9
MO7P=F_W0T?Z&!I106@*EI1&U6"R>^OI*$:J<'[OQ3 NI.%$PTN_>"5(U\@-]
MX?  5=5+,C.,[)GAA94B]K5LD1D\S>:^=@&P($I1*T7L)SK:'=",$$IC4!J'
MT@24EJ%HJKEEYAB-7LNFF)OT].6U;-&PM6P1L98MF$_U-:\)4:Z[C#:NN,A2
M7AC,]1Z**!C.9I&^0H(3!?6%;$21*)CJ-ZI(Q3AR3Q35#U F9M&7;^XX(&:(
MS"@E-#Y4:#0&I2506@JE,2B-0VD"2LM0-+4MR*@MLD=M7S;OT@X?/2Z$)G(1
ML1A-OT<+54RA- :E<2A-#*C;#*6H&ENF9]&PG2+/;W1J!XPV+S0IB\PLQ_ N
M-":#TAB4QJ$T<;EJ,Y2@:EV9D47VC&S0C$L[8[1[H0%91$0XOK'; E0S)30-
M20:5Y%":@-(R%$VQ<"SSL7CP%H]/<Q?.=\-VTE@C0VG+F(AS].D*4,442F-0
M&H?2Q("ZS5"*JHME4!;;@[(OG(<6F[''1)^%9C^#T7Z%QEA06@JE,2B-0VD"
M2LM0-+4-R%@LML=B+YN%9H>.[M2A@5A,/.-+GUX,54RA- :E<2A-#*C;#*6H
M&EKF7+$]YQHZ \V.&6UA:.85F\F-_HRE!*J80FD,2N-0FB#J=J)7;H:25#TL
M\[78GJ]][0VG[?*CO8^D+:&T)"9B1'V_::@B@](XE"8&U$:&4E2M+].WV)Z^
M?<DT'3MZM*VA*P.AM 1*2Z$T!J5Q*$W$%]/+#"6H^E^&E[$]O%Q4NVX\?KL_
M^/W'IP3:^G1D.V^TZ:-!*354-('24BB-06D<2A-06A832P?//^0[EA%D;(\@
M;1//[(>.-B\T8(32$B@MC8DED+ZOKX%D5#%W&H:QOO\G].S$L+/+!IR=:CD9
M#L;V</#"7NN!_;:>&2#-YC-7O[%GEJ+FI]E/=+2)H)D@E,:@- ZE"2@M0]%4
M<\OX,+;'AQ?V6@](3S\A;?/3CD7B2X8V26XPF\6N?GO"+#=Q75^_]*)*!6&D
M;XS,B+.;1// "UR])[OX3@51Q'>-;3%)Q6A^JOCT 5XW#T71+O,VOWG]F-\7
MW8=Q7^X:9U/<=4=.O^\'E'5Y__#\HJT>WURY5\YMU;;5]O#C0Y&OB[HOT/W]
MKJK:SR^N._['JO[]H''S/U!+ P04    "  Y@-58U&<'U\<"   @"   &
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M#M(HX/U2"+T[F ?:/P7Q/U!+ P04    "  Y@-58OI-9G @4  !'W   &
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M%D!I(90606DQBC9.M<$=-13AH#R[C)O:))!<QFU C5$HS8'27"C-@])\*"V
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M339IV1[0_/VI*.JW7UJ!=OE/=YMW_P]02P,$%     @ .8#56 U1FCP=!P
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MA.M;:QZQC?C^1GMIE>F(L=0RDP)@1+33J1@,.5Z#%UWQ )'F.*&<D*A874T
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M4^064HK)RIFK3YM,4\5=H%Z/%.1OJWZ@6TV0QE!/X (#AW9;("VJ&1P'\;9
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M8%_75XYC:7JK,.-OPV/WMNQ0VVU@W96NVIZS1]_ KH5GVS.W!FO;8"PM="=
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M-M5.NG9.-9'&+!T*" Z<<QE^@XOBEF]FW8XI<A#N$JDDK=&%^AGTSN:AHV9
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MX]@4!2?A-H5^D/45@5PI*L19 (_63-? [QBIS.B+''TZQ;!2^G6#W(36 S]
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MRCFPIH[>!BG6KU0,J5*,X$,\=9Y7/DOM?5/2--0]P+UGP*UV:G'R8]94R++
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MKA6<48T7P._+"AA4/N #KJOZ X'W[/\#4$L#!!0    ( #F U5AMJF/=RQ,
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MZQLZCL5[9;P8SU6"^DPPHQ#"L-E MBE#R._W9C1777E2%^/UC?1H-00"M8#
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M: $^7SO7IV_H@O$//SS]&U!+ P04    "  Y@-588!FJY78*  !W*   &0
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M1.]P2'"I<OVSS4YI6F3P(GL""1K\)(*J0\D5WH7]UKE J8\DK^%YJG0N?Z_
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M5IPUH,;D0P I4RJ9)&-FF@)L/XPYQ!;S-#+F"C;>,!>X/<>?K3Q)C37 AWH
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M89@[(L#S!XLUM[X@!>WWM*M_ %!+ P04    "  Y@-584B1M9304   B0
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M<%(:V1;2+)V)O"C%BG"6B,RVB$P]&]) +O7XI;Q7(LW750GR:UTD&*+PDT0
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M8-'MO/[IY\Y9XPI)@/2 JEI^)#G0&WP'7*6P9F?D\$I3X@=9%>:N,- L8>7
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M@+AD9?<#(L\KRO5J"C9R,>QZ"WKUH4X8V/<Y%)HJ0?I$A:<M$\AVMV2SS56
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M[=VL96&,O9:TE1N;9-244DX9Y\A/;#$U5V0,N9-&CGPIG3%Y3@WK9)7EL=L
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M2 T3S9AMC6J?_D?I(-<06F'.&<5'S?B>,CI#(.?-3O$-:]NN>*<N\ KP.!.
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M6J7/7&DY1D3=3?E$ZJ 4B&GNWMN^@(_-%\35$YX&?YRYAAQ+2_GM.%8T7F>
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M/GV#%XE4V=^P*,?Z!PY$A=(BJXS)@XSGY5_VJ8I#PV#?>\3 KPS\KS4(*H/
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M#8>8:50N7$N>1WS&4F!Y3#/00%1DQ);WH'&!I5-HH$%, %F4@,%T*;4J$VD
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MY&Z22^$C#V";2VD$\PYM8.ATHL6?*2E!>^+QU,:/VTIC&RKLS+7MJ.!U_Y^
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M!=B74#0 [V<2/4/VA18H;AU_^ ]02P,$%     @ .8#56/%TIAUB#P  -3@
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M=#JT!A(1S-@*=L(<  XF4HS8><V6SP&=I<PUV2-/*6Q@CRC[591-3,+0$\)
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M91JZ%=K*%CEJQ%7GYPRVO!AB/WB:EGN*$:R6J[BUTBXO"@"07)#/'+D<ERT
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MQTGZ-/S:Z,H[X0WD-X *JV,H1JXFPP"-M)I#]5>@#E,ZPR1Y2R$$XX)^JZ?
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M2<)""B[ !5300D(?';,F#>I? 9$7C?G\G7S(=P_43^L0K&=BPB#7JQ@0[S>
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MM?E>(+=VDM+61-LSE0$%<(H]$2*SQT1N;!C@6ZE1=/E)S^OVP)B<0X\\-)1
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ML"A/@(;2H&F0P^"5*I*8+?@M^A<#ZHGX. --P2.M_9'%)TD07<%9R9\.NRZ
M-X @@":&MJ;5T'+F&1A.Q$$(8$2 [<QYG;9@!?VQ]:RP!Z0_B$*@")8HXW1+
M)2 PT@^*'TH9R\QF2N28IR#8G=LT@!C8"^. ;=YS1EZN=P^)\"FZ@<CK7:N]
M./4KM:STH:3QWH\Z4X%D#?:MUNG4@SUGU^X$6T22D55^UR.HM_L;4-WDJ(HW
M:I[TX='5W7P"^<6F5T F3'%K8= #I5.GEX8] %_X@/6"P:@'/\-!CSY==$.V
MYTS;7/X^CS4>#FJ'ZDZ&K"U=V9]>A&'GZ'EV*[7*\/Q ?-/ESR%=R1<NXH73
MJB4!-$5*-@)"A##%]#_@@%"-$KZRE&LQ=]X*5E&W0F=D.02-$!=%'CC(?U44
MD*EAP-VV#L6$Q,^",(7,GAPE# 06 T?Q\11"UQ0?0Z9!P)*#.\/0KA'0P#!P
MA;<8FF'<MBQC&-RE!ER C[ <N$V0KD5,!L\Q D_ [!!MVVAM;@52AR5C87,'
MZZ[)3:?\H_#9@?4. ;U&-"J<*Z?=UW9GLLWV_;YV2M8.-IM/P^VLS#/<^=C[
M2=,^'U'^;EG=(7/[ZID;.V1N7R]S^^M?QF'OXB<#2IW-K5[5(TPMP.<@B-<"
MIB*KK>M((OLU%$$7QECU>@M\8I/ 0N96R&\G?.VP?PN7*(*NR((5B*Q>-ZC'
M8247ONLL-@#:KSBEKG\KDO^-S+9%('6\1(KLH;;/T:XW]Z4SAZSK_K.NT@R_
MZ]RK/?8IC?%;9EP[LY.;A2H,4$>J]"&C,O,U1B.&/0/N<6W871,8ZS$?'KVJ
MF<2)Q?I3EWR4_WYCWM.>X)PX!#_=E>K\&@Z%WXY#%Z.!_?^]<"D,1H,1_)QT
MD4_]8#BX8.^E^0@&FO$Y,8AA)G:+G=/-] 2R#H5LI(P#X%CF$"5+\%HQQC"H
M]0X7-*QH+%G21G/-2+<1H=XLP EE2"9$O;=P*O-9BZT3(C@81AG[TL[!QG!%
MJ2=$?_!F"6%X1$EIAM&;@NC-"(OF5DE\KD@,(9"!)2&.+C2%:+\4@%L2@1[
M#".*A"@Q#ME=& AQL2KF"T>Y%=B^9D[%FBHYZ+ KXC$1T/A=&ANTX^\-O@(M
MQJ<(7G"$VK:@J9=<@Z!@ &_WE( OB<TYL?&/HL/X17-T2@FP,9%S7A4>.!!
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MC0/@_4P!O]P'W*#\$_!/_A]02P,$%     @ .8#56,9/ '7W P  X0@  !D
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MZO4-/P(7SD[/S;)?A 8H;NX_8C!9K]0@N"7<A,Q;8U_KC7_HSC99:6/,@E?
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MA0KOL/% %_;W=>%U1D82_\.6S*N*3X 8,W!9*&>:A5#%#3?4IH5;1-Q!]ZX
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M)HUQLL.$PQ 4V&=!ZH08&RZWFMTS]FQK]HB=) V(RL>.YT:&RB>QXR;$%H,
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M)5675DQ5!C'FL,I)N49Z'*9.CTQ/N<H6C#I101L1@BI-Y@3X%AF B/2P*5V
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M$_!^D::V?* -JE\=7_P;4$L#!!0    ( #F U5@J#63K*$   /@V 0 9
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;.U]:W/;1I;H=_\*E'9V8U51BAYV
MWDF5+#M9Y3H9E^W,U*VM^P$BFR02$.#@(87[Z^]Y=I\&0(BTE4VVBA]V)Q:!
M1O?I\WY^<U]6O]5+YYKD]U5>U-\>+9MF_=6GG];3I5NE]6FY=@7\,B^K5=K
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M<D)OE[K@TFV%7RR$U%MO[XLEC^+?7>;N79!#*GV"E]]H=LY[V#A:3T:CJ F
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MHGH>;YBSB^+M -F5*V\C!XP+B?L?PC0YNY#"[0T8VPV;7V4+]X>1PQ 98^<
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M_)^FQSV^DOH9AN9FGM)8 9FG*8Z@.W>,A:H\CF6-!:-D7# S>'I[/-BV'MN
MM TJ] A;^)"4"+K5;3DCO=F'\:0INFW/'QBM# 3H(! A,7H6N%+'!^ZDV)!Z
M'W2B6//.&N1+$F[J&Z7*]'4;'E23(5O=8ITWX..<,"G%SKV"R40T6MP8CSGU
M+VI1:QS:,PV/V'+ "L*RP 9$2C>]%130G7'4V@F&;U#&Z)IIFJ8E!I5> L"
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MEP[NJ,('X/=Y"00J_\ /W)?5;[2][_X_4$L#!!0    ( #F U5BDA!9)%P0
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M+Q"UH^X1O&Y3>]?C]3ZJG5YX4@D$E0(S!JT!-);356,"E<&T$B#HS1CXY56
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M%$_-Y8KB^Y+0 OA\P;FJ;K2!^E/:Z#]02P,$%     @ .8#56*B>K%>=!
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M[Q5@N-,Y2M0SWQ\-O<6%M%43V:YN6_!%U7G^N%?]^X[I&9>&"F)*H5&]W0Q
M5SVQ,JR:^SXT49:ZFI\6]!E![1QH?ZJ4W1@NP?;#U/\-4$L#!!0    ( #F
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M[01:'8<%(3SMH$#2T#VC5J^[LUY(9<N8DDAP9J#E.6Z'D<&ES!=@4&5?03Q
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M$/Z(N"T1[HK?(*G_*L94+-VUBIMHL; W$S.AL2FRPSG'U"O-!OQ^(X3>3(R
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M<^15PTAV[)/S/G(E;PTY*=3D\U;#].ZV71<$/C%SB5\M)2D;/Y/6SP8]K^!
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M95.2P5U)"!1*4*D8?BM#R=<WE'PY_'TCAA*"<C1!Y:3WM2TE"N])@H$:KO9
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MJU<*WVSK;0:2K<J=L3F3DF7E80(D!JXO4.<7C,F7@=YLJS=7QW\!4$L#!!0
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MS'UYHW#GMR@9*T!H)@51,!]YY\'99&CS7<(#@TIOK(E5,I/RR6XNLY'7MX2
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MUV7H&3W_M0S78:&$B)0R47% OR]F0G*UK?_TQ=,(!OV"^JB?BQ*G,+;461;
M5V#%'S^XD?.E+ZSW%$O>26PK2+\+TC^D'D]PK?:V!$XP%4AM+=6-RI(2Z-UB
MC59HM'1W6\6N$ZKML-K,I@?D#IUM4+(/\OSHO])6+4%72W"PEFM2$'4L,[1@
MK/^(-/QH8]6A>[;K?Q\T\+WACO]]4.0/@W[_8><_/.C_GDE,^VR'>V&=>4&T
M8WL?- R=7=L]H$$PV+%M;_0V?1&IUK$@A4 4YHKFG X4GS?-O9E(5IIV-V-2
M-4\S7*K[$+@&J.]SQN1ZHCMH=\/&_P!02P,$%     @ .8#56(\>(X&' P
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M+UAQ0+V,-XF#-']%S\6^6@=-EBF/PR)8C"#TH]6[]ZOX(M8""-D20(H LFN
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M"%J]D58V5+ I%6Q"#LNUKF'E96RUF9%T"-]PDN#T$32_1<"Z=BQ 7DCB!8R
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M5#-0S40U"]5L5'-0S44U#]5\5 M0+:2T9K;6G; +\2QM5^FZ2-;W\;KH<RX
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MTDWY'G0BW:1%D:YV-Q=Q=!MGU0/*G]^E:?'TAVJ KVGV^^[E^OC_4$L#!!0
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MT^;''N_+IBF7FY>/(IN+:AW0_OU+63;?WZP3['^1]/+_4$L#!!0    ( #F
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M+U6^?'DDTHR+O*KR>?WCC"=37L@#Q.>7>5[=_2(KD*)._37/_@M02P,$%
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MKJ%/<K5K>O(?Z9+TZJ?H7>70K!>J4:CF0C4&U3A4$U#-0VEJRS29KW&>T->
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M-(L9WZ2/\W)'2;RNB[)TKFN:/<_B))\M%_5S=W2Y*/8L37)R1U&YS[*8_OI
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MH_:9S']HBC7+$"_Q U#7$%0M@E+KD^U2-GPR9K-.D!T&9+*=?*,VFHSV/-<
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MLTG,V;/%JW_=U7?)$3T2\TDL(+&0Q"((ZT3+XC%:%G\O6O8%R6)PP" /8N2
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M:*&T$$KC4%H$I0D438^9LK8V;6U[6!"HDX72PD.3DY/-7G8GGSO# 36Q4)I
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M4)I T?1L*!'K0^JFTA3C@$!M*I3&_7;=U.;W(T([%"B:'@"E2'U(W52:8AP
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MBG,A%-M!CS01.XX620CA*8 I>97DG%=R,Z<1T8>@@US[5^18CHM^1B;B.\R
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M >#/EQBSPXUP4)P6CW\!4$L#!!0    ( #F U5C>NL60K0@  )E1   9
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M[67:+3/MUJF/OJY5N:D6J<]H!HLH366-DDTF)FD ND3GLEXFJ_KMV\AV>N[
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M<R,W%BP_E\QO!%UEYV@S*@1-LLLED!"8 LCW<TK%]D8%*$^'1[\ 4$L#!!0
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M?7L:]O5IV/>GO1=OKKB',U5AF3W[@^%[N;GRT<V2R9"AS^'DRIZD0)TR*(V
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M8%@OM"C=;/4@M)G4W./&#-,@[0'S?B6$?EE8!^UXGOP'4$L#!!0    ( #F
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MJF$+L^&>V=#([ .E\VV2ICI4QI)=40TUHTNY+=ATC%3'%E;0J1?ZCOE^2F(
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MT=/=&T'7Y;.5,RH$S<J7*X+GA!47R.\7E(JG-\7CFOL'@,?_ 5!+ P04
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M6!:15:?\U86@>7F,_4B%H&DYW .66J8,Y/=;*L6POE W:-ZU+/X#4$L#!!0
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M)7NFNR!^C%XMEFW0,/$642#2_\EKMFZO0Q8[$4>;K+'LP<8/]S_I6_:+:-)
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MN:NTO ?X+,PDTN4H%G>R:_!^*-NSS6VUFP=%NES?:'J;%D6Z6&_.A9QXL[)
MOGZ7IL6O!^6]J]7-S>/_ 5!+ P04    "  Y@-58F?A4%ZD"  "P!P  &@
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M_C,T>G2 ,2VX?J*]L1T&%HIK+FC9@&4$94[,&S\V>3@"2)YN@-< O%/ Z S
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M,3,?S$;02G?,#16R_^IE)D<J,&4@OV\I%8>-<M .Z? W4$L#!!0    ( #F
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M.)ZWW;IHNH4&NH7!%<W9N@11OB +A7VHMX=(0S#F,=H%"CT%Z@)I&:_BXAW
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MUKS<B7@MRCI ?;\I"OG]3=W Z><D%G\!4$L#!!0    ( #F U5B#NHP*XP0
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MH^H= 7I'U3L"](ZJ=P3H'57O"- [JMX1H'=2O1- [Z1Z)X#>2?5. +V3ZIT
M>B?5.P'T3MW/2H#>2?5. +V3ZIT >B?5.P'T3JIW NB=5>\,T#NKWAF@=U:]
M,T#OK'IG@-Y9]<X O;/JG0%ZYVZS"4#OK'IG@-Y9]<X O;/JG0%Z%]6[ /0N
MJG<!Z%U4[P+0NZC>!:!W4;T+0.^B>A> WD7U+@"]2[=9$*!W4;T+0.^B>A>
MWE7UK@"]J^I= 7I7U;L"]*ZJ=P7H757O"M"[JMX5H'=5O2M [ZIZ5X#>M=OL
M#="[JMX5H'=3O1M [Z9Z-X#>3?5N +V;ZMT >C?5NP'T;JIW ^C=5.\&T+NI
MW@V@=U.]&T#OUI5U 'J;Z^LZ +_-=84=!Q#<7%?9<0##S76E'0=0W%Q7VW$
MQ\UUQ1T'D-Q<5]UQ ,O-=>4=!]#<7%??<0#/S74%'D<0O2]@?FL#<YK?MN/T
MF>ACW07X3KWG\[WCY_/?EQ\G^]+G.]?#UQC3S5]02P,$%     @ .8#56,>%
ME:QZ @  )SX  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=M/;YLP&,?QMQ)Q
MK0*V 1NFII=VUZV'O0$&3H/"/V&W2]_]'-)6VM1%JS)IWPL(;#^_!UOZW+C^
M]CQ9MSKTW> VT<[[Z5.2N'IG^\K%XV2',+(=Y[[RX7%^2*:JWE</-E%"Z*0>
M!V\'O_;'&M'-]9W=5H^=7WT^A->N'8=---O.1:O;T\1CUB:JIJEKZ\J'\>1I
M:'Y+6;\DQ&'E,L?MVLE=A0E1\F["<>3/ 2_KOC[9>6X;N[JO9O^EZL.LY- E
MSC]WUL7G2[S3X[C=MK5MQOJQ#TMB-\VV:MS.6M]W\:GHU?ED'W;8GJ[RXORE
MS+G ,/-^'B<73FRV'X][/9+CZO44"MG9M^<_\2TQE+[X^^SQM!O;_&5VV-X?
MX[Q?SL,ER^WR/?[UC-_J?[ /!>DCA?210?K((7UH2!\&TD<!Z:.$]"$%I1&*
MJ))"JJ28*BFH2HJJDL*JI+@J*;!*BJR*(JNBR*HHLBJ*K(HBJZ+(JBBR*HJL
MBB*KHLB:4F1-*;*F%%E3BJPI1=:4(FM*D36ER)I29$TILF8463.*K!E%UHPB
M:T:1-:/(FE%DS2BR9A19,XJL.476G")K3I$UI\B:4V3-*;+F%%ESBJPY1=:<
M(JNFR*HILFJ*K)HBJZ;(JBFR:HJLFB*KILBJ*;(:BJR&(JNAR&HHLAJ*K(8B
MJZ'(:BBR&HJLAB)K09&UH,A:4&0M*+(6%%D+BJP%1=:"(FM!D;6@R%I29"TI
MLI8464N*K"5%UI(B:TF1M:3(6E)D+2FR2D&A50J*K5)0<)6"HJL4%%ZEH/@J
M!058*2C"2D$A5@J,L?_U=ZSOX[C_Q_'+/>ZK=GC-3Y;_PV]^ E!+ 0(4 Q0
M   ( #F U5@'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ .8#56.6D'./N    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ .8#56)E<
MG",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    "  Y@-58Y8<ON'P"  #8!@  &               @($-
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ .8#56-MW
M=8S\#0  HX   !@              ("!OPH  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( #F U5@D:W!(LP(  /,'   8
M  " @?$8  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  Y
M@-58(=%^IEH0   !IP  &               @(':&P  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ .8#56-&$(Z>N @  [@<  !@
M         ("!:BP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( #F U5C&N>)22A(  +K>   8              " @4XO  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  Y@-58U&<'U\<"   @"
M&               @('.00  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ .8#56+Z369P(%   1]P  !@              ("!RT0  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #F U5@-49H\'0<
M +X7   8              " @0E9  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    "  Y@-58IQ*^R#83  "C:@  &0              @(%<
M8   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #F U5AI
M"V&'PBP  % " 0 9              " @<ES  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ .8#56&VJ8]W+$P  !&(  !D
M     ("!PJ   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F U5CN59]83 <  %L3   9              "
M@>7/  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ .8#5
M6%(D;64T%   (D   !D              ("!:-<  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    "  Y@-58!"^--]$(   A&0  &0
M        @('3ZP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( #F U5B!JR>/BA0  -MH   9              " @=OT  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ .8#56"E]0RK%!0  K1@
M !D              ("!G D! 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    "  Y@-581I95#[0)   2*@  &0              @(&8#P$
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( #F U5APPA<$
M]@P  ($L   9              " @8,9 0!X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ .8#56/%TIAUB#P  -3@  !D
M ("!L"8! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  Y
M@-58<V*5?OH&   F&   &0              @(%)-@$ >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #F U5B>?<4V;0@  .@;   9
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M970S,"YX;6Q02P$"% ,4    "  Y@-58QD\ =?<#  #A"   &0
M    @(',?P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M #F U5A/#;C>YPH  # A   9              " @?J# 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ .8#56!)54A%!#   @2P  !D
M             ("!&(\! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    "  Y@-58*@UDZRA   #X-@$ &0              @(&0FP$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( #F U5BDA!9)%P0
M ) *   9              " @>_; 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ .8#56/)P" C+ @  ' 8  !D              ("!
M/> ! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  Y@-58
M=$YU( $&  !6$P  &0              @($_XP$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( #F U5BHGJQ7G00  .X.   9
M      " @7?I 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ .8#56-63][O/ @  (0<  !D              ("!2^X! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  Y@-58!:LGMI0#  #%"@
M&0              @(%1\0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( #F U5C];#!1\@(  *0&   9              " @1SU 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ .8#56.VF",FV
M!   B@\  !D              ("!1?@! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    "  Y@-58+#3K*@ &  #G$@  &0
M@($R_0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #F
MU5A:JN)@OP4  *47   9              " @6D# @!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ .8#56, ,#P3)!0  O!   !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( #F U5C+S6(=$ ,  /P'   9
M  " @8D? @!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M.8#56/J#28&7!   /0T  !D              ("!T"(" 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    "  Y@-58N7X<9=D&   _%   &0
M            @(&>)P( >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( #F U5A2[SUK(0<  .Q,   9              " @:XN @!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ .8#56&*,?*-R"@
ME5<  !D              ("!!C8" 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    "  Y@-58:NQM !0$  "0%   &0              @(&O
M0 ( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( #F U5BP
M(CRPG ,  &@5   9              " @?I$ @!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ .8#56'4V+1>: P  ,1(  !D
M     ("!S4@" 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F U5C L$1F# 0  .<9   9              "
M@3EF @!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ .8#5
M6!LX ^A%!   /1@  !D              ("!?&H" 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    "  Y@-58*E]E:34$  !U&@  &0
M        @('X;@( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( #F U5C_-J$:+P,  -P(   9              " @61S @!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ .8#56,H<5@&1 @  <08
M !D              ("!RG8" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    "  Y@-58!HQZ%J("  !M!P  &0              @(&2>0(
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( #F U5B/'B.!
MAP,  /,0   9              " @6M\ @!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ .8#56)-4'&;2!0   S0  !D
M ("!*8 " 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  Y
M@-58XX9O"8(%  #"'   &0              @($RA@( >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( #F U5BD/]E9D04  (\H   9
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M970W-2YX;6Q02P$"% ,4    "  Y@-58(1V&=>X"  "T"P  &0
M    @('WS ( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (
M #F U5@.@S8RVP(  /((   9              " @1S0 @!X;"]W;W)K<VAE
M971S+W-H965T-S<N>&UL4$L! A0#%     @ .8#56+')E& H!0   "$  !D
M             ("!+M," 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"
M% ,4    "  Y@-58PJX0NT<2   IS   &0              @(&-V ( >&PO
M=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( #F U5BSFY79(0@
M !1G   9              " @0OK @!X;"]W;W)K<VAE971S+W-H965T.# N
M>&UL4$L! A0#%     @ .8#56&BJ1OT2!   <A8  !D              ("!
M8_," 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    "  Y@-58
MT==E9\T&  "J-   &0              @(&L]P( >&PO=V]R:W-H965T<R]S
M:&5E=#@R+GAM;%!+ 0(4 Q0    ( #F U5A=.X4U9P8    U   9
M      " @;#^ @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%
M  @ .8#56$RW<PJ-%@  /HX! !D              ("!3@4# 'AL+W=O<FMS
M:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    "  Y@-584].8XHH)   B6P
M&0              @($2' , >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+
M 0(4 Q0    ( #F U5CM"D<7X@@  .95   9              " @=,E P!X
M;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ .8#56 <7L*%M
M#0   +0  !D              ("!["X# 'AL+W=O<FMS:&5E=',O<VAE970X
M-RYX;6Q02P$"% ,4    "  Y@-58''\RK/$#  #-$   &0
M@(&0/ , >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( #F
MU5A1] BKC 0  #D6   9              " @;A  P!X;"]W;W)K<VAE971S
M+W-H965T.#DN>&UL4$L! A0#%     @ .8#56-ZZQ9"M"   F5$  !D
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M=#DT+GAM;%!+ 0(4 Q0    ( #F U5A.I%AG !4  +0^ 0 9
M  " @69E P!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%     @
M.8#56.PZ]I][!0  ZR   !D              ("!G7H# 'AL+W=O<FMS:&5E
M=',O<VAE970Y-BYX;6Q02P$"% ,4    "  Y@-58PKASE(T&  "&.   &0
M            @(%/@ , >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4
M Q0    ( #F U5C95\';S 0  #<A   9              " @1.' P!X;"]W
M;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ .8#56#!J].F; P
MJ@L  !D              ("!%HP# 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX
M;6Q02P$"% ,4    "  Y@-58%D<:J$T&   ,+   &@              @('H
MCP, >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    "  Y@-58
MY2I*L%P$  !W&0  &@              @(%ME@, >&PO=V]R:W-H965T<R]S
M:&5E=#$P,2YX;6Q02P$"% ,4    "  Y@-58<E>DE%X)  #_90  &@
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M:&5E=#$P-BYX;6Q02P$"% ,4    "  Y@-58\%TM@$,(  !:0@  &@
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( #F U5B/S%>9> <  .M'   /
M      "  3O> P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  Y@-58.IM
M-1@#  "90   &@              @ '@Y0, >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  Y@-58QX65K'H"   G/@  $P
M    @ $PZ0, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     =@!V 'P@  #;
%ZP,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>608</ContextCount>
  <ElementCount>582</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>181</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Consolidated Statements of Financial Position (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical</Role>
      <ShortName>Consolidated Statements of Financial Position (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Consolidated Statements of Loss and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Loss and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Consolidated Statements of Loss and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Loss and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - Consolidated Statement of Shareholders' Equity (Deficiency)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Shareholders' Equity (Deficiency)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Statement - Unaudited Condensed Interim Consolidated Statement of Shareholders' Equity (Deficiency) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/UnauditedCondensedInterimConsolidatedStatementOfShareholdersEquityDeficiencyParentheticals</Role>
      <ShortName>Unaudited Condensed Interim Consolidated Statement of Shareholders' Equity (Deficiency) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties</Role>
      <ShortName>CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS</Role>
      <ShortName>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - TRADE AND AMOUNTS RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/TradeAndAmountsReceivable</Role>
      <ShortName>TRADE AND AMOUNTS RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/INVESTMENTS</Role>
      <ShortName>INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinations</Role>
      <ShortName>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - IMPAIRMENT OF ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IMPAIRMENTOFASSETS</Role>
      <ShortName>IMPAIRMENT OF ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ShareCapital</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - SHARE BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ShareBasedCompensation</Role>
      <ShortName>SHARE BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/WARRANTS</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - RELATED PARTY DISCLOSURES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/RelatedPartyDisclosures</Role>
      <ShortName>RELATED PARTY DISCLOSURES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/LossPerShare</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/FinancialInstruments</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - CAPITAL MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/CapitalManagement</Role>
      <ShortName>CAPITAL MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - SEGMENTED INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SegmentedInformation</Role>
      <ShortName>SEGMENTED INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/BasisOfPresentationTables</Role>
      <ShortName>BASIS OF PRESENTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/BasisOfPresentation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables</Role>
      <ShortName>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/TradeAndAmountsReceivableTables</Role>
      <ShortName>TRADE AND AMOUNTS RECEIVABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/TradeAndAmountsReceivable</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/INVENTORY</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/InvestmentsTables</Role>
      <ShortName>INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/INVESTMENTS</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables</Role>
      <ShortName>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinations</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0043 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0044 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/LEASES</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0045 - Disclosure - SHARE BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ShareBasedCompensationTables</Role>
      <ShortName>SHARE BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ShareBasedCompensation</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0046 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/WarrantsTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/WARRANTS</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0047 - Disclosure - RELATED PARTY DISCLOSURES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/RelatedPartyDisclosuresTables</Role>
      <ShortName>RELATED PARTY DISCLOSURES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/RelatedPartyDisclosures</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0048 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0049 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0050 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/LossPerShareTables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/LossPerShare</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0051 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/FinancialInstrumentsTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/FinancialInstruments</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0052 - Disclosure - SEGMENTED INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SegmentedInformationTables</Role>
      <ShortName>SEGMENTED INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SegmentedInformation</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0053 - Disclosure - BASIS OF PRESENTATION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/BasisOfPresentationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0054 - Disclosure - BASIS OF PRESENTATION (Schedule of subsidiaries) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/BasisOfPresentationDetails</Role>
      <ShortName>BASIS OF PRESENTATION (Schedule of subsidiaries) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/BasisOfPresentationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of assets estimated useful lives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of assets estimated useful lives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of intangible assets estimated useful lives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of intangible assets estimated useful lives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0058 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails</Role>
      <ShortName>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0059 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of major classes of assets and liabilities held for sale) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails</Role>
      <ShortName>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of major classes of assets and liabilities held for sale) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0060 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of loss from discontinued operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1</Role>
      <ShortName>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of loss from discontinued operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0061 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of significant operating and investing items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2</Role>
      <ShortName>ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of significant operating and investing items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0062 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails</Role>
      <ShortName>TRADE AND AMOUNTS RECEIVABLE (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/TradeAndAmountsReceivableTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0063 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of trade and other receivables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails</Role>
      <ShortName>TRADE AND AMOUNTS RECEIVABLE (Schedule of trade and other receivables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/TradeAndAmountsReceivableTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0064 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of aging of trade accounts receivable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1</Role>
      <ShortName>TRADE AND AMOUNTS RECEIVABLE (Schedule of aging of trade accounts receivable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/TradeAndAmountsReceivableTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0065 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of allowance for expected credit losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2</Role>
      <ShortName>TRADE AND AMOUNTS RECEIVABLE (Schedule of allowance for expected credit losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/TradeAndAmountsReceivableTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0066 - Disclosure - INVENTORY (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/InventoryDetailsNarrative</Role>
      <ShortName>INVENTORY (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/InventoryTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0067 - Disclosure - INVENTORY (Schedule of inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Schedule of inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/InventoryTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0068 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0069 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Schedule of property, plant and equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Schedule of property, plant and equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0070 - Disclosure - INVESTMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/InvestmentsDetailsNarrative</Role>
      <ShortName>INVESTMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/InvestmentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0071 - Disclosure - INVESTMENTS (Schedule of investments activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/InvestmentsDetails</Role>
      <ShortName>INVESTMENTS (Schedule of investments activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/InvestmentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0072 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative</Role>
      <ShortName>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0073 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Schedule of major class of assets acquired and liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1</Role>
      <ShortName>ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Schedule of major class of assets acquired and liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0074 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0075 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of intangible assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Schedule of intangible assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0076 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of amortization) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/DummyDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Schedule of amortization) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0077 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of estimation of amortization expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Schedule of estimation of amortization expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0078 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of goodwill) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Schedule of goodwill) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0079 - Disclosure - IMPAIRMENT OF ASSETS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative</Role>
      <ShortName>IMPAIRMENT OF ASSETS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IMPAIRMENTOFASSETS</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0080 - Disclosure - DEBT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/DEBT</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0081 - Disclosure - LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/LeasesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0082 - Disclosure - LEASES (Schedule of leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Schedule of leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/LeasesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0083 - Disclosure - LEASES (Schedule of maturities of operating lease liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/LeasesDetails1</Role>
      <ShortName>LEASES (Schedule of maturities of operating lease liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/LeasesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0084 - Disclosure - SHARE CAPITAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1</Role>
      <ShortName>SHARE CAPITAL (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ShareCapital</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0085 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative</Role>
      <ShortName>SHARE BASED COMPENSATION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0086 - Disclosure - SHARE BASED COMPENSATION (Schedule of stock options roll forward) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>SHARE BASED COMPENSATION (Schedule of stock options roll forward) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0087 - Disclosure - SHARE BASED COMPENSATION (Schedule of stock options outstanding and exercisable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable</Role>
      <ShortName>SHARE BASED COMPENSATION (Schedule of stock options outstanding and exercisable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0088 - Disclosure - SHARE BASED COMPENSATION (Schedule of weighted average inputs and assumptions)  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ShareBasedCompensationDetails2</Role>
      <ShortName>SHARE BASED COMPENSATION (Schedule of weighted average inputs and assumptions)  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0089 - Disclosure - SHARE BASED COMPENSATION (Schedule of restricted stock awards) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/ShareBasedCompensationDetails1</Role>
      <ShortName>SHARE BASED COMPENSATION (Schedule of restricted stock awards) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0090 - Disclosure - WARRANTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>WARRANTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/WarrantsTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0091 - Disclosure - WARRANTS (Schedule of warrants outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/WarrantsDetails</Role>
      <ShortName>WARRANTS (Schedule of warrants outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/WarrantsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0092 - Disclosure - WARRANTS (Schedule of warrants outstanding by date of expiry) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/WarrantsDetails1</Role>
      <ShortName>WARRANTS (Schedule of warrants outstanding by date of expiry) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/WarrantsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0093 - Disclosure - RELATED PARTY DISCLOSURES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative</Role>
      <ShortName>RELATED PARTY DISCLOSURES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/RelatedPartyDisclosuresTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0094 - Disclosure - RELATED PARTY DISCLOSURES (Schedule of key management personnel compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails</Role>
      <ShortName>RELATED PARTY DISCLOSURES (Schedule of key management personnel compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/RelatedPartyDisclosuresTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0095 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0096 - Disclosure - COMMITMENTS AND CONTINGENCIES (Schedule of provisions and contingent liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Schedule of provisions and contingent liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0097 - Disclosure - INCOME TAXES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IncomeTaxesTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0098 - Disclosure - INCOME TAXES (Schedule of components of the income tax provision) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Schedule of components of the income tax provision) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IncomeTaxesTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0099 - Disclosure - INCOME TAXES  (Schedule of corporate income tax rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES  (Schedule of corporate income tax rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IncomeTaxesTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0100 - Disclosure - INCOME TAXES (Schedule of deferred income tax assets and liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/IncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Schedule of deferred income tax assets and liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/IncomeTaxesTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0102 - Disclosure - LOSS PER SHARE (Schedule of anti-dilutive shares) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/LossPerShareDetails</Role>
      <ShortName>LOSS PER SHARE (Schedule of anti-dilutive shares) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/LossPerShareTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0103 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0105 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of information about the financial instruments and their classifications) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of information about the financial instruments and their classifications) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0106 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of assets and liabilities denominated in foreign currencies) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of assets and liabilities denominated in foreign currencies) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0107 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SegmentedInformationDetailsNarrative</Role>
      <ShortName>SEGMENTED INFORMATION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SegmentedInformationTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0108 - Disclosure - SEGMENTED INFORMATION (Schedule of operation segments information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SegmentedInformationDetails</Role>
      <ShortName>SEGMENTED INFORMATION (Schedule of operation segments information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SegmentedInformationTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0109 - Disclosure - SEGMENTED INFORMATION (Schedule of other significant items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SegmentDetails</Role>
      <ShortName>SEGMENTED INFORMATION (Schedule of other significant items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SegmentedInformationTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0110 - Disclosure - SEGMENTED INFORMATION (Schedule of disaggregation of net sales by geographic area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SegmentedInformationDetails1</Role>
      <ShortName>SEGMENTED INFORMATION (Schedule of disaggregation of net sales by geographic area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SegmentedInformationTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0111 - Disclosure - SEGMENTED INFORMATION  (Schedule of disaggregation of property, plant and equipment and other long-lived assets by geographic area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SegmentedInformationDetails3</Role>
      <ShortName>SEGMENTED INFORMATION  (Schedule of disaggregation of property, plant and equipment and other long-lived assets by geographic area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SegmentedInformationTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="formprer14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0112 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.floragrowth.com/role/SubsequentEvents</ParentRole>
      <Position>110</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate in us-gaap/2023 used in 1 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. formprer14a.htm 17867</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate in us-gaap/2023 used in 1 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. formprer14a.htm 17867</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept LossContingencyTrialOrAlternativeDisputeResolution in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. formprer14a.htm 20662, 26190</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:ProfessionalFees has a value of -3000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:ProfessionalFees fact are: Context: C_20230101to20230331, Unit: USD, Rule Element Id: 2094. formprer14a.htm 23173</Log>
    <Log type="Warning">[DQC.US.0099.9533] The following elements are in the presentation linkbase of http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows but are not included in any calculation relationship in the filing.

AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities

All elements appearing in the face of the financial statements should be included in a calculation relationship somewhere in the filing. Items not included in the financial statement calculations but included in the presentation are referred to as parenthetical items. These usually appear as a referenced item, or as a value in parenthesis describing that the value reported includes another specific amount.  These values should be reported in a seperate link role for parenthetical items.

This rule will produce an error irrespective of a fact value being entered for the item(s) listed above.

If the item is an additional disclosure in the cash flow statement then make sure that is included as a child of one of the following abstract items: {nonCFabstracts} - formprer14a.htm  - formprer14a.htm </Log>
  </Logs>
  <InputFiles>
    <File>flgc-20240331.xsd</File>
    <File>flgc-20240331_cal.xml</File>
    <File>flgc-20240331_def.xml</File>
    <File>flgc-20240331_lab.xml</File>
    <File>flgc-20240331_pre.xml</File>
    <File doctype="PRER14A" isDefinitelyFs="true" isUsgaap="true" original="formprer14a.htm">formprer14a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>formprer14axz001.jpg</File>
    <File>formprer14axz002.jpg</File>
    <File>formprer14axz003.jpg</File>
    <File>formprer14axz004.jpg</File>
    <File>formprer14axz005.jpg</File>
    <File>formprer14axz006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2432">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>131
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "formprer14a.htm": {
   "nsprefix": "flgc",
   "nsuri": "http://www.floragrowth.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "flgc-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "flgc-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "flgc-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "flgc-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "flgc-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "formprer14a.htm"
     ]
    }
   },
   "keyStandard": 436,
   "keyCustom": 146,
   "axisStandard": 36,
   "axisCustom": 1,
   "memberStandard": 46,
   "memberCustom": 125,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 608,
   "entityCount": 1,
   "segmentCount": 181,
   "elementCount": 1074,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 2432,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "report": {
    "R1": {
     "role": "http://www.floragrowth.com/role/Cover",
     "longName": "0001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "b",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "b",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
     "longName": "0002 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical",
     "longName": "0003 - Statement - Consolidated Statements of Financial Position (Parenthetical)",
     "shortName": "Consolidated Statements of Financial Position (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
     "longName": "0004 - Statement - Consolidated Statements of Loss and Comprehensive Loss",
     "shortName": "Consolidated Statements of Loss and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLossParenthetical",
     "longName": "0005 - Statement - Consolidated Statements of Loss and Comprehensive Loss (Parenthetical)",
     "shortName": "Consolidated Statements of Loss and Comprehensive Loss (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
     "longName": "0006 - Statement - Consolidated Statement of Shareholders' Equity (Deficiency)",
     "shortName": "Consolidated Statement of Shareholders' Equity (Deficiency)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.floragrowth.com/role/UnauditedCondensedInterimConsolidatedStatementOfShareholdersEquityDeficiencyParentheticals",
     "longName": "0007 - Statement - Unaudited Condensed Interim Consolidated Statement of Shareholders' Equity (Deficiency) (Parenthetical)",
     "shortName": "Unaudited Condensed Interim Consolidated Statement of Shareholders' Equity (Deficiency) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
     "longName": "0008 - Statement - Consolidated Statement of Cash Flows",
     "shortName": "Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.floragrowth.com/role/NatureOfOperations",
     "longName": "0009 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.floragrowth.com/role/BasisOfPresentation",
     "longName": "0010 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.floragrowth.com/role/SignificantAccountingPolicies",
     "longName": "0011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties",
     "longName": "0012 - Disclosure - CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES",
     "shortName": "CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:UnusualRisksAndUncertaintiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:UnusualRisksAndUncertaintiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS",
     "longName": "0013 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS",
     "shortName": "ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.floragrowth.com/role/TradeAndAmountsReceivable",
     "longName": "0014 - Disclosure - TRADE AND AMOUNTS RECEIVABLE",
     "shortName": "TRADE AND AMOUNTS RECEIVABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.floragrowth.com/role/INVENTORY",
     "longName": "0015 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.floragrowth.com/role/PropertyPlantAndEquipment",
     "longName": "0016 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.floragrowth.com/role/INVESTMENTS",
     "longName": "0017 - Disclosure - INVESTMENTS",
     "shortName": "INVESTMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinations",
     "longName": "0018 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS",
     "shortName": "ASSET ACQUISITIONS AND BUSINESS COMBINATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwill",
     "longName": "0019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.floragrowth.com/role/IMPAIRMENTOFASSETS",
     "longName": "0020 - Disclosure - IMPAIRMENT OF ASSETS",
     "shortName": "IMPAIRMENT OF ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.floragrowth.com/role/DEBT",
     "longName": "0021 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.floragrowth.com/role/LEASES",
     "longName": "0022 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.floragrowth.com/role/ShareCapital",
     "longName": "0023 - Disclosure - SHARE CAPITAL",
     "shortName": "SHARE CAPITAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.floragrowth.com/role/ShareBasedCompensation",
     "longName": "0024 - Disclosure - SHARE BASED COMPENSATION",
     "shortName": "SHARE BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.floragrowth.com/role/WARRANTS",
     "longName": "0025 - Disclosure - WARRANTS",
     "shortName": "WARRANTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "flgc:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "flgc:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.floragrowth.com/role/RelatedPartyDisclosures",
     "longName": "0026 - Disclosure - RELATED PARTY DISCLOSURES",
     "shortName": "RELATED PARTY DISCLOSURES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.floragrowth.com/role/CommitmentsAndContingencies",
     "longName": "0027 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.floragrowth.com/role/IncomeTaxes",
     "longName": "0028 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.floragrowth.com/role/LossPerShare",
     "longName": "0029 - Disclosure - LOSS PER SHARE",
     "shortName": "LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.floragrowth.com/role/FinancialInstruments",
     "longName": "0030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.floragrowth.com/role/CapitalManagement",
     "longName": "0031 - Disclosure - CAPITAL MANAGEMENT",
     "shortName": "CAPITAL MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:CapitalManagementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:CapitalManagementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.floragrowth.com/role/SegmentedInformation",
     "longName": "0032 - Disclosure - SEGMENTED INFORMATION",
     "shortName": "SEGMENTED INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.floragrowth.com/role/SubsequentEvents",
     "longName": "0033 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.floragrowth.com/role/BasisOfPresentationTables",
     "longName": "0035 - Disclosure - BASIS OF PRESENTATION (Tables)",
     "shortName": "BASIS OF PRESENTATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:ScheduleOfSubsidiariesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:ScheduleOfSubsidiariesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.floragrowth.com/role/SignificantAccountingPoliciesTables",
     "longName": "0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables",
     "longName": "0037 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Tables)",
     "shortName": "ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables",
     "longName": "0038 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Tables)",
     "shortName": "TRADE AND AMOUNTS RECEIVABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.floragrowth.com/role/InventoryTables",
     "longName": "0039 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables",
     "longName": "0040 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.floragrowth.com/role/InvestmentsTables",
     "longName": "0041 - Disclosure - INVESTMENTS (Tables)",
     "shortName": "INVESTMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:ScheduleOfCompanysInvestmentsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:ScheduleOfCompanysInvestmentsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables",
     "longName": "0042 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Tables)",
     "shortName": "ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables",
     "longName": "0043 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.floragrowth.com/role/LeasesTables",
     "longName": "0044 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.floragrowth.com/role/ShareBasedCompensationTables",
     "longName": "0045 - Disclosure - SHARE BASED COMPENSATION (Tables)",
     "shortName": "SHARE BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.floragrowth.com/role/WarrantsTables",
     "longName": "0046 - Disclosure - WARRANTS (Tables)",
     "shortName": "WARRANTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "flgc:ScheduleOfWarrantsOutstandingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "flgc:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "flgc:ScheduleOfWarrantsOutstandingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "flgc:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.floragrowth.com/role/RelatedPartyDisclosuresTables",
     "longName": "0047 - Disclosure - RELATED PARTY DISCLOSURES (Tables)",
     "shortName": "RELATED PARTY DISCLOSURES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.floragrowth.com/role/CommitmentsAndContingenciesTables",
     "longName": "0048 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.floragrowth.com/role/IncomeTaxesTables",
     "longName": "0049 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.floragrowth.com/role/LossPerShareTables",
     "longName": "0050 - Disclosure - LOSS PER SHARE (Tables)",
     "shortName": "LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.floragrowth.com/role/FinancialInstrumentsTables",
     "longName": "0051 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.floragrowth.com/role/SegmentedInformationTables",
     "longName": "0052 - Disclosure - SEGMENTED INFORMATION (Tables)",
     "shortName": "SEGMENTED INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "0053 - Disclosure - BASIS OF PRESENTATION (Narrative) (Details)",
     "shortName": "BASIS OF PRESENTATION (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "flgc:GoingConcernPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:CumulativeEarningsDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "flgc:GoingConcernPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.floragrowth.com/role/BasisOfPresentationDetails",
     "longName": "0054 - Disclosure - BASIS OF PRESENTATION (Schedule of subsidiaries) (Details)",
     "shortName": "BASIS OF PRESENTATION (Schedule of subsidiaries) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember",
      "name": "us-gaap:BusinessAcquisitionNameOfAcquiredEntity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "flgc:ScheduleOfSubsidiariesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember",
      "name": "us-gaap:BusinessAcquisitionNameOfAcquiredEntity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "flgc:ScheduleOfSubsidiariesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "longName": "0055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
     "longName": "0056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of assets estimated useful lives) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of assets estimated useful lives) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "flgc:ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "flgc:ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1",
     "longName": "0057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of intangible assets estimated useful lives) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of intangible assets estimated useful lives) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "flgc:ScheduleOfIntangibleAssetsEstimatedUsefulLives",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "flgc:ScheduleOfIntangibleAssetsEstimatedUsefulLives",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
     "longName": "0058 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Narrative) (Details)",
     "shortName": "ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
     "longName": "0059 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of major classes of assets and liabilities held for sale) (Details)",
     "shortName": "ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of major classes of assets and liabilities held for sale) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "flgc:ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
     "longName": "0060 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of loss from discontinued operations) (Details)",
     "shortName": "ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of loss from discontinued operations) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfLossFromDiscontinuedOperationsTableTextBlock",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
     "longName": "0061 - Disclosure - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of significant operating and investing items) (Details)",
     "shortName": "ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS (Schedule of significant operating and investing items) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember",
      "name": "us-gaap:DepreciationAndAmortizationDiscontinuedOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember",
      "name": "us-gaap:DepreciationAndAmortizationDiscontinuedOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails",
     "longName": "0062 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Narrative) (Details)",
     "shortName": "TRADE AND AMOUNTS RECEIVABLE (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails",
     "longName": "0063 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of trade and other receivables) (Details)",
     "shortName": "TRADE AND AMOUNTS RECEIVABLE (Schedule of trade and other receivables) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "flgc:TradeAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:ValueAddedTaxReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1",
     "longName": "0064 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of aging of trade accounts receivable) (Details)",
     "shortName": "TRADE AND AMOUNTS RECEIVABLE (Schedule of aging of trade accounts receivable) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "flgc:TradeAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember",
      "name": "flgc:TradeAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfCompanyAgingOfTradeAccountsReceivable",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2",
     "longName": "0065 - Disclosure - TRADE AND AMOUNTS RECEIVABLE (Schedule of allowance for expected credit losses) (Details)",
     "shortName": "TRADE AND AMOUNTS RECEIVABLE (Schedule of allowance for expected credit losses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_20221231",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.floragrowth.com/role/InventoryDetailsNarrative",
     "longName": "0066 - Disclosure - INVENTORY (Narrative) (Details)",
     "shortName": "INVENTORY (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:InventoryExpensedToCostOfSales",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:InventoryExpensedToCostOfSales",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.floragrowth.com/role/InventoryDetails",
     "longName": "0067 - Disclosure - INVENTORY (Schedule of inventory) (Details)",
     "shortName": "INVENTORY (Schedule of inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative",
     "longName": "0068 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details)",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
     "longName": "0069 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Schedule of property, plant and equipment) (Details)",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Schedule of property, plant and equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.floragrowth.com/role/InvestmentsDetailsNarrative",
     "longName": "0070 - Disclosure - INVESTMENTS (Narrative) (Details)",
     "shortName": "INVESTMENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:PurchaseOfCommonStock",
      "unitRef": "EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:PurchaseOfCommonStock",
      "unitRef": "EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.floragrowth.com/role/InvestmentsDetails",
     "longName": "0071 - Disclosure - INVESTMENTS (Schedule of investments activity) (Details)",
     "shortName": "INVESTMENTS (Schedule of investments activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member",
      "name": "us-gaap:InvestmentOwnedAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "flgc:ScheduleOfCompanysInvestmentsActivityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
     "longName": "0072 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details)",
     "shortName": "ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
     "longName": "0073 - Disclosure - ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Schedule of major class of assets acquired and liabilities) (Details)",
     "shortName": "ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Schedule of major class of assets acquired and liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
     "longName": "0074 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember_usgaapReportingUnitAxis_flgcJustCBDMember",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
     "longName": "0075 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of intangible assets) (Details)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Schedule of intangible assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.floragrowth.com/role/DummyDetails",
     "longName": "0076 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of amortization) (Details)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Schedule of amortization) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "flgc:ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1",
     "longName": "0077 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of estimation of amortization expense) (Details)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Schedule of estimation of amortization expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2",
     "longName": "0078 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Schedule of goodwill) (Details)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Schedule of goodwill) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_20211231",
      "name": "us-gaap:GoodwillGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231",
      "name": "us-gaap:GoodwillGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
     "longName": "0079 - Disclosure - IMPAIRMENT OF ASSETS (Narrative) (Details)",
     "shortName": "IMPAIRMENT OF ASSETS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:AssetImpairmentChargesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.floragrowth.com/role/DebtDetailsNarrative",
     "longName": "0080 - Disclosure - DEBT (Narrative) (Details)",
     "shortName": "DEBT (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.floragrowth.com/role/LEASESNarrativeDetails",
     "longName": "0081 - Disclosure - LEASES (Narrative) (Details)",
     "shortName": "LEASES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "flgc:MonthlyLeasePayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "flgc:MonthlyLeasePayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.floragrowth.com/role/LeasesDetails",
     "longName": "0082 - Disclosure - LEASES (Schedule of leases) (Details)",
     "shortName": "LEASES (Schedule of leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.floragrowth.com/role/LeasesDetails1",
     "longName": "0083 - Disclosure - LEASES (Schedule of maturities of operating lease liabilities) (Details)",
     "shortName": "LEASES (Schedule of maturities of operating lease liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
     "longName": "0084 - Disclosure - SHARE CAPITAL (Narrative) (Details)",
     "shortName": "SHARE CAPITAL (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative",
     "longName": "0085 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details)",
     "shortName": "SHARE BASED COMPENSATION (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_20230606",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230606",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.floragrowth.com/role/ShareBasedCompensationDetails",
     "longName": "0086 - Disclosure - SHARE BASED COMPENSATION (Schedule of stock options roll forward) (Details)",
     "shortName": "SHARE BASED COMPENSATION (Schedule of stock options roll forward) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_20220101to20220131",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
     "longName": "0087 - Disclosure - SHARE BASED COMPENSATION (Schedule of stock options outstanding and exercisable) (Details)",
     "shortName": "SHARE BASED COMPENSATION (Schedule of stock options outstanding and exercisable) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember",
      "name": "flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.floragrowth.com/role/ShareBasedCompensationDetails2",
     "longName": "0088 - Disclosure - SHARE BASED COMPENSATION (Schedule of weighted average inputs and assumptions)  (Details)",
     "shortName": "SHARE BASED COMPENSATION (Schedule of weighted average inputs and assumptions)  (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:SharePrice",
      "unitRef": "CAD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.floragrowth.com/role/ShareBasedCompensationDetails1",
     "longName": "0089 - Disclosure - SHARE BASED COMPENSATION (Schedule of restricted stock awards) (Details)",
     "shortName": "SHARE BASED COMPENSATION (Schedule of restricted stock awards) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "flgc:ScheduleOfRestrictedStockAwards",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "flgc:ScheduleOfRestrictedStockAwards",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.floragrowth.com/role/WarrantsDetailsNarrative",
     "longName": "0090 - Disclosure - WARRANTS (Narrative) (Details)",
     "shortName": "WARRANTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:IntrinsicValueOfWarrantsExercised",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "flgc:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:IntrinsicValueOfWarrantsExercised",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "flgc:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.floragrowth.com/role/WarrantsDetails",
     "longName": "0091 - Disclosure - WARRANTS (Schedule of warrants outstanding) (Details)",
     "shortName": "WARRANTS (Schedule of warrants outstanding) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfWarrantsOutstandingTableTextBlock",
       "div",
       "div",
       "flgc:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfWarrantsOutstandingTableTextBlock",
       "div",
       "div",
       "flgc:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.floragrowth.com/role/WarrantsDetails1",
     "longName": "0092 - Disclosure - WARRANTS (Schedule of warrants outstanding by date of expiry) (Details)",
     "shortName": "WARRANTS (Schedule of warrants outstanding by date of expiry) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember",
      "name": "flgc:WarrantsDateOfExpiry",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "div",
       "div",
       "flgc:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember",
      "name": "flgc:WarrantsDateOfExpiry",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "div",
       "div",
       "flgc:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative",
     "longName": "0093 - Disclosure - RELATED PARTY DISCLOSURES (Narrative) (Details)",
     "shortName": "RELATED PARTY DISCLOSURES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember",
      "name": "us-gaap:OtherAccountsPayableAndAccruedLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember",
      "name": "us-gaap:OtherAccountsPayableAndAccruedLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails",
     "longName": "0094 - Disclosure - RELATED PARTY DISCLOSURES (Schedule of key management personnel compensation) (Details)",
     "shortName": "RELATED PARTY DISCLOSURES (Schedule of key management personnel compensation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "0095 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails",
     "longName": "0096 - Disclosure - COMMITMENTS AND CONTINGENCIES (Schedule of provisions and contingent liabilities) (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Schedule of provisions and contingent liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:LossContingencyAccrualPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative",
     "longName": "0097 - Disclosure - INCOME TAXES (Narrative) (Details)",
     "shortName": "INCOME TAXES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "flgc:CurrentTaxExpenseIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.floragrowth.com/role/IncomeTaxesDetails",
     "longName": "0098 - Disclosure - INCOME TAXES (Schedule of components of the income tax provision) (Details)",
     "shortName": "INCOME TAXES (Schedule of components of the income tax provision) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.floragrowth.com/role/IncomeTaxesDetails1",
     "longName": "0099 - Disclosure - INCOME TAXES  (Schedule of corporate income tax rate) (Details)",
     "shortName": "INCOME TAXES  (Schedule of corporate income tax rate) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.floragrowth.com/role/IncomeTaxesDetails2",
     "longName": "0100 - Disclosure - INCOME TAXES (Schedule of deferred income tax assets and liabilities) (Details)",
     "shortName": "INCOME TAXES (Schedule of deferred income tax assets and liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.floragrowth.com/role/LossPerShareDetails",
     "longName": "0102 - Disclosure - LOSS PER SHARE (Schedule of anti-dilutive shares) (Details)",
     "shortName": "LOSS PER SHARE (Schedule of anti-dilutive shares) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative",
     "longName": "0103 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Narrative) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "flgc:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails",
     "longName": "0105 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of information about the financial instruments and their classifications) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of information about the financial instruments and their classifications) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications",
       "div",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications",
       "div",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1",
     "longName": "0106 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of assets and liabilities denominated in foreign currencies) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Schedule of assets and liabilities denominated in foreign currencies) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "flgc:GoingConcernPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_srtCurrencyAxis_currencyCAD",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "flgc:ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.floragrowth.com/role/SegmentedInformationDetailsNarrative",
     "longName": "0107 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)",
     "shortName": "SEGMENTED INFORMATION (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.floragrowth.com/role/SegmentedInformationDetails",
     "longName": "0108 - Disclosure - SEGMENTED INFORMATION (Schedule of operation segments information) (Details)",
     "shortName": "SEGMENTED INFORMATION (Schedule of operation segments information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.floragrowth.com/role/SegmentDetails",
     "longName": "0109 - Disclosure - SEGMENTED INFORMATION (Schedule of other significant items) (Details)",
     "shortName": "SEGMENTED INFORMATION (Schedule of other significant items) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "flgc:ScheduleOfOtherSignificantItemsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.floragrowth.com/role/SegmentedInformationDetails1",
     "longName": "0110 - Disclosure - SEGMENTED INFORMATION (Schedule of disaggregation of net sales by geographic area) (Details)",
     "shortName": "SEGMENTED INFORMATION (Schedule of disaggregation of net sales by geographic area) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "C_20240101to20240331",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240331_srtStatementGeographicalAxis_countryUS",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.floragrowth.com/role/SegmentedInformationDetails3",
     "longName": "0111 - Disclosure - SEGMENTED INFORMATION  (Schedule of disaggregation of property, plant and equipment and other long-lived assets by geographic area) (Details)",
     "shortName": "SEGMENTED INFORMATION  (Schedule of disaggregation of property, plant and equipment and other long-lived assets by geographic area) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "C_20240331",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:OtherIndefiniteLivedIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative",
     "longName": "0112 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)",
     "shortName": "SUBSEQUENT EVENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240301to20240308_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formprer14a.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "flgc_ACAMullerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ACAMullerMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for ACA Muller.",
        "label": "A C A Muller [Member]",
        "terseLabel": "ACA Muller [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_AccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "AccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Pronouncements Not Yet Adopted Policy Text Block",
        "terseLabel": "Accounting pronouncements not yet adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r1018"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Accounts Payable]",
        "verboseLabel": "Trade payables and accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1179"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade payables",
        "label": "Accounts Payable, Trade",
        "terseLabel": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 60.0
      },
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade and amounts receivable, net of allowance",
        "totalLabel": "Total",
        "verboseLabel": "Amounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued liabilities",
        "label": "Other accrued liabilities",
        "totalLabel": "Accrued Liabilities, Total",
        "verboseLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r275",
      "r734"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net income and comprehensive income",
        "verboseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r176",
      "r286",
      "r729",
      "r771",
      "r772"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive (loss) income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r25",
      "r55",
      "r612",
      "r615",
      "r652",
      "r767",
      "r768",
      "r1066",
      "r1067",
      "r1068",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "flgc_AcquisitionOfNoncontrollingInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "AcquisitionOfNoncontrollingInterestAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of noncontrolling interest, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_AcquisitionOfNoncontrollingInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "AcquisitionOfNoncontrollingInterestShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of noncontrolling interest, shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_AdditionalLegalDisputesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "AdditionalLegalDisputesMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Legal Disputes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r1018",
      "r1188"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional common shares",
        "terseLabel": "Additional common shares",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r789",
      "r1078",
      "r1079",
      "r1080",
      "r1158",
      "r1193"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net income (loss) to cash provided by (Used in) operating activities",
        "totalLabel": "Net income (loss) to cash provided by (Used in) operating activities",
        "documentation": "The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "verboseLabel": "Restricted stock vested",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "verboseLabel": "Options vested",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r215"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to net loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising costs",
        "terseLabel": "Advertising costs [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Advertising Expense]",
        "verboseLabel": "Advertising costs",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "flgc_AegisCapitalCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "AegisCapitalCorpMember",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents about aegis capital corp.",
        "label": "Aegis Capital Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails": {
       "parentTag": "us-gaap_CostsAndExpensesRelatedParty",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Share based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r566"
     ]
    },
    "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for expected credit losses",
        "terseLabel": "Schedule of allowance for expected credit losses [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss on financing receivable."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r1090"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for expected credit losses",
        "negatedPeriodEndLabel": "Allowance for expected credit losses, ending balance",
        "negatedPeriodStartLabel": "Allowance for expected credit losses, beginning balance",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Trade and amounts receivable, allowance",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r379",
      "r414"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "verboseLabel": "Write-offs of trade receivables",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible assets, Accumulated Amortization, Additions",
        "verboseLabel": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r75",
      "r79"
     ]
    },
    "flgc_AmountsPayablePerViolationOfStopSaleOrders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "AmountsPayablePerViolationOfStopSaleOrders",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of amounts payable per violation of stop sale orders.",
        "label": "Amounts Payable Per Violation Of Stop Sale Orders",
        "verboseLabel": "Amounts payable per violation of stop sale orders"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_AnnualGoodwillImpairmentTestOfFghMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "AnnualGoodwillImpairmentTestOfFghMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Goodwill Impairment Test Of Fgh [Member]",
        "verboseLabel": "2023 Annual Goodwill Impairment Test of FGH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_AnnualGoodwillImpairmentTestOfJustCBDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "AnnualGoodwillImpairmentTestOfJustCBDMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Goodwill Impairment Test of Just C B D [Member]",
        "verboseLabel": "2023 Annual Goodwill Impairment Test of JustCBD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total anti-dilutive",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetails",
      "http://www.floragrowth.com/role/LossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Total purchase consideration",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Contingent purchase consideration",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Contingent purchase consideration from asset acquisitions and business combinations",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 20.0
      },
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment",
        "verboseLabel": "Asset impairment",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r80"
     ]
    },
    "us-gaap_AssetImpairmentChargesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentChargesTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IMPAIRMENTOFASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges [Text Block]",
        "terseLabel": "IMPAIRMENT OF ASSETS [Text Block]",
        "documentation": "The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Total Assets",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Purchased assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r279",
      "r311",
      "r347",
      "r362",
      "r368",
      "r411",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r467",
      "r469",
      "r470",
      "r605",
      "r609",
      "r626",
      "r724",
      "r826",
      "r1018",
      "r1032",
      "r1115",
      "r1116",
      "r1170"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Assets, Current]",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r290",
      "r311",
      "r411",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r467",
      "r469",
      "r470",
      "r605",
      "r609",
      "r626",
      "r1018",
      "r1115",
      "r1116",
      "r1170"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets",
        "verboseLabel": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current",
        "verboseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "totalLabel": "Total assets held for sale",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r206",
      "r267",
      "r268"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets held for sale",
        "totalLabel": "Total current assets held for sale",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r203",
      "r206",
      "r267",
      "r268"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm Id",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038",
      "r1039"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038",
      "r1039"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ]
    },
    "flgc_BasisOfAccountingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "BasisOfAccountingLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Accounting [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_BasisOfAccountingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "BasisOfAccountingTable",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Accounting [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building [Member]",
        "verboseLabel": "Buildings [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r108",
      "r599",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Description of Acquired Entity",
        "terseLabel": "Country of Incorporation",
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Value of common shares in purchase consideration",
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of common shares in purchase consideration",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionNameOfAcquiredEntity",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Name of Acquired Entity",
        "terseLabel": "Subsidiaries",
        "documentation": "Name of the acquired entity."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Net asset acquired",
        "verboseLabel": "Ownership %",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Common shares issued, price per share",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired through business combinations",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsDescription",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration Arrangements, Description",
        "verboseLabel": "Description of contingent purchase consideration",
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Contingent purchase consideration unpaid balance",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r114",
      "r602"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent purchase considerations",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r114"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent purchase considerations",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r114"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisitions And Business Combinations",
        "terseLabel": "ASSET ACQUISITIONS AND BUSINESS COMBINATIONS [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r600"
     ]
    },
    "flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current lease liabilities assumed in business combination.",
        "negatedLabel": "Current lease liabilities",
        "label": "Business Combination Recognized Identifiable Asset Acquired And Liability Assumed Current Lease Liabilities",
        "totalLabel": "Liabilities, Current, Total"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent lease liabilities assumed in business combination.",
        "negatedLabel": "Long term lease liability",
        "label": "Business Combination Recognized Identifiable Asset Acquired And Liability Assumed Noncurrent Lease Liabilities",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total net assets acquired",
        "verboseLabel": "Total Net Assets Acquired",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash",
        "verboseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of indemnity receivables recognized as of the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Indemnity Receivables",
        "terseLabel": "Indemnity receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Trade receivables",
        "totalLabel": "Nontrade Receivables, Total",
        "verboseLabel": "Trade Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade Payables And Accrued Liabilities",
        "negatedTerseLabel": "Trade payables and accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Trade payables and accrued liabilities",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current portion of debt",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Customer Relationships",
        "terseLabel": "Customer relationships acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred Tax",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventory acquired",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total Liabilities",
        "negatedTerseLabel": "Total liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets [Abstract]",
        "verboseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Total",
        "verboseLabel": "Other non-current assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property, Plant And Equipment",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "verboseLabel": "Property, plant, and equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110"
     ]
    },
    "flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of provision for sales tax attributable at the acquisition date.",
        "negatedLabel": "Provision for sales tax",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Provision For Sales Tax"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right of use assets acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Assets",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Total net assets acquired",
        "totalLabel": "Total net assets acquired",
        "verboseLabel": "Total Net Assets Acquired",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations",
        "terseLabel": "Business combinations [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation",
        "terseLabel": "BASIS OF PRESENTATION [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r195",
      "r196"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CAD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CAD",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "terseLabel": "CAD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CHF": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CHF",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "CHF [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_CO": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CO",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COLOMBIA",
        "terseLabel": "Colombia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_COP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "COP",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Colombia, Pesos",
        "terseLabel": "COP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CanadaIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CanadaIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada Income Tax Authority [Member]",
        "terseLabel": "Canada [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CanadaRevenueAgencyMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada Revenue Agency [Member]",
        "verboseLabel": "Canada [Member]",
        "documentation": "Designated tax department of the government of Canada."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Capital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Capital",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "documentation": "Amount of total capital as defined by regulatory framework."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditure, Discontinued Operations",
        "terseLabel": "Purchases of property, plant and equipment",
        "documentation": "Amount of capital expenditure attributable to discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_CapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLeaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Lease Obligations",
        "terseLabel": "Lease liability",
        "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r249",
      "r250"
     ]
    },
    "flgc_CapitalManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CapitalManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Management [Abstract]",
        "terseLabel": "Capital Management [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CapitalManagementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CapitalManagementDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/CapitalManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Management disclosure text block",
        "terseLabel": "CAPITAL MANAGEMENT [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r727",
      "r790",
      "r820",
      "r1018",
      "r1032",
      "r1059"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r272",
      "r980"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and restricted cash [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and restricted cash at end of period",
        "periodStartLabel": "Cash and restricted cash at beginning of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "terseLabel": "Cash and restricted cash",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r192",
      "r307"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]",
        "totalLabel": "Change in cash during the period",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r192"
     ]
    },
    "flgc_CashConsiderationReturned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CashConsiderationReturned",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash consideration returned"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Cash Equivalents, at Carrying Value]",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1181"
     ]
    },
    "flgc_CashFlowModelHighRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CashFlowModelHighRate",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow model, high rate"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CashFlowModelLowRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CashFlowModelLowRate",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow model, low rate"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Clifford Starke [Member]",
        "verboseLabel": "Clifford Starke [Member]"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "verboseLabel": "Dany Vaiman [Member]"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1",
      "http://www.floragrowth.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r342",
      "r501",
      "r502",
      "r503",
      "r505",
      "r508",
      "r513",
      "r515",
      "r778",
      "r779",
      "r780",
      "r781",
      "r1002",
      "r1045",
      "r1074"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails",
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails",
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails",
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of warrants, ending balance",
        "periodStartLabel": "Number of warrants, beginning balance",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails",
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "flgc_ClassicPlanPremiumFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ClassicPlanPremiumFinancingMember",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for classic plan premium financing.",
        "label": "Classic Plan Premium Financing [Member]",
        "terseLabel": "ClassicPlan Premium Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_CollateralAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollateralAxis",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collateral Held [Axis]",
        "documentation": "Information by category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_CollateralDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollateralDomain",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collateral Held [Domain]",
        "documentation": "Category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ColombiaRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ColombiaRevenueAgencyMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Colombia Revenue Agency [Member]",
        "verboseLabel": "Colombia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ColombianRelatedSubsidiariesAndColombianAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ColombianRelatedSubsidiariesAndColombianAssetsMember",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Colombian related subsidiaries and Colombian assets.",
        "label": "Colombian Related Subsidiaries And Colombian Assets [Member]",
        "terseLabel": "Colombian related subsidiaries and Colombian assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CommercialAndWholesaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CommercialAndWholesaleMember",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial And Wholesale [Member]",
        "terseLabel": "Commercial &amp; Wholesale [Member]",
        "verboseLabel": "Commercial &amp; Wholesale [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r133",
      "r726",
      "r811"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r449",
      "r450",
      "r962",
      "r1106"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "verboseLabel": "Commitments and contingencies [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r963"
     ]
    },
    "flgc_CommonSharesDeliveredToTheSellers": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CommonSharesDeliveredToTheSellers",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares delivered to the sellers"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CommonSharesIssuedForInvestmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CommonSharesIssuedForInvestmentsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for Investments, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CommonSharesIssuedForInvestmentsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CommonSharesIssuedForInvestmentsShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for investments, shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CommonSharesIssuedForOtherAgreementsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CommonSharesIssuedForOtherAgreementsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for other agreements, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CommonSharesIssuedForOtherAgreementsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CommonSharesIssuedForOtherAgreementsShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for other agreements, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "terseLabel": "Common shares",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1022",
      "r1023",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1078",
      "r1079",
      "r1158",
      "r1185",
      "r1193"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "terseLabel": "Share capital, shares issued",
        "verboseLabel": "Issued Common Shares",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPositionParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r167",
      "r812",
      "r832",
      "r1193",
      "r1194"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital, no par value, unlimited authorized, 135,573 issued and outstanding (65,517 at 2021)",
        "terseLabel": "Share capital, no par value, unlimited authorized",
        "verboseLabel": "Common stock value",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r728",
      "r1018"
     ]
    },
    "us-gaap_CommonUnitIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonUnitIssued",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Unit, Issued",
        "terseLabel": "Offering unit",
        "documentation": "Number of common units issued of limited liability company (LLC)."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_Communication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Communication",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promotion and communication",
        "documentation": "The amount of expense incurred in the period for communication, which is the exchange of information by several methods."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss attributable to Flora Growth Corp.",
        "verboseLabel": "Net income and comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r292",
      "r294",
      "r302",
      "r718",
      "r744"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests",
        "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r119",
      "r123",
      "r292",
      "r294",
      "r301",
      "r717",
      "r743"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests in subsidiaries",
        "totalLabel": "Comprehensive loss for the period",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r229",
      "r292",
      "r294",
      "r300",
      "r716",
      "r742"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r605",
      "r606",
      "r609",
      "r610",
      "r660",
      "r973",
      "r1114",
      "r1117",
      "r1118"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r605",
      "r606",
      "r609",
      "r610",
      "r660",
      "r973",
      "r1114",
      "r1117",
      "r1118"
     ]
    },
    "flgc_ConsolidatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ConsolidatedMember",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated [Member]",
        "verboseLabel": "Consolidated [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ConsolidatedRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ConsolidatedRevenue",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Consolidated Revenue",
        "terseLabel": "Consolidated revenue"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r349",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r370",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r466",
      "r468",
      "r469",
      "r1115",
      "r1116"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r349",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r370",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r466",
      "r468",
      "r469",
      "r1115",
      "r1116"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r985"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_Contributionamont": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "Contributionamont",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents Contribution.",
        "label": "Contributionamont",
        "terseLabel": "Contribution,Amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_Contributionshares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "Contributionshares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value represents contribution shares.",
        "label": "Contributionshares",
        "terseLabel": "Contribution,Shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CorporateAndEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CorporateAndEliminationsMember",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate And Eliminations [Member]",
        "terseLabel": "Corporate &amp; Eliminations [Member]",
        "verboseLabel": "Corp &amp; Eliminations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CosechemosAndKasaWholefoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CosechemosAndKasaWholefoodsMember",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents about Cosechemos YA S.A.S. and Kasa Wholefoods.",
        "label": "Cosechemos And Kasa Wholefoods [Member]",
        "verboseLabel": "Cosechemos YA S.A.S. and Kasa Wholefoods Company S.A.S [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r700"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Related Party Costs]",
        "totalLabel": "Total",
        "verboseLabel": "Total",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r475",
      "r503",
      "r658",
      "r982",
      "r984"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CreditFacilityDue": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CreditFacilityDue",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility due"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditRiskMember",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Risk [Member]",
        "terseLabel": "Credit risk [Member]",
        "documentation": "The risk that a borrower will fail to pay interest or principal on a loan or debt security when due."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CriticalJudgmentsAndEstimationUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CriticalJudgmentsAndEstimationUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Critical Judgments and Estimation Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CumulativeEarningsDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CumulativeEarningsDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "label": "Accumulated deficit",
        "documentation": "Amount of cumulative earnings (deficits) for relevant time periods."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CumulativeImpairmentRelatedToCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CumulativeImpairmentRelatedToCommonShares",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative impairment related to common shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current tax expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r586",
      "r592",
      "r1077"
     ]
    },
    "flgc_CurrentPortionOfContingentPurchaseConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CurrentPortionOfContingentPurchaseConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current portion of contingent purchase consideration.",
        "label": "Current Portion Of Contingent Purchase Consideration",
        "terseLabel": "Current portion of contingent purchase consideration"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense income",
        "verboseLabel": "Current income tax expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer and supplier relationships [Member]",
        "verboseLabel": "Customer relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "flgc_CustomersRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "CustomersRelationshipsMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers Relationships [Member]",
        "verboseLabel": "Customer relationships [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DE",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt",
        "terseLabel": "DEBT [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r309",
      "r471",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r487",
      "r494",
      "r495",
      "r497"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Axis",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r161",
      "r162",
      "r233",
      "r235",
      "r315",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r637",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1075"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Interest-bearing loan",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r235",
      "r498"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Loan agreement, face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r472",
      "r637",
      "r998",
      "r999"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of debt",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r625",
      "r998",
      "r999"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "verboseLabel": "Risk-free interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r126",
      "r490"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Loan agreement, interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r473"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r637",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1075"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r315",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r637",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1075"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Principal and interest payments",
        "verboseLabel": "Leases, monthly amount",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r135"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.floragrowth.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r89",
      "r92",
      "r125",
      "r126",
      "r127",
      "r134",
      "r213",
      "r214",
      "r315",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r637",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1075"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127",
      "r1120"
     ]
    },
    "flgc_DecemberTwoThousandTwentyTwoUnitOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DecemberTwoThousandTwentyTwoUnitOfferingMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Two Thousand Twenty Two Unit Offering [Member]",
        "verboseLabel": "December 2022 unit offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DecemberUnitOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DecemberUnitOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December unit offering, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DecemberUnitOfferingIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DecemberUnitOfferingIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "December unit offering issuance costs",
        "label": "December unit offering issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DecemberUnitOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DecemberUnitOfferingShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Unit offering shares",
        "verboseLabel": "December unit offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total deferred tax expense",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r224",
      "r260",
      "r591",
      "r592",
      "r1077"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "verboseLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r234",
      "r580"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred Tax",
        "label": "Deferred tax",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r574",
      "r725"
     ]
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementTypeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "documentation": "Information by type of deferred revenue arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementTypeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Domain]",
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DeferredTaxAssetsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DeferredTaxAssetsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Allowance For Doubtful Accounts",
        "verboseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DeferredTaxAssetsGoodwil": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DeferredTaxAssetsGoodwil",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill.",
        "label": "Deferred Tax Assets, Goodwil",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "verboseLabel": "Sec 174 - R&amp;D expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r1152"
     ]
    },
    "flgc_DeferredTaxAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of intangible assets.",
        "label": "Deferred Tax Assets, Intangible Assets",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred Tax Assets, Net, Total",
        "verboseLabel": "Net deferred tax liabilities",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Net Assets Acquired",
        "terseLabel": "Total net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Non-capital loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r1152"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Deferred Tax Assets, Other]",
        "verboseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r1152"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "verboseLabel": "Fixed assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DeferredTaxAssetsRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DeferredTaxAssetsRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Right Of Use Assets",
        "verboseLabel": "Right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DeferredTaxAssetsShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DeferredTaxAssetsShareIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Share Issuance Costs",
        "verboseLabel": "Share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DeferredTaxAssetsUnrealizedGainsLossesOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DeferredTaxAssetsUnrealizedGainsLossesOnInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Unrealized Gains (Losses) On Investments",
        "verboseLabel": "Unrealized gains (losses) on investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "[Deferred Tax Assets, Valuation Allowance]",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "flgc_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income tax benefit",
        "label": "Deferred tax expense income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "verboseLabel": "Intangible assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r1152"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "verboseLabel": "Lease obligations",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r1152"
     ]
    },
    "flgc_DenmarkRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DenmarkRevenueAgencyMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denmark Revenue Agency [Member]",
        "verboseLabel": "Denmark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r81"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/SegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r81"
     ]
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation and amortization",
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r1073"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Depreciation, Depletion and Amortization]",
        "verboseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r352"
     ]
    },
    "flgc_DerecognitionOfEquityRelatedToColombiaAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DerecognitionOfEquityRelatedToColombiaAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of derecognition of equity related to Colombia assets.",
        "label": "Derecognition Of Equity Related To Colombia Assets",
        "verboseLabel": "Derecognition of equity related to Colombia assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "documentation": "Disclosure of information about derivatives and hedging activities."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DescriptionOfDiscountRates": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DescriptionOfDiscountRates",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of discount rates"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DescriptionOfExchangeRate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DescriptionOfExchangeRate",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent Description Of Exchange Rate",
        "label": "Description Of Exchange Rate",
        "terseLabel": "Description of exchange rate"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DescriptionOfImpairment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DescriptionOfImpairment",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to Impairment.",
        "label": "Description Of Impairment",
        "terseLabel": "Description of impairment"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DescriptionOfSensitivityAnalysis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DescriptionOfSensitivityAnalysis",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of sensitivity analysis.",
        "label": "Description of sensitivity analysis"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DescriptionOfShares": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DescriptionOfShares",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of shares",
        "terseLabel": "Description of shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DescriptionOfTaxJurisdictions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DescriptionOfTaxJurisdictions",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Tax Jurisdictions",
        "verboseLabel": "Description of tax jurisdictions"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DescriptionOfValuation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DescriptionOfValuation",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Valuation",
        "terseLabel": "Description of valuation"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors",
        "terseLabel": "Directors and officers [Member]"
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1187"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE BASED COMPENSATION [Text Block]",
        "verboseLabel": "Share based compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r530",
      "r558",
      "r559",
      "r561",
      "r1011"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of discontinued operations",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "totalLabel": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total",
        "verboseLabel": "Loss on disposal of discontinued operations",
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r145",
      "r147",
      "r158"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Net loss before income taxes",
        "verboseLabel": "Net loss before income taxes",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r153",
      "r179",
      "r1182"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "terseLabel": "Basic loss per share from discontinued operations",
        "verboseLabel": "Basic loss per share from discontinued operations",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "terseLabel": "Diluted loss per share from discontinued operations",
        "verboseLabel": "Diluted loss per share from discontinued operations",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Income tax expense (benefit)",
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r153",
      "r158",
      "r575",
      "r590",
      "r595"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations, Held-for-Sale [Member]",
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r267"
     ]
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "terseLabel": "Discontinued operations and assets and liabilities held for sale [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r40"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Trade and amounts receivable",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r206"
     ]
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Asset impairment attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Asset Impairment",
        "terseLabel": "Asset impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Noncurrent assets held for sale",
        "totalLabel": "Total noncurrent assets held for sale",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r139",
      "r156",
      "r206",
      "r267",
      "r268"
     ]
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationBadDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationBadDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Bad debt expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Bad Debt Expense",
        "verboseLabel": "Bad debt expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash included in assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash",
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r206"
     ]
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consulting and management fees attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consulting And Management Fees",
        "terseLabel": "Consulting and management fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r268"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "verboseLabel": "General and administrative",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "totalLabel": "Gross profit from discontinued operations",
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r268"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Intangible assets",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r139",
      "r156",
      "r206"
     ]
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income (expense) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group Including Discontinued Operation Interest Income Expense",
        "terseLabel": "Interest (income) expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "verboseLabel": "Inventory",
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r203",
      "r206"
     ]
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as long-term debt attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Long Term Debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "terseLabel": "Operating loss from discontinued operations",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "\"Disposal Group, Including Discontinued Operation, Operating Lease Expense\"",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as operating lease liability attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as operating lease right of use assets attributable to disposal group held for sale or disposed of.",
        "label": "\"Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Assets\"",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r203",
      "r206"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Other (income) expense",
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "verboseLabel": "Other assets",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r139",
      "r156",
      "r206"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "verboseLabel": "Non-current operating lease liability",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r139",
      "r156",
      "r206"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r203",
      "r206"
     ]
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of professional fees attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of promotion and communication attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Promotion And Communication",
        "terseLabel": "Promotion and communication"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property, plant and equipment",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r139",
      "r156",
      "r206"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r268"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r202"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038",
      "r1039"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038",
      "r1039",
      "r1041"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_DrManaloMorganMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "DrManaloMorganMember",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Manalo Morgan [Member]",
        "terseLabel": "Dr. Manalo-Morgan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "EUR",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "EUR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per share attributable to Flora Growth Corp.",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r330",
      "r332",
      "r334",
      "r335",
      "r336",
      "r340",
      "r620",
      "r621",
      "r719",
      "r745",
      "r989"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per share attributable to Flora Growth Corp.",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r332",
      "r334",
      "r335",
      "r336",
      "r340",
      "r620",
      "r621",
      "r719",
      "r745",
      "r989"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Loss per share [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "LOSS PER SHARE [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r337",
      "r338",
      "r339"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate on changes on cash",
        "terseLabel": "Effect of exchange rate on changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1",
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory Canadian rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r576",
      "r593"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1153"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Earnings in jurisdictions taxed at different rates",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1153"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairments",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1153"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "verboseLabel": "Prior year adjustments, change in tax rates",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1153"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1150"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on investments",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to investment tax credit."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1153"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "terseLabel": "Other permanent items",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1153"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal settlement",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1153"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits and Share-Based Compensation",
        "verboseLabel": "Share based compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Remaining cost for nonvested awards",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
      "http://www.floragrowth.com/role/BasisOfPresentation",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/CommitmentsAndContingencies",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties",
      "http://www.floragrowth.com/role/DEBT",
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstruments",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstrumentsTables",
      "http://www.floragrowth.com/role/IncomeTaxes",
      "http://www.floragrowth.com/role/IncomeTaxesDetails2",
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative",
      "http://www.floragrowth.com/role/IncomeTaxesTables",
      "http://www.floragrowth.com/role/LEASES",
      "http://www.floragrowth.com/role/LEASESNarrativeDetails",
      "http://www.floragrowth.com/role/LeasesDetails",
      "http://www.floragrowth.com/role/LeasesDetails1",
      "http://www.floragrowth.com/role/LeasesTables",
      "http://www.floragrowth.com/role/NatureOfOperations",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipment",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables",
      "http://www.floragrowth.com/role/RelatedPartyDisclosures",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresTables",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareCapital",
      "http://www.floragrowth.com/role/SignificantAccountingPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesTables",
      "http://www.floragrowth.com/role/SubsequentEvents",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative",
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivable",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r263",
      "r296",
      "r297",
      "r298",
      "r316",
      "r317",
      "r318",
      "r320",
      "r326",
      "r328",
      "r341",
      "r412",
      "r413",
      "r517",
      "r563",
      "r564",
      "r565",
      "r587",
      "r588",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r635",
      "r652",
      "r767",
      "r768",
      "r769",
      "r789",
      "r858"
     ]
    },
    "flgc_EquityIssuedForOtherAgreementsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "EquityIssuedForOtherAgreementsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity issued for other agreements, amount",
        "verboseLabel": "Equity issued for other agreements, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_EquityIssuedForOtherAgreementsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "EquityIssuedForOtherAgreementsShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity issued for other agreements, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership %",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "flgc_EstimatedLossOnPotentialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "EstimatedLossOnPotentialLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated loss on potential liabilities.",
        "label": "Estimated Loss On Potential Liabilities",
        "terseLabel": "Estimated loss on potential liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_EstimatedRecoverableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "EstimatedRecoverableAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Recoverable Amount",
        "verboseLabel": "Estimated recoverable amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_EuroCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "EuroCreditFacilityMember",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Euro credit facility.",
        "label": "Euro Credit Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ExercisePriceOfInvestmentWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ExercisePriceOfInvestmentWarrants",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of investment warrants",
        "label": "Exercise price of investment warrants"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ExpectedSharesToBeIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ExpectedSharesToBeIssued",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected shares to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FGHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FGHMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for FGH.",
        "label": "F G H [Member]",
        "terseLabel": "FGH [Member]",
        "verboseLabel": "FGH asset group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FGHOwnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FGHOwnersMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "F G H Owners [Member]",
        "verboseLabel": "FGH owners [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Gain on warrant modifications",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r17"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Fair Value Hierarchy Level Axis",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r623",
      "r667",
      "r668",
      "r669",
      "r998",
      "r999",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "flgc_FairValueDiscount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FairValueDiscount",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value discount",
        "verboseLabel": "Fair value discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r519",
      "r524",
      "r623",
      "r667",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r519",
      "r524",
      "r623",
      "r668",
      "r998",
      "r999",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r623",
      "r669",
      "r998",
      "r999",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/SegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized (gain) loss from changes in fair value",
        "negatedTerseLabel": "Changes in fair value of investments and liabilities",
        "positiveLabel": "Unrealized (gain) loss from changes in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r667",
      "r668",
      "r669",
      "r998",
      "r999",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Fair Value, Net Asset (Liability), Total",
        "verboseLabel": "Net carrying value",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Assets",
        "terseLabel": "Financial assets [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r37"
     ]
    },
    "flgc_FairValueOfRestrictedStockAwardsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FairValueOfRestrictedStockAwardsIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of restricted stock awards issued"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FairValueOfWarrantsIssuedDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FairValueOfWarrantsIssuedDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Warrants Issued During Period",
        "verboseLabel": "Fair value of warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on changes in fair value",
        "verboseLabel": "Loss on changes in fair value",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FinancialAssetNotPastDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialAssetNotPastDueMember",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, Not Past Due [Member]",
        "terseLabel": "Current [Member]",
        "documentation": "Financial asset not past due."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r994"
     ]
    },
    "flgc_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount for Financial Assets Pledged As Collateral For Liabilities Or Contingent Liabilities",
        "label": "Financial Assets Pledged As Collateral For Liabilities Or Contingent Liabilities",
        "terseLabel": "Financial assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2",
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r415",
      "r416",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r496",
      "r513",
      "r617",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r741",
      "r995",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "flgc_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FinancialInstrumentsAndRiskManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FinancialInstrumentsAndRiskManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [Abstract]",
        "terseLabel": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS [Text Block]",
        "verboseLabel": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FinancialIntermediariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FinancialIntermediariesMember",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents about financial intermediaries.",
        "label": "Financial Intermediaries [Member]",
        "verboseLabel": "Held with financial intermediaries [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FinancialLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FinancialLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities [Policy Text Block]",
        "terseLabel": "Financial liabilities [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Past Due [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1091"
     ]
    },
    "flgc_FinancingReceivables180PlusDaysPastDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FinancingReceivables180PlusDaysPastDueMember",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets more than 180 days.",
        "label": "Financing Receivables180 Plus Days Past Due [Member]",
        "terseLabel": "180+ Days [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivables1To29DaysPastDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivables1To29DaysPastDueMember",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, 1 to 29 Days Past Due [Member]",
        "terseLabel": "1-30 Days [Member]",
        "documentation": "Financial asset fewer than 30 days past due."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_FinancingReceivables30To59DaysPastDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivables30To59DaysPastDueMember",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, 30 to 59 Days Past Due [Member]",
        "terseLabel": "31-60 Days [Member]",
        "documentation": "Financial asset more than 29 days past due but fewer than 60 days past due."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_FinancingReceivables60To89DaysPastDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivables60To89DaysPastDueMember",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, 60 to 89 Days Past Due [Member]",
        "terseLabel": "61-90 Days [Member]",
        "documentation": "Financial asset more than 59 days past due but fewer than 90 days past due."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivablesEqualToGreaterThan90DaysPastDueMember",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, Equal to or Greater than 90 Days Past Due [Member]",
        "terseLabel": "91-180 Days [Member]",
        "documentation": "Financial asset equal to or greater than 90 days past due."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, Aging [Axis]",
        "documentation": "Information by period in which financial asset is past due or not past due."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r419",
      "r994"
     ]
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, Aging [Domain]",
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r419",
      "r994"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Weighted average amortization period",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension",
        "verboseLabel": "Weighted average period before next renewal or extension",
        "documentation": "Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Intangible assets, Accumulated Amortization, Ending balance",
        "periodStartLabel": "Intangible assets, Accumulated Amortization, Beginning balance",
        "label": "[Finite-Lived Intangible Assets, Accumulated Amortization]",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r444"
     ]
    },
    "flgc_FiniteLivedIntangibleAssetsAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FiniteLivedIntangibleAssetsAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets Additions",
        "verboseLabel": "Intangible assets, Cost, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months",
        "verboseLabel": "2024",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five",
        "verboseLabel": "Thereafter",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "verboseLabel": "2027",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimation of amortization expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r443",
      "r444",
      "r445",
      "r701",
      "r702"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets, Foreign Currency translation",
        "label": "[Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)]",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Intangible assets, Cost, Ending balance",
        "periodStartLabel": "Intangible assets, Cost, Beginning balance",
        "label": "[Finite-Lived Intangible Assets, Gross]",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r702"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r78"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible Assets",
        "totalLabel": "Total",
        "verboseLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r701"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "verboseLabel": "Weighted average amortization period remaining for intangible assets",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, Cost, Acquired through business combinations",
        "verboseLabel": "Intangible assets, Cost, Acquired through business combinations",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "flgc_FirstClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FirstClosingMember",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Closing [Member]",
        "label": "First Closing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FirstLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FirstLoanAgreementMember",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Loan Agreement [Member]",
        "label": "First Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FirstLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FirstLoanMember",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for First Loan.",
        "label": "First Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FirstTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FirstTrancheMember",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FloraBeautyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FloraBeautyMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Flora Beauty [Member]",
        "label": "Flora Beauty [Member]",
        "terseLabel": "Flora Beauty LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FloraGrowthCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FloraGrowthCorpMember",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Flora Growth Corp.",
        "label": "Flora Growth Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FloraMedSasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FloraMedSasMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Flora Med SAS [Member]",
        "label": "Flora Med Sas [Member]",
        "terseLabel": "Flora Med S.A.S [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FoodAndBeveragesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FoodAndBeveragesMember",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Food And Beverages [Member]",
        "verboseLabel": "Food and beverage [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange (income) loss",
        "label": "Foreign exchange (gain) loss",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1030",
      "r1160",
      "r1161",
      "r1192"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "terseLabel": "Foreign currency translation [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "flgc_ForeignExchangeImpacts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ForeignExchangeImpacts",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange impacts"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ForeignIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ForeignIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Authority [Member]",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ForeignRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ForeignRevenueAgencyMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Revenue Agency [Member]",
        "verboseLabel": "Foreign [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FortLauderdaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FortLauderdaleMember",
     "presentation": [
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fort Lauderdale [Member]",
        "verboseLabel": "Fort Lauderdale, FL [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_FranchiseGlobalHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FranchiseGlobalHealthIncMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise Global Health Inc [Member]",
        "terseLabel": "Franchise Global Health Inc. (\"FGH\") business combination [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FranchiseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FranchiseMember",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise [Member]",
        "terseLabel": "FGH [Member]",
        "documentation": "Right granted by another party to operate business using grantor's name, merchandise, service, methodology, promotional support, marketing and supplies."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "flgc_FunctionalCurrencyOfSubsidiary": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "FunctionalCurrencyOfSubsidiary",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional Currency Of Subsidiary",
        "verboseLabel": "Functional Currency"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_GBP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "GBP",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "GBP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "verboseLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r838"
     ]
    },
    "flgc_GerardoAndresGarciaMendezMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "GerardoAndresGarciaMendezMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gerardo Andres Garcia Mendez.",
        "label": "Gerardo Andres Garcia Mendez [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_GermanSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "GermanSubsidiariesMember",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "German subsidiaries [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_GermanyRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "GermanyRevenueAgencyMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany Revenue Agency [Member]",
        "verboseLabel": "Germany [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going concern [Policy Text Block]",
        "terseLabel": "Going concern [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Carrying value of goodwill",
        "periodEndLabel": "Net book value as at June 30, 2023",
        "periodStartLabel": "Net book value as at December 31, 2022",
        "label": "Goodwill",
        "terseLabel": "Net book value",
        "verboseLabel": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r428",
      "r715",
      "r996",
      "r1018",
      "r1093",
      "r1100"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquired through business combinations",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r996"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "flgc_GoodwillDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "GoodwillDescription",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "verboseLabel": "Foreign currency translation",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_GoodwillGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillGross",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross goodwill",
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r438",
      "r996"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment recorded",
        "label": "[Goodwill, Impaired, Accumulated Impairment Loss]",
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r438",
      "r996"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill impairment loss",
        "terseLabel": "Goodwill impairment",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r429",
      "r435",
      "r440",
      "r996"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r996"
     ]
    },
    "us-gaap_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillMember",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Member]",
        "verboseLabel": "Goodwill [Member]",
        "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_GrantDateFairValueOfWarrantsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "GrantDateFairValueOfWarrantsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Date Fair Value Of Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r311",
      "r347",
      "r361",
      "r367",
      "r370",
      "r411",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r467",
      "r469",
      "r470",
      "r626",
      "r991",
      "r1115"
     ]
    },
    "flgc_HampsteadPrivateCapitalLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "HampsteadPrivateCapitalLimitedMember",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hampstead Private Capital Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_HarvestedCannabis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "HarvestedCannabis",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Harvested Cannabis"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents about amount held With Large Financial Institutions And National Central Banks.",
        "label": "Held with large financial institutions and national central banks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_HouseOfBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "HouseOfBrandsMember",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "House of Brands [Member]",
        "terseLabel": "House of Brands [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_HouseOfBrandsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "HouseOfBrandsSegmentMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for house of brands segment.",
        "label": "House Of Brands Segment [Member]",
        "terseLabel": "House of Brands Segment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_HypoverinsbankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "HypoverinsbankMember",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypoverinsbank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038",
      "r1039"
     ]
    },
    "flgc_ImpairmentOfAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ImpairmentOfAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Of Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ImpairmentOfGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ImpairmentOfGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 140.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of goodwill",
        "terseLabel": "Impairment of goodwill",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Other asset impairments",
        "totalLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total",
        "verboseLabel": "Other asset impairments",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r35"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "verboseLabel": "Intangible assets, Cost, Impairment",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1103"
     ]
    },
    "flgc_ImpairmentOfLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ImpairmentOfLicenses",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of licenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of goodwill and indefinite-lived intangible assets",
        "terseLabel": "Impairment of goodwill and indefinite-lived intangible assets [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long lived assets",
        "terseLabel": "Impairment of long-lived assets [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r208"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Net Loss from Continuing Operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Flora Growth Corp. continuing operations",
        "totalLabel": "Net loss from continuing operations",
        "verboseLabel": "Net loss",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r184",
      "r194",
      "r321",
      "r322",
      "r323",
      "r324",
      "r333",
      "r336"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/SegmentedInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes and discontinued operations",
        "verboseLabel": "Net Loss Before Income Taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r178",
      "r240",
      "r347",
      "r361",
      "r367",
      "r370",
      "r720",
      "r736",
      "r991"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic loss per share from continuing operations",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r239",
      "r241",
      "r303",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r332",
      "r334",
      "r335",
      "r621",
      "r719",
      "r1183"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted loss per share from continuing operations",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r303",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r332",
      "r334",
      "r335",
      "r336",
      "r621",
      "r719",
      "r1183"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations, net of taxes",
        "totalLabel": "Loss from discontinued operations",
        "verboseLabel": "Loss from discontinued operations",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r158",
      "r268",
      "r596",
      "r737"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r34",
      "r39",
      "r139",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r157",
      "r159",
      "r160",
      "r207"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails",
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails",
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r102",
      "r222",
      "r223"
     ]
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxCreditsAndAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Credits and Adjustments",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "verboseLabel": "Income tax benefit",
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "terseLabel": "INCOME TAXES [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r570",
      "r577",
      "r578",
      "r584",
      "r589",
      "r594",
      "r597",
      "r598",
      "r783"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/IncomeTaxesDetails",
      "http://www.floragrowth.com/role/SegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income taxes",
        "positiveLabel": "Income taxes",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Total income tax benefit",
        "verboseLabel": "Income tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r261",
      "r327",
      "r328",
      "r355",
      "r575",
      "r590",
      "r748"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income taxes [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r571",
      "r572",
      "r578",
      "r579",
      "r583",
      "r585",
      "r777"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 170.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade and other receivables",
        "label": "Trade and other receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 160.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables and accrued liabilities",
        "terseLabel": "Trade payables and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "verboseLabel": "Trade and amounts payable",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 190.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "[Increase (Decrease) in Inventories]",
        "verboseLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net change in non-cash working capital:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 180.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "flgc_IndemnificationReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "IndemnificationReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of indemnification receivables.",
        "label": "Indemnification Receivables",
        "verboseLabel": "Indemnification receivables"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_InitialPublicOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InitialPublicOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_InitialPublicOfferingIssuanceCostsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InitialPublicOfferingIssuanceCostsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering issuance costs, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_InitialPublicOfferingIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InitialPublicOfferingIssuanceCostsShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_InitialPublicOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InitialPublicOfferingShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recoveries collected",
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "flgc_IntangibleAssetsAcquiredForContingentConsiderationNonCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "IntangibleAssetsAcquiredForContingentConsiderationNonCash",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents Intangible assets acquired for contingent consideration.",
        "label": "Intangible Assets Acquired For Contingent Consideration Non Cash",
        "terseLabel": "Intangible assets acquired for contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible assets [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r697",
      "r698",
      "r699",
      "r701",
      "r986"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Carrying value of identified intangible assets",
        "positiveTerseLabel": "Intangible assets",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Carrying amount of intangible asset",
        "verboseLabel": "Intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Intangible assets, Net book value, Ending balance",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "verboseLabel": "Goodwill and identified intangible assets",
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Debt Expense",
        "terseLabel": "Bad debt expense",
        "totalLabel": "Interest and Debt Expense, Total",
        "verboseLabel": "Bad debt expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/SegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense (income)",
        "negatedTerseLabel": "Interest expense (income)",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income",
        "totalLabel": "Interest Income (Expense), Net, Total",
        "verboseLabel": "Interest expense (income)",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "totalLabel": "Interest Income (Expense), Net, Total",
        "verboseLabel": "Interest expense (income)",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 130.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest Income, Operating",
        "totalLabel": "Interest Income, Operating, Total",
        "verboseLabel": "Interest paid",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r836",
      "r938",
      "r940",
      "r1029",
      "r1030",
      "r1195"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable",
        "terseLabel": "Accrued interest",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1179"
     ]
    },
    "flgc_IntrinsicValueOfWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "IntrinsicValueOfWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_InventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/INVENTORY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "flgc_InventoryExpensedToCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InventoryExpensedToCostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Expensed To Cost Of Sales",
        "verboseLabel": "Inventory expensed to cost of sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished Goods",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "flgc_InventoryImpactedByStopSaleOrders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InventoryImpactedByStopSaleOrders",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of Inventory impacted by stop sale orders.",
        "label": "Inventory impacted by stop sale orders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.floragrowth.com/role/InventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "terseLabel": "Inventory",
        "totalLabel": "Total",
        "verboseLabel": "Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r981",
      "r1018"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "terseLabel": "Inventories [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r271",
      "r288",
      "r425",
      "r426",
      "r427",
      "r696",
      "r987"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsAndSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw Materials And Supplies",
        "terseLabel": "Raw materials and supplies",
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "flgc_InvesteeCommonSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InvesteeCommonSharesMember",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee common shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_InvestingActivitiesOfDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InvestingActivitiesOfDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investing Activities Of Discontinued Operations [Abstract]",
        "terseLabel": "Investing activities of discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_InvestmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "InvestmentDescription",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Description",
        "verboseLabel": "Investment description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentInAffiliateActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentInAffiliateActivityLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in and Advances to Affiliates, Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Investments, ending balance",
        "periodStartLabel": "Investments, beginning balance",
        "label": "Investment Owned, Fair Value",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r792",
      "r793",
      "r794",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r803",
      "r804",
      "r815",
      "r816",
      "r867",
      "r876",
      "r877",
      "r886",
      "r899",
      "r900",
      "r913",
      "r914",
      "r915",
      "r923",
      "r926",
      "r945",
      "r947",
      "r950",
      "r1023",
      "r1032",
      "r1186"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r773",
      "r774",
      "r775",
      "r776",
      "r887",
      "r889"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/INVESTMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment [Text Block]",
        "terseLabel": "INVESTMENTS [Text Block]",
        "verboseLabel": "Investments",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1051",
      "r1084"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails",
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type Axis",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r795",
      "r796",
      "r798",
      "r800",
      "r867",
      "r876",
      "r892",
      "r900",
      "r913",
      "r917",
      "r918",
      "r947",
      "r951",
      "r952",
      "r953",
      "r954",
      "r1023"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails",
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r795",
      "r796",
      "r798",
      "r800",
      "r867",
      "r876",
      "r892",
      "r900",
      "r913",
      "r917",
      "r918",
      "r947",
      "r951",
      "r952",
      "r953",
      "r954",
      "r1023"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]",
        "terseLabel": "INVESTMENTS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInAndAdvancesToAffiliatesTable",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in and Advances to Affiliates [Table]",
        "documentation": "Disclosure of information about investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944"
     ]
    },
    "flgc_JustBrandsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "JustBrandsLLCMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Just Brands L L C [Member]",
        "label": "Just Brands L L C [Member]",
        "terseLabel": "Just Brands LLC [Member]",
        "verboseLabel": "Just Brands FL LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_JustBrandsLlcAndHighRollerPrivateLabelLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "JustBrandsLlcAndHighRollerPrivateLabelLlcMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Just Brands Llc And High Roller Private Label Llc [Member]",
        "terseLabel": "Just Brands LLC and High Roller Private Label LLC business combination [Member]",
        "verboseLabel": "Just Brands LLC and High Roller Private Label LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_JustCBDInsurancePremiumLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "JustCBDInsurancePremiumLoanMember",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for JustCBD insurance premium loan.",
        "label": "Just C B D Insurance Premium Loan [Member]",
        "terseLabel": "JustCBD insurance premium loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_JustCBDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "JustCBDMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://www.floragrowth.com/role/LossPerShareDetails",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "netLabel": "JustCBD potential additional shares to settle contingent consideration [Member]",
        "label": "Just C B D [Member]",
        "terseLabel": "JustCBD [Member]",
        "verboseLabel": "JustCBD asset group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_JustCBDOwnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "JustCBDOwnersMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Just C B D Owners [Member]",
        "verboseLabel": "JustCBD owners [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_KnowHowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "KnowHowMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Know How [Member]",
        "terseLabel": "Know-how [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/LeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r1017"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of leases [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "terseLabel": "LEASES [Text Block]",
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "flgc_LegalDisputesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LegalDisputesMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Disputes [Member]",
        "terseLabel": "Legal disputes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
      "http://www.floragrowth.com/role/BasisOfPresentation",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/CommitmentsAndContingencies",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties",
      "http://www.floragrowth.com/role/DEBT",
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstruments",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstrumentsTables",
      "http://www.floragrowth.com/role/IncomeTaxes",
      "http://www.floragrowth.com/role/IncomeTaxesDetails2",
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative",
      "http://www.floragrowth.com/role/IncomeTaxesTables",
      "http://www.floragrowth.com/role/LEASES",
      "http://www.floragrowth.com/role/LEASESNarrativeDetails",
      "http://www.floragrowth.com/role/LeasesDetails",
      "http://www.floragrowth.com/role/LeasesDetails1",
      "http://www.floragrowth.com/role/LeasesTables",
      "http://www.floragrowth.com/role/NatureOfOperations",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipment",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables",
      "http://www.floragrowth.com/role/RelatedPartyDisclosures",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresTables",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareCapital",
      "http://www.floragrowth.com/role/SignificantAccountingPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesTables",
      "http://www.floragrowth.com/role/SubsequentEvents",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative",
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivable",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/LEASES",
      "http://www.floragrowth.com/role/LEASESNarrativeDetails",
      "http://www.floragrowth.com/role/LeasesDetails",
      "http://www.floragrowth.com/role/LeasesDetails1",
      "http://www.floragrowth.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.floragrowth.com/role/LEASES",
      "http://www.floragrowth.com/role/LEASESNarrativeDetails",
      "http://www.floragrowth.com/role/LeasesDetails",
      "http://www.floragrowth.com/role/LeasesDetails1",
      "http://www.floragrowth.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of operating lease liabilities",
        "terseLabel": "Schedule of maturities of operating lease liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1167"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "verboseLabel": "Lessee, operating lease, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total Liabilities",
        "label": "[Liabilities]",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r311",
      "r411",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r467",
      "r469",
      "r470",
      "r606",
      "r609",
      "r610",
      "r626",
      "r810",
      "r990",
      "r1032",
      "r1115",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_LiabilitiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LiabilitiesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Amount",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Liabilities and Equity]",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r238",
      "r732",
      "r1018",
      "r1076",
      "r1089",
      "r1159"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current lease liabilities",
        "label": "[Liabilities, Current]",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r270",
      "r311",
      "r411",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r467",
      "r469",
      "r470",
      "r606",
      "r609",
      "r610",
      "r626",
      "r1018",
      "r1115",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "verboseLabel": "Non-current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total liabilities held for sale",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r206",
      "r267",
      "r268"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "Liabilities held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities held for sale",
        "totalLabel": "Total current liabilities held for sale",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r156",
      "r203",
      "r206",
      "r267",
      "r268"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities held for sale",
        "totalLabel": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent, Total",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r139",
      "r156",
      "r206",
      "r267",
      "r268"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "verboseLabel": "Licenses [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "flgc_LicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LicensesMember",
     "presentation": [
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licenses [Member]",
        "verboseLabel": "Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Line of Credit",
        "terseLabel": "Credit facility",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r235",
      "r1180"
     ]
    },
    "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding amount of Credit facility",
        "terseLabel": "Outstanding amount",
        "documentation": "Average amount borrowed under the credit facility during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDescription",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate Description",
        "terseLabel": "Line of credit facility, interest rate description",
        "documentation": "Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit facility rate",
        "terseLabel": "Credit facility interest rate",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Available credit facilities",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_LineOfCreditFacilityPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility",
        "documentation": "Amount of the required periodic payments of both interest and principal."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Periodic Payment, Interest",
        "terseLabel": "Principal and interest payments",
        "documentation": "Amount of the required periodic payment applied to interest."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Available credit facilities",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r1075"
     ]
    },
    "flgc_LisanFarmaColombiaLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LisanFarmaColombiaLLCMember",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lisan Farma Colombia L L C [Member]",
        "label": "Lisan Farma Colombia L L C [Member]",
        "terseLabel": "Lisan Farma Colombia LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_LoanAgreementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LoanAgreementsAxis",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Loan Agreements [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_LoanAgreementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LoanAgreementsDomain",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Loan Agreements [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Amounts Receivable",
        "terseLabel": "TRADE AND AMOUNTS RECEIVABLE [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable",
        "terseLabel": "Loans payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r235",
      "r1180"
     ]
    },
    "flgc_LoansReceivableAndAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LoansReceivableAndAdvances",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans receivable and advances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansReceivableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansReceivableFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Receivable, Fair Value Disclosure",
        "terseLabel": "Loans receivable",
        "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of long-lived assets by geographic area",
        "terseLabel": "Schedule of disaggregation of long-lived assets by geographic area [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Long term debt",
        "positiveLabel": "Outstanding debt",
        "label": "Long-Term Debt",
        "totalLabel": "Long-Term Debt, Total",
        "verboseLabel": "Long term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r235",
      "r484",
      "r499",
      "r998",
      "r999",
      "r1180"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments",
        "terseLabel": "Investments",
        "totalLabel": "Long-Term Investments, Total",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r1046"
     ]
    },
    "flgc_LossContingencyAccrualForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LossContingencyAccrualForeignCurrencyTranslation",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation affecting the loss contingency liability.",
        "label": "Loss Contingency Accrual, Foreign Currency Translation",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/settlements",
        "label": "Loss Contingency Accrual, Payments",
        "documentation": "Amount of cash outflow reducing loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Additional provisions",
        "verboseLabel": "Loss contingency provision",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1108",
      "r1110"
     ]
    },
    "flgc_LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that the company is obligated to issue pre-one-for three reverse stock split.",
        "label": "Loss Contingency Damages Sought Share To Be Issued Pre One For Three Reverse Stock Split",
        "verboseLabel": "Number of shares to be issued pre-one-for three reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Value of damages sought",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1108",
      "r1110"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r456",
      "r457"
     ]
    },
    "flgc_LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about loss contingency estimate of possible loss based on number of shares.",
        "label": "Loss Contingency Estimate Of Possible Loss Based On Number Of Shares",
        "terseLabel": "Number of shares loss estimate is based on"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_LossContingencyEstimateOfPossibleLossInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LossContingencyEstimateOfPossibleLossInterestAccrued",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency, estimate of possible loss, interest accrued.",
        "label": "Loss Contingency, Estimate Of Possible Loss, Interest Accrued",
        "terseLabel": "Loss contingency, estimate of possible loss, interest accrued"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_LossContingencyInterestPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "LossContingencyInterestPaymentTerms",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about loss contingency interest payment terms.",
        "label": "Loss Contingency Interest Payment Terms",
        "terseLabel": "Loss contingency interest payment terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyLossInPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyLossInPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Loss in Period",
        "verboseLabel": "Loss recorded within contingencies and within indemnification receivables",
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_LossContingencyTrialOrAlternativeDisputeResolution": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyTrialOrAlternativeDisputeResolution",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Trial or Alternative Dispute Resolution",
        "verboseLabel": "Description of settlement of disputes",
        "documentation": "Identifies whether the action is pursued in a court of law, an arbitration or mediation, and whether a decision by the Trier of fact in a nontrial proceeding is binding or nonbinding."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r210"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and office equipment [Member]",
        "verboseLabel": "Machinery and office equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ManagementContractsTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ManagementContractsTerms",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about management contracts terms.",
        "label": "Management contracts terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementFeeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting and management fees",
        "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r838",
      "r1030",
      "r1189"
     ]
    },
    "us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Servicing Assets and Servicing Liabilities Risk [Axis]",
        "documentation": "Information by type of risks inherent in servicing assets and servicing liabilities."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "flgc_MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres.",
        "label": "Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_MaximumLimitOfIndemnificationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "MaximumLimitOfIndemnificationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reprsents the value of maximum limit of the indemnification agreement.",
        "label": "Maximum Limit Of Indemnification Agreement",
        "terseLabel": "Maximum limit of indemnification agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r455",
      "r526",
      "r695",
      "r766",
      "r801",
      "r802",
      "r870",
      "r891",
      "r896",
      "r897",
      "r928",
      "r974",
      "r975",
      "r992",
      "r1002",
      "r1010",
      "r1020",
      "r1119",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177"
     ]
    },
    "flgc_MaximumPortionOfNetProfitsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "MaximumPortionOfNetProfitsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum portion of net profits payable.",
        "label": "Maximum Portion Of Net Profits Payable",
        "verboseLabel": "Maximum portion of net profits payable"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_MedicalServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "MedicalServices",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical services"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r455",
      "r526",
      "r695",
      "r766",
      "r801",
      "r802",
      "r870",
      "r891",
      "r896",
      "r897",
      "r928",
      "r974",
      "r975",
      "r992",
      "r1002",
      "r1010",
      "r1020",
      "r1119",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest in subsidiaries",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r237",
      "r311",
      "r411",
      "r458",
      "r461",
      "r462",
      "r463",
      "r469",
      "r470",
      "r626",
      "r731",
      "r814"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "terseLabel": "Percentage of non-controlling interest",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_MonthlyLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "MonthlyLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly lease payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.floragrowth.com/role/NatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations",
        "terseLabel": "NATURE OF OPERATIONS [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r262"
     ]
    },
    "flgc_NatureOfOperationsAndGoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NatureOfOperationsAndGoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations And Going Concern [Abstract]",
        "verboseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Flora Growth Corp",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r194",
      "r242",
      "r268",
      "r291",
      "r293",
      "r298",
      "r311",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r333",
      "r347",
      "r361",
      "r367",
      "r370",
      "r411",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r467",
      "r469",
      "r470",
      "r621",
      "r626",
      "r740",
      "r835",
      "r856",
      "r857",
      "r991",
      "r1030",
      "r1115"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net income (loss) attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r230",
      "r291",
      "r293",
      "r327",
      "r328",
      "r739",
      "r1068"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Of Accounting Standards And Amendments",
        "terseLabel": "Adoption of accounting standards and amendments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NoCapHempCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NoCapHempCoMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Cap Hemp Co [Member]",
        "verboseLabel": "No Cap Hemp Co. business combination [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NonCashAssetsAcquiredForContingentConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NonCashAssetsAcquiredForContingentConsideration",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Assets Acquired For Contingent Consideration",
        "verboseLabel": "Assets acquired for contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NonCashCommonSharesIssuedForBusinessCombinations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NonCashCommonSharesIssuedForBusinessCombinations",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Common Shares Issued For Business Combinations",
        "verboseLabel": "Common shares issued for business combinations"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NonCashCommonSharesIssuedForOtherAgreements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NonCashCommonSharesIssuedForOtherAgreements",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Common Shares Issued For Other Agreements",
        "verboseLabel": "Common shares issued for other agreements"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NonCashOperatingLeaseAdditionsToRightOfUseAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NonCashOperatingLeaseAdditionsToRightOfUseAssets",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Operating Lease Additions To Right Of Use Assets",
        "verboseLabel": "Operating lease additions to right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NonCashOptionCancellationsReclassifiedToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NonCashOptionCancellationsReclassifiedToEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Option Cancellations Reclassified To Equity",
        "verboseLabel": "Option cancellations reclassified to equity"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NonControllingInterestsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NonControllingInterestsPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests [Policy Text Block]",
        "terseLabel": "Non-controlling interests [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NonVestedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NonVestedShares",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-vested shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncompeteAgreementsMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Non-Compete Agreements [Member]",
        "verboseLabel": "Non-compete agreements [Member]",
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest in subsidiaries (deficiency)",
        "terseLabel": "Non-controlling interests in subsidiaries (deficiency)",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r517",
      "r1078",
      "r1079",
      "r1080",
      "r1193"
     ]
    },
    "us-gaap_NontradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NontradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables",
        "totalLabel": "Nontrade Receivables, Total",
        "verboseLabel": "Indemnification receivables",
        "documentation": "Carrying amounts due as of the balance sheet date of the sum of amounts receivable other than from customers."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "flgc_NovemberTwoThousandTwentyOneUnitOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NovemberTwoThousandTwentyOneUnitOfferingMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November Two Thousand Twenty One Unit Offering [Member]",
        "verboseLabel": "November 2021 offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "flgc_NumberOfSharesUnderPlaintiffClaim": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NumberOfSharesUnderPlaintiffClaim",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about number of shares under plaintiff claim.",
        "label": "Number Of Shares Under Plaintiff Claim",
        "terseLabel": "Number of shares under plaintiff claim"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NumberOfTrials": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NumberOfTrials",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trials.",
        "label": "Number Of Trials",
        "terseLabel": "Number of trials"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NumberOfViolationsClaimed": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NumberOfViolationsClaimed",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about number of violations claimed.",
        "label": "Number Of Violations Claimed",
        "terseLabel": "Number of violations claimed"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NumberOfViolationsInStopSaleOrders": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NumberOfViolationsInStopSaleOrders",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of violations in stop sale orders"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NumberOfWarrantsIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NumberOfWarrantsIssuedDuringPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Warrants Issued During Period",
        "terseLabel": "Warrant issued",
        "verboseLabel": "Number of warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NumberOfWarrantsWithAmendedExercisePrice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NumberOfWarrantsWithAmendedExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants with amended exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_NumberOfWarrantsWithExercisePriceAmended": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "NumberOfWarrantsWithExercisePriceAmended",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants with exercise price amended"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails": {
       "parentTag": "us-gaap_CostsAndExpensesRelatedParty",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors' And Officers' Compensation",
        "terseLabel": "Directors' and officers' compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "flgc_OperatingActivitiesOfDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "OperatingActivitiesOfDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities Of Discontinued Operations [Abstract]",
        "terseLabel": "Operating activities of discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Operating Expenses]",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Operating Income (Loss)]",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r361",
      "r367",
      "r370",
      "r991"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.floragrowth.com/role/LeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "verboseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Impairment Loss",
        "verboseLabel": "Operating lease expense net of cash payments",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetails1",
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Lease liability",
        "positiveTerseLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Current portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liability",
        "totalLabel": "Total non-current lease liabilities",
        "verboseLabel": "Total non-current lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r647"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use assets",
        "verboseLabel": "Right Of Use Assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate for operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r1017"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term in years for operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r1017"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Non-capital loss carryforwards",
        "verboseLabel": "Unused loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "flgc_OptionsExercisableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "OptionsExercisableMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable [Member]",
        "verboseLabel": "Options exercisable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_OriginalHempAssetAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "OriginalHempAssetAcquisitionMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original Hemp asset acquisition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payable and accrued liabilities",
        "terseLabel": "Trade payables and accrued liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Accrued Liabilities, Total",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Other asset impairments",
        "totalLabel": "Asset Impairment Charges, Total",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1104"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other Assets",
        "verboseLabel": "Other long-lived assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation, net of income taxes",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation, net of income taxes of $nil ($nil in 2022)",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLossParenthetical",
      "http://www.floragrowth.com/role/UnauditedCondensedInterimConsolidatedStatementOfShareholdersEquityDeficiencyParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation, tax amount",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Total",
        "verboseLabel": "Foreign currency translation, tax amount",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r10",
      "r628",
      "r634"
     ]
    },
    "flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Loss Exchange Differences On Foreign Operations Net Of Income Taxes",
        "terseLabel": "Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss- exchange differences on foreign operations (net of income taxes of $nil)",
        "terseLabel": "Other comprehensive loss -exchange differences (net of income taxes of $nil)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other expenses (income), net",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r747"
     ]
    },
    "flgc_OtherEquityIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "OtherEquityIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other equity issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-lived assets",
        "terseLabel": "Other Long-lived Assets",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "flgc_OtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "OtherInformationAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information [Abstract]",
        "verboseLabel": "Other Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-Term Investments",
        "verboseLabel": "Net carrying value",
        "documentation": "Amount of long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r1060"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "terseLabel": "Other receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r821"
     ]
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current period additions for expected credit losses",
        "label": "[Other than Temporary Impairment, Credit Losses Recognized in Earnings, Additions, Additional Credit Losses]",
        "documentation": "This item represents an increase to the cumulative amount of credit losses recognized in earnings for an other than temporary impairment (OTTI) of a debt security held for which a previous OTTI was recognized and the investor does not intend to sell the debt security and it is not more likely than not that the investor will be required to sell the debt security before recovery of its amortized cost basis."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PatentAndDevelopedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PatentAndDevelopedTechnologyMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent And Developed Technology [Member]",
        "verboseLabel": "Patents and developed technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and developed technology [Member]",
        "verboseLabel": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Settlements",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Settlement payment",
        "verboseLabel": "Payments/Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net cash on disposal",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1070"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common shares repurchased",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Exercise of warrant",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForUnderwritingExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Underwriting Expense",
        "terseLabel": "Underwriting expense",
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity issue costs",
        "label": "Payment of stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Cash consideration",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r601"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Business and asset acquisitions, net of cash acquired",
        "label": "[Payments to Acquire Businesses, Net of Cash Acquired]",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of equipment",
        "label": "Payments to Acquire Machinery and Equipment",
        "documentation": "The cash outflow for acquisition of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment and intangible assets",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "flgc_PercentageOfAggregateGrossProceedsFromSaleOfCommonShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PercentageOfAggregateGrossProceedsFromSaleOfCommonShares",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about percentage of aggregate gross proceeds from sale of common shares.",
        "label": "Percentage Of Aggregate Gross Proceeds From Sale Of Common Shares",
        "terseLabel": "Percentage of aggregate gross proceeds from sale of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PercentageOfIssuedAndOutstandingCommonShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PercentageOfIssuedAndOutstandingCommonShares",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about percentage of issued and outstanding common shares.",
        "label": "Percentage Of Issued And Outstanding Common Shares",
        "terseLabel": "Percentage of issued and outstanding common shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Recoverable amounts exceeded the market capitalization of common shares.",
        "label": "Percentage Of Recoverable Amounts Exceeded Market Capitalization Of Common Shares",
        "terseLabel": "Percentage of recoverable amounts exceeded market capitalization of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PharmaceuticalsMember",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2",
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pharmaceuticals [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "flgc_PompanoBeachMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PompanoBeachMember",
     "presentation": [
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pompano Beach [Member]",
        "verboseLabel": "Pompano Beach, FL [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PostTerminationExercisePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PostTerminationExercisePeriod",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post Termination Exercise Period",
        "label": "Post Termination Exercise Period",
        "verboseLabel": "Post-termination exercise period"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PotentialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PotentialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of potential liabilities.",
        "label": "Potential liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "flgc_PriceToBookValue": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PriceToBookValue",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price to book value"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PriceToTangibleBookValue": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PriceToTangibleBookValue",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price to tangible book value"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ProceedsFromExerciseOfWarrantsAndOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ProceedsFromExerciseOfWarrantsAndOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Exercise Of Warrants And Options",
        "verboseLabel": "Exercise of warrants and options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "September units issued",
        "verboseLabel": "Proceeds from issuance of shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan borrowings",
        "terseLabel": "Proceeds from issuance of debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "verboseLabel": "Warrants issued",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale, Property, Held-for-Sale",
        "terseLabel": "Proceeds from property held for sale",
        "verboseLabel": "Purchase price",
        "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r372",
      "r700",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r978",
      "r1003",
      "r1019",
      "r1049",
      "r1111",
      "r1112",
      "r1121",
      "r1184"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r372",
      "r700",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r978",
      "r1003",
      "r1019",
      "r1049",
      "r1111",
      "r1112",
      "r1121",
      "r1184"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 130.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "verboseLabel": "Professional fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 150.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss for the period",
        "verboseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r291",
      "r293",
      "r305",
      "r311",
      "r319",
      "r327",
      "r328",
      "r347",
      "r361",
      "r367",
      "r370",
      "r411",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r467",
      "r469",
      "r470",
      "r604",
      "r607",
      "r608",
      "r621",
      "r626",
      "r720",
      "r738",
      "r788",
      "r835",
      "r856",
      "r857",
      "r991",
      "r1015",
      "r1016",
      "r1031",
      "r1068",
      "r1115"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant And Equipment",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r256",
      "r257",
      "r258"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Property, Plant and Equipment, Gross]",
        "verboseLabel": "Property, plant and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r274",
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveTerseLabel": "Property, plant and equipment",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, Plant And Equipment",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r721",
      "r735",
      "r1018"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property, plant and equipment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r256",
      "r257",
      "r733"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Bad debt expense",
        "verboseLabel": "Bad debt expense",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r417"
     ]
    },
    "flgc_ProvisionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ProvisionsPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions [Policy Text Block]",
        "terseLabel": "Provisions [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r236"
     ]
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r236"
     ]
    },
    "flgc_PurchaseConsiderationDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PurchaseConsiderationDiscountRate",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Consideration, Discount Rate",
        "verboseLabel": "Discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PurchaseConsiderationPercentageOfSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PurchaseConsiderationPercentageOfSales",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase consideration, percentage of sales"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PurchaseConsiderationPercentageOfSalesAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PurchaseConsiderationPercentageOfSalesAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Consideration, Percentage Of Sales Amount Payable",
        "verboseLabel": "Purchase consideration, percentage of sales, amount payable"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_PurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "PurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RamonRicardoCastellanosSaenzAndMiriamOrtizMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RamonRicardoCastellanosSaenzAndMiriamOrtizMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for Ramon Ricardo Castellanos Saenz and Miriam Ortiz.",
        "label": "Ramon Ricardo Castellanos Saenz and Miriam Ortiz [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r455",
      "r518",
      "r526",
      "r553",
      "r554",
      "r555",
      "r670",
      "r695",
      "r766",
      "r801",
      "r802",
      "r870",
      "r891",
      "r896",
      "r897",
      "r928",
      "r974",
      "r975",
      "r992",
      "r1002",
      "r1010",
      "r1020",
      "r1023",
      "r1105",
      "r1119",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r455",
      "r518",
      "r526",
      "r553",
      "r554",
      "r555",
      "r670",
      "r695",
      "r766",
      "r801",
      "r802",
      "r870",
      "r891",
      "r896",
      "r897",
      "r928",
      "r974",
      "r975",
      "r992",
      "r1002",
      "r1010",
      "r1020",
      "r1023",
      "r1105",
      "r1119",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177"
     ]
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsEightMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Eight [Member]",
        "verboseLabel": "June 3, 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsEighteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Eighteen [Member]",
        "verboseLabel": "July 5, 2033 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsElevenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Eleven [Member]",
        "verboseLabel": "September 25, 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsFifteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Fifteen [Member]",
        "verboseLabel": "May 16, 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsFiveMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Five [Member]",
        "verboseLabel": "September 8, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsFourMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Four [Member]",
        "verboseLabel": "July 15, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsFourteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Fourteen [Member]",
        "verboseLabel": "January 26, 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsNineMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Nine [Member]",
        "verboseLabel": "June 10, 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsOneMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options One [Member]",
        "verboseLabel": "June 28, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsSevenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Seven [Member]",
        "verboseLabel": "December 23, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsSeventeenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Seventeen [Member]",
        "verboseLabel": "August 18, 2032 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsSixMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Six [Member]",
        "verboseLabel": "November 4, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsSixteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsSixteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Sixteen [Member]",
        "verboseLabel": "December 31, 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsTenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Ten [Member]",
        "verboseLabel": "September 21, 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsThirteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Thirteen [Member]",
        "verboseLabel": "January 17, 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsThreeMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Three [Member]",
        "verboseLabel": "July 6, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsTwelveMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Twelve [Member]",
        "verboseLabel": "December 16, 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RangesOfExercisePricesForOutstandingShareOptionsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsTwoMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges Of Exercise Prices For Outstanding Share Options Two [Member]",
        "verboseLabel": "April 23, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable from Shareholders or Affiliates for Issuance of Capital Stock",
        "verboseLabel": "Receivable",
        "documentation": "Amount due from owner or affiliate of reporting entity for issuance of shares. Includes, but is not limited to, amount due for award under share-based payment arrangement. Excludes amount due from officer or director."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "flgc_RegulationAAndOtherOfferingsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RegulationAAndOtherOfferingsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulation A and other offerings, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RegulationAAndOtherOfferingsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RegulationAAndOtherOfferingsShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulation A and other offerings, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r656",
      "r657",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r831",
      "r833",
      "r866"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r657",
      "r1169"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r843"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r656",
      "r657",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r831",
      "r833",
      "r866",
      "r1169"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Disclosures",
        "terseLabel": "RELATED PARTY DISCLOSURES [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r657",
      "r659",
      "r784",
      "r785",
      "r786",
      "r841",
      "r842",
      "r843",
      "r863",
      "r865"
     ]
    },
    "flgc_RemainingWeightedAverageVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RemainingWeightedAverageVestingPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining weighted average vesting period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loan repayments",
        "label": "[Repayments of Debt]",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "srt_ReportableGeographicalComponentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ReportableGeographicalComponentsMember",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Geographical Components [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReportingUnitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Unit [Axis]",
        "documentation": "Information by reporting unit."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r440",
      "r996"
     ]
    },
    "us-gaap_ReportingUnitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitDomain",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Unit [Domain]",
        "documentation": "Level of reporting at which goodwill is tested for impairment."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r440",
      "r996"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r475",
      "r503",
      "r658",
      "r983",
      "r984"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r569",
      "r1178"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Expenses",
        "terseLabel": "Research expenses [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Investments, Current, Total",
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r961",
      "r1065"
     ]
    },
    "flgc_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock or Unit Expense",
        "verboseLabel": "Restricted stock awards expense",
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted stock awards [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RestrictedStockVestingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RestrictedStockVestingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock vesting amount",
        "terseLabel": "Restricted stock vesting, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RestrictedStockVestingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RestrictedStockVestingShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock vesting shares",
        "terseLabel": "Restricted stock vesting, shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_RetailSpaceInMiamiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RetailSpaceInMiamiMember",
     "presentation": [
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retail space in Miami [Member]",
        "label": "Retail space In Miami [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r215",
      "r730",
      "r770",
      "r772",
      "r782",
      "r813",
      "r1018"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r316",
      "r317",
      "r318",
      "r320",
      "r326",
      "r328",
      "r412",
      "r413",
      "r563",
      "r564",
      "r565",
      "r587",
      "r588",
      "r611",
      "r613",
      "r614",
      "r616",
      "r619",
      "r767",
      "r769",
      "r789",
      "r1193"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "terseLabel": "Revenue recognition [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r977",
      "r988"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/SegmentedInformationDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Net Sales",
        "totalLabel": "Revenues, Total",
        "verboseLabel": "Revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r311",
      "r348",
      "r349",
      "r360",
      "r365",
      "r366",
      "r372",
      "r374",
      "r376",
      "r411",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r467",
      "r469",
      "r470",
      "r626",
      "r720",
      "r1115"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r648",
      "r1017"
     ]
    },
    "us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks Inherent in Servicing Assets and Servicing Liabilities, Type [Domain]",
        "documentation": "The nature of risks inherent in servicing assets and servicing liabilities."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "flgc_RoyaltyOnGrossRevenuesFromSaleOfProducts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "RoyaltyOnGrossRevenuesFromSaleOfProducts",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty on gross revenues from sale of products",
        "terseLabel": "Payment of royalty"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SalesTaxesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SalesTaxesMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales taxes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of trade and amounts receivable [Table Text Block]",
        "verboseLabel": "Schedule of trade and amounts receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetails",
      "http://www.floragrowth.com/role/LossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive shares [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "flgc_ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets And Liabilities Denominated In Foreign Currencies [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities denominated in foreign currencies [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assets estimated useful life [Table Text Block]",
        "terseLabel": "Schedule of assets estimated useful lives [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetails1",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r108",
      "r599"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "flgc_ScheduleOfCommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfCommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfCommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfCommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schdeule Of Commitments And Contingencies.",
        "label": "Schedule Of Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfCompanyAgingOfTradeAccountsReceivable": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfCompanyAgingOfTradeAccountsReceivable",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of company aging of trade accounts receivable.",
        "label": "Schedule Of Company Aging Of Trade Accounts Receivable",
        "terseLabel": "Schedule of aging of trade accounts receivable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfCompanysInvestmentsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfCompanysInvestmentsActivityTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Companys Investments Activity [Table Text Block]",
        "terseLabel": "Schedule of investments activity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Tax Provision",
        "terseLabel": "Schedule of components of the income tax provision [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets And Liabilities",
        "terseLabel": "Schedule of deferred income tax assets and liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of corporate income tax rate",
        "terseLabel": "Schedule of corporate income tax rate [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "flgc_ScheduleOfFairValueOfWarrantsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfFairValueOfWarrantsTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Warrants [Table Text Block]",
        "terseLabel": "Schedule of fair value of warrants [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFinancingReceivablesPastDueTable",
     "presentation": [
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Past Due [Table]",
        "documentation": "Disclosure of information about aging analysis for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1091"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r78",
      "r701"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r78"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r996"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102"
     ]
    },
    "flgc_ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications",
     "presentation": [
      "http://www.floragrowth.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information About Companys Financial Instruments And Their Classifications",
        "terseLabel": "Schedule of information about the financial instruments and their classifications [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfIntangibleAssetsEstimatedUsefulLives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfIntangibleAssetsEstimatedUsefulLives",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Estimated Useful Lives",
        "terseLabel": "Schedule of intangible assets estimated useful lives [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Inventory",
        "terseLabel": "Schedule of inventory [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r173",
      "r174",
      "r175"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r888",
      "r890",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r888",
      "r890",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r919",
      "r920",
      "r921",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLossContingenciesByContingencyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]",
        "terseLabel": "Schedule of provisions and contingent liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1109",
      "r1111",
      "r1113"
     ]
    },
    "flgc_ScheduleOfLossFromDiscontinuedOperationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfLossFromDiscontinuedOperationsTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to\u00a0loss net of tax discontinued operations.",
        "label": "Schedule Of Loss From Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of loss from discontinued operations [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to assets and liabilities\u00a0held for sale.",
        "label": "Schedule Of Major Classes Of Assets And Liabilities Held For Sale [Table Text Block]",
        "verboseLabel": "Schedule of major classes of assets and liabilities held for sale [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfOtherSignificantItemsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfOtherSignificantItemsTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of other significant items [Table Text Block]",
        "terseLabel": "Schedule of other significant items [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Major Class Of Assets Acquired And Liabilities",
        "terseLabel": "Schedule of major class of assets acquired and liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r839",
      "r840",
      "r843"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfRestrictedStockAwards": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfRestrictedStockAwards",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Stock Awards",
        "terseLabel": "Schedule of restricted stock awards [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of net sales and net loss before income taxes by geographic area",
        "terseLabel": "Schedule of disaggregation of net sales by geographic area [Table Text Block]",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r182"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operation segment information",
        "terseLabel": "Schedule of operation segment information [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Options Outstanding And Exercisable",
        "terseLabel": "Schedule of stock options outstanding and exercisable [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average inputs and assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "flgc_ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to\u00a0operating and investing items\u00a0discontinued operations.",
        "label": "Schedule Of Significant Operating And Investing Items [Table Text Block]",
        "verboseLabel": "Schedule of significant operating and investing items [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r213",
      "r214",
      "r215",
      "r282",
      "r283",
      "r284",
      "r342",
      "r501",
      "r502",
      "r503",
      "r505",
      "r508",
      "r513",
      "r515",
      "r778",
      "r779",
      "r780",
      "r781",
      "r1002",
      "r1045",
      "r1074"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of stock options roll forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding by date of expiry [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "flgc_ScheduleOfSubsidiariesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfSubsidiariesTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of subsidiaries [Table Text Block]",
        "terseLabel": "Schedule of subsidiaries [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants outstanding [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Amortization Period Of Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of weighted average amortization period of intangible assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SecondClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SecondClosingMember",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Closing [Member]",
        "label": "Second Closing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SecondLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SecondLoanAgreementMember",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Loan Agreement [Member]",
        "label": "Second Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SecondLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SecondLoanMember",
     "presentation": [
      "http://www.floragrowth.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Second Loan.",
        "label": "Second Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SecondTrancheMember",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuritiesFinancingTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuritiesFinancingTransactionAxis",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetails",
      "http://www.floragrowth.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Financing Transaction [Axis]",
        "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_SecuritiesFinancingTransactionTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuritiesFinancingTransactionTypeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetails",
      "http://www.floragrowth.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Financing Transaction [Domain]",
        "documentation": "Measurement of financing transaction securities held."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued operations [Member]",
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r140",
      "r141",
      "r142"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r376",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r447",
      "r448",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r996",
      "r1049",
      "r1184"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r794",
      "r797",
      "r799",
      "r876",
      "r892",
      "r913",
      "r947",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r979",
      "r1004",
      "r1023",
      "r1121",
      "r1184"
     ]
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentOperatingActivitiesDomain",
     "presentation": [
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Domain]",
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENTED INFORMATION [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r359",
      "r364",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SeptemberTwoThousandTwentyThreeUnitOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SeptemberTwoThousandTwentyThreeUnitOfferingMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Two Thousand Twenty Three Unit Offering [Member]",
        "verboseLabel": "September 2023 unit offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SeptemberUnitOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SeptemberUnitOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Unit Offering Amount",
        "verboseLabel": "September unit offering, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SeptemberUnitOfferingIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SeptemberUnitOfferingIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "September unit offering issuance costs",
        "label": "September Unit Offering Issuance Costs",
        "verboseLabel": "September unit offering issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SeptemberUnitOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SeptemberUnitOfferingShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Unit Offering Shares",
        "verboseLabel": "September unit offering shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Termination benefits expense",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 80.0
      },
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/SegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "verboseLabel": "Award vesting rights",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Terms of share-based payment arrangement",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of restricted stock awards, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "verboseLabel": "Number of restricted stock awards, Cancelled",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted average grant date fair value, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Exercise Price, Cancelled",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Number of restricted stock awards, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in dollars per share)",
        "verboseLabel": "Weighted average grant date fair value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of restricted stock awards, Ending Balance",
        "periodStartLabel": "Number of restricted stock awards, Beginning Balance",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average grant date fair value, ending balance",
        "periodStartLabel": "Weighted average grant date fair value, beginning balance",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value]",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in dollars per share)",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period]",
        "verboseLabel": "Number of restricted stock awards, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "verboseLabel": "Fair value of warrants vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted average grant date fair value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Exercise Price, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1",
      "http://www.floragrowth.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "verboseLabel": "Non-option equity instruments, forfeitures and expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative",
      "http://www.floragrowth.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Issued",
        "verboseLabel": "Non-option equity instruments granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Number of shares authorized under compensation plan",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "flgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards cancelled, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining life, Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options exercisable, ending balance",
        "periodStartLabel": "Number of options exercisable, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable, ending balance",
        "periodStartLabel": "Weighted average exercise price, exercisable, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options exercisable price per share",
        "verboseLabel": "Weighted average exercise price, Exercisable balance",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options, exercises in period, intrinsic value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Options expired in period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted",
        "verboseLabel": "Number of options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, ending balance",
        "periodStartLabel": "Number of options, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "verboseLabel": "Options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Weighted average price",
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Stock options granted, exercise price",
        "verboseLabel": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation",
        "terseLabel": "Share based compensation [Policy Text Block]",
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r562"
     ]
    },
    "flgc_ShareBasedCompensationOptionsVestedGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ShareBasedCompensationOptionsVestedGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation , Options, Vested, Grant Date Fair Value",
        "verboseLabel": "Grant date fair value vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "flgc_ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation , Warrants, Grant Date Fair Value Per Warrant",
        "verboseLabel": "Warrants issued, grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate]",
        "terseLabel": "Common share volatility",
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Current stock price",
        "verboseLabel": "Closing share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SharePurchaseAgreementMember",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement [Member].",
        "label": "Share Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Award expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life",
        "verboseLabel": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining life (years) Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Options unvested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Weighted average exercise price, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining life, Ending Balance",
        "verboseLabel": "Remaining life in years",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "verboseLabel": "Options, vested in period, fair value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "flgc_SharedServicesAndSpaceCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SharedServicesAndSpaceCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shared services and space commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "verboseLabel": "Shares Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "flgc_SharesIssuedDuringPeriodSharesWarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SharesIssuedDuringPeriodSharesWarrantsExpired",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued during period warrants expired.",
        "label": "Shares Issued During Period Shares Warrants Expired",
        "terseLabel": "Warrants expired/cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Offering price per common share",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price per share",
        "verboseLabel": "Price per unit",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SharesIssuedToPurchaseWarrantsFromExistingInvestors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SharesIssuedToPurchaseWarrantsFromExistingInvestors",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued to purchase warrants from existing investors",
        "label": "Shares issued to purchase warrants from existing investors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/LeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease expense",
        "verboseLabel": "Short-term lease expense",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r1017"
     ]
    },
    "flgc_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "verboseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r308"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r376",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r446",
      "r447",
      "r448",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r996",
      "r1049",
      "r1184"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r51",
      "r263",
      "r296",
      "r297",
      "r298",
      "r316",
      "r317",
      "r318",
      "r320",
      "r326",
      "r328",
      "r341",
      "r412",
      "r413",
      "r517",
      "r563",
      "r564",
      "r565",
      "r587",
      "r588",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r635",
      "r652",
      "r767",
      "r768",
      "r769",
      "r789",
      "r858"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r794",
      "r797",
      "r799",
      "r876",
      "r892",
      "r913",
      "r947",
      "r959",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r979",
      "r1004",
      "r1023",
      "r1121",
      "r1184"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentation",
      "http://www.floragrowth.com/role/CommitmentsAndContingencies",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties",
      "http://www.floragrowth.com/role/FinancialInstruments",
      "http://www.floragrowth.com/role/FinancialInstrumentsTables",
      "http://www.floragrowth.com/role/IncomeTaxes",
      "http://www.floragrowth.com/role/IncomeTaxesDetails2",
      "http://www.floragrowth.com/role/IncomeTaxesTables",
      "http://www.floragrowth.com/role/NatureOfOperations",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipment",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables",
      "http://www.floragrowth.com/role/RelatedPartyDisclosures",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresTables",
      "http://www.floragrowth.com/role/SignificantAccountingPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesTables",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivable",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r341",
      "r700",
      "r773",
      "r791",
      "r803",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r812",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r822",
      "r823",
      "r824",
      "r825",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r833",
      "r837",
      "r838",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r858",
      "r1024"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Interim Consolidated Statement of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Interim Consolidated Statements of Financial Position"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "presentation": [
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Axis]",
        "documentation": "Information by continuing and discontinuing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentation",
      "http://www.floragrowth.com/role/CommitmentsAndContingencies",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties",
      "http://www.floragrowth.com/role/FinancialInstruments",
      "http://www.floragrowth.com/role/FinancialInstrumentsTables",
      "http://www.floragrowth.com/role/IncomeTaxes",
      "http://www.floragrowth.com/role/IncomeTaxesDetails2",
      "http://www.floragrowth.com/role/IncomeTaxesTables",
      "http://www.floragrowth.com/role/NatureOfOperations",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipment",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables",
      "http://www.floragrowth.com/role/RelatedPartyDisclosures",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresTables",
      "http://www.floragrowth.com/role/SignificantAccountingPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesTables",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivable",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r341",
      "r700",
      "r773",
      "r791",
      "r803",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r812",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r822",
      "r823",
      "r824",
      "r825",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r833",
      "r837",
      "r838",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r858",
      "r1024"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, Forfeited",
        "terseLabel": "Options expired/cancelled",
        "documentation": "Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Options issued",
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued",
        "terseLabel": "Gross proceeds",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Stock issued during period, acquisitions (shares)",
        "label": "Common shares issued for business combinations shares",
        "terseLabel": "Common shares issued for business combinations, shares",
        "verboseLabel": "Common share issued for acquisition",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215",
      "r778",
      "r858",
      "r955"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Stock issued during period, other (shares)",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock cancelled, shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Restricted stock cancelled",
        "verboseLabel": "Number of restricted shares forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/LossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock awards",
        "terseLabel": "Restricted units granted, shares",
        "verboseLabel": "Restricted Stock Options",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares in purchase consideration",
        "verboseLabel": "Share-based compensation, shares issued",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Options exercised shares",
        "verboseLabel": "Number of stock option exercise",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215",
      "r539"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Common shares issued for business combinations, amount",
        "verboseLabel": "Stock issued during period, acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r51",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock issued value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215",
      "r789",
      "r858",
      "r955",
      "r1031"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Stock issued during period, other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock cancelled, amount",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Restricted units granted, amount",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r166",
      "r167",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Options exercised, amount",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r51",
      "r215"
     ]
    },
    "flgc_StockOptionDateOfExpiry": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "StockOptionDateOfExpiry",
     "presentation": [
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Date Of Expiry",
        "verboseLabel": "Date of expiry"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Related To Options Granted",
        "terseLabel": "Expense (benefit) related to options granted",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "flgc_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetails",
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options [Member]",
        "verboseLabel": "Stock options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share repurchase, shares",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchased (shares)",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215",
      "r781",
      "r858",
      "r956"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share repurchase, amount",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stock repurchased",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166",
      "r167",
      "r215",
      "r789",
      "r858",
      "r956",
      "r1031"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Stockholders' Equity Attributable to Parent]",
        "totalLabel": "Total Flora Growth Corp. shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r170",
      "r171",
      "r197",
      "r814",
      "r832",
      "r859",
      "r860",
      "r1018",
      "r1032",
      "r1076",
      "r1089",
      "r1159",
      "r1193"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, amount",
        "periodStartLabel": "Balance, amount",
        "label": "[Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest]",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r121",
      "r263",
      "r264",
      "r297",
      "r316",
      "r317",
      "r318",
      "r320",
      "r326",
      "r412",
      "r413",
      "r517",
      "r563",
      "r564",
      "r565",
      "r587",
      "r588",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r629",
      "r630",
      "r635",
      "r652",
      "r768",
      "r769",
      "r787",
      "r814",
      "r832",
      "r859",
      "r860",
      "r957",
      "r1031",
      "r1076",
      "r1089",
      "r1159",
      "r1193"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital",
        "terseLabel": "SHARE CAPITAL [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r310",
      "r500",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r517",
      "r618",
      "r861",
      "r864",
      "r958"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "verboseLabel": "Share capital [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r862"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.floragrowth.com/role/LeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sublease Income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r1017"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEvents",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r662"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r662"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEvents",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r662"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r662"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r662"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r663"
     ]
    },
    "flgc_SubsidiaryEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryEightMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary eight [member]",
        "verboseLabel": "Subsidiary 8 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryEighteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary eighteen [member]",
        "verboseLabel": "Subsidiary 18 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryElevenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary eleven [member]",
        "verboseLabel": "Subsidiary 11 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryFifteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary fifteen [member]",
        "verboseLabel": "Subsidiary 15 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryFiveMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary five [member]",
        "verboseLabel": "Subsidiary 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryFourMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary four [member]",
        "verboseLabel": "Subsidiary 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryFourteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary fourteen [member]",
        "verboseLabel": "Subsidiary 14 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryNineMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary nine [member]",
        "verboseLabel": "Subsidiary 9 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryNineteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary nineteen [member]",
        "verboseLabel": "Subsidiary 19 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryOneMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary one [member]",
        "verboseLabel": "Subsidiary 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiarySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiarySevenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary seven [member]",
        "verboseLabel": "Subsidiary 7 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiarySeventeenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiarySeventeenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary seventeen [member]",
        "verboseLabel": "Subsidiary 17 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiarySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiarySixMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary six [member]",
        "verboseLabel": "Subsidiary 6 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiarySixteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiarySixteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary sixteen [member]",
        "verboseLabel": "Subsidiary 16 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary ten [member]",
        "verboseLabel": "Subsidiary 10 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryThirteenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary thirteen [member]",
        "verboseLabel": "Subsidiary 13 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryThirtyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryThirtyFiveMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary thirty five [member]",
        "verboseLabel": "Subsidiary 35 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryThirtyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryThirtyFourMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary thirty four [member]",
        "verboseLabel": "Subsidiary 34 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryThirtyMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary thirty [member]",
        "verboseLabel": "Subsidiary 30 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryThirtyOneMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary thirty one [member]",
        "verboseLabel": "Subsidiary 31 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryThirtyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryThirtyThreeMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary thirty three [member]",
        "verboseLabel": "Subsidiary 33 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryThirtyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryThirtyTwoMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary thirty two [member]",
        "verboseLabel": "Subsidiary 32 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryThreeMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary three [member]",
        "verboseLabel": "Subsidiary 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwelveMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twelve [member]",
        "verboseLabel": "Subsidiary 12 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentyEightMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty eight [member]",
        "verboseLabel": "Subsidiary 28 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentyFiveMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty five [member]",
        "verboseLabel": "Subsidiary 25 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentyFourMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty four [member]",
        "verboseLabel": "Subsidiary 24 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentyMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty [member]",
        "verboseLabel": "Subsidiary 20 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentyNineMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty nine [member]",
        "verboseLabel": "Subsidiary 29 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentyOneMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty one [member]",
        "verboseLabel": "Subsidiary 21 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentySevenMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty seven [member]",
        "verboseLabel": "Subsidiary 27 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentySixMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty six [member]",
        "verboseLabel": "Subsidiary 26 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentyThreeMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty three [member]",
        "verboseLabel": "Subsidiary 23 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwentyTwoMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary twenty two [member]",
        "verboseLabel": "Subsidiary 22 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SubsidiaryTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SubsidiaryTwoMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary two [member]",
        "verboseLabel": "Subsidiary 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_SupplierRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "SupplierRelationshipsMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for supplier relationships.",
        "label": "Supplier relationships [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment of property plant and equipment",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r205"
     ]
    },
    "flgc_TerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TerminationBenefitsMember",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetails",
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Benefits",
        "terseLabel": "Termination Benefits [Member]",
        "verboseLabel": "Termination Benefits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_ThresholdLimitOfEstimateOfLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "ThresholdLimitOfEstimateOfLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold Limit Of Estimate Of Loss",
        "terseLabel": "Threshold limit of estimate of loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Write-offs charges against allowance",
        "documentation": "Amount of decrease in the allowance for uncollectible accounts, for time sharing transactions, from direct write-offs charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1168"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetailsNarrative",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TotalAmountClaimedUnderIndemnificationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TotalAmountClaimedUnderIndemnificationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total amount claimed under the indemnification agreement.",
        "label": "Total Amount Claimed Under Indemnification Agreement",
        "verboseLabel": "Amount claimed under the indemnification agreement"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TotalAmountPayableInViolationOfStopSaleOrders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TotalAmountPayableInViolationOfStopSaleOrders",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of total amount payable in violation of stop sale orders.",
        "label": "Total Amount Payable In Violation Of Stop Sale Orders"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TradeAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TradeAccountsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of trade accounts receivable.",
        "label": "Trade Accounts Receivable",
        "terseLabel": "Total trade receivables",
        "totalLabel": "Financing Receivable, before Allowance for Credit Loss, Total",
        "verboseLabel": "Trade accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Receivables [Abstract]",
        "verboseLabel": "Trade and Amount Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TrademarksAndBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TrademarksAndBrandsMember",
     "presentation": [
      "http://www.floragrowth.com/role/DummyDetails",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks and brands [Member]",
        "terseLabel": "Trademarks and Brands [Member]",
        "verboseLabel": "Trademarks and brands [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksMember",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "flgc_TradenamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TradenamesMember",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative",
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tradenames [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.floragrowth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2",
      "http://www.floragrowth.com/role/SHAREBASEDCOMPENSATIONShareOptionsOutstandingAndExercisable",
      "http://www.floragrowth.com/role/SegmentDetails",
      "http://www.floragrowth.com/role/SegmentedInformationDetails",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails",
      "http://www.floragrowth.com/role/ShareBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r496",
      "r513",
      "r617",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r741",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Travel expenses",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "flgc_TruhcHoldingGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TruhcHoldingGmbhMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents about TruHC Holding GmbH.",
        "label": "TruHC Holding GmbH [Member]",
        "terseLabel": "TruHC Holding GmbH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TruhcPharmaGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TruhcPharmaGmbhMember",
     "presentation": [
      "http://www.floragrowth.com/role/BasisOfPresentation",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/CommitmentsAndContingencies",
      "http://www.floragrowth.com/role/CondensedInterimConsolidatedStatementsOfFinancialPosition",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfCashFlows",
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss",
      "http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties",
      "http://www.floragrowth.com/role/DEBT",
      "http://www.floragrowth.com/role/DebtDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstruments",
      "http://www.floragrowth.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative",
      "http://www.floragrowth.com/role/FinancialInstrumentsTables",
      "http://www.floragrowth.com/role/IncomeTaxes",
      "http://www.floragrowth.com/role/IncomeTaxesDetails2",
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative",
      "http://www.floragrowth.com/role/IncomeTaxesTables",
      "http://www.floragrowth.com/role/LEASES",
      "http://www.floragrowth.com/role/LEASESNarrativeDetails",
      "http://www.floragrowth.com/role/LeasesDetails",
      "http://www.floragrowth.com/role/LeasesDetails1",
      "http://www.floragrowth.com/role/LeasesTables",
      "http://www.floragrowth.com/role/NatureOfOperations",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipment",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetailsNarrative",
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentTables",
      "http://www.floragrowth.com/role/RelatedPartyDisclosures",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetails",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresDetailsNarrative",
      "http://www.floragrowth.com/role/RelatedPartyDisclosuresTables",
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/ShareCapital",
      "http://www.floragrowth.com/role/SignificantAccountingPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesTables",
      "http://www.floragrowth.com/role/SubsequentEvents",
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative",
      "http://www.floragrowth.com/role/TRADEANDAMOUNTSRECEIVABLENarrativeDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivable",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails",
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about TruHC Pharma GmbH.",
        "label": "TruHC Pharma GmbH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TwoThousandTwentyThreeAnnualImpairmentTestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TwoThousandTwentyThreeAnnualImpairmentTestMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Annual Impairment Test [Member]",
        "terseLabel": "2023 Annual Impairment Test [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2023 Other Long-Lived Asset Impairment Test",
        "label": "Two Thousand Twenty Three Other Longlived Asset Impairment Test [Member]",
        "verboseLabel": "December 31, 2023 Other Long-Lived Asset Impairment Test [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Annual Goodwill Impairment Test Of Justcbd [Member]",
        "verboseLabel": "December 31, 2022 Annual Goodwill Impairment Test of JustCBD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Annual Goodwill Impairment Test Of Vessel [Member]",
        "verboseLabel": "December 31, 2022 Annual Goodwill Impairment Test of Vessel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TwoThousandTwentyTwoImpairmentTestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TwoThousandTwentyTwoImpairmentTestMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Impairment Test [Member]",
        "terseLabel": "2022 Annual Impairment Test [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Other Longlived Asset Impairment Tests [Member]",
        "verboseLabel": "December 31, 2022 Other Long-Lived Asset Impairment Tests [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_TwoThousandTwentyTwoPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "TwoThousandTwentyTwoPlanMember",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Plan [Member]",
        "verboseLabel": "2022 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails1",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSDetails2",
      "http://www.floragrowth.com/role/ASSETSHELDFORSALEANDDISCONTINUEDOPERATIONSNarrativeDetails",
      "http://www.floragrowth.com/role/BasisOfPresentationDetailsNarrative",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.floragrowth.com/role/SegmentedInformationDetails1",
      "http://www.floragrowth.com/role/SegmentedInformationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_USFederalIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "USFederalIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. federal Income Tax Authority [Member]",
        "terseLabel": "U.S. federal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_USStateIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "USStateIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U S State Income Tax Authority [Member]",
        "terseLabel": "U.S. state [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnderwritingCommitments": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnderwritingCommitments",
     "presentation": [
      "http://www.floragrowth.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Commitments",
        "terseLabel": "Underwriting commitments",
        "documentation": "Disclose the effect on the financial statements of underwriting commitments open at year-end and subsequently settled."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "flgc_UnitedKingdomRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "UnitedKingdomRevenueAgencyMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom Revenue Agency [Member]",
        "verboseLabel": "United Kingdom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_UnitedStatesRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "UnitedStatesRevenueAgencyMember",
     "presentation": [
      "http://www.floragrowth.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States Revenue Agency [Member]",
        "verboseLabel": "United States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_UnrealizedLossesOnSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "UnrealizedLossesOnSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/AssetAcquisitionsAndBusinessCombinationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized losses on securities",
        "verboseLabel": "Unrealized loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnusualRisksAndUncertaintiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnusualRisksAndUncertaintiesTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/CriticalJudgmentsAndEstimationUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Critical Judgments And Estimation Uncertainties",
        "terseLabel": "CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES [Text Block]",
        "documentation": "Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValueAddedTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValueAddedTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.floragrowth.com/role/TradeAndAmountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Added Tax Receivable",
        "terseLabel": "HST/VAT receivable",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.floragrowth.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.floragrowth.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicle [Member]",
        "terseLabel": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "flgc_VesselAssetGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "VesselAssetGroupMember",
     "presentation": [
      "http://www.floragrowth.com/role/ImpairmentOfAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for vessel asset group.",
        "label": "Vessel Asset Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_VesselMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "VesselMember",
     "presentation": [
      "http://www.floragrowth.com/role/IntangibleAssetsAndGoodwillDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vessel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_VesselOwnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "VesselOwnersMember",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vessel Owners [Member]",
        "verboseLabel": "Vessel owners [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarehousingAndOfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarehousingAndOfficeSpaceMember",
     "presentation": [
      "http://www.floragrowth.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warehousing And Office Space [Member]",
        "label": "Warehousing and office space [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantAmendedExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantAmendedExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant amended exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantExercisePricePriorToAmendment": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantExercisePricePriorToAmendment",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price prior to amendment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.floragrowth.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1022",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "flgc_WarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsCadOnePointZeroZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsCadOnePointZeroZeroMember",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Warrants CAD 1.00.",
        "label": "Warrants Cad One Point Zero Zero [Member]",
        "verboseLabel": "Warrants CAD 1.00 exercise price [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsCadZeroPointThreeZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsCadZeroPointThreeZeroMember",
     "presentation": [
      "http://www.floragrowth.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Warrants CAD 0.30.",
        "label": "Warrants Cad Zero Point Three Zero [Member]",
        "verboseLabel": "Warrants CAD 0.30 exercise price [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsDateOfExpiry": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsDateOfExpiry",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Date of expiry",
        "terseLabel": "Date of expiry",
        "verboseLabel": "Date of expiry"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsDisclosureTextBlock",
     "presentation": [
      "http://www.floragrowth.com/role/WARRANTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Disclosure [Text Block]",
        "terseLabel": "WARRANTS [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsExercisedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsExercisedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised, amount"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsExercisedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsExercisedShares",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsExpiredOrCancelledAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsExpiredOrCancelledAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued during period warrants expired.",
        "label": "Warrants Expired Or Cancelled Amount",
        "terseLabel": "Warrants expired/cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsFiveMember",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Five [Member]",
        "verboseLabel": "September 21, 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsFourMember",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Four [Member]",
        "terseLabel": "September 21, 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsIssuedDuringPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsIssuedDuringPeriodExercisePrice",
     "presentation": [
      "http://www.floragrowth.com/role/SHARECAPITALDetailsNarrative1",
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued during period, exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails",
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsOneMember",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants One [Member]",
        "terseLabel": "November 18, 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsRemainingLifeInYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsRemainingLifeInYears",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Remaining Life In Years",
        "terseLabel": "Remaining life in years"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsSixMember",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Six [Member]",
        "verboseLabel": "March 21, 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsTable",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsThreeMember",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Three [Member]",
        "verboseLabel": "December 8, 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WarrantsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WarrantsTwoMember",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Two [Member]",
        "verboseLabel": "November 18, 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WeightedAverageExercisePriceOfWarrantsCancelled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WeightedAverageExercisePriceOfWarrantsCancelled",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Of Warrants Cancelled",
        "verboseLabel": "Weighted average exercise price, Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WeightedAverageExercisePriceOfWarrantsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WeightedAverageExercisePriceOfWarrantsExercised",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Of Warrants Exercised",
        "verboseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WeightedAverageExercisePriceOfWarrantsIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WeightedAverageExercisePriceOfWarrantsIssued",
     "presentation": [
      "http://www.floragrowth.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Of Warrants Issued",
        "verboseLabel": "Weighted average exercise price, Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r336"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.floragrowth.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r336"
     ]
    },
    "flgc_WritedownsReversalsOfInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WritedownsReversalsOfInventories",
     "crdr": "debit",
     "presentation": [
      "http://www.floragrowth.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Writedowns reversals of inventories",
        "verboseLabel": "Write-downs to cost of sales for impairment of inventory"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_WrongfullyTransferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.floragrowth.com/20240331",
     "localname": "WrongfullyTransferredShares",
     "presentation": [
      "http://www.floragrowth.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of wrongfully transferred shares.",
        "label": "Wrongfully transferred shares"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "c(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "b",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "940",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481804/940-20-50-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8B"
  },
  "r246": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//840/tableOfContent"
  },
  "r249": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1"
  },
  "r250": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "80",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//321/tableOfContent"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//325/tableOfContent"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>132
<FILENAME>0001062993-24-012882-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062993-24-012882-xbrl.zip
M4$L#!!0    ( #F U5A@^U? /B\  *EG @ 1    9FQG8RTR,#(T,#,S,2YX
M<V3M?5MWVSBR[OO^%3IY.3-K;;?CI'NFTZM[]I)EV5&/;6DD.3US7O:"24CB
M#D5H -*V\NL/"B3%"RX$)26&LOG0O6*A %;5ATNA4"C\^E\OZ[#WA"D+2/3;
MFXL?WK[IX<@C?A M?WN3Q(NSG]_\U]_^XU?FK? :]3AQQ'Y9A$OOMS>K.-[\
M<G[^_/S\PR(D%"TI>8Y7/WAD??[N[;L?W[Y_?_$FK5"A?7[_ Z%+3O+VXOR?
M=[<ST7!&^$L81)\KU"^/-,SIWY]#\2-B.">'4C_>52@3_W2>%NY(0T.[_[SE
M#9<;#0S$0<1B%'D%$Q+3F8@7'SY\.!>E.6F$ERC&OK;Q#^>4A/@\(\MK4;S0
MUOC+.2_-"7V\H=AK^ *BGOC( GGQ&7[9A"A",:';:_[WKJ&8GL7;#6;J=GCQ
M.10#SN_.WKX_VR'-60BJ<##L_; D3^>\ ,C?YX0>2:*8;M7$66&U0D(I[YFZ
M&EEII0I^\59J<BBID$8H\)B:5A15B%G@J4EY094PWE -)2^ID":LIO$%8H]"
MVWE)M64:RY3\QSJ1KM%=455A4;)^IQI.[]YRE<4X8L%CB,^ #%,4\RF#G;V#
M*2.K[OD:=7M^7=@E0ANEK%"0$<>(+G%\C]:8;9"'+:<<'.(UCN)K0M=7>(&2
MD&OJWPD*@T7 Q]3?_J/7^_7_G)WU1O?SX<WHG[W';6_XY>R?E]/;WMF9* W6
M&T+C7J3\KFXN2"?(6^()M1BJP%]G>;TS^.GLXAT?03^\,/_->5L&BAFQ'0-Y
MO98,J&=8RT_G%>";/^TC;GUZM/EN2&FE%GS\ PA\\9>#6+ 4N_3Y^.!/FZ=N
M6W;*K0R+1EIRIYG<54PP'3G\XPS^T?J#U07"ZJ/E*OD?>WZ\NM;8?;U<9_?7
M?M\O+5Y6W][1BW_M]\WR(FCUT:)"^L_]/ELLJ%8?S<GA'WM^L%B7[;Z8TXM_
M67]3M[@;OZE<)<]Q&+-=,^T9*&P&NV_G].EWP8S8YY-[""U_N)W$+:P9'4.U
M&=G<3/MAO3.2[$9U1@[_V*O?E0RM [H=_&+]^>9=A)7J%37%WZS$ XHB$HM&
MX$_X8;,)H@5)_^)_@P7T"RR$<UZS!_]XF(Z,)J98-0>$;Y;?] )NZ:;_S!O,
MF_3Q(H@"\>&W?(_;.^M=$2\!BY3_4U3Y];Q.6&LB8=@?1W\3_^8[.L;K"DE@
MEYI5SD@,%8OF6U7S4.@EH?ESV8^Y\@Y7:>3S483]411C&JSYWXR$@0_FVHQ+
M+LQY-EY<!Q&WF0,43@@3@N4P[%O=#-T[CM>NOL"N:+<H8#VRZ.V:[N5M=Q@?
M">,)XI92O,)QP+D^$/!J6V;TWQ^"?N]/E4_]N>L-4F]0(G9+&.M'_H"LN1)6
ML+(^8?AMAWN[6F:$?[1'&%KKH<CO5;XA?NZ@/0Q:]?@^H DSZ#\=!?1N?._1
M"<:+64R\SRL2^IBRX;^3(-X: %>2F\']BQ6X@.ULQ?'+FOZ_O;3QWI^N>&M>
M !OS#M$:H@\12OR Z]%J\>78E12<JK=0;F7L9'/[5VS?W&?^6NLS.T9Z.TYZ
M&2N']*=NQMAKQA@@MKH.R;/) BA3F;'^V7I^@!9[HLD.J"I0]RA.*!XOQIO<
MV9%"H_C=#,8'V!D'S L)XQ7Y'_?]^<-TV!M?]\:3X;0_'XWO9YWVJ]J_1"S@
MEM"D)&FJ?E6!4?\7;^OZO^S/1C-0_V0ZG WOYP*!#H J +-@&05\5D=1W/?$
M*4(0+2=\$N'S?#82S"1F4"[JH,Q&-_>CZ]&@?S_O]0>#\</]?'1_TYN,;T>#
MT; ;'_5EA 9B??T]\9?"D.?[A2&+@[7@XB'R,(U1P!')P6I3P0S=NSIT@^EH
MSH&[[?W^<'5SQP?4K->_O^H-9_/1G1A;O8?[P7 Z[X\XIAV4=2C[L]EP/OLX
MO+VZ'D]G_=LA5][5:#88PPAX&%X5BT2*9 MZ,Y#OZT"F+?>@Z1YONP>-"RC+
MS7>+EA;).44^YN.JOX;)D$VQAX,G]!CB%#A]L1FG'^LXS:?]JQ28_AU,E+/>
M=#@8CC[U+V^''2953$;WG_B,-)[^*\6@^-.L\Y_J.M]5[!1<5?"$$FX)Q]M)
M"'8 7U3XGG #*TRJ<'VQ&8"_U &83&'BF?_K/WN36V$DP!+SCX?1!%:<#A2Y
MU\_F8BTN^GW^@UGQ?U7U_*QJI^;:TLT8YK8O[]+I<0@859<)"R+,V("L'X.H
MO'.TIC8#]+-RV>9&,Q\,LY%8F,7@N'R8C>Z'LUEO,+Z['-UW2[9RH'#QHB7$
M-0AT )(;0OSG(,Q\]"8",T[2OI^;O_W[F]$E&%6II04PW8S'5W^,;F\[9&K(
MW$WZHRE,.^/K5%T9(/+O1AS>2?O_H@5P J1M=-JO:O]J>#E/]2W^9=:PM)F'
M.IU&JQKE^[39,.O#V;_-6I7VV6FM3J\U1Q6<2 S0)HCS8]7*+V8=2UO@V<?^
M=-@;]">C>;^;DE6JOD0,BZ-I'+&27U939E:_M+--U7_)^_D5F"V3X?VL\\XJ
MD/BC/YWV=\;][B^SMJ4];5ZOTVY5NU,<PDG9!/%]:Z&PS(K7%9IU+VUGI\/;
M_ISW\DF?[VF%@^UV/'N8=O.[?&"Z7@=Q[K(>$''*@*/B&,)$8 9%VNKR*>=N
M-"]<V*G3\V9XWQU!J+9._)]XCEYR(,H_F!4O;6%']USUP]Z\_\].SY+A")%?
MF(H%-C,?R[^8-2UM0ODL,^M-AM-TJ>UT7=7U+L)U%+&8BF#VK',K2XRZ?R]M
M/*]']WT^E?1O>7^?S:</Q40S'<W^WKOKW_=OAIT[4[$&I,;\'8K0$A>^9?EG
M,R#2/C6S\SO-ZTU^+$Z+(4IM0>BZ;/"K2LSZEW:TLZ$X+^9FT.C^>CR]ZVQ]
M%03)(\/_3KB4PZ=B/I)^-:M>WN@^7,Z&_W@ )]CP4^?;;QD TR(0QBX@YKV\
M%38'Q/3^E#?<A5@VQX[-X9B=:2/(LF(S0M+V61E'UOM3VEB'2IOQ5,;'AM",
ME+39;AQ+'68'AB:5 6Q=RXRFM$MO&Z;4P=LV7JF,9A.1&3QIIV^*7>J TKI:
MP,8C=%L&IOZC&0C%:706T-1IO6UD4QF%)B(C*C]*+@)CE%.'E&%\L-0%7!\A
MU9_-:$C^@5+H4Z?[ V.@*A9"NSIFU"2O0IMXJ [6]H%1U2'61&8&3_)+F(.D
M.KATAP08L>HVJO*+&03)]Y!&FG3*;A4'4=G#FBC,8$AN!EU,1 >/+C@"48IJ
MID#M-S,$DO\@#Y3H5-XN8J*,@)G$#(CD M!&3W0(M0^C**/43&9&2MKO&T,J
M.K2:8RNJUE;]9S,:BDU_$6?1*=\BX*)B4<F_&]7_D[2[KP9?= "TB,(H V$H
M-P,B;?"M(S(ZK%H$"%0L87VY&2N[8($.%_M#T"L<HR!D]V *Q\$3UAZ'2H1F
MI*0]O.9@=-?>GR%CD/A$!YLU;$UH-8 D[?$U(,$S)7X28D@.Q))'%O@!HA!E
MT&&VU\FV>M"UJV)&5G88-)UV=P/Q.*#:8]D 8?N A?(P1<+SVL-I-A?L][AB
M%DG8"SG"W;@]#.(+>XPO&D"6G!BM0 YVCO8.[SWQMH]+V4V0E8%^0'USSU#?
MZ&\5X=)-Z<?$?T_8[="6G#+MT2Y/#&OT/X3VO!!F!59:#B"A;QB@QR ,(*E7
M;X5#O\>W8#V&PJZ7'+&77.S931K6B[](WJ/#^DD(Z9P7E*Q[/F]4.'83OG:0
M71K+KD\<KT^\V[-/O&OH$Y(#Z[ ^P0JS)N\(T5+,'($(G8&_@ABON[YA"**$
M@$:N\2R<L8AF5!L1]N3FGB"YQ\R!E9U]<$ X;!7 )BHS;I*SS(Q;>;3&\&4Q
M.DF\PK1'=Y_NQN?^J%[8P=JT6K=*TEC;OR]AGBT 3C>8K(1O!^_>\+ZS@[=I
MX96<;"W@#4/R#&^@"NL;OVRP!YMVCV(_B(59UHU?F]AWM2=57VP&5'*YE>+A
MN\6R/2QJ-!I 4.::S$"H.K^R9CM VM]64(\;>W(SA)+OJN$&0S>V#H?2#L$&
MX"0W5 -PY?&XR3[]GSUX53D6-BG./]\!:W-/1;^:Z0B,</Y5SG)9OKO2C;I]
MP-%AT@"%^1I1?5W+FN9F/\<GB+LE[O"K1NJQM7=M,]H'7C_J1N;1<;_8"^^&
M#?Y?U:]E6..L.;(I']@ JWQ36#^YZ3K&/I?4=.NK?05S=Y#\/4T7U[J!?@P\
M;6%L0$_QO(<9/6,H1H>H/H]XLEY770257\PH*7PT]BBA-:%Q\$5(VP%TP)"[
ML!US32NHPMMC#R?>O556!U>X5"/6S:N'@/S.%N0&1_E?%:E=[4%>9M_JH-1#
MN=Z@@*;/P:88:2R=9CHSD/+=,<6S&9U98[4(XD>-%U998L3E9\G1 X]M=#C8
M/\&ACLO0E)FQD#P]>>*$#@W;E!55$"H_F76O>1ZE%O0F&NQ L /A0H%"@U'W
ML^064<&PAC>STS!4_E<1:2;@Z7P==K<5X,IPEK"ZOF3DMQ2,)&8<-4^QY!FR
MNQEM[[PPFAM@=K1FT%KDBNGP.Q _"]@:T))O>6G1J@3IQL3[S"=-X:P&84((
M)'I&U.^@-,^60K-EQ0KTQJDFQTG,^&;7Y^L0')Z_8.H%K'BL^9 &S-U O@>V
M1S<@Q<?3T_?B\UVOV&^ O[,8X0W>CY\E[X<=ML\X6*X@*! ]<=-HB7M!M$FR
M.SR(L62=HO[G7@?M7M!>6$#;9"!)_A [:+GF8QJ(B,]T!".8N3M#MSE]F]IN
MTI8:T?L@>4V*E&Z=9=0:$R44#0A(OI("@<I4F#5:7N$Z8&R!N5 BTS"U?9!<
M*?;0]!ZW/1_%Z1'-RR;H0G3;9TE43W2VQ&9H)?>,(7-B-Q$>"J$-<@V 27X8
M V#EP?D9;WOKW4-HO0VFC$01#GM>R=3I@-TG/Z9Z?+:I8(9<\N(TY,SLQNDQ
MX+1%L0$\R:G3 %XMC/XI8&(_#SL]+_]ZW+G$VV9)U87[Z0G,L"IB5<J94[LA
MN \Z.E :L#"^%EP=4;#8D4C$T\-]VA5X4N!KO1B]%,.M ZT%:!<ZU)IV%>;D
MPW7<Z(9S$U?P@K\[J%I ]4X'E=EM>?%6<7E(-\)X14PA2KT$E#KC4 >=589I
M]<IEI#"#*0>EU+).=XO77@AI@6G 0PY4J>%1B5KF)N"9'X0)X--C\)5N(+7+
M%,[M^&G /A>O@JM'V'Y5S5!+WI86^<6[47E<N-NCW "NM$UO 6[U^L@N$7H/
M/9(D%G;J(F>4E^\X%4LJ+PVRVV(B5U=V%-AUDB-TDHOVO<1L]EZ\E1P">W83
M31I''T=D#5<7A0D&D2 X6$8]+^%&F7!;=#VCU5L%FN@L&TIS/Y##/-3O%W3S
M_D' ->+5 ),<L:&&J3PT=SDS>RS]+BM/ZAV.33BJH+-#2P["L$!+),LKI[KL
M4EKN/=PN&L=;P_IX(?D:+"#T X:62XJ7NPN $8Y%(F,&!]!+3)84;5:!U^/[
M)=0ANP^R[QN1?=^ K.1X4"/;!*TQN5 I_65(HN49Y+SW<UNIZPIMND+RR+A:
MN93#)WU"HD8J<Y>0'W%ZN)P-__$ UN[PT__6W$3POT?$\!0O>B_BEYC3_/:&
M!>L-Q!^GOZTH7OSV9A$NO;-W;]_]^/;]^XO_YJ+^\+(.<Q)HOH+TRR,-?R!T
M>?[N[=OW*<YU[60?SIM U)-:>7XOVKCX\.'#N: ZS\8DWUZ<Y\R_.3^64!R&
MMD)5D7-/I! ]MA6)5\&AF]+P#M]6FMH8.;9,OYZCS09L;OB3_Q%%).WAXF\<
MID$P$5KS;_0'_;LD##&]P^M'3--Y#03\;ZDD58@?TS/X%_O%)VL41"-N+L(@
M?M-#CRRFR(M_>Q/3!%3&!0]^X4P&Q)^G=9-T9_!&/)X5!W$"?]U0DFQ^>Y.2
M@_7YIA<%80C1^EE3YRK&BY=F*(GX/SU1RNY)_"\<]WVR@2@C$@;>=HY?XLN0
M>)_+TNU5O:Z"."]2:6&!0O8-U+!+X31>W),(PB3@%@P7;,0-%0BP3K/Z5F2W
MKI,*G/*T)MRN1'3[363-FGI$(20'_NU-FA!X7Q7(G=N^CFO=OI%Q<?K"V@F;
MURGCG9ZOO%[/]GW!,@ION?T;<D-ID\28R5":Z>SA^\9235#@RT-367SP* 2O
M.8*6OMX@!,:![^T :/FZX:=]ZA,*$UR7T$!X$C,.7@9L@#9!C,(!H1NY3VH(
M')M+^,Y2_-U_"2KS1?7WRIP04Y@UCLFP'__B!_QK$'LT:LWZE="@BOF\Q#&=
MBR$]05N@@Z=*R2*(V36AQ<B7)P7[.G5AN1@>__CK37?IBP(9[Q-,/P4D-7S'
MBUE,-C/$):(^IDR2UZ[2*4R-492@,,\45:0>FO-U=[RX7J[DZ<.VAF-]V\CV
M[PF+!Y=7+86MU7)M-3?R/N'KVAIYF'^ [_@4ELL^M5W3@' N?L2AS^<C&)A\
M P5W.\8+,,0(X_)!N]SJ'(A#V,J\UKZN*\/=QX^:T9Z]05WL+VN+JZ;<Q456
M8O4VB##4-LI3(OK*0K7HIA*7\R*9@5J,C.#KX[+:PB*=/.*VN-QA!'YC*-#[
M.2QHW7-J7&)$6;XUG:*X I1<=@RC9\]Y0<D]X6L61OX,>UE>I]O;@33Y&ZD<
MF^0ON4G]!9?<"+(T.@JW+)24S5OT".'TA&YG2%Z5#32."2.G:Y]BCRRCX OV
M1SXG#!8!RK.5]K,$ZOW(O\TBIK9]R)Z!_6QU%9G-;HMHJK).OOJG7%G8#7;\
MT90 +KAOIW+3U[X[K3.%(KBDU=Z74HXB'Z\CKJ?BN;O]]7_P=UU!PF#8'E4A
M+"9K3,5E<-X06P6;KZ=\Y;?^=RE\DM_NRW9:;(Y>OI*^U9]R1=W?:*:90LJJ
M\>*!9<1?2=?R9US1L[Y;#U"$?+2[AM=/XA7A!O!6,L2:"!TSDFO'&55!JB4.
MG;)EAQ1%('\_^WZ%?RV-.SM\B<DBLDJU+[8C=V]K/$!L->"+6.!G4=93'"<T
MPGY%-BV-,Z=KIOF!K>"UQB>^=L!-DWB *-WRGB4.""]J<AHI3V$R9*OKD#S?
M$1^''_EL7O-V:,H=\WA4N+PESR8A=L4.R@!G[C6^TY]<Z4@&ZV4@KL!Y\-[I
MA.)UD*RS>UO14EY9FVG=<G4,2 C6$HJR[%$0>!OX :)@"D%FFJPXM8)D>?>J
M[J8*IO@)1PGN0QX>A<UDHG)-H/4:TO*BD$/PQXKPG0*?QQ42F<A.0:3LTH"E
M9#5J]P0D46K&7F&X7L GI#F9KSC;$"K*:N(UT+ID!Y>X'?'-%88SR=+CME)0
MAFT%9RPNT]K1((N\H[&LX#K 8[@KLXL8L@194^ED@:[)8P>VII)[@$-:Z1W7
M4Y:P3[R35K=+#81NR;1!T5;L;VHBE'\_C:X8,1(&D![75RR-<J%K[IX2BYFU
MI1%@5WJ,'<^118AI\"A:0+R?5&<^J>Q$>M6.;29/9'*A4X,[2_,&#V:$P3I_
M@ELQ.LR$KMF,&;<[3ZY*E%*A>\.$86^%UP3VBG]'# E;?4&(KX*FD=8Q=,18
MND:>.#*^JDYB<IF=O_?;P )1,QX*?T_\99Z39KA[!_>!SQ0TYHH5IR4*G_8^
MM1WR=B=K<8'P"1=AHYES8T[*!EM99/LZKOB[#([3]$A] B\=0USX+CEQ/$FH
MMT(,5SS@%36TK'DRRN"SYS!][3F=366A90IG%G63=.D!/JN<X,M3KY',K5GW
M"GN"K_DSF:](PE#DSY]Y\9;_\! %\7BQP%3EN6U;T4VQRYQ*>VX3D3.]U6""
MJOB'?254Y.9!)1; @M89D?4#5"6%M/J8B!PRPJ^R#+X0<)#&7X0A>08-7!-Z
M19+'>)&$691X5;Q6]=Q?4R2!LGLJ)IEW)"<HWBCB'UP&N[@;DYPR[0D*; A1
MLJ ]08'%;*.?B2VH3U#HAXAB%$)HV0U?^!DD:,9L')5\]28EV-0^*:7H[&,]
MR4FLOSOFRR&"LF%E(G,%1J-EI1+@'C<+*6A.0L)HC>AG\QF_B<@Q)_D5IFEH
M:[K5AF MB'O?^1S28 7%^M.FFC,CU @L\VBP2>6!4$,8=! '515;3^20XZW"
MYO#%6W%;"-="O@PT[DJRP? 2[2>1:P \GN7WK&_@<<?*F=L^E5US;5=D*+R"
M.BG+%*["F$V+-R*AHTZ0&I&SL@3L\S7%N'S=M46GM*[N=+><P:WU.'B"&VV0
M-H@%VCE32>HJN H/B:+45>ZY??5[0@/F!Y[H2SHY9#I7)8+@B?I9@8[ )1E*
M=D*9\\K/S@WP<GX/OM,*$W@N6? ,AS$)]L=Y%GEAY:F7I@,:<<9F-.SJ[,6[
M1/X5?HRSG>M^*JJW\7UI"([TDE"D6XG\XM+/-:[.P$=J\/O276X^I!Z1@SJ9
MIJGO2U^W)%K.,5W#<-I/3=463L%O82];]H]H*;(1'-2;-$U]7[VI*N0NN8.<
M3>N(;7[//<YT['&\-EW1X%&Z("2<Q RN]*-P_Q53;N7[&JA<OC41QB;<*%NO
MDRA[CFYO=>F:.P6]4;")0G)'Z!+)Z:+4Q8XYKX>+!?9$N%P>FPJ;*<C5$$%$
M9+JQX!8?1(J%LQCQ;Q&Z?9A5R$M"'ZD]U_9RJ7?>^DJ-';DS7=RP!)DED=P[
M=N0.A<)DX;#8AXVS!QE)20S925!8=NA?AXD7IWZ1BK1[5#X)T'.YX"Q\'.VD
M4B?QLJ)V1FS]=+Z3 V:K)SX_0>B+-+(-1.[;0\.$DFK N[1JZ4GL5ZYO$68Y
M?(%KQ0Q/:.#A\:*(UO@#'I.JAGQ8T"H6G#0XYAO@IQ8O/6N["IX"'T=^'YX<
MAR40+1M.1UK7=&ZMS02X#198(5?Z<WFLY1]_=8Y3S0*#H^A?D,)5P;Z"QDE9
MTK5Z3BYQNIHK1)%)#ES8CSA^KE% Q4W1/-V%2 WLCR$-64+A,$,D#1Z(59J-
MHFH0&*QD)8&/T9@S"Z!AW=_)F1^LJ'10E+DV<>Q8% \ X?4F)%N,Q9WG?**7
MI\LVE9S!4+_"E\298CBU$P,5I.D_(^HS:3#;5G!&=IO^.U[DV*7L7R4P2">"
M&[7L)OJ3$/WFHV3*E7YSRW;CC(V?(TSE^TU2B6.,IQFD4)@N!),0^TO,+:P!
M"2%NCZ*0;WI+^YXQ+2[>J3=/1VO1_<W'3M01_Q)-4E>(?&G53&87E/!-^T*9
MS\B'>"1CHLF6]9P4F'?,-<YRB\ECV$SGZ(@N#2;]0Q-6U'4!7S^?YB[Q72D;
M]\7/;R=APJ[0EDT0BZ\2.2M9NVK.X<II;^%M\/I%IOQ!L=HT;$'NC"%@FF0I
MBP<A8:J+M:I"UV#C'-X2%.V<QFHAE"2.BJ*7P&'&Y]P:]E:J.4$N=.Q(ZSIX
M 0NJ=NY=^?4$C*604'2)4:)PT2K*'.M!@L':$S,:,314#@J4!M(KGT+5E#LH
MQ!W?W"O> U*4.<8\(? ZP"6&,Y>ERNK4$+@F!L7!,LJ/!]-SP\HTI2$X!=,C
M9=WBT8-&2M=6E)1?\XU%$Y%[\L2W*/$Q]579B-7%C@TD88($#-^$A/?-CQB%
M\8IW*%F8!D+'Q$HB<84$A6F<HK<=+W:)O+=EL1H([=P&WZ2WW? )F?J$3\X4
MLQL$R:#O<.3C+Q)6C91N@<797:.HG&==)9&&Q$51MN89SD3DV QW0WB/'Q#(
M<!?IW3E&*O?<./DCRGQ\Y$\HR>Z*BGA6].YOAG)!2C?5%&)62EV:_^!@Z0H"
MP>3CIG$2@^X@0+8LD6T-5Z S'$S=T&1#KHM7OLF DHB;?<IMB VQ6Q/G1[3>
MB"=N)S1XXHAE3R[=!NM E?/9CMPU$>F3R!(^0%&$'BLWDQ5EKO1)_70"C['_
M$<2K6T27N'(<DWT,SF/N469>\7H4A9<H^BSWUX-;<@QIDC ^U5SRB4:1]E=9
MZMBZ7^%1]R:)B<@Q0+8;"#+E(^*1]QI9$&6Q8Y 4-Y+'B^Q$13X4-1'9+>7?
M HXRE[G5H1&B*#X!STV9\=O @QN&3"-747QB<DT0A*7KQ-J5NK]Z5=BFA'\[
MWL(C9S$D]_YW$FQJ&00LZ4] \(B;F0B2UE6>0,PGC++(392G(*QX0'N1W8=3
M/]]M(CH%$0.X)C))'OG.6YLIV4CES!QDV  I!:CDW+2365GE^U" =(W,ODK%
M.'C=JV1*IB6;S4CEEO6I9-4.*R?AJ<7U9&^.7Y-22&7E581[$L'KJ!59]V[#
MF9%JFI#!NF:!5W,YY=>G_*HFFFB=D=@X-SWQ/PC=JO8D<IE#6Y&<N2PCB$@9
MRKB)-T-U&\%,Z Q*IGZ9B9">AF/_<CN+R08$&%._^B"G!:TKEE%#MV0QQN4'
M:Q0KB9[(-1^ 8!4,-T]D+H1 ]H4R(X32.;!/;;>&:GK=5'U^H2EWZ 2CX+!R
MDU8I0XVBWA'WNE=[5%DTN?%/[T62WQ,6IS[,V]#CF_F/P7(U)?#J<':X<(L>
M<<C+I)FC=4VW[-(2^[<#DW!%J7L"#"ZO1A%+(#H%9^_3*X.%+6B=%$XGB--,
M:VZE*4O=$N#O$7G^2)XEUFN_N\5T)3-;]5Z<7.2*V::?D 7/8[X-7DJ98N0B
M5\0Q6*&":7;'K:Q5N)6<5,I29Y9-HUA+%$*2LB166-7*4L?,:=,#**?YZDF)
M:SA3OR84=FSW))X@&@MCOT@I)V>%W*OV=Z85<#0=I)AR R>AF_0@DINO<XI\
M#*_%*$:SB<JY49WRJA7"T44\8"@2,5OYFS4JJ]Q(Y9A Y;N%K/]2"7A2%7YE
M5X,?_^(':WCU(4T+M(<05T*A6C'R8O=PF.(-V@H>T\/-B@]:1^",$6(P%3GK
M;$()I.BJBU3ZW1E)3!,QL%P</?.9MN\_0:WZL-$1N;+8F-!B;'>^XVW[GD<3
MD9@#+OSD]R_@4BP+Z\EPVU=U!G-K?5RA-=RXFY%DN8J%=Z_("3:A>!S!\[#S
M%9]MX.H 96EVI=F&&R9Z31W4Z(''CD?,0U:3*D\?":E"&8.#1""XY#LI?QS=
M)[ <*A[-.:01ATY@K<3(7T\0(Z4V-^Y3_>1FEUR"2;JNP1,)AKZ@IG;H[. .
M>:L@PG3+Y_SQ8L%-V5W0F60D6M Z9K,7&7L $_@PJP.F)W$*)1I 2@'.Q9=K
M3",$M^[&O&O!9;P9HFA  SB"0[\CN+-[Q2=CJCJ3/+ =MPS0._02K).UN)P!
M66,KP78[Z[DBO5T%5^8D@U67B9)-*WPV3=:)>)J4K[JJ1\0LZ4](<D*AZ?'B
M'L?PJD,0,RX<-*F0VD!["A+S$@^%,TR?@JK9+I6<@'&:>:2%>SKKCF6)5*4G
M@-$]_[_F*KA<Y-#"<H_BA%OKBU*(1N27[]TJXCU:U/G*KI<V@N)8_2QW63 ]
MS2ET03) FX]XO1D0:=U7E#EFJ8E S/2R)5C0<"]@0:A(<5N1PT#E"D;ZN2^+
M-K4-3JT+WJ:F0_O*C/=R'-SN!9++A/$=!6R9UH_<[*R?R[:O>@(KH$FHVHLL
MEJJ0:KF'?O6QLEW2QCDQO(76OJJ+<D,3 ^@38>I"!#]KB!@3Z1[F)'V21R6U
M9<43Z?&PN29A""9 YA,Q)'*UK5!?Q%X_"0CG_).X<2]Y":624UBOGH2U,'\F
M\Q5)&(K\^3,OWHXC_!#!)EISBZ9M1;<<"U4?[4/$5]5)R/F)@\5BP/^Q+DO:
M3.O2I)1Q.Z<!_YQ"C+R@S#,7!B\Q?76F/P4DFPB%8BO.9P.-2[LMB<M1I+TJ
M84-<ELW'7K!&X6N=I.3LYC>-LI4+^\.7#1BK"LGTI X.&:L7*VR('98-<J7T
MUY#2S=?=)+"OXLXAGXKG"K.9  UBJJNX(^;.3M[K%L]>M=WQ[V2OIF48 ;%D
ME.A)'/.%[!@5L^%N=E2)4J=P9C-@<%2-X;W=X(OX#'@MN%'OIT<P$80.,$Z)
M4G_]+F43O$2;[FUO^9X?!"JOE,=JT*'>3(,E9S4$EYW8VPJ7#Q,;7[E?6Q"[
MUL/!83$@ZPW%*XB<>Q+! 7E6Y:L M@<8PH_&41:+4\P^]U@<WF6YB2M;K.,V
M>Q)CZ8@2CQ?W0?B5M)FU?3(J+1Y*5EU&U).<C("C:$'H.ITE%<: EL2A.5+P
MF*E?GA15I6ZY&02+MR1:BG=MQ,Q=)(.:@[]++955%1<G_"KCTH"2BMUWD F^
MM5XP9:E;?7"" C^]AS0GZ5L?G_B^AI2ET),X,]GI 4H3QW$[\ H_X9!LL#_'
MWBHB(5G*";1MB!V#;_=T]'A1LOK*,NDHZH)L7OEUV JCRR7%2XX&;XI!O+V'
ML<^N*5D+Y]>B? BFD[55$RXK(_4A0<AED5K:0@'-U5P6>HH]2)TJ+B.(N0?L
M3HX@]N\0_8SC+ H@V_19]8C#FCR&LH[HZYFLBBS<_'/R5*8N=\PJF(2<11&0
MN%3%&ZN+'9N!^?X(1>02(V\E"Z H=(U])H+2LP"*G8NS[MANH*N<0V3LO5ZO
M(K",5U\!K8BB*G;%UC3LVZJN+-B8(U#:$U9XM?1'ZP>UXMYY.Q?G*2 )"[?I
M@I<Y[*L"JRG<\=R+$P5N71/R6>3KJW!?+W+HS"]C;IXE733PKR!Q2H["/,RG
MMN+L!VRH33TRS;[**>R2LKS3HVB&((6FCZF\ENEI'%O2X'HN7,8V3H):&@>G
MN(1Z*\2P+C944WX*_4[%N? XU]*9-A$Z(ZMI^3;*(/89UA)GU Z%$BCY%<?'
M?*<UY09%DVQ56N?VIBJ6R[O+>EY7VPJG*6BZ@98O7.U5^Q1,[TRNG5<@KJTG
MZO)3F):FB',V#3QXV7& 6 S1QA%A,X2C+]R,N0MH@-9C&@?R>Y#MJ[IE*4SA
M').-%Y7 '@;Q](7+3,RT>;@%Q)MC+)_ ']J08VZ9O<0YCE*^DXX2PAN<AVND
MTLR)=Y+K8'&4L5-KY^2U\B2?71_2R&D/G&N2R#O/0QHY?74<9]#4&CKQ47,?
M1(>/FG(CI]U-QD?0QOA[4<;L*$OO;+^5UUF%'&46D5HZ\6ED%KP<KI.BC1/O
M)L'+<3I)M9T3[R+S(VAD_OUH8Q4<QQZI-W3R>J'X\"6XTLII3R;S9QP>86-3
M;>;4.\FSG)?E@#8<ZR 8A4,&@0-I\*XLJ8; -3&627K9M@]'N.7X73F5OPWQ
M27B #7)($74VQ X=2TVQR'('^?2W<,(4$I9P?A17'AHI*U*]ZLV'*88QDEXI
M;@C_;28]Q@'4$4,Q=@S_@863W.]#S.82?TJ?F),"TRSIR^"]>H#:%$/_@=</
MQ3E17^2O4LR8!BK7UL(JKYGR%3.FB>PTYDJ5!(I9TD3FU/P8HR"<;9"'1]%=
M@-:!HA_J2!Q;N\D6A9!A1D3\0];Q*,&EB/\))7[B5:X=V5=Q[9A>G*.+FY42
M7G*18Y/%S%MA/P']9NGL(K\4BGN%(R+"C+$_RN^59HGX Y"+MZV*Z#IFHW5]
MO7X(6%VZ/+FZ_\#P(@EO@P6VUHQ%79<5  $6@7C*%# N4JUS'%6Y =I6=,?*
ML^)\7@O :5/I*XOJQ[^LMC!/)H]"N>V%WJ!HVU]ROB O%?)QWQ,18J6'2G22
MV]1TO).#"*QXMY=E:5FV%N.\16V7E7"- EI[OMY">(M:K83^MD.]<N>>)'$.
MY>YRQHAOM6B2#^OY"@=TD"6%3//8JR>_H[3K<F<904RZN&*@6>6>L$XS-A5=
M%AVR<H#-JD[69#%DVC7@LBKNT/^0M-^"5U5E"9;>6;30S$'MN:PHX;B;<2M8
MC.]T(V/35:SJN2QX<?.C;!7%)40MM-"^$9=5HG0T*>764+HL7*FO%AGN(C\U
MC3*3UP;RO=IQ6C'Y@Q1V7=Y$[K*8N0U8.E"SD-:BEM-"5WWA_34\@/,EOXS!
M/RZ;/39*.;Q5!Y6&N<GC#T+"5!E\E*5NN3U3%BL/QFK$4-*X*HQ!!I=9G_-I
M@P\8#?>U4M?\LCA-!4",/4E+XQH<FUB=@EZ$V1BSU^]1UU'ARZQ*IW%&JE,X
MC%,*H,O9:$/LC-#Z*]-*,:3S1R.50\>/,QS'89;B1S_E:&D<&W6@2_',+WC7
M<,32>1(LR?2!T<MM09*_Q A;J)W+DAM-R;J2I3J-"./FE0SQM_B:XMA3%+U6
M=,C>0F?Q<[M,V35;=A=%DK\!FZ 0TAT=0]][?[H\3E\]9N50\?,>QD;99N';
M([ _"]\5$C>PLWV-$=#VPR>@=5U*%BOJ4[ VE')D>*:O60E4KU",=^M*HQX:
MZQ^LF:^?$4(M6>XWDH7B,XZ<FNR01HZR-!]]A/CY6\3PGCB$C!5A"'6YC:3.
MC(VF+I!G_C#8KT8R!TW8*=YDW*IED<N=%D)M.<OE+FV+2L][EA^/2G_/YP?Y
M8:V6]1R5>$[RT9)SG";9"]*#%G'B0JB$:-O:+DE?'"YED4H '62FTT6U65:H
MR/BZT6PFCJ4H-@OBKRS:?M%K<"J:6C>P;L.]+C[4RH^[:BGLQ/DVO;'@L?16
MEEJ("H%+(ZI@41$AK2ATS1</+!9K5&4VEQVY%L3.&%2&S0:(D4W::LQJA:YA
MEA^1;[6)PO0D;LO2)(C[4J@S<ND(G)5#ET5+2^&P)(H+XNIB=V50I:M2%SLM
M0U.7<CM[5,&H,B^4NMAI&1KPJ),X*XLJ,96RU%D)U-FD-.5N2]'0J5Q/[E3B
M5)&V25GJL@1-:#B=1:G@4Y4?25GJK@2ZG$9Z$K=E:;*L9"+7Y3%;63*1X_(T
MRG(B<IA7=XG&<6G4.;R,5*Y+I$@X9:!Q6)HF9$X"$W5*-!V!RW)$<:-72$'E
MN$1-JZ9$Y+H\#:NF1.2X/(VRG(@<#3X*F<AQ>1JL@#J-X](T[?<55*Y+9-PM
M2S2.2]-H"\A4KDMDMM+J- Y+8Y;#70DVFS# 5.1_A!/A5;!1'!F;J.PE^A:1
M%J5G>B]QA!>!(ANK@<8Q>& HLQ4)_=M@#5=9\O0<:=:*LD@-A*E<3A^ STF,
MPO3 ?A"B8(W]!WAF<\3_MXYVB5AV(81EX=O6/%@;1XJPM5)&]E+<*/H4D'3X
MC1>SF&Q$DC[*Y61J5=C4.Y5N,4"4;H-H68^P5A6> +B-Z;P:TG:Y+UR6'+E@
M795TN)FT+.[K1O )7M>(?H: [4N*(D7.6@.-:^L*< K_U A1*7)L@0?^](/&
MQ<%BB**O\7R)ET$$UX$NT[IZZ61*5Z0U30W)ROO(C13.]LWZ<:7H>VH"UWH@
MYW*R0G2-]%+(Y8X)4;_</X[X5!PE*!RM-RB@0#K'3/9RMJWHN-ABL[R?X(U5
M3T%TL?;>DF@9!D_8%WEK]M*#=3NN*^69I)#>$.(_\P:J4HP7OR<L]AY]"[6T
M;.G4%?,)<]##(^BEVI#[:FD]7G15W!>U<90K[,F#FG%?)9-0D:ZIB="Q[0#D
M2<'^W[G5Q1G)'@+H0[IL^=RIF=1)V6;P]A*S$<U Z59G-"9Q<C]+TT-$,0J#
M+]@'#R5FXVB&O82*_*$504QD)^"_>H@2EC(O_%0+0NL91K44[N_H'L2%4NQ/
M69(GN)B3X0M'*.8S.^^ @5?U3]I6J#A^VE^F.V+2G8?9-8:L%>$H\L@:S]%+
M/XE7A/= Q0S23.O:[#@3\YV5; V4CDF66I'"MA -2 +I"-R:)C56];XV\C=4
M_?@YXD-9PWFUT$65ZSAWU:4+^61&T3C"_\)(#GU2ECJG=LZB<"8 DTK]*PG<
M$N,/OEB!Z9]FR$Y7-)'@19*GD=(YP6#![O.??.Q7<N95A=)3U05Z[81Z&;/5
M_'_\2W1.A "U<V8[<D>%3/.#R-+DO[MC<66,J4+KY"(GQTB>@T7FO"AQ3M^J
M$UJYJ,+VJY[(YKP-D,_[PX0$4?S_,"7PGZ[?F&B=[$C ,# I.!8K7Y-X>FHW
M!=1DBE$7VW6^;V)N[1C</9:L>C[ 2%4'Y/6? RAR9*4KG)QL14OAC"?&<-@N
M,2\E1]-2'#A;?QV01"*S,=WEUC6@I2,])=B4=U14A6[.=,HK*:I"QS:6.8MR
M8KV&/4!SC:.8RE]/UCF<V7A9\G7E5D!+Z)YUITJDIRASS[[3CAG'QXMA_\+<
MO1*4<[A+3 TO)(\BX7!1"*(F*W>B5\]=G;.JN@JD*',4CWJ2R-KO7WG8[I4/
M<L>B\M:2LM3-E5MUN4=1YACSU43SE96W>.)M9Q"616M;T[UEW$J"G9'?6O92
MS1.57?8&MJKFGM048C?(<R0B-RCCWX3W^""I$Z'5B()F4F<V1?J#=R&$8CM1
M^=FUI8R2:+E(PG [YYV)+3"EJBVXB>KUMN&_GC-OQ8V=O_U_4$L#!!0    (
M #F U5@_;S]>%Q0   8Y 0 5    9FQG8RTR,#(T,#,S,5]C86PN>&UL[1W;
M=MLV\KU?X?4^.XZD=MOD).V1;3G5.;;E(RG;[A,/34$2MQ2AY<67?OT"H"A1
M$JXD-124O+2) H S V#N,_CTV^LB.'M&4>SC\/-YZ]W[\S,4>GCBA[//YVDR
MO?CE_+=??_@4^.%?3VZ,SLCP,/Y\/D^2Y<?+RY>7EW>O3U'P#D>SR_;[]YW+
M?.!Y-O+C:^QOC7[IY&-;EW_>WXV\.5JX%WX8)V[H;6;197CS6A\^?+AD_TJ&
MQO['F,V_PYZ;, 24<)T)1]"_7>3#+NA/%ZWV1:?U[C6>G/_ZP]G9IW]<7)SU
M'\:]+_T_SY[>SGI_7_QY-;P[N[A@_QKA  W1](Q!]S%Y6Z+/Y[&_6 84*_;;
M/$+3S^?38.:1Y=L_ON]DB__S&H<3%,9HT@\3%/D+\O<8!_[$3=!DE)#_+E"8
MQ(/IK1\2(OEN\(ACG^)[?D8_^G78WT)\&N#(G47X)9F_\_#BDHZY+/^-R^K8
M<;]TA^.X&TZN\6(9H3F!S7]&]#<SI,R6/@@N@^FU&\]O _Q2&?;B4E5A'4?N
M!!$J=!<X)509(@_YS^Y3@&Y0XOJ!":S*I:K"V@^?"?8X>C.';6]J=5@(*YKY
M!+MN'*.$'J0O&$]>_"!8?:)E!)YZM:H0WR'"L6)STFW/JPK%$ 7T+#^Z4?)V
MX\=>@.,T*@.68J&J<'9'H]YX]'OO[N9V,!QU[WK=AYN;_NAZ\##N/WSMW0P>
M>\/NN#]X&)F#;KXV.#8FA[?$XAD^GAMX:<!D\AV!?@LO])H@(HLF.6;T2X>4
M7Q0@ E* O2TP JHSX&B;OA2*F(#!-(.I&S\Q]2"-+V:NNR1J0KMSB8(DSG^A
M6]%AV[#ZP<DN>;YHX#ZA@'W*V1[@O,\(!0S7=1I%A$Q*\%;CG!8PE&M>_H!D
M0!:'@<,X1'$2^1XY=E14$W9.H8D3=OS4]-68[;3-,-KG"?07YPZ[84%24^D]
M>:8Z-N]T*F8X'6 B/^ PH3K'!AK9G>*,=GX$AO@Q0DO7G_1>EY1+$=H-DCF*
M=*^=QFSG)V",5@>4_J_WOY30-:"'M)M<NU'T1LS#?[M!BB0X:<UW_@7-"#UO
M1X<E3$2#+TJF.3\WPLP'4Z(<+7'L!E\BG"[[H1>DU&RG*A.Y$'Z8HLE@B2(F
MA74Y?YE%G5^ \2]<#G+U/25JW/%."UH&K^@6SIC>/?1G<V+O?8TSPT &OFR>
MTX(6@+GY(H$X'^*T#&599>#N<#@;HVA1$*L2.#FCG1:TK-NU$ ECZ;VNKIT&
MK76F.RUX<8C)J4W>'@,W3(@4H!)@20DLU^QDTYP6M 0T8(4&W*C"JDX+6ES>
M^>Z3'Q!#"E'/Q2C!WE]S'$Q0%-.M2=YDETLQU6E!R\T"1'IP.RUHT99SI!OT
ME&B=)OZ$!@#?4$VM:^P/=EH?&J2T!L3[H^%!WE8$<B*^J:&73W3:T)K0-5XL
M_$S>,C<]Y7LS%'KRBRF9Y;2AM:#<('ATWZ@UH&]!;$]PVM :TE4:^R&*8T+-
M)S_,]/B<E GUJOF3E?0Q.&#E%W7:T/I69@UX7D0DK1'7DD]TVM Z5@&&FFW!
MBBL[;6A-K<3YTY*NE=9UVM *S@V:(O+I"=DEO$!C][6PD7+%6S'3:8/;^'R1
MI6?OJ^8Z;7!MH^2-TM,!*R_N=*!5@'U[8 WK(XZ8\9,DD?^4)E1:CC&%E;IY
M<4"@F+$@$#'9)42IYP-.!UH^W_LACABT2A1WA\(#:V00<DS #K3PISHD#ADD
M2O_USE!X8+N3"0MANL&CZQ/6?.TN_<25.8,$,YP.M&XRI/'@$$UZ;A22ZQ03
MM2E=I"RN3T2-[_GR()EJLM.!UC *,# ]<"NW*).:-,.(R,K!E(A/N2%@LI+3
MV?A\"F'U;K2-M1MY^3?)'_=BZMNI;JL1EW&Z6+#5+OP$+?+YTP@O!$'K_)-8
M'C4^PQ&YY)_/R80T)H#@978HS\]>$'5??SYO'0E.!9CYJ.W$FD\(,[U0=(YP
MRV*,U='M',NVQ5CFP_C1\!S#S@E@J!<MSS'^\00PUHVEYSC_= (X*T+N.:K_
M.@54J\3><T+\?/R$$&L0PA"]1?)'@ITJ@F^1_!%C68SZ6R1NQ @)T@,L$BQB
MW'33!BR2*&)D56D%%LD2,9(5\PJL$",Z.06BR[P=UK?!D-L%6<ZE]C, 3@A'
M;L* %;J! '3U7G(0/1D\U0D)I[>WBO0%*U1 (X3%&0]6:(=&N%9+@+!"HS2[
MX,I<"2L42S/F73UKP@I%5$]D5TZ=L(TA2FBAD5UA&TN48*N5?F$;R]-33BND
M7]C&#TWMK_KR,:Q0#6M$ET]/7O*'#7;"P0G#3S.Q]- PT,7VQ&Y^BIT'0(*D
M)*'E]'94+^_%"KW(;)/-,V+TU:5/ESO-* [7H,*L%Q%L03U*-H24)"=MC0/O
M4O$8X:F?*$#<#&J@/T5.FEMRXKE*G4X&F,DR#>.8F6PIX48;T+0QXTTV[6X!
M@,\5FN((K6TS%/=>D\@E#(:8K=%;G]SDV#C[^(!?!:?@+8'3GZW<%-[;.'+#
MV/4H$E^(N*(X#I$;^']O.":'(/J+P./G^A'3H.Z)O9I&C''_X2?SKR%^BE'$
M4D_ZX3)EJ2AD2X@!Q+:0_(U@0W;FRHW]>&WGYOAD:BTU^G-Y+B,/% S@K5S6
M)WR5KG6%0J++J._.W@SP!BA;LK!B-8+Q6N!--3A*EX8HD\QRH&ML)+#47%M2
M\Y<::$4B4;/%G)JHL>QO*WMB\M\TRXK1.">'^2 \X8PU5&CU;>U\U5+W.:,;
M!'G%[[4 SL?"@TO]+FGH9QV'Y4QB,ZY!JC(O_(I<.I0MCH=OX,-2D_J+)=&'
MZ$V_GKO13'HB^!/@V_BL.%S,\LLRZJU)JF:,W&GP;7MRB42 H2DHZE/#G]!
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MWCMW2>@S%YQA&X2U'$7A[;#"QV6X?;LWR0J1:XBC^*X=H[C=SM<D\.81_Y4
M;L%*8'J_$W3G/U/?QS9L<IDLGP@NI27@%-/IUZF0K\DPZR@\?D'!,[K'83*7
M]H^I8WUPV]X,ZA7$_T%N=$NFU$:-G77!%9%2T':GA*4<BA1;BX,K.*5W;TP
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MB@MI*MYID&+'72Y'?]=.?SUB!L#MT*S7&9Y+BLXE1>>2HG-)T:F5%*V%ATT
M&V;XF+%Y">+X-:/-C$T[$$>(%8YF:,X!$V0REI38-;-X>P?\2+%NAG*3%M@)
M1,,9REI:('L206<HDVF!&C?*;CH,AQZ09VBB4PL<N4%[AF8OM4"5&N!G:/6.
M%BARP@ -K?S: E%ZQ&"!XZ?1XT@/+JRD@M$C20]$+)$<O^S#B5<L,1V_X,.+
M:BQ1';\@1 R#+/$;O_1#B9HL,31,]I'1ET6#*0T5\V10E0NN-%38DT)89[2D
MH9*CW%WH-1C24)%3GD+$>$E#A4VUW[]>T=(TB;,]IORP2E,%4!F<FW&8I@J:
M,ABUBL@T5>QLC7BC'*=ALJ9:[G,2RSD- ;1%5&>)^(BE,VKL9XG<B$4I1GQH
MB=Z(Y2#I:-$2Z1&+1RTB1RLWUGC15A@M6I+#,#%*)8I,8U@/@:1F^KS[IV@/
M@::&>M@'I:5H9*JA#OM!:5>OW4K1-@8LA8B>ZY/BC7,-1--J(':",_NH^(2&
M0=IIB%PC46B>=BR.@*!6#F2.UPYUK4@WM08C=:QV:"DUM[F0,^=9NK-;!$IJ
M\S$27</2G9!R7#&;BPIY@J4]&9GXHG*A9TVS=&<JJ^%!W4N9]E4)MTNVJOJ2
MKY+0]%<)URRR#%,)-[-GW$11PDR$K@_37Y]0365VIDBDI/2[;,5#RM%^!(<X
M/:'?D'JPWFP =E)G7X!VP!E3I L:RD"UV.,>GE)095.D:Q3*0(7/J1TX (<E
MR9&L,5.Z'"$%QBO@2'Y.^@SI2H,2,+$_)GV&=!%!"9B$/B5WHOX:@2E'>0"'
M!#H['$]^E6"@[A%HH4O]]N*3]=<+9,&41M^TQ"?K<21;3Y!R@FZP/05I*\FS
M[SEB5XTQ1;IDH Q4[,O&F&*=JWEEB%LT;DT+PA'F2]<H; UO"Y(2YDN7'*3
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MNY4&P-_L#[8'\7U;HN^Y99;484^<6_(:H"/-M6G,47=F@_\8E!H9!G+$MB>
M$9>E&]$KMPI7CP:)YZ[VOPD6FXWGHR, %@Z2^M$Q%Q' Q1;0+I37Z'J3*J/N
M"ZY/%#V%)9#<+K7":^BOHX .<UJ Z/*M_.<7#T!TG79OM^ %^+P"'D(+#(?7
M5V!'"<SJ#I\"R$_FEEEG."QO@D,21RFY+_@U!.BSWLEW&D;OJ;B 0-3[Z6#M
M(==-$):(26U#F)OAN(>,/UE118IL(P"6X7X?!FGW*GH0,&>&(I!^3SM)Q='2
M=O\O@.%]B(24)S0#X)_8L E,E=6%^4"N Y!NA/>0 I$\47O$>M\'=6AVL?X>
M '<1E^Q,")OC2=:9[AI&#R"UZM_;,'ZK%?4O>LNE?0WJ8QAHR2ZE/SK[WG[+
MWIP0/H!##M=Z4UP6!FZ<F=:9[KI%TC8OBF*DO:MO>=;7J?Z%X @0'#=!^?O/
MZ/''35?.1"0)[B+UKL :K7G">A)%G9511B9G_)-"GDP_88W'.).A/ 8<"@@J
M16:9'%MCP2$&49LRST YS"$81?24 N9 5-O,C6 F@RN"&D6C,_.JBX%.\#LP
M5<6)X2JF>AIJSU>!-56;'3#^D<?%%5]@P_U0ZD1?DG8\4:3;Z,Z&!M)U)86
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M''<R_G 56V43[K54;,W>ML;31CL8O6]LG>LN]_6 WH0@8=80*(;H3_I'=#Y
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M0IF6J=D+[BSEU=2D3C41+@UEU]0<3L6HUK1B8],X%:/<5)YY:9QZW*R/2,,
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M2(#V'$S#I1W%P/?M((P>;1#\A:#XZB$0]VL8>YS/(+N.;(X&K7TS8F#.SHO
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MMJJBI>F'^X,=A)? =CCW]G2D;(\J6L&B$,:W=H*><[=LE$T#@C2V4X,J\^Y
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M5.JR%%&KQXN!"G^R?C=@0=Y[^PW#] 1M%^3418_T'1*KA;\0;PG]#D($&4R
M6Z@ Z%K*HR:P@'[77#,ONU1Q&)A09M2==[IN4+!] G"/4ZV9=Z4:AGLK#^19
M1KPF5:)$2$R?9)W]HR<UDNDB[:I\4&T1[27ZR7E0.Q&C25^"LF&<XY0$8Q,+
MCCIBEF>/!RP%M4R3F08JJ1)DF%&\)2Z9 F68O;LE+IGR99@MN^T92Q4W QUQ
M';F9X1ZTGI[_0GM\7UCSU%##N$[/U!#39 WC7II.B(@:;*B_KC_*"&K1AGKA
M>J(+0R<WM#5Z;^RDJ>P;VBJ])^S9=@-.0W7S/+=E=YS9@SM[<.=V/',[GM'T
M:$Y9&>YDB-A:=!/L !9+;H(RTC(+IZG'7M9$FLLW''*YWN#)G"1JI?MHS\EL
M!36&F9N&V7%E[9180N!Z<?H(\EI#'P]5U%OH,Q*:[. Q>8X\U[,A(@?[[M/&
MR_86FO A&LAC'_J^'2-U@%:#E3Q0OQ>_VI_[)8Z'2@-+*S4 ?!?'@=[:< L:
MDJD7)VDN!-8K[4Q*7J)3@""XM(,_>&4)NBVK"KO:SHAV>R!TKYF3]$=)=#DD
MPT7,X/_A(DXOM@]22Q\2=CTG!B[^ ]9V&K^HC>2$VK1>5]KOS3M2&0^\]Y'@
M#MQ%5-'^.H0U;KB&R[0Q[Q8!4?LU]_!U6[[N).^";:WB^WJS>G5V-MKI 0%"
M@Y\ZP3I3TFA.)C@"*8[K328L7-M.:@1X /A>X'#V$"*U'/UC:1_0WYBQ"'(+
M66>?#(Q0.]>O/->K_Y=F&:9J3)QAG2NJ]8/(<.V'W[^&+O"_>-L=ZQ@3!UOG
M:BKKX#0;S*'2O*KH*;P$-U&4 %)W/N9XZUQ1@9TZLK?A=V'"Y&.M<]TA6RDE
M[A&?9Q8-*P=9YX-459A#AD85,C0W$YR;"<[-!/N]8WU9[<SK4]@;IF2"=C?W
MF<4?%.)%)AC!B/A.*, S7@YXEWA%'D9RF=XK5S^UIVJ/Y!+FRP18>4A5EE<S
M.0414L+=5V"<'3<!N!9>@UE@^W/[?B-L.QF-WP>Y5!N?WT<(+]_D_;["=N4M
MY>\K>+<PQ;^OT%R&8?]]A.:R70KO(T"7Z\G@Q.9.B0PT)TI!@D^3)@'9/U.)
M64/&9N.:9O< IJ -&X*]0(*5Z_D)WOD1%V%+*8S$B[3>VC7Z2+@88Q+;N=R1
MEU\K@+\5B,96M<6 S84ZHB#>=TC%1MH;^^!N:G?V'G#"X.K#!H.1&]S4'*@J
MV/M[^+0+D\@.W*?OB*V]H5_@C3A1W\Q9HR'A0,U5XM#Y(WOVKQ)<61+=$2_,
M18)*$T^'+;[;T/T,$5-F7=)6"]:B=#6&!"ADN;17537+FES(@'H*D;_$$5LU
M+I" !B<;&T/C">A@DJ(*>/S;O/""3A_+<,NO!J;8]HG@4$R/4O( L/75O;=A
M_%93L30W*2WZ&(MH%J>#]>L(!0A<&;\Q<$ZS) $TIUGRR3*,-%WG#6E'"]M)
M/;@5GWA"3.<2;?X'XPY(K#*,W$QD*%1F?W2AIR?!GF#8I,0<R3I'LKZ72%;1
MW@\2#$2.&YHL(J;\81849T%Q%A3-(<M 9M?2ZD5C;^FQ%I$699>:1<999)Q%
MQEEDG+#(V((EFBPWYJ$/L^ X"XZSX&@,6881'->;C>< &-5[OS(..VFX]HI8
M"S]=-P\T/&E=F_<Y985&"2U@219945 +*$HC[_+]HSK[9F##FF;].@OGLW ^
M"^>S<#Y9X9SR)$T ,^%GRM!T+!E<.8\8)]'*!'5JH$ARBD8JHF7QI@X8^4W3
MLR_?&G\1#O"66&_6X&8-;DP:G-C1YB0)B"^BOXAVG>MR2QJ?#%8#+Z<W^I4'
M@8.6HI[ATT%:X%KN/+!9O0(GC;[,)24FD(P9LGH^K2:QO3]$,;#=^S3O#"SM
M@Q?;_JVW]]"7XQ0>%I@KJ[;3:J-"7([&#[\B,O,R1DAC+=T%4;O>DU;<BT(\
MW/1JL84 9,F$9-Y#&2G=V%D(!BI%J&-5P7'MP2AN;, K4$T>KPJ>1^"$@2L!
M$'6"=)?JOK[40*;3> ?@42LSI,&<MO!BV5-%U]!?8)D954_62)E>$NG5])=:
MI@"9UC-0A3%C,>DRSI3[]!"^V7[\M@[2/(<'\ *"!$0XT^+1QLK0/0S=Q"$6
M8Y>:KZIV\U?@>H[M9V77Z,73CX9)UVON7G*\13]VV2+.BBMSIR6P0!3C&@3U
M4\@ 7VP!_56A"TAR+DGJB\C 2F#V0'6D!:PP--=)2_/&]#PL;0DQ.V)F1\S[
M=,0,<;]:&9O,K?TLAP:?%*;7:B:"VD2+:.8:-SIL@YBA7D81Y&0,:H8Z&(71
MI!CHM)=O%*\$T!-S>4_/#<.^:%[A:A:P7+0J@Z59O)8-*@$MENUSY*@QK:@&
M5J16<2 -CS)JKWE+F6TGAWU+6^X(A @E=.!8> VM&2U/!FE;L:'5H%MB3C!'
M&UKXN?T)/S9E&UK0N3V"XL9N0^LXMT==T"+.*=RL)_(2,5(OPLP$1 BLE)6V
M26*C^)_RU?/W/.W[0P^>Y,R0C9D4!8D6ZL@8K:92*2_""&ECH>^Y^!"FADTD
M]%#B/5C#!X.5&FW GJ H!++LT(4>4,")PC@=JAR(I^^A*!#E4$M15$JU,AHG
M3(O:8$M-,$JU]G68T&/EJ&,M2;\H'PSO19@<U5C9\$(N&(_>JR@4Y5!%$8.U
ME;%\*0Q&-5A13&"U]LK;[GAA4Z3!LE&!7$#N/''&48VU)"-K^)=6_+.40W%W
M*\5?Q9<Y'_71N"V8:EX*?/&+6Q^M+-"OQB4]& .)3]08KRK,K\DM9>!ICK?.
MU+/8C10X]>'660^<5@::QG#<TJP'EBL%3W,";A?6 ^^5 *@Y7CJ04H@%R\#3
M'"\=Y2C">8+X38+SE*-5!2 >KRXAW!Y-4!5B>+R!E*3;F" ==B@*D938>SQ%
M.LY0$"H9&?AXAG2(H"A,$@+Q\8QZC)]*F"2DXZ,)UKEJCIUO(",*G4RQSE5S
M[6P+*;GY9(IUKIIW9UO("-'',ZQSY?P;2U_B_+LVVKI0SK_3U67X=W."=:&<
M?Z<;R/#OY@3KHA?I6M9L<33%NE#.O],MI/CWT0SK0CG_SG:0X=]',ZP++6F3
M"@V%P^0F7281XE!1M'#^3+PH-<7CCB'81HQ^ 7,H656%!%>P/N@N$D  K-&C
MMPN&C(6L#[H;?^%.U9BSQ[O0O0E>0!1C']7Z>P!@M/,.]P ZV!FR955 $%[#
M^J HVS$)G,P_E#F4G+?UIKK.M O/GF5]J)BCAL0,OH>GV#=D39A<M@4'S29-
M.,X>XY(J>/"*86=HK@4?7,*!)CN<)H58W8EE6)165\P:?C'#(J\ZXM;PM1D6
M3=45M;K_SK!PJ8ZHU9V"AL5)=<6LX6<T+$2J(VY-UZ5A,5 =<6NX0PWK3]^5
M_==]K(;UG>]Z(H^\MKS.\B-#[]@17*(W%;GDV+-<(C@=X:3IJBX1G(J(<N3\
M+O&;C)S2=*>7^$U(6FFZYTL,)R2S-/S])8+3$5R: 00E@A,17XYB$DKTIB'"
M$&(<*@U]0A@V8B9*#"<BR) B,$H<IR'+D (Z2A2G(<V0XD-*%*<AT!#B34H,
MIR'2$*-72ARG(=008V%*'*<AUY!":TH4)R+9'$7KE.A-1+(YC?ZI#/03PK 1
M351B.!')AA2;5.(X$<F&$.I4HC@1R880.56BJ$VRX=<94>IX-[3@B'1$28L@
MK FCS(G*,LR[W1ISJ5@MP_S>[6*F^&%?'!^XGNH#C]XV\#:>8P=QA=L]8D$.
M+NZNN4+YW$5W[L$T]V RK <3DT.4;<%9QU]H@5H^_=S-=>[F.A<1GXN(FZSV
MM&(@HHR0@ZL!DN$L(<X2XBPASA)BUM_8CG:+P,7_P7K^B^T#7#H6LX@W$0%1
M:+YLO:7.6%W;'DS+G:XWUUY@!XYG^U4YQ1P\!E9"\V6+-RGH-(1#I$+X)OYY
M:%.T=X&\AR$29N.W>]].BSGBPW+ Q!3'170)V2)2*CI V<'6P[66HPC$T35^
MS,&M]P)<[DGCSI6N1J7DF&4V/KES1IPC7<"J._C[ [J]J8D27GG1(8QL?[W!
M%6-3JF9DEL"LQ7+2E;*4)1\OP_TS8EA8E.1S.?HDZ=):>K[:3>#XB8M$V>-;
MDT&M^*/*[::J^E?YWM2JM?,1$YVJJBH8XL4O7E0=&"YLU G2E<'4=-/<A3Y2
MTZ+,MR%^<+ASI<N*=4>'6-'].H0;X,4)%#D];9?2W_P5P0*0;ENX9>J]5Y!$
MD/[HUQF9"-:MU]3?"/8!1,"&#I:XK\ +\,-4_EF]XF\%N/Q>8+9TI34%**6E
M^1^ $VXS&XCXE^/.E2[3UAF=A?N"9%3$Z8+M,HQD! W.S ':RB+1 (!;@/B!
M!!J,6?J;SJ(G/-R#)_M51I(E3]'?6'9EPP =AN@>P)0QB^/ F:FJV-Q=&"S#
M((:A[V=24EJW7U0B$)LM78:N>Z-B+\)N'@\Q%G>-%$[9YT1HOG0=N^Z&GG"_
M]^*L7U+@+E,(M^B]$Q(OY1>1+HG7&<$[\+UFZX9A@/[I@)J]1AQ-V:54U=JC
M;7H7QO\-XH4;'N+"+,"]7FW64E6G[W.8/F)H2RCPFO.F2-?J4W!7BD@^*7&$
M-:U>WF_VD<\^\ME'/OO(I^8C%_4%30!540>183' ;5!EN) ,"_9M@YV$4\FP
MNE?MOJ6 M\FP*EAMSRS5'658):Q6^+5T2AE6**L-ZFRGE6'ELGK[MO*^*<.J
M;<E01L:Y95K9+6D\F8XRTZINM5,S!5QHIE7?:H5H"V^::46Y6LG&7?QIIE7M
M:D, 03^;:06\VJ$JX($SK8Y7&T0%O'.F5?-J@R;'>V=:/:]VN@'=P6=:0:\V
M^ DX_TRKZB4M)(G[#DTK[]7FBPI[%$VK\]7*B"CE8C2M[%<;C-MX&TVK!29]
M@]NZ)TTK$2:-.,?1:5IYL'97F.T'Y94',R!'+G40SAER<X:<$ICF#+GA,N1H
MS?^<'7 3'Y<L2NVFJRCV]KART[<(;!+_UMN ]+1R U>D%Y)-AN,B<&P"/H'@
M!9"N08M5:AEO<PS+',,RQ[#,,2Q3B6%IS<NG@[/@"\ ):3% >+\"L>WY<M([
M[95E[<.2TR5FRPKN;4"EB>B",V>9?9;9QU35@AK5=?GVA+:E'#*)V9:2=M\J
M,,(043^'Q&SM&'VUG1UB@?"M#@_UP O,TH[!;V#G.3Z(N$ W!VJOAG*9>#Z.
M%>+"V1RHO;Y)_V=<(3>*8%S#"?U4X8.+03\@48K&9QI_5U0@0P0<ZO<_&J$'
MI*]((MPG>R90C3&:P+)?^6#5QR@J]J'T QKVZE;J4YO[6\VN%U?08("2D^&)
MRI6(9#T9$Y4$RK/-:K99O4^;5;\W24Z%T6Z[XEXQ2?@ED6]H.V;=2DG8R8BS
ME:,)(GRB6!EJC>V$Y(E6ICVID,^#M=W;:;+M$XUPP$],X<RG(%)0J)0ULQ@.
M"<!3%$XTSE$B<:R?#OC0L_IKR9PG0WV,G71$2=77_-+RN>?M;':]F>%Z:U5B
ML<H)/_8(7[Y]M?\GA$O?CB*.#T5B%9,PK"##_>RX-F?)E;1C>F_'.*B::_AO
MC-,.Y3*)XG /X /(\P)WWH$/,V.6)6F1I3IC;1?L;?@'SD2XA';@TJ%B3[ D
M"Q]2 +KU')Q"R(&B.<K27;;P+L0)5@<0@\46@BRJG_LQZ9.T>_6&XPXF>J>4
M5+A5ZMO0 9&\;TH+5/*N*24Y 1-P3=&OHI!O2F1ZO;3Z[)R:CG.JG41KG/.J
M)1K2M*#(O6:943K@0='@CP3HB:/+EKT-,]$HPYXKXQM:[4\-XB=JA:'5_Y0=
M<J9.HKT8H+@/9A ._Q[\,I\,=)B?0,BVHG\R[&4BP,?SR8P3A6.US'B/#/<H
M3=DA(ZKOC<8C<V=#7#;F!>@M:; ,?:1-A]G6"P0".CY%:9?T>27_N5XRCN7I
MZ6,;_644R@0\!6AP2S$HWTR-MX!C8EI_#P#$2@;#9MD8HQ<JJB68,$I1HM@R
MC #ZEOL0?Z__M"/[]QWB!9LPY/DHN!,-)MTPMD,<?;3>U.X Q_5)'*_=C7%Z
MI6WR+>;Z9B17DL64YE-/:]<ET-G94:6 L<\V:\X[^@#=KTE?*;M=O"3J<U/5
M-&VZ]2([N,9Q\NA)Q47)[=O;)<]#2YUB&(F&X;BU8JMYU5S6[3@9+-V*MWLN
MJQ>$$%&MJ$19/ESW #KHDMI;</F62E5ET<IL" .OUFM*]_A5D?CE .!&UT@+
M>[2Q=%E$M'T!OGL=0OQ+5OB)R/QZHV"-U8<4ZQ84A;,7N7PROKM^J71JYCA6
M)8QSYA&!9.!AJ!N. B/!^2"BM9B7F=;R,QEM2]=Y%WD:E7GF>"[$9 3E52RS
M+G('/ B7G:/&F7?/-7WUF2\P\L4_&9@S18'S%)DCM=2LRTT"D'!KV4JM>9>V
MW<<QU.NE5ULAJ]SOFB2=M'5#XX;T4$Y8^>?$&^EQMM:Z\^5%0H?UL'Y&*M!W
MS_=%W*0G8P?T=1:PB#LL&S.TYRBED8[ O;?1N:P=<(XKB#'+% RX62S,>:K*
M7GX/GW9A@@0(]^D[NEMO3V@X6 1!8OO5C7M"?)63@"6YCB+PLPV* ]K<:+VY
MWG+J> I.5Y35QM[MWTD4+R^ON@#<6$)1YAOYPZ[C'8"X,ZI?=D;M?EH$%Y7-
MJQ-&['O8#0?R?$5>6=)V[-/P&^XHY\LC(;ZJHH8*\D#@@^X\NZIQ:RPK6X13
M CGN0>=ENW98T_IU$J_?,.[1!W ((0[R^X9$6ZX$<C164;G*MN *$/QDM#3(
ME$N0,8WT4'Z&87)@'V_R:%6P7'_^PMZ^'(#;FJO84>AE;[[=VOWHW8_*,#>R
M[+90=*=_S)RFO"H9S'FX'[1F-++=N81OC),&DW(^OZ"G!*EY64I5O@/[L-)G
MC(5TPYS64\'C-HQ$# ?-";@AL.:XH-3@PHH%2@?@3KYZ 3M.D;I#8D_@^ DN
MVU<0CP&VR'3<MU<O4JDLEP,4!D[:SCUF8$$<CWOP:JXF8Q^\V/;3'M;K9]_;
M9AFJ#, I,W!'716,K>RC@[NDOP"([5>+/<[3H#$V^@S<\W: .U==_.7.AEMB
M/SGV!-RT5@4QKT#D0"\U_"(MT/:3]%O1"$D>C?O(JH"EN)JU76B $(;B;J\J
MH*@<#.O-R7F)5J_8N [<KS;\ \3Y2??^LC.2X&;+89#ZVZF5U%2MCSN_JL"W
M;H$O<I)IL)/&6A?5LZ4QCI!D?*=X1.@V[PE'])V@2J8-VZ)N7*">(-A2N!H:
MS"<,=1/9MG;[Z2 O;OXWU,.N'NEC%X*A#G)U1UW<Z6!HU0TUI*#Z+K27V]"+
MM92SHZ#%Q_=(BV/G2$&,7Z9)# E_2D&)?Y@38M>C]#.R6%AAZ9;@K3$WRIT,
MK@!JE5_'5#&.#"SAUM+=1*-'K>&",E;V%$;GQ+=E<!^5KC=KFNR1ZRXS+P5
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MNTG@H$S=8V-A-U%25 # 1K8.]5_*T@ VGG70X&F5%K QJSM;IEO7!BK+"<)
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MN&70G7&'@'<#:>H75WODNT>^>^2[1[Y_->0[&FM(4  ]7BOFCP,,P>MV Q#
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MQM,B34F\^BPK(]L&QMEL$-7]!B/@G>(6D*]-&6<DKY(;QP57"EM5-V?D]CV
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M ($J?VY'3BS)?;_EY!U1D:$309!ES%- 4&7,O,:P!(/Z*53+XK6@=5G?U O
M46723L!1Y==.P%%EW6*:S4M'*Z!-2P!!E7,3.5W(98R/>OY+),*L@&9Q'%B#
M9.D($*ER<H<0J7)VAQ")<CHL&%5Z+:9FR_=5@\+O-YR\(RHT=(E'2J<B_,\L
MF.=K%?A]):E:FI_7UV@J=2I49#8PV%["MA\*:!!I0K;,< O@D]R6TB@>G8[C
M\FJG%KSK  "92$'R#<,CO'("2^^@6*EHCG^5Z>E")'+G96<]\%;# 'PBC?$%
MGTB%?,$GTJE\7E"=3R\K&26%"EE@[C<'.$2*106'2)V*;<')SKY@2]9OZ /
MB#2)'AB-$EW)J1EP_!R/%W&6B"@8/\-'] I_\352Z7 VD]KZ]K/=*)/W1-6
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M3(6;E3(9#%?%_B2SIG.P(4>/"*2(LGV_2!$I1+]($:F*.X0+$5S)Q[1X&DS
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MYM6O2AOWZI'5]0!01/F:%A11[J8%193'\492$8ZRQU!-A[,9ROJ\N69(0Q>
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M$:D_S=<!'YC#>C_(-[I$N.L_@16AR-^+;VZQ>H"_R1\RWJI(WL"?:ZT)S>A
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M"C1JN)T9M\FKU!QWA6_'YKX]_ ;<V@H"MQL%P-,HIB?P-.KJ-.VXZ2R&^P@
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M6K<=W>&)V7YC@$*H9R="(:K<E0^77]1[E>E-Y9[\[]<__T\O*Z7K+X1L-0A
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M[@XF:<;N#";1:>OU7"XWJ%2U!2"D6?X4(*3Y_A0@M)G_2B73,$XR+<?R);V
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M^"Q4A$_HAVA)5G$BPN&LLJ%#K3^:"3 T[*[O?$+#[@_/)S3L'O-\0L/N4ZL
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MM!H1R7-[GUZ1Y_9(]S*$F8.1 *=CS7.'C1$RMP,JHRC7K&J6I89>2(+;_]3
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M)YK7L9Y)92Z>R/-J%]%KCP*#W ^O^<:#W ]7_,:#W!/_3D<OTS+Y7:)XRF"
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M/_(_;V/^QV3]__R.)N^^+'[W_\ZF-]/SZ?\MNK\I005D?[ENI^J]CJH@":*
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MZ$*P#U&=B.@U-(2K<)7)V[AI45#N)5N/OJ$Y4;=WM0Y>KFJOZ3J(Y?[,=/:
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M%-XC9,^I3 LKKK(@M0'D[RSO9,7C/8L;;*Q_&M5'AE]0'+M^85N^#?2W"^N
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M*7]V=31D\[$Y&A84!B5"%/ZXGK)D/4N3D&:)2R0&MH>J(M!A/!$8-AA:OON
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MMWK_CS]^?O_3^?^L7K/E&,8JGJ%Q6E;\JQAVD%#R3(.,CP U1K:<H WDZ\'
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M'K) .I!G/@[Q8M9>X##PO8"G*!!; $W'(@&\A ."7!\J&X4@$B2 &#R\'3*
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M0KUW*0<^"?$?,L,0(J\25,H%N[% ^SS-.QJG,=LP5@L9"FWG6R-7O+,@AR>
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M'!M%2;-FF*('&*XH\LINM5*5]+8N]M4Z_EW9R5\., L0XS)J ^*_1IL%D:G
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M%+.D22=,13TL,Q+:.A^5D+:APIT%G&VY>T<HUX):(WI/UR#V#/X-0QFAVC&
MS@-">G$O>+]:\EGF7Z(<EN%IL%;@);PF<<N'!X.8\#/I<V"W<"D'7H71BP>_
MRE=CR()/(Z'V JJH]1")"W>$AS=J(<6(;QYR%:66$<*):R,8!)W6'^<K%A21
MN%$A=)\="8F5'<PI^6TI+VE:*X68+FY9EC%FN^\BN6@]Q"BTMB+RU>1QS$)#
MUAI?^I$L[0J!9+JX@.L8+-WXJ;$<H.#S)*.,A-SG55[:\"),<2MO6&;S--Q
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M^OH&\T:6@Q_Q5*[5$&D"HK-(&TBRX'V-B8O+X^.Q=#T3(EWF2HBHW\MBGA^
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M&1:NMF36W;0G\9F=QJ,&QT<T.1OW"9^#C#JF8@+RC<"Y2^\1]: 8.@R-^";
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M%L8,ICJ?4JR"0-T7\L0KV;R&[\P3G XD8"@HG7%$_=\YG_R%0?E<@ ,]0H-
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MZR2]3(JG?%%$97ER *;/'X:U0F>Q85CU:<:P5IRQ:_DX!X>ESSE0!F>L52-
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M+%)-\D#-GT O,6L'R<@.T_P)]!^S=I",[T#-NZ^=:C%$GH^IAP2D7.;>#9]
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MG$2AC^P&%C)O2L)X>0&$:=PY?X%4?33QD%G#B$,?ZDT\=/9(@I<PBOBP<Q-
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M([E2EY1L#$@R426TO!A;G^ ICVXAU53-7'06,&-!$ALCEZMV05(7(Q?9*)K
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MR7GR[AI',L%C"_(_R,>1+/78@I!EAWL"K0;)[*9<G;?7/)))4PETJJ/,'A9
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M%_(PG,=IIA8Z8L^PAV+N<8<[I)T?=!S%3!RR)TO1[@&UDY >M$.G$?4JDBR
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M3,UP"4#;+Q4W;T\ [1!Z0NKD.5^:W#"$S- Z.;KA>RI6>7@3K.#T!2]28Z6
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MVKA*VZIR#]KJY@A> :"'&@8C; ?6R!AXWXFIK*RN4^ Y]K=;,AB?ZY>-!RN
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M$*7\':$_#P9JUD/9!") !VX@<7V4301XG,/Q()XWL[>RJ8QX 1S/G=E?V32
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M/. E.)"]'F;C2\ EB$T//8SAYHF,PGN1!#&\0\13K/92Q'E\=P 3_*./(EZ
M;[0/?O"\K;0DLS'\PWL+7O*7LSA)XI]%=4[Y%_7B"4_MVDO1A !;\1RS(EZ
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MA!A;,#B!(<2X@L&I#2[F<@[MG-5K.'CB7U+0=:@1@'#"0PHZ!93!A[+:![*
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M.RU=FEQ<397[O1NQ]L)'D66AJ%<0E,!0<DY'@(2#TA52CBL</!$O)>?P0,,
M!Z4KE)S# PC-K/LD7@KAIU>R44E].Y+#?L43ZO;5Q>,9LX6-TJ'>NEC ?A";
M/%D^>W(WNCJ/7U[BZ#%3V=*^XOET+<1YC"D!#J4@-N+LP/WE)8E73CT$MZ!E
M^8V9#HO@'P99%K"^1[Y(?B:!EA $4-F0DBY1'F.%@+*A)IVB[D'=K=0C?IVF
MN2<%X;P.H@]/HTL*,A@E#)"1H'0+N@?T%"^6?^=!(L[R-(@$;.V^)2I?Q5<\
M-:Y1F,%(4<",I ,79@E,O;6 Y.7E7WP :>0;5HIXCF0G8",'L5/$"'!GV3>
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M+1Y>C>IH1LQRJFH[VL%>>L>(64XY;4<[V"KO&C%_1S_%F1=NS>8.MKVD2;_
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MZJ2]*L]=",_BIS!84U-755J)UMR1IK"T!.<QN#Q)Q8E]M)?G^6K[]B;=/[<
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M'BX 5-DN>?-<AV^K4;H()R 7H8J^V2A=A'.,BU!5VS4M@,/TMR[5W#_L^5I
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MM4/> NI':3:UKOK*JE<Y0)] Z" CYP8LU[\%627H_'8I5H78B<PQH'6E6]R
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M?JPXKD;D*$0IB#LRQLFN2)2JM2/CD==OJ>1X$I\%G*)*U*0EZWT0N2BZ>=3
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M[1U465P'83BWHQAXGNT'T8L-_+\@%5]=2.)N&<8NXS.(CJ,H(/(6'@504HK
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M/;5K'MK%USK0'C\%A^KOG9-'Q"&(L1T+!43IMF?]H&NV&6"S9([!P\9D@ $
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M BG<B21_5DIK-2Z0+->V$BBP2NT/4$0FN$?1FO=&*]&-BMY!D9]K66L5"BV
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M '=^P%0MN<J<YDS I69:5N8;9P R=5NW,N\W Y"I6=\+8'Z9@*D[!!3 ?)F
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MZ#G,(V7T9T[9%@SCWMX@LGZC&BH]Z<+G:91 % U%2S *?&M69E0U(&1&Z'D
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M:&C;XQ1.1ZY6-*CN<4D5XN=% ^T>H8BD[F8\Q.YQ20;DQ+8+N;N1F!IXP_$
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M/TX)^C*L]8I5,[V)#H#/6[W7Y45?ZL6F ]:JG2XO>M,R\#FK=0JNZXZI;73
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M)MSC\=M C @857+KE\+DE&TEA+ZD>T\(K9^;3PC=6H2NJ$-E>9_/;#YD_L\
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MBB042:BR%;^\A"(;Z%DES-V31Q*&),PR'+.M$H9L())0)*%(0I6M^.4E%-E
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M;>AW1,8O?[A&_L&RT2#R#NH-C5.'O.?EW0.'W&>KY@"Y>^(.':\M?9B0$H\
M4FF 4+[2C/&4KV0,K:<3?3<0?LC)'%J:KTWR;2MKD[RG'*.UPF+[<XSJ*>TQ
M,9*D_4IYI23MK5I*>\HVVMELHYK*>G%/HGX%"^:>)+U53TE/X?]=3IZKI[0'
M)4S2?A43AJ2]54MI3[F@.YT+6E-ICVJ8Y/UJ9@Q)?&L[)/YJ=0"$DI7$/X%D
M.T!"R=/3QU/R=#JTGD81[@M)^Y78FJ2]M1W2?I7<3C<<$T26S>U,B$< J3-
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MS:%UX&7R,,G#K!,_4^R=8N_E0^O!X>1ODK]994XNN#KQ-@22(ZW.N??@L]$
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M=M>V!:86,^>:"?O"/6$C$3*'F'Q))I]*3V+X"C!\OQ\-(YE$?Q4.N(^#?#[
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MOW@908MB<#/&4PQN!C5W T(4PWMIV-0HAI?I!%RUN#7%VW+O>FG&KW&\K8Y
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M)M4477[M.S">PZ ?WR_N3K]8MW?=N]-;2\_G]S?PU9[_9KY'W)Z>_+BYN+N
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MO+PE(<?<GW(&&""0+TD:_J&4!=!+:P!@-*\P5_:;?JMI^H"E[@.4T#QRV"@
MWS/^UV3$'=P^[CA@46!FT5_VFNKG$;-M_7/)D4(X[:PDM!=2SWKN1VBU)29K
M."5C:(47Q+1)/C]X=S0*K<!SP(*/#<G9LX!/2@BPM939^WSBB'O@3AN-4_\G
MW[75#P2_!T>']R,9GKJ2*MW?)!566>!"WRV>*OP61<CD!^IQE77D.IMSY'J?
MOU_=79R<6E=GUMW74VWI?O_^HWLI3\QNKT]/+N#?WTY/[RZ^G^.PVZ_=F].O
M5Y=?3F]N5['KKT EF(;0<M$5/?V+6^OKZ<WI\3^M\XM_G'Y7VGPITUW$+6IA
M^-AB]K]!=;FHJ@+4PR,O",%6Y.H7J)VY=]^P7M3>QWGMR1?!.T5 UO^D78Q&
M/.YP;##EUGCO*;HKZQ=_,XI@AP(>-, ($_V!?,#0@__<1^@F9AP"Z0:$(>L/
M^(0EK[<J%P.!?<KX#>$ MDTY#W.>%3G\'L3,NW;B@PL73V0^6ONM]^7G!*]:
MKS.A&RUVWDT\16J+XHA;+L@&0 :[+A# N@T),'$/U(%5 K/8CR) @=NPN(/Q
M'A; ,WWXE^<'FMX1FK9#>#J:KFR8$C0?-<(M8C!)?XA<IQ@0?3GA2Z@F8#_*
M[VT>X/"<".Q0![\@T"Q'/T<JP"#J U,'.#GI]$6PT7+B7)G+?\)C98!]%ANN
MMD?M%]HCG^^ST<@#56-]88_"1L3^'S8<?8KQK?"+B@EF,.)R&NBQ")0@R/I1
MSP%W$3D;*8RX$OZP@=O.0*+*7<]*C!1X(NC#GHTY\\%IDC#]PONJ2*"C8X%R
MYBP*00."N)1?,[@)_=U?R9X.(U?W%-_L7G4VN5>XX$;Q7LD#YD<N=X,EA_VA
MEQ/'V+()W&(T )#!\0-P297>N7;@NTHZR6'XLPH=@;8!:R=0)'8CN0FP;]I'
M%$$024=,*C^EL^Y];VA].&HVP)C!)[0;1TWU@_Y2[CU6FJ  .)?]X?=>;W:G
M#C>]4U,W2I+R09[4H3S"DDBK"Q^A+2)WXP;MQF!R!TN,=/E"]9DNDP'TZ,\D
MX#(*2BJN;-@J)UXW2_NCET6)7+!D6VU&O>T<-3IO.PE'NU)F^;;\7!YE?6>!
MS?ZT+D&TH2R2.0M'\+573"*$]>7!D7PP*"\02"&&CE$,!G*'[_SHZXFENM%9
MY\/>5^N5RENV+N)Y/!?CO]TP\>.4FUX4P#<"?6 *]@RFP'#?P8!8+GPVY&E4
M+F=DYVWLV,1>SO*3&2C&L8&*0@V' +A8,*$5C3_KK/)XBC)$BE])E@5CU-'4
M4:R.?(REAB)T5##938*_N*Z"2%M)?'F2"(EC@>8Y&)]::<)#\ MQ(#O@TBH"
M;A6N/+X,K-;^D<5ZR/(J:BT!H>/<T@A5'"??B2$R9?@X8^W Q ."@[UL/F'Y
MV;J*K<OE):>IN'0#>9AJZT0J>JSFDC*$R"V#XW)'>AI63X:0E>T7&#;<;_KY
MK#@*/RG;YCE +.8@<)!Q@6E@/PXR6]U'$*>L)QS$/F8WR+<FB3VXM!Y7^R4T
MAP09.Q1=/]RM*%3HLC!CPC!U8L>+J1<YDH&DPUUT^HIQ!+D?\R?;8%EHH.M"
M^P Y7, !T/'-/?J2#])G?:-.8<T\EJ6C^#I$#H1YY#[(RR'XP-@_\B!KH&.L
M7PY4QEP,5#QU+P)0PP*+N?"X00IV^U%*6R3=RY)-GDJ P3COR820@7M 3Y_K
M6+ZO/TYR*_!1^-V#./<G=U:#N-%"HY ^1JQ##[,YLW&9P6LI0=3GY4Z9-'M<
MXP@"9WY@G2%>%SP]:EA $30Z?7Z/41!E"&6^+-^4.,J-^,V!3AW6DGC/R&.V
MNL=7/^ZLJQ\W4V):>T:D);,Z6(4WN3B0"'],GLNH4\7<L7&>4?4*8V4@5P\>
MCR/0:@"5^LA=P9%;>V,C%%%,A\+I9N=J\D^R3Y)?RL-V%8EX'BY=C3 ] #ZM
M.J,A?VX$@*U[P^39X$F4&IP<0FWL4&IM8?=C/".VE3N(S'3L(9O!#U]B1[Q1
MX^.#%YAJ94[OUD;Z9SQS6]^<UW-25GK\M'@E0-%93EERU[I2S*6-NO#_Q7E\
M%58V1QL[7KOK'E_*H[63J^]WI]_O;N=0)Q,E@G/JEPWK$'/%&(E(YO7^P\&'
MYKOV"AC[G^QFRTP5F9_]L%'Q\/PKVKR8GKVF(IAP^0>=(&8-?"R'^&\)C+=Y
M8-Q&PR&F]-[A,8R\^//W-^SS>LBSTL1:T^=!S++<FE;:DPL7]/Q0A;>[&.:0
MX;?RHWAB)6(EM2>M]_E-2?P+?2(Y88L%+\,]DS-M=8A_-K&F17:E/5'Y<J(3
M;KAUCNG">&+&7X9C)N?6>D<<LXDU+;(KG8E=4:=U5T\NR):!&+T,LTQ.JTW,
MLI$U+;0K$]')I'O%6SP@/N8N!Z4DC^1C_K%N.)YV8#Q7EKR)EY- D]-O?R"F
MVL2:%MJ5B2B$T9ZD&V<]V?),)\DA4-DWIW]&> 8YD=WS0C;1Y$HZ3>*O3:QI
MH5V9<'12&]KDG!?BF8G9=<@/V\B:%MF5HPGS(TTV2\X=7TC*3,[MD$RCC:QI
MM5V)<XI4)RIKWSIUM+%D'AM:_Y>XB+@HV96)@J<,%[6!BVZ29/6XA\N%D91^
MDR:E7ZND]&Z:E/Y2K#:QJ,/WQ&J;6--"NS)AK&98K0.LUHUS#772P[0L]A=C
MKHEE')'-O9$U+;(K[Z9KP\,"YBHO#7AI%IM<S%M2E1M9TT*[\FXJBQT5L5AQ
M'<*+\=7$"MZUB:\VL::%#K;:$QYY%VOX5'_/,.1<1S1?Z-QM<GJM-D4,-K*F
MQ?9EXD#T#RQEP<3H<RR:2%N@&ND!+\5#DX>W;3J]W<B:5MR7$T^5U4UT[R6^
M(;Z9LB]&79%47)$K^E+BO%2Z"+'.LZUIL7WYD-\7U8?X.*[^?"'CN&!B+<RF
M7IQAYD@^GS?1_/]:=[*,$^N89(N9;%EOA7*]\S5 :@$3"> 3MF11 GCN%ACY
MJV>X]V7NE/,FT$G6J][^^/:M>_-/Z^[TYIMU^_7T]&[AQJZ_\@61YOQ;$_-W
MT9!S<M55W5'H!0TK8&ZP']=4_2[*'UO067AJM985/_1N( (E< *=GBR[Q 28
MGFRI7\$; B":'S*!W4O2O%1L20B_B\OC5-5ZOG\/_/;__/?[=KOY*6=_R-^V
M/KVV>E$HRU:Q&E _4G80UQZW^<:X.CZI?D73>.Q%LHDD3-J+'-L"A-A8PL=5
MMR$Y!2PU]R>J_AI66L.9Z4/4=5W^"\LJ5>,<V0)"EYWJO %8H^JTHF<9UY6K
M&NVXPC^MVE]K)ZW[&<VT-,&S%90QO0_RC?7%]";1D5,B*1U1QO\E53!3N3<+
MBE;SW?_,*#A,6/C*!;CXPK%:<9.N#?8-TZ35/48T37$[] ?RU0EK2TDC\8&U
MK59/*)X!-@I5'2"*3L7%<5<,D_.#(-+=D[PH3#A.UW27-,J0O]M[K;K*J %?
M=>\N<T3\2VQZYLI&.(ZS'\CXJ<V!:<S%=G%J@70]DY7)1O"ZRSN"I-UX]Z[9
M.'K;SK:(: "J04WYUB-S(M[(=S#*D31M)3'!K'@70FP8.6)K./)MS)+FJG-<
MH:@^BGP@9P ,\.!SL_N9"FI?QQ]WXX]AYV2WE<QVJB9T95]!^8P7T@5)ZRB6
M;JV\N0GT_F+<UU"M=K'+F_SR$X//GEQU+4!N:@E9VNTBLL0"UM9-K7RLZW:\
M -^J2'$F?W>B?K<WR80,@!2J6&V[T>H<-5H?/E@9OFJDG82E:,7H[B^!/0%
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M1\^3HC/> B1Y(6WQ<JJX86T#W1*83N0P;+/W +_2RG>!S3)FLMW[9@IQ)-\
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MBU\&R8UW1:*V"R,0'=Q]Y Y,)/\ +;NY_XC"HF&UE!S7R&]8G>;O033Z' Y
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M3]_ @CZ5FH4MV6JL)N<E@3GE4:RVC<>YEUM>OP]&Q).Z"&8R;R,PS@'WC(/
M/=T$<:+S<-)W(#;\DA8'<5%:4FZJD^A%*%,],!O$R!0K;-YK]%0M>J],\7#
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M>?M\WIU\%AKZCH$_'LU?&/:G=T_@/'PSAJ*G)?61,'-=%IC##VA?HTKQFQ=
M#]AS+=!?B@87MI]9[J3UPW+7/YYF_86A86D'-2:I.E34L;"$D&<@GV]1R<8T
MZJ^*9,;/X=O/H*\. LX(7SU>3MC\NJ'LK%N=U/Y<F]&+Q<6G,6%I9/#TJPD'
M]_?6E3K>HTWV>Q""^:8I0_JK^-X9D$AO0R++(I&11CO_;531/EX[U>4RB7?/
M)2W,SDK:J"\;]:7^K<MGT.<]#%!X?R2)YL_OL)PAPP9>43'HA,&&42]MJT9?
MR8HALH?MY@ZS OI[1HQ<'7>>2T4Y(/QZ&6(H8?S_J/LP]KX$C[!9C?-2">Y[
MO]V<OA2>KQLR+Q]CUX=''QRL*W]^E^+$T1AX<#^,HHT._2I9\VO7I/=G)@_X
M%",-BRCX'*E%V7K[_SG_FZZLU(*A/BB$)=/G3JR20E(F*F-BU-P1S_;\XX'
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M]W*?FY#K'K%S EPD98,GJ9[A B2>AI3/URV<2F?D55A)9 H-=6%#HWI,U*+
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M@<^5BL1:*_6-+2OA@N!$1F17)@^LM!"J.5$Q9!KPP".MRR.%<3#4,*40+ \
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MK-H?.XN1P$ZD7VZ\+6.11AI.RMW<%CB$".!C*7?L^; /\WT01B0VI8_Z@^J
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M$5G%)P^^<NHMX! 9\:2: VHD.O&9TSZTA.=8@UQ&K*.UW!:I).+<GC5./:Q
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M+ .X'X"</ZDL2Y%6N<\(\129ZUN6;:) (-4CF ,/N&&.$^1ACT.<83XLTJS
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M_CU0Q]8.J_J [DB\=4NV*TO.9YI^80DR3#+#E2P,0I8AP *ST@98ZZR(!N;
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M"P2-F""$.!+LXOOP+;_3'#K+$F3:L!B%0]GL(\,BZX=#>',$%%#<]>U2*%M
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MP+T-RHDAH(KX\$[V_.;^8?UKW#-@*C"EA.HFFK?5F19NIBBEPJY&>#Q-B:3
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M(X=,G-?K.%/ZU'YQFW3D<1G_%*A_U=T;'6#*-"TQ42*[_7MGA_\6SS+^W7"
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M3!20%T_)BZ?DQ5/RAUK;)JYC89[<)+VGK7)3A6%]KNK-=Z;#/&=%Y3O31OX
M*L>SDN'?I?*PV@ZTNC;:W0A_.%[8I$M[#<Z*CY&-Y?5<;_,79\6+L^*9J <O
MSHH7P_#YZ1LOSHH_.D_Z]1[X%.N19M7N^K2;M5<AO^IM$1C B%.%[R4YV("F
M2K=+:=I: 7<;I#EAV\BO-3B6 $?8X.1V!Z377+3+4'/=O8/N__RI=P@;T:ZF
MN94:N&+A\ZO=K> JCH/.WY(WY]B<6T'249D]54 _N(7[U[B=VYRIO?V6B.0
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M**5)8RG2[FM>+>),P)AR_+$%?I9&Y<1&/&O@B^> @-)*K_/5R#56Z+7UY:T
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M6!YN;2R[U)SP 0@=V5'6GXO\"VP]:L]=,8XXPPFM#_=!/ ^8T4/%P]>*&_,
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M8_.23T6.XG_HH\/2%QT<5882[BM%#BZ<F#3-,HY_UWVHF'$TM] =E#&_T#X
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M7800TB+.I0UN?"F>4%*,=1P%Y[!FE^;!SN:[-#W>R\/54#+G!#/A>'RD<TO
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M9FG4-)U[#B9[GTR,6M8P@,?[9>2 N!9HW$E":@K!EXL_@!XPY*2G8MM%R9X
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M*%OQPV9:-0M_K[2/BJ34\Y3VWAS*:"7ZJ_<>,62BQ3(M_/+*> ;@#\M(%*.
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M+"8 >6B&W/)0?,HX0<QW(Y<I?0]_T9D2WZ\>DM; _(!)-Y,BC[@=(_?EFZG
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M'9W8,\#.>T,PB.O9P;Y9A8&EW\->P4V$75=&\,!_\)@(! DZRR=!&F.^:>^
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M,CJ2%BNVLI],[ADV?U1-:V>VMO:)GCF,*R@;;^O?*'@V)[6 IHAN)07J3;]
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M$I:<B_P%Y&7,KAIR5I(I)&@;_Y4933/5(5KW1YPHYY(DTOO;G;8[$G13_(9
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M!!#X*=CN'3=7T/6\!72]G=HH.ZU+ZMI#!:MZ1&P^8]4<X+89GS>[]FZF!3D
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M.W.BC[K'!\W<N.L]U,YO'O-8GZI.XE1?! PW-;61<&S3.!HR6#EWH<3G4M@
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M #)V=WI'8? EIG2(@?0):\Y](^$<I5^P:3,V#Z^N@/,LI6DYE:G/6,)Y7F6
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MNL&PB+N2U%Q<A/.M=#BZ$=T!'VQ-J@\_P/O,2I)Q)> HGL U!P2 $0ET V8
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M!O.NA-U#M%_R'.;_'FY!@L+ GWPJ\"J&*;WJ_/S^4V<+S(4<=/\HU08,.WJ
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MOI2%M@*-_I*KM[(OIG8EU+2%?':>E)"M,>^)1TM*4Q[9>]U]_?K/]>4V;,"
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M76UBQE]B+H14%_DX'F D0B](I=JY"R/7,EE^DU(GYIGH93FE-#[SP" IM37
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MWO!707B?GK8C( T/G=,]CE#[:K_KMCV6O1/[UP9(%B6T08 #@)+5G_[-HRZ
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M$V:8< Q'C1N0W2W4B7W73L,;P_$14+X5O.5HP7.85Y'1)!I-*?\B+R0/U?R
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M!Z"IX6>WD7GEY#.+LK?-/(/'2)"L=@P_^U0]BZ[84EW14,K;K1IG]-KNO>O
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M51:A"0*J[,F.TN&SW @^QI87<W:0L)^S1 83--Q10O!+4U8^&2]F:FZG!8"
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M<+C&#8<=4)^,U#!3PWRBQ3A?2*@&,Z#^EF.C (>*(!+V"!@$D;@*)PL:_L$
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M H97CH=;][^>F&9NDXO@>R,!O"$0CF3:B+9NMYU6+PCM(XVY>V=5ZQY)3"U
M+;+Y&A>?%BS!2?!])/C0'YQLV1K:B/CLI%=!!Y3 4LIFCJ:FD,ZWC ZZQ2PB
MOR?3I7*OKT6)+9]I)Z=;3MBWWF]Q\KTS\@TFVV%KW?\=PA\N)&0,+-J9E9#I
M CH*@KF,[RJ=NR=J6PF8ATND"M "5/511@%X9:KH[[&86Q XL=7>H"7DR5VP
MQ45(NP[T86R.8D.F6!!ER>Z33>U>JC=YJ^M-.KMUL<TV1):N+*!Y] 8^[#&8
M8QQ&Y6VKE\&">._%W+*!Z1:<@4B#:VHB705O@[V4UR**N#E;-5YIT%_LJ:W
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M .W/57-EE)A7I@?J'BNZ'1 >H5@,L$Z>W#6;I-L3239*P0%3,(BRY(F146D
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MO'YUU+QC)P>_-^</0/INK&B#-.9-O $^(+D+$:%4Z51XQ *S"*A0"QN@$$[
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M*^FV5_K[K>_TZV6J'CM*1?!]+YC"F_P#*'\ABJ(KW]&[%+CE_^$=SG_\XJF
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M\=\0(=VAW3([M3F'X]-<8&-E? &T##*A:D)</+U1+_#HL.-NH!.$C0C"T"$
M=44.7,#.<:8=ZW"<<9QI]:G6/SWI^+'6+N^A9G:]%O-4C,- ][$&LP36\5?#
MA3>[Y34WB4_D@AT/#W8XKG60:X/@>7CUPK&NBZP[/G)\JX=O+KR^(4+6&Q(Z
M[,29TRX+N3E?Y[< *T-&N0NLM\'S;#(WY2(0[9$#5P?;%3%P(<*V<L9M4"<&
M;H.VF#/.DKIU#:UR4&KFUEF6B=P+9_,@3%V!^N;H>M)D)LL%4;IH7NPVUUP,
M<4.$=.+?1:XY\=\0(=VIW9B%.DK2B4C-9_O'A_/<RY(HG'C_U:/_M3#._BF_
M%*E&-/2>A_$XF8D77BP:-':=HQB_/!YTO=C+"4+7C0XG!BZDMQ.<<1O4B8';
MH"WFC#.E=LVEJ9FGOXXT\49+;-TL=R45F%25)%B+3EN-$]2PYJV'&X#%1_YP
M>-I]#M<1=G)2V9A4]GM.)IU,MDLF=^4P=&*Y4V));2=.)IU,MD@FG:IT8ME"
ML3SRCP<'3TPJVU5,N,U8V=UL:$M4[WXK;5/<KU6ZOBW!8B=XS:_5\=_QOV[^
M/^H@M!B^O.ZV+K;W4Z5$M'2Y@T[1ME.+=8+@!,$)@KW05KE96ZEH#7,Q<P.Z
MN^=(/=W2?=<#\80(6=M9W,8#MWVGJN.;XYOC6QOYUBY3M;G8]?LX%ZG('/Y9
M*S()@T''"XB='&Q$#AK$4'5BX%H]=H(SKA?+B8';H"WF3+V6E&O%*K]*BV/I
M;Y-4P./ "1E?!O&%\*(D<U'U38WS&3;H5>QV"'A7;8S=YEH7 O>=(*03_RYR
MS8G_A@CI3NU.(@8TYY1\BU,!:_E+3,C ]:9I,O/8XLV\,/:F09AZ5T&T<&'X
M9L.OO:ZC9SM!Z+H-XL3 A?EV@C-N@SHQ<!NTQ9QQIE0;/9S&X,X^H&<R$M,D
M%1ZC-'MY\$-DK6YN;:;?O^EB^>=#?W#0"N"3VX,)==/A1:M)\$1EL]\_;#5;
MG&0^4<GL!E;#_\_>NW^UC62+PO^*%J?G-%F?H/T&NGOR+9J0-/<D(0?(])V?
MLF2[C#61)8\>$.:OOWOOJI)*EOP +*ED:^Y=IP/84M5^O[=.K>/[22>'F@P5
M:R180YF-!&OHY$7^P:![HC^=Z"S#F@3GL[J)9+Q ]A,9ASX;>7#0IS>ET.!J
M@.D2K=O"H,#JD-PNNK;VU8,!M49E0W=ZYGH:JM/FL%K,6&L(H?K#ZB1^T)X^
M+6\A0T'DI[.IW9!\(_L:0M!1]N%R)'U9NLGTOTQ6?V:A:+33.$"TMY&[[HD6
M4_KK&[EK:+/)[#>4N4^4V>3%&CK93(*=-EFQ1H)I2)F-!&OH9-/,?E.=5,O,
MOG9)^S^LP!X9ECLVQK83A;(Y><Y\(YA:/C.L,/3M811:0X<9H6>\A]-9Q@??
M>PRGQH7GSX^;=N4JHW.'K>.NKN.N"KUXP24E#=VMI;M6NZ&[ANZ:;L_Z8&97
M/)B&)!IFW7G,%&XV-NI;?X?Q-:7@!4/R4LYK'=N3"?.9.X(G>JXQ$?-</7 B
MK=#VW(*'N6J[+/XUY1Y%LW^GX,D,6]COKJ48:&AR;TN\JT=)/8BDZC,U>-.0
MN<$Y/-*].KBAE8;'=QQOC5&IHU'9)"-C)7'AS>8^FS(WL!]8+0J4*^@C>'%M
M0K4-5%VSV].^]&I/&J@:8B^8V&M0)]V0>D/J-4KZ%4CL6E4TZGM2S0BO#I7<
MC8QM2+V1L96CLR&\ESMM)ZUNK0E/9RFK5^1GMS>V-:OO&D V@-Q)0.Z*^;6_
M&&Q889<!J9>94YVU^!=#C+&Q8<'1K'MFN-%LR'S#F_!NN\ X@L.E.O+LAV8?
M:*5.T*EYUAZ8X()H6BW=%,XW+0T-9AK,:"Q".^;)2<OL#RI<:MZ00\.H.X&9
M0AFUW38'IX,=X-35#@?\%<=9K/C ?,'/P$,"K-"I4,_^KR@([<E3['V0.Z)"
MM+"8A/WV;LH,:S3R9O#SD^W>&ZX7PF-I9H=KV&[([GW+,>:6'Z)_$4Y9P(RY
M[QU-/']F&2//I0"[A>[(Q'8M=V3#QX,0?C%C;OC[+_:R8,=\!>#&]L,:S,2@
M50$Y@C<ROW#R;O5><*5?5M[I]ZDO7SOTF?7]R)K 37X%N-^S-+&(.QI3<@)_
M-?KS'[\9DL)EEB.'^.6?8@F!?OXO!=,7?<@>__T [_&MW6Y](XJR?YR[HZGG
M'RRC#?K/YGR5<M?S@%4V8WUUK6AL(T]\\3WC/;'*A<HJMY)!D*EH72ZZZNFR
MU8]4MOIL0EL$SNK@1OGL T+GD*X_!O%BW$V]*("[!PB(KZX= R<PWGF.8_G!
MFQ?*D.5P>'8!>&F  4I!$6L\,<LWF#L&8+QC(T;1G6[;-#JM3O>%X."CE\01
M4D( KN<X\(01B/^_'[3XSW-K/!8_:Q1R>YP"@1SA60%XKO?H6_.7FU7-29J3
M-">IN+U(:NC<TZ%=@Z+M[P?M^IRT77PB\7R,+@.:#^7UM52)TAI.S<B]?>R?
M:M%K*$,&*PZJ50?BJG.6DK]7AU;^/O1_>2L&5VK'@1M K*' .E+@G1_]>4&D
M]V5J@5-)__PP&_[9$.'F): U(].R;U(*(7_V0J9#.? >4_4J,ZUF9+W154JA
MZ_/1OR,[L'%>&0:T%N6U4:JL+AO$#>%K>96=JFUM2'L+EDH)<94JK);D6ITR
M1HPDZ9Q:DOV&EDR= C;/K]1-1V0*I9D;]L#<J/0RW/5W+ZF^?(.#%*^I3@9F
MZZ3TB<4;T%\I1?>UHP4-(-)@IL%,K3!3Y^FZ#1DT#%H,9HIT>5Z.I?(\%IT-
MGSJY&*_+"9?F;%QX 946WGO>.,#CC:MK_]NM/N[^J=GM=IL&[AJBKG3C95^P
MIF6W>!T!V9!_';&VL^1?LM%<C65<N4*OD_FK=83]]^';#S[MG?:]B1WJD)71
M)9#PHNF!6D2< *GM$_,$MU/7$YW5I(X;PJO5KJ&&YAJ:TZV0IB&\AO :PFL(
MKR&\W2&\:BO_ZI HVPE_8Q=""N7%#2Y_S)D;L.#7/<J1[6S,L@%D \@&D T@
M&T#JG]<I$\"[8!)ID67!QI?("7%6(,XL@Z=8]WR4V82Q90/+FKK,4KSI=ML\
M/1GHAP.=*D'WA1::4NVZD($&$&DP\TH&Y;\P#<FB1PV_:8M5#2"B$V;VO35"
M9Z-I%[R6\ER3+[XW84%@>Z[E5.*-[&KI<,?LMDIO'MJ7,%.Q>Z<:K!6#M9T-
M#NI+_A78V/N"A)VE9EU"W86KY[.F@Z'^L?4/S&6X;@<#Z]9X9KMV$/I6%=L[
M:^?4%^LBFH.>IAZB+E&$?2&%3J=TD[HAA";0MV.8:3)?#1GH 1&=,+/WD7CS
M]&39;L4F$%^O0/S,HR'HZ,F,O-DL<N%$^)LF)+\=$/?,DW:K">[6$'/-'):"
ML+:S04Q]R;\)R1>&A)VEYKT(R5>MGG?!7M4B)'_G6P_,,9CH$=3/.]',I2^6
MJ]JE#^JJ5P1A7PBATY!!3<A  X@TF&EB\ T9- S:Q. W,K'Z>K+N+G@TY;DM
MMU/+9T=#*V 4?T?GI0F_;S55U3]K*N+KB+DF_%X0UG8V8-F0?X.U/2;_O8C7
M5ZW/=\&ZU2)>?\,"9OFC*56>C-D#<[PY3J?1SZG1+ Y0*%8&3<"VH8,F+%@C
M,M  (@UF&@9MR*!AT"9N7V,+:Q<<F_*\E^LYPWY?]QY@; 5,EATU4?MM>?F=
M=A.UKR7FFIW+1>%M9P.7#2 ;0.H%R#T)I7=[I7=Q[IC%J44H_1V;^VQD6W$C
MIS7SX+C_J:20I';^>=$3G[J:UFGI$A#8%U)H-X.)&CI D6 =V@]O&EIH: %-
ML':K40]U(04-(*(39O8]DM\U>WU-=?HNN%;E^4]_6%B!- R;*/Z6+9UNZ>RQ
M+Y&WW:HMV!>L[6R\5%_R;P;?%(:$G:7FO8C^5ZN<=\% U2+V?QX$+#3LV=RR
M_:9\ONIX3O?,[+=.],.!3F&#?:&%ID*W+F2@ 40:S#0,VI!!PZ!-X+WF5E:=
M')NAYX^9G_SN^*0_#XW <^RQ\5\M^I\.X?GK<,K\>+"G<6B[(V_&WA@N*]W;
MJ47(ZT5E2IU6E:6 .QTGVRTC9E^PMK/1S8;\&ZSM,?GO1W"_8GV^-U:P%CF
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MGBC?<QR<^&2[(?-9$!;<!J5+(%O7"/3@]$P_!.BT(GU?"*'T1:(-&;R0##2
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M@3A2:/+#.R3(QZD'I&0I*"?PSX",0L(H^X'_W%VP+X%[^[C5?@7H/UO^R -
M!S%8'VW0BAE:!Z[&$'8=59NBFY&-@>7!;N!F%CI)JG$0Z_K82@BG8(7?3XWP
M$22%XZ% !.%PS77CQ/:#4/[:%-^P@R "@'7,=K=OML_.\*%V2.IM!J_@D7\I
MR^ \[-\1*$DX5?OL^.SL;_AQ>M#/@7P44K<7A2AHQB@14T\"^6BCT>(9 0!6
M*LUYY(^F%F#3NO<9&4W"4'E/1[[@1P9315XE8&B@+=[E$<PJ?@IC +?I#KJY
MMS'(V0&PCIC]@$>@7P/#DD4P!PG^ %=$?@TBNG00@4U'\AF=5W],/Q'AX5E\
M4AK"=OML!6/KWV#\ ?&"WO*_,\!:2&=P@9X,D-ED'7IH>[@(RGOF,G1Z9XR%
M>!B9;N'GD1;F+;^P @FDE11X#&\TBGR?VT+G &?'Z'1,H]/J].C3 -[5=JKQ
MR):;J6D35;P*X0"_&7H"%.GS("'@;]-GKR-/KH$;&@SAU M8S UT]ZGUP(PA
M8VX"4ZZ#1P!58F].S/#T'T_)\Y*'3(1Y'\V!?A&BDE;()!"4I- -<89*.^)W
MPEJN(>37TRS"?F@%G.JE))K:J #(G%\;,R)@DAA]]A?A_X\1%IQ9[K&UA4TF
M#-@$?ESTY*2P?A[G+F$BDL0_@ +$N^D!2$_GT3T<B#/]+J)[C(U"(<A2-++!
M]@6CV&=@K /,'Z<@:!%4L<<N7#3 :X(_A*) "*J   QMXI-DCX?Q2!9[PKU3
M:YS%IH(Q_!N2"6A >/8("8:0_&183N"!1?9$9QX"(P=L$CF()Y (\-$P]AJY
M!Y!W3"2 _',*[EZ\+BA)H 5TEU"+/>N)>%2^YX2KYPG<Q@T!QA/?FW%-'4=(
MK!GZ*H$$/[Q_"NH#KC:.R&NRR%=BX1.^ [TWS]^^EU$\20)6$DIP/<'QG!AG
MUICE<#Z/"H"#%Y+ > *9?6^CB>"CD7N4_((;50AT@!2Z"!+*B@U80Y"1E02T
M0>XPB- 1WC5"$2T4'E>'EA2+X7,T;  &%5B7^"@I[84A)8-XN;):JM(G9OG@
MC(_A<^] AE"!2[=-LK9KHD1_9&!#PG^)X3=X<&R#;_@&X#UX.AF6P90$#<@%
MGUEC[OZ[_XI<;ON3?4F?6_7^EY"'YMF.P5:S'4O^M.S7E>1%%@O".$#*2)9D
M4R:=YZ1,\C(G.9#-I[CE=+B:0C<+@,35=IN!XZ50)GFW)(&0F(^!:MLG;#SW
MA#6!EF2([B)PNY 5/5 [P:+W@/K!=ND%]#TP\D'UC!/%$4>?"PXZ4Q I+_=5
M,+3_^[]..YW!;ZF'Y >.8@;K'_,7I^)(4G4DF$L2/M1X;L]>C\'?&ARLPH'T
MN1(<O 3(IA&BL>18PA/ZZM*CR'9 =\%Q+'"$B4'BU +^@QZ%+,,?USD37$?!
M#GA]^[AU<G8B U]Q"(X;!HX%/M80G'@7O!"P_9^D93,#8$[QZ^*I9;EAE0HT
M/L[!Y0[(PI0':16%4Y\)\ 3".FK$74W$W5;PVPC#UPA#Q4??&.(IR0A8?H%L
MI'<<<:$FNP(4 7G:/VFDVSJ?KT+!MAF'Y)8KU81MXA! (M9>@49@,ML36/@_
M%OC^_I,AL0CLDT%M(],VDFF;2K35D9-7FGGA(W,>5LFR=BTM-24>JP0F*<4T
M9H;E.")L%B81Q>SHK860(R&$V[TBOCQW6*A&IWFLDX?EO.&_X-_ 2\X3R#&P
M)68VU;K4$9H;1"$QDH\F$Y$I)>=Y]H$RP?EA>E]DWS/^3(@9"R7;P&/VE-+
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M8V(.R-^$< 7J<>3F9/+CIN:]FP7:U02,PL=4<BL.-V)X$+[CN2+4+XXQ%HY
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M<$K>6&L'R4I ^'<4@CW^'SXSAC<V\8]XL[GGRI$Y/IMX/N.3A5(]NNE+XA@
MR\&IA\HD  RJTT0=G'KU@$VWJ0;_&=__)VZ;VL7V\^).PFC.I_(%T4SV36>:
MF O>%GK2R4X#6+HM=)M6_;(=K:_;)'RWB-"%%CC1CIXS 8M0N@5T9E_*^\3E
MI*+T\,?T2(B)$^$T4#X[P,X_@+K9DA9.VD$R)Y)OIK;%P$A^"V6]W8.'TYK
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M9P%#?&>AH >^V%K$%?BK>>[1E0ZCG((L(B1B]_>$KBB'^V- K6XDE)C.H&I
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M& M3-%5PYDQC7S/O 0^/UXZ_JLXI"C-C6G)G%>653GRV@K'U;^.C*/VZB0#
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MD48I8-[T:AH/<IYIUC@S2=R15/3XQ,:4[(F%(M:]@ /.^_;Y+UW/'@?&(1?
M@7'QQSL^\_;/BS=BK#>I!L7<W%'CVV?*<GG%T)[ %T<."$W$1HA",) Z7VU(
M?B&,E1Z:U*YK)7)CB7'D9JS6"=%A-*9=T$(-DG[![TX6R\"?24GCI$ID)3&9
MTMB-S2DR4!8@A4J!%P[P='BJE67(2!?[?$T8V9H4[[1PU83H-5-NP\/*:7\F
MKJ@RXX-E[5$)JV4''/O6(]@6\WBUQLB)@F0\B"=;D>*^#M[Q/YHFYHWZ)66N
MOH1] C0UL/MLRS(5_)!.R;)<?I&!+)&S$K/Y=T<.J-F.G(HG%(<4L>: 1,1+
MEQA#H;[G&,$3V)6S7921J6^O.L5Z\%GK(7@LYQSR"MR !)S00MQ8Y8-J^#9W
M*L\--GGHE"6?<I7B6\D0^5^,QRTJAK^HEZ.91.)>6&"*E3$1=A-&/N]TH?(K
M9AP>?/CTY> -)3V2<?&+?4,V%9@J#S"YOQPDFS(8KS>"3_"C).G85.LH[V=<
MW [$%VQ*AV3QLFH6@O8 B<G@][XU$UF]!2 P-XBS/82!V=SQGFBX]'@J!GJH
MX%V2])#83J4ME)@!F!U\^ HY+""&;(\$*T61./#@[3\G0*'<FN5$6(PP6HS_
M)TDH0(ETQ,1TRO>)TY-.2_#-(LE'B<!E*H^?'DA!WA-8YP&Q+GKJ?%(E<2HM
ME7P!P3X2E<XB")UJ].*#WO'&V?E48FMJYF4_+Q-+*CDX'J=^A$&**,T7)T.6
MM"RZX^>X?C66D*NUAP\"YU%->B+N'&IDW4%U<8L504G1)]#F'(F,SZ82?!JW
M)'.81:&-$08>22; C,7B=V1Q"J=B^E6&.6SJ=<#9NLHS<N!.K0!BW#Q\'4DW
M\,2()3[35V0#J:48&U)Y>?38@\^9B2$>[U16$H@8[Z'G!VK_4!R+/#8^VM\9
MKDZ3S:,+AZ:#B#?CT4$ 8E H63N2M'LD]:!@8%*7#055TL/L+%>V+4A>#L4<
M_618/A4+*/%#2@^#_,#FZ1B*MAQ'D#,Y,<:&Q%&,S1T,YYPVX9R7A7-Z^Q;.
MV=0^%D-85!V?*%-ISJK&AV*PJ"4EW.&3*QEE^>"0D:4H2VPLW\=M"8J2%@%>
M/^Y84LI7\NN(8GDGSKMZBY$96Q92J*S3;O55<IE2PZ1PDR3GE%D/-LTR(+31
MADMINRD&4GI2B9QME:E56BRK ZF>JC>RHA 8392-+@P+6#!F<VC*\Y_2!FZZ
M^DQHN0<FJ_7(!U)R5DGD07D@ZEBTW5-I/[);%U*XZK<?O*3+.59,(O8SL\7P
M&YYK46Q[4<R9/&ALS3 [;N$P%4PW 6(HMP4.Y8R211."(H8R&/S(BS_5<P2A
M;\L1,V[JKE,+[ B)29_-HS"N,[E'$/D8P5+R)NJ@PQT*EZQ)-REU=^M(PEP@
M"/H43@8+U.WC2]M43&I000=%)BCSQP2+@!:O@4ZRE-*W4<>)[!":SI/90PB;
MI&":1 XE NU %//=4P.;B*N8?!'QH@.]3&#(2M 5<HEGPN.R\70CG.KPBZ:E
M]8)LV6'2I:8Y4A>U'QBPXY1G'EA\87(F<*)*)9K9Y"4K&E(*--E=[,;"2XS:
MB8*Y<!3XN*+(H1_XT#6U_B(IS$BEHSV*['QG3R@( URWQ1LTEQ\'@U.X<P4E
M&:%6ADNX:R!"29PK,(W Q[,E4!0QG]3C8ZDYXL&?7>*4C6VXU*A#J1 3U<<I
M*&$"CDHL4J"ABFK!,8(T]2V)LP?[WO/1#E!#1&2X87C%SQW&+>:?;:"YLPRQ
M0JMNI-=(9"]H;_F6E!:/!U.C+H_]4+RSN5QNT$@V.KZH3E"KJ6G2D#H=Q4\!
M+8DS&D(KX:!EF3?)G9(2@\>]]SA3Q%)F$3A*."*K N5SXJX6:9=S*<;KJ^(:
MZO5&_PX&S9Z75L">UR .HL5TQ:OO:*!R/&7>(7AZKE![F6U)*W&6P5@<Y%_
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MVZ_GGR\N53E]_OF=\>7F^O]>7=X:E__W\N+K'8KUS_BXNZ\WG^&'OZX^?C1
M[M]>TU/?&5\_?[R\Q9?04_^\_OCN\L;X$U3![9?+BZOW5_"1B^O/=S>H$:X^
MW][=?+W 5]W"#W08?-T_CU]HEN@MH#NM1D"_3$ /"A30$C 5R.?SK^_ 7D+&
MO+J[NT3.^W)]<U=#DQP$Z%W*,N;!J'C0*,:!:4J3'8:,)3MT: .T'48AM15C
MZPN?>BHK5K"$E2_]%14!8YQGA<4HCKIP\?;R@GJ\^=YWZB]6]U[(*M6YY\M9
MUCX36PEX,P3%N6T'7YZ,D+QEHTC$+L[YC&?\[>4/$<0XQY)7G/\XCU5./+)0
M:"XY$4JFVT6Y4WP4K(G+.XTXRW$-!RG@6/1%=(MF'<HH7DPMVS>-_V$/H'CO
MK"<'JS6H^81AX1M8\I=C3/<8?WD>_?X/ ,P8#G1A36D^)M+9'QY^8FJEAX%2
M/S_6]"Z^GS\:0P4'MLN+[3!&?H#^1?*+$9]3DO_E@$\>G=";1'^S$M\1D\0<
M,4D,4QMCS%EQ%R3"X:%R=-HEW_P,6/]\9?0[1^UV2[T4=6<OW@JI6IYC"4M9
MZC8LH#+'#L5RN8!G?JEP1KF$>@".@4_^<8P1_+?$ /Z;0Y^#ERK3)D\TLM;-
M'"2I$\-20,Q +#L!@/$**S-[K1.\U4W2WGU[]#]*63VO>.2S>(*U[Q.A^L6/
M$=VIA!8O.1"#<BU7&;,N&==%6'")@(@C3"*PC /^L@/Z1K+F:")*<61])=7S
M!7+%1;Y0F:16,XIGU<W61 +V/8<M(T^;0M:'UAN:+1 PL:$O&;.;+C%,<AFB
M=C8![H4RK(F>P7.,F5&=RCRCN&7A-^-PF#Y!\OG%%!GOY%X8M*%F5N!AH_3#
M4@M#%L\CQF\X_, X+(ER./"4\1N:*6GRIH1D[J)0(EPN+-R>?T&)71G)8#_U
M2)Q7DTDH*7$G$O*KSAQ+2WYLSX=KX]<.V1NQ!XJ)Y!KI^[C&37A^&=$7]XPH
MBZC4-UK<UYLO[*VH(3=D.$#VRO,]"A[55N)L2Y?K'5GOF\,$)I][E9"0J D6
MR3T&!@]O#\*1X9Z?&B-#PTN#.6I@=1(7QYT(:HH-;LG08AY^5YSRU6QEQH]5
M"%(MS5_@<X6[93%YW!8>*7&#>*ZUVCW# IQ!9P?3>+1TIAL@ Z>%6G6A47A@
M6-2_9TK,DR.GM;FB]?-F17%=GL<X8IIQ&A?T1YFA5H61G/B=&OZF-%_EC#.E
MH$=\UG@D.?5=2[FA##:_IF(+#(%S"7-X\.7B_/H/G&PNMAMQ?"4]V_&R98P'
M>9C\>XIK;W,/2<>ZC\>K6W*\N@+<>3Q>?=EK11/56BSSJ35Y.N20YC%)V?0F
MH2<?K%#VF 4_/=J>K4=#'053+FT*^1V/^1*(7A!BG+@7)=M4K(8)4/_+C.^3
MK-3AY*Y,*(P5G*>H-QKWY6%1ESHF*/>H$T\9Q"LD17K>,+4G"4U"*\ORSXVF
MJ+QOGHR$EWA "7P@M,]$!9)I<-M<R$Z4&R!"++E")_Z4:%Z)!YC$W";N]NCY
MW]?>,TS/24XV+U*/:A )5N$FA?2YXY71]$%>'H4?, 6]\\W$6#HB^TXRAF_=
MZ/J*1FMV\TW_&>-Z8LH<G <9C** F^0DGI3U\OBA=Z!"QX%,]>6;0C[.I>*C
M(_G$#E6@8:@[G][$JV7@8LF+%PTBL5QSO4;@VP9RF[-2"@^.'8V8<%2^,\>>
M>GQCB"@]@7^YGGN4*1DC4VY!VZ46S2N0%70M;!J3_"PD!6D-8#>R;&!.;[Q9
MN$&B'-1Y%?^*QO?)I>5.$_P0[_5[CG80B^X=2]H[> _'"W@/77(]&[NOQ->X
M)WJ!?AP:7N=2B7]"MO+C&:+I(%@.D^?3">=2L?!%&L2.Y:;WD)'\X.:T8'=N
M."4$S)U=W*$:8NH[Z>-!:X^;^PH-$I(3(O0D/D6QCK*R14H;L3DQ$70Y7M@2
MDU6U@)615,M,S1A9?"J6.LR(PUFI&I3.AN4/+3 5CJY_..R)^]H3$!*M3GP
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M-B]-^/4V&L[L0,[340S,N(^66X;OA%H%72OK6KA6Z+0Z_87NNT7F-]25ZK1
MN]VSCDZ5+HITOT2LME135]0?B@F3]!]^N@FI,C&6&WF"?*:T1R<1/)-Z^"DN
M[Y(Y"%&%(Y8* CJD+ROWK@]I#BR2<4H9B5/ S2+.D31UPGF*>1$'VZA[O!<I
M<NH!50('\-FQXI96_.CL_7A^?MW]J )JI%XJ!U.\%U.=1T&RZ"EV\I.\\>*Z
MRX56!?SW]1\7YR8O_^?57G1<N=SE%K/'"<!D%RA:@%Q.1S2W@X9=$O,&&G@A
MQM>81O/2YVG,QBA#P2O3*D-93$$%(6LP01- Q<8CD'PX2X[V&[G&H&6,<5WM
M'"<$2P$%9N\1I5& U&@L%HX9D,7UZ<?31(MQ+.V5S-L+^4<9RB\* _B;CE/<
M+LEB51%">LL]@H&WB,7C/Y0:I="3%8 LMG;Q A0 $/6GL0=@<$C96%1"Y4RH
ML$3I3S+*+U0* 26OHW6J""#R8E3P<18G YX.+)"&WH'-BV:>$(I$!]+S48Z1
MJF*4=+/T>/BD/(H9LO 1MUB0A^:(ZK]DZI>;2:OU1!53SD?/@:X<8T ?ZY/B
M?63*(!YC;(6QAY5[EB<^S8AH-9S::&T0O0[9A";^R'%'F0]0'-U\)CF;7+JH
M2?($]%8^4_+AY;RE<(%!U=1E'O5+WL2)C _(-*:8!^_( 1*":7D1F\*VI$P
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M;P1STV?U%:/N(&<;*TQWDI/U)L#;YYW1>7M-U?U3!7)?F4^$]AW)*Q:8[;3
M[![&!!O#H\?\L6^'I[W*1SCO(!+5D'N:>X^/>WOMWJA@3&NMW/NDM9/FWD[W
MM%-YIJJQ[*N&V5*'=??>=J*06;7:-"_!,6R*0Y>7@J/1:$,1WQHI*$CK95@Q
MC?;:-)\VGT\'G?/S'9IQ#LRGZMDKC694->R4:L,K&U-IIY6OJ3@:>5:3T.IU
MVMU!I]L_&X >SPDM.><0I ,)!Z**V@R(L].S2L+'ZCM)FG448IWS?O>LG:NX
MJ81URNOTWNFP]L'[:O".&HI;H0"#<EI=.S#U.C!GG?[962[<NBK0!#6]:&M
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M7I&SU!1R:*K(66]LPF_0F%KSRZ4\7QH(4X8.1FQF$NC6OM.> @AO;^;,,*=
MO'"'1PSMN%X(5]" -I?B/+>^Z1A+TZ?2IG#. H;T2<@TL9%V9KNF.[7A2T$(
M'V#>-0!ST<X!<ID'QF\_6_9=]N.BC^"39P-L'43X!RTCALDZ4/=.>_!G^? K
MCBH^7WVYPD,7O/#<E_>>^,S\Z\2<P2O\ O"]95F6D"\WI_[#7XP!/-F0O!!S
M69Y-Y*^D:&VW_Y[S7#B0?BX%^()W*/PT2]=E?"<):Y2X^/[CL_:8",Y^N'"G
M<\_/_B2^_C0O&-L\>'OR*'O[R=MR'M1&!MD.JF6DA1H0NDQ+D.]2;J"$H?[6
MN>> ]@C^87SX3V2'C[]-_)_?OK9=$#]>%)BN1665/T 'RJL#P_(<Q_3A'.QA
MRE#;\"&3"V".,##NY_9T3E)M]2Z\W3\78EB'"^XB"[AD>$QHO"F>8QD N.6_
M?C52.!BE@@8K+ MZGSD./'\*<IAZAO'GI6E9XN?JPQKE5]GM*:\Q2HCO.8I<
MAD#7<EP=V_XVFT%"YJ,!B'0 QF"GXH3OKD=&!@O9"1(O8-'U[GUSF7Z/_L%1
M?LFG=_#V^,+=RDU _28X5DT/I8^HZK$.3'47()S1US(=TE%+T[9.;)?^/367
M=@A6<=VDV'@4*GJL0U/6=!HM(H<,) ^K8CE1I8,.W"SB"7O1<Z*)[3B/51VQ
M$5&]9S-[:H>:G([T6 <FIR^>>T)T=)EDS^GGN&[($$HRB":!;=FF;[. BS-.
M>EC@_^9%D]_VIN/F]SF^LQ^8D#/!"*)/$9"H@C / ,6JVSU$\.+$%S',TSX&
M%^2G&/6//RS3,BW]XV,('Q2^UX%FQU0%M[\=6&+7 K.&X^08:'DG3:W""8X
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MN).K5/P(^/H3T?4',X/(IX;1?]GA_(?K3>!)=]A@>.4NHS#XQH##IX ]"L[
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MN5;4^</]'7,9P*O*?PEHIFVN%9#S1XD[_.^K-D@&YC@ &:PICW]>8K"#_UQ
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MIJP#UIY-M]@G&7"Q5WB0/"9:QMR[!Z+U*1KHN<YCAG1G6,XP-UYWWL!+X#?
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M!"9) ,9!G,I)JF-2)3BBJB (L5CN%I@#:\U=YJ>^S6F2  ]'!P%"4$U 9;M
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MC1(=!]]!C*;H^J/Y"'\;-VPZ=SW'NX6+]/K0QI,;EYTJ]1ZLD)VVW%2RW$9
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M!LXBPH%X:4K^QR+ \5!_41 QD8WKKLE&'<D\*>0RUUI['!^7'T5<=H'%Q-R
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M ,,SP4;J6WB:I#XP95U??D[CCX=K>%\;C1^29#*+0JQ_R5(++Q.#9Z";"><
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MYRCV+-)48AI_D-0-"9*S@[^"9'&[B*[':ED2OGPHF=0!;147M?\N9KT3G9J
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MM!_^?<^OY2/Q) 0BOD4A7G( 5KGI\!4Z\5!+^;OX9>@^V)6,Y_.!1$B.-E
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MPYR)$3Z+4TDC?W:2D#RD1Q2LH."O<*84HNIZ8JZYS;=).H7YRNAR.@G?WDQ
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M#ZWIS/R3CI*4%BUT1BQGBB/O)TZCX*$=V<=EBH%)MA",R9"\Q%0Q?"D]FS:
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ME_^): ^$P&A)34:*_1F L#?BQ6RS8BD\8U^]_"+URF7Q\*Y$^Q8T:#J\X"K
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M])NARBJEK[9XD\2;?7+B#H0WK2ZJ"-[T.GUURI2W+M?&N%P7#D$0ZJ.P61;
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M@,"4((VJX<O<L1C6&M<\]H3;\&>-)V!_TB?R0?R#WS$)&C\XI1OA^ZDS P#
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MP>E?(/^N!<Z1^L485BED36!YU-6:,,Z5:M;:P;<:6 $-;)RC@1T65?94P79
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M'?E-T9AZ%2R3PU<9+''5\_MCIA6"<7_<ZV>L_,N(5ZYCK *_6PQ_ 9B\7#A
MM/_2YRLAM%+5H3_NUXN=%94GK)0K,GTS5:10N]W+VNXY"E#&7Z':9L\O5)Y;
MD$]]5F[T9C\2;\GVU=T.Y%-96P>@H]GL0&$'=;5+;UZT='T]TP_M*1H/!N.+
MXC$7E9=D+5 <LCE+KI OJ=W9Q[ZSLT=6O5KV]0H76+]7LV:GV,XNIG05J@.[
ML>9?P;JOBI5/XO_&;159Y)3*>6ZJ_KI%D4_8*IG*2/'W'JBF9_<TZ^G8L:8G
MS"CC[:EB1AM+>*Z>D:C:JF-QSBEN0 ,+8\9=EG2!'K-)9>7,1,6[J,X=%H)
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M06-1^S'52P;IXQ@^XC9XX+L@$Z8/,WO\S-Q'VLYH<@YR]G)!1!]&&?N-F#M
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M(>G_[B5QK /"%:QRZ><7J$:+)*&LPR7J.M_(2JTK=1!_-GC,+SMV0+](A>M
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MS!U8/1W[P[.GAB@2-UP7>]&CTRLT=?ZIVX'NOFJ]CH:,U)'3!3:'"USVS.R
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M+[+=PTU_TH_O^O[VF[[?'Q;8ZL@RG.4^6=-+VT!^X^PFN(V8#;[+[/W/@<M
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MS!38'6+\?_=PC71QW.0#Y1K@(,(%6;%U<?T2YR.($T4W<S;DZ;/^2OK#@R/
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MIC 6?IHM>;R1ECRJ?P=Z<J+1=93T F.*K:$- *7U^D+X-,2/&3/F!*1LYF\
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M@$DFS4!QDFS=LZ)0NA2?3&U04$OK5RY0*U[^[.I6MOD:]JK&,F8M#3YU;WY
M3FUT$X8=YJM&!X5"5N[@<;@R?:N4IJ' :? %^M_ Q$/KK;3RUX>).AKEN'_J
MVCJ;>B)\-YA9G6%.=7%C=5%K1,D#BEMEZO C'F4.<RMH8LROS"OLVPQ4NCA3
M"I6^(^BI0Y+?V!AVY[@[MX=-D:;V%K$[C*=1.M4H$UE1;CT[P0X- ZU19S3(
M'DZVRE31*39-F;JC\L/3NOPCK3X%6#1\'&7BC2K3IVC!FP9*.=%VK295NR9U
M@*W:< WGT!1JY675\O+6L4]::5D#7Q\I\Q:H*JF,B?O9Q08Y_FM'6UHZ-1#!
MNO\@[9<8\G.80]7"A%)!<FP[Y@;9SZ"S5MI"0_+:9^0T<3A!;-8TU7507J/.
M0^R4>C2(0J5;Z<+551_S2@EKA=D^2Y%HKFOBY\)Q%:\&O4W![?CCCZ?P]JB[
M3^'M[4D>WM&H0MSAJ+<D2Y,*<T>#WD(!BVYJ"W4K5J@[7)K"JK>XNACZ\XNW
MZEBP2S7[-FRWJ6&[7W".&+$;>.PPYOE6I%'()MDJ.+4A!LD@D0I4IC5"?'4W
M^^J)BQMFA)R=98N)*KLO6A_F8<[\[-:363-DC1Y'E;9$I'6^=>QI_/RO8=#5
MZV>KN+9'?[4?_5461)5L7MC&4C5!]0(<.WAOT&:@U[ S&F2[#[715$6G6/X!
M6_?TK*#]6MF>^DVT5#WL,<#FB1],)]MZ9 HJ;IEZ'G)5&X90_6'G_");7D)I
MWCQ>/2QN-1='JCH4@P=J:G5P%]OV*':,>8S;4:1!FN3X<;2R44P9FF0C3>#!
M>6<X.G@ [!Z[[KO4,_-5R!I"9-N@P+4O;"HOU5*"0+B'8S6G6H],&_N=';52
M.Z7BQ/.E_DK9R!0SH4^G+A9"56.'-%:AK<G8+U:^%I32:LMO<)2-?\%+#7J?
M.:LU3%_M=_IG2CD]*^.?G4O -19;:]5"J,RI&DA;M^17PZ8OC)\7>T3FY&#G
M:PHYD3%B\-DPO!P/FY-PWP*IZDKJ9VS$Y.%FQ*K"GHZ:JJ]_:V-[#HQZ9X_C
M;F7QB.$B?W3<>USB!_U;PU#OXOS@,8FMCJ@=JXYXS7BWA)JAKE4+MP+(2JN>
M2)8 :&RN;MAO5<.CQD_UHI.2!:$.9VVWX4J50FVER?I9#V83JTQ=9!L3*<WS
MK=9:79C5SKA<7RS6P:&Z3/*U45L[D:U)^O[YXSC3<K!,(=1<)7_8P61]Y>*[
M]I9.K;E0N^#JG_;Q(L,),*>J'HN"BR>;^>E^=JIQ> %B'4W$117$42U- R1.
M6?FU,KLC5_+<LJ95)1L,.\-^75D?U6W("B-""]6HV5!M1M);=-M<<^':CJ?9
M:E\'[H#NIQNPP.\SBTT1VE<T[DWV%!UT+WK]P2"30W7-)OZ-[?EN@&6/OL*7
MV*,<-N:UZ"M?7@O?@VRS[FDV#BIJW"OF)*M @:+D\1;4>&F V36BB2QVCL7.
MKKROK^-J2\='H((/7^&-6)T(B,^SIODMI]J]B1?G=IOUYZ"2/<VSS8$[&L[W
MZOTUK.<SLV'!B[:X'G?[C^/,<G[A3RFQ\7*_/SYDX^7_Q]Z;-[>-).G#7P7A
M;>_8$12;N'ATSSA"EF6WYF=;?BUU3^Q?#) $)8PI@ . DC6?_LVL D  !9
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MW?,XSK)H\$SE)GA6C,1B4$\UM.N.'V<,B"[7V:=QORG0P4#?D=+$M1=5((5
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M7NK.[Y\IX,0?%;$/8!)@(EHS9-&P&?\VY[CBA>$;TM)U'NB9BE_NP1D\1_+
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MWYW74\1JZ4GI(%D]63]8FS0:*V-.LGY2&G3MF3\[<WYH6A!-UJ%J,5YO;+.
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MGBMEGT.C&<(5=5YEE$7OT(;"7-0/&_,K4."6#!+\0N8(5I;%E=G6=< .Q.T
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MZKG^!?'ENFO#!8B&-YS_M+SI<G4W_]?V,\_MQ37YR!O\QB^D.(\2*AJWC(R
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M[?GN!@7V&X$X:QZD#45V\"!N!P^.;&^^$\^#3R1?&"!YNL?SH#?(**J##7C
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M-AQ.LFB8+=VGR4EC55&VEA1'5*B*@3+/ZET,A  6IB6!@;5?%QH.!MH OFS
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MH<P/P92&B#QG2IP^I7LMUDR>;QL,<(WZ;#[?ZWB4-YP]$?41<K&3GDNR3L'
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M&.U[&WP,X(_^I)<R3:,&'W\ _24LA??KZ..ZU X?67T[ID+U[3BHZ#16)'+
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MEF_PT*6J$9^Z#*YT^?86"!OWAJ-^Z$B8:&1W,(([.2(T/O^9347&,5ZAKD)
MTAFI_U0M'T<^(W_L&O<:A_/&X%<Z5C4.LY7ON#X"!&ZDH]\2SS7HN/5<@Y1'
M@WLE/7 F>V8[&SE_@\.3XNQZ_?73":4,/;G8F#9;))K:'668]C61A9< "VX4
MG#CP'J&7.N2P:^(]!U[A\UB+AN+>,:R=0#@D.-GF-$Q_X8*!28!H0-HL*B<
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M[A:@[Y!6'9=0C^P6#!OO5+^5\H/K>'=@(8&E"!K!>#1TS*(&],_AQ<#%H,6
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MEQZO0;X-EI"X.&38"R7.L05VY/KF.^35.V743?/ISW38=W*ZJ90:N$MAB0)
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M0.SE0[)R/TX=Z+QAA&0]_ $ONHJ_IV($LPO8QG)@>#CLCK:B&$6E 0PY TW
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M*JT'?"Q>R-I;XM<SHME+_'IITV:%+. -.C/9_7!&3 /VY-+&C+$^@_@6T(,
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MFA+/W'(<@E$BI')1.L96-7*04RS79H'GVL0&@IN'Z,D%";WX,@B' '1O)L_
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MEH<(3 I@R$D";AOX'/E2B/D2K[P&B44%^'V>7"QTX 'V5'H( F>.L^QB'$"
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MSN^S50,J-906^S];N[SXH9M7N;*:PFG4VG"D4HWU[I)QA/Y,P-:^>H)_1??
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MCB]S(V;#V1!ITB0%D_04B2M#6H0^]@Y]T,)15U7E */FTQ*W+,0CF,6W$W
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M3C24I3^LT)Y*NBI+F.EJ9:5TMPKY:(W9M',-7^0$R=A#Y<1<T^'[.MZIQ<<
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ML7:$3ZVQAPK^,'<&EU=D(]BR<-7'V\@O%;'3A_LI*"?;#A[A#J]8D_E!#-\
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M2E\PK]S-QZ=0K8=\(\TRPK.O,[X97<@8!<):2(VCMF$^R;KZ;Y!N\#\ 3+X
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M9KK#LO30W>Z8.402SWCK60,%P>0G8: A\#2/)=_N84+[PDB2S?H<&Q<-TPT
MRC)HN>IH]&Y3G<LCM3S&BC2,H6$,<<8PC/?D*(HQ9)Y^4C5W.![&<X"$P;'"
M^(.8VE=A5'*&71,PN T(G&GTV':GNUZ?7L=2J_-TK6=M5?.O]=G#Z_D7'KYU
M._V*&2_WAJ8T&DZ%.-X3!<<;RDM'>;'$UL(IKW8J!%A>>TR 8JH*5>C:@/$6
M=G;&OF]KD[[$U!_S&!M9Z&IK95'%4J4S\$5"I(3^@8U"4C))[)?+I?+5UHB
M3^+=*XHFX-KI-=U^]QW2L9CZ3G'UD_[@=O:ZP!X<XFHO0G(X 195IH'=')U
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MOYD2Y6)I8Z^+8*]?,\OZ+,F3B3-W-*I]4]C"!"R4$95$RYVMWM3?L1]4X?Z
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MCKB:[;S3.?H*TXRRCPM;5GW*QY8SP[)+0):=X!?6MQ(\R'FZC7-?\F!YS6X
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M"J.(-&9/\'B$!]9H#5K=X4"R_FE+4[M-=:+3J3IA$I5*(5@N#=.6KF4 HJD
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MYN<5/R5\O=9JWU*2>N=*!PK_>XWJ<1X^!!Z*)3BD:5MS_!@+'-[;QN3'S-!
MK; NP&I&UY)-?9LTPW+,7)O5K-9SUVO %?@^BM53QJ?=;INTA_ 3@*H6F@QW
MJ[JFZNQ@C& /-/##17A\FJ?DW/\^^GX!3/#NZF%T+:T>)+4S(RH2&B,'U" 3
M'J80EU4MRV%*O781EF8@3N1@1R"=:$.P-5 W-75..I[ND P%OC@QYL#^7.VN
M!=(%A9CT+&L.:TNWNO0_#DC4$V*&_:@O)**@JL!7.>"XP'1L4%1UA08)A=\
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M&Y]@\=VJ;;.$%)8O!KX9OCY737B@@< ^BYK")AG>FJ_GTGA?^5E6-7ZD@?/
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MX$2#$X03?BKRIQ)08E\$Z[XI"ONVGT;Q><\LS1M'VLBX!B$((=R)VPT^-/A
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ME+>,3Q]""1))RD(^60OO#*B4:%((-"NG/6&8@$ +J9XFML[R*BZ)K&%:[_B
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M8"O2QX4)VS"Q5^[EU]\ERQF#(%/A"V;QCL0XDX-Z]HY-&LT1NL'KCHZ7_<E
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M4<=S>*_"_:(%(1'%;$_2!5PZQI[E_P8.LO3<*?!!#74@SE6MNSN/W=&R?1L
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MAM=2R2[(93)MJ7<OD@FI+F<<I594KNHMLU5'05P'%#R0Q2LEKY&9';1[T5N
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MY3"9U:.3<0[''CEE*;D*)<@<TS:F,C&'HZQ(YA'&L[5<SD5F#^$<?3AC4\K
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M&48O8K?^=03%"Q8(Q;4^_'V@#S#\^5)R*N>\)86]_KR;AG]K6/Z&^)?AZUO
MOQ+8^4!OYXR ; [^U9FQ;Z+@7V%!CSV-^L7R69L\#4]D1F(6\+H\E(*HOW%4
MY$6:V;:DQ#H@%]GI9E3>RT@9<6ZBZR[.EL4S&]%1U4W8F"V]W>F7K[N]%J.V
M:'$T$/E?9I54@?P9$;<]Y'^]I-MGY&^0YQB3PUQLWIB6:N/2CF)-W*XD\M^N
M@"M&R..-:+F?-9=J*;*ZICXP\_331J#+]H/V=47PM4*L$@3/VF.U%$O=CMXR
M\\32?B%X?274)D;:A>L<34H*?6Z69+)[-?2ET9J=Y.3LW,!HS+&^-.91!W U
M1W4N*3!P15V@@R>=FA8$?/SK?T)[N2@[&6/W>N]FMNDPQS'#876%D +3]$S"
MZ8+51[T==O1!NP*C=(LZ:;V4R0VQ)L>C43G6E."T;W7T?K];3[2I,T/=1->[
MY%W+:)"81<TNL$L0SFWS65FN^%>I @7MIEJH@15X(XU6AN5'1_8-3^P:%W4Y
M^^XSLOQJP_,[_5?&W"I)H=@N-C40\6OCAC=:&:FU#<0OP=71;>O#=F\_$;^^
M#H[5+OA=NMY!CN!%V!MRSC9S3<+ZH\R_$I;^ A]\_N(W]E$:V6F;W$E9&UG5
M,WMZJY>G:38#9W;N@*\?FF_@B2\-S5?XXFLCF?J&J??;>6G6>X;FC9%2:WUZ
MW\Y'G\^_G=^>G[V^[E ]G1<3ZQOUP[\84>N_T+?MB=_-P3:&.553_U@'EWOU
MYOV^NY]K!,$Z>V(W$?>WGC7E'5IE=V Q!W3?ZL^V41!I9"LB9:'"%8=JW5+
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M/6*L!/W CYI*<NT%CPO==,C[W4?*PHH8@@3:4701G(YUK)W$&R4@17>FD![
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MRSM$H)^/0+?W,P)M'B+0APBTLKU#!+J&$>CG%?OV<)BIWP!=;C21=6Q7GNO
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M__CCCCN*OA2S6%&7K-,5,[#!;9G<+RZ/@9[T6F*"M!BE=5;T='EKXJ6("4<
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M\E,9?7QCOO\19Q*$?(YULNGS(=-RNXS(-($/I8.+JY2+47QHI\J9P>]SAK\
MN:M]KE<RC-ID1I@=W:P7\SDD8NX<\_,D<\TP__5!O*'>[;::C?B-%:V[T$K7
M!DQT;)#8]'R+O39S]C@=J@BO;H.)T"KNZ[A@]5$QAAU]T.YOF],V+KNI+OLZ
M<)']Y2(=T^P-!SO@(B5D3+8Z>K^_=4NE<6QD#Y(D*Z,1U7"1DP^C&3Q/V-Q[
M5>?;1\N7F8_%O)NFT<Z*:_7]98GG$E/[C([>RZ&P=.IG 0 ,VZ;1ZG?[6P!
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M31$QH&_"_[.[NO9#K[U&>QM17-3'F#SD@S39]]+I=HV<B6;K] V94GL:L@L
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M6^AYCP^-V#6^/O09;\P/%TV00J?:F$TL_!C0P;JC;AOX3 _6YCI !$_:!'B
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M%60*]P9'&JN:Q@Y,G=BW_OTET[7MN3ZH>9PI]AJ+"2>*=0M* A,>JN1'( H
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M8*Y@Z(BOCIC/)BY.#>*[Q&M8S\@W):MJM$D83+6 5]T$/@[<A96&;A!'<-H
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MPN*/'B@U$1VD^ $"FCS:$0,6R1SF%,.9C/-GP>MX>I?R,.PLB$.9P\A\[@%
MW%"2+$GOX;E6R2:DS9?N/HL;""<1&J?LX5/M<QRBH;;H2,CR8UC/#%% 3@FA
M%2'F\36P'X@<W):DO%T'$WZ1(T?\&>1 \6P6A'-M%$<(8>1>^&]4+5V6+HV,
MT6I94&%$8V<I,'<;TXM*;:[_&*#4E@^11DEO1'AZ+@NY0\=VIB +*'N7/$G<
MXS-!^!->JMD$63I('4/)MZ1$!?H Y=/#;Q,B< 47'J<%B!6)Y$K5P2!"N2ZG
M(P\/&W#7UP8MS;&?X?NWB'WI!D@5X)D6B&I !"'F00#C Q*7'U]T2: Z@XI'
M('QIE+V,.L]]$#B+WA/X)(,OCA^8$WM<1^%YG!Z9(2@1W3F/3P.-8?1 &Q 0
MZ4\SR<];I&*N3ZLF19K7CE3LV=(*0+LEBN+I3,UX25)">38+J2B!2$+A86[8
M#5Z%&^"U&_D#5KB0WWQ>H&69O4$N\G\[#\;?'P+/ 9S$@>+S9SS]AF4&[CG?
M3Q9_&6V9]7?[Y_#F7#L;7E_<#;^@CJ8MJ8ZJ7QH^[&/(\ZG1TB?S"$B8.9NF
M)]8R6PG%NIWN#NM#<'.83A_[TG_AQV3V8Z81&@V^B'7JJ#G-;)&/LQ%76A_7
MVBB45CY$5W@(,I>A(%IF&JU2"0HEPX1*(D(F!P&S$HKS*S*)!XM9"<L3$3+9
M#.]^EB3)SZ9*@%:2BK"=[(/7-&@XQ"R#W;6WV%$&P5;*3TM$Y<OPIHIK3W<J
M'ZYX?4J(5:?<Z9QU*Z'TTTK$,5J=#OS1RO4#)Q7K@E[SB0S(:R**6\)M6!3]
M%*GQC8O+SQL'>EZA??T51[C0&ZZY7V.<%:P=/^);C7Y_5G_)ONI/T!QA1X5Q
M$[Y!$"K%,XXE<0,KX=Q&O(O8#>4+I])VP[A:J]4Q>I:5.PCZ(#^):_0+PT'0
MM>(HD[GY&;3K 7EDHG_!YOXB$+_[S3@M@C_P9GX&//93$/'0-ZRX['2M7.'1
M31(Z_PS&+(%;F!M7X7 R ?,?G>X@+_!<,/YR-3GCLUJ);JJ*@];F:"B8:.J=
MHA-Y;3:ST;4&II$+I-;C"#:/P>[A"#Z(8E$UY0-]$E1"Z[,YV@>RRI6\KP]4
MF".&"XL(XK%442OADF@-.FW+Z.>3[V_C4<3^'8,N>?Z("F4C7!!-*DXTK,1/
M\>WWV_/__H;EA^?_Q,K$2JW\;6ILPUGH>IK1)39IZ=IGL ?!4N$U>V>@S)UJ
M[]%C:;8^TD_TM_'Q@T:&)B4C42H9<3CM.@['#^@4'=Z'C < WB-YBS?D?TY>
M1^&F OU%??P63#H6)H_,XA#9+(4H>:4\7SP/.X^Y)QAKB83#5&B@E%X6SZ,Y
M_$%^7ZX^9;VJW,V=K)>TG*10?V:[_#41Z+G1Q(67CI[%QS$WZRG0T.N'H9Y3
M[4I4YKDAL#IQ68)Y YW8!&PS^KD^#+^+@,@0M\LC5=S[>"%"LT)-N^(R";CP
M)7EEKB:J$O=*G=EJ68)=P%]&]R6RJ6 ?R7,$*XZ1B)"9Y^0)G25.^',RL:@S
MA7^/>3GI3^D;\3#.^%ED7K? ,N^>9XP>*OQUN:*N&^V.;@P&><T$HS+S:-$A
MQK'7!?/^WQ@" 7PNAQ+FH&LD[>QP8[^ LHHN(/L>= ]^MD/?N4JQ_8P^+!8J
M]9$34T4 ZWC\+SM^6 S:"(/3@H/_!YY\PD I_+.$'650(XU340Z&R$+)LU$=
M;^'L,>$X$2:O.9+E+#!2^DF 0#)47>6?W)];"@W-SJ#=SRG+1\[T$M3D)[,]
MUM0%QM3NMLLQIA2I-'(X"UT^$9K<^.&5O(_ MS#025%45]@_&D^M"D(G+7RG
M;)782R7NI1TY]K^% B%RUFR>>.[#86K1C/%<!/B2CU7[LDP_S6"9J.O9*"=K
M;SV:'-X9JY"6I7(@P]D\"(QE_JC-^ Q#[MC7+9JS622*,+[S0#2P?X35").R
MV 0.9"[J_WU "^P/IQZ<A!_895& @7_\HAT%/E CAL@1-\8R<8"?,N\\E.4?
M/'F6-_R"%8A,V@0KQ#$O/),-L?\494\PJWVERB02.%F5O#Y@#.<$T 50(#F!
M($VRZ64>ZY,=@J7+$XFP'9EO^Z)%G>2+:=HCSX7 # EI&O.U8T(<)B4TH?E7
MHM&;IM3H<]JG/!'%!T!;+\7L+1,[X]2?V9MF_9G]_M10SF$$E\><<T0-YC2T
MO=9%@O2$\/#-!Q%50ZS_$MA^DM\ON!!=H]:&@&+W+H!QZ[ZFY0DUFP>7C<+E
M+5M:_8+'>_*D+3J9UG8I6%<'*P%@3*Q!S\DNS<RX$I<CU7%5<E5+P^6;K#/Q
M_)5M1;%ZF;2J;[X-K!Q=UF<!NB&Q!J8P8O_RQ;Y@83(UX.X!M"/M*R\1.J?\
M -"B00L7L0]+)@>T=[>V%R#8\7NO^][+Y M*$[,YTH1T4OS47T;'^ O+3^[=
M'T-__!"$[PY3TL@-FT8[M]\%B%C=W!WK..J6&>OHMY1ADB7@3A5V22ZQA(U>
MBT(+OKX7K8@'C08KUYC$D0:KELWC^ 5L-)]Y]9+U%GXVR=KZ4/RZ3,K<)@U[
MEJ3791H0O2Q];F6RUR[F%CV 5#[!9<-F_> IM&<E<\(VGXZP?M"4I.4FK2J+
MXG5;73UA5L]52<[T*R7)CWZ3#*INZUP'O>79F7OF-N^X5/BE*H!N-':O:JP[
M?OSX\5=^O+:$NG+ X_#V]AS3<UX)TH(I6:\=*WG\ZO&KU7RUMI3Y[C<Q*6D+
M$-OB81Q?7:=7[P:[C2X)R@HE#[;AJA1@&XZ1%D,GJV=592="KX\OMZQ6MV6T
M!L9?EEG4Q6SH._@_&%I^M#WT(0WG9Z+!7I6-Q:V-JQP*NKWU"P*OVSO_*@9;
M'_$OQ;]<BL,N\6]KW0;KBW\UYNI@-.3:EY8&9"GO^;+5*+25 _S&)%W)2CK_
M*!;:F]!6)\?;AV-J416E!5:7;"Y4Q=JP=-/0C;[Y<I*J OYF?3"A/BNI!"=S
M_'X'.%D!F^^#FI$?7]($G*PQPU\IR*ZQJY3KR(&P:KOJL1@#S.>&[M[QOJ%"
MMI\HQA:5MFY.L(C#.N=GA:4P>%!\+'SMY$M+;UN]ZE6VUZ'1CNR*(ZYOBNLY
M@;4[7'^]W#I,7*^QWQ4S@7#Z=TY&C2H#^HKPTJNI>X>AL J(G,"]"3'W\A91
M+454IZ-;9I%7H0%89-8;B]X:QN?MK5H*JHZI]\TB/^ZA8'QM9=9*27P9^"?C
MBD*)FV5'[%'OW"A_H[32N9<U[M'$.)YS4\^YQAXC= MAYVV<0#WSL"<-M=[_
M=^S2L/NMAMVVF862%?$;R/=!@2N& ^@:P0/6Z;D$SB6KCX([,/36H+/;L-E.
M8K/U1)("'\;6D>3U.N' TOOM+3@OFJ#(5>]/OZ*!!=B6@(]3H*]C:1!.0ZW(
MD[YOP;XCGZ#1RG'=!+I?$+@W^.VKR;>(D;55&[9K=09ZQ]@QWZUYNDRS$"_'
MR7>!>*]GY5:OK[<;E:=56WM=\3'OT[=LGIIXDQ/$6"U9VM5637+:-E9;@;/-
M,);XEVLC +JMKMYJU\6SO"D.[=6U_&80GM>J;X3V2YS,M1$_71/0OEND]XC"
M_(/!_MJ*K97"^,O%\/>++Q=W%^>OKQA3S^$%-+MKW]Z+"+6&B]RWI_EXU,T\
MZMHRK.W4T.W-7[AM0_O@'*RU %A3G8U+Y^D>"Z/**M7YRCR9*7_-05FWI"6K
MIW?,5]1M'*!OL6$8M[0V8RL8]WJSKFWI/>S1VAB,JS$[3]0=#0>^BY[<P4+,
M2,X_?SX,$;\1=>2KZ;*N]R\2-G7CRUU+MWJU"Z,>+IZL"=%L"4\J<)*U]58_
M/['BJ &_+-Q.E6KV>!SB\!G).%UV+%?;>0F/D:]7XR4[_'"^I&=3-]9M&'K7
MS ]];'CYSA'/MX7G>=&S"SROH+S: -/QX/"\QJ[-7)E:1D UH.;B\"MWC'RQ
M6ITEE=G6N\8A%_#49*UO ?%S8JS.HJLUT-M&46N00T'\VHJQ8^7:L:*I+BL\
MGG,=SKG&SJ(,1U)][ X;'4B*P49"/E^XA@,<[U@X_00  5B-:Z;A]LR6WFMO
MP4@]^M&+$22O!6X302KPGUL=O=W><8U#HWEB605NBW'(HY-Q0[HTU]6^)?&M
M&O)PJ]W2!]O@X4>'^F'B>ME8;@W%D87Y6/TM9,<<G>KKG.I'9WK=?(IFOC)/
M\2G61CX9NMGKP'^.?O0CSE> \ZO\Z+614X#S+5,WVT<7^JKM[<.%?OOG\.;\
MSZLOG\YO;G_2SO_[V\7=_QY]K&_=QWH\Y[=QSC7V&P%K J'"M+$]<T'??GO.
M4;.=']L53*>!?SL/QM_K-:'+[.B J'7SBAXN9N0':FT',RK0_$R]4S_,J#'?
M6SUP=SR.I[%GSYD#QSIQQVYEB0]OVV/X?B/ZRY=MWK"Y[?K,.;=#'Q @4@[J
M$S^GEU%D!)OYSW<GVZD9&EBZ:37.>?CAB/%[P/B<Q-D]QE?0@+[?U[O=+41O
M]X;QM74Z*)[R"/7XA\ #"$4_41]GC.DVP.W33/?A9H2=KW@E)5(<USD=UH4_
M]F)$AVN>T32<ST-W%,^Q7/PNP+ 8D&H8>![<<@%$&[*HCN*N.U@B[AJ BJ8X
MW ^-6.V;()R<1*PGX50@-7M=W2B4F@U Q9*$4ULYNCK/H2 830UYZB-RJV_9
MUJ1FF^M.;R..DZ]P5D)]0]_)\Y_:^ <;WY*V'G& (VUMC;96A=&W25O;['O[
M%FBK6'##5=2Q"GZ8R1V+X=Q<, ].V^2HI66ZOL-\N'B2N2H6/V:HIR6SO0DP
M!D[V?O?;W0/#7B#!=&;[SYC'[ =SE,<A-LG37'CN/@19/;-#&LDQA]L!'1P<
M,.O0SZ$[U2:N;_MC%\WFN3UG.*XE.OWUYUG!5ASW<0E,DDT6K/S=;Z;1+G[A
MSX5O_/4AE*\;A<S^?F)/X#V_P#[N63%L'IC0@68_/FKR1!-\R1^V_$D2=ZL%
M2MO/O$DUD2U^"ILS_45 ='\,_?%#$+Z3K9W_OS6[0$C)+4R  $\F]M3UGG_1
M[MPI'- E>])N@JGM?]3HU\C]FXE#!<7*9R=R/R[0'9P,@' ]7B7JZ@8(M+AA
MJY?;,"A\8?SGF<:9@@9<X4].YZ+'==&Q+BYM]8#Z0I2![YXEJ'HA4/4V05!$
MYR]!Q'7/,R  4#[A7O>1T66^PA<M39#GRL6F]+IJ_9^#D$CN[B%D3/L*!_T0
M:>?PJ*-]M</Q@]8V= TE VT".?-+EEWX]?>NKYW'81!]*'X=\2KY2I4()',%
M0O'L6018*?\J0-7T7I6H0.0PSP/L& -'(OF$_Q9F"?Z[GE;/TX,[9R>X;-B?
M'SR%]BSA#]WN:;\SZ%?O8]C<@[!BE<9IRS+[O;JOTC@=M#O&/PIHY-=1^/-O
M*IWP"QE:J5+'J!CZ@^Z@_M!O!HY8IP.K-RC"$;EJP )$#O@YPU@S/ZB(T]XO
MXFR,(_5U#^5Y(L Z'0/'?LQ0:$?:CJR!5=#>$JZ_;#4IWZO#:K;%K0[AI%+N
M4X?5' +/6&YO%["3ZS"8L"AR Q]LT@FKH+?E<O^41+R=>*D6.4'1J;^VR- R
M.T9WT/[++)K@FX#U,ZNP/,EH&?.@FD(EC)?N,G4O(:[]=GS?"Q9*+K=5+"P:
M$;P-+&PG6-A^-1;V=SEMH!H,K"_GS[/W/YC/T"M)8SR<J>N[T1QUQ\=M3O&H
M7,$HP<LW(Y5\[KT U-!WAADPG7,-NX;\V^KIK?XN6Y54K\;N 856,.(-42C'
M;7>#0E4R7[.KFZU=CA5X>_KU76@_,B\QU/>OU^R*(5>FUN2S\3E,@<[.T0./
M><H8IJ@OIVZ;W<8I.8U$QUUHV?E4^5V@8Y5<'W;2.'2LKS3(L_RKA4YG@O<W
M45NJ3.%>-WFIOLS;'.B#WE[<)$<U&Q%G3?NN^K+9MJ'#%NJ)./5EIQLIUY_8
M+(2SM F+Q*12^-;?=&'?=83-T<=+[70SLLTG,ZMGA2:R<E(UY/IMO6=MP3/Y
M6I3:H6;?0.Q_F?J_#>S/":WM8W^5HLO0!^TM3!&L _;75_*M2?7PDDS+/79U
MVI.A4;)X3Y)??NI2 L8+?QQ,&6:M5E_!6F%HMM72C<*^K_L^_T3#W&&Q:NW,
METW1<;D)LSUTK%(<= $;NT7R8-_'OP$VUI?O;V3QR#)BZ532WH-:$<#WGO?>
M-^5-VSO]G,B1)\5)7+@I+@,_F8-PR;;01:$Z&=31VX/:-0\Z6D![M( V$GK]
MG-#;'D%L-T:^#>?O+JB@B6V%BHT@0 PR?Q +J#@!,,8-G$8TJ-B+R516P&VH
MR.;G?6&"H3NOOSG5T3N](G=>(Q!H'S9779%^I8#;#M(79M5N!^FKE%N=@=X?
M[,UHVR'.UU>8;639I>/<,P76M9%[&W<C:5"U1[F];LX[C/R@M4SY/%>%0;VY
MFMS9/^K03NQPQ>[F^%M&R=Z?2&X&/59CD%9'CT6=U>M,CP>K$>R+'(\-A0I@
MLJZAD-7,AD+MM]90J%^CAD))^R#$W=M,PTK>84U[SQN),W_\_.$5/81*K4:V
MM;@F#;J6G8$V:0:TI(O0@7<&:ING@U:_L\]^*I(::][VI=0R,WU?\JU>^,P9
M^A>1;Z79)U5#?._M@(Z(4<NM'!&CPF4. )H=TUJ*&,J,$+KT28XP.J+'6T"/
M+-_(J'R$#ESMHS_SJE\M-W0(!17;UIU*9FXE\*Y'$ZK%Y610]S_VD-F6@\]^
M6X8UZ;@4070\L]J>V5+EX7AFM3VSQM-9?<7R^MBP(K%_MSW;'S-=^\3&Y-J7
M/BOS0!HXE.@/^>H&#IU>Q^ST![FQ3F3"7D11S!PU9G-Q^7G3M$-SXV$/?\41
M+B+QE7(5&6-2@8^>?'J:WZ., ,Z%=_@>]C"GN5F]1JH);>X$5_NM5M?JU6D$
M67VP?3^#I[>"ZJ5B&NMB[ GVY]>^PU!_HM]MVGRG5 2_TS>M?J]5)X)8'K3?
M*F4L#N9=DK5N=/7^:WIK5H.9DF0VP\S7ES+51%2\MB]52=)H]]I67J\Y$-+(
M87;+TMLU[!K;Y'(+Q=20M19[+W'9N\M[:9_ZD[W#9N]1B^-9'<]J$_6ONOK"
MSJ#5Z^1;@M:S)J-RM6YI"F==D/S#86-Y!?5');'<[+;S->7UQ/+F(6D35;6-
M',:_CE*?\?8F<^V_6*&V@YE?Y!@L-]2XTV]U^ZV\*Z0Z/_96!=VK_-C-P-W=
M]Z@X4N*>*'%@%5!BG;ST>Z/EU5[Z(R$?-"&_+B90=?E?IV\9/:M6=+I*$]^[
ME6GVNGJO5S0DX'#(]O *=VO82*H"PNT8AG&HA)L?QV3IYINGN_J:X#M)I7XQ
M>]C7:G8YS_?%.%F3U1R/ZLT>50F5N"8[?Q/GL+K%<RUV?LQR3IW6^\X':DZ6
M<]_HFYWV-KW#QRSG8Y;S6EP5T"B7VMDRC6Z=C+SZX/P!Y3K7'.%WE,9L]7K]
MIC@T]I_&W.GW]6YW+T/.CQG*56+]8)!OO7<H6)]#VEY7-YJ%M/6U(/)FPAGB
M &)%%3,>=VAX[BA?=8>&?=V 5X(7=5H=J]-M)=HF$O4O*D;9H(I5I36^IIGN
M8>B/342U4HZZ(YV^PKM6BDZ[1J^7%OS5EDZ;1&OUE?(;^0GK5J)4RUE4+_'9
MU*98II80/1[^\? ;GTKWNJ*4=M?J6LV8 56Y*VKY-(L&D,V;' ZZ_V&(0#']
M?CZT44^*>2L(7U\M>(,Z+JLI.8&[[V=768G(!G4@1M>TMAESWYO_Z+ JLFJ-
MA<L)IYI03TTIQ^CV:A4/K0_M\9SP(^$UG?!>T"'C]843':O5;4A/J!H8=]V!
MI9M6T;C[AI%9 \N:=IS,4#FAF899J^2U*@DM1R?=P5NADV(S\=?CH$#:9,'*
ML>EDIYF# JVW-BAP4*-!@6<)JEX(5,V,#CRSHP?MLQ<\1:^8$2B(<>724NHL
M,TCP[B%D3/L*Q_I0RVF".81;,5Y0)0_EOAU.$UPCT;N#TW[/K++B,N^7+N7U
MW7= ;]6P(CGZ/(^F-'))155^86O^Q&KWM?\.BJ5669L>F"_#$4T=Y)9A:YD?
MJN\EMH\TEK+L9ETE.\FF"<HF;1(&4RV8L=">HX:&>O$C"'46_5(ME/801Y-(
ML\MO[C(9X C;%WQS=T188<+7^HD)U3LCDA,NRH0LX6,P3+-K6&8K-PSDC4>1
MU\\8J"+MH:D8T^ZWVL?VL54B3$VTCJ&#Z0+DO='F@>8+UOC+#C!]+W)QPWJT
M;8G*O0+C>"3;/Y(=DG<V4<CHD(ON$YN%P&=MXNGH.K*G&"CXVZZDS*V<&-L5
MNI2I $$AUND:G9P04P$%?WN,HBF^,U3@5<.ZD+;>L_:D!>V,&]40AWH&+"@7
M!]\A#E6I&1GZH+TGQ:C>[',EYY?15(W]F&&<X2B62S830O(Q.X:18\$2HA?^
M.)BR<PY6,-+K;(=V]/:@*&Y=;ZWDB)$YC.ST 2LKQ<B)^X,Y)W^S,-@R_SYI
M'/[M6RN^2ASJ'K,C)EDXF;W!1!NC_WUF/Y,Y_#85G'Z[!7KR(CTD</N"8+N8
MSFPW1""]W/>S9>6X:_;JJ=@<,NX,6IW!(->69P>X4R53M?1!ZZ@4KV+R&#X9
M/]C^/=-<7P,HG1#?? K"[\A9Q_;,G=O>T8/8)'?5\4AJ=R3[UI6&4UCW/-)"
M-F;N(^:"'9Q4*Q?\&L#_-W(^'S -0A1HGQC_WPM_.!X3Q&X2@-50-3)UL]^O
M73#L4/$'%1-T>70'^\2?*M4C4Q_4$']J["Z\#AEHO(XT-2,*Q@3S!Q9J=A2Q
MG=B931#*95AQN]7JFIT2I"2 _HE-6!@R1SAPAKYSA8 ?$MQ?[\NIDB\WSY=S
MQ,Y%[#1:5JN7LW_WA9U'3^,^M>>[T':8#+R3'CVSGW>D1.^V^* 4:95:4#DB
MZQ@]*Y>\N%R;NN9@I_.HH3YN@$)E["F0M \L>:-8:QH]P\BU.MLIUE;J)+7T
MCK&7]).*L*0FKM1?1]R;2G&G,'ATL4!F]*R]CWFI[8?"$I#M5( T4R\K55>/
M!&@.!H-<8Q@ /M;<7 O0__[\#>!^X2<ABV$"\SKG(O1-W>@7S0?80CG5AFA2
M6?^(-X:N[5:_U\J%8?>'KI6FG1EZIS#OK GHNLLZI0.-)>\L_'*$X)N)21<4
MSXH&)=GB6>THC!H6!CT>2>V.9-^^-=!_QHPY@L[=*(JQHRTF\#EL-#\X;E]&
M8;0LH]LQ6@45F@2ISP"H"P&GJ\DG@%(-76&]UG;FL+YA1:$4ZG3:EF7FPA:O
M1)W##DW4G4>NB4@O8Y\1=6>NBZ^W-@+[M6LM185=H]\>E&3@2I??&O+Q;8VL
MJL@Y7!=MM&9+K0$%M-M6?M)\-11PV.)H^\BT2[?7^J!(D6F_*\M^QPI<F;[W
M2#M6KY.? [[$7_Q9@N^U_N)M1S6*Q<A.W,2':Q*4Q*B>8;1:N8AUQ1BU5[9<
M$SRJB0?UZ(=KG!_N>"2U.Y(=ZTF+,0_7?V31;AJ&'D-@1P@V4 1NZBP;CO\=
MNY%+>E(PT1C\:X;5RT<7P3Y<!#W+L/)CB*Y%QX:[@$XK9%_M\8/KL_!YZ#OG
M\L2.]1[UPZ@C\O.UEDH*L_JMOI$O)*P0^W?<?FRPEQX=KS^M6A0BEO&3%:F#
M!ZD-EG5J#%K=5B<7ZESBU+B0T*O2J;%M&5(3IT9S\:@<*QZT^P4MU"M&I'WE
MYQ;RY1TA5ITR<.NB"=5$R6F\<^9X)+4[DEW[RY*V5:0U.7&(RA$.+9JQT V<
MMZT<==JPWD69A@(-_X.6Q".(+&I0$LU#=SQG#OX 5D;V@G+G-4$U7^8H9I>>
M_^!]Q&[L.3N?3-BXCFF)[<+RW*.>M0L]JV-U3$#,)N+DSFJI>NT]!LD;HZY1
MI,2>:R-V[_HXN1N]N9+I'[U9.W?E=CJ=EIDWQ5]%V57YN+#+Q.NHLJUW]M,E
MJW:(=J2)#6BBV^H/6KEFY'6@"?/U--'1S7Y]&YTTRHH1LHQA)[G);DV716":
MIR8"TPEB'!:M=$49I7/L*ES8!C2Z8F7EB+%C]/*]YNI C!6DZ+?U_F"/'2/*
MG=3>1-'A(G6OU3>ZN;X2=4#JU]M"H'1U]F:J5X73Q:($KF([J((?9G+IZHK&
M#.>7?-2F=@C6SLD\F,':6[POW0/3[/$XF,YL_QG-(#^88U/2$)O5:2X\=Q_:
MGC:S0YJ(@:XQ."H'&Q0Z]'/H)J7U<%\T!S.9PL^GO_X\*UB?XSXNV>BJE;_[
MS32ZQ2_\N?"-OSZ$\G4CL.>_G]@3>,\OL(][ECTM"9L'A@3VB]:9_?BH28F_
M0AF0/TE4:+5 &O_\VZ_1S.:TAI_ZR^AT_B(@NC^&_O@A"($T?\9;LDLNV 5"
M2FYA L1Q,K&GKO?\BW;G3N& +MF3=A-,;?^C1K]&[M],'*KFN3X[D?MQ@2;@
M9 "$FQP&H9?\O+I%B=< !L^>1?!-^5=^(>_$S43]8^9Y.#4><"SYMTB^PG^O
M(L<5*A._P2E:Z;O\6;1R9S'Z#5C)GV<:YR4:,),_.8.@,Z*Q])=$$/. </\L
MP?T+@?N?$]R_37"?GOL<A/3(_"%D3)ORD?>,1MYGQMQ;U!62YMWC8^]=7SN/
MPR#2-?9CS% QI2I,T3=R7=/LI9KG:T!949.UU0M<RM/HQX0[J#R,L%U<2-8V
M4YV7&W ,+B<NXRD<Z[A 6L)_+&-@%=1 V/,X9%<3T78I\$$$,I"!,^1E8<RJ
M]D<O@=!28BZ$G\AW["$$B1VZB-APZ<3HG?8[R67!)7$HL#MYSHH0#FI.92JG
M4EE P<]+&)E._]8C /]$/B?_>_2;<<J/5+L<WGV[.=>N/FM7U^<WP[N+J\M;
ME62+_Z< #_*@*=KP3O:7XT':>^0<[\ZX6'ZG 2MY1S>]^Z ]V1$P]7$0S@)
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M#<N*X<<@PHT*KWMFL*A'UCG26R1P\EF+&/M.9A&!3,&#2>P[".LPB.\?>%A
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M<J24R@;*5<:>4H2.?"0(Y\I\./EKL, =TG'M>LIX?78?S&E@G U_/_%G=4T
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MUQL3/;.;F[,".N-P+&L(K\/ AS]Y1I\P)@[4I-CIO)6A$Z2E) FTT<;U'1I
MRG49H'7.#1H8X-+^*P:5WVP979Z@^<UW4?DB%A<I/"]%-OQ-;/_W /X'QVX/
M;W]_]T&6H UOO]$+3XRVKKSA(FU-IYUH9WQ&X1<QN?,NF '^M\WNAU^TKUG_
M3/9..(S"5YZJGY5%ZUP?7?#W2 _QDD&-V;"#<,E1U[W"4%#JX^?S&[$M/+TZ
M=-'=J2>?2V<HZB+70^1JR[&:,TJ0%HVS^2Q&V)2"@>H&R803NTS\XK(& )['
M^;@G7A!\IPICGT]N2"KHR2K :[$GK 'L-)Z"(36J4/W% N69+%Q(4T-E_$SJ
MQAQPT5BT.<>X#Q JZ>JD2&F?V)BXA69T2!Z:I]JY'6(5I9-FT,]0P8?U.5G%
MFV[)XI:R%)ML#-Z=7%1_B1!=Q$VH!QOS&A94_J*&AFD<MG$^O!2^ * !IV8D
MS 6R')P8IJZ)R/8=.=\$]?6LU@>@S%LJ^9D\2SM)H7P\8O5)6=?E*FWA,10C
MW@"V5$A!3SOBK1P4R]K.OE5U!IZJ2Q555E%2T,!U)3Z+E*MJ8'%1$<4LA+>X
M,X^[+I,]I4P:L!?$&'WS/G8=\N_S"<"8^L_+,B(*2E"P;RQ*Z]35/ 4Q<((1
M6T$'*=K_E^W'&/TP)+KG4FY2]%\\H/HA]UX<J6;?, >9KCK+M![0WO^7S8<<
ME@>J_&Q5UTD)<I8!;!*#$7C:/"WG3-:*P>^)[J8KBAL?'(=VW@Q'T"M26BT+
MXN5B@H&D.F :S9_%(\^-'M( %;%??$U6J[IEH!2D8>ES6=9++NV(/$84#Q%!
M%H2]P@[@"?HDCQ#"9R7_X-Q$?%K0?];I"<<+#%))<_"\;"!MX>236*OX@HCQ
M3-P0RT,7NZ'RL792;,C28865RO['L'*4[Q>*6A)LZW1DX3&R[5F S)V7U@IN
MN9Y5RDQ;V_5XO<YKI_?503\PV\OT [-]TAHLUP]^P9'M&9BG=VJ?0/L#]1%T
M[50S$+*5_".A[</J0W*0 F8XZ>VJ9L"KO)+$.\I!1;\K'(RGSGE4PX=8YRR"
M#0K:A*O$-.#R1MIJ9Z6V*JK3?:Q"+,2B-/$G$](6L,>0"]6Q9X;GX(^HI&05
M!S=)/<0<GK16E%0AJ=80A%!E$&@>",+=E9Z[VSB9K'6EX$>&CQ3Q#H5C"_"K
MW%:-/]"-=M([JE$JUHIWE7I'>K[\*.492O]=P78*/EET":Z4.>2"^:68TGXB
MG>ZBROAC@?Y59@ZB8?7,06Z Y#<_!IKS;K"-U]!WOOG"[$!AO5=U<K4*62.?
MF77*,40[N[FXNS@;?M'^Z]NG/[Z>7][=:L/+3]KY[=W%U^'=Q=6E]NWR[/SF
M;GAQ>7=Q?KNA6EDC]G/'.W-0N81PU910*Q(7E3(P&$<RV-]9$N#&T$ 2WA89
MC/%46K^DP?'>=Q0,510MS#A&$TBJF%Q78TX^[5;/3V.0,4T2.Q%;6 *N3=&,
ME%ES0HM-'&*I%XP>1+ZL>J)4S2R->(OHO=B>]' I/'@AXWIU3C'F>JN9$EP;
M0)\#SPP0W2' QN<-!/@Z(HK"\YS%I&I>!42VD(O#)5OSDYP23S(4>6NDNL!_
MWP=X&Z6?GFHW3+8CS+I%E-=G2P9 HR)_"F4*;R)FUINA&T5Z7VO5KHSPFE4)
M3+JM-I%=XZ61W0V 7>.(;@4C; \^DKOSH<#;CMYN871L645Y+2];\Z+:Y.=C
M7SX79*'CBCE_7(2@5<S"A8:/F\8A]UC(B^*.M"22R45JDN)=(Q6+"26(6[QV
MQH/#_56R2R-/ ,O *>,-F\:1S -<T-=D[Q31J6_)RXIG HF F9+SF$EI%-W^
MR"+UL>L9:E/"Q97)9$P2RRBW-1F!*/TJB?9H9S(CT[PZ1:M,-+:-=(5F]9_<
MTW(5='(3E=Z1<=@$\)J;SUU,9CSQ?N.^DS;["I)9:B$#K1D;6Z6]OXK*N.6[
M,_9']@-ISS'A7UO2>(\351+F$F,A1"M*+Z"YFS8?886ZPQPC;[P7$JA8Z-?.
MMCYC#.GI_CX$\Y=6(9_11=M[*J^7KXQ< +H=)FVSU?YAD7"Q21POO%=6S7-#
MAA=C(-#LY/:D!QCS']TP\$4G<=P613'Y"%1=I1]9140R?L9L9+<A%C;-&<VK
M4X?N\?J%F%0&[@[DU4!SZ4M*EDU] I'JY8)XWRE:RR*NJ(!0%B;3>7D9Y(3[
ML^U%IS:8@8*38#65FSI9^5OA,=%H4PDISA\VZ_2WB*G-X#3GRSMQ9$:.%\T5
MY@5+$W1",?Y<,SC6,#,ZG2016.U44[!L8R("@HGM1 ZSP,_*JASTGM9/A9?.
MA84^)J!Y8\)W+OT_D_*_<CU$ 9+;)8T59>?#A-IH JD=?F?9S)Q)2)W2>( B
MCI)*;QDX<]2AR5C1VPQ,_[0H()1AQ-%BTYHYHR!:,_#YA1(XMW_.$!^QC$)6
MDN9IGC@H*VCTDU$LLZ)65#WD>_@I6B8VL/PNU@0WD8^,BD]YH0TIFCFOX@A;
M%J#R&ONN:$\LZ4CZ ^5L"K&SY-RE0$ZFMWA>P#V'^F(QA_2[4;WVI+"[3237
MR7]T-XM]',KD^'WQ<Q61%QRRH%T]!2> KK,"\M:F@<.\4^T;#<VYQ9L,[7W2
M@4K@)MS[09>GGG:+3H)DPH^JS&@G?VDR')X6)D853+GY)K0/Y?>?HD4?[J*#
M5=A0(@,!=4%*0:"MT::SRF"^CY;JD]6%>@V?XYT$,.SGP1MXU$\73F6Q(USB
M$TC$1$W/Z=:GVJUB@BT87CG.) J9@!ZQFOQ>N)8SRQ.A<V$#%-N*= !)+D1*
ML]G1#V1(BL?3[L/3*5#I6&%%0A#F2ND4DUC&DWT',#JDJ 8_>@Z>9!C/PD&2
M0XPY40$*)<I7#H?TO/Z9LG7!'P&Y"6=-9: SH:LN2\G'V/W,YVB^8%]GT 5[
MI.&ZXHAZ&H\ <ZKC7[MU$5UD:K1]IZBC 1=W!7T'FAN N_ 72OMX(PE7"BU>
MW,\SH9.\$B&ZTKA*QK3",)R2!JWFIZBDIQ299KL,Z3(<1^TLL"V09_/LDH#R
MO%%,4L M33=PR:=%R\7V,;8G_$ BI:FXZ8QD2-1WPGT(9.\$^F3 9T4#\<%N
M_"2;*X(SLDG;YJKS#SO1#+$-1G;=LJV"BU&O"RQEY"GE<]7'%65@=\_M (<K
MU<!YGICL+L.7]"@#@O=\:#U[Q-$78^%[$+T[ A)CO!O.(QZTBSECYRJ+*H0\
MR8,D!BE3Z9F3DU$+ZEA!"#6%/?8[P?8]4AG[5QRZD>..\[,W4N4OTYVB^/C3
M9D.*!I4R75%<K=,=$[#!75DM(&Y/@9[U6F+^M9B1=E[V='FGZ)F($R< !(;O
MPO'$HDF]\$>ZX3B><E=)(BRR^Q6X)["+6DPK,\Y15B46H3Q^.1QM88T$>![$
MIF+K)*S*7'*7Q2 GF1V*'DI2]Y%!UD>;BZ-<_J#L[Y%X-I+:>HZ%J9FW$/PE
M!.7U[J)BFVO(F!JF1./36/0JIB-G/14QZE-MZ$6@CDCYJ*Q(@H5'STEWR=9B
M((*G;$]VN$J&.R:MX ODP&+%<U(JCUU2E'8?BYL"4!1[Q \T0MW>4H0:(\4G
MF3"U[3W9SU$VN)P+2F<BULLCU$5!:?,8E#X&I==L^1B4/JB@=$F38K6^GBG0
MH_:(46KSYAIVJ+-L0%[[O+4(KVQ"-0UV04T07<>U0WS5^R">H\J@G8&:X]@?
M$@46=!+&'=0>S83U'[E/CF0UFG.9UY#I)[^7[:TVL^?D'W.6Z7"X-J6N<X:#
M9ERI=X.5\2^NNZ-V)]I(HY\Y\WF"@]":Y]G0</5FYCISJ_)CYT%T./MGQ=>Z
M].A=WM2-FR/4=RT))RDZ8\:92E%","*>_Q9AKB++)EOSHHL:&5*@B=2$4<0K
MZ0J89I+K+ZZV\76HE3-*"E^R3O'ULJ>XA*K7)F-OF(A=VXSK3M\R#3/7%>U+
M +1#LO$NM!TV])TK!/Y-TL8W2LM*CAG8Y6A7_O?HMPX8$5^OOF'R]<WYV?G%
M/X>_?SDO\O34W<]]EW5'"NM*:?:<'>6[.-Q(%@?E'AO9'B^8(0,FSPB*V(,I
M2X5YJG'ZTL3IG-A7_R2_Y-#!16&)U/MW_QS>O?O ;Y#ET:HW0:8NB/9B"1&<
M2G(O?U E2'+0,ON=7&^1V_$#<V*/74U$42BG3Z)4H$^AJ?KW*8W6HM*V9#.K
MC"6R@?$AS:]!UFC)&%?5&"4;J<^*ZBP^=!(*2_#4PF7+JQZ;I!<!4>>HTDCZ
MY8I#-A<Z85Y/#Z!JG>"V !9^\!3:LY=JW>EBEZV@C,J?62;MMM&+W%Y (*OK
M%/']6@.F$:?7B$5N,[5D060>/)9MX#JH&2,O< NR+IM,2AA]+\404'<4-6;+
M>*%N&J&4NDS_L9?-_Y__Z+>[5DYIV^*N):*+;7?VLV^A>GX.>8?8(MVS"S0Z
M&!BY EQ2F$E?!G4Y53#?:5BJSTBG<MC8G=I>1/_@]83_^<[],?_%CZ<G3C _
M$3<4:I\;ZYR4T41O./]V\^XW8Z /C($TVN4.M\WPEB*VN>: MR2<CH36)$(S
MK$Z[M5M":QOF:PG-TCL=XV )K;%*Q-9P^6K1Y;%'96$GC#//0O;,)\QNS^C^
M54Y.+SIIZR.@=;/;KA/;V(L0/B+P.OFW)01^O>"S]+;5< 1NK'#;APYW%\QM
M;S<.$QY^*O26++A4S%,3;W*"&)WEA3Z5MZ/W;P-Z3;(?K$'+LA;YIPP-I2ST
MDLW%G-;:* .FH1M]<]?,=.O4MB>K_\A%Z@:])G$1<]"V^B65LQTPEPH\%'V]
M/[".S&7=GDHI@Z6R+-<E1I;NC;EA!N7.VPG*]#K'=9(YFZ&C/848O\(1S;Q.
M*#%>Y#S2<GG"[RFSY403?$];3K^12JJFU>L99HY49;W"YR#\!#@VG\1>GGS_
M!U=^!0LO0[TG$1LC!3_!GB/F%Q%ODD7R>C(NQ;UJM/=79= L[-UWO0+^M7#A
MPV:Y1V\[SQ'.9M#I=,V<OGR-O6/"^?.U9_OSH>^<_SMV9YCB>DQOW"SAH"L;
MS%[?7%V?W]S]KZY=?QE>WO'NLO_][>(:F\TVHWI?(H5.*>1BH*E$#)EE* OL
MDO[ZF[2>+X&PIF&81C?'W)8B["$F^Q7G\ZW, 7Q#R7YRV]WNZ<"TMNE>WCBS
M1Y;HK5JV<0K&1[=QJS9.!]V!L4VG>A,2!,N RCQM=0;;#+4<T3)=M04\@ /[
MC2<5;A<S#S&&4B!'MM86;/P *GW(VQJ"Q>R.6:I9[2VS0%#\X3HY%V57D;>R
MEAY* _3@CM5JY1(=EJK!?X1!M+^TA[_B")>W='6_/]\]SQB]@]^94(1ZUQ+'
MIC'06]V=ATV6>R0%$ZU7IN.;H64I\)M$RVW3Z.^)EC?W2!YI^:TF4^Y.(?K"
MHN@7[+<?\Z'/V1;'^U:(ML:^2^DCI9J,[)6;65VC:Q0$2>5A?E+.$O[V&/X!
MS$'M]KR4O=0G6Z.G#[J]&K*J[76AJ40!V>?R2BD)M2<PRP#E?U!S GM]J-.T
M=-/LU([ WI+ KX-S9&742<>6A$W/87D[QMD&BLT2(-;5A+/:+:/7+6W"7;+Z
M*#(#0V\-=LYGMY\9MD<_S)%E5,8R-E#5FL8R.H;1*^_UJ8YEO%XU&UAZO[US
MVZ>9+., ,DJW1B>JH2*'""8#;M:GAC[9D4P++45Q':,_,'-"6EU$94*YNJS'
MMMZS\A[1Q;384OOO&F WY@S'+>Q?R7BMH$1VT,Y7&'[@G>7M*&VC1T.3%'RB
M64'J #'1LEZ9UTF3="+1)CZ8PL,/@(+8Y1\OOZSCZ2ZSKX?4!W!)8^7,8!)
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MKF:(GG?!^8\Y\YW*:P]QEWQ'KD\UJ9$&T KHHUC8R^BS5*RK-$B;B/I=(&R
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M8Z-UJIU=??UZ<??U_/+N5AM>?H)_7]Y=7/YQ?GEV4>P97]4]M=36=AUFU9P
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MX+H$?(:^K"_<'I"& CH _#(#59.[EV"Y\$%LO,#X&'#.QJ5*0:?&<\NC[\W
MMC,Z$UIP,Q!,63"R=\KMQ[\SR.(%D6)EB2CT1+,UWCPC%*FV//DRCV$H5SRN
M;S% 3<1'Y%/(2#"-(1C!7J7RAP(6%@ KG@$>C-T9*8&$QUF,R@OD$-BS^RAD
M,EQ'P0TVO.=PW6UD^]_Y!P)X4YA9*4I'@ -\F35!E4.N,+;#\)DH)8DJ4M4'
M;CID,U!>217 :U,;%(AX*AA&2KHV IGN*U!(BO61A@ G89EX^@22C9*/C$Z[
MU>GU<^W)S^!-M=%3C+;>'^1#?\6:VRN3 P$@H$;TM@F0"F*A;;W3[Q?H*3E;
M$,N3(G04^8$6 5:Z$S EL2C)'X>B3$L2"S%#+D:YXY^JFNY]KIUG,K/L1V!S
MHB:3J"?V'6$)\)(ILA:#D,MI#.V#F3Q6K6])Q(6LZ9GG]*!!'7MS+F"),=LX
MUX^L8[$T-'T<+D;)X.?%8IB4X;E3=\[3AN8TN$?ZON##W"Q&JXGO'-\-W%#[
M7>X1E 18/=9>JMH!WZ#M(%W#?2C%X3]/=NB<>$'P'1?!W\PY?#;]$ \#0U')
M@=B+6^*PC01C&]D>7MU&9&J_>L/75&MKAMZ@+#BC-\P?X%S(,41*I%1',8_%
M%0A 3A0[HM!C0'HKB/HQ:H: . R6C]8IO8$FU@L22E)EQ+4G%[U DPDYOC*:
M@<^(DH,ITX2;EYNTJ_1?EFJH>)^B1"\4+9+3""]P%0/5F,#+W"_%:T1J!X#
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MADEER"X_42/>M\GW!)QX@O+W<).WJ)#CB.GCJL0GR6%NG">FQ-KU&<<]U&?
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M!!3A,RF!RW-(X^,K\[K Q,XHFK#=8O:'_81>':Y.,C3M\2.\U1 ^ ?<_@;U
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M\IO0;B9'_<BM>"?AZNQR5@GW,]D!X)6 .E*<F<4=AFXYQ(B_H+"! U-D$.%
M '7X>NB,)>JV,Q245#D+0)53"?($AI:/2I/#BO7!X*_YVPVF;XR&*C+$\/3"
M<0#CKA#DZ^(E&\=!Q9P-CI3C<87S903F:M<"/N&NET6$MA >-KPH@ICTI181
M"\6$L:'N*-$_=!*5,!#1"OQ5S@!?_L-%\<J#)WP,P5 P/ZES.4Y2_;=,,:9>
M\R'-H9 DF''9T8SR(0>!*B=<Q#.A6%>=!#(;_]IU$(J)>_9RHK5&; K\95R-
MYCKPG*\]^'BTG<''-LE:W\%'*C)))L'&%-]V#NC1BW!U5)N6LGN/-A38N291
MWAR&DA?D!"Y#^369/!,'H#R=DX$)HNL(]##B1U@)!)HAQ=_DA08ID(_</ .K
M*=07;_'WF-]+?!;]0 -266_,\+>WKK4O=70;E[GY+^7GP<E3IJE"_O5S&9CO
MA>7#K2E6,])P_&"H/#7Z/'22MA:]@+G\JJ@YG/?5?3K5,Q.8@JQ0^ CNQ!$/
M.S _)D5L1NC/"T_+6J>F ]#$(,R8V&+0 QG1+HS=.#\S+X1Z9G((G%Y:'!R!
MR<Q"91"A>]GPN(;$>8X%O*"!);PW3@@QNXP?*O[]04"$=W6IG[]<\S"XF&.5
M4K<DZRC NLK3$2^P6%YY82)/I:)$*.]063J;TC66N$X4A72];TP<,NZ;I7DI
M=JJ@))VU":F6@>BXZ*\3M5A5N&C(&E"CI$KIX2<1R&I":0QEI%J2%M;4?740
M9H1IHI*.*MBZ63PK?^8@G%;0X@TMOM3@A0EQ3($T'ZB)QI[&/?T;$!1'?Y^8
M>(^IRWD3_$?RG_(7#!+\"1QR^!__GOPG1P2;D\I0 _0M^(40[8/%(->QG6'A
M5_ 3?:S04(_C-') ,%I0P.84%7$D=:URHFFIX&2$E5ZQ]'%NJB\LWX65Y\Q0
M3(H+47^ABP@K CDA)5,4LM+&0*I9Z1D2/:!P4 R >!\PLDJ0VP3FGF>&F:=(
M^U_"@7Q)473-ON#,R5CA]XJK56<ME-@L29YX,QI DH'NV IQMTYR5P)F<=7$
MB80*E*0161"UG"U53EJZGN (F\@B9IN*)U-.* N['7IL="+CA$1ELH3XS5FH
M+D&\ZX+-9YGR0XHT08*LIUU;Y?\(=I)=M4T"+'?/)\G0S[-;OD-P.Y-DUR5
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ML;SFLN#&J%:M6>YW=.ZX>'L<A2\/7SQ H;+3^>R1J+TE;W8W;F\'_+]>@]D
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M;(.@L<&F366-,0^ $H6R^PQW7&0(I*167_MX:8A5[5)4=>UNB+M6Y0[*6(@
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MPSS3'#>> $5< &:OKYCW$+5Q(%06$$5_&#D@;)1&+QB-WW503)K&CM<L>L
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M\G5S6&YNDU*J#+:_;;H3_9Z#W0%%L"M6@P6VST&2AX!#L!@EQ&GASY@6PE@
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MG6  TFE70-$]"F>9_M[MEP0+IL@IM)DUD"P=[6TCD_KKS+PTNL>=2$T;403
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MHZ-:B]P$S4"R"#%ZKMQ5>M48O36)>?"_7= $W?4GTXE%WP>'_%-H];[ F:7
M0Y-2V-(OQP9ZM"1>1Q^W.8%#IN;V_&FRA8@JU2&H!G6,3;__D*F L84^*KS4
M8ZRSH0P[$BBY49L;3=P8>*F:;2![BWRLK">C!#Q%8@[2,%)W[,&!IT461$XI
M4:>O342DM"XW;],#XYN+]IZ'3;\-V]'U+*:ENW2+'>BTW(FZ\2JW:IU0NZA2
MA9%JW,\@2L+CN.Y@[L%V!G/W'SV8VT/>OYD])<7BRH"7,)T;61'+,_0:CW64
MH;EULZ;TB\,KU,>+OG ?;_576U]REAEUGG'0X=M+UI^V7L$H9F'D7O @4V'3
M];#(9#FI1JTPO3!,F("&HC4_B7V6142&;I\&! @6L-Y.KPI;OX0ZG\X$AW8P
MY)J/4=+H?VD+&SWV5]6?Z'*.)DB6)*T8W <2<*%Y^)7*PXBL<32O'&W0$BOG
MBV@$9S 2-[D_1HP=GGT,=7"/%*5OYP $0=$E;W7W<C]/_[WA%L/^].I"L8S8
M-J 8D*.OY%JS@HV.G]Y%<L+IW'+1DRWM! '*1H,\_UJ:>#>O9&=NG.L:(G=0
M.FCJ,.9?O-MJ6>N*+KZZ-LTDIV,4X[8;P>?7U.RN K\+WPX)Q+1;#=5(4-C2
MC< U;]T=66Q4O!,A*V_U$4\UU;[3XQ-W2<PT&[)(^$U%M<:&-=7K/V(A9I<&
MGPY&Z*C?-$ /$(#3IEK%"E(\[4D[H1UFZMM'+2?8$M'.<_,6-8BU<3PS_6[2
M0'5X.,<08@2N8[,XS%.&5,I5+]=LPA!M536;HIW.?C"C8*E%@[XL2CUYSUTL
M!;0'$EO6:5(;7E""CR2*(PNEFTBX2/-"LW,9:[/%2DC]5]%6TPY$^*11/JVD
M0W#(6F2F*71F+6CN+!-\-W7>8)L4E\I::]V0.6"&%4NE/2'K=3?UD(&^T$I1
M$)*[U:4)R:FG3?UEV7'D&^Q$N"K6 EHB_I)#8-=P(+:,"*>+)SXY%B80#T[F
MXN^YI=15;,IZZ1R 3129/8*R@ADE8F==P,W:OHN8'GH7;GXE_@_C7KDRDZ+3
MQ% ;TL\F&1SPX&U<YVD-SREF3CJ!HG?C9\*9+W=6&T+]9.-B+F:4W;9F<VTL
ME[$O VYYGX%S,33<\RR/2RM71S#)J[0!$V-FF-72F>_B$6AJFENT#,<SV1OU
M(I;P.K7FLC@2ZW)K,\\,/H)@&O2+%!O?JD+2WQGMK]&">=:#PYWC[42B%05%
MC\?,!(N&L7QQM\VJ!Z]NM;M1^/8,6$[A1VX14[/2W%O+T*67:*TFB@GK^#D'
M6>ZZ5?//L#6\TF.>85O8^(WL-1LTTL;8<!"493).VF 76NEY:V'4!2?-4>+M
MC7!+3.L",QUD)/O[FV@F-%J)E)Z10)3;GOJVX3@Z>[8*:L6U5/P==B<CAQ#=
M._*<**5]7 3U5!A I#0K<^C21YSW8;9[[/N U2AP)[)22^DIAJY6E<9S ITK
M[]9F?!/+^#0TCKPJY@"AUQ*B%0EN8,/,E! ;/%D<.->+0A-6@%L0([RT7?&5
MOL/69Q,!'DS6!O6]:W:)7<8%X=L]I"$1 W<PC9[PF=)XN_7B,*%HPHE26JB-
M) +0]2K*=6/L'A<KJQ-IW"-'0;M%1\WGK3TN>KB=<=&#QR,M/=CO/0E)>N1I
MI!_W[Y!^=!&C4V&44:8BA\RL6YV5OC[K0FZTD_3-#CG&X)6SETS -,:,"([+
M4@Q3H4%44<\>(;J"C8[_"MWNNO2I_5M;BQBJ/$/KV-!;7;%JK%<6A<LG 9[A
MT@W3U9,VF9>FS[2L%P]X^F-75>(5M@(GK211/)H7C6B:B#J9XJAT?;U<""FB
M06.,8_PM!4,G@A>3U*V-LYFD;H<6%S0<Q0Z; 4J:#"^)ZJ P-7_0G,$YH(R3
M;C&0[D)^!EHG%%0.=2F>6" <O1E^:HKA-93HWD./ %3D".!<58917 QWI23$
M.?6&2SS/U^^NM==2VVYJ#C>P3@>8?B-#5-^B-<0N[\B?E*YY)$LFOKVN>Y,K
M6!-;RKRH KI)986 5G%>4)2M_J>Z3?NG<N,;TE(8,7O1L>)9[0U(QCB,$L/:
MA0'W4RI#3[HXW3)'$!L4]HZ>5,X--Z"5@C->6#+44!ALG?'GU-&JSB@"''*/
MD:[7<Z$C%(@N$@U)A=@@*V*L,J7OHU3!H&X'^R%*6#Z2;RPZP_36LQ$U!%!-
MDDM%!LI.O\)V!6#X72-?R"1NRN]5DH[XA4/4H@IKD6ZDM*V<4#,F(.V:M%K4
M(:A6B4O)IE(.W= V"[J""Z37.S8X6T!H2D=5Z9Q5<CJ5R?"KG&-XESISYM@D
M\OJ!;!WT:"U=1-_BK320D$8%!A^<Q6!"9&43_3(F_C]6ZP-L9QO/*]1N1 2,
MJK>UQ0,,1H,4IS.^[5YPCB>E^W0"+'G7%W4<^CA/";R2]Y(:[D&A"*5U,"2?
M3*W:&-E.(QAD6EC@EW8PN[>\ DKS-A\2&JNGOD7,B K;DPP8G 17#IQV3:T?
M=.1GE*%1K5$AN&TFI+KU/2PV/#7A?PD7?8C< D5\E:?BOZKK7VC+Q'8[/Y<[
M@S.]"C'C-HC\*CG5LEK*2E98WKFX;;G6C\)XZD+?1K&F(:KH&\V#29M(#."O
MNDC*42*K:" B*BS4O1HW"VY<;\=2Z)RH+$.%B.$F<3A:\6K:@G"A^YC'2+L=
M[JU2E(C$1FCJE,J'<A,EU\(53O7[0LYD*T9<KBOD(\P4#1*7!@#=,%%9@S6(
M>;<O3>2$T9P7^;FT6#[R(=A3E9<FFF/VN-'N"#2WV3Q]?HF',6'A#_=#.+P/
M#HU\AH8E5CN*<+NZ>-0([4DPF9_)3]^!"\6P-.WDQGEA<<%TV6Z[9=BO2ET<
MG)O&GYS17\,<^ SA,1'"<\B0VRWP=9P%LW'YKB$)0<L#S1)F!(B7VDE[3<%B
MQDR=DGS-Y<X&VX)U/Y\S8I"WB L8,$SU=SI0\X[Z0G@R@*E.YKB<2RX8P^1M
M9;J33+Q7REJO'_SY8CN#G(>/#O[L)]'E>@?PB(7A01LL^\==U/'+@[646!VO
M5F)%V9#H&^T#!F2T@Y)>/;IC!,T[VK0%FZG:%5-,6]_B]:PT#'\[,17&HS>]
M3N"\(K65I@\KL7CB;/M1!Z-2JN9M&%A^EPF3Z:<88[^3,&<6]E?;,#P1OB0M
MF)#V9' C ,KR$^!?0Q#<KW[+<KCH<<+!1Y3QTA@ CL1*6/6<<G:RP4-#$-Q,
MG3L@8/*1&M/8:;A;J<(8Z@/XHST4%3>"EJ@AE"E?K&&_+7=S$AJ='AR"PQ;H
M;>Y$/D:][(K*W"E)&,5IPI:?J49P,.!$D8MMP-*0F]*'1%K",3XTIV&\: [E
MR'LVQM#;%8)N75"\X^N%'BC/L#XT.M[#<UM;HL0<B\>_A$%]J:?RT6%J_^)S
MM8=7GROT5R\KY(FEVSO:M:0=@!=UFY!,%W^+>V$65\U^-;L6OM%9%M[K7'U]
M8 U HD(-,DA,-#Z'3YED5 V&?TH!9\ 3B\(CO#P/!,%*>Y&@CSE'W;'RE:H$
M@J)&\&J)6/GA%=9&$)4@^D63>)*#>(TB%XD:N5AG^:US:)@@1.@7MA,JECBK
MYQT\7241#R%]DWD&S:H[U<D8BN\XB+WX)V><&')C6[:CUB3 ,&;.OS6O0(^8
M&M#DW.0[-$:3_%)[.NG'XLA3*KV@GU62-953;5&1>\.*N,U!N6<"Y;#'!,I;
M4SITQJ1!MF\['#G89-P6%W%U-9,+R<?-)"%3?8E9>FN;-^V+W9%EX$2J_;U+
M;=L,7I2LJI2ZPR02]]JOT?"^!'IB.2R\ D*GLS63KL85:P*FO1"P+!*Y4G<A
M4W"5E;3]QWS"TJQQ#+WD3P9Y5% \R?;AT]HMSJM7L0U%=ES<FG0N"9#Q\4'/
MPC-O<*$M54/@A#?"K@<6=F VODT)">N$\#P[3J=@3V,X5H31F0_F2J==0D&U
M^3$OTEYP4K7WFY$M=H6L5.HJ:>>X#CZH98[J^\>6CK8SMO3B$0%T+_K4:$7^
M55%SV!-A0']C[TY3?F+K2 =1]I6IC@5=:^H1^6=4:\F__-DMDXUCLRE8QN;4
M2]VQ-HI1461JNA6X)I6$ \ "OJLH'=O:@*6H5IIR"S-U<G;Q_MV'T^#]/VDY
M!L6_XZ=GIY_/3L]//UZ<7+S_]/$\./GX2_#GR=G9R<>+]Z?GP:=?@[=?_N_I
MV1(Y]Z6/N]-OPWA:X6'J409QP9E69H(. '<[(S8>F*1S&^R:%SH,Q3,S]0VL
M,&YH:KEKG-M9BY6U<:@\)<5+9>:+-)G#E2)G5B?@K >; *.O/>Z@3\5EE"5_
MVU( I]IK+ U::7?Q]";, %J _<0_@<E'4:6;H*%+;672&3<*TW0P3"IV8PX,
MX(Q1TCA[A"V2F?R,*6*!7'["DK DWY/GXD%$.#9]-BK]&R7^-$-&2!3*/-O9
M_IZC"A0D\9HA]HVJ5UTN2UQ!;4@I4#GGS]Q60\:W;';\Y6!F[S*0%HRV (':
M\G)0888[W1 P-92$ML=PR7#<R^_V"LV*3O_!=WLCQUPC 7! L'@A04; MB<.
M2KMB8J@TFJ.:)L#>NQO+@^[/<R>6A8W'Z"NP6;1#O*;$@(F;58:D#$5S9Y_5
MPFYS\G&NX)1@[BNN9@H[&K.ZI5;R+B""U(N!$V(2CI3MLZ"*>H^W)LF*%7J<
M2V$W*X7NC.F1N-6 ]Y8N-#6:(N B0JIQ2G46.;BZ,959"C!.8*K(&*C:DO_M
M5G26"I:=SOAG"+Z[1 X8M?.PS8E^(-8R+K]<+'6MG&),KA.8Q]A'03*3T1LP
M[,<5$:31^@C91F2=-&HDF#/B89ACI%=:J> ?+B):7A=+1"<$F@,K-,9JVBDV
MTAPA62:B\&#>1@+18ZN?9I)9!.TT>@,)B5I5-)J!OKPA&R,3RH4&\(EGE*)*
M(57OU&E4RE#*DK'!2L$_,L>:!B# RKN<N<$(>G[N=:VY_YR' N(9U5@E@W>/
M2SB'\.$%VB!E/"RHX?C7++]Y=I7?A$P*.65"$(O]T0$H[KN**3U52Q#4>8*A
M=+4SW"&9S7O?X;Y>CPS>)<S#0AMJ7K,TG^=QV4S)/4_S/B&28 *_R[,Q[%[D
MHGG'#J#CYALM&%H52'(RYX1IGJ"=!\D]SH]0NV^3C28AH7]03]>AC-^T,7,*
MJ=R. @4!:(GKAPG$_3;+3 :N79)EB$.$^!+Y2JSQ)6/)(!OVLY2L$;7\<\<V
M\BAZ5=-SW^U[C+@]/*+@XJ8([4:9C8:'\FRX%!MWQ]T&M2MQBPUG"<.9A:65
MMDWCY#SQDD32CLLV\-;VS$U>,MN7>2^88_DO/] LM^/3\RV43A%AQ[2AD(,R
MM/V A)N &VRSAJ:>('FX@#\ W\%$*MDO:X9GS>'>Y1;.L3SFFWOKVV0B&E1(
M@I$7?G_2=PPBM"]F+?+?S\\PG]>3]NLSOGEBK=!W3)&]%QC5YYBHW'", O!*
MI2W3J]F]K$R$A#I"*2=$!ES-#JF4K4[@A0@S6X8V#+K_/#Q^M1\>'A[[ES@&
MLWI(/ (.BWK%.*63;99X7_:,4WR,%>$[DNJ,)<HFKP,BZ#5=D98(ST!**F[5
MK#416L#$VQ:/5&L6TLWP^*\%4&"S%7:2<D,9ZR@GT)][NBI]2$^?L:3W-E+T
MF8OEFX[O$/>*P@3/>17*/"6P?<X=:!'FCA9^G6E[07-34X'/2RK'!9X0\8TF
MXL8TJV.>WC)*XPZE$@IA0\F4F4X68\]PY7U5:IK2ACMDP!J7=<QXN_?/[9J?
M,,'+_NO#0Z:K4!HIR:E0],05DI3(\UG_^(]$72,I'V4AEN;B,'LCU5)N(32#
M+R\MG9R/'E]NJ '3'CC5U:ZH@EJ>3!WWHA DI(.J[GQ%B4,K!7K9Y/)8=\3Y
M>#LCSD>/%7$&+7'T,)VX:?\Z8HBAK&TL3\+=9'H=PS[Z%58ZTKV+21OJS1YY
M(5C0D,,KK!/^7* %94)-(2I*]KLJHUE.[*YK3!?K"_"9,SUCR!F8?UAJXN=.
M!Z;K9#CWGG-F,BO'7TZYP-U/T*E.S^V':->1[9^H;CGF_*F\$]YS3752JQ1Z
MV$D@'^'+N5-"-'1HK/";:3V M]:/2>.2/4OMX[#E:SS6X/TC3="<(J.CE6IA
M*"_J;L;61I%3U9570WH2CQR\ WW#(&-D4L4$L'Y[VQ[5GQ-Y%-DD^@2N8V)0
M:@5'+D9L9SD!V[X] ]NWNO*3)+GMJ>Y5+Y%CT]614W7ZT=[^_F.4,JVR>"5E
M,IIE- >AL_L7%8]36)BK()5H-\EJ;+-BPX1>\/_69339!"'P#1&Q%+?L&5TQ
M\-:9&2[*1HU&/6H"7\89XAZ=[JZ(=Z2NUJ&0#2B'IFE1'[EM6N4).ZP_\3 P
M38Y"W[OUX*:6:VQL:G!4(2/9Y*XF%#7 AUUHL 2=@AT8FRF=%C%DP3',K_";
MG;D^(?F,6.!3#\IDE AE;T;9L S,V&3$F5YDC0L-)L;A>V8=ELYL?^I>%=*\
M?H$K*20,\C8RIZTDKNAJ1TH%1.1.9\B>JU8>4TK5J3*-I2FURWRM-<@<14E&
M+KB$I2HI?7*[9HY6F?J=T>N>L/M1"S 5HI.-$YPE8FYNB*V2&_-.7_08%@?N
M$>_?$WV'JIE&[E,PP(3%.I]Y!O**C0@=N&W4Z,0.#UY*-'!H%.HSTSV6_C_F
M S<_0#FR C:]H3KDK"%R&G.2D">?F2=];&:[]IK6[$[##2G"=!6Q'-%0[7":
M0\D9R:C<+6%;:.S#>HJ@'/] XZP%C:/(B#[6Z.6\-=I_O1H0%Q[S 1/9B+3
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M[7(EB'B7^1V<[727Y*0H)+MY2;? 9;).?G:]<)\ILV&'2FM.\TS3;!B;NI*
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MB%FS)Q >N6#;<2)G!PR"TIRWU *_42/=10:XN&>_<0K'1NE8CQ%W4RT/5$Q
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M[^O(T'V%E1"C,'QD^JI%-Q?*0"F1V<1QW=6QF,W] >Y1=$10-!X[HNUYKVC
M\$LX%QGBL1T[ 22'G-:$N84ZRC!5Z6J*Q+\_6DBMG4I4ACTLVMNBN"*I7L!D
MNE_I>+W:P6W>08=H#>!K+_[",L7TF4Z6%Q>-R@6R5,-A:A>>!8/\*CI,G4,K
M/94)DT:7!TRQ Y<-1'P/SJ"K)0NXU8?"LM+ OT O835H7Z3KTIF5P-"6"/H/
M6'>X18Q/TA1Y87N-'D&>T))]><JT5_$&8JXY.P/%!;@<O;1,0J_3W!1D^:GN
M, GG'AF*]:%4PY.ZK(3O;DXTB4$M_1>XY#-@M$D!"ZNXOIN>IAW5M*W<[$B0
M _&J5ERJDS0)N5D:0>4BN"(Z(,;D,&?4<U^C-5WM=H*KA\;H\V7S5''2,-9D
M,81'JNZPVVY@$RU7MG[%(8?.FLH=N"MP*82G8R-WVN@#^^TK;*"!84[3687>
MI;T8,4V!C52[\0ZZ0PXQF&X!$04/SZJ?JCQ()6$E5AO:/G)XTW8O-%5&-IO
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M6K4^\C=1U)OH+C#@,/TO)D;:=0I%CT*##R=0P*&%"11TN%C>P*;,B0EB*P6
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M0BH:^%D\"'56#$MKPL=8$9.-:Y77C/:GN6=OM6 T\OGK:P9R4P8=HOC&%U
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M\@YMI,N=D1U5+CO:F +TYCW1D"QWBN6RS^M!,LD9[Y'+K'LX9?(;G,[F*(?
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M1KC91X7%")1-74K!*959=;]&2-*&9;3UYQ!,N9MX+Z&UNXW E.BJ$5T:T,9
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M6'F@4$D\X<JE["P2_7&)04?8$84<\7H%2CV?S/>M&/66(O!67<+ 89PA7.=
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M0:6M\A&A@#B:8>^U%6YJU$ N1W5)<Z38$W59#;;H=&O(>WZ;HV_ >!,CHS-
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M@7$G6Y(+E)[N6&Y"I#;.;:DJ&;2IW[*9I_IP:.;$4P R?8OZ)A;6],9#,W$
M=HU><M,=K"O2[[)((*9.9(3GQ@E"*9:IS7CJ);^](VHM2THHG/-R7'5^$^LP
M^0U#DB5(:U>5^B%6'[H!=+UP;.M&Y3=%-+C5LBE>$33!8:H_FVR10KGWC-CW
M&HD+TY2H>G<(B@9E6=U!!=^ (3T0-W"V3?^HWY2,/]*+]LX\B>?>;<:XG<1Y
M+\3ESERZ?B-T<<(V D,_CFV""-A?(/4DC18\G_4'06=;(]L.@[<%!:$K'?&B
M$3$H[;N(6:LJ0<DADT:D\4[P)^V!AHBX\<-+O[A8VP-RPF'C0(P#UK@(?3/<
M=SOB-WWTK!5Y!\FVV'PNFV2AXC$+_B1.8-SPH!39'>Q?,-V58(1K,=)!UM)1
MM^#I:!BM[@2\;CJ$_";Q^"0;0-WEZ<@L),?1!%2;< $<"3G11-7:@YG%T&(Q
M]B](?.<->0_><)#7,BWHV8*+.^9MY9S3"'_*+C8D]3Q=8@&Y(7(_+,J98?(\
M727I]))K#GF/=H+?8178)B,#UIHK<'N#R<8IN#,PA2-*AG3V):\BFC7F*J9-
M8;:B.#4"Y8I2=!RKR%AP-*E\.)AV\;[&&6-XA<>)TB,4,.6 <CXCY$N)Y39F
MZ36(85+'*NUZ!>_Y;H3F2JBQSZ#]$O0>ZW]Q\N(LL4/$=56Y$2N.<1%2:&E9
MO,UDF;=CQFCRV(IV3Q8_LX"@KXK,63;8>=;B?, 4.(X@HC'B[$3V];#+2N ,
M63A0;-*QJQ2<0YKFD:B[;0P26\O@(G\C7C$&)<Z[2324HSD%VX*->MC?3/ +
ML]3O$#X$G*=1GYV>L5*#P)*+&RI!,U#L"N/8T65 97?HZ3-XVP:#PB@F/3)<
M8I *,H=2[ON0N$TQS3+E%*0TL:@:^J3381=<;PX],'AL&>HHFOEW4SS"9;JD
M5V8HA?K+A0<(WJQF@.#U\@ (Y$B_*<PIVV S5HTC.<R=.+5"276N=VB^CVOV
M'$%'UO.YWO_^!RL[K?%C5]O!0!  %=5)H40^*W9CA#T:#;!]UT8CB!7RP:":
M;?!$T(W$?=. X?IOHHSO(#/[(3^-.B#$9I>=HC$_?W[@@%LU80W>SII]RICU
M?"/M]<RQ:+R+9I'%P2_[C_X54T(A7BR$J]-_FZMEY(TV:YPS(R+2M'A_Z8HJ
MXW/4N\F;^X_K#'!Z'O%UUGKE\L(+6P<$0DWJA(N/RY]9APAXQ<]._"?)M%>$
ME;YYB4'NY&B__(.O7#UF55%X$Y50!OG^A5F987+10Q"R@1HZ*JPGE0NSVM>=
MWTZP990; N!&5G8SU3/+SV46O%-==K ?-P7>G( R,J^:&Q)MKHNHC*/_A)I-
MET^P"$8?\VK>LHM:Z-&(K@Q='VYV&DT7T<SRH/K4EXJ)G.5T>V3*8X03E_P4
M?C_ZA2JM>%)HJSHH5P%_@H$(.G _(P[JT?'NT69W:W-_:_-DB\H7/$QINNVZ
M@P]U*T2O+1Y"<_VF">!,='G,>\GAEC\VC.=$5&PGB42%KHYQB&5R\ETEF7O6
M8E /A2YE(RTJTL1"N5K7!#$1R\XAZQ0S.F@S:',09-D$621T<T@./ KA,6_6
M%,W@K4A1P0Z!3G^$"_K^:]W:\%9Y'BIF$E;H+L"Q.,/"M8Z&FE[$;66VC7,I
MC3@]"=[FZ <$^R1/"-;\(UC4;Y$@*<+$^]N$4RDCHT?DIDPSA#!. D=5\4WZ
M,AC2H# O3N<3B6SRI9R)D^0* '<3I) 9*M= ,[^8;=PGA/A=PPC&H?(0L<L\
M QQ<HA.YLH]DD#Q?%*2J;6#9L#AAYBH%Y_MT^\RM5N%Z'I#SG/1H-5+%&T ;
MQ8D/XE;M-SXCN86^+H#W/-RS617T/]68NIQG^EW-58+SA!K%;^2:73,UY;I7
MK<<)+H5RFY%J)KT/Q#S/B[;D-F'H<TL0=$IK21S2G"5G$N3TG7Z;BSUX%[A>
M5UM@4/4$#^\Q"?W?= 1S)\G$\V+PE R%@1=\F,M$&))*W9 @M/![3X*H;:JG
M]D#QMO=>3\"MW6O$K3T6RMH9T?7^H PMF,ZW=+$FXM/I1E8K1F]%XYT\K/UE
M# MM'$39%RO,I 3.MC,Y_J17'JD/,2LDN,WO*QK<2:Q!&>((01PV/-E2!(\2
M2'F$Y'"B9VQ\+E9=1JOL1U\I+I!RUDWI.*/(YD2O"7WN0$OR]JIWQ%BK3CC#
M!I]8\.5P9@90V)<SNLFO&^8*+U!4QZ@WO3[1O N]B;/K['?*LW*3J%HS9,3G
MB22[VM+1^2(\$5Y.CW]J<)9EA#&V&ZJ<D;?P%17.9W2@W8E%1YVV_E'?I^RY
MD!L^;G(F.ZE9<\]W,"K%%V<+7GOPMNURJ ;LO(/9-ZK4U@5[1(040^=++ASA
M/6(8R8Q<]4=T7V2%"B/CN$HWO\DPLC*EOJPKQ]JP]G8:84:/=XZF5@_G7&0Z
MUKG][ 2H5.?\.J,>G&((^PL>@@<AZY".B;SJ$2YQ1 ?SC^B=$2V*<3OA2LI\
M7&+G#^?O_(GHXN:^ZWCOM.LTRRG</+2C^8?V6>]AL[EIV^.EQL]WQ(M*V4M$
MT;2,==%NU]>[J^EV?;,\MZM8^(S2H?5O4&>69=G41J\8'5RIK6,U22P&C0<R
M;9.JR057:IQ8C3J=./7=E+."[T2F;DGN[Y//@TM:*!M;J]P=!"\K[=T!6F&.
M]'ADDH2'T3>J1:;,7 YY=M1ME/8$/@/NF0)P:V+DE"N@<4(H+PKOX#H,QSL4
ML06H1CV4DHI"@36"OCE3F56HCC$K=)4DB@G!V%82PB;6UXW=0UX*YH,R^;9-
M*3U8.0$39HDL/9.DVRU&3M6=*CF$YV:FF^IWF_&B*X]XQ-TTHGRC<CBC+[$R
M5E%;XE/3\^4P!]*$LF>8ART)<.0GS]ITA5T_\A7JJ!"WUBC<Y(P@;8I9.J2F
M=& 2Q5N+H65%UGUU-@$!QR0#S8&M@;*QAA ]%N3O\M4UP[57)6 0C1E#F;#<
M^5Z,H0N^P-*(=K$;![M!'(V=)!7=3=F#V'NA$(:>#@EP:32@JH/DFR2!S1S&
MQ-@!)>?AG*(K0&O^.<U-$6NYQ\A+BNC>H)24.G)-SMC05#E0YEM2WGK@ @[4
M@RT1P/U<W$FAA3L,$COM89MP@P?Q\CJDMR()DBZZT"U35H5^-(3%HF-A6YB>
M03W!#>.]WW.W/=V,%(7[LY!&'?$01BCD=..2I!3O6F3RE?7%+[9;/</M8^K*
MR%\8(>XUI3'7YXRFZ%M7%Z/F'23W)&IT4X'A0]O\9Q3I@!<J%BJJA9?]FQ4*
M)F3T=<!,$K71$]>-=)Y9QBGBF'&#:T!Q?=XQ&I^AYT'+X&')N1%ZZGA2J7H8
M5:FXN+' 5IS=T-O$GW7NEJ=X\/=\R>O#[FGZQM:GV]R&DFZ&1)Z*4B1IN)7E
M,,DBC>)JN2EGWJR7QA-P)@&L13CO?F[,5R<7V$!$T14T_PYI2[Q;[G>C5'=$
M8-?%3238<%B%@%]O#\<#]0L=PDW@<-14FC3ZUO9?[;2SEO@O?;US:*O3,G2L
M:F^#Z_Q0/*\V%S5*(\E^T"2Q;@ Q4/U!FH^5<L.&MK(HQ3"D/0K=4U.[[&W>
M=1@XQ.B:4UV@B3"6DY$PRUDB<<<^:ITAIUZ%'%F1>[P;/@B-*Y42A2O."A#)
M-'F*:?]4Y#U%8"+0_]I,ZY G^>*ME65FFV*[$AYP-RI#)YA"TZ)\LO'\WKH4
MWL!T'FTEZBV*!3V5MY&(GL!$8+H+2IT]&\I11QL<!%Q0-DJ5W<JN>^PIU[>?
MF]0\#*>,,AWP58[2,@:@@YO0T^OH^=LX:<I4!9GV)</"2T65M&:;_L2U]TY]
M4]5)!S^_*:)^J1$,)FYTO8IFPS_9M%XS[(8W@UQ.294[*7/'IGE\HR<*)(^0
MU"K9#E@9)48LLV83-EN(D$DZW0)368R_54*S3S?2JQ;]Y6XGWZK$9 H!F:RD
MU'.1$];O^AF#7/O+27HZ"QZ=S63*\)?\HR<;]><6O4RCAN^]A;=;QKE%37U(
MN7NK[3CP3J0:-) ^?IIWV^?_%?4'O[YSBXF>:A:M?90JM-UE F2WB / %YXV
MY4D-E&%]KD72T)3%NS<=WWBU!EE[VI/T'0X()]Z M_;16/L?3]?RKC%XKF(Y
MXQ%%MQ<JYF6S.1?2[$J6,Q==_^RX&4:EZH%1EY+30]\6GV;(;Z.8JQC=T;DH
M81XDH$,'WW!.6E\(V!.P6=(<$];\4/%HF&!12,G7LCL=>P--\8TR^F1.J%R;
M' XMC3[5_% (BZY-26&TAZ<S+1XG:(GAO9*4FA[\0%*MN<2A*,:T^L87*&G%
M:LB1\IW@)'->1 .M>&3N=;Y..>K+/4LNBZ-,^]J4A^R;E%Z>E[+]X*XQ4YG;
MBR=3++X9NLE5E5LAWFH].Z\/ P-=&64*BZS-#^A*&^=4&(J:>2@UTN@#(-F4
M>:.M2RX%UK1RNQJW#/3O?QNE"TK3O<BS;:L^-\]Y@/:>.6^R"+;?<,O4\^9
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MX,C4]S_]!PLH2/@1SS_'I9.7"ZMTF3'-^<7D,B,U3GCX>G[7SGP9RQ.SL'[
M%3EX-7_@:8DK\F*W^43EU0P/]?PU54]8\S!/N=5DH^!X836XLY=AO<B)_!Y7
M^_6;A54R/=-JOU@-!FI*"=2A,)1:E*L6&*CUR6E.SH-P_]FKK]:V3&5%%N!Q
M7]LR%?WF .NM3[0%G&A["W!JK.V755GMS5<O?;5746$YI@M#P[*M0F#F:V.E
MZ6@\6$#H?FVL+')%]EZ_://QQ>[]B<KL02#;]:FVB%-M_NC>VH)9E;7>?+4X
M1+2U"=-HP@AJ)H,@/\&A4%F-_9U]?"C.1P@$/.51^A1(?H_OY[-:/W-.ZY/9
M2#_<\K_9?8JHXY*7OUF3P:<(W]WPQ>/Y&%P<=_I1K+HYVTV_(,N-*I @!)[4
M,+_7!%;^D2%^SQK RD.#5BZH[S-@WS=I?@,ICPQK,(;@"O'Z+W'^D4OQ/3R5
MQ%'P3B&?(C,?]X*3FR+ICE+$>:=N$<83\F!?:9J^=XF0(L'3[_,\AF9[:C@.
M-G&P&[:UC:T9F18FCN4R"RZ[PQSI#S0\,C.[.L-(RA+MV8/#77@-C)MX"DCN
MF,=6]0<!O)=8G V58(R '4EG-&2FR7] 9X*W!8+WN]08C(//[%F$E%^.8"5-
M(_>(+Q\K9'].,J;,Z"BDWRN(&8V(^[JW21H7*@N(.4THJXC[ E[V-Q":-.JH
MU'"SE+?1P- @9="1- QN1_T(N6B1+*@8YGGV*_[=41%QD"+K3%3F&2'6(_]9
MOT,T,\2ZCL00PFC6A?<94G)JK8/C1?!]7%;Y8B<X02XLAOL/O7FYC4J:X(&*
M[?01\\(MO-6E.Z>17!%7"$H-2Q[Q"!1$EY/E2#HQ*KB;MTSL[3:!U, PDT1&
MX7 EN7PB-(((F3#26>@H'I*Z?T39",GV]O?UKFV6NJ@J<R@T^P=[OMA9GM.U
M /XX C@[,=+^:A(C[2V(&*E];S:=T;!;3V#+I,$L6_7UX6-WZA\P=\'G/$WI
MF?5.U3L5YP6F1&9FU?;J U1#(&,?HW'P2DN8JY:(S-F7N.@&C$!:Y B)B(8I
MXV3BDYI9M5!4VQH&Q%)3.0'NDQ2?Z.=WRI6#$EFCD&%1$\P9.Z]D0T_\?"0=
ME1D-01^,J_W\Z7@W/-K=Q>8*E?0[HZ)4E6=^+E%*\R)3R#?4(PIT*N3K=A68
M\E'0 ^G='H.$(=U=WC5L=PDQ^*"XH,P/C=365OKM."AAND4X[,1X$Q(AL5 H
MDQD+H2\]&..J!MTT2OH@3D.0O!A7NX\JCKF)HILHR<IA96 +MQI<6E'-&UH:
MB<5=4(R(C]@L4JGJ%BMV'P1ZE/6B.[AHX$[%JI$NF>L_P2T+1I:F-,=([DL$
M%D$,LB[3]R!9$O,Y#7.DC38\8,CZE\$JC^5EFG^]H8/WL+-_VMMY8_H!XZN\
M858R-\/'\>!%0HX!XSMKX_LT'!\\8!C63WNO=W9MWS/\Y,W.@?GD\:13(:I
M9,X"$4W'/+UP2RRH=!UGRYX2,?)C97IJ#7?9+\VC':55?QM[UFBT[D%('Z2@
M9;?I^>WA>*!^(6__KVUL4HOC3L5M>OKV'<4;]3'YT]'.H9E1V?@/3R@SG;'>
M_.G-SNO'MG#0,/?^C%OB-'B(K[7P+B<L @KFCM3S*&/<==J ^AAF+E#9;+ST
M#G.VMUM*O5VP\5%):JH#ZOQI^&S_I>"-J;\D>XZ03[LDH;\F>SO'CU^3)QGP
M-3*\T5X#[9[ @8"\ECTLN>L@83KRPK%,@+)Z__L?H3!1^A.T@!ER=<N<,[1
MYE\F$O@D1 (S\F&Z; 16FQZX!T%&._]9=*E^*);=!^LLBJEQK?>=<W0V_70X
MRTH+E6(?[!%4(0XY+UJZ,1U3SE!N:,IY36E(LJ_I?@"VP-&<8]A]_"P<B-4/
M1AW>)N'>A^8#,IW2O).A[78[=/4N#!V9%Z'-_;W_XC5__5^/EY+#B5+BT3[+
ME+K65#_Y%O(,:J40BPG-ND'$Q=[ZA!*7WA7 @0UW"QY;,+B-BG[452/RCL].
M8FN+HPP9]ZR[]+).P&WVZK&S-6FOOG+6_W&KX,O$0^M1(CEHU&6Q0 J!06I
M?30!NF;>MOO $@P0:RM8-]W1D(:6((TZK4B)]BK?KO"B:<W@4B'C*%C3:0\%
M5/3L+,LS=00 %K)"D?#14B2\5WI19_7Y/T3 P"X&T&RSZ%]/+1S,(!:LVV Y
MJ2L(9>CP2"M8HWQLKL!=.PY2RA$Y2'!']H4.R[?5[$ ]>RM."A"Y'-G1)RN
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M90+3&Q7V?>* X$:XR(I^D6'4C8Z@*.V.*$BKAR%:B,1+5/LFBL76!(PR=$[
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M@0S[#]*DCW"G936_D\!@<?1K5/1S.FOPEG>TY[;(49^Z\F=6(?,A&\#4%N>
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MV3#HQ?V(IR_KES8\:*K ?(Y_#8HU@^$C&R<'&QP.):1CO10V_T?"9HJ>_->
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M$LFT&] ,#66J;\7 RVU2 .HW1]#D1/9H9O/0W]T?^XR,7UU6:T7N<9YD7"C
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M. W/STY7\E"O.C-Y?M%':_.(G:L7T71?3?Y]M'J1[DN]R&[7BVR6DK=>+_+
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MU].;MK-8S5;R/$%F1I^?Y&$CA7OI@^L9O=B0%.YK=P2N?$&!FGSL]'C.^6H
MS#2J&$9]R^(7@"_T2 .(G4L''6[GI4$YF Y2U12I^NE7[OH#$YG0Q&OFQ2M]
MFT@3EDVWIF^#O>0U$C^+R/:5NXTC+3?QX:_A=4"3K)+8:]EV32LA[T(R28LL
M&N3XYS!%^SYD413X$^\@N4E*2$2\D\35Y/I?%8EN?#7I'WQ'&Z&=1 %**E,
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MH;]'BN>8>](N19.@"*'RM+"CR3EK4!E0(?R8N[(W28W%8&0\JRGB7$Z[;]D
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MA"EKYDFDI2/]D+U"^ZS((VBFMCLM&^FNZGG4Q&.Z.6>[X4EFN"F(V9U^+6.
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M[U,<H!>J^D.^#^H ]DZS;$*= M=VR%:3ZTT01!1K?)/A'ENB,,T',FB964K
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MV\/'CTZ>7#F 7)SH9M. F,)VD\[_0*K55U+*\W"SIUI()&I-E<I>"6LBWQ7
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M3;?,,0W$2$G=3@?H1'OR>=83'W^23K2_M9>$42_&>O)_H^U^Q'W8F<4V9,;
MV@[RZQ]O<"VOLVN.XTZ+UO/1<.M?;3M'OI S$PLU849Y7IA-O8E)Y8!-01=D
M5H&M4*]&O0>7,C6KD)O4K$ZQ;!<[0#LU@ICOEJ>BR*)$]F:91];"5LNSNH#Y
MTS6BASF ?0:R2^VB/;%$SN\B[->EO+,\BQR6X(]0OLY+D:"&M=X+:4)")<.F
M5VX-YU9-W1I*>+9MY9JQ=GOWO/&[:LJV?C%F6_LK]LN(;?T-&_S6]O0WA"/D
M&#!S$62U.X$8WJ$O.NF*%LY'9WF:29?Z]CYN^M,N+LCX<T4>N)>M3&4&I4JC
MJ/#NQA11R&/1)V?!)[F7)D CUR_^.,/_FY_>SEZ\^>Z[-]_/WOWM^=N7[P['
M[/^S"W$91" U$2.*+49HR)4YN&T$2QCV*#E7PLWKJZ"@ F9G%&1/5N_J- T]
MWW4AQ$)U.Z&^&\BI.ZGGPP3_&<ME"/_/J..-V7OWS$,L$E@1T,'D98Z]N650
M)+F7)N5#K+\>6:E:"4::2"A$\08FX9RS*7T['0S#E%T;"6>",,"$L<R1-:;U
MNMDK3F1'/NE)2F;#T (U6# HW#CD71\-'1_:%W2TJ_.M#GHGFC,@<>;VBXQ8
MVD)A]T\)AUI?-77;Z36;%H \R%TO=<<B9@P4BV 12,11N?F8DH4W'SM>Z^I#
MS77[ZV2L$9[KSUVZA):[PD<36S'EH27(V_*-$KD^J.DN55%EW2I_H8H/F:[Z
MR@ZP9*]&N,DQS5PJ''[O6F&HZS:IA2D^T0H;8:MK+*@M$UL/C9#NBHR[FKE<
M+["VE'I8(&NJ1HFN]'V[D^61#;+6C++A6<.[[OD&,5QIG50A#]1N\[<(!QA<
M,]+S9M529EF'55+.0&$R'!,1..8V$MJRP=KR=:H\5@<CFN/M3W UHC)@1-.Y
M#[3YH/&XZ$U[?E/I?W->'GV<I*ZK<.+:?54IL1FMV 4!F#AED-?5J2VYX>3_
M.+O]:5<:$6BSMVY*;EV0@W,)\IBM(I:, C*YT*0S&=>=XBS&2(435^).2GXW
MN^9]\IH)X6+]7[JM'15:TJV-/XA_MG!%^&R)ZCY)6"^KBW:;2GI )H2J,]7E
MS(FZ,@(6@AF'3.SG[U XG76L#T5!)B :C$)S2F%1$_9<U:'S6[3N[/MJYH9S
MZV]A-/ 5>5N?R%LE#*ED[FHF\A>Z;HQ:U!_DL0/ZY6KVKNSF93!^QV\^K*M]
M CVX=S3\(S5JX'"PXNNP4O[NY0M\X/NR7Y;_4ZBGIEWSJ2O3I--:<P>&YB?3
MAA+2O"#IF*;9T91(/[,VXE".[GA)&J^->.;#8#@Q]6GG6WI-NKM1&%#'RB>Q
MQ.8BDL'/<NP@F3<IU#)A'O:OE;.9MM;LAN<QKLK-<*_($4GUJQS;E1P7=2W&
M#DRJRB!QWQD1RCE;%Z:BI^3*VD7A.Q.T(!_&4IU;(3>(JW8R^Z[MJE9]4Z6/
M&R )QTY"E!W@+M9\9C.Q:\OBL/8MA02>5YS@V9@3%OS3DT3?7=_]A?S#KJ,[
M%+M.4:^/'SQ6LSURYL)9BY^C0^;<(&\95[NNP4[42%;XZMQ^:6];.)*HJ_@8
M,X9VHWEE3-@U6P**A%WL':/N6X350CTB+W@KZ9S@9(;-NC@#4;;;*MBF?D%<
M\^UYL!2+KI[3CP(@'M= LW!B:D3;Z:,FF6XZ4,;RSE,N224($;F$6@N;Q36%
M9%*Y]M5;2U86L67)E ,,]"W-2=%[(<P&&*-%(_.R[=XCMRF'7@VF3022<,NP
M+WT2[A9S86\1EO&<_3$IA&MJ2;*,W/[JBLN%IB+);1/E*\F]X1Z,)A>\@BSP
M(9Z(#E^<++N]C'YBQU>480QB@3[*TO=:/[UQP?RN*R5//\]*R9-/4BE)'!Z
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M4!9R,JKM.C36]SITBDT*W7C<JINNF]%$6[U"M#R#O>=M0NY'^A7V)*#!0T2
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MOO)OFW!2P(&?J\J+W5R0;$!*N>7DW#6;TG'I\K6TI_>(K.1W--BGJK6?7)!
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M3)_F:/:6PNUI[Y.B#>J*BG"XXY_E,61#6I>W!O/\",XT<%JK<1"GLD*RJ?R
M?A-XQ_*UZ99.&NC7TWLO4!M6U8(&7SN.9UA5?4-.M'!$XQD$CDCFCB[@-D/H
MQ8^/T):&X;)+!V^XX?3H!Q]>&EZ_N;97"D8^D.4>E<)OZM=[X=?BC6Z@=.<\
M]BB[$4\MX<4(5 00=:<P\:TCH7B%I>V F(Y;6]NA^433<PYBMS5K<X<>&YI[
MD#.$#_-MV=;R@D/G>QU%HD#*"_<-48<KG3&"OC!QP$/&]3<4D <#AGTJ7R8'
MUY'!O?2Q(+H*$P#"=]QP V9X:9SL- 5K,_SNFNF8<E@ZR-%S>OYT JRDH>E&
MKNYC4UJ&G-8]I2^+)-2O/N9Y^E]V/H&ZC$C#[::_86=V(F4X2IZ86<^1BAXR
MIO[PAX:82W*J8%^M+IG)*:-"2!6!6@"ENR!BD/0+*A!Y:%QS=KF)DP!23 )U
M:E2?TU4^8?1M0MPF;;U/K_PR;O.FI-& VXX7CG3?;#44$K<PUJH[FQ\VUNU9
M7QGK!X^Z(D$2VWF=K8(*ES VKLLX*'JG\4<LSLT#1_0Q ]1V]%BZ[#K"=;($
M1<%"#%7>-8L6;Q>.IQE$-V<-Y(D_(N!H1P:#CNA_24AN=>9G(HE(LGD[GNX,
M&<^D(KLAN[PKUI/>L=SI7@Y!!O"1$I_]]:@%TK?B=4>5VP]VG]CE$K4'BEY2
M+OYY7RU_+CO\?DC.;<W^@!!9IYL>UD:?JY^%5]X.JU8""_RI4N6%Q1,LA*&P
MIK<#POK2(3&WE,G$:1@]M?C5<HS]_-_:S_P"CQKI[^*WKC$E4>2W5 *@BU@+
MKL!:LS]P()R>-O#H!DOO+<NCMHD!26;97#'+C"@![D_Y^S?6/@Y6ZQ]JR#4\
MC!W2F2S65[*"6[/C\-3B+0+] @702F"GMAZE+E.!K: 9>YPZ\$+B/*1F&:XX
M AO2A[H_RQ/_6ET3A59^AALND;/C@NXA"WWDV03$=?2X=CM<&;"DX=/4P<-_
MT'';-@5Q\VF71C7B_O:7B @MNZ11]O+!%]HT>.!XR;M#Q:1@PIRHKL)^A_!U
M-$: L3; *932J(5)J?53$[:I,-.B:"^GP7FWGK'JL]G/ T\)K9L#$RAF!A#,
M8Y4#P(69C].O9RPM, XSL*G&!!:Z.-!9<\#PT7%'B<I\]=7:"9W?MZYE@D[#
M^Z4&MH_O 5.0M8UKH?0^9N/01CTDSN<(?2-5/Z3W9'/3L,'HPA&E+EG!G-2P
M!GC<?V2Z#XA ;R03PW/5>>#EC7#CB2G6189<5>QZ:4)#\_C?"U.7=."IL-']
M:J.N:C\WMQQ'@C91PA5!L!F>1K56/=>E:#?KW"Y:' DNK.IS LRWF$$_VH[P
M0.L6,^13T+#O!>(6%P)H*G,I#@=K,&5U6>_-]2Z=G&->]!U4!FUK<"3^ A(E
MG $"_10E*EO9I=49\8AU%)QH.._2=6ERA7_MS+<'CVOVB6^Z?P^18[I@(5R0
MT'?<V'W#-3>>\'D,^*/\PL5^%DCHNW60?CR]LN!I63AQR^YG@P-:JV/)_LH/
MQPB&E:+G1I<A!"CHV88DA$KLZ_F-I#=/ODK'ZUN7C<1V'CBK<>OMP@&=FZ&B
M>OWP8YPI'TE FV$ZT.XZZJ/)6"0F_71:$V[5FG&0PK_N1N43 IKTEP5+M-J<
MM;Y6ZZG+9D@\L,'Y\_#6M1U$0-M4.$,4A3\].\@T;#CCH4OCJ$&I>5DT:53L
MBK_?2K55YA$;SNY%6;Z-:2W>AG_$F%&KDC<=H;.(R#9=K,A#8KB#[ZN?.,.1
M(.CQIB;\!S'*^*4IK\Y% 9J_=>39VQ(AB,8MEIQ,.Y3NB!8+:-, LHJ!']B]
M;YP$G^/V#-<M5=W4:,KKUQ6C.>\)JC[DWT>./DA\[CK&DMVBWGJX<PK?80DW
MQIPBAC5L'0M[.:-FZV)<OH]$4PG/%1FS5#[J>PK\ _7[ ?,Z/9>'QYHGAR.Y
MH&I"+$<7]NVU'PVOW#WSH.%9HP/L.9)LNON(;^:'RW9?&L]]*N.)K/$I?I]:
MQME8O]?+8P>GE[>314)1=\1NI6+R3VB\5I4[8 T>'!N UC>RY$[,Y*R&[MAB
M+0&'RBY:"IYF2-P,. R3L1H97J>Y0.;?VOF<=/\Q;B?W=';+6-K*\^\B1UAK
MY\P*'H+WWWA$J:WJSC^O@E3G?%9.;I9\&1XR[3F-P8(SG0B"A/G'44K6:ZIW
M9/K&^O&R%K!PAB%'U&5'BH5AR+UCDK9ZD8](H]5EY$E=CQ"")#F@^E0128JE
MV>ZY/%8W]IO?"EH$K5_D>=C!@RU43,W#JP$:M&1MFMR?RO27;07%'?<;[V=U
MQCE IB:EM55?"P1IG1V]?,C%PH.73^X"X?0D&B'&0HMAUH60YLA<PC 9(5/\
M%QBNT7N'T>MD%1AG3*#VE&J\QOR3LC9!C!M+57O7%":->>"4DBN[&&L,F;_C
MA:=?2)NH[<7379?:H"RMAS.41RQ!*@*"(0T0.0<8_H\6:I+S4$8'DKR/*1IH
M9=LO_(9LN&O>^.@@3P+!R]C5O,HJG@MZG]95H=*-D*IW'0Y)"2>:JBO7I\L:
MF;EEK!ZWUI JBL^V'>A3/6NE"8KPI*'W3\Q=O!?V^G)"RD#4X+6HS#]57P<
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MEV'><0XV735C*!<@'7"_1/[K15BGKGX&T:%L0.7]W\%-/^VETX O,X2=9A'
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M%NG#!75RE(#28K-HN*FG=+IC>&%1Q8K-05=$ZQ.KT;-?W"N7K,RM32IXM(<
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MJ!SHBFN!X/"0*W<T$Q&V IXO66%=@-;9*SPM9B/(E_Z)'(SK?/C:N+LKE4&
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MJ+;U6.GD1#$1PP]D\*3B<\2R8W.27](Y42&";?W9XF3]"TH*6QT3>\A7C?[
M49T5_5\V?2(^0$;+$:J&>T\!@:6Q4']<YSEV?J+M^@\3A+(H9*FO*N6[G[3
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MF@SH97F'$%FH_R#F%"AOQB))3*? AC6E.+''^J? I",>3:9%[-> %KV1=*=
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M^S>)^A0:J$&HXVI^=9[8U)6!4T7HOG[Q3(M\ _S6^G+"XA66(K\:CE1O8H^
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MVPW$M@'=AR#6_4'M *K@6@?N!!572:EL"RCM#_3+CW1=\*?W"4@F)&>5/*5
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MGVBV17")^@3N^5]":GIN)FM(9TU:JJ?BBDU!H\5($%B( &#GL)$X-L0W,!N
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M6G!-S>:LR30.OH563<^;X-[IXFOQY8IO>;F5V_U.172E^Q]H@R5&LY8G#,-
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MM++$S(F-PVX&G#^"ZI;I&6?X%_=[^TM_DM7ZXI@P3UN^I_>JHKAH3=Z^U\I
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M S^FT9)HGJ &#= PUAD13>,A*^"O3>/SY_(7-N6?C3GQ14:J>W+'!A>6=;3
M$W^K>[4O7"Q1U+EC]F8B,)]RCXPK#"@YPWQ(U/U>"._Z\=6@>$34-[=G#P]^
MS=XK-GCY_J;+PLGT9:MDG*^_,-LIP ,>>0I@4M<BR$AN&Y)T2C%"T3:FH]7Q
M4H.5-5\_W[-!=XQ9Z'1?4+8E-2I,Z)\\#;!7P_%/\S,!^X@)'^BBD%$1TOH0
M:9E[>4#T\L/B1TS5SL)WUPWN/3< .2%3$T$D2RR\/LP8DE9RYNKI*,(8^EA
M>%-K7C/*NK!C.QRC0)0+<T>_59>BYLO,IAS\8,KAD/;,D:R.O#YPK>22"!=O
M!W2;(/=WA# S)S $M7,MM/U+SD0;E8#28-Q$9!1A>,O=$?TRY<7<?B+A!<:D
M__TCE@]SF PTM09]JZ$\OM!5@Y4T$8.4VVLTL@] J_W@7RA\Y/6!H*0FL"EN
M_"Z#5E!(S-[4]"4@IL)LR1;JO&73KE,AX?Y72GL=UC(F&;<_5PC9/KT3I2?^
MC=4SYGF822(D$,:2;DBDW'?T'OFZZ43^A]7L,K.B9M%8UC2OPIUMLJ^:%.+^
MKJ&B@]^-\Z56<1?=?]%?MPGZ','IH-_3.L^M*>^+O$ ";J0LG)P")N7PES_F
MK4[P^<=1A ,/3F8EGH[A?S6D?.EM[$&?6]!_]$[K6X(-EFL,-@RL+8RFL5),
M2,QAN=8!&DSR;=S<J,-?Y'2:33#UE5$/PL3\R.KS.R_^;R3@2[))NP5-CE@;
MC[0JD2DH<F+:DSP%!(A%"7IO1W"> F(RS2?2EGY/ Y-/&ESX1MQ83@9/ ><-
M3@'I)\=K4+4?M%YA-JC@/)*.C-0E-BT7$F9Y.I(#8K9;89(D.TR^PO;7\^T#
M$.ZY6ZFVWU]GDM?KLE.3"8<;"Z1@PLUXO#"O38"6";$P^CX5^+RQCHA]K_"S
M&C3$];N3VP+K%)"U<C?[WL/O]WX!?)%&Y,,3?:@UV9$ 9%NS5OK@DTH.P9?$
M\H-B,\'EUYO&\^J<+KHNO8NOKAWY-)- E9+H@M=JQE/4%K#LN%7,M:&W9"#^
M@5?OP_%RV8+/;O'J)Q=ZZ.EZ&?F5+]X1(X7U3.D>IJ(L"]-:,2M;9<%EK&JM
MFP?^N[/4=;M&CXWG9.#)G8#<EKGK9!XI,NQ81DZG?F)K_V^-71#.-+5O[F%Q
MS'#IL\#&OP+A\;]>+D4M5V%X:5U"\C7UY,S<]5U=UYPI%TL:-U%FQ#@)7-V8
MZIINP=#Q.9[4Z0_P"P5T^-FK4_,Q,@&:A%N9:+K\*8K**2"\ -?Z1_=G1E1-
MIOZB2$CQF+&H2[W8.Z]S*T6"=/&:;AF-<E,V+=E,Z@H%-FY\VK.4=%ACF7%I
M+U/WAP(;%X9?0@X_+;RT ((ZY_*=S,4P8Q-SR4=6[L?>-OZOP"--M/[L&1S.
M;]\.O.2] @_'59BT&_9+M//YQY2J:^>LL058;[<=PPI+ J9PIK^\)2]=N93G
MUX*/%!'@U9EAYFMBF3]LQ<6BA/DQ;.LP:3(HCZSYA/CVH_^/_L#"M=I#EG=/
MS[&_B'IDYJ!AQA^3M%21?F(<,Z1?=!MN69UR"MAQ7M32[^@Z1C46T@P0R3 E
M,@\A->/$"-[:2C1I*Y/O:K B1A[PM_U<\SOXDK+B!\YZ+?%1ZMM[7JOW[A,?
M*:_/H#X[%'A1@W$UW>^'*PL"DK[;@OK4?!+^:2U>M-IU-EPZ0/2],6@OO4).
MG0W?K]4^GB7:\.=^8S;KE.[BM-N(E<[ANT)-20/+(&3?S(4$DS*G:WF?[8O7
M:&G)H)6^D9VW"6"4>!.67RS[=\_QCSDF8E-VJ+IX#CG8^)%@0HHSTV<&-3$7
M3E@HNNH@@.Q+$#Y/SEU@FJLOI$;@@"3WXZQTFH]7X$$_GR2&+=HV15V115!J
M^E8)^+<QQ"_]9 JR(Z^OP\#H!&D]!2Q#ETXTR38$NF;<Y/ #9;+4":C#<UWI
M13S'B<7<U1:%=:6,E:61I?C#S0%C12*H%^LZ.-G8B65'PQ<80_CQFN$U491G
MM89@TGF[)QW!N5&A$:XW$O^FGGNG,?"38>&=8_-)4$R&5,&QS9:!U"D ;&*H
MABOXN*O0-V&#S0"? C;[0?EE$Z;SD'CABL-8C9M0JZ1)&'^ JXP'1-J.)MY2
MA+:\,2X2X93:UZTU4_%8?>PAO;)$DFX!;!8^E6M)%CH62G$N=R.1?ZO(^,P^
M?B2@=$^:_4[\MU >Y6:'.\Q,(396#:B(ZOB@%>.ZT;T2&9T%XV]V5H;^'DE-
MI<VL8E&_Q(4OQO>&]3\(&9LR &;W$G]53PRH8R-QY&Q%"BLQNT,XTHN\W<6'
M:.N]/T'Q)!CJYQ/S4VO.EZ>]+5KJ\1J9ST/T>)7T!G-\:%[3K-R.VZ:PE/XU
MQ"M+-#61T>H&W8>*[;WY@=^/VM,Z%5.IDVI'HA"%0R[.B881.^FT/%MKBB,9
M*R7AEQX"@5OD86_#& =. 8IDCE8A#?)SDA1AJ[& S.5;(L=!SC!.^BTV!B[3
M_4MYG\9CFWH*L/""5G)EH,J")EJWHRQ/ :S)'2S!WT\!KPL2R^U<N;=DQY<@
MCE$_>1A^?Y?5%RE4,_AD_.A"74[2L*1<CCX46W@8-H::Q1U3-!9VY9MQE<@8
MBG")K?TZMA)%N7F\$=1W>$"[?E9M1'-G?Y;GB:4*BDOMQ/FNSUCFT?X &; N
MFC$P,9)LIE*D3A6^V[?D@>&3NK#V9]./!$N]=)Z>'Y%:-CK\TB/_ZG7M;BUF
M+2<J..9*2(;-4B^$*@Y:G_&&;H&I);B5?CCU-DT0$:>P_5'SVOULQ+TYJ"HQ
M9>7#'F@ST)?)U"JRTW/6Y9 D'W8_R37IL:!3HJ[:W; 9ZMH2[3JM3Y@+;?D=
M:DL<*XBHK47!E(3N#_G:A+C=$GY^\2/(:?Z+H)D'NW+GO')S?\BVMD%\3NXT
MA3 Q0RBMQ2T9&_7T8L_X&\LE 2M<.8@^N1FPLX ?X=]F7.^R&X.ZYKJEYV='
M4X"N93,/RHH^Z<L__=6*]255^<2UZ  Z66K(7?,13>50.#F18$ZD\*@J%A')
M_ZQ]>WOIMF4G%V587TRG74];%I%[ %IUN]U_NU#H$ A5T91!=_ J5Y_8$-,T
M5\A"H!,%LI8ED:[9Y'R -[#ZA+FFP/79M-UT8)%$VHTXKIGPHN-0[8#4-*)4
M%S?N/-SE#.![<L#CZG9(D%*#.&IJ7A,4X?.(T0-7H\0:X)7G?QZ#RLD$XE3J
M0_*=#PN/KYM2AV,0.MFS<)I^]C4[VH#0?32&1&W'\"4XC\*XK,@@$_]ZE/C^
MQ?>EG^*PO1&,N]^N-Q^5?".= C:"%^"\_V@\0WN;-W%/7FKP(".WRC$C#'E!
M,?V<.73T'5_NZEP:O4=I7YR8,WNN"3M<1]+23@&]PC/HK4<[UK.:O_]S+Q$8
MO(-J!5[0$ K8/8 ,0\$DM78:"TEAN:GPGZ=KZKC&==)F>8'O10Z=QUI+4PBQ
MJX(Q=HC^ZNLRZ<?\!S_(-F44'S+=SW]\JBV@\J=@"+X*X[W8*_9"K. *LZKB
M<'VG?!RA*2O&VP,$E JTPNU.'#L@ZK;0IP!!31D-F!Y9OBL;@)&#.E>14PC]
M-LVJSF$*C:> *UKX>/DV55@)Y-UA'^IYWTC/'2F^]QQN$2(?/DQG>Q#A+9O>
M;=CJ@VC"EVKE4O1=,/% D,'FRYN/C^?$?Z-2EDH\E!\=AFXN\")_N/S0L/2E
MNHJ? E!*ZXL2Q55[%(<S$YEAB#DQM_^OS4C^2XYS7^@Z2*>> D(5IH&,1JX0
M@LI&?JQ)UM&D2(S?"[:9XHK6Y"S.O;)C22<NY;JFK\^38U_8L40LG#W@NV[/
M050*+X?*D*3LZTBX2-G-?4,;09"Y#)Z\U199=[?]%T^<(I"I1^6HX9LUN>A$
MA (DJ6,Y?.#, 6FMW!@6$J;L<J/GY>]IFNX)^*ON?R+-)"NVX@3_BFT*R!J%
MU&B[^O?WK\#EJLC!%7 QL4UJ$$UC#W, LZ -PR3&*5<6L/&G@*O5(8]*2]&.
MGI"@!B/:1_6)J93ITE=E<17<<>T&\8.RX\*^9I^,0@1)/ >VY+*2]3E1+%$W
M2EV^P)5VAYB"C-S_J?"W$!3%=^LIO/YN*/:.&+?'5^47#Y$5MTI'+:L6@TX!
M*=_ AYHM4)S\B^6$V'VT'8V<2T!$PRLFVH%< 9"6=.-DX;8HC[WXRX,&<'83
MH5Q(Z:0^IT$<T?;AFOBSYLHK; \'Z+?M*^9Q'^:4B2:;K)A[L7;#O@BF-2&!
MJJ']:+GVMA>IP2Y_I2OFW8]F(ASZL_0N- 53N0KEE[W6_4X!1+$1"@[?%%6Y
MM+3Z!K.<3D&<!8H;RV0C@:5SD*-'*+XX0 9Z]Z?K@DF6'5S'JN:!&+>&>ZI\
ML4=O40OS/+-GW&)08=M+M!$>Q[,&8PG1&-<$D(/U1L#W;4A7B[SOA]ZKS(OK
M<MRDC[P;Q_170N7"R*TB1%V]Q=0I "C5&+0O:9)A286W30/_'&D1)EIP"(PL
M>9TE=B^0QK\&XQOJ_D^#>%V2^G%8?MX7_O+T6X[F\LF-5ZU"0Q7G=ZVR5*D)
M%'\"1# @=:"WO8$)U6;"LYYJ?WT"+![A^+/+D[F59/-)D=/OH5<[6Y> (.[U
M\R</!FQ\3@'W][>+3<9D8UK^T\!E9!>8#%H^;LR^Z8:E@[M(;4\)083U-=OL
M@'JH[.ZA,M^O^U><AMUC7T]=U!M6J/,Y&9A."+@HQY7\GZYD#XR_DEA:&@8C
M-$3)G3(WVVSJQO:EP%JV;8^'SW>4CJN%%&^M@%)%O=CO&84D:[,>J@3Z)^!"
M]K?+,3\D!OOA-30+2K4*]@*\U8Z:#3\+_[0#B6D83O/O*> 795MN(QCKO1R(
M/FJ$'6C8[I4GQ=RB89'KGI<XGS_\'S^X2)HM<A^R!,DG"_"$J:YX)-KD)] U
MF\U7\.;@QIS$J/M"Z+ R.%TY5=E9&\#++^ CXG.^"4B[YHBW/%2W.]/U\HI3
M0(_9N3TFKMU#RIVN5N16P%F"9+1S/ 4DE7RE)NV9$Y6Z<%-2+7R^M!)/?-GE
M4X"6*KB@J&@&R _1-+)RFMIMQ/:M2&2;/'HH;#H$O X-(G5%[<&G>+J"P)%1
M"H:"JM-XYA]%+:[@8#%/;;^J.IN/#YNEOP,N?*@+FD"0;18.$^C:LL/GKI T
MH_8-(;SP5E/\>LTHH2E%?+S:IK\O'Z>2!N+@_%!YQ7S VT 878/RHSC=H@F@
M]O8<TQ>-,&>!-!R(G0\ZSLZMMFR5F#<^6Q"3BP;_?RXCDINHH=#;9P:GRSB;
M'*FY@R? E"HUQ:/@8/! \ %20>/F.-2(9$C(<3O&;DH5RT3&(C=*N]H8TS*>
MUGYX<^0 ;M_P3-Z) ^0'Y,AEI,Z:PKV7**> OD)^;U -EG.*PG;LJ0WS@ W!
M'F2WXJHE8NY3_3NR^<O04CED?Z-T3?)#A1O8M]Y"?*#9#3:E5TZ_[DWVOQR'
M6I'&1_ LS9;5)-D<FNQH3<E)B5CVL[FILL^>O)L_&ETRWG0,>?9H0IV_C1@I
M] ^OANQ\AA],2/FM;1B:0,ZJY\5BX(F7Y8A]Y+]9KB,4"720/(X.Q&_'"TD0
MLV-\9V_TJ$M]MYVRMG;C>'SL-#(7M?7\_*^=Q>XW#G42 HN6/V"#69P007+8
MLV&<+?7GWLV&H16MGP'+VQL'=],8&K\GTW'$3W]:B..8^F::LC=]"J@]!<A0
M_JCI6E*AFI34N:<G,3'DC ,(^7DI$/9'DUUZGR46RU$#8CD'4GS^<M)-2#SP
M>Y-N9)]3@XZMGGPG#X1K?R*!XON#(D],R"? V7'PM_^"W!UL2I"WEW9&?]EN
M:K]53_S#9Y1_27'/[10@\<NJODZ\V.\H8\\R@O* 6DMCA)J1(C+Q$$;RX(FI
MW2AOZM3(B>2!\)UB'DWU3\6(%/W%A)0MLXWA>J7Q%FW.%]?^N_^1]/\8YW8E
M-IP"KZKB-MDK!P7.N(?1QJ+9'["P<0"KV4L[B"^D4+5. ?!+4!#)D7;E 3&2
M< IH1[ %3)A-J ,=B];3$"&^ESYN5C97UO>ZLWCTG5-1E@Z:6)'8S#ZY3G;$
M2\3[S++,;Z(2U!U^,4;Y%BDPW7/5KFGWNF06/SRE\.H=[MX6W06ZT0N':2<Z
M(S38CU, -A0#H6:]T8>#!J<RAU+^X,C>5PM%SEZ:+[4(G*RB70DDFBY 6LM8
M;+ 3-)&7 9^M;.(].A*ED\9).4S2+E63H;^O?:)_*[S)=Q)Y8$5%4#A.;OQK
MV,J<GVYR((/DM1_,'/>W>W4_?1UZ:6=!&P#QF%PI _AHW*=F4E06D +K&I+8
MIK'KH[Y QD'\;4)MJD(T6-QK8^WJF^A'$A>3L!OI[22>C=AY",<T1=:F7N%^
M(]EGO$L/$_$R-? %4X;CMR_=/C<5Q&Z9?ILO-X(>G;@$Z+XTB4_%\ ]QZ\EH
MW',]R!)NJH^"%Z6/;PKF:V#_;?62+5/(AMHD'@2&,Z!Q@3G7^19)N$UIR&?V
M+O_VV;(+F8)@B*9!O*FQP6\3;1ZXH2)RQQMX6V-<-L_NR-_+8A_M U3@QFZ.
MS5 9->E]O$G?H48G1H<'Q"'-7[#!98E)*$)M8!;U=O.D;F##$16T8W@*^.NM
MD]Q.$QVO1L1D<Z)O31WD*Y8$.N*WV<0SB[(L>N]H1_X[)_8-<,\3* Z]33P%
M1*O[DI1:,5<GOJ>'<!#L2R DU3W]0_:+2D__*/UTD(&;N#5CQBG.Q*J7&2\C
MI"*KR8S>-T,3L]*> VUM<S3_/!E?V#DXPU-?9^="<,C23H9A?^/J:XK1S\;-
M75P*A9"Q,UUTK(1'OA<2(J[$*V Y>H*+0?['X[&@'\ "Y'WO+G76F\V#.Y>=
MWQGOZ%],;BX'M9P"*N7"*>SJ_%P)-83;&VC1$CNWJ0>9LZ/W=-V='Y<!-)XY
M,FR)ZVPV)Z<^D.J@/#X$,L,=90SQ)N%R2),.&;76VN.Y?,?7%W-67]?5,?G>
MT.-Q=6QX_=%AQF?5WC//%7O9=S ,R^ZNP4M&=,UQ$;^E*K*4N%E:**6EJ_M+
MW9+CC=>=0G>=2W7X$G>;[H&4OM*5 9PS91J;DYR2O6LGL^',67CM(.U(#..A
MWN WD3_X7>,VK><40$?1S*.8DEBB%)I,6M-U$YA^CHNAZJ)O1#RILV)MOBJM
MU2-[CYF2JGQ!88HB2_UBB8^,V51H)Y>1U#IN0_@[[R/9R;&;J;*\!DLY.VGB
MWHF#%QG(0L<CK5EWJ$F8&]:N0BSA ? VU?$T.*3\GW]0VRK*:7%GQ>5[DZ.8
M>V)CY 71%;K*]#(2(XUS)&";4.=+8IB6C<YEB6PSY)FSGCD%.(O4T@D<U;$M
M#*RXP EY6']?H8P@KX+JK:-T;85-I> Y&KH',OUD$98>P(]G1LRS\)%Q[<<A
M_7L3--G&B)UCM:]L.=$$1.]S5K.+5WUG;+((C3%DT19-!F=RQHF1M=%"27 L
MCMM%DWG/Z/FK=(+>9[?N+O>DCZ_1)5O=[HBOE5*_::RUV6?"B&SS'T+$=&V>
M5W_2U=5E>O(LW+5Q\<1D2HFV\GL2Y:$IY#<F[BKIO[-3^9F ,4RI]S-ZH.=!
M\M6 *UWKW?;7]P]R@>4/ ;^> B[</P70NVE6IZ#Y\K-R3@&7:VQF[2?P!%QE
MIMIFN;D'NJ:+X12 9G,F'E4E1,X#WR,U;D&?59)5"+WZ'M 'Q)@1RZK,95Z;
M*K]-IJ\4F<FHO8['Z"17MQ&_O5E-A:U3P/SS75E][=_;3S8/-R$2Q?NQ=BQ_
MCM]4YMU%)]W1^\/]UO$]8,T(!B9?T"/'+XB1N#]"+@U-T.@#'$W_5'_]!#WD
M^]PO]LZ0IX11[X]<2(>)IQGF$MF[94Z.A(OP,8FHI=U"ASTG#OP D1[CS$ =
M,599TV[2!8\!7_ILA*Q61\A%!O;KGA.&2$/]0H_QA*8,PY]'[INR"8/CJPHP
MV@XJ)%@X%\9*BHA?P+%8@S#"HS?&?(*;:-J+O#M+#$O7BD03Z_4&M>(2I-YB
M>0I".P?GG=NDC#34U#09.@*+Y&)YVAE+9;\U_+DENMN1O>U/?]%&'9M\?7?@
M^.1DG@6!1#\XT20;M@1%QCB,8T3=CF7S/?&3-VHPC/Z<:GU&#6OTLWZ7XUCN
MGV\^K\3LMN+2Z66]L[F2O[=?!6H8_9Q]W^&8QC<--,I^&Z*K#7L%Y<]XB&@]
MA!/+3P%X!^$I+K12,0L[?7L!;C/+1F#NZ!30A14R21Z@-A9/-&^3=1#Q:'48
M^UE-9;)R-LD4P5M_T\9.+),/LBNSY?IW,4"UP0%%SX3L#E.E[HRY'JS-;37D
MUDGM\M;X1QWU?IGR37*^,W73Q^Y%4'9!M>525\M_FL?SC99K.O.[>BBD1'8=
MW_R9):;G"XKJH-P12;K&/,$O^H(3_/0-,VA]\"\S 7\*>-LO.0[Z6I[4]F+4
M_3LHFK&R37 T)C9Y  !@<1MK'=#?PNI[83N0[;T9>C43^T;('AK=D,]S[;?/
M_@?H_O]1!W0_(ET8(*,"YQ&_'#>.Q52[IM';39C &SN4)K1C[\#F+"E!WG8?
MVS7+/778\0GTS*B0B0?(QU1IK:U [?PA-WFCON^=%H>>\:2-Y(]?HM+&JN9G
M;D?09*"\B>VR5HJ4A=H4SO[3TFG\-5(.QC=^7,C,3]#F8=?F_[$K<&>.OG5>
MX-N[-/B5_<:R"U;C-<C+;JH1964!Q48ATN@'R"ZGXG^]!T]JHW]D]R7<%IMD
M9<YR*Q!_G=9YM6 C.QF+5,P^DNNM-Y*QS,<2>>!=*W_WU081F,M50WM-AB?V
MH+H:3;6-V@,^W[&QD4"96O XZ<EP82I.:NO1+^)?A:IBZ)-A,$; /F#"^/.Z
MM;IU\!HK)@NA4O?P8\2?F#[ON'=Y"5[*R&\\\X?MUY'_[*5(QID$Q#7.D:V]
M@E]#E!?WR^R'+_@XU;@NH^IJ(_QV!B;OD,_*FT4.^R4\R[G:>.)#LOW@$R!3
MOVRV+]\JN%C_)S5+/RY.R[9G5\]03U]"6>R]'N!K25^141>A"K5PEK,P#4%C
M&D!7+IERY/$WW0A-T!D_K,D5QKNU/1M::"".94<]C2ZT'[P1;?_F\WTI2-.-
MN%:6K+\ZS(4BK"9P C!A[C+Q<^W0&M\D1&-(@>5>YT!P-[X&7N\IW\9?>E=
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M\,EF%2_KW_/SLA$C#8I%\[*II+\ULQ6]]WWR<$(]/W(C.3!G<K7VV#]V(X5
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M#JUQG1S)-;N<IE SA_ L_*?OGGIX![.4Y>OZ1E[^:JYDM9[Y-$/AU>KAR5.
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MI@ V>E-MBJ>_QU2IKBT7S 6GHWMF#N*5FG/%O05]3[U E+32AHPL.?PJ,8V
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M,DGEQ\#?FIX;2PF!'&T;PFPP3YQP-)RM[*UWD ;1#=1U3>]COGZ1]>._X.Y
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M"L"0\S%D)V1T&PV @/ZL%/*+Z]$>0L*A2L5!DAU0KO[0F9)?2SAS]6K)I2R
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MNSUP5(8F)&"_&JV6-&7@#9S8*JQ)UK#72AHWS+(UU(VH9[Y*WP\B9%&$3VD
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M6=8+ADEQKT02:K*TT] #.5NC3U?2"7\F[=R.C[U7=X#M_6+C[?,5"7MUI2K
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M9]+U"-O?DU)R76#P0R(6%=-5Y0=$1B3?^Y8H[@)^%F]C?:Z51C%S!M.!K3<
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M:0FZ.P[6!*0B12TF&A=INNO+%.OKZ_1;%<*=]9+)8"'JU@_ (R%:DIA-T(;
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M9'Z>$&''&KO:=V&1)%NANTH2$\03I)P'/B>P?C6KLY(&RUT%BY^9S@JCO,5
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MK^(=<VIP"G49*^JUR$E']QVPMLGGYM]"_L./CA+_:!38[_N/D,<K],7FV?U
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MJ5Y%F_&:"E$M?75TOV[8RM%T%MSIC^/ZU[[3[3X9N$Q]R][R9@VJ]H_$YO$
M>&>FEGDE+*747&LVS_F.G*MW6]O#+XAMIWFE<B(@[.D5O'SQRUM5^N#_[6<3
ML$HY:)89'E0RC<';O<?1FZ+":RM7DL;*A;@:S*!.^='\2F-VWQSC^?=6>36Y
M>&4XQ-*REA%7XY=R5RE.B..+#)&WGY(H2=;%#HV) )MA&[X!+W8SI@^QUH&)
M,<Z&2WZ/"NT96'1.\KWMG#CK)PK,(NH,99*4(YC\&MKDWK[@O+?'/,R?KORK
M'NWHD>K8E9981FOV0DZ<0_@YLTE'N3,%TS@?\YGR,']($^3"BPC@U8%;EKG!
MT$0 $G4(V<&JB^,Z"1JH_V_HG4]S=:=%?V% _Q=N(Q@&]BO$WS(*$(@A>34U
M;J^^6_F;I\&CH;Y/B);K<O3CV5UXR+[/4T=4UIDF?&\!Y>V2V. ^0ZB$7T *
M"KNS&/X!::"L9E5C!MU>++9I\L\I]Q.*P0OB$X*6JP9Q?\5E0_?V*8_*'W7G
M?E2I8Q!C7=LJK,?Q>)V?AJ_A'M=@]D(BCQV%6<EK!;Z-&SY9'I^"MO9W/3("
MAU%92#_AC"I\?EX7CD00X )-!%-87+QAN%X5, BEX.<$DRN ;NA5MHS^.\49
MA=56,)KA14RRNI*>+4H@96UP4OZ?>MFRQX8FD3>8WF2_D>J<Z%M68G3(Y)OT
M$*&>@=:=*-"NFEZGS&2ID%6*^0_>;BUC<X*FW_KCQ>K#7I+T<]^D#[[- 7FK
MXG *UIV7UEU( YTG\OG.GH]63& 7J3'XX*.EQ6XE:GM,9K;?-?V8UB7GS"U:
M*G2/<0@\>Y*I8M%?DW)OUPQ@_<,0$D1X="G0/-9,<5V]=5G*43D=IHN:HS\Y
M('^T,/6)Y=S]*3*#-M8<<HU?RL";6D]9'"7]QB[&'(B *")@>=K"<YNP/I7U
M]>R<H-2$\XQ;$6 5N3^OE[^]0.?;\+[9P 4Q]'!LP:0(]"J.1RKY:;74!53Q
M/8^-\JQE[LK%O%&[HE)$QQ0[%]IN%-U5!VR:D-3<S[-.UT!Y?P+Q?-JCB:>'
M"X6]Z?P" /A9J3Z-,X@('SL%!@*#>IE-S0?/0D[HB( X=0LBH,+O%A'P6M;/
M3T'U08OFA>9SN!GR/+7;M6)GX#(@G+^L7QRF201P[1<3 9951, F6?/I$C#J
M4HZQ722DZ)R0%-W*/MXI8*E&KF0;$WAD5"PK&-K?SVS\H9B9Q(B7"+CKVP8\
MYH&Z$0&D4D3 I2K #7A74D[!; 727;SKM-02>&'8#9OU)HF(*YBUMF8S*C&T
M#5SV8^V8.GR1L\4@^XI6*05G;,9S=R_2.@A ]X4,K/O_7+LF=+)SC[E#HCGH
M/DU(:@LPFPH]211VHI7B_AUK?5.=?C%,D7=,,H;]\F% Y_NJEA1HN9WHK#E/
M).,%X[L-0.9SC@RO1G3G(@4T'K^P36 9_:?=D4W9O??-0..=.VNJ9EL!2(FR
MF?OG-@UP*Y-AU'UGTVUM#@/ZT_W4^KYS_\_( /6'83^IHO_K1S5WGH0V!(^T
MLPB>TN;=5U]!48OW<9.^OV54T\>#)?7QTY\\ME#J8H$ER>9'U>5;"5/,6JI4
M]> Y(TMO4I'?WN:_&7+)9\E"!&2':!$!;=,H?,DJRC95'_[5GR:)SX3;U]#&
M_?F]>S$!U"YFB]C"2U(B0$4]1 EK "$"NHQT"K>FTE2_2WE*_9HQ:<OF0B(C
MU=G FR7/ "?T-VS_M_99JQR.KR>&SFP1VB[8[+;Z &=MR=T\!I-;GI87NM>H
M\#<.N>^(V9U>^GNK_JI([(L>4T6EP,@!@1SO:X#U"FN6=N/=33(]R58L%NQX
M?\VWUBZ<\;<I#IGFW\?&:G!:IYD6NUV36B#'J,*5[%S>).+J6KZ;?1[MVH2S
MU5Z]M)AL5LC#P_"!76\=,-]L,43 NV@,N1#"<%I#_U7=B(AS>&A_5[RV%F U
M_==5@;R1BU3ABG'STV1%QCIL:VK%PK1>49[8UH# O/<*UR,KE\?3WW<_15Q4
M!Y,<_<%7+Y$A\@2]6LE0C7 :/;B'ET<9<$?3ZIG9MR#;F#L?936B/T2%[ZH9
MFI=6.%;<]1]F40O#[N]T2C<F_AM,BPE&R$O#76Z5K,LP?%Q_Q6Q<2B<?LBXT
M"EU:SYT_OO1$]:./4/KNM4T$X,:5\>IU6;$?H<4+75JY5&RE"8"P4$2-G^SY
MD9&OMH &:8Y.>G%WKK?RFF<\A\@3_7YZ<4\@?2LO-&U@:3UD!4YA8MQ=LBU]
M_MJ1=.%G%*VZB\<]IQS[W%0VZ=1JGX";E2[QV;J(Q7;^* +2*Q_?V;7 D?P.
M9:&*UDV;[J5O50Y6YDZZ;62D^KHLNXW_[N?G0TT5@2P\612?+V^#W> %6TEJ
M\WOE>]8OW>A_#5;W\@M'!C5WW7NA4AB'9'O7^ZIB/!E;2[A0,HLZ."4\F3VZ
MI()W*CWTH(28_5DXZ.BS6K: OZD?JVFQD!21 @EST?X8@*R))+.>T>Y^V-4;
M:##P8HOI0D7 [\.>KQXP3(.2ZO2WTOQ&@E=_1<OE'ZU+>[6^J_P%E?H9][+8
M<?<-5R))Y>PF^T,\11[4J\N0)7Q'=OY?=+J' B$CQV*$IJJJ(44FR;ZCJUSS
MR*:CJ8HO9?8!M'N$!L8XUJRY<A%S7Z]X.U;3U7TCL_]VJ%D?;^((1NBO7*XP
ME?:3&U^>]D9^:4>LPK,(V@3],\EU:I#9&A&0X!^M)'%N?#1"2YC<6<)SC]?.
M"[SXT_S^JM0E?X"L8L6Z9BRA+^ )1J^NCYR'OO[;TS.Y"%&F&]I&JD677BPC
M;100#J@MJYM;<1]I5-H(9R:YDTV3F<+@I@L/B)LND5.V@L2V]E_%5UG#PC)+
ML*'I0NW/G?%MO>+>$E!5^WK;".1!<US) %W/:-4+YJ>;B\]^<]]Z2-K;&27P
M%@_G"_QG4O$/(67F1H)FB9H=\'C"YY5B^_O#<NL'(U8-5F? #9$0B^,KD=/2
M"B.X>DY\'890=^EX:/B<4FNCFX/L>,^HR^<THAP&7KYP5-0LJ&JJJ@O .07R
MASE&TO2TFB4]-;3HH@WQ%S>1+=R[L:)$M2 54@IE6!!A5!C.>M":!4:<U55U
M>O-4]HI@[MU]E]NQC!Y8<LW'(SHO%$ L)0OPCK<KU/>A8YIEO..<":;U0:;]
M=SS/ CBJN^]3>?(=&$MD\9\UKNM(+S$D0^#L^<7X0$L<0TURDA<0DY;WASG<
M--F>L\LYA[P]2<4Y.Z62-VR]&%*^6'A&2!/RX-TKN*XS9_Z->]D]2GMRY5L8
MFY[<4NA=5CD-GLDRBI>(L\'3D_MZ$J&YO\W;=APY3719%3[=2L,HL?]#B V\
MM_#MD#)E*";+@)1BNCU6R.-'$3;) R(NKKB?7W-DQ/A-9+@_QOYX?\ & _Q"
M-].4;/DXKO4[T(Z4;DM%>3P-#9K_US(HS"/ K*A_5?R[;>Y9<QVYI-55ZO'
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M-5D:4YFZF8S.0I]*W_AZQ+8DIP!#E?J<W=F"*.WL'\G)"FQ87U5P \/IH+I
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M;!-Q&_\'SRF4F5*?OG256]H.9R5 H:5M=_S8DC$AY^V4=8CL"U?4I)C$0^,
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MX,<]<RHHK!KGGK;$R$NRZ5-[DZMWA&Z8[X/Z)!?H# 7<3#63R!8F5_=?V_V
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ML>GB!M=:VB=E9%:ZN_,FWQ?O\[[\G+PH9YGB<M^ <OL7M9\U,.14B>2!9^_
M&]N8=4]^:L44C]]N ]D56SYP>>$1]]1SD++A=J.)OG%%'H$+#O9-.%E+\^5_
MG+:%Y+;$4NJ;9CI*8$S;C+Z[9+HHMEB(#+R;=[FF T@NHI03[2HY?(G9:79.
MT**^C31ZV!*VLNROT?=6X?NKP--8:I4,KF+OS\?IE4("F=?9NO06)PU]/G9)
MH4Y-]^522O,<K<[/X(>[>TI [5-%F$MOV$!\4*CL0;@QR&:R!M';C2A0RC+M
M1+S19LTY3GZU=Y7+E8%AJ?]>50'#6399;G&$'=PM%&>'.;AE/62+P@#G'N(Y
M6&;G[Z?_=/8VVL-1 %I[Q)"LH;Y;!T0XGJ&EELR;U=LMX7L3!%MZ,%$O*RWR
M!?E*NAP)([?$]W$C[6QCZ6Q9OM..-6B!+2>622BBOS*1O53Q3S?SG,- &<MU
MI$B!Y_1]N1T*"?[;T>P =HFK\?F!UA_++D%H+:K^]Y@DMH7COS^SU>&%_T:>
M-YVE==*4DW@&YMD:LRR;Q\D>GR\ 8"_F/L6H0.E5J216X?Z'_64F;-%,;6UK
M27PB9V_)<GACG[VC4T@O-S1[%0'!\WP4[%]E:\I]\O*3W7?/]WO?E.@^O2YH
MI:-@O(J)4HMX2)+&25L\0D[E]XKR4_U5*TO&*%M_#YR6\=&MZ5".GRRQ0LM^
M&*"D_Z4'^<L_/=#O)$-4=)+]0G09] ],,7S:V-;=-N[\Q#./U3_7;'VO4^Y[
MC8GFNL1WORG$\DJ6V:G6*:3QM,UF;B5 )LKSCM$V?/O'[F['_NF/J<)&TQCI
MH&W-TU./7N;UD^ *>-7TWTP'].$]D4Y#9MQ]INLW6O)ZJ?TMS\:N""RA3UE@
MNH'YM<IP%E+=WI@S_2#.(!._\><LWQ3,KFM ]-%T%0>XSQJ(!>_(+3HS1+A4
MDZRU+L&5JW&QW1R\+S*(?A5!2<NKH!OXV!LCTX%+\SL^;*^D6/U.P0;T($8/
M\$F3.)9J67J[18E\&?A(X-^01I QI")MUC0XHP,=ZM5M>;C'TJ:?4Z.\V)EH
MRPLN$^_3]<E=^HZB/1M"8H=;?QAWY9-5"_%+1RC4/[[^42FIVFT7J=$>[OZR
M]G1J:KA$037XMT9=(90NUW]AD/=12M"]!\*]=!Q/$ZNS)K:?J"Y>Z;.K%=Z9
M<3<SU!5^G4B Q_/S!MVBQ9^-Q#XC,J3ANKB_87MV?!"R],Y>#U9;,\T:=FX7
MB-?:>.E1&*4_+OA3#ZNT'WCO;3&Z]Z4XD3CGO.1441$1B"#\ !^.+$[" JOG
M+&/WGT]Z)*S&"H1 IU>**3(^[O?+JS%!1/@N )B#U;$-'C&9!<S!<J'+G\_U
M/%F'Q82#&I6CD"A^XJV<+*AHB2]#I4:-X/P>_OOC\1YV$>D.:&=-V:09,IU'
MX)7P0O.O%(_R60<GDDOO(4>BM_V,46OS&T>GOI![K^=M7[ZK&[\-J&YLAS/7
MZ9E/.L)M+@!Q/,8^X51L*\J%S<KO_2K14-E8H#[8\ZBZ3+-"47EU2EKGU7GL
MSZPF+I4,]@,+CO=[Q^\KMR\ GO0<YN/_0"F2NAA$VP'T=E!\3>"I3B8LHRQ5
M)/&)P[79SF1YD[X]-ZD-#I'__A(^.*[.T=!,)"[0D</AG.3'OR-4/4I'2OL4
M[6O":@NJXGVE96JC^LTHM"5[+<OF\58?>.NN];!MMH0\^8,=#O 31%.*CQD*
M?:!Z(F]X"'B"-5L-AZ?;M?QH$2GNCB N;-N>>+S:#;I%TX/%;QRQ&T5^JJOW
MI7RQH;PM99:?S0^V:'@\RL+S;EE0]_C^(-\*;EKI>C.]FK&=E9)^2TI=MB 3
MU=O/\U>OB]!&%U"FTASE5P:''<.=R[N0LZ9&,I=F(:L$Z"429#FB1OD$")B4
M3NW2BC<^=5+-PP&/QG!YBHGZG:#2V2%.#D#"=2%PD"7%+K])#!Q,+P,K>CWR
MK4!L0FD/\W 7?3AUN!W^'/FS6N''8[QT4;N+:ZKSBS\\'QZ!ZWPW3\CM?Z"*
M6V$K;/FXD9M_8"WH$Y^6LE\RS7-Z\^K5X)="$3Z?WB[NW1.*=HI<*DP-@Z,7
M.#?:W8N;9@<@Y>M'<O8@D%ZCD=+DQ!3Q<X%1C(G]7>7VXGJ+VW,(T)&SY*R1
M56#81[85%>=FY4)(:/D?_NNP<F/[C7FCMG_-S7';UB]*RT4S2A0H[LU>YW??
M3Z*[2WG39*ZE7X-]0T-U"O/DZJES.V'K:6]I4A)<*_PFCSKC="&E6ZK-"M<]
MBI,SN'9'<:>OQ5E%8 J5KQ8R0@1?R^>Y_;P;@>QHCA[I?FT47XL>8/[Y\PV0
MZ*[ZQA^P$"*0V%W8+%HP57^=T!*/Z1VJO,P0:;3O:E-.30_]_-*_P84\,K5W
M%:AN7:??&SV#.V,^;[M,>M8+MY^5-ANI?C#"C;#H0SUX96OFAIYG#!1SF3#Y
M1'_GU^J-*$NGNCV(U>8'58SA]VY(_@Q:2,LS2<#3#FN=,CIT-S1V)1FU36T_
MB]NZNV# ,H24VJO><<]4FK_97[.H4'\/OG5\2?F9(TQ)44!#O+&RAB!HJ*U[
MT#V]F'-[$EF^"DIX$R>P@@KY%74?()7;576.:#E8J?MZ-O??M+#]W__:);]'
MW2.[=) B:TCA]\=VH%)!&O8\U2C$/%@E[+-!T1Y:PMX^.T=/U&KY[K6JK8!D
MWC3N"#>B5FR$"*Z03;\2)OUO6(]'*;&?RZ,U']3^_J6G=ZGHW6@P74SFP]#9
MSZP-0KO0^04-E(96.>/< N(RL+X?V4OVD$6( V9$V;YM?9W"7C7-]Z7:-;/K
MRF&!\SS="D[-=_:KO/3\H*N[S/Q2>L,(M8",+F(37C_^G,O0HW+&">9UZ]9*
M"R+:",6,+*EQ&!0=]_71+N[M>6&YG1LRG/XJA,FK&(.=68-$>?*E&OZ[ $2?
M/SZHDNQ17,#2/,&<2\YZ(E5.;B$S?&N&/ITEGGP[<"^PG=@5/'N 3#5?W$:Z
MR?Q5\>%Y69>&&^B%W]Q ,1\4TFP>=?-.^DHIDG;K3./8K;@=ZDYU2U?U7838
MCK.)7+<-Y>ILA".7\S;JCR#'D L 0YW17'NDEC-)K,9,-U1KX KQQJX-P?WC
MHOK01PV9G;7SB?:83PGF;/&-.WD@2<3CE@<K*0,I0U.IE2'!_'JG? VZ$:,U
ML!%\)]]MXF-K_5[F^0=\7SA,H%>TFFJ+4KD8"C5J1[+.,X"IM^<XWHO)+ T9
MEVB,;*U$$JF7=##0;B'#4-%::%B2CZ]@\BK[:V6ZK#ZH+V^5+>JJP'?_VDQY
M@],?YS;GJ/KOYD<ANRZ8S\6=%GC]M',!SP6N3B6/(IB'[020!;(BVA($\6!!
M"SDTZ;UA?W9GST#?Y4;KE9FHWU22&[GPS9.#!Z/= XA19W%2.![>GV\+=#SL
M8G&<DD4U8+:08Y[X*QXU0/QMJK:[NKS(C7K4,+C<L2$G))G7@@?/.)"B?<Y4
M#9(6LAY'&(7#%B=*)O[!.O/SX^N#FPRE'A&+\@#7/3\4A[ZI/ ;70M=\^R\
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M(\U!3#,*0!(<U\\R'VV.5,9<QVW2G ^;RG"NN5DAS#_K^*E3.E9<,_D=VN>
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M5"?;TIO?'@WC\_<Z]:FZ9FOJRC6X;8O, H[.3V8=BMFU9-BZS2:,F@RU$!>
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MCU/(@- 5.+U*X:;7'%\=-=31C- +K [6$=%"]]'RADHD>?1:+_\E7J['=%B
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M=0+AS]KU_RISCDK#9( ,EK! [?/4; =DB^5OJT>I;L]_55!.KW@FQ!F64_4
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M\,%]V(7\N5$\2#(:.J_"1Y)"Z*^0 8N&WO\F8P[J[U_I!R(#).!_+F!,%$(
M3\PUC@:[Q$^9%.G)@!##M0OUZ#3\-XM>^C]=^U_+-4&,'QCO]61(AE87>HT@
MI.E<NESG'MMIG)JLIWU3*M^C!:&&*T/Z:2_Z<QL_/$_;8'D_>\*#<IX+0JY=
M>30@%62@S$\&],CC0>?!9>@#;0,P-7PY&:9!:CF"GPK<OU+P'[^-_$\PA#1.
MCIB(#B<##@>?DP%#C,:YF/]SG%T9_OOS_WC$^7^OK?U?U5X(' [<TVU\10:\
M*4:<,XZQMLV?"%HRD 'E2IFD\.> C?^1DO]'3+@K9[P&<=G/$E]S3.3AXL54
M;YO1*I4BW#\A83TQ<L:O5G6C*/D]NY6<)NTOP'N!EYY"^)#8A1J_,@G?,^3&
MU<F(GPK,/2(#6GS%2<__"W9)K(*Y9,"SAFYN KW-1:,8P-N61]%_DV!+9,"E
M+?2)T'^!+N%U2M(YX^X=^()2$AD@H'=!D+[JDP$_+99BB=<KR8#EHO^"W44W
M1_"!=J/KQ<AQ!"8F:!#%=+1)X5XQ0!Q7'QD07_P?8?6?GOTOY-D=?%(GIYTY
M+K0NWXPHBJ]Z/3L!@MZT%PD4PU>6@:9JER,.0&&G'EUQ"T#:B;EG;QHN>%56
M"J_*_4W&T#NNK==0?__G#_S_:?^[T;/AT=WGVD\)^1X+D.MM1SYSQ0[65\_,
M-VYO^4 Z]YX/-#A;QTNB:%+IM@=O!S^9[8?,$'UQ<^$>6 .,^-T*"VX#U# +
MQ[.ZAH9$K#VC0=@O3<GA+T01P;?5=N\?&RXWRQ.%+Z#<1 90T7WUOD E_33,
M_TVHPBS0<*AT9\?=Z&W'..:RR=2<!AM/KNG#)\)!G6[S3 $ 6&3;T"PLN_68
M%DOK!T/H8DJQ=1)\YORRVC:"N[(&VHGO*+8E5>*)CX3W7UA&IIXV@'%PY;^%
MHO[SFQKG 9S)?_=(8VCJI?*:1BZ>VA1A!/*[T;QF4Z(Z2TRANU_UIW*&1/9?
MZU__,,H< J?H%TE?O7+,![%7K8M:G3Y 99IR]ELJ7B/[O!+?/?U2$MW&;NK%
M==6;NXU^,JF#Y8C%#!/A(9'O!.7^/.QT"WHG"EB]PZ+F:;]ROR2238"I7*"<
M.RK#"6NW-;EX$6?VS0PU>&@7+7W[J6=ZWKJ\31Q>M-'^I^]U8TDS[R3-"O8G
MEY]<04KL![76[C(KB8V1/-&'>P(;N7UE1T3(N=^@ PZX+;4(8M\TBTGB-XN)
M]: /%\3UI\RO'U.*NUB'YRB8=#'#8E2#W2Z7;;&^=!=!.]"'I23FYIJ8.7VU
ML-B(5)C6H$OV/-%TH6T<6%;[/"2@GSM3%%,WW>^]G=_"4.PD-Q46&L#KX&:A
M@AU:,@=(+WJ*6J[.+L%6J=R:G=WX$M6Y3-D&!X3^[3R;5!:_,FNF50!+/ZP=
M>3KFKC7FK-;P H7J6E^FX8?D>C&U7%=RDS?PG:DOA1PWP/>T\J?W\ON\[/YM
MVB0#OJ*3URTO$_H6R(!PC)?LW)VQE",8C_;/KV8@9YN@'BI%2T?QU%O,=[6X
MEA\M8)S 2D0! LU\E6"ZS&I"=NN2=I 37=)55*@B,,_!N/]&_ N,W"T0>^V7
MQ2NWA#Y6,W!IR<QQ1V3<8[A 6UL:OL*J@ZUS->S+M<= O&07G;\O5YJ=1M\1
M'+&I2\H1/B2A$7'K3,:)DWX.XS6:<]KTGTABH[PQQL%:HAZ<5\<?ZT5H<3 4
MXOZV%--U,$R5YG>";DF5 Z_[.09>5I59#?L8U+*DOSN"7V,6,#GP$>[OOGC^
M/?F"U>G")A[>I>Q?#8NG\^:^*/B:DF],XR)])Y0) ,3VPV;6RAO_U%X0OX3+
M2H(1^P[*(K (CD\QH$^6DM&<;509QZHWM,B VD0XC6WQ.O"V3*G7BTB]$=(M
M0OU>%RS1US?27U4E4>&3\YOLLCP5BCMKCUHV1^YR9:MYHXBB4";(=1(3)GH_
M(]/Y3Q49D"]D3"C$>@A=;QWD4'["']E/'VN=_CQ0B3=B/Y-@9BFPGPY<!!%&
M''<Z,IV&9)&7NH!8ZPS7H"_R4=B+FE";=W)<N!(BL^1WZE_U](*&"AE<6I<V
M3D5U@F\5\=%_#)"UFNR]^*CPO]L2DO9RH1$!@J:&&JWSMRO3;"Y:/BAND-A1
MU:V;7MM_18DK8M_]PAE/4RK"XZ5W0G67$-**%;_8V$;K]S-<_QRW9)-8$.'$
MIGE<'A'2\&CRJ)\>"#ZALC[,TLC1LW0A Y@5=7]07KQJ)R+Y=,X>+G[O8[HV
M(D!J/+N>@$:8J'QP]<)][6+Q3,0W5LZ"_'_DV!?EAO-OO*:ARP=XM?1D>2I)
M1NS;DX0)B28O(G%>73EOF"\?JRJT[E".5IP.<T?,W6\!XO+\H =GMB'=)(,"
MEM.,!#7O/X1L["MYC0ON#N\*XG"Q.;,,K_D0M482?+S4?&F]RR$<;]RQW0"\
MKNC\G9T#(0U,G;#6)[E?NH!5')@(;QY.7)CW>XA7RYQ<#GT0TE6\>+ W9T3-
MB/30I:ZXD;77$2CUJA4_:- PRE^.))AC&XH)*E)3JH5_144HK'DP9Z"[BU_.
M.?WMV3=&C=.T\*".'JDL@L*2L2$_%<N^ZM3$CE2A7>9[X TU0C'6+:I[83XZ
MB*TMM9_^W_DYX8E >0HCPB"^L)G9T9)I>&&D1 S1J.8JT]0T4%,$MW7 5;ON
M3@MT)XAQ[G]Z$N9Z/2["/ZFKML1E6Y1H;N.PL!E+T"CS4X$[></7^AR8I/A=
MIK'163 TC .>PIW !18Q!H(_=L!9MXUZF;BN94S(3?M)+2F)ZXZ_&;W[Y:U
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M$/^=^5@U-V@HO/HQ(2&;^&QLFRCGFK^>P=Q07Q541AJB0?4#_%<2S=U-3EY
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MUT;,_ T_<P?[RA+>#7_5IS&"7N_C LWU[S14%GT,UKX4E:*C>A$4.5.1D63
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MGH,, E_J-HPQ_5LIU(L3=,!9B%K%\GG+A=<<FO?)^R)SO^<$@)AH^E*WG1B
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MEB+)?88R>NJ%*B)F3#X>:7$J3'XC4S.6+-)0>Y=JW&&VJAP-P78B:S&4[G.
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M:U_2%KVHVD$7S3JZ4] U]2S]K-S[J/Q,Y<3NV'6:%Q&MS=$^;QIY#JA/ZL[
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MN;]GTOC)3F\&XN#I7C^:<FNX=KH?2#RI'_6GKQ"-R(9LQ!ON;YIY #DTKQ>
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MJTL@_[.M(4J-F767YJJ(9@XR^2+-+Y(B59=@>A9J?0Y8?^Q72JI)RSN$D5-
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M\:]:[W]G?4%#ULU#7VQ#/"(S7F3=Q?J+=RW;&^J #.7_C@PA-GQ"G?LX *J
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MQ"A>;0V(L3.P6]3>6?]O!#+C_":EUXR@-8M]97O@#4N__ ]_T[H[]\>5E3F
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MO^\.O#.>*4<+QQ4B(,W4D>+2ILLE!OPXZ0T-",NW8A@= ^5O4J>AVL208K2
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M7.<NM!H7R0$XF5AU6?*>G989*5>J$3]_5"W[2,<IU4O+N?IV--:ZXDJ_X8X
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MD2>T8(0#(#A$!9&@I]S8)ZD[1>7+NT"GP>H)-Q7E=0W5/6^#@NS:XBNON&X
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M3HKSU]'>Q3&'EO2KQM7E]*D[BD]?&^CQ'.:V*XIDJ]%5.CF D]L< />+_=5
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M_CIOTOM#Q^Z%B_B8XH,9#K$7* X,=0^_I3UKZP2E+ORW0*SM"MMKL15SB97
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M# .JURJ2O#0\[+4/Y*X<LF[$W-H$WR^NB-4Y4@8?V@E@E3'EJ>T6M/5F,D6
MCKL=\IU]H9YQ=Z2NN%)5?#+^F] IKE!@O40YC$P,0RHQS]&M2)18]C7Z8LD2
M^UHUUEHM5.P61C%7S?/\VSH-_)F]Q#!6(E]*8XJIB;Y"W?I*14:ZHH/7_K['
MW*7._HVRK;H\*T@O! =1I30HMNC8,QY@7X.=[;E)H!].9:10U_O5&C?ONOOZ
M%T_>/7ZWA" 9XW@S@J<YB,@4>HZ35J/APD#G^LEE,/,1_T;(:2,OLEE#$*;O
MK@?F4JO<^:-3$7:7UFQ\L&XW4=W8Z52L)&NJ;R^]*@*R$!R*A[;A1OVL.L!4
M<X@H/?'V"$;0S0:8N V)"L@8^:J;S2XK6CYM8\BO_QFJ89]\SCE>5;.O12!(
MR@.G Z;Q= &Y#H(9'1FL&77PBZ-3"N")9@DXL^]B9?#W!AOG3_OJ+)=%73G^
M$RSS"_>D@#&21O!2'$;J_W7XK3-M1U1"]3[?/AJ[UV[.:FB2=*4!.T!'*ZE%
M[VHHIUX$MO4L$PT&S>=.99?=4%3I/9W\N6H-?+5%AVQ%<EW+GDF,DE9OHGZX
M"8EANI).@$YY?[6F0^YKXB")@/6L]8<_#PN%>>=XWU\J4$Z$X?=#@A)3"\G#
MTMOZ<,UH[$L.@.L%\<A+]F6WD7%\K(ZLTJ_J^DS]VG<+W]_3XJ+GDHX_?2^@
MVJOB<GAR$.R!/@(O(>5DSZCPV;I/*_U=WZH9GMXUC!6KJGZ3$KPWJ//-(EJA
MY5%?[,V4R"U/?^A\_Y['TM^<]"4.X"@Q)YN9Z)G;]*@%55,7AD!1PSM1ISP_
M#_M-R;8+>HL6.'^](QR8I'-)XL/Y7[UIO_@V^7-NE&_.JG0T N/!@FI0\:5@
MY)="M_%J@Y"04'.U!'+OY"V7QX$/)27$G[<*KV%3L5(8]NLM8B-4'3OU=^5?
MQ0$K2- W<4!)#L!-,!HC/@)^(487@<U.;+KFN8%\Q\M(AUJ?_$P[U_G:LE=5
M:.%$R1N'FD*F YU,5=UY0"LLH?$]^$G0,2[H&=D7C%;C *J6%7R]E@/L?Y]_
M3U)33%[G:K^HIU7ZEU"Y4U%#R/":3B=XLA=>S+"*JFRGIS.@ZYL<@.J:N^+<
MP2JNO?@IE]U[D^<=2&8"GC.^QW_3.X,#,.W87YLHG]FY+[E;/'8#]@&1[QV[
MAI%"CH&$Z'$D$VB[\2Q:G.[;&1R0?;$0 Z0=3=RQ7?GYT&GO6I1G'[PMF1<O
M12O-ZY67)LZC>AUV_CF+]8LH<P"+,+PI83ED2H0&7HUB.+H33ZJC8P-S0-6$
M4K\RT YI1]><8GIR*4,WZS+/F/,KG!-=2R%2+KR;U*S9"JQS;2=*PM'Z@P*?
M2&A!FY6J4+3!R/:43%GUFNF#F2M"7EK=,U[<R3R/C.25;;T&4:B5O2T,&4E1
MWS&I:-S?\_^Q92^RB4\ >W( A^F2)&B,#K=*%-.^#(Z^FZ#E@+\SJ$^V5^RJ
M%#IIK?K6\DC<6^Z_A(.A/5AP$>9P!\&33]QR5(:WYB=8!4J1L?9^[_ U^A/I
MQR*B9Q0U0AX7YI?7LM,7'L69]J-LV8;#?E8)3"/6-R8OE=">(SKLE&)..SNM
M\,[ESQ9:<"RS9$U/XL[1A"L5XLZ,#G^<S==9V#BEA:U,#R2#1<8G5C22X2 )
M^9$F<+$U7ZCYD'O:^)_&(]W'1_=^O-<[G[D;E,G0WK-%->SO+,M5]'HU(G88
M^X&ZM;%[-H+T2P?6?N]*M9*I/;!+(T=ZV.D>N&YQ(&!I9^A[=Z11^'M[5+0A
M5ER'9E>!JQ@G'- #JZ*);V9*6X]FL1OQ],TZ[*6:YR434"V%>S7$]Z?$ET2?
MM-:'9S1_!\2Z:5["-=;])K";K8RK,7T%8U!:W2('P(-?NZFH;4\[BIY]=XAA
M.UQNV?[@1UU(26;,SU,&L=8?60#US<((#N#(87I0Z4KPB;+?;\@F?/<(Y1$'
MR=\$>O>J6WJR4 VB/C!93W>'1CP[Z+!5+WH0*77$(>RM8,/L-1:8CIR"%%VJ
M.$)/9+C 56;3.XWQ4>G[FC';$*$[SE*KHN/*'U5.+#!/"5].;.J._S'Y[;/"
M7H/KG5GT6B!UDP3[K]R&CN%KG#K:WL[?6V:SDC:MWQ\#0&<+UQJU A3DWANH
M=LH-Q26/>6PT8W7!!<'>;L7-Q.5RS%:(Q7]7,=@B)]-R=.D*S^1?V^(<>+#U
M(^="E&Q"K*M'MQ7]IR]L*)_WD=)33)63SO+&$3.Z&A#:,XS^IZ-$]WYG)X)!
MKVG<[X:?ES-K[WZ2G/KQ^OKU>T75%S1S38EAJ++&V.FMIW7N_Q7UED<.B^S-
M4^-VOM/J.F%CN^3AZ0JQF#7_7N/0^^QV:%VU1NU-A!N_AU2^KZR+UI]D!L^-
M"W%"]E8M*A-#;=,GZ4K4G8DN<I?-AZ&.6BOVM?JA^9Q6K[@?"DJ3[^HG^5U?
M(+C63!6Z)\IR64$5>S;3C5#CKR%81#J;&W; -9&U2[M2(G- "; [D!<A/J+V
M[O1ZKRW-,,;_R;O.PC>S(=RA(7*R6NDN\UQP75-3 :[6+@Z@-3$!)$JGS7[=
M1O-#7ATI:+=Q&(6V/&VLS [&77%=K_N31&G-;UZI&6)+;@X1;@7;L""W<IN,
MR<0V? Q4I DR^P[<GJ.3WH(Y$A>RDO*"('BTXM6HMJC$8:?+\8(D(#Q9$F#5
M#Q1 N4&%$0K?67E;=TB-^.@,\.MSUFJZ@4_>VYG*!UP[5O !57;H#I$=5'M5
MX+!O?C[Q+K';AIW>4+.KDE1;-ERP&5@W7P%3W3H=RYP=;(+1Y&<",JF2)&09
M3;$#I%A+?Q,B?(8=4S+)^S+7^%UIY+B.X_GB#MJ4X:U[%3 ZGHHB&=17P#F
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M2'6<EOOO*BSDGRNR#_O+IIW(Y4=JP9=9MW*K7K&(5>Q%%3:D'_6G0!N"9O1
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M)+9:^^D_HQ"!S6=R4!R*D+>X\Q+,/1"KM*?$LQ4CE=NE1*AM%-7V'_GE*6[
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M1F(]\FMU]RG 9R<V1OGL]>7.WD*@WG<PP27GM_FB7F:IIADKR+QGCY)-Y60
M+^BZQL3W;GS[8'XC8:,"X36%DL&43-K,UN)U,H)F*_)WA!V5P$"4%.SX^ ;,
M:#+F,DSUS)Z;4_Y-[%OW':U>R9B0SO6NF09?EW[@J"_\IVJM['$I!84?T5RR
M(-0N6J1?5FCNL$@4&HN?7ABS/Y;\V:S2J@KX\3SI*4@_)YE=-0[\E*I'U,@C
MCGT_$HL/=D K*!DW9DP UN1M#365__8NYVR:^8]!>7\K\(R7C6NR9LMZ@!Y
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MSF@^]66;V"S:K*/SJH&'"?"NF$ZR".,F_6=1,]>3 ^FFF274 O\X^!B;3C@
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M>"$)Z(Q\1#:AU6.-\7W#BX$'*X] RA7CXSN-GO;_/N^G\^R()&#=1?BH:1U
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MXEM-N0,U;['S8_KE][R2V^RK(E("]_7%!<ZF]$W#)^"JI.X(H/PJ4)XTGEA
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M4L>!U'NOZ>T\O.T80&O RCOE?PARD<9D'5'HN_K#M:#?#!'RQ";;@DA,9F0
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ME,VRS&"&_\9?@HE4, 8F-#Z&U\D1V,0=T.,O0IJ"K'][A$F]9REH>'_+Y1@
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MZSA@Q;=!B<C;Z5'Y=;$.X4&]:H(>*X>R7PZ4\) V66"3GHY]''Q_@=K;/Q+
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ME(S1!XE%C:E/,R%\SHG?^;+EIW51G__3*,]%M%D&'P23,B^B]1NJSU7(ZE>
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MTGMX\6)* (45=O/,7H1:NS*_/H2_7V]7!EL&C]0,EI 4[CN9BP))7"!?XRM
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M:@H0#Z B>&2/#F@*U3UK@F1..CN!,0SQM_=4_N@E%D>E:@PK5M"<5KN]NLP
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M/_^]B=&K\+0A(8C26!M0=%VK>!W7*B)QIUF5<E_967QB9@X\;G]U='F Y1[
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MB+7?O,WNM _].*=PY&J2>9"@FZ.!"NOZNX?%;J)>.92SIM"^<N6_GEZ!E[Q
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M&N049!T9K,*N$ 8ZL/3;^/]&R]WTI=;/S'=6=^;0F9:^BY(G;E^R=!4!]$C
M?XZ-/\>:9L<X*_*U[Y@E_/].9A-0-V! 4CJ1,4A5=^E<L&,"^D"N[R"_>'B\
MJ%"X6::V&>GHB!.^=[DL)JD%^!7TU[ 1[&U5E]!%X%4H>UN!GI']0=FYQYDY
MD=;(YXY)HHZ[4Z)@XEC.3'7?FSM2S[Y:7N[!#MF-F[_ZQZ!IG;>@#O:V9P'
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M7G94:4,^83=)*<O8*/7;Q)%X&ZQ6*T$^9SG'6*S,.J''-)5F\CE$W-1[;V)
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MW*4MT0A<6!C 'U\N9!^JS%9IMR$ M82''Z$"RRE0TA+A F#POA/)%199XN'
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M^1@J\=%_OL;I+O3<D^,/WD_\Y\OCST=\6MJ_EN4RM6EE$%DKGY-/Z"F6#BO
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M[T[1CV6>5!]-6GYW/S=U]UU.<7W%[A3M[V+R,Q6'?T@"M'=I0J,=@I6*$6>
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M1S^/?#>49]QBWOO888MW@=3]O+-N??0;#X^BP8M*-E9R6_7(JA88H*\0B&)
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MOU2,:Q+XO&SGVZ"9$0SQ%;?Q)/W33S6\'/CQ1,.94]U-58 4XE9_C!=+6TU
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MBJ2KZ.#62GR#2Z&VB:^HQ>L3'Q\(I61RV;FI(.>4CSF,UEKI=KN.0#7XKU[
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MHPDE">-L-48RR2;AN8L-&27T;U8L?B')Z&+55Q.?GS_$+MQ-.79&P,B*BNC
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M35C(<L-MF'X?+&ZQ+DP.:*=P>6]$+"T-:@2!FU+DJGT/9V6$77D[AL=BV^J
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M;M&;\U^$  !CX3EY:G1$SA"YQ4G>>%']H;WQ<]6XJ>%Y%'&)N% XL8E[B=:
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M@YUYW:^L4;6]IU(;C7-[5LIV 2G<DIY1MOW\D9UELT__O?\^L;;>6+X2=JD
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M=D"82)N<D>O><;;6=/SF_S68>/!VW_FP@X;T^,QI^"[@"1!PC3G03I (94A
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MB#_ K6$(2G9"7Z/#QE?[NB; L/><**+U._M'T+?CF!R#KLO6OH6, F;AOHQ
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M@^_\4@TBRYDF/J)P7#8_<@"2-0A2\8($"N6V&4Q4 9AB'^9\>\>H"F)(Z9I
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M ?/MK"__N[,W_R?^_Q,B9U/_"U!+ P04    "  Z@-58P-;5:!(M   Q+P
M%    &9O<FUP<F5R,31A>'HP,#8N:G!GQ;=W4)-?%#88>N^]AB:]*%5J*-)%
MBD@+1>D0 9$6)-)[%5!0D")%>F]2!"$4 4$Z&'I >DE ,9 0EM\WW^[^LSOS
M[<[.['G?,_/.W'O?.<^Y]Y[G.3=+-QL >B,]0ST  0$!X.GM [A9!N@ " D(
M_GO_IQ&1$/UGI,3$1"1DI&1D_SDY!14%.3DE.1D9)0TE)17UK9%1T-+14-/^
M]_W?3_Y;_M^JVY>:G(R<^O^QW7P#,) #/ F*B0@$ (0,!$0,!#># "  0$!"
M\#\,\#^-@)"(F(3T-B1*JML);?2WX1,1$=X&2T),?#OZ^G8<0,Q PLA_3XN4
MR?P9F8 _LVQ4YB=R0>VF?A:+:920G//+: I*5C9V#LX[PB*B8N+R"HI*]Y55
M=![HZND;&!H]MGQB96UC:^?BZN;NX>GE'1 8%!P"#7T5$QL7GY"8E)R5_?9=
M3N[[#WDEI67EGRLJJZJ;6UK;VCN^='8-P >'AD>^CX[-S,[-+RPN_4)L(K>V
M?^_L[NT?H,_.__R]^(>YO/H/%P& B.!_M_]+7 RWN AO]X"8[#]<!(0A_TU@
M(";AOT?*J&5.]LR?24 VBIQ9._-34S^%H)P%BL7YY30EJY#\YAWT?]#^![+_
M-6#1_Z^0_1_ _D]<"  U$<'MYA$Q $" :UQ)LBC@?\WU?$J%(UF3+X$763>
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MO$8\W^;$XN4[("AG#PT9M&93]'?GH^_,,$T7&-/P&3S_LEC5,0 DP$\#*?!
M:(P-RC0^R >,I"UEK7$)K=YK- EU\_*7S"O5<WP@JS?PRTZ#G/_['F051H7R
M&'"B5I-Y70(-@-OQQI4>A"BQY08KLIHO+Z],*$O)IR<3YKQ\A-17KH.JR50@
M5FP,>3XRM.<2@>V>VU-!EY^*EQ:SZP*U,FZ+/PA/\1LU"8P'M2:,^!%K.D?0
MXJ31]GVHY&^"B,#QUZ\69FU[(B,:.^08>.^UW6_@O&[?[;EEV8CE\%-M<P_)
M-0"*.N]C^V%36K;CH?GZV%#H]^;SYE5-QQ[K/=.$7DYHP("&T()"@83F=."$
MTZ!L&:+N;WFJV<J!;TH;;RB+CM%8#^'VF_LL%C+1:[0Q0W9K785,J!E(^)UV
ML)2+F8,L0U#UM^*X9*1#=[DF!8']&P(UL]N+R=$K_1--A*>D*H>IH7*RRS':
M6_ UT:XO7^=/Z->6('D]CLS@ OEQPO?-@FWO&RUN .$3!C< R[+K**P(S*GW
MNCC"[0:0$*XZ]^?WC *0 ^IGNE!?:Y;5GK4"UI<8+CMO9>/S^.A<T7S]'L^[
MO\;C(TY'B@F7(.LVODAZ/N4>&*N9=3)\/$Y8*QXPJ*FGH=7>;4Q%'M@M6E?W
M*7UM;9787Y<SSF".FL3L/H 6P$R@P&RN2?)_XT#1\-7#"C!^<;WYAP]OWJ)2
M[[U%ZJF)1JKB-:8%J2D#NC6K4(&4PL\/',LH+T.^ >EQIDA0+)  YQ& 9H4/
MX67G@PHX3M64A&28NX!) E,X QG=<4.UHKZ< T\?Q!V#6.<9/J9=PCY+RI@E
M2ZL+>CL.M4KGC(D P6--I:8#TZI_Q73CK^6&<C5$,((H.;L%#67OJ_2DK>[8
M=C2WG6-%6)EQV8I,5!LVI:W[@^^OM%E'1+_$ UB?.-@?VVA_LJLFAU9".B7@
M^?=Y!1/,YK8PH]5#Y;\.NKQZLN1[^_SBKMXM9OL_YQIW5ZEK*Y*,36*P9/@(
MG*5+[FOYG(T&#_?1_:U)J<DGQ80V3"!552&>G\[\?-T:NQO]U%3N26RO_?QG
M5/ ;#)*F"Q<$!#(37$94XG3F@U9UX'F2C@IHRQL ;1N/QP"Z[7+QI.YW3^<7
MU.<:C4]$D\T2[UQX<U\<=A-"HE=4.0\C-@IO ,PX#W0'TCIF?<B)F?1#K2="
M)#9(U8'QA,/C*]K]0\"FIJ]#1'A-_+SPUU#7,U?^/Q@X0UMP>")X">X9YQPO
M^K;)F8$PVG!4+40DCR:5=,]T>VBW^JVM(DV_(7'JWV%-7"719L-RC<%B/4P=
M:ZW]9F5E/*@88[>M3\F694HGV9RR-$>=<^DR_[(4NYN17\1Y72*MYH,L2G3B
M MO.RZ@Y;9+CN6 Z**?(OWH&*=Z/'6VA[B<2#Z#O+&SM-D^?IGBNP$W=1L4A
M?R[.!X*5UH3:Y]<(KDN]J'.F)\OBSSY6N=[??/OV<<Q'EN\UAF6($3]F;00!
MLY"\IR"7B^ GHC8 S'I#"HS4CXK8*+\!4/: D*.P^WSS,")D0@]KH>B7#R<S
M5&D$DF4YTW7FK&X4+\W5%H'[*C&UD6*&HCC-&36ML-OV\M%B:5O\ 53Z65>/
M ;_V))[KM=?.V;R^4(3+1Q*>+R/>V  GU-^.I%9PG<:^;9V?@*>P9;#V=SBQ
MKP7Y]ZT8*\E:_ME:Y_9HT<V.*&+_X606!LUO9F0 @F%1HK/%BX8;0.P_Y$A*
MCXM/!:;SMB--:,+4;PT4"L[/* >N<T.#CM1 "K=,6$%//ICY,T!M.A3-(._T
M"WVTUC]VO7O=UX#IMDJPF,*I5]P ?&^KSO0*8@]1A_UE%^'I&*G;,SM"/4&D
MG8,UEI2]"ZYG(R.;)\WPY$N6:5Z^M#KB%3J+7UH*%+_7?V4Y#=8GZA;R3)/P
M?5D3O0MPO?H( !%H C\XL>(),2-;BQDPVPTZQN%"'K1?1KB<;K5#@?#QJ<ML
M:RB>EXKC1&H'NADJ-?/@2[NMG6B'0;=1U7.KX8:-C.1>GED-#4P)"/- .,4
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M9V,M,C R-# S,S$N>'-D4$L! A0#%     @ .8#56#]O/UX7%   !CD! !4
M             ( !;2\  &9L9V,M,C R-# S,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( #F U5B87X%*U90  *,G"P 5              "  ;=#  !F;&=C+3(P
M,C0P,S,Q7V1E9BYX;6Q02P$"% ,4    "  Y@-587^>ET?.= 0 9K!< %0
M            @ &_V   9FQG8RTR,#(T,#,S,5]L86(N>&UL4$L! A0#%
M  @ .8#56/=.OA$.J0  -/\, !4              ( !Y78" &9L9V,M,C R
M-# S,S%?<')E+GAM;%!+ 0(4 Q0    ( #F U5@'KB::K9X' %B%6P /
M          "  28@ P!F;W)M<')E<C$T82YH=&U02P$"% ,4    "  Z@-58
MVG7@GN<F  "K*@  %               @ $ OPH 9F]R;7!R97(Q-&%X>C P
M,2YJ<&=02P$"% ,4    "  Z@-58KZ6ZW&PF  !G*@  %
M@ $9Y@H 9F]R;7!R97(Q-&%X>C P,BYJ<&=02P$"% ,4    "  Z@-58Q*XO
M7Q<J  #;+   %               @ &W# L 9F]R;7!R97(Q-&%X>C P,RYJ
M<&=02P$"% ,4    "  Z@-58>A" 7@A6 @!*?0( %               @ $
M-PL 9F]R;7!R97(Q-&%X>C P-"YJ<&=02P$"% ,4    "  Z@-58>(D\J/MW
M @!^F0( %               @ $ZC0T 9F]R;7!R97(Q-&%X>C P-2YJ<&=0
M2P$"% ,4    "  Z@-58P-;5:!(M   Q+P  %               @ %G!1
J9F]R;7!R97(Q-&%X>C P-BYJ<&=02P4&      P #  4 P  JS(0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>formprer14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:flgc="http://www.floragrowth.com/20240331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="flgc-20240331.xsd" xlink:type="simple"/>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoImpairmentTestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselAssetGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeAnnualImpairmentTestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeAnnualImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeAnnualImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:FGHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfFghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfFghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfFghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfJustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfJustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:AnnualGoodwillImpairmentTestOfJustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselAssetGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:FGHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:FGHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:TwoThousandTwentyTwoImpairmentTestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20240304to20240308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMaximumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMaximumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-05</endDate>
        </period>
    </context>
    <context id="C_20231231_srtOwnershipAxis_flgcCosechemosAndKasaWholefoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">flgc:CosechemosAndKasaWholefoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_srtStatementGeographicalAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_srtStatementGeographicalAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_srtStatementGeographicalAxis_countryDE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_srtStatementGeographicalAxis_countryDE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_srtStatementGeographicalAxis_countryGB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_srtStatementGeographicalAxis_countryGB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">flgc:EuroCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">flgc:EuroCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_srtRangeAxis_srtMinimumMember_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">flgc:EuroCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_srtRangeAxis_srtMaximumMember_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">flgc:EuroCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20220222_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapBusinessAcquisitionAxis_flgcJustBrandsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:OptionsExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">flgc:RangesOfExercisePricesForOutstandingShareOptionsNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231101to20231115_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="C_20220705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <instant>2022-07-05</instant>
        </period>
    </context>
    <context id="C_20230606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220901to20220928_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-28</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcHampsteadPrivateCapitalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:HampsteadPrivateCapitalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcDrManaloMorganMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:DrManaloMorganMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcDrManaloMorganMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:DrManaloMorganMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiarySeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">flgc:SubsidiaryFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:TerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:TerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:TerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230131_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:GerardoAndresGarciaMendezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="C_20231231_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20220314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-03</instant>
        </period>
    </context>
    <context id="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:MariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_20231101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:RamonRicardoCastellanosSaenzAndMiriamOrtizMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:GerardoAndresGarciaMendezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraGrowthCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:FirstClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraGrowthCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:SecondClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="C_20240401to20240422_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraGrowthCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:FirstClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancialAssetNotPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables1To29DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables30To59DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables60To89DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">flgc:FinancingReceivables180PlusDaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancialAssetNotPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables1To29DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables30To59DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables60To89DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">flgc:FinancingReceivables180PlusDaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20221201to20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcSupplierRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:SupplierRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcCustomersRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:CustomersRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-24</instant>
        </period>
    </context>
    <context id="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-24</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220226to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-26</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TradenamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-24</instant>
        </period>
    </context>
    <context id="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcCustomersRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:CustomersRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-24</instant>
        </period>
    </context>
    <context id="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcKnowHowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:KnowHowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-24</instant>
        </period>
    </context>
    <context id="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustBrandsLlcAndHighRollerPrivateLabelLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-20</endDate>
        </period>
    </context>
    <context id="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="C_20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraBeautyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="C_20220101to20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraBeautyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="C_20220131_usgaapBusinessAcquisitionAxis_flgcFloraMedSasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraMedSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFloraMedSasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FloraMedSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:OriginalHempAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="C_20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:OriginalHempAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20221223_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:NoCapHempCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_20240401to20240416_usgaapBusinessAcquisitionAxis_flgcTruhcHoldingGmbhMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:FirstClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">flgc:SecondClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="C_20240402to20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:AegisCapitalCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-02</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="C_20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:AegisCapitalCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-04</instant>
        </period>
    </context>
    <context id="C_20240407to20240408_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:AegisCapitalCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-07</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="C_20240402to20240404_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-02</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="C_20240404_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-04</instant>
        </period>
    </context>
    <context id="C_20240424to20240426_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="C_20240224_usgaapBusinessAcquisitionAxis_flgcJustCBDMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-24</instant>
        </period>
    </context>
    <context id="C_20240301to20240308_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapInvestmentTypeAxis_flgcFirstTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:FirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadOnePointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:WarrantsCadZeroPointThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:InvesteeCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapInvestmentTypeAxis_flgcSecondTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">flgc:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapCollateralAxis_flgcHeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">flgc:HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapCollateralAxis_flgcHeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">flgc:HeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapCollateralAxis_flgcFinancialIntermediariesMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">flgc:FinancialIntermediariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapCollateralAxis_flgcFinancialIntermediariesMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">flgc:FinancialIntermediariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyCAD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyCOP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:COP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyGBP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyEUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyCHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyCAD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyGBP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyEUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_flgcGermanSubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">flgc:GermanSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CommercialAndWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:HouseOfBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:PharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">flgc:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementGeographicalAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementGeographicalAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementGeographicalAxis_countryDE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementGeographicalAxis_countryDE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementGeographicalAxis_countryGB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementGeographicalAxis_countryGB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementGeographicalAxis_countryCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementGeographicalAxis_countryCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtStatementGeographicalAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtStatementGeographicalAxis_countryDE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryDE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryCO">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtStatementGeographicalAxis_countryCO">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryGB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtStatementGeographicalAxis_countryGB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtStatementGeographicalAxis_countryCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20221201to20221223_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFGHOwnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FGHOwnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="C_20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:DecemberTwoThousandTwentyTwoUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-08</instant>
        </period>
    </context>
    <context id="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:DecemberTwoThousandTwentyTwoUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-08</endDate>
        </period>
    </context>
    <context id="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:NovemberTwoThousandTwentyOneUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-08</instant>
        </period>
    </context>
    <context id="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:DecemberTwoThousandTwentyTwoUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-08</endDate>
        </period>
    </context>
    <context id="C_20220201to20220225_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustCBDOwnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustCBDOwnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FloraBeautyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="C_20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FloraBeautyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="C_20220101to20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FloraMedSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:FloraMedSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_20220101to20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_20220401to20220405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="C_20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:SeptemberTwoThousandTwentyThreeUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:SeptemberTwoThousandTwentyThreeUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:NovemberTwoThousandTwentyOneUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:DecemberTwoThousandTwentyTwoUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flgc:SeptemberTwoThousandTwentyThreeUnitOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="C_20230101to20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_20230401to20230426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="C_20230501to20230514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-14</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:FirstLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="flgc:LoanAgreementsAxis">flgc:SecondLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtCounterpartyNameAxis_flgcWarehousingAndOfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">flgc:WarehousingAndOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtCounterpartyNameAxis_flgcRetailSpaceInMiamiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">flgc:RetailSpaceInMiamiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtCounterpartyNameAxis_flgcPompanoBeachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">flgc:PompanoBeachMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtCounterpartyNameAxis_flgcFortLauderdaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">flgc:FortLauderdaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:CanadaIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:CanadaIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:USFederalIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:USFederalIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:USStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:USStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:ForeignIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">flgc:ForeignIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedStatesRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:UnitedStatesRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:ColombiaRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcGermanyRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:GermanyRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcDenmarkRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:DenmarkRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedKingdomRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:UnitedKingdomRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:ColombiaRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcForeignRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:ForeignRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_usgaapCanadaRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:ColombiaRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedStatesRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:UnitedStatesRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcDenmarkRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:DenmarkRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcGermanyRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:GermanyRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedKingdomRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">flgc:UnitedKingdomRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementOperatingActivitiesSegmentAxis_usgaapSegmentDiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancialAssetNotPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables1To29DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables30To59DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivables60To89DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">flgc:FinancingReceivables180PlusDaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:TruhcHoldingGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_20220218to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220218to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">flgc:WarrantsSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TrademarksAndBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">flgc:TradenamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapReportingUnitAxis_flgcVesselMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapReportingUnitAxis_usgaapFranchiseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">us-gaap:FranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapReportingUnitAxis_flgcVesselMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapReportingUnitAxis_usgaapFranchiseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">us-gaap:FranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapReportingUnitAxis_flgcVesselMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapReportingUnitAxis_usgaapFranchiseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">us-gaap:FranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapReportingUnitAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapReportingUnitAxis_usgaapFranchiseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">us-gaap:FranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapReportingUnitAxis_flgcVesselMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">flgc:VesselMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:ACAMullerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:LegalDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:SalesTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:GerardoAndresGarciaMendezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:GerardoAndresGarciaMendezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20231101_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flgc:FranchiseGlobalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">flgc:ACAMullerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240401to20240430_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_20240331to20240331_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-31</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20240501to20240507_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flgc:JustBrandsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <context id="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">flgc:ColombianRelatedSubsidiariesAndColombianAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">flgc:ColombianRelatedSubsidiariesAndColombianAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">flgc:ColombianRelatedSubsidiariesAndColombianAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">flgc:ColombianRelatedSubsidiariesAndColombianAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">flgc:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:LisanFarmaColombiaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:FirstLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">flgc:SecondLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flgc:TruhcPharmaGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">flgc:JustCBDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="CAD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Euro_Per_share">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>flgc:Segment</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="Trial">
        <measure>flgc:Trial</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Violation">
        <measure>flgc:Violation</measure>
    </unit>
    <dei:DocumentType
      contextRef="C_20240101to20240331"
      id="Fxbrl_20240527144459834">PRER14A</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="C_20240101to20240331" id="F20231025072913927_0">0001790169</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="C_20240101to20240331" id="F20231025072913927_1">true</dei:AmendmentFlag>
    <dei:AmendmentDescription
      contextRef="C_20240101to20240331"
      id="Fxbrl_20240621223801423">Amendment No. 1</dei:AmendmentDescription>
    <dei:EntityRegistrantName
      contextRef="C_20240101to20240331"
      id="Fxbrl_20240527144439699">Flora Growth Corp.</dei:EntityRegistrantName>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095102395"
      unitRef="USD">4350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055321_0"
      unitRef="USD">8935000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055322_1"
      unitRef="USD">35000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055323_2"
      unitRef="USD">0</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095048484"
      unitRef="USD">315000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055323_3"
      unitRef="USD">1385000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095109779"
      unitRef="USD">3950000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055324_4"
      unitRef="USD">5259000</us-gaap:AccountsReceivableNetCurrent>
    <flgc:LoansReceivableAndAdvances
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055325_5"
      unitRef="USD">0</flgc:LoansReceivableAndAdvances>
    <flgc:LoansReceivableAndAdvances
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055325_6"
      unitRef="USD">271000</flgc:LoansReceivableAndAdvances>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095134387"
      unitRef="USD">1368000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055326_7"
      unitRef="USD">805000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NontradeReceivables
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055326_8"
      unitRef="USD">3153000</us-gaap:NontradeReceivables>
    <us-gaap:NontradeReceivables
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055327_9"
      unitRef="USD">3429000</us-gaap:NontradeReceivables>
    <us-gaap:InventoryNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095146651"
      unitRef="USD">8508000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055327_10"
      unitRef="USD">8747000</us-gaap:InventoryNet>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305094643762_xbrl_20231021095146651"
      unitRef="USD">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305094643762_20231019113055327_10"
      unitRef="USD">3709000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055328_11"
      unitRef="USD">21364000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055328_12"
      unitRef="USD">31155000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095346348"
      unitRef="USD">847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055329_13"
      unitRef="USD">1218000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095352475"
      unitRef="USD">389000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055329_14"
      unitRef="USD">2118000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095358579"
      unitRef="USD">946000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055330_15"
      unitRef="USD">17739000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055330_16"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055331_17"
      unitRef="USD">23372000</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055332_18"
      unitRef="USD">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055332_19"
      unitRef="USD">730000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095405923"
      unitRef="USD">80000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055321_00"
      unitRef="USD">263000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305094714448_xbrl_20231021095405923"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305094714448_20231019113055321_00"
      unitRef="USD">4392000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055321_01"
      unitRef="USD">23626000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055321_02"
      unitRef="USD">80987000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095453324"
      unitRef="USD">5111000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055321_06"
      unitRef="USD">7831000</us-gaap:AccountsPayableCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055321_07"
      unitRef="USD">5500000</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055321_08"
      unitRef="USD">5044000</us-gaap:CommitmentsAndContingencies>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055321_09"
      unitRef="USD">1931000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055322_10"
      unitRef="USD">1086000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095503090"
      unitRef="USD">799000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055322_12"
      unitRef="USD">1116000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305094840425_xbrl_20231021095503090"
      unitRef="USD">1095000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305094840425_20231019113055322_12"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095508499"
      unitRef="USD">1844000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055322_14"
      unitRef="USD">1760000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305094907256_xbrl_20231021095508499"
      unitRef="USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305094907256_20231019113055322_14"
      unitRef="USD">610000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055322_15"
      unitRef="USD">16280000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055322_16"
      unitRef="USD">17447000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095538259"
      unitRef="USD">942000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055322_19"
      unitRef="USD">1561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055323_20"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055323_21"
      unitRef="USD">1712000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055323_22"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055323_23"
      unitRef="USD">3547000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305095309612_20231019113055323_22"
      unitRef="USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305095309612_20231019113055323_23"
      unitRef="USD">308000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055323_24"
      unitRef="USD">17222000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055323_25"
      unitRef="USD">24575000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095624190"
      unitRef="Shares">8935000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231021095620114"
      unitRef="Shares">8935000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055342_56"
      unitRef="Shares">6776000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055325_57"
      unitRef="Shares">6776000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055342_55"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055323_28"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055337_41"
      unitRef="USD">149093000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055337_42"
      unitRef="USD">150420000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055338_43"
      unitRef="USD">-140000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055338_44"
      unitRef="USD">-2732000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055339_45"
      unitRef="USD">-142549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055339_46"
      unitRef="USD">-90865000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055340_47"
      unitRef="USD">6404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055340_48"
      unitRef="USD">56823000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055341_49"
      unitRef="USD">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055341_50"
      unitRef="USD">-411000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055324_40"
      unitRef="USD">6404000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055324_41"
      unitRef="USD">56412000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055324_42"
      unitRef="USD">23626000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055324_43"
      unitRef="USD">80987000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055363_0"
      unitRef="USD">76071000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055363_1"
      unitRef="USD">33401000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055364_2"
      unitRef="USD">58333000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055364_3"
      unitRef="USD">20150000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055364_4"
      unitRef="USD">17738000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055365_5"
      unitRef="USD">13251000</us-gaap:GrossProfit>
    <us-gaap:ManagementFeeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055365_6"
      unitRef="USD">11876000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055365_7"
      unitRef="USD">9232000</us-gaap:ManagementFeeExpense>
    <us-gaap:ProfessionalFees
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055366_8"
      unitRef="USD">2301000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055366_9"
      unitRef="USD">3884000</us-gaap:ProfessionalFees>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055366_10"
      unitRef="USD">1646000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055366_11"
      unitRef="USD">3287000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:Communication
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055367_12"
      unitRef="USD">4710000</us-gaap:Communication>
    <us-gaap:Communication
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055367_13"
      unitRef="USD">8033000</us-gaap:Communication>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055367_14"
      unitRef="USD">413000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055368_15"
      unitRef="USD">930000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055368_16"
      unitRef="USD">1591000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055368_17"
      unitRef="USD">3404000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055369_18"
      unitRef="USD">62000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055369_19"
      unitRef="USD">388000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055369_20"
      unitRef="USD">1211000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055369_21"
      unitRef="USD">937000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055370_22"
      unitRef="USD">2335000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055370_23"
      unitRef="USD">2144000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055370_24"
      unitRef="USD">236000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055371_25"
      unitRef="USD">941000</us-gaap:InterestAndDebtExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055371_26"
      unitRef="USD">23372000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055371_27"
      unitRef="USD">25072000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055372_28"
      unitRef="USD">16135000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055372_29"
      unitRef="USD">709000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055372_30"
      unitRef="USD">2204000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055372_31"
      unitRef="USD">1511000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055373_32"
      unitRef="USD">68092000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055373_33"
      unitRef="USD">60472000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055373_34"
      unitRef="USD">-50354000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055374_35"
      unitRef="USD">-47221000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055374_36"
      unitRef="USD">-92000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055374_37"
      unitRef="USD">29000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055375_38"
      unitRef="USD">158000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055375_39"
      unitRef="USD">323000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055375_40"
      unitRef="USD">1991000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055375_41"
      unitRef="USD">-593000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055376_42"
      unitRef="USD">-48297000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055376_43"
      unitRef="USD">-48108000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055376_44"
      unitRef="USD">-1628000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055377_45"
      unitRef="USD">-1405000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305101012018"
      unitRef="USD">-46669000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240305101027542"
      unitRef="USD">-46703000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305101034337"
      unitRef="USD">-9678000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240305101048224"
      unitRef="USD">-5926000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055377_46"
      unitRef="USD">-56347000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055377_47"
      unitRef="USD">-52629000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055379_54"
      unitRef="USD">689000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240306014913971"
      unitRef="USD">-214000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055379_52"
      unitRef="USD">-57036000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055379_53"
      unitRef="USD">-52415000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20240305100819805"
      unitRef="USD_Per_Share">-6.34</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20240305100830396"
      unitRef="USD_Per_Share">-12.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20240305100839994"
      unitRef="USD_Per_Share">-6.34</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20240305100851882"
      unitRef="USD_Per_Share">-12.19</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20231025124753012"
      unitRef="USD_Per_Share">-7.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20231025124842701"
      unitRef="USD_Per_Share">-13.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20240305100714776"
      unitRef="USD_Per_Share">-7.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20240305100636197"
      unitRef="USD_Per_Share">-13.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="0"
      id="F20231019113055381_62"
      unitRef="Shares">7356</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="0"
      id="F20231019113055382_63"
      unitRef="Shares">3832</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20231231"
      decimals="0"
      id="Fxbrl_20240305100737048"
      unitRef="Shares">7356</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="0"
      id="Fxbrl_20240305100750101"
      unitRef="Shares">3832</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305102209332_20231019113055377_46"
      unitRef="USD">-56347000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240305102209332_20231019113055377_47"
      unitRef="USD">-52629000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20231021102513477"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20231021102525336"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055378_48"
      unitRef="USD">2592000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055378_49"
      unitRef="USD">-1624000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055378_50"
      unitRef="USD">-53755000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055378_51"
      unitRef="USD">-54253000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055381_58"
      unitRef="USD">689000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055381_59"
      unitRef="USD">-214000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055380_56"
      unitRef="USD">-54444000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055380_57"
      unitRef="USD">-54039000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055392_0"
      unitRef="Shares">3276</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240305110235456"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055395_1"
      unitRef="USD">116810000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20231019113055396_2"
      unitRef="USD">-1108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20231019113055396_3"
      unitRef="USD">-38536000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="F20231019113055397_4"
      unitRef="USD">-225000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20211231"
      decimals="-3"
      id="F20231019113055397_5"
      unitRef="USD">76941000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <flgc:DecemberUnitOfferingShares
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055416_46"
      unitRef="Shares">625</flgc:DecemberUnitOfferingShares>
    <flgc:DecemberUnitOfferingAmount
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055417_47"
      unitRef="USD">5000000</flgc:DecemberUnitOfferingAmount>
    <flgc:DecemberUnitOfferingAmount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055417_48"
      unitRef="USD">5000000</flgc:DecemberUnitOfferingAmount>
    <flgc:DecemberUnitOfferingIssuanceCosts
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055417_49"
      unitRef="USD">415000</flgc:DecemberUnitOfferingIssuanceCosts>
    <flgc:DecemberUnitOfferingIssuanceCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055418_50"
      unitRef="USD">415000</flgc:DecemberUnitOfferingIssuanceCosts>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055418_51"
      unitRef="Shares">18</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055419_52"
      unitRef="USD">255000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055419_53"
      unitRef="USD">255000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055419_54"
      unitRef="Shares">2651</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055420_55"
      unitRef="USD">24492000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055420_56"
      unitRef="USD">24492000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <flgc:EquityIssuedForOtherAgreementsShares
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055421_57"
      unitRef="Shares">40</flgc:EquityIssuedForOtherAgreementsShares>
    <flgc:EquityIssuedForOtherAgreementsAmount
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055421_58"
      unitRef="USD">1554000</flgc:EquityIssuedForOtherAgreementsAmount>
    <flgc:EquityIssuedForOtherAgreementsAmount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055421_59"
      unitRef="USD">1554000</flgc:EquityIssuedForOtherAgreementsAmount>
    <flgc:AcquisitionOfNoncontrollingInterestShares
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055422_60"
      unitRef="Shares">6</flgc:AcquisitionOfNoncontrollingInterestShares>
    <flgc:AcquisitionOfNoncontrollingInterestAmount
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055422_61"
      unitRef="USD">283000</flgc:AcquisitionOfNoncontrollingInterestAmount>
    <flgc:AcquisitionOfNoncontrollingInterestAmount
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20231019113055423_62"
      unitRef="USD">-365000</flgc:AcquisitionOfNoncontrollingInterestAmount>
    <flgc:AcquisitionOfNoncontrollingInterestAmount
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="F20231019113055423_63"
      unitRef="USD">28000</flgc:AcquisitionOfNoncontrollingInterestAmount>
    <flgc:AcquisitionOfNoncontrollingInterestAmount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055423_64"
      unitRef="USD">-54000</flgc:AcquisitionOfNoncontrollingInterestAmount>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055424_65"
      unitRef="USD">4003000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055424_66"
      unitRef="USD">4003000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055424_67"
      unitRef="Shares">27</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055425_68"
      unitRef="USD">82000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055425_69"
      unitRef="USD">82000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055426_70"
      unitRef="USD">1580000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20231019113055426_71"
      unitRef="USD">-451000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055426_72"
      unitRef="USD">1129000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <flgc:RestrictedStockVestingShares
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055427_73"
      unitRef="Shares">146</flgc:RestrictedStockVestingShares>
    <flgc:RestrictedStockVestingAmount
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055427_74"
      unitRef="USD">446000</flgc:RestrictedStockVestingAmount>
    <flgc:RestrictedStockVestingAmount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055428_75"
      unitRef="USD">446000</flgc:RestrictedStockVestingAmount>
    <flgc:WarrantsExercisedShares
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055428_76"
      unitRef="Shares">23</flgc:WarrantsExercisedShares>
    <flgc:WarrantsExercisedAmount
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055428_77"
      unitRef="USD">105000</flgc:WarrantsExercisedAmount>
    <flgc:WarrantsExercisedAmount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055429_78"
      unitRef="USD">105000</flgc:WarrantsExercisedAmount>
    <flgc:WarrantsExpiredOrCancelledAmount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055435_91"
      unitRef="USD">0</flgc:WarrantsExpiredOrCancelledAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055429_79"
      unitRef="USD">105000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055430_80"
      unitRef="USD">105000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240418094004408"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20231019113055430_81"
      unitRef="USD">-1624000</flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes>
    <flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055430_82"
      unitRef="USD">-1624000</flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20231019113055432_83"
      unitRef="USD">-52415000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="F20231019113055433_84"
      unitRef="USD">-214000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055433_85"
      unitRef="USD">-52629000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20231021105708069"
      unitRef="Shares">6776</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240305110318221"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055411_41"
      unitRef="USD">150420000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20231019113055415_42"
      unitRef="USD">-2732000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20231019113055415_43"
      unitRef="USD">-90865000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="F20231019113055415_44"
      unitRef="USD">-411000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055416_45"
      unitRef="USD">56412000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <flgc:SeptemberUnitOfferingShares
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20231019113055398_6"
      unitRef="Shares">1369</flgc:SeptemberUnitOfferingShares>
    <flgc:SeptemberUnitOfferingAmount
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055398_7"
      unitRef="USD">2738000</flgc:SeptemberUnitOfferingAmount>
    <flgc:SeptemberUnitOfferingAmount
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055398_8"
      unitRef="USD">2738000</flgc:SeptemberUnitOfferingAmount>
    <flgc:SeptemberUnitOfferingIssuanceCosts
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055399_9"
      unitRef="USD">254000</flgc:SeptemberUnitOfferingIssuanceCosts>
    <flgc:SeptemberUnitOfferingIssuanceCosts
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055399_10"
      unitRef="USD">254000</flgc:SeptemberUnitOfferingIssuanceCosts>
    <flgc:EquityIssuedForOtherAgreementsShares
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240305104938392"
      unitRef="Shares">126</flgc:EquityIssuedForOtherAgreementsShares>
    <flgc:EquityIssuedForOtherAgreementsAmount
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240305104947894"
      unitRef="USD">590000</flgc:EquityIssuedForOtherAgreementsAmount>
    <flgc:EquityIssuedForOtherAgreementsAmount
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305105000475"
      unitRef="USD">590000</flgc:EquityIssuedForOtherAgreementsAmount>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240305105013894"
      unitRef="USD">226000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305105025196"
      unitRef="USD">226000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240305110951286"
      unitRef="USD">5627000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240305111018527"
      unitRef="USD">-5352000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305111027165"
      unitRef="USD">275000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240305105439295_20231019113055427_73"
      unitRef="Shares">838</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240305105439295_20231019113055427_74"
      unitRef="USD">1989000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305105439295_20231019113055428_75"
      unitRef="USD">1989000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240305105544611_xbrl_20240305105439295_20231019113055427_73"
      unitRef="Shares">174</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240305105544611_xbrl_20240305105439295_20231019113055427_74"
      unitRef="USD">844000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305105544611_xbrl_20240305105439295_20231019113055428_75"
      unitRef="USD">844000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240305105505209_20231019113055429_79"
      unitRef="USD">145000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305105505209_20231019113055430_80"
      unitRef="USD">145000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <flgc:DerecognitionOfEquityRelatedToColombiaAssets
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240305111243701"
      unitRef="USD">1310000</flgc:DerecognitionOfEquityRelatedToColombiaAssets>
    <flgc:DerecognitionOfEquityRelatedToColombiaAssets
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="Fxbrl_20240305111259126"
      unitRef="USD">-278000</flgc:DerecognitionOfEquityRelatedToColombiaAssets>
    <flgc:DerecognitionOfEquityRelatedToColombiaAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305111323109"
      unitRef="USD">1032000</flgc:DerecognitionOfEquityRelatedToColombiaAssets>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240418093944499"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240305105516144_20231019113055430_81"
      unitRef="USD">1282000</flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes>
    <flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305105516144_20231019113055430_82"
      unitRef="USD">1282000</flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxes>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240305105523932_20231019113055432_83"
      unitRef="USD">-57036000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="Fxbrl_20240305105523932_20231019113055433_84"
      unitRef="USD">689000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305105523932_20231019113055433_85"
      unitRef="USD">-56347000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20231021105754452"
      unitRef="Shares">8935</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240305110019123"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20231019113055433_86"
      unitRef="USD">149093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20231019113055434_87"
      unitRef="USD">-140000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20231019113055434_88"
      unitRef="USD">-142549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="Fxbrl_20240305110008120"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055435_90"
      unitRef="USD">6404000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641044_0"
      unitRef="USD">-56347000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641044_1"
      unitRef="USD">-52629000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641045_2"
      unitRef="USD">2484000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641045_3"
      unitRef="USD">2629000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641045_4"
      unitRef="USD">1591000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641045_5"
      unitRef="USD">3404000</us-gaap:ShareBasedCompensation>
    <flgc:ImpairmentOfGoodwill
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641045_6"
      unitRef="USD">23372000</flgc:ImpairmentOfGoodwill>
    <flgc:ImpairmentOfGoodwill
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641046_7"
      unitRef="USD">25452000</flgc:ImpairmentOfGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641046_8"
      unitRef="USD">20840000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641046_9"
      unitRef="USD">783000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641046_10"
      unitRef="USD">1991000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641047_11"
      unitRef="USD">-593000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641047_12"
      unitRef="USD">801000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641047_13"
      unitRef="USD">1607000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305112654419_20240530124641047_12"
      unitRef="USD">-3132000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240305112654419_20240530124641047_13"
      unitRef="USD">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641047_14"
      unitRef="USD">-94000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641047_15"
      unitRef="USD">56000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeOperating
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641048_16"
      unitRef="USD">94000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641048_17"
      unitRef="USD">4000</us-gaap:InterestIncomeOperating>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641048_18"
      unitRef="USD">-1617000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641048_19"
      unitRef="USD">-1538000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641048_20"
      unitRef="USD">-7735000</us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641049_21"
      unitRef="USD">-19759000</us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641049_22"
      unitRef="USD">-1522000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641049_23"
      unitRef="USD">-143000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641049_24"
      unitRef="USD">-576000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641049_25"
      unitRef="USD">-1219000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641050_26"
      unitRef="USD">419000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641050_27"
      unitRef="USD">-1372000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641050_28"
      unitRef="USD">-2340000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641050_29"
      unitRef="USD">1090000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641050_30"
      unitRef="USD">-8396000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641050_31"
      unitRef="USD">-15935000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641051_32"
      unitRef="USD">2738000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641051_33"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641051_34"
      unitRef="USD">396000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641051_35"
      unitRef="USD">520000</us-gaap:PaymentsOfStockIssuanceCosts>
    <flgc:ProceedsFromExerciseOfWarrantsAndOptions
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641051_36"
      unitRef="USD">0</flgc:ProceedsFromExerciseOfWarrantsAndOptions>
    <flgc:ProceedsFromExerciseOfWarrantsAndOptions
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641052_37"
      unitRef="USD">187000</flgc:ProceedsFromExerciseOfWarrantsAndOptions>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641052_38"
      unitRef="USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641052_39"
      unitRef="USD">255000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641052_40"
      unitRef="USD">995000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641052_41"
      unitRef="USD">197000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641053_42"
      unitRef="USD">187000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641053_43"
      unitRef="USD">196000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641053_44"
      unitRef="USD">3150000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641053_45"
      unitRef="USD">4413000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641053_46"
      unitRef="USD">163000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641054_47"
      unitRef="USD">1294000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305112623375_20240530124641053_46"
      unitRef="USD">71000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240305112623375_20240530124641054_47"
      unitRef="USD">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641054_48"
      unitRef="USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641054_49"
      unitRef="USD">14508000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641054_50"
      unitRef="USD">-234000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641054_51"
      unitRef="USD">-15802000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641054_52"
      unitRef="USD">930000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641055_53"
      unitRef="USD">-755000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641055_54"
      unitRef="USD">-4550000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641055_55"
      unitRef="USD">-28079000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="F20240530124641055_57"
      unitRef="USD">37616000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305112543551_20240530124641055_56"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305112543551_20240530124641055_57"
      unitRef="USD">602000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124641056_58"
      unitRef="USD">4385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <flgc:NonCashCommonSharesIssuedForBusinessCombinations
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240530124641060_60"
      unitRef="USD">0</flgc:NonCashCommonSharesIssuedForBusinessCombinations>
    <flgc:NonCashCommonSharesIssuedForBusinessCombinations
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240530124641060_61"
      unitRef="USD">24712000</flgc:NonCashCommonSharesIssuedForBusinessCombinations>
    <flgc:NonCashCommonSharesIssuedForOtherAgreements
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="F20240530124641060_62"
      unitRef="Shares">95</flgc:NonCashCommonSharesIssuedForOtherAgreements>
    <flgc:NonCashCommonSharesIssuedForOtherAgreements
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="F20240530124641060_63"
      unitRef="Shares">1470</flgc:NonCashCommonSharesIssuedForOtherAgreements>
    <flgc:NonCashOptionCancellationsReclassifiedToEquity
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240529194722865_20240530124641060_62"
      unitRef="USD">5352000</flgc:NonCashOptionCancellationsReclassifiedToEquity>
    <flgc:NonCashOptionCancellationsReclassifiedToEquity
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240529194722865_20240530124641060_63"
      unitRef="USD">451000</flgc:NonCashOptionCancellationsReclassifiedToEquity>
    <flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="F20240530124641061_64"
      unitRef="Shares">245</flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets>
    <flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="F20240530124641061_65"
      unitRef="Shares">2919</flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets>
    <flgc:IntangibleAssetsAcquiredForContingentConsiderationNonCash
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240531042636946"
      unitRef="USD">194000</flgc:IntangibleAssetsAcquiredForContingentConsiderationNonCash>
    <flgc:IntangibleAssetsAcquiredForContingentConsiderationNonCash
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240531042709392"
      unitRef="USD">0</flgc:IntangibleAssetsAcquiredForContingentConsiderationNonCash>
    <us-gaap:NatureOfOperations contextRef="C_20230101to20231231" id="F20231019113055475_0">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;NATURE OF OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Flora Growth Corp. (the "Company" or "Flora") was incorporated under the laws of the Province of Ontario, Canada on March 13, 2019. The Company is manufacturer and distributor of global cannabis and pharmaceutical products and brands, building a connected, design-led collective of plant-based wellness and lifestyle brands. The Company's registered office is located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1, Canada and our principal place of business in the United States is located at 3406 SW 26th Terrace, Suite C-1, Fort Lauderdale, Florida 3312.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On December 23, 2022, Flora completed its acquisition of all the issued and outstanding common shares of Franchise Global Health Inc. ("FGH"), a corporation existing under the laws of the Province of British Columbia by way of a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). FGH, through its wholly-owned subsidiaries, is a multi-national distributor in the pharmaceutical and medical cannabis industry with principal operations in Germany. See Note 10 for further discussion.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On February 24, 2022, Flora Growth U.S. Holdings Corp., a wholly-owned subsidiary of the Company, completed the acquisition of 100% of the outstanding equity interests in each of (i) Just Brands LLC and (ii) High Roller Private Label LLC. JustCBD is a manufacturer and distributor of consumable cannabinoid products, including gummies, tinctures, vape cartridges, and creams with principal operations in Florida, United States. See Note 10 for further discussion.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These consolidated financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055518_144">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;BASIS OF PRESENTATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These consolidated financial statements have been presented in United States dollars and are prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The Company has determined that the United States dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in United States dollars and our financial results are prepared and reviewed internally by management in United States dollars.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prior to January 1, 2023, Flora was a foreign private issuer reporting its financial statements under International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Boards. These consolidated financial statements, for all periods, are presented in accordance with U.S. GAAP.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Going concern&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;

                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company had cash of $4.4 million at December 31, 2023, net loss of $56.3 million for the year ended December 31, 2023, and an accumulated deficit of $142.5 million at December 31, 2023. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions, through the disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. These consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Presentation of comparative financial statements&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion in Note 15.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. As at December 31, 2023, the Company had the following subsidiaries:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;

                                            &lt;div style="margin-bottom: 10pt;"&gt;
                                                &lt;table border="1" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 14%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Country of&lt;br/&gt;Incorporation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Functional Currency&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Kasa Wholefoods Company LLC
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Flora Beauty LLC
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Vessel Brand Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Vessel Brand Canada Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Just Brands LLC
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Just Brands International LTD
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United Kingdom
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    British Pound (GBP)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    High Roller Private Label LLC
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Flora Growth US Holdings Corp.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Cardiff Brand Corp.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Franchise Global Health Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Harmony Health One Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    ACA Mueller ADAG Pharma Vertriebs GmbH
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Germany
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Euro (EUR)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Sativa Verwaltungs GmbH
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Germany
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Euro (EUR)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Sativa Verwaltungs GmbH and Co. KG
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Germany
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Euro (EUR)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    CBD Med Therapeutics Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Fayber Technologies Canada Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Catalunia SAS
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Colombia
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Colombia Peso (COP)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Green CannaHealth SAS
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Colombia
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Colombia Peso (COP)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Klokken Aarhus Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Rangers Pharmaceuticals A/S
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Denmark
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Danish Krone (DAK)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    1200325 B.C. LTD.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Phatebo
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Germany
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Euro (EUR)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Franchise Cannabis Corp.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                            &lt;/div&gt;

                                    &lt;/div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $0.8 million (USD $0.6 million).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company sold all of its shares and assets related to the following Colombian companies and branches:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Flora Growth Corp Colombia S.A.S. (formerly Hemp Textiles &amp;amp; Co. S.A.S.)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Flora Lab S.A.S. (formerly Grupo Farmaceutico Cronomed S.A.S.)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Flora Med S.A.S. (formerly Breeze Laboratory S.A.S.)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Labcofarm Laboratorios S.A.S&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Cosechemos Ya S.A.S.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Kasa Wholefoods Company S.A.S.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Flora Growth Corp. Sucursal Colombia&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Flora Beauty LLC Sucursal Colombia&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The applicable capital stock of the Colombian entities was transferred to Lisan at the date of closing. All assets underlying this sale were transferred to Lisan on an "as is where is" basis. The results of these subsidiaries are included in discontinued operations in the accompanying consolidated financial statements. See discussion in Note 5.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;During the fourth quarter of the year ending December 31, 2023, the Company voluntarily dissolved the following U.S. companies:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Hemp Textiles &amp;amp; Co. LLC&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Keel Brand Corp.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Flora Growth F&amp;amp;B Corp&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Flora Growth Management Corp.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-left: 63.6pt; text-indent: -18pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;span style="display: inline-block; width: 10pt;"&gt;&#160;&lt;/span&gt;Masaya Holding Corp.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                                &lt;div&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Basis of measurement&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments that are measured at fair value as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of trade and amounts receivable, indemnification receivables, prepaids and other current assets, and trade and other payables, accrued liabilities, current portion of long term debt, and current portion of lease liability approximate their fair values due to their short periods to maturity. The Company calculates the estimated fair value of financial instruments, including investments, and contingent consideration, using quoted market prices when available. When quoted market prices are not available, fair value is determined based on valuation techniques using the best information available and may include quoted market prices, market comparable, and discounted cash flow projections.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The consolidated financial statements are presented in United States dollars ("$") unless otherwise noted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                            &lt;div&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Use of estimates&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:Cash
      contextRef="C_20231231"
      decimals="-5"
      id="Fxbrl_20231021114344055"
      unitRef="USD">4400000</us-gaap:Cash>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055480_1"
      unitRef="USD">-56300000</us-gaap:ProfitLoss>
    <us-gaap:CumulativeEarningsDeficit
      contextRef="C_20231231"
      decimals="-5"
      id="F20231019113055480_2"
      unitRef="USD">-142500000</us-gaap:CumulativeEarningsDeficit>
    <flgc:ScheduleOfSubsidiariesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305124000279">
                                            &lt;div style="margin-bottom: 10pt;"&gt;
                                                &lt;table border="1" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 14%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Country of&lt;br/&gt;Incorporation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Functional Currency&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Kasa Wholefoods Company LLC
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Flora Beauty LLC
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Vessel Brand Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Vessel Brand Canada Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Just Brands LLC
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Just Brands International LTD
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United Kingdom
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    British Pound (GBP)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    High Roller Private Label LLC
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Flora Growth US Holdings Corp.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Cardiff Brand Corp.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    United States Dollar (USD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Franchise Global Health Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Harmony Health One Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    ACA Mueller ADAG Pharma Vertriebs GmbH
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Germany
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Euro (EUR)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Sativa Verwaltungs GmbH
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Germany
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Euro (EUR)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Sativa Verwaltungs GmbH and Co. KG
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Germany
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Euro (EUR)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    CBD Med Therapeutics Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Fayber Technologies Canada Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Catalunia SAS
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Colombia
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Colombia Peso (COP)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Green CannaHealth SAS
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Colombia
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Colombia Peso (COP)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Klokken Aarhus Inc.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Rangers Pharmaceuticals A/S
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Denmark
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Danish Krone (DAK)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    1200325 B.C. LTD.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Phatebo
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Germany
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Euro (EUR)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Franchise Cannabis Corp.
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canada
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="width: 21%; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; padding-left: 5.4pt; padding-right: 5.4pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                    Canadian Dollar (CAD)
                                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                            &lt;/div&gt;
                                        </flgc:ScheduleOfSubsidiariesTableTextBlock>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember"
      id="F20231019113055480_4">Kasa Wholefoods Company LLC</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember"
      id="F20231019113055487_33">United States</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember"
      decimals="2"
      id="F20231019113055487_34"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryOneMember"
      id="F20231019113055489_35">United States Dollar (USD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember"
      id="F20231019113055481_8">Flora Beauty LLC</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember"
      id="F20231019113055484_21">United States</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember"
      decimals="2"
      id="F20231019113055484_22"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwoMember"
      id="F20231019113055484_23">United States Dollar (USD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember"
      id="F20231019113055482_12">Vessel Brand Inc.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember"
      id="F20231019113055492_49">United States</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember"
      decimals="2"
      id="F20231019113055493_50"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThreeMember"
      id="F20231019113055493_51">United States Dollar (USD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember"
      id="F20231019113055483_16">Vessel Brand Canada Inc.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember"
      id="Fxbrl_20240305124530374">Canada</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember"
      decimals="2"
      id="Fxbrl_20240305124542118"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourMember"
      id="Fxbrl_20240305124553509">United States Dollar (USD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember"
      id="F20231019113055484_20">Just Brands LLC</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember"
      id="F20231019113055493_53">United States</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember"
      decimals="2"
      id="F20231019113055494_54"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFiveMember"
      id="F20231019113055494_55">United States Dollar (USD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember"
      id="F20231019113055485_24">Just Brands International LTD</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember"
      id="F20231019113055494_57">United Kingdom</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember"
      decimals="2"
      id="F20231019113055494_58"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixMember"
      id="F20231019113055495_59">British Pound (GBP)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember"
      id="F20231019113055486_28">High Roller Private Label LLC</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember"
      id="F20231019113055495_61">United States</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember"
      decimals="2"
      id="F20231019113055495_62"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySevenMember"
      id="F20231019113055495_63">United States Dollar (USD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember"
      id="F20231019113055486_32">Flora Growth US Holdings Corp.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember"
      id="F20231019113055496_65">United States</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember"
      decimals="2"
      id="F20231019113055496_66"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEightMember"
      id="F20231019113055496_67">United States Dollar (USD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember"
      id="F20231019113055489_36">Cardiff Brand Corp.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember"
      id="F20231019113055498_73">United States</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember"
      decimals="2"
      id="F20231019113055498_74"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineMember"
      id="F20231019113055498_75">United States Dollar (USD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember"
      id="F20231019113055491_40">Franchise Global Health Inc</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember"
      id="F20231019113055502_89">Canada</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember"
      decimals="2"
      id="F20231019113055502_90"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTenMember"
      id="F20231019113055502_91">Canadian Dollar (CAD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember"
      id="F20231019113055491_44">Harmony Health One Inc.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember"
      id="F20231019113055503_93">Canada</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember"
      decimals="2"
      id="F20231019113055503_94"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryElevenMember"
      id="F20231019113055503_95">Canadian Dollar (CAD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember"
      id="F20231019113055492_48">ACA Mueller ADAG Pharma Vertriebs GmbH</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember"
      id="F20231019113055504_97">Germany</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember"
      decimals="2"
      id="F20231019113055504_98"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwelveMember"
      id="F20231019113055505_99">Euro (EUR)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember"
      id="F20231019113055493_52">Sativa Verwaltungs GmbH</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember"
      id="F20231019113055505_101">Germany</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember"
      decimals="2"
      id="F20231019113055505_102"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryThirteenMember"
      id="F20231019113055505_103">Euro (EUR)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember"
      id="F20231019113055494_56">Sativa Verwaltungs GmbH and Co. KG</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember"
      id="F20231019113055506_105">Germany</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember"
      decimals="2"
      id="F20231019113055506_106"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFourteenMember"
      id="F20231019113055506_107">Euro (EUR)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember"
      id="F20231019113055495_60">CBD Med Therapeutics Inc.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember"
      id="F20231019113055507_109">Canada</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember"
      decimals="2"
      id="F20231019113055507_110"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryFifteenMember"
      id="F20231019113055508_111">Canadian Dollar (CAD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember"
      id="F20231019113055496_64">Fayber Technologies Canada Inc.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember"
      id="F20231019113055508_113">Canada</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember"
      decimals="2"
      id="F20231019113055509_114"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySixteenMember"
      id="F20231019113055509_115">Canadian Dollar (CAD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember"
      id="F20231019113055497_68">Catalunia SAS</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember"
      id="F20231019113055511_117">Colombia</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember"
      decimals="2"
      id="F20231019113055512_118"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiarySeventeenMember"
      id="F20231019113055513_119">Colombia Peso (COP)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember"
      id="F20231019113055497_72">Green CannaHealth SAS</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember"
      id="F20231019113055513_121">Colombia</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember"
      decimals="2"
      id="F20231019113055514_122"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryEighteenMember"
      id="F20231019113055514_123">Colombia Peso (COP)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember"
      id="F20231019113055498_76">Klokken Aarhus Inc.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember"
      id="F20231019113055514_125">Canada</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember"
      decimals="2"
      id="F20231019113055514_126"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryNineteenMember"
      id="F20231019113055515_127">Canadian Dollar (CAD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember"
      id="F20231019113055499_80">Rangers Pharmaceuticals A/S</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember"
      id="F20231019113055515_129">Denmark</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember"
      decimals="2"
      id="F20231019113055515_130"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyMember"
      id="F20231019113055516_131">Danish Krone (DAK)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember"
      id="F20231019113055500_84">1200325 B.C. LTD.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember"
      id="F20231019113055516_133">Canada</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember"
      decimals="2"
      id="F20231019113055516_134"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyOneMember"
      id="F20231019113055516_135">Canadian Dollar (CAD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember"
      id="F20231019113055501_88">Phatebo</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember"
      id="F20231019113055517_137">Germany</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember"
      decimals="2"
      id="F20231019113055517_138"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyTwoMember"
      id="F20231019113055517_139">Euro (EUR)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember"
      id="F20231019113055502_92">Franchise Cannabis Corp.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember"
      id="F20231019113055518_141">Canada</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember"
      decimals="2"
      id="F20231019113055518_142"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <flgc:FunctionalCurrencyOfSubsidiary
      contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_flgcSubsidiaryTwentyThreeMember"
      id="F20231019113055518_143">Canadian Dollar (CAD)</flgc:FunctionalCurrencyOfSubsidiary>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20240306105805596"
      unitRef="CAD">800000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20240306105849820"
      unitRef="USD">600000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055528_37">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The significant accounting policies used by the Company are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Cash and restricted cash&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash in the consolidated statement of financial position includes cash on hand and deposits held with banks and other financial intermediaries that have a maturity of less than three months at the date they are acquired. Restricted cash in the consolidated statement of financial position includes cash required to be held in deposit accounts related to credit card accounts and merchant accounts.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows. Non-derivative financial assets are classified and measured as "financial assets at fair value", as either fair value through profit or loss ("FVPL"), or "financial assets at amortized cost", as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;All financial assets are recognized initially at fair value plus, in the case of financial assets not at FVPL, directly attributable transaction costs on the trade date at which the Company becomes a party to the contractual provisions of the instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets with embedded derivatives are considered in their entirety when determining their classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial assets at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these consolidated financial statements, cash, trade and amounts receivables, indemnification receivables, and loans receivable are classified in this category.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial assets at FVPL&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets measured at FVPL include financial assets such as the Company's equity investments in other entities, and any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial assets measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in a separate caption in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Impairment of financial assets&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, trade and amounts receivables, and loans receivable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade and note receivables are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by country and customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for trade receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the consolidated statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off. This is determined with judgment or otherwise when discharged by bankruptcy or other legal proceedings.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Inventories &lt;/span&gt;&lt;/span&gt;&lt;span&gt;are comprised of raw materials and supplies, and finished goods. Inventories are initially valued at cost and subsequently at the lower of cost and net realizable value. Inventory cost is determined either on a weighted&#160;average cost or specific identification basis and any trade discounts and rebates are deducted from the purchase price&lt;/span&gt;&lt;span&gt;&lt;span&gt;. Raw material costs include the purchase cost of the materials, freight-in and duty. Costs incurred during the production process are capitalized as incurred to the extent that cost is less than net realizable value. These costs include materials, labor and manufacturing overhead used in the production processes. Finished goods include the cost of direct materials and labor and a proportion of manufacturing overhead allocated based on normal production capacity.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;

                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net realizable value represents the estimated selling price for inventories in the ordinary course of business, less all estimated costs of completion and costs necessary to make the sale. The determination of net realizable value requires significant judgment, including consideration of factors such as shrinkage, the aging of and future demand for inventory and contractual arrangements with customers. Reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The impact of changes in inventory reserves is reflected in cost of sales.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                            &lt;div&gt;
                                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            5-10 years
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vehicle&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Building&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;30 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Lesser of useful life and remaining term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/div&gt;

                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use, including interest on borrowings when significant. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the consolidated statements of loss and comprehensive loss of the related year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization is provided on a straight-line basis over the assets' estimated useful lives, which do not exceed the contractual period, if any. The Company's finite-lived intangible assets are amortized as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                            &lt;div&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Patents and developed technology&#160; &#160; &#160; &#160; &#160;9 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Customer and supplier relationships&#160; &#160; &#160;5-10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trademarks and brands&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;8-10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Licenses&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-compete agreements&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/div&gt;

                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Amortization expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Investments include investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence and are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the "measurement alternative"). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in unrealized loss from changes in fair value on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company reviews long-lived assets, including property and equipment and definite life intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Business combinations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition related costs are generally recognized in the consolidated statements of loss and comprehensive loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed, are recognized at their fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any noncontrolling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date. If, after assessment, the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in the consolidated statements of loss and comprehensive loss as a bargain purchase gain.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured at the fair value of the acquiree's identifiable net assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or liability is remeasured at subsequent reporting dates, with the corresponding gain or loss recognized in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;When a business combination is achieved in stages, the Company's previously held equity interest in the acquiree is remeasured to its acquisition date fair value and the resulting gain or loss, if any, is recognized in the consolidated statements of loss and comprehensive loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to the consolidated statements of loss and comprehensive loss where such treatment would be appropriate if that interest were disposed of.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Purchase price allocations may be preliminary and, during the measurement period not to exceed one year from the date of acquisition, changes in assumptions and estimates that result in adjustments to the fair value of assets acquired and liabilities assumed are recorded in the period the adjustments are determined.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of goodwill and indefinite-lived intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company operates in three operating segments which are the reporting units and goodwill is allocated at the operating segment level. The Company reviews goodwill and indefinite-lived intangible assets annually for impairment in the fourth quarter, or more frequently, if events or circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables and other accrued liabilities and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial liabilities at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial liabilities at FVPL&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial liabilities measured at FVPL include any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial liabilities measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in other income or expense in the consolidated statements of loss and comprehensive loss. In these consolidated financial statements, trade and other payables and other accrued liabilities, lease liability and loans payable are measured at amortized cost.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The expense relating to any provision is presented in the consolidated statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued common shares are recorded as equity at par value. Additional proceeds from the issuance of common shares are classified as equity in additional paid in capital. Incremental costs directly attributable to the issue of common shares, stock options and warrants are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received. The fair value of options and warrants is determined using the Black Scholes model.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share based compensation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Share based compensation to employees is measured at the fair value of the instruments issued and amortized over the vesting periods. Share based compensation to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued if it is determined the fair value of the goods or services cannot be reliably measured and are recorded at the date the goods or services are received. The Company operates an equity based compensation plan. The corresponding amount is recorded to the stock option caption within shareholders&#x2019; equity, and the expense to the consolidated statements of loss and comprehensive loss over the vesting period. The fair value of options is determined using the Black&#x2013;Scholes pricing model which incorporates all market vesting conditions. For awards with graded vesting schedules, the Company has elected to calculate the fair value as a single award and recognize expense over the total expected vesting period rather than in tranches. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest. Upon exercise of a stock option, any amount related to the initial value of the stock option, along with the proceeds from exercise are recorded to share capital. Upon expiration of a stock option, any amount related to the initial value of the stock option is recorded to accumulated deficit. The Company also grants employees and non-employees restricted stock awards (&#x201c;RSAs&#x201d;). The fair value of the RSAs is determined using the fair value of the common shares on the date of the grant. The Company has elected to recognize forfeitures as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Foreign currency translation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These consolidated financial statements are presented in U.S. dollars ("USD"), which is the Company's reporting currency; however, the functional currency of the entities in these financial statements are their respective local currencies, including Canadian dollar, USD, British pound and euro.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Translation into functional currency&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Transactions in foreign currencies are recorded in the functional currency at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the period end exchange rates. Non-monetary items are translated at the exchange rates in effect on the date of the transactions. Foreign exchange gains and losses arising on translation are presented in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Translation into presentation currency&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The assets and liabilities of foreign operations are translated into USD at year-end exchange rates. Revenue, expenses, and cash flows of foreign operations are translated into USD using average exchange rates of the reporting period. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in shareholders' equity. The cumulative exchange differences are reclassified to the consolidated statements of loss and comprehensive loss upon the disposal of the foreign operation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Research expenses&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Research expenses are expensed as they are incurred, net of any related investment tax credits, unless the criteria for capitalization of development expenses are met.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Revenue recognition&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company primarily generates revenue as a distributor of pharmaceuticals and a distributor and retailer of cannabidiol oil derived products. See disaggregation of the Company&#x2019;s revenue by operating segments and sales by country in Note 24.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company uses the following five-step contract-based analysis of transactions to determine if, when and how much revenue can be recognized:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="width: 4%; vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Identify the contract with a customer;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Identify the performance obligations in the contract;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Determine the transaction price;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Recognize revenue when or as the Company satisfies the performance obligations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Gross revenue excludes duties and taxes collected on behalf of third parties. Revenue is presented net of expected price discounts, sales returns, customer rebates and other incentives.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's contracts with customers for the sales of products consist of one performance obligation. Revenue from product sales is recognized at the point in time when control is transferred to the customer, which is on shipment or delivery, depending on the contract terms. The Company's payment terms generally range from 0 to 30 days from the transfer of control, and sometimes up to two months.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company elected as a permitted practical expedient to not adjust the customer contract consideration for significant financing components when the period between the transfer of the Company's goods and services and customer payment is one year or less.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company elected as a permitted practical expedient to expense, as incurred, the costs of obtaining a customer contract such as sales commissions and other selling transaction costs when the amortization period of the assets otherwise would be one year or less. Accordingly, the Company has no assets recorded for costs to obtain a customer contract as at December 31, 2023 and 2022 as there are no contracts where the underlying asset would have a life exceeding one year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;

                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company elected as a permitted practical expedient for shipping and handling not to be a separate performance obligation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                &lt;div&gt;

                                        &lt;div&gt;
                                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Advertising costs&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Advertising costs are expensed as incurred and recorded within the promotion and communication caption on the consolidated statements of loss and comprehensive loss. Advertising costs were $3.4 million in 2023 ($4.4 million in 2022).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;

                                &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the consolidated statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the consolidated statements of loss and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable income or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;

                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Basic loss per share is calculated using the weighted average number of shares outstanding during the year. Diluted loss per share reflects the potential dilution of common share equivalents, such as outstanding options and warrants, in the weighted average number of common shares outstanding during the period, if dilutive. The diluted loss per share calculation excludes any potential conversion of options and warrants that would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Non-controlling interests&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-controlling interests of subsidiaries ("NCI") are recognized either at fair value or at the NCI's proportionate share of the net assets, determined on an acquisition-by-acquisition basis at the date of acquisition. Subsequently, the NCI's share of net loss and comprehensive loss is attributed to the NCI.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;During 2023, the Company completed the sale of Cosechemos YA S.A.S. and Kasa Wholefoods Company S.A.S to Lisan. These entities each had 10% NCI which was derecognized when the Company lost control during the year ended December 31, 2023. See discussion in Note 5.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Discontinued operations and assets and liabilities held for sale&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $0.8 million (USD $0.6 million). The assets and liabilities of these Colombian companies are reflected in the accompanying consolidated balance sheets as assets and liabilities held for sale, respectively. The results of operations of these Colombian companies are included in loss from discontinued operations, net of tax in the accompanying consolidated statements of operations and comprehensive loss. For comparative purposes, all prior periods presented have been reclassified to reflect the classifications on a consistent basis. See discussion in Note 5.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;


                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Adoption of accounting standards and amendments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ("ASU 2021-08"), which requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers ("ASC 606") rather than adjust them to fair value at the acquisition date. The effects of adoption are applied prospectively to business combinations occurring on or after the effective date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective as of January 1, 2023, and as such had no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Accounting pronouncements not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In June 2022, the FASB issued Accounting Standards Update 2022-03-Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU 2022-03"), which requires that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The effects of adoption are accounted for prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is assessing the impacts of adoption, but it is not expected to have an impact based on amounts recorded at December 31, 2023 as any changes required are for transactions occurring prospectively upon adoption.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segments Disclosures. The amendments enhance disclosures of significant segment expenses by requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM), extend certain annual disclosures to interim periods, and permit more than one measure of segment profit or loss to be reported under certain conditions. The amendments are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption of the amendment is permitted, including adoption in any interim periods for which financial statements have not been issued. The Company is currently evaluating the guidance and its impact to the financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_20230101to20231231" id="F20231019113055525_0">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Cash and restricted cash&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash in the consolidated statement of financial position includes cash on hand and deposits held with banks and other financial intermediaries that have a maturity of less than three months at the date they are acquired. Restricted cash in the consolidated statement of financial position includes cash required to be held in deposit accounts related to credit card accounts and merchant accounts.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_20230101to20231231"
      id="F20231019113055528_36">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows. Non-derivative financial assets are classified and measured as "financial assets at fair value", as either fair value through profit or loss ("FVPL"), or "financial assets at amortized cost", as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;All financial assets are recognized initially at fair value plus, in the case of financial assets not at FVPL, directly attributable transaction costs on the trade date at which the Company becomes a party to the contractual provisions of the instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets with embedded derivatives are considered in their entirety when determining their classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial assets at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these consolidated financial statements, cash, trade and amounts receivables, indemnification receivables, and loans receivable are classified in this category.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial assets at FVPL&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets measured at FVPL include financial assets such as the Company's equity investments in other entities, and any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial assets measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in a separate caption in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Impairment of financial assets&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, trade and amounts receivables, and loans receivable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade and note receivables are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by country and customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for trade receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the consolidated statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off. This is determined with judgment or otherwise when discharged by bankruptcy or other legal proceedings.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055526_15">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Inventories &lt;/span&gt;&lt;/span&gt;&lt;span&gt;are comprised of raw materials and supplies, and finished goods. Inventories are initially valued at cost and subsequently at the lower of cost and net realizable value. Inventory cost is determined either on a weighted&#160;average cost or specific identification basis and any trade discounts and rebates are deducted from the purchase price&lt;/span&gt;&lt;span&gt;&lt;span&gt;. Raw material costs include the purchase cost of the materials, freight-in and duty. Costs incurred during the production process are capitalized as incurred to the extent that cost is less than net realizable value. These costs include materials, labor and manufacturing overhead used in the production processes. Finished goods include the cost of direct materials and labor and a proportion of manufacturing overhead allocated based on normal production capacity.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;

                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net realizable value represents the estimated selling price for inventories in the ordinary course of business, less all estimated costs of completion and costs necessary to make the sale. The determination of net realizable value requires significant judgment, including consideration of factors such as shrinkage, the aging of and future demand for inventory and contractual arrangements with customers. Reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The impact of changes in inventory reserves is reflected in cost of sales.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055526_16">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                            &lt;div&gt;
                                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            5-10 years
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vehicle&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Building&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;30 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Lesser of useful life and remaining term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/div&gt;

                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use, including interest on borrowings when significant. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the consolidated statements of loss and comprehensive loss of the related year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <flgc:ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055528_38">
                                            &lt;div&gt;
                                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            5-10 years
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vehicle&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Building&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;30 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Lesser of useful life and remaining term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/div&gt;
                                        </flgc:ScheduleOfAssetsEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      id="F20231019113055525_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      id="F20231019113055525_2">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember"
      id="F20231019113055525_3">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember"
      id="F20231019113055525_4">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="C_20230101to20231231"
      id="F20231019113055526_17">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization is provided on a straight-line basis over the assets' estimated useful lives, which do not exceed the contractual period, if any. The Company's finite-lived intangible assets are amortized as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                            &lt;div&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Patents and developed technology&#160; &#160; &#160; &#160; &#160;9 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Customer and supplier relationships&#160; &#160; &#160;5-10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trademarks and brands&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;8-10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Licenses&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-compete agreements&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/div&gt;

                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Amortization expense is recorded within depreciation and amortization on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <flgc:ScheduleOfIntangibleAssetsEstimatedUsefulLives
      contextRef="C_20230101to20231231"
      id="F20231019113055528_39">
                                            &lt;div&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Patents and developed technology&#160; &#160; &#160; &#160; &#160;9 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Customer and supplier relationships&#160; &#160; &#160;5-10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trademarks and brands&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;8-10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Licenses&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-compete agreements&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/div&gt;
                                        </flgc:ScheduleOfIntangibleAssetsEstimatedUsefulLives>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      id="F20231019113055525_5">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      id="F20231019113055526_6">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_20231231_srtRangeAxis_srtMaximumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      id="F20231019113055526_7">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      id="F20231019113055526_8">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_20231231_srtRangeAxis_srtMaximumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      id="F20231019113055526_9">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      id="F20231019113055526_10">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      id="F20231019113055526_12">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055526_18">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Investments include investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence and are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the "measurement alternative"). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in unrealized loss from changes in fair value on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055526_19">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company reviews long-lived assets, including property and equipment and definite life intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_20230101to20231231"
      id="F20231019113055527_20">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Business combinations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition related costs are generally recognized in the consolidated statements of loss and comprehensive loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed, are recognized at their fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any noncontrolling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date. If, after assessment, the net of the amounts of identifiable assets acquired and liabilities assumed on the acquisition date exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in the consolidated statements of loss and comprehensive loss as a bargain purchase gain.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured at the fair value of the acquiree's identifiable net assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or liability is remeasured at subsequent reporting dates, with the corresponding gain or loss recognized in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;When a business combination is achieved in stages, the Company's previously held equity interest in the acquiree is remeasured to its acquisition date fair value and the resulting gain or loss, if any, is recognized in the consolidated statements of loss and comprehensive loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to the consolidated statements of loss and comprehensive loss where such treatment would be appropriate if that interest were disposed of.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Purchase price allocations may be preliminary and, during the measurement period not to exceed one year from the date of acquisition, changes in assumptions and estimates that result in adjustments to the fair value of assets acquired and liabilities assumed are recorded in the period the adjustments are determined.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_21">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of goodwill and indefinite-lived intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company operates in three operating segments which are the reporting units and goodwill is allocated at the operating segment level. The Company reviews goodwill and indefinite-lived intangible assets annually for impairment in the fourth quarter, or more frequently, if events or circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <flgc:FinancialLiabilitiesPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_22">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables and other accrued liabilities and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial liabilities at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial liabilities at FVPL&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial liabilities measured at FVPL include any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial liabilities measured at FVPL are carried at fair value in the consolidated statement of financial position with changes in fair value recognized in other income or expense in the consolidated statements of loss and comprehensive loss. In these consolidated financial statements, trade and other payables and other accrued liabilities, lease liability and loans payable are measured at amortized cost.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </flgc:FinancialLiabilitiesPolicyTextBlock>
    <flgc:ProvisionsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_23">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The expense relating to any provision is presented in the consolidated statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </flgc:ProvisionsPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_24">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued common shares are recorded as equity at par value. Additional proceeds from the issuance of common shares are classified as equity in additional paid in capital. Incremental costs directly attributable to the issue of common shares, stock options and warrants are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received. The fair value of options and warrants is determined using the Black Scholes model.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_25">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share based compensation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Share based compensation to employees is measured at the fair value of the instruments issued and amortized over the vesting periods. Share based compensation to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued if it is determined the fair value of the goods or services cannot be reliably measured and are recorded at the date the goods or services are received. The Company operates an equity based compensation plan. The corresponding amount is recorded to the stock option caption within shareholders&#x2019; equity, and the expense to the consolidated statements of loss and comprehensive loss over the vesting period. The fair value of options is determined using the Black&#x2013;Scholes pricing model which incorporates all market vesting conditions. For awards with graded vesting schedules, the Company has elected to calculate the fair value as a single award and recognize expense over the total expected vesting period rather than in tranches. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest. Upon exercise of a stock option, any amount related to the initial value of the stock option, along with the proceeds from exercise are recorded to share capital. Upon expiration of a stock option, any amount related to the initial value of the stock option is recorded to accumulated deficit. The Company also grants employees and non-employees restricted stock awards (&#x201c;RSAs&#x201d;). The fair value of the RSAs is determined using the fair value of the common shares on the date of the grant. The Company has elected to recognize forfeitures as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_26">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Foreign currency translation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These consolidated financial statements are presented in U.S. dollars ("USD"), which is the Company's reporting currency; however, the functional currency of the entities in these financial statements are their respective local currencies, including Canadian dollar, USD, British pound and euro.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Translation into functional currency&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Transactions in foreign currencies are recorded in the functional currency at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the period end exchange rates. Non-monetary items are translated at the exchange rates in effect on the date of the transactions. Foreign exchange gains and losses arising on translation are presented in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Translation into presentation currency&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The assets and liabilities of foreign operations are translated into USD at year-end exchange rates. Revenue, expenses, and cash flows of foreign operations are translated into USD using average exchange rates of the reporting period. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in shareholders' equity. The cumulative exchange differences are reclassified to the consolidated statements of loss and comprehensive loss upon the disposal of the foreign operation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_20230101to20231231"
      id="F20231019113055527_27">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Research expenses&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Research expenses are expensed as they are incurred, net of any related investment tax credits, unless the criteria for capitalization of development expenses are met.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_28">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Revenue recognition&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company primarily generates revenue as a distributor of pharmaceuticals and a distributor and retailer of cannabidiol oil derived products. See disaggregation of the Company&#x2019;s revenue by operating segments and sales by country in Note 24.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company uses the following five-step contract-based analysis of transactions to determine if, when and how much revenue can be recognized:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="width: 4%; vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Identify the contract with a customer;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Identify the performance obligations in the contract;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Determine the transaction price;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="vertical-align: middle;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: top;"&gt;
                                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Recognize revenue when or as the Company satisfies the performance obligations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Gross revenue excludes duties and taxes collected on behalf of third parties. Revenue is presented net of expected price discounts, sales returns, customer rebates and other incentives.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's contracts with customers for the sales of products consist of one performance obligation. Revenue from product sales is recognized at the point in time when control is transferred to the customer, which is on shipment or delivery, depending on the contract terms. The Company's payment terms generally range from 0 to 30 days from the transfer of control, and sometimes up to two months.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company elected as a permitted practical expedient to not adjust the customer contract consideration for significant financing components when the period between the transfer of the Company's goods and services and customer payment is one year or less.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company elected as a permitted practical expedient to expense, as incurred, the costs of obtaining a customer contract such as sales commissions and other selling transaction costs when the amortization period of the assets otherwise would be one year or less. Accordingly, the Company has no assets recorded for costs to obtain a customer contract as at December 31, 2023 and 2022 as there are no contracts where the underlying asset would have a life exceeding one year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;

                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company elected as a permitted practical expedient for shipping and handling not to be a separate performance obligation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305145803411">
                                        &lt;div&gt;
                                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Advertising costs&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Advertising costs are expensed as incurred and recorded within the promotion and communication caption on the consolidated statements of loss and comprehensive loss. Advertising costs were $3.4 million in 2023 ($4.4 million in 2022).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;
                                    </us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055526_13"
      unitRef="USD">3400000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113055526_14"
      unitRef="USD">4400000</us-gaap:AdvertisingExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_30">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the consolidated statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_31">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the consolidated statements of loss and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable income or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;

                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_32">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Basic loss per share is calculated using the weighted average number of shares outstanding during the year. Diluted loss per share reflects the potential dilution of common share equivalents, such as outstanding options and warrants, in the weighted average number of common shares outstanding during the period, if dilutive. The diluted loss per share calculation excludes any potential conversion of options and warrants that would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:EarningsPerSharePolicyTextBlock>
    <flgc:NonControllingInterestsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055527_33">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Non-controlling interests&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-controlling interests of subsidiaries ("NCI") are recognized either at fair value or at the NCI's proportionate share of the net assets, determined on an acquisition-by-acquisition basis at the date of acquisition. Subsequently, the NCI's share of net loss and comprehensive loss is attributed to the NCI.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;During 2023, the Company completed the sale of Cosechemos YA S.A.S. and Kasa Wholefoods Company S.A.S to Lisan. These entities each had 10% NCI which was derecognized when the Company lost control during the year ended December 31, 2023. See discussion in Note 5.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </flgc:NonControllingInterestsPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="C_20231231_srtOwnershipAxis_flgcCosechemosAndKasaWholefoodsMember"
      decimals="2"
      id="Fxbrl_20240305174603466"
      unitRef="Pure">0.10</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305170819615">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Discontinued operations and assets and liabilities held for sale&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan, to sell all of its shares in certain Colombian companies and other Flora assets related to its Colombian operations for a purchase price of CAD $0.8 million (USD $0.6 million). The assets and liabilities of these Colombian companies are reflected in the accompanying consolidated balance sheets as assets and liabilities held for sale, respectively. The results of operations of these Colombian companies are included in loss from discontinued operations, net of tax in the accompanying consolidated statements of operations and comprehensive loss. For comparative purposes, all prior periods presented have been reclassified to reflect the classifications on a consistent basis. See discussion in Note 5.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20240305174121971"
      unitRef="CAD">800000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20240305174217121"
      unitRef="USD">600000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055528_34">
                                    &lt;div&gt;
                                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Adoption of accounting standards and amendments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ("ASU 2021-08"), which requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers ("ASC 606") rather than adjust them to fair value at the acquisition date. The effects of adoption are applied prospectively to business combinations occurring on or after the effective date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective as of January 1, 2023, and as such had no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055528_35">
                                    &lt;div&gt;
                                        &lt;p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Accounting pronouncements not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In June 2022, the FASB issued Accounting Standards Update 2022-03-Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU 2022-03"), which requires that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The effects of adoption are accounted for prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is assessing the impacts of adoption, but it is not expected to have an impact based on amounts recorded at December 31, 2023 as any changes required are for transactions occurring prospectively upon adoption.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segments Disclosures. The amendments enhance disclosures of significant segment expenses by requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM), extend certain annual disclosures to interim periods, and permit more than one measure of segment profit or loss to be reported under certain conditions. The amendments are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption of the amendment is permitted, including adoption in any interim periods for which financial statements have not been issued. The Company is currently evaluating the guidance and its impact to the financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:UnusualRisksAndUncertaintiesTextBlock contextRef="C_20230101to20231231" id="F20231019113055532_1">
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;4.&#160; &#160; &#160; &#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, revenues, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Going concern considerations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company&#x2019;s ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of revenues, expenses and cash flows, which requires a significant amount of management judgement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Determination of functional currency&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company determines the functional currency through an analysis of several indicators. Primary considerations include the currency in which the Company's goods and services are sold and the currency of the country whose competitive forces and regulations mainly determine the sales prices of its goods and services. The Company also considers the currency in which funds from financing debt and equity activities are generated and the currency in which receipts from operating activities are retained. Management judgment is applied when there are indicators supporting more than one currency for a Company subsidiary.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Expected credit losses on financial assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Determining an allowance for expected credit losses for all financial asset receivables not held at fair value through profit or loss requires judgment. Factors that cause the estimate to be sensitive to change include historical and expected future patterns for the probability of default, the timing of collection and the amount of incurred credit losses, and management's judgment about whether economic conditions and credit terms are such that actual losses may be higher or lower than what the historical patterns suggest. These conditions are applied across each of the Company's business units to the extent the expected risk of loss differ from each other.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory is valued at the lower of cost and net realizable value. Determining net realizable value requires the Company to make assumptions about estimated selling prices in the ordinary course of business, the estimated costs of completion and the estimated variable costs to sell. Management judgment is applied to determine potential impairment exposure related to potential excess product inventory levels, obsolescence, and expiration.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Business combinations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In a business combination, the Company may acquire assets and assume certain liabilities of an acquired entity. Judgement is used in determining whether an acquisition is a business combination or an asset acquisition. Estimates are made as to the fair value of the identifiable assets acquired and the liabilities assumed on the acquisition date, as well as the fair value of consideration paid and contingent consideration payable. In certain circumstances, such as the valuation of property, plant and equipment, intangible assets and goodwill acquired, the Company obtains assistance from third-party valuation specialists. The determination of these fair values involves a variety of judgment in assumptions, include revenue growth rates, expected operating income, discount rates, and earnings multiples.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Estimated useful lives and depreciation of long-lived assets with finite lives&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Determination of reporting units and asset groups for impairment testing&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Management is required to use judgement in determining which assets or group of assets make up appropriate reporting units and asset groups for the level at which goodwill and other long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of goodwill and long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For reporting units to which goodwill and other long-lived assets is allocated is based on a recoverable amount, the impairment test is determined in accordance with the expected cash flow approach or another suitable model depending on the asset type. The calculation is based on assumptions including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For reporting units that test using the market based fair value approach, the fair value is determined based on guideline public companies similar to the reporting unit and considers similar financial metrics, operations and sales channels. The fair value calculation is based on assumptions including the determination of guideline public companies, determining the relevant financial metric to measure the reporting unit's recoverable value, and selecting the amount of the financial metric from the observable range of guideline public company amounts to apply to the reporting unit.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions discussed above. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Revenue recognition&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Management judgment is required to determine when the Company is acting as principal or agent in a sales contract where the Company is an intermediary, which affects whether the amount of revenue recognized is presented on a gross or net basis, respectively. The Company first considers whether it has obtained control over the product when acting as an intermediary before transferring it to the customer, and if the Company combines or transforms the product with other goods and services before transferring the good to the customer. The Company considers secondary factors, including whether the Company is primarily responsible for the fulfillment of the product obligations to the customer, whether the Company has inventory risk (acquiring and/or paying for the product prior to transferring to the customer, Company liability for damages and sales returns), and whether the Company has price discretion when selling the product to its customers. Management considers the terms of the customer and supplier contracts, as well as established business practices for the arrangements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Management judgment is required to determine the effects on the sales contract transaction price for the potential impacts of sales returns, discounts, rebates, and other customer incentives. The Company considers the terms of the contract, historical experience, as well as actual and expected customer activity after the end of the reporting period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's primary sale of products requires management judgment to determine at what point in time control passes to the customer to recognize revenue. The Company considers the customer contract terms, logistic supplier terms, local law, and established business practices to make this determination.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share based compensation transactions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company measures the cost of equity-settled transactions with employees and applicable non-employees by reference to the fair value of the equity instruments at the date at which they are vested. Estimating fair value for share based compensation requires judgment to determine the appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the stock price, stock option, risk-free interest rates, volatility, and dividend yield. For awards with market or performance-based features, the Company applies judgment to determine its expectation of achieving the agreement milestones. Due to the Company's limited history of publicly traded common shares, the volatility and expected term assumptions require additional judgment. The Company considers the Company's actual trading volatility to date compared to actual and expected volatility of comparable companies of similar size and industry that have been publicly traded longer than the Company's shares.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For expected term, the Company generally uses the maximum stated term in the award agreement unless there is reasonable likelihood established to shorten the expected term for potential early exercises.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes and valuation allowances for deferred tax assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of December 31, 2023 and 2022, there were no uncertain tax positions taken.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:UnusualRisksAndUncertaintiesTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20240528073307247_81">
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;5.&#160; &#160; &#160; &#160; &#160;ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all its shares in its Colombian related subsidiaries and its Colombian assets for a purchase price of CAD $0.8 million (USD $0.6 million). The sale relates to all of Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab S.A.S., Flora Med S.A.S. and Flora's Colombian food and beverage and consumer products business. The Company has received proceeds of CAD $0.5 million during the year ended December 31, 2023 which completed the sale and transfer of Flora Growth Corp Colombia S.A.S, Flora Lab S.A.S., Flora Med S.A.S., Labcofarm Laboratorios S.A.S., Kasa Wholefoods Company S.A.S., Flora Growth Corp. Sucursal Colombia and Flora Beauty LLC Sucursal Colombia. The Company and Lisan completed the sale of Cosechemos Ya S.A.S on November 1, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The sale enables the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Company has presented the associated assets and liabilities of the Colombian subsidiaries as held for sale. The major classes of assets and liabilities classified as held for sale as of December 31, 2023 and December 31, 2022 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                            &lt;div&gt;
                                &lt;div&gt;

                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;
                                                    &lt;div&gt;
                                                        &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Assets held for sale&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;602&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Trade and amounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,592&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Prepaid expenses and other current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Inventory&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,341&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Total current assets held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,709&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,592&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Operating lease right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;358&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Other assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; Total noncurrent assets held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,392&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8,101&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Liabilities held for sale&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; &#160;Current portion of operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;538&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; Total current liabilities held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;610&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Non-current operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;918&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                        &lt;/table&gt;
                                                    &lt;/div&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;

                                    &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The following table summarizes the major classes of line items included in loss from discontinued operations, net of tax, &lt;/span&gt;&lt;/span&gt;for years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;
                                                    &lt;div&gt;
                                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year ended&lt;br/&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Revenue&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,770&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,123&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,607&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gross profit from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;327&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,163&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Consulting and management fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;847&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,110&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;282&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,208&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Promotion and communication&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;383&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;485&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Bad debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Asset impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,704&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;454&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other (income) expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,145&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating loss from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,533&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,086&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest expense (income)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,535&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,059&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss on disposal of discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,132&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(133&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(9,678&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(5,926&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Basic loss per share from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1.55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Diluted loss per share from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1.55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                        &lt;/table&gt;
                                                    &lt;/div&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;

                                    &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                    &lt;p style="margin: 0pt 0pt 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The following table summarizes the significant operating and investing items related to the Colombian subsidiaries &lt;/span&gt;&lt;/span&gt;for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year&lt;br/&gt;months ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year&lt;br/&gt;months ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Operating activities of discontinued operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;485&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Bad debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Asset impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,704&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;454&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Investing activities of discontinued operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Purchases of property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;951&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;div&gt;
                                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The subsidiaries sold included Cosechemos Ya S.A.S, which was part of the commercial and wholesale segment; Flora Lab S.A.S, Flora Med S.A.S. and Labcofarm Laboratories S.A.S, which were part of the pharmaceuticals segment; Flora Growth Corp Colombia S.A.S., Kasa Wholefoods Company, S.A.S. and Flora Beauty LLC Sucursal Colombia which were part of the house of brands segment; Flora Growth Corp. Sucursal Colombia which was part of the corporate segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company applies significant judgement in determining whether a disposal meets the criteria to present as held for sale at the reporting date, and whether the disposal represents a strategic shift that has (or will have) a major effect on its operations and financial results in order to be classified as a discontinued operation. The criteria evaluated are both quantitative and qualitative in nature, to evaluate the significance of the disposal relative to the operations of the Company as a whole. The Company has determined this disposition represents a strategic shift in operations that will have a major effect on the Company's operations and financial results, and accordingly, has been presented as discontinued operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;During the year ended December 31, 2023, the Company recorded a loss on disposal of $3.1 million driven by the write-off of the Company's net investment in the Colombian assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    </us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="F20240528073307245_73"
      unitRef="CAD">800000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="F20240528073307245_74"
      unitRef="USD">600000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="F20240528073307246_79"
      unitRef="CAD">500000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <flgc:ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock
      contextRef="C_20230101to20231231"
      id="F20240528073307247_82">
                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;
                                                    &lt;div&gt;
                                                        &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Assets held for sale&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;602&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Trade and amounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,592&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Prepaid expenses and other current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Inventory&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,341&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Total current assets held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,709&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,592&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Operating lease right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;358&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Other assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; Total noncurrent assets held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,392&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8,101&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Liabilities held for sale&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; &#160;Current portion of operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;538&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; Total current liabilities held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;610&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Non-current operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;918&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                        &lt;/table&gt;
                                                    &lt;/div&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                    </flgc:ScheduleOfMajorClassesOfAssetsAndLiabilitiesHeldForSaleTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307223_0"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307224_1"
      unitRef="USD">602000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307224_2"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307225_3"
      unitRef="USD">1592000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307225_4"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307225_5"
      unitRef="USD">174000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307225_6"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307226_7"
      unitRef="USD">1341000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307226_8"
      unitRef="USD">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307226_9"
      unitRef="USD">3709000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307227_10"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307227_11"
      unitRef="USD">3592000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307227_12"
      unitRef="USD">0</flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets>
    <flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307227_13"
      unitRef="USD">419000</flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307228_14"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307228_15"
      unitRef="USD">358000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307228_16"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307228_17"
      unitRef="USD">23000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307229_18"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307229_19"
      unitRef="USD">4392000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307229_20"
      unitRef="USD">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307230_21"
      unitRef="USD">8101000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307230_22"
      unitRef="USD">0</flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent>
    <flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307230_23"
      unitRef="USD">72000</flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307230_24"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307231_25"
      unitRef="USD">538000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307233_26"
      unitRef="USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307233_27"
      unitRef="USD">610000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307233_28"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307234_29"
      unitRef="USD">308000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="C_20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307234_30"
      unitRef="USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="C_20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307234_31"
      unitRef="USD">918000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <flgc:ScheduleOfLossFromDiscontinuedOperationsTableTextBlock
      contextRef="C_20230101to20231231"
      id="F20240528073307247_83">
                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;
                                                    &lt;div&gt;
                                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year ended&lt;br/&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Revenue&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,770&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,123&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,607&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gross profit from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;327&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,163&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Consulting and management fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;847&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,110&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;282&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,208&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Promotion and communication&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;383&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;485&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Bad debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Asset impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,704&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;454&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other (income) expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,145&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating loss from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,533&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,086&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest expense (income)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,535&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,059&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss on disposal of discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,132&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(133&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(9,678&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(5,926&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Basic loss per share from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1.55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Diluted loss per share from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1.55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                        &lt;/table&gt;
                                                    &lt;/div&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                    </flgc:ScheduleOfLossFromDiscontinuedOperationsTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307234_32"
      unitRef="USD">1450000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307235_33"
      unitRef="USD">3770000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307235_34"
      unitRef="USD">1123000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307235_35"
      unitRef="USD">2607000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307235_36"
      unitRef="USD">327000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307236_37"
      unitRef="USD">1163000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307236_38"
      unitRef="USD">847000</flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees>
    <flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307236_39"
      unitRef="USD">2110000</flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees>
    <flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307236_40"
      unitRef="USD">82000</flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees>
    <flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307237_41"
      unitRef="USD">514000</flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307237_42"
      unitRef="USD">282000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307237_43"
      unitRef="USD">1208000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307237_44"
      unitRef="USD">14000</flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication>
    <flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307238_45"
      unitRef="USD">383000</flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication>
    <flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307238_46"
      unitRef="USD">93000</flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307238_47"
      unitRef="USD">284000</flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307238_48"
      unitRef="USD">148000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307239_49"
      unitRef="USD">485000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307239_50"
      unitRef="USD">565000</flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307239_51"
      unitRef="USD">666000</flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307239_52"
      unitRef="USD">4704000</flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment>
    <flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307235_331"
      unitRef="USD">454000</flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307240_54"
      unitRef="USD">125000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307240_55"
      unitRef="USD">1145000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307240_56"
      unitRef="USD">-6533000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307241_57"
      unitRef="USD">-6086000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307241_58"
      unitRef="USD">2000</flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307241_59"
      unitRef="USD">-27000</flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307241_60"
      unitRef="USD">-6535000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307242_61"
      unitRef="USD">-6059000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307242_62"
      unitRef="USD">-3132000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307242_63"
      unitRef="USD">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307243_64"
      unitRef="USD">11000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307243_65"
      unitRef="USD">-133000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307234_328"
      unitRef="USD">-9678000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapDisposalGroupClassificationAxis_usgaapDiscontinuedOperationsHeldforsaleMember_usgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_flgcColombianRelatedSubsidiariesAndColombianAssetsMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307234_3211"
      unitRef="USD">-5926000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20231108100011769_20240528073307234_328"
      unitRef="CAD_Per_Share">-1.32</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20231108100011769_20240528073307234_3211"
      unitRef="CAD_Per_Share">-1.55</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20231108100013814_20240528073307234_328"
      unitRef="CAD_Per_Share">-1.32</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20231108100013814_20240528073307234_3211"
      unitRef="CAD_Per_Share">-1.55</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <flgc:ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock
      contextRef="C_20230101to20231231"
      id="F20240528073307247_84">
                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year&lt;br/&gt;months ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year&lt;br/&gt;months ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Operating activities of discontinued operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;485&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Bad debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Asset impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,704&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;454&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Investing activities of discontinued operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Purchases of property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;951&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                    </flgc:ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307243_68"
      unitRef="USD">148000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307244_69"
      unitRef="USD">485000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307245_75"
      unitRef="USD">565000</flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307246_77"
      unitRef="USD">666000</flgc:DisposalGroupIncludingDiscontinuedOperationBadDebtExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307245_76"
      unitRef="USD">4704000</flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment>
    <flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307246_78"
      unitRef="USD">454000</flgc:DisposalGroupIncludingDiscontinuedOperationAssetImpairment>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307244_70"
      unitRef="USD">92000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240528073307244_71"
      unitRef="USD">951000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="F20240528073307244_72"
      unitRef="USD">-3100000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055537_28">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;TRADE AND AMOUNTS RECEIVABLE &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's trade and amounts receivable are recorded at amortized cost. The trade and other receivables balance as at December 31, 2023 and December 31, 2022 consists of trade accounts receivable, amounts recoverable from the Government of Canada for Harmonized Sales Taxes ("HST"), as well as Value Added Tax ("VAT") from various jurisdictions, and other receivables.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade accounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,299&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,288&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,385&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;HST/VAT receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,840&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,294&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,950&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,259&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Changes in the trade accounts receivable allowance in the year ended December 31, 2023 relate to establishing an allowance for expected credit losses. The Company recorded $1.3 million of write-offs of trade receivables during 2023 (2022 - $0.2 million), $1.1 million of which was related to discontinued operations. The Company has no amounts written-off that are still subject to collection enforcement activity as at December 31, 2023. The Company's aging of trade accounts receivable is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 80%;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 398px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; white-space: nowrap;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 9px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 112px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 13px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 6px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 118px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 12px;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,202&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1-30 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;588&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;838&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31-60 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;577&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;660&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;61-90 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;159&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;91-180 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;321&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;180+ Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,108&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 9px; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 112px; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,299&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 13px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 6px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 118px; text-align: right;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;4,288&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 12px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A continuity schedule of the allowance for expected credit losses for the years ended December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at January 1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,385&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current period additions for expected credit losses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(236&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,186&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Write-offs charges against allowance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,282&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;151&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Recoveries collected&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at December 31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,385&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305114135362">
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade accounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,299&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,288&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,385&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;HST/VAT receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,840&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,294&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,950&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,259&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231025124348806"
      unitRef="USD">2299000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055535_1"
      unitRef="USD">4288000</flgc:TradeAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231025124355398"
      unitRef="USD">315000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055535_2"
      unitRef="USD">1385000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055535_3"
      unitRef="USD">1840000</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055535_4"
      unitRef="USD">2294000</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:OtherReceivables
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231025124405358"
      unitRef="USD">126000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055535_5"
      unitRef="USD">62000</us-gaap:OtherReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231025124415141"
      unitRef="USD">3950000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055535_6"
      unitRef="USD">5259000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055535_7"
      unitRef="USD">1300000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="Fxbrl_20240423112350339"
      unitRef="USD">200000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20230101to20231231_usgaapStatementOperatingActivitiesSegmentAxis_usgaapSegmentDiscontinuedOperationsMember"
      decimals="-5"
      id="Fxbrl_20240305210028848"
      unitRef="USD">1100000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <flgc:ScheduleOfCompanyAgingOfTradeAccountsReceivable
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305114350466">
                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 80%;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 398px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; white-space: nowrap;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 9px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 112px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 13px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 6px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 118px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; background-color: #e6efff; text-align: center; width: 12px;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,202&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1-30 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;588&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;838&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31-60 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;577&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;660&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;61-90 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;159&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;91-180 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 9px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 112px; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 6px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 118px; text-align: right;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;321&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;180+ Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 9px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 112px; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 13px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 6px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 118px; text-align: right; background-color: #e6efff;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,108&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 398px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 9px; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 112px; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,299&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 13px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 6px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 118px; text-align: right;"&gt;
                                                &lt;p style="font-size: 10pt; font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;4,288&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; width: 12px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </flgc:ScheduleOfCompanyAgingOfTradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember"
      decimals="-3"
      id="F20231019113055536_9"
      unitRef="USD">218000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember"
      decimals="-3"
      id="Fxbrl_20240314042022094_20231019113055536_9"
      unitRef="USD">1202000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember"
      decimals="-3"
      id="F20231019113055536_10"
      unitRef="USD">588000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember"
      decimals="-3"
      id="Fxbrl_20240314042022096_20231019113055536_10"
      unitRef="USD">838000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember"
      decimals="-3"
      id="F20231019113055536_11"
      unitRef="USD">577000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember"
      decimals="-3"
      id="Fxbrl_20240314042022098_20231019113055536_11"
      unitRef="USD">660000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember"
      decimals="-3"
      id="F20231019113055536_12"
      unitRef="USD">448000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember"
      decimals="-3"
      id="Fxbrl_20240314042022101_20231019113055536_12"
      unitRef="USD">159000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember"
      decimals="-3"
      id="F20231019113055536_13"
      unitRef="USD">401000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember"
      decimals="-3"
      id="Fxbrl_20240314042022104_20231019113055536_13"
      unitRef="USD">321000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember"
      decimals="-3"
      id="F20231019113055536_14"
      unitRef="USD">67000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20221231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember"
      decimals="-3"
      id="Fxbrl_20240314042022107_20231019113055536_14"
      unitRef="USD">1108000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305114324358"
      unitRef="USD">2299000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240314042022108_xbrl_20240305114324358"
      unitRef="USD">4288000</flgc:TradeAccountsReceivable>
    <us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305114452403">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at January 1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,385&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current period additions for expected credit losses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(236&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,186&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Write-offs charges against allowance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,282&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;151&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Recoveries collected&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at December 31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,385&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055536_16"
      unitRef="USD">1385000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20231019113055536_17"
      unitRef="USD">400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055536_18"
      unitRef="USD">236000</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055536_19"
      unitRef="USD">1186000</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsAdditionalCreditLosses>
    <us-gaap:TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055537_20"
      unitRef="USD">1282000</us-gaap:TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance>
    <us-gaap:TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055537_21"
      unitRef="USD">151000</us-gaap:TimeSharingTransactionsDirectWriteOffsChargedAgainstAllowance>
    <us-gaap:InsuranceRecoveries
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055537_22"
      unitRef="USD">24000</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055537_23"
      unitRef="USD">50000</us-gaap:InsuranceRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055537_26"
      unitRef="USD">315000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055537_27"
      unitRef="USD">1385000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055542_12">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;INVENTORY &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory is comprised of the following as at December 31, 2023 and 2022:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,180&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,363&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Finished goods&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;7,328&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;8,508&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8,747&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In the year ended December 31, 2023, $54.9 million of inventory was expensed to cost of sales (2022 - $14.5 million) and write-downs to cost of sales for impairment was $2.7 million (2022 - $0.5 million), with the increase in 2023 due to write-downs related to a flooding incident at a JustCBD facility in Florida and other factors. There were no reversals of previous inventory impairments in the years ended December 31, 2023 or 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305114756087">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; background-color: #e6efff; border-top: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,180&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,363&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Finished goods&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;7,328&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;8,508&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8,747&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231020175304783_20231019113055541_1"
      unitRef="USD">1180000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055541_1"
      unitRef="USD">2363000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231020175304792_20231019113055541_6"
      unitRef="USD">7328000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055541_6"
      unitRef="USD">6384000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231020175304793_20231019113055541_01"
      unitRef="USD">8508000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055541_01"
      unitRef="USD">8747000</us-gaap:InventoryNet>
    <flgc:InventoryExpensedToCostOfSales
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055541_02"
      unitRef="USD">54900000</flgc:InventoryExpensedToCostOfSales>
    <flgc:InventoryExpensedToCostOfSales
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113055541_03"
      unitRef="USD">14500000</flgc:InventoryExpensedToCostOfSales>
    <flgc:WritedownsReversalsOfInventories
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055541_04"
      unitRef="USD">2700000</flgc:WritedownsReversalsOfInventories>
    <flgc:WritedownsReversalsOfInventories
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113055541_05"
      unitRef="USD">500000</flgc:WritedownsReversalsOfInventories>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_20230101to20231231" id="F20231019113055545_0">
                &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;8.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;PROPERTY, PLANT AND EQUIPMENT &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Property, plant and equipment consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span style="color: #ff0000;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span style="color: #ff0000;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Land&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;298&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Buildings&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;696&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Vehicles&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,426&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr style="background-color: #e6efff;"&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;(208&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;847&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,218&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Depreciation expense for the year ended December 31, 2023 was $0.2 million (2022 - $0.2 million) and was recorded in depreciation and amortization in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;During the year ended December 31, 2023, the Company recorded an impairment charge of the remaining value of the property, plant and equipment of Vessel within the House of Brands segment. The amount of $0.2 million (2022 - $nil) is included in "other asset impairments" in the consolidated statements of operations and comprehensive loss. See Note 12 for further discussion.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;As at December 31, 2023, the Company's property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305115502811">
                            &lt;div&gt;
                                &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 80%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span style="color: #ff0000;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span style="color: #ff0000;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Land&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;298&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Buildings&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;696&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Vehicles&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,426&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr style="background-color: #e6efff;"&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;(208&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;847&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,218&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                        </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember"
      decimals="-3"
      id="Fxbrl_20231025120459670"
      unitRef="USD">298000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember"
      decimals="-3"
      id="F20231019113055545_2"
      unitRef="USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember"
      decimals="-3"
      id="Fxbrl_20231025120506459"
      unitRef="USD">78000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember"
      decimals="-3"
      id="F20231019113055545_3"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      decimals="-3"
      id="Fxbrl_20231025120514730"
      unitRef="USD">696000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      decimals="-3"
      id="F20231019113055545_4"
      unitRef="USD">1098000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember"
      decimals="-3"
      id="Fxbrl_20231025120524602"
      unitRef="USD">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember"
      decimals="-3"
      id="F20231019113055546_5"
      unitRef="USD">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231025120534594"
      unitRef="USD">1109000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055545_13"
      unitRef="USD">1426000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231025120626122"
      unitRef="USD">262000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055545_15"
      unitRef="USD">208000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20231025120633690"
      unitRef="USD">847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055546_10"
      unitRef="USD">1218000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055546_11"
      unitRef="USD">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113055546_12"
      unitRef="USD">200000</us-gaap:Depreciation>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055546_13"
      unitRef="USD">200000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="C_20220101to20221231"
      decimals="-6"
      id="F20231019113055546_14"
      unitRef="USD">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:InvestmentTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055561_42">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;INVESTMENTS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at December 31, 2023, the Company's investments consist of common shares and warrants to purchase additional common shares in an early-stage European cannabis company. The Company purchased common shares from the investee during 2021 for Euro 2.0 million ($2.4 million) and purchased its first tranche of warrants from existing investors in exchange for 11,250 common shares of the Company, and obtained a second tranche of warrants from the investee as an inducement to exercise some of the first tranche of warrants. As at December 31, 2023, the Company owns approximately 9.6% of the investee, or approximately 9% on a diluted basis including exercisable warrants of the Company and other investors.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The warrants allowed the holder to purchase one common share of the investee for CAD 0.30 ($0.22) for the first tranche, and CAD 1.00 ($0.74) for the second tranche. The Company did not exercise the warrants and they expired on February 1, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's cost of the investments was recorded based on the fair value of the consideration exchanged as at the respective transaction dates. The investee is not a publicly listed entity and has no active quoted prices for its common shares or warrants. The Company has elected the measurement alternative to record the common share investment at cost and test for impairment. The investment had impairment indicators during 2022 and 2023, and impairments were recorded as indicated in the table below. The Company also considers observable transactions of the common shares for indicators of fair value but there have been none. Cumulative impairment related to the common shares was $2.9 million and the net carrying value was $nil at December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;When impairment indicators were present, the investee common shares were valued considering price to book value and price to tangible book value of the investee (3.6 and 4.8, respectively) as well as comparable guideline publicly traded companies at the time of initial investment. These initial investment multiples were compared to the guideline public company multiples observed as at December 31, 2023 (negligible or nil price to book and price to tangible values), with these updated valuation multiples applied to the investee's estimated book value. The Company also considered the status of the investee's milestones since the purchase date, as well as recent transactions in the European cannabis market for indicators of change in value. The impairment valuation model for the common shares uses Level 3 inputs of the fair value hierarchy.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A schedule of the Company's investments activity is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;

                                &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Financial asset hierarchy level&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Investee common&lt;br/&gt;shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Warrants CAD 0.30&lt;br/&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Warrants CAD 1.00&lt;br/&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Level 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Level 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Level 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,987&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,670&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,257&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,257&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss on changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(591&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(649&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;764&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss on changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The impairment of common shares and loss on changes in fair value appear in the unrealized loss on fair value of investments caption in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The value of the investee common shares appears in the investment line on the consolidated statement of financial position. The value of the warrants appeared in current assets within the prepaid expenses and other accrued assets line on the consolidated statement of financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As a sensitivity assessment to the fair value calculations, a 10% change in the valuation multiples applied to the investee common shares results in a 10% change in the fair value as at December 31, 2023 of less than $0.1 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:InvestmentTextBlock>
    <flgc:PurchaseOfCommonStock
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055561_41"
      unitRef="EUR">2000000</flgc:PurchaseOfCommonStock>
    <flgc:PurchaseOfCommonStock
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055553_0"
      unitRef="USD">2400000</flgc:PurchaseOfCommonStock>
    <flgc:SharesIssuedToPurchaseWarrantsFromExistingInvestors
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="F20231019113055553_1"
      unitRef="Shares">11250</flgc:SharesIssuedToPurchaseWarrantsFromExistingInvestors>
    <flgc:InvestmentDescription contextRef="C_20230101to20231231" id="F20231019113055554_2">the Company owns approximately 9.6% of the investee, or approximately 9% on a diluted basis including exercisable warrants of the Company and other investors.</flgc:InvestmentDescription>
    <flgc:ExercisePriceOfInvestmentWarrants
      contextRef="C_20231231_usgaapInvestmentTypeAxis_flgcFirstTrancheMember"
      decimals="INF"
      id="F20231019113055562_49"
      unitRef="CAD_Per_Share">0.3</flgc:ExercisePriceOfInvestmentWarrants>
    <flgc:ExercisePriceOfInvestmentWarrants
      contextRef="C_20231231_usgaapInvestmentTypeAxis_flgcFirstTrancheMember"
      decimals="INF"
      id="F20231019113055554_3"
      unitRef="USD_Per_Share">0.22</flgc:ExercisePriceOfInvestmentWarrants>
    <flgc:ExercisePriceOfInvestmentWarrants
      contextRef="C_20231231_usgaapInvestmentTypeAxis_flgcSecondTrancheMember"
      decimals="2"
      id="F20231019113055562_50"
      unitRef="CAD_Per_Share">1</flgc:ExercisePriceOfInvestmentWarrants>
    <flgc:ExercisePriceOfInvestmentWarrants
      contextRef="C_20231231_usgaapInvestmentTypeAxis_flgcSecondTrancheMember"
      decimals="2"
      id="F20231019113055562_51"
      unitRef="USD_Per_Share">0.74</flgc:ExercisePriceOfInvestmentWarrants>
    <flgc:CumulativeImpairmentRelatedToCommonShares
      contextRef="C_20231231"
      decimals="-5"
      id="F20231019113055554_4"
      unitRef="USD">2900000</flgc:CumulativeImpairmentRelatedToCommonShares>
    <us-gaap:OtherLongTermInvestments
      contextRef="C_20231231"
      decimals="-6"
      id="F20231019113055554_5"
      unitRef="USD">0</us-gaap:OtherLongTermInvestments>
    <flgc:DescriptionOfImpairment
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240529164218324">the investee common shares were valued considering price to book value and price to tangible book value of the investee (3.6 and 4.8, respectively) as well as comparable guideline publicly traded companies at the time of initial investment. These initial investment multiples were compared to the guideline public company multiples observed as at December 31, 2023 (negligible or nil price to book and price to tangible values), with these updated valuation multiples applied to the investee's estimated book value.</flgc:DescriptionOfImpairment>
    <flgc:ScheduleOfCompanysInvestmentsActivityTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305121221185">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Financial asset hierarchy level&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Investee common&lt;br/&gt;shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Warrants CAD 0.30&lt;br/&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Warrants CAD 1.00&lt;br/&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Level 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Level 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Level 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,987&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,670&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,257&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,257&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss on changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(591&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(649&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;764&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss on changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </flgc:ScheduleOfCompanysInvestmentsActivityTableTextBlock>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember"
      decimals="-3"
      id="F20231019113055555_9"
      unitRef="USD">1987000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember"
      decimals="-3"
      id="F20231019113055555_10"
      unitRef="USD">625000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember"
      decimals="-3"
      id="F20231019113055555_11"
      unitRef="USD">58000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20211231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="F20231019113055556_12"
      unitRef="USD">2670000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember"
      decimals="-3"
      id="F20231019113055557_21"
      unitRef="USD">1257000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember"
      decimals="-3"
      id="F20231019113055557_22"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember"
      decimals="-3"
      id="F20231019113055558_23"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="F20231019113055558_24"
      unitRef="USD">1257000</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember"
      decimals="-3"
      id="F20231019113055558_25"
      unitRef="USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember"
      decimals="-3"
      id="F20231019113055558_26"
      unitRef="USD">-591000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember"
      decimals="-3"
      id="F20231019113055558_27"
      unitRef="USD">-58000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="C_20220101to20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="F20231019113055559_28"
      unitRef="USD">-649000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember"
      decimals="-3"
      id="Fxbrl_20231016175253416_20231019113055555_9"
      unitRef="USD">730000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember"
      decimals="-3"
      id="Fxbrl_20231016175253416_20231019113055555_10"
      unitRef="USD">34000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember"
      decimals="-3"
      id="Fxbrl_20231016175253416_20231019113055555_11"
      unitRef="USD">0</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="Fxbrl_20231016175253416_20231019113055556_12"
      unitRef="USD">764000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember"
      decimals="-3"
      id="F20231019113055559_29"
      unitRef="USD">730000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember"
      decimals="-3"
      id="F20231019113055559_30"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember"
      decimals="-3"
      id="F20231019113055559_31"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="F20231019113055559_32"
      unitRef="USD">730000</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember"
      decimals="-3"
      id="F20231019113055560_33"
      unitRef="USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember"
      decimals="-3"
      id="F20231019113055560_34"
      unitRef="USD">-34000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember"
      decimals="-3"
      id="F20231019113055560_35"
      unitRef="USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="C_20230101to20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="F20231019113055560_36"
      unitRef="USD">-34000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcInvesteeCommonSharesMember"
      decimals="-3"
      id="F20231019113055560_37"
      unitRef="USD">0</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadZeroPointThreeZeroMember"
      decimals="-3"
      id="F20231019113055560_38"
      unitRef="USD">0</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapInvestmentTypeAxis_flgcWarrantsCadOnePointZeroZeroMember"
      decimals="-3"
      id="F20231019113055561_39"
      unitRef="USD">0</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="F20231019113055561_40"
      unitRef="USD">0</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306015948787">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;10.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;ASSET ACQUISITIONS AND BUSINESS COMBINATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Original Hemp asset acquisition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On March 1, 2023, the Company completed its acquisition of all the assets operating under the brand "Original Hemp". The Company analyzed the acquisition under ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, determining Original Hemp did not meet the definition of a business as it did not have inputs, processes, and outputs in place that constituted a business under Topic 805. As a result, the transaction has been accounted for as an asset acquisition whereby all of the assets acquired and liabilities assumed are assigned a carrying amount based on relative fair values. Total purchase consideration was $0.3 million and will consist of paying a portion of net profits not to exceed $0.6 million. The assets acquired included $0.1 million of Inventory and $0.2 million of customer relationships.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Since the acquisition date through December 31, 2023, Original Hemp revenue was $0.2 million with net income and comprehensive income of $0.1 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company was not able to obtain reliable financial records for the period from January 1, 2023 through the acquisition date, March 1, 2023. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Franchise Global Health Inc. ("FGH") business combination&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On December 23, 2022, the Company completed its acquisition of all the issued and outstanding common shares (the "Franchise Common Shares") of FGH, a corporation existing under the laws of the Province of British Columbia, by way of a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). FGH, through its wholly owned subsidiaries, is a multi-national operator in the medical cannabis and pharmaceutical industry with principal operations in Germany. The Company acquired FGH to expand its product offerings, accelerate its revenue growth, expand its customer and distribution capabilities in Germany and to improve synergies and cost savings.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pursuant to the Arrangement Agreement, at completion of the Arrangement, Flora acquired the Franchise Common Shares in exchange for 2,176,297 of Flora's common shares, no par value (the "Flora Shares"), for total purchase consideration of $9.8 million. The issuance of the Flora Shares in exchange for the Franchise Common Shares was, subject to applicable securities laws, exempt from the registration requirements of (i) the Securities Act of 1933, as amended, pursuant to the exemption provided by Section 3(a)(10) thereof and (ii) applicable U.S. state securities laws. Notwithstanding the foregoing, in accordance with the terms set forth in the Arrangement Agreement, all Flora Shares delivered to the former shareholders of FGH bear a restrictive legend and may not be sold for a period of ninety (90) days following the closing of the Arrangement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(Thousands of United States dollars)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,271&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Indemnity receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,415&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prepaid assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;452&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,102&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,716&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;18,959&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade payables and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,245&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current portion of debt&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,062&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Long term lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,717&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(9,143&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total net assets acquired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,816&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As part of the acquisition terms, Clifford Starke, the Company's current Chief Executive Officer and a Director and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $5.0 million. A total of $3.4 million of liabilities were recognized in the trade payables and accrued liabilities of FGH on the date of acquisition that were subject to this indemnification obligation. The Company believes it will be fully indemnified by the current CEO of Flora, and, as such, has recorded $3.4 million of indemnification receivables. The indemnified losses include:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.&lt;span style="display: inline-block; width: 10.5pt;"&gt;&#160;&lt;/span&gt;any losses that are related to the ownership or the operation of FGH and its Canadian subsidiaries, in each case prior to the closing of the Arrangement, that are unknown to the Company and that: (i) have not been disclosed or accounted for in FGH filings; or (ii) have not been disclosed in the FGH Disclosure Letter, in each case as at the date of the Arrangement Agreement;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.&lt;span style="display: inline-block; width: 10.5pt;"&gt;&#160;&lt;/span&gt;any losses that may arise from amounts owed or that may become owed to certain persons or in respect of certain matters identified in the indemnity agreement, as amended; and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-left: 36pt; text-indent: -18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3.&lt;span style="display: inline-block; width: 10.5pt;"&gt;&#160;&lt;/span&gt;any fraud, intentional misrepresentation, willful breach, or willful misconduct on the part of FGH or any other entity identified in the indemnity agreement of any of the foregoing in connection with the indemnity agreement or the Arrangement Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The intangible assets of $6.1 million are comprised of the following categories and estimated useful lives: supplier relationships of $2.4 million for five years, customer relationships of $2.3 million for five years, and licenses of $1.4 million for five years. The Company does not expect the goodwill and intangible asset values to be deductible for Canadian income tax purposes. The goodwill is assigned to the commercial and wholesale segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;If FGH was acquired at January 1, 2022, the combined revenue and net loss of FGH and the Company would have increased approximately $40.3 million and $19.0 million, respectively (unaudited).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company incurred acquisition related costs of $0.3 million which were expensed as incurred in professional fees on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Just Brands LLC and High Roller Private Label LLC (collectively "JustCBD") business combination&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On February 24, 2022, Flora Growth U.S. Holdings Corp., a wholly owned subsidiary of the Company, completed the acquisition of 100% of the outstanding equity interests in each of (i) Just Brands LLC and (ii) High Roller Private Label LLC for total purchase consideration of $37.0 million. JustCBD is a manufacturer and distributor of consumable cannabinoid products, including gummies, tinctures, vape cartridges, and creams. JustCBD is based in Florida in the United States and was formed in 2017. The Company acquired JustCBD to expand its product offerings, accelerate its revenue growth, expand its customer and distribution capabilities in the United States and for the acquisition of human capital through JustCBD's management team.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The purchase consideration was comprised of (i) $16.0 million of cash, less $0.2 million returned to the Company in August 2022 due to final calculated closing working capital falling short of the target working capital, (ii) 475,000 common shares of the Company valued at $14.7 million, inclusive of a 15% fair value discount for the required six-month holding period of the shares, and (iii) $4.0 million of contingent purchase consideration. The contingent purchase consideration is based on a clause in the purchase agreement that provides that if at any time during the 24 months following the acquisition date, the five-day volume weighted average price ("VWAP") per share of the Company's common shares as quoted on the Nasdaq Capital Market fails to equal or exceed $100.00, then the Company shall issue a number of additional common shares to the sellers equal to the difference between (x) a fraction, the numerator of which is $47.5 million and the denominator of which is the highest five day VWAP at any point during the 24 months following the closing and (y) the 475,000 common shares delivered to the sellers at the closing. In no event shall the Company be required to issue more than 182,500 common shares unless, if required by applicable law, it shall have obtained the consent of the Company's shareholders to do so. In the event the Company is required to deliver in excess of 182,500 shares to the sellers ("Excess Shares") and the Company shall not have obtained shareholder consent, if required, the Company may deliver cash to the sellers in lieu of such Excess Shares determined by a formula set forth in the purchase agreement. The contingent purchase consideration was classified as a financial liability within the contingent purchase considerations line on the statement of financial position as the Company may be required to settle any amounts due in cash instead of common shares if the Company's common shareholders do not provide requisite shareholder approval to issue additional common shares. It is now included in the current portion of contingent purchase consideration&#160;line on the statement of financial position as the settlement date is within the next 12 months.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The fair value of the contingent purchase consideration at February 24, 2022 was determined using a Monte Carlo simulation incorporating Brownian motion with 100,000 trials through a binomial model. The significant inputs to the valuation included the two-year time period, the Company's closing share price at February 24, 2022 ($36.40), estimated Company common share volatility (100%), and risk-free rate of 1.5% to discount the ending result to present value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The fair value of the contingent purchase consideration at December 31, 2023 was determined using a simplified calculation because the end of the 24 month period after the acquisition date is within two months after the reporting date. The calculation took the expected shares to be issued (632,484) multiplied by the Company's closing share price at December 31, 2023 ($1.35). The Company determined that the balance of this contingent consideration at December 31, 2023 was $0.9 million, with the $1.8 million decrease in the balance from December 31, 2022 recorded in the unrealized (gain) loss from changes in fair value caption in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(Thousands of United States dollars)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;975&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,534&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;540&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;536&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                                &lt;p style="margin-top: 0pt; margin-bottom: 10pt; font-family: Times New Roman,Times,serif; text-align: left;"&gt;&#160;&lt;/p&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;772&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Intangible asset&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,533&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;24,898&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;38,450&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade payables and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(2,273&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(644&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Provision for sales tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(982&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(4,022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total net assets acquired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;34,428&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The fair value of the trade receivables reflects a $0.3 million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. Since the acquisition date through December 31, 2022, JustCBD revenue was $26.4 million with net loss and comprehensive loss of $6.5 million. The acquired provision for sales tax is discussed at Note 19 below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The intangible assets of $4.5 million are comprised of the following categories and estimated useful lives: tradenames of $3.1 million for eight to nine years, customer relationships of $1.2 million for five to seven years, and know-how of $0.2 million for three years. The Company expects the goodwill and intangible asset values to be deductible for United States income tax purposes. The goodwill is assigned to the house of brands segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;If JustCBD was acquired at January 1, 2022, the combined revenue and net loss of JustCBD and the Company would have increased approximately $5.2 million and $1.6 million, respectively (unaudited).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company incurred acquisition related costs of $0.6 million which were expensed as incurred in professional fees on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;No Cap Hemp Co. ("No Cap") business combination&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On July 20, 2022, Just Brands LLC., a wholly owned subsidiary of the Company, acquired certain assets, assumed certain liabilities, retained certain employees and processes (together the "purchased assets") of No Cap for total purchase consideration of $0.9 million. No Cap is a manufacturer and distributor of high quality and affordable CBD products. No Cap is based in Florida in the United States and was formed in 2017. Just Brands LLC acquired No Cap to expand its product offerings and accelerate its revenue growth.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As consideration for the purchased assets of No Cap, Just Brands LLC will pay an amount equal to 10% of the sales of No Cap until such a time that Just Brands LLC will have paid a total of $2.0 million. Also on July 20, 2022, Just Brands LLC advanced $0.2 million to the former owners of No Cap. This $0.2 million will be settled prior to and in the same manner as the consideration for the purchased assets. As these entire amounts are considered contingent consideration, it was valued using discounted cash flow models utilizing two different rates, high and low. The significant inputs to the original valuation included the estimated nine-year time period to accumulate the $2.0 million maximum payment and discount rates of 23.5%, high, and 14.3%, low, to estimate the present value of the future cash outflows. The resulting acquisition date fair value of $0.9 million contingent purchase consideration is classified within the contingent purchase considerations line on the statement of financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company plans to discontinue the No Cap brand during fiscal 2024. As such, the Company determined that the balance of this contingent consideration at December 31, 2023 was $nil, with the $0.9 million decrease in the balance from December 31, 2022 recorded in the unrealized (gain) loss from changes in fair value caption in the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The purchase is accounted for as a business combination with amounts recognized as at the acquisition date for each major class of assets acquired and liabilities assumed are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;

                            &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; border-top: 1.5pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(Thousands of United States dollars)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-top: 1.5pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff; border-top: 1.5pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-top: 1.5pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;725&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr style="background-color: #e6efff;"&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;417&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,173&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr style="background-color: #e6efff;"&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr style="background-color: #e6efff;"&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade payables and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(272&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(272&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr style="background-color: #e6efff;"&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total net assets acquired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The fair value of the trade receivables reflects a $0.2 million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. Since the acquisition date through December 31, 2022, No Cap revenue was $0.6 million with net income and comprehensive loss of $0.1 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company expects the goodwill to be deductible for Unites States income tax purposes. The goodwill is assigned to the house of brands segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;If No Cap was acquired at January 1, 2022, the combined revenue of No Cap and the Company would have increased approximately $1.9 million, and the combined net loss would have decreased by $1.0 million (unaudited). &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Acquisition of Minority interests&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On January 18, 2022, the Company acquired the remaining 13% of the outstanding equity interests in Flora Beauty LLC from its minority shareholder in exchange for 5,000 common shares of the Company and a stock option exercisable for up to 2,500 common shares of the Company at an exercise price of $34.00 per share that expire five years from the date of the grant. The Company dissolved Flora Beauty LLC during the year ended December 31, 2023. See Note 2.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On January 31, 2022, the Company completed its acquisition of Flora Med S.A.S by acquiring the remaining 10% of the equity interests in Flora Med S.A.S. from its minority shareholders in exchange for 1,514 common shares of the Company. The Company sold Flora Med S.A.S. as part of the Share Purchase Agreement with Lisan on July 5, 2023. See Note 5.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember"
      decimals="-5"
      id="Fxbrl_20240305221837012"
      unitRef="USD">300000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <flgc:MaximumPortionOfNetProfitsPayable
      contextRef="C_20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember"
      decimals="-5"
      id="Fxbrl_20240305221843612"
      unitRef="USD">600000</flgc:MaximumPortionOfNetProfitsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="C_20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember"
      decimals="-5"
      id="Fxbrl_20240305221846667"
      unitRef="USD">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships
      contextRef="C_20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember"
      decimals="-5"
      id="Fxbrl_20240305221849411"
      unitRef="USD">200000</flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationships>
    <us-gaap:Revenues
      contextRef="C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember"
      decimals="-5"
      id="Fxbrl_20240305222042371"
      unitRef="USD">200000</us-gaap:Revenues>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20230228to20230301_usgaapBusinessAcquisitionAxis_flgcOriginalHempAssetAcquisitionMember"
      decimals="-5"
      id="Fxbrl_20240305222104514"
      unitRef="USD">100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20221201to20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="INF"
      id="F20231019113055630_144"
      unitRef="Shares">2176297</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_20221201to20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113055573_0"
      unitRef="USD">9800000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      id="Fxbrl_20240306020236137">
                            &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(Thousands of United States dollars)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,271&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Indemnity receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,415&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prepaid assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;452&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,102&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,716&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;18,959&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade payables and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,245&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current portion of debt&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,062&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Long term lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,717&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(9,143&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total net assets acquired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,816&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055574_1"
      unitRef="USD">730000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055574_2"
      unitRef="USD">2271000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055575_3"
      unitRef="USD">2019000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055575_4"
      unitRef="USD">3415000</flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsIndemnityReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055575_5"
      unitRef="USD">139000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055576_6"
      unitRef="USD">452000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055576_7"
      unitRef="USD">115000</flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055630_143"
      unitRef="USD">6102000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055576_8"
      unitRef="USD">3716000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055577_9"
      unitRef="USD">18959000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055577_10"
      unitRef="USD">6245000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055577_11"
      unitRef="USD">98000</flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055578_12"
      unitRef="USD">1062000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055578_13"
      unitRef="USD">21000</flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedNoncurrentLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055578_14"
      unitRef="USD">1717000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055579_15"
      unitRef="USD">9143000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-3"
      id="F20231019113055579_16"
      unitRef="USD">9816000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <flgc:LiabilitiesAmount
      contextRef="C_20221223_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="Fxbrl_20240306023257362"
      unitRef="USD">5000000</flgc:LiabilitiesAmount>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="Fxbrl_20240306023300330"
      unitRef="USD">3400000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:NontradeReceivables
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="Fxbrl_20240306023305966"
      unitRef="USD">3400000</us-gaap:NontradeReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113055584_22"
      unitRef="USD">6100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcSupplierRelationshipsMember"
      decimals="-5"
      id="F20231019113055584_23"
      unitRef="USD">2400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcCustomersRelationshipsMember"
      decimals="-5"
      id="F20231019113055584_24"
      unitRef="USD">2300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20221223_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapLicenseMember"
      decimals="-5"
      id="F20231019113055585_25"
      unitRef="USD">1400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Revenues
      contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113055585_26"
      unitRef="USD">40300000</us-gaap:Revenues>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113055585_27"
      unitRef="USD">19000000</us-gaap:ProfitLoss>
    <us-gaap:ProfessionalFees
      contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113055631_145"
      unitRef="USD">300000</us-gaap:ProfessionalFees>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="2"
      id="F20231019113055586_28"
      unitRef="Pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055586_29"
      unitRef="USD">37000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055586_30"
      unitRef="USD">16000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <flgc:CashConsiderationReturned
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055587_31"
      unitRef="USD">200000</flgc:CashConsiderationReturned>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="INF"
      id="Fxbrl_20240306024132327"
      unitRef="Shares">475000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055587_32"
      unitRef="USD">14700000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <flgc:FairValueDiscount
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="2"
      id="Fxbrl_20240306024325016"
      unitRef="Pure">0.15</flgc:FairValueDiscount>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055587_33"
      unitRef="USD">4000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="2"
      id="Fxbrl_20240529182337490"
      unitRef="CAD_Per_Share">100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="Fxbrl_20240529184355801"
      unitRef="USD">47500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <flgc:CommonSharesDeliveredToTheSellers
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="INF"
      id="Fxbrl_20240529195114226"
      unitRef="Shares">475000</flgc:CommonSharesDeliveredToTheSellers>
    <flgc:DescriptionOfShares
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      id="Fxbrl_20240529195346798">In no event shall the Company be required to issue more than 182,500 common shares unless, if required by applicable law, it shall have obtained the consent of the Company's shareholders to do so. In the event the Company is required to deliver in excess of 182,500</flgc:DescriptionOfShares>
    <flgc:NumberOfTrials
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="0"
      id="F20231019113055589_38"
      unitRef="Trial">100000</flgc:NumberOfTrials>
    <us-gaap:SharePrice
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="INF"
      id="F20231019113055589_39"
      unitRef="USD_Per_Share">36.4</us-gaap:SharePrice>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="2"
      id="F20231019113055590_40"
      unitRef="Pure">1</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="C_20220201to20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="3"
      id="F20231019113055590_41"
      unitRef="Pure">0.015</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="INF"
      id="F20231019113055591_42"
      unitRef="Shares">632484</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SharePrice
      contextRef="C_20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="INF"
      id="F20231019113055591_43"
      unitRef="CAD_Per_Share">1.35</us-gaap:SharePrice>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055592_46"
      unitRef="USD">900000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <flgc:UnrealizedLossesOnSecurities
      contextRef="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055592_47"
      unitRef="USD">1800000</flgc:UnrealizedLossesOnSecurities>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      id="Fxbrl_20240306020311588">
                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(Thousands of United States dollars)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;975&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,534&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;540&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;536&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                                &lt;p style="margin-top: 0pt; margin-bottom: 10pt; font-family: Times New Roman,Times,serif; text-align: left;"&gt;&#160;&lt;/p&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;772&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 1.5pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Intangible asset&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,533&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;24,898&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;38,450&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade payables and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(2,273&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(644&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Provision for sales tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(982&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(4,022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total net assets acquired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;34,428&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                        </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055593_48"
      unitRef="USD">535000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055593_49"
      unitRef="USD">975000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055593_50"
      unitRef="USD">5534000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055594_51"
      unitRef="USD">540000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055594_52"
      unitRef="USD">536000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055594_53"
      unitRef="USD">772000</flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055595_54"
      unitRef="USD">127000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055595_55"
      unitRef="USD">4533000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055595_56"
      unitRef="USD">24898000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055596_57"
      unitRef="USD">38450000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055596_58"
      unitRef="USD">2273000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055596_59"
      unitRef="USD">644000</flgc:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedCurrentLeaseLiabilities>
    <flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055597_60"
      unitRef="USD">982000</flgc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProvisionForSalesTax>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055597_61"
      unitRef="USD">24000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055597_62"
      unitRef="USD">99000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055598_63"
      unitRef="USD">4022000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-3"
      id="F20231019113055598_64"
      unitRef="USD">34428000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="Fxbrl_20240306030912336"
      unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:Revenues
      contextRef="C_20220226to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055602_66"
      unitRef="USD">26400000</us-gaap:Revenues>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20220226to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055602_67"
      unitRef="USD">6500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="Fxbrl_20240306040354808"
      unitRef="USD">4500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember"
      decimals="-5"
      id="F20231019113055603_68"
      unitRef="USD">3100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcCustomersRelationshipsMember"
      decimals="-5"
      id="F20231019113055603_69"
      unitRef="USD">1200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="C_20220224_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcKnowHowMember"
      decimals="-5"
      id="F20231019113055603_70"
      unitRef="USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Revenues
      contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055604_71"
      unitRef="USD">5200000</us-gaap:Revenues>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055604_72"
      unitRef="USD">1600000</us-gaap:ProfitLoss>
    <us-gaap:ProfessionalFees
      contextRef="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcJustBrandsLlcAndHighRollerPrivateLabelLlcMember"
      decimals="-5"
      id="F20231019113055604_73"
      unitRef="USD">600000</us-gaap:ProfessionalFees>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="F20231019113055605_74"
      unitRef="USD">900000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <flgc:PurchaseConsiderationPercentageOfSales
      contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="2"
      id="F20231019113055605_75"
      unitRef="Pure">0.10</flgc:PurchaseConsiderationPercentageOfSales>
    <flgc:PurchaseConsiderationPercentageOfSalesAmountPayable
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="F20231019113055605_76"
      unitRef="USD">2000000</flgc:PurchaseConsiderationPercentageOfSalesAmountPayable>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="F20231019113055606_77"
      unitRef="USD">200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="Fxbrl_20240306133317531"
      unitRef="USD">200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <flgc:DescriptionOfDiscountRates
      contextRef="C_20220701to20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      id="Fxbrl_20240529202632953">the $2.0 million maximum payment and discount rates of 23.5%, high, and 14.3%, low, to estimate the present value of the future cash outflows. The resulting acquisition date fair value of $0.9 million</flgc:DescriptionOfDiscountRates>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-6"
      id="Fxbrl_20240306041301302"
      unitRef="USD">0</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <flgc:UnrealizedLossesOnSecurities
      contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="Fxbrl_20240306041246176"
      unitRef="USD">900000</flgc:UnrealizedLossesOnSecurities>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_20230101to20231231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      id="Fxbrl_20240306020339673">
                            &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; border-top: 1.5pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(Thousands of United States dollars)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-top: 1.5pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff; border-top: 1.5pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-top: 1.5pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;725&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr style="background-color: #e6efff;"&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;417&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,173&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr style="background-color: #e6efff;"&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr style="background-color: #e6efff;"&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade payables and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(272&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(272&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr style="background-color: #e6efff;"&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total net assets acquired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-3"
      id="F20231019113055614_101"
      unitRef="USD">31000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-3"
      id="F20231019113055614_102"
      unitRef="USD">725000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:Goodwill
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-3"
      id="F20231019113055616_108"
      unitRef="USD">417000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-3"
      id="F20231019113055617_109"
      unitRef="USD">1173000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-3"
      id="F20231019113055617_110"
      unitRef="USD">272000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-3"
      id="F20231019113055620_113"
      unitRef="USD">272000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-3"
      id="F20231019113055620_114"
      unitRef="USD">901000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_20220720_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="Fxbrl_20240306041443838"
      unitRef="USD">200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="Fxbrl_20240306041600591"
      unitRef="USD">600000</us-gaap:Revenues>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20220101to20221231_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="Fxbrl_20240306041603738"
      unitRef="USD">100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:Revenues
      contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="Fxbrl_20240306041959666"
      unitRef="USD">1900000</us-gaap:Revenues>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcNoCapHempCoMember"
      decimals="-5"
      id="Fxbrl_20240306042004368"
      unitRef="USD">1000000</us-gaap:ProfitLoss>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember"
      decimals="2"
      id="F20231019113055626_132"
      unitRef="Pure">0.13</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20220101to20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember"
      decimals="INF"
      id="F20231019113055626_133"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember"
      decimals="INF"
      id="F20231019113055627_134"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20220118_usgaapBusinessAcquisitionAxis_flgcFloraBeautyMember"
      decimals="INF"
      id="F20231019113055627_135"
      unitRef="USD_Per_Share">34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_20220131_usgaapBusinessAcquisitionAxis_flgcFloraMedSasMember"
      decimals="2"
      id="F20231019113055628_136"
      unitRef="Pure">0.10</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20220101to20220131_usgaapBusinessAcquisitionAxis_flgcFloraMedSasMember"
      decimals="INF"
      id="F20231019113055628_137"
      unitRef="Shares">1514</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055884_221">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;INTANGIBLE ASSETS AND GOODWILL &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A continuity of intangible assets for the years ended December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;License&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Customer&lt;br/&gt;Relationships&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Trademarks&lt;br/&gt;and Brands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Non-&lt;br/&gt;Compete&lt;br/&gt;Agreements&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,570&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,300&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,190&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Acquired through business combinations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,397&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,945&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,063&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,031&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;39,666&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(128&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(25,073&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(25,201&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,469&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,515&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,153&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,530&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,190&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,633&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;43,490&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;322&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;583&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;573&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;397&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,941&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;618&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;621&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,122&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Foreign Currency translation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(257&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net book value at December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1,402&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7,184&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;4,517&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3,909&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;727&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;23,372&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;41,111&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;div&gt;
                                        &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                        &lt;div&gt;

                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;In Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;License&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Customer and&lt;br/&gt;Supplier&lt;br/&gt;Relationships&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Trademarks&lt;br/&gt;and Brands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Non-&lt;br/&gt;Compete&lt;br/&gt;Agreements&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,469&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;7,515&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;5,153&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;4,530&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,190&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;23,633&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;43,490&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(1,216&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(6,502&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(3,249&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(3,432&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(529&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(23,372&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(38,300&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;253&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,207&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xbrl_20231101234502607"&gt;1,904&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;661&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xbrl_20231101234536599"&gt;5,384&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;618&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;621&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2,122&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;916&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2,119&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;272&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,264&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,132&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;912&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;661&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xbrl_20231101234621352"&gt;4,241&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Foreign Currency translation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(197&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Net book value at December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;760&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;186&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;946&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;

                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's intangible asset additions in 2022 primarily consist of assets acquired as part of the February 2022 purchase of JustCBD and the December 2022 purchase of FGH (Note 10). Information regarding the significant JustCBD intangible assets within the indicated categories of the table above is as follows as at December 31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="width: 4%; vertical-align: middle;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="width: 4%; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: top;"&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Tradenames: carrying amount $0.5 million with 74 months of remaining amortization periods&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's intangible asset additions in 2023 primarily consist of customer relationships acquired as part of the March 2023 purchase of Original Hemp (Note 10). These customer relationships were fully impaired and their carrying amount at December 31, 2023 was $nil.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The gross cost of the intangible assets is amortized over their estimated useful lives, as the Company does not expect the assets to have significant residual value for any of the asset classes. The weighted average amortization period at December 31, 2023 by asset class subject to amortization is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                        &lt;div&gt;
                                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trademarks and brands &lt;span style="display: inline-block; width: 42.5pt;"&gt;&#160;&lt;/span&gt;
                                                        6.1 years
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Patents &lt;span style="display: inline-block; width: 107.31pt;"&gt;&#160;&lt;/span&gt;
                                                        6.8 years
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total &lt;span style="display: inline-block; width: 114.99pt;"&gt;&#160;&lt;/span&gt;
                                                        6.2&#160;years
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;

                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain trademarks have renewal or extension terms available, with a weighted average of 6.1 years remaining before the next renewal or extension is due at December 31, 2023. The Company expenses such costs as incurred. The Company's trademarks and brands are registered to protect the assets from use by others, and cash flows of the related reporting units and asset groups could be negatively impact if the Company did not successfully renew them.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2023, the estimated aggregate amortization expense for each of the next five years is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;

                            &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 20%; border-collapse: collapse; font-size: 10pt;"&gt;
                                        &lt;tr&gt;
                                            &lt;td colspan="2" style="text-align: left; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;

                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's goodwill is assigned to the following reporting units for the years ended December 31, 2022 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Vessel &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;JustCBD &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;FGH &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gross goodwill recorded prior to December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment recorded prior to December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net book value as at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Acquired through business combinations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;25,315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,716&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(5,398&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(25,073&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Foreign exchange impacts&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(277&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(261&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net book value as at December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,640&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,732&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,372&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(19,640&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(3,732&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(23,372&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net book value as at December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="C_20230101to20231231" id="F20231019113055650_0">
                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;License&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Customer&lt;br/&gt;Relationships&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Trademarks&lt;br/&gt;and Brands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Non-&lt;br/&gt;Compete&lt;br/&gt;Agreements&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,570&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,300&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,190&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Acquired through business combinations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,397&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,945&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,063&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,031&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;39,666&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(128&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(25,073&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(25,201&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,469&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,515&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,153&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,530&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,190&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,633&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;43,490&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;322&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;583&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;573&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;397&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,941&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;618&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;621&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,122&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Foreign Currency translation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(257&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net book value at December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1,402&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7,184&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;4,517&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3,909&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;727&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;23,372&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;41,111&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;div&gt;
                                        &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                        &lt;div&gt;

                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 9pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;In Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;License&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Customer and&lt;br/&gt;Supplier&lt;br/&gt;Relationships&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Trademarks&lt;br/&gt;and Brands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Non-&lt;br/&gt;Compete&lt;br/&gt;Agreements&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,469&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;7,515&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;5,153&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;4,530&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,190&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;23,633&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;43,490&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(1,216&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(6,502&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(3,249&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(3,432&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(529&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(23,372&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(38,300&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;253&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,207&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xbrl_20231101234502607"&gt;1,904&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;661&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xbrl_20231101234536599"&gt;5,384&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 7%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;618&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;621&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2,122&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;916&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2,119&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;At December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;272&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,264&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,132&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;912&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;661&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xbrl_20231101234621352"&gt;4,241&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Foreign Currency translation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(261&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(197&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Net book value at December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;760&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;186&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 9pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;946&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055651_1"
      unitRef="USD">200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055654_2"
      unitRef="USD">1570000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055655_3"
      unitRef="USD">2090000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055656_4"
      unitRef="USD">4300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055657_5"
      unitRef="USD">1190000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055658_6"
      unitRef="USD">19675000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20211231"
      decimals="-3"
      id="F20231019113055659_7"
      unitRef="USD">29025000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055671_15"
      unitRef="USD">1397000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055672_16"
      unitRef="USD">5945000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055673_17"
      unitRef="USD">3063000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055673_18"
      unitRef="USD">230000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055674_19"
      unitRef="USD">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055675_20"
      unitRef="USD">29031000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055676_21"
      unitRef="USD">39666000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055677_22"
      unitRef="USD">-128000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055678_23"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055679_24"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055680_25"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055681_26"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055682_27"
      unitRef="USD">-25073000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055684_28"
      unitRef="USD">-25201000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055685_29"
      unitRef="USD">1469000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055686_30"
      unitRef="USD">7515000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055687_31"
      unitRef="USD">5153000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055688_32"
      unitRef="USD">4530000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055689_33"
      unitRef="USD">1190000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055689_34"
      unitRef="USD">23633000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055690_35"
      unitRef="USD">43490000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055691_36"
      unitRef="USD">6000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055692_37"
      unitRef="USD">26000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055693_38"
      unitRef="USD">35000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055694_39"
      unitRef="USD">48000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055695_40"
      unitRef="USD">66000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20211231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055698_41"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20211231"
      decimals="-3"
      id="F20231019113055698_42"
      unitRef="USD">181000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055699_43"
      unitRef="USD">66000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055700_44"
      unitRef="USD">322000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055701_45"
      unitRef="USD">583000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055702_46"
      unitRef="USD">573000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055703_47"
      unitRef="USD">397000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055704_48"
      unitRef="USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055705_49"
      unitRef="USD">1941000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055706_50"
      unitRef="USD">72000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055707_51"
      unitRef="USD">348000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055708_52"
      unitRef="USD">618000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055709_53"
      unitRef="USD">621000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055712_54"
      unitRef="USD">463000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055713_55"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055714_56"
      unitRef="USD">2122000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055715_57"
      unitRef="USD">-5000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055716_58"
      unitRef="USD">-17000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055717_59"
      unitRef="USD">18000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055718_60"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055718_61"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055719_62"
      unitRef="USD">261000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055720_63"
      unitRef="USD">257000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055721_64"
      unitRef="USD">1402000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055722_65"
      unitRef="USD">7184000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055723_66"
      unitRef="USD">4517000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055726_67"
      unitRef="USD">3909000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055727_68"
      unitRef="USD">727000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055728_69"
      unitRef="USD">23372000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055728_70"
      unitRef="USD">41111000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055729_71"
      unitRef="USD">1469000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055730_72"
      unitRef="USD">7515000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055731_73"
      unitRef="USD">5153000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055732_74"
      unitRef="USD">4530000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055733_75"
      unitRef="USD">1190000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055734_76"
      unitRef="USD">23633000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055735_77"
      unitRef="USD">43490000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <flgc:FiniteLivedIntangibleAssetsAdditions
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="Fxbrl_20240305134234036_20231019113055744_85"
      unitRef="USD">0</flgc:FiniteLivedIntangibleAssetsAdditions>
    <flgc:FiniteLivedIntangibleAssetsAdditions
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="Fxbrl_20240305134234036_20231019113055745_86"
      unitRef="USD">194000</flgc:FiniteLivedIntangibleAssetsAdditions>
    <flgc:FiniteLivedIntangibleAssetsAdditions
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="Fxbrl_20240305134234036_20231019113055746_87"
      unitRef="USD">0</flgc:FiniteLivedIntangibleAssetsAdditions>
    <flgc:FiniteLivedIntangibleAssetsAdditions
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="Fxbrl_20240305134234036_20231019113055747_88"
      unitRef="USD">0</flgc:FiniteLivedIntangibleAssetsAdditions>
    <flgc:FiniteLivedIntangibleAssetsAdditions
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="Fxbrl_20240305134234036_20231019113055747_89"
      unitRef="USD">0</flgc:FiniteLivedIntangibleAssetsAdditions>
    <flgc:FiniteLivedIntangibleAssetsAdditions
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="Fxbrl_20240305134234036_20231019113055748_90"
      unitRef="USD">0</flgc:FiniteLivedIntangibleAssetsAdditions>
    <flgc:FiniteLivedIntangibleAssetsAdditions
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305134234036_20231019113055749_91"
      unitRef="USD">194000</flgc:FiniteLivedIntangibleAssetsAdditions>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055744_85"
      unitRef="USD">-1216000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055745_86"
      unitRef="USD">-6502000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055746_87"
      unitRef="USD">-3249000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055747_88"
      unitRef="USD">-3432000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055747_89"
      unitRef="USD">-529000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055748_90"
      unitRef="USD">-23372000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055749_91"
      unitRef="USD">-38300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="Fxbrl_20231101234452936"
      unitRef="USD">253000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="Fxbrl_20231101234457312"
      unitRef="USD">1207000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055750_92"
      unitRef="USD">1098000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055753_93"
      unitRef="USD">661000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055754_94"
      unitRef="USD">261000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055755_95"
      unitRef="USD">72000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055756_96"
      unitRef="USD">348000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055756_97"
      unitRef="USD">618000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055757_98"
      unitRef="USD">621000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055758_99"
      unitRef="USD">463000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055759_100"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055760_101"
      unitRef="USD">2122000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055761_102"
      unitRef="USD">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055762_103"
      unitRef="USD">916000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055763_104"
      unitRef="USD">514000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055764_105"
      unitRef="USD">291000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055766_106"
      unitRef="USD">198000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055767_107"
      unitRef="USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055768_108"
      unitRef="USD">2119000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="Fxbrl_20231101234559711"
      unitRef="USD">272000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="Fxbrl_20231101234603959"
      unitRef="USD">1264000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="Fxbrl_20231101234608343"
      unitRef="USD">1132000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="Fxbrl_20231101234612431"
      unitRef="USD">912000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="Fxbrl_20231101234617111"
      unitRef="USD">661000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055769_109"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055770_110"
      unitRef="USD">-19000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055771_111"
      unitRef="USD">-57000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055772_112"
      unitRef="USD">12000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055773_113"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055774_114"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055775_115"
      unitRef="USD">261000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055775_116"
      unitRef="USD">197000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcLicensesMember"
      decimals="-3"
      id="F20231019113055776_117"
      unitRef="USD">0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-3"
      id="F20231019113055777_118"
      unitRef="USD">0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20231019113055779_119"
      unitRef="USD">760000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20231019113055780_120"
      unitRef="USD">186000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapNoncompeteAgreementsMember"
      decimals="-3"
      id="F20231019113055781_121"
      unitRef="USD">0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapGoodwillMember"
      decimals="-3"
      id="F20231019113055782_122"
      unitRef="USD">0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055783_123"
      unitRef="USD">946000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-5"
      id="F20231019113055794_134"
      unitRef="USD">500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTradenamesMember_usgaapReportingUnitAxis_flgcJustCBDMember"
      id="F20231019113055795_135">P74M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapCustomerRelationshipsMember"
      decimals="-6"
      id="F20231019113055785_125"
      unitRef="USD">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <flgc:ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306153622550">
                                        &lt;div&gt;
                                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trademarks and brands &lt;span style="display: inline-block; width: 42.5pt;"&gt;&#160;&lt;/span&gt;
                                                        6.1 years
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Patents &lt;span style="display: inline-block; width: 107.31pt;"&gt;&#160;&lt;/span&gt;
                                                        6.8 years
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total &lt;span style="display: inline-block; width: 114.99pt;"&gt;&#160;&lt;/span&gt;
                                                        6.2&#160;years
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;
                                    </flgc:ScheduleOfWeightedAverageAmortizationPeriodOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      id="Fxbrl_20240306153012620">P6Y1M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      id="Fxbrl_20240306153022551">P6Y9M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="C_20231231" id="Fxbrl_20240306153025916">P6Y2M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapTrademarksMember"
      id="F20231019113055814_153">P6Y1M6D</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055815_155">
                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 20%; border-collapse: collapse; font-size: 10pt;"&gt;
                                        &lt;tr&gt;
                                            &lt;td colspan="2" style="text-align: left; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055816_156"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055817_157"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055820_158"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055821_159"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055822_160"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055823_161">
                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Vessel &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;JustCBD &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;FGH &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gross goodwill recorded prior to December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment recorded prior to December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net book value as at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Acquired through business combinations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;25,315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,716&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(19,675&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(5,398&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(25,073&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Foreign exchange impacts&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(277&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(261&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net book value as at December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,640&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,732&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,372&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(19,640&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(3,732&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(23,372&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net book value as at December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            </us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillGross
      contextRef="C_20211231_usgaapReportingUnitAxis_flgcVesselMember"
      decimals="-3"
      id="F20231019113055825_164"
      unitRef="USD">19675000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="C_20211231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055826_165"
      unitRef="USD">0</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="C_20211231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055827_166"
      unitRef="USD">0</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="C_20211231"
      decimals="-3"
      id="F20231019113055828_167"
      unitRef="USD">19675000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20211231_usgaapReportingUnitAxis_flgcVesselMember"
      decimals="-3"
      id="F20231019113055831_170"
      unitRef="USD">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20211231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055833_171"
      unitRef="USD">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20211231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055834_172"
      unitRef="USD">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20211231"
      decimals="-3"
      id="F20231019113055835_173"
      unitRef="USD">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="C_20211231_usgaapReportingUnitAxis_flgcVesselMember"
      decimals="-3"
      id="F20231019113055838_176"
      unitRef="USD">19675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20211231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055838_177"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20211231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055839_178"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20211231"
      decimals="-3"
      id="F20231019113055840_179"
      unitRef="USD">19675000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="C_20220101to20221231_usgaapReportingUnitAxis_flgcVesselMember"
      decimals="-3"
      id="F20231019113055843_182"
      unitRef="USD">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="C_20220101to20221231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055844_183"
      unitRef="USD">25315000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="C_20220101to20221231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055846_184"
      unitRef="USD">3716000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055847_185"
      unitRef="USD">29031000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20221231_usgaapReportingUnitAxis_flgcVesselMember"
      decimals="-3"
      id="F20231019113055850_188"
      unitRef="USD">19675000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20221231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055851_189"
      unitRef="USD">5398000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20221231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055852_190"
      unitRef="USD">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055853_191"
      unitRef="USD">25073000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapReportingUnitAxis_flgcVesselMember"
      decimals="-3"
      id="F20231019113055874_211"
      unitRef="USD">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055875_212"
      unitRef="USD">-277000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055876_213"
      unitRef="USD">16000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055877_214"
      unitRef="USD">-261000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="C_20221231_usgaapReportingUnitAxis_flgcVesselMember"
      decimals="-3"
      id="F20231019113055856_194"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20221231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055856_195"
      unitRef="USD">19640000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20221231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055857_196"
      unitRef="USD">3732000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113055860_197"
      unitRef="USD">23372000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20231231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055868_206"
      unitRef="USD">19640000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20231231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055869_207"
      unitRef="USD">3732000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055870_208"
      unitRef="USD">23372000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="C_20231231_usgaapReportingUnitAxis_flgcVesselMember"
      decimals="-3"
      id="F20231019113055880_217"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20231231_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113055880_218"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20231231_usgaapReportingUnitAxis_usgaapFranchiseMember"
      decimals="-3"
      id="F20231019113055881_219"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055882_220"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:AssetImpairmentChargesTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055908_31">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left: 15pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;IMPAIRMENT OF ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company tests its goodwill for impairment as part of its annual fourth quarter impairment test, and at interim periods when impairment indicators exist. For the year ended December 31, 2023, the Company tested its goodwill for impairment at June 30, 2023 and&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt; due to indicators such as a decline in the value of the Company's publicly traded common shares, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. In addition, the Company assessed its other long-lived assets for impairment at this time. The Company's goodwill was assigned to the reporting units associated with the original acquisition of those operations. Management determined the Company's reporting units for 2023 impairment testing are its reportable segments shown in Note 24, but with the house of brands segment broken down into separate reporting units for the Company's JustCBD and Vessel product groups of assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company may consider the results of both an income approach (discounted cash flows) and market approach (guideline public companies) when determining the recoverable amount of its reporting units. For the income approach, the significant assumptions used in the calculation of the recoverable amounts of the reporting units include forecasted revenue, expenses and net cash flows, terminal period cash flows and growth rates, and the weighted average cost of capital used as the discount rate. These assumptions are considered Level 3 inputs in the fair value hierarchy. The assumptions consider historical and projected data from internal sources as well as external industry trends and expectations. For the market approach, the significant assumptions include identifying and calibrating relevant guideline public companies, and determining the financial metric to measure against. The results of the two approaches are considered, and judgment is applied in weighting each approach to determine the recoverable amount of the reporting unit.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For long-lived assets other than goodwill, which show impairment indicators are present, the Company compares its expected undiscounted future cash flows to the carrying value of the asset group. If the undiscounted future cash flows are less than the carrying value of the assets, then the fair value of the asset group is calculated using an income or market approach as discussed in the prior paragraph. The significant assumptions used in calculating the undiscounted future cash flows include determining the primary asset of the asset group which sets the length of time to project the cash flows, and the forecasted revenue, expenses and net cash flows relating to the asset group.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023 Annual Impairment Test&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company concluded that the carrying values of its JustCBD and FGH reporting units were higher than their respective estimated fair values, and a goodwill impairment loss totaling $23.4 million was recognized in the year ended December 31, 2023, with details of these impairment tests discussed below. The goodwill impairment loss was comprised of (i) $19.6 million related to the JustCBD reporting unit, representing the entirety of the goodwill assigned to the JustCBD reporting unit, part of the house of brands segment; and (ii) $3.7 million related to the FGH reporting unit, part of the commercial and wholesale segment. See Note 24 for discussion of the Company's segments. Certain negative trends, including slower growth rates, resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation for the JustCBD and FGH reporting units.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;

                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                    &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023 Annual Goodwill Impairment Test of FGH&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At June 30, 2023, the Company's FGH reporting unit had external indicators of impairment primarily due to the Company's declining share price, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. As such, the Company tested the FGH reporting unit for impairment as at June 30, 2023 and determined that the carrying value of the reporting unit's assets exceeded the recoverable amount, resulting in goodwill impairment of $3.7 million recorded in the first half of fiscal 2023. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;FGH's June 30, 2023 carrying value of $7.7 million was comprised primarily of goodwill and identified intangible assets of $5.2 million and other long-lived assets of $0.5 million. The carrying value is reduced by inseparable market participant liabilities associated with the December 2022 acquisition of FGH which includes $0.1 million of lease liability. The estimated recoverable amount of FGH at June 30, 2023 was $1.5 million, resulting in goodwill impairment of the remaining $3.7 million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                The reporting unit's fair value was determined based on an income approach discounted cash flow model. After working capital adjustments, the resulting fair value was estimated at $1.5 million. The income approach used a discount rate of 17%, operating margins of about 2%, working capital requirements of 6% revenue, and a terminal period growth rate of 2%. The revenue growth rates start at 5% in 2023 and trend down to 2% in 2028 and thereafter. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After the impairment recorded at June 30, 2023, FGH's carrying value was equal to its recoverable amount. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $0.3 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023 Annual Goodwill Impairment Test of JustCBD&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At June 30, 2023 and December 31, 2023, the Company&#x2019;s JustCBD reporting unit had external indicators of impairment primarily due to the Company's declining share price, the declining share price of comparable public companies and challenging economic factors making it difficult to access capital. As such, the Company tested the JustCBD reporting unit for impairment as at June 30, 2023 and December 31, 2023 and determined that the carrying value of the reporting unit&#x2019;s assets exceeded the recoverable amount, resulting in goodwill impairment of $19.6 million recorded in 2023. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;JustCBD&#x2019;s June 30, 2023 and December 31, 2023 carrying values of $23.8 and $7.0 million, respectively, were comprised primarily of goodwill and identified intangible assets of $20.8 million and $3.5 million and other long-lived assets of $1.2 million and $0.7 million. The carrying value is reduced by inseparable market participant liabilities associated with the February 2022 acquisition of JustCBD which includes $1.6 million and $0.4 million of lease liability. The estimated recoverable amount of JustCBD at June 30, 2023 and December 31, 2023 was $7.1 million and $nil, respectively, resulting in goodwill impairment of $19.6 million for the year ended December 31, 2023 as the carrying value of the reporting unit&#x2019;s assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                The reporting unit&#x2019;s fair value at June 30, 2023 and December 31, 2023 was determined based on an income approach discounted cash flow. After working capital adjustments, the resulting fair value was estimated at $7.1 million and $nil. The income approach used a weighted average discount rate of 28%, operating margins from 8.5% to -19.7%, weighted average working capital requirements of 1% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 17% in 2023 and taper down to 3% in 2025 and thereafter.  The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;

                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                    &lt;p style="text-align: justify; margin-top: 1pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After the impairment recorded for the year ended December 31, 2023, JustCBD&#x2019;s carrying value was equal to its recoverable amount. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a decrease of the reporting unit fair value of approximately $1.5 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023 Other Long-Lived Asset Impairment Tests&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For asset groups that had indicators of impairment, the Company performed a quantitative analysis as of June 30, 2023 to determine if impairment existed by comparing the carrying amount of each asset group to the future undiscounted cash flows the asset group is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of property, plant and equipment, operating lease right of use assets, customer relationships, trademarks, patents and non-compete agreements within its Vessel asset group within the house of brands segment totaling $7.4 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at 10.7% in 2023 and tapering down to 3% thereafter, weighted average royalty rate of 1%, weighted average discount rate of 17% and a customer attrition rate of 18%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. Likewise, the Company recorded an impairment of supplier relationships, customer relationships and licenses within its FGH asset group within the commercial and wholesale segment totaling $3.7 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at -2.6% in 2023, 5% in 2024 and tapering down to 4% thereafter, weighted average discount rate of 20% and customer attrition rate of 10%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.1 million decrease of the recoverable amounts. Finally, the Company recorded an impairment of customer relationships, trademarks and patents within its JustCBD asset group within the house of brands segment totaling $2.3 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at 16.5% in 2023 and tapering down to 3% thereafter, royalty rate of 1.5%, weighted average discount rate of 32.5% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.2 million decrease of the recoverable amounts. These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company performed a similar analysis for its asset groups as of December 31, 2023, and determined that indicators of impairment were present. These include external indicators such as a decline in the value of the Company&#x2019;s publicly traded common shares as well as internal indicators such as reduced forecasted revenue and cash flow generation. The Company performed a quantitative analysis as of December 31, 2023 to determine if impairment existed by comparing the carrying amount of each asset group to the future undiscounted cash flows the asset group is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of operating lease right of use assets, supplier relationships and licenses within its FGH asset group within the commercial and wholesale segment totaling $1.4 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at 2.5% in 2024 and tapering down to 2.5% thereafter and a weighted average discount rate of 21%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts.  Likewise, the Company recorded an impairment of operating lease right of use assets, customer relationships and trademarks within its JustCBD asset group within the house of brands segment totaling $1.0 million. The key inputs included in the recoverable amount calculations are revenue growth rates starting at -37.5% in 2023 and then increasing to 2.5% thereafter, royalty rate of 1.5%, weighted average discount rate of 25% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2022 Annual Impairment Test&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company concluded that the carrying values of its Vessel and JustCBD reporting units were higher than their respective estimated fair values, and a goodwill impairment loss totaling $25.1 million was recognized in the year ended December 31, 2022, with details of these impairment tests discussed below. The goodwill impairment loss was comprised of (i) $19.7 million related to the Vessel reporting unit, representing the entirety of the goodwill assigned to the Vessel reporting unit, part of the house of brands segment; and (ii) $5.4 million related to the JustCBD reporting unit, part of the house of brands segment. See Note 24 for discussion of the Company's segments. Certain negative trends, including slower growth rates, resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation for the Vessel reporting unit. No impairment was noted for the FGH reporting unit, as the acquisition of FGH occurred close to the end of the year and fair value calculated at the December 23, 2022 acquisition date approximates fair value as at December 31, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company reconciled the sum of its reporting unit recoverable amounts discussed above plus all other net assets to the Company's market capitalization of common shares as December 31, 2022. The Company's recoverable amounts at December 31, 2022 exceeded the market capitalization of its common shares by 98%. The Company believes the 98% excess is due to implied equity control premium and is within an acceptable range of values based on control premiums observed in business combinations within the cannabis and wholesale industries.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022 Annual Goodwill Impairment Test of Vessel&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At June 30, 2022, the Company's Vessel reporting unit had external indicators of impairment primarily due to a decline in comparable public company share prices which would negatively impact the implied valuation of Vessel. As such, the Company tested the Vessel reporting unit for impairment as at June 30, 2022 and determined that the carrying value of the reporting unit's assets exceeded the recoverable amount, resulting in goodwill impairment of $16.0 million recorded in the first half of fiscal 2022. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;

                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vessel's December 31, 2022 carrying value of $11.6 million was comprised primarily of goodwill and identified intangible assets of $11.3 million and other long-lived assets of $1.0 million. The carrying value is reduced by inseparable market participant liabilities associated with the November 2021 acquisition of Vessel which includes $1.1 million of lease liability. The estimated recoverable amount of Vessel at December 31, 2022 was $7.0 million, resulting in goodwill impairment of the remaining $3.7 million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                The reporting unit's fair value was determined based on an income approach discounted cash flow model of $7.6 million (80% weighting) and a market approach guideline public company method of $7.0 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $7.0 million. The income approach used a discount rate of 17%, operating margins from 0% to 18%, working capital requirements of 15% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 14% in 2023 and taper down to 3% in the terminal period after 2030. The market approach considered guideline public companies similar to Vessel considering financial metrics such as historical revenue growth, gross margin and EBITDA profitability and with operations focused on consumer brands and similar sales channels. An enterprise value to latest twelve months revenue multiple of 1.0 was selected based on consideration of the enterprise value to latest twelve months multiples of the guideline companies. The multiple was applied to Vessel's revenue for the twelve months ended December 31, 2022. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After the impairment recorded at December 31, 2022, Vessel's carrying value was equal to its recoverable amount. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $1.8 million. Reducing the market approach selected revenue multiple by 0.10 from 1.00 above down to 0.90 (approximately 10% change) would result in a decrease of the reporting unit fair value of approximately $0.7 million. However, there would be no impact on the goodwill impairment amount for either of these unfavorable changes in the models as the imputed fair value of the goodwill exceeded its carrying amount by $1.1 million with the goodwill impaired to zero.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022 Annual Goodwill Impairment Test of JustCBD&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;JustCBD's December 31, 2022 carrying value of $34.4 million was comprised primarily of goodwill and identified intangible assets of $29.0 million and other long-lived assets of $2.0 million. The carrying value is reduced by inseparable market participant liabilities associated with the February 2022 acquisition of JustCBD which includes $1.2 million of lease liability. The estimated recoverable amount of JustCBD at December 31, 2022 was $29.0 million, resulting in goodwill impairment of $5.4 million as the carrying value of the reporting unit's assets exceeds the recoverable amount. The impairment is recorded in the goodwill impairment caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                The reporting unit's fair value was determined based on an income approach discounted cash flow model of $28.0 million (80% weighting) and a market approach guideline public company method of $21.9 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $29.0 million. The income approach used a discount rate of 32%, operating margins from 5% to 28%, working capital requirements of 10% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 21% in 2023 and taper down to 3% in the terminal period after 2030. The market approach considered guideline public companies similar to JustCBD considering financial metrics such as historical revenue growth, gross margin and EBITDA profitability and with operations focused on consumer brands and similar sales channels. An enterprise value to latest twelve months revenue multiple of 0.6 was given the most weight in the valuation and was selected based on consideration of the enterprise value to latest twelve months multiples of the guideline companies. The multiple was applied to JustCBD's revenue for the twelve months ended December 31, 2022. The impairment test valuation is considered a Level 3 method within the ASC 820 fair value hierarchy.
                                            &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After the impairment recorded at December 31, 2022, JustCBD's carrying value was equal to its recoverable amount. Any change in the significant assumptions could result in additional impairment of its goodwill as at December 31, 2022. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% from 32% above up to 35% (approximately 9% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.5 million. Reducing the market approach selected revenue multiple by 0.1 from 0.6 above down to 0.5 (approximately 17% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.7 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;

                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022 Other Long-Lived Asset Impairment Tests&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For asset groups that had indicators of impairment, the Company performed a quantitative analysis as of December 31, 2022 to determine if impairment existed by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over their remaining lives. This analysis indicated that certain asset values may not be recoverable. The Company then calculated the fair value of these assets using an income approach. As a result, the Company recorded an impairment of the licenses within the corporate segment totaling $0.1 million. This charge was recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;During the fourth quarter of 2022, the Company decided to consolidate operations and looked for subtenants for two building leases that have contractual lease obligations through 2026 and 2027. These leases are recorded on the Company's statement of financial position as operating lease right of use assets. The lease assets had indicators of impairment as they were no longer used in the asset groups' operations, but the Company was actively seeking to sublease both spaces to generate income from the spaces. The Company calculated the fair value of the two leases using an income approach on the expected sublease income. The resulting fair values were compared to the operating right of use asset values at December 31, 2022, resulting in an impairment of $0.6 million. The discounted cash flow models assumed the spaces would be subleased within 2023 at 75% to 100% of the Company's cost of the leases, less upfront costs to obtain a sublease tenant. The cash flows were discounted at 8% to 9% which approximates the discount rate in the Company's right of use asset and lease liability calculations. These charges were recorded in the other asset impairments caption on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:AssetImpairmentChargesTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember"
      decimals="-5"
      id="Fxbrl_20240305182113141"
      unitRef="USD">23400000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240305184718244"
      unitRef="USD">19600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeAnnualImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember"
      decimals="-5"
      id="Fxbrl_20240305184742260"
      unitRef="USD">3700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      decimals="-5"
      id="Fxbrl_20240305184906107"
      unitRef="USD">3700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Assets
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      decimals="-5"
      id="Fxbrl_20240305185043668"
      unitRef="USD">7700000</us-gaap:Assets>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      decimals="-5"
      id="Fxbrl_20240305185121487"
      unitRef="USD">5200000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      decimals="-5"
      id="Fxbrl_20240305185237172"
      unitRef="USD">500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CapitalLeaseObligations
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      decimals="-5"
      id="Fxbrl_20240305185248246"
      unitRef="USD">100000</us-gaap:CapitalLeaseObligations>
    <flgc:EstimatedRecoverableAmount
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      decimals="-5"
      id="Fxbrl_20240305185347524"
      unitRef="USD">1500000</flgc:EstimatedRecoverableAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      decimals="-5"
      id="Fxbrl_20240305185446823"
      unitRef="USD">3700000</us-gaap:GoodwillImpairmentLoss>
    <flgc:DescriptionOfValuation
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      id="Fxbrl_20240305185805700">The reporting unit's fair value was determined based on an income approach discounted cash flow model. After working capital adjustments, the resulting fair value was estimated at $1.5 million. The income approach used a discount rate of 17%, operating margins of about 2%, working capital requirements of 6% revenue, and a terminal period growth rate of 2%. The revenue growth rates start at 5% in 2023 and trend down to 2% in 2028 and thereafter.</flgc:DescriptionOfValuation>
    <flgc:GoodwillDescription
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfFghMember"
      id="Fxbrl_20240305185929227">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $0.3 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.</flgc:GoodwillDescription>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240327185610251"
      unitRef="USD">19600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Assets
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328100833817"
      unitRef="USD">23800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328100849725"
      unitRef="USD">7000000</us-gaap:Assets>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328105107151"
      unitRef="USD">20800000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328105324896"
      unitRef="USD">3500000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328110154985"
      unitRef="USD">1200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328110158581"
      unitRef="USD">700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CapitalLeaseObligations
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328110203533"
      unitRef="USD">1600000</us-gaap:CapitalLeaseObligations>
    <us-gaap:CapitalLeaseObligations
      contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328110211747"
      unitRef="USD">400000</us-gaap:CapitalLeaseObligations>
    <flgc:EstimatedRecoverableAmount
      contextRef="C_20230630_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328110216205"
      unitRef="USD">7100000</flgc:EstimatedRecoverableAmount>
    <flgc:EstimatedRecoverableAmount
      contextRef="C_20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-6"
      id="Fxbrl_20240328110220157"
      unitRef="USD">0</flgc:EstimatedRecoverableAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328110226181"
      unitRef="USD">19600000</us-gaap:GoodwillImpairmentLoss>
    <flgc:DescriptionOfValuation
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      id="Fxbrl_20240305190536851">The reporting unit&#x2019;s fair value at June 30, 2023 and December 31, 2023 was determined based on an income approach discounted cash flow. After working capital adjustments, the resulting fair value was estimated at $7.1 million and $nil. The income approach used a weighted average discount rate of 28%, operating margins from 8.5% to -19.7%, weighted average working capital requirements of 1% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 17% in 2023 and taper down to 3% in 2025 and thereafter. </flgc:DescriptionOfValuation>
    <flgc:GoodwillDescription
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcAnnualGoodwillImpairmentTestOfJustCBDMember"
      id="Fxbrl_20240305190617828">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a decrease of the reporting unit fair value of approximately $1.5 million. However, there would be no impact on the goodwill impairment amount for this unfavorable change in the model as the imputed fair value of the goodwill exceeded its carrying amount with the goodwill impaired to zero.</flgc:GoodwillDescription>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember"
      decimals="-5"
      id="Fxbrl_20240328113101671"
      unitRef="USD">7400000</us-gaap:AssetImpairmentCharges>
    <flgc:DescriptionOfValuation
      contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember"
      id="Fxbrl_20240328114109801">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 10.7% in 2023 and tapering down to 3% thereafter, weighted average royalty rate of 1%, weighted average discount rate of 17% and a customer attrition rate of 18%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts.</flgc:DescriptionOfValuation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember"
      decimals="-5"
      id="Fxbrl_20240328114710552"
      unitRef="USD">3700000</us-gaap:AssetImpairmentCharges>
    <flgc:DescriptionOfValuation
      contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember"
      id="Fxbrl_20240328114807441">The key inputs included in the recoverable amount calculations are revenue growth rates starting at -2.6% in 2023, 5% in 2024 and tapering down to 4% thereafter, weighted average discount rate of 20% and customer attrition rate of 10%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.1 million decrease of the recoverable amounts.</flgc:DescriptionOfValuation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328114912129"
      unitRef="USD">2300000</us-gaap:AssetImpairmentCharges>
    <flgc:DescriptionOfValuation
      contextRef="C_20230101to20230630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember"
      id="Fxbrl_20240328115011657">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 16.5% in 2023 and tapering down to 3% thereafter, royalty rate of 1.5%, weighted average discount rate of 32.5% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a $0.2 million decrease of the recoverable amounts.</flgc:DescriptionOfValuation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember"
      decimals="-5"
      id="Fxbrl_20240328115119120"
      unitRef="USD">1400000</us-gaap:AssetImpairmentCharges>
    <flgc:DescriptionOfValuation
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcFGHMember"
      id="Fxbrl_20240328115217468">The key inputs included in the recoverable amount calculations are revenue growth rates starting at 2.5% in 2024 and tapering down to 2.5% thereafter and a weighted average discount rate of 21%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. </flgc:DescriptionOfValuation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-5"
      id="Fxbrl_20240328120027434"
      unitRef="USD">1000000</us-gaap:AssetImpairmentCharges>
    <flgc:DescriptionOfValuation
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyThreeOtherLonglivedAssetImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember"
      id="Fxbrl_20240328120037683">The key inputs included in the recoverable amount calculations are revenue growth rates starting at -37.5% in 2023 and then increasing to 2.5% thereafter, royalty rate of 1.5%, weighted average discount rate of 25% and customer attrition rate of 15%. As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% would result in a nominal decrease of the recoverable amounts. </flgc:DescriptionOfValuation>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember"
      decimals="-5"
      id="F20231019113055906_0"
      unitRef="USD">25100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember_usgaapReportingUnitAxis_flgcVesselAssetGroupMember"
      decimals="-5"
      id="F20231019113055907_1"
      unitRef="USD">19700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember_usgaapReportingUnitAxis_flgcJustCBDMember"
      decimals="-5"
      id="F20231019113055907_2"
      unitRef="USD">5400000</us-gaap:GoodwillImpairmentLoss>
    <flgc:PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember"
      decimals="2"
      id="Fxbrl_20240328120708274"
      unitRef="Pure">0.98</flgc:PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares>
    <flgc:PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoImpairmentTestMember"
      decimals="2"
      id="Fxbrl_20240328120720070"
      unitRef="Pure">0.98</flgc:PercentageOfRecoverableAmountsExceededMarketCapitalizationOfCommonShares>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20220101to20220630_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      decimals="-5"
      id="F20231019113055907_4"
      unitRef="USD">16000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Assets
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      decimals="-5"
      id="Fxbrl_20231101235532848"
      unitRef="USD">11600000</us-gaap:Assets>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      decimals="-5"
      id="Fxbrl_20231101235540020"
      unitRef="USD">11300000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      decimals="-5"
      id="Fxbrl_20231101235546236"
      unitRef="USD">1000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CapitalLeaseObligations
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      decimals="-5"
      id="Fxbrl_20231101235557500"
      unitRef="USD">1100000</us-gaap:CapitalLeaseObligations>
    <flgc:EstimatedRecoverableAmount
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      decimals="-5"
      id="Fxbrl_20231101235607956"
      unitRef="USD">7000000</flgc:EstimatedRecoverableAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      decimals="-5"
      id="Fxbrl_20231101235618421"
      unitRef="USD">3700000</us-gaap:GoodwillImpairmentLoss>
    <flgc:DescriptionOfValuation
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      id="F20231019113055907_5">The reporting unit's fair value was determined based on an income approach discounted cash flow model of $7.6 million (80% weighting) and a market approach guideline public company method of $7.0 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $7.0 million. The income approach used a discount rate of 17%, operating margins from 0% to 18%, working capital requirements of 15% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 14% in 2023 and taper down to 3% in the terminal period after 2030.</flgc:DescriptionOfValuation>
    <flgc:GoodwillDescription
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfVesselMember"
      id="Fxbrl_20231101235807075">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate by 3% in the income approach model would decrease the reporting unit fair value by $1.8 million. Reducing the market approach selected revenue multiple by 0.10 from 1.00 above down to 0.90 (approximately 10% change) would result in a decrease of the reporting unit fair value of approximately $0.7 million. However, there would be no impact on the goodwill impairment amount for either of these unfavorable changes in the models as the imputed fair value of the goodwill exceeded its carrying amount by $1.1 million with the goodwill impaired to zero.</flgc:GoodwillDescription>
    <us-gaap:Assets
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember"
      decimals="-5"
      id="F20231019113055907_7"
      unitRef="USD">34400000</us-gaap:Assets>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember"
      decimals="-5"
      id="F20231019113055907_8"
      unitRef="USD">29000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember"
      decimals="-5"
      id="F20231019113055907_9"
      unitRef="USD">2000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CapitalLeaseObligations
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember"
      decimals="-5"
      id="F20231019113055907_10"
      unitRef="USD">1200000</us-gaap:CapitalLeaseObligations>
    <flgc:EstimatedRecoverableAmount
      contextRef="C_20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember"
      decimals="-5"
      id="F20231019113055907_11"
      unitRef="USD">29000000</flgc:EstimatedRecoverableAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember"
      decimals="-5"
      id="F20231019113055907_12"
      unitRef="USD">5400000</us-gaap:GoodwillImpairmentLoss>
    <flgc:DescriptionOfValuation
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember"
      id="F20231019113055907_13">The reporting unit's fair value was determined based on an income approach discounted cash flow model of $28.0 million (80% weighting) and a market approach guideline public company method of $21.9 million (20% weighting). After working capital adjustments, the resulting fair value was estimated at $29.0 million. The income approach used a discount rate of 32%, operating margins from 5% to 28%, working capital requirements of 10% revenue, and a terminal period growth rate of 3%. The revenue growth rates start at 21% in 2023 and taper down to 3% in the terminal period after 2030.</flgc:DescriptionOfValuation>
    <flgc:GoodwillDescription
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoAnnualGoodwillImpairmentTestOfJustcbdMember"
      id="F20231019113055907_14">As a sensitivity assessment to the recoverable amount calculations, increasing the discount rate in the income approach model by 3% from 32% above up to 35% (approximately 9% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.5 million. Reducing the market approach selected revenue multiple by 0.1 from 0.6 above down to 0.5 (approximately 17% change) would result in a decrease of the reporting unit fair value and additional goodwill impairment of approximately $3.7 million.</flgc:GoodwillDescription>
    <flgc:ImpairmentOfLicenses
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember"
      decimals="-5"
      id="F20231019113055908_23"
      unitRef="USD">100000</flgc:ImpairmentOfLicenses>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember"
      decimals="-5"
      id="F20231019113055908_24"
      unitRef="USD">600000</us-gaap:AssetImpairmentCharges>
    <flgc:DescriptionOfValuation
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_flgcTwoThousandTwentyTwoOtherLonglivedAssetImpairmentTestsMember"
      id="F20231019113055908_25">The discounted cash flow models assumed the spaces would be subleased within 2023 at 75% to 100% of the Company's cost of the leases, less upfront costs to obtain a sublease tenant. The cash flows were discounted at 8% to 9% which approximates the discount rate in the Company's right of use asset and lease liability calculations.</flgc:DescriptionOfValuation>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_20230101to20231231" id="F20231019113055918_0">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;13.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;DEBT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Euro credit facility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company, through FGH, has credit facilities totaling 4.0 million Euro ($4.4 million USD), at two different banks in Germany. These arrangements are open ended without predetermined maturity dates. Principal and interest payments are due at the end of each term. Interest rates can change with each new amount drawn. As of December 31, 2023, the total outstanding amount on these credit facilities was 1.8 million Euro ($1.9 million USD) with interest rates ranging from 5.45% to 6.46% and due within the next twelve months. These credit facilities were secured by various guarantees, including joint and several guarantees of two managing directors of Phatebo, a subsidiary of FGH, and payment guarantees upon default.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_20231231"
      decimals="-5"
      id="F20231019113055918_1"
      unitRef="EUR">4000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_20231231"
      decimals="-5"
      id="Fxbrl_20240305140532288"
      unitRef="USD">4400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055918_4"
      unitRef="EUR">1800000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113055918_2"
      unitRef="USD">1900000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember"
      decimals="4"
      id="F20231019113055918_3"
      unitRef="Pure">0.0545</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember"
      decimals="4"
      id="Fxbrl_20240305140617433"
      unitRef="Pure">0.0646</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055927_27">
                &lt;div&gt;
                    &lt;p style="margin: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;14.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;LEASES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's leases primarily consist of administrative real estate leases in Germany and the United States. Management has determined all the Company's leases are operating leases through December 31, 2023. Information regarding the Company's leases is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Year ended&lt;br/&gt;December 31, 2023 &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Components of lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,211&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;937&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Short-term lease expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;324&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Sublease income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(71&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,464&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,245&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; width: 15%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,403&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;859&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;245&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2,609&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Weighted-average remaining lease term in years for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;
                                                                    2.7
                                                                &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;
                                                                3.5
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Weighted-average discount rate for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;7.9%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;7.9%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                &lt;/div&gt;

                            &lt;div&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                            &lt;/div&gt;
                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Maturities of operating lease liabilities as of December 31, 2023 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Operating Leases &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;900&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;460&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;374&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;192&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Total future lease payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,926&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(185&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,741&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(799&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;942&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;

                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Most of the Company's leases contain renewal options to continue the leases for another term equivalent to the original term, which are generally up to two years. The lease liabilities above include renewal terms that management has executed or is reasonably certain of renewing, which only included leases that would have expired in 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's operating lease of warehousing and office space for Vessel Brand Inc. expires August 31, 2027. The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term. At December 31, 2023, the renewal option is not included in the related operating right of use asset recorded. At the end of 2022, the Company decided to move Vessel's operations and to consolidate them with JustCBD's operations in Florida. See Note 11. The Company began subleasing this space to a third party during the fourth quarter of 2023. The sublease is effective through August 31, 2027 and does not contain renewal options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's operating lease of retail space in Miami, FL expires November 30, 2026. The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term. At December 31, 2023, the renewal option is not included in the related operating right of use asset recorded. The Company began subleasing this retail space to a third party during the third quarter of 2023. The sublease agreement is effective through November 30, 2026 and contains one option to renew for five more years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's operating lease of manufacturing and warehousing for High Roller Private Label LLC expires June 30, 2024. The lease does not contain a renewal option.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company&#x2019;s operating lease of warehousing and office space for Just Brands LLC expires April 30, 2024. The lease does not contain a renewal option. In January 2024, the Company began leasing 14,280 sq. ft. of warehousing space in Pompano Beach, FL, for $20,000 a month, pursuant to a lease agreement that expires in February 2029. In March 2024, the Company began leasing 4,184 sq. ft. of office space in Fort Lauderdale, FL, for $8,000 a month, pursuant to a lease agreement that expires in March 2028.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_20230101to20231231" id="F20231019113055922_0">
                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Year ended&lt;br/&gt;December 31, 2023 &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Year ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Components of lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,211&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;937&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Short-term lease expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;324&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Sublease income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(71&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,464&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1,245&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; width: 15%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,403&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;859&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;245&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2,609&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Weighted-average remaining lease term in years for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;
                                                                    2.7
                                                                &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;
                                                                3.5
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Weighted-average discount rate for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;7.9%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;7.9%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055923_1"
      unitRef="USD">1211000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055923_2"
      unitRef="USD">937000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055923_3"
      unitRef="USD">324000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055923_4"
      unitRef="USD">308000</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305194616035_20231019113055923_3"
      unitRef="USD">71000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240305194616035_20231019113055923_4"
      unitRef="USD">0</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055923_5"
      unitRef="USD">1464000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055924_6"
      unitRef="USD">1245000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055924_7"
      unitRef="USD">1403000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055924_8"
      unitRef="USD">859000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113055924_9"
      unitRef="USD">245000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113055924_10"
      unitRef="USD">2609000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20231231" id="F20231019113055924_11">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20221231" id="F20231019113055925_12">P3Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20231231"
      decimals="3"
      id="F20231019113055925_13"
      unitRef="Pure">0.079</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20221231"
      decimals="3"
      id="F20231019113055925_14"
      unitRef="Pure">0.079</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055925_15">
                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Operating Leases &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;900&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;460&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;374&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;192&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Total future lease payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,926&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 36pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(185&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1,741&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-indent: 18pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(799&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;942&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055925_16"
      unitRef="USD">900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055925_17"
      unitRef="USD">460000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055926_18"
      unitRef="USD">374000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055926_19"
      unitRef="USD">192000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055926_22"
      unitRef="USD">1926000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055927_23"
      unitRef="USD">185000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055927_24"
      unitRef="USD">1741000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055927_25"
      unitRef="USD">799000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113055927_26"
      unitRef="USD">942000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20230101to20231231_srtCounterpartyNameAxis_flgcWarehousingAndOfficeSpaceMember"
      id="Fxbrl_20231025114759031">The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20230101to20231231_srtCounterpartyNameAxis_flgcRetailSpaceInMiamiMember"
      id="Fxbrl_20231025114822932">The lease includes an option to extend the lease term for the entire space for a period of five years at the end of the current lease term.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="C_20230101to20231231_srtCounterpartyNameAxis_flgcPompanoBeachMember"
      decimals="0"
      id="Fxbrl_20240328110246301"
      unitRef="USD">20000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="C_20230101to20231231_srtCounterpartyNameAxis_flgcFortLauderdaleMember"
      decimals="0"
      id="Fxbrl_20240328110255244"
      unitRef="USD">8000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113055950_61">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;15.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;SHARE CAPITAL &#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Authorized and issued&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company is authorized to issue an unlimited number of common shares, no par value. On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion below.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;

                            &lt;/div&gt;
                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company had the following significant common share transactions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span style="text-decoration: underline;"&gt;&lt;b&gt;Year ended December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;SEPTEMBER 2023 UNIT OFFERING&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;On September 21, 2023, the Company closed a registered direct offering of 1,369,000 units of the Company at a price of $2.00 per unit for gross proceeds of $2.7 million. Each unit is comprised of one common share of the Company and one common share purchase warrant (1,369,000 total warrants) to purchase one additional common share at an exercise price of $2.50 per warrant share through March 21, 2029. Additionally, the Company amended the exercise price with respect to 61,250 and 624,995 warrants that were previously issued in the November 2021 and December 2022 offerings, respectively, from $8.00 per share to $2.50 per share and recorded a $0.2 million gain on these warrant modifications. There was no increase to the value of the additional paid-in capital as it was offset by a corresponding increase to unit issuance costs. The Company paid $0.3 million in issuance costs relating to the September 2023 unit offering, as well as 54,760 warrants with a fair value of $0.1 million, with an exercise price of $2.39 per share through September 21, 2028, issued to the placement agent. See Note 17.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;REVERSE STOCK SPLIT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;
                                            On June 7, 2023, the Company filed an amendment to its Articles of Incorporation (the "Reverse Stock Split Articles Amendment") with the Ontario Ministry of Public and Business Service Delivery to effect a reverse stock split of the Company's common shares, no par value per share (the "common shares"), at a ratio of 1-for-20, which became effective at 12:00:01 a.m. Eastern Time on June 9, 2023 (the "Reverse Stock Split").
                                        &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Upon the effectiveness of the Reverse Stock Split, every twenty shares of the issued and outstanding common shares were automatically combined and reclassified into one issued and outstanding common share. The Reverse Stock Split did not affect any shareholder's ownership percentage of the common shares, alter the par value of the common shares or modify any voting rights or other terms of the common shares. The number of authorized shares of common shares under the Company's Articles remained unchanged. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional interest as a result of the Reverse Stock Split was rounded down to the nearest whole common share.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;All common shares and per share amounts have been restated to give retroactive effect to the share consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;OTHER ISSUANCES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;On January 31, 2023, the Company entered into a settlement agreement with a third party pursuant to which the Company issued 16,250 common shares of the Company, valued at $0.1 million, to a third party to settle a legal dispute that arose in April 2019. See Note 16.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;On April 12, 2023, Luis Merchan tendered his resignation as both Chairman of the Board of Directors of the Company and as its Chief Executive Officer. On this date, the Company entered into a separation agreement with Mr. Merchan, pursuant to which the Company issued 80,000 common shares of the Company, valued at $0.4 million, on April 26, 2023, and 30,000 common shares of the Company, valued at $0.1 million, on May 14, 2023 to Mr. Merchan.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&lt;span style="text-decoration: underline;"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&#160;&lt;/p&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;DECEMBER 2022 PAYMENT TO FGH OWNERS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"&gt;&#160;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;div&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;As discussed in Note 10, the Company issued 2,176,297 common shares of the Company valued at $9.8 million, inclusive of a 7.5% fair value discount for the required three-month holding period of the shares, to the prior owners of FGH as part of the Company's acquisition of FGH on December 23, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;DECEMBER 2022 UNIT OFFERING&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On December 8, 2022, the Company closed a registered direct offering of 625,000 units of the Company at a price of $8.00 per unit for gross proceeds of $5.0 million. Each unit is comprised of one common share of the Company and one common share purchase warrant (625,000 total warrants) to purchase one additional common share at an exercise price of $8.00 per warrant share through December 8, 2027. Additionally, the Company amended the exercise price with respect to 66,250 warrants that were previously issued in the November 2021 offering (see Note 17) from $75.00 per share to $8.00 per share with no increase to the value of additional paid-in capital as it was offset by a corresponding increase to issuance costs. The Company paid $0.4 million in issuance costs relating to the December 2022 unit offering, as well as 25,000 warrants issued to the placement agent as discussed in Note 17.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                    &lt;div&gt;

                    &lt;/div&gt;
                    &lt;p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;FEBRUARY 2022 PAYMENT TO JUSTCBD OWNERS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;p style="margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As discussed in Note 10, the Company issued 475,000 common shares of the Company valued at $14.7 million, inclusive of a 15% fair value discount for the required six-month holding period of the shares, to the prior owners of JustCBD as part of the Company's acquisition of JustCBD on February 25, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                    &lt;p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;ACQUISITION OF NONCONTROLLING INTERESTS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-size: 10pt; font-family: Times New Roman; margin: 0pt 0px 10pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;On January 18, 2022, the Company issued 5,000 common shares of the Company valued at $0.2 million to acquire the remaining 13% of the outstanding equity interests in Flora Beauty LLC from its minority shareholders. In addition to the common shares, the Company granted a stock option, exercisable for up to 2,500 common shares of the Company at an exercise price of $34.00 per share that expire five years from the date of the grant.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The Company dissolved Flora Beauty LLC during the year ended December 31, 2023. See Note 2.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;p style="margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On January 31, 2022, the Company issued 1,514 common shares of the Company valued at $0.1 million to complete its acquisition of Flora Med S.A.S. by acquiring the remaining 10% of the equity interests in Flora Med S.A.S. from its minority shareholders. The Company sold Flora Med S.A.S. during the year ended December 31, 2023. See Note 2.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                    &lt;p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;OTHER ISSUANCES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In January 2022, the Company amended an agreement with a consultant pursuant to which the Company issued 5,555 common shares of the Company valued at $0.2 million and a stock option, exercisable for up to 4,166 common shares of the Company at an exercise price of $45.00 per share that expire five years from the date of the grant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On April 5, 2022, the Company issued 35,000 common shares of the Company valued at $1.3 million as part of a settlement agreement with Boustead Securities, LLC ("Boustead") to resolve certain disputes arising under a prior underwriting agreement and engagement letter. In addition to the common shares, the Company paid Boustead $0.4 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                    &lt;div&gt;
                        &lt;p style="margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;SHARE REPURCHASE&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; margin-bottom: 10pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company repurchased 18,411 common shares for $0.3 million during the year ended December 31, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Any future repurchases will depend on factors such as market conditions, share price and other opportunities to invest capital for growth. From time to time when management does not possess material nonpublic information about the Company or its securities, the Company may enter a pre-defined plan with a broker to allow for the repurchase of shares at times when the Company ordinarily would not be active in the market due to internal trading blackout periods, insider trading rules or otherwise. Any such plans entered with our broker will be adopted in accordance with applicable securities laws such as the requirements of Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonUnitIssued
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240305223350067"
      unitRef="Shares">1369000</us-gaap:CommonUnitIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240305223456191"
      unitRef="USD_Per_Share">2</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssued1
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="-5"
      id="Fxbrl_20240305223516630"
      unitRef="USD">2700000</us-gaap:StockIssued1>
    <flgc:NumberOfWarrantsIssuedDuringPeriod
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="0"
      id="Fxbrl_20240305223536582"
      unitRef="Shares">1369000</flgc:NumberOfWarrantsIssuedDuringPeriod>
    <flgc:WarrantsIssuedDuringPeriodExercisePrice
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240305223552680"
      unitRef="USD_Per_Share">2.5</flgc:WarrantsIssuedDuringPeriodExercisePrice>
    <flgc:NumberOfWarrantsWithAmendedExercisePrice
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="0"
      id="Fxbrl_20240305223619315"
      unitRef="Shares">61250</flgc:NumberOfWarrantsWithAmendedExercisePrice>
    <flgc:NumberOfWarrantsWithAmendedExercisePrice
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="0"
      id="Fxbrl_20240305224559262"
      unitRef="Shares">624995</flgc:NumberOfWarrantsWithAmendedExercisePrice>
    <flgc:WarrantExercisePricePriorToAmendment
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240419113152671"
      unitRef="USD_Per_Share">8</flgc:WarrantExercisePricePriorToAmendment>
    <flgc:WarrantExercisePricePriorToAmendment
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240305223750424"
      unitRef="USD_Per_Share">8</flgc:WarrantExercisePricePriorToAmendment>
    <flgc:WarrantAmendedExercisePrice
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240419113134669"
      unitRef="USD_Per_Share">2.5</flgc:WarrantAmendedExercisePrice>
    <flgc:WarrantAmendedExercisePrice
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240305223832267"
      unitRef="USD_Per_Share">2.5</flgc:WarrantAmendedExercisePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="-5"
      id="Fxbrl_20240306004009208"
      unitRef="USD">200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="-5"
      id="Fxbrl_20240305223855849"
      unitRef="USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <flgc:NumberOfWarrantsIssuedDuringPeriod
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240306005447893"
      unitRef="Shares">54760</flgc:NumberOfWarrantsIssuedDuringPeriod>
    <flgc:FairValueOfWarrantsIssuedDuringPeriod
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="-5"
      id="Fxbrl_20240306005553103"
      unitRef="USD">100000</flgc:FairValueOfWarrantsIssuedDuringPeriod>
    <flgc:WarrantsIssuedDuringPeriodExercisePrice
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240306005624287"
      unitRef="USD_Per_Share">2.39</flgc:WarrantsIssuedDuringPeriodExercisePrice>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306005828726">On June 7, 2023, the Company filed an amendment to its Articles of Incorporation (the "Reverse Stock Split Articles Amendment") with the Ontario Ministry of Public and Business Service Delivery to effect a reverse stock split of the Company's common shares, no par value per share (the "common shares"), at a ratio of 1-for-20, which became effective at 12:00:01 a.m. Eastern Time on June 9, 2023 (the "Reverse Stock Split").</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_20230101to20230131"
      decimals="0"
      id="Fxbrl_20240306010115856"
      unitRef="Shares">16250</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="C_20230101to20230131"
      decimals="-5"
      id="Fxbrl_20240306010257734"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_20230401to20230426"
      decimals="0"
      id="Fxbrl_20240306010352038"
      unitRef="Shares">80000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="C_20230401to20230426"
      decimals="-5"
      id="Fxbrl_20240306010502366"
      unitRef="USD">400000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_20230501to20230514"
      decimals="0"
      id="Fxbrl_20240306010548551"
      unitRef="Shares">30000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="C_20230501to20230514"
      decimals="-5"
      id="Fxbrl_20240306010630391"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20221201to20221223_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFGHOwnersMember"
      decimals="0"
      id="F20231019113055934_0"
      unitRef="Shares">2176297</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20221201to20221223_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFGHOwnersMember"
      decimals="-5"
      id="F20231019113055934_1"
      unitRef="USD">9800000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <flgc:FairValueDiscount
      contextRef="C_20221201to20221223_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFGHOwnersMember"
      decimals="3"
      id="F20231019113055935_2"
      unitRef="Pure">0.075</flgc:FairValueDiscount>
    <us-gaap:CommonUnitIssued
      contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="F20231019113055935_3"
      unitRef="Shares">625000</us-gaap:CommonUnitIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="F20231019113055935_4"
      unitRef="USD_Per_Share">8</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssued1
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="-5"
      id="F20231019113055935_5"
      unitRef="USD">5000000</us-gaap:StockIssued1>
    <flgc:NumberOfWarrantsIssuedDuringPeriod
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="F20231019113055936_6"
      unitRef="Shares">625000</flgc:NumberOfWarrantsIssuedDuringPeriod>
    <flgc:WarrantsIssuedDuringPeriodExercisePrice
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="F20231019113055936_7"
      unitRef="USD_Per_Share">8</flgc:WarrantsIssuedDuringPeriodExercisePrice>
    <flgc:NumberOfWarrantsWithAmendedExercisePrice
      contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="INF"
      id="F20231019113055936_8"
      unitRef="Shares">66250</flgc:NumberOfWarrantsWithAmendedExercisePrice>
    <flgc:WarrantExercisePricePriorToAmendment
      contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="INF"
      id="F20231019113055936_9"
      unitRef="USD_Per_Share">75</flgc:WarrantExercisePricePriorToAmendment>
    <flgc:WarrantAmendedExercisePrice
      contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="INF"
      id="F20231019113055936_10"
      unitRef="USD_Per_Share">8</flgc:WarrantAmendedExercisePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="-5"
      id="F20231019113055937_11"
      unitRef="USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <flgc:NumberOfWarrantsIssuedDuringPeriod
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="0"
      id="F20231019113055937_12"
      unitRef="Shares">25000</flgc:NumberOfWarrantsIssuedDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20220201to20220225_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustCBDOwnersMember"
      decimals="0"
      id="F20231019113055937_13"
      unitRef="Shares">475000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20220201to20220225_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustCBDOwnersMember"
      decimals="-5"
      id="F20231019113055937_14"
      unitRef="USD">14700000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <flgc:FairValueDiscount
      contextRef="C_20220201to20220225_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustCBDOwnersMember"
      decimals="2"
      id="F20231019113055937_15"
      unitRef="Pure">0.15</flgc:FairValueDiscount>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember"
      decimals="0"
      id="F20231019113055938_16"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember"
      decimals="-5"
      id="F20231019113055938_17"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember"
      decimals="2"
      id="F20231019113055938_18"
      unitRef="Pure">0.13</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember"
      decimals="0"
      id="F20231019113055938_19"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20220118_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraBeautyMember"
      decimals="INF"
      id="F20231019113055939_20"
      unitRef="USD_Per_Share">34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20220101to20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember"
      decimals="0"
      id="F20231019113055939_21"
      unitRef="Shares">1514</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20220101to20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember"
      decimals="-4"
      id="F20231019113055939_22"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_20220131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcFloraMedSasMember"
      decimals="2"
      id="F20231019113055939_23"
      unitRef="Pure">0.10</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_20220101to20220131"
      decimals="0"
      id="F20231019113055939_24"
      unitRef="Shares">5555</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="C_20220101to20220131"
      decimals="-5"
      id="F20231019113055940_25"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20220131"
      decimals="0"
      id="F20231019113055940_26"
      unitRef="Shares">4166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20220131"
      decimals="INF"
      id="F20231019113055940_27"
      unitRef="USD_Per_Share">45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_20220401to20220405"
      decimals="0"
      id="F20231019113055940_28"
      unitRef="Shares">35000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="C_20220401to20220405"
      decimals="-5"
      id="F20231019113055941_29"
      unitRef="USD">1300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="C_20220401to20220405"
      decimals="-5"
      id="F20231019113055941_30"
      unitRef="USD">400000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_20220101to20221231"
      decimals="0"
      id="F20231019113055943_31"
      unitRef="Shares">18411</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113055944_32"
      unitRef="USD">300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113056114_171">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;p style="margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;16.&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left: 15pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;SHARE BASED COMPENSATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;
                                        &lt;div style="text-align: justify; margin-bottom: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company adopted the Flora Growth Corp. 2022 Incentive Compensation Plan (the "2022 Plan") to attract, retain and motivate independent directors, executives, key employees and consultants. The 2022 Plan was approved by the Company's shareholders on July 5, 2022, and reserves an aggregate of 300,000 of the Company's common shares for issuance in connection with Awards (as defined in the 2022 Plan) granted under the 2022 Plan. The 2022 Plan was amended on June 6, 2023, with approval from the Company's shareholders, to increase the shares available under the 2022 Plan from 300,000 to 950,000. Previously, the Company's shareholders had adopted a "rolling" stock option plan (the "Prior Plan") which authorized the Company to grant stock options constituting up to 10% of the Company's issued and outstanding common shares at the time of each option grant. Since the adoption of the 2022 Plan, no further grants have been made or will be made under the Prior Plan; however, any currently outstanding stock options granted prior to July 5, 2022 will remain in effect until they have been exercised or terminated or have expired in accordance with the terms of the Prior Plan. Under the 2022 Plan, the Compensation Committee of our Board of Directors (the "Committee") may grant a variety of awards including stock options, stock appreciation rights ("SAR"s), restricted stock, restricted stock units, dividend equivalents and other stock-based awards. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                    &lt;/div&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;

                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On December 15, 2023, the Company &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;proposed to grant, upon approval by a majority of shareholders at the Company&#x2019;s next annual meeting,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt; Clifford Starke, the current CEO of the Company, SARs valued at 12% of the total outstanding shares of the Company on the grant date, which vest in 12 tranches with each tranche representing 1% of the total outstanding shares of the Company. The exercise price of the SARs is the closing share price of the Company's shares on the grant date. The first tranche will vest upon the Company's share price increasing by 50% from the Company's closing share price on the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest. The SARs expire 10 years from the grant date with a post-termination exercise period of one year. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;On December 15, 2023, the Company &lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;proposed to grant, upon approval by a majority of shareholders at the Company&#x2019;s next annual meeting&lt;/span&gt;,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt; Dany Vaiman, the current CFO of the Company, SARs valued at 4% of the total outstanding shares of the Company on the grant date, which vest in 8 tranches with each tranche representing 0.5% of the total outstanding shares of the Company. The exercise price of the SARs is the closing share price on the grant date. The first tranche will vest upon the Company's share price increasing by 50% from the closing share price as of the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest. The SARs expire 10 years from the grant date with a post-termination exercise period of one year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;All &lt;/span&gt;&lt;/span&gt;&lt;span&gt;SARs proposed grants to Mr. Starke and Mr. Vaiman remain unexercisable, and subject to forfeiture, unless the Company's shareholders approve such SAR grant at the Company's annual shareholder meeting&lt;/span&gt;&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;OPTIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock options granted under the Prior Plan are non-transferable and non-assignable and may be granted for a term not exceeding five years. Under the 2022 Plan, stock options may be granted with a term of up to ten years and in the case of all stock options, the exercise price may not be less than 100% of the fair market value of a Common Share on the date the award is granted. Stock option vesting terms are subject to the discretion of the Committee. Common shares are newly issued from available authorized shares upon exercise of awards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Information relating to share options outstanding and exercisable as at December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;

                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;
                                                    &lt;div&gt;
                                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Number of&lt;br/&gt;options (in&lt;br/&gt;thousands)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Number of&lt;br/&gt;options (in&lt;br/&gt;thousands)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;272&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;39.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;272&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;39.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;19.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;29.60&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;52.44&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;54.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;34.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;41.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;5&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;7.00&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;14&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;17.43&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(246&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;35.05&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(182&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;42.31&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Balance, December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;49&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;27.04&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;44&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;29.30&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                        &lt;/table&gt;
                                                    &lt;/div&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;


                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;&#160;
                                            &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Date of expiry&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Options&lt;br/&gt;outstanding &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Options&lt;br/&gt;exercisable&lt;/b&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Exercise&lt;br/&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 14%; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Grant date fair value&lt;br/&gt;vested &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Remaining life in&lt;br/&gt;years &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Thousands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Thousands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td colspan="3" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Thousands of Dollars&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                June 28, 2024
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 14%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                0.5
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                July 15, 2025
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;45.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                1.5
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                December 23, 2025
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;45.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                2.0
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                September 25, 2026
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;138.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;205&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                2.7
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                December 16, 2026
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;40.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;185&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                3.0
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                January 17, 2027
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;34.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                3.0
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                January 26, 2027
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                3.1
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                March 17, 2033
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                9.2
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                July 5, 2033
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; width: 14%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                9.5
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;27.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 14%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;861&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                2.8
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                            &lt;/table&gt;
                                            &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;

                    &lt;div&gt;

                    &lt;/div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The fair value of stock options issued during the years ended December 31, 2023 and 2022 was determined at the time of issuance using the Black-Scholes option pricing model with the following weighted average inputs, assumptions and results:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Risk-free annual interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2.77%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.85%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current stock price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6.90&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;18.95&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Expected annualized volatility&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;100%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;
                                                            10
                                                        &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                        7
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Expected annual dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Exercise price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7.00&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7.00&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;
                    &lt;/div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The total benefit related to the options granted in the year ended December 31, 2023 was less than $0.1 million (2022 - $3.0 million expense). This (benefit) expense is included in the share based compensation line on the statement of comprehensive loss. Generally, the options granted in 2023 and 2022 vest one to two years following the date of grant provided that the recipient is still employed or engaged by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;During the year ended December 31, 2023, 245,959 (2022 - 45,187) unexercised stock options expired following the termination of certain employees and were charged to deficit.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The intrinsic value of options exercised for the year ended December 31, 2023 was $nil ($0.8 million in 2022). The total fair value of options vested during the year ended December 31, 2023 was $0.1 million ($4.0 million in 2022).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For the years ended December 31, 2023 and 2022, there has been no recognized income tax benefits associated with stock options, and no amounts capitalized as part of the cost of an asset.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At December 31, 2023 the total remaining stock option cost for nonvested awards is expected to be less than $0.1 million over a weighted average future period of 0.2 years until the awards vest. A total of 5,000 options issued in 2023 will vest in 2024 provided if the award holder is still employed or engaged by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px; text-align: justify;"&gt;&lt;b&gt;RESTRICTED STOCK AWARDS&lt;/b&gt;&lt;/p&gt;
                    &lt;p style="font-size: 10pt; font-family: Times New Roman; margin: 10pt 0px; text-align: justify;"&gt;Restricted stock is a grant of common shares which may not be sold or disposed of, and which is subject to such risks of forfeiture and other restrictions as the Committee, in its discretion, may impose. A participant granted restricted stock generally has all of the rights of a shareholder of the Company, unless otherwise determined by the Committee. Subject to certain exceptions, the vesting of restricted stock awards is subject to the holder&#x2019;s continued employment or engagement through the applicable vesting date. Unvested restricted stock awards will be forfeited if the holder&#x2019;s employment or engagement ceases during the vesting period and may, in certain circumstances, be accelerated. The Company values restricted stock awards based on the closing share price of the Company&#x2019;s common shares as of the date of grant. The fair value of the restricted stock award is recorded as expense over the vesting period.&lt;/p&gt;
                    &lt;div&gt;

                    &lt;/div&gt;
                    &lt;p style="font-size: 10pt; font-family: Times New Roman; margin: 0px 0px 10pt; text-align: justify;"&gt;Information relating to restricted stock awards outstanding as at December 31, 2023 and December 31, 2022:&lt;/p&gt;

                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Number of&lt;br/&gt;restricted stock&lt;br/&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Weighted&lt;br/&gt;average grant&lt;br/&gt;date fair value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Thousands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;14.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;838&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(174&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(8.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(419&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(2.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;391&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;

                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The total expense related to the restricted stock awards in the year ended December 31, 2023 was $1.1 million (2022 - $0.4 million). This expense is included in the share based compensation line on the consolidated statements of loss and comprehensive loss. For the years ended December 31, 2023 and 2022, there has been no recognized income tax benefits associated with restricted stock awards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company issued 363,617 restricted stock awards that vested immediately on November 15, 2023 at a total fair value of $0.3 million. The Company issued 1,000 restricted stock awards that vested immediately on September 28, 2022 at a total fair value of less than $0.1 million. The remaining restricted stock awards issued in 2023 and 2022 vest over the next three years provided the award holder is still employed or engaged by the Company. As of December 31, 2023, the Company had $0.1 million of unrecognized compensation expense related to restricted stock awards which will be recognized over the next three years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A total of 174,304 restricted stock awards expired or were forfeited in the year ended December 31, 2023 (2022 - $nil).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20220705"
      decimals="INF"
      id="Fxbrl_20240306001336259"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20220705"
      decimals="INF"
      id="Fxbrl_20240306012000977"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20230606"
      decimals="INF"
      id="Fxbrl_20240306012019167"
      unitRef="Shares">950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      id="Fxbrl_20240419144720236">SARs valued at 12% of the total outstanding shares of the Company on the grant date, which vest in 12 tranches with each tranche representing 1% of the total outstanding shares of the Company</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      id="Fxbrl_20240306030227390">The first tranche will vest upon the Company's share price increasing by 50% from the Company's closing share price on the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      id="Fxbrl_20240306030322999">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <flgc:PostTerminationExercisePeriod
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      id="Fxbrl_20240306030408371">P1Y</flgc:PostTerminationExercisePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      id="Fxbrl_20240419144747220">SARs valued at 4% of the total outstanding shares of the Company on the grant date, which vest in 8 tranches with each tranche representing 0.5% of the total outstanding shares of the Company</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      id="Fxbrl_20240306030250514">The first tranche will vest upon the Company's share price increasing by 50% from the closing share price as of the grant date with each tranche thereafter requiring an additional 50% increase in share price to vest</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      id="Fxbrl_20240306030302917">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <flgc:PostTerminationExercisePeriod
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      id="Fxbrl_20240306030421465">P1Y</flgc:PostTerminationExercisePeriod>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="C_20230101to20231231" id="F20231019113055964_1">
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;div&gt;
                                                    &lt;div&gt;
                                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Number of&lt;br/&gt;options (in&lt;br/&gt;thousands)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Number of&lt;br/&gt;options (in&lt;br/&gt;thousands)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;272&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;39.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;272&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;39.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;19.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;29.60&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;52.44&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;54.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;34.17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;41.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;5&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;7.00&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;14&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;17.43&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(246&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;35.05&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;(182&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;42.31&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                            &lt;tr&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Balance, December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;49&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;27.04&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;44&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;29.30&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                            &lt;/tr&gt;
                                                        &lt;/table&gt;
                                                    &lt;/div&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;

                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;div&gt;
                                        &lt;div&gt;&#160;
                                            &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Date of expiry&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Options&lt;br/&gt;outstanding &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Options&lt;br/&gt;exercisable&lt;/b&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Exercise&lt;br/&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 14%; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Grant date fair value&lt;br/&gt;vested &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Remaining life in&lt;br/&gt;years &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Thousands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Thousands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td colspan="3" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Thousands of Dollars&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                June 28, 2024
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 14%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                0.5
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                July 15, 2025
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;45.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                1.5
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                December 23, 2025
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;45.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                2.0
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                September 25, 2026
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;138.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;205&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                2.7
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                December 16, 2026
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;40.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;185&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                3.0
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                January 17, 2027
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;34.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                3.0
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                January 26, 2027
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                3.1
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                March 17, 2033
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 14%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                9.2
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                July 5, 2033
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: center; border-bottom: 0.75pt solid #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; border-bottom: 0.75pt solid #000000; width: 14%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; border-bottom: 0.75pt solid #000000; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                9.5
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;27.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 14%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;861&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                                2.8
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                            &lt;/table&gt;
                                            &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20231019113055965_2"
      unitRef="Shares">272000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113055965_3"
      unitRef="USD_Per_Share">39.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20211231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="F20231019113055966_4"
      unitRef="Shares">272000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_20211231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="2"
      id="F20231019113055967_5"
      unitRef="USD_Per_Share">39.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20231019113055968_6"
      unitRef="Shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113055971_7"
      unitRef="USD_Per_Share">19.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="F20231019113055972_8"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="INF"
      id="F20231019113055973_9"
      unitRef="USD_Per_Share">29.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20231019113055973_10"
      unitRef="Shares">27000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113055974_11"
      unitRef="USD_Per_Share">3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="F20231019113055975_12"
      unitRef="Shares">27000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="INF"
      id="F20231019113055976_13"
      unitRef="USD_Per_Share">3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="Fxbrl_20240306023629637_20231019113055973_10"
      unitRef="Shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="Fxbrl_20240306023629637_20231019113055974_11"
      unitRef="USD_Per_Share">52.44</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="Fxbrl_20240306023629637_20231019113055975_12"
      unitRef="Shares">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="INF"
      id="Fxbrl_20240306023629637_20231019113055976_13"
      unitRef="USD_Per_Share">54.39</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="Fxbrl_20240306014522236"
      unitRef="Shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113055977_15"
      unitRef="USD_Per_Share">34.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="F20231019113056115_172"
      unitRef="Shares">212000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="INF"
      id="F20231019113055978_16"
      unitRef="USD_Per_Share">41.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20231019113055979_17"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113055980_18"
      unitRef="USD_Per_Share">7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="F20231019113056116_173"
      unitRef="Shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="INF"
      id="F20231019113055980_19"
      unitRef="USD_Per_Share">17.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="Fxbrl_20240306023720045_xbrl_20240306023629637_20231019113055973_10"
      unitRef="Shares">246000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="Fxbrl_20240306023720045_xbrl_20240306023629637_20231019113055974_11"
      unitRef="USD_Per_Share">35.05</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="Fxbrl_20240306023720045_xbrl_20240306023629637_20231019113055975_12"
      unitRef="Shares">182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="INF"
      id="Fxbrl_20240306023720045_xbrl_20240306023629637_20231019113055976_13"
      unitRef="USD_Per_Share">42.31</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="Fxbrl_20231025100527496"
      unitRef="Shares">49000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="Fxbrl_20231025100557051"
      unitRef="USD_Per_Share">27.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="F20231019113056118_176"
      unitRef="Shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="INF"
      id="F20231019113055988_26"
      unitRef="USD_Per_Share">29.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember"
      id="F20231019113055989_27">June 28, 2024</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember"
      decimals="-3"
      id="F20231019113055990_28"
      unitRef="Shares">17000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember"
      decimals="-3"
      id="F20231019113055991_29"
      unitRef="Shares">17000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember"
      decimals="INF"
      id="F20231019113055992_30"
      unitRef="USD_Per_Share">3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember"
      decimals="-3"
      id="F20231019113055992_31"
      unitRef="USD">13000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsOneMember"
      id="F20231019113055993_32">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember"
      id="F20231019113055994_33">July 15, 2025</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember"
      decimals="-3"
      id="F20231019113055995_34"
      unitRef="Shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember"
      decimals="-3"
      id="F20231019113055995_35"
      unitRef="Shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember"
      decimals="INF"
      id="F20231019113055996_36"
      unitRef="USD_Per_Share">45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember"
      decimals="-3"
      id="F20231019113055997_37"
      unitRef="USD">83000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsTwoMember"
      id="F20231019113055998_38">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember"
      id="F20231019113056000_39">December 23, 2025</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember"
      decimals="-3"
      id="F20231019113056001_40"
      unitRef="Shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember"
      decimals="-3"
      id="F20231019113056001_41"
      unitRef="Shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember"
      decimals="INF"
      id="F20231019113056002_42"
      unitRef="USD_Per_Share">45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember"
      decimals="-3"
      id="F20231019113056003_43"
      unitRef="USD">230000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsThreeMember"
      id="F20231019113056004_44">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember"
      id="F20231019113056005_45">September 25, 2026</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember"
      decimals="-3"
      id="F20231019113056005_46"
      unitRef="Shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember"
      decimals="-3"
      id="F20231019113056006_47"
      unitRef="Shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember"
      decimals="INF"
      id="F20231019113056007_48"
      unitRef="USD_Per_Share">138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember"
      decimals="-3"
      id="F20231019113056008_49"
      unitRef="USD">205000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFourMember"
      id="F20231019113056008_50">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember"
      id="F20231019113056009_51">December 16, 2026</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember"
      decimals="-3"
      id="F20231019113056010_52"
      unitRef="Shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember"
      decimals="-3"
      id="F20231019113056011_53"
      unitRef="Shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember"
      decimals="INF"
      id="F20231019113056012_54"
      unitRef="USD_Per_Share">40.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember"
      decimals="-3"
      id="F20231019113056014_55"
      unitRef="USD">185000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsFiveMember"
      id="F20231019113056015_56">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember"
      id="F20231019113056016_57">January 17, 2027</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember"
      decimals="-3"
      id="F20231019113056016_58"
      unitRef="Shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember"
      decimals="-3"
      id="F20231019113056017_59"
      unitRef="Shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember"
      decimals="INF"
      id="F20231019113056018_60"
      unitRef="USD_Per_Share">34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember"
      decimals="-3"
      id="F20231019113056019_61"
      unitRef="USD">63000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSixMember"
      id="F20231019113056019_62">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember"
      id="F20231019113056020_63">January 26, 2027</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember"
      decimals="-3"
      id="F20231019113056021_64"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember"
      decimals="-3"
      id="F20231019113056022_65"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember"
      decimals="INF"
      id="F20231019113056022_66"
      unitRef="USD_Per_Share">29.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember"
      decimals="-3"
      id="F20231019113056023_67"
      unitRef="USD">25000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsSevenMember"
      id="F20231019113056024_68">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember"
      id="F20231019113056025_69">March 17, 2033</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember"
      decimals="-3"
      id="F20231019113056026_70"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember"
      decimals="-3"
      id="F20231019113056028_71"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember"
      decimals="INF"
      id="F20231019113056029_72"
      unitRef="USD_Per_Share">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember"
      decimals="-3"
      id="F20231019113056029_73"
      unitRef="USD">26000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsEightMember"
      id="F20231019113056030_74">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <flgc:StockOptionDateOfExpiry
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember"
      id="F20231019113056031_75">July 5, 2033</flgc:StockOptionDateOfExpiry>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember"
      decimals="-3"
      id="F20231019113056032_76"
      unitRef="Shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember"
      decimals="-3"
      id="F20231019113056033_77"
      unitRef="Shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember"
      decimals="INF"
      id="F20231019113056033_78"
      unitRef="USD_Per_Share">13.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember"
      decimals="-3"
      id="F20231019113056034_79"
      unitRef="USD">31000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_flgcRangesOfExercisePricesForOutstandingShareOptionsNineMember"
      id="F20231019113056035_80">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="Fxbrl_20231025100650842"
      unitRef="Shares">49000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcOptionsExercisableMember"
      decimals="-3"
      id="F20231019113056078_131"
      unitRef="Shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20231025100717635"
      unitRef="USD_Per_Share">27.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20231019113056079_132"
      unitRef="USD">861000</flgc:ShareBasedCompensationOptionsVestedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      id="F20231019113056080_133">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113056081_134">
                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Risk-free annual interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2.77%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.85%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current stock price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6.90&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 22%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;18.95&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Expected annualized volatility&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;100%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;
                                                            10
                                                        &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                        7
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Expected annual dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Exercise price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7.00&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7.00&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 22%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="4"
      id="F20231019113056083_135"
      unitRef="Pure">0.0277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="4"
      id="F20231019113056084_136"
      unitRef="Pure">0.0285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="INF"
      id="F20231019113056085_137"
      unitRef="USD_Per_Share">6.9</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="INF"
      id="F20231019113056086_138"
      unitRef="USD_Per_Share">18.95</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113056087_139"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113056087_140"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      id="F20231019113056088_141">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      id="F20231019113056089_142">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113056090_143"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20231019113056090_144"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="INF"
      id="Fxbrl_20240306122516749"
      unitRef="USD_Per_Share">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="INF"
      id="F20231019113056092_146"
      unitRef="USD_Per_Share">19.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="INF"
      id="F20231019113056093_147"
      unitRef="USD_Per_Share">7</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="INF"
      id="F20231019113056094_148"
      unitRef="USD_Per_Share">19.16</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113056094_149"
      unitRef="USD">-100000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113056095_150"
      unitRef="USD">3000000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="F20231019113056097_151"
      unitRef="Shares">245959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20231025101311550"
      unitRef="Shares">45187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_20230101to20231231"
      decimals="-6"
      id="F20231019113056098_152"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113056099_153"
      unitRef="USD">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113056100_154"
      unitRef="USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113056101_155"
      unitRef="USD">4000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20231231"
      decimals="-5"
      id="F20231019113056101_156"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <flgc:RemainingWeightedAverageVestingPeriod
      contextRef="C_20230101to20231231"
      id="F20231019113056102_157">P0Y2M12D</flgc:RemainingWeightedAverageVestingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_20231231"
      decimals="INF"
      id="F20231019113056103_158"
      unitRef="Shares">5000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <flgc:ScheduleOfRestrictedStockAwards
      contextRef="C_20230101to20231231"
      id="F20231019113056104_160">
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Number of&lt;br/&gt;restricted stock&lt;br/&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Weighted&lt;br/&gt;average grant&lt;br/&gt;date fair value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Thousands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;14.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;838&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(174&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(8.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(419&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(2.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;391&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 2.25pt double #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    </flgc:ScheduleOfRestrictedStockAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20211231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="F20231019113056105_161"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20211231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="0"
      id="F20231019113056106_162"
      unitRef="USD_Per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="F20231019113056107_163"
      unitRef="Shares">147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="F20231019113056107_164"
      unitRef="USD_Per_Share">13.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="F20231019113056108_165"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="F20231019113056109_166"
      unitRef="USD_Per_Share">14.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fxbrl_20240306020138262_20231019113056105_161"
      unitRef="Shares">146000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20240306020138262_20231019113056106_162"
      unitRef="USD_Per_Share">13.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fxbrl_20240306020147605_20231019113056107_163"
      unitRef="Shares">838000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20240306020147605_20231019113056107_164"
      unitRef="USD_Per_Share">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fxbrl_20240306020152741_20231019113056108_165"
      unitRef="Shares">174000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20240306020152741_20231019113056109_166"
      unitRef="USD_Per_Share">8.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fxbrl_20240306122630213_xbrl_20240306020152741_20231019113056108_165"
      unitRef="Shares">419000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20240306122630213_xbrl_20240306020152741_20231019113056109_166"
      unitRef="USD_Per_Share">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fxbrl_20240306020140477_20231019113056105_161"
      unitRef="Shares">391000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20240306020140477_20231019113056106_162"
      unitRef="USD_Per_Share">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="F20231019113056111_167"
      unitRef="USD">1100000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fxbrl_20231025103311462"
      unitRef="USD">400000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_20231101to20231115_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="F20231019113056112_168"
      unitRef="Shares">363617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <flgc:FairValueOfRestrictedStockAwardsIssued
      contextRef="C_20231101to20231115_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="F20231019113056112_169"
      unitRef="USD">300000</flgc:FairValueOfRestrictedStockAwardsIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_20220901to20220928_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20240306022535429"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <flgc:FairValueOfRestrictedStockAwardsIssued
      contextRef="C_20220901to20220928_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fxbrl_20240306022605807"
      unitRef="USD">100000</flgc:FairValueOfRestrictedStockAwardsIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="F20231019113056113_170"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20240306023906700"
      unitRef="Shares">174304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fxbrl_20240306023917167"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <flgc:WarrantsDisclosureTextBlock contextRef="C_20230101to20231231" id="F20231019113056133_0">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;17.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;WARRANTS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On September 21, 2023, the Company issued 1,369,000 warrants issued as part of the September 2023 unit offering (Note 15). Each warrant permits the holder to purchase one common share of the Company through March 21, 2029 for $2.50. The issue date fair value of the warrants was estimated at $1.1 million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 100% based on comparable companies; risk-free interest rate of 4.3% and an expected life of 5.5 years. The resulting grant date fair value of each warrant was $0.82. Additionally, the Company amended the exercise price with respect to 66,245 and 624,995 warrants that (Note 15) that were previously issued in the November 2021 and December 2022 (described below) offerings, respectively, from $8.00 per share to $2.50 per share and recorded at $0.2 million gain on these warrant modifications.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Related to the September 2023 unit offering, 54,760 warrants were issued to the placement agent and recorded as issuance costs to share capital. Each warrant permits the holder to purchase one common share of the Company after the 181st day immediately following the date of issuance through September 21, 2028 for $2.39. The issue date fair value of the warrants was estimated at $0.1 million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 100% based on comparable companies; risk-free interest rate of 4.25% and an expected life of 5 years. The resulting grant date fair value of each warrant was $1.48.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On December 8, 2022, the Company issued 625,000 warrants issued as part of the December 2022 unit offering (Note 15). Each warrant permits the holder to purchase one common share of the Company through December 8, 2027 for $8.00. The issue date fair value of the warrants was estimated at $2.0 million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 100%&#160;based on comparable companies; risk-free interest rate of 3.0% and an expected life of 5 years. The resulting grant date fair value of each warrant was $3.25. Additionally, the Company amended the exercise price with respect to 66,250 warrants (Note 15) that were previously issued in the November 2021 offering from $75.00 per share to $8.00 per share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="margin: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Related to the December 2022 unit offering, 25,000 warrants were issued to the placement agent and recorded as issuance costs to share capital. Each warrant permits the holder to purchase one common share of the Company after the 180th day immediately following the date of issuance through December 8, 2027 for $8.00. The issue date fair value of the warrants was estimated at $0.1 million using the Black Scholes option pricing model with the following assumptions: expected dividend yield of 0%; expected volatility of 100% based on comparable companies; risk-free interest rate of 3.0% and an expected life of 5 years. The resulting grant date fair value of each warrant was $5.95.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The intrinsic value of warrants exercised for the year ended December 31, 2023 was less than $0.1 million ($0.5 million in 2022). The total fair value of warrants vested during the year ended December 31, 2023 was $1.3 million ($2.3 million in 2022).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For all warrants, common shares are newly issued from available authorized shares upon exercise of awards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;The following tables show warrants outstanding as at December 31, 2023:&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Number of warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Weighted average&lt;br/&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;438&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;67.46&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(103&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;60.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;650&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;961&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24.84&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,115&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,384&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9.90&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        &lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Date of expiry&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Warrants&lt;br/&gt;outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Exercise&lt;br/&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Grant date fair&lt;br/&gt;value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Remaining life&lt;br/&gt;in years&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                November 18, 2026
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;75.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,700&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                2.88
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                November 18, 2027
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,055&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                3.88
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                December 8, 2027
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                3.94
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                September 21, 2028
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;522&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                4.73
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                September 21, 2028
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                4.73
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                March 21, 2029
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,339&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                5.22
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,846&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                4.83
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                    &lt;/div&gt;
                &lt;/div&gt;
            </flgc:WarrantsDisclosureTextBlock>
    <flgc:NumberOfWarrantsIssuedDuringPeriod
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="INF"
      id="F20231019113056133_1"
      unitRef="Shares">1369000</flgc:NumberOfWarrantsIssuedDuringPeriod>
    <flgc:WarrantsIssuedDuringPeriodExercisePrice
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20231023113822705"
      unitRef="USD_Per_Share">2.5</flgc:WarrantsIssuedDuringPeriodExercisePrice>
    <flgc:FairValueOfWarrantsIssuedDuringPeriod
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="-5"
      id="F20231019113056133_2"
      unitRef="USD">1100000</flgc:FairValueOfWarrantsIssuedDuringPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="F20231019113056133_3"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="F20231019113056133_4"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="3"
      id="F20231019113056134_5"
      unitRef="Pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      id="F20231019113056134_6">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="F20231019113056134_7"
      unitRef="USD_Per_Share">0.82</flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant>
    <flgc:NumberOfWarrantsWithExercisePriceAmended
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20231023114819976"
      unitRef="Shares">66245</flgc:NumberOfWarrantsWithExercisePriceAmended>
    <flgc:NumberOfWarrantsWithExercisePriceAmended
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240305173409286"
      unitRef="Shares">624995</flgc:NumberOfWarrantsWithExercisePriceAmended>
    <flgc:WarrantExercisePricePriorToAmendment
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240422110210583"
      unitRef="USD_Per_Share">8</flgc:WarrantExercisePricePriorToAmendment>
    <flgc:WarrantExercisePricePriorToAmendment
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20231023114909403"
      unitRef="USD_Per_Share">8</flgc:WarrantExercisePricePriorToAmendment>
    <flgc:WarrantAmendedExercisePrice
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240422110217028"
      unitRef="USD_Per_Share">2.5</flgc:WarrantAmendedExercisePrice>
    <flgc:WarrantAmendedExercisePrice
      contextRef="C_20230921_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20231023115327739"
      unitRef="USD_Per_Share">2.5</flgc:WarrantAmendedExercisePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_20230901to20230921_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="-5"
      id="Fxbrl_20240306151543863"
      unitRef="USD">200000</us-gaap:FairValueAdjustmentOfWarrants>
    <flgc:NumberOfWarrantsIssuedDuringPeriod
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="INF"
      id="F20231019113056134_8"
      unitRef="Shares">54760</flgc:NumberOfWarrantsIssuedDuringPeriod>
    <flgc:WarrantsIssuedDuringPeriodExercisePrice
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20231023114142001"
      unitRef="USD_Per_Share">2.39</flgc:WarrantsIssuedDuringPeriodExercisePrice>
    <flgc:FairValueOfWarrantsIssuedDuringPeriod
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="-5"
      id="F20231019113056134_9"
      unitRef="USD">100000</flgc:FairValueOfWarrantsIssuedDuringPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="F20231019113056134_10"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="F20231019113056135_11"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="4"
      id="F20231019113056135_12"
      unitRef="Pure">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      id="F20231019113056135_13">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant
      contextRef="C_20230901to20230921_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcSeptemberTwoThousandTwentyThreeUnitOfferingMember"
      decimals="2"
      id="F20231019113056135_14"
      unitRef="USD_Per_Share">1.48</flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant>
    <flgc:NumberOfWarrantsIssuedDuringPeriod
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240305172406322"
      unitRef="Shares">625000</flgc:NumberOfWarrantsIssuedDuringPeriod>
    <flgc:WarrantsIssuedDuringPeriodExercisePrice
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240305180159495"
      unitRef="USD_Per_Share">8</flgc:WarrantsIssuedDuringPeriodExercisePrice>
    <flgc:FairValueOfWarrantsIssuedDuringPeriod
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="-5"
      id="Fxbrl_20240305180117817"
      unitRef="USD">2000000</flgc:FairValueOfWarrantsIssuedDuringPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240305172439752"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240422111340315"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="3"
      id="Fxbrl_20240305172456216"
      unitRef="Pure">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      id="Fxbrl_20240305172501272">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant
      contextRef="C_20221201to20221208_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240305172515369"
      unitRef="USD_Per_Share">3.25</flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant>
    <flgc:NumberOfWarrantsWithExercisePriceAmended
      contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="INF"
      id="Fxbrl_20240306151759032"
      unitRef="Shares">66250</flgc:NumberOfWarrantsWithExercisePriceAmended>
    <flgc:WarrantExercisePricePriorToAmendment
      contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240306151903741"
      unitRef="USD_Per_Share">75</flgc:WarrantExercisePricePriorToAmendment>
    <flgc:WarrantAmendedExercisePrice
      contextRef="C_20221208_usgaapRelatedPartyTransactionAxis_flgcNovemberTwoThousandTwentyOneUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240306151926888"
      unitRef="USD_Per_Share">8</flgc:WarrantAmendedExercisePrice>
    <flgc:NumberOfWarrantsIssuedDuringPeriod
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="INF"
      id="F20231019113056140_28"
      unitRef="Shares">25000</flgc:NumberOfWarrantsIssuedDuringPeriod>
    <flgc:WarrantsIssuedDuringPeriodExercisePrice
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20231023114308139"
      unitRef="USD_Per_Share">8</flgc:WarrantsIssuedDuringPeriodExercisePrice>
    <flgc:FairValueOfWarrantsIssuedDuringPeriod
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="-5"
      id="F20231019113056140_29"
      unitRef="USD">100000</flgc:FairValueOfWarrantsIssuedDuringPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="Fxbrl_20240305180257132"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="F20231019113056141_31"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="3"
      id="F20231019113056141_32"
      unitRef="Pure">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      id="F20231019113056141_33">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant
      contextRef="C_20221201to20221208_srtTitleOfIndividualAxis_flgcPlacementAgentMember_usgaapRelatedPartyTransactionAxis_flgcDecemberTwoThousandTwentyTwoUnitOfferingMember"
      decimals="2"
      id="F20231019113056141_34"
      unitRef="USD_Per_Share">5.95</flgc:ShareBasedCompensationWarrantsGrantDateFairValuePerWarrant>
    <flgc:IntrinsicValueOfWarrantsExercised
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113056141_35"
      unitRef="USD">100000</flgc:IntrinsicValueOfWarrantsExercised>
    <flgc:IntrinsicValueOfWarrantsExercised
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113056142_36"
      unitRef="USD">500000</flgc:IntrinsicValueOfWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113056142_37"
      unitRef="USD">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113056142_38"
      unitRef="USD">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <flgc:ScheduleOfWarrantsOutstandingTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305171328631">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Number of warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Weighted average&lt;br/&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;438&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;67.46&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(103&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;60.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;650&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;961&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24.84&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,115&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td colspan="2" style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,384&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9.90&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </flgc:ScheduleOfWarrantsOutstandingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20211231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20231019113056144_47"
      unitRef="Shares">438000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20211231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="F20231019113056144_48"
      unitRef="USD_Per_Share">67.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20231019113056142_41"
      unitRef="Shares">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <flgc:WeightedAverageExercisePriceOfWarrantsExercised
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="F20231019113056143_42"
      unitRef="USD_Per_Share">9.83</flgc:WeightedAverageExercisePriceOfWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20231019113056143_43"
      unitRef="Shares">103000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <flgc:WeightedAverageExercisePriceOfWarrantsCancelled
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="F20231019113056143_44"
      unitRef="USD_Per_Share">60</flgc:WeightedAverageExercisePriceOfWarrantsCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20231019113056143_45"
      unitRef="Shares">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <flgc:WeightedAverageExercisePriceOfWarrantsIssued
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="F20231019113056143_46"
      unitRef="USD_Per_Share">1.2</flgc:WeightedAverageExercisePriceOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="Fxbrl_20231023115931713"
      unitRef="Shares">961000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20221231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="Fxbrl_20231023115944690"
      unitRef="USD_Per_Share">24.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20231019113056144_49"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <flgc:WeightedAverageExercisePriceOfWarrantsExercised
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="F20231019113056144_50"
      unitRef="USD_Per_Share">8</flgc:WeightedAverageExercisePriceOfWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20231019113056144_51"
      unitRef="Shares">691000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <flgc:WeightedAverageExercisePriceOfWarrantsCancelled
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="F20231019113056144_52"
      unitRef="USD_Per_Share">8</flgc:WeightedAverageExercisePriceOfWarrantsCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20231019113056145_53"
      unitRef="Shares">2115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <flgc:WeightedAverageExercisePriceOfWarrantsIssued
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="F20231019113056145_54"
      unitRef="USD_Per_Share">2.5</flgc:WeightedAverageExercisePriceOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="Fxbrl_20240305174120553_xbrl_20231023115931713"
      unitRef="Shares">2384000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="INF"
      id="Fxbrl_20240305174120553_xbrl_20231023115944690"
      unitRef="USD_Per_Share">9.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305171316951">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Date of expiry&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Warrants&lt;br/&gt;outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Exercise&lt;br/&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Grant date fair&lt;br/&gt;value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Remaining life&lt;br/&gt;in years&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                November 18, 2026
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;75.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,700&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                2.88
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                November 18, 2027
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,055&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                3.88
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                December 8, 2027
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                3.94
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                September 21, 2028
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;522&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                4.73
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                September 21, 2028
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                4.73
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                March 21, 2029
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,339&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                5.22
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; padding-right: 5.4pt; padding-left: 5.4pt; border-top: 0.75pt solid #000000; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,846&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                4.83
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      id="F20231019113056145_55">November 18, 2026</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      decimals="-3"
      id="F20231019113056145_56"
      unitRef="Shares">221000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      decimals="2"
      id="F20231019113056145_57"
      unitRef="USD_Per_Share">75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      decimals="0"
      id="F20231019113056146_58"
      unitRef="USD">6700</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      id="F20231019113056146_59">P2Y10M17D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      id="F20231019113056146_60">November 18, 2027</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      decimals="-3"
      id="F20231019113056146_61"
      unitRef="Shares">23000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      decimals="2"
      id="F20231019113056146_62"
      unitRef="USD_Per_Share">66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      decimals="0"
      id="F20231019113056146_63"
      unitRef="USD">1055</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      id="F20231019113056147_64">P3Y10M17D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      id="F20231019113056147_65">December 8, 2027</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      decimals="-3"
      id="F20231019113056148_71"
      unitRef="Shares">25000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      decimals="2"
      id="F20231019113056148_72"
      unitRef="USD_Per_Share">8.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      decimals="0"
      id="F20231019113056148_73"
      unitRef="USD">149</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      id="F20231019113056148_74">P3Y11M8D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      id="Fxbrl_20240305174716627">September 21, 2028</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      decimals="-3"
      id="Fxbrl_20240305174700169_20231019113056148_71"
      unitRef="Shares">691000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      decimals="2"
      id="Fxbrl_20240305174700169_20231019113056148_72"
      unitRef="USD_Per_Share">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      decimals="0"
      id="Fxbrl_20240305174700169_20231019113056148_73"
      unitRef="USD">522</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      id="Fxbrl_20240305174700169_20231019113056148_74">P4Y8M23D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      id="Fxbrl_20240305174720418">September 21, 2028</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      decimals="-3"
      id="Fxbrl_20240305174826721_xbrl_20240305174700169_20231019113056148_71"
      unitRef="Shares">55000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      decimals="2"
      id="Fxbrl_20240305174826721_xbrl_20240305174700169_20231019113056148_72"
      unitRef="USD_Per_Share">2.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      decimals="0"
      id="Fxbrl_20240305174826721_xbrl_20240305174700169_20231019113056148_73"
      unitRef="USD">81</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      id="Fxbrl_20240305174826721_xbrl_20240305174700169_20231019113056148_74">P4Y8M23D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      id="Fxbrl_20240305174724122">March 21, 2029</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      decimals="-3"
      id="Fxbrl_20240305174829001_xbrl_20240305174700169_20231019113056148_71"
      unitRef="Shares">1369000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      decimals="2"
      id="Fxbrl_20240305174829001_xbrl_20240305174700169_20231019113056148_72"
      unitRef="USD_Per_Share">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      decimals="0"
      id="Fxbrl_20240305174829001_xbrl_20240305174700169_20231019113056148_73"
      unitRef="USD">1339</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      id="Fxbrl_20240305174829001_xbrl_20240305174700169_20231019113056148_74">P5Y2M19D</flgc:WarrantsRemainingLifeInYears>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember"
      decimals="-3"
      id="Fxbrl_20231023120018738"
      unitRef="Shares">2384000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember"
      decimals="2"
      id="Fxbrl_20231023120032650"
      unitRef="USD_Per_Share">9.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember"
      decimals="0"
      id="F20231019113056149_80"
      unitRef="USD">9846</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember"
      id="F20231019113056150_81">P4Y9M29D</flgc:WarrantsRemainingLifeInYears>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113056156_13">
                &lt;div&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;18.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;RELATED PARTY DISCLOSURES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Key management personnel compensation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In addition to their contracted fees, directors and officers also participate in the Company's stock option program. Certain executive officers are subject to termination notices of 6 to 24 months and change of control payments (Note 19). Key management personnel compensation is comprised of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                            &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; width: 1px; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Year ended&lt;br/&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 426.4px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Directors' and officers' compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,862&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,560&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,577&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;797&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 426.4px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,439&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,357&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;

                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company defines key management personnel as those persons having authority and responsibility for planning, directing, and controlling the activities of the Company directly or indirectly, and was determined to be executive officers and directors (executive and non-executive) of the Company. The remuneration of directors and key executives is determined by the Board of Directors of the Company having regard to the performance of individuals and market trends.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at December 31, 2023, $0.1 million of the above directors' and officers' compensation was included in the trade payables and accrued liabilities (2022 - $0.2 million). These amounts are unsecured, non-interest bearing and due on demand. The share-based compensation amount above for 2023 includes 110,000 common shares to the former Chief Executive Officer of the Company, valued at $0.4 million, that were recorded as share based compensation expense as part of a separation agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Related party transactions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prior to its acquisition by the Company, Harmony Health One, a subsidiary of FGH, entered into an Intellectual Property License Agreement with Hampstead Private Capital Limited ("Hampstead") - a corporation controlled by the CEO of the Company and former CEO of FGH. Under the terms of this agreement, Harmony is to pay Hampstead a royalty in the amount of 3.5% of the gross revenues from the sale of Harmony products. No royalty amounts have been recorded by the Company for the years ended December 31, 2023 and December 31, 2022, as there were no sales for the period after the Company acquired FGH.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prior to 2022, the Company entered into an agreement with Dr. Manalo-Morgan, a former member of the Company's board of directors, to serve in the additional capacity as Medical Advisor to the Company. In connection with this agreement, Dr. Manalo-Morgan was responsible for developing and identifying medical applications of cannabinoids for the Company for the treatment of various ailments and supporting the Company's public relations efforts and assisting the Company with its media engagements. For these services, the Company paid Dr. Manalo-Morgan $0.1 million and $0.2 million for the years ended December 31, 2023 and December 31, 2022, respectively. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305123314560">
                                &lt;div&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 60%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; width: 1px; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Year ended&lt;br/&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 426.4px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Directors' and officers' compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,862&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,560&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 426.4px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,577&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;797&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff; width: 426.4px;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1px; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,439&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 15%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,357&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &lt;/div&gt;
                            </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056156_0"
      unitRef="USD">1862000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056156_1"
      unitRef="USD">2560000</us-gaap:OfficersCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056156_2"
      unitRef="USD">1577000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056156_3"
      unitRef="USD">797000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056156_4"
      unitRef="USD">3439000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056156_5"
      unitRef="USD">3357000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember"
      decimals="-5"
      id="Fxbrl_20240306055613042"
      unitRef="USD">100000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember"
      decimals="-5"
      id="F20231019113056156_7"
      unitRef="USD">200000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember"
      decimals="INF"
      id="F20231019113056156_8"
      unitRef="Shares">110000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtChiefExecutiveOfficerMember"
      decimals="-5"
      id="F20231019113056156_9"
      unitRef="USD">400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <flgc:RoyaltyOnGrossRevenuesFromSaleOfProducts
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcHampsteadPrivateCapitalLimitedMember"
      decimals="3"
      id="F20231019113056156_10"
      unitRef="Pure">0.035</flgc:RoyaltyOnGrossRevenuesFromSaleOfProducts>
    <flgc:MedicalServices
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcDrManaloMorganMember"
      decimals="-5"
      id="F20231019113056156_11"
      unitRef="USD">100000</flgc:MedicalServices>
    <flgc:MedicalServices
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcDrManaloMorganMember"
      decimals="-5"
      id="F20231019113056156_12"
      unitRef="USD">200000</flgc:MedicalServices>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113056165_33">
                &lt;div&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;19.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;An indemnification arrangement exists when one party has contractually agreed to reimburse another party for losses incurred because of circumstances that existed prior to the arrangement. The Company and its legal counsel assess whether a legal agreement exists and the maximum potential loss to be reimbursed.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's current known provisions and contingent liabilities consist of termination benefits and legal disputes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Termination benefits&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Legal disputes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Sales tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance as at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,831&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,044&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Payments/settlements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(183&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(281&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Additional provisions&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;707&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;715&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Foreign currency translation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance as at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,962&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,538&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;

                            &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                            &lt;div&gt;

                            &lt;/div&gt;
                            &lt;p style="margin: 0pt 0pt 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The termination benefits related to contractual termination benefits owed to a former board member of the Company, a consultant and a former member of the management team. The amounts were recorded within contingencies on the consolidated statements of financial position and $nil expense (2022 - $0.4 million) on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The legal disputes from 2022 relate to the settlement of two contractual disputes involving the Company. The first involves a third party that entered into a conditional share grant arrangement dated April 2, 2019 with Franchise Cannabis Corp and Rangers Pharmaceuticals A/S - two entities that were part of the Company's acquisition of FGH in December 2022. In January 2023, the Company entered into a settlement agreement with this third party pursuant to which the Company issued 16,250 common shares of the Company, valued at $0.1 million, to the third party to settle the dispute. The provision balance as of December 31, 2022 reflected the value of the Company's shares as of the date of the settlement agreement. The second dispute involves a former shareholder of ACA Mueller, an entity that was part of the Company's acquisition of FGH in December 2022, who filed a statement of claim against a wholly-owned subsidiary of the Company in the Constance Regional Court in Germany. While the Company believes that this claim is without merit, at this time the Company believes it is probable that a liability has been incurred and the Company is able to reasonably estimate the loss of $3.0 million. As a result, without acknowledgement (explicitly or implicitly) of any amount of liability arising from this claim, the Company recognized a provision of $3.0 million to reflect the value of the claim. This dispute is covered under the indemnification agreement between the Company and the former Chief Executive Officer and shareholder of FGH as discussed in Note 10. The Company intends to vigorously defend itself through appropriate legal proceedings. Both of the above amounts are recorded within contingencies and $3.0 million within indemnification receivables on the consolidated statements of financial position and $nil (2022- $0.1 million) is recorded as expense on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The additional legal dispute in 2023 related to the settlement of an action brought against the Company in the Ontario Superior Court of Justice by Gerardo Andres Garcia Mendez claiming that the Company was obligated to issue 3,000,000 common shares (pre-splits) to him for a purchase price of $0.05 per share as a result of alleged consulting services he performed in 2019. In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute. The payment was made in January 2023. The amount is recorded within contingencies on the consolidated statements of financial position and expense on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Sales tax relates to estimated amounts owed to certain jurisdictions in the Unites States for sales from the Company's JustCBD operations. The opening balance was acquired during the February 24, 2022 acquisition of JustCBD, with additional provision for estimated amounts due on sales subsequent to the acquisition. The ending balance is recorded within contingencies on the consolidated statement of financial position, and additions to the provision as a reduction of revenue on the consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For the sales tax provision and 2023 matters with accruals recorded as discussed above, it is at least reasonably possible that a change in the estimated liability could occur in the near term. Such changes in the Company's judgment could continue to change until the matters are ultimately resolved.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Legal proceedings&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company records liabilities for legal proceedings in those instances where it can reasonably estimate the amount of the loss and where liability is probable. The Company is engaged from time-to-time in various legal proceedings and claims that have arisen in the ordinary course of business. The outcome of all the proceedings and claims against the Company is subject to future resolution, including the uncertainties of litigation. Based on information currently known to the Company and after consultation with outside legal counsel, management believes that the probable ultimate resolution of any such proceedings and claims, individually or in the aggregate, will not have a material adverse effect on the financial condition of the Company, taken as a whole as at December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On November 1, 2023, Just Brands filed an Emergency Complaint for Declaratory Judgment and Injunctive Relief in the Southern District of Florida against the Florida Department of Agriculture and Consumer Services (the "Department") stemming from Stop Sale Orders issued by the Department whereby the Department prohibited Just Brands from selling and moving most of its products. Relying on Florida Statute Section 581.217, which includes the definition of "attractive to children," the Department determined Just Brand's product could not be sold or moved because the products were manufactured in the shape of humans, cartoons, or animals; in a form that bears a reasonable resemblance to an existing candy product; and containing color additives. The Court ruled in favor of the Department and that Order is being appealed to the Eleventh Circuit Court of Appeals. Since then, the Department has initiated an Administrative Action claiming Just Brands moved product outside the State of Florida in violation of the Stop Sale Orders. The statute provides for a penalty of up to $5,000 per violation. The Department seeks to assess penalties on what they claim to be a total of 215,154 violations (one for each package). The Company disputes their claim and intends to vigorously defend against this action. The Company believes that it is too early in the proceedings to determine an outcome, and, as such, has not accrued a liability as of December 31, 2023. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="color: black;"&gt;The total value of inventory impacted by the stop sale orders was&lt;/span&gt;&lt;span&gt;&lt;span&gt;&#160;$1.6&#160;million &lt;/span&gt;&lt;/span&gt;&lt;span style="color: black;"&gt;at December 31, 2023&lt;/span&gt;&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;

                            &lt;/div&gt;
                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On May 31, 2023, Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres brought an action against the Company claiming that the Company is obligated to issue 500,000 common shares (pre-splits) each for a purchase price of $0.05 per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On May 31, 2023, Ramon Ricardo Castellanos Saenz and Miriam Ortiz brought an action against the Company claiming that the Company is obligated to issue 1,500,000 common shares (pre-splits) each for a purchase price of $0.05 per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In connection with the Company's acquisition of FGH, the Company's current CEO and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $5.0 million. In addition to the matter regarding the former shareholder of ACA Mueller, discussed above, the following actions are pending as of the date hereof:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;On February 3, 2023, an action was brought in the Ontario Superior Court of Justice by Nathan Shantz and Liberacion e Inversiones S.A. against various parties including Clifford Starke, the Company's current CEO and FGH's former Chief Executive Officer, and FGH. The statement of claim alleges that, prior to the closing of the Arrangement, 8,831,109 FGH shares purportedly owned by the plaintiffs were wrongfully transferred to third parties, in part through alleged unauthorized steps taken by Mr. Starke. Plaintiffs seek, among other things, a declaration that they are the rightful owners of the shares or, in the alternative, damages. Against FGH, they claim a declaration that, by virtue of the alleged unauthorized transfer of shares, FGH acted oppressively and seek damages in the amount of $4.0 million. The defendants have brought motions to stay the proceedings on the grounds that the Ontario court lacks jurisdiction over the claim. In the event FGH should incur any losses in connection with this matter, such losses are to be indemnified by Mr. Starke subject to the maximum threshold of the indemnity agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The total amount claimed against the former entities of FGH currently exceeds the maximum $5.0 million of the indemnification agreement. However, the Company is estimating the likelihood of loss in these cases will not exceed $3.0 million.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Management contracts&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Company is party to management contracts with certain of its executive officers. As at December 31, 2023, these contracts would require payments totaling approximately $1.0 million to be made in the event that such executive officers are terminated (i) "without cause" or (ii) within twelve months following a "change in control" (as such terms are defined in the management contracts). The Company is also obligated to make payments to certain individuals upon termination "without cause" of approximately $1.0 million pursuant to the terms of these contracts. As a triggering event has not taken place, these amounts have not been recorded in these consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Shared services and space commitment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Company had an agreement in 2021 and through March 2022 to share general and administrative, promotion, corporate development, consulting services, and office space with other companies with monthly payments and a minimum commitment of CAD 45,000. This agreement could be terminated by either party giving at least 90 days' prior written notice (or such shorter period as the parties may mutually agree upon) to the other party of termination. These services were provided by 2227929 Ontario Inc which was a related party. This agreement expired by its terms on March 14, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305140243803">
                                &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Termination benefits&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Legal disputes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Sales tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance as at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,831&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,044&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Payments/settlements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(183&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(281&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Additional provisions&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;707&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;715&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Foreign currency translation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance as at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,962&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,538&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            </us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember"
      decimals="-3"
      id="F20231019113056160_0"
      unitRef="USD">183000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="F20231019113056161_1"
      unitRef="USD">3030000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="F20231019113056161_2"
      unitRef="USD">1831000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056161_3"
      unitRef="USD">5044000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember"
      decimals="-3"
      id="F20231019113056162_8"
      unitRef="USD">183000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="F20231019113056162_9"
      unitRef="USD">98000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="F20231019113056162_10"
      unitRef="USD">0</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056162_11"
      unitRef="USD">281000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember"
      decimals="-3"
      id="F20231019113056162_12"
      unitRef="USD">0</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="Fxbrl_20231023111001690"
      unitRef="USD">8000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="F20231019113056163_13"
      unitRef="USD">707000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056163_14"
      unitRef="USD">715000</us-gaap:LossContingencyAccrualProvision>
    <flgc:LossContingencyAccrualForeignCurrencyTranslation
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember"
      decimals="-3"
      id="Fxbrl_20240305141410684_20231019113056162_12"
      unitRef="USD">0</flgc:LossContingencyAccrualForeignCurrencyTranslation>
    <flgc:LossContingencyAccrualForeignCurrencyTranslation
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="Fxbrl_20240305141410684_xbrl_20231023111001690"
      unitRef="USD">22000</flgc:LossContingencyAccrualForeignCurrencyTranslation>
    <flgc:LossContingencyAccrualForeignCurrencyTranslation
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="Fxbrl_20240305141410684_20231019113056163_13"
      unitRef="USD">0</flgc:LossContingencyAccrualForeignCurrencyTranslation>
    <flgc:LossContingencyAccrualForeignCurrencyTranslation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240305141410684_20231019113056163_14"
      unitRef="USD">22000</flgc:LossContingencyAccrualForeignCurrencyTranslation>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcTerminationBenefitsMember"
      decimals="-3"
      id="F20231019113056163_15"
      unitRef="USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="F20231019113056163_16"
      unitRef="USD">2962000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="F20231019113056163_17"
      unitRef="USD">2538000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056163_18"
      unitRef="USD">5500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SeveranceCosts1
      contextRef="C_20230101to20231231"
      decimals="-6"
      id="F20231019113056165_38"
      unitRef="USD">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="F20231019113056163_19"
      unitRef="USD">400000</us-gaap:SeveranceCosts1>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_20230101to20230131_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="INF"
      id="F20231019113056164_23"
      unitRef="Shares">16250</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="C_20230101to20230131_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-5"
      id="F20231019113056164_24"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-5"
      id="F20231019113056165_39"
      unitRef="USD">3000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20220101to20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-5"
      id="F20231019113056165_35"
      unitRef="USD">3000000</us-gaap:LossContingencyAccrualProvision>
    <flgc:IndemnificationReceivables
      contextRef="C_20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-5"
      id="F20231019113056165_36"
      unitRef="USD">3000000</flgc:IndemnificationReceivables>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="C_20230101to20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="Fxbrl_20240305145055134"
      unitRef="USD">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="C_20220101to20221231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-5"
      id="F20231019113056164_25"
      unitRef="USD">100000</us-gaap:LossContingencyLossInPeriod>
    <flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit
      contextRef="C_20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember"
      decimals="INF"
      id="F20231019113056164_26"
      unitRef="Shares">3000000</flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember"
      decimals="2"
      id="F20231019113056164_27"
      unitRef="USD_Per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:LossContingencyTrialOrAlternativeDisputeResolution
      contextRef="C_20230101to20231231_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember"
      id="Fxbrl_20240305161356715">In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute.</us-gaap:LossContingencyTrialOrAlternativeDisputeResolution>
    <flgc:AmountsPayablePerViolationOfStopSaleOrders
      contextRef="C_20231101"
      decimals="0"
      id="Fxbrl_20240305145238109"
      unitRef="USD">5000</flgc:AmountsPayablePerViolationOfStopSaleOrders>
    <flgc:NumberOfViolationsInStopSaleOrders
      contextRef="C_20231101"
      decimals="0"
      id="Fxbrl_20240422132400816"
      unitRef="Pure">215154</flgc:NumberOfViolationsInStopSaleOrders>
    <flgc:InventoryImpactedByStopSaleOrders
      contextRef="C_20231231"
      decimals="-5"
      id="Fxbrl_20240305145430019"
      unitRef="USD">1600000</flgc:InventoryImpactedByStopSaleOrders>
    <flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit
      contextRef="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember"
      decimals="INF"
      id="Fxbrl_20240305142824112"
      unitRef="Shares">500000</flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember"
      decimals="2"
      id="Fxbrl_20240305142851560"
      unitRef="USD_Per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
    <flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit
      contextRef="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember"
      decimals="INF"
      id="Fxbrl_20240305160420847"
      unitRef="Shares">1500000</flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember"
      decimals="2"
      id="Fxbrl_20240305160428164"
      unitRef="USD_Per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
    <flgc:PotentialLiabilities
      contextRef="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113056165_37"
      unitRef="USD">5000000</flgc:PotentialLiabilities>
    <flgc:WrongfullyTransferredShares
      contextRef="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="INF"
      id="F20231019113056164_28"
      unitRef="Shares">8831109</flgc:WrongfullyTransferredShares>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113056164_29"
      unitRef="USD">4000000</us-gaap:LossContingencyDamagesSoughtValue>
    <flgc:PotentialLiabilities
      contextRef="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113056166_40"
      unitRef="USD">5000000</flgc:PotentialLiabilities>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="C_20231231_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20231019113056165_30"
      unitRef="USD">3000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <flgc:ManagementContractsTerms
      contextRef="C_20230101to20231231"
      id="Fxbrl_20231023111710279">these contracts would require payments totaling approximately $1.0 million to be made in the event that such executive officers are terminated (i) "without cause" or (ii) within twelve months following a "change in control" (as such terms are defined in the management contracts). The Company is also obligated to make payments to certain individuals upon termination "without cause" of approximately $1.0 million pursuant to the terms of these contracts.</flgc:ManagementContractsTerms>
    <flgc:SharedServicesAndSpaceCommitment
      contextRef="C_20210101to20220314"
      decimals="0"
      id="F20231019113056165_31"
      unitRef="CAD">45000</flgc:SharedServicesAndSpaceCommitment>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113056195_83">
                &lt;div&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;20.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;INCOME TAXES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The components of the income tax provision include the following. As the Company is domiciled in Canada, the Federal caption below represents the provision amount for Canada.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;For the year ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; U.S. federal&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;17&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160;U.S. state&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;5&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Foreign&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;103&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total current tax expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;125&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(1,767&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160;&#160;U.S. federal&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,055&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; U.S. state&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(316&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Foreign&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;14&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total deferred tax expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(1,753&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,405&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 81pt;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total income tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(1,628&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,405&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;

                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 26.5% for the year ended December 31, 2023 and 2022 to the effective rate is as follows. As the Company is domiciled in Canada, the reconciliation is to the Company's home country income tax rate rather than the applicable statutory rates in the United States. The statutory tax rate as of December 31, 2023 in other countries relevant to the Company's subsidiaries include the following: United States 21%, Colombia 33%, Germany 27.73%, Denmark 22%, and United Kingdom 19%. The Colombian Government lowered the corporate income tax rate from 35% to 33% during the tax year 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;For the year ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Statutory Canadian&#160;rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;26.5%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;26.5%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Earnings in jurisdictions taxed at different rates&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-1.3%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.5%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-1.9%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-12.9%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-0.8%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-1.7%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss on investments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-3.0%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-23.8%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-12.3%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other permanent items&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1.3%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.8%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prior year adjustments, change in tax rates&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6.4%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3.4%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.9%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                            &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                            &lt;div&gt;

                            &lt;/div&gt;
                            &lt;p style="margin: 0pt 0pt 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Components of the Company's deferred income tax assets and liabilities at December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Non-capital loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;19,725&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;20,240&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Share issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;847&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,406&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Unrealized gains (losses) on investments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;5,858&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;823&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;287&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;614&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Fixed assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;77&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;718&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7,747&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Sec 174 - R&amp;amp;D expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;263&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;564&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;677&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Allowance for doubtful accounts&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;64&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;36,150&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,760&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(36,150&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(20,909&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,851&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,094&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,563&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,712&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;

                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred taxes are a result of temporary differences that arise due to the differences between the income tax values and the carrying values of assets and liabilities. The Company's deferred tax asset valuation allowances are primarily the result of uncertainties regarding the future realization of recorded tax benefits on the tax loss carryforwards from operations in various jurisdictions. Current evidence does not suggest the Company will realize sufficient taxable income of the appropriate character within the carryforward period to allow the Company to realize the deferred tax benefits. If the Company were to identify and implement tax planning strategies to recover these deferred tax assets or generate sufficient income of the appropriate character in these jurisdictions in the future, it could lead to the reversal of these valuation allowances and income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company asserts that the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company may need to accrue and pay taxes if those earnings were repatriated to Canada. As at December 31, 2023, the amount of cash and cash equivalents related to foreign operations subject to these assertions is $1.7 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Unused loss carryforwards in Canada totaling $55.6 million expire beginning 2036. Unused loss carryforwards in Columbia totaling $0.9 million in Colombia expire beginning 2031. Unused loss carryforwards in the United States totaling $13.0 million have an indefinite carryforward period. Unused loss carryforwards in Denmark totaling $6.1 million have an indefinite carryforward period. Unused loss carryforwards in Germany of $0.7 have an indefinite carryforward period. Unused loss carryforwards in the United Kingdom of $0.7 have an indefinite carryforward period. Deferred tax assets have not been recognized for legal entities where it is not probable that future taxable profit will be available against which the Company can use the benefits. Tax attributes are subject to review, and potential adjustment, by tax authorities. The tax years that remain subject to examination by significant tax jurisdictions of the Company as of December 31, 2023 are as follows:&#160; Canada 2020 to 2023, United States 2020 to 2023, Colombia 2020 to 2023, Germany 2019 to 2023, Denmark 2020 to 2023, and United Kingdom 2022 to 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The amount of current income tax expense for the year ended December 31, 2023 was $0.1 million and deferred income tax benefit was $1.6 million within the consolidated statements of loss and comprehensive loss. The amount of current income tax expense recorded for the year ended December 31, 2022 was $nil and deferred income tax benefit was $1.4 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company had no unrecognized income tax benefits because of uncertain income tax positions for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305113932630">
                                &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;For the year ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; U.S. federal&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;17&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160;U.S. state&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;5&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Foreign&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;103&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total current tax expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;125&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(1,767&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160;&#160;U.S. federal&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,055&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; U.S. state&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(316&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Foreign&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;14&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total deferred tax expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(1,753&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,405&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 81pt;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total income tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(1,628&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,405&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056173_0"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056173_1"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056173_2"
      unitRef="USD">17000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056174_3"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056174_4"
      unitRef="USD">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056174_5"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056175_6"
      unitRef="USD">103000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056175_7"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056175_8"
      unitRef="USD">125000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056175_9"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056175_10"
      unitRef="USD">-1767000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcCanadaIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056176_11"
      unitRef="USD">-11000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056176_12"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSFederalIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056176_13"
      unitRef="USD">-1055000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056176_14"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcUSStateIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056177_15"
      unitRef="USD">-316000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056177_16"
      unitRef="USD">14000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_flgcForeignIncomeTaxAuthorityMember"
      decimals="-3"
      id="F20231019113056177_17"
      unitRef="USD">-23000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056177_18"
      unitRef="USD">-1753000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056178_19"
      unitRef="USD">-1405000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056179_20"
      unitRef="USD">-1628000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056180_21"
      unitRef="USD">-1405000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231"
      decimals="3"
      id="F20231019113056180_22"
      unitRef="Pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedStatesRevenueAgencyMember"
      decimals="2"
      id="F20231019113056181_23"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember"
      decimals="2"
      id="F20231019113056181_24"
      unitRef="Pure">0.33</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcGermanyRevenueAgencyMember"
      decimals="4"
      id="F20231019113056181_25"
      unitRef="Pure">0.2773</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcDenmarkRevenueAgencyMember"
      decimals="2"
      id="F20231019113056182_26"
      unitRef="Pure">0.22</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedKingdomRevenueAgencyMember"
      decimals="2"
      id="F20231019113056182_27"
      unitRef="Pure">0.19</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember"
      decimals="2"
      id="F20231019113056182_28"
      unitRef="Pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember"
      decimals="2"
      id="F20231019113056182_29"
      unitRef="Pure">0.33</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306172218086">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;For the year ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Statutory Canadian&#160;rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;26.5%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;26.5%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 17%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Earnings in jurisdictions taxed at different rates&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-1.3%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.5%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Impairments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-1.9%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-12.9%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-0.8%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-1.7%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss on investments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-3.0%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-23.8%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-12.3%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other permanent items&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1.3%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.8%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prior year adjustments, change in tax rates&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6.4%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3.4%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.9%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240305115538263"
      unitRef="Pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240305120029963"
      unitRef="Pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240306162335361"
      unitRef="Pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240305120035782"
      unitRef="Pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240306162348472"
      unitRef="Pure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240306162449610"
      unitRef="Pure">-0.129</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240306162401633"
      unitRef="Pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240306162507127"
      unitRef="Pure">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240306162415205"
      unitRef="Pure">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240305120102110"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240306162430885"
      unitRef="Pure">-0.238</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240306162525146"
      unitRef="Pure">-0.123</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240305115627419"
      unitRef="Pure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240305120113652"
      unitRef="Pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240305131911209_xbrl_20240305115627419"
      unitRef="Pure">0.064</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240305131911209_xbrl_20240305120113652"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20230101to20231231"
      decimals="3"
      id="Fxbrl_20240305115634786"
      unitRef="Pure">0.034</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20220101to20221231"
      decimals="3"
      id="Fxbrl_20240305120121020"
      unitRef="Pure">0.029</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305114432331">
                                &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Non-capital loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;19,725&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;20,240&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Share issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;847&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,406&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Unrealized gains (losses) on investments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;5,858&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;823&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;287&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;614&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Fixed assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;77&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;718&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7,747&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Sec 174 - R&amp;amp;D expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;263&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;564&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;677&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Allowance for doubtful accounts&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;64&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;36,150&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,760&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(36,150&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(20,909&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,851&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,094&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160; &#160; Lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,563&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 17%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 17%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,712&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056185_41"
      unitRef="USD">19725000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056185_42"
      unitRef="USD">20240000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <flgc:DeferredTaxAssetsShareIssuanceCosts
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056185_43"
      unitRef="USD">847000</flgc:DeferredTaxAssetsShareIssuanceCosts>
    <flgc:DeferredTaxAssetsShareIssuanceCosts
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056186_44"
      unitRef="USD">1406000</flgc:DeferredTaxAssetsShareIssuanceCosts>
    <flgc:DeferredTaxAssetsUnrealizedGainsLossesOnInvestments
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056186_45"
      unitRef="USD">5858000</flgc:DeferredTaxAssetsUnrealizedGainsLossesOnInvestments>
    <flgc:DeferredTaxAssetsUnrealizedGainsLossesOnInvestments
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056186_46"
      unitRef="USD">823000</flgc:DeferredTaxAssetsUnrealizedGainsLossesOnInvestments>
    <flgc:DeferredTaxAssetsRightOfUseAssets
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056186_47"
      unitRef="USD">287000</flgc:DeferredTaxAssetsRightOfUseAssets>
    <flgc:DeferredTaxAssetsRightOfUseAssets
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056187_48"
      unitRef="USD">614000</flgc:DeferredTaxAssetsRightOfUseAssets>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305114536213_20231019113056186_47"
      unitRef="USD">77000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305114536213_20231019113056187_48"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <flgc:DeferredTaxAssetsIntangibleAssets
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056190_61"
      unitRef="USD">718000</flgc:DeferredTaxAssetsIntangibleAssets>
    <flgc:DeferredTaxAssetsIntangibleAssets
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056190_62"
      unitRef="USD">0</flgc:DeferredTaxAssetsIntangibleAssets>
    <flgc:DeferredTaxAssetsGoodwil
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305114816362_20231019113056190_61"
      unitRef="USD">7747000</flgc:DeferredTaxAssetsGoodwil>
    <flgc:DeferredTaxAssetsGoodwil
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305114816362_20231019113056190_62"
      unitRef="USD">0</flgc:DeferredTaxAssetsGoodwil>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305114847773_xbrl_20240305114816362_20231019113056190_61"
      unitRef="USD">263000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305114847773_xbrl_20240305114816362_20231019113056190_62"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056187_49"
      unitRef="USD">564000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056187_50"
      unitRef="USD">677000</us-gaap:DeferredTaxAssetsOther>
    <flgc:DeferredTaxAssetsAllowanceForDoubtfulAccounts
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056188_53"
      unitRef="USD">64000</flgc:DeferredTaxAssetsAllowanceForDoubtfulAccounts>
    <flgc:DeferredTaxAssetsAllowanceForDoubtfulAccounts
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056188_54"
      unitRef="USD">0</flgc:DeferredTaxAssetsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056188_55"
      unitRef="USD">36150000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056188_56"
      unitRef="USD">23760000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056189_57"
      unitRef="USD">36150000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056189_58"
      unitRef="USD">20909000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056189_59"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056189_60"
      unitRef="USD">2851000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240305114756861_20231019113056190_63"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240305114756861_20231019113056190_64"
      unitRef="USD">4094000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056190_63"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056190_64"
      unitRef="USD">469000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056190_65"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056191_66"
      unitRef="USD">4563000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_20231231"
      decimals="-3"
      id="F20231019113056191_67"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056191_68"
      unitRef="USD">1712000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcForeignRevenueAgencyMember"
      decimals="-5"
      id="F20231019113056191_69"
      unitRef="USD">1700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_usgaapCanadaRevenueAgencyMember"
      decimals="-5"
      id="F20231019113056192_70"
      unitRef="USD">55600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcColombiaRevenueAgencyMember"
      decimals="-5"
      id="F20231019113056192_72"
      unitRef="USD">900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedStatesRevenueAgencyMember"
      decimals="-5"
      id="F20231019113056193_74"
      unitRef="USD">13000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcDenmarkRevenueAgencyMember"
      decimals="-5"
      id="F20231019113056193_75"
      unitRef="USD">6100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcGermanyRevenueAgencyMember"
      decimals="-5"
      id="F20231019113056193_77"
      unitRef="USD">700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20231231_usgaapIncomeTaxAuthorityNameAxis_flgcUnitedKingdomRevenueAgencyMember"
      decimals="-5"
      id="Fxbrl_20240305114505869"
      unitRef="USD">700000</us-gaap:OperatingLossCarryforwards>
    <flgc:DescriptionOfTaxJurisdictions
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240529174923515">Canada 2020 to 2023, United States 2020 to 2023, Colombia 2020 to 2023, Germany 2019 to 2023, Denmark 2020 to 2023, and United Kingdom 2022 to 2023.</flgc:DescriptionOfTaxJurisdictions>
    <flgc:CurrentTaxExpenseIncome
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113056194_79"
      unitRef="USD">100000</flgc:CurrentTaxExpenseIncome>
    <flgc:DeferredTaxExpenseIncome
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="F20231019113056194_80"
      unitRef="USD">-1600000</flgc:DeferredTaxExpenseIncome>
    <flgc:CurrentTaxExpenseIncome
      contextRef="C_20220101to20221231"
      decimals="-6"
      id="Fxbrl_20240422140513526"
      unitRef="USD">0</flgc:CurrentTaxExpenseIncome>
    <flgc:DeferredTaxExpenseIncome
      contextRef="C_20220101to20221231"
      decimals="-4"
      id="F20231019113056194_81"
      unitRef="USD">-1400000</flgc:DeferredTaxExpenseIncome>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_20230101to20231231" id="F20231019113056206_0">
                &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;21.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;LOSS PER SHARE&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive as the Company has a net loss for each period presented:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of securities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;961&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Restricted stock awards&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;391&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;JustCBD potential additional shares to settle contingent consideration&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;632&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;657&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total anti-dilutive&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,456&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,054&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306164033432">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of securities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; background-color: #ffffff; border-bottom: 0.75pt solid #000000; text-align: right;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;961&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Restricted stock awards&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;391&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;JustCBD potential additional shares to settle contingent consideration&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;632&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;657&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1.5pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total anti-dilutive&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,456&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,054&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 1.5pt solid #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember"
      decimals="-3"
      id="Fxbrl_20231021123311306"
      unitRef="Shares">49000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20231019113056206_1"
      unitRef="Shares">290000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember"
      decimals="-3"
      id="Fxbrl_20231021123318682"
      unitRef="Shares">2384000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember"
      decimals="-3"
      id="F20231019113056206_2"
      unitRef="Shares">961000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember"
      decimals="-3"
      id="Fxbrl_20231021123325954"
      unitRef="Shares">391000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember"
      decimals="-3"
      id="F20231019113056206_7"
      unitRef="Shares">146000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember"
      decimals="-3"
      id="Fxbrl_20231021123333073"
      unitRef="Shares">632000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20231019113056206_8"
      unitRef="Shares">657000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20231021123338817"
      unitRef="Shares">3456000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056206_3"
      unitRef="Shares">2054000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113056233_89">
                &lt;div&gt;
                    &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;22.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;FINANCIAL INSTRUMENTS AND RISK MANAGEMENT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Environmental&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company's financial instruments measured at amortized cost as at December 31, 2023 and December 31, 2022 consist of cash, restricted cash, trade and amounts receivable, loans receivable, trade payables, contingencies, accrued liabilities, contingent purchase consideration liabilities, lease liabilities, and debt and loans payable. The amounts reflected in the consolidated statements of financial position approximate fair value due to the short-term maturity of these instruments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial instruments recorded at the reporting date at fair value are classified into one of three levels based upon the fair value hierarchy. Items are categorized based on inputs used to derive fair value based on:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Level 1 - quoted prices that are unadjusted in active markets for identical assets or liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Level 2 - inputs other than quoted prices included in level 1 that are observable for the asset/liability either directly or indirectly; and&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Level 3 - inputs for the instruments are not based on any observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company&#x2019;s long-term investments require significant unobservable inputs and as discussed at Note 9, are measured at FVPL and as a Level 3 fair value financial instrument within the fair value hierarchy as at December 31, 2023. As discussed in Note 10, the Company&#x2019;s contingent purchase considerations consist of the estimated fair value of contingent purchase consideration from the acquisitions of JustCBD in February 2022, NoCap in July 2022 and Original Hemp in March 2023. The amount for JustCBD is measured at FVPL as a Level 2 fair value financial instrument within the fair value hierarchy as at December 31, 2023. The amounts for NoCap and Original Hemp are measured at FVPL as a Level 3 fair value financial instrument within the fair value hierarchy as at December 31, 2023. As valuations of investments for which market quotations are not readily available are inherently uncertain, may fluctuate within short periods of time and are based on estimates, determination of fair value may differ materially from the values that would have resulted if a ready market existed for the investments. Such changes may have a significant impact on the Company&#x2019;s financial condition or operating results.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The following tables present information about the Company's financial instruments and their classifications as at December 31, 2023 and 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Fair value measurements at December 31, 2023 using:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Thousands of United States Dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Investments (Note 9)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Contingent purchase consideration from business combinations (Note 10)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;854&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;1,095&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;

                            &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                            &lt;div&gt;

                            &lt;/div&gt;
                            &lt;div&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Fair value measurements at December 31, 2022 using:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Thousands of United States Dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Investments (Note 9)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;764&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;764&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Contingent purchase consideration from business combinations (Note 10)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;2,646&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;3,547&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Risk management overview&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk. Further quantitative disclosures are included throughout these condensed interim consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Credit risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's trade and other receivables, loans receivable and cash held with banks and other financial intermediaries.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The carrying amount of the cash, restricted cash, trade and amounts receivables, indemnification receivable, and loan receivable represents the maximum credit exposure as presented in the statement of financial position.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company has assessed that there has been no significant increase in credit risk of the loans receivable from initial recognition based on the financial position of the borrowers, and the regulatory and economic environment of the borrowers. Based on historical information, and adjusted for forward-looking expectations, the Company has assessed an insignificant loss allowance on the loans' receivable and advances as at December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company provides credit to certain customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Credit risk for customers is assessed on a case-by-case basis and an allowance for specific expected credit losses is recorded where required, in addition to an estimate of lifetime expected credit losses for the portfolio of accounts receivable. See credit risk analysis for trade receivables at Note 6.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company held cash and restricted cash of $4.4 million as at December 31, 2023 (2022 - $8.9 million), of which, $4.4 million (2022 - $8.9 million) is held with large financial institutions and national central banks. The remaining cash amount of less than $0.1 million cash (2022 - less than $0.1 million) are held with financial intermediaries in the United States, Canada, Germany and United Kingdom. The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has assessed an insignificant loss allowance on these cash and restricted cash balances as at December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Market risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Foreign currency exchange rate risk is the risk that the fair value of future cash flows will fluctuate due to changes in foreign exchange rates. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk as management has determined that this risk is not significant. As such, the Company's financial position and financial results may be adversely affected by the unfavorable fluctuations in currency exchange rates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="margin: 0pt 0pt 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;As at December 31, 2023, the Company had the following monetary assets and liabilities denominated in foreign currencies:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;CAD&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;GBP&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;EUR&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Thousands of foreign currencies&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;969&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Amounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;2,995&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Loans receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Trade payables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(6,767&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(69&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(126&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Long term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(2,560&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Net carrying value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(5,537&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;As at December 31, 2022, the Company had the following monetary assets and liabilities denominated in foreign currencies:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;CAD&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;COP&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;GBP&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;EUR&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;CHF&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Thousands of foreign currencies&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;1,691&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;2,961,487&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Amounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;2,964&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;15,127,223&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Loans receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Trade payables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(9,333&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(2,975,794&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(56&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(161&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(522&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(1,173,118&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(153&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(1,809,970&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Long term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(1,446&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Net carrying value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(6,799&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;12,129,828&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(160&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Monetary assets and liabilities denominated in Canadian dollars, Colombian pesos, British pounds, Euros and Swiss Francs are subject to foreign currency risk. The Company has estimated that as at December 31, 2023, the effect of a 10% increase or decrease in Canadian dollars, British pounds, and Euros against the Unites States dollar on financial assets and liabilities would result in an increase or decrease of approximately $0.4 million (December 31, 2022 - $0.1 million) to net loss and comprehensive loss.&lt;b&gt; &lt;/b&gt;Subsequent to December 31, 2023 and through the date of issuance of these financial statements, the exchange rates remained within the 10% range discussed above, and the Company does not expect significant changes in unsettled transactions from December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company calculates this sensitivity analysis based on the net financial assets denominated in each currency using the December 31 exchange rate, then changing the rate by 10%. Management determined 10% is a 'reasonably possible' change in foreign currency rates by considering the approximate change in rates in the prior twelve months.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;It is management's opinion that the Company is not subject to significant commodity or interest rate risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Management considers concentration risk with counterparties considering the level of purchases and sales of its business segments (Note 24). Several of the Company's business units purchase substantially all their inventory or materials from a single supplier.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Liquidity risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#x2019;s financial liabilities consist of trade payables and accrued liabilities, loans payable and debt, and lease liabilities as presented on the statement of financial position. The Company had cash and restricted cash as presented on the statement of financial position. As discussed in Note 13, the Company has 2.2 million Euros ($2.4 million USD) available on credit facilities through one of its German subsidiaries as of December 31, 2023. The Company has no other available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#x2019;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Trade payables and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials and inventory require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 14 and other commitments at Note 19.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;The Company's long-term investments in equity of other entities are not publicly traded and there is not an active market to sell the investments for cash.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306165848913">
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Fair value measurements at December 31, 2023 using:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Thousands of United States Dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Investments (Note 9)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Contingent purchase consideration from business combinations (Note 10)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;854&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;1,095&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Fair value measurements at December 31, 2022 using:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Thousands of United States Dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Investments (Note 9)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;764&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;764&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Financial liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; background-color: #e6efff; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Contingent purchase consideration from business combinations (Note 10)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;2,646&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;3,547&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="Fxbrl_20240306151702254"
      unitRef="USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member"
      decimals="-3"
      id="Fxbrl_20240306151717190"
      unitRef="USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="Fxbrl_20240306151755902"
      unitRef="USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240306151929547"
      unitRef="USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="Fxbrl_20240306152017199_xbrl_20240306151702254"
      unitRef="USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member"
      decimals="-3"
      id="Fxbrl_20240306152017199_xbrl_20240306151717190"
      unitRef="USD">854000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="Fxbrl_20240306152017199_xbrl_20240306151755902"
      unitRef="USD">241000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240306152017199_xbrl_20240306151929547"
      unitRef="USD">1095000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="Fxbrl_20240306151046156"
      unitRef="USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member"
      decimals="-3"
      id="Fxbrl_20240306151100534"
      unitRef="USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="Fxbrl_20240306151104621"
      unitRef="USD">764000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240306151110420"
      unitRef="USD">764000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="Fxbrl_20240306151124002_xbrl_20240306151046156"
      unitRef="USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member"
      decimals="-3"
      id="Fxbrl_20240306151124002_xbrl_20240306151100534"
      unitRef="USD">2646000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="Fxbrl_20240306151124002_xbrl_20240306151104621"
      unitRef="USD">901000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240306151124002_xbrl_20240306151110420"
      unitRef="USD">3547000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember"
      decimals="-5"
      id="F20231019113056215_8"
      unitRef="USD">4400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember"
      decimals="-5"
      id="F20231019113056215_9"
      unitRef="USD">8900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231_usgaapCollateralAxis_flgcHeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember"
      decimals="-5"
      id="F20231019113056215_10"
      unitRef="USD">4400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231_usgaapCollateralAxis_flgcHeldWithLargeFinancialInstitutionsAndNationalCentralBanksMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember"
      decimals="-5"
      id="F20231019113056216_11"
      unitRef="USD">8900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231_usgaapCollateralAxis_flgcFinancialIntermediariesMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember"
      decimals="-5"
      id="F20231019113056216_12"
      unitRef="USD">100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231_usgaapCollateralAxis_flgcFinancialIntermediariesMember_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_usgaapCreditRiskMember"
      decimals="-5"
      id="F20231019113056216_13"
      unitRef="USD">100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <flgc:ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305105725907">
                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;CAD&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;GBP&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;EUR&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Thousands of foreign currencies&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;969&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Amounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;2,995&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Loans receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Trade payables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(6,767&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(18&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(69&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(126&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Long term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(2,560&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Net carrying value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(5,537&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;CAD&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;COP&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;GBP&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;EUR&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;CHF&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Thousands of foreign currencies&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;1,691&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;2,961,487&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Amounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;2,964&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;15,127,223&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Loans receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Trade payables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(9,333&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(2,975,794&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(56&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(161&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(522&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(1,173,118&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(153&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(1,809,970&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Long term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(1,446&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Net carrying value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(6,799&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;12,129,828&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;(160&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                        </flgc:ScheduleOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTableTextBlock>
    <us-gaap:Cash
      contextRef="C_20231231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306155911469"
      unitRef="USD">969000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20231231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306155924657"
      unitRef="USD">35000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20231231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306160032181"
      unitRef="USD">1000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306160353008_xbrl_20240306155911469"
      unitRef="USD">2995000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306160353008_xbrl_20240306155924657"
      unitRef="USD">125000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306160353008_xbrl_20240306160032181"
      unitRef="USD">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:LoansReceivableFairValueDisclosure
      contextRef="C_20231231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306160355367_xbrl_20240306155911469"
      unitRef="USD">0</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:LoansReceivableFairValueDisclosure
      contextRef="C_20231231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306160355367_xbrl_20240306155924657"
      unitRef="USD">0</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:LoansReceivableFairValueDisclosure
      contextRef="C_20231231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306160355367_xbrl_20240306160032181"
      unitRef="USD">0</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306160356878_xbrl_20240306155911469"
      unitRef="USD">6767000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306160356878_xbrl_20240306155924657"
      unitRef="USD">22000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306160356878_xbrl_20240306160032181"
      unitRef="USD">18000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306160357743_xbrl_20240306155911469"
      unitRef="USD">48000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306160357743_xbrl_20240306155924657"
      unitRef="USD">69000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_20231231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306160357743_xbrl_20240306160032181"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306160400672_xbrl_20240306155911469"
      unitRef="USD">126000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306160400672_xbrl_20240306155924657"
      unitRef="USD">41000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306160400672_xbrl_20240306160032181"
      unitRef="USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306160403033_xbrl_20240306155911469"
      unitRef="USD">2560000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306160403033_xbrl_20240306155924657"
      unitRef="USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306160403033_xbrl_20240306160032181"
      unitRef="USD">0</us-gaap:LongTermDebt>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_20231231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306160404816_xbrl_20240306155911469"
      unitRef="USD">-5537000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_20231231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306160404816_xbrl_20240306155924657"
      unitRef="USD">28000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_20231231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306160404816_xbrl_20240306160032181"
      unitRef="USD">-17000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:Cash
      contextRef="C_20221231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306153126944"
      unitRef="USD">1691000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20221231_srtCurrencyAxis_currencyCOP"
      decimals="-3"
      id="Fxbrl_20240306153134098"
      unitRef="USD">2961487000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20221231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306153137016"
      unitRef="USD">64000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20221231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306153140144"
      unitRef="USD">1000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20221231_srtCurrencyAxis_currencyCHF"
      decimals="-3"
      id="Fxbrl_20240306153234791"
      unitRef="USD">0</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306153636645_xbrl_20240306153126944"
      unitRef="USD">2964000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCOP"
      decimals="-3"
      id="Fxbrl_20240306153636645_xbrl_20240306153134098"
      unitRef="USD">15127223000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306153636645_xbrl_20240306153137016"
      unitRef="USD">61000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306153636645_xbrl_20240306153140144"
      unitRef="USD">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCHF"
      decimals="-3"
      id="Fxbrl_20240306153636645_xbrl_20240306153234791"
      unitRef="USD">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:LoansReceivableFairValueDisclosure
      contextRef="C_20221231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306153641216_xbrl_20240306153126944"
      unitRef="USD">0</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:LoansReceivableFairValueDisclosure
      contextRef="C_20221231_srtCurrencyAxis_currencyCOP"
      decimals="-3"
      id="Fxbrl_20240306153641216_xbrl_20240306153134098"
      unitRef="USD">0</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:LoansReceivableFairValueDisclosure
      contextRef="C_20221231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306153641216_xbrl_20240306153137016"
      unitRef="USD">0</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:LoansReceivableFairValueDisclosure
      contextRef="C_20221231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306153641216_xbrl_20240306153140144"
      unitRef="USD">0</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:LoansReceivableFairValueDisclosure
      contextRef="C_20221231_srtCurrencyAxis_currencyCHF"
      decimals="-3"
      id="Fxbrl_20240306153641216_xbrl_20240306153234791"
      unitRef="USD">250000</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306153642661_xbrl_20240306153126944"
      unitRef="USD">9333000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCOP"
      decimals="-3"
      id="Fxbrl_20240306153642661_xbrl_20240306153134098"
      unitRef="USD">2975794000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306153642661_xbrl_20240306153137016"
      unitRef="USD">56000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306153642661_xbrl_20240306153140144"
      unitRef="USD">161000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCHF"
      decimals="-3"
      id="Fxbrl_20240306153642661_xbrl_20240306153234791"
      unitRef="USD">0</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306153645312_xbrl_20240306153126944"
      unitRef="USD">522000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCOP"
      decimals="-3"
      id="Fxbrl_20240306153645312_xbrl_20240306153134098"
      unitRef="USD">1173118000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306153645312_xbrl_20240306153137016"
      unitRef="USD">22000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306153645312_xbrl_20240306153140144"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_20221231_srtCurrencyAxis_currencyCHF"
      decimals="-3"
      id="Fxbrl_20240306153645312_xbrl_20240306153234791"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306153646583_xbrl_20240306153126944"
      unitRef="USD">153000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyCOP"
      decimals="-3"
      id="Fxbrl_20240306153646583_xbrl_20240306153134098"
      unitRef="USD">1809970000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306153646583_xbrl_20240306153137016"
      unitRef="USD">17000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306153646583_xbrl_20240306153140144"
      unitRef="USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyCHF"
      decimals="-3"
      id="Fxbrl_20240306153646583_xbrl_20240306153234791"
      unitRef="USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306153647813_xbrl_20240306153126944"
      unitRef="USD">1446000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_srtCurrencyAxis_currencyCOP"
      decimals="-3"
      id="Fxbrl_20240306153647813_xbrl_20240306153134098"
      unitRef="USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306153647813_xbrl_20240306153137016"
      unitRef="USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306153647813_xbrl_20240306153140144"
      unitRef="USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_srtCurrencyAxis_currencyCHF"
      decimals="-3"
      id="Fxbrl_20240306153647813_xbrl_20240306153234791"
      unitRef="USD">0</us-gaap:LongTermDebt>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyCAD"
      decimals="-3"
      id="Fxbrl_20240306153649767_xbrl_20240306153126944"
      unitRef="USD">-6799000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyCOP"
      decimals="-3"
      id="Fxbrl_20240306153649767_xbrl_20240306153134098"
      unitRef="USD">12129828000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyGBP"
      decimals="-3"
      id="Fxbrl_20240306153649767_xbrl_20240306153137016"
      unitRef="USD">30000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyEUR"
      decimals="-3"
      id="Fxbrl_20240306153649767_xbrl_20240306153140144"
      unitRef="USD">-160000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_20221231_srtCurrencyAxis_currencyCHF"
      decimals="-3"
      id="Fxbrl_20240306153649767_xbrl_20240306153234791"
      unitRef="USD">250000</us-gaap:FairValueNetAssetLiability>
    <flgc:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities
      contextRef="C_20231231"
      decimals="-5"
      id="Fxbrl_20240422151628734"
      unitRef="USD">400000</flgc:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <flgc:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities
      contextRef="C_20221231"
      decimals="-5"
      id="Fxbrl_20240422151635777"
      unitRef="USD">100000</flgc:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <flgc:DescriptionOfExchangeRate
      contextRef="C_20230101to20230331"
      id="Fxbrl_20240529162707048"> then changing the rate by 10%. Management determined 10% is a 'reasonably possible' change in foreign currency rates by considering the approximate change in rates in the prior twelve months.</flgc:DescriptionOfExchangeRate>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_flgcGermanSubsidiariesMember"
      decimals="-5"
      id="Fxbrl_20240328191947032"
      unitRef="EUR">2200000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_20231231_usgaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_flgcGermanSubsidiariesMember"
      decimals="-5"
      id="Fxbrl_20240328192013262"
      unitRef="USD">2400000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <flgc:CapitalManagementDisclosureTextBlock contextRef="C_20230101to20231231" id="F20231019113056240_0">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;23.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;CAPITAL MANAGEMENT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company considers the aggregate of its common shares, options, warrants and borrowings as capital. The Company's capital management objective is to ensure sufficient resources are available to meet day to day operating requirements and to safeguard its ability to continue as a going concern to provide returns for shareholders and benefits for other shareholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's capital management objectives were being met in 2023 primarily from the use of cash balances from the 2022 and 2023 issuances of common shares and warrants and generating increasing revenue in 2023 from the Company's reportable segments as presented in Note 24.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's officers and senior management take full responsibility for managing the Company's capital and do so through quarterly meetings and regular review of financial information. The Company's Board of Directors is responsible for overseeing this process.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company is not subject to any external capital requirements. As at December 31, 2023, there were no changes in the Company's approach to capital management.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </flgc:CapitalManagementDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306053907406">
                    &lt;div&gt;
                        &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;SEGMENTED INFORMATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prior to the fourth quarter of the year ended December 31, 2022, the Company had the following four operating segments, which were also its reportable segments: cannabis growth and derivative production, consumer products, pharmaceuticals and nutraceuticals, and beverage and food. Since the acquisition of FGH in December 2022 (Note 10), the Company has been reporting its financial results for the following three operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH and the former Cosechemos subsidiary in Colombia), house of brands (primarily JustCBD and Vessel, as well as the former Kasa Wholefoods Company subsidiary in Colombia), and pharmaceuticals (formerly the Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries in Colombia). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As discussed in Note 2 and Note 5, on July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan to sell all its shares in its Colombian related subsidiaries and its Colombian assets. This sale was completed in full on November 1, 2023. As such, the Company has presented the associated assets and liabilities of these Colombian subsidiaries as held for sale and the results of these subsidiaries are included in discontinued operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's operates its manufacturing and distribution business within its United States and Germany subsidiaries. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations and includes the Company's long-term investments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The following tables show information regarding the Company's segments for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In 2023, the Company did not have sales to a single customer exceeding 10% of its consolidated revenue. In 2022, the Company did not have sales to a single customer exceeding 10% of its consolidated revenue.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Sales&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;38,262&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;44,602&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;39,419&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pharmaceuticals&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,793&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,105&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;76,071&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;33,401&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Gross Profit&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;15,520&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13,290&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pharmaceuticals&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Corp &amp;amp; Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;17,738&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13,251&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Loss from Continuing Operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(8,763&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(109&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(31,399&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(29,594&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pharmaceuticals&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Corp &amp;amp; Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,426&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(17,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(46,669&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(46,703&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other significant items:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Commercial &amp;amp;&lt;br/&gt;Wholesale&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;House of&lt;br/&gt;Brands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Pharmaceuticals&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Corporate &amp;amp;&lt;br/&gt;Eliminations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,591&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,591&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest expense (income)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,650&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,628&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;857&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,335&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Unrealized gain from changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(964&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,991&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,096&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11,608&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,922&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,626&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,404&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,404&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest expense (income)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,393&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,405&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,077&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,144&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Unrealized loss from changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;593&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;593&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;22,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;48,950&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,313&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,499&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;80,987&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Disaggregation of net sales and net loss before income taxes by geographic area:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Sales&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;36,536&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;32,312&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;38,262&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,273&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,002&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;76,071&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;33,401&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                                &lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;
                                                &lt;div&gt;

                                                &lt;/div&gt;
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Loss Before Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(31,013&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(27,867&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(10,258&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(121&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(364&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(3,120&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,662&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(17,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(48,297&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(48,108&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                    &lt;/div&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Disaggregation of property, plant and equipment and other long-lived assets by geographic area:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Property, Plant and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;354&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;759&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;493&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;847&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-top: 10pt;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Other Long-lived Assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;33,332&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,969&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Colombia&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,392&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;191&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;186&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,415&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;48,614&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total Assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11,094&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;45,341&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,096&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,382&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Colombia&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8,122&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;559&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,922&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,583&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,626&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;80,987&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_20220101to20221231"
      decimals="0"
      id="Fxbrl_20240306054207925"
      unitRef="Segment">4</us-gaap:NumberOfOperatingSegments>
    <flgc:ConsolidatedRevenue
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20240530103546458"
      unitRef="Pure">0.10</flgc:ConsolidatedRevenue>
    <flgc:ConsolidatedRevenue
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20240530103600498"
      unitRef="Pure">0.10</flgc:ConsolidatedRevenue>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305102800152">
                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Sales&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;38,262&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;44,602&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;39,419&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pharmaceuticals&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,793&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,105&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;76,071&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;33,401&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Gross Profit&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;15,520&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13,290&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pharmaceuticals&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Corp &amp;amp; Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;17,738&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13,251&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Loss from Continuing Operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(8,763&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(109&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(31,399&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(29,594&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pharmaceuticals&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Corp &amp;amp; Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,426&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(17,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(46,669&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(46,703&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056248_1"
      unitRef="USD">38262000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056248_2"
      unitRef="USD">87000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056249_3"
      unitRef="USD">44602000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056249_4"
      unitRef="USD">39419000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056250_5"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056250_6"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056250_7"
      unitRef="USD">-6793000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056251_8"
      unitRef="USD">-6105000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056251_9"
      unitRef="USD">76071000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056252_10"
      unitRef="USD">33401000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056252_11"
      unitRef="USD">2218000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056253_12"
      unitRef="USD">-39000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056253_13"
      unitRef="USD">15520000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056253_14"
      unitRef="USD">13290000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056254_15"
      unitRef="USD">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056254_16"
      unitRef="USD">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056255_17"
      unitRef="USD">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056255_18"
      unitRef="USD">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056256_19"
      unitRef="USD">17738000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056256_20"
      unitRef="USD">13251000</us-gaap:GrossProfit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056256_21"
      unitRef="USD">-8763000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056257_22"
      unitRef="USD">-109000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056257_23"
      unitRef="USD">-31399000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056258_24"
      unitRef="USD">-29594000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056258_25"
      unitRef="USD">-81000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056259_26"
      unitRef="USD">0</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056259_27"
      unitRef="USD">-6426000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056259_28"
      unitRef="USD">-17000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056262_29"
      unitRef="USD">-46669000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056262_30"
      unitRef="USD">-46703000</us-gaap:IncomeLossFromContinuingOperations>
    <flgc:ScheduleOfOtherSignificantItemsTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305102839535">
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Commercial &amp;amp;&lt;br/&gt;Wholesale&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;House of&lt;br/&gt;Brands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Pharmaceuticals&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Corporate &amp;amp;&lt;br/&gt;Eliminations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,591&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,591&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest expense (income)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,650&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,628&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;857&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,335&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Unrealized gain from changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(964&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,991&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,096&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11,608&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,922&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,626&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock based compensation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,404&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,404&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest expense (income)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,393&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(1,405&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,077&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,144&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Unrealized loss from changes in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;593&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;593&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;22,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;48,950&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,313&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,499&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;80,987&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </flgc:ScheduleOfOtherSignificantItemsTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056263_31"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056263_32"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056264_33"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056264_34"
      unitRef="USD">1591000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056265_35"
      unitRef="USD">1591000</us-gaap:ShareBasedCompensation>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056265_36"
      unitRef="USD">-93000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056266_37"
      unitRef="USD">-11000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056266_38"
      unitRef="USD">0</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056266_39"
      unitRef="USD">12000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056267_40"
      unitRef="USD">-92000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056267_41"
      unitRef="USD">-1650000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056268_42"
      unitRef="USD">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056268_43"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056269_44"
      unitRef="USD">19000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056269_45"
      unitRef="USD">-1628000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056269_46"
      unitRef="USD">857000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056270_47"
      unitRef="USD">1478000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056270_48"
      unitRef="USD">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056271_49"
      unitRef="USD">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056271_50"
      unitRef="USD">2335000</us-gaap:DepreciationAndAmortization>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056272_51"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056272_52"
      unitRef="USD">964000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056272_53"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056273_54"
      unitRef="USD">1027000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056273_55"
      unitRef="USD">1991000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056274_56"
      unitRef="USD">9096000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056274_57"
      unitRef="USD">11608000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056275_58"
      unitRef="USD">0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056275_59"
      unitRef="USD">2922000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056275_60"
      unitRef="USD">23626000</us-gaap:Assets>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056276_61"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056276_62"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056277_63"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056277_64"
      unitRef="USD">3404000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056278_65"
      unitRef="USD">3404000</us-gaap:ShareBasedCompensation>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056280_66"
      unitRef="USD">-1000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056280_67"
      unitRef="USD">27000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056281_68"
      unitRef="USD">0</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056281_69"
      unitRef="USD">3000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056282_70"
      unitRef="USD">29000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056282_71"
      unitRef="USD">-12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056283_72"
      unitRef="USD">-1393000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056283_73"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056284_74"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056284_75"
      unitRef="USD">-1405000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056284_76"
      unitRef="USD">1000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056285_77"
      unitRef="USD">2077000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056285_78"
      unitRef="USD">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056286_79"
      unitRef="USD">66000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056286_80"
      unitRef="USD">2144000</us-gaap:DepreciationAndAmortization>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056286_81"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056287_82"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056287_83"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056288_84"
      unitRef="USD">-593000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20220101to20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056288_85"
      unitRef="USD">-593000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:Assets
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20231019113056289_86"
      unitRef="USD">22225000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20231019113056289_87"
      unitRef="USD">48950000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcPharmaceuticalsMember"
      decimals="-3"
      id="F20231019113056289_88"
      unitRef="USD">3313000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20231019113056290_89"
      unitRef="USD">6499000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_usgaapFinancialInstrumentAxis_flgcConsolidatedMember"
      decimals="-3"
      id="F20231019113056290_90"
      unitRef="USD">80987000</us-gaap:Assets>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306165041492">
                                    &lt;div&gt;
                                        &lt;div&gt;
                                            &lt;div&gt;
                                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Sales&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;36,536&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;32,312&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;38,262&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,273&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,002&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;76,071&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;33,401&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                                &lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;
                                                &lt;div&gt;

                                                &lt;/div&gt;
                                                &lt;div&gt;
                                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Loss Before Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(31,013&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(27,867&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(10,258&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(121&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(364&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(3,120&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6,662&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(17,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                        &lt;tr&gt;
                                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(48,297&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(48,108&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;/tr&gt;
                                                    &lt;/table&gt;
                                                &lt;/div&gt;
                                            &lt;/div&gt;
                                        &lt;/div&gt;
                                    &lt;/div&gt;
                                </us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="F20231019113056291_91"
      unitRef="USD">36536000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="F20231019113056291_92"
      unitRef="USD">32312000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="F20231019113056292_93"
      unitRef="USD">38262000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="F20231019113056292_94"
      unitRef="USD">87000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="F20231019113056293_97"
      unitRef="USD">1273000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="F20231019113056294_98"
      unitRef="USD">1002000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056295_101"
      unitRef="USD">76071000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056295_102"
      unitRef="USD">33401000</us-gaap:Revenues>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="F20231019113056297_103"
      unitRef="USD">-31013000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="F20231019113056298_104"
      unitRef="USD">-27867000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="F20231019113056298_105"
      unitRef="USD">-10258000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="F20231019113056298_106"
      unitRef="USD">-121000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="F20231019113056300_109"
      unitRef="USD">-364000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="F20231019113056300_110"
      unitRef="USD">-3120000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryCA"
      decimals="-3"
      id="F20231019113056301_111"
      unitRef="USD">-6662000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryCA"
      decimals="-3"
      id="F20231019113056301_112"
      unitRef="USD">-17000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20231019113056301_113"
      unitRef="USD">-48297000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20231019113056302_114"
      unitRef="USD">-48108000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240306053921106">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Property, Plant and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;354&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;759&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;493&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;847&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000; margin-top: 10pt;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Other Long-lived Assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;33,332&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,969&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Colombia&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,392&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;191&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;186&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;730&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,415&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;48,614&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 70%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total Assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11,094&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;45,341&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,096&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,382&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Colombia&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8,122&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;559&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Canada&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,922&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 22%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,583&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,626&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 22%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;80,987&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="F20231019113056302_115"
      unitRef="USD">354000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="F20231019113056303_116"
      unitRef="USD">759000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="F20231019113056303_117"
      unitRef="USD">493000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="F20231019113056304_118"
      unitRef="USD">459000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240306162914937"
      unitRef="USD">847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20231019113056305_121"
      unitRef="USD">1218000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240306171326826"
      unitRef="USD">1140000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240306171357258"
      unitRef="USD">33332000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="Fxbrl_20240306171335271"
      unitRef="USD">0</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="Fxbrl_20240306171408598"
      unitRef="USD">9969000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryCO"
      decimals="-3"
      id="Fxbrl_20240306171342307"
      unitRef="USD">0</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryCO"
      decimals="-3"
      id="Fxbrl_20240306171412791"
      unitRef="USD">4392000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="Fxbrl_20240306171345867"
      unitRef="USD">89000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="Fxbrl_20240306171417231"
      unitRef="USD">191000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryCA"
      decimals="-3"
      id="Fxbrl_20240306171349546"
      unitRef="USD">186000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryCA"
      decimals="-3"
      id="Fxbrl_20240306171545578"
      unitRef="USD">730000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240306171353010"
      unitRef="USD">1415000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240306171424607"
      unitRef="USD">48614000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:Assets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240306162335757"
      unitRef="USD">11094000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240306162350533"
      unitRef="USD">45341000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="Fxbrl_20240306162401019_xbrl_20240306162335757"
      unitRef="USD">9096000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="Fxbrl_20240306162401019_xbrl_20240306162350533"
      unitRef="USD">19382000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryCO"
      decimals="-3"
      id="Fxbrl_20240306162404821_xbrl_20240306162335757"
      unitRef="USD">0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryCO"
      decimals="-3"
      id="Fxbrl_20240306162404821_xbrl_20240306162350533"
      unitRef="USD">8122000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="Fxbrl_20240306162406653_xbrl_20240306162335757"
      unitRef="USD">514000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="Fxbrl_20240306162406653_xbrl_20240306162350533"
      unitRef="USD">559000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_srtStatementGeographicalAxis_countryCA"
      decimals="-3"
      id="Fxbrl_20240306162408964_xbrl_20240306162335757"
      unitRef="USD">2922000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_srtStatementGeographicalAxis_countryCA"
      decimals="-3"
      id="Fxbrl_20240306162408964_xbrl_20240306162350533"
      unitRef="USD">7583000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240306162413939_xbrl_20240306162335757"
      unitRef="USD">23626000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240306162413939_xbrl_20240306162350533"
      unitRef="USD">80987000</us-gaap:Assets>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20230101to20231231"
      id="F20231019113056329_11">
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;25.&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left: 15pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;SUBSEQUENT EVENTS &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;OTHER&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The contingent purchase consideration related to the acquisition of JustCBD was due on February 24, 2024. The balance of $0.9 million remains unpaid as of the date of filing these consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On March 8, 2024, the Company entered into a settlement agreement with a third party pursuant to which the Company issued 50,000 common shares of the Company, valued at $0.1 million, to a third party to settle outstanding amounts owed.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_20240224_usgaapBusinessAcquisitionAxis_flgcJustCBDMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="-5"
      id="Fxbrl_20240305101445832"
      unitRef="USD">900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240301to20240308_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20240328105152872"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20240301to20240308_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="-5"
      id="Fxbrl_20240328105230084"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728082_0"
      unitRef="USD">4156000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728083_1"
      unitRef="USD">4350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728091_54"
      unitRef="USD">35000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728091_55"
      unitRef="USD">35000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728090_50"
      unitRef="USD">317000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728090_51"
      unitRef="USD">315000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728083_2"
      unitRef="USD">3218000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728083_3"
      unitRef="USD">3950000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728083_4"
      unitRef="USD">1049000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728083_5"
      unitRef="USD">1368000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NontradeReceivables
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728083_6"
      unitRef="USD">4063000</us-gaap:NontradeReceivables>
    <us-gaap:NontradeReceivables
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728084_7"
      unitRef="USD">3153000</us-gaap:NontradeReceivables>
    <us-gaap:InventoryNet
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728084_8"
      unitRef="USD">9246000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728084_9"
      unitRef="USD">8508000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728084_10"
      unitRef="USD">21767000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728084_11"
      unitRef="USD">21364000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728084_12"
      unitRef="USD">786000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728085_13"
      unitRef="USD">847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728085_14"
      unitRef="USD">710000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728085_15"
      unitRef="USD">389000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728085_16"
      unitRef="USD">908000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728085_17"
      unitRef="USD">946000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728085_18"
      unitRef="USD">103000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728085_19"
      unitRef="USD">80000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728086_20"
      unitRef="USD">24274000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728086_21"
      unitRef="USD">23626000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728086_22"
      unitRef="USD">5005000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728086_23"
      unitRef="USD">5111000</us-gaap:AccountsPayableCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728086_24"
      unitRef="USD">6591000</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728086_25"
      unitRef="USD">5500000</us-gaap:CommitmentsAndContingencies>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728086_26"
      unitRef="USD">3078000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728087_27"
      unitRef="USD">1931000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728087_28"
      unitRef="USD">803000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728087_29"
      unitRef="USD">799000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="Fxbrl_20240507230908314_20240530124728087_28"
      unitRef="USD">1702000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240507230908314_20240530124728087_29"
      unitRef="USD">1095000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728087_30"
      unitRef="USD">2140000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728087_31"
      unitRef="USD">1844000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728087_32"
      unitRef="USD">19319000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728087_33"
      unitRef="USD">16280000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728088_34"
      unitRef="USD">1817000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728088_35"
      unitRef="USD">942000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728088_36"
      unitRef="USD">21136000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728088_37"
      unitRef="USD">17222000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728091_58"
      unitRef="Shares">8981000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728090_52"
      unitRef="Shares">8981000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728091_59"
      unitRef="Shares">8935000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728090_53"
      unitRef="Shares">8935000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728088_38"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728088_39"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728088_40"
      unitRef="USD">148871000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728089_41"
      unitRef="USD">149093000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728089_42"
      unitRef="USD">-113000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728089_43"
      unitRef="USD">-140000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728089_44"
      unitRef="USD">-145620000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728089_45"
      unitRef="USD">-142549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728089_46"
      unitRef="USD">3138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728089_47"
      unitRef="USD">6404000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20240331"
      decimals="-3"
      id="F20240530124728090_48"
      unitRef="USD">24274000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728090_49"
      unitRef="USD">23626000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705218_1"
      unitRef="USD">18031000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705217_0"
      unitRef="USD">19319000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705219_5"
      unitRef="USD">14177000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705219_4"
      unitRef="USD">13973000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705219_3"
      unitRef="USD">3854000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705218_2"
      unitRef="USD">5346000</us-gaap:GrossProfit>
    <us-gaap:ManagementFeeExpense
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705220_7"
      unitRef="USD">2302000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705220_6"
      unitRef="USD">3671000</us-gaap:ManagementFeeExpense>
    <us-gaap:ProfessionalFees
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705220_9"
      unitRef="USD">453000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705220_8"
      unitRef="USD">-3000</us-gaap:ProfessionalFees>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705224_11"
      unitRef="USD">442000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705221_10"
      unitRef="USD">352000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:Communication
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705225_13"
      unitRef="USD">1104000</us-gaap:Communication>
    <us-gaap:Communication
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705225_12"
      unitRef="USD">1308000</us-gaap:Communication>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705226_15"
      unitRef="USD">69000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705225_14"
      unitRef="USD">132000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705226_17"
      unitRef="USD">10000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705226_16"
      unitRef="USD">654000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705227_19"
      unitRef="USD">47000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705227_18"
      unitRef="USD">16000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705227_21"
      unitRef="USD">165000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705227_20"
      unitRef="USD">316000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705248_59"
      unitRef="USD">74000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705228_22"
      unitRef="USD">864000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705229_24"
      unitRef="USD">47000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705228_23"
      unitRef="USD">29000</us-gaap:InterestAndDebtExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705253_76"
      unitRef="USD">898000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705253_77"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705229_26"
      unitRef="USD">728000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705229_25"
      unitRef="USD">377000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OperatingExpenses
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705230_28"
      unitRef="USD">6339000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705230_27"
      unitRef="USD">7716000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705231_30"
      unitRef="USD">-2485000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705230_29"
      unitRef="USD">-2370000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705231_32"
      unitRef="USD">-22000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705231_31"
      unitRef="USD">-23000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705232_34"
      unitRef="USD">-132000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705232_33"
      unitRef="USD">12000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705236_45"
      unitRef="USD">-607000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705236_46"
      unitRef="USD">-883000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230807135627414_20240527045705233_36"
      unitRef="USD">-3246000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230807135627414_20240527045705233_35"
      unitRef="USD">-3264000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705233_36"
      unitRef="USD">128000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705233_35"
      unitRef="USD">-78000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230807140320575_20240527045705233_36"
      unitRef="USD">-3374000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230807140320575_20240527045705233_35"
      unitRef="USD">-3186000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230807140323110_20240527045705233_36"
      unitRef="USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230807140323110_20240527045705233_35"
      unitRef="USD">-719000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705234_38"
      unitRef="USD">-3374000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705234_37"
      unitRef="USD">-3905000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705248_60"
      unitRef="USD">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705248_61"
      unitRef="USD">-29000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705235_40"
      unitRef="USD">-3374000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705234_39"
      unitRef="USD">-3876000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20240101to20240331"
      decimals="2"
      id="F20240527045705241_54"
      unitRef="CAD_Per_Share">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20230101to20230331"
      decimals="2"
      id="F20240527045705241_53"
      unitRef="CAD_Per_Share">-0.48</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20240101to20240331"
      decimals="2"
      id="F20240527045705247_56"
      unitRef="CAD_Per_Share">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20230101to20230331"
      decimals="2"
      id="F20240527045705246_55"
      unitRef="CAD_Per_Share">-0.48</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20240101to20240331"
      decimals="2"
      id="F20240527045705235_42"
      unitRef="CAD_Per_Share">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20230331"
      decimals="2"
      id="F20240527045705235_41"
      unitRef="CAD_Per_Share">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20240101to20240331"
      decimals="2"
      id="F20240527045705249_62"
      unitRef="CAD_Per_Share">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20230331"
      decimals="2"
      id="F20240527045705249_63"
      unitRef="CAD_Per_Share">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240101to20240331"
      decimals="0"
      id="F20240527045705236_44"
      unitRef="Shares">8916</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20230331"
      decimals="0"
      id="F20240527045705236_43"
      unitRef="Shares">6640</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20240101to20240331"
      decimals="0"
      id="F20240527045705247_57"
      unitRef="Shares">8916</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20230331"
      decimals="0"
      id="F20240527045705247_58"
      unitRef="Shares">6640</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705249_64"
      unitRef="USD">-3374000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705250_65"
      unitRef="USD">-3905000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705252_74"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705253_75"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705250_66"
      unitRef="USD">27000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705250_67"
      unitRef="USD">357000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705251_68"
      unitRef="USD">-3347000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705251_69"
      unitRef="USD">-3548000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705252_73"
      unitRef="USD">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705252_72"
      unitRef="USD">-29000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705251_70"
      unitRef="USD">-3347000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705251_71"
      unitRef="USD">-3519000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20240527045705269_4"
      unitRef="Shares">8935</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="F20240527045705271_13"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705269_5"
      unitRef="USD">149093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20240527045705269_6"
      unitRef="USD">-140000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20240527045705270_7"
      unitRef="USD">-142549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="F20240527045705270_8"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705270_9"
      unitRef="USD">6404000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <flgc:EquityIssuedForOtherAgreementsShares
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20240527045705280_53"
      unitRef="Shares">50</flgc:EquityIssuedForOtherAgreementsShares>
    <flgc:EquityIssuedForOtherAgreementsAmount
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705280_52"
      unitRef="USD">55000</flgc:EquityIssuedForOtherAgreementsAmount>
    <flgc:EquityIssuedForOtherAgreementsAmount
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705279_51"
      unitRef="USD">55000</flgc:EquityIssuedForOtherAgreementsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705268_0"
      unitRef="USD">5000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705268_1"
      unitRef="USD">5000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705274_26"
      unitRef="USD">303000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20231102180402039_20240527045705273_22"
      unitRef="USD">-303000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705275_32"
      unitRef="USD">14000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705275_31"
      unitRef="USD">14000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20240527045705275_30"
      unitRef="Shares">4</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705275_29"
      unitRef="USD">9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705275_28"
      unitRef="USD">9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705268_2"
      unitRef="USD">-16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705269_3"
      unitRef="USD">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705281_61"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20240527045705272_14"
      unitRef="USD">27000</flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil>
    <flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705272_15"
      unitRef="USD">27000</flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20231102180654223_20240527045705270_10"
      unitRef="USD">-3374000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20231102180654223_20240527045705271_12"
      unitRef="USD">-3374000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20240527045705277_40"
      unitRef="Shares">8981</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="F20240527045705277_41"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20231102180715636_20240527045705273_18"
      unitRef="USD">148871000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20240527045705276_38"
      unitRef="USD">-113000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20240527045705276_37"
      unitRef="USD">-145620000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="Fxbrl_20231102180715636_20240527045705272_17"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331"
      decimals="-3"
      id="Fxbrl_20231102180715636_20240527045705272_16"
      unitRef="USD">3138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20231102180914189_20240527045705269_4"
      unitRef="Shares">6776</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20231102180914189_20240527045705271_13"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20231102180914189_20240527045705269_5"
      unitRef="USD">150420000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20240527045705280_57"
      unitRef="USD">-2732000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20240527045705281_58"
      unitRef="USD">-90865000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="Fxbrl_20231102180914189_20240527045705270_8"
      unitRef="USD">-411000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20231102180914189_20240527045705270_9"
      unitRef="USD">56412000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <flgc:EquityIssuedForOtherAgreementsShares
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240508003741968_20240527045705280_53"
      unitRef="Shares">16</flgc:EquityIssuedForOtherAgreementsShares>
    <flgc:EquityIssuedForOtherAgreementsAmount
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240508003741968_20240527045705280_52"
      unitRef="USD">95000</flgc:EquityIssuedForOtherAgreementsAmount>
    <flgc:EquityIssuedForOtherAgreementsAmount
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20240508003741968_20240527045705279_51"
      unitRef="USD">95000</flgc:EquityIssuedForOtherAgreementsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705274_24"
      unitRef="USD">119000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705274_23"
      unitRef="USD">119000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705273_22"
      unitRef="USD">765000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20240527045705274_27"
      unitRef="USD">-765000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20240527045705279_50"
      unitRef="Shares">52</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20231102183748527_20240527045705275_32"
      unitRef="USD">534000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20231102183748527_20240527045705275_31"
      unitRef="USD">534000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705282_62"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230806185457906_20240527045705272_14"
      unitRef="USD">357000</flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil>
    <flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806185457906_20240527045705272_15"
      unitRef="USD">357000</flgc:OtherComprehensiveLossExchangeDifferencesOnForeignOperationsNetOfIncomeTaxesOfNil>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20240527045705270_10"
      unitRef="USD">-3876000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="F20240527045705271_11"
      unitRef="USD">-29000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705271_12"
      unitRef="USD">-3905000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20240527045705273_19"
      unitRef="Shares">6844</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="F20240527045705278_42"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="F20240527045705273_18"
      unitRef="USD">150403000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="F20240527045705281_59"
      unitRef="USD">-2375000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="F20240527045705281_60"
      unitRef="USD">-93976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="-3"
      id="F20240527045705272_17"
      unitRef="USD">-440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331"
      decimals="-3"
      id="F20240527045705272_16"
      unitRef="USD">53612000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240530124728097_0"
      unitRef="USD">-3374000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728097_1"
      unitRef="USD">-3905000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240530124728098_2"
      unitRef="USD">74000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728098_3"
      unitRef="USD">942000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240530124728098_4"
      unitRef="USD">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728098_5"
      unitRef="USD">654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240530124728102_54"
      unitRef="USD">898000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728102_55"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130108415_20240530124728098_6"
      unitRef="USD">-607000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130108415_20240530124728098_7"
      unitRef="USD">-883000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240530124728098_6"
      unitRef="USD">47000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728098_7"
      unitRef="USD">29000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806125958481_20240530124728098_6"
      unitRef="USD">-22000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806125958481_20240530124728098_7"
      unitRef="USD">-23000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeOperating
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240530124728102_53"
      unitRef="USD">22000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130002597_20240530124728098_7"
      unitRef="USD">23000</us-gaap:InterestIncomeOperating>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130004302_20240530124728098_6"
      unitRef="USD">128000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130004302_20240530124728098_7"
      unitRef="USD">-66000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130006270_20240530124728098_6"
      unitRef="USD">-1610000</us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130006270_20240530124728098_7"
      unitRef="USD">-1463000</us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130008464_20240530124728098_6"
      unitRef="USD">292000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130008464_20240530124728098_7"
      unitRef="USD">-91000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130010614_20240530124728098_6"
      unitRef="USD">738000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130010614_20240530124728098_7"
      unitRef="USD">113000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130017839_20240530124728098_6"
      unitRef="USD">-268000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728101_47"
      unitRef="USD">920000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130019118_20240530124728098_6"
      unitRef="USD">1032000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130019118_20240530124728098_7"
      unitRef="USD">-1919000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130020150_20240530124728098_6"
      unitRef="USD">-1340000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130020150_20240530124728098_7"
      unitRef="USD">-4324000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130029242_20240530124728098_6"
      unitRef="USD">3078000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130029242_20240530124728098_7"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130031176_20240530124728098_6"
      unitRef="USD">1890000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130031176_20240530124728098_7"
      unitRef="USD">19000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130106020_20240530124728098_6"
      unitRef="USD">1188000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728101_46"
      unitRef="USD">-19000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130103950_20240530124728098_6"
      unitRef="USD">88000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130103950_20240530124728098_7"
      unitRef="USD">102000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130059797_20240530124728098_6"
      unitRef="USD">-88000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728101_48"
      unitRef="USD">-102000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130101466_20240530124728098_6"
      unitRef="USD">46000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20230806130101466_20240530124728098_7"
      unitRef="USD">167000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20230806130044959_20240530124728098_6"
      unitRef="USD">-194000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728101_49"
      unitRef="USD">-4278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="F20240530124728101_44"
      unitRef="USD">4385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240530115425045"
      unitRef="USD">9537000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="C_20240331"
      decimals="-3"
      id="Fxbrl_20230807174133573_20240530124728101_44"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="C_20230331"
      decimals="-3"
      id="Fxbrl_20230807174133573_20240530124728101_45"
      unitRef="USD">203000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20240331"
      decimals="-3"
      id="Fxbrl_20230806130043016_20240530124728098_6"
      unitRef="USD">4191000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230331"
      decimals="-3"
      id="Fxbrl_20230806130043016_20240530124728098_7"
      unitRef="USD">5056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <flgc:NonCashAssetsAcquiredForContingentConsideration
      contextRef="C_20240101to20240331"
      decimals="INF"
      id="Fxbrl_20230806130036889_20240530124728098_6"
      unitRef="Shares">0</flgc:NonCashAssetsAcquiredForContingentConsideration>
    <flgc:NonCashAssetsAcquiredForContingentConsideration
      contextRef="C_20230101to20230331"
      decimals="INF"
      id="Fxbrl_20230806130036889_20240530124728098_7"
      unitRef="Shares">303</flgc:NonCashAssetsAcquiredForContingentConsideration>
    <flgc:NonCashCommonSharesIssuedForOtherAgreements
      contextRef="C_20240101to20240331"
      decimals="INF"
      id="Fxbrl_20230806130035042_20240530124728098_6"
      unitRef="Shares">55</flgc:NonCashCommonSharesIssuedForOtherAgreements>
    <flgc:NonCashCommonSharesIssuedForOtherAgreements
      contextRef="C_20230101to20230331"
      decimals="INF"
      id="F20240530124728102_52"
      unitRef="Shares">95</flgc:NonCashCommonSharesIssuedForOtherAgreements>
    <flgc:NonCashOptionCancellationsReclassifiedToEquity
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240530124728102_56"
      unitRef="USD">303000</flgc:NonCashOptionCancellationsReclassifiedToEquity>
    <flgc:NonCashOptionCancellationsReclassifiedToEquity
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240530124728102_57"
      unitRef="USD">765000</flgc:NonCashOptionCancellationsReclassifiedToEquity>
    <flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets
      contextRef="C_20240101to20240331"
      decimals="INF"
      id="Fxbrl_20230806130041094_20240530124728098_6"
      unitRef="Shares">1247</flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets>
    <flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets
      contextRef="C_20230101to20230331"
      decimals="INF"
      id="Fxbrl_20230806130041094_20240530124728098_7"
      unitRef="Shares">97</flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets>
    <us-gaap:NatureOfOperations contextRef="C_20240101to20240331" id="F20240527045705303_0">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;NATURE OF OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Flora Growth Corp. (the "Company" or "Flora") was incorporated under the laws of the Province of Ontario, Canada on March 13, 2019. The Company is a manufacturer and distributor of global cannabis and pharmaceutical products and brands, building a connected, design-led collective of plant-based wellness and lifestyle brands. The Company's registered office is located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1, Canada and our principal place of business in the United States is located at 3230 W. Commercial Boulevard, Suite 180, Fort Lauderdale, Florida 33309.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Presentation of comparative financial statements&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation. See discussion in Note 11.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_20240101to20240331" id="F20240527045705307_0">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;BASIS OF PRESENTATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These unaudited condensed interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP. The Company believes that the disclosures made are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2023. These unaudited condensed interim consolidated financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These unaudited condensed interim consolidated financial statements apply the same accounting policies as those used in the financial statements included in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Prior to January 1, 2023, Flora was a foreign private issuer reporting its financial statements under International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Boards. These consolidated financial statements, for all periods, are presented in accordance with U.S. GAAP.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;

                                        &lt;div&gt;
                                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Going concern&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The accompanying unaudited condensed interim consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these unaudited condensed interim consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company had cash of $4.2 million at March 31, 2024, net loss of $3.4 million for the three months ended March 31, 2024, and an accumulated deficit of $145.6&#160;million at March 31, 2024. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed interim consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. The unaudited condensed interim consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;

                                &lt;/div&gt;
                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;
                                &lt;div&gt;

                                        &lt;div&gt;
                                            &lt;p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. At March 31, 2024, the Company's subsidiaries and respective ownership percentage have not changed from the year ended December 31, 2023, except as noted below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;During the three months ended March 31, 2024, the Company voluntarily dissolved the Cardiff Brand Corp. U.S. entity. Also during the three months ended March 31, 2024, the Company signed articles of organization for Just Brands FL LLC, a United States domestic limited liability company, which is 100% owned by the Company and has a functional currency of the United States dollar.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;

                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <flgc:GoingConcernPolicyTextBlock contextRef="C_20240101to20240331" id="F20240527045705307_4">
                                        &lt;div&gt;
                                            &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Going concern&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The accompanying unaudited condensed interim consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue one year after the date these unaudited condensed interim consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company had cash of $4.2 million at March 31, 2024, net loss of $3.4 million for the three months ended March 31, 2024, and an accumulated deficit of $145.6&#160;million at March 31, 2024. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed interim consolidated financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners, through obtaining credit from financial institutions or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company's ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company's performance and investor sentiment with respect to it and its industry. The unaudited condensed interim consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;
                                    </flgc:GoingConcernPolicyTextBlock>
    <us-gaap:Cash
      contextRef="C_20240331"
      decimals="-5"
      id="F20240527045705307_1"
      unitRef="USD">4200000</us-gaap:Cash>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331"
      decimals="-5"
      id="F20240527045705307_2"
      unitRef="USD">-3400000</us-gaap:ProfitLoss>
    <us-gaap:CumulativeEarningsDeficit
      contextRef="C_20240331"
      decimals="-5"
      id="F20240527045705307_3"
      unitRef="USD">-145600000</us-gaap:CumulativeEarningsDeficit>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_20240101to20240331" id="F20240527045705308_5">
                                        &lt;div&gt;
                                            &lt;p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement in the entity and can affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are included in the consolidated financial results of the Company from the date of acquisition up to the date of disposition or loss of control. At March 31, 2024, the Company's subsidiaries and respective ownership percentage have not changed from the year ended December 31, 2023, except as noted below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;During the three months ended March 31, 2024, the Company voluntarily dissolved the Cardiff Brand Corp. U.S. entity. Also during the three months ended March 31, 2024, the Company signed articles of organization for Just Brands FL LLC, a United States domestic limited liability company, which is 100% owned by the Company and has a functional currency of the United States dollar.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;/div&gt;
                                    </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_20240331_usgaapBusinessAcquisitionAxis_flgcJustBrandsLLCMember"
      decimals="2"
      id="F20240527045705308_6"
      unitRef="Pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="C_20240101to20240331"
      id="F20240529105303682_42">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan Farma Colombia LLC ("Lisan"), a Delaware limited liability company, to sell all its shares in its Colombian related subsidiaries and its Colombian assets for a purchase price of CAD $0.8 million (USD $0.6 million). The sale relates to all of Flora's operations in Colombia, including its interest in (i) its 361-acre Cosechemos farm located in Giron, Colombia and its related processing facilities and inventory and (ii) all other assets relating to Flora Lab 2, Flora Lab 4 and Flora's Colombian food and beverage and consumer products business. The Company received proceeds of CAD $0.5 million during the year ended December 31, 2023 which completed the sale and transfer of Flora Growth Corp Colombia S.A.S, Flora Lab S.A.S., Flora Med S.A.S., Labcofarm Laboratorios S.A.S., Kasa Wholefoods Company S.A.S., Flora Growth Corp. Sucursal Colombia and Flora Beauty LLC Sucursal Colombia. The Company and Lisan completed the sale of Cosechemos Ya S.A.S on November 1, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The sale enabled the Company to concentrate on its core business divisions, which are lifestyle brands in the United States and international pharmaceutical distribution. The sale was part of several strategic changes to cut costs and streamline operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The following table summarizes the major classes of line items included in loss from discontinued operations, net of tax, for the three months ended March 31, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Revenue&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;788&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;657&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gross profit from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Consulting and management fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Promotion and communication&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating loss from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(708&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(708&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(719&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Basic loss per share from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(0.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Diluted loss per share from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(0.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The following table summarizes the significant operating and investing items related to the Colombian subsidiaries for the three months ended March 31, 2024 and 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Operating activities of discontinued operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Investing activities of discontinued operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Purchases of property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The subsidiaries sold included Cosechemos Ya S.A.S, which was part of the commercial and wholesale segment; Flora Lab S.A.S, Flora Med S.A.S. and Labcofarm Laboratories S.A.S, which were part of the pharmaceuticals segment; Flora Growth Corp Colombia S.A.S., Kasa Wholefoods Company, S.A.S. and Flora Beauty LLC Sucursal Colombia which were part of the house of brands segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company applies significant judgement in determining whether a disposal meets the criteria to present as held for sale at the reporting date, and whether the disposal represents a strategic shift that has (or will have) a major effect on its operations and financial results in order to be classified as a discontinued operation. The criteria evaluated are both quantitative and qualitative in nature, to evaluate the significance of the disposal relative to the operations of the Company as a whole. The Company has determined this disposition represents a strategic shift in operations that will have a major effect on the Company's operations and financial results, and accordingly, has been presented as discontinued operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="F20240529105303665_32"
      unitRef="CAD">800000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230701to20230705_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="F20240529105303673_33"
      unitRef="USD">600000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-5"
      id="F20240529105303681_34"
      unitRef="CAD">500000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <flgc:ScheduleOfLossFromDiscontinuedOperationsTableTextBlock
      contextRef="C_20240101to20240331"
      id="F20240529105303682_40">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Revenue&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;788&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;657&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gross profit from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Consulting and management fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Promotion and communication&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating loss from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(708&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Net loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(708&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(719&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Basic loss per share from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(0.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Diluted loss per share from discontinued operations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(0.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </flgc:ScheduleOfLossFromDiscontinuedOperationsTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303657_0"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303658_1"
      unitRef="USD">788000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303658_2"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303658_3"
      unitRef="USD">657000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303658_4"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303659_5"
      unitRef="USD">131000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303659_6"
      unitRef="USD">0</flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees>
    <flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303659_7"
      unitRef="USD">369000</flgc:DisposalGroupIncludingDiscontinuedOperationConsultingAndManagementFees>
    <flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303659_8"
      unitRef="USD">0</flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees>
    <flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303660_9"
      unitRef="USD">36000</flgc:DisposalGroupIncludingDiscontinuedOperationProfessionalFees>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303660_10"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303660_11"
      unitRef="USD">176000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303660_12"
      unitRef="USD">0</flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication>
    <flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303661_13"
      unitRef="USD">6000</flgc:DisposalGroupIncludingDiscontinuedOperationPromotionAndCommunication>
    <flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303661_14"
      unitRef="USD">0</flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303661_15"
      unitRef="USD">50000</flgc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303661_16"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303661_17"
      unitRef="USD">78000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303681_35"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303657_05"
      unitRef="USD">124000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303662_19"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303662_20"
      unitRef="USD">-708000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303662_21"
      unitRef="USD">0</flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense>
    <flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303662_22"
      unitRef="USD">0</flgc:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303658_12"
      unitRef="USD">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303658_15"
      unitRef="USD">-708000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303683_43"
      unitRef="USD">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303663_25"
      unitRef="USD">11000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303663_26"
      unitRef="USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303663_27"
      unitRef="USD">-719000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20231108100011769_20240529105303663_26"
      unitRef="CAD_Per_Share">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20231108100011769_20240529105303663_27"
      unitRef="CAD_Per_Share">-0.11</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20231108100013814_20240529105303663_26"
      unitRef="CAD_Per_Share">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20231108100013814_20240529105303663_27"
      unitRef="CAD_Per_Share">-0.11</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <flgc:ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock
      contextRef="C_20240101to20240331"
      id="F20240529105303682_41">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Operating activities of discontinued operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Investing activities of discontinued operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Purchases of property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </flgc:ScheduleOfSignificantOperatingAndInvestingItemsTableTextBlock>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303664_28"
      unitRef="USD">0</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303664_29"
      unitRef="USD">78000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303664_30"
      unitRef="USD">0</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcLisanFarmaColombiaLLCMember_usgaapTypeOfArrangementAxis_flgcSharePurchaseAgreementMember"
      decimals="-3"
      id="F20240529105303664_31"
      unitRef="USD">94000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705324_28">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;4.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;TRADE AND AMOUNTS RECEIVABLE &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company's trade and amounts receivable are recorded at amortized cost. The trade and other receivables balance as at March 31, 2024 and December 31, 2023 consists of trade accounts receivable, amounts recoverable from the Government of Canada for Harmonized Sales Taxes ("HST"), as well as Value Added Tax ("VAT") from various jurisdictions, and other receivables.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Trade accounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2,595&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2,299&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(317&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;HST/VAT receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;765&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1,840&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;175&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3,218&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;3,950&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Changes in the trade accounts receivable allowance in the three months ended March 31, 2024 relate to establishing an allowance for expected credit losses and reclassification of assets held for sale. There were $nil and less than $0.1 million in write-offs of trade receivables during the three months ended March 31, 2024 and 2023, respectively. The Company has no amounts written-off that are still subject to collection enforcement activity as at March 31, 2024. The Company's aging of trade accounts receivable is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;567&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1-30 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1,314&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;588&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;31-60 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;577&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;61-90 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;173&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;91-180 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;238&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;180+ Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2,595&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2,299&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                    &lt;/div&gt;
                </us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705324_19">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Trade accounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;2,595&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2,299&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;(317&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;(315&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;HST/VAT receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;765&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1,840&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;175&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;126&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;3,218&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;3,950&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <flgc:TradeAccountsReceivable
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705322_0"
      unitRef="USD">2595000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705322_1"
      unitRef="USD">2299000</flgc:TradeAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705322_2"
      unitRef="USD">317000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705322_3"
      unitRef="USD">315000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705323_4"
      unitRef="USD">765000</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705323_5"
      unitRef="USD">1840000</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:OtherReceivables
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705323_6"
      unitRef="USD">175000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705323_7"
      unitRef="USD">126000</us-gaap:OtherReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705323_8"
      unitRef="USD">3218000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705323_9"
      unitRef="USD">3950000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20240101to20240331"
      decimals="-6"
      id="F20240527045705324_17"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20230101to20230331"
      decimals="-5"
      id="F20240527045705324_18"
      unitRef="USD">100000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <flgc:ScheduleOfCompanyAgingOfTradeAccountsReceivable
      contextRef="C_20240101to20240331"
      id="F20240527045705324_27">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;567&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1-30 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;1,314&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;588&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;31-60 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;577&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;61-90 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;173&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;91-180 Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;238&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;180+ Days&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Total trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2,595&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;2,299&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </flgc:ScheduleOfCompanyAgingOfTradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember"
      decimals="-3"
      id="F20240527045705324_20"
      unitRef="USD">567000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancialAssetNotPastDueMember"
      decimals="-3"
      id="F20240527045705323_10"
      unitRef="USD">218000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember"
      decimals="-3"
      id="F20240527045705324_21"
      unitRef="USD">1314000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables1To29DaysPastDueMember"
      decimals="-3"
      id="F20240527045705323_11"
      unitRef="USD">588000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember"
      decimals="-3"
      id="F20240527045705324_22"
      unitRef="USD">236000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables30To59DaysPastDueMember"
      decimals="-3"
      id="F20240527045705323_12"
      unitRef="USD">577000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember"
      decimals="-3"
      id="F20240527045705324_23"
      unitRef="USD">173000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivables60To89DaysPastDueMember"
      decimals="-3"
      id="F20240527045705323_13"
      unitRef="USD">448000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember"
      decimals="-3"
      id="F20240527045705324_24"
      unitRef="USD">238000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_usgaapFinancingReceivablesEqualToGreaterThan90DaysPastDueMember"
      decimals="-3"
      id="F20240527045705324_14"
      unitRef="USD">401000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20240331_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember"
      decimals="-3"
      id="F20240527045705324_25"
      unitRef="USD">67000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231_usgaapFinancingReceivablesPeriodPastDueAxis_flgcFinancingReceivables180PlusDaysPastDueMember"
      decimals="-3"
      id="F20240527045705324_15"
      unitRef="USD">67000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705324_26"
      unitRef="USD">2595000</flgc:TradeAccountsReceivable>
    <flgc:TradeAccountsReceivable
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705324_16"
      unitRef="USD">2299000</flgc:TradeAccountsReceivable>
    <us-gaap:InventoryDisclosureTextBlock contextRef="C_20240101to20240331" id="F20240527045705328_6">
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;INVENTORY &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Inventory is comprised of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;

                                            &lt;div&gt;
                                                &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1,053&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,180&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Finished goods&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8,193&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,328&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9,246&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8,508&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                            &lt;/div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="C_20240101to20240331" id="F20240527045705328_7">
                                            &lt;div&gt;
                                                &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1,053&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,180&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Finished goods&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8,193&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,328&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                    &lt;tr&gt;
                                                        &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9,246&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8,508&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                        &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;/tr&gt;
                                                &lt;/table&gt;
                                            &lt;/div&gt;
                                        </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705327_0"
      unitRef="USD">1053000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705327_1"
      unitRef="USD">1180000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705327_2"
      unitRef="USD">8193000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705327_3"
      unitRef="USD">7328000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705327_4"
      unitRef="USD">9246000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705328_5"
      unitRef="USD">8508000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705331_12">
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;PROPERTY, PLANT AND EQUIPMENT &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;
                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 9px;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 91px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Land&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;292&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;298&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Buildings&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 9px;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 91px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;91&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 9px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 91px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;697&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;696&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vehicles&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 9px;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 91px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;37&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1,117&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 9px;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 91px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(331&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 9px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 91px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;786&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;847&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                            &lt;/table&gt;

                                        &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;Depreciation expense for the three months ended March 3, 2024 was less than $&lt;/span&gt;0.1 million, (March 31, 2023 - $0.1&lt;span&gt; million) and was recorded in depreciation and amortization in the unaudited condensed interim consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;See Note 8 for discussion of impairment of property, plant and equipment during the three months ended March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705331_15">
                                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 9px;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; width: 91px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Land&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;292&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;298&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Buildings&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 9px;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 91px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;91&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 9px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 91px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;697&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;696&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vehicles&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 9px;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 91px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;37&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 9px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 91px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1,117&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 9px;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 91px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(331&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;/tr&gt;
                                                &lt;tr&gt;
                                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 9px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 91px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;786&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;847&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;/tr&gt;
                                            &lt;/table&gt;
                                        </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember"
      decimals="-3"
      id="F20240527045705330_0"
      unitRef="USD">292000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLandMember"
      decimals="-3"
      id="F20240527045705330_1"
      unitRef="USD">298000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember"
      decimals="-3"
      id="F20240527045705331_16"
      unitRef="USD">91000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapBuildingMember"
      decimals="-3"
      id="F20240527045705331_17"
      unitRef="USD">78000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      decimals="-3"
      id="F20240527045705330_2"
      unitRef="USD">697000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      decimals="-3"
      id="F20240527045705330_3"
      unitRef="USD">696000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20240331_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember"
      decimals="-3"
      id="F20240527045705330_4"
      unitRef="USD">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapVehiclesMember"
      decimals="-3"
      id="F20240527045705330_5"
      unitRef="USD">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705330_6"
      unitRef="USD">1117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705330_7"
      unitRef="USD">1109000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705331_8"
      unitRef="USD">331000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705331_9"
      unitRef="USD">262000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705331_10"
      unitRef="USD">786000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705331_11"
      unitRef="USD">847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_20240101to20240331"
      decimals="-5"
      id="F20240527045705331_13"
      unitRef="USD">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20230101to20230331"
      decimals="-5"
      id="F20240527045705331_14"
      unitRef="USD">100000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="C_20240101to20240331" id="F20240527045705334_0">
                &lt;p style="font-size: 10pt; font-family: Times New Roman; margin: 0pt 0px 0px 0in; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;INTANGIBLE ASSETS AND GOODWILL &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A continuity of intangible assets for the three months ended March 31, 2024 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 8pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; width: 311px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 12px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Trademarks&lt;br/&gt;and Brands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 13px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 12px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,892&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 13px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 10px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,990&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At March 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,892&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,990&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 12px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 124px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,132&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 18px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 13px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 93px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;912&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 45px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 10px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 75px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,044&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At March 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,163&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;919&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,082&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 12px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 124px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 13px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 93px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 75px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Net book value at March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 12px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;729&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 13px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;179&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 10px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;908&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="background-color: #ffffff;"&gt;Amortization expense for the three months ended March 31, 2024 was less than $&lt;/span&gt;&lt;span id="xbrl_20240530114158815"&gt;0.1&lt;/span&gt;&lt;span style="background-color: #ffffff;"&gt; million (March 31, 2023 - &lt;/span&gt;$0.8)&lt;span style="background-color: #ffffff;"&gt; and was recorded in depreciation and amortization in the unaudited condensed interim consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At March 31, 2024, the weighted average amortization period remaining for intangible assets was 6.0 years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At March 31, 2024, the estimated future amortization expense related to intangible assets is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 30%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thereafter&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;185&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;908&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705340_36">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 8pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; width: 311px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 12px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Trademarks&lt;br/&gt;and Brands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 13px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 12px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,892&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 13px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 10px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,990&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At March 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,892&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,990&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff; width: 311px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 124px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 18px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 13px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 93px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 45px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10px; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 75px; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 12px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 124px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,132&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 18px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 13px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 93px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;912&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 45px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 10px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 75px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,044&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; background-color: #e6efff; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At March 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 12px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 124px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,163&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 18px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 13px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 93px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;919&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 45px; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 10px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 75px; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,082&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 311px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 12px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 124px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 13px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 93px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 10px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 75px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 16pt; width: 311px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Net book value at March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 12px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 124px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;729&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 18px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 13px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 93px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;179&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 45px;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 10px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 75px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;908&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20240527045705335_1"
      unitRef="USD">1892000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20240527045705335_2"
      unitRef="USD">1098000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705335_3"
      unitRef="USD">2990000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20240527045705335_4"
      unitRef="USD">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20240527045705335_5"
      unitRef="USD">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705335_6"
      unitRef="USD">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20240527045705335_7"
      unitRef="USD">1892000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20240527045705335_8"
      unitRef="USD">1098000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705335_9"
      unitRef="USD">2990000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20240527045705336_10"
      unitRef="USD">1132000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20240527045705336_11"
      unitRef="USD">912000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705336_12"
      unitRef="USD">2044000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20240527045705336_13"
      unitRef="USD">31000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20240101to20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20240527045705336_14"
      unitRef="USD">7000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705336_15"
      unitRef="USD">38000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20240527045705337_16"
      unitRef="USD">1163000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20240527045705337_17"
      unitRef="USD">919000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705337_18"
      unitRef="USD">2082000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgcTrademarksAndBrandsMember"
      decimals="-3"
      id="F20240527045705338_23"
      unitRef="USD">729000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20240331_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapPatentsMember"
      decimals="-3"
      id="F20240527045705338_24"
      unitRef="USD">179000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705338_26"
      unitRef="USD">908000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20230101to20230331"
      decimals="-5"
      id="F20240527045705338_27"
      unitRef="USD">800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="C_20240331" id="F20240527045705339_28">P6Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705340_37">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 30%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thereafter&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;185&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: right; vertical-align: bottom; width: 12%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;908&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="text-align: left; vertical-align: bottom; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705339_29"
      unitRef="USD">115000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705339_30"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705339_31"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705339_32"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705339_33"
      unitRef="USD">152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705340_34"
      unitRef="USD">185000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705340_35"
      unitRef="USD">908000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AssetImpairmentChargesTextBlock contextRef="C_20240101to20240331" id="F20240527045705345_1">
                &lt;div&gt;
                    &lt;p style="margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;ASSET IMPAIRMENT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As discussed in Note 14, on May 7, 2024, Just Brands agreed to a settlement and general release, whereby Just Brands will remove the products subject to the stop sales orders from the state of Florida and accept a five-year revocation of its food permit in the state of Florida. As a result of this settlement, the Company began negotiations to exit its current warehouse lease in Pompano Beach, FL, and searching for a new warehousing facility in a different state. The Company considered this to be an indicator of impairment and, thus, performed a quantitative analysis as of March 31, 2024 to determine if impairment existed by comparing the carrying amount of the operating lease right of use asset and related leasehold improvements to the future undiscounted cash flows the asset is expected to generate over its remaining life. This analysis indicated the asset values may not be recoverable. The Company then calculated the fair value of this asset using an income approach. As a result, the Company recorded an impairment of operating lease right of use assets and property, plant and equipment within its Vessel asset group within the house of brands segment totaling $0.9 million. These charges were recorded in the asset impairment caption on the unaudited condensed interim consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/div&gt;
            </us-gaap:AssetImpairmentChargesTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_20240101to20240331"
      decimals="-5"
      id="F20240527045705345_0"
      unitRef="USD">900000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_20240101to20240331" id="F20240527045705348_0">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;
                                    &lt;p style="margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;DEBT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Euro credit facility&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company, through FGH, has credit facilities totaling 4.3&#160;million Euro ($4.6&#160;million USD), at three different banks in Germany. These arrangements are open ended without predetermined maturity dates. Principal and interest payments are due at the end of each term. Interest rates can change with each new amount drawn. As of March 31, 2024, the total outstanding amount on these credit facilities was 2.9 million Euro ($3.1 million USD) with interest rates ranging from 5.45% to 6.44% and due within the next twelve months. These credit facilities were secured by various guarantees, including joint and several guarantees of two managing directors of Phatebo, a subsidiary of FGH, and payment guarantees upon default.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCredit
      contextRef="C_20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember"
      decimals="-5"
      id="F20240527045705348_1"
      unitRef="EUR">4300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember"
      decimals="-5"
      id="F20240527045705348_3"
      unitRef="USD">4600000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount
      contextRef="C_20240101to20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember"
      decimals="-5"
      id="F20240527045705348_2"
      unitRef="EUR">2900000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount
      contextRef="C_20240101to20240331_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember"
      decimals="-5"
      id="F20240527045705348_4"
      unitRef="USD">3100000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_20240101to20240331_srtRangeAxis_srtMinimumMember_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember"
      decimals="4"
      id="F20240527045705348_5"
      unitRef="Pure">0.0545</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_20240101to20240331_srtRangeAxis_srtMaximumMember_usgaapCreditFacilityAxis_flgcEuroCreditFacilityMember"
      decimals="4"
      id="F20240527045705348_6"
      unitRef="Pure">0.0644</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="C_20240101to20240331" id="F20240527045705352_0">
                &lt;p style="font-size: 10pt; font-family: times new roman; margin: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;10.&lt;span style="display: inline-block; width: 20pt;"&gt;&#160;&lt;/span&gt;LEASES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's leases primarily consist of administrative real estate leases in Germany and the United States. Management has determined all the Company's leases are operating leases through March 31, 2024. Information regarding the Company's leases is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Three months&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;ended March&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;31, 2024 &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;Three months&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;ended March 31,&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Components of lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;165&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Short-term lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;142&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Sublease income&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(84&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;223&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 12%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;345&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;324&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1,247&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted-average remaining lease term in years for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;
                                                    3.7
                                                &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                2.9
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted-average discount rate for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8.9%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7.7%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Maturities of operating lease liabilities as of March 31, 2024 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Operating Leases &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;794&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;766&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;678&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;505&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;322&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thereafter&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total future lease payments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,093&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(473&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,620&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(803&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,817&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Some of the Company's leases contain renewal options to continue the leases for another term equivalent to the original term, which are generally up to five years. The lease liabilities above include renewal terms that management has executed or is reasonably certain of renewing, which only included leases that would have expired in 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;In April 2024, the Company began leasing 4,184 sq. ft. of office space in Fort Lauderdale, FL, for $8,000 a month, pursuant to a lease agreement that expires in March 2028.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company began subleasing retail space in Miami, Florida to a third party during the third quarter of 2023. The sublease agreement is effective through November 30, 2026 and contains one option to renew for five more years. The Company began subleasing warehousing and office space in Carlsbad, CA to a third party during the fourth quarter of 2023. The sublease is effective through August 31, 2027 and does not contain renewal options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 13.3333px;"&gt;See Note 8 for discussion of impairment of operating lease right of use assets during the three months ended March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_20240101to20240331" id="F20240527045705352_1">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Three months&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;ended March&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;31, 2024 &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;Three months&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;ended March 31,&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Components of lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;165&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Short-term lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;142&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Sublease income&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(84&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;223&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 12%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 12%; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;345&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;324&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1,247&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted-average remaining lease term in years for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;
                                                    3.7
                                                &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                2.9
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted-average discount rate for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8.9%&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7.7%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705353_12"
      unitRef="USD">165000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705353_15"
      unitRef="USD">316000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705353_13"
      unitRef="USD">142000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705353_14"
      unitRef="USD">55000</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20231102183650157_20240527045705353_13"
      unitRef="USD">84000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="Fxbrl_20231102183650157_20240527045705353_14"
      unitRef="USD">0</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705354_16"
      unitRef="USD">223000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705354_17"
      unitRef="USD">371000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705354_18"
      unitRef="USD">345000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705354_20"
      unitRef="USD">324000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705354_19"
      unitRef="USD">1247000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705354_21"
      unitRef="USD">97000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20240331" id="F20240527045705354_22">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20230331" id="F20240527045705354_23">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20240331"
      decimals="3"
      id="F20240527045705354_24"
      unitRef="Pure">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20230331"
      decimals="3"
      id="F20240527045705354_25"
      unitRef="Pure">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_20240101to20240331" id="F20240527045705352_2">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands of United States dollars&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Operating Leases &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;794&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;766&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;678&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;505&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;322&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thereafter&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total future lease payments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;3,093&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(473&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,620&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(803&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-indent: 18pt; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,817&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705352_3"
      unitRef="USD">794000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705352_4"
      unitRef="USD">766000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705352_5"
      unitRef="USD">678000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705353_6"
      unitRef="USD">505000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705353_7"
      unitRef="USD">322000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705354_29"
      unitRef="USD">28000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705353_8"
      unitRef="USD">3093000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705353_9"
      unitRef="USD">473000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705353_10"
      unitRef="USD">2620000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705353_11"
      unitRef="USD">803000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705354_26"
      unitRef="USD">1817000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <flgc:MonthlyLeasePayment
      contextRef="C_20240331"
      decimals="0"
      id="F20240527045705354_30"
      unitRef="USD">8000</flgc:MonthlyLeasePayment>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_20240101to20240331" id="F20240527045705357_0">
                &lt;div&gt;
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;SHARE CAPITAL &#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Authorized and issued&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company is authorized to issue an unlimited number of common shares, no par value. On June 9, 2023, the Company consolidated its issued and outstanding common shares based on one new common share of the Company for every twenty existing common shares of the Company. All common shares and per share amounts have been restated to give retroactive effect to the share consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company had the following significant common share transactions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;b&gt;Three months ended March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;OTHER ISSUANCES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On March 8, 2024, the Company entered into a settlement agreement with a third party pursuant to which the Company issued 50,000 common shares of the Company, valued at $0.1 million, to a third party to settle outstanding amounts owed.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;See Note 18 for subsequent issuance of shares.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                &lt;/div&gt;
            </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_20240304to20240308"
      decimals="INF"
      id="F20240527045705357_1"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="C_20240304to20240308"
      decimals="-5"
      id="F20240527045705357_2"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705363_28">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;span style="display: inline-block; width: 15.5pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;SHARE BASED COMPENSATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's 2022 Incentive Compensation Plan (the "2022 Plan") and its previous "'rolling" stock option plan (the "Prior Plan") are described in the Company's 2023 Form 10-K.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;OPTIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock options granted under the Prior Plan are non-transferable and non-assignable and may be granted for a term not exceeding five years. Under the 2022 Plan, stock options may be granted with a term of up to ten years and in the case of all stock options, the exercise price may not be less than 100% of the fair market value of a Common Share on the date the award is granted. Stock option vesting terms are subject to the discretion of the Compensation Committee of the Company's Board of Directors. Common shares are newly issued from available authorized shares upon exercise of awards. The Company no longer makes new grants of stock options under the Prior Plan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Information relating to share options outstanding and exercisable as at March 31, 2024 and December 31, 2023 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;options (in&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;thousands)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Weighted average&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;remaining life&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;(years)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Outstanding balance, December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;27.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            2.8
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;44.03&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            2.0
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Outstanding balance, March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;38&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;22.25&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;
                                                                2.7
                                                            &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Exercisable balance, March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;38&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;22.25&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;
                                                                2.7
                                                            &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The total expense related to the options granted in the three months ended March 31, 2024 was less than $0.1 million (2023 total expense - $0.1 million). This expense is included in the share-based compensation line on the unaudited condensed interim consolidated statements of loss and comprehensive loss. Generally, the options granted in 2023 vest one to two years following the date of grant provided that the recipient is still employed or engaged by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At March 31, 2024 the total remaining stock option cost for nonvested awards is $nil.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;RESTRICTED STOCK AWARDS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Restricted stock is a grant of common shares which may not be sold or disposed of, and which is subject to such risks of forfeiture and other restrictions as the Committee, in its discretion, may impose. A participant granted restricted stock generally has all of the rights of a shareholder of the Company, unless otherwise determined by the Committee. Subject to certain exceptions, the vesting of restricted stock awards is subject to the holder's continued employment or engagement through the applicable vesting date. Unvested restricted stock awards will be forfeited if the holder's employment or engagement ceases during the vesting period and may, in certain circumstances, be accelerated. The Company values restricted stock awards based on the closing share price of the Company's common shares as of the date of grant. The fair value of the restricted stock award is recorded as expense over the vesting period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Information relating to restricted stock awards outstanding as at March 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;restricted stock&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;average grant&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;date fair value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Thousands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;391&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(363&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(0.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;10.24&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The total expense related to the restricted stock awards in the three months ended March 31, 2024 was less than $0.1 million ($0.5 million in the three months ended March 31, 2023). This expense is included in the share based compensation line on the unaudited condensed interim consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The outstanding restricted stock awards vest over the next two years provided the award holder is still employed or engaged by the Company. As of March 31, 2024, the Company had $0.1 million of unrecognized compensation expense related to restricted stock awards which will be recognized over the next two years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705363_29">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td colspan="4" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td colspan="1" style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;options (in&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;thousands)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Weighted average&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;remaining life&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;(years)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Outstanding balance, December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;27.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            2.8
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;44.03&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            2.0
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Outstanding balance, March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;38&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;22.25&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;
                                                                2.7
                                                            &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Exercisable balance, March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;38&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;22.25&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;
                                                                2.7
                                                            &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705360_0"
      unitRef="Shares">49000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20240527045705360_1"
      unitRef="CAD_Per_Share">27.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      id="F20240527045705360_2">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705360_3"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705360_4"
      unitRef="Shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20240527045705360_5"
      unitRef="CAD_Per_Share">44.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <flgc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      id="F20240527045705360_6">P2Y</flgc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705361_7"
      unitRef="Shares">38000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20240527045705361_8"
      unitRef="CAD_Per_Share">22.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      id="F20240527045705361_9">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705361_10"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705362_18"
      unitRef="Shares">38000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="2"
      id="F20240527045705362_19"
      unitRef="CAD_Per_Share">22.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      id="F20240527045705362_20">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705362_21"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20240101to20240331"
      decimals="-5"
      id="F20240527045705361_11"
      unitRef="USD">100000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20230101to20230331"
      decimals="-5"
      id="F20240527045705362_22"
      unitRef="USD">100000</us-gaap:StockOptionPlanExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705363_31"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <flgc:ScheduleOfRestrictedStockAwards
      contextRef="C_20240101to20240331"
      id="F20240527045705363_30">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;restricted stock&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;average grant&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;date fair value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; border-bottom: 0.75pt solid #000000; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Thousands&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;391&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(363&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(0.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(6.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;10.24&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </flgc:ScheduleOfRestrictedStockAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="F20240527045705361_12"
      unitRef="Shares">391000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="F20240527045705361_13"
      unitRef="CAD_Per_Share">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="F20240527045705362_23"
      unitRef="Shares">363000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="F20240527045705363_25"
      unitRef="CAD_Per_Share">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="F20240527045705362_24"
      unitRef="Shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="F20240527045705363_26"
      unitRef="CAD_Per_Share">6.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-3"
      id="F20240527045705362_14"
      unitRef="Shares">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="F20240527045705362_15"
      unitRef="CAD_Per_Share">10.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense
      contextRef="C_20240101to20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="F20240527045705362_16"
      unitRef="USD">100000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="C_20230101to20230331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="F20240527045705363_27"
      unitRef="USD">500000</us-gaap:RestrictedStockExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_20240331_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="F20240527045705362_17"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <flgc:WarrantsDisclosureTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705370_28">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;WARRANTS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The following summarizes the number of warrants outstanding as of March 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; border-top: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Number of warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Weighted average&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;
                                                &lt;p style="font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,384&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9.90&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                &#160;
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Date of expiry&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Grant date fair&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Remaining life&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;in years&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            November 18, 2026
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;75.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,729&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            2.64
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            November 18, 2027
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,055&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            3.64
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            December 8, 2027
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            3.69
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            September 21, 2028
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;712&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            4.48
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            September 21, 2028
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            4.48
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            March 21, 2029
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            4.98
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,846&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            4.58
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </flgc:WarrantsDisclosureTextBlock>
    <flgc:ScheduleOfWarrantsOutstandingTableTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705370_29">
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000; white-space: nowrap; vertical-align: bottom; border-top: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Number of warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Weighted average&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; border-top: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;
                                                &lt;p style="font-family: Times New Roman, Times, serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance, March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,384&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9.90&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </flgc:ScheduleOfWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      id="Fxbrl_20240530202721185"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20240527045705367_0"
      unitRef="Shares">2384000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20231231_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="2"
      id="F20240527045705367_1"
      unitRef="CAD_Per_Share">9.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20240527045705368_2"
      unitRef="Shares">2384000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20240331_usgaapSecuritiesFinancingTransactionAxis_flgcWarrantsMember"
      decimals="2"
      id="Fxbrl_20240529170615653"
      unitRef="CAD_Per_Share">9.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705371_40">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Date of expiry&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;outstanding&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Grant date fair&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Remaining life&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;in years&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thousands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            November 18, 2026
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;75.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;6,729&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            2.64
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            November 18, 2027
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;66.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,055&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            3.64
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            December 8, 2027
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            3.69
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            September 21, 2028
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;712&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            4.48
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            September 21, 2028
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            4.48
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            March 21, 2029
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; width: 10%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            4.98
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: right; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,384&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 10%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,846&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; width: 2%; text-align: left; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; width: 10%; background-color: #e6efff; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                            4.58
                                                        &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      id="F20240527045705370_24">November 18, 2026</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      decimals="-3"
      id="F20240527045705368_4"
      unitRef="Shares">221000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      decimals="2"
      id="F20240527045705368_5"
      unitRef="CAD_Per_Share">75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      decimals="-3"
      id="F20240527045705368_6"
      unitRef="USD">6729000</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsOneMember"
      id="F20240527045705368_7">P2Y7M20D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      id="F20240527045705370_25">November 18, 2027</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      decimals="-3"
      id="F20240527045705368_8"
      unitRef="Shares">23000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      decimals="2"
      id="F20240527045705368_9"
      unitRef="CAD_Per_Share">66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      decimals="-3"
      id="F20240527045705368_10"
      unitRef="USD">1055000</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsTwoMember"
      id="F20240527045705369_11">P3Y7M20D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      id="F20240527045705370_26">December 8, 2027</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      decimals="-3"
      id="F20240527045705369_12"
      unitRef="Shares">25000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      decimals="2"
      id="F20240527045705369_13"
      unitRef="CAD_Per_Share">8.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      decimals="-3"
      id="F20240527045705369_14"
      unitRef="USD">149000</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsThreeMember"
      id="F20240527045705369_15">P3Y8M8D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      id="F20240527045705370_27">September 21, 2028</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      decimals="-3"
      id="F20240527045705369_16"
      unitRef="Shares">691000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      decimals="2"
      id="F20240527045705369_17"
      unitRef="CAD_Per_Share">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      decimals="-3"
      id="F20240527045705369_18"
      unitRef="USD">712000</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFourMember"
      id="F20240527045705369_19">P4Y5M23D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      id="F20240527045705370_30">September 21, 2028</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      decimals="-3"
      id="F20240527045705371_32"
      unitRef="Shares">55000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      decimals="2"
      id="F20240527045705371_34"
      unitRef="CAD_Per_Share">2.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      decimals="-3"
      id="F20240527045705371_36"
      unitRef="USD">81000</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsFiveMember"
      id="F20240527045705371_38">P4Y5M23D</flgc:WarrantsRemainingLifeInYears>
    <flgc:WarrantsDateOfExpiry
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      id="F20240527045705370_31">March 21, 2029</flgc:WarrantsDateOfExpiry>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      decimals="-3"
      id="F20240527045705371_33"
      unitRef="Shares">1369000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      decimals="2"
      id="F20240527045705371_35"
      unitRef="CAD_Per_Share">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      decimals="-3"
      id="F20240527045705371_37"
      unitRef="USD">1120000</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsSixMember"
      id="F20240527045705371_39">P4Y11M23D</flgc:WarrantsRemainingLifeInYears>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20240527045705370_20"
      unitRef="Shares">2384000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember"
      decimals="2"
      id="F20240527045705370_21"
      unitRef="CAD_Per_Share">9.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flgc:GrantDateFairValueOfWarrantsOutstanding
      contextRef="C_20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember"
      decimals="-3"
      id="F20240527045705370_22"
      unitRef="USD">9846000</flgc:GrantDateFairValueOfWarrantsOutstanding>
    <flgc:WarrantsRemainingLifeInYears
      contextRef="C_20240101to20240331_usgaapClassOfWarrantOrRightAxis_flgcWarrantsMember"
      id="F20240527045705370_23">P4Y6M29D</flgc:WarrantsRemainingLifeInYears>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_20240101to20240331" id="F20240527045705376_3">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's current known provisions and contingent liabilities consist of the following as of March 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Legal disputes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Sales tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance as at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,962&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,538&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Payments/Settlements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(168&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(175&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Additional provisions&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,007&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,165&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Foreign currency translation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance as at March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;4,063&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,528&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6,591&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The legal disputes balance as of March 31, 2024, relate to the settlement of a contractual dispute involving the Company. It involves a former shareholder of ACA Mueller, an entity that was part of the Company's acquisition of FGH in December 2022, who filed a statement of claim against a wholly owned subsidiary of the Company in the Constance Regional Court in Germany. In March 2024, the Constance Regional Court in Germany ordered the Company to pay the plaintiff $3.0 million plus interest thereon at a rate of 5% above the prime rate since September 6, 2020 in addition to 83% of the legal fees. The Company has since filed an appeal. While the Company believes that this claim is without merit, at this time the Company believes it is probable that a liability has been incurred and the Company is able to reasonably estimate the loss of $4.1 million, including $1.0 million of interest accrued in the three months ended March 31, 2024. As a result, without acknowledgement (explicitly or implicitly) of any amount of liability arising from this claim, the Company recognized a provision of $4.1 million to reflect the value of the claim. This dispute is covered under an indemnification agreement between the Company and the former Chief Executive Officer and shareholder of FGH. The Company intends to vigorously defend itself through appropriate legal proceedings. The $4.1 million is recorded within contingencies and within indemnification receivables on the&#160;unaudited condensed consolidated statements of financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The settlement of legal disputes in 2024 related to the settlement of an action brought against the Company in the Ontario Superior Court of Justice by Gerardo Andres Garcia Mendez claiming that the Company was obligated to issue 3,000,000 common shares (pre-splits) to him for a purchase price of $0.05 per share as a result of alleged consulting services he performed in 2019. In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute. The payment was made in January 2024. The amount was recorded within contingencies on the consolidated statements of financial position and expense on the consolidated statements of loss and comprehensive loss for the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On April 30, 2024, a group representing the sellers of Just Brands LLC to Flora in February 2022 brought an action against the Company in the United States District Court for the Southern District of New York claiming that the Company failed to promptly issue additional shares in accordance with a specific formula set forth in the securities purchase agreement after the two-year anniversary of the closing, which occurred on February 24, 2024. The plaintiffs claim that they are entitled to 182,889 common shares and $38.0 million to complete the acquisition of Just Brands LLC. The Company has assessed the claims and concluded that it is probable that a liability has been incurred and that the Company is able to reasonably estimate the loss based on the fair value of 632,484 common shares of the Company. As at March 31, 2024, this value is $1.5 million and has been recorded in the contingent purchase considerations on the unaudited condensed interim consolidated statement of financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Sales tax relates to estimated amounts owed to certain jurisdictions in the Unites States for sales from the Company's JustCBD operations. The ending balance is recorded within contingencies on the unaudited condensed interim consolidated statement of financial position, and additions to the provision as a reduction of revenue on the unaudited condensed interim consolidated statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Legal proceedings&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company records liabilities for legal proceedings in those instances where it can reasonably estimate the amount of the loss and where liability is probable. The Company is engaged from time-to-time in various legal proceedings and claims that have arisen in the ordinary course of business. The outcome of all the proceedings and claims against the Company is subject to future resolution, including the uncertainties of litigation. Based on information currently known to the Company and after consultation with outside legal counsel, management believes that the probable ultimate resolution of any such proceedings and claims, individually or in the aggregate, will not have a material adverse effect on the financial condition of the Company, taken as a whole as at March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On November 1, 2023, Just Brands filed an Emergency Complaint for Declaratory Judgment and Injunctive Relief in the Southern District of Florida against the Florida Department of Agriculture and Consumer Services (the "Department") stemming from stop sale orders issued by the Department whereby the Department prohibited Just Brands from selling and moving most of its products. Relying on Florida Statute Section 581.217, which includes the definition of "attractive to children," the Department determined Just Brand's product could not be sold or moved because the products were manufactured in the shape of humans, cartoons, or animals; in a form that bears a reasonable resemblance to an existing candy product; and containing color additives. The Court ruled in favor of the Department and that Order was being appealed to the Eleventh Circuit Court of Appeals. Since then, the Department has initiated an Administrative Action claiming Just Brands moved product outside the State of Florida in violation of the stop sale orders. The statute provides for a penalty of up to $5,000 per violation. The Department sought to assess penalties on what they claimed to be a total of 215,154 violations (one for each package). The Company disputed their claim and intended to vigorously defend against this action. The Company has not accrued a liability as of March 31, 2024. The total value of inventory impacted by the stop sale orders was $1.9 million at March 31, 2024.&#160;On May 7, 2024, Just Brands and the Department agreed to a settlement and general release, whereby Just Brands will remove the products subject to the stop sales orders from the state of Florida, pay the Department $60,500 to reimburse the Department&#x2019;s attorney&#x2019;s fees, and accept a five-year revocation of its food permit in the state of Florida. By signing the release, Just Brands waived, settled and released all claims it had or might have against the Department.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On May 31, 2023, Maria Beatriz Fernandez Otero and Sara Cristina Jacome De Torres brought an action against the Company in the Ontario Superior Court of Justice claiming that the Company is obligated to issue 500,000 common shares (pre-splits) each for a purchase price of $0.05 per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                &lt;/div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On May 31, 2023, Ramon Ricardo Castellanos Saenz and Miriam Ortiz brought an action against the Company in the Ontario Superior Court of Justice claiming that the Company is obligated to issue 1,500,000 common shares (pre-splits) each for a purchase price of $0.05 per share. The plaintiffs claim that they are entitled to such shares as compensation for alleged consulting services performed. The Company disputes their claim and intends to vigorously defend against this action. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In connection with the Company's acquisition of FGH, the Company's current CEO and the former Chief Executive Officer of FGH, together with certain affiliated entities under his control, entered into an agreement pursuant to which they agreed to indemnify the Company for certain potential liabilities of FGH and its subsidiaries, up to a maximum of $5.0 million. In addition to the matter regarding the former shareholder of ACA Mueller, discussed above, the following actions are pending as of the date hereof:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On February 3, 2023, an action was brought in the Ontario Superior Court of Justice by Nathan Shantz and Liberacion e Inversiones S.A. against various parties including Clifford Starke, the Company's current CEO and FGH's former Chief Executive Officer, and FGH. The statement of claim alleges that, prior to the closing of the Arrangement, 8,831,109 FGH shares purportedly owned by the plaintiffs were wrongfully transferred to third parties, in part through alleged unauthorized steps taken by Mr. Starke. Plaintiffs seek, among other things, a declaration that they are the rightful owners of the shares or, in the alternative, damages. Against FGH, they claim a declaration that, by virtue of the alleged unauthorized transfer of shares, FGH acted oppressively and seek damages in the amount of $4.0 million. The defendants have brought motions to stay the proceedings on the grounds that the Ontario court lacks jurisdiction over the claim. In the event FGH should incur any losses in connection with this matter, such losses are to be indemnified by Mr. Starke subject to the maximum threshold of the indemnity agreement. The Company believes that an unfavorable settlement in this matter is remote, and, as such, has not accrued a liability as of March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The total amount claimed against the former entities of FGH currently exceeds the maximum $5.0 million of the indemnification agreement. However, the Company is estimating the likelihood of loss in these cases will not exceed $4.1 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock contextRef="C_20240101to20240331" id="F20240527045705377_4">
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Legal disputes&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Sales tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Balance as at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,962&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,538&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;5,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Payments/Settlements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(168&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(175&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Additional provisions&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,007&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,165&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Foreign currency translation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Balance as at March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;4,063&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,528&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 10%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6,591&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff; border-bottom: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
                                </us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="F20240527045705377_5"
      unitRef="USD">2962000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20231231_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="F20240527045705377_10"
      unitRef="USD">2538000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705378_15"
      unitRef="USD">5500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="F20240527045705377_6"
      unitRef="USD">7000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="F20240527045705377_11"
      unitRef="USD">168000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705378_16"
      unitRef="USD">175000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="F20240527045705377_7"
      unitRef="USD">1007000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="F20240527045705378_12"
      unitRef="USD">158000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705378_17"
      unitRef="USD">1165000</us-gaap:LossContingencyAccrualProvision>
    <flgc:LossContingencyAccrualForeignCurrencyTranslation
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="Fxbrl_20240305141410684_20240527045705377_7"
      unitRef="USD">101000</flgc:LossContingencyAccrualForeignCurrencyTranslation>
    <flgc:LossContingencyAccrualForeignCurrencyTranslation
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="Fxbrl_20240305141410684_20240527045705378_12"
      unitRef="USD">0</flgc:LossContingencyAccrualForeignCurrencyTranslation>
    <flgc:LossContingencyAccrualForeignCurrencyTranslation
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="Fxbrl_20240305141410684_20240527045705378_17"
      unitRef="USD">101000</flgc:LossContingencyAccrualForeignCurrencyTranslation>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcLegalDisputesMember"
      decimals="-3"
      id="F20240527045705377_9"
      unitRef="USD">4063000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcSalesTaxesMember"
      decimals="-3"
      id="F20240527045705378_14"
      unitRef="USD">2528000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705378_19"
      unitRef="USD">6591000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember"
      decimals="-5"
      id="F20240527045705376_0"
      unitRef="USD">3000000</us-gaap:LossContingencyDamagesAwardedValue>
    <flgc:LossContingencyInterestPaymentTerms
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember"
      id="F20240527045705380_34">rate of 5% above the prime rate since September 6, 2020 in addition to 83% of the legal fees.</flgc:LossContingencyInterestPaymentTerms>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember"
      decimals="-5"
      id="F20240527045705380_32"
      unitRef="USD">4100000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <flgc:LossContingencyEstimateOfPossibleLossInterestAccrued
      contextRef="C_20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember"
      decimals="-5"
      id="F20240527045705380_33"
      unitRef="USD">1000000</flgc:LossContingencyEstimateOfPossibleLossInterestAccrued>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember"
      decimals="-5"
      id="F20240527045705376_2"
      unitRef="USD">4100000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20240101to20240331_usgaapDeferredRevenueArrangementTypeAxis_flgcACAMullerMember"
      decimals="-5"
      id="F20240527045705376_1"
      unitRef="USD">4100000</us-gaap:LossContingencyAccrualProvision>
    <flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit
      contextRef="C_20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember"
      decimals="INF"
      id="F20240527045705379_20"
      unitRef="Shares">3000000</flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember"
      decimals="2"
      id="F20240527045705379_21"
      unitRef="USD_Per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:LossContingencyTrialOrAlternativeDisputeResolution
      contextRef="C_20240101to20240331_srtTitleOfIndividualAxis_flgcGerardoAndresGarciaMendezMember"
      id="F20240527045705379_22">In December 2023, the Company entered into a settlement agreement with Mr. Garcia Mendez pursuant to which the Company will pay less than $0.1 million to Mr. Garcia Mendez to settle the dispute.</us-gaap:LossContingencyTrialOrAlternativeDisputeResolution>
    <flgc:NumberOfSharesUnderPlaintiffClaim
      contextRef="C_20240401to20240430_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="F20240527045705381_35"
      unitRef="Shares">182889</flgc:NumberOfSharesUnderPlaintiffClaim>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="C_20240401to20240430_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="-5"
      id="F20240527045705382_41"
      unitRef="USD">38000000</us-gaap:LossContingencyDamagesSoughtValue>
    <flgc:LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares
      contextRef="C_20240401to20240430_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="F20240527045705381_36"
      unitRef="Shares">632484</flgc:LossContingencyEstimateOfPossibleLossBasedOnNumberOfShares>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="C_20240331to20240331_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember"
      decimals="-5"
      id="F20240527045705381_37"
      unitRef="USD">1500000</us-gaap:LossContingencyAccrualProvision>
    <flgc:AmountsPayablePerViolationOfStopSaleOrders
      contextRef="C_20231101_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember"
      decimals="0"
      id="F20240527045705379_23"
      unitRef="USD">5000</flgc:AmountsPayablePerViolationOfStopSaleOrders>
    <flgc:NumberOfViolationsInStopSaleOrders
      contextRef="C_20231101_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember"
      decimals="0"
      id="F20240527045705381_40"
      unitRef="Violation">215154</flgc:NumberOfViolationsInStopSaleOrders>
    <flgc:InventoryImpactedByStopSaleOrders
      contextRef="C_20240331_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember"
      decimals="-5"
      id="F20240527045705379_24"
      unitRef="USD">1900000</flgc:InventoryImpactedByStopSaleOrders>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="C_20240501to20240507_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcJustBrandsLLCMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="0"
      id="F20240527045705382_42"
      unitRef="USD">60500</us-gaap:LossContingencyDamagesAwardedValue>
    <flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit
      contextRef="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember"
      decimals="INF"
      id="F20240527045705379_25"
      unitRef="Shares">500000</flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20230531_srtTitleOfIndividualAxis_flgcMariaBeatrizFernandezOteroAndSaraCristinaJacomeDeTorresMember"
      decimals="2"
      id="F20240527045705379_26"
      unitRef="USD_Per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
    <flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit
      contextRef="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember"
      decimals="INF"
      id="F20240527045705379_27"
      unitRef="Shares">1500000</flgc:LossContingencyDamagesSoughtShareToBeIssuedPreOneForThreeReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20230531_srtTitleOfIndividualAxis_flgcRamonRicardoCastellanosSaenzAndMiriamOrtizMember"
      decimals="2"
      id="F20240527045705380_28"
      unitRef="USD_Per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
    <flgc:PotentialLiabilities
      contextRef="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20240527045705381_39"
      unitRef="USD">5000000</flgc:PotentialLiabilities>
    <flgc:WrongfullyTransferredShares
      contextRef="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="INF"
      id="F20240527045705380_29"
      unitRef="Shares">8831109</flgc:WrongfullyTransferredShares>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="C_20230201to20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20240527045705381_38"
      unitRef="USD">4000000</us-gaap:LossContingencyDamagesSoughtValue>
    <flgc:PotentialLiabilities
      contextRef="C_20230203_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20240527045705380_30"
      unitRef="USD">5000000</flgc:PotentialLiabilities>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="C_20240331_srtTitleOfIndividualAxis_flgcFranchiseGlobalHealthIncMember"
      decimals="-5"
      id="F20240527045705380_31"
      unitRef="USD">4100000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_20240101to20240331" id="F20240527045705385_0">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;LOSS PER SHARE&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company calculates basic earnings per share based upon the weighted average number of common shares outstanding during the period, while the calculation of diluted earnings per share includes the dilutive effect of potential common shares outstanding during the period. The calculation of diluted earnings per share excludes all potential common shares if their inclusion would have an anti-dilutive effect. Restricted stock award recipients under the 2022 Plan have a non-forfeitable right to receive dividends declared by the Company and are therefore included in computing earnings per share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Three months&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Three months&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;38&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;275&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,384&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;960&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Restricted stock awards&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;JustCBD potential additional shares to settle contingent consideration&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;632&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;657&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total anti-dilutive&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3,078&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705385_11">
                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Three months&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Three months&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;38&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;275&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,384&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;960&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Restricted stock awards&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;JustCBD potential additional shares to settle contingent consideration&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;632&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;657&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total anti-dilutive&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3,078&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705385_1"
      unitRef="Shares">38000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcStockOptionsMember"
      decimals="-3"
      id="F20240527045705385_2"
      unitRef="Shares">275000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember"
      decimals="-3"
      id="F20240527045705385_4"
      unitRef="Shares">2384000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_usgaapWarrantMember"
      decimals="-3"
      id="F20240527045705385_3"
      unitRef="Shares">960000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember"
      decimals="-3"
      id="F20240527045705385_6"
      unitRef="Shares">24000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcRestrictedStockAwardsMember"
      decimals="-3"
      id="F20240527045705385_5"
      unitRef="Shares">198000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20240331_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20240527045705385_8"
      unitRef="Shares">632000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230331_usgaapSecuritiesFinancingTransactionAxis_flgcJustCBDMember"
      decimals="-3"
      id="F20240527045705385_7"
      unitRef="Shares">657000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705385_10"
      unitRef="Shares">3078000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705385_9"
      unitRef="Shares">2090000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="C_20240101to20240331" id="F20240527045705388_7">
                    &lt;div&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;16.&lt;/b&gt;&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;b&gt;FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;The Company's financial instruments measured at amortized cost as at March 31, 2024 and December 31, 2023 consist of cash, trade and amounts receivable, loans receivable, trade payables, contingencies, accrued liabilities, lease liabilities, and debt and loans payable. The amounts reflected in the unaudited condensed interim consolidated statements of financial position approximate fair value due to the short-term maturity of these instruments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Financial instruments recorded at the reporting date at fair value are classified into one of three levels based upon the fair value hierarchy. Items are categorized based on inputs used to derive fair value based on:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                                &lt;p style="margin-bottom: 0pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Level 1 - quoted prices that are unadjusted in active markets for identical assets or liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Level 2 - inputs other than quoted prices included in level 1 that are observable for the asset/liability either directly or indirectly; and&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Level 3 - inputs for the instruments are not based on any observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;The Company's contingent purchase considerations consist of the estimated fair value of contingent purchase consideration from the acquisitions of JustCBD in February 2022 and Original Hemp in March 2023. The amount for JustCBD is measured at FVPL as a Level 2 fair value financial instrument within the fair value hierarchy as at March 31, 2024. The fair value was determined using a simplified calculation which took the expected shares to be issued (632,484) multiplied by the Company's closing share price at March 31, 2024 ($2.31).&#160; The amount for Original Hemp is measured at FVPL as a Level 3 fair value financial instrument within the fair value hierarchy as at March 31, 2024. The fair value was determined using discounted cash flow models utilizing two different rates, high (25.1%) and low (18.4%), to estimate the present value of the future cash outflows.&#160; As valuations of investments for which market quotations are not readily available are inherently uncertain, may fluctuate within short periods of time and are based on estimates, determination of fair value may differ materially from the values that would have resulted if a ready market existed for the investments. Such changes may have a significant impact on the Company's financial condition or operating results.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;The following tables present information about the Company's financial instruments and their classifications as at March 31, 2024 and December 31, 2023 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Fair value measurements at March 31, 2024 using:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Financial liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Contingent purchase consideration from asset acquisitions and business combinations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;1,461&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;241&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;1,702&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Fair value measurements at December 31, 2023 using:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Financial liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Contingent purchase consideration from asset acquisitions and business combinations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;854&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,095&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <flgc:ExpectedSharesToBeIssued
      contextRef="C_20240331"
      decimals="INF"
      id="F20240527045705388_10"
      unitRef="Shares">632484</flgc:ExpectedSharesToBeIssued>
    <us-gaap:SharePrice
      contextRef="C_20240331"
      decimals="2"
      id="F20240527045705388_11"
      unitRef="CAD_Per_Share">2.31</us-gaap:SharePrice>
    <flgc:CashFlowModelHighRate
      contextRef="C_20240331"
      decimals="3"
      id="F20240527045705388_12"
      unitRef="Pure">0.251</flgc:CashFlowModelHighRate>
    <flgc:CashFlowModelLowRate
      contextRef="C_20240331"
      decimals="3"
      id="F20240527045705388_13"
      unitRef="Pure">0.184</flgc:CashFlowModelLowRate>
    <flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications contextRef="C_20240101to20240331" id="F20240527045705388_8">
                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Fair value measurements at March 31, 2024 using:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Financial liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Contingent purchase consideration from asset acquisitions and business combinations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;1,461&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;241&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;1,702&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Fair value measurements at December 31, 2023 using:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Financial liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;Contingent purchase consideration from asset acquisitions and business combinations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;854&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;1,095&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </flgc:ScheduleOfInformationAboutCompanysFinancialInstrumentsAndTheirClassifications>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="F20240527045705388_0"
      unitRef="USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member"
      decimals="-3"
      id="F20240527045705388_1"
      unitRef="USD">1461000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20240331_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="F20240527045705388_2"
      unitRef="USD">241000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705388_9"
      unitRef="USD">1702000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member"
      decimals="-3"
      id="F20240527045705388_3"
      unitRef="USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member"
      decimals="-3"
      id="F20240527045705388_4"
      unitRef="USD">854000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member"
      decimals="-3"
      id="F20240527045705388_5"
      unitRef="USD">241000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705388_6"
      unitRef="USD">1095000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705394_31">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;17.&lt;span style="display: inline-block; width: 15pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;SEGMENTED INFORMATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company reports its financial results for the following two operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH subsidiaries) and house of brands (primarily JustCBD and Vessel subsidiaries). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;For the year ended December 31, 2023, the Company had three operating segments, which were also its reportable segments: commercial and wholesale, house of brands and pharmaceuticals (formerly the Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries in Colombia). Due to the sale of the Colombian subsidiaries during 2023 and the resulting reclassification into discontinued operations, the Company no longer reports a pharmaceuticals segment. &#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's operates its manufacturing and distribution business within its United States and Germany subsidiaries. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations and includes the Company's long-term investments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Information regarding the Company's segments is summarized as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Sales&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11,342&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,958&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8,020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13,765&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(1,331&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(2,404&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;18,031&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,319&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net (Loss) Income from Continuing Operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(236&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(967&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(354&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Corp &amp;amp; Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(2,171&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(2,972&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(3,374&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(3,186&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

                                &lt;div&gt;

                                &lt;/div&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;10,473&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,096&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11,377&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11,608&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Corp &amp;amp; Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,424&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,922&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24,274&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,626&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Disaggregation of net sales by geographic area:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Sales&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6,518&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;10,999&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11,343&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,958&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;170&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;18,031&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,319&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_20240101to20240331"
      decimals="0"
      id="F20240527045705394_34"
      unitRef="Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_20230101to20231231"
      decimals="0"
      id="F20240527045705394_36"
      unitRef="Segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705394_35">
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Sales&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11,342&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,958&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8,020&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;13,765&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(1,331&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(2,404&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;18,031&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,319&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: right; width: 12%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net (Loss) Income from Continuing Operations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(236&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(967&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(354&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Corp &amp;amp; Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(2,171&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(2,972&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;(3,374&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(3,186&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

                                    &lt;div&gt;
                                        &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; white-space: nowrap; text-align: right; border-top: 2.25pt double #000000;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Commercial &amp;amp; Wholesale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;10,473&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,096&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;House of Brands&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11,377&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;11,608&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Corp &amp;amp; Eliminations&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2,424&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2,922&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;24,274&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;23,626&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                                &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                    &lt;/div&gt;
                                </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20240527045705392_7"
      unitRef="USD">11342000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20240527045705392_8"
      unitRef="USD">7958000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20240527045705392_9"
      unitRef="USD">8020000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20240527045705392_10"
      unitRef="USD">13765000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20240527045705392_11"
      unitRef="USD">-1331000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20240527045705393_12"
      unitRef="USD">-2404000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705393_13"
      unitRef="USD">18031000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705393_14"
      unitRef="USD">19319000</us-gaap:Revenues>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20240527045705393_15"
      unitRef="USD">-236000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20240527045705393_16"
      unitRef="USD">140000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20240527045705393_17"
      unitRef="USD">-967000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20240527045705393_18"
      unitRef="USD">-354000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20240101to20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20240527045705393_19"
      unitRef="USD">-2171000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20230331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20240527045705393_20"
      unitRef="USD">-2972000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705393_21"
      unitRef="USD">-3374000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705393_22"
      unitRef="USD">-3186000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:Assets
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20240527045705392_0"
      unitRef="USD">10473000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcCommercialAndWholesaleMember"
      decimals="-3"
      id="F20240527045705392_1"
      unitRef="USD">9096000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20240527045705392_2"
      unitRef="USD">11377000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcHouseOfBrandsMember"
      decimals="-3"
      id="F20240527045705392_3"
      unitRef="USD">11608000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20240331_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20240527045705392_4"
      unitRef="USD">2424000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_usgaapFinancialInstrumentAxis_flgcCorporateAndEliminationsMember"
      decimals="-3"
      id="F20240527045705392_5"
      unitRef="USD">2922000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20240331"
      decimals="-3"
      id="F20240527045705392_6"
      unitRef="USD">24274000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="F20240527045705394_32"
      unitRef="USD">23626000</us-gaap:Assets>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="C_20240101to20240331"
      id="F20240527045705394_33">
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 70%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; white-space: nowrap; margin-top: 0pt; margin-bottom: 0pt;"&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                                &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Net Sales&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6,518&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;10,999&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Germany&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11,343&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;7,958&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;United Kingdom&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;170&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 12%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;18,031&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 12%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,319&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="F20240527045705393_24"
      unitRef="USD">6518000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331_srtStatementGeographicalAxis_countryUS"
      decimals="-3"
      id="F20240527045705393_23"
      unitRef="USD">10999000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="F20240527045705393_26"
      unitRef="USD">11343000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331_srtStatementGeographicalAxis_countryDE"
      decimals="-3"
      id="F20240527045705393_25"
      unitRef="USD">7958000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="F20240527045705393_27"
      unitRef="USD">170000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331_srtStatementGeographicalAxis_countryGB"
      decimals="-3"
      id="F20240527045705393_28"
      unitRef="USD">362000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240331"
      decimals="-3"
      id="F20240527045705393_29"
      unitRef="USD">18031000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230331"
      decimals="-3"
      id="F20240527045705393_30"
      unitRef="USD">19319000</us-gaap:Revenues>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_20240101to20240331" id="F20240527045705397_0">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;18.&#160; &#160; &#160; &#160;&#160;&lt;/b&gt;&lt;b&gt;SUBSEQUENT EVENTS &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-bottom: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;ACQUISTION OF TRUHC HOLDING GMBH ("TRUHC")&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="margin-top: 0pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;On April 16, 2024, the Company entered into a Stock Purchase Agreement (the "Purchase Agreement") with TruHC Holding GmbH (the "Seller") pursuant to which the Company will acquire all of the issued and outstanding shares of TruHC Pharma GmbH in exchange for 2,770,562 common shares of the Company (the "Purchase Price").&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Purchase Price will be paid and satisfied by the Company in two closings. At the first closing on April 22, 2024, the Company issued 2,135,199 of its common shares, which is equal to 19.99% of the Company's issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the "Second Closing"), the Company will issue 635,363 of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Under the Purchase Agreement, the Company is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Due to the timing of the closing of this transaction, purchase accounting is incomplete. The Company is evaluating the potential effects of this acquisition on the financial statements. The acquisition will be accounted for in accordance with Accounting Standards Codification ("ASC") Topic 805, "Business Combinations".&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;APRIL EQUITY OFFERING&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;On April 4, 2024, Flora entered into an underwriting agreement with Aegis Capital Corp. ("Aegis") as underwriter, relating to the offering, issuance and sale of up to 1,700,000 of the Company's common shares ("Common Shares"), no par value per Common Share, at a public offering price of $1.90 per Common Share.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The offering closed on April 8, 2024. The net proceeds to the Company for the offering was approximately $2.8 million, after deducting the underwriting discounts and commissions and estimated offering expenses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The offering of the securities described above was made pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-274204), filed with the Securities and Exchange Commission (the "SEC") on August 25, 2023 and amended on August 30, 2023, which was declared effective, on September 6, 2023, and the base prospectus included therein, as supplemented by the preliminary prospectus supplement filed with the SEC on April 4, 2024 and the final prospectus supplement with the SEC on April 5, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;div&gt;

                                    &lt;/div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Aegis acted as sole underwriter for the offering. The Company agreed to provide Aegis an underwriting discount of 7.0% for underwriter-introduced investors and an underwriting discount of 3.0% for Company-introduced investors.&#160;The Company reimbursed Aegis for certain of its expenses, in an amount of up to $0.1 million, including legal fees.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Company's CEO, Clifford Starke, subscribed to purchase 1,000,000 of the Common Shares at the public offering price of $1.90 per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;AT THE MARKET ("ATM") OFFERING&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;On April 26, 2024, the Company entered into an ATM Issuances Sales Agreement (the "Sales Agreement") with Aegis Capital Corp. (the "Agent") pursuant to which the Company may sell from time to time, at its option, common shares through the Agent in its capacity as sales agent. The sale of common shares, if any, will be made under the Company's registration statement filed on Form S-3 (File No. 333-274204) (the "Registration Statement"), by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act").&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Subject to the terms and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market to sell on the Company's behalf all of the common shares requested to be sold by the Company. The Agent will offer the common shares, subject to the terms and conditions of the Sales Agreement, on a daily basis or as otherwise agreed upon by the Company and the Agent. The Company will designate the maximum amount of common shares to be sold through the Agent on a daily basis or otherwise determine such maximum amount, together with the Agent. The Company may instruct the Agent not to sell common shares if the sales cannot be effected at or above the price designated by the Company in any such instruction. The Company or the Agent may suspend the offering of common shares being made through the Agent under the Sales Agreement upon proper notice to the other parties.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The aggregate compensation payable to the Agent, on behalf of the Agent, shall be up to 3.0% of the aggregate gross proceeds from each sale of the common shares sold through the Agent pursuant to the Sales Agreement. In addition, the Company has agreed in the Sales Agreement to provide indemnification and contribution to the Agent against certain liabilities, including liabilities under the Securities Act.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Company is not obligated to make any sales of common shares under the Sales Agreement. The offering of common shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement by the Company or by the Agent, only with respect to itself, under the circumstances specified in the Sales Agreement. The Company has yet to sell any of its common shares under the Sales Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240401to20240416_usgaapBusinessAcquisitionAxis_flgcTruhcHoldingGmbhMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="F20240527045705397_2"
      unitRef="Shares">2770562</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="F20240527045705397_4"
      unitRef="Shares">2135199</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <flgc:PercentageOfIssuedAndOutstandingCommonShares
      contextRef="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="4"
      id="F20240527045705397_5"
      unitRef="Pure">0.1999</flgc:PercentageOfIssuedAndOutstandingCommonShares>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240418to20240422_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="F20240527045705397_6"
      unitRef="Shares">635363</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240402to20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="F20240527045705397_7"
      unitRef="Shares">1700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="2"
      id="F20240527045705397_8"
      unitRef="USD_Per_Share">1.9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20240407to20240408_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="-5"
      id="F20240527045705397_9"
      unitRef="USD">2800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:UnderwritingCommitments
      contextRef="C_20240402to20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      id="F20240527045705398_10">The Company agreed to provide Aegis an underwriting discount of 7.0% for underwriter-introduced investors and an underwriting discount of 3.0% for Company-introduced investors.</us-gaap:UnderwritingCommitments>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="C_20240402to20240404_usgaapBusinessAcquisitionAxis_flgcAegisCapitalCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="-5"
      id="F20240527045705398_11"
      unitRef="USD">100000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240402to20240404_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="F20240527045705398_12"
      unitRef="Shares">1000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20240404_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="2"
      id="F20240527045705398_13"
      unitRef="USD_Per_Share">1.9</us-gaap:SharesIssuedPricePerShare>
    <flgc:PercentageOfAggregateGrossProceedsFromSaleOfCommonShares
      contextRef="C_20240424to20240426_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="3"
      id="F20240527045705398_14"
      unitRef="Pure">0.03</flgc:PercentageOfAggregateGrossProceedsFromSaleOfCommonShares>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_42"
      unitRef="EUR">13588</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_45"
      unitRef="EUR">15281</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_52"
      unitRef="EUR">18894</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_55"
      unitRef="EUR">18399</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_62"
      unitRef="EUR">20347</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_65"
      unitRef="EUR">20347</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_72"
      unitRef="EUR">52829</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_75"
      unitRef="EUR">54027</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_92"
      unitRef="EUR">94837</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_95"
      unitRef="EUR">104775</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_102"
      unitRef="EUR">478399</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_105"
      unitRef="EUR">553936</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_112"
      unitRef="EUR">626065</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_115"
      unitRef="EUR">712738</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_142"
      unitRef="EUR">34711</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_145"
      unitRef="EUR">27341</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_152"
      unitRef="EUR">63083</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_155"
      unitRef="EUR">57805</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_162"
      unitRef="EUR">11520</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_165"
      unitRef="EUR">2720</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_172"
      unitRef="EUR">109314</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_175"
      unitRef="EUR">87866</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529003536383"
      unitRef="EUR">645339</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529003548418"
      unitRef="EUR">318590</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_202"
      unitRef="EUR">447581</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_205"
      unitRef="EUR">510664</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_212"
      unitRef="EUR">1202234</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_215"
      unitRef="EUR">917120</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_232"
      unitRef="EUR">12500</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_235"
      unitRef="EUR">12500</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_242"
      unitRef="EUR">-588669</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_245"
      unitRef="EUR">-216882</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_252"
      unitRef="EUR">-576169</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_255"
      unitRef="EUR">-204382</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_262"
      unitRef="EUR">626065</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529000819276_265"
      unitRef="EUR">712738</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfessionalFees
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_22"
      unitRef="EUR">7589</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_25"
      unitRef="EUR">5038</us-gaap:ProfessionalFees>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_32"
      unitRef="EUR">210622</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_35"
      unitRef="EUR">113458</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_42"
      unitRef="EUR">2037</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_45"
      unitRef="EUR">451</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_52"
      unitRef="EUR">123105</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_55"
      unitRef="EUR">84783</us-gaap:OperatingLeaseExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_62"
      unitRef="EUR">14675</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_65"
      unitRef="EUR">9550</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_72"
      unitRef="EUR">-358028</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_75"
      unitRef="EUR">-213280</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_82"
      unitRef="EUR">-13759</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_85"
      unitRef="EUR">-3602</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_92"
      unitRef="EUR">-371787</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115821900"
      unitRef="EUR">-216882</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_102"
      unitRef="EUR">-371787</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529010655326_105"
      unitRef="EUR">-216882</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240529014135623"
      unitRef="Shares">25000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20240529014141591"
      unitRef="EUR">12500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240530130751211"
      unitRef="EUR">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529014213084"
      unitRef="EUR">12500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_20220218to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529014232753"
      unitRef="EUR">-216882</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220218to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529014255896"
      unitRef="EUR">-216882</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240529014614051"
      unitRef="Shares">25000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20240529014616292"
      unitRef="EUR">12500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529014624909"
      unitRef="EUR">-216882</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529014631025"
      unitRef="EUR">-204382</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529014659178"
      unitRef="EUR">-371787</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529014705294"
      unitRef="EUR">-371787</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240529014640693"
      unitRef="Shares">25000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20240529014648656"
      unitRef="EUR">12500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529014906064"
      unitRef="EUR">-588669</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529014917849"
      unitRef="EUR">-576169</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529094610771"
      unitRef="EUR">-371787</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529094842660"
      unitRef="EUR">-216882</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529095002806"
      unitRef="EUR">14675</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529100715614"
      unitRef="EUR">9550</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529100738653"
      unitRef="EUR">-13749</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529100825458"
      unitRef="EUR">-3590</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111753047"
      unitRef="EUR">17732</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111829490"
      unitRef="EUR">14533</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120333569"
      unitRef="EUR">495</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120352588"
      unitRef="EUR">18399</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120517079"
      unitRef="EUR">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120533295"
      unitRef="EUR">20347</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120545291"
      unitRef="EUR">16170</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120601047"
      unitRef="EUR">30061</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120615904"
      unitRef="EUR">-309956</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120631302"
      unitRef="EUR">-197894</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120710637"
      unitRef="EUR">313000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120725936"
      unitRef="EUR">315000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120734902"
      unitRef="EUR">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122246087"
      unitRef="EUR">12500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121223632"
      unitRef="EUR">313000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121245702"
      unitRef="EUR">327500</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121605467"
      unitRef="EUR">4737</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121640127"
      unitRef="EUR">114325</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121651807"
      unitRef="EUR">-4737</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121706526"
      unitRef="EUR">-114325</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121713294"
      unitRef="EUR">-1693</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121747101"
      unitRef="EUR">15281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121832048"
      unitRef="EUR">15281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20220217_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121958581"
      unitRef="EUR">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122046678"
      unitRef="EUR">13588</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122059782"
      unitRef="EUR">15281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="INF"
      id="Fxbrl_20240529122318943"
      unitRef="Shares">0</flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets>
    <flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="INF"
      id="Fxbrl_20240529122349949"
      unitRef="Shares">604294</flgc:NonCashOperatingLeaseAdditionsToRightOfUseAssets>
    <us-gaap:NatureOfOperations
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529020914405">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;1.&#160; NATURE OF OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;TruHC Pharma GmbH (the "Company" or "TruHC") was incorporated under the laws of Germany on February 17, 2022. The Company engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility. The Company's registered office and principal place of business in Germany is located at Poppenb&#xfc;tteler Bogen 68 22399 Hamburg, Germany. At December 31, 2023, all of the Company's issued and outstanding shares were owned by TruHC Holding GmbH ("TruHC Holding").&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529021555276">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;2.&#160; BASIS OF PRESENTATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;These financial statements have been presented in Euros and are prepared in accordance with United States generally accepted accounting principles (&#x201c;US GAAP&#x201d;). The Company has determined that the Euro is the functional and reporting currency as the majority of our operations are conducted in Euros and the financial results are prepared and reviewed internally by management in Euros.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Going concern&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue for a period of at least one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company had cash of &#x20ac;13,588 at December 31, 2023, net loss of &#x20ac;371,787 for the year ended December 31, 2023, and an accumulated deficit of &#x20ac;588,669 at December 31, 2023. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners or, through obtaining credit from financial institutions and the possible disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#x2019;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company&#x2019;s performance and investor sentiment with respect to it and its industry. These financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Basis of measurement &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The financial statements have been prepared on the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of amounts receivable, prepaids and other current assets, and trade and amounts payable, accrued liabilities, and current portion of lease liability approximate their fair values due to their short periods to maturity.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The financial statements are presented in Euros ("&#x20ac;") unless otherwise noted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Use of estimates&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:Cash
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529021821837"
      unitRef="EUR">13588</us-gaap:Cash>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529021829997"
      unitRef="EUR">-371787</us-gaap:ProfitLoss>
    <us-gaap:CumulativeEarningsDeficit
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529021837249"
      unitRef="EUR">-588669</us-gaap:CumulativeEarningsDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024007738">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;03.&#160; SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;The significant accounting policies used by the Company are as follows:&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Cash &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash in the statements of financial position includes cash on hand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial assets at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Impairment of financial assets&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;

                        &lt;div&gt;

                        &lt;/div&gt;
                        &#160;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                    5-10 years
                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Lesser of useful life and remaining term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company reviews long-lived assets, including property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial liabilities at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;

                        &lt;div&gt;

                        &lt;/div&gt;
                        &#160;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share capital &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;

                        &lt;div&gt;

                        &lt;/div&gt;
                        &#160;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Commitments and contingencies&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;

                        &lt;div&gt;

                        &lt;/div&gt;
                        &#160;
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Adoption of accounting standards and amendments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;


                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Accounting pronouncements not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;

                    &lt;/div&gt;
                </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024256117">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Cash &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash in the statements of financial position includes cash on hand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024304960">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial assets at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Impairment of financial assets&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024249599">
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                    5-10 years
                                                &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Lesser of useful life and remaining term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      id="Fxbrl_20240529040034874">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      id="Fxbrl_20240529040031186">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024244895">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company reviews long-lived assets, including property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <flgc:FinancialLiabilitiesPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024241192">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial liabilities at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;

                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </flgc:FinancialLiabilitiesPolicyTextBlock>
    <flgc:ProvisionsPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024228304">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </flgc:ProvisionsPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024224489">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share capital &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024219848">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;

                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024213710">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024208895">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Commitments and contingencies&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024203998">
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Adoption of accounting standards and amendments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529024159278">
                            &lt;div&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Accounting pronouncements not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:UnusualRisksAndUncertaintiesTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529040531693">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;4.&#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Liquidity and going concern considerations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company's ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of expenses and cash flows, which requires a significant amount of management judgement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Management is required to use judgement in determining the discount rate and whether to include renewal options in the lease term. The determination of the discount rate considers the incremental borrowing rate that would be charged for a loan that is collateralized or secured by the lessee's aggregate collateral, has a term that is similar to the lease term, is for an amount similar to the lease payments, and occurs in a similar economic environment. In this instance, management utilized European corporate debt instruments compounded annually that have a similar term and economic rating. In determining the lease term, management evaluated the fact that the Company's licenses are tied to the lease facility and as such the Company is reasonably certain to exercise the renewal option.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Estimated useful lives and depreciation of long-lived assets with finite lives&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Determination of asset groups for impairment testing&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Management is required to use judgement in determining asset groups for the level at which long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions, including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes and valuation allowances for deferred tax assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of December 31, 2023 and 2022, there were no uncertain tax positions taken.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:UnusualRisksAndUncertaintiesTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529054836689">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;5.&#160; AMOUNTS RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Company&#x2019;s amounts receivable are recorded at amortized cost. The amounts receivable balance as at December 31, 2023 and December 31, 2022 consists of amounts recoverable from the Value Added Tax (&#x201c;VAT&#x201d;) from various jurisdictions, and other receivables.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;VAT receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;14,551&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#160; &#160;6,761&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;4,343&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;11,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#160;18,894&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;18,399&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Company did not record write-offs of receivables during 2023 (2022 - &#x20ac; nil).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529054901273">
                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;VAT receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;14,551&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#160; &#160;6,761&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;4,343&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;11,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#160;18,894&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;18,399&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                        </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529055438806"
      unitRef="EUR">14551</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529055445086"
      unitRef="EUR">6761</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:OtherReceivables
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529055452958_xbrl_20240529055438806"
      unitRef="EUR">4343</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529055452958_xbrl_20240529055445086"
      unitRef="EUR">11638</us-gaap:OtherReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529055511014"
      unitRef="EUR">18894</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529055454951_xbrl_20240529055445086"
      unitRef="EUR">18399</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529055637679"
      unitRef="EUR">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529055608083"
      unitRef="EUR">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529061947005">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6.&#160; PROPERTY, PLANT AND EQUIPMENT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;119,062&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;114,325&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;24,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,550&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;94,837&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;104,775&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation expense for the year ended December 31, 2023 was &#x20ac;14,675 (2022 - &#x20ac;9,550) and was recorded in depreciation and amortization in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at December 31, 2023 and 2022, the Company&#x2019;s property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the periods ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529061953441">
                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;119,062&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;114,325&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;24,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;9,550&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;94,837&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;104,775&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                        </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      decimals="0"
      id="Fxbrl_20240529062010860"
      unitRef="EUR">119062</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      decimals="0"
      id="Fxbrl_20240529062016961"
      unitRef="EUR">114325</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529062229611_xbrl_20240529062010860"
      unitRef="EUR">24225</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529062229611_xbrl_20240529062016961"
      unitRef="EUR">9550</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529062332500"
      unitRef="EUR">94837</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529062422698"
      unitRef="EUR">104775</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529062021300"
      unitRef="EUR">14675</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529093210757"
      unitRef="EUR">9550</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529144346653">
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;7.&#160; DEBT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#x20ac;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, the &#x20ac;250,000 (December 31, 2022 - &#x20ac;250,000) was outstanding under the First Loan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#x20ac;450,000, in installments based on the individual installments requested by the Company (&#x201c;Second Loan&#x201d;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, &#x20ac;378,000 (December 31, 2022 &#x2013; &#x20ac;65,000) was outstanding under the Second Loan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at December 31, 2023, the amount of accrued interest on the First Loan and Second Loan totals &#x20ac;17,339 (December 31, 2022 &#x2013; &#x20ac;13,590).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In April 2024, both the First Loan and the Second Loan, including all accrued interest, were forgiven by TruHC Holding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember"
      decimals="0"
      id="Fxbrl_20240529143806633"
      unitRef="EUR">250000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember"
      decimals="3"
      id="Fxbrl_20240529143852304"
      unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember"
      decimals="0"
      id="Fxbrl_20240529144100216"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember"
      decimals="0"
      id="Fxbrl_20240529144154258"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember"
      decimals="0"
      id="Fxbrl_20240529143822972"
      unitRef="EUR">450000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember"
      decimals="3"
      id="Fxbrl_20240529143934678"
      unitRef="Pure">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember"
      decimals="0"
      id="Fxbrl_20240529144126378"
      unitRef="EUR">378000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember"
      decimals="0"
      id="Fxbrl_20240529144204869"
      unitRef="EUR">65000</us-gaap:LongTermDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529144215509"
      unitRef="EUR">17339</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529144241460"
      unitRef="EUR">13590</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529111323752">
                            &lt;div&gt;
                                &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8.&#160; LEASE&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company&#x2019;s lease consist of an administrative real estate lease in Germany. Management has determined the Company&#x2019;s lease is an operating lease through December 31, 2023. Information regarding the Company&#x2019;s lease is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the period from&lt;br/&gt;February 17, 2022 to &lt;/b&gt;&lt;br/&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Components of lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;123,105&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;84,783&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;123,105&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;84,783&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;70,249&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;604,294&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Weighted-average remaining lease term in years for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;
                                                                6.33
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;
                                                                7.33
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Weighted-average discount rate for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;8.77%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;8.77%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;

                                &lt;div&gt;

                                &lt;/div&gt;
                                &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Maturities of operating lease liabilities as of December 31, 2023 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Thereafter&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;140,497&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total future lease payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;667,362&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(156,698&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;510,664&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(63,083&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;447,581&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;

                                &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;The Company's operating lease expires on April 30, 2025. The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term. At December 31, 2023, the renewal option is included in the related operating right of use asset recorded because management is reasonably certain of renewing.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529111408810">
                                    &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Year ended&lt;br/&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the period from&lt;br/&gt;February 17, 2022 to &lt;/b&gt;&lt;br/&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Components of lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;123,105&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;84,783&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Total lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;123,105&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;84,783&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;70,249&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;604,294&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Weighted-average remaining lease term in years for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;
                                                                6.33
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;
                                                                7.33
                                                            &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Weighted-average discount rate for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;8.77%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;8.77%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115746952"
      unitRef="EUR">123105</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111710971"
      unitRef="EUR">84783</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCost
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111716911"
      unitRef="EUR">123105</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111732060"
      unitRef="EUR">84783</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112047606"
      unitRef="EUR">105373</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112101517"
      unitRef="EUR">70249</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112130108"
      unitRef="EUR">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20220217to20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112147037"
      unitRef="EUR">604294</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529112153107">P6Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529112204716">P7Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="4"
      id="Fxbrl_20240529112209974"
      unitRef="Pure">0.0877</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="4"
      id="Fxbrl_20240529112240566"
      unitRef="Pure">0.0877</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529111433612">
                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Thereafter&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;140,497&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total future lease payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;667,362&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(156,698&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;510,664&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(63,083&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;447,581&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112455158"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112508047"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112536044"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112549950"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112614263"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112806235"
      unitRef="EUR">140497</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529112941738"
      unitRef="EUR">667362</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529113031051"
      unitRef="EUR">156698</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115142751"
      unitRef="EUR">510664</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115201951"
      unitRef="EUR">63083</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115239372"
      unitRef="EUR">447581</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240530130203871">The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529110912216">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;9.&#160; RELATED PARTY DISCLOSURES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;Related party transactions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="text-decoration: underline;"&gt;Long-term debt with TruHC Holding&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#x20ac;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, the &#x20ac;250,000 (December 31, 2022 - &#x20ac;250,000) was outstanding under the First Loan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#x20ac;450,000, in installments based on the individual installments requested by the Company (&#x201c;Second Loan&#x201d;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at December 31, 2023, &#x20ac;378,000 (December 31, 2022 &#x2013; &#x20ac;65,000) was outstanding under the Second Loan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at December 31, 2023, the amount of accrued interest on the First Loan and Second Loan totals &#x20ac;17,339 (December 31, 2022 &#x2013; &#x20ac;13,590).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LongTermDebt
      contextRef="C_20220222_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529165245105"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember"
      decimals="3"
      id="Fxbrl_20240529142617020"
      unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529122002071"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529122006058"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529165346350"
      unitRef="EUR">450000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember"
      decimals="3"
      id="Fxbrl_20240529142656852"
      unitRef="Pure">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529122137633"
      unitRef="EUR">378000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529122656559"
      unitRef="EUR">65000</us-gaap:LongTermDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122635283"
      unitRef="EUR">17339</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122644695"
      unitRef="EUR">13590</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529100939326">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;10.&#160; COMMITMENTS AND CONTINGENCIES &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company does not have commitments or contingencies as at December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529110030555">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11.&#160; INCOME TAXES &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Components of the Company's deferred income tax assets and liabilities at December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;div&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                                &lt;div&gt;
                                    &lt;p style="margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
                                &lt;/div&gt;
                            &lt;/div&gt;
                        &lt;/div&gt;
                        &lt;div&gt;
                            &lt;div&gt;

                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 64%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;8,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;3,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;ROU asset&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(154,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(179,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;165,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;183,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Non-capital losses available for future period&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;174,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;64,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;193,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;71,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Unrecognized deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(193,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(71,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;

                            &lt;/div&gt;
                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred taxes are a result of temporary differences that arise due to the differences between the income tax values and the carrying values of assets and liabilities. The Company's deferred tax asset valuation allowances are primarily the result of uncertainties regarding the future realization of recorded tax benefits on the tax loss carryforwards from operations in various jurisdictions. Current evidence does not suggest the Company will realize sufficient taxable income of the appropriate character within the carryforward period to allow the Company to realize the deferred tax benefits. If the Company were to identify and implement tax planning strategies to recover these deferred tax assets or generate sufficient income of the appropriate character in these jurisdictions in the future, it could lead to the reversal of these valuation allowances and income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Unused loss carryforwards totaling &#x20ac;538,000 do not have an expiry date. Deferred tax assets have not been recognized for legal entities where it is not probable that future taxable profit will be available against which the Company can use the benefits. Tax attributes are subject to review, and potential adjustment, by tax authorities. The tax years that remain subject to examination by significant tax jurisdictions of the Company as of December 31, 2023 are as follows: 2022 to 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company had no unrecognized income tax benefits because of uncertain income tax positions for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240530101316945">
                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%; border-color: #000000;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 64%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: center; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;8,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;3,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;ROU asset&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(154,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(179,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;165,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;183,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Non-capital losses available for future period&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="width: 15%; text-align: right;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;174,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;64,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;193,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;71,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Unrecognized deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(193,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;(71,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Total net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 15%; text-align: right;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 0.75pt solid #000000; width: 2%; text-align: left;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 64%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;-&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110222586"
      unitRef="EUR">8000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110229458"
      unitRef="EUR">3000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <flgc:DeferredTaxAssetsRightOfUseAssets
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110236010"
      unitRef="EUR">-154000</flgc:DeferredTaxAssetsRightOfUseAssets>
    <flgc:DeferredTaxAssetsRightOfUseAssets
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110252623"
      unitRef="EUR">-179000</flgc:DeferredTaxAssetsRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110426362"
      unitRef="EUR">165000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110926378"
      unitRef="EUR">183000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240530101541769_xbrl_20240529110426362"
      unitRef="EUR">174000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240530101541769_xbrl_20240529110926378"
      unitRef="EUR">64000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110733412"
      unitRef="EUR">193000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110750847"
      unitRef="EUR">71000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110952248"
      unitRef="EUR">193000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111006088"
      unitRef="EUR">71000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111015913"
      unitRef="EUR">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111032675"
      unitRef="EUR">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111044455"
      unitRef="EUR">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111107203"
      unitRef="EUR">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111337957"
      unitRef="EUR">538000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529105657480">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;12.&#160; FINANCIAL INSTRUMENTS AND RISK MANAGEMENT &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Environmental&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company&#x2019;s financial instruments measured at amortized cost as at December 31, 2023 and December 31, 2022 consist of cash, trade and amounts payable, accrued liabilities, and debt. The amounts reflected in the statements of financial position approximate fair value for all financial instruments due to their short-term maturity, except for debt whose fair value as at December 31, 2023 is &#x20ac;504,264 (December 31, 2022 - &#x20ac;228,704.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;
                                &lt;div&gt;

                                &lt;/div&gt;
                            &lt;/div&gt;
                            &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Risk management overview&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Credit risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's amounts receivable, and cash held with banks and other financial intermediaries.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The carrying amount of the cash and represents the maximum credit exposure as presented in the statement of financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company held cash of &#x20ac;13,588 as at December 31, 2023 (2022 - &#x20ac;15,281). The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has not assessed a loss allowance on these cash balances as at December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Market risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;It is management's opinion that the Company is not subject to significant commodity or interest rate risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Liquidity risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#x2019;s financial liabilities consist of trade and amounts payable, and accrued liabilities, and debt as presented on the statement of financial position. The Company had cash as presented on the statement of financial position. The Company has no available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#x2019;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Trade and amounts payable, and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 9 and Note 2 for the Company&#x2019;s assessment of the uncertainty related to the assumption of the Company continuing to operate as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/div&gt;
                    &lt;/div&gt;
                </us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529114245869"
      unitRef="EUR">504264</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529114320623"
      unitRef="EUR">228704</us-gaap:DebtInstrumentFairValue>
    <us-gaap:Cash
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529113023656"
      unitRef="EUR">13588</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529113359236"
      unitRef="EUR">15281</us-gaap:Cash>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529105442799">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;13.&#160; SHARE CAPITAL&lt;/b&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Authorized and issued&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company is authorized to issue an unlimited number of common shares, no par value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On incorporation, the Company issued 25,000 shares to TruHC Holding GmbH at a par value of &#x20ac;1.00 per share. As at December 31, 2023, &#x20ac;12,500 (December 31, 2022 - &#x20ac;12,500) remains receivable as been netted against the share capital balance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember"
      decimals="INF"
      id="Fxbrl_20240529105540508"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember"
      decimals="2"
      id="Fxbrl_20240529110051744"
      unitRef="Euro_Per_share">1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111335640"
      unitRef="EUR">12500</us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock>
    <us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111649216"
      unitRef="EUR">12500</us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529095341823">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;114.&#160; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On April 16, 2024, Flora Growth Corp. (&#x201c;Flora&#x201d;) entered into a Stock Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with TruHC Holding GmbH (the &#x201c;Seller&#x201d;) pursuant to which Flora will acquire all of the issued and outstanding shares of the Company. The Purchase Price will be paid and satisfied by Flora in two closings. On the first closing, Flora issued 2,135,199 of its common shares, which is equal to 19.99% of Flora&#x2019;s issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the &#x201c;Second Closing&#x201d;), Flora will issue 635,363 of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Under the Purchase Agreement, Flora is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On April 22, 2024, the first closing of the Transaction for 2,135,199 Flora shares was closed.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In April 2024, both the First Loan and the Second Loan were forgiven.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20240529102114187"
      unitRef="Shares">2135199</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <flgc:PercentageOfIssuedAndOutstandingCommonShares
      contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="4"
      id="Fxbrl_20240529102129615"
      unitRef="Pure">0.1999</flgc:PercentageOfIssuedAndOutstandingCommonShares>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20240529102259386"
      unitRef="Shares">635363</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240401to20240422_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20240529102420565"
      unitRef="Shares">2135199</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_42"
      unitRef="EUR">13899</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_45"
      unitRef="EUR">13588</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_52"
      unitRef="EUR">21182</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_55"
      unitRef="EUR">18894</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_62"
      unitRef="EUR">20347</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_65"
      unitRef="EUR">20347</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_72"
      unitRef="EUR">55428</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_75"
      unitRef="EUR">52829</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_92"
      unitRef="EUR">91095</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_95"
      unitRef="EUR">94837</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_102"
      unitRef="EUR">459515</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_105"
      unitRef="EUR">478399</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_112"
      unitRef="EUR">606038</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_115"
      unitRef="EUR">626065</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_142"
      unitRef="EUR">47522</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_145"
      unitRef="EUR">34711</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_152"
      unitRef="EUR">64477</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_155"
      unitRef="EUR">63083</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_162"
      unitRef="EUR">11620</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_165"
      unitRef="EUR">11520</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_172"
      unitRef="EUR">123619</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_175"
      unitRef="EUR">109314</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_192"
      unitRef="EUR">720730</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_195"
      unitRef="EUR">645339</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_202"
      unitRef="EUR">430930</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_205"
      unitRef="EUR">447581</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_212"
      unitRef="EUR">1275279</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_215"
      unitRef="EUR">1202234</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_232"
      unitRef="EUR">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_235"
      unitRef="EUR">12500</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_242"
      unitRef="EUR">-694241</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_245"
      unitRef="EUR">-588669</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_252"
      unitRef="EUR">-669241</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_255"
      unitRef="EUR">-576169</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_262"
      unitRef="EUR">606038</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529040601091_265"
      unitRef="EUR">626065</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfessionalFees
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_22"
      unitRef="EUR">19240</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_25"
      unitRef="EUR">82</us-gaap:ProfessionalFees>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_32"
      unitRef="EUR">47089</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_35"
      unitRef="EUR">26207</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_42"
      unitRef="EUR">326</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_45"
      unitRef="EUR">425</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_52"
      unitRef="EUR">29970</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_55"
      unitRef="EUR">31516</us-gaap:OperatingLeaseExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_62"
      unitRef="EUR">3742</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_65"
      unitRef="EUR">1933</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_72"
      unitRef="EUR">-100181</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_75"
      unitRef="EUR">-60163</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_82"
      unitRef="EUR">-5391</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_85"
      unitRef="EUR">270</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_92"
      unitRef="EUR">-105572</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_95"
      unitRef="EUR">-59893</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_102"
      unitRef="EUR">-105572</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529044251693_105"
      unitRef="EUR">-59893</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240529045752589"
      unitRef="Shares">25000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20240529045800647"
      unitRef="EUR">12500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529045824870"
      unitRef="EUR">-216882</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529045837349"
      unitRef="EUR">-204382</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529045907542"
      unitRef="EUR">-59893</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529045926382"
      unitRef="EUR">-59893</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240529045806800"
      unitRef="Shares">25000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20240529045809400"
      unitRef="EUR">12500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529045841740"
      unitRef="EUR">-276775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529045845111"
      unitRef="EUR">-264275</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240529045818253"
      unitRef="Shares">25000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20240529045820216"
      unitRef="EUR">12500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529045847781"
      unitRef="EUR">-588669</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529045849905"
      unitRef="EUR">-576169</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <flgc:Contributionamont
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20240529050545606"
      unitRef="EUR">12500</flgc:Contributionamont>
    <flgc:Contributionamont
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529050617770"
      unitRef="EUR">12500</flgc:Contributionamont>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529045936464"
      unitRef="EUR">-105572</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529045938816"
      unitRef="EUR">-105572</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240529045816243"
      unitRef="Shares">25000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20240529045811671"
      unitRef="EUR">25000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20240529045854069"
      unitRef="EUR">-694241</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529045852126"
      unitRef="EUR">-669241</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122614207"
      unitRef="EUR">-105572</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122638032"
      unitRef="EUR">-59893</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122656152"
      unitRef="EUR">3742</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122711609"
      unitRef="EUR">1933</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122725112"
      unitRef="EUR">-5391</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122758272"
      unitRef="EUR">0</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122830656"
      unitRef="EUR">3627</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122905995"
      unitRef="EUR">4903</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529122929219"
      unitRef="EUR">2288</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240530102511699"
      unitRef="EUR">2988</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529123006259"
      unitRef="EUR">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529123104075"
      unitRef="EUR">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529123151747"
      unitRef="EUR">12911</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529123217114"
      unitRef="EUR">44512</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529123229991"
      unitRef="EUR">-82189</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529123308706"
      unitRef="EUR">-11533</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124416510"
      unitRef="EUR">70000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124534425"
      unitRef="EUR">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124618390"
      unitRef="EUR">12500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124633453"
      unitRef="EUR">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124647581"
      unitRef="EUR">82500</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124711004"
      unitRef="EUR">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124741469"
      unitRef="EUR">0</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124808199"
      unitRef="EUR">197</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124906055"
      unitRef="EUR">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124938207"
      unitRef="EUR">-197</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529124953287"
      unitRef="EUR">311</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529125452249"
      unitRef="EUR">-11730</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529125550255"
      unitRef="EUR">13588</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529125608902"
      unitRef="EUR">15281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529125651759"
      unitRef="EUR">13899</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529125708166"
      unitRef="EUR">3551</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529052419404">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;1.&#160; NATURE OF OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;TruHC Pharma GmbH (the "Company" or "TruHC") was incorporated under the laws of Germany on February 17, 2022. The Company engages in the import, distribution, and manufacturing of medical cannabis and operates a production facility. The Company's registered office and principal place of business in Germany is located at Poppenb&#xfc;tteler Bogen 68 22399 Hamburg, Germany. At December 31, 2023, all of the Company's issued and outstanding shares were owned by TruHC Holding GmbH ("TruHC Holding").&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;These condensed interim financial statements have been prepared on a going concern basis, meaning that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529052457890">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;2.&#160; BASIS OF PRESENTATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;These financial statements have been presented in Euros and are prepared in accordance with United States generally accepted accounting principles (&#x201c;US GAAP&#x201d;). The Company has determined that the Euro is the functional and reporting currency as the majority of our operations are conducted in Euros and the financial results are prepared and reviewed internally by management in Euros.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Going concern&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue for a period of at least one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effects of management's plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company had cash of &#x20ac;13,899 at March 31, 2024, net loss of &#x20ac;105,572 for the three months ended March 31, 2024 and an accumulated deficit of &#x20ac;694,241 at March 31, 2024. Current economic and market conditions have put pressure on the Company's growth plans. The Company's ability to continue as a going concern is dependent on its ability to obtain additional capital. The Company believes that its current level of cash is not sufficient to continue investing in growth, while at the same time meeting its obligations as they become due. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these financial statements. To alleviate these conditions, management is currently evaluating various cost reductions and other alternatives and may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners or, through obtaining credit from financial institutions and the possible disposition of assets or otherwise. The actual amount that the Company may be able to raise under these alternatives will depend on market conditions and other factors. As it seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#x2019;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including but not limited to market and economic conditions, the Company&#x2019;s performance and investor sentiment with respect to it and its industry. These financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Basis of measurement &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The financial statements have been prepared on the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of amounts receivable, prepaids and other current assets, and trade and amounts payable, accrued liabilities, and current portion of lease liability approximate their fair values due to their short periods to maturity.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The financial statements are presented in Euros ("&#x20ac;") unless otherwise noted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Use of estimates&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:Cash
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529052620296"
      unitRef="EUR">13899</us-gaap:Cash>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529052643811"
      unitRef="EUR">-105572</us-gaap:ProfitLoss>
    <us-gaap:CumulativeEarningsDeficit
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529052708307"
      unitRef="EUR">-694241</us-gaap:CumulativeEarningsDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053143498">
                        &lt;div&gt;
                            &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;3.&#160; SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;The significant accounting policies used by the Company are as follows:&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;div&gt;

                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Cash &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash in the statements of financial position includes cash on hand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                            &lt;div&gt;

                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial assets at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Impairment of financial assets&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;

                            &lt;/div&gt;
                            &lt;div&gt;

                            &lt;/div&gt;
                            &#160;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                        5-10 years
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Lesser of useful life and remaining term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company reviews long-lived assets, including property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial liabilities at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                            &lt;div&gt;

                            &lt;/div&gt;
                            &#160;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share capital &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                            &lt;div&gt;

                            &lt;/div&gt;
                            &#160;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Commitments and contingencies&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                            &lt;div&gt;

                            &lt;/div&gt;
                            &#160;
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Adoption of accounting standards and amendments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;


                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Accounting pronouncements not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                        &lt;/div&gt;
                    </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053159603">
                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Cash &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Cash in the statements of financial position includes cash on hand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053206506">
                                    &lt;div&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company aggregates its financial assets into classes at the time of initial recognition based on the Company's business model and the contractual terms of the cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;No financial assets are or were elected to be carried at fair value through profit or loss ("FVPL") or where changes in fair value are recognized in the statement of loss and comprehensive loss.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial assets at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial assets measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. In these financial statements, cash, amounts receivable&#160; are classified in this category.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company no longer retains substantially all the risks and rewards of ownership.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Impairment of financial assets&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial assets classified subsequently as amortized cost are subject to impairment based on the expected credit losses ("ECL's"). The Company's financial assets subject to impairment are cash, and amounts receivable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Amounts receivable are recognized initially at fair value and subsequently measured at amortized cost, less any provisions for impairment. Impairment provisions are estimated using the ECL impairment model where any expected future credit losses are provided for, irrespective of whether a loss event has occurred at the reporting date. Estimates of expected credit losses consider the Company's collection history by customer, deterioration of collection rates during the average credit period, as well as observable changes in and forecasts of future economic conditions that affect default risk. The Company utilizes a provision matrix to estimate lifetime ECL's for receivables, supplemented by specific allowance based on customer-specific data. Changes in the allowance are recognized as bad debt expense in the statements of loss and comprehensive loss. When the Company determines that no recovery of the amount owed is possible, the amount is deemed irrecoverable, and the financial asset is written off.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053212305">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Depreciation is provided for on a straight-line basis over the assets' estimated useful lives, which management has determined to be as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 100%;"&gt;
                                        &lt;tr&gt;
                                            &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                        5-10 years
                                                    &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                            &lt;td style="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Lesser of useful life and remaining term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company assesses an asset's residual value, useful life and depreciation method at each financial year end and adjusts if appropriate. During their construction, property, plant and equipment are not subject to depreciation. The Company capitalizes all costs necessary to get the asset to its intended use. When the asset is available for use, depreciation commences. Depreciation expense is recorded within depreciation and amortization on the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Gains and losses on disposal of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment and are recognized in the statements of loss and comprehensive loss of the related year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      id="Fxbrl_20240529054048347">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      id="Fxbrl_20240529054012546">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053217099">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company reviews long-lived assets, including property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying amount of the asset group.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <flgc:FinancialLiabilitiesPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053222366">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Financial liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Initial recognition and measurement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Financial liabilities are measured at amortized cost, unless they are required to be measured at FVPL as is the case for held for trading or derivative instruments, or when the Company has opted to measure the financial liability at FVPL. The Company's financial liabilities include trade and other payables, accrued liabilities, and long-term debt, which are measured at amortized cost. All financial liabilities are recognized initially at fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Subsequent measurement - Financial liabilities at amortized cost&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the EIR method. Amortized cost is calculated by considering any discount or premium on acquisition and any fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;i&gt;Derecognition&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A financial liability is derecognized when the obligation under the liability is discharged, cancelled, or expires with any associated gain or loss recognized in other income or expense in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </flgc:FinancialLiabilitiesPolicyTextBlock>
    <flgc:ProvisionsPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053230418">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Provisions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Provisions are recognized when (a) the Company has a present obligation (legal or constructive) due to a past event, and (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is probable. The Company expenses legal costs as incurred related to such matters.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The expense relating to any provision is presented in the statements of loss and comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </flgc:ProvisionsPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053254826">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Share capital &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Issued common shares are recorded as equity at par value. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. Common shares are considered issued when consideration has been received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053243033">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's estimated incremental borrowing rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The lease term at the lease commencement date is determined based on the noncancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considers several factors when evaluating whether the options in its lease contracts are reasonably certain of exercise, such as length of time before an option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to the Company's operations, costs to negotiate a new lease, any contractual or economic penalties, and the economic value of leasehold improvements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;For finance leases, from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, the right-of-use asset is amortized on a straight-line basis and the interest expense is recognized on the lease liability using the effective interest method. For operating leases, lease expense is recognized on a straight-line basis over the term of the lease and presented as a single charge in the statements of operations and comprehensive income. The lease liability is subsequently measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;

                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company has elected not to separate non-lease components from lease components for real estate leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053302723">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in the statements of loss and comprehensive loss, or items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Interest and penalties in respect of income taxes are not recognized in the statement of operations as a component of income taxes but as a component of interest expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053310098">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Commitments and contingencies&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Contingencies are possible liabilities arising from past events which, by their nature, will only be resolved when one or more future events not wholly within our control occur or fail to occur. The assessment of such contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events. Management assesses loss contingencies related to legal proceedings, tax or other regulatory actions pending against the Company, as well as unasserted claims that may result in such actions. The Company, its legal counsel and other subject matter advisors evaluate the perceived merits of any legal proceedings or unasserted claims or actions as well as the perceived merits of the nature and amount of relief sought or expected to be sought, when determining the amount, if any, to recognize as a provision or assessing the impact on the carrying value of assets. The Company recognizes legal expenses on contingency and provision matters when incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053317265">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Adoption of accounting standards and amendments&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In June 2016, the United States Financial Accounting Standards Board ("FASB") issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require entities to use forward-looking information to better formulate their credit loss estimates. This update is effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2016-13 effective as of its inception, and as such had no impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 would be effective for the Company beginning January 1, 2022. The Company has early adopted ASU 2019-12, effective as of its inception, and as such had no impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529053328129">
                                &lt;div&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Accounting pronouncements not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain new standards, amendments and interpretations, and improvements to existing standards have been published by the FASB and United States Securities and Exchange Commission but are not yet effective and have not been adopted early by the Company. Management anticipates that all the relevant pronouncements will be adopted in the first reporting period following the date of application unless noted. Information on new standards, amendments and interpretations, and improvements to existing standards which could potentially impact the Company's financial statements are detailed as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improve the transparency of disclosures related to the income tax rate reconciliation and income taxes paid. The amendments are effective for the Company in fiscal years beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the guidance and its impact to the financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Certain other new standards and interpretations have been issued but are not expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;/div&gt;
                            </flgc:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:UnusualRisksAndUncertaintiesTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529054147297">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;4.&#160; CRITICAL JUDGMENTS AND ESTIMATION UNCERTAINTIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Liquidity and going concern considerations&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Management must assess the Company's ability to continue as a going concern each reporting period. This assessment involves the use of internal budgets and estimates of expenses and cash flows, which requires a significant amount of management judgement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Management is required to use judgement in determining the discount rate and whether to include renewal options in the lease term. The determination of the discount rate considers the incremental borrowing rate that would be charged for a loan that is collateralized or secured by the lessee's aggregate collateral, has a term that is similar to the lease term, is for an amount similar to the lease payments, and occurs in a similar economic environment. In this instance, management utilized European corporate debt instruments compounded annually that have a similar term and economic rating. In determining the lease term, management evaluated the fact that the Company's licenses are tied to the lease facility and as such the Company is reasonably certain to exercise the renewal option.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Estimated useful lives and depreciation of long-lived assets with finite lives&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Amortization of intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, and anticipated changes in laws.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Determination of asset groups for impairment testing&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Management is required to use judgement in determining asset groups for the level at which long-lived assets are tested for impairment. Management considers the nature of operations and ability to track asset performance within each of the Company's business units to determine the appropriate level of asset aggregation and allocation, as well as the materiality of the underlying assets within the units.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Impairment of long-lived assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Asset groups are subject to a two-step impairment testing model. Under Step 1 (recoverability test), the undiscounted expected future cash flows from an asset group are compared to the asset group's carrying amount. The estimates involved in this first step are similar to the recoverable amount assumptions, including, but not limited to, the cash flow growth rate and the discount rate. Significant management judgment is required when developing these assumptions, which include internal budgets and expectations, as well as consideration of external Company communications and market estimates of the Company's and its industry's future growth. If the carrying amount exceeds the undiscounted estimated future cash flows, the Company is required to perform a Step 2 fair value test, with a chosen model and estimates similar to those discussed above.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Income taxes and valuation allowances for deferred tax assets&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In assessing the probability of realizing income tax assets recognized, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. The Company considers relevant tax planning opportunities that are within the Company's control, are feasible and within management's ability to implement. Examination by applicable tax authorities is supported based on individual facts and circumstances of the relevant tax position examined considering all available evidence. Where applicable tax laws and regulations are either unclear or subject to ongoing varying interpretations, it is reasonably possible that changes in these estimates can occur that materially affect the amounts of income tax assets recognized net of valuation allowances. Also, future changes in tax laws could limit the Company from realizing the tax benefits from the deferred tax assets. The Company reassesses unrecognized income tax assets at each reporting period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company applies judgment when determining whether the earnings of its foreign subsidiaries (outside Canada) will be indefinitely reinvested in those subsidiaries and earnings will not be repatriated. The Company considers its historical practices and projected plans for such subsidiaries when making this assessment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company must apply judgement when determining whether it has taken an uncertain tax position. Management has analyzed the tax positions taken by the Company, and has concluded that as of March 31, 2024 and December 31, 2023 there were no uncertain tax positions taken.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:UnusualRisksAndUncertaintiesTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529055842128">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;5. AMOUNTS RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's amounts receivable are recorded at amortized cost. The amounts receivable balance as at December 31, 2023 and December 31, 2022 consists of amounts recoverable from the Value Added Tax ("VAT") from various jurisdictions, and other receivables.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;VAT receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,919&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;14,551&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,263&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,343&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;21,182&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;18,894&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company did not record write-offs of receivables during the three months ended March 31, 2024 (2023 - &#x20ac; nil).&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529055902855">
                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;VAT receivable&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;19,919&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;14,551&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;1,263&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;4,343&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;21,182&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;18,894&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                        </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529060009917"
      unitRef="EUR">19919</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529060014530"
      unitRef="EUR">14551</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:OtherReceivables
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529060026716_xbrl_20240529060009917"
      unitRef="EUR">1263</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529060026716_xbrl_20240529060014530"
      unitRef="EUR">4343</us-gaap:OtherReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529060049044"
      unitRef="EUR">21182</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529060029348_xbrl_20240529060014530"
      unitRef="EUR">18894</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20230101to20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_s_20240529060247712"
      unitRef="EUR">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529060247712"
      unitRef="EUR">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529101955624">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;6.&#160; PROPERTY, PLANT AND EQUIPMENT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 90%;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 66.9241%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9691%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9292%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 11.9691%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;119,062&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 14.9292%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;119,062&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.9241%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1.0296%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;27,967&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2.0592%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1.0296%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;24,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2.0592%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;91,095&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;94,837&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Depreciation expense for the three months ended March 31, 2024 was &#x20ac;3,742 (2023 - &#x20ac;1,933) and was recorded in depreciation and amortization in the statements of loss and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at March 31, 2024 and 2023, the Company&#x2019;s property, plant and equipment have no significant restrictions on title or pledges as security for liabilities, there are no significant commitments for future purchases, and there were no significant disposals during the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529102112162">
                            &lt;div&gt;
                                &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; border-color: #000000; font-size: 10pt; width: 90%;"&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap; width: 66.9241%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 11.9691%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 1.0296%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 14.9292%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap; width: 2.0592%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Machinery and office equipment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 11.9691%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;119,062&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1.0296%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 14.9292%; text-align: right; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;119,062&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2.0592%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; width: 66.9241%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1.0296%;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;27,967&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2.0592%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 1.0296%; border-bottom: 0.75pt solid #000000;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 0.75pt solid #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;24,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; text-align: left; width: 2.0592%;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                    &lt;tr&gt;
                                        &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff; width: 66.9241%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 11.9691%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;91,095&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1.0296%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; width: 14.9292%; text-align: right; border-bottom: 2.25pt double #000000; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;94,837&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                        &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2.0592%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;/tr&gt;
                                &lt;/table&gt;
                            &lt;/div&gt;
                        </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      decimals="0"
      id="Fxbrl_20240529110254007"
      unitRef="EUR">119062</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapMachineryAndEquipmentMember"
      decimals="0"
      id="Fxbrl_20240529110321807"
      unitRef="EUR">119062</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110346161"
      unitRef="EUR">27967</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110412549"
      unitRef="EUR">24225</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110430176"
      unitRef="EUR">91095</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110451177"
      unitRef="EUR">94837</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110518926"
      unitRef="EUR">3742</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529110615499"
      unitRef="EUR">1933</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529115221811">
                    &lt;div&gt;
                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;7.&lt;/b&gt;&#160; &lt;b&gt;DEBT&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#x20ac;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, the &#x20ac;250,000 (December 31, 2023 - &#x20ac;250,000) was outstanding under the First Loan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#x20ac;450,000, in installments based on the individual installments requested by the Company (&#x201c;Second Loan&#x201d;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, &#x20ac;448,000 (December 31, 2023 &#x2013; &#x20ac;378,000) was outstanding under the Second Loan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at March 31, 2024, the amount of accrued interest on the First Loan and Second Loan totals &#x20ac;22,730 (December 31, 2023 &#x2013; &#x20ac;17,339).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In April 2024, both the First Loan and the Second Loan, including all accrued interest, were forgiven by TruHC Holding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember"
      decimals="0"
      id="Fxbrl_20240529115317886"
      unitRef="EUR">250000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember"
      decimals="3"
      id="Fxbrl_20240529120327111"
      unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember"
      decimals="0"
      id="Fxbrl_20240529141757196"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcFirstLoanMember"
      decimals="0"
      id="Fxbrl_20240529141832200"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember"
      decimals="0"
      id="Fxbrl_20240529120313216"
      unitRef="EUR">450000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember"
      decimals="3"
      id="Fxbrl_20240529120357133"
      unitRef="Pure">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember"
      decimals="0"
      id="Fxbrl_20240529141810376"
      unitRef="EUR">448000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapDebtInstrumentAxis_flgcSecondLoanMember"
      decimals="0"
      id="Fxbrl_20240529141845864"
      unitRef="EUR">378000</us-gaap:LongTermDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529141906388"
      unitRef="EUR">22730</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529141931801"
      unitRef="EUR">17339</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529120116686">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;8.&#160; LEASE&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span&gt;The Company&#x2019;s lease consists of an administrative real estate lease in Germany. Management has determined the Company&#x2019;s lease is an operating lease through March 31, 2024. Information regarding the Company&#x2019;s lease is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the Three&lt;br/&gt;Months Ended&lt;br/&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the Three &lt;/b&gt;&lt;br/&gt;&lt;b&gt;Months Ended &lt;/b&gt;&lt;br/&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Components of lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,970&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31,516&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,970&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31,516&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;26,343&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;26,343&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted-average remaining lease term in years for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                6.08
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                7.08
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted-average discount rate for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.77%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.77%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Maturities of operating lease liabilities as of March 31, 2024 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

                            &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;79,030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thereafter&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;140,497&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total future lease payments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;641,019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;145,612&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;495,407&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(64,477&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;430,930&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;

                        &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's operating lease expires on April 30, 2025. The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term. At March 31, 2024, the renewal option is included in the related operating right of use asset recorded because management is reasonably certain of renewing.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529120154546">
                            &lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the Three&lt;br/&gt;Months Ended&lt;br/&gt;March 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;span&gt;&lt;b&gt;For the Three &lt;/b&gt;&lt;br/&gt;&lt;b&gt;Months Ended &lt;/b&gt;&lt;br/&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Components of lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: center; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating lease expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,970&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31,516&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Total lease expense&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;29,970&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;31,516&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Other Information&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;26,343&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;26,343&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#160;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted-average remaining lease term in years for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                6.08
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;
                                                7.08
                                            &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Weighted-average discount rate for operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.77%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;8.77%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120310705"
      unitRef="EUR">29970</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120659089"
      unitRef="EUR">31516</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCost
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120758670"
      unitRef="EUR">29970</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120828027"
      unitRef="EUR">31516</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120919131"
      unitRef="EUR">26343</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120937040"
      unitRef="EUR">26343</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529120950072"
      unitRef="EUR">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20230101to20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121003079"
      unitRef="EUR">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529121025478">P6Y29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529121045112">P7Y29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="4"
      id="Fxbrl_20240529121100192"
      unitRef="Pure">0.0877</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20230331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="4"
      id="Fxbrl_20240529121104255"
      unitRef="Pure">0.0877</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529120211464">
                            &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 90%; border-color: #000000;"&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: center; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;79,030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;105,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Thereafter&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;140,497&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total future lease payments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;641,019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;145,612&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid #000000; text-align: left; width: 2%;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;495,407&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 16.75pt; vertical-align: bottom; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: right; width: 15%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;(64,477&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; text-align: left; width: 2%;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                &lt;/tr&gt;
                                &lt;tr&gt;
                                    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom; text-align: justify; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 1%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&#x20ac;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: right; width: 15%; background-color: #e6efff;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;430,930&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                                    &lt;td style="vertical-align: bottom; border-top: 0.75pt solid #000000; border-bottom: 2.25pt double #000000; text-align: left; width: 2%; background-color: #e6efff;"&gt;&#160;&lt;/td&gt;
                                &lt;/tr&gt;
                            &lt;/table&gt;
                        </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121155720"
      unitRef="EUR">79030</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121206147"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121212641"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121216027"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121219012"
      unitRef="EUR">105373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121222235"
      unitRef="EUR">140497</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121230928"
      unitRef="EUR">641019</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121234728"
      unitRef="EUR">145612</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121238744"
      unitRef="EUR">495407</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121243079"
      unitRef="EUR">64477</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529121303672"
      unitRef="EUR">430930</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240530130259095">The lease includes an option to extend the lease term for the entire space for a period of 5 years at the end of the current lease term.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529110941023">
                                    &lt;div&gt;
                                        &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span&gt;&lt;b&gt;9.&#160; RELATED PARTY DISCLOSURES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Related party transactions&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Long-term debt with TruHC Holding&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In February 2022, the Company entered into a first loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#x20ac;250,000, in installments based on the individual installments requested by the Company ("First Loan"). The First Loan bears interest at 2.0% per annum. The First Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, the &#x20ac;250,000 (December 31, 2023 - &#x20ac;250,000) was outstanding under the First Loan.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In February 2022, the Company entered into a second loan agreement with TruHC Holding, which granted the Company an interest-bearing loan of &#x20ac;450,000, in installments based on the individual installments requested by the Company (&#x201c;Second Loan&#x201d;). The Second Loan bears interest at 4.0% per annum. The Second Loan is due to be repaid by December 31, 2026. The Company is entitled to make early repayments. As at March 31, 2024, &#x20ac;448,000 (December 31, 2023 &#x2013; &#x20ac;378,000) was outstanding under the Second Loan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                        &lt;p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;As at March 31, 2024, the amount of accrued interest on the First Loan and Second Loan totals &#x20ac;22,730 (December 31, 2023 &#x2013; &#x20ac;17,339).&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                    &lt;/div&gt;
                                </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LongTermDebt
      contextRef="C_20220222_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529143313709"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember"
      decimals="3"
      id="Fxbrl_20240529143322395"
      unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529143331545"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcFirstLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529143342345"
      unitRef="EUR">250000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529143353843"
      unitRef="EUR">450000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_20220201to20220228_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember"
      decimals="3"
      id="Fxbrl_20240529143402687"
      unitRef="Pure">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529143414654"
      unitRef="EUR">448000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_flgcLoanAgreementsAxis_flgcSecondLoanAgreementMember"
      decimals="0"
      id="Fxbrl_20240529143423443"
      unitRef="EUR">378000</us-gaap:LongTermDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529143433083"
      unitRef="EUR">22730</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529143445054"
      unitRef="EUR">17339</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529101519456">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;10. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company does not have commitments or contingencies as at March 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529115032929">
                    &lt;div&gt;
                        &lt;p style="text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;11. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Environmental&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company's growth and development activities are subject to laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company&#x2019;s financial instruments measured at amortized cost as at March 31, 2024 and December&#160;31,&#160;2023 consist of cash, trade and amounts payable, accrued liabilities, and debt. The amounts reflected in the statements of financial position approximate fair value for all financial instruments due to their short-term maturity, except for debt whose fair value as at March 31, 2024 is &#x20ac;577,354 (December 31, 2022 - &#x20ac;504,264).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Risk management overview&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company has exposure to credit, liquidity and market risks from its use of financial instruments. This note provides information about the Company's exposure to each of these risks, the Company's objectives, policies and processes for measuring and managing risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Credit risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's trade and amounts receivable, and cash held with banks and other financial intermediaries.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The carrying amount of the cash represents the maximum credit exposure as presented in the statement of financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company held cash of &#x20ac;13,899 as at March 31, 2024 (December 31, 2023 - &#x20ac;13,588). The Company has assessed no significant increase in credit risk from initial recognition based on the availability of funds, and the regulatory and economic environment of the financial intermediary. As a result, the loss allowance recognized during the period was limited to twelve months of expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has not assessed a loss allowance on these cash balances as at March 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Market risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Market risk is the risk that changes in market conditions, such as commodity prices, foreign exchange rates, and interest rates, will affect the Company's net income or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing the Company's returns.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;It is management's opinion that the Company is not subject to significant commodity or interest rate risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Liquidity risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with its financial liabilities. The Company&#x2019;s financial liabilities consist of trade and amounts payable, and accrued liabilities, and debt as presented on the statement of financial position. The Company had cash as presented on the statement of financial position. The Company has no available credit lines of facilities to draw borrowings from should additional liquidity be needed. The Company&#x2019;s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;div&gt;

                        &lt;/div&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt; margin-bottom: 0pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;span style="font-size: 10pt;"&gt;Trade and amounts payable, and accrued liabilities consist of invoices payable to trade suppliers for administration and professional expenditures. The Company processes invoices within a normal payment period. Trade payables have contractual maturities of less than 90 days. Some suppliers of materials require full prepayment from the Company prior to providing such goods to the Company. See schedule of future lease commitments at Note 9 and Note 2 for the Company&#x2019;s assessment of the uncertainty related to the assumption of the Company continuing to operate as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115226276"
      unitRef="EUR">577354</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115236799"
      unitRef="EUR">504264</us-gaap:DebtInstrumentFairValue>
    <us-gaap:Cash
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115305781"
      unitRef="EUR">13899</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20231231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      decimals="0"
      id="Fxbrl_20240529115323171"
      unitRef="EUR">13588</us-gaap:Cash>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529111804841">
                    &lt;div style="margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;12.&#160; SHARE CAPITAL &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;
                        &lt;p style="text-align: justify; margin-top: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;Authorized and issued&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;The Company is authorized to issue an unlimited number of common shares, no par value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On incorporation, the Company issued 25,000 shares to TruHC Holding GmbH at a par value of &#x20ac;1.00 per share. As at March 31, 2024, nil (December 31, 2022 - &#x20ac;12,500) remains receivable as been netted against the share capital balance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/div&gt;
                </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember"
      decimals="INF"
      id="Fxbrl_20240529111842492"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember"
      decimals="2"
      id="Fxbrl_20240529111849179"
      unitRef="Euro_Per_share">1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
      contextRef="C_20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111907258"
      unitRef="EUR">0</us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock>
    <us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
      contextRef="C_20221231_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_flgcTruhcHoldingGmbhMember"
      decimals="0"
      id="Fxbrl_20240529111926731"
      unitRef="EUR">12500</us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20240101to20240331_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember"
      id="Fxbrl_20240529102906963">
                            &lt;div&gt;
                                &lt;p style="margin-left: 17pt; text-indent: -17.85pt; text-align: justify; margin-top: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;&lt;b&gt;13.&#160; SUBSEQUENT EVENTS &lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On April 16, 2024, Flora Growth Corp. (&#x201c;Flora&#x201d;) entered into a Stock Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with TruHC Holding GmbH (the &#x201c;Seller&#x201d;) pursuant to which Flora will acquire all of the issued and outstanding shares of the Company. The Purchase Price will be paid and satisfied by Flora in two closings. On the first closing, Flora issued 2,135,199 of its common shares, which is equal to 19.99% of Flora&#x2019;s issued and outstanding common shares prior to signing the Purchase Agreement, to Seller. On the second closing (the &#x201c;Second Closing&#x201d;), Flora will issue 635,363 of its common shares to Seller after receiving shareholder approval for such issuance in accordance with the rules of the Nasdaq Stock Market at its next special or annual general meeting of shareholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;Under the Purchase Agreement, Flora is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing and to recommend the approval of the Second Closing to the Company's shareholders. The Purchase Agreement contains other customary terms, representations, warranties, covenants and closing conditions for a transaction of this nature.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;On April 22, 2024, the first closing of the Transaction for 2,135,199 Flora shares was closed.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                                &lt;p style="text-align: justify; margin-bottom: 0pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman,Times,serif;"&gt;In April 2024, both the First Loan and the Second Loan were forgiven.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                            &lt;/div&gt;
                        </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20240529103612377"
      unitRef="Shares">2135199</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <flgc:PercentageOfIssuedAndOutstandingCommonShares
      contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="4"
      id="Fxbrl_20240529103639864"
      unitRef="Pure">0.1999</flgc:PercentageOfIssuedAndOutstandingCommonShares>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240401to20240416_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcSecondClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20240529103713547"
      unitRef="Shares">635363</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_20240401to20240422_deiLegalEntityAxis_flgcTruhcPharmaGmbhMember_usgaapBusinessAcquisitionAxis_flgcFloraGrowthCorpMember_usgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_flgcFirstClosingMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20240529103803035"
      unitRef="Shares">2135199</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
